

Venous thromboembolism in over 16s

Reducing the risk of hospital-acquired deep vein
thrombosis or pulmonary embolism

NICE guideline NG89

Appendices A – I

March 2018

Final

*Developed by the National Guideline Centre,
hosted by the Royal College of Physicians*

Disclaimer

The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and, where appropriate, their carer or guardian.

Local commissioners and providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties.

NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the [Welsh Government](#), [Scottish Government](#), and [Northern Ireland Executive](#). All NICE guidance is subject to regular review and may be updated or withdrawn.

Copyright

© NICE 2018. All rights reserved. Subject to [Notice of rights](#).

ISBN

978-1-4731-2871-2

Contents

Appendices.....	5
Appendix A: Scope.....	5
Appendix B: Declarations of interest	17
Appendix C: Clinical review protocols.....	43
Appendix D: Health economic review protocol	134
Appendix E: Clinical study selection.....	136
Appendix F: Health economic study selection.....	139
Appendix G: Literature search strategies	140
Appendix H: Clinical evidence tables.....	154
Appendix I: References	958

Appendices

Appendix A: Scope

FINAL VERSION

NATIONAL INSTITUTE FOR HEALTH AND CARE
EXCELLENCE

Guideline scope

Venous thromboembolism in people aged 16 and over: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism

Topic

This guideline will update the NICE guideline on [Venous thromboembolism in adults admitted to hospital](#) (CG92) as set out in the [update decision](#).

For more information about why this guideline is being developed, and how the guideline will fit into current practice, see the [context](#) section.

Who the guideline is for

- People using services, families and carers and the public
- Healthcare professionals in the primary and secondary sectors
- Clinical commissioning groups

NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the [Welsh Government](#), [Scottish Government](#), and [Northern Ireland Executive](#).

Equality considerations

NICE has carried out [an equality impact assessment](#) during scoping. The assessment:

- lists equality issues identified, and how they have been addressed
- explains why any groups are excluded from the scope.

The guideline will look at inequalities relating to heparin which is derived from the tissue of pigs or cattle. If recommended we will need to ensure that people

NICE guideline: Venous thromboembolism in people aged 16 and over: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism final scope

1 of 12

with religious or personal beliefs about the use of animal-derived products are given the opportunity to express their concerns and to receive information about alternative options.

1 What the guideline is about

1.1 Who is the focus?

Groups that will be covered

- Adults and young people (16 years and older) admitted to hospital.
- Adults and young people (16 years and older) discharged from hospital (including from A&E) with lower-limb devices such as plaster casts and braces.
- Adults and young people (16 years and older) attending hospital for day procedures including cancer treatment and surgery.
- Adults and young people (16 years and older) with psychiatric illness admitted to community mental health hospitals or units.
- Special consideration will be given to:
 - pregnant women admitted to hospital and midwife units including up to 6 weeks after giving birth
 - people in whom pharmacological prophylaxis is contraindicated (**new area**)
 - people in whom mechanical prophylaxis is contraindicated (**new area**)
 - people already using anticoagulants in whom bridging prophylaxis is required for VTE prophylaxis. (**new area**)
 - people using antiplatelets for cardiovascular disease. (**new area**)
 - people who are obese
 - people who have kidney disease

Groups that will not be covered

- People with suspected or confirmed venous thromboembolism (VTE).

1.2 Settings

Settings that will be covered

- Primary and community care when continuing prophylaxis after hospital discharge.
- Secondary care.

Settings that will not be covered

- Community settings and hospices, except when continuing prophylaxis that has been started in hospital.

1.3 Activities, services or aspects of care

Key areas that will be covered

Note that guideline recommendations will normally fall within licensed indications; exceptionally, and only if clearly supported by evidence, use outside a licensed indication may be recommended. The guideline will assume that prescribers will use a medicine's summary of product characteristics to inform decisions made with individual patients.

Areas from the published guideline that will be updated

1. Risk assessment
 - Patient risk factors for venous thromboembolism (VTE)
2. Methods of prophylaxis for reducing the incidence of VTE:
 - Mechanical prophylaxis including anti-embolism stockings (above or below the knee), intermittent pneumatic compression devices (full leg or below the knee), foot impulse devices, electrical stimulation, continuous passive motion and vena caval filters
 - Pharmacological prophylaxis including aspirin, dabigatran, fondaparinux, unfractionated heparin, low molecular weight heparin (LMWH), rivaroxaban and vitamin k antagonists [for example warfarin])
 - Timing of prophylaxis
 - Duration of prophylaxis

3. Information and support
 - Content of information on prophylaxis methods and VTE provided to patients and their family members or carers.

Areas not in the published guideline that will be included in the update

1. Risk assessment
 - Risk prediction tools (for bleeding or VTE)
 - Reassessment of risk
2. Methods of prophylaxis
 - New interventions (for example apixaban and geko devices)
 - Bridging prophylaxis
 - Prophylaxis for patients already prescribed antiplatelet agents for cardiovascular disease

Areas that will not be covered

Areas from the published guideline that will not be updated

1. Methods of prophylaxis
 - Early mobilisation and leg exercises
 - Physiotherapy
 - Hydration
 - Regional compared with general anaesthetic.

Areas from the published guideline that will be removed

1. Methods of prophylaxis
 - Leg elevation

Areas not covered by the published guideline or the update

1. Secondary prevention of VTE

Recommendations in areas that are not being updated may be edited to ensure that they meet current editorial standards, and reflect the current policy and practice context.

1.4 Economic aspects

We will take economic aspects into account when making recommendations. We will develop an economic plan that states for each review question (or key area in the scope) whether economic considerations are relevant, and if so whether this is an area that should be prioritised for economic modelling and analysis. We will review the economic evidence and carry out economic analyses, using an NHS and personal social services (PSS) perspective, as appropriate.

1.5 Key issues and questions

While writing this scope we have identified the following key issues, and key questions related to them. The term 'VTE' in this section refers to both deep vein thrombosis (DVT) and pulmonary embolism (PE):

1. Risk assessment:
 - 1.1 What is the accuracy of individual risk assessment or prediction tools in predicting the likelihood of VTE in patients who are admitted to hospital?
 - 1.2 What is the accuracy of individual risk assessment or prediction tools in predicting the likelihood of VTE in patients who are having day procedures (including surgery and chemotherapy) at hospital?
 - 1.3 What is the accuracy of individual risk assessment or prediction tools in predicting the likelihood of VTE in pregnant women who are admitted to hospital or midwife units?
 - 1.4 What is the accuracy of individual risk assessment or prediction tools in predicting the likelihood of major bleeding or the risk of bleeding in patients who are admitted to hospital?
 - 1.5 What is the accuracy of individual risk assessment or prediction tools in predicting the likelihood of major bleeding or the risk of in patients who are having day procedures (including surgery and chemotherapy) at hospital?
 - 1.6 What is the accuracy of individual risk assessment or prediction tools in predicting the likelihood of major bleeding or the risk of bleeding in pregnant women who are admitted to hospital or midwife units?

1.7 How clinically and cost effective are risk assessment or prediction tools at reducing the rates of VTE in patients who are admitted to hospital?

1.8 How clinically and cost effective are risk assessment or prediction tools at reducing the rates of VTE in patients who are having day procedures (including surgery and chemotherapy) at hospital?

1.9 How clinically and cost effective are risk assessment or prediction tools at reducing the rates of VTE in pregnant women who are admitted to hospital or midwife units?

1.10 How effective is reassessment of patients who are admitted to or having day procedures at hospital?

If appropriate evidence is not identified from the questions above (1.1 to 1.10) the following 2 questions may also be considered:

1.11 What are the individual risk factors for VTE in patients who are admitted to hospital?

1.12 What are the individual risk factors for VTE in patients who are having day procedures (including surgery and chemotherapy) at hospital?

1.13 What are the individual risk factors for VTE in pregnant women who are admitted to hospital or midwife units?

2. Prophylaxis:

Each of the following questions will investigate individual populations separately. Populations include:

- people having the following types of surgery:
 - elective hip surgery
 - elective knee surgery
 - hip fracture
 - knee arthroscopy
 - other orthopaedic surgery
 - abdominal surgery (bariatric, liver, gastrointestinal, gynaecological, laparoscopic, thoracic and urological)

- cranial surgery
- spinal surgery
- cardiac surgery
- vascular surgery
- dental/maxillofacial surgery
- vaginal surgery
- people discharged with lower-limb immobilisation (including boots, braces, Plaster of Paris [POP] and other devices)
- people being treated for:
 - major trauma
 - spinal injury
 - stroke
 - acute coronary syndromes
 - cancer
- people attending hospital as medical admissions
- people with central venous catheters
- people having palliative care
- pregnant women and up to 6 weeks after giving birth
- people with psychiatric disorders
- people who are obese
- people with kidney disease.

Each of the questions will consider the following settings, if appropriate: people in hospital and those having day procedures (including surgery, chemotherapy)

Each of the questions will include the following prophylaxis methods, if applicable:

- mechanical prophylaxis, including:
 - anti-embolism stockings (above or below knee)
 - intermittent pneumatic compression devices (full leg or below knee)
 - foot impulse devices
 - electrical stimulation (including geko devices)

- continuous passive motion
- vena caval filters.
- pharmacological prophylaxis, including:
 - apixaban
 - aspirin
 - dabigatran
 - fondaparinux
 - unfractionated heparin
 - low molecular weight heparin (LMWH)
 - rivaroxaban
 - vitamin k antagonists (for example warfarin).

2.1 What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination)?

2.2 What is the effectiveness of vena caval filters in people admitted to hospital who are at high risk of DVT or PE admitted to hospital?

2.3 What is the most effective timing for starting prophylaxis with LMWH for people having surgery?

2.4 What is the most effective prophylaxis duration (covering the time in hospital only or continuing after discharge)?

2.5 What is the most effective prophylaxis strategy for inpatients in whom pharmacological prophylaxis is contraindicated?

2.6 What is the most effective prophylaxis strategy for inpatients in whom mechanical prophylaxis is contraindicated?

2.7 What is the most effective prophylaxis strategy for patients in whom both mechanical and pharmacological prophylaxis are contraindicated?

2.8 What is the most effective VTE prophylaxis strategy for bridging patients who are already using anticoagulants agents for other reasons?

2.9 What is the most effective VTE prophylaxis strategy in managing patients who are already using antiplatelets for cardiovascular disease?

2.10 What is the most effective VTE prophylaxis strategy for pregnant women admitted to hospital or a midwifery-led unit during labour?

3. Information for patients, family members and carers:
 - 3.1 What specific information should be provided to people who need VTE prophylaxis?
 - 3.2 What information do patients, their family members and carers say they want about VTE prophylaxis?

1.6 Main outcomes

The main outcomes that will be considered when searching for and assessing the evidence are:

1. All-cause mortality
2. Pulmonary embolism
3. Fatal pulmonary embolism
4. Deep vein thrombosis (symptomatic or asymptomatic)
5. Major bleeding
6. Fatal bleeding
7. Heparin-induced thrombocytopenia
8. Post-thrombotic syndrome
9. Pulmonary hypertension
10. Quality of life (validated scores)
11. Hospital length of stay
12. Readmission
13. Neurological events (for example haemorrhagic stroke)

2 Links with other NICE guidance, NICE quality standards and NICE Pathways

2.1 NICE guidance

- [Venous thromboembolism in adults admitted to hospital: reducing the risk](#) (2010) NICE guideline CG92
- [Venous thromboembolic diseases: the management of venous thromboembolic diseases and the role of thrombophilia testing](#) (2012) NICE clinical guideline 144
- [Caesarean section](#) (2011) NICE clinical guideline 132

NICE guideline: Venous thromboembolism in people aged 16 and over: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism final scope

9 of 12

- [Stroke: Diagnosis and initial management of acute stroke and transient ischaemic attack \(TIA\) \(2008\) NICE clinical guideline 68.](#)
- [Apixaban for the prevention of venous thromboembolism after total hip or knee replacement in adults \(2012\) NICE technology appraisal 245](#)
- [Dabigatran etexilate for the prevention of venous thromboembolism after hip or knee replacement surgery in adults \(2008\) NICE technology appraisal 157.](#)
- [Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults \(2009\) NICE technology appraisal 170](#)
- [The geko device for reducing the risk of venous thromboembolism \(2014\) NICE medical technology guidance 19.](#)

NICE guidance that will be updated by this guideline

- [Venous thromboembolism in adults admitted to hospital: reducing the risk \(2010\) NICE guideline CG92](#)

NICE guidance about the experience of people using NHS services

NICE has produced the following guidance on the experience of people using the NHS. This guideline will not include additional recommendations on these topics unless there are specific issues related to VTE:

- [Patient experience in adult NHS services \(2012\) NICE guideline CG138](#)
- [Service user experience in adult mental health \(2011\) NICE guideline CG136](#)
- [Medicines adherence \(2009\) NICE guideline CG76](#)

2.2 NICE quality standards

NICE quality standards that may need to be revised or updated when this guideline is published

- [Venous thromboembolism prevention \(2010\) NICE quality standard 3.](#)

2.3 NICE Pathways

When this guideline is published it will update the existing NICE pathway on [venous thromboembolism](#). NICE Pathways bring together all related NICE

NICE guideline: Venous thromboembolism in people aged 16 and over: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism final scope

10 of 12

guidance and associated products on a topic in an interactive topic-based flow chart.

3 Context

3.1 Key facts and figures

Hospital acquired venous thromboembolism, also known as hospital acquired thrombosis (HAT), covers all venous thromboembolism (VTE) that occurs in hospital and for 90 days after a hospital admission. Epidemiological studies have shown that HAT accounts for somewhere between 50-60% of all VTE seen. Hospital Episode Statistics showed that in 2013–14 there were 24,725 admissions for pulmonary embolism and 19,463 for DVT in England, resulting in 205,448 and 67,028 bed-days and 47,594 and 25,958 finished consultant episodes respectively. In 2013, in England and Wales there were 2,191 deaths recorded as due to pulmonary embolism (PE) and 2,816 due to deep vein thrombosis (DVT), but the actual number of people dying from these conditions is likely to be higher because of misdiagnosis and the failure to recognise VTE as the underlying cause. Thus hospital-acquired VTE accounts for thousands of deaths annually in the UK.

3.2 Current practice

In 2010, the CQUIN target introduced a payment linked to at least 90% of adults being risk assessed on admission to hospital. Figures reporting the uptake of some of the recommendations in CG92 are reported on [NICE's website](#). Recent evidence also estimates that the national mortality rate from VTE has fallen by 8–9% since the recommendations in CG92 were introduced.

In addition, since the publication of the last version of the guideline, [CG92](#), two new interventions for preventing venous thromboembolism (VTE) have become available: apixaban and geko devices.

3.3 Policy, legislation, regulation and commissioning

Policy

The [National VTE prevention programme](#) was launched in England in 2010 by the Department of Health. This included the mandatory VTE risk assessment of 90% (later increased to 95%) of all people admitted to hospital. A risk assessment tool was created by the Department of Health and this was incorporated into the last version of this guideline. Risk assessment will be a key part of this update.

4 Further information

Registered stakeholders were consulted with on the draft scope between 11 December 2015 and 20 January 2016.

The guideline is expected to be published in February 2018.

You can follow progress of the [guideline](#).

Our website has information about how [NICE guidelines](#) are developed.

Appendix B: Declarations of interest

The September 2014 version of the NICE code of practice for declaring and dealing with conflicts of interest policy was applied to this guideline.

Peter Barry (Chair from April 2017)

Committee meeting	Declaration of interest	Classification	Action taken
First meeting (02.03.2016)	Not yet recruited	N/A	N/A
Second meeting (22.04.2016)	Not yet recruited	N/A	N/A
Third meeting (01.06.2016)	Not yet recruited	N/A	N/A
Fourth meeting (20.07.2016)	Not yet recruited	N/A	N/A
Fifth meeting (16.09.2016)	Not yet recruited	N/A	N/A
Sixth meeting (19.10.2016)	Not yet recruited	N/A	N/A
Seventh meeting (01.12.2016)	Not yet recruited	N/A	N/A
Eight meeting (05.01.2017)	Not yet recruited	N/A	N/A
Ninth meeting (08.02.2017)	Not yet recruited	N/A	N/A
Tenth meeting (09.02.2017)	Not yet recruited	N/A	N/A
Eleventh meeting (15.03.2017)	Not yet recruited	N/A	N/A
Twelfth meeting (19.04.2017)	None	N/A	N/A
Thirteenth meeting (25.05.2017)	None	N/A	N/A
Fourteenth meeting	None	N/A	N/A

Committee meeting	Declaration of interest	Classification	Action taken
(26.05.2017)			
Fifteenth meeting (22.06.2017)	<p>Attended an educational meeting on the subject of paediatric critical care transport, where the company CareFusion sponsored room hire, lunch and mid - afternoon refreshments.</p> <p>The meeting was not about Venous ThromboEmbolism, and as far as I am aware, CareFusion do not market any of the interventions under consideration by the committee.</p> <p>I was not paid to attend the meeting.</p>	Personal non-financial non-specific	Declare and participate
Sixteenth meeting (28.07.2017)	No change to existing declarations	N/A	N/A
Seventeenth meeting (07.12.2017)	No change to existing declarations	N/A	N/A

Jagjot Chahal

Committee meeting	Declaration of interest	Classification	Action taken
First meeting (02.03.2016)	Not yet recruited	N/A	N/A
Second meeting (22.04.2016)	Not yet recruited	N/A	N/A
Third meeting (01.06.2016)	None	N/A	N/A
Fourth meeting (20.07.2016)	None	N/A	N/A
Fifth meeting (16.09.2016)	None	N/A	N/A
Sixth meeting (19.10.2016)	None	N/A	N/A
Seventh meeting (01.12.2016)	None	N/A	N/A
Eight meeting	None	N/A	N/A

Committee meeting	Declaration of interest	Classification	Action taken
(05.01.2017)			
Ninth meeting (08.02.2017)	None	N/A	N/A
Tenth meeting (09.02.2017)	None	N/A	N/A
Eleventh meeting (15.03.2017)	None	N/A	N/A
Twelfth meeting (19.04.2017)	Abstract accepted for the ISTH 2017 conference on the safety and cost-effectiveness of LMWH in comparison to NOACs for treatment indications.	Personal non-financial specific	Declare and participate
Thirteenth meeting (25.05.2017)	No change to existing declarations.	N/A	N/A
Fourteenth meeting (26.05.2017)	No change to existing declarations	N/A	N/A
Fifteenth meeting (22.06.2017)	No change to existing declarations	N/A	N/A
Sixteenth meeting (28.07.2017)	Publication of a CPD learning article in the Pharmaceutical Journal: Heparin-induced thrombocytopenia.	Personal non-financial specific	Declare and participate
Seventeenth meeting (07.12.2017)	No change to existing declarations	N/A	N/A

Deepak Chandra

Committee meeting	Declaration of interest	Classification	Action taken
On application	None	N/A	N/A
First meeting (02.03.2016)	No change to existing declarations	N/A	N/A
Second meeting (22.04.2016)	No change to existing declarations	N/A	N/A
Third meeting (01.06.2016)	Pharmaceutical company support for venue hire, catering cost and keynote speaker for launch of thrombosis and anticoagulation services.	Non-personal financial specific	Declare and participate

Committee meeting	Declaration of interest	Classification	Action taken
Fourth meeting (20.07.2016)	No change to existing declarations	N/A	N/A
Fifth meeting (16.09.2016)	No change to existing declarations	N/A	N/A
Sixth meeting (19.10.2016)	No change to existing declarations	N/A	N/A
Seventh meeting (01.12.2016)	No change to existing declarations	N/A	N/A
Eight meeting (05.01.2017)	No change to existing declarations	N/A	N/A
Ninth meeting (08.02.2017)	No change to existing declarations	N/A	N/A
Tenth meeting (09.02.2017)	No change to existing declarations	N/A	N/A
Eleventh meeting (15.03.2017)	No change to existing declarations	N/A	N/A
Twelfth meeting (19.04.2017)	No change to existing declarations	N/A	N/A
Thirteenth meeting (25.05.2017)	Apologies received	N/A	N/A
Fourteenth meeting (26.05.2017)	No change to existing declarations	N/A	N/A
Fifteenth meeting (22.06.2017)	Participation in APEX study as a site investigator. Did not have any role in design of study or data review and final publication Betrixaban was not included in any review protocol for this guideline.	Personal non-financial non-specific	Declare and participate
Sixteenth meeting (28.07.2017)	Apologies received	N/A	N/A
Seventeenth meeting (07.12.2017)	No change to existing declarations	N/A	N/A

Sarah Chissell (obstetric subgroup member)

Committee meeting	Declaration of interest	Classification	Action taken
First meeting (14.03.2017)	None	N/A	N/A
Second meeting (24.05.2017)	None	N/A	N/A

Ian Donald

Committee meeting	Declaration of interest	Classification	Action taken
On application	<p>Took part in a medical advisory panel for Vifor Pharmaceuticals in 2015.</p> <p>Secondary Care Member of the Board for Bristol Clinical Commissioning Group.</p>	Personal financial non-specific	Declare and participate
First meeting (02.03.2016)	No change to existing declarations	N/A	N/A
Second meeting (22.04.2016)	No change to existing declarations	N/A	N/A
Third meeting (01.06.2016)	No change to existing declarations	N/A	N/A
Fourth meeting (20.07.2016)	No change to existing declarations	N/A	N/A
Fifth meeting (16.09.2016)	No change to existing declarations	N/A	N/A
Sixth meeting (19.10.2016)	No change to existing declarations	N/A	N/A
Seventh meeting (01.12.2016)	No change to existing declarations	N/A	N/A
Eight meeting (05.01.2017)	No change to existing declarations	N/A	N/A
Ninth meeting (08.02.2017)	No change to existing declarations	N/A	N/A
Tenth meeting (09.02.2017)	No change to existing declarations	N/A	N/A
Eleventh	No change to existing	N/A	N/A

Committee meeting	Declaration of interest	Classification	Action taken
meeting (15.03.2017)	declarations		
Twelfth meeting (19.04.2017)	No change to existing declarations	N/A	N/A
Thirteenth meeting (25.05.2017)	Apologies received.	N/A	N/A
Fourteenth meeting (26.05.2017)	No change to existing declarations	N/A	N/A
Fifteenth meeting (22.06.2017)	No change to existing declarations	N/A	N/A
Sixteenth meeting (28.07.2017)	No change to existing declarations	N/A	N/A
Seventeenth meeting (07.12.2017)	Apologies received	N/A	N/A

Xavier Griffin

Committee meeting	Declaration of interest	Classification	Action taken
On application	Co-editor Bone Joint and Musculoskeletal Trauma Cochrane Group with multiple systematic reviews in trauma surgery.	Personal non-financial specific	Declare and participate
	Grants (paid to University) from X-Bolt Orthopaedics for two investigator-initiated, industry funded randomised trials testing a novel implant for hip fracture fixation.	Non-personal financial non-specific	Declare and participate
	Grant from Orthodynamics (paid to University) for investigator-initiated, industry-funded randomised trials testing a novel implant for total hip arthroplasty for fracture.	Non-personal financial non-specific	Declare and participate
	NIHR RfPB grant (paid to NHS Trust) for a randomised trial testing alternative arthroplasties for hip fracture.	Non-personal financial non-specific	Declare and participate
First meeting	No change to existing declarations	N/A	N/A

Committee meeting	Declaration of interest	Classification	Action taken
(02.03.2016)			
Second meeting (22.04.2016)	No change to existing declarations	N/A	N/A
Third meeting (01.06.2016)	No change to existing declarations	N/A	N/A
Fourth meeting (20.07.2016)	No change to existing declarations	N/A	N/A
Fifth meeting (16.09.2016)	No change to existing declarations	N/A	N/A
Sixth meeting (19.10.2016)	No change to existing declarations	N/A	N/A
Seventh meeting (01.12.2016)	No change to existing declarations	N/A	N/A
Eight meeting (05.01.2017)	No change to existing declarations	N/A	N/A
Ninth meeting (08.02.2017)	No change to existing declarations	N/A	N/A
Tenth meeting (09.02.2017)	No change to existing declarations	N/A	N/A
Eleventh meeting (15.03.2017)	Joining lower limb immobilisation modelling study for HTA as a stakeholder member. Study not yet started. https://www.sheffield.ac.uk/sc-harr/sections/hsr/cure/projects/tilli	Non-personal financial specific	Declare and participate
Twelfth meeting (19.04.2017)	No change to existing declarations	N/A	N/A
Thirteenth meeting (25.05.2017)	No change to existing declarations	N/A	N/A
Fourteenth meeting (26.05.2017)	No change to existing declarations	N/A	N/A
Fifteenth meeting (22.06.2017)	No change to existing declarations	N/A	N/A
Sixteenth	No change to existing	N/A	N/A

Committee meeting	Declaration of interest	Classification	Action taken
meeting (28.07.2017)	declarations		
Seventeenth meeting (07.12.2017)	No change to existing declarations	N/A	N/A

Nihal Gurusinghe (co-opted member)

Committee meeting	Declaration of interest	Classification	Action taken
Eight meeting (05.01.2017)	None	N/A	N/A
Twelfth meeting (19.04.2017)	None	N/A	N/A

Elizabeth Houghton

Committee meeting	Declaration of interest	Classification	Action taken
First meeting (02.03.2016)	None	N/A	N/A
Second meeting (22.04.2016)	None	N/A	N/A
Third meeting (01.06.2016)	None	N/A	N/A
Fourth meeting (20.07.2016)	None	N/A	N/A
Fifth meeting (16.09.2016)	None	N/A	N/A
Sixth meeting (19.10.2016)	None	N/A	N/A
Seventh meeting (01.12.2016)	None	N/A	N/A
Eight meeting (05.01.2017)	None	N/A	N/A
Ninth meeting (08.02.2017)	None	N/A	N/A
Tenth	None	N/A	N/A

Committee meeting	Declaration of interest	Classification	Action taken
meeting (09.02.2017)			
Eleventh meeting (15.03.2017)	None	N/A	N/A
Twelfth meeting (19.04.2017)	None	N/A	N/A
Thirteenth meeting (25.05.2017)	None	N/A	N/A
Fourteenth meeting (26.05.2017)	None	N/A	N/A
Fifteenth meeting (22.06.2017)	Apologies received.	N/A	N/A
Sixteenth meeting (28.07.2017)	None	N/A	N/A
Seventeenth meeting (07.12.2017)	None	N/A	N/A

Beverley Hunt

Committee meeting	Declaration of interest	Classification	Action taken
On application	Medical director and trustee of Thrombosis UK.	Personal non-financial specific	Declare and participate
First meeting (02.03.2016)	Thrombosis UK now accepts payment from pharmaceutical companies. BH has previously declared her involvement with Thrombosis UK.	Non-personal financial specific	Declare and participate
Second meeting (22.04.2016)	No change to existing declarations	N/A	N/A
Third meeting (01.06.2016)	Apologies received	N/A	N/A
Fourth meeting (20.07.2016)	Apologies received	N/A	N/A
Fifth meeting (16.09.2016)	No change to existing declarations	N/A	N/A
Sixth meeting (19.10.2016)	No change to existing declarations	N/A	N/A

Committee meeting	Declaration of interest	Classification	Action taken
Seventh meeting (01.12.2016)	Attended the All-party parliamentary thrombosis group (APPTG) round table.	Personal non-financial specific	Declare and participate
Eight meeting (05.01.2017)	No change to existing declarations	N/A	N/A
Ninth meeting (08.02.2017)	Principal Investigator for NIHR funded trial of stockings for VTE prophylaxis in surgical patients	Non-personal financial specific	Declare and participate
Tenth meeting (09.02.2017)	No change to existing declarations	N/A	N/A
Eleventh meeting (15.03.2017)	<p>Declared 20 recent articles 4 related to VTE prophylaxis. None applicable to topic under discussion:</p> <ol style="list-style-type: none"> Hunt BJ. The effect of BMI on haemostasis: Implications for thrombosis in women's health. <i>Thrombosis Research</i>. 2017; 151 Suppl 1:S53-s55 ISTH Steering Committee for World Thrombosis Day. Venous thromboembolism: A Call for risk assessment in all hospitalised patients. <i>Thrombosis and Haemostasis</i>. 2016; 116(5):777-779 Humes DJ, Walker AJ, Hunt BJ, Sultan AA, Ludvigsson JF, West J. Risk of symptomatic venous thromboembolism following emergency appendicectomy in adults. <i>British Journal of Surgery</i>. 2016; 103(4):443-450 Hunt BJ. Blood clots are more common (and deadly) than you may think. <i>Huffington Post</i>. 2016. Full text available from: http://www.huffingtonpost.co.uk/dr-beverley-hunt/blood-clots-are-more-comm_b_12466180.html 	Personal non-financial non-specific	Declare and participate
Twelfth meeting (19.04.2017)	Apologies received	N/A	N/A

Committee meeting	Declaration of interest	Classification	Action taken
Thirteenth meeting (25.05.2017)	No change to existing declarations	N/A	N/A
Fourteenth meeting (26.05.2017)	No change to existing declarations	N/A	N/A
Fifteenth meeting (22.06.2017)	No change to existing declarations	N/A	N/A
Sixteenth meeting (28.07.2017)	Chaired meeting Thrombosis TB.	Personal non-financial non-specific interest	Declare and participate
Seventeenth meeting (07.12.2017)	No change to existing declarations	N/A	N/A

Josie Jenkinson (co-opted member)

Committee meeting	Declaration of interest	Classification	Action taken
Ninth meeting (08.02.2017)	None	N/A	N/A

Nicholas Levy (co-opted member)

Committee meeting	Declaration of interest	Classification	Action taken
On application	None	N/A	N/A

Donald McBride (orthopaedic subgroup member)

Committee meeting	Declaration of interest	Classification	Action taken
First meeting (24.06.2016)	None	N/A	N/A
Second meeting (20.10.2016)	None	N/A	N/A
Third meeting (27.01.2017)	None	N/A	N/A
Fourth meeting (31.03.2017)	None	N/A	N/A
Fifth meeting (26.05.2017)	None	N/A	N/A
Sixth meeting (22.06.2017)	None	N/A	N/A

Colin Nnadi (orthopaedic subgroup member)

Committee meeting	Declaration of interest	Classification	Action taken
First meeting (24.06.2016)	None	N/A	N/A
Second meeting (20.10.2016)	None	N/A	N/A
Third meeting (27.01.2017)	None	N/A	N/A
Fourth meeting (31.03.2017)	None	N/A	N/A
Fifth meeting (26.05.2017)	None	N/A	N/A
Sixth meeting (22.06.2017)	None	N/A	N/A

Simon Noble

Committee meeting	Declaration of interest	Classification	Action taken
On application	Has given lectures for Leo Pharma and Pfizer in the past 12 months; no fee taken.	Non-personal non-financial specific	Declare and participate
	Medical Director (Wales) for Thrombosis UK (formerly Lifeblood).	Personal non-financial specific	Declare and participate
First meeting (02.03.2016)	Thrombosis UK now accepts payment from pharmaceutical companies. SN has previously declared his involvement with Thrombosis UK.	Non-personal financial specific	Declare and participate
Second meeting (22.04.2016)	No change to existing declarations	N/A	N/A
Third meeting (01.06.2016)	Apologies received	N/A	N/A
Fourth meeting (20.07.2016)	Apologies received	N/A	N/A
Fifth meeting (16.09.2016)	No change to existing declarations	N/A	N/A
Sixth	No change to existing	N/A	N/A

Committee meeting	Declaration of interest	Classification	Action taken
meeting (19.10.2016)	declarations		
Seventh meeting (01.12.2016)	No change to existing declarations	N/A	N/A
Eight meeting (05.01.2017)	No change to existing declarations	N/A	N/A
Ninth meeting (08.02.2017)	No change to existing declarations	N/A	N/A
Tenth meeting (09.02.2017)	No change to existing declarations	N/A	N/A
Eleventh meeting (15.03.2017)	Apologies received	N/A	N/A
Twelfth meeting (19.04.2017)	Apologies received	N/A	N/A
Thirteenth meeting (25.05.2017)	No change to existing declarations	N/A	N/A
Fourteenth meeting (26.05.2017)	Apologies received	N/A	N/A
Fifteenth meeting (22.06.2017)	Apologies received	N/A	N/A
Sixteenth meeting (28.07.2017)	Apologies received	N/A	N/A
Seventeenth meeting (07.12.2017)	No change to existing declarations	N/A	N/A

Rachel Rayment (obstetric subgroup member)

Committee meeting	Declaration of interest	Classification	Action taken
On application	Attendance at Bayer annual expert clotters meeting 2016 (travel, accommodation and food).	Personal financial specific	Declare and participate (relates to accepted expenses under DOI policy)
First meeting (14.03.2017)	Bayer annual expert clotters meeting 2017. CSL expenses for EAHAD 2017	Personal, financial, specific	Declare and participate (relates to accepted expenses under DOI policy)
Second meeting (24.05.2017)	No change to existing declarations.	N/A	N/A

Mike Reed (orthopaedic subgroup member)

Committee meeting	Declaration of interest	Classification	Action taken
On application	<p>No links to manufacturers or bodies involved in VTE.</p> <p>Grants:</p> <p>Academic Health Science Network - NENC and Heraeus Medical - Spreading the use of high dose antibiotic cement to prevent infection following surgery for hip fracture (lead applicant) -£84,452</p> <p>Stryker - A randomised multicentre trial of 964 patients comparing the Thompsons stem with the Exeter/unitrax for hemiarthroplasty (chief investigator) £313,003 with treatment costs</p> <p>Heraeus Medical GMBH - Investigation of NucB anti-biofilm role in joints (co-applicant) £84,000</p> <p>Zimmer Educational fellowship grant £45,923</p> <p>Convatec Clinical audit: £30,000</p> <p>Speaker fees:</p> <p>Zimmer Biomet Heraeus</p>	<p>Non-personal, financial, non-specific</p> <p>Non-personal, financial, non-specific</p> <p>Non-personal, financial, non-specific</p> <p>Non-personal, financial, non-specific</p> <p>Non-personal, financial, non-specific</p> <p>Non-personal, financial, non-specific</p> <p>Personal, financial, non-specific Personal, financial, non-specific</p>	<p>Declare and participate</p> <p>Declare and participate</p> <p>Declare and participate</p> <p>Declare and participate</p> <p>Declare and participate</p> <p>Declare and participate</p> <p>Declare and participate</p> <p>Declare and participate</p>
First meeting (24.06.2016)	No change to existing declarations.	N/A	N/A
Second meeting (20.10.2016)	No change to existing declarations	N/A	N/A
Third meeting (27.01.2017)	No change to existing declarations	N/A	N/A

Committee meeting	Declaration of interest	Classification	Action taken
Fourth meeting (31.03.2017)	No changes to existing declarations	N/A	N/A
Fifth meeting (26.05.2017)	None	N/A	N/A
Sixth meeting (22.06.2017)	None	N/A	N/A

Alexandra Rees

Committee meeting	Declaration of interest	Classification	Action taken
First meeting (02.03.2016)	None	N/A	N/A
Second meeting (22.04.2016)	None	N/A	N/A
Third meeting (01.06.2016)	Apologies received	N/A	N/A
Fourth meeting (20.07.2016)	None	N/A	N/A
Fifth meeting (16.09.2016)	None	N/A	N/A
Sixth meeting (19.10.2016)	None	N/A	N/A
Seventh meeting (01.12.2016)	None	N/A	N/A
Eight meeting (05.01.2017)	None	N/A	N/A
Ninth meeting (08.02.2017)	None	N/A	N/A
Tenth meeting (09.02.2017)	None	N/A	N/A
Eleventh meeting (15.03.2017)	None	N/A	N/A
Twelfth meeting (19.04.2017)	None	N/A	N/A

Committee meeting	Declaration of interest	Classification	Action taken
Thirteenth meeting (25.05.2017)	None	N/A	N/A
Fourteenth meeting (26.05.2017)	Apologies received	N/A	N/A
Fifteenth meeting (22.06.2017)	None	N/A	N/A
Sixteenth meeting (28.07.2017)	None	N/A	N/A
Seventeenth meeting (07.12.2017)	Apologies received	N/A	N/A

Nigel Rossiter (orthopaedic subgroup member)

Committee meeting	Declaration of interest	Classification	Action taken
First meeting (24.06.2016)	Director OrthoISIS Medical Indemnity Insurance Scheme (remunerated)	Personal financial non-specific	Declare and participate
	Trustee Primary Trauma Care Foundation charity (not remunerated)	Personal non-financial non-specific	Declare and participate
Second meeting (20.10.2016)	No change to existing declarations	N/A	N/A
Third meeting (27.01.2017)	No change to existing declarations	N/A	N/A
Fourth meeting (31.03.2017)	No change to existing declarations	N/A	N/A
Fifth meeting (26.05.2017)	None	N/A	N/A
Sixth meeting (22.06.2017)	None	N/A	N/A

Karen Sheares

Committee meeting	Declaration of interest	Classification	Action taken
On application	Received educational support (travel, accommodation and registration) from GSK to attend the European Respiratory Society Annual	Personal financial non-specific	Declare and participate (relates to accepted expenses under DOI policy)

Committee meeting	Declaration of interest	Classification	Action taken
	Congress in September 2015.		
First meeting (02.03.2016)	No change to existing declarations	N/A	N/A
Second meeting (22.04.2016)	No change to existing declarations	N/A	N/A
Third meeting (01.06.2016)	Giving a VTE update lecture for the Royal College of Physicians in June 2016.	Personal non-financial specific	Declare and participate
Fourth meeting (20.07.2016)	No change to existing declarations	N/A	N/A
Fifth meeting (16.09.2016)	No change to existing declarations	N/A	N/A
Sixth meeting (19.10.2016)	Educational support to attend the Annual European respiratory Society International Conference from Actelion (paid for registration).	Personal financial non-specific	Declare and participate (relates to accepted expenses under DOI policy)
Seventh meeting (01.12.2016)	No change to existing declarations	N/A	N/A
Eight meeting (05.01.2017)	No change to existing declarations	N/A	N/A
Ninth meeting (08.02.2017)	No change to existing declarations	N/A	N/A
Tenth meeting (09.02.2017)	No change to existing declarations	N/A	N/A
Eleventh meeting (15.03.2017)	No change to existing declarations	N/A	N/A
Twelfth meeting (19.04.2017)	Apologies received. Receiving educational support (registration, accommodation and travel) from Actelion to attend the American Thoracic Society Annual Congress in May 2017.	Personal financial non-specific	Declare and participate (relates to accepted expenses under DOI policy)
Thirteenth meeting (25.05.2017)	No new DOIs	N/A	N/A
Fourteenth meeting (26.05.2017)	No new DOIs	N/A	N/A

Committee meeting	Declaration of interest	Classification	Action taken
Fifteenth meeting (22.06.2017)	Apologies received	N/A	N/A
Sixteenth meeting (28.07.2017)	Apologies received	N/A	N/A
Seventeenth meeting (07.12.2017)	Educational support from Actelion for: American Thoracic Society Annual Meeting in Washington May 2017- registration fee, travel and accommodation Registration fee to attend the International Chronic Thromboembolic Pulmonary Hypertension Conference June 2017 in Leuven, Belgium Skills, Excellence and Leadership in Pulmonary Hypertension Clinical Leadership Training Programme with the University of Cambridge Judge Business School from Nov 2017	Personal financial non-specific Personal financial specific Personal financial non-specific	Declare and participate (relates to accepted expenses under the DoI policy) Declare and participate (relates to accepted expenses under the DoI policy) Declare and participate (relates to accepted expenses under the DoI policy)

Kimberley Skinner (obstetric subgroup member)

Committee meeting	Declaration of interest	Classification	Action taken
First meeting (14.03.2017)	None	N/A	N/A
Second meeting (24.05.2017)	None	N/A	N/A

Gerard Stansby (Chair from September 2015-March 2017; Clinical Lead from April 2017)

Committee meeting	Declaration of interest	Classification	Action taken
First meeting (02.03.2016)	None	N/A	N/A
Second meeting (22.04.2016)	None	N/A	N/A
Third	None	N/A	N/A

Committee meeting	Declaration of interest	Classification	Action taken
meeting (01.06.2016)			
Fourth meeting (20.07.2016)	None	N/A	N/A
Fifth meeting (16.09.2016)	None	N/A	N/A
Sixth meeting (19.10.2016)	None	N/A	N/A
Seventh meeting (01.12.2016)	None	N/A	N/A
Eight meeting (05.01.2017)	None	N/A	N/A
Ninth meeting (08.02.2017)	<p>Author on two systematic reviews for VTE prophylaxis:</p> <ul style="list-style-type: none"> thigh versus knee length stockings in postoperative surgical patients Cochrane review of IPCD plus pharmacological prophylaxis in surgical, trauma or ICU patients 	Personal non-financial specific	Declare and step down as Chair, participation as committee member thereafter
Tenth meeting (09.02.2017)	No change to existing declarations.	N/A	N/A
Eleventh meeting (15.03.2017)	<p>Paper to be published for protocol relating to research, not any results.</p> <p>Graduated compression stockings as an adjunct to low dose low molecular weight heparin in venous thromboembolism prevention in surgery - a multi-centre randomised controlled trial [ISRCTN13911492] by Mr. Joseph Shalhoub, John Norrie; Christopher Baker; Andrew Bradbury; Karen Dhillon; Tamara Everington; Manj Gohel; Zaed Hamady; Francine Heatley; Jemma Hudson; Beverley J Hunt; Gerard Stansby; Annya Stephens-Boal; David Warwick; Alun H Davies is accepted by the European</p>	Personal non-financial specific	Declare and participate

Committee meeting	Declaration of interest	Classification	Action taken
	Journal of Vascular and Endovascular Surgery.		
Twelfth meeting (19.04.2017)	GAPS protocol (ISRCTN13911492) declared at last committee meeting for which Gerry is one of the authors has now been published.	Personal non-financial specific	Declare and participate
Thirteenth meeting (25.05.2017)	No change to existing declarations	N/A	N/A
Fourteenth meeting (26.05.2017)	No change to existing declarations	N/A	N/A
Fifteenth meeting (22.06.2017)	No change to existing declarations	N/A	N/A
Sixteenth meeting (28.07.2017)	No change to existing declarations	N/A	N/A
Seventeenth meeting (07.12.2017)	No change to existing declarations	No change to existing declarations	No change to existing declarations

Hazel Trender

Committee meeting	Declaration of interest	Classification	Action taken
First meeting (02.03.2016)	None	N/A	N/A
Second meeting (22.04.2016)	None	N/A	N/A
Third meeting (01.06.2016)	None	N/A	N/A
Fourth meeting (20.07.2016)	Apologies received	N/A	N/A
Fifth meeting (16.09.2016)	None	N/A	N/A
Sixth meeting (19.10.2016)	None	N/A	N/A
Seventh meeting (01.12.2016)	None	N/A	N/A
Eight	Sponsored by MEDI UK to	Personal non-financial	Declare and participate

Committee meeting	Declaration of interest	Classification	Action taken
meeting (05.01.2017)	attend the vascular Society annual conference in Manchester in November 2016. This included accommodation and registration. MED1 manufacture compression hosiery amongst other things.	specific	(relates to accepted expenses under the DoI policy)
Ninth meeting (08.02.2017)	No change to existing declarations	N/A	N/A
Tenth meeting (09.02.2017)	No change to existing declarations	N/A	N/A
Eleventh meeting (15.03.2017)	No change to existing declarations	N/A	N/A
Twelfth meeting (19.04.2017)	No change to existing declarations	N/A	N/A
Thirteenth meeting (25.05.2017)	No change to existing declarations	N/A	N/A
Fourteenth meeting (26.05.2017)	Apologies received	N/A	N/A
Fifteenth meeting (22.06.2017)	No change to existing declarations	N/A	N/A
Sixteenth meeting (28.07.2017)	No change to existing declarations	N/A	N/A
Seventeenth meeting (07.12.2017)	No change to existing declarations	N/A	N/A

Jen Watson

Committee meeting	Declaration of interest	Classification	Action taken
First meeting (02.03.2016)	LEO Pharma has sponsored masterclasses at the Marsden hospital; no direct involvement in organizing these. Paid for article written in the Nursing Times on VTE and thrombosis.	Non-personal financial specific Personal financial specific	Declare and participate Declare and participate (Educational article. Nursing Times does not fund or gain from any product relating to

Committee meeting	Declaration of interest	Classification	Action taken
			VTE)
Second meeting (22.04.2016)	Approached by Anti-coagulation and Leo Pharma to work alongside them in raising awareness. Discussions are preliminary but may use the Leo Pharma Patient Education film as part of our patient and staff education amongst patients and staff.	Non-personal non-financial specific	Declare and participate
Third meeting (01.06.2016)	No change to existing declarations	N/A	N/A
Fourth meeting (20.07.2016)	No change to existing declarations	N/A	N/A
Fifth meeting (16.09.2016)	No change to existing declarations	N/A	N/A
Sixth meeting (19.10.2016)	Attended the All-party parliamentary thrombosis group (APPTG) round table	Personal non-financial specific	Declare and participate
Seventh meeting (01.12.2016)	No change to existing declarations	N/A	N/A
Eight meeting (05.01.2017)	No change to existing declarations	N/A	N/A
Ninth meeting (08.02.2017)	No change to existing declarations	N/A	N/A
Tenth meeting (09.02.2017)	No change to existing declarations	N/A	N/A
Eleventh meeting (15.03.2017)	No change to existing declarations	N/A	N/A
Twelfth meeting (19.04.2017)	Apologies received	N/A	N/A
Thirteenth meeting (25.05.2017)	No change to existing declarations	N/A	N/A
Fourteenth meeting (26.05.2017)	Apologies received	N/A	N/A
Fifteenth meeting (22.06.2017)	Apologies received	N/A	N/A

Committee meeting	Declaration of interest	Classification	Action taken
Sixteenth meeting (28.07.2017)	No change to existing declarations	N/A	N/A
Seventeenth meeting (07.12.2017)	Apologies received	N/A	N/A

Martin Yates

Committee meeting	Declaration of interest	Classification	Action taken
First meeting (02.03.2016)	None	N/A	N/A
Second meeting (22.04.2016)	Guest Speaker – VTE Patient Experience – Thrombosis UK. Travel expenses only.	Personal non-financial specific	Declare and participate
	VTE Patient Experience Story – Hayward Medical Communications	Personal non-financial specific	
	Volunteer - Patient Experience Panel – Papworth Hospital	Personal non-financial specific	
Third meeting (01.06.2016)	Apologies received	N/A	N/A
Fourth meeting (20.07.2016)	No change to existing declarations	N/A	N/A
Fifth meeting (16.09.2016)	No change to existing declarations	N/A	N/A
Sixth meeting (19.10.2016)	No change to existing declarations	N/A	N/A
Seventh meeting (01.12.2016)	No change to existing declarations	N/A	N/A
Eighth meeting (05.01.2017)	No change to existing declarations	N/A	N/A
Ninth meeting (08.02.2017)	No change to existing declarations	N/A	N/A
Tenth meeting (09.02.2017)	No change to existing declarations	N/A	N/A

Committee meeting	Declaration of interest	Classification	Action taken
Eleventh meeting (15.03.2017)	No change to existing declarations	N/A	N/A
Twelfth meeting (19.04.2017)	No change to existing declarations	N/A	N/A
Thirteenth meeting (25.05.2017)	<p>I have been invited to review a research funding application for the National Institute for Health Research Central Commissioning Facility:-The Research for Patient Benefit (RfPB) Programme</p> <p>Research Title: Advanced Resuscitation Room Monitoring Study (ARMS): Randomised controlled trial to test the feasibility of comparing combined advanced minimally-invasive patient monitoring in the emergency department versus standard care.</p> <p>The RfPB programme offers reimbursement for the time and effort involved in commenting on funding applications in accordance with the Guide for CCF public contributors about the payment of fees and expenses.</p>	Personal financial non-specific	Declare and participate
Fourteenth meeting (26.05.2017)	No changes to existing declarations	N/A	N/A
Fifteenth meeting (22.06.2017)	<p>I have been invited to review a research funding application for the National Institute for Health Research Central Commissioning Facility:-The Research for Patient Benefit (RfPB) Programme</p> <p>Research Title: Advanced Resuscitation Room Monitoring Study (ARMS): Randomised controlled trial to test the feasibility of comparing combined advanced minimally-invasive patient monitoring in the emergency department versus standard care.</p> <p>The RfPB programme offers reimbursement for the time</p>	Personal financial non-specific	Declare and participate

Committee meeting	Declaration of interest	Classification	Action taken
	and effort involved in commenting on funding applications in accordance with the Guide for CCF public contributors about the payment of fees and expenses.		
Sixteenth meeting (28.07.2017)	No change to existing declarations	N/A	N/A
Seventeenth meeting (07.12.2017)	No changes to existing declarations	N/A	N/A

NGC team

Committee meeting	Declaration of interest	Classification	Action taken
First meeting (02.03.2016)	In receipt of NICE commissions	N/A	N/A
Second meeting (22.04.2016)	No change to existing declarations	N/A	N/A
Third meeting (01.06.2016)	No change to existing declarations	N/A	N/A
Fourth meeting (20.07.2016)	No change to existing declarations	N/A	N/A
Fifth meeting (16.09.2016)	No change to existing declarations	N/A	N/A
Sixth meeting (19.10.2016)	No change to existing declarations	N/A	N/A
Seventh meeting (01.12.2016)	No change to existing declarations	N/A	N/A
Eight meeting (05.01.2017)	No change to existing declarations	N/A	N/A
Ninth meeting (08.02.2017)	No change to existing declarations	N/A	N/A
Tenth meeting (09.02.2017)	No change to existing declarations	N/A	N/A
Eleventh	No change to existing	N/A	N/A

Committee meeting	Declaration of interest	Classification	Action taken
meeting (15.03.2017)	declarations		
Twelfth meeting (19.04.2017)	No change to existing declarations	N/A	N/A
Thirteenth meeting (25.05.2017)	No change to existing declarations	N/A	N/A
Fourteenth meeting (26.05.2017)	No change to existing declarations	N/A	N/A
Fifteenth meeting (22.06.2017)	No change to existing declarations	N/A	N/A
Sixteenth meeting (28.07.2017)	No change to existing declarations	N/A	N/A
Seventeenth meeting (07.12.2017)	No change to existing declarations	N/A	N/A

NIHR team

Committee meeting	Declaration of interest	Classification	Action taken
Nicholas Hicks (10.07.2017)	None	N/A	N/A

Appendix C: Clinical review protocols

C.1 Risk assessment for people admitted to hospital

C.1.1 Patients admitted to hospital

Table 1: Review protocol: What is the accuracy of individual risk assessment or predication tools in predicting the likelihood of VTE in a patient who is admitted to hospital?

Review question	What is the accuracy of individual risk assessment or predication tools in predicting the likelihood of VTE in a patient who is admitted to hospital?
Objective	To evaluate which risk tool can best identify those people at risk of VTE, in order to identify people who will need prophylaxis
Population	Adults and young people (aged 16 or over) admitted to hospital
Risk tools	Derived and validated risk tools identified in literature
Target condition(s)	<ul style="list-style-type: none"> • VTE (symptomatic or asymptomatic) (up to 90 days): DVT and PE • VTE-related mortality (up to 90 days): DVT/PE related morality confirmed by: CT scan; pulmonary angiogram; ventilation/ perfusion scan; spiral CT scan; autopsy; echocardiography ; clinical examination with the presence of proven VTE. Diagnosis should not be based on Chest X-rays or clinical examination alone. • DVT alone (up to 90 days): DVT confirmed by: radioiodine fibrinogen uptake test; venography; duplex (Doppler) ultrasound; MRI; impedance Plethysmography (used as rule out tool). Diagnosis should not be based on d-dimer assay test or clinical examination alone. • PE alone (up to 90 days): PE confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical examination with the presence of proven VTE. Diagnosis should not be based on Chest X-rays or clinical examination alone.
Exclusions	<ul style="list-style-type: none"> • Children and young people (<16 years) • Pregnant women • Tools not externally validated or not validated by split half validation • Derivation studies
Search strategy	Databases: Medline, Embase, the Cochrane Library Dates/cut-offs: None
The review strategy	Prospective and retrospective cohort, externally validated or internally validated by split half validation
Analysis	<p>Analysis: the ability of risk tool to predict each of the target conditions will be analysed separately</p> <p>Appraisal of methodological quality: methodological quality of each risk tool will be assessed using PROBAST</p> <p>Indirectness: risk tools will be downgraded for indirectness if definition of target conditions varies from definitions of above</p>

C.1.2 Hospital admissions

Table 2: Review protocol: What is the accuracy of individual risk assessment or predication tools in predicting the likelihood of major bleeding or the risk of bleeding in a patient who is admitted to hospital?

Review question	What is the accuracy of individual risk assessment or predication tools in predicting the likelihood of major bleeding or the risk of bleeding in a patient who is admitted to hospital?
Objective	To evaluate which risk tool can best identify those people at risk of bleeding in order to identify those patients who will need prophylaxis
Population	Adults and young people (aged 16 or over) admitted to hospital
Risk tools	Derived and (externally or temporally) validated risk tools identified in literature
Target condition(s)	Major bleeding (up to 90 days). A major bleeding event meets one or more of the following criteria: <ul style="list-style-type: none"> • results in death • occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal) • results in the need for a transfusion of at least 2 units of blood • leads to a drop in haemoglobin of $\geq 2\text{g/dl}$ • a serious or life threatening clinical event • a surgical or medical intervention.
Exclusions	<ul style="list-style-type: none"> • Children and young people (<16 years) • Pregnant women • Tools not externally or temporally validated • Derivation studies
Search strategy	Databases: Medline, Embase, the Cochrane Library Dates/cut-offs: None
The review strategy	Prospective and retrospective cohort, externally validated or internally validated by split half validation
Analysis	Inclusion will be limited to papers which predict major bleeding associated with VTE. If no tools are identified the inclusion of tools to predict bleeding in similar populations (for example HAS-BLED score used for atrial fibrillation) will be considered. Appraisal of methodological quality: methodological quality of each risk tool will be assessed using PROBAST Indirectness: risk tools will be downgraded for indirectness if definition of target conditions varies from definitions of above

C.1.3 Risk assessment tools in patients admitted to hospital

Table 3: Review protocol: Reducing the rate of VTE in patients who are admitted to hospital

Review question	How clinically and cost effective are risk assessment tools at reducing the rate of VTE in patients who are admitted to hospital?
Review population	Adults (aged 16 or over) admitted to hospital
Interventions and comparisons	Intervention: Derived and validated risk tool for predicting the risk of VTE/DVT/PE/major bleeding The Department of Health risk tool (not validated) Comparisons: No risk tool, other risk tools
Outcomes	Critical: All-cause mortality (up to 90 days from hospital discharge)

Review question	How clinically and cost effective are risk assessment tools at reducing the rate of VTE in patients who are admitted to hospital?
	<p>VTE (symptomatic or asymptomatic) (up to 90 days from hospital discharge)</p> <p>DVT (symptomatic or asymptomatic) (up to 90 days from hospital discharge)</p> <p>Pulmonary embolism (up to 90 days from hospital discharge)</p> <p>Fatal pulmonary embolism (up to 90 days from hospital discharge)</p> <p>Major bleeding (up to 90 days from hospital discharge)</p> <p>Quality of life (validated scores) (up to 90 days from hospital discharge)</p> <p>Important:</p> <p>Fatal bleeding (up to 90 days from hospital discharge)</p> <p>Clinically relevant non-major bleeding (up to 45 days from hospital discharge)</p> <p>Heparin-induced thrombocytopenia (up to 90 days from hospital discharge)</p> <p>Hospital length of stay (up to 90 days from hospital discharge)</p> <p>Unplanned readmission (up to 90 days from hospital discharge)</p> <p>Haemorrhagic stroke (up to 90 days from hospital discharge)</p>
Study design	Systematic reviews of RCTs or RCTs. If no RCTs are identified, observational studies (including before and after studies) will be considered
Crossover study	Not permitted
Duration of study	Minimum: 7 days Maximum: 90 days
Sensitivity/other analysis	If studies have pre-specified in their protocols that results for any of these subgroup populations will be analysed separately, then they will be included in the subgroup analysis.
Subgroup analyses if there is heterogeneity	<p>Strata:</p> <p>Target condition (VTE/PE/DVT/major bleeding)</p> <p>Medical/surgery</p> <p>Type of surgery</p> <p>Cancer</p> <p>Subgroup: none</p>
Search criteria	<p>Databases: Medline, Embase, the Cochrane Library</p> <p>Date limits for search: None</p> <p>Language: English only</p>

C.2 Risk assessment for people having day procedures

C.2.1 VTE day procedures

Table 4: Review protocol: What is the accuracy of individual risk assessment or predication tools in predicting the likelihood of VTE in patients who are having day procedures (including surgery and chemotherapy) at hospital?

Review question	What is the accuracy of individual risk assessment or predication tools in predicting the likelihood of VTE in patients who are having day procedures (including surgery and chemotherapy) at hospital?
Objective	To evaluate which risk tool can best identify those people at risk of VTE, in order to identify people who will need prophylaxis
Population	Adults and young people (aged 16 or over) who are having day procedures (including

	surgery and chemotherapy
Risk tools	Derived and validated risk tools identified in literature
Target condition(s)	<ul style="list-style-type: none"> • VTE (symptomatic or asymptomatic) (7- 90 days; up to 180 days for people having cancer treatment): DVT and PE • VTE-related mortality (7-90 days; up to 180 days for people having cancer treatment): DVT/PE related mortality confirmed by: CT scan; pulmonary angiogram; ventilation/ perfusion scan; spiral CT scan; autopsy; echocardiography ; clinical examination with the presence of proven VTE. Diagnosis should not be based on Chest X-rays or clinical examination alone. • DVT alone (7-90 days; up to 180 days for people having cancer treatment): DVT confirmed by: radioiodine fibrinogen uptake test; venography; duplex (Doppler) ultrasound; MRI; impedance Plethysmography (used as rule out tool). Diagnosis should not be based on d-dimer assay test or clinical examination alone. • PE alone (7- 90 days; up to 180 days for people having cancer treatment): PE confirmed by: CT scan; pulmonary angiogram; ventilation/ perfusion scan; spiral CT scan; autopsy; echocardiography ; clinical examination with the presence of proven VTE. Diagnosis should not be based on Chest X-rays or clinical examination alone.
Exclusions	<ul style="list-style-type: none"> • Children and young people (<16 years) • Pregnant women • Tools not externally validated or not validated by split half validation • Derivation studies
Search strategy	Databases: Medline, Embase, the Cochrane Library Dates/cut-offs: None
The review strategy	Prospective and retrospective cohort, externally validated or internally validated by split half validation
Analysis	<p>Analysis: the ability of risk tool to predict each of the target conditions will be analysed separately</p> <p>Appraisal of methodological quality: methodological quality of each risk tool will be assessed using PROBAST</p> <p>Indirectness: risk tools will be downgraded for indirectness if definition of target conditions varies from definitions of above</p>

C.2.2 Major bleeding day procedures

Table 5: Review protocol: What is the accuracy of individual risk assessment or predication tools in predicting the likelihood of major bleeding or the risk of bleeding in patients who are having day procedures (including surgery and chemotherapy) at hospital?

Review question	What is the accuracy of individual risk assessment or predication tools in predicting the likelihood of major bleeding or the risk of bleeding in patients who are having day procedures (including surgery and chemotherapy) at hospital?
Objective	To evaluate which risk tool can best identify those people at risk of bleeding in order to identify those patients who will need prophylaxis
Population	Adults (aged 16 or over) who are having day procedures (including surgery and chemotherapy)
Risk tools	Derived and validated risk tools identified in literature
Target condition(s)	<p>Major bleeding (up to 90 days). A major bleeding event meets one or more of the following criteria:</p> <ul style="list-style-type: none"> • results in death • occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal)

	<ul style="list-style-type: none"> • results in the need for a transfusion of at least 2 units of blood • leads to a drop in haemoglobin of $\geq 2\text{g/dl}$ • a serious or life threatening clinical event a surgical or medical intervention.
Exclusions	<ul style="list-style-type: none"> • Children and young people (<16 years) • Pregnant women • Tools not externally validated or not validated by split half validation • Derivation studies
Search strategy	Databases: Medline, Embase, the Cochrane Library Dates/cut-offs: None
The review strategy	Prospective and retrospective cohort, externally validated or internally validated by split half validation
Analysis	<p>Inclusion will be limited to papers which predict major bleeding associated with VTE. If no tools are identified the inclusion of tools to predict bleeding in similar populations (for example HAS-BLED score used for atrial fibrillation) will be considered.</p> <p>Appraisal of methodological quality: methodological quality of each risk tool will be assessed using PROBAST</p> <p>Indirectness: risk tools will be downgraded for indirectness if definition of target conditions varies from definitions of above</p>

C.2.3 Risk assessment tools in patients who are having day procedures (including surgery and chemotherapy) at hospital

Table 6: Review protocol: Reducing the rate of VTE in patients who are having day procedures (including surgery and chemotherapy)

Review question	How clinically and cost effective are risk assessment tools at reducing the rates of VTE in patients who are having day procedures (including surgery and chemotherapy) at hospital?
Review population	Adults (aged 16 or over) who are having day procedures (including surgery and chemotherapy)
Interventions and comparisons	<p>Intervention: Derived and validated risk tool for predicting the risk of VTE/DVT/PE/major bleeding</p> <p>The Department of Health risk tool (not validated)</p> <p>Comparisons: No risk tool, other risk tools</p>
Outcomes	<p>Critical:</p> <p>All-cause mortality (up to 90 days from hospital discharge)</p> <p>VTE (symptomatic or asymptomatic) (7- 90 days from hospital discharge)</p> <p>DVT (symptomatic or asymptomatic) (7- 90 days from hospital discharge)</p> <p>Pulmonary embolism (7- 90 days from hospital discharge)</p> <p>Fatal pulmonary embolism (up to 90 days from hospital discharge)</p> <p>Major bleeding (up to 90 days from hospital discharge)</p> <p>Quality of life (validated scores) (up to 90 days from hospital discharge)</p> <p>Important:</p> <p>Fatal bleeding (up to 90 days from hospital discharge)</p> <p>Clinically relevant non-major bleeding (up to 45 days from hospital discharge)</p> <p>Heparin-induced thrombocytopenia (up to 90 days from hospital discharge)</p> <p>Hospital length of stay (up to 90 days from hospital discharge)</p>

Review question	How clinically and cost effective are risk assessment tools at reducing the rates of VTE in patients who are having day procedures (including surgery and chemotherapy) at hospital?
	Unplanned readmission (up to 90 days from hospital discharge) Haemorrhagic stroke (up to 90 days from hospital discharge)
Study design	Systematic reviews of RCTs or RCTs. If no RCTs are identified, consider observational studies (including before and after studies)
Crossover study	Not permitted
Duration of study	Minimum: 7 days Maximum: 90 days
Sensitivity/other analysis	If studies have pre-specified in their protocols that results for any of these subgroup populations will be analysed separately, then they will be included in the subgroup analysis.
Subgroup analyses if there is heterogeneity	Strata: Target condition Medical/surgery Type of surgery Cancer
Search criteria	Databases: Medline, Embase, the Cochrane Library Date limits for search: None Language: English only

C.3 Reassessment

C.3.1 Reassessment of people who are admitted to hospital

Table 7: Review protocol: Reassessment of the risk of VTE of people who are admitted to hospital

Review question	How effective is reassessment of the risk of VTE of people who are admitted to hospital?
Review population	Adults (aged 16 or over) admitted to hospital
Interventions and comparisons	Intervention: Tools identified in intervention risk assessment reviews only: derived and (temporally or externally) validated risk tool reassessment for predicting the risk of VTE/DVT/PE/major bleeding; Department of Health risk tool (not validated) Comparisons: No risk tool, other risk tools, first assessment
Outcomes	Critical: All-cause mortality (duration of study) VTE (symptomatic or asymptomatic) (duration of study) DVT (symptomatic or asymptomatic) (duration of study) Pulmonary embolism (duration of study) Fatal pulmonary embolism (duration of study) Major bleeding (duration of study) Quality of life (validated scores) (duration of study) Important: Fatal bleeding (duration of study) Heparin-induced thrombocytopenia (duration of study) Clinically relevant non-major bleeding (duration of study)

Review question	How effective is reassessment of the risk of VTE of people who are admitted to hospital?
	Hospital length of stay (duration of study) Unplanned readmission (duration of study) Haemorrhagic stroke (duration of study)
Study design	Systematic reviews of RCTs or RCTs. If no RCTs are identified, consider observational studies (including before and after studies)
Crossover study	Not permitted
Duration of study	Minimum: 7 days Maximum: 90 days
Sensitivity/other analysis	If studies have pre-specified in their protocols that results for any of these subgroup populations will be analysed separately, then they will be included in the subgroup analysis.
Subgroup analyses if there is heterogeneity	Strata: Target condition Medical/surgery Type of surgery Cancer
Search criteria	Databases: Medline, Embase, the Cochrane Library Date limits for search: None Language: English only

C.3.2 Reassessment of people who are having day procedures at hospital

Table 8: Review protocol: Reassessment of the risk of VTE of people who are having day procedures at hospital

Review question	How effective is reassessment of the risk of VTE of people who are having day procedures at hospital?
Review population	Adults (aged 16 or over) who are having day procedures (including surgery and chemotherapy)
Interventions and comparisons	Intervention: Tools identified in intervention risk assessment reviews only: derived and (temporally or externally) validated risk tool reassessment for predicting the risk of VTE/DVT/PE/major bleeding; Department of Health risk tool (not validated) Comparisons: No risk tool, other risk tools, first assessment
Outcomes	Critical: All-cause mortality (duration of study) VTE (symptomatic or asymptomatic) (duration of study) DVT (symptomatic or asymptomatic) (duration of study) Pulmonary embolism (duration of study) Fatal pulmonary embolism (duration of study) Major bleeding (duration of study) Quality of life (validated scores) (duration of study) Important: Fatal bleeding (duration of study) Heparin-induced thrombocytopenia (duration of study) Clinically relevant non-major bleeding (duration of study) Hospital length of stay (duration of study)

Review question	How effective is reassessment of the risk of VTE of people who are having day procedures at hospital?
	Unplanned readmission (duration of study) Haemorrhagic stroke (duration of study)
Study design	Systematic reviews of RCTs or RCTs. If no RCTs are identified, consider observational studies (including before and after studies)
Crossover study	Not permitted
Duration of study	Minimum: 7 days Maximum: 90 days
Sensitivity/other analysis	If studies have pre-specified in their protocols that results for any of these subgroup populations will be analysed separately, then they will be included in the subgroup analysis.
Subgroup analyses if there is heterogeneity	Strata: Target condition Medical/surgery Type of surgery Cancer
Search criteria	Databases: Medline, Embase, the Cochrane Library Date limits for search: None Language: English only

C.4 Risk assessment for pregnant women and women up to 6 weeks postpartum

Table 9: Review protocol: Prognostic accuracy of risk tools for VTE in pregnant women

Review question	What is the accuracy of individual risk assessment or predication tools in predicting the likelihood of VTE in pregnant women who are admitted to hospital and midwife units including up to 6 weeks after giving birth?
Objective	To evaluate which risk tool can best identify those people at risk of VTE, in order to identify those patients who will need prophylaxis
Population	Pregnant women who are admitted to hospital and midwife units including up to 6 weeks after giving birth.
Risk tool	Derived and validated risk tools identified in literature
Target condition(s)	<ul style="list-style-type: none"> VTE (symptomatic or asymptomatic) (up to 90 days) VTE-related mortality (up to 90 days) DVT alone (up to 90 days) PE alone (up to 90 days)
Statistical outcomes	Statistical outputs may include: <ul style="list-style-type: none"> Discrimination (sensitivity, specificity, predictive values) (define thresholds) Area under the ROC curve (c-statistic) Predicted risk versus observed risk (calibration) Reclassification Other statistical measures: for example, D statistic, R² statistic and Brier score
Study types	Prospective and retrospective cohort, externally validated or internally validated by split half validation
Exclusions	Tools not externally validated or not validated by split half validation

Review question	What is the accuracy of individual risk assessment or predication tools in predicting the likelihood of VTE in pregnant women who are admitted to hospital and midwife units including up to 6 weeks after giving birth?
Search study	Databases: Medline, Embase, the Cochrane Library Dates/cut-offs: None
The review strategy	Appraisal of methodological quality: methodological quality of each risk tool will be assessed using PROBAST Indirectness: risk tools will be downgraded for indirectness if definition of target conditions varies from definitions above

Table 10: Review protocol: Prognostic accuracy of risk tools for major bleeding in pregnant women

Review question	What is the accuracy of individual risk assessment or predication tools in predicting the likelihood of major bleeding or the risk of bleeding in pregnant women who are admitted to hospital and midwife units including up to 6 weeks after giving birth?
Objective	To evaluate which risk tool can best identify those people at risk of bleeding in order to identify those patients who will need prophylaxis
Population	Adults (aged 16 or over) who are having day procedures (including surgery and chemotherapy)
Risk tools	Derived and validated risk tools identified in literature
Target condition(s)	Major bleeding (up to 90 days). A major bleeding event meets one or more of the following criteria: <ul style="list-style-type: none"> • results in death • occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal) • results in the need for a transfusion of at least 2 units of blood • leads to a drop in haemoglobin of $\geq 2\text{g/dl}$ • a serious or life threatening clinical event a surgical or medical intervention.
Exclusions	<ul style="list-style-type: none"> • Children and young people (<16 years) • Pregnant women • Tools not externally validated or not validated by split half validation • Derivation studies
Search strategy	Databases: Medline, Embase, the Cochrane Library Dates/cut-offs: None
The review strategy	Prospective and retrospective cohort, externally validated or internally validated by split half validation
Analysis	Inclusion will be limited to papers which predict major bleeding associated with VTE. If no tools are identified the inclusion of tools to predict bleeding in similar populations (for example HAS-BLED score used for atrial fibrillation) will be considered. Appraisal of methodological quality: methodological quality of each risk tool will be assessed using PROBAST Indirectness: risk tools will be downgraded for indirectness if definition of target conditions varies from definitions of above

Table 11: Review protocol: Clinical and cost-effectiveness of risk tools in pregnant women

Review question	What is the clinical and cost-effectiveness of risk assessment tools, when each tool is followed by the appropriate treatment, at reducing the rates of VTE and/or bleeding in pregnant women who are admitted to hospital or midwife units?
------------------------	--

Objectives	To evaluate the clinical effectiveness of different tools to predict the risk of VTE and/or major bleeding, when followed by appropriate treatment
Population and target condition	<p>Pregnant women (including up to 6 weeks after giving birth) who are:</p> <ul style="list-style-type: none"> Admitted to hospital for 24 hours or more Having day procedures including early pregnancy loss (miscarriage and termination) <p>Target condition: VTE/DVT/PE/major bleeding</p>
Prognostic test	Any structured risk assessment for predicting the risk of VTE/DVT/PE/major bleeding in pregnancy and postpartum women
Comparator	No risk assessment Different structured risk assessment tools compared to each other
Outcomes	<p>Critical:</p> <ul style="list-style-type: none"> All-cause mortality (up to 90 days from hospital discharge) VTE (symptomatic or asymptomatic) (inpatient to 90 days from hospital discharge) DVT (symptomatic or asymptomatic) (inpatient to 90 days from hospital discharge) Pulmonary embolism (inpatient to 90 days from hospital discharge) Fatal pulmonary embolism (up to 90 days from hospital discharge) Major bleeding (up to 90 days from hospital discharge) Quality of life (validated scores) (up to 90 days from hospital discharge) <p>Important:</p> <ul style="list-style-type: none"> Fatal bleeding (up to 90 days from hospital discharge) Clinically relevant non-major bleeding (up to 45 days from hospital discharge) Hospital length of stay (up to 90 days from hospital discharge) Unplanned readmission (up to 90 days from hospital discharge) Haemorrhagic stroke (up to 90 days from hospital discharge)
Study design	Systematic reviews of RCTs or RCTs. If no RCTs then observational cohort data.
Search strategy	Databases: Medline, Embase, the Cochrane Library Date limits for search: None Language: English only
Duration of study	Minimum: 7 days follow-up Maximum: 150 days
Review strategy	Strata: <ul style="list-style-type: none"> Target condition (VTE/PE/DVT/major bleeding)
Subgroup analyses if there is heterogeneity	Medical vs. surgical Pre- vs. post-natal

Table 12: Review protocol: Risk tools for reassessment for VTE and/or bleeding in pregnant women

Review question	How effective is reassessment of the risk of VTE and/or bleeding of pregnant women who are admitted to hospital or midwife units?
Objectives	<p>To evaluate the effectiveness of reassessing the risk of VTE and/or bleeding of pregnant women who are admitted to hospital or midwife units.</p> <p>Reassessment may include booking, admission, admission for delivery, post-delivery assessment, re-admission post-delivery.</p>

Population and target condition	<p>Pregnant women (including up to 6 weeks after giving birth) who are:</p> <ul style="list-style-type: none"> Admitted to hospital for 24 hours or more Having day procedures including early pregnancy loss (miscarriage and termination) <p>Target condition: VTE/DVT/PE/major bleeding</p>
Prognostic test	Any structured risk assessment for predicting the risk of VTE/DVT/PE/major bleeding in pregnancy and postpartum women
Comparator	No risk tool, other risk tools, first assessment
Outcomes	<p>Critical:</p> <ul style="list-style-type: none"> All-cause mortality (duration of study) VTE (symptomatic or asymptomatic) (duration of study) DVT (symptomatic or asymptomatic) (duration of study) Pulmonary embolism (duration of study) Fatal pulmonary embolism (duration of study) Major bleeding (duration of study) Quality of life (validated scores) (duration of study) <p>Important:</p> <ul style="list-style-type: none"> Fatal bleeding (duration of study) Clinically relevant non-major bleeding (duration of study) Hospital length of stay (duration of study) Unplanned readmission (duration of study) Haemorrhagic stroke (duration of study)
Study design	Systematic reviews of RCTs or RCTs. If no RCT's identified then observational cohort data.
Search strategy	<p>Databases: Medline, Embase, the Cochrane Library</p> <p>Date limits for search: None</p> <p>Language: English only</p>
Review strategy	<p>Strata:</p> <ul style="list-style-type: none"> Target condition (VTE/PE/DVT/major bleeding)
Subgroup analyses if there is heterogeneity	<p>Medical vs. surgical</p> <p>Pre- vs. post-natal</p>

C.5 Giving information to patients and planning for discharge

Table 13: Review protocol: What information about VTE and VTE prophylaxis should be given to people who are admitted to hospital, having day procedures or outpatients post-discharge, and their family or carers?

Component	Description
Review question	What information about VTE and VTE prophylaxis should be given to people who are admitted to hospital, having day procedures or outpatients post-discharge, and their family or carers?
Objective	To identify the information about VTE and VTE prophylaxis that people who are admitted to hospital, having day procedures or outpatients post-discharge, and their family or carers want.
Population and setting	<p>Adults and young people (16 years and older) who are:</p> <ul style="list-style-type: none"> Admitted to hospital

Component	Description
	<ul style="list-style-type: none"> • Having day procedures • Outpatients post-discharge <p>who require information about VTE and VTE prophylaxis, and their family and carers</p> <p>Setting:</p> <ul style="list-style-type: none"> • Primary and community care when continuing prophylaxis after hospital discharge • Secondary care
Context	<p>Examples of possible themes</p> <ul style="list-style-type: none"> • Standardised vs. conflicting information • Lack of information • Too much information • Types of information • When information is given • Informed consent for VTE prophylaxis • Who information is given to e.g. patient, family/carer • Who is giving information
Exclusions	<ul style="list-style-type: none"> • Community settings and hospices, except when continuing prophylaxis that has been started in hospital • Non-English studies
Search strategy	<p>Databases: The databases to be searched are Medline, Embase, The Cochrane Library, CINAHL, PsychINFO</p> <p>Studies will be restricted to English language only.</p> <p>Date limits: Update of previous NICE guideline: Venous thromboembolism - reducing the risk (CG92). Final search date for CG92: 10 December 2008</p>
Review strategy	<p>Study designs to be considered:</p> <ul style="list-style-type: none"> • Qualitative studies (for example, interviews, focus groups, observations) • Systematic review of qualitative studies <p>Review strategy:</p> <ul style="list-style-type: none"> • Population size and directness: <ul style="list-style-type: none"> ○ No minimum sample size ○ Studies with indirect populations will not be considered <p>Appraisal of methodological quality</p> <p>The methodological quality of each study will be assessed using NGC modified NICE checklists and the quality of the body of evidence as a whole will be assessed by a GRADE CerQual approach for each review finding.</p> <p>Data synthesis</p> <p>Synthesis of qualitative research: thematic analysis – information synthesised into main review findings. Results presented in a detailed narrative and in table format with summary statements of main review findings.</p>

C.6 General VTE prevention for everyone in hospital

None

C.7 Nursing care: Early mobilisation and hydration

None

C.8 Obesity

Table 14: Review protocol: What is the effectiveness of weight based dose-adjustment strategies of LMWH compared to fixed dose strategies of LMWH for people who are obese?

Review question	What is the effectiveness of weight based dose-adjustment strategies of LMWH compared to fixed dose strategies of LMWH for people who are obese?
Objectives	To find the most effective strategy for preventing VTE in people who are obese
Population	Adults and young people (16 years and older) who are obese (BMI > 30) and who are: <ul style="list-style-type: none"> Admitted to hospital Having day procedures Outpatients post-discharge
Interventions	Pharmacological (fixed dose or weight adjusted dose): <ul style="list-style-type: none"> Low molecular weight heparin (LMWH), licensed in UK: <ul style="list-style-type: none"> enoxaparin (standard prophylactic dose 40 mg daily; minimum 20 mg daily* to maximum 60 mg twice daily*) dalteparin (standard prophylactic dose 5000 units once daily; minimum 1250 units once daily* to maximum 5000 units twice daily*; obese patients – maximum 7500 twice units daily*) tinzaparin (standard prophylactic dose 3500 units once daily; minimum 2500 units once daily* to maximum 4500 units twice daily*; obese patients – maximum 6750 twice daily*) LMWH, licensed in countries other than UK: <ul style="list-style-type: none"> Bemiparin (standard 2500 units daily; minimum 2500 units daily to maximum 3500 units daily) Certoparin (3000 units daily) Nadroparin (standard 2850 units once daily; minimum 2850 units once daily to maximum up to 57 units/kg once daily) Parnaparin (standard 3200 units once daily; minimum 3200 units once daily to maximum 4250 units once daily) Reviparin (minimum 1750 units once daily to maximum 4200 units once daily) <p>*off-label</p>
Comparisons	Fixed dose Weight adjusted dose
Outcomes	Critical outcomes: <ul style="list-style-type: none"> All-cause mortality (up to 90 days from hospital discharge) Deep vein thrombosis (symptomatic and asymptomatic) (7-90 days from hospital discharge). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) Pulmonary embolism (7-90 days from hospital discharge). Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE Major bleeding (up to 45 days from hospital discharge). A major bleeding event meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood ; leads to a drop in

Review question	What is the effectiveness of weight based dose-adjustment strategies of LMWH compared to fixed dose strategies of LMWH for people who are obese?
	<p>haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event. Includes unplanned visit to theatre for control of bleeding</p> <ul style="list-style-type: none"> Fatal PE (7- 90 days from hospital discharge). Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE <p>Important outcomes:</p> <ul style="list-style-type: none"> Clinically relevant non-major bleeding (up to 45 days from hospital discharge): bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy. Health-related quality of life (validated scores only)(up to 90 days from hospital discharge) Heparin-induced thrombocytopenia (HIT) (duration of study)
Study design	Randomised controlled trials (RCTs), systematic reviews of RCTs.
Settings	Primary and community care when continuing prophylaxis after hospital discharge Secondary care
Exclusions	<p>People who are contraindicated for both mechanical and pharmacological prophylaxis Community settings and hospices, except when continuing prophylaxis that has been started in hospital People with suspected or confirmed venous thromboembolism Secondary prevention of VTE Early mobilisation and leg exercises Non-English studies Duration of follow-up <7 days; >150 days</p>
Review strategy	<p>Drug groups combined for analysis:</p> <ul style="list-style-type: none"> LMWH <p>Outcomes reported at different time points will be analysed together</p>
Stratification	<p>People who are contraindicated for pharmacological prophylaxis People who are contraindicated for mechanical prophylaxis</p>
Subgroup analyses if there is heterogeneity	<p>BMI: obese (obesity I and II, $30\text{--}34.9\text{ kg/m}^2$); severely obese (obesity III, $\geq 40\text{ kg/m}^2$) Renal impairment (no renal impairment $\text{eGFR} > 30$; renal impairment $\text{eGFR} < 30$)</p>
Other analysis	<p>The quality of the data will be assessed using GRADE. Outcomes that are not confirmed by methods listed in protocol, or where methods of confirmation are not reported, will be downgraded for indirectness For all-cause mortality, DVT, PE, fatal PE, quality of life and heparin-induced thrombocytopenia outcomes measured at 91 to 150 days will be downgraded for indirectness</p>
Search strategy	<p>Databases: Medline, Embase, The Cochrane Library Date limits: Update of previous NICE guideline: Venous thromboembolism - reducing the risk (CG92). Final search date for CG92: 10 December 2008</p>

C.9 People using antiplatelets

Table 15: Review protocol: People using anti-platelet agents at time of presentation

Review question	What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) for people using antiplatelets agents at time of presentation?
Objectives	To find the most effective strategy for preventing VTE in people using antiplatelets (for example for people with chronic cardiovascular disease) on presentation to hospital?
Population	Adults and young people (16 years and older) in people using antiplatelet agents on presentation to hospital
Interventions	<p>Mechanical:</p> <ul style="list-style-type: none"> Anti-embolism stockings (AES) (above or below knee) Intermittent pneumatic compression (IPCD) devices (full leg or below knee) Foot pumps or foot impulse devices (FID) Electrical stimulation (including Geko devices) Continuous passive motion Vena caval filters <p>Pharmacological:</p> <ul style="list-style-type: none"> Unfractionated heparin (UFH) (low dose, administered subcutaneously) Low molecular weight heparin (LMWH), licensed in UK: <ul style="list-style-type: none"> enoxaparin (standard prophylactic dose 40mg daily; minimum 20mg daily* to maximum 60mg twice daily*) dalteparin (standard prophylactic dose 5000 units once daily; minimum 1250 units once daily* to maximum 5000 units twice daily*; obese patients – maximum 7500 twice units daily*) tinzaparin (standard prophylactic dose 3500 units once daily; minimum 2500 units once daily* to maximum 4500 units twice daily*; obese patients – maximum 6750 twice daily*) LMWH, licensed in countries other than UK: <ul style="list-style-type: none"> Bemiparin (standard 2500 units daily; minimum 2500 units daily to maximum 3500 units daily) Certoparin (3000 units daily) Nadroparin (standard 2850 units once daily; minimum 2850 units once daily to maximum up to 57 units/kg once daily) Parnaparin (standard 3200 units once daily; minimum 3200 units once daily to maximum 4250 units once daily) Reviparin (minimum 1750 units once daily to maximum 4200 units once daily) Vitamin K Antagonists: <ul style="list-style-type: none"> warfarin (variable dose only) acenocoumarol (all doses) phenindione (all doses) Fondaparinux (all doses)* Apixaban (all doses)* Dabigatran (all doses)* Rivaroxaban (all doses)* Aspirin (up to 300mg)* <p>*off-label</p>

Review question	What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) for people using antiplatelets agents at time of presentation?
Comparisons	<p>Continuing/stopping antiplatelets (including single and dual agents) plus VTE prophylaxis treatment, versus continuing/stopping antiplatelets, plus one of the following: Other VTE prophylaxis treatment, including monotherapy and combination treatments (between class comparisons for pharmacological treatments only) No VTE prophylaxis treatment (no treatment, usual care, placebo)</p> <p>Within intervention (including same drug) comparisons, including: Above versus below knee stockings Full leg versus below knee IPC devices Standard versus extended duration prophylaxis Low versus high dose for LMWH Preoperative versus post-operative initiation of LMWH</p>
Outcomes	<p>Critical outcomes: All-cause mortality (up to 90 days from hospital discharge) Deep vein thrombosis (symptomatic and asymptomatic) (7-90 days from hospital discharge) (NMA outcome). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) Pulmonary embolism (7-90 days from hospital discharge). Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE Major bleeding (up to 45 days from hospital discharge). A major bleeding event meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood ; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event. Includes unplanned visit to theatre for control of bleeding Fatal PE (7- 90 days from hospital discharge). Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE</p> <p>Important outcomes: Clinically relevant non-major bleeding (up to 45 days from hospital discharge): bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy. Health-related quality of life (validated scores only)(up to 90 days from hospital discharge) Heparin-induced thrombocytopenia (HIT) (duration of study) Technical complications of mechanical interventions (duration of study)</p>
Study design	Randomised controlled trials (RCTs), systematic reviews of RCTs.
Settings	Primary and community care when continuing prophylaxis after hospital discharge Secondary care
Exclusions	<p>People using antiplatelets for acute coronary syndromes (included in separate review) Community settings and hospices, except when continuing prophylaxis that has been started in hospital People who are contraindicated for both mechanical and pharmacological prophylaxis People with suspected or confirmed venous thromboembolism Secondary prevention of VTE Early mobilisation and leg exercises Non-English studies Duration of follow-up <7 days; >150 days</p>

Review question	What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) for people using antiplatelets agents at time of presentation?
Review strategy	Drug groups combined for analysis: LMWH Vitamin K Antagonists Outcomes reported at different time points will be analysed together
Stratification	People who are contraindicated
Subgroup analyses if there is heterogeneity	BMI: not obese (BMI under 30kg/m ²) obese (obesity I and II, 30–34.9kg/m ²); severely obese (obesity III, ≥40kg/m ²) Renal impairment (no renal impairment eGFR >30; renal impairment eGFR <30) Antiplatelet treatment
Other analysis	The quality of the data will be assessed using GRADE. Outcomes that are not confirmed by methods listed in protocol, or where methods of confirmation are not reported, will be downgraded for indirectness For all-cause mortality, DVT, PE, fatal PE, quality of life and heparin-induced thrombocytopenia outcomes measured at 91 to 150 days will be downgraded for indirectness.
Search strategy	Databases: Medline, Embase, The Cochrane Library Date limits: Update of previous NICE guideline: Venous thromboembolism - reducing the risk (CG92). Final search date for CG92: 10 December 2008

C.10 People using anticoagulation therapy

Table 16: Review protocol: What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) for people having to interrupt anticoagulation therapy?

Review question	What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) for people having to interrupt anticoagulation therapy?
Objectives	To find the most effective strategy, including bridging therapy (stopping warfarin and replacing with pharmacological therapy), for preventing VTE in people having to interrupt anticoagulation therapy (for example warfarin)
Population	Adults and young people (16 years and older) having to interrupt anticoagulation therapy who are : Admitted to hospital Having day procedures Discharged from hospital Outpatients post-discharge
Interventions	Mechanical: Anti-embolism stockings (AES) (above or below knee) Intermittent pneumatic compression (IPCD) devices (full leg or below knee) Foot pumps or foot impulse devices (FID) Electrical stimulation (including Geko devices) Continuous passive motion

Review question	What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) for people having to interrupt anticoagulation therapy?
	<p>Vena caval filters</p> <p>Pharmacological:</p> <p>Unfractionated heparin (UFH) (low dose, administered subcutaneously)</p> <p>Low molecular weight heparin (LMWH), licensed in UK:</p> <p>enoxaparin (standard prophylactic dose 40mg daily; minimum 20mg daily* to maximum 60mg twice daily*)</p> <p>dalteparin (standard prophylactic dose 5000 units once daily; minimum 1250 units once daily* to maximum 5000 units twice daily*; obese patients – maximum 7500 twice units daily*)</p> <p>tinzaparin (standard prophylactic dose 3500 units once daily; minimum 2500 units once daily* to maximum 4500 units twice daily*; obese patients – maximum 6750 twice daily*)</p> <p>LMWH, licensed in countries other than UK:</p> <p>Bemiparin (standard 2500 units daily; minimum 2500 units daily to maximum 3500 units daily)</p> <p>Certoparin (3000 units daily)</p> <p>Nadroparin (standard 2850 units once daily; minimum 2850 units once daily to maximum up to 57 units/kg once daily)</p> <p>Parnaparin (standard 3200 units once daily; minimum 3200 units once daily to maximum 4250 units once daily)</p> <p>Reviparin (minimum 1750 units once daily to maximum 4200 units once daily)</p> <p>Vitamin K Antagonists:</p> <p>warfarin (variable dose only)</p> <p>acenocoumarol (all doses)</p> <p>phenindione (all doses)</p> <p>Fondaparinux (all doses)*</p> <p>Apixaban (all doses)*</p> <p>Dabigatran (all doses)*</p> <p>Rivaroxaban (all doses)*</p> <p>Aspirin (up to 300mg)*</p> <p>*off-label</p>
Comparisons	<p>Continuing/stopping anticoagulants plus VTE prophylaxis treatment versus continuing/stopping anticoagulants, plus one of the following:</p> <p>Other VTE prophylaxis treatment, including monotherapy and combination treatments (between class comparisons for pharmacological treatments only)</p> <p>No VTE prophylaxis treatment (no treatment, usual care, placebo)</p> <p>Within intervention (including same drug) comparisons, including:</p> <p>Above versus below knee stockings</p> <p>Full leg versus below knee IPC devices</p> <p>Standard versus extended duration prophylaxis</p> <p>Low versus high dose for LMWH</p>
Outcomes	<p>Critical outcomes:</p> <p>All-cause mortality (up to 90 days from hospital discharge)</p> <p>Deep vein thrombosis (symptomatic and asymptomatic) (7-90 days from hospital discharge). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool)</p>

Review question	What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) for people having to interrupt anticoagulation therapy?
	<p>Pulmonary embolism (7-90 days from hospital discharge). Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE</p> <p>Major bleeding (up to 45 days from hospital discharge). A major bleeding event meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood ; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event. Includes unplanned visit to theatre for control of bleeding</p> <p>Fatal PE (7- 90 days from hospital discharge). Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE</p> <p>Important outcomes:</p> <p>Clinically relevant non-major bleeding (up to 45 days from hospital discharge): bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy.</p> <p>Health-related quality of life (validated scores only)(up to 90 days from hospital discharge)</p> <p>Heparin-induced thrombocytopenia (HIT) (duration of study)</p> <p>Technical complications of mechanical interventions (duration of study)</p> <p>Haemorrhagic stroke (up to 45 days from hospital discharge)</p> <p>Embolic stroke (up to 45 days from hospital discharge)</p>
Study design	Randomised controlled trials (RCTs), systematic reviews of RCTs.
Settings	Primary and community care when continuing prophylaxis after hospital discharge Secondary care
Exclusions	<p>Community settings and hospices, except when continuing prophylaxis that has been started in hospital</p> <p>People who are contraindicated for both mechanical and pharmacological prophylaxis</p> <p>People with suspected or confirmed venous thromboembolism</p> <p>Secondary prevention of VTE</p> <p>Early mobilisation and leg exercises</p> <p>Non-English studies</p> <p>Duration of follow-up <7 days; >150 days</p>
Review strategy	<p>Drug groups combined for analysis:</p> <p>LMWH</p> <p>Vitamin K Antagonists</p> <p>Outcomes reported at different time points will be analysed together</p>
Stratification	People who are contraindicated
Subgroup analyses if there is heterogeneity	<p>BMI: not obese (BMI under 30kg/m²) obese (obesity I and II, 30–34.9kg/m²); severely obese (obesity III, $\geq 40\text{kg/m}^2$)</p> <p>Renal impairment (no renal impairment eGFR >30; renal impairment eGFR <30)</p> <p>Medical/surgical</p> <p>Atrial fibrillation</p> <p>Mechanical heart valves</p>
Other analysis	<p>The quality of the data will be assessed using GRADE.</p> <p>Outcomes that are not confirmed by methods listed in protocol, or where methods of</p>

Review question	What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) for people having to interrupt anticoagulation therapy?
	confirmation are not reported, will be downgraded for indirectness For all-cause mortality, DVT, PE, fatal PE, quality of life and heparin-induced thrombocytopenia outcomes measured at 91 to 150 days will be downgraded for indirectness
Search strategy	Databases: Medline, Embase, The Cochrane Library Date limits: Update of previous NICE guideline: Venous thromboembolism - reducing the risk (CG92). Final search date for CG92: 10 December 2008

C.11 Acute coronary syndromes

Table 17: Review protocol: What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) for people being treated for acute coronary syndromes (using anticoagulants and/or anti-platelets)?

Review question	What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) for people being treated for acute coronary syndromes (using anticoagulants and/or anti-platelets)?
Objectives	To find the most effective strategy for preventing VTE in people being treated for acute coronary syndromes who are already being treated with anticoagulants and/or anti-platelets
Population	Adults and young people (16 years and older) being treated for acute coronary syndromes with anticoagulants and/or anti-platelets who are: Admitted to hospital Having day procedures Discharged from hospital Outpatients post-discharge
Interventions	Mechanical: Anti-embolism stockings (above or below knee) Intermittent pneumatic compression (IPCD) devices (full leg or below knee) Foot pumps or foot impulse devices (FID) Electrical stimulation (including Geko devices) Continuous passive motion Vena caval filters Pharmacological: Unfractionated heparin (UFH) (low dose, administered subcutaneously) Low molecular weight heparin (LMWH), licensed in UK: enoxaparin (standard prophylactic dose 40mg daily; minimum 20mg daily* to maximum 60mg twice daily*) dalteparin (standard prophylactic dose 5000 units once daily; minimum 1250 units once daily* to maximum 5000 units twice daily*; obese patients – maximum 7500 twice units daily*) tinzaparin (standard prophylactic dose 3500 units once daily; minimum 2500 units once daily* to maximum 4500 units twice daily*; obese patients – maximum 6750 twice daily*) LMWH, licensed in countries other than UK:

Review question	What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) for people being treated for acute coronary syndromes (using anticoagulants and/or anti-platelets)?
	<p>Bemiparin (standard 2500 units daily; minimum 2500 units daily to maximum 3500 units daily)</p> <p>Certoparin (3000 units daily)</p> <p>Nadroparin (standard 2850 units once daily; minimum 2850 units once daily to maximum up to 57 units/kg once daily)</p> <p>Parnaparin (standard 3200 units once daily; minimum 3200 units once daily to maximum 4250 units once daily)</p> <p>Reviparin (minimum 1750 units once daily to maximum 4200 units once daily)</p> <p>Vitamin K Antagonists:</p> <p>warfarin (variable dose only)</p> <p>acenocoumarol (all doses)</p> <p>phenindione (all doses)</p> <p>Fondaparinux (all doses)*</p> <p>Apixaban (all doses)*</p> <p>Dabigatran (all doses)*</p> <p>Rivaroxaban (all doses)*</p> <p>Aspirin (up to 300mg)*</p> <p>*off-label</p>
Comparisons	<p>Treatment for acute coronary syndrome (anti-platelets; anticoagulants; anti-platelets and anticoagulants) plus VTE prophylaxis treatment, versus treatment for acute coronary syndromes plus one of the following:</p> <p>Other VTE prophylaxis treatment, including monotherapy and combination treatments (between class comparisons for pharmacological treatments only)</p> <p>No VTE prophylaxis treatment (no treatment, usual care, placebo)</p> <p>Within intervention (including same drug) comparisons, including:</p> <p>Above versus below knee stockings</p> <p>Full leg versus below knee IPC devices</p> <p>Standard versus extended duration prophylaxis</p> <p>Low versus high dose for LMWH</p>
Outcomes	<p>Critical outcomes:</p> <p>All-cause mortality (up to 90 days from hospital discharge)</p> <p>Deep vein thrombosis (symptomatic and asymptomatic) (7-90 days from hospital discharge) (NMA outcome). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool)</p> <p>Pulmonary embolism (7-90 days from hospital discharge). Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE</p> <p>Major bleeding (up to 45 days from hospital discharge). A major bleeding event meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood ; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event. Includes unplanned visit to theatre for control of bleeding</p> <p>Fatal PE (7- 90 days from hospital discharge). Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE</p>

Review question	What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) for people being treated for acute coronary syndromes (using anticoagulants and/or anti-platelets)?
	<p>Important outcomes:</p> <p>Clinically relevant non-major bleeding (up to 45 days from hospital discharge): bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy.</p> <p>Health-related quality of life (validated scores only)(up to 90 days from hospital discharge)</p> <p>Heparin-induced thrombocytopenia (HIT) (duration of study)</p> <p>Technical complications of mechanical interventions (duration of study)</p>
Study design	Randomised controlled trials (RCTs), systematic reviews of RCTs.
Settings	<p>Primary and community care when continuing prophylaxis after hospital discharge</p> <p>Secondary care</p>
Exclusions	<p>Community settings and hospices, except when continuing prophylaxis that has been started in hospital</p> <p>People who are contraindicated for both mechanical and pharmacological prophylaxis</p> <p>People with suspected or confirmed venous thromboembolism</p> <p>Secondary prevention of VTE</p> <p>Early mobilisation and leg exercises</p> <p>Non-English studies</p> <p>Duration of follow-up <7 days; >150 days</p>
Review strategy	<p>Drug groups combined for analysis:</p> <p>LMWH</p> <p>Vitamin K Antagonists</p> <p>Outcomes reported at different time points will be analysed together</p>
Stratification	People who are contraindicated
Subgroup analyses if there is heterogeneity	<p>BMI: not obese (BMI under 30kg/m²) obese (obesity I and II, 30–34.9kg/m²); severely obese (obesity III, ≥40kg/m²)</p> <p>Renal impairment (no renal impairment eGFR >30; renal impairment eGFR <30)</p> <p>Treatment for acute coronary syndrome</p>
Other analysis	<p>The quality of the data will be assessed using GRADE.</p> <p>Outcomes that are not confirmed by methods listed in protocol, or where methods of confirmation are not reported, will be downgraded for indirectness</p> <p>For all-cause mortality, DVT, PE, fatal PE, quality of life and heparin-induced thrombocytopenia outcomes measured at 91 to 150 days will be downgraded for indirectness</p>
Search strategy	<p>Databases:</p> <p>Medline, Embase, The Cochrane Library</p> <p>Date limits:</p> <p>Update of previous NICE guideline: Venous thromboembolism - reducing the risk (CG92).</p> <p>Final search date for CG92: 10 December 2008</p>

C.12 Acute stroke patients

Table 18: Review protocol: What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) for people who are admitted to hospital with a stroke or who have a stroke in hospital?

Review question	What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) for people who are admitted to hospital with a stroke or who have a stroke in hospital
Objectives	To find the most effective strategy for preventing VTE in people who are admitted to hospital with a stroke or who have a stroke in hospital
Population	Adults and young people (16 years and older) who are admitted to hospital with a stroke or who have a stroke in hospital
Interventions	<p>Mechanical:</p> <ul style="list-style-type: none"> Anti-embolism stockings (above or below knee) Intermittent pneumatic compression (IPCD) devices (full leg or below knee) Foot pumps or foot impulse devices (FID) Electrical stimulation (including Geko devices) Continuous passive motion Vena caval filters <p>Pharmacological:</p> <ul style="list-style-type: none"> Unfractionated heparin (UFH) (low dose, administered subcutaneously) Low molecular weight heparin (LMWH), licensed in UK: <ul style="list-style-type: none"> enoxaparin (standard prophylactic dose 40mg daily; minimum 20mg daily* to maximum 60mg twice daily*) dalteparin (standard prophylactic dose 5000 units once daily; minimum 1250 units once daily* to maximum 5000 units twice daily*; obese patients – maximum 7500 twice units daily*) tinzaparin (standard prophylactic dose 4500 units once daily; minimum 2500 units once daily* to maximum 4500 units twice daily*; obese patients – maximum 6750 twice daily*) LMWH, licensed in countries other than UK: <ul style="list-style-type: none"> Bemiparin (standard 2500 units daily; minimum 2500 units daily to maximum 3500 units daily) Certoparin (3000 units daily) Nadroparin (standard 2850 units once daily; minimum 2850 units once daily to maximum up to 57 units/kg once daily) Parnaparin (standard 3200 units once daily; minimum 3200 units once daily to maximum 4250 units once daily) Reviparin (minimum 1750 units once daily to maximum 4200 units once daily) Vitamin K Antagonists: <ul style="list-style-type: none"> warfarin (variable dose only) acenocoumarol (all doses) phenindione (all doses) Fondaparinux (all doses)* Apixaban (all doses)* Dabigatran (all doses)* Rivaroxaban (all doses)* Aspirin (up to 300mg)* <p>*off-label</p>

Review question	What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) for people who are admitted to hospital with a stroke or who have a stroke in hospital
Comparisons	<p>Treatment for stroke (anti-platelets/warfarin) plus VTE prophylaxis treatment, versus treatment for stroke (anti-platelets/warfarin), plus one of the following:</p> <p>Other VTE prophylaxis treatment, including monotherapy and combination treatments (between class comparisons for pharmacological treatments only)</p> <p>No VTE prophylaxis treatment (no treatment, usual care, placebo)</p> <p>Within intervention (including same drug) comparisons, including:</p> <p>Above versus below knee stockings</p> <p>Full leg versus below knee IPC devices</p> <p>Standard versus extended duration prophylaxis</p> <p>Low versus high dose for LMWH</p>
Outcomes	<p>Critical outcomes:</p> <p>All-cause mortality (up to 90 days from hospital discharge)</p> <p>Deep vein thrombosis (symptomatic and asymptomatic) (7-90 days from hospital discharge) (NMA outcome). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool)</p> <p>Pulmonary embolism (7-90 days from hospital discharge). Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE</p> <p>Major bleeding (up to 45 days from hospital discharge). A major bleeding event meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood ; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event. Includes unplanned visit to theatre for control of bleeding</p> <p>Fatal PE (7- 90 days from hospital discharge). Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE</p> <p>Important outcomes:</p> <p>Clinically relevant non-major bleeding (up to 45 days from hospital discharge): bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy.</p> <p>Health-related quality of life (validated scores only)(up to 90 days from hospital discharge)</p> <p>Heparin-induced thrombocytopenia (HIT) (duration of study)</p> <p>Technical complications of mechanical interventions (duration of study)</p> <p>Haemorrhagic transformation (for people without haemorrhagic stroke only) (up to 45 days from hospital discharge)</p>
Study design	Randomised controlled trials (RCTs), systematic reviews of RCTs.
Settings	Primary and community care when continuing prophylaxis after hospital discharge Secondary care
Exclusions	<p>Community settings and hospices, except when continuing prophylaxis that has been started in hospital</p> <p>People who are contraindicated for both mechanical and pharmacological prophylaxis</p> <p>People with suspected or confirmed venous thromboembolism</p> <p>Secondary prevention of VTE</p> <p>Early mobilisation and leg exercises</p> <p>Non-English studies</p>

Review question	What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) for people who are admitted to hospital with a stroke or who have a stroke in hospital
	Duration of follow-up <7 days; >150 days
Review strategy	Drug groups combined for analysis: LMWH Vitamin K Antagonists Outcomes reported at different time points will be analysed together
Stratification	People who are contraindicated
Subgroup analyses if there is heterogeneity	BMI: not obese (BMI under 30kg/m ²) obese (obesity I and II, 30–34.9kg/m ²); severely obese (obesity III, ≥40kg/m ²) Renal impairment (no renal impairment eGFR >30; renal impairment eGFR <30) Type of stroke: ischemic; haemorrhagic; embolic
Other analysis	The quality of the data will be assessed using GRADE. Outcomes that are not confirmed by methods listed in protocol, or where methods of confirmation are not reported, will be downgraded for indirectness For all-cause mortality, DVT, PE, fatal PE, quality of life and heparin-induced thrombocytopenia outcomes measured at 91 to 150 days will be downgraded for indirectness
Search strategy	Databases: Medline, Embase, The Cochrane Library Date limits: Update of previous NICE guideline: Venous thromboembolism - reducing the risk (CG92). Final search date for CG92: 10 December 2008

C.13 Acutely ill medical patients

Table 17: Review protocol: Acutely ill medical patients admitted to hospital

Review question	What is the effectiveness of different pharmacological prophylaxis strategies (alone or in combination) for acutely ill medical patients admitted to hospital?
Guideline condition and its definition	VTE prophylaxis. Definition: Prevention of VTE (DVT and PE) in hospital patients
Review population	Adults and young people (16 years and older) who are acutely ill medical patients admitted to hospital
	Adults Young people (aged 16 years or over)
	Line of therapy not an inclusion criterion
Interventions and comparators: generic/class; specific/drug	Anti-embolism stockings; Above knee Anti-embolism stockings; Below knee Anti-embolism stockings; Mixed above/below knee Intermittent pneumatic compression devices ; Full leg Intermittent pneumatic compression devices ; Below knee
(All interventions will be compared with each	Intermittent pneumatic compression devices ; Mixed full leg/below knee Foot pumps or foot impulse devices ; Foot pumps

Review question	What is the effectiveness of different pharmacological prophylaxis strategies (alone or in combination) for acutely ill medical patients admitted to hospital?
other, unless otherwise stated)	<p>Foot pumps or foot impulse devices ; Foot impulse Electrical stimulation Continuous passive motion Vena cava filters Unfractionated heparin ; Unfractionated heparin (low dose, administered subcutaneously) Low molecular weight heparin (licensed in UK); Dalteparin (1,250 units once daily - 5,000 units twice daily) Low molecular weight heparin (licensed in UK); Tinzaparin (2,500 units once daily – 9,000 units once daily) Low molecular weight heparin (licensed in UK); Enoxaparin (20mg once daily – 60mg twice daily) Vitamin K antagonists ; Warfarin (all doses) Vitamin K antagonists ; Acenocoumarol (all doses) Vitamin K antagonists ; Phenindione (all doses) Fondaparinux; Fondaparinux (all doses) Apixaban; Apixaban (all doses) Dabigatran; Dabigatran (all doses) Rivaroxaban; Rivaroxaban (all doses) Aspirin; Aspirin (up to 300mg) No treatment; Usual care No treatment; Placebo Low molecular weight heparin (not licensed in UK); bemiparin (2500 units once daily - 3500 units once daily) Low molecular weight heparin (not licensed in UK); certoparin (3000 units once daily) Low molecular weight heparin (not licensed in UK); nadroparin (2850 units once daily - up to 57 units/kg once daily) Low molecular weight heparin (not licensed in UK); parnaparin (3200 units once daily - 4250 units once daily) Low molecular weight heparin (not licensed in UK); reviparin (1750 units once daily - 4200 units once daily)</p>
Outcomes	<ul style="list-style-type: none"> - All-cause mortality at up to 90 days from hospital discharge (Dichotomous) CRITICAL - Deep vein thrombosis (symptomatic and asymptomatic) at 7-90 days from hospital discharge. Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) (Dichotomous) CRITICAL - Pulmonary embolism) at 7-90 days from hospital discharge. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE (Dichotomous) CRITICAL - Major bleeding at up to 45 days from hospital discharge. A major bleeding event meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood ; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event (Dichotomous) CRITICAL - Fatal PE at up to 90 days from hospital discharge. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE (Dichotomous) CRITICAL - Clinically relevant non-major bleeding at up to 45 days from hospital discharge. Bleeding that does not meet the criteria for major bleed but requires

Review question	What is the effectiveness of different pharmacological prophylaxis strategies (alone or in combination) for acutely ill medical patients admitted to hospital?
	<p>medical attention and/or a change in antithrombotic therapy (Dichotomous) IMPORTANT</p> <ul style="list-style-type: none"> - Health-related quality of life (validated scores only) at up to 90 days from hospital discharge (Continuous) IMPORTANT - Heparin-induced thrombocytopenia at up to 90 days from hospital discharge (Dichotomous) IMPORTANT - Technical complications of mechanical interventions at up to 90 days from hospital discharge (Continuous) IMPORTANT
Study design	Systematic Review RCT
Unit of randomisation	Patient
Crossover study	Not permitted
Minimum duration of study	Not defined
Other exclusions	<p>People with suspected or confirmed venous thromboembolism</p> <p>Community settings and hospices, except when continuing prophylaxis that has been started in hospital</p> <p>Secondary prevention of VTE</p> <p>Early mobilisation and leg exercises</p> <p>People who are contraindicated for pharmacological and mechanical prophylaxis</p>
Population stratification	<p>People who are contraindicated for mechanical prophylaxis</p> <p>People who are contraindicated for pharmacological prophylaxis</p>
Reasons for stratification	<p>People who are contraindicated for pharmacological/mechanical prophylaxis are not able to undergo pharmacological/mechanical prophylaxis and so cannot be lumped together with people who are not contraindicated. People who are contraindicated for both pharmacological and mechanical prophylaxis are excluded from this review as a separate review will be conducted on this population.</p>
Sensitivity/other analysis	<p>Vitamin K Antagonists (warfarin, acenocoumarol and phenindione) will be combined for the analysis</p> <p>LMWH licensed in the UK (dalteparin, tinzaparin, enoxaparin) will be combined for the analysis</p> <p>LMWH not licensed in the UK (Bemiparin, Certoparin, Nadroparin, Parnaparin, Reviparin) will be combined for the analysis</p>
Subgroup analyses if there is heterogeneity	<ul style="list-style-type: none"> - BMI (Mixed; Obese (BMI over 30 kg/m²); Severely obese (BMI over 35 kg/m²); Not obese (BMI under 30 kg/m²)); People who are obese (BMI over 30 kg/m²) and severely obese (BMI over 35 kg/m²) are at higher risk of VTE and major bleeding - Renal impairment (Renal impairment (eGFR less than 45 ml/min/1.73m²); No renal impairment (eGFR greater than 45 ml/min/1.73m²)); People with renal impairment (estimated glomerular filtration rate (eGFR) of less than 45 ml/min/1.73m²) are at higher risk of VTE and major bleeding - Mobility (Mobile; Totally immobile); People who are immobile are at higher risk of VTE
Search criteria	<p>Databases: Medline, Embase, The Cochrane Library</p> <p>Date limits for search: Update of previous NICE guideline: Venous thromboembolism - reducing the risk (CG92). Final search date for CG92: 10 December 2008</p> <p>Language: Studies published in English language only</p>

C.14 Cancer

Table 19: Review protocol: What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) for people with cancer having day procedures?

Review question	What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) for people being treated for cancer who are having day procedures?
Objectives	To find the most effective strategy for preventing VTE in people being treated for cancer who are having day procedures
Population	<p>Adults and young people (16 years and older) with cancer who are having day procedures</p> <p>Active cancer defined as receiving active anti-mitotic treatment; or was diagnosed within last 6 months; or recurrent or metastatic; or where the cancer is inoperable. This definition excludes squamous skin cancer and basal cell carcinoma.</p>
Interventions	<p>Mechanical:</p> <ul style="list-style-type: none"> Anti-embolism stockings (AES) (above or below knee) Intermittent pneumatic compression (IPCD) devices (full leg or below knee) Foot pumps or foot impulse devices (FID) Electrical stimulation (including Geko devices) Continuous passive motion <p>Pharmacological:</p> <p>Unfractionated heparin (UFH) (low dose, administered subcutaneously)</p> <p>Low molecular weight heparin (LMWH), licensed in UK:</p> <ul style="list-style-type: none"> enoxaparin (standard prophylactic dose 40mg daily; minimum 20mg daily* to maximum 60mg twice daily*) dalteparin (standard prophylactic dose 5000 units once daily; minimum 1250 units once daily* to maximum 5000 units twice daily*; obese patients – maximum 7500 twice units daily*) tinzaparin (standard prophylactic dose 3500 units once daily; minimum 2500 units once daily* to maximum 4500 units twice daily*; obese patients – maximum 6750 twice daily*) <p>LMWH, licensed in countries other than UK:</p> <ul style="list-style-type: none"> Bemiparin (standard 2500 units daily; minimum 2500 units daily to maximum 3500 units daily) Certoparin (3000 units daily) Nadroparin (standard 2850 units once daily; minimum 2850 units once daily to maximum up to 57 units/kg once daily) Parnaparin (standard 3200 units once daily; minimum 3200 units once daily to maximum 4250 units once daily) Reviparin (minimum 1750 units once daily to maximum 4200 units once daily) <p>Vitamin K Antagonists:</p> <ul style="list-style-type: none"> warfarin (variable dose only) acenocoumarol (all doses) phenindione (all doses) Fondaparinux (all doses)* Apixaban (all doses)* Dabigatran (all doses)* Rivaroxaban (all doses)* Aspirin (up to 300mg)*

Review question	What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) for people being treated for cancer who are having day procedures?
	*off-label
Comparisons	<p>Compared to:</p> <p>Other VTE prophylaxis treatment, including monotherapy and combination treatments (between class comparisons for pharmacological treatments only)</p> <p>No VTE prophylaxis treatment (no treatment, usual care, placebo)</p> <p>Within intervention (including same drug) comparisons, including:</p> <p>Above versus below knee stockings</p> <p>Full leg versus below knee IPC devices</p> <p>Standard versus extended duration prophylaxis</p> <p>Low versus high dose for LMWH</p> <p>Preoperative versus post-operative initiation of LMWH</p>
Outcomes	<p>Critical outcomes:</p> <p>All-cause mortality (up to 180 days from hospital discharge)</p> <p>Deep vein thrombosis (symptomatic and asymptomatic) (7-180 days from hospital discharge). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool)</p> <p>Pulmonary embolism (7-180 days from hospital discharge). Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE</p> <p>Major bleeding (up to 45 days from hospital discharge). A major bleeding event meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood ; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event. Includes unplanned visit to theatre for control of bleeding</p> <p>Fatal PE (7- 90 days from hospital discharge). Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE</p> <p>Important outcomes:</p> <p>Clinically relevant non-major bleeding (up to 45 days from hospital discharge): bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy.</p> <p>Health-related quality of life (validated scores only)(up to 180 days from hospital discharge)</p> <p>Heparin-induced thrombocytopenia (HIT) (duration of study)</p> <p>Technical complications of mechanical interventions (duration of study)</p>
Study design	Randomised controlled trials (RCTs), systematic reviews of RCTs.
Settings	Primary and community care when continuing prophylaxis after hospital discharge Secondary care
Exclusions	<p>Studies where people received or were assumed to have received treatment for their conditions that is not used in current practice</p> <p>Community settings and hospices, except when continuing prophylaxis that has been started in hospital</p> <p>People with suspected or confirmed venous thromboembolism</p> <p>Secondary prevention of VTE</p> <p>Early mobilisation and leg exercises</p> <p>Non-English studies</p>

Review question	What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) for people being treated for cancer who are having day procedures?
	Duration of follow-up <7 days; >150 days
Review strategy	<p>Drug groups combined for analysis:</p> <ul style="list-style-type: none"> • LMWH • Vitamin K Antagonists <p>Outcomes reported at different time points will be analysed together GRADE assessments will be conducted. Outcomes that are not confirmed by methods listed in protocol, or where methods of confirmation are not reported, will be downgraded for indirectness.</p>
Stratification	<p>People who are contraindicated for pharmacological prophylaxis</p> <p>People who are contraindicated for mechanical prophylaxis</p>
Subgroup analyses if there is heterogeneity	<p>BMI: not obese (BMI under 30kg/m²) obese (obesity I and II, 30–34.9kg/m²); severely obese (obesity III, ≥40kg/m²)</p> <p>Renal impairment (no renal impairment eGFR >30; renal impairment eGFR <30)</p> <p>Chemotherapy</p> <p>Tumour (solid; haematological)</p>
Search strategy	<p>Databases: Medline, Embase, The Cochrane Library</p> <p>Date limits: Update of previous NICE guideline: Venous thromboembolism - reducing the risk (CG92). Final search date for CG92: 10 December 2008</p>

C.15 Patients with central venous catheters

Table 20: Review protocol: What is the effectiveness of different pharmacological prophylaxis strategies (alone or in combination) for people with central venous catheters?

Review question	What is the effectiveness of different pharmacological prophylaxis strategies (alone or in combination) for people with central venous catheters?
Objectives	To find the most effective strategy for preventing VTE in people admitted to or discharged from hospital with central venous catheters
Population	<p>Adults and young people (16 years and older) with central venous catheters who are:</p> <p>Admitted to hospital</p> <p>Discharged from hospital</p> <p>Outpatients</p>
Interventions	<p>Pharmacological:</p> <p>Unfractionated heparin (UFH) (low dose, administered subcutaneously)</p> <p>Low molecular weight heparin (LMWH), licensed in UK: enoxaparin (standard prophylactic dose 40 mg daily; minimum 20 mg daily* to maximum 60 mg twice daily*) dalteparin (standard prophylactic dose 5000 units once daily; minimum 1250 units once daily* to maximum 5000 units twice daily*; obese patients – maximum 7500 twice units daily*) tinzaparin (standard prophylactic dose 4500 units once daily; minimum 2500 units once daily* to maximum 4500 units twice daily*; obese patients – maximum 6750 twice daily*)</p>

Review question	What is the effectiveness of different pharmacological prophylaxis strategies (alone or in combination) for people with central venous catheters?
	<p>LMWH, licensed in countries other than UK: Bemiparin (standard 2500 units daily; minimum 2500 units daily to maximum 3500 units daily) Certoparin (3000 units daily) Nadroparin (standard 2850 units once daily; minimum 2850 units once daily to maximum up to 57 units/kg once daily) Parnaparin (standard 3200 units once daily; minimum 3200 units once daily to maximum 4250 units once daily) Reviparin (minimum 1750 units once daily to maximum 4200 units once daily) Vitamin K Antagonists: warfarin (variable dose only) acenocoumarol (all doses) phenindione (all doses) Fondaparinux (all doses)* Apixaban (all doses)* Dabigatran (all doses)* Rivaroxaban (all doses)* Aspirin (up to 300 mg)*</p> <p>*off-label</p>
Comparisons	<p>Compared to: Other VTE prophylaxis treatment, including monotherapy and combination treatments (between class comparisons for pharmacological treatments only) No VTE prophylaxis treatment (no treatment, usual care, placebo)</p> <p>Within intervention (including same drug) comparisons, including: Standard versus extended duration prophylaxis. Extended duration = extended beyond discharge Low versus high dose for LMWH Preoperative versus post-operative initiation of LMWH</p>
Outcomes	<p>Critical outcomes: All-cause mortality (up to 90 days after line removed) (NMA outcome) Deep vein thrombosis (symptomatic and asymptomatic) (up to 90 days after line removed). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) Pulmonary embolism (up to 90 days after line removed). Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE Major bleeding (up to 45 days after line removed). A major bleeding event meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood ; leads to a drop in haemoglobin of ≥ 2 g/dL; a serious or life threatening clinical event. Includes unplanned visit to theatre for control of bleeding Fatal PE (up to 90 days after line removed). Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE</p> <p>Important outcomes: Clinically relevant non-major bleeding (up to 45 days after line removed): bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change</p>

Review question	What is the effectiveness of different pharmacological prophylaxis strategies (alone or in combination) for people with central venous catheters?
	<p>in antithrombotic therapy.</p> <p>Health-related quality of life (validated scores only)(up to 90 days after line removed)</p> <p>Heparin-induced thrombocytopenia (HIT) (duration of study)</p> <p>Technical complications of mechanical interventions (duration of study)</p>
Study design	Randomised controlled trials (RCTs), systematic reviews of RCTs
Settings	<p>Primary and community care when continuing prophylaxis after hospital discharge</p> <p>Secondary care</p>
Exclusions	<p>Community settings and hospices, except when continuing prophylaxis that has been started in hospital</p> <p>People who are contraindicated for both mechanical and pharmacological prophylaxis</p> <p>People with suspected or confirmed venous thromboembolism</p> <p>Secondary prevention of VTE</p> <p>Early mobilisation and leg exercises</p> <p>Non-English studies</p> <p>Duration of follow-up <7 days; >150 days</p>
Review strategy	<p>Drug groups combined for analysis:</p> <p>LMWH</p> <p>Vitamin K Antagonists</p> <p>Outcomes reported at different time points will be analysed together</p>
Stratification	People who are contraindicated
Subgroup analyses if there is heterogeneity	<p>BMI: not obese (BMI under 30 kg/m²); obese (BMI over 30 kg/m²); severely obese (BMI over 35 kg/m²);</p> <p>Renal impairment (no renal impairment eGFR >30; renal impairment eGFR <30)</p> <p>Active cancer (defined as receiving active anti-mitotic treatment; or was diagnosed within last 6 months; or recurrent or metastatic; or where the cancer is inoperable. This definition excludes squamous skin cancer and basal cell carcinoma); no active cancer</p>
Other analysis	<p>The quality of the data will be assessed using GRADE.</p> <p>Outcomes that are not confirmed by methods listed in protocol, or where methods of confirmation are not reported, will be downgraded for indirectness</p> <p>For all-cause mortality, DVT, PE, fatal PE, quality of life and heparin-induced thrombocytopenia outcomes measured at 91 to 150 days will be downgraded for indirectness</p> <p>For major bleeding and clinically relevant non-major bleeding outcomes measured at 46 to 90 days will be downgraded for indirectness</p>
Search strategy	<p>Databases:</p> <p>Medline, Embase, The Cochrane Library</p> <p>Date limits:</p> <p>Update of previous NICE guideline: Venous thromboembolism - reducing the risk (CG92).</p> <p>Final search date for CG92: 10 December 2008</p>

C.16 Palliative care

Table 21: Review protocol: People who are having palliative care

Review question	What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) for people who are having palliative care?
Objectives	To find the most effective strategy for preventing VTE in people admitted to and discharged from hospital who are having palliative care
Population	<p>Adults and young people (16 years and older) admitted to hospital and discharged from who are having palliative care.</p> <p>Definition from NHS the More Care, Less Pathway review: palliative care focuses on the relief of pain and other symptoms and problems experienced in serious illness. The goal of palliative care is to improve quality of life, by increasing comfort, promoting dignity and providing a support system to the person who is ill and those close to them.</p>
Interventions	<p>Mechanical:</p> <ul style="list-style-type: none"> Anti-embolism stockings (AES) (above or below knee) Intermittent pneumatic compression (IPCD) devices (full leg or below knee) Foot pumps or foot impulse devices (FID) Electrical stimulation (including Geko devices) Continuous passive motion Vena caval filters <p>Pharmacological:</p> <ul style="list-style-type: none"> Unfractionated heparin (UFH) (low dose, administered subcutaneously) Low molecular weight heparin (LMWH), licensed in UK: <ul style="list-style-type: none"> enoxaparin (standard prophylactic dose 40mg daily; minimum 20mg daily* to maximum 60mg twice daily*) dalteparin (standard prophylactic dose 5000 units once daily; minimum 1250 units once daily* to maximum 5000 units twice daily*; obese patients – maximum 7500 twice units daily*) tinzaparin (standard prophylactic dose 3500 units once daily; minimum 2500 units once daily* to maximum 4500 units twice daily*; obese patients – maximum 6750 twice daily*) LMWH, licensed in countries other than UK: <ul style="list-style-type: none"> Bemiparin (standard 2500 units daily; minimum 2500 units daily to maximum 3500 units daily) Certoparin (3000 units daily) Nadroparin (standard 2850 units once daily; minimum 2850 units once daily to maximum up to 57 units/kg once daily) Parnaparin (standard 3200 units once daily; minimum 3200 units once daily to maximum 4250 units once daily) Reviparin (minimum 1750 units once daily to maximum 4200 units once daily) Vitamin K Antagonists: <ul style="list-style-type: none"> warfarin (variable dose only) acenocoumarol (all doses) phenindione (all doses) Fondaparinux (all doses)* Apixaban (all doses)* Dabigatran (all doses)* Rivaroxaban (all doses)* Aspirin (up to 300mg)*

Review question	What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) for people who are having palliative care?
	*off-label
Comparisons	<p>Compared to:</p> <p>Other VTE prophylaxis treatment, including monotherapy and combination treatments (between class comparisons for pharmacological treatments only)</p> <p>No VTE prophylaxis treatment (no treatment, usual care, placebo)</p> <p>Within intervention (including same drug) comparisons, including:</p> <p>Above versus below knee stockings</p> <p>Full leg versus below knee IPC devices</p> <p>Standard versus extended duration prophylaxis</p> <p>Low versus high dose for LMWH</p>
Outcomes	<p>Critical outcomes:</p> <p>Health-related quality of life (validated scores only)(up to 90 days from hospital discharge)</p> <p>Deep vein thrombosis (symptomatic and asymptomatic) (7-90 days from hospital discharge). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool)</p> <p>Pulmonary embolism (7-90 days from hospital discharge). Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE</p> <p>Major bleeding (up to 45 days from hospital discharge). A major bleeding event meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood ; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event. Includes unplanned visit to theatre for control of bleeding</p> <p>Important outcomes:</p> <p>All-cause mortality (up to 90 days from hospital discharge)</p> <p>Fatal PE (7- 90 days from hospital discharge). Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE</p> <p>Clinically relevant non-major bleeding (up to 45 days from hospital discharge): bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy.</p> <p>Heparin-induced thrombocytopenia (HIT) (duration of study)</p> <p>Technical complications of mechanical interventions (duration of study)</p>
Study design	Randomised controlled trials (RCTs), systematic reviews of RCTs.
Settings	Primary and community care when continuing prophylaxis after hospital discharge Secondary care
Exclusions	<p>Community settings and hospices, except when continuing prophylaxis that has been started in hospital</p> <p>People who are contraindicated for both mechanical and pharmacological prophylaxis</p> <p>People with suspected or confirmed venous thromboembolism</p> <p>Secondary prevention of VTE</p> <p>Early mobilisation and leg exercises</p> <p>Non-English studies</p> <p>Duration of follow-up <7 days; >150 days</p>
Review strategy	<p>Drug groups combined for analysis:</p> <p>LMWH</p> <p>Vitamin K Antagonists</p>

Review question	What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) for people who are having palliative care?
	Outcomes reported at different time points will be analysed together
Stratification	People who are contraindicated End of life care (last days of life 2-3 days; last year of life)
Subgroup analyses if there is heterogeneity	BMI: not obese (BMI under 30kg/m ²) obese (obesity I and II, 30–34.9kg/m ²); severely obese (obesity III, ≥40kg/m ²) Renal impairment (no renal impairment eGFR >30; renal impairment eGFR <30) Active cancer (defined as receiving active anti-mitotic treatment; or was diagnosed within last 6 months; or recurrent or metastatic; or where the cancer is inoperable. This definition excludes squamous skin cancer and basal cell carcinoma); no active cancer
Other analysis	The quality of the data will be assessed using GRADE. Outcomes that are not confirmed by methods listed in protocol, or where methods of confirmation are not reported, will be downgraded for indirectness For all-cause mortality, DVT, PE, fatal PE, quality of life and heparin-induced thrombocytopenia outcomes measured at 91 to 150 days will be downgraded for indirectness
Search strategy	Databases: Medline, Embase, The Cochrane Library Date limits: Update of previous NICE guideline: Venous thromboembolism - reducing the risk (CG92). Final search date for CG92: 10 December 2008

C.17 Critical care

Table 22: Review protocol: People admitted to intensive care units

Review question	What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) for people admitted to intensive care units?
Objectives	To find the most effective strategy for preventing VTE in people admitted to intensive care units
Population	Adults and young people (16 years and older) admitted to intensive care units
Interventions	Mechanical: Anti-embolism stockings (AES) (above or below knee) Intermittent pneumatic compression (IPCD) devices (full leg or below knee) Foot pumps or foot impulse devices (FID) Electrical stimulation (including Geko devices) Continuous passive motion Vena caval filters Pharmacological: Unfractionated heparin (UFH) (low dose, administered subcutaneously) Low molecular weight heparin (LMWH), licensed in UK: enoxaparin (standard prophylactic dose 40mg daily; minimum 20mg daily* to maximum 60mg twice daily*) dalteparin (standard prophylactic dose 5000 units once daily; minimum 1250

Review question	What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) for people admitted to intensive care units?
	<p>units once daily* to maximum 5000 units twice daily*; obese patients – maximum 7500 twice units daily*)</p> <p>tinzaparin (standard prophylactic dose 3500 units daily; minimum 2500 units once daily* to maximum 4500 units twice daily*; obese patients – maximum 6750 twice daily*)</p> <p>LMWH, licensed in countries other than UK:</p> <p>Bemiparin (standard 2500 units daily; minimum 2500 units daily to maximum 3500 units daily)</p> <p>Certoparin (3000 units daily)</p> <p>Nadroparin (standard 2850 units once daily; minimum 2850 units once daily to maximum up to 57 units/kg once daily)</p> <p>Parnaparin (standard 3200 units once daily; minimum 3200 units once daily to maximum 4250 units once daily)</p> <p>Reviparin (minimum 1750 units once daily to maximum 4200 units once daily)</p> <p>Vitamin K Antagonists:</p> <p>warfarin (variable dose only)</p> <p>acenocoumarol (all doses)</p> <p>phenindione (all doses)</p> <p>Fondaparinux (all doses)*</p> <p>Apixaban (all doses)*</p> <p>Dabigatran (all doses)*</p> <p>Rivaroxaban (all doses)*</p> <p>Aspirin (up to 300mg)*</p> <p>*off-label</p>
Comparisons	<p>Compared to:</p> <p>Other VTE prophylaxis treatment, including monotherapy and combination treatments (between class comparisons for pharmacological treatments only)</p> <p>No VTE prophylaxis treatment (no treatment, usual care, placebo)</p> <p>Within intervention (including same drug) comparisons, including:</p> <p>Above versus below knee stockings</p> <p>Full leg versus below knee IPC devices</p> <p>Standard versus extended duration prophylaxis</p> <p>Low versus high dose for LMWH</p> <p>Preoperative versus post-operative initiation of LMWH</p>
Outcomes	<p>Critical outcomes:</p> <p>All-cause mortality (up to 90 days after leaving ICU)</p> <p>Deep vein thrombosis (symptomatic and asymptomatic) (up to 90 days after leaving ICU). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool)</p> <p>Pulmonary embolism (up to 90 days after leaving ICU). Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQspect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE</p> <p>Major bleeding (up to 45 days after leaving ICU). A major bleeding event meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the</p>

Review question	What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) for people admitted to intensive care units?
	<p>need for a transfusion of at least 2 units of blood ; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event. Includes unplanned visit to theatre for control of bleeding</p> <p>Fatal PE (up to 90 days after leaving ICU). Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE</p> <p>Important outcomes:</p> <p>Clinically relevant non-major bleeding (up to 45 days after leaving ICU): bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy.</p> <p>Health-related quality of life (validated scores only)(up to 90 after leaving ICU)</p> <p>Heparin-induced thrombocytopenia (HIT) (duration of study)</p> <p>Technical complications of mechanical interventions (duration of study)</p> <p>Line associated thrombosis (duration of study)</p>
Study design	Randomised controlled trials (RCTs), systematic reviews of RCTs.
Settings	Intensive care units
Exclusions	<p>Community settings and hospices, except when continuing prophylaxis that has been started in hospital</p> <p>People who are contraindicated for both mechanical and pharmacological prophylaxis</p> <p>People with suspected or confirmed venous thromboembolism</p> <p>Secondary prevention of VTE</p> <p>Early mobilisation and leg exercises</p> <p>Non-English studies</p> <p>Duration of follow-up < 7 days; > 150 days</p>
Review strategy	<p>Drug groups combined for analysis:</p> <p>LMWH</p> <p>Vitamin K Antagonists</p> <p>Outcomes reported at different time points will be analysed together</p>
Stratification	People who are contraindicated
Subgroup analyses if there is heterogeneity	<p>BMI: not obese (BMI under 30kg/m^2) obese (obesity I and II, $30\text{--}34.9\text{kg/m}^2$); severely obese (obesity III, $\geq 40\text{kg/m}^2$)</p> <p>Renal impairment (no renal impairment $\text{eGFR} > 30$; renal impairment $\text{eGFR} < 30$)</p> <p>Active cancer (defined as receiving active anti-mitotic treatment; or was diagnosed within last 6 months; or recurrent or metastatic; or where the cancer is inoperable. This definition excludes squamous skin cancer and basal cell carcinoma); no active cancer</p> <p>Surgical; medical; trauma</p>
Other analysis	<p>The quality of the data will be assessed using GRADE.</p> <p>Outcomes that are not confirmed by methods listed in protocol, or where methods of confirmation are not reported, will be downgraded for indirectness</p> <p>For all-cause mortality, DVT, PE, fatal PE, quality of life and heparin-induced</p>

Review question	What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) for people admitted to intensive care units?
	thrombocytopenia outcomes measured at 91 to 150 days will be downgraded for indirectness
Search strategy	Databases: Medline, Embase, The Cochrane Library Date limits: Update of previous NICE guideline: Venous thromboembolism - reducing the risk (CG92). Final search date for CG92: 10 December 2008

C.18 Pregnant women and women up to 6 weeks postpartum

Table 23: Review protocol: What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) for pregnant women admitted to hospital (including up to 6 weeks after giving birth)?

Review question	What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) for pregnant women admitted to hospital (including up to 6 weeks after giving birth)?
Objectives	To find the most effective strategy for preventing VTE in pregnant women admitted to hospital (including up to 6 weeks after giving birth)
Population	Pregnant women (including up to 6 weeks after giving birth) who are: <ul style="list-style-type: none"> Admitted to hospital for 24 hours or more Having day procedures including early pregnancy loss (miscarriage and termination)
Interventions	<p>Mechanical:</p> <ul style="list-style-type: none"> Anti-embolism stockings (AES) (above or below knee) Intermittent pneumatic compression (IPCD) devices (full leg or below knee) Foot pumps or foot impulse devices (FID) Electrical stimulation (including Geko devices) Continuous passive motion <p>Pharmacological:</p> <ul style="list-style-type: none"> Unfractionated heparin (UFH) (low dose, administered subcutaneously) <ul style="list-style-type: none"> Low dose 5000 units three times a day, except in third trimester this may increase to 10,000 twice a day Low molecular weight heparin (LMWH), licensed in UK: <ul style="list-style-type: none"> enoxaparin (standard prophylactic dose 40mg daily; minimum 20mg daily* to maximum 60mg twice daily*) dalteparin (standard prophylactic dose 5000 units once daily; minimum 1250 units once daily* to maximum total daily dose 10000*; obese patients – maximum 15000 units daily*) tinzaparin (standard prophylactic dose 3500 units once daily; minimum 2500 units once daily* to maximum 4500 units twice daily*; obese patients – maximum 6750 twice daily*) LMWH, licensed in countries other than UK: <ul style="list-style-type: none"> Bemiparin (standard 2500 units daily; minimum 2500 units daily to maximum 3500 units daily) Certoparin (3000 units daily)

	<ul style="list-style-type: none"> ○ Nadroparin (standard 2850 units once daily; minimum 2850 units once daily to maximum up to 57 units/kg once daily) ○ Parnaparin (standard 3200 units once daily; minimum 3200 units once daily to maximum 4250 units once daily) ○ Reviparin (minimum 1750 units once daily to maximum 4200 units once daily) ● Fondaparinux (all doses) ● Danaperoid (used in people with heparin allergy) ● Aspirin (up to 300mg)* <p>*off-label</p>
Comparisons	<p>Compared to:</p> <ul style="list-style-type: none"> ● Other VTE prophylaxis treatment, including monotherapy and combination treatments (between class comparisons for pharmacological treatments only) ● No VTE prophylaxis treatment (no treatment, usual care, placebo) <p>Within intervention (including same drug) comparisons, including:</p> <ul style="list-style-type: none"> ● Above versus below knee stockings ● Full leg versus below knee IPC devices ● Short versus extended duration prophylaxis ● Weight adjusted versus non-weight adjusted
Outcomes	<p>Critical outcomes:</p> <ul style="list-style-type: none"> ● All-cause mortality (up to 90 days from hospital discharge) ● Deep vein thrombosis (symptomatic and asymptomatic) (inpatient and up to 90 days from hospital discharge) . Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) ● Pulmonary embolism (Inpatient and up to 90 days from hospital discharge). Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE ● Major bleeding (inpatient and up to 45 days from hospital discharge). A major bleeding event meets one or more of the following criteria: results in death (including foetal death); occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of red blood cells; leads to a drop in haemoglobin of $\geq 20\text{g/l}$; a serious or life threatening clinical event (including having an adverse effect on the foetus). Includes unplanned visit to theatre for control of bleeding. ● Fatal PE (inpatient and up to 90 days from hospital discharge). Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE <p>Important outcomes:</p> <ul style="list-style-type: none"> ● Clinically relevant non-major bleeding (up to 45 days from hospital discharge): bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy (including the foetus). ● Health-related quality of life (validated scores only)(up to 90 days from hospital discharge) ● Heparin-induced thrombocytopenia (HIT) (duration of study) ● Technical complications of mechanical interventions (duration of study)
Study design	Randomised controlled trials (RCTs), systematic reviews of RCTs.
Settings	<ul style="list-style-type: none"> ● Secondary care (including midwifery units) ● Primary and community care when continuing prophylaxis after hospital

	discharge
Exclusions	<ul style="list-style-type: none"> • Initiation of prophylaxis in community settings and hospices • People with suspected or confirmed venous thromboembolism • Secondary prevention of arterial and venous thromboembolism • Early mobilisation and leg exercises • Non-English studies • Duration of follow-up <7 days; >150 days
Review strategy	<ul style="list-style-type: none"> • Outcomes reported at different time points will be analysed together • Doses of LMWH will be analysed together • GRADE assessments will be conducted • Outcomes that are not confirmed by methods listed in protocol, or where methods of confirmation are not reported, will be downgraded for indirectness
Stratification	<ul style="list-style-type: none"> • People who are contraindicated for pharmacological prophylaxis • People who are contraindicated for mechanical prophylaxis • Pregnant women undergoing caesarean section and any other surgery during pregnancy or postpartum (including day case termination surgery and surgical management of miscarriage) • Pregnant or postpartum women not undergoing surgery
Subgroup analyses if there is heterogeneity	<ul style="list-style-type: none"> • BMI: not obese (BMI under 30kg/m²) obese (obesity I and II, 30–34.9kg/m²); severely obese (obesity III, ≥40kg/m²) • Renal impairment (no renal impairment eGFR >30; renal impairment eGFR <30) • Assisted conception (assisted vs non-assisted pregnancy) • LMWH doses (high, standard, low)
Search strategy	<p>Databases:</p> <ul style="list-style-type: none"> • Medline, Embase, The Cochrane Library <p>Date limits:</p> <ul style="list-style-type: none"> • Update of previous NICE guideline: Venous thromboembolism - reducing the risk (CG92). • Final search date for CG92: 10 December 2008

C.19 People with psychiatric illness

Table 24: Review protocol: What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) for people with psychiatric disorders?

Review question	What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) for people with psychiatric disorders?
Guideline condition and its definition	VTE prophylaxis. Definition: Prevention of VTE in people admitted to and discharged from hospital, and people undergoing day procedures
Objectives	To find the most effective strategy for preventing VTE in people with psychiatric disorders
Review population	Adults and young people (16 years and older) with psychiatric disorders who are: <ul style="list-style-type: none"> • Admitted to hospital, psychiatric hospital or residential psychiatric unit • Having day procedures (for example electroconvulsive therapy) • Outpatients post-discharge

Review question	What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) for people with psychiatric disorders?
Pulmonary embolism	Adults Young people (aged 16 years or over)
	Line of therapy not an inclusion criterion
<p>Interventions and comparators: generic/class; specific/drug</p> <p>(All interventions will be compared with each other, unless otherwise stated)</p>	<p>Anti-embolism stockings; Above knee Anti-embolism stockings; Below knee Anti-embolism stockings; Mixed above/below knee Intermittent pneumatic compression devices ; Full leg Intermittent pneumatic compression devices ; Below knee Intermittent pneumatic compression devices ; Mixed full leg/below knee Foot pumps or foot impulse devices ; Foot pumps Foot pumps or foot impulse devices ; Foot impulse Electrical stimulation Continuous passive motion Unfractionated heparin ; Unfractionated heparin (low dose, administered subcutaneously) Low molecular weight heparin (licensed in UK); Dalteparin (1,250 units once daily - 5,000 units twice daily) Low molecular weight heparin (licensed in UK); Tinzaparin (2,500 units once daily – 9,000 units once daily) Low molecular weight heparin (licensed in UK); Enoxaparin (20mg once daily – 60mg twice daily) Vitamin K antagonists ; Warfarin (all doses) Vitamin K antagonists ; Acenocoumarol (all doses) Vitamin K antagonists ; Phenindione (all doses) Fondaparinux; Fondaparinux (all doses) Apixaban; Apixaban (all doses) Dabigatran; Dabigatran (all doses) Rivaroxaban; Rivaroxaban (all doses) Aspirin; Aspirin (up to 300mg) No treatment; Usual care No treatment; Placebo Low molecular weight heparin (not licensed in UK); Bemiparin (2500 units once daily - 3500 units once daily) Low molecular weight heparin (not licensed in UK); Certoparin (3000 units once daily) Low molecular weight heparin (not licensed in UK); Nadroparin (2850 units once daily - up to 57 units/kg once daily) Low molecular weight heparin (not licensed in UK); Parnaparin (3200 units once daily - 4250 units once daily) Low molecular weight heparin (not licensed in UK); Reviparin (1750 units once daily - 4200 units once daily)</p>
Outcomes	<p>- All-cause mortality at up to 90 days from hospital discharge (Dichotomous) CRITICAL</p> <p>- Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge (Dichotomous) CRITICAL</p> <p>- Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQspect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge (Dichotomous) CRITICAL</p> <p>- Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular,</p>

Review question	What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) for people with psychiatric disorders?
	<p>retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge (Dichotomous) CRITICAL</p> <p>- Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge (Dichotomous) CRITICAL</p> <p>- Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge (Dichotomous) IMPORTANT</p> <p>- Health-related quality of life (validated scores only) at up to 90 days from hospital discharge (Continuous) IMPORTANT</p> <p>- Heparin-induced thrombocytopenia at duration of study (Dichotomous) IMPORTANT</p> <p>- Technical complications of mechanical interventions at duration of study (Continuous) IMPORTANT</p>
Study design	Systematic Review RCT
Unit of randomisation	Patient
Crossover study	Not permitted
Minimum duration of study	Not defined
Other exclusions	<p>People with suspected or confirmed venous thromboembolism</p> <p>Community settings and hospices, except when continuing prophylaxis that has been started in hospital</p> <p>Secondary prevention of VTE</p> <p>Early mobilisation and leg exercises</p> <p>People who are contraindicated for pharmacological and mechanical prophylaxis</p>
Population stratification	<p>People who are contraindicated for mechanical prophylaxis</p> <p>People who are contraindicated for pharmacological prophylaxis</p>
Reasons for stratification	<p>People who are contraindicated for pharmacological/mechanical prophylaxis are not able to undergo pharmacological/mechanical prophylaxis and so cannot be lumped together with people who are not contraindicated. People who are contraindicated for both pharmacological and mechanical prophylaxis are excluded from this review as a separate review will be conducted on this population.</p>
Other stratifications	None
Sensitivity/other analysis	<p>Vitamin K Antagonists (warfarin, acenocoumarol and phenindione) will be combined for the analysis</p> <p>LMWH licensed in the UK (dalteparin, tinzaparin, enoxaparin) will be combined for the analysis</p> <p>LMWH not licensed in the UK (Bemiparin, Certoparin, Nadroparin, Parnaparin, Reviparin) will be combined for the analysis</p>
Subgroup analyses if there is heterogeneity	<p>- BMI (Mixed; Obese (BMI over 30 kg/m²); Severely obese (BMI over 35 kg/m²); Not obese (BMI under 30 kg/m²)); People who are obese (BMI over 30 kg/m²) and severely obese (BMI over 35 kg/m²) are at higher risk of VTE and major bleeding</p> <p>- Renal impairment (Renal impairment (eGFR less than 30 ml/min/1.73m²); No renal impairment (eGFR greater than 30ml/min/1.73m²)); People with renal</p>

Review question	What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) for people with psychiatric disorders?
	<p>impairment (estimated glomerular filtration rate (eGFR) of less than 30ml/min/1.73m²) are at higher risk of VTE and major bleeding</p> <p>-Antipsychotic use (Antipsychotic use; no antipsychotic use)</p> <p>-Mobility (Catatonic/immobile; mobile)</p>
Search criteria	<p>Databases: Medline, Embase, The Cochrane Library</p> <p>Date limits for search: Update of previous NICE guideline: Venous thromboembolism - reducing the risk (CG92). Final search date for CG92: 10 December 2008</p> <p>Language: Studies published in English language only</p>

C.20 Anaesthesia

None

C.21 Lower limb immobilisation

Table 25: Review protocol: What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) in people with lower limb immobilisation?

Review question	What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) in people with lower limb immobilisation?
Objectives	To find the most effective strategy for preventing VTE in people with lower limb immobilisation
Population	<p>Adults and young people (16 years and older) with lower limb immobilisation who are:</p> <p>Admitted to hospital</p> <p>Having day procedures</p> <p>Outpatients post-discharge</p> <p>Immobilisation is defined as any clinical decision taken to manage the affected limb in such a way as to prevent normal weight bearing status and/or use of that limb.</p>
Interventions	<p>Mechanical:</p> <p>Anti-embolism stockings (AES) (above or below knee)</p> <p>Intermittent pneumatic compression (IPCD) devices (full leg or below knee)</p> <p>Foot pumps or foot impulse devices (FID)</p> <p>Electrical stimulation (including Geko devices)</p> <p>Pharmacological:</p> <p>Unfractionated heparin (UFH) (low dose, administered subcutaneously)</p> <p>Low molecular weight heparin (LMWH), licensed in UK:</p> <p>enoxaparin (standard prophylactic dose 40mg daily; minimum 20mg daily* to maximum 60mg twice daily*)</p> <p>dalteparin (standard prophylactic dose 5000 units once daily; minimum 1250 units once daily* to maximum 5000 units twice daily*; obese patients – maximum 7500 twice units daily*)</p> <p>tinzaparin (standard prophylactic dose 4500 units once daily; minimum 2500 units once daily* to maximum 4500 units twice daily*; obese patients – maximum 6750 twice daily*)</p>

Review question	What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) in people with lower limb immobilisation?
	<p>LMWH, licensed in countries other than UK: Bemiparin (standard 2500 units daily; minimum 2500 units daily to maximum 3500 units daily) Certoparin (3000 units daily) Nadroparin (standard 2850 units once daily; minimum 2850 units once daily to maximum up to 57 units/kg once daily) Parnaparin (standard 3200 units once daily; minimum 3200 units once daily to maximum 4250 units once daily) Reviparin (minimum 1750 units once daily to maximum 4200 units once daily) Vitamin K Antagonists: warfarin (variable dose only) acenocoumarol (all doses) phenindione (all doses) Fondaparinux (all doses)* Apixaban (all doses)* Dabigatran (all doses)* Rivaroxaban (all doses)* Aspirin (up to 300mg)*</p> <p>*off-label</p>
Comparisons	<p>Compared to: Other VTE prophylaxis treatment, including monotherapy and combination treatments (between class comparisons for pharmacological treatments only) No VTE prophylaxis treatment (no treatment, usual care, placebo)</p> <p>Within intervention (including same drug) comparisons, including: Above versus below knee stockings Full leg versus below knee IPC devices Standard versus extended duration prophylaxis Low versus high dose for LMWH Preoperative versus post-operative initiation of LMWH</p>
Outcomes	<p>Critical outcomes: All-cause mortality (up to 90 days from hospital discharge) Deep vein thrombosis (symptomatic and asymptomatic) (7-90 days from hospital discharge. Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) Pulmonary embolism (7-90 days from hospital discharge). Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE Major bleeding (up to 45 days from hospital discharge). A major bleeding event meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood ; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event. Includes unplanned visit to theatre for control of bleeding Fatal PE (7- 90 days from hospital discharge). Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE</p> <p>Important outcomes:</p>

Review question	What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) in people with lower limb immobilisation?
	<p>Clinically relevant non-major bleeding (up to 45 days from hospital discharge): bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy.</p> <p>Health-related quality of life (validated scores only)(up to 90 days from hospital discharge)</p> <p>Heparin-induced thrombocytopenia (HIT) (duration of study)</p> <p>Technical complications of mechanical interventions (duration of study)</p> <p>Unplanned return to theatre (up to 45 days from hospital discharge)</p>
Study design	Randomised controlled trials (RCTs), systematic reviews of RCTs
Settings	<p>Primary and community care when continuing prophylaxis after hospital discharge</p> <p>Secondary care</p>
Exclusions	<p>Studies where people received or were assumed to have received treatment for their conditions that is not used in current practice</p> <p>Community settings and hospices, except when continuing prophylaxis that has been started in hospital</p> <p>People with suspected or confirmed venous thromboembolism</p> <p>Secondary prevention of VTE</p> <p>Early mobilisation and leg exercises</p> <p>Non-English studies</p> <p>Duration of follow-up <7 days; >150 days</p>
Review strategy	<p>Drug groups combined for analysis:</p> <p>LMWH</p> <p>Vitamin K Antagonists</p> <p>Outcomes reported at different time points will be analysed together</p> <p>GRADE assessments will be conducted. Outcomes that are not confirmed by methods listed in protocol, or where methods of confirmation are not reported, will be downgraded for indirectness. For all-cause mortality, DVT, PE, fatal PE, quality of life and heparin-induced thrombocytopenia outcomes measured at 91 to 150 days will be downgraded for indirectness</p> <p>Network-meta analysis will be conducted for the outcomes specified above where possible.</p>
Stratification	<p>People who are contraindicated for pharmacological prophylaxis</p> <p>People who are contraindicated for mechanical prophylaxis</p>
Subgroup analyses if there is heterogeneity	<p>BMI: not obese (BMI under 30kg/m²); obese (obesity I and II, 30–34.9kg/m²); severely obese (obesity III, ≥40kg/m²)</p> <p>Renal impairment (no renal impairment eGFR >30; renal impairment eGFR <30)</p> <p>Active cancer (defined as receiving active anti-mitotic treatment; or was diagnosed within last 6 months; or recurrent or metastatic; or where the cancer is inoperable. This definition excludes squamous skin cancer and basal cell carcinoma); no active cancer</p> <p>Weight bearing; non-weight bearing</p>
Search strategy	<p>Databases:</p> <p>Medline, Embase, The Cochrane Library</p> <p>Date limits:</p> <p>Update of previous NICE guideline: Venous thromboembolism - reducing the risk (CG92).</p> <p>Final search date for CG92: 10 December 2008</p>

C.22 Fragility fractures of the pelvis, hip and proximal femur

Table 26: Review protocol: What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) for people with fragility fractures of the pelvis, hip or proximal femur?

Review question	What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) for people with fragility fractures of the pelvis, hip or proximal femur?
Guideline condition and its definition	VTE prophylaxis. Definition: Prevention of VTE in people admitted to and discharged from hospital, and people undergoing day procedures
Objectives	To find the most effective strategy for preventing VTE in people with fragility fractures of the pelvis, hip or proximal femur
Review population	Adults and young people (16 years and older) with fragility fractures of the pelvis, hip or proximal femur
	Adults Young people (aged 16 years or over)
	Line of therapy not an inclusion criterion
Interventions and comparators: generic/class; specific/drug (All interventions will be compared with each other, unless otherwise stated)	Anti-embolism stockings; Above knee Anti-embolism stockings; Below knee Anti-embolism stockings; Mixed above/below knee Intermittent pneumatic compression devices ; Full leg Intermittent pneumatic compression devices ; Below knee Intermittent pneumatic compression devices ; Mixed full leg/below knee Foot pumps or foot impulse devices ; Foot pumps Foot pumps or foot impulse devices ; Foot impulse Electrical stimulation Continuous passive motion Vena cava filters Unfractionated heparin ; Unfractionated heparin (low dose, administered subcutaneously) Low molecular weight heparin (licensed in UK); Dalteparin (1,250 units once daily - 5,000 units twice daily) Low molecular weight heparin (licensed in UK); Tinzaparin (2,500 units once daily – 9,000 units once daily) Low molecular weight heparin (licensed in UK); Enoxaparin (20mg once daily – 60mg twice daily) Vitamin K antagonists ; Warfarin (all doses) Vitamin K antagonists ; Acenocoumarol (all doses) Vitamin K antagonists ; Phenindione (all doses) Fondaparinux; Fondaparinux (all doses) Apixaban; Apixaban (all doses) Dabigatran; Dabigatran (all doses) Rivaroxaban; Rivaroxaban (all doses) Aspirin; Aspirin (up to 300mg) No treatment; Usual care No treatment; Placebo Low molecular weight heparin (not licensed in UK); Bemiparin (2500 units once daily - 3500 units once daily) Low molecular weight heparin (not licensed in UK); Certoparin (3000 units once daily) Low molecular weight heparin (not licensed in UK); Nadroparin (2850 units once daily - up to 57 units/kg once daily)

Review question	What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) for people with fragility fractures of the pelvis, hip or proximal femur?
	<p>Low molecular weight heparin (not licensed in UK); Parnaparin (3200 units once daily - 4250 units once daily)</p> <p>Low molecular weight heparin (not licensed in UK); Reviparin (1750 units once daily - 4200 units once daily)</p>
Outcomes	<ul style="list-style-type: none"> - All-cause mortality at up to 90 days from hospital discharge (Dichotomous) CRITICAL - Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge (Dichotomous) CRITICAL - Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge (Dichotomous) CRITICAL - Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge (Dichotomous) CRITICAL - Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge (Dichotomous) CRITICAL - Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge (Dichotomous) IMPORTANT - Health-related quality of life (validated scores only) at up to 90 days from hospital discharge (Continuous) IMPORTANT - Heparin-induced thrombocytopenia at duration of study (Dichotomous) IMPORTANT - Technical complications of mechanical interventions at duration of study (Continuous) IMPORTANT - Infection at duration of study (Dichotomous) IMPORTANT - VTE at 7-90 days from hospital discharge (Dichotomous) ADDITIONAL - DVT (symptomatic) at 7-90 days from hospital discharge (Dichotomous) ADDITIONAL - DVT (distal) at 7-90 days from hospital discharge (Dichotomous) ADDITIONAL - DVT (proximal) at 7-90 days from hospital discharge (Dichotomous) ADDITIONAL - Fatal bleeding at 45 days from hospital discharge (Dichotomous) ADDITIONAL - Site of bleeding (gastrointestinal ; surgical site; brain/spine; other) at 45 days from hospital discharge (Dichotomous) ADDITIONAL
Study design	Systematic Review RCT
Unit of randomisation	Patient
Crossover study	Not permitted
Minimum duration of study	Follow-up <7 days
Other exclusions	<p>People with suspected or confirmed venous thromboembolism</p> <p>Community settings and hospices, except when continuing prophylaxis that has been started in hospital</p> <p>Secondary prevention of VTE</p>

Review question	What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) for people with fragility fractures of the pelvis, hip or proximal femur?
	<p>Early mobilisation and leg exercises</p> <p>People who are contraindicated for pharmacological and mechanical prophylaxis</p> <p>Non-English studies</p> <p>Duration of follow-up <7 days or >150 days</p>
Population stratification	<p>People who are contraindicated for mechanical prophylaxis</p> <p>People who are contraindicated for pharmacological prophylaxis</p>
Reasons for stratification	<p>People who are contraindicated for pharmacological/mechanical prophylaxis are not able to undergo pharmacological/mechanical prophylaxis and so cannot be lumped together with people who are not contraindicated. People who are contraindicated for both pharmacological and mechanical prophylaxis are excluded from this review as a separate review will be conducted on this population.</p>
Other stratifications	<p>People who are contraindicated</p>
Sensitivity/other analysis	<p>Vitamin K Antagonists (warfarin, acenocoumarol and phenindione) will be combined for the analysis</p> <p>LMWH licensed in the UK (dalteparin, tinzaparin, enoxaparin) will be combined for the analysis</p> <p>LMWH not licensed in the UK (Bemiparin, Certoparin, Nadroparin, Parnaparin, Reviparin) will be combined for the analysis</p>
Subgroup analyses if there is heterogeneity	<ul style="list-style-type: none"> - BMI (Mixed; Obese (BMI over 30 kg/m²); Severely obese (BMI over 35 kg/m²); Not obese (BMI under 30 kg/m²)); People who are obese (BMI over 30 kg/m²) and severely obese (BMI over 35 kg/m²) are at higher risk of VTE and major bleeding - Renal impairment (Renal impairment (eGFR less than 30 ml/min/1.73m²); No renal impairment (eGFR greater than 30ml/min/1.73m²)); People with renal impairment (estimated glomerular filtration rate (eGFR) of less than 30ml/min/1.73m²) are at higher risk of VTE and major bleeding - Cancer status (Not applicable; Not stated / Unclear; Active cancer (defines as receiving active anti-mitotic treatment, or was diagnosed in the last 6 months, or recurrent or metastatic, or where tumour is inoperable. Excludes squamous skin cancer and basel cell carcinoma); No active cancer); People with active cancer are at higher risk of VTE - Immobilisation (Internal fixation/immobilisaton; No fixation/immobilisation); People with fixation/immobilisation are at higher risk of VTE due to reduced mobility
Search criteria	<p>Databases: Medline, Embase, The Cochrane Library</p> <p>Date limits for search: Update of previous NICE guideline: Venous thromboembolism - reducing the risk (CG92). Final search date for CG92: 10 December 2008</p> <p>Language: Studies published in English language only</p>

C.23 Elective hip replacement

Table 27: Review protocol: What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) for people undergoing elective hip replacement?

Review question	What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) for people undergoing elective hip replacement?
Guideline condition and its definition	VTE prophylaxis. Definition: Prevention of VTE in people admitted to and discharged from hospital, and people undergoing day procedures
Objectives	To find the most effective strategy for preventing VTE in people undergoing elective hip replacement
Review population	Adults and young people (16 years and older) undergoing elective hip replacement admitted to and discharged from hospital
	Adults Young people (aged 16 years or over)
	Line of therapy not an inclusion criterion
Interventions and comparators: generic/class; specific/drug (All interventions will be compared with each other, unless otherwise stated)	Anti-embolism stockings; Above knee Anti-embolism stockings; Below knee Anti-embolism stockings; Mixed above/below knee Intermittent pneumatic compression devices ; Full leg Intermittent pneumatic compression devices ; Below knee Intermittent pneumatic compression devices ; Mixed full leg/below knee Foot pumps or foot impulse devices ; Foot pumps Foot pumps or foot impulse devices ; Foot impulse Electrical stimulation Continuous passive motion Unfractionated heparin ; Unfractionated heparin (low dose, administered subcutaneously) Low molecular weight heparin (licensed in UK); Dalteparin (1,250 units once daily - 5,000 units twice daily) Low molecular weight heparin (licensed in UK); Tinzaparin (2,500 units once daily – 9,000 units once daily) Low molecular weight heparin (licensed in UK); Enoxaparin (20mg once daily – 60mg twice daily) Vitamin K antagonists ; Warfarin (all doses) Vitamin K antagonists ; Acenocoumarol (all doses) Vitamin K antagonists ; Phenindione (all doses) Fondaparinux; Fondaparinux (all doses) Apixaban; Apixaban (all doses) Dabigatran; Dabigatran (all doses) Rivaroxaban; Rivaroxaban (all doses) Aspirin; Aspirin (up to 300mg) No treatment; Usual care No treatment; Placebo Low molecular weight heparin (not licensed in UK); Bemiparin (2500 units once daily - 3500 units once daily) Low molecular weight heparin (not licensed in UK); Certoparin (3000 units once daily) Low molecular weight heparin (not licensed in UK); Nadroparin (2850 units once daily - up to 57 units/kg once daily) Low molecular weight heparin (not licensed in UK); Parnaparin (3200 units once daily - 4250 units once daily) Low molecular weight heparin (not licensed in UK); Reviparin (1750 units once daily - 4200 units once daily)

Review question	What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) for people undergoing elective hip replacement?
Outcomes	<ul style="list-style-type: none"> - All-cause mortality at up to 90 days from hospital discharge (Dichotomous) CRITICAL - Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge (Dichotomous) CRITICAL - Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge (Dichotomous) CRITICAL - Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge (Dichotomous) CRITICAL - Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge (Dichotomous) CRITICAL - Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge (Dichotomous) IMPORTANT - Surgical site haematoma at up to 45 days from hospital discharge (Dichotomous) CRITICAL - Health-related quality of life (validated scores only) at up to 90 days from hospital discharge (Continuous) IMPORTANT - Heparin-induced thrombocytopenia at duration of study (Dichotomous) IMPORTANT - Technical complications of mechanical interventions at duration of study (Continuous) IMPORTANT - Infection at duration of study (Dichotomous) IMPORTANT - VTE at 7-90 days from hospital discharge (Dichotomous) ADDITIONAL - DVT (symptomatic) at 7-90 days from hospital discharge (Dichotomous) ADDITIONAL - DVT (distal) at 7-90 days from hospital discharge (Dichotomous) ADDITIONAL - DVT (proximal) at 7-90 days from hospital discharge ADDITIONAL - Fatal bleeding at 45 days from hospital discharge (Dichotomous) ADDITIONAL - Site of bleeding (gastrointestinal ; surgical site; brain/spine; other) at 45 days from hospital discharge (Dichotomous) ADDITIONAL
Study design	Systematic Review RCT
Unit of randomisation	Patient
Crossover study	Not permitted
Minimum duration of study	Not defined
Other exclusions	<p>People with suspected or confirmed venous thromboembolism</p> <p>Community settings and hospices, except when continuing prophylaxis that has been started in hospital</p> <p>Secondary prevention of VTE</p> <p>Early mobilisation and leg exercises</p> <p>People who are contraindicated for pharmacological and mechanical prophylaxis</p>

Review question	What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) for people undergoing elective hip replacement?
Population stratification	People who are contraindicated for mechanical prophylaxis People who are contraindicated for pharmacological prophylaxis
Reasons for stratification	People who are contraindicated for pharmacological/mechanical prophylaxis are not able to undergo pharmacological/mechanical prophylaxis and so cannot be lumped together with people who are not contraindicated. People who are contraindicated for both pharmacological and mechanical prophylaxis are excluded from this review as a separate review will be conducted on this population.
Other stratifications	People who are contraindicated
Sensitivity/other analysis	Vitamin K Antagonists (warfarin, acenocoumarol and phenindione) will be combined for the analysis LMWH licensed in the UK (dalteparin, tinzaparin, enoxaparin) will be combined for the analysis LMWH not licensed in the UK (Bemiparin, Certoparin, Nadroparin, Parnaparin, Reviparin) will be combined for the analysis
Subgroup analyses if there is heterogeneity	- BMI (Mixed; Obese (BMI over 30 kg/m ²); Severely obese (BMI over 35 kg/m ²); Not obese (BMI under 30 kg/m ²)); People who are obese (BMI over 30 kg/m ²) and severely obese (BMI over 35 kg/m ²) are at higher risk of VTE and major bleeding - Renal impairment (Renal impairment (eGFR less than 30 ml/min/1.73m ²); No renal impairment (eGFR greater than 30ml/min/1.73m ²)); People with renal impairment (estimated glomerular filtration rate (eGFR) of less than 30ml/min/1.73m ²) are at higher risk of VTE and major bleeding
Search criteria	Databases: Medline, Embase, The Cochrane Library Date limits for search: Update of previous NICE guideline: Venous thromboembolism - reducing the risk (CG92). Final search date for CG92: 10 December 2008 Language: Studies published in English language only

C.24 Elective knee replacement

Table 28: Review protocol: What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) for people undergoing elective knee replacement?

Review question	What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) for people undergoing elective knee replacement?
Guideline condition and its definition	VTE prophylaxis. Definition: Prevention of VTE in people admitted to and discharged from hospital, and people undergoing day procedures
Objectives	To find the most effective strategy for preventing VTE in people undergoing elective knee replacement
Review population	Adults and young people (16 years and older) undergoing elective knee replacement admitted to and discharged from hospital
	Adults Young people (aged 16 years or over)
	Line of therapy not an inclusion criterion

<p>Interventions and comparators: generic/class; specific/drug</p> <p>(All interventions will be compared with each other, unless otherwise stated)</p>	<p>Anti-embolism stockings; Above knee Anti-embolism stockings; Below knee Anti-embolism stockings; Mixed above/below knee Intermittent pneumatic compression devices ; Full leg Intermittent pneumatic compression devices ; Below knee Intermittent pneumatic compression devices ; Mixed full leg/below knee Foot pumps or foot impulse devices ; Foot pumps Foot pumps or foot impulse devices ; Foot impulse Electrical stimulation Continuous passive motion Vena cava filters Unfractionated heparin ; Unfractionated heparin (low dose, administered subcutaneously) Low molecular weight heparin (licensed in UK); Dalteparin (1,250 units once daily - 5,000 units twice daily) Low molecular weight heparin (licensed in UK); Tinzaparin (2,500 units once daily – 9,000 units once daily) Low molecular weight heparin (licensed in UK); Enoxaparin (20mg once daily – 60mg twice daily) Vitamin K antagonists ; Warfarin (all doses) Vitamin K antagonists ; Acenocoumarol (all doses) Vitamin K antagonists ; Phenindione (all doses) Fondaparinux; Fondaparinux (all doses) Apixaban; Apixaban (all doses) Dabigatran; Dabigatran (all doses) Rivaroxaban; Rivaroxaban (all doses) Aspirin; Aspirin (up to 300mg) No treatment; Usual care No treatment; Placebo Low molecular weight heparin (not licensed in UK); Bemiparin (2500 units once daily - 3500 units once daily) Low molecular weight heparin (not licensed in UK); Certoparin (3000 units once daily) Low molecular weight heparin (not licensed in UK); Nadroparin (2850 units once daily - up to 57 units/kg once daily) Low molecular weight heparin (not licensed in UK); Parnaparin (3200 units once daily - 4250 units once daily) Low molecular weight heparin (not licensed in UK); Reviparin (1750 units once daily - 4200 units once daily)</p>
<p>Outcomes</p>	<p>- All-cause mortality at up to 90 days from hospital discharge (Dichotomous) CRITICAL - Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge (Dichotomous) CRITICAL - Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge (Dichotomous) CRITICAL - Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge (Dichotomous) CRITICAL - Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital</p>

	<p>discharge (Dichotomous) CRITICAL</p> <ul style="list-style-type: none"> - Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge (Dichotomous) IMPORTANT - Surgical site haematoma at up to 45 days from hospital discharge (Dichotomous) CRITICAL - Health-related quality of life (validated scores only) at up to 90 days from hospital discharge (Continuous) IMPORTANT - Heparin-induced thrombocytopenia at duration of study (Dichotomous) IMPORTANT - Technical complications of mechanical interventions at duration of study (Continuous) IMPORTANT - Infection at duration of study (Dichotomous) IMPORTANT - VTE at 7-90 days from hospital discharge (Dichotomous) ADDITIONAL - DVT (symptomatic) at 7-90 days from hospital discharge (Dichotomous) ADDITIONAL - DVT (distal) at 7-90 days from hospital discharge (Dichotomous) ADDITIONAL - DVT (proximal) at 7-90 days from hospital discharge (Dichotomous) ADDITIONAL - Fatal bleeding at 45 days from hospital discharge (Dichotomous) ADDITIONAL - Site of bleeding (gastrointestinal ; surgical site; brain/spine; other) at 45 days from hospital discharge (Dichotomous) ADDITIONAL
Study design	Systematic Review RCT
Unit of randomisation	Patient
Crossover study	Not permitted
Minimum duration of study	Not defined
Other exclusions	<p>People with suspected or confirmed venous thromboembolism</p> <p>Community settings and hospices, except when continuing prophylaxis that has been started in hospital</p> <p>Secondary prevention of VTE</p> <p>Early mobilisation and leg exercises</p> <p>People who are contraindicated for both pharmacological and mechanical prophylaxis</p>
Population stratification	<p>People who are contraindicated for mechanical prophylaxis</p> <p>People who are contraindicated for pharmacological prophylaxis</p>
Reasons for stratification	<p>People who are contraindicated for pharmacological/mechanical prophylaxis are not able to undergo pharmacological/mechanical prophylaxis and so cannot be lumped together with people who are not contraindicated. People who are contraindicated for both pharmacological and mechanical prophylaxis are excluded from this review as a separate review will be conducted on this population.</p>
Other stratifications	People who are contraindicated
Sensitivity/other analysis	<p>Vitamin K Antagonists (warfarin, acenocoumarol and phenindione) will be combined for the analysis</p> <p>LMWH licensed in the UK (dalteparin, tinzaparin, enoxaparin) will be combined for the analysis</p> <p>LMWH not licensed in the UK (Bemiparin, Certoparin, Nadroparin, Parnaparin, Reviparin) will be combined for the analysis</p>
Subgroup analyses if there is heterogeneity	<ul style="list-style-type: none"> - BMI (Mixed; Obese (BMI over 30 kg/m²); Severely obese (BMI over 35 kg/m²); Not obese (BMI under 30 kg/m²)); People who are obese (BMI over 30 kg/m²) and severely obese (BMI over 35 kg/m²) are at higher risk of VTE and major

	<p>bleeding</p> <p>- Renal impairment (Renal impairment (eGFR less than 30 ml/min/1.73m²); No renal impairment (eGFR greater than 30ml/min/1.73m²)); People with renal impairment (estimated glomerular filtration rate (eGFR) of less than 30ml/min/1.73m²) are at higher risk of VTE and major bleeding</p>
Search criteria	<p>Databases: Medline, Embase, The Cochrane Library</p> <p>Date limits for search: Update of previous NICE guideline: Venous thromboembolism - reducing the risk (CG92). Final search date for CG92: 10 December 2008</p> <p>Language: Studies published in English language only</p>

C.25 Non-arthroplasty orthopaedic knee surgery

Table 29: Review protocol: What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) in people having non-arthroplasty knee surgery?

Review question	What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) in people having non-arthroplasty knee surgery?
Objectives	To find the most effective strategy for preventing VTE in people having non-arthroplasty knee surgery (including knee arthroscopy, osteotomy and peri-articular trauma)
Population	<p>Adults and young people (16 years and older) having non-arthroplasty knee surgery who are:</p> <ul style="list-style-type: none"> • Admitted to hospital • Having day procedures • Outpatients post-discharge
Interventions	<p>Mechanical:</p> <ul style="list-style-type: none"> • Anti-embolism stockings (AES) (above or below knee) • Intermittent pneumatic compression (IPCD) devices (full leg or below knee) • Foot pumps or foot impulse devices (FID) • Electrical stimulation (including Geko devices) • Continuous passive motion <p>Pharmacological:</p> <ul style="list-style-type: none"> • Unfractionated heparin (UFH) (low dose, administered subcutaneously) • Low molecular weight heparin (LMWH), licensed in UK: <ul style="list-style-type: none"> ○ enoxaparin (standard prophylactic dose 40mg daily; minimum 20mg daily* to maximum 60mg twice daily*) ○ dalteparin (standard prophylactic dose 5000 units once daily; minimum 1250 units once daily* to maximum 5000 units twice daily*; obese patients – maximum 7500 twice units daily*) ○ tinzaparin (standard prophylactic dose 4500 units once daily; minimum 2500 units once daily* to maximum 4500 units twice daily*; obese patients – maximum 6750 twice daily*) • LMWH, licensed in countries other than UK: <ul style="list-style-type: none"> ○ Bemiparin (standard 2500 units daily; minimum 2500 units daily to maximum 3500 units daily) ○ Certoparin (3000 units daily) ○ Nadroparin (standard 2850 units once daily; minimum 2850 units once daily to maximum up to 57 units/kg once daily) ○ Parnaparin (standard 3200 units once daily; minimum 3200 units once daily to maximum 4250 units once daily) ○ Reviparin (minimum 1750 units once daily to maximum 4200 units once

Review question	What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) in people having non-arthroplasty knee surgery?
	<p>daily)</p> <ul style="list-style-type: none"> • Vitamin K Antagonists: <ul style="list-style-type: none"> ○ warfarin (variable dose only) ○ acenocoumarol (all doses) ○ phenindione (all doses) • Fondaparinux (all doses)* • Apixaban (all doses)* • Dabigatran (all doses)* • Rivaroxaban (all doses)* • Aspirin (up to 300mg)* <p>*off-label</p>
Comparisons	<p>Compared to:</p> <ul style="list-style-type: none"> • Other VTE prophylaxis treatment, including monotherapy and combination treatments (between class comparisons for pharmacological treatments only) • No VTE prophylaxis treatment (no treatment, usual care, placebo) <p>Within intervention (including same drug) comparisons, including:</p> <ul style="list-style-type: none"> • Above versus below knee stockings • Full leg versus below knee IPC devices • Standard versus extended duration prophylaxis • Low versus high dose for LMWH • Preoperative versus post-operative initiation of LMWH
Outcomes	<p>Critical outcomes:</p> <ul style="list-style-type: none"> • All-cause mortality (up to 90 days from hospital discharge) • Deep vein thrombosis (symptomatic and asymptomatic) (7-90 days from hospital discharge. Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) • Pulmonary embolism (7-90 days from hospital discharge). Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE • Major bleeding (up to 45 days from hospital discharge). A major bleeding event meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood ; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event. Includes unplanned visit to theatre for control of bleeding • Fatal PE (7- 90 days from hospital discharge). Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE <p>Important outcomes:</p> <ul style="list-style-type: none"> • Clinically relevant non-major bleeding (up to 45 days from hospital discharge): bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy. • Health-related quality of life (validated scores only)(up to 90 days from hospital discharge) • Heparin-induced thrombocytopenia (HIT) (duration of study) • Technical complications of mechanical interventions (duration of study) • Unplanned return to theatre (up to 45 days from hospital discharge)
Study design	Randomised controlled trials (RCTs), systematic reviews of RCTs
Settings	<ul style="list-style-type: none"> • Primary and community care when continuing prophylaxis after hospital discharge

Review question	What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) in people having non-arthroplasty knee surgery?
Exclusions	<ul style="list-style-type: none"> • Secondary care • Studies where people received or were assumed to have received treatment for their conditions that is not used in current practice • People with knee arthroplasty • Community settings and hospices, except when continuing prophylaxis that has been started in hospital • People with suspected or confirmed venous thromboembolism • Secondary prevention of VTE • Early mobilisation and leg exercises • Non-English studies • Duration of follow-up <7 days; >150 days
Review strategy	<p>Drug groups combined for analysis:</p> <ul style="list-style-type: none"> • LMWH • Vitamin K Antagonists <p>Outcomes reported at different time points will be analysed together</p> <p>GRADE assessments will be conducted. Outcomes that are not confirmed by methods listed in protocol, or where methods of confirmation are not reported, will be downgraded for indirectness. For all-cause mortality, DVT, PE, fatal PE, quality of life and heparin-induced thrombocytopenia outcomes measured at 91 to 150 days will be downgraded for indirectness</p>
Stratification	<ul style="list-style-type: none"> • People who are contraindicated for pharmacological prophylaxis • People who are contraindicated for mechanical prophylaxis • Major arthroscopic surgery (combined anaesthetic and surgery longer than 1 hour) • Minor arthroscopic surgery (combined anaesthetic and surgery less than 1 hour) • Osteotomy • Peri-articular trauma
Subgroup analyses if there is heterogeneity	<ul style="list-style-type: none"> • BMI: not obese (BMI under 30kg/m²); obese (obesity I and II, 30–34.9kg/m²); severely obese (obesity III, ≥40kg/m²) • Renal impairment (no renal impairment eGFR >30; renal impairment eGFR <30) • Active cancer (defined as receiving active anti-mitotic treatment; or was diagnosed within last 6 months; or recurrent or metastatic; or where the cancer is inoperable. This definition excludes squamous skin cancer and basal cell carcinoma); no active cancer
Search strategy	<p>Databases:</p> <ul style="list-style-type: none"> • Medline, Embase, The Cochrane Library <p>Date limits:</p> <ul style="list-style-type: none"> • Update of previous NICE guideline: Venous thromboembolism - reducing the risk (CG92). • Final search date for CG92: 10 December 2008

C.26 Foot and ankle orthopaedic surgery

Table 30: Review protocol: What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) in people having foot and ankle surgery?

Review question	What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) in people having foot and ankle surgery?
Objectives	To find the most effective strategy for preventing VTE in people having foot and ankle surgery
Population	Adults and young people (16 years and older) having foot and ankle surgery who are: Admitted to hospital Having day procedures Outpatients post-discharge
Interventions	<p>Mechanical:</p> <ul style="list-style-type: none"> Anti-embolism stockings (AES) (above or below knee) Intermittent pneumatic compression (IPCD) devices (full leg or below knee) Foot pumps or foot impulse devices (FID) Electrical stimulation (including Geko devices) <p>Pharmacological:</p> <ul style="list-style-type: none"> Unfractionated heparin (UFH) (low dose, administered subcutaneously) Low molecular weight heparin (LMWH), licensed in UK: <ul style="list-style-type: none"> enoxaparin (standard prophylactic dose 40mg daily; minimum 20mg daily* to maximum 60mg twice daily*) dalteparin (standard prophylactic dose 5000 units once daily; minimum 1250 units once daily* to maximum 5000 units twice daily*; obese patients – maximum 7500 twice units daily*) tinzaparin (standard prophylactic dose 4500 units once daily; minimum 2500 units once daily* to maximum 4500 units twice daily*; obese patients – maximum 6750 twice daily*) LMWH, licensed in countries other than UK: <ul style="list-style-type: none"> Bemiparin (standard 2500 units daily; minimum 2500 units daily to maximum 3500 units daily) Certoparin (3000 units daily) Nadroparin (standard 2850 units once daily; minimum 2850 units once daily to maximum up to 57 units/kg once daily) Parnaparin (standard 3200 units once daily; minimum 3200 units once daily to maximum 4250 units once daily) Reviparin (minimum 1750 units once daily to maximum 4200 units once daily) Vitamin K Antagonists: <ul style="list-style-type: none"> warfarin (variable dose only) acenocoumarol (all doses) phenindione (all doses) Fondaparinux (all doses)* Apixaban (all doses)* Dabigatran (all doses)* Rivaroxaban (all doses)* Aspirin (up to 300mg)* <p>*off-label</p>
Comparisons	Compared to:

Review question	What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) in people having foot and ankle surgery?
	<p>Other VTE prophylaxis treatment, including monotherapy and combination treatments (between class comparisons for pharmacological treatments only)</p> <p>No VTE prophylaxis treatment (no treatment, usual care, placebo)</p> <p>Within intervention (including same drug) comparisons, including:</p> <p>Above versus below knee stockings</p> <p>Full leg versus below knee IPC devices</p> <p>Standard versus extended duration prophylaxis</p> <p>Low versus high dose for LMWH</p> <p>Preoperative versus post-operative initiation of LMWH</p>
Outcomes	<p>Critical outcomes:</p> <p>All-cause mortality (up to 90 days from hospital discharge)</p> <p>Deep vein thrombosis (symptomatic and asymptomatic) (7-90 days from hospital discharge. Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool)</p> <p>Pulmonary embolism (7-90 days from hospital discharge). Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE</p> <p>Major bleeding (up to 45 days from hospital discharge). A major bleeding event meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood ; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event. Includes unplanned visit to theatre for control of bleeding</p> <p>Fatal PE (7- 90 days from hospital discharge). Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE</p> <p>Important outcomes:</p> <p>Clinically relevant non-major bleeding (up to 45 days from hospital discharge): bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy.</p> <p>Health-related quality of life (validated scores only)(up to 90 days from hospital discharge)</p> <p>Heparin-induced thrombocytopenia (HIT) (duration of study)</p> <p>Technical complications of mechanical interventions (duration of study)</p> <p>Unplanned return to theatre (up to 45 days from hospital discharge)</p>
Study design	Randomised controlled trials (RCTs), systematic reviews of RCTs.
Settings	<p>Primary and community care when continuing prophylaxis after hospital discharge</p> <p>Secondary care</p>
Exclusions	<p>Studies where people received or were assumed to have received treatment for their conditions that is not used in current practice</p> <p>Community settings and hospices, except when continuing prophylaxis that has been started in hospital</p> <p>People with suspected or confirmed venous thromboembolism</p> <p>Secondary prevention of VTE</p> <p>Early mobilisation and leg exercises</p> <p>Non-English studies</p> <p>Duration of follow-up <7 days; >150 days</p>
Review strategy	<p>Drug groups combined for analysis:</p> <p>LMWH</p>

Review question	What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) in people having foot and ankle surgery?
	<p>Vitamin K Antagonists</p> <p>Outcomes reported at different time points will be analysed together</p> <p>GRADE assessments will be conducted. Outcomes that are not confirmed by methods listed in protocol, or where methods of confirmation are not reported, will be downgraded for indirectness. For all-cause mortality, DVT, PE, fatal PE, quality of life and heparin-induced thrombocytopenia outcomes measured at 91 to 150 days will be downgraded for indirectness</p>
Stratification	<p>People who are contraindicated for pharmacological prophylaxis</p> <p>People who are contraindicated for mechanical prophylaxis</p>
Subgroup analyses if there is heterogeneity	<p>BMI: not obese (BMI under 30kg/m²); obese (obesity I and II, 30–34.9kg/m²); severely obese (obesity III, ≥40kg/m²)</p> <p>Renal impairment (no renal impairment eGFR >30; renal impairment eGFR <30)</p> <p>Active cancer (defined as receiving active anti-mitotic treatment; or was diagnosed within last 6 months; or recurrent or metastatic; or where the cancer is inoperable. This definition excludes squamous skin cancer and basal cell carcinoma); no active cancer</p> <p>Achilles tendon (elective and injury)</p>
Search strategy	<p>Databases: Medline, Embase, The Cochrane Library</p> <p>Date limits: Update of previous NICE guideline: Venous thromboembolism - reducing the risk (CG92). Final search date for CG92: 10 December 2008</p>

C.27 Upper limb orthopaedic surgery

Table 31: Review protocol: What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) in people having upper limb surgery?

Review question	What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) in people having upper limb surgery?
Objectives	To find the most effective strategy for preventing VTE in people having upper limb surgery
Population	<p>Adults and young people (16 years and older) having upper limb surgery who are:</p> <p>Admitted to hospital</p> <p>Having day procedures</p> <p>Outpatients post-discharge</p>
Interventions	<p>Mechanical:</p> <p>Anti-embolism stockings (AES) (above or below knee)</p> <p>Intermittent pneumatic compression (IPCD) devices (full leg or below knee)</p> <p>Foot pumps or foot impulse devices (FID)</p> <p>Electrical stimulation (including Geko devices)</p> <p>Pharmacological:</p> <p>Unfractionated heparin (UFH) (low dose, administered subcutaneously)</p>

Review question	What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) in people having upper limb surgery?
	<p>Low molecular weight heparin (LMWH), licensed in UK: enoxaparin (standard prophylactic dose 40mg daily; minimum 20mg daily* to maximum 60mg twice daily*) dalteparin (standard prophylactic dose 5000 units once daily; minimum 1250 units once daily* to maximum 5000 units twice daily*; obese patients – maximum 7500 twice units daily*) tinzaparin (standard prophylactic dose 4500 units once daily; minimum 2500 units once daily* to maximum 4500 units twice daily*; obese patients – maximum 6750 twice daily*) LMWH, licensed in countries other than UK: Bemiparin (standard 2500 units daily; minimum 2500 units daily to maximum 3500 units daily) Certoparin (3000 units daily) Nadroparin (standard 2850 units once daily; minimum 2850 units once daily to maximum up to 57 units/kg once daily) Parnaparin (standard 3200 units once daily; minimum 3200 units once daily to maximum 4250 units once daily) Reviparin (minimum 1750 units once daily to maximum 4200 units once daily) Vitamin K Antagonists: warfarin (variable dose only) acenocoumarol (all doses) phenindione (all doses) Fondaparinux (all doses)* Apixaban (all doses)* Dabigatran (all doses)* Rivaroxaban (all doses)* Aspirin (up to 300mg)*</p> <p>*off-label</p>
Comparisons	<p>Compared to: Other VTE prophylaxis treatment, including monotherapy and combination treatments (between class comparisons for pharmacological treatments only) No VTE prophylaxis treatment (no treatment, usual care, placebo)</p> <p>Within intervention (including same drug) comparisons, including: Above versus below knee stockings Full leg versus below knee IPC devices Standard versus extended duration prophylaxis Low versus high dose for LMWH Preoperative versus post-operative initiation of LMWH</p>
Outcomes	<p>Critical outcomes: All-cause mortality (up to 90 days from hospital discharge) Deep vein thrombosis (symptomatic and asymptomatic) (7-90 days from hospital discharge. Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) Pulmonary embolism (7-90 days from hospital discharge). Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQScpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE Major bleeding (up to 45 days from hospital discharge). A major bleeding event meets one or more of the following criteria: results in death; occurs at a critical site (intracranial,</p>

Review question	What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) in people having upper limb surgery?
	<p>intrasplinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood ; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event. Includes unplanned visit to theatre for control of bleeding Fatal PE (7- 90 days from hospital discharge). Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE</p> <p>Important outcomes:</p> <p>Clinically relevant non-major bleeding (up to 45 days from hospital discharge): bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy.</p> <p>Health-related quality of life (validated scores only)(up to 90 days from hospital discharge)</p> <p>Heparin-induced thrombocytopenia (HIT) (duration of study)</p> <p>Technical complications of mechanical interventions (duration of study)</p> <p>Unplanned return to theatre (up to 45 days from hospital discharge)</p> <p>Upper limb DVT (7-90 days from hospital discharge. Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool)</p>
Study design	Randomised controlled trials (RCTs), systematic reviews of RCTs.
Settings	Primary and community care when continuing prophylaxis after hospital discharge Secondary care
Exclusions	<p>Studies where people received or were assumed to have received treatment for their conditions that is not used in current practice</p> <p>Community settings and hospices, except when continuing prophylaxis that has been started in hospital</p> <p>People with suspected or confirmed venous thromboembolism</p> <p>Secondary prevention of VTE</p> <p>Early mobilisation and leg exercises</p> <p>Non-English studies</p> <p>Duration of follow-up <7 days; >150 days</p>
Review strategy	<p>Drug groups combined for analysis:</p> <p>LMWH</p> <p>Vitamin K Antagonists</p> <p>Outcomes reported at different time points will be analysed together</p> <p>GRADE assessments will be conducted. Outcomes that are not confirmed by methods listed in protocol, or where methods of confirmation are not reported, will be downgraded for indirectness. For all-cause mortality, DVT, PE, fatal PE, quality of life and heparin-induced thrombocytopenia outcomes measured at 91 to 150 days will be downgraded for indirectness</p>
Stratification	<p>People who are contraindicated for pharmacological prophylaxis</p> <p>People who are contraindicated for mechanical prophylaxis</p> <p>Major (anaesthetic and surgery longer than 90 minutes)</p> <p>Minor (anaesthetic and surgery less than 90 minutes)</p>
Subgroup analyses if there is	<p>BMI: not obese (BMI under 30kg/m²); obese (obesity I and II, 30–34.9kg/m²); severely obese (obesity III, $\geq 40\text{kg/m}^2$)</p> <p>Renal impairment (no renal impairment eGFR >30; renal impairment eGFR <30)</p>

Review question	What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) in people having upper limb surgery?
heterogeneity	Active cancer (defined as receiving active anti-mitotic treatment; or was diagnosed within last 6 months; or recurrent or metastatic; or where the cancer is inoperable. This definition excludes squamous skin cancer and basal cell carcinoma); no active cancer
Search strategy	Databases: Medline, Embase, The Cochrane Library Date limits: Update of previous NICE guideline: Venous thromboembolism - reducing the risk (CG92). Final search date for CG92: 10 December 2008

C.28 Spinal surgery

Table 32: Review protocol: What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) for people undergoing spinal surgery?

Review question	What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) for people undergoing spinal surgery?
Guideline condition and its definition	VTE prophylaxis. Definition: Prevention of VTE in people admitted to and discharged from hospital, and people undergoing day procedures
Objectives	To find the most effective strategy for preventing VTE in people undergoing spinal surgery
Review population	Adults and young people (16 years and older) undergoing spinal surgery who are admitted to hospital, having day procedures, and outpatients post-discharge
	Adults Young people (aged 16 years or over)
	Line of therapy not an inclusion criterion
Interventions and comparators: generic/class; specific/drug (All interventions will be compared with each other, unless otherwise stated)	Anti-embolism stockings; Above knee Anti-embolism stockings; Below knee Anti-embolism stockings; Mixed above/below knee Intermittent pneumatic compression devices ; Full leg Intermittent pneumatic compression devices ; Below knee Intermittent pneumatic compression devices ; Mixed full leg/below knee Foot pumps or foot impulse devices ; Foot pumps Foot pumps or foot impulse devices ; Foot impulse Electrical stimulation Continuous passive motion Unfractionated heparin ; Unfractionated heparin (low dose, administered subcutaneously) Low molecular weight heparin (licensed in UK); Dalteparin (1,250 units once daily - 5,000 units twice daily) Low molecular weight heparin (licensed in UK); Tinzaparin (2,500 units once daily – 9,000 units once daily) Low molecular weight heparin (licensed in UK); Enoxaparin (20mg once daily – 60mg twice daily) Vitamin K antagonists ; Warfarin (variable dose) Vitamin K antagonists ; Acenocoumarol (all doses) Vitamin K antagonists ; Phenindione (all doses) Fondaparinux; Fondaparinux (all doses) Apixaban; Apixaban (all doses)

Review question	What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) for people undergoing spinal surgery?
	<p>Dabigatran; Dabigatran (all doses) Rivaroxaban; Rivaroxaban (all doses) Aspirin; Aspirin (up to 300mg) No treatment; Usual care No treatment; Placebo Low molecular weight heparin (not licensed in UK); Bemiparin (2500 units once daily - 3500 units once daily) Low molecular weight heparin (not licensed in UK); Certoparin (3000 units once daily) Low molecular weight heparin (not licensed in UK); Nadroparin (2850 units once daily - up to 57 units/kg once daily) Low molecular weight heparin (not licensed in UK); Parnaparin (3200 units once daily - 4250 units once daily) Low molecular weight heparin (not licensed in UK); Reviparin (1750 units once daily - 4200 units once daily)</p>
Outcomes	<ul style="list-style-type: none"> - All-cause mortality at up to 90 days from hospital discharge (Dichotomous) CRITICAL - Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge (Dichotomous) CRITICAL - Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge (Dichotomous) CRITICAL - Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge (Dichotomous) CRITICAL - Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge (Dichotomous) CRITICAL - Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge (Dichotomous) IMPORTANT - Health-related quality of life (validated scores only) at up to 90 days from hospital discharge (Continuous) IMPORTANT - Heparin-induced thrombocytopenia at duration of study (Dichotomous) IMPORTANT - Technical complications of mechanical interventions at duration of study (Continuous) IMPORTANT
Study design	Systematic Review RCT
Unit of randomisation	Patient
Crossover study	Not permitted
Minimum duration of study	7 days
Other exclusions	<p>People with suspected or confirmed venous thromboembolism Community settings and hospices, except when continuing prophylaxis that has been started in hospital</p>

Review question	What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) for people undergoing spinal surgery?
	<p>Secondary prevention of VTE</p> <p>Early mobilisation and leg exercises</p> <p>Study not published in English</p> <p>Duration of follow up >150 days</p> <p>Studies where people received or were assumed to have received treatment for their conditions that is not used in current practice</p>
Population stratification	<p>People who are contraindicated for mechanical prophylaxis</p> <p>People who are contraindicated for pharmacological prophylaxis</p> <p>Spinal injections</p> <p>Vertebroplasty and kyphoplasty</p>
Reasons for stratification	<p>People who are contraindicated for pharmacological/mechanical prophylaxis are not able to undergo pharmacological/mechanical prophylaxis and so cannot be lumped together with people who are not contraindicated. People who are contraindicated for both pharmacological and mechanical prophylaxis are excluded from this review as a separate review will be conducted on this population.</p>
Sensitivity/other analysis	<p>Vitamin K Antagonists will be combined for the analysis</p> <p>LMWH will be combined for the analysis</p>
Subgroup analyses if there is heterogeneity	<p>- BMI (Mixed; Obese (BMI over 30 kg/m²); Severely obese (BMI over 35 kg/m²); Not obese (BMI under 30 kg/m²)); People who are obese (BMI over 30 kg/m²) and severely obese (BMI over 35 kg/m²) are at higher risk of VTE and major bleeding</p> <p>- Renal impairment (Renal impairment (eGFR less than 30 ml/min/1.73m²); No renal impairment (eGFR greater than 30ml/min/1.73m²)); People with renal impairment (estimated glomerular filtration rate (eGFR) of less than 30ml/min/1.73m²) are at higher risk of VTE and major bleeding</p> <p>- Active cancer (Not applicable; Not stated / Unclear; Active cancer; No active cancer); to be added</p> <p>- Weight bearing (Weight bearing; Non-weight bearing); to be added</p>
Search criteria	<p>Databases: Medline, Embase, The Cochrane Library</p> <p>Date limits for search: Update of previous NICE guideline: Venous thromboembolism - reducing the risk (CG92). Final search date for CG92: 10 December 2008</p> <p>Language: Studies published in English language only</p>

C.29 Cranial surgery

Table 33: Review protocol: What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) for people undergoing intracranial surgery?

Review protocol	
Review question	What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) for people undergoing intracranial surgery?
Objectives	To find the most effective strategy for preventing VTE in people undergoing intracranial surgery
Population	Adults and young people (16 years and older) who are having intracranial surgery

Review protocol	
	who are admitted to hospital, having day procedures or outpatients post-discharge
Interventions	<p>Mechanical:</p> <ul style="list-style-type: none"> Anti-embolism stockings (AES) (above or below knee) Intermittent pneumatic compression (IPCD) devices (full leg or below knee) Foot pumps or foot impulse devices (FID) Electrical stimulation (including Geko devices) Continuous passive motion <p>Pharmacological (no minimum duration):</p> <ul style="list-style-type: none"> Unfractionated heparin (UFH) (low dose, administered subcutaneously) Low molecular weight heparin (LMWH), licensed in UK: <ul style="list-style-type: none"> enoxaparin (standard prophylactic dose 40 mg daily; minimum 20 mg daily* to maximum 60 mg twice daily*) dalteparin (standard prophylactic dose 5000 units once daily; minimum 1250 units once daily* to maximum 5000 units twice daily*; obese patients – maximum 7500 twice units daily*) tinzaparin (standard prophylactic dose 3500 units once daily; minimum 2500 units once daily* to maximum 4500 units twice daily*; obese patients – maximum 6750 twice daily*) LMWH, licensed in countries other than UK: <ul style="list-style-type: none"> Bemiparin (standard 2500 units daily; minimum 2500 units daily to maximum 3500 units daily) Certoparin (3000 units daily) Nadroparin (standard 2850 units once daily; minimum 2850 units once daily to maximum up to 57 units/kg once daily) Parnaparin (standard 3200 units once daily; minimum 3200 units once daily to maximum 4250 units once daily) Reviparin (minimum 1750 units once daily to maximum 4200 units once daily) Vitamin K Antagonists: warfarin (variable dose), acenocoumarol (all doses), phenindione (all doses) Fondaparinux (all doses) Apixaban (all doses) Dabigatran (all doses) Rivaroxaban (all doses) Aspirin (up to 300 mg)
Comparisons	<p>Compared to:</p> <ul style="list-style-type: none"> Other VTE prophylaxis treatment, including monotherapy and combination treatments (between class comparisons for pharmacological treatments only) No VTE prophylaxis treatment (no treatment, usual care, placebo) <p>Within intervention (including same drug) comparisons, including:</p> <ul style="list-style-type: none"> Above versus below knee stockings Full leg versus below knee IPC devices Standard versus extended duration prophylaxis. Extended duration = extended beyond discharge Low versus high dose for LMWH only Preoperative versus post-operative initiation of LMWH
Outcomes	<p>Critical outcomes:</p> <ul style="list-style-type: none"> All-cause mortality (up to 90 days from hospital discharge) Deep vein thrombosis (symptomatic and asymptomatic) (7–90 days from hospital)

Review protocol	
	<p>discharge). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool)</p> <p>Pulmonary embolism (7–90 days from hospital discharge). Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE</p> <p>Major bleeding (up to 45 days from hospital discharge). A major bleeding event meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood ; leads to a drop in haemoglobin of ≥ 2 g/dl; a serious or life threatening clinical event. Includes unplanned visit to theatre for control of bleeding</p> <p>Fatal PE (7–90 days from hospital discharge). Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE</p> <p>Important outcomes:</p> <p>Clinically relevant non-major bleeding (up to 45 days from hospital discharge): bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy</p> <p>Health-related quality of life (validated scores only)(up to 90 days from hospital discharge)</p> <p>Heparin-induced thrombocytopenia (HIT) (duration of study)</p> <p>Technical complications of mechanical interventions (duration of study)</p>
Study design	Randomised controlled trials (RCTs), systematic reviews of RCTs.
Settings	Primary and community care when continuing prophylaxis after hospital discharge Secondary care
Exclusions	<p>People with stroke (sub arachnoid haemorrhage that results in neurological impairment)</p> <p>Community settings and hospices, except when continuing prophylaxis that has been started in hospital</p> <p>People with suspected or confirmed venous thromboembolism</p> <p>Secondary prevention of VTE</p> <p>Early mobilisation and leg exercises</p> <p>Non-English studies</p> <p>Duration of follow-up <7 days; >150 days</p>
Review strategy	<p>Drug groups combined for analysis:</p> <p>LMWH</p> <p>Vitamin K Antagonists</p> <p>Outcomes reported at different time points will be analysed together</p> <p>GRADE assessments will be conducted. Outcomes that are not confirmed by methods listed in protocol, or where methods of confirmation are not reported, will be downgraded for indirectness. For all-cause mortality, DVT, PE, fatal PE, quality of life and heparin-induced thrombocytopenia outcomes measured at 91 to 150 days will be downgraded for indirectness</p>
Stratification	<p>People who are contraindicated for pharmacological prophylaxis</p> <p>People who are contraindicated for mechanical prophylaxis</p> <p>People with intracranial tumour having neurosurgery [population must be >80% tumour]</p>

Review protocol	
Subgroup analyses if there is heterogeneity	<p>BMI: not obese (BMI under 30 kg/m²); obese (BMI over 30 kg/m²); severely obese (BMI over 35 kg/m²);</p> <p>Renal impairment (no renal impairment eGFR >30; renal impairment eGFR <30)</p> <p>Active cancer (defined as receiving active anti-mitotic treatment; or was diagnosed within last 6 months; or recurrent or metastatic; or where the cancer is inoperable. This definition excludes squamous skin cancer and basal cell carcinoma); no active cancer</p> <p>Immobility; mobile</p>
Search strategy	<p>Databases: Medline, Embase, The Cochrane Library</p> <p>Date limits: Update of previous NICE guideline: Venous thromboembolism - reducing the risk (CG92). Final search date for CG92: 10 December 2008</p>

C.30 Spinal injury

Table 34: Review protocol: What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) for people with spinal injury?

Review question	What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) for people with spinal injury?
Objectives	To find the most effective strategy for preventing VTE in people with spinal cord or spinal column injury
Population	Adults and young people (16 years and older) with cord or spinal column injury who are: Admitted to hospital Outpatients post-discharge
Interventions	<p>Mechanical:</p> <ul style="list-style-type: none"> Anti-embolism stockings (above or below knee) Intermittent pneumatic compression (IPCD) devices (full leg or below knee) Foot pumps or foot impulse devices (FID) Electrical stimulation (including Geko devices) Continuous passive motion <p>Pharmacological:</p> <ul style="list-style-type: none"> Unfractionated heparin (UFH) (low dose, administered subcutaneously) Low molecular weight heparin (LMWH), licensed in UK: <ul style="list-style-type: none"> enoxaparin (standard prophylactic dose 40 mg daily; minimum 20 mg daily* to maximum 60 mg twice daily*) dalteparin (standard prophylactic dose 5000 units once daily; minimum 1250 units once daily* to maximum 5000 units twice daily*; obese patients – maximum 7500 twice units daily*) tinzaparin (standard prophylactic dose 3500-4500 units once daily; minimum 2500 units once daily* to maximum 4500 units twice daily*; obese patients – maximum 6750 twice daily*) LMWH, licensed in countries other than UK: <ul style="list-style-type: none"> Bemiparin (standard 2500 units daily; minimum 2500 units daily to maximum 3500 units

Review question	What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) for people with spinal injury?
	<p>daily)</p> <p>Certoparin (3000 units daily)</p> <p>Nadroparin (standard 2850 units once daily; minimum 2850 units once daily to maximum up to 57 units/kg once daily)</p> <p>Parnaparin (standard 3200 units once daily; minimum 3200 units once daily to maximum 4250 units once daily)</p> <p>Reviparin (minimum 1750 units once daily to maximum 4200 units once daily)</p> <p>Vitamin K Antagonists: warfarin (variable dose only) acenocoumarol (all doses) phenindione (all doses) Fondaparinux (all doses)* Apixaban (all doses)* Dabigatran (all doses)* Rivaroxaban (all doses)* Aspirin (up to 300mg)*</p> <p>*off-label</p>
Comparisons	<p>Compared to:</p> <p>Other VTE prophylaxis treatment, including monotherapy and combination treatments (between class comparisons for pharmacological treatments only)</p> <p>No VTE prophylaxis treatment (no treatment, usual care, placebo)</p> <p>Within intervention (including same drug) comparisons, including:</p> <p>Above versus below knee stockings</p> <p>Full leg versus below knee IPC devices</p> <p>Standard versus extended duration prophylaxis. Extended duration = extended beyond discharge</p> <p>Low versus high dose for LMWH</p> <p>Preoperative versus post-operative initiation of LMWH</p>
Outcomes	<p>Critical outcomes:</p> <p>All-cause mortality (up to 90 days from hospital discharge)</p> <p>Deep vein thrombosis (symptomatic and asymptomatic) (7-90 days from hospital discharge). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool)</p> <p>Pulmonary embolism (7- 90 days from hospital discharge). Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE</p> <p>Major bleeding (up to 45 days from hospital discharge). A major bleeding event meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood ; leads to a drop in haemoglobin of ≥ 2 g/dl; a serious or life threatening clinical event. Includes returning to theatre for surgery for control of bleeding and epidural bleeding</p> <p>Fatal PE (7–90 days from hospital discharge). Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE</p> <p>Important outcomes:</p> <p>Clinically relevant non-major bleeding (up to 45 days from hospital discharge): bleeding</p>

Review question	What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) for people with spinal injury?
	<p>that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy.</p> <p>Health-related quality of life (validated scores only)(up to 90 days from hospital discharge)</p> <p>Heparin-induced thrombocytopenia (HIT) (duration of study)</p> <p>Technical complications of mechanical interventions (duration of study)</p>
Study design	Randomised controlled trials (RCTs), systematic reviews of RCTs.
Settings	<p>Primary and community care when continuing prophylaxis after hospital discharge</p> <p>Secondary care</p> <p>Specialist rehab hospitals</p>
Exclusions	<p>Community settings and hospices, except when continuing prophylaxis that has been started in hospital</p> <p>People with suspected or confirmed venous thromboembolism</p> <p>Secondary prevention of VTE</p> <p>Early mobilisation and leg exercises</p> <p>Non-English studies</p> <p>Duration of follow-up <7 days; >150 days</p>
Review strategy	<p>Drug groups combined for analysis:</p> <p>LMWH</p> <p>Vitamin K Antagonists</p> <p>Outcomes reported at different time points will be analysed together</p> <p>GRADE assessments will be conducted</p> <p>Outcomes that are not confirmed by methods listed in protocol, or where methods of confirmation are not reported, will be downgraded for indirectness</p> <p>For all-cause mortality, DVT, PE, fatal PE, quality of life and heparin-induced thrombocytopenia outcomes measured at 91 to 150 days will be downgraded for indirectness</p>
Stratification	People who are contraindicated
Subgroup analyses if there is heterogeneity	<p>BMI: not obese (BMI under 30 kg/m²) obese (obesity I and II, 30–34.9 kg/m²); severely obese (obesity III, ≥40 kg/m²)</p> <p>Renal impairment (no renal impairment eGFR >30; renal impairment eGFR <30)</p> <p>Active cancer (defined as receiving active anti-mitotic treatment; or was diagnosed within last 6 months; or recurrent or metastatic; or where the cancer is inoperable. This definition excludes squamous skin cancer and basal cell carcinoma); no active cancer</p> <p>Isolated spinal injury; multiple injury</p>
Search strategy	<p>Databases:</p> <p>Medline, Embase, The Cochrane Library</p> <p>Date limits:</p> <p>Update of previous NICE guideline: Venous thromboembolism - reducing the risk (CG92).</p> <p>Final search date for CG92: 10 December 2008</p>

C.31 Major trauma

Table 35: Review protocol: What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) for people with major trauma?

Review question	What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) for people with major trauma?
Objectives	To find the most effective strategy for preventing VTE in people with major trauma
Population	Adults and young people (16 years and older) who are attending hospital with major trauma (major trauma defined as Injury Severity Score ≥ 16) and outpatients post-discharge
Interventions	<p>Mechanical:</p> <ul style="list-style-type: none"> • Anti-embolism stockings (above or below knee) • Intermittent pneumatic compression (IPCD) devices (full leg or below knee) • Foot pumps or foot impulse devices (FID) • Electrical stimulation (including Geko devices) • Continuous passive motion • Vena caval filters <p>Pharmacological:</p> <ul style="list-style-type: none"> • Unfractionated heparin (UFH) (low dose, administered subcutaneously) • Low molecular weight heparin (LMWH), licensed in UK: <ul style="list-style-type: none"> ○ enoxaparin (standard prophylactic dose 40 mg daily; minimum 20 mg daily* to maximum 60 mg twice daily*) ○ dalteparin (standard prophylactic dose 5000 units once daily; minimum 1250 units once daily* to maximum 5000 units twice daily*; obese patients – maximum 7500 twice units daily*) ○ tinzaparin (standard prophylactic dose 3500-4500 units once daily; minimum 2500 units once daily* to maximum 4500 units twice daily*; obese patients – maximum 6750 twice daily*) • LMWH, licensed in countries other than UK: <ul style="list-style-type: none"> ○ Bemiparin (standard 2500 units daily; minimum 2500 units daily to maximum 3500 units daily) ○ Certoparin (3000 units daily) ○ Nadroparin (standard 2850 units once daily; minimum 2850 units once daily to maximum up to 57 units/kg once daily) ○ Parnaparin (standard 3200 units once daily; minimum 3200 units once daily to maximum 4250 units once daily) ○ Reviparin (minimum 1750 units once daily to maximum 4200 units once daily) • Vitamin K Antagonists: <ul style="list-style-type: none"> ○ warfarin (variable dose only) ○ acenocoumarol (all doses) ○ phenindione (all doses) • Fondaparinux (all doses)* • Apixaban (all doses)* • Dabigatran (all doses)* • Rivaroxaban (all doses)* • Aspirin (up to 300 mg)* <p>*off-label</p>
Comparisons	Compared to:

	<ul style="list-style-type: none"> • Other VTE prophylaxis treatment, including monotherapy and combination treatments (between class comparisons for pharmacological treatments only) • No VTE prophylaxis treatment (no treatment, usual care, placebo) <p>Within intervention (including same drug) comparisons, including:</p> <ul style="list-style-type: none"> • Above versus below knee stockings • Full leg versus below knee IPC devices • Standard versus extended duration prophylaxis. Extended duration = extended beyond discharge • Low versus high dose for LMWH • Preoperative versus post-operative initiation of LMWH
Outcomes	<p>Critical outcomes:</p> <ul style="list-style-type: none"> • All-cause mortality (up to 90 days from hospital discharge) • Deep vein thrombosis (symptomatic and asymptomatic) (7–90 days from hospital discharge). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) • Pulmonary embolism (7–90 days from hospital discharge). Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE • Major bleeding (up to 45 days from hospital discharge). A major bleeding event meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of ≥ 2 g/dl; a serious or life threatening clinical event. Includes returning to theatre for surgery for control of bleeding. • Fatal PE (7–90 days from hospital discharge). Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE <p>Important outcomes:</p> <ul style="list-style-type: none"> • Clinically relevant non-major bleeding (up to 45 days from hospital discharge): bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy. • Health-related quality of life (validated scores only)(up to 90 days from hospital discharge) • Heparin-induced thrombocytopenia (HIT) (duration of study) • Technical complications of mechanical interventions (duration of study)
Study design	Randomised controlled trials (RCTs), systematic reviews of RCTs.
Settings	<ul style="list-style-type: none"> • Primary and community care when continuing prophylaxis after hospital discharge • Secondary care • Specialist rehab hospitals
Exclusions	<ul style="list-style-type: none"> • Community settings and hospices, except when continuing prophylaxis that has been started in hospital • People with suspected or confirmed venous thromboembolism • Secondary prevention of VTE • Early mobilisation and leg exercises • Non-English studies • Duration of follow-up <7 days; >150 days
Review strategy	<p>Drug groups combined for analysis:</p> <ul style="list-style-type: none"> • LMWH

	<ul style="list-style-type: none"> • Vitamin K Antagonists <p>Outcomes reported at different time points will be analysed together</p> <p>GRADE assessments will be conducted. Outcomes that are not confirmed by methods listed in protocol, or where methods of confirmation are not reported, will be downgraded for indirectness. For all-cause mortality, DVT, PE, fatal PE, quality of life and heparin-induced thrombocytopenia outcomes measured at 91 to 150 days will be downgraded for indirectness</p>
Stratification	<ul style="list-style-type: none"> • People who are contraindicated for pharmacological prophylaxis • People who are contraindicated for mechanical prophylaxis
Subgroup analyses if there is heterogeneity	<p>BMI: not obese (BMI under 30 kg/m²) obese (obesity I and II, 30–34.9 kg/m²); severely obese (obesity III, ≥40 kg/m²)</p> <p>Renal impairment (no renal impairment eGFR >30; renal impairment eGFR <30)</p> <p>Active cancer (defined as receiving active anti-mitotic treatment; or was diagnosed within last 6 months; or recurrent or metastatic; or where the cancer is inoperable. This definition excludes squamous skin cancer and basal cell carcinoma); no active cancer</p>
Search strategy	<p>Databases: Medline, Embase, The Cochrane Library</p> <p>Date limits: Update of previous NICE guideline: Venous thromboembolism - reducing the risk (CG92). Final search date for CG92: 10 December 2008</p>

C.32 Abdominal surgery (excluding bariatric surgery)

Table 36: Review protocol: What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) for people undergoing abdominal surgery (gastrointestinal, gynaecological, urological)?

Review question	What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) for people undergoing abdominal surgery (gastrointestinal, gynaecological, urological)?
Objectives	To find the most effective strategy for preventing VTE in people undergoing abdominal surgery who are admitted to and discharged from hospital
Population	Adults and young people (16 years and older) undergoing abdominal surgery (including gynaecology) who are admitted to hospital, and outpatients post-discharge
Interventions	<p>Mechanical:</p> <ul style="list-style-type: none"> • Anti-embolism stockings (AES) (above or below knee) • Intermittent pneumatic compression (IPCD) devices (full leg or below knee) • Foot pumps or foot impulse devices (FID) • Electrical stimulation (including Geko devices) • Continuous passive motion <p>Pharmacological (no minimum duration):</p> <ul style="list-style-type: none"> • Unfractionated heparin (UFH) (low dose, administered subcutaneously) • Low molecular weight heparin (LMWH), licensed in UK: • Low molecular weight heparin (LMWH), licensed in UK:

Review question	What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) for people undergoing abdominal surgery (gastrointestinal, gynaecological, urological)?
	<ul style="list-style-type: none"> ○ enoxaparin (standard prophylactic dose 40mg daily; minimum 20mg daily* to maximum 60mg twice daily*) ○ dalteparin (standard prophylactic dose 5000 units once daily; minimum 1250 units once daily* to maximum 5000 units twice daily*; obese patients – maximum 7500 twice units daily*) ○ tinzaparin (standard prophylactic dose 3500 units once daily; minimum 2500 units once daily* to maximum 4500 units twice daily*; obese patients – maximum 6750 twice daily*) ● LMWH, licensed in countries other than UK: <ul style="list-style-type: none"> ○ Bemiparin (standard 2500 units daily; minimum 2500 units daily to maximum 3500 units daily) ○ Certoparin (3000 units daily) ○ Nadroparin (standard 2850 units once daily; minimum 2850 units once daily to maximum up to 57 units/kg once daily) ○ Parnaparin (standard 3200 units once daily; minimum 3200 units once daily to maximum 4250 units once daily) ○ Reviparin (minimum 1750 units once daily to maximum 4200 units once daily) ● Vitamin K Antagonists: warfarin (variable dose), acenocoumarol (all doses), phenindione (all doses) ● Fondaparinux (all doses) ● Apixaban (all doses) ● Dabigatran (all doses) ● Rivaroxaban (all doses) ● Aspirin (up to 300mg)* <p>*off-licence</p>
Comparisons	<p>Compared to:</p> <ul style="list-style-type: none"> ● Other VTE prophylaxis treatment, including monotherapy and combination treatments (between class comparisons for pharmacological treatments only) ● No VTE prophylaxis treatment (no treatment, usual care, placebo) <p>Within intervention (including same drug) comparisons, including:</p> <ul style="list-style-type: none"> ● Above versus below knee stockings ● Full leg versus below knee IPC devices ● Standard versus extended duration prophylaxis. Extended duration = extended beyond discharge ● Low versus high dose for LMWH
Outcomes	<p>Critical outcomes:</p> <ul style="list-style-type: none"> ● All-cause mortality (up to 90 days from hospital discharge) (NMA outcome) ● Deep vein thrombosis (symptomatic and asymptomatic) (7-90 days from hospital discharge). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) (NMA outcome) ● Pulmonary embolism (7- 90 days from hospital discharge). Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with

Review question	What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) for people undergoing abdominal surgery (gastrointestinal, gynaecological, urological)?
	<p>the presence of proven VTE (NMA outcome)</p> <ul style="list-style-type: none"> • Major bleeding (up to 45 days from hospital discharge). A major bleeding event meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood ; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event (NMA outcome) • Fatal PE (up to 90 days from hospital discharge). Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE <p>Important outcomes:</p> <ul style="list-style-type: none"> • Clinically relevant non-major bleeding (up to 45 days from hospital discharge): bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy • Health-related quality of life (validated scores only)(up to 90 days from hospital discharge) • Heparin-induced thrombocytopenia (HIT) (duration of study) • Technical complications of mechanical interventions (duration of study)
Study design	Randomised controlled trials (RCTs), systematic reviews of RCTs.
Settings	Primary and community care when continuing prophylaxis after hospital discharge Secondary care
Exclusions	<p>Studies where people received or were assumed to have received treatment for their conditions that is not used in current practice</p> <p>Thoracic surgery</p> <p>Bariatric surgery</p> <p>People with suspected or confirmed venous thromboembolism</p> <p>Community settings and hospices, except when continuing prophylaxis that has been started in hospital</p> <p>Secondary prevention of VTE</p> <p>Early mobilisation and leg exercises</p> <p>Non-English studies</p> <p>Duration of study <7 days; >150 days</p>
Review strategy	<p>Drug groups combined for analysis:</p> <p>LMWH</p> <p>Vitamin K Antagonists</p> <p>Outcomes reported at different time points will be analysed together</p> <p>Outcomes reported pre- and post-operative discharge will be analysed together</p> <p>GRADE assessments will be conducted. Outcomes that are not confirmed by methods listed in protocol, or where methods of confirmation are not reported, will be downgraded for indirectness. For all-cause mortality, DVT, PE, fatal PE, quality of life and heparin-induced thrombocytopenia outcomes measured at 91 to 150 days will be downgraded for indirectness</p> <p>Network-meta analysis will be conducted for the outcomes specified above where possible.</p>

Review question	What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) for people undergoing abdominal surgery (gastrointestinal, gynaecological, urological)?
Stratification	People who are contraindicated for pharmacological prophylaxis People who are contraindicated for mechanical prophylaxis
Subgroup analyses if there is heterogeneity	BMI: not obese (BMI under 30kg/m ²) obese (obesity I and II, 30–34.9kg/m ²); severely obese (obesity III, ≥40kg/m ²) Renal impairment (no renal impairment eGFR >30; renal impairment eGFR <30) Active cancer (defined as receiving active anti-mitotic treatment; or was diagnosed within last 6 months; or recurrent or metastatic; or where the cancer is inoperable. This definition excludes squamous skin cancer and basal cell carcinoma); no active cancer Acute; elective Laparoscopic surgery; open surgery
Search strategy	Databases: Medline, Embase, The Cochrane Library Date limits: Update of previous NICE guideline: Venous thromboembolism - reducing the risk (CG92). Final search date for CG92: 10 December 2008

C.33 Bariatric surgery

Table 37: Review protocol: What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) for people undergoing bariatric surgery?

Review protocol	
Objectives	To find the most effective strategy for preventing VTE in people undergoing bariatric surgery who are admitted to and discharged from hospital
Population	Adults and young people (16 years and older) undergoing bariatric surgery who are admitted to hospital, and outpatients post-discharge
Interventions	Mechanical: Anti-embolism stockings (above or below knee) Intermittent pneumatic compression (IPCD) devices (full leg or below knee) Foot pumps or foot impulse devices (FID) Electrical stimulation (including Geko devices) Continuous passive motion Pharmacological (no minimum duration): Unfractionated heparin (UFH) (low dose, administered subcutaneously) Low molecular weight heparin (LMWH), licensed in UK: enoxaparin (standard prophylactic dose 40mg daily; minimum 20mg daily* to maximum 60mg twice daily*) dalteparin (standard prophylactic dose 5000 units once daily; minimum 1250 units once daily* to maximum 5000 units twice daily*; obese patients – maximum 7500 twice units daily*) tinzaparin (standard prophylactic dose 3500 units once daily; minimum 2500 units

Review protocol	
	<p>once daily* to maximum 4500 units twice daily*; obese patients – maximum 6750 twice daily*)</p> <p>LMWH, licensed in countries other than UK:</p> <p>Bemiparin (standard 2500 units daily; minimum 2500 units daily to maximum 3500 units daily)</p> <p>Certoparin (3000 units daily)</p> <p>Nadroparin (standard 2850 units once daily; minimum 2850 units once daily to maximum up to 57 units/kg once daily)</p> <p>Parnaparin (standard 3200 units once daily; minimum 3200 units once daily to maximum 4250 units once daily)</p> <p>Reviparin (minimum 1750 units once daily to maximum 4200 units once daily)</p> <p>Vitamin K Antagonists: warfarin (variable dose), acenocoumarol (all doses), phenindione (all doses)</p> <p>Fondaparinux (all doses)</p> <p>Apixaban (all doses)</p> <p>Dabigatran (all doses)</p> <p>Rivaroxaban (all doses)</p> <p>Aspirin (up to 300mg)</p>
Comparisons	<p>Compared to:</p> <p>Other VTE prophylaxis treatment, including monotherapy and combination treatments (between class comparisons for pharmacological treatments only)</p> <p>No VTE prophylaxis treatment (no treatment, usual care, placebo)</p> <p>Within intervention (including same drug) comparisons, including:</p> <p>Above versus below knee stockings</p> <p>Full leg versus below knee IPC devices</p> <p>Standard versus extended duration prophylaxis. Extended duration = extended beyond discharge</p> <p>Low versus high dose for LMWH licensed in UK only</p> <p>Preoperative versus post-operative initiation of LMWH</p>
Outcomes	<p>Critical outcomes:</p> <p>All-cause mortality (up to 90 days from hospital discharge) (NMA outcome)</p> <p>Deep vein thrombosis (symptomatic and asymptomatic) (7-90 days from hospital discharge). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool).</p> <p>Pulmonary embolism (7- 90 days from hospital discharge). Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE</p> <p>Major bleeding (up to 45 days from hospital discharge). A major bleeding event meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood ; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event</p> <p>Fatal PE (up to 90 days from hospital discharge). Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE</p> <p>Important outcomes:</p> <p>Clinically relevant non-major bleeding (up to 45 days from hospital discharge): bleeding that does not meet the criteria for major bleed but requires medical</p>

Review protocol	
	<p>attention and/or a change in antithrombotic therapy</p> <p>Health-related quality of life (validated scores only)(up to 90 days from hospital discharge)</p> <p>Heparin-induced thrombocytopenia (HIT) (duration of study)</p> <p>Technical complications of mechanical interventions (duration of study)</p>
Study design	Randomised controlled trials (RCTs), systematic reviews of RCTs.
Settings	<p>Primary and community care when continuing prophylaxis after hospital discharge</p> <p>Secondary care</p>
Exclusions	<p>Studies where people received or were assumed to have received treatment for their conditions that is not used in current practice</p> <p>People with suspected or confirmed venous thromboembolism</p> <p>Community settings and hospices, except when continuing prophylaxis that has been started in hospital</p> <p>Secondary prevention of VTE</p> <p>Early mobilisation and leg exercises</p> <p>Non-English studies</p>
Review strategy	<p>Drug groups combined for analysis:</p> <p>LMWH</p> <p>Vitamin K Antagonists</p> <p>Outcomes reported at different time points will be analysed together</p> <p>Outcomes reported pre- and post-operative discharge will be analysed together</p> <p>GRADE assessments will be conducted. Outcomes that are not confirmed by methods listed in protocol, or where methods of confirmation are not reported, will be downgraded for indirectness. For all-cause mortality, DVT, PE, fatal PE, quality of life and heparin-induced thrombocytopenia outcomes measured at 91 to 150 days will be downgraded for indirectness.</p>
Stratification	<p>People who are contraindicated for pharmacological prophylaxis</p> <p>People who are contraindicated for mechanical prophylaxis</p>
Subgroup analyses if there is heterogeneity	<p>BMI: not obese (BMI under 30kg/m²) obese (obesity I and II, 30–34.9kg/m²); severely obese (obesity III, ≥40kg/m²)</p> <p>Renal impairment (no renal impairment eGFR >30; renal impairment eGFR <30)</p> <p>Active cancer (defined as receiving active anti-mitotic treatment; or was diagnosed within last 6 months; or recurrent or metastatic; or where the cancer is inoperable. This definition excludes squamous skin cancer and basal cell carcinoma); no active cancer</p>
Search strategy	<p>Databases:</p> <p>Medline, Embase, The Cochrane Library</p> <p>Date limits:</p> <p>Update of previous NICE guideline: Venous thromboembolism - reducing the risk (CG92).</p> <p>Final search date for CG92: 10 December 2008</p>

C.34 Cardiac surgery

Table 38: Review protocol: What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) for people undergoing cardiac surgery?

Review question	What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) for people undergoing cardiac surgery?
Objectives	To find the most effective strategy for preventing VTE in people undergoing cardiac surgery who are admitted to and discharged from hospital
Population	Adults and young people (16 years and older) undergoing cardiac surgery who are : <ul style="list-style-type: none"> • Admitted to hospital • Outpatients post-discharge
Interventions	<p>Mechanical:</p> <ul style="list-style-type: none"> • Anti-embolism stockings (AES) (above or below knee) • Intermittent pneumatic compression (IPCD) devices (full leg or below knee) • Foot pumps or foot impulse devices (FID) • Electrical stimulation (including Geko devices) • Continuous passive motion <p>Pharmacological:</p> <ul style="list-style-type: none"> • Unfractionated heparin (UFH) (low dose, administered subcutaneously) • Low molecular weight heparin (LMWH), licensed in UK: <ul style="list-style-type: none"> ○ enoxaparin (standard prophylactic dose 40 mg daily; minimum 20 mg daily* to maximum 60mg twice daily*) ○ dalteparin (standard prophylactic dose 5000 units once daily; minimum 1250 units once daily* to maximum 5000 units twice daily*; obese patients – maximum 7500 twice units daily*) ○ tinzaparin (standard prophylactic dose 4500 units once daily; minimum 2500 units once daily* to maximum 4500 units twice daily*; obese patients – maximum 6750 twice daily*) • LMWH, licensed in countries other than UK: <ul style="list-style-type: none"> ○ Bemiparin (standard 2500 units daily; minimum 2500 units daily to maximum 3500 units daily) ○ Certoparin (3000 units daily) ○ Nadroparin (standard 2850 units once daily; minimum 2850 units once daily to maximum up to 57 units/kg once daily) ○ Parnaparin (standard 3200 units once daily; minimum 3200 units once daily to maximum 4250 units once daily) ○ Reviparin (minimum 1750 units once daily to maximum 4200 units once daily) • Vitamin K Antagonists: <ul style="list-style-type: none"> ○ warfarin (variable dose only) ○ acenocoumarol (all doses) ○ phenindione (all doses) • Fondaparinux (all doses)* • Apixaban (all doses)* • Dabigatran (all doses)* • Rivaroxaban (all doses)* <p>Aspirin (up to 300mg)*</p>

Review question	What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) for people undergoing cardiac surgery?
	*off-label
Comparisons	<p>Compared to:</p> <ul style="list-style-type: none"> • Other VTE prophylaxis treatment, including monotherapy and combination treatments (between class comparisons for pharmacological treatments only) • No VTE prophylaxis treatment (no treatment, usual care, placebo) <p>Within intervention (including same drug) comparisons, including:</p> <ul style="list-style-type: none"> • Above versus below knee stockings • Full leg versus below knee IPC devices • Standard versus extended duration prophylaxis. • Low versus high dose for LMWH • Preoperative versus post-operative initiation of LMWH
Outcomes	<p>Critical outcomes:</p> <ul style="list-style-type: none"> • All-cause mortality (up to 90 days from hospital discharge) • Deep vein thrombosis (symptomatic and asymptomatic) (up to 90 days from hospital discharge). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) • Pulmonary embolism (up to 90 days from hospital discharge) (NMA outcome). Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE • Major bleeding (up to 45 days from hospital discharge). A major bleeding event meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood ; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event. Includes unplanned visit to theatre for control of bleeding • Fatal PE (up to 90 days from hospital discharge). Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE <p>Important outcomes:</p> <ul style="list-style-type: none"> • Clinically relevant non-major bleeding (up to 45 days from hospital discharge): bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy. • Health-related quality of life (validated scores only)(up to 90 days from hospital discharge) • Heparin-induced thrombocytopenia (HIT) (duration of study) • Technical complications of mechanical interventions (duration of study) • Major adverse cardiac events (MACE) (duration of study): death, Q-wave myocardial infarction (MI) and the need for repeat revascularization by redo-CABG or repeat percutaneous intervention
Study design	Randomised controlled trials (RCTs), systematic reviews of RCTs.
Settings	<ul style="list-style-type: none"> • Primary and community care when continuing prophylaxis after hospital discharge • Secondary care

Review question	What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) for people undergoing cardiac surgery?
Exclusions	<ul style="list-style-type: none"> • Community settings and hospices, except when continuing prophylaxis that has been started in hospital • People who are contraindicated for both mechanical and pharmacological prophylaxis • People with suspected or confirmed venous thromboembolism • Secondary prevention of VTE • Early mobilisation and leg exercises • Non-English studies • Duration of follow-up <7 days; >150 days
Review strategy	<p>Drug groups combined for analysis:</p> <ul style="list-style-type: none"> • LMWH • Vitamin K Antagonists <p>Outcomes reported at different time points will be analysed together</p>
Stratification	<ul style="list-style-type: none"> • People who are contraindicated for pharmacological prophylaxis • People who are contraindicated for mechanical prophylaxis
Subgroup analyses if there is heterogeneity	<ul style="list-style-type: none"> • BMI: not obese (BMI under 30kg/m²); obese (BMI over 30kg/m²); severely obese (BMI over 35kg/m²); • Renal impairment (no renal impairment eGFR >30; renal impairment eGFR <30) • Cardiac bypass • Bowel surgery • Dual antiplatelet therapy; single antiplatelet therapy
Other analysis	<p>The quality of the data will be assessed using GRADE.</p> <p>Outcomes that are not confirmed by methods listed in protocol, or where methods of confirmation are not reported, will be downgraded for indirectness</p> <p>For all-cause mortality, DVT, PE, fatal PE, quality of life and heparin-induced thrombocytopenia outcomes measured at 91 to 150 days will be downgraded for indirectness</p> <p>For major bleeding and clinically relevant non-major bleeding outcomes measured at 46 to 90 days will be downgraded for indirectness</p>
Search strategy	<p>Databases:</p> <ul style="list-style-type: none"> • Medline, Embase, The Cochrane Library <p>Date limits:</p> <ul style="list-style-type: none"> • Update of previous NICE guideline: Venous thromboembolism - reducing the risk (CG92). • Final search date for CG92: 10 December 2008

C.35 Thoracic surgery

Table 39: Review protocol: What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) for people undergoing thoracic surgery?

Objectives	To find the most effective strategy for preventing VTE in people undergoing thoracic surgery who are admitted to and discharged from hospital
Population	Adults and young people (16 years and older) undergoing thoracic surgery who are admitted to hospital, and outpatients post-discharge
Interventions	<p>Mechanical:</p> <ul style="list-style-type: none"> Anti-embolism stockings (AES) (above or below knee) Intermittent pneumatic compression (IPCD) devices (full leg or below knee) Foot pumps or foot impulse devices (FID) Electrical stimulation (including Geko devices) Continuous passive motion <p>Pharmacological (no minimum duration):</p> <ul style="list-style-type: none"> Unfractionated heparin (UFH) (low dose, administered subcutaneously) Low molecular weight heparin (LMWH), licensed in UK: <ul style="list-style-type: none"> enoxaparin (standard prophylactic dose 40mg daily; minimum 20mg daily* to maximum 60mg twice daily*) dalteparin (standard prophylactic dose 5000 units once daily; minimum 1250 units once daily* to maximum 5000 units twice daily*; obese patients – maximum 7500 twice units daily*) tinzaparin (standard prophylactic dose 3500 units once daily; minimum 2500 units once daily* to maximum 4500 units twice daily*; obese patients – maximum 6750 twice daily*) LMWH, licensed in countries other than UK: <ul style="list-style-type: none"> Bemiparin (standard 2500 units daily; minimum 2500 units daily to maximum 3500 units daily) Certoparin (3000 units daily) Nadroparin (standard 2850 units once daily; minimum 2850 units once daily to maximum up to 57 units/kg once daily) Parnaparin (standard 3200 units once daily; minimum 3200 units once daily to maximum 4250 units once daily) Reviparin (minimum 1750 units once daily to maximum 4200 units once daily) Vitamin K Antagonists: warfarin (variable dose), acenocoumarol (all doses), phenindione (all doses) Fondaparinux (all doses) Apixaban (all doses) Dabigatran (all doses) Rivaroxaban (all doses) Aspirin (up to 300mg)* <p>*off-licence</p>
Comparisons	<p>Compared to:</p> <ul style="list-style-type: none"> Other VTE prophylaxis treatment, including monotherapy and combination treatments (between class comparisons for pharmacological treatments only) No VTE prophylaxis treatment (no treatment, usual care, placebo) <p>Within intervention (including same drug) comparisons, including:</p>

Objectives	To find the most effective strategy for preventing VTE in people undergoing thoracic surgery who are admitted to and discharged from hospital
	<p>Above versus below knee stockings</p> <p>Full leg versus below knee IPC devices</p> <p>Standard versus extended duration prophylaxis. Extended duration = extended beyond discharge</p> <p>Low versus high dose for LMWH</p>
Outcomes	<p>Critical outcomes:</p> <p>All-cause mortality (up to 90 days from hospital discharge) (NMA outcome)</p> <p>Deep vein thrombosis (symptomatic and asymptomatic) (7-90 days from hospital discharge). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) (NMA outcome)</p> <p>Pulmonary embolism (7- 90 days from hospital discharge). Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE (NMA outcome)</p> <p>Major bleeding (up to 45 days from hospital discharge). A major bleeding event meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood ; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event (NMA outcome)</p> <p>Fatal PE (up to 90 days from hospital discharge). Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE</p> <p>Important outcomes:</p> <p>Clinically relevant non-major bleeding (up to 45 days from hospital discharge): bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy</p> <p>Health-related quality of life (validated scores only)(up to 90 days from hospital discharge)</p> <p>Heparin-induced thrombocytopenia (HIT) (duration of study)</p> <p>Technical complications of mechanical interventions (duration of study)</p>
Study design	Randomised controlled trials (RCTs), systematic reviews of RCTs.
Settings	Primary and community care when continuing prophylaxis after hospital discharge Secondary care
Exclusions	<p>Studies where people received or were assumed to have received treatment for their conditions that is not used in current practice</p> <p>Thoracic surgery</p> <p>Bariatric surgery</p> <p>People with suspected or confirmed venous thromboembolism</p> <p>Community settings and hospices, except when continuing prophylaxis that has been started in hospital</p> <p>Secondary prevention of VTE</p> <p>Early mobilisation and leg exercises</p> <p>Non-English studies</p> <p>Duration of study <7 days; >150 days</p>
Review strategy	<p>Drug groups combined for analysis:</p> <p>LMWH</p> <p>Vitamin K Antagonists</p>

Objectives	To find the most effective strategy for preventing VTE in people undergoing thoracic surgery who are admitted to and discharged from hospital
	<p>Outcomes reported at different time points will be analysed together</p> <p>Outcomes reported pre- and post-operative discharge will be analysed together</p> <p>GRADE assessments will be conducted. Outcomes that are not confirmed by methods listed in protocol, or where methods of confirmation are not reported, will be downgraded for indirectness. For all-cause mortality, DVT, PE, fatal PE, quality of life and heparin-induced thrombocytopenia outcomes measured at 91 to 150 days will be downgraded for indirectness</p>
Stratification	<p>People who are contraindicated for pharmacological prophylaxis</p> <p>People who are contraindicated for mechanical prophylaxis</p>
Subgroup analyses if there is heterogeneity	<p>BMI: not obese (BMI under 30kg/m²) obese (obesity I and II, 30–34.9kg/m²); severely obese (obesity III, ≥40kg/m²)</p> <p>Renal impairment (no renal impairment eGFR >30; renal impairment eGFR <30)</p> <p>Active cancer (defined as receiving active anti-mitotic treatment; or was diagnosed within last 6 months; or recurrent or metastatic; or where the cancer is inoperable. This definition excludes squamous skin cancer and basal cell carcinoma); no active cancer</p> <p>Surgery type: Thoracoscopic; open thoracic</p>
Search strategy	<p>Databases: Medline, Embase, The Cochrane Library</p> <p>Date limits: Update of previous NICE guideline: Venous thromboembolism - reducing the risk (CG92). Final search date for CG92: 10 December 2008</p>

C.36 Vascular surgery

Table 40: Review protocol: What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) for people undergoing vascular surgery?

Review question	What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) for people undergoing vascular surgery?
Objectives	To find the most effective strategy for preventing VTE in people undergoing vascular surgery who are admitted to and discharged from hospital
Population	<p>Adults and young people (16 years and older) undergoing cardiac surgery who are :</p> <p>Admitted to hospital</p> <p>Discharged from hospital</p> <p>Outpatients</p>
Interventions	<p>Mechanical:</p> <p>Anti-embolism stockings (above or below knee)</p> <p>Intermittent pneumatic compression (IPCD) devices (full leg or below knee)</p> <p>Foot pumps or foot impulse devices (FID)</p>

Review question	What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) for people undergoing vascular surgery?
	<p>Electrical stimulation (including Geko devices) Continuous passive motion Vena caval filters</p> <p>Pharmacological:</p> <p>Unfractionated heparin (UFH) (low dose, administered subcutaneously) Low molecular weight heparin (LMWH), licensed in UK: enoxaparin (standard prophylactic dose 40mg daily; minimum 20mg daily* to maximum 60mg twice daily*) dalteparin (standard prophylactic dose 5000 units once daily; minimum 1250 units once daily* to maximum 5000 units twice daily*; obese patients – maximum 7500 twice units daily*) tinzaparin (standard prophylactic dose 4500 units once daily; minimum 2500 units once daily* to maximum 4500 units twice daily*; obese patients – maximum 6750 twice daily*) LMWH, licensed in countries other than UK: Bemiparin (standard 2500 units daily; minimum 2500 units daily to maximum 3500 units daily) Certoparin (3000 units daily) Nadroparin (standard 2850 units once daily; minimum 2850 units once daily to maximum up to 57 units/kg once daily) Parnaparin (standard 3200 units once daily; minimum 3200 units once daily to maximum 4250 units once daily) Reviparin (minimum 1750 units once daily to maximum 4200 units once daily) Vitamin K Antagonists: warfarin (variable dose only) acenocoumarol (all doses) phenindione (all doses) Fondaparinux (all doses)* Apixaban (all doses)* Dabigatran (all doses)* Rivaroxaban (all doses)* Aspirin (up to 300mg)*</p> <p>*off-label</p>
Comparisons	<p>Compared to: Other VTE prophylaxis treatment, including monotherapy and combination treatments (between class comparisons for pharmacological treatments only) No VTE prophylaxis treatment (no treatment, usual care, placebo)</p> <p>Within intervention (including same drug) comparisons, including: Above versus below knee stockings Full leg versus below knee IPC devices Standard versus extended duration prophylaxis. Low versus high dose for LMWH Preoperative versus post-operative initiation of LMWH</p>
Outcomes	<p>Critical outcomes: All-cause mortality (up to 90 days from hospital discharge) Deep vein thrombosis (symptomatic and asymptomatic) (up to 90 days from hospital discharge). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex</p>

Review question	What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) for people undergoing vascular surgery?
	<p>(Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool)</p> <p>Pulmonary embolism (up to 90 days from hospital discharge). Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE</p> <p>Major bleeding (up to 45 days from hospital discharge). A major bleeding event meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood ; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event. Includes unplanned visit to theatre for control of bleeding</p> <p>Fatal PE (up to 90 days from hospital discharge). Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE</p> <p>Important outcomes:</p> <p>Clinically relevant non-major bleeding (up to 45 days from hospital discharge): bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy.</p> <p>Health-related quality of life (validated scores only)(up to 90 days from hospital discharge)</p> <p>Heparin-induced thrombocytopenia (HIT) (duration of study)</p> <p>Technical complications of mechanical interventions (duration of study)</p>
Study design	Randomised controlled trials (RCTs), systematic reviews of RCTs.
Settings	Primary and community care when continuing prophylaxis after hospital discharge Secondary care
Exclusions	<p>Community settings and hospices, except when continuing prophylaxis that has been started in hospital</p> <p>People who are contraindicated for both mechanical and pharmacological prophylaxis</p> <p>People with suspected or confirmed venous thromboembolism</p> <p>Secondary prevention of VTE</p> <p>Early mobilisation and leg exercises</p> <p>Non-English studies</p> <p>Duration of follow-up <7 days; >150 days</p>
Review strategy	<p>Drug groups combined for analysis:</p> <p>LMWH</p> <p>Vitamin K Antagonists</p> <p>Outcomes reported at different time points will be analysed together</p>
Stratification	<p>People who are contraindicated</p> <p>Varicose veins</p> <p>Lower limb amputation</p> <p>Open vascular surgery (major aortic/leg bypass)</p>
Subgroup analyses if there is heterogeneity	<p>BMI: not obese (BMI under 30kg/m^2); obese (BMI over 30kg/m^2); severely obese (BMI over 35kg/m^2);</p> <p>Renal impairment (no renal impairment $\text{eGFR} > 30$; renal impairment $\text{eGFR} < 30$)</p> <p>Active cancer (defined as receiving active anti-mitotic treatment; or was diagnosed within last 6 months; or recurrent or metastatic; or where the cancer is inoperable. This definition excludes squamous skin cancer and basal cell carcinoma); no active cancer</p> <p>Open; endovascular aortic/iliac; not aortic/iliac</p>
Other analysis	The quality of the data will be assessed using GRADE.

Review question	What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) for people undergoing vascular surgery?
	<p>Outcomes that are not confirmed by methods listed in protocol, or where methods of confirmation are not reported, will be downgraded for indirectness</p> <p>For all-cause mortality, DVT, PE, fatal PE, quality of life and heparin-induced thrombocytopenia outcomes measured at 91 to 150 days will be downgraded for indirectness</p> <p>For major bleeding and clinically relevant non-major bleeding outcomes measured at 46 to 90 days will be downgraded for indirectness</p>
Search strategy	<p>Databases: Medline, Embase, The Cochrane Library</p> <p>Date limits: Update of previous NICE guideline: Venous thromboembolism - reducing the risk (CG92). Final search date for CG92: 10 December 2008</p>

C.37 Head and neck surgery

C.37.1 Oral and maxillofacial surgery

Table 41: Review protocol: What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) for people undergoing oral or maxillofacial surgery?

Review question	What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) for people undergoing oral or maxillofacial surgery?
Objectives	To find the most effective strategy for preventing VTE in people undergoing oral or maxillofacial surgery who are admitted to and discharged from hospital, and people having day procedures
Population	<p>Adults and young people (16 years and older) undergoing oral or maxillofacial surgery who are:</p> <p>Admitted to hospital</p> <p>Having day procedures</p> <p>Outpatients post-discharge</p>
Interventions	<p>Mechanical:</p> <p>Anti-embolism stockings (AES) (above or below knee)</p> <p>Intermittent pneumatic compression (IPCD) devices (full leg or below knee)</p> <p>Foot pumps or foot impulse devices (FID)</p> <p>Electrical stimulation (including Geko devices)</p> <p>Continuous passive motion</p> <p>Pharmacological:</p> <p>Unfractionated heparin (UFH) (low dose, administered subcutaneously)</p> <p>Low molecular weight heparin (LMWH), licensed in UK:</p> <p>enoxaparin (standard prophylactic dose 40 mg daily; minimum 20 mg daily* to maximum 60 mg twice daily*)</p> <p>dalteparin (standard prophylactic dose 5000 units once daily; minimum 1250 units once daily* to maximum 5000 units twice daily*; obese patients – maximum 7500 twice units daily*)</p> <p>tinzaparin (standard prophylactic dose 3500 units once daily; minimum 2500 units once</p>

Review question	What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) for people undergoing oral or maxillofacial surgery?
	<p>daily* to maximum 4500 units twice daily*; obese patients – maximum 6750 twice daily*) LMWH, licensed in countries other than UK: Bemiparin (standard 2500 units daily; minimum 2500 units daily to maximum 3500 units daily) Certoparin (3000 units daily) Nadroparin (standard 2850 units once daily; minimum 2850 units once daily to maximum up to 57 units/kg once daily) Parnaparin (standard 3200 units once daily; minimum 3200 units once daily to maximum 4250 units once daily) Reviparin (minimum 1750 units once daily to maximum 4200 units once daily) Vitamin K Antagonists: warfarin (variable dose only) acenocoumarol (all doses) phenindione (all doses) Fondaparinux (all doses)* Apixaban (all doses)* Dabigatran (all doses)* Rivaroxaban (all doses)* Aspirin (up to 300 mg)*</p> <p>*off-label</p>
Comparisons	<p>Compared to: Other VTE prophylaxis treatment, including monotherapy and combination treatments (between class comparisons for pharmacological treatments only) No VTE prophylaxis treatment (no treatment, usual care, placebo)</p> <p>Within intervention (including same drug) comparisons, including: Above versus below knee stockings Full leg versus below knee IPC devices Standard versus extended duration prophylaxis Low versus high dose for LMWH Preoperative versus post-operative initiation of LMWH</p>
Outcomes	<p>Critical outcomes: All-cause mortality (up to 90 days from hospital discharge) Deep vein thrombosis (symptomatic and asymptomatic) (7–90 days from hospital discharge) (NMA outcome). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) Pulmonary embolism (7–90 days from hospital discharge). Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE Major bleeding (up to 45 days from hospital discharge). A major bleeding event meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood ; leads to a drop in haemoglobin of ≥ 2 g/dl; a serious or life threatening clinical event. Includes unplanned visit to theatre for control of bleeding Fatal PE (7–90 days from hospital discharge). Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE</p>

Review question	What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) for people undergoing oral or maxillofacial surgery?
	<p>Important outcomes:</p> <p>Clinically relevant non-major bleeding (up to 45 days from hospital discharge): bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy.</p> <p>Health-related quality of life (validated scores only)(up to 90 days from hospital discharge)</p> <p>Heparin-induced thrombocytopenia (HIT) (duration of study)</p> <p>Technical complications of mechanical interventions (duration of study)</p> <p>Cerebral sinus thrombosis (30 days)</p>
Study design	Randomised controlled trials (RCTs), systematic reviews of RCTs.
Settings	<p>Primary and community care when continuing prophylaxis after hospital discharge</p> <p>Secondary care</p>
Exclusions	<p>Dental surgery</p> <p>People who are contraindicated for both mechanical and pharmacological prophylaxis</p> <p>People with suspected or confirmed venous thromboembolism</p> <p>Secondary prevention of VTE</p> <p>Community settings and hospices, except when continuing prophylaxis that has been started in hospital</p> <p>Early mobilisation and leg exercises</p> <p>Non-English studies</p> <p>Duration of follow-up <7 days; >150 days</p>
Review strategy	<p>Drug groups combined for analysis:</p> <p>LMWH</p> <p>Vitamin K Antagonists</p> <p>Outcomes reported at different time points will be analysed together</p>
Stratification	<p>People who are contraindicated</p> <p>Active cancer (defined as receiving active anti-mitotic treatment; or was diagnosed within last 6 months; or recurrent or metastatic; or where the cancer is inoperable. This definition excludes squamous skin cancer and basal cell carcinoma); no active cancer</p>
Subgroup analyses if there is heterogeneity	<p>BMI: not obese (BMI under 30 kg/m²) obese (obesity I and II, 30–34.9 kg/m²); severely obese (obesity III, ≥40 kg/m²)</p> <p>Renal impairment (no renal impairment eGFR >30; renal impairment eGFR <30)</p>
Other analysis	<p>The quality of the data will be assessed using GRADE.</p> <p>Outcomes that are not confirmed by methods listed in protocol, or where methods of confirmation are not reported, will be downgraded for indirectness</p> <p>For all-cause mortality, DVT, PE, fatal PE, quality of life and heparin-induced thrombocytopenia outcomes measured at 91 to 150 days will be downgraded for indirectness</p>
Search strategy	<p>Databases:</p> <p>Medline, Embase, The Cochrane Library</p> <p>Date limits:</p> <p>Update of previous NICE guideline: Venous thromboembolism - reducing the risk (CG92).</p> <p>Final search date for CG92: 10 December 2008</p>

C.37.2 Ear, nose and throat (ENT) surgery

Table 42: Review protocol: What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) for people undergoing ear, nose or throat (ENT) surgery?

Review question	What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) for people undergoing ear, nose or throat (ENT) surgery?
Objectives	To find the most effective strategy for preventing VTE in people undergoing ear, nose or throat (ENT) surgery who are admitted to and discharged from hospital, and having day procedures
Population	<p>Adults and young people (16 years and older) undergoing ear, nose or throat (ENT) who are:</p> <ul style="list-style-type: none"> Admitted to hospital Having day procedures Outpatients post-discharge
Interventions	<p>Mechanical:</p> <ul style="list-style-type: none"> Anti-embolism stockings (AES) (above or below knee) Intermittent pneumatic compression (IPCD) devices (full leg or below knee) Foot pumps or foot impulse devices (FID) Electrical stimulation (including Geko devices) Continuous passive motion Vena caval filters <p>Pharmacological:</p> <ul style="list-style-type: none"> Unfractionated heparin (UFH) (low dose, administered subcutaneously) Low molecular weight heparin (LMWH), licensed in UK: <ul style="list-style-type: none"> enoxaparin (standard prophylactic dose 40 mg daily; minimum 20 mg daily* to maximum 60 mg twice daily*) dalteparin (standard prophylactic dose 5000 units once daily; minimum 1250 units once daily* to maximum 5000 units twice daily*; obese patients – maximum 7500 twice units daily*) tinzaparin (standard prophylactic dose 3500 units once daily; minimum 2500 units once daily* to maximum 4500 units twice daily*; obese patients – maximum 6750 twice daily*) LMWH, licensed in countries other than UK: <ul style="list-style-type: none"> Bemiparin (standard 2500 units daily; minimum 2500 units daily to maximum 3500 units daily) Certoparin (3000 units daily) Nadroparin (standard 2850 units once daily; minimum 2850 units once daily to maximum up to 57 units/kg once daily) Parnaparin (standard 3200 units once daily; minimum 3200 units once daily to maximum 4250 units once daily) Reviparin (minimum 1750 units once daily to maximum 4200 units once daily) Vitamin K Antagonists: <ul style="list-style-type: none"> warfarin (variable dose only) acenocoumarol (all doses) phenindione (all doses) Fondaparinux (all doses)* Apixaban (all doses)* Dabigatran (all doses)* Rivaroxaban (all doses)*

Review question	What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) for people undergoing ear, nose or throat (ENT) surgery?
	<p>Aspirin (up to 300 mg)*</p> <p>*off-label</p>
Comparisons	<p>Compared to:</p> <p>Other VTE prophylaxis treatment, including monotherapy and combination treatments (between class comparisons for pharmacological treatments only)</p> <p>No VTE prophylaxis treatment (no treatment, usual care, placebo)</p> <p>Within intervention (including same drug) comparisons, including:</p> <p>Above versus below knee stockings</p> <p>Full leg versus below knee IPC devices</p> <p>Standard versus extended duration prophylaxis</p> <p>Low versus high dose for LMWH</p> <p>Preoperative versus post-operative initiation of LMWH</p>
Outcomes	<p>Critical outcomes:</p> <p>All-cause mortality (up to 90 days from hospital discharge)</p> <p>Deep vein thrombosis (symptomatic and asymptomatic) (7-90 days from hospital discharge). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool)</p> <p>Pulmonary embolism (7-90 days from hospital discharge). Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE</p> <p>Major bleeding (up to 45 days from hospital discharge). A major bleeding event meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood ; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event. Includes unplanned visit to theatre for control of bleeding</p> <p>Fatal PE (7- 90 days from hospital discharge). Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE</p> <p>Important outcomes:</p> <p>Clinically relevant non-major bleeding (up to 45 days from hospital discharge): bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy.</p> <p>Health-related quality of life (validated scores only)(up to 90 days from hospital discharge)</p> <p>Heparin-induced thrombocytopenia (HIT) (duration of study)</p> <p>Technical complications of mechanical interventions (duration of study)</p> <p>Cerebral sinus thrombosis</p>
Study design	Randomised controlled trials (RCTs), systematic reviews of RCTs.
Settings	<p>Primary and community care when continuing prophylaxis after hospital discharge</p> <p>Secondary care</p>
Exclusions	<p>People undergoing diagnostic tests only</p> <p>People who are contraindicated for both mechanical and pharmacological prophylaxis</p> <p>People with suspected or confirmed venous thromboembolism</p> <p>Secondary prevention of VTE</p> <p>Early mobilisation and leg exercises</p> <p>Community settings and hospices, except when continuing prophylaxis that has been</p>

Review question	What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) for people undergoing ear, nose or throat (ENT) surgery?
	<p>started in hospital</p> <p>Non-English studies</p> <p>Duration of follow-up <7 days; >150 days</p>
Review strategy	<p>Drug groups combined for analysis:</p> <p>LMWH</p> <p>Vitamin K Antagonists</p> <p>Outcomes reported at different time points will be analysed together</p>
Stratification	<p>People who are contraindicated</p> <p>Active cancer (defined as receiving active anti-mitotic treatment; or was diagnosed within last 6 months; or recurrent or metastatic; or where the cancer is inoperable. This definition excludes squamous skin cancer and basal cell carcinoma); no active cancer</p> <p>Diagnostic and endoscopic surgery</p>
Subgroup analyses if there is heterogeneity	<p>BMI: not obese (BMI under 30 kg/m²) obese (obesity I and II, 30–34.9 kg/m²); severely obese (obesity III, ≥40 kg/m²)</p> <p>Renal impairment (no renal impairment eGFR >30; renal impairment eGFR <30)</p>
Other analysis	<p>The quality of the data will be assessed using GRADE.</p> <p>Outcomes that are not confirmed by methods listed in protocol, or where methods of confirmation are not reported, will be downgraded for indirectness</p> <p>For all-cause mortality, DVT, PE, fatal PE, quality of life and heparin-induced thrombocytopenia outcomes measured at 91 to 150 days will be downgraded for indirectness</p>
Search strategy	<p>Databases:</p> <p>Medline, Embase, The Cochrane Library</p> <p>Date limits:</p> <p>Update of previous NICE guideline: Venous thromboembolism - reducing the risk (CG92).</p> <p>Final search date for CG92: 10 December 2008</p>

Appendix D: Health economic review protocol

Table 43: Health economic review protocol

Review question	All questions – health economic evidence
Objectives	To identify economic studies relevant to any of the review questions.
Search criteria	<ul style="list-style-type: none"> • Populations, interventions and comparators must be as specified in the individual review protocol above. • Studies must be of a relevant economic study design (cost-utility analysis, cost-effectiveness analysis, cost-benefit analysis, cost-consequences analysis, comparative cost analysis). • Studies must not be a letter, editorial or commentary, or a review of economic evaluations. (Recent reviews will be ordered although not reviewed. The bibliographies will be checked for relevant studies, which will then be ordered.) • Unpublished reports will not be considered unless submitted as part of a call for evidence. • Studies must be in English.
Search strategy	An economic study search will be undertaken using population-specific terms and an economic study filter – see appendix G. For questions being updated from the previous guidelines, the search will be run from the latest guideline (CG92) cut-off date (2008).
Review strategy	<p>Studies not meeting any of the search criteria above will be excluded. Studies published before 2001 will be excluded. Abstract-only studies and studies from non-OECD countries or the USA will also be excluded.</p> <p>Studies published after 2001 that were included in the previous guidelines will be re-assessed for inclusion and may be included or selectively excluded based on their relevance to the questions covered in this update and whether more applicable evidence is identified.</p> <p>Each remaining study will be assessed for applicability and methodological limitations using the NICE economic evaluation checklist which can be found in appendix H of Developing NICE guidelines: the manual (2014).²³⁶</p> <p>Inclusion and exclusion criteria</p> <ul style="list-style-type: none"> • If a study is rated as both ‘Directly applicable’ and with ‘Minor limitations’ then it will be included in the guideline. An economic evidence table will be completed and it will be included in the economic evidence profile. • If a study is rated as either ‘Not applicable’ or with ‘Very serious limitations’ then it will usually be excluded from the guideline. If it is excluded then an economic evidence table will not be completed and it will not be included in the economic evidence profile. • If a study is rated as ‘Partially applicable’, with ‘Potentially serious limitations’ or both then there is discretion over whether it should be included. <p>Where there is discretion</p> <p>The health economist will make a decision based on the relative applicability and quality of the available evidence for that question, in discussion with the Committee if required. The ultimate aim is to include economic studies that are helpful for decision-making in the context of the guideline and the current NHS setting. If several studies are considered of sufficiently high applicability and methodological quality that they could all be included, then the health economist, in discussion with the Committee if required, may decide to include only the most applicable studies and to selectively exclude the remaining studies. All studies excluded on the basis of applicability or methodological limitations will be listed with explanation as excluded economic studies in appendix O.</p>

The health economist will be guided by the following hierarchies.

Setting:

- UK NHS (most applicable).
- OECD countries with predominantly public health insurance systems (for example, France, Germany, Sweden).
- OECD countries with predominantly private health insurance systems (for example, Switzerland).
- Studies set in non-OECD countries or in the USA will have been excluded before being assessed for applicability and methodological limitations.

Economic study type:

- Cost-utility analysis (most applicable).
- Other type of full economic evaluation (cost-benefit analysis, cost-effectiveness analysis, cost-consequences analysis).
- Comparative cost analysis.
- Non-comparative cost analyses including cost-of-illness studies will have been excluded before being assessed for applicability and methodological limitations.

Year of analysis:

- The more recent the study, the more applicable it will be.
- Studies published in [2001] or later that were included in the previous guidelines but that depend on unit costs and resource data entirely or predominantly from before [2001] will be rated as 'Not applicable'.
- Studies published before [2001] will be excluded.


Quality and relevance of effectiveness data used in the economic analysis:

- The more closely the clinical effectiveness data used in the economic analysis matches with the outcomes of the studies included in the clinical review the more useful the analysis will be for decision-making in the guideline.

Appendix E: Clinical study selection


E.1 Risk assessment

Figure 1: Clinical study selection for risk assessment




E.2 Patient information

Figure 2: Clinical study selection for patient information




E.3 VTE prophylaxis

Figure 3: Clinical study selection for VTE prophylaxis



Appendix F: Health economic study selection

Figure 4: Flow chart of economic study selection for the guideline



* Non-relevant population, intervention, comparison, design or setting; non-English language; † Author contact. ** One article identified was applicable to eTHR, eTKR, bariatric, thoracic and abdominal surgery. It has been included under abdominal surgery only and selectively excluded for eTHR and eTKR. CG92 models covered 4 populations: abdominal surgery, eTHR, eTKR and general medical. It has been included under "abdominal surgery" only. *** One article identified was applicable to general medical and risk assessment-VTE, for the purposes of this diagram it has been included under the first only. ~ two articles identified were applicable to abdominal surgery, eTHR and eTKR. It has been included under abdominal surgery only. ~ ~ Twenty-two articles identified were applicable to eTHR and eTKR. These have been included under eTHR only. # All 5 articles were applicable to eTHR and eTKR. Two were applicable to eTHR, eTKR and lower limb fragility fracture. These have been included only under eTHR.

Appendix G: Literature search strategies

G.1 Contents

Introduction	Search methodology
Section G.2	Population search strategy
G.2.1	Standard venous thromboembolism population This population was used for all search questions unless stated
Section G.3	Study filter search terms
G.3.1	Excluded study designs and publication types
G.3.2	Randomised controlled trials (RCT)
G.3.3	Systematic reviews (SR)
G.3.4	Health economic studies (HE)
G.3.5	Quality of life studies (QoL)
G.3.6	Qualitative reviews (QUAL)
Section G.4	Searches for specific questions with intervention
G.4.1	Risk assessment
G.4.2	Provision of information to patients and planning for discharge
G.4.3	General VTE prevention for all populations
Section G.5	Health economics search terms
G.5.1	Health economic reviews
G.5.2	Quality of life reviews

Search strategies used for the venous thromboembolism (VTE) guideline are outlined below and were run in accordance with the methodology in the NICE guidelines manual 2014, updated 2017 available from <https://www.nice.org.uk/article/pmg20/>. All searches were run up to 19 June 2017 unless otherwise stated. Any studies added to the databases after this date (even those published prior to this date) were not included unless specifically stated in the text. Where possible searches were limited to retrieve material published in English.

Searches for the **clinical reviews** were run in Medline (OVID), Embase (OVID) and the Cochrane Library (Wiley). Additional searches were run in CINAHL, Current Nursing and Allied Health Literature (EBSCO) and PsycINFO (ProQuest), see Table 44.

Searches for **intervention and diagnostic studies** were usually constructed using a PICO format where population (P) terms were combined with Intervention (I) and sometimes Comparison (C) terms. An intervention can be a drug, a procedure or a diagnostic test. Outcomes (O) are rarely used in search strategies for interventions. Search filters were also added to the search where appropriate.

Searches for **patient views** were run in Medline, Embase, CINAHL and PsycINFO. Searches were constructed by adding a patient views search filter to the population terms.

Table 44: Databases searched

Question	Question number	Databases
General VTE prevention for all populations	G.4.3	Medline, Embase and Cochrane Library
Provision of information to patients and	G.4.2	Medline, Embase, CINAHL and

Question	Question number	Databases
planning for discharge		PsycINFO
Risk assessment	G.4.1	Medline, Embase and Cochrane Library

Searches for **health economic reviews** were run in Medline, Embase, the NHS Economic Evaluations Database (NHS EED) and the Health Technology Assessment (HTA). NHS EED and HTA databases are hosted by the Centre for Research and Dissemination (CRD).

For Medline and Embase an economic filter (instead of a study type filter) was added to the same clinical search strategy. Searches in CRD were constructed using population terms only.

G.2 Population search strategies

G.2.1 Standard venous thromboembolism (VTE) population

Medline search terms

1.	pulmonary embolism/ or thromboembolism/ or venous thromboembolism/ or venous thrombosis/ or upper extremity deep vein thrombosis/
2.	(((venous or vein) adj (thrombosis or thromboses or thrombus or thromboembolism)) or (dvt or vte) or ((pulmonary or lung) adj3 (embolism or emboli or embolus or emboliz* or thromboembolism))).ti,ab.
3.	1 or 2

Embase search terms

1.	thromboembolism/ or venous thromboembolism/ or vein thrombosis/ or deep vein thrombosis/ or leg thrombosis/ or lower extremity deep vein thrombosis/ or postoperative thrombosis/ or lung embolism/ or upper extremity deep vein thrombosis/
2.	(((venous or vein) adj (thrombosis or thromboses or thrombus or thromboembolism)) or (dvt or vte) or ((pulmonary or lung) adj3 (embolism or emboli or embolus or emboliz* or thromboembolism))).ti,ab.
3.	1 or 2

Cochrane search terms

#1.	MeSH descriptor: [venous thromboembolism] this term only
#2.	MeSH descriptor: [pulmonary embolism] this term only
#3.	MeSH descriptor: [venous thrombosis] this term only
#4.	MeSH descriptor: [thromboembolism] this term only
#5.	MeSH descriptor: [upper extremity deep vein thrombosis] this term only
#6.	(((*venous or *vein) next (thrombosis or thromboses or thrombus or thromboembolism) or dvt or vte or (pulmonary or lung) near/3 (embolism or emboli or embolus or emboliz* or thromboembolism)):ti,ab
#7.	#1 or #2 or #3 or #4 or #6

CINAHL search terms

S1.	(mh "pulmonary embolism") or (mh "venous thrombosis") or (mh "venous thromboembolism") or (mh "thromboembolism")
S2.	(((venous or vein) n1 (thrombosis or thrombus or thromboembolism)) or (dvt or vte) or ((pulmonary or lung) n3 (embolism or emboli or embolus or thromboembolism)))
S3.	s1 or s2

PsycINFO search terms

1.	su.exact.explode("embolisms") or su.exact.explode("thromboses") or ti,ab((venous or vein) n/1 (thrombosis or thromboses or thrombus or thromboembolism)) or ti,ab(dvt or vte) or ti,ab((pulmonary or lung) n/3 (embolism or emboli or embolus or emboliz* or thromboembolism))
----	--

CRD search terms

#1.	MeSH descriptor venous thromboembolism explode all trees
#2.	MeSH descriptor pulmonary embolism explode all trees
#3.	MeSH descriptor venous thrombosis explode all trees
#4.	MeSH descriptor thromboembolism explode all trees
#5.	MeSH descriptor upper extremity deep vein thrombosis explode all trees
#6.	(dvt)
#7.	(vte)
#8.	(((venous or vein) adj1 (thrombosis or thromboses or thrombus or thromboembolism)))
#9.	((pulmonary or lung) adj3 (embolism or emboli or embolus or emboliz* or thromboembolism))
#10.	#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9

G.3 Study filter search terms

G.3.1 Excluded study designs and publication types

The following study designs and publication types were removed from retrieved results using the NOT operator:

Medline search terms

1.	letter/
2.	editorial/
3.	news/
4.	exp historical article/
5.	anecdotes as topic/
6.	comment/
7.	case report/
8.	(letter or comment*).ti.
9.	or/1-8
10.	randomized controlled trial/ or random*.ti,ab.
11.	9 not 10
12.	animals/ not humans/
13.	exp animals, laboratory/
14.	exp animal experimentation/
15.	exp models, animal/
16.	exp rodentia/
17.	(rat or rats or mouse or mice).ti.
18.	or/11-17

Embase search terms

1.	letter.pt. or letter/
2.	note.pt.
3.	editorial.pt.

4.	case report/ or case study/
5.	(letter or comment*).ti.
6.	or/1-5
7.	randomized controlled trial/ or random*.ti,ab.
8.	6 not 7
9.	animal/ not human/
10.	nonhuman/
11.	exp animal experiment/
12.	exp experimental animal/
13.	animal model/
14.	exp rodent/
15.	(rat or rats or mouse or mice).ti.
16.	or/8-15

G.3.2 Randomised controlled trials (RCT)

Medline search terms

(Based on the sensitivity and precision maximising version reported in the Cochrane Handbook (<http://handbook.cochrane.org/>)).

1.	randomized controlled trial.pt.
2.	controlled clinical trial.pt.
3.	randomi#ed.ti,ab.
4.	placebo.ab.
5.	randomly.ab.
6.	clinical trials as topic.sh.
7.	trial.ti.
8.	or/1-7

Embase search terms

1.	random*.ti,ab.
2.	factorial*.ti,ab.
3.	(crossover* or cross over*).ti,ab.
4.	((doubl* or singl*) adj blind*).ti,ab.
5.	(assign* or allocat* or volunteer* or placebo*).ti,ab.
6.	crossover procedure/
7.	double blind procedure/
8.	single blind procedure/
9.	randomized controlled trial/
10.	or/1-9

G.3.3 Systematic reviews (SR)

Medline search terms

1.	meta-analysis/
2.	meta-analysis as topic/
3.	(meta analy* or metanaly* or metaanaly*).ti,ab.

4.	((systematic* or evidence*) adj3 (review* or overview*)).ti,ab.
5.	(reference list* or bibliograph* or hand search* or manual search* or relevant journals).ab.
6.	(search strategy or search criteria or systematic search or study selection or data extraction).ab.
7.	(search* adj4 literature).ab.
8.	(medline or pubmed or cochrane or embase or psychlit or psyclit or psychinfo or psycinfo or cinahl or science citation index or bids or cancerlit).ab.
9.	cochrane.jw.
10.	((multiple treatment* or indirect or mixed) adj2 comparison*).ti,ab.
11.	or/1-10

Embase search terms

1.	systematic review/
2.	meta-analysis/
3.	(meta analy* or metanaly* or metaanaly*).ti,ab.
4.	((systematic or evidence) adj3 (review* or overview*)).ti,ab.
5.	(reference list* or bibliograph* or hand search* or manual search* or relevant journals).ab.
6.	(search strategy or search criteria or systematic search or study selection or data extraction).ab.
7.	(search* adj4 literature).ab.
8.	(medline or pubmed or cochrane or embase or psychlit or psyclit or psychinfo or psycinfo or cinahl or science citation index or bids or cancerlit).ab.
9.	cochrane.jw.
10.	((multiple treatment* or indirect or mixed) adj2 comparison*).ti,ab.
11.	or/1-10

G.3.4 Health economic studies (HE)

Medline search terms

1.	economics/
2.	value of life/
3.	exp "costs and cost analysis"/
4.	exp economics, hospital/
5.	exp economics, medical/
6.	economics, nursing/
7.	economics, pharmaceutical/
8.	exp "fees and charges"/
9.	exp budgets/
10.	budget*.ti,ab.
11.	cost*.ti.
12.	(economic* or pharmaco?economic*).ti.
13.	(price* or pricing*).ti,ab.
14.	(cost* adj2 (effective* or utilit* or benefit* or minimi* or unit* or estimat* or variable*)).ab.
15.	(financ* or fee or fees).ti,ab.
16.	(value adj2 (money or monetary)).ti,ab.
17.	or/1-16

Embase search terms

1.	health economics/
2.	exp economic evaluation/

3.	exp health care cost/
4.	exp fee/
5.	budget/
6.	funding/
7.	budget*.ti,ab.
8.	cost*.ti.
9.	(economic* or pharmaco?economic*).ti.
10.	(price* or pricing*).ti,ab.
11.	(cost* adj2 (effective* or utilit* or benefit* or minimi* or unit* or estimat* or variable*)).ab.
12.	(financ* or fee or fees).ti,ab.
13.	(value adj2 (money or monetary)).ti,ab.
14.	or/1-13

G.3.5 Quality of life studies (QoL)

Medline search terms

1.	quality-adjusted life years/
2.	sickness impact profile/
3.	(quality adj2 (wellbeing or well-being)).ti,ab.
4.	sickness impact profile.ti,ab.
5.	disability adjusted life.ti,ab.
6.	(qal* or qtime* or qwb* or daly*).ti,ab.
7.	(euroqol* or eq5d* or eq 5d*).ti,ab.
8.	(qol* or hql* or hqol* or h qol* or hrqol* or hr qol*).ti,ab.
9.	(health utility* or utility score* or disutilit*).ti,ab.
10.	(hui or hui1 or hui2 or hui3).ti,ab.
11.	health* year* equivalent*.ti,ab.
12.	(hye or hyes).ti,ab.
13.	rosser.ti,ab.
14.	(willingness to pay or time tradeoff or time trade off or tto or standard gamble*).ti,ab.
15.	(sf36 or sf 36 or short form 36 or shortform 36 or shortform36).ti,ab.
16.	(sf20 or sf 20 or short form 20 or shortform 20 or shortform20).ti,ab.
17.	(sf12 or sf 12 or short form 12 or shortform 12 or shortform12).ti,ab.
18.	(sf8 or sf 8 or short form 8 or shortform 8 or shortform8).ti,ab.
19.	(sf6 or sf 6 or short form 6 or shortform 6 or shortform6).ti,ab.
20.	or/1-19

Embase search terms

1.	quality adjusted life year/
2.	"quality of life index"/
3.	short form 12/ or short form 20/ or short form 36/ or short form 8/
4.	sickness impact profile/
5.	(quality adj2 (wellbeing or well-being)).ti,ab.
6.	sickness impact profile.ti,ab.
7.	disability adjusted life.ti,ab.

8.	(qal* or qtime* or qwb* or daly*).ti,ab.
9.	(euroqol* or eq5d* or eq 5d*).ti,ab.
10.	(qol* or hql* or hqol* or h qol* or hrqol* or hr qol*).ti,ab.
11.	(health utility* or utility score* or disutilit*).ti,ab.
12.	(hui or hui1 or hui2 or hui3).ti,ab.
13.	health* year* equivalent*.ti,ab.
14.	(hye or hyes).ti,ab.
15.	rosser.ti,ab.
16.	(willingness to pay or time tradeoff or time trade off or tto or standard gamble*).ti,ab.
17.	(sf36 or sf 36 or short form 36 or shortform 36 or shortform36).ti,ab.
18.	(sf20 or sf 20 or short form 20 or shortform 20 or shortform20).ti,ab.
19.	(sf12 or sf 12 or short form 12 or shortform 12 or shortform12).ti,ab.
20.	(sf8 or sf 8 or short form 8 or shortform 8 or shortform8).ti,ab.
21.	(sf6 or sf 6 or short form 6 or shortform 6 or shortform6).ti,ab.
22.	or/1-21

G.3.6 Qualitative reviews (QUAL)

Medline search terms

1.	qualitative research/ or narration/ or exp interviews as topic/ or exp questionnaires/ or health care surveys/
2.	(qualitative or interview* or focus group* or theme* or questionnaire* or survey*).ti,ab.
3.	(metasynthes* or meta-synthes* or metasummar* or meta-summar* or metastud* or meta-stud* or metathem* or meta-them* or ethno* or emic or etic or phenomenolog* or grounded theory or constant compar* or (thematic* adj3 analys*) or theoretical sampl* or purposive sampl* or hermeneutic* or heidegger* or husserl* or colaizzi* or van kaam* or van manen* or giorgi* or glaser* or strauss* or ricoeur* or spiegelberg* or merleau*).ti,ab.
4.	or/1-3

Embase search terms

1.	health survey/ or exp questionnaire/ or exp interview/ or qualitative research/ or narrative/
2.	(qualitative or interview* or focus group* or theme* or questionnaire* or survey*).ti,ab.
3.	(metasynthes* or meta-synthes* or metasummar* or meta-summar* or metastud* or meta-stud* or metathem* or meta-them* or ethno* or emic or etic or phenomenolog* or grounded theory or constant compar* or (thematic* adj3 analys*) or theoretical sampl* or purposive sampl* or hermeneutic* or heidegger* or husserl* or colaizzi* or van kaam* or van manen* or giorgi* or glaser* or strauss* or ricoeur* or spiegelberg* or merleau*).ti,ab.
4.	or/1-3

CINAHL search terms

S1.	(mh "qualitative studies+")
S2.	(mh "qualitative validity+")
S3.	(mh "interviews+") or (mh "focus groups") or (mh "surveys") or (mh "questionnaires+")
S4.	(qualitative or interview* or focus group* or theme* or questionnaire* or survey*)
S5.	(metasynthes* or meta-synthes* or metasummar* or meta-summar* or metastud* or meta-stud* or metathem* or meta-them* or ethno* or emic or etic or phenomenolog* or grounded theory or constant compar* or (thematic* adj3 analys*) or theoretical sampl* or purposive sampl* or hermeneutic* or heidegger* or husserl* or colaizzi* or van kaam* or van manen* or giorgi* or glaser* or strauss* or ricoeur* or spiegelberg* or merleau*)
S6.	S1 or s2 or S3 or S4 or S5

G.4 Searches for specific questions

G.4.1 Risk Assessment

- What is the accuracy of individual risk assessment or predication tools in predicting the likelihood of VTE in patients?

Medline search terms

1.	Standard population [G.2.1]
2.	Excluded study designs and publication types [G.3.1]
3.	1 not 2
4.	Limit 3 to English language
5.	(risk* adj2 assess*).ti,ab.
6.	((score* or scoring) adj2 (tool* or system*)).ti,ab.
7.	((risk* or predict* or prognos*) adj4 (tool* or rule* or index* or indices or score* or scoring or scale* or model* or system* or algorithm* or stratif* or criteria or calculat*)).ti,ab.
8.	(vienna adj5 cats).ti,ab.
9.	(vienna cancer and thrombosis study).ti,ab.
10.	trauma embolic scoring.ti,ab.
11.	tess.ti,ab.
12.	(roger* or caprini* or kucher* or cohen* or padua* or khorana* or autar).ti,ab.
13.	(well* adj2 (score* or scoring)).ti,ab.
14.	department of health.ti,ab,au.
15.	or/5-14
16.	4 and 15
	Date parameters: 1946 – 19 June 2017

Embase search terms

1.	Standard population [G.2.1]
2.	Excluded study designs and publication types [G.3.1]
3.	1 not 2
4.	Limit 3 to English language
5.	(risk* adj2 assess*).ti,ab.
6.	((score* or scoring) adj2 (tool* or system*)).ti,ab.
7.	((risk* or predict* or prognos*) adj4 (tool* or rule* or index* or indices or score* or scoring or scale* or model* or system* or algorithm* or stratif* or criteria or calculat*)).ti,ab.
8.	(vienna adj5 cats).ti,ab.
9.	(vienna cancer and thrombosis study).ti,ab.
10.	trauma embolic scoring.ti,ab.
11.	tess.ti,ab.
12.	(roger* or caprini* or kucher* or cohen* or padua* or khorana* or autar).ti,ab.
13.	(well* adj2 (score* or scoring)).ti,ab.
14.	department of health.ti,ab,au.
15.	or/5-14
16.	4 and 15
	Date parameters: 1974 – 19 June 2017

Cochrane search terms

#1.	Standard population [G.2.1]
#2.	(risk* near/2 assess*):ti,ab
#3.	((score* or scoring) near/2 (tool* or system*)):ti,ab
#4.	((risk* or predict* or prognos*) near/4 (tool* or rule* or index* or indices or score* or scoring or scale* or model* or system* or algorithm* or stratif* or criteria or calculat*)):ti,ab
#5.	(vienna near/5 cats):ti,ab
#6.	(vienna cancer and thrombosis study):ti,ab
#7.	trauma embolic scoring:ti,ab
#8.	tess:ti,ab
#9.	(roger* or caprini* or kucher* or cohen* or padua* or khorana* or autar):ti,ab
#10.	(well* near/2 (score* or scoring)):ti,ab
#11.	(department of health):ti,ab
#12.	(or #2-#11)
#13.	#1 and #12
	Inception – 19 June 2017

G.4.2 Provision of information to patients and planning for discharge

- What information about VTE and VTE prophylaxis should be given to people who are admitted to hospital, having day procedures or outpatients post-discharge, and their family or carers?

Medline search terms

1.	Standard population [G.2.1]
2.	Excluded study designs and publication types [G.3.1]
3.	1 not 2
4.	Limit 3 to English language
5.	"patient acceptance of health care"/ or exp patient satisfaction/
6.	patient education as topic/
7.	((information* or advice or advising or advised or support*) adj3 (patient* or need* or requirement* or assess* or seek* or access* or disseminat*)):ti,ab.
8.	(information* adj2 support*):ti,ab.
9.	((client* or patient* or user* or carer* or consumer* or customer*) adj2 (attitud* or priorit* or perception* or preferen* or expectation* or choice* or perspective* or view* or satisfact* or inform* or experience or experiences or opinion*)):ti,ab.
10.	or/5-9
11.	Study filter QUAL (G.3.6)
12.	4 and 10 and 11
	Date parameters: 2008-19 June 2017

Embase search terms

1.	Standard population [G.2.1]
2.	Excluded study designs and publication types [G.3.1]
3.	1 not 2
4.	Limit 3 to English language
5.	patient attitude/ or patient preference/ or patient satisfaction/ or consumer attitude/
6.	patient information/ or consumer health information/
7.	patient education/
8.	((information* or advice or advising or advised or support*) adj3 (patient* or need* or requirement* or assess* or seek* or access* or disseminat*)):ti,ab.

9.	(information* adj2 support*).ti,ab.
10.	((client* or patient* or user* or carer* or consumer* or customer*) adj2 (attitud* or priorit* or perception* or preferen* or expectation* or choice* or perspective* or view* or satisfact* or inform* or experience or experiences or opinion*)).ti,ab.
11.	or/5-10
12.	Study filter QUAL (G.3.6)
13.	4 and 11 and 12
	Date parameters: 2008-19 June 2017

PsycINFO search terms

1.	Standard population [G.2.1]
2.	su.exact("client education") or su.exact.explode("client attitudes") or ti,ab((information* or advice or advising or advised or support*) n/3 (patient* or need* or requirement* or assess* or seek* or access* or disseminat*)) or ti,ab(information* n/2 support*) or ti,ab((client* or patient* or user* or carer* or consumer* or customer*) n/2 (attitud* or priorit* or perception* or preferen* or expectation* or choice* or perspective* or view* or satisfact* or inform* or experience or experiences or opinion*))
3.	Study filter QUAL (G.3.6)
4.	1 and 2 and 3
	Date parameters: 2008-19 June 2017

Cinahl search terms

S1.	Standard population [G.2.1]
S2.	Limit 1 to English language
S3.	(MH "consumer satisfaction+") OR (MH "patient education") OR (MH "health education")
S4.	((information* or advice or advising or advised or support*) n3 (patient* or need* or requirement* or assess* or seek* or access* or disseminat*))
S5.	(information* n2 support*)
S6.	((client* or patient* or user* or carer* or consumer* or customer*) n2 (attitud* or priorit* or perception* or preferen* or expectation* or choice* or perspective* or view* or satisfact* or inform* or experience or experiences or opinion*))
S7.	S3 or S4 or S5 or S6
S8.	S2 and S7
	Date parameters: 2008-19 June 2017

G.4.3 General VTE prevention for all populations

- What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination)?

Medline search terms

1.	Standard population [G.2.1]
2.	Excluded study designs and publication types [G.3.1]
3.	1 not 2
4.	Limit 3 to English language
5.	exp anticoagulants/
6.	exp fibrinolytic agents/
7.	(anticoagula* or anti coagula* or antithromb* or anti thromb* or antiemboli* or anti emboli* or thrombin inhibit* or direct thrombin).ti,ab.
8.	(dabigatran or pradaxa or danaparoid or orgaran).ti,ab.
9.	exp heparin/

10.	(heparin or lmwh).ti,ab.
11.	(calciparine or monoparin or calcium multiparin or bemiparin or zibor or dalteparin or fragmin* or enoxaparin or clexane or lovenox or tinzaparin or innohep or antixarin or cy 222 or embolex or monoembolex or tinzaparin or suleparoid* or ardeparin or certoparin or nadroparin or parnaparin or reviparin or tedelparin* or minolteparin or semuloparin).ti,ab.
12.	acenocoumarol/ or warfarin/
13.	phenindione/
14.	(warfarin or marevan or acenocoumarol or nicoumalone or sinthrome or phenindione).ti,ab.
15.	(apixaban or eliquis or rivaroxaban or xarelto or edoxaban or lixiana or savaysa or fondaparinux or arixtra).ti,ab.
16.	aspirin/
17.	(aspirin or acetylsalicylic acid).ti,ab.
18.	stockings, compression/
19.	(stocking or stockings or hose).ti,ab.
20.	intermittent pneumatic compression devices/
21.	((inflat* or pneumat*) adj2 (jacket* or sleeve* or glove* or boot*)).ti,ab.
22.	((calf or elastic or graded or limb or leg or pneumatic or plantar or foot) adj compression) or (compression adj device)).ti,ab.
23.	((foot or feet) adj2 (pump or pumps or device*)).ti,ab.
24.	flowtron.ti,ab.
25.	motion therapy, continuous passive/
26.	(therap* adj3 (cpm or continuous passive)).ti,ab.
27.	electric stimulation/
28.	((electric* or electro*) adj2 stimulat*).ti,ab.
29.	or/5-28
30.	Study filters RCT (G.3.2) or SR (G.3.3)
31.	4 and 29 and 30
	Date parameters: 2008-19 June 2017

Embase search terms

1.	Standard population [G.2.1]
2.	Excluded study designs and publication types [G.3.1]
3.	1 not 2
4.	Limit 3 to English language
5.	exp anticoagulant agent/
6.	exp fibrinolytic agent/
7.	(anticoagula* or anti coagula* or antithromb* or anti thromb* or antiemboli* or anti emboli* or thrombin inhibit* or direct thrombin).ti,ab.
8.	dabigatran/ or dabigatran etexilate/
9.	danaparoid/
10.	(dabigatran or pradaxa or danaparoid or orgaran).ti,ab.
11.	heparin/
12.	low molecular weight heparin/
13.	dalteparin/ or enoxaparin/ or nadroparin/ or heparinoid/
14.	(heparin or lmwh).ti,ab.
15.	(calciparine or monoparin or calcium multiparin or bemiparin or zibor or dalteparin or fragmin* or enoxaparin or clexane or lovenox or tinzaparin or innohep or antixarin or cy 222 or embolex or monoembolex or fragmin or tinzaparin or suleparoid* or ardeparin or certoparin

	or nadroparin or parnaparin or reviparin or tedelparin).ti,ab.
16.	acenocoumarol/ or warfarin/ or phenindione/
17.	(warfarin or marevan or acenocoumarol or nicoumalone or sinthrome or phenindione).ti,ab.
18.	apixaban/ or rivaroxaban/ or edoxaban/ or fondaparinux/
19.	(apixaban or eliquis or rivaroxaban or xarelto or edoxaban or lixiana or savaysa or fondaparinux or arixtra).ti,ab.
20.	acetylsalicylic acid/
21.	(aspirin or acetylsalicylic acid).ti,ab.
22.	compression stocking/
23.	(stocking or stockings or hose).ti,ab.
24.	intermittent pneumatic compression device/
25.	((inflat* or pneumat*) adj2 (jacket* or sleeve* or glove* or boot*)).ti,ab.
26.	((calf or elastic or graded or limb or leg or pneumatic or plantar or foot) adj compression) or (compression adj device)).ti,ab.
27.	((foot or feet) adj2 (pump or pumps or device*)).ti,ab.
28.	flowtron.ti,ab.
29.	passive movement/
30.	(therap* adj3 (cpm or continuous passive)).ti,ab.
31.	electrostimulation/
32.	((electric* or electro*) adj2 stimulat*).ti,ab.
33.	or/5-32
34.	Study filters RCT (G.3.2) or SR (G.3.3)
35.	4 and 33 and 34
	Date parameters: 2008-19 June 2017

Cochrane search terms

#1.	Standard population [G.2.1]
#2.	MeSH descriptor: [anticoagulants] explode all trees
#3.	MeSH descriptor: [fibrinolytic agents] explode all trees
#4.	(anticoagula* or anti coagula* or antithromb* or anti thromb* or antiemboli* or anti emboli* or thrombin inhibit* or direct thrombin):ti,ab
#5.	(dabigatran or pradaxa or danaparoid or orgaran):ti,ab
#6.	MeSH descriptor: [heparin] explode all trees
#7.	(heparin or lmwh):ti,ab
#8.	(calciparine or monoparin or calcium multiparin or bemiparin or zibor or dalteparin or fragmin* or enoxaparin or clexane or lovenox or tinzaparin or innohep or antixarin or cy 222 or embolex or monoembolex or fragmin or tinzaparin or suleparoid* or ardeparin or certoparin or nadroparin or parnaparin or reviparin or tedelparin):ti,ab
#9.	MeSH descriptor: [acenocoumarol] explode all trees
#10.	MeSH descriptor: [warfarin] explode all trees
#11.	MeSH descriptor: [phenindione] explode all trees
#12.	(warfarin or marevan or acenocoumarol or nicoumalone or sinthrome or phenindione):ti,ab
#13.	(apixaban or eliquis or rivaroxaban or xarelto or edoxaban or lixiana or savaysa or fondaparinux or arixtra):ti,ab
#14.	MeSH descriptor: [aspirin] explode all trees
#15.	(aspirin or acetylsalicylic acid):ti,ab
#16.	MeSH descriptor: [stockings, compression] explode all trees
#17.	(stocking or stockings or hose):ti,ab

#18.	MeSH descriptor: [intermittent pneumatic compression devices] explode all trees
#19.	((inflat* or pneumat*) near/2 (jacket* or sleeve* or glove* or boot*)):ti,ab
#20.	((calf or elastic or graded or limb or leg or pneumatic or plantar or foot) near/1 compression) or (compression near/1 device)):ti,ab
#21.	((foot or feet) near/2 (pump or pumps or device*)):ti,ab
#22.	flowtron.ti,ab
#23.	MeSH descriptor: [motion therapy, continuous passive] explode all trees
#24.	(therap* near/3 (cpm or continuous passive)):ti,ab
#25.	MeSH descriptor: [electric stimulation] explode all trees
#26.	((electric* or electro*) near/2 stimulat*):ti,ab
#27.	(or #2-#26)
#28.	#1 and #27
	Date parameters: 2008-19 June 2017

G.5 Health economics search terms

Economic searches were conducted in Medline, Embase and NHS EED and HTA databases hosted by CRD.

G.5.1 Health economic (HE) reviews

Economic searches were conducted in Medline, Embase, Cochrane and CRD.

Medline & Embase search terms

1.	#29. Standard population [G.2.1]
2.	#30. Excluded study designs and publication types [G.3.1]
3.	#31. 1 not 2
4.	#32. Limit 3 to English language
5.	#33. Study filter HE (G.3.4)
6.	#34. 4 and 5
#35.	#36. Date parameters: 2013-19 June 2017

Cochrane search terms

#1.	Standard population [G.2.1]
	Date parameters: 2008-19 June 2017

CRD search terms

#1.	Standard population [G.2.1]
	Date parameters: 1999 - 2008

G.5.2 Quality of life (QoL) reviews

Quality of life searches were conducted in Medline and Embase only

Medline & Embase search terms

1.	#37. Standard population [G.2.1]
2.	#38. Excluded study designs and publication types [G.3.1]
3.	#39. 1 not 2

4.	#40.	Limit 3 to English language
5.	#41.	Study filter QOL (G.3.5)
6.	#42.	4 and 5
#43.	#44.	Date parameters: 2008-19 June 2017

Appendix H: Clinical evidence tables

H.1 Risk assessment for people admitted to hospital

H.1.1 Patients admitted to hospital

Reference	Bahl 2010 ¹²
Study type	Retrospective cohort
Study methodology	Data source: general, vascular and urologic surgery inpatients from the University of Michigan Health System (UMHS) National Surgical Quality Improvement (NSQIP) program discharged between July 2001 and January 2008. Data for VTE risk factor were obtained from electronic sources. Validation: external validation.
Number of patients	n=8216
Patient characteristics	Age: <40 years 19.28%, 40-60 years 39.59%, 61-74 years 28.4%, 75+ years 12.73% Gender (male to female ratio): not reported Ethnicity: not reported Condition(s): acute myocardial infarction 0.22%; heart failure 3.93%; varicose veins 0.11%; obesity (BMI >25) 24.71%; inflammatory bowel disease 2.98%; sepsis (<1 month) 0.85%; COPD or abnormal pulmonary function 7.57%; severe lung disease, including pneumonia (<1 month) 0.68%; pregnancy or postpartum (<1 month) 0.19%; malignancy (present or previous) 34.98%; Surgery: major surgery (>45 minutes) 88.16%; general 67%, vascular 16%, 17% urologic; minor surgery planned 5.66%; arthroscopic surgery 0%; laparoscopic procedure (>45 minutes) 6.18%; history of DVT/PE 3.47%; stroke (<1 month) 0.15%; multiple trauma (<1 month) 0.04% Other relevant characteristics: central venous access 7.64%; elective major lower extremity arthroplasty 0.01%; hip, pelvis or leg fracture 0%; acute spinal cord injury (paralysis) 0% Setting: hospital Country: USA

Reference	Bahl 2010 ¹²
	<p>Inclusion criteria: general, vascular and urologic surgery inpatients from the University of Michigan Health System (UMHS) National Surgical Quality Improvement (NSQIP) program discharged between July 2001 and January 2008</p> <p>Exclusion criteria: none stated</p>
Target condition(s)	VTE (30 days): not defined. Prevalence: n= 188 (1.44%)
Risk tool(s)	<p><u>Caprini score</u></p> <p>Total score is used to place people in one of three main risk categories: low (scores 0-4), moderate (5-8) and high (≥9). Includes 25 predictors.</p> <p>Score 1:</p> <ul style="list-style-type: none"> • Age 40-59 (years) • Abnormal pulmonary function • Acute myocardial infarction (<1 month) • BMI ≥30 (kg/m²) • Congestive heart failure (<1 month) • History of inflammatory bowel disease • History of prior major surgery (<1 month) • Complications of pregnancy (history of unexplained stillborn infant, recurrent or spontaneous abortion (>3), premature birth with toxemia of pregnancy, or growth-restricted infant) • Oral contraceptive use or hormone replacement therapy (HRT) • Sepsis (<1 month) • Serious acute lung disease (<1 month) • Swollen legs (current) • Varicose veins <p>Score 2:</p> <ul style="list-style-type: none"> • Age 60-74 (years) • Central venous access • Confined to bed (>72 hours) • Major open surgery (≥45 minutes) • Present cancer • Prior cancer, except non-melanoma skin <p>Score 3:</p> <ul style="list-style-type: none"> • Age ≥75 (years)

Reference	Bahl 2010 ¹²
	<ul style="list-style-type: none"> • History of VTE • Family history of VTE • Chemotherapy • Positive anticardiolipin antibody • Positive Lupus anticoagulant • Acute spinal cord injury (<1 month) • Major surgery (≥6 hours)
Statistical measures	<p><u>Caprini score</u></p> <ul style="list-style-type: none"> • C-statistic 0.698 (no variance data reported) • Hosmer and Lemeshow test p=0.607
Source of funding	Not reported
Limitations	<p>Patient selection: Unclear if patients were enrolled at a similar state of health</p> <p>Outcome: No VTE definition reported</p> <p>Analysis: Not all relevant performance measures evaluated</p> <p>Sample size and participants: There was not a reasonable number of outcome events</p>
Comments	

Reference	Bilimoria 2013 ³⁰
Study type	Retrospective cohort
Study methodology	<p>Data source: American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP). Data collected by trained and audited Surgical Clinical Reviewers (SCR) at each individual hospital using data definitions which are standardized across all hospitals. Thirty-day outcomes are ascertained from the medical record or patients are contacted after discharge. Outcomes are ascertained irrespective of whether the patient was an inpatient, outpatient, or admitted to another facility. Patients were identified who underwent operations from 1 January 2009 to 30 June 2012, spanning all surgical subspecialties. From the overall dataset, 88,334 cases were identified as colon operations based on primary Current Procedural Terminology (CPT) codes</p> <p>Derivation: Universal ACS NSQIP Surgical Risk Calculator - Preoperative risk factors to be used in calculating patient-specific risks of surgical events were selected a priori based on predictive value, routine availability to the surgeon prior to the operation, and clinical face validity. Missing data were handled with imputation using the Buck's method per the standard ACS NSQIP modelling approach. In prior procedure-specific risk calculators, the operations were grouped into surgery subtypes based on CPT codes (6 groups for colectomy) and into surgical</p>

Reference	Bilimoria 2013 ³⁰
	<p>indication categories based on International Classification of Disease (ICD-9) codes (8 groups for colectomy). For the universal Surgical Risk Calculator model, a CPT-specific linear risk (different for each outcome) replaced CPT procedure categories in the procedure-specific model, and the universal model did not include an indication variable. The individual CPT-specific linear risks were logit transformed predicted probabilities, from preliminary models where CPT (2,805 different CPTs), as a random effect in a hierarchical model, was used to predict each outcome. Random intercept, fixed slope hierarchical models (using SAS GLIMMIX), which account for clustering of cases within hospitals and impose an empirical-Bayes type shrinkage adjustment, were used. Only fixed (patient-level) effects were used for risk prediction.</p> <p>Validation: Universal ACS NSQIP Surgical Risk Calculator: externally validated, split sample by year ACS NSQIP Colorectal Risk Calculator: externally validated, split sample by year ⁶⁴</p>
Number of patients	<p>All surgery n= 1,414,006 (derivation) Colon surgery n= 88,334 (validation)</p>
Patient characteristics	<p>Age: not reported Gender (male to female ratio): 42.7:57.3 Ethnicity: not reported</p> <p>Condition(s): disseminated cancer 2%; diabetes 15.2%; hypertension requiring medication 46.6%; congestive heart failure 30 days before surgery 0.9%; history of severe COPD 4.8%; acute renal failure 0.5%</p> <p>Surgery: colectomy</p> <p>Systemic sepsis with 48 hours before surgery: systemic inflammatory response syndrome (SIRS) 3.9%, sepsis 2.4%, septic shock 0.6%</p> <p>Previous cardiac event: 7.4%</p> <p>Functional status: independent 95.1%, partially dependent 3.7%, totally dependent 1.2%</p> <p>Ventilator dependent: 0.7%</p> <p>Dialysis: 1.6%</p> <p>Current smoker 19.3%</p> <p>Setting: 393 hospitals Country: USA</p> <p>Inclusion criteria: Universal ACS NSQIP Surgical Risk Calculator – people undergoing any operation; ACS NSQIP Colorectal Risk Calculator - people</p>

Reference	Bilimoria 2013 ³⁰
	undergoing colon operations Exclusion criteria: none stated
Target condition(s)	VTE (30 days): not defined. Incidence: all surgery – 12,671 (0.9%); colon surgery – n=3508 (4%)
Risk tool(s)	<p><u>Universal ACS NSQIP Surgical Risk Calculator</u> Web-based tool with 21 preoperative factors</p> <ul style="list-style-type: none"> • Age group (<65, 65-74, 75-84, ≥85) • Sex • Functional status (Independent, partially dependent, totally dependent) • Emergency case • American Society of Anaesthesiologists (ASA) Class (1 or 2, 3, 4 or 5) • Steroid use for chronic condition • Ascites within 30 days preoperatively • System sepsis within 48 h preoperatively (None, SIRS, sepsis, septic shock) • Ventilator dependent • Disseminated cancer • Diabetes (No, Oral, Insulin) • Hypertension requiring medication • Previous cardiac event • Congestive heart failure in 30 days preoperatively • Dyspnoea • Current smoker within 1 year • History of COPD • Dialysis • Acute renal failure • Body mass index (BMI) Class (Underweight, normal, overweight, obese 1, obese 2, obese 3) • CPT-specific linear risk (2,805 values) <p><u>ACS NSQIP Colorectal Risk Calculator</u> 22 factors</p> <ul style="list-style-type: none"> • Age group (<65, 65-74, 75-84, ≥85) • Sex • Functional status (Independent, partially dependent, totally dependent)

Reference	Bilimoria 2013 ³⁰
	<ul style="list-style-type: none"> • Emergency case • American Society of Anaesthesiologists (ASA) Class (1 or 2, 3, 4 or 5) • Steroid use for chronic condition • Ascites within 30 days preoperatively • System sepsis within 48 h preoperatively (None, SIRS, sepsis, septic shock) • Ventilator dependent • Disseminated cancer • Diabetes (No, Oral, Insulin) • Hypertension requiring medication • Previous cardiac event • Congestive heart failure in 30 days preoperatively • Dyspnoea • Current smoker within 1 year • History of COPD • Dialysis • Acute renal failure • BMI Class (Underweight, normal, overweight, obese 1, obese 2, obese 3) • Colon surgery group (colectomy) (Partial lap with anastomosis, partial lap with ostomy, partial open with anastomosis, partial open with ostomy, total lap with ostomy, total open with ostomy) • Indication for colon surgery (Diverticulitis, enteritis/colitis, haemorrhage, neoplasm, obstruction/perforation, vascular insufficiency, volvulus, other)
Statistical measures	<p>All surgery population:</p> <p>Universal ACS NSQIP Surgical Risk Calculator</p> <ul style="list-style-type: none"> • C-statistic 0.819 • Brier score 0.009
	<p>Colon surgery population:</p> <p>Universal ACS NSQIP Surgical Risk Calculator</p> <ul style="list-style-type: none"> • C-statistic 0.7203 • Brier score 0.0218
Source of funding	Part funded by the Agency for Healthcare Research and Quality
Limitations	Predictors: Unclear if predictor assessments were made without knowledge of outcome data

Reference	Bilimoria 2013 ³⁰
	Outcome: No VTE definition reported, too few events compared to number of factors in the risk tool. Analysis: No relevant performance measures evaluated
Comments	

Reference	Grant 2016 ¹²⁷
Study type	Retrospective cohort (data registry)
Study methodology	Recruitment: January 2011 to March 2014, data spanning 63,548 eligible patients across 48 hospitals was collected. Follow-up data are collected through both medical record review and direct telephone follow up at 90 days post-hospital discharge. Validation: External validation
Number of patients	n= 63,548
Patient characteristics	Age: mean 65.8 years (≥ 75 years 35.66%) Gender (male to female ratio): 1:1.4 Ethnicity: not reported Average length of hospital stay: 4.5 days. Prophylaxis: 60.9% received pharmacologic venous thromboembolism prophylaxis Setting: Michigan Hospital Medicine Safety Consortium (48 Michigan hospitals) Country: USA Inclusion criteria: Hospitalised medical patients admitted to a medicine service for two or more days Exclusion criteria: 1) Under the age of 18; 2) pregnant; 3) underwent any surgical procedure during the admission; 4) direct admission to an intensive care unit; 5) direct admission for end-of-life care; 6) diagnosis of venous thromboembolism in the 6 months prior to admission; 7) admitted for presumed venous thromboembolism; 8) admitted under observation status; 9) re-admitted within 90 days of discharge from an admission including in the registry; or 10) received systemic anticoagulation on day one or day two of the index hospitalisation.
Target condition(s)	Clinically-suspected and image-confirmed hospital associated VTE (90 days): Including proximal upper or proximal lower extremity DVT and PE. VTE events must have occurred on the third day after admission or later (up to 90 days after admission). Diagnosis of DVT was based on positive findings via compression Doppler ultrasound or venography, PE was confirmed via computed tomography (CT) scan, ventilation perfusion (V/Q)

Reference	Grant 2016 ¹²⁷
	scan or pulmonary angiography Incidence: n= 670 (1.05%)
Risk tool(s)	<p><u>Caprini Risk Assessment Model (RAM)</u></p> <ul style="list-style-type: none"> • Five points allocated to: Stroke, acute spinal cord injury or paralysis (<1 month), Hip, pelvis, or leg fracture (<1 month), multiple trauma (<1 month) • Three points allocated to: age 75 (years), history of VTE, Family history of VTE, History of thrombophilia, HIT • Two points allocated to: age 61-74 (years), positive history of cancer, immobilising plaster cast, patient confined to a bed (≥72 hours) • One point allocated to: age 41-60 (years), congestive heart failure, COPD or abnormal pulmonary function, IBD, severe lung disease, acute MI, Sepsis (<1 month), surgery (<1 month), postpartum (<1 month), history of unexpected stillborn infant, recurrent spontaneous abortion (≥3 month) or premature birth, varicose veins, obesity (BMI > 25), current swollen leg, CVC on admission, immobile/not ambulating, HRT or oral contraceptives.
Statistical measures	<p><u>Caprini score</u></p> <ul style="list-style-type: none"> • Caprini score 5 cut-off: sensitivity 69.70%, specificity 50.28%; PLR 1.4019, NLR 0.6026; PPV 0.01472, NPV 0.99362 • Caprini score 7 cut-off: sensitivity 42.69%, specificity 74.71%; PLR 1.6879, NLR 0.7671; PPV 0.01767, NPV 0.99189 • Caprini score 9 cut-off: sensitivity 18.51%, specificity 89.03%; PLR 1.6875, NLR 0.9153; PPV 0.01766, NPV 0.99034
Source of funding	Blue Cross/Blue Shield of Michigan and Blue Care Network
Limitations	<p>Very serious risk of bias: Retrospective nature of the design means unclear if those assessing predictors retrospectively were aware of outcome data, low event rate compared to number of predictors in the model, no calibration data reported and unclear reference standard used to calculate sensitivity and specificity so 2x2 table unable to be calculated.</p> <p>Applicability issues with US population and risk factor definitions.</p>
Comments	

Reference	Greene 2016 ¹²⁹
Study type	Prospective cohort

Reference	Greene 2016 ¹²⁹
Study methodology	<p>Recruitment: Michigan Hospital Medicine Safety (HMS) Consortium. The HMS Consortium is a group of hospitals working to prevent adverse events in hospitalized medical patients in Michigan through creation of a data registry and sharing of best practices. Although participation is voluntary, each hospital receives payments for participating in the consortium and for data collection. Clinical data on patients are collected through a standardized process at each hospital using dedicated, trained medical record abstractors. Patients discharged from each participating hospital were sampled on an 8 day rolling cycle; data on the first 18 eligible cases discharged during the cycle were collected.</p> <p>Validation: External validation ^{14,178,303,342}</p>
Number of patients	n= 63,548
Patient characteristics	<p>Age: mean 65.8 years (≥ 75 years 35.66%) Gender (male to female ratio): 1:1.4 Ethnicity: not reported</p> <p>Cancer within last year – 7.85% Central venous catheter present on admission – 7.89% Prior VTE – 6.40% Family history of VTE – 0.69% Postpartum (<1 month) – 0.06% Surgery (<1 month) – 2.67% Pneumonia (<1 month) – 14.22% Other acute infection – 13.81% Congestive heart failure – 9.33% Sepsis (<1 month) – 10.32% Obesity (BMI > 30) – 35.20% Myocardial infection (<1 month) – 1.67% Inflammatory bowel disease – 3.17% Stroke – 4.78% Transferred to ICU 1.86% Prophylaxis: 60.9% received pharmacologic venous thromboembolism prophylaxis</p> <p>Setting: 48 Michigan hospitals</p>

Reference	Greene 2016 ¹²⁹
	<p>Country: USA</p> <p>Inclusion criteria: Those admitted to a medicine service for two days or longer</p> <p>Exclusion criteria: 1) Under the age of 18; 2) pregnant; 3) underwent any surgical procedure during the admission; 4) direct admission to an intensive care unit; 5) direct admission for end-of-life care; 6) diagnosis of venous thromboembolism in the 6 months prior to admission; 7) admitted for presumed venous thromboembolism; 8) admitted under observation status; 9) re-admitted within 90 days of discharge from an admission including in the registry; or 10) received systemic anticoagulation on day one or day two of the index hospitalisation.</p>
Target condition(s)	<p>Hospital associated VTE (90 days): Proximal upper or proximal lower extremity DVT and PE. VTE events must have occurred on the third day after admission or later (up to 90 days after admission). Diagnosis of DVT was based on positive findings via compression Doppler ultrasound or venography, PE was confirmed via computed tomography (CT) scan, ventilation perfusion (V/Q) scan or pulmonary angiography</p> <p>Incidence: n= 670 (1.05%)</p>
Risk tool(s)	<p><u>Kucher Score</u></p> <ul style="list-style-type: none"> • Three points allocated to: cancer, prior VTE, hypercoagulability • Two points allocated to: major surgery • One point allocated to: bed rest, age > 70 years, obesity (BMI > 30), hormone replacement therapy/oral contraceptives <p><u>Padua Prediction Score</u></p> <p>Data was also applied to the Padua Prediction Score</p> <ul style="list-style-type: none"> • Three points were allocated to: active cancer, previous VTE, reduced mobility, already known thrombophilic condition • Two points were allocated to: recent trauma and/or surgery • One point allocated to: elderly age ≥70 years, heart and/or respiratory failure, acute myocardial infarction or ischaemic stroke, acute infection and/or rheumatologic disorder, obesity (BMI ≥30 kg/m², and on-going hormonal treatment. <p>Patients were classified as high (Padua Prediction Score ≥4) or low (Padua Prediction Score <4) risk of VTE.</p> <p><u>International Medical Prevention on Venous Thromboembolism (IMPROVE)</u></p> <p>The following risk factors are given 1-3 points each and points are added to achieve a final score which is then categorised into tiers of low (0-1 points), moderate(2-3 points) or high risk of VTE (≥4 points):</p> <ul style="list-style-type: none"> • Three points allocated to: previous VTE • Two points allocated to: Known thrombophilia, lower limb paralysis, current cancer • One point allocated to: Immobilisation ≥ 7 days, ICU/ CCU stay, age > 60 years <p><u>Intermountain risk assessment model</u></p>

Reference	Greene 2016 ¹²⁹
	<p>Risk factors included in the RAM are:</p> <ul style="list-style-type: none"> • Prior VTE • An order for bed rest • PICC insertion • Diagnosis of cancer <p>The number of points allocated to each risk factor was not reported. At risk ≥ 1.</p>
Statistical measures	<p><u>Kucher Score</u> (at risk ≥ 4: 10.34%)</p> <ul style="list-style-type: none"> • C-statistic – 0.563 (0.558-0.568) <p><u>Padua Prediction Score</u> (at risk ≥ 4: 16.66%)</p> <ul style="list-style-type: none"> • C-statistic – 0.600 (0.594-0.606) <p><u>IMPROVE</u> (at risk ≥ 2: 11.71%)</p> <ul style="list-style-type: none"> • C-statistic – 0.570 (0.565-0.576) <p><u>Intermountain risk assessment model</u> (at risk ≥ 1: 19.13%)</p> <ul style="list-style-type: none"> • C-statistic – 0.611 (0.605-0.618)
Source of funding	Blue Cross/Blue Shield of Michigan and Blue Care Network
Limitations	Risk of bias introduced by analysis: relevant performance measures were not evaluated (sensitivity and specificity) for all four risk tools Applicability issues with US population and risk factor definitions.
Comments	

Reference	Hachey 2016 ¹³²
Study type	Retrospective cohort
Study methodology	<p>Recruitment: people who underwent segmenectomy, lobectomy or pneumonectomy for lung cancers within the Division of Thoracic Surgery were identified between June 2005 and June 2013. Pertinent cases were selected based on current procedural terminology for open and minimally invasive operations, and all cases were included that matched the ICD-9 codes for non-small cell lung cancers and small cell lung cancers.</p> <p>Validation: External validation in multiple specialties including general, vascular, plastic surgery and gynaecologic oncology^{251,12,43,307,345}.</p>

Reference	Hachey 2016 ¹³²
Number of patients	n=232
Patient characteristics	<p>Age: Adults (with VTE mean 63.83±10.2 years, without VTE mean 64.36±11 years) Gender (male to female ratio): 100:132 Ethnicity: not reported</p> <p>Condition(s): lung cancer Surgery: lobectomy (84.5%), segmenectomy (8.2%), pneumonectomy (7.3%) Prophylaxis: pharmacological with VTE 100%, without VTE 91.8%; intermittent pneumatic compression with VTE 100%, without VTE 91.8% BMI (kg/m²): with VTE mean 27.38±5.05, without VTE mean 27.42±7.02</p> <p>Setting: 1 hospital Country: USA</p> <p>Inclusion criteria: documentation of at least 60 day follow up; received routine postoperative, prophylactic, subcutaneous, unfractionated heparin 3 times daily, and/or intermittent pneumatic compression during the hospitalisation Exclusion criteria: lost to follow-up or missing records; deceased due to non-VTE causes before 60 days after surgery; multiple operations after the first; preoperative inferior vena cava filter placement; and hospital discharge on therapeutic anticoagulation for indications not related to postoperative VTE</p>
Target condition(s)	VTE (60 days): defined as any PE or DVT identified via clinical imaging studies (i.e., computed tomography pulmonary angiogram or duplex ultrasound) and treated with therapeutic anticoagulation or inferior vena cava filter. Incidence n=12 (5.2%)
Risk tool(s)	<p><u>Caprini score</u> Total score is used to place people in one of three main risk categories: low (scores 0-4), moderate (5-8) and high (≥9).</p> <p>Score 1:</p> <ul style="list-style-type: none"> • Age 40-59 (years) • Abnormal pulmonary function • Acute myocardial infarction (<1 month) • BMI ≥30 (kg/m²) • Congestive heart failure (<1 month) • History of inflammatory bowel disease

Reference	Hachey 2016 ¹³²
	<ul style="list-style-type: none"> • History of prior major surgery (<1 month) • Complications of pregnancy (history of unexplained stillborn infant, recurrent or spontaneous abortion (>3), premature birth with toxemia of pregnancy, or growth-restricted infant) • Oral contraceptive use or HRT • Sepsis (<1 month) • Serious acute lung disease (<1 month) • Swollen legs (current) • Varicose veins <p>Score 2:</p> <ul style="list-style-type: none"> • Age 60-74 (years) • Central venous access • Confined to bed (>72 hours) • Major open surgery (≥45 minutes) • Present cancer • Prior cancer, except non-melanoma skin <p>Score 3:</p> <ul style="list-style-type: none"> • Age ≥75 (years) • History of VTE • Family history of VTE • Chemotherapy • Positive anticardiolipin antibody • Positive Lupus anticoagulant • Acute spinal cord injury (<1 month) • Major surgery (≥6 hours)
Statistical measures	<p><u>Caprini score</u></p> <ul style="list-style-type: none"> • Score >5: Sensitivity 100 (100 – 100); Specificity 7.2 (4.1 – 11) • Score >7: Sensitivity 100 (100 – 100); Specificity 31.4 (25 – 37.3) • Score >9: Sensitivity 83.3 (58.3 – 100); Specificity 60.5 (54.4 – 67.3) • Score > 10: Sensitivity 75 (50 -100); Specificity 69.6 (64.4 – 76.4) • C-statistic 0.72 • PPV 10.3 • NPV 98.5

Reference	Hachey 2016 ¹³²
	<ul style="list-style-type: none"> Hosmer-Lemeshow test p=0.61
Source of funding	Not reported
Limitations	<p>Predictors: Unclear if predictor assessments were made without knowledge of outcome data</p> <p>Sample size and participant flow: There was not a reasonable number of outcome events compared to number of factors in the model</p>
Comments	

Reference	Hegsted 2013 ¹⁴²
Study type	Retrospective cohort
Study methodology	<p>Data source: The cohort was identified from the prospectively defined trauma registry for the years 2003 and 2006. Data elements were obtained from the trauma registry, chart abstraction, and manual calculation of RAP</p> <p>Validation: Externally validated within a cohort analysis involving 184 trauma patients in 2000 ¹¹⁸</p>
Number of patients	n=2281
Patient characteristics	<p>Age (mean): 45.2 years</p> <p>Gender (male to female ratio): 2.33:1</p> <p>Ethnicity: not reported</p> <p>Condition(s): People with trauma (not details provided about type of trauma)</p> <p>Setting: Level I trauma centre</p> <p>Country: USA</p> <p>Inclusion criteria: Patients aged 13 years and older admitted to a level I trauma centre and hospitalised for longer than 48 hours.</p> <p>Exclusion criteria: None reported</p>
Target condition(s)	<p>DVT (definition not reported) (time point unclear)</p> <p>PE detected by computed tomography-angiography or post-mortem examination (time point unclear)</p> <p>Prevalence: DVT n= 239 (10.5%), PE n=34 (1.5%)</p>

Reference	Hegsted 2013 ¹⁴²
Risk tool(s)	<p><u>Risk Assessment Profile (RAP)</u></p> <p>Each patient's risk for the development of VTE is defined by RAP score and categorised as being at low (RAP ≤5), medium/moderate (RAP≤14) or high (RAP>14) risk.</p> <p>Risk factors:</p> <ul style="list-style-type: none"> • Four points allocated to: complex lower extremity fracture, pelvic fracture, spinal cord injury, paraplegia or quadriplegia, ≥75 years old • Three points allocated to: history of thromboembolism, repair or ligation of major vascular injury, spinal fractures, GCS <8 for >4 hours, 60 ≥ but <75 years • Two points allocated to: obesity, malignancy, abnormal coagulation, central femoral line >24 hours, transfusion more than 4 units in 24 hours, surgery >2 hours, chest AIS >2, abdomen AIS >2, head AIS >2, ≥40 but <60 years
Statistical measures	<p><u>RAP</u></p> <p><u>Outcome: DVT</u></p> <ul style="list-style-type: none"> • Moderate cut-off (5 to ≤ 14): Sensitivity 82% (77-87%); Specificity 57% (55-59%) ; PPV 18% (16-21%); NPV 96% (95-97%) • High cut-off (>14): Sensitivity 15% (11-20%); Specificity 97% (97-98%); PPV 41% (31-51%); NPV 91% (90-92%) <p><u>Outcome: PE</u></p> <ul style="list-style-type: none"> • Moderate cut-off (5 to ≤ 14): Sensitivity 71% (55-86%); Specificity 53% (51-56%) ; PPV 2% (1-3%); NPV 99% (99-100%) • High cut-off (>14): Sensitivity 12% (1-23%); Specificity 96% (95-97%) ; PPV 4% (0-9%) ; NPV 99% (98-99%)
Source of funding	This study was supported by Legacy Health Research Foundation
Limitations	<p>Patient selection: Unclear if patients were enrolled at a similar state of health and if inclusions and exclusions were appropriate.</p> <p>Predictors: Unclear if predictor assessments were made without knowledge of outcome data</p> <p>Outcome: time point unclear for target conditions and definition for one of the target conditions not reported</p>
Comments	

Reference	Hewes 2015 ¹⁴⁶
Study type	Retrospective cohort

Reference	Hewes 2015 ¹⁴⁶
Study methodology	<p>Data source: records of patients who underwent an oesophagectomy for cancer by the thoracic surgery service between June 2005 and June 2013 were reviewed. The Caprini risk score and the number of VTE events were recorded retrospectively for each patient. Patients were identified by the oesophagectomy Current Procedural Terminology codes in the thoracic surgery billing lists and then cross-correlated with the ICD codes for cancer.</p> <p>Validation: Externally validated in multiple surgical specialities ^{126,251,12,43,307,345}</p>
Number of patients	n=70
Patient characteristics	<p>Age: with VTE mean 64.9±6.4, without VTE mean 61.6±11.7</p> <p>Gender (male to female ratio): 58:12</p> <p>Ethnicity: white 70%, black 20%, Asian or Pacific Islander 2.9%, Hispanic 2.9%</p> <p>Condition(s): oesophageal cancer</p> <p>Surgery: oesophagectomy</p> <p>BMI (kg/m² (IQR)): with VTE 26.9 (9.7), without VTE 25.1 (6.9)</p> <p>Setting: 1 hospital</p> <p>Country: USA</p> <p>Inclusion criteria: diagnosis of oesophageal cancer treated with oesophagectomy (any approach) and with available 60-day postoperative follow-up</p> <p>Exclusion criteria: patients with missing records and with incomplete follow-up; the presence of an inferior vena cava filter or chronic anticoagulation therapy</p>
Target condition(s)	VTE (60 days): defined as any thromboembolic event diagnosed by appropriate imaging findings and treated with therapeutic anticoagulation or inferior vena cava filter. Incidence: n= 10 (14.3%)
Risk tool(s)	<p><u>Modified Caprini risk assessment model (1 – 60 days)</u></p> <p>Assigned score was the sum of the risk factors accrued before the first occurrence of one of the following: date of maximum Caprini score, date of discharge, or within 24 hours before VTE diagnosis. Standardised case definitions for each risk factor were established for homogeneity of review among the chart reviewers. For sepsis, systemic inflammatory response syndrome criteria were used.</p> <p>Score 1:</p> <ul style="list-style-type: none"> Age 41-59 (years)

Reference	Hewes 2015 ¹⁴⁶
	<ul style="list-style-type: none"> • Abnormal pulmonary function • Acute myocardial infarction (<1 month) • BMI ≥30 (kg/m²) • Congestive heart failure (<1 month) • History of inflammatory bowel disease • History of prior major surgery (<1 month) • Sepsis (<1 month) • Serious acute lung disease (<1 month) • Swollen legs (current) • Varicose veins • Minor surgery planned • Medical patient currently on bed rest • Leg plaster cast or brace • Central venous access <p>Score 2:</p> <ul style="list-style-type: none"> • Age 60-74 (years) • Major surgery (> 60 minutes) • Previous malignancy • Arthroscopic surgery (>60 minutes) • Laparoscopic surgery (>60 minutes) • Morbid obesity (BMI> 40 kg/m²) <p>Score 3:</p> <ul style="list-style-type: none"> • Age ≥75 (years) • History of SVT, DVT/PE • Family history of VTE • Present cancer or chemotherapy • Positive anticardiolipin antibody • Positive Lupus anticoagulant

Reference	Hewes 2015 ¹⁴⁶
	<ul style="list-style-type: none"> • Acute spinal cord injury (<1 month) • Major surgery (2-3 hours) • BMI > 50 kg/m² (venous stasis syndrome) • Congenital thrombophilia: positive factor V Leiden, positive prothrombin 20210A, elevated serum homocysteine • Acquired thrombophilia: positive lupus anticoagulant, elevated anticardiolipin antibodies, HIT • Other thrombophilia <p>Score 5:</p> <ul style="list-style-type: none"> • Elective major lower extremity arthroplasty • Hip, pelvis or leg fracture (<1 month) • Stroke (<1 month) • Multiple trauma (<1 month) • Acute spinal cord injury (paralysis) (<1 month) • Major surgery >3 hours <p>Further details provided in other studies. ^{126,251,12,43,307,345}</p>
Statistical measures	<p><u>Modified Caprini RAM</u></p> <ul style="list-style-type: none"> • Cut-off score >15: Sensitivity 100 (100 – 100); Specificity 66.7 (55 – 78.3) • PPV 33.3% • NPV 100% (FP n=20, FN n=0) • C-statistic 0.818 (0.7111 – 0.908) • Hosmer-Lemeshow goodness of fit test 10.282 (6) <i>p</i>=0.113
Source of funding	National Institutes of Health (NIH) Clinical and Translational Science Award (CTSA) program grant
Limitations	<p>Predictors: Unclear if predictor assessments were made without knowledge of outcome data</p> <p>Sample size and participants: There was not a reasonable number of outcome events and unclear if all enrolled participants were included in the analysis</p>
Comments	

Reference	Ho 2014 ¹⁴⁸
Study type	Retrospective cohort
Study methodology	<p>Data source: This study utilised the VTE data from two datasets of major trauma patients who were admitted to the Royal Perth Hospital in Western Australia. The first dataset contained 134 consecutive patients who died after major trauma between 1994 and 2002 with accurate information on the causes of death including those who had fatal PE. The second dataset contained 224 consecutive patients who required an IVC filter between 2007 and 2012 for either primary or secondary VTE prophylaxis due to contraindications to pharmacological VTE prophylaxis or treatment. Both datasets contained the five variables needed by the TESS to calculate the predicted risk of VTE. The clinical information recorded within the first 24 hours of trauma admission prior to the occurrence of VTE was used to generate the predicted risk of VTE by the TESS for each patient in this study.</p> <p>Validation: External validation in trauma population ²⁷⁸</p>
Number of patients	n=357
Patient characteristics	<p>Age: mean (IQR): VTE event 42 (23-55) years; No VTE event 31 (21-45) years Gender (male to female ratio): VTE event 3.6:1; No VTE event 2.82:1 Ethnicity: Not reported</p> <p>Condition(s): Trauma patients Chest injury: 61.9% Abdominal injury: 29.1% Spinal fractures: 43.4% Pelvic fractures: 32.8% Lower limb fractures: 38.4%</p> <p>Setting: Royal Perth Hospital, a university teaching hospital, Western Australia's largest trauma centre. Country: Australia</p> <p>Inclusion criteria: Major trauma patients Exclusion criteria: not reported</p>
Target condition(s)	VTE (time point unclear): DVT and PE confirmed by colour Doppler compression ultrasound and computed tomography pulmonary angiography or post mortem examination.

Reference	Ho 2014 ¹⁴⁸
	Prevalence: Overall VTE: n=74 (21%); Fatal PE: n= 16 (4.48%); Non-fatal PE: 22 (6.16%); DVT: 47 (13.17%). 3 people had concurrent PE and upper and lower limb DVT, 3 patients had concurrent upper and lower limb DVT and 2 patients had concurrent lower limb DVT and PE.
Risk tool(s)	<p><u>Trauma Embolic Scoring System (TESS)</u></p> <p>The scoring system requires data from five clinical variables for a score (score per variable not reported in study)</p> <ul style="list-style-type: none"> • Injury Severity Score • Age • Use of mechanical ventilation • Obesity status • Lower limb injuries
Statistical measures	<p><u>TESS (<9)</u></p> <p><u>Outcome: VTE</u></p> <ul style="list-style-type: none"> • Sensitivity: 97% (91-99%) • Specificity: 27% (22-32%) • PPV: 26% (21-31%) • NPV: 97% (91-99%) • C-statistic: 0.71 (0.65-0.77) <p><u>Fatal and non-fatal PE</u></p> <ul style="list-style-type: none"> • Sensitivity: 97% (87-99%) • Specificity: 24% (20-29%) • PPV: 13% (10-18%) • NPV: 99% (93-99%) • C-statistic: 0.67 (0.59-0.75) <p><u>Fatal PE</u></p> <ul style="list-style-type: none"> • Sensitivity: 100% (81-100%) • Specificity: 20% (13-28%) • PPV: 14% (9-22%) • NPV: 100% (86-100%) <ul style="list-style-type: none"> • Hosmer-Lemeshow test – p=13.7

Reference	Ho 2014 ¹⁴⁸
Source of funding	Department of Intensive Care Medicine, Royal Perth Hospital
Limitations	Patient selection: Unclear study inclusion and exclusion criteria Predictors: Unclear if predictor assessments were made without knowledge of outcome data Analysis: No relevant performance measures evaluated Outcome: unclear time point for target conditions
Comments	

Reference	Liu 2014 ²⁰⁹
Study type	Prospective cohort
Study methodology	Data source: The following variables were prospectively recorded on separate case report forms: age, gender, BMI, smoking habit, hypertension, diabetes, atrial fibrillation. TIA, ischemic heart disease, malignancy, history of VTE, and treatment methods (medical treatment, and the use of elastic stockings). The presence of clinical symptoms or signs of DVT/PE at any stage during the study period was noted. Ischemic stroke phenotypes were determined by the Oxfordshire Community Stroke Project classification. At each Doppler scan, the NIHSS score was assessed by a certified trial coordinator. Validation: Internal split half validation
Number of patients	n=287
Patient characteristics	Age: ≥65 years 58.2% Gender (male to female ratio): 1.68:1 Ethnicity: Not reported. Condition(s): Acute stroke patients Obesity (BMI ≥ 25 kg/m ²): 40.8% Active cancer: 2.4% Vein puncture: 3.8% Setting: Capital Medical University affiliated Tiantan Hospital Country: China

Reference	Liu 2014 ²⁰⁹
	<p>Inclusion criteria: older than 18; had acute stroke (ischemic or haemorrhagic) within 7 days; mRS \geq 2 before enrolment; weakness in the lower limbs with NIH Stroke Scale score of \geq1 on item VI; able to obtain consent from the patient, patient's legal representative.</p> <p>Exclusion criteria: TIAs, subarachnoid haemorrhage (SAH), brain tumour, cerebral venous thrombosis, history of VTE.</p>
Target condition(s)	<p>DVT (14\pm3 days): Diagnosis of DVT if complete compression duplex ultrasonography (CCUS) showed loss of vein compressibility by ultrasonic probe pressure, a clot, or an abnormal flow pattern (loss of phasic flow signal or loss of augmentation of flow) with distal compression</p> <p>Prevalence: n=30 (10.6%)</p>
Risk tool(s)	<p><u>Post-stroke DVT Prediction System</u></p> <p>A multivariable model that predicts DVT risk at 14 days for patients admitted with an acute stroke, developed using data from the assessment cohort. The final multivariate model predicting DVT after acute stroke contained six variables which increased the risk of DVT:</p> <p>One point allocated to:</p> <ul style="list-style-type: none"> • Older age (\geq65 years) • Female gender • Obesity (BMI \geq 25 kg/m²) • Haemorrhagic stroke subtype • Lower limb NIHSS score \geq2 <p>Two points allocated to:</p> <ul style="list-style-type: none"> • Active cancer <p>The probability of post-stroke DVT incidence was estimated by summing points assigned to the value of each predictor. Total point score ranges from 0 to 7.</p>
Statistical measures	<p><u>Post-stroke DVT Prediction System</u></p> <ul style="list-style-type: none"> • C-statistic: 0.65 (0.59-0.70)
Source of funding	The study was supported by Beijing Natural Science Foundation, the Ministry of Science and Technology and the Ministry of Health of the People's Republic of China. The study was also supported by the GlaxoSmithKline (China) Ltd.
Limitations	<p>Analysis: Missing some relevant performance measures evaluated</p> <p>Sample size and participant flow: There was not a reasonable number of outcome events compared to the number of predictors in the model</p>
Comments	

Reference	Lobastov 2016 ²¹⁰
Study type	Prospective cohort retrospectively analysed
Study methodology	Data source: Data collected prospectively through a form designed for the study to be filled out by investigators during observation period according to medical records, examination of the patient and results of duplex scanning. Patients assessed using the Caprini model on completion of the study (achieving an end point, being discharged from hospital or lethal outcome). Validation: External validation
Number of patients	n=140
Patient characteristics	Age, mean (SD; range): 69.2 (12.2; 40-83) Gender (male to female ratio): 68:72 Ethnicity: Not reported. All surgical interventions were made in an emergency manner General surgical n=67 Neurosurgical n=73 Primary pathological condition: Cerebral and meningeal tumours n=7 Parenchymal intracranial haemorrhage n=24 Non-traumatic subarachnoid, subarachnoid-parenchymal haemorrhage n=23 Traumatic intracranial haemorrhage n=19 Intestinal gangrene n=12 Purulent peritonitis n=13 Malignant gastrointestinal tumours n=38 Thoracic and abdominal penetrating wounds n=4 All patients received the standard post-operative VTE prophylaxis for high-risk people: 18 to 21 mmHg compression hospital stockings and UFH 5000IU dose three times a day. Setting: Multi clinical sites including Pirogov Russian National Research Medical University, Moscow Clinical Hospital No 12, and no 13, Clinical

Reference	Lobastov 2016 ²¹⁰
	<p>Hospital no 1 of the President’s Administration of the Russian Federation. Country: Russia</p> <p>Inclusion criteria: Age older than 40 years, history of major surgery, a high risk of post-operative VTE and informed consent. Initial VTE classification based on 2008 ACCP guidelines (classifies high risk as ages 40-60 and presence of risk factors similar to Caprini model). Exclusion criteria: History of partial occlusion of inferior vena cave, no anticoagulant prophylaxis effect 5 days after surgery, need for therapeutic anticoagulants, preoperative use of anticoagulants, coagulopathies, thrombocytopenia, haemorrhagic diathesis, lower limb soft tissue infections, ankle-brachial index <0.6 or >1.3, patient death within the first 5 days of surgery, or refusal of autopsy.</p>
Target condition(s)	<p>Fresh DVT or PE at the hospital treatment stage – occlusion of previously unaffected vein segments: duplex ultrasonography of the lower limbs, and static lung perfusion scintigraphy or combined single proton emission CT and x-ray CT of the lungs, or autopsy. Incidence: 39/140 (27.83%)</p>
Risk tool(s)	<p><u>Caprini score</u> Total score is used to place people in one of three main risk categories: low (scores 0-4), moderate (5-8) and high (≥9).</p> <p>Score 1:</p> <ul style="list-style-type: none"> • Age 41-60 (years) • Swollen legs (current) • Varicose veins • BMI >25 (kg/m²) • Minor surgery planned • Sepsis (<1 month) • Acute myocardial infarction (<1 month) • Congestive heart failure (<1 month) • Medical patient currently receiving bed rest • History of inflammatory bowel disease • History of prior major surgery (<1 month) • Abnormal pulmonary function • Serious acute lung disease (<1 month) • Oral contraceptive use or hormone replacement therapy (HRT) • Complications of pregnancy (history of unexplained stillborn infant, recurrent or spontaneous abortion (>3), premature birth with toxemia of pregnancy, or growth-restricted infant)

Reference	Lobastov 2016 ²¹⁰
	<p>Score 2:</p> <ul style="list-style-type: none"> • Age 61-74 (years) • Arthroscopic surgery • Malignancy (present or previous) • Laparoscopic surgery (>45 minutes) • Confined to bed (>72 hours) • Immobilising plaster cast • Central venous access • Major surgery (≥45 minutes) <p>Score 3:</p> <ul style="list-style-type: none"> • Age ≥75 (years) • History of VTE • Positive Factor V Leiden • Increased serum homocysteine level • HIT • Positive anticardiolipin antibody • Positive prothrombin 20210A • Positive Lupus anticoagulant • Other congenital or acquired thrombophilia <p>Score 5:</p> <ul style="list-style-type: none"> • Stroke (<1 month) • Multiple trauma (<1 month) • Elective major lower extremity arthroplasty • Hip, pelvis or leg fracture (<1 month) • Acute spinal cord injury (paralysis) (<1 month)
Statistical measures	<p><u>Caprini risk assessment model</u></p> <ul style="list-style-type: none"> • At 10.5% cut off – sensitivity 0.95, specificity 0.73 • C-statistic: 0.87 (0.81-0.93)
Source of funding	None stated
Limitations	Analysis: Prospective collection of risk factors but retrospective calculation of full risk tool score means unclear whether predictor assessments

Reference	Lobastov 2016 ²¹⁰
	made without knowledge of outcome and vice versa. Sample size and participant flow: There was not a reasonable number of outcome events compared to the number of predictors in the model. Applicability: Patients already assessed as high risk for VTE and receiving combination pharmaceutical and mechanical prophylaxis. Only really applicable if assessing those who are very high risk and may need increased prophylaxis from that offered as usual.
Comments	

Reference	Nendaz 2014 ²³⁷
Study type	Prospective cohort
Study methodology	Data source: Data was collected by physician-investigators or dedicated study coordinators and entered in a standardised electronic case report form between December 2010 and November 2011. Validation: Externally validated ¹⁴
Number of patients	n=1478
Patient characteristics	Age: 65%(>60 years); 44% (≥ 70 years) Gender (male to female ratio): not reported Ethnicity: not reported Condition(s): Acutely medically ill patients Immobilisation: 37.2% Acute infection/sepsis: 30% Active malignancy: 25.4% Respiratory failure: 23.9% Obesity (BMI >30): 14.8% Cardiac failure: 12% Dehydration: 11.3% Prior VTE: 8.2% Chronic venous insufficiency: 6.6%

Reference	Nendaz 2014 ²³⁷
	<p>Recent trauma or surgery ≤ 1month: 6.4% Hormonal therapy: 4.7% Acute inflammatory/rheumatic disease: 4.1% Recent travel for >6 hours: 3.4% Recent myocardial infarction: 2.2% Myeloproliferative syndrome: 2.1% Recent stroke <3 months: 2.1% Nephrotic syndrome: 1.6% Known thrombophilia: 0.6% Pregnancy: 0.2%</p> <p>Setting: Three academic and five non-academic acute care hospitals Country: Switzerland</p> <p>Inclusion criteria: Aged ≥18 years and admission to a medical ward with a minimum stay of >24 hours Exclusion criteria: Anticoagulant treatment or indication of therapeutic anticoagulation upon hospital admission and inability to provide informed consent</p>
Target condition(s)	<p>Symptomatic VTE (90 days) including PE or DVT. PE was confirmed by contrast-enhanced computer tomography, ventilation perfusion scan or conventional pulmonary angiography, and DVT by compression ultrasound or venography. Prevalence: n= 30 (2.3%)</p>
Risk tool(s)	<p><u>Geneva Risk Score</u> Was calculated after patient discharge, from data at hospital admission.</p> <ul style="list-style-type: none"> Two points allocated to: cardiac failure, respiratory failure, recent stroke (<3 months), recent myocardial infarction (<4 weeks), acute infectious disease (including sepsis), acute rheumatic disease, active cancer, myeloproliferative syndrome, nephrotic syndrome, prior VTE, and known hypercoagulable state. One point allocated to: immobilisation (complete bed rest or inability to walk for >30 minutes per day), recent travel >6 hours, age >60 years, body mass index [BMI] > 30 kg/m², chronic venous insufficiency, pregnancy, hormonal therapy, and dehydration (assessed subjectively by the treating physician). <p>Patients were classified as having a high (Geneva Risk Score ≥3) or low (Geneva Risk Score <3) risk of VTE.</p>

Reference	Nendaz 2014 ²³⁷
	<p><u>Padua Prediction Score</u></p> <p>Data was also applied to the Padua Prediction Score</p> <ul style="list-style-type: none"> • Three points were allocated to: active cancer, previous VTE, reduced mobility, already known thrombophilic condition • Two points were allocated to: recent trauma and/or surgery • One point allocated to: elderly age ≥ 70 years, heart and/or respiratory failure, acute myocardial infarction or ischaemic stroke, acute infection and/or rheumatologic disorder, obesity (BMI ≥ 30 kg/m², and on-going hormonal treatment. <p>Patients were classified as high (Padua Prediction Score ≥ 4) or low (Padua Prediction Score < 4) risk of VTE.</p>
Statistical measures	<p><u>Geneva Risk Score (< 3)</u></p> <p>Sensitivity: 90% (73.5-97.9%) Specificity: 35.3% (32.8-37.8%) PPV: 2.8% (1.9-4.1%) NPV: 99.4% (98.3-99.9%) NLR: 0.28 (0.10-0.83)</p> <p><u>Padua Prediction Score (≥ 4)</u></p> <p>Sensitivity: 73.3% (54.1-87.7%) Specificity: 51.9% (49.3-54.5%) PPV: 3.1% (2.0-4.7%) NPV: 98.9% (97.9-99.5%) NLR: 0.51 (0.28-0.94)</p>
Source of funding	This study was funded by an unrestricted educational grant from the International Society of Thrombosis and Haemostasis (ISTH), 2007 Presidential Fund and Sanofi-Aventis (Suisse) SA, Vernier, Switzerland
Limitations	Sample size and participant flow: There was not a reasonable number of outcome events
Comments	

Reference	Obi 2015 ²⁴³
Study type	Retrospective cohort

Reference	Obi 2015 ²⁴³
Study methodology	<p>Data source: data from admissions to a 20-bed SICU, 5 year period (July 1, 2007-June 30, 2012). Patients were retrospectively identified with internal billing and quality improvement records.</p> <p>Validation: External validation¹²</p>
Number of patients	n=4844
Patient characteristics	<p>Age: <41 years 15.9%; 41-60 years 40%; 61-74 years 29.4%; ≥75 years 14.8%</p> <p>Gender (male to female ratio): not reported</p> <p>Ethnicity: not reported</p> <p>Condition(s): Surgical patients including general surgery, transplant, urology, and orthopaedic patients and patients with respiratory failure requiring extracorporeal membrane oxygenation (82% major operative procedures)</p> <p>Setting: SICU, a large tertiary care academic hospital</p> <p>Country: USA</p> <p>Inclusion criteria: Critically ill postsurgical patients and patients with respiratory failure with a mean Acute Physiology and Chronic Health Evaluation score greater than 50</p> <p>Exclusion criteria: Patients younger than 18 years</p>
Target condition(s)	<p>VTE (time point unclear): defined as patients with DVT or PE which occurred during the patient's initial hospital admission. Investigation for VTE was at the discretion of the ICU and/or surgical attending physicians because no formal screening was in place. DVT included acute thrombosis of lower-extremity veins (iliac, femoral, popliteal, or calf veins) or upper-extremity veins (axillary, subclavian, brachial, or internal jugular veins). PE defined as acute thrombosis within the pulmonary vasculature.</p> <p>VTE considered present if identified with an objective imaging study, including duplex ultrasonography or PE protocol computed tomography. Patients who experienced sudden death were included if post-mortem examination documented definitive evidence of VTE</p> <p>Prevalence of DVT: n=308 (6.4%)</p> <p>Prevalence of PE: n=79 (1.6%)</p>
Risk tool(s)	<p><u>Caprini score</u></p> <p>Total score is used to place people in one of three main risk categories: low (scores 0-4), moderate (5-8) and high (≥9).</p> <p>Score 1:</p>

Reference	Obi 2015 ²⁴³
	<ul style="list-style-type: none"> • Age 40-59 (years) • Abnormal pulmonary function • Acute myocardial infarction (<1 month) • BMI ≥30 (kg/m²) • Congestive heart failure (<1 month) • History of inflammatory bowel disease • History of prior major surgery (<1 month) • Complications of pregnancy (history of unexplained stillborn infant, recurrent or spontaneous abortion (>3), premature birth with toxemia of pregnancy, or growth-restricted infant) • Oral contraceptive use or hormone replacement therapy (HRT) • Sepsis (<1 month) • Serious acute lung disease (<1 month) • Swollen legs (current) • Varicose veins <p>Score 2:</p> <ul style="list-style-type: none"> • Age 60-74 (years) • Central venous access • Confined to bed (>72 hours) • Major open surgery (≥45 minutes) • Present cancer • Prior cancer, except non-melanoma skin <p>Score 3:</p> <ul style="list-style-type: none"> • Age ≥75 (years) • History of VTE • Family history of VTE • Chemotherapy • Positive anticardiolipin antibody • Positive Lupus anticoagulant • Acute spinal cord injury (<1 month) • Major surgery (≥6 hours)
Statistical measures	<u>Caprini risk assessment model</u>

Reference	Obi 2015²⁴³
	C-statistic: 0.5846 Hosmer and Lemeshow test: p=0.69
Source of funding	Not reported
Limitations	Analysis: No relevant performance measures evaluated Outcome: unclear time point for measurement of target condition (VTE)
Comments	

Reference	Pannucci 2012²⁵³
Study type	Retrospective cohort
Study methodology	Data source: Data from the American Burn Association's National Burn Repository was obtained, it is a voluntary dataset composed of burn patients from participating centres in both United States and Canada. Patients with DVT and VTE were identified using the complications database Validation: Internal split half validation
Number of patients	n=5761
Patient characteristics	Age (mean): 45.6 years Gender (male to female ratio): 2.33:1 Ethnicity: Not reported Condition(s): People with thermal injury (details not reported about types of burns) Setting: Not reported Country: USA and Canada Inclusion criteria: Patients from the NBR admitted between 1995 and 2009 with age ≥ 18 years and length of stay at least 2 days Exclusion criteria: Patients with non-thermal injury (desquamating skin disease, radiation associated burns, and electrical injury) and patients who died within 3 days of admission were excluded.
Target condition(s)	VTE (time point unclear: not defined). Prevalence: n=1635 (9.7%)

Reference	Pannucci 2012 ²⁵³
Risk tool(s)	<u>Simple Venous Thromboembolism Risk Scoring Tool</u> Independent variables used in the analysis were TBSA burned, inhalation injury, gender and age. Score = 0-8 Scoring details were not provided for each factor within the risk scoring tool.
Statistical measures	<u>Simple Venous Thromboembolism Risk Scoring Tool</u> <ul style="list-style-type: none"> C-statistic – 0.750
Source of funding	Supported by NIH grant
Limitations	Predictors: Unclear if predictor assessments were made without knowledge of outcome data Sample size and participant flow: There was not a reasonable number of outcome events Analysis: No relevant performance measures evaluated Outcome: target condition not defined and unclear time point
Comments	

Reference	Pannucci 2014 ²⁵²
Study type	Retrospective cohort
Study methodology	Data source: Analyses of identified Michigan Surgical Quality Collaborative (MSQC) data. Data acquisition took place between March 2010 and October 2012. Validation: Internal split population validation
Number of patients	n=3576
Patient characteristics	Overall age: ≥ 60 years: 62% Overall gender (male to female ratio): 1:1.36 Ethnicity: not reported Condition(s): Postsurgical patients (details of surgical procedures not provided for validation sample)

Reference	Pannucci 2014 ²⁵²
	<p>Setting: 52 Michigan hospitals, Blue Cross Blue Shield of Michigan, and the Blue Care Network Country: USA</p> <p>Inclusion criteria: Inpatient, non-emergent surgical cases. Exclusion criteria: Age < 18 years and admission for palliative care. Patients with recently diagnosed VTE for which they were actively receiving anticoagulation treatment were also excluded.</p>
Target condition(s)	<p>VTE (90 days): Patients with either PE or PE. Upper extremity DVT included clots in the jugular, subclavian, axillary, or brachial veins. Lower extremity DVT included clots in the vena cava, femoral, tibial, or popliteal veins. Visceral DVT (e.g. portal or mesenteric vein) or cerebral sinus thrombosis were not included in the primary outcome. PE included clots in the pulmonary vasculature. All VTE events were diagnosed using an objective imaging study. Prevalence: n= 50 (1.40%)</p>
Risk tool(s)	<p><u>Unnamed (Pannucci 2014)</u> Risk model included risk factors:</p> <ul style="list-style-type: none"> • One point allocated to: Age ≥ 60 years, BMI ≥ 40 kg/m² • Two points allocated to: Male sex • Three points allocated: Sepsis/septic shock/systemic inflammatory response syndrome (SIRS), personal history of VTE • Four points allocated to: Family history of VTE • Five points allocated: Current cancer
Statistical measures	<p><u>Unnamed risk assessment model</u></p> <ul style="list-style-type: none"> • C-statistic – 0.70
Source of funding	Not reported
Limitations	<p>Sample size and participant flow: There was not a reasonable number of outcome events Analysis: Some relevant performance measures were not evaluated (sensitivity and specificity)</p>
Comments	
Reference	Patell 2017 ²⁵⁶
Study type	Retrospective cohort

Reference	Patell 2017 ²⁵⁶
Study methodology	<p>Data source: Consecutive oncology inpatients at the Cleveland Clinic from 11/2012 to 12/2014. Electronic query system of electronic health records.</p> <p>Validation: External validation in cancer outpatients.</p>
Number of patients	n=2780
Patient characteristics	<p>Age, median (range): 62 (19-98)</p> <p>Gender (male to female ratio): 1545:1235</p> <p>Ethnicity: not reported.</p> <p>Solid tumours 62%</p> <p>Tumour sites:</p> <p>GI tract 20%</p> <p>Lung 13%</p> <p>Breast 6%</p> <p>Head and neck 5%</p> <p>Haematological malignancy 38%</p> <p>Sites:</p> <p>Leukaemia 14%</p> <p>Lymphoma 14%</p> <p>Myeloma 8%</p> <p>Reasons for admission;</p> <p>Elective chemotherapy 21%</p> <p>Infection 20%</p> <p>GI symptoms 14%</p> <p>Setting: Single centre, Cleveland Clinic</p> <p>Country: USA</p>

Reference	Patell 2017 ²⁵⁶
	Inclusion criteria: Diagnosis of malignancy and care provided by a haematologist/oncologist admitted to the Cleveland Clinic. Patients over the age of 18 with an active malignancy at the time of admission. Exclusion criteria: VTE on admission, incomplete KS data.
Target condition(s)	VTE: defined by ICD-9 codes. Events coded as not present on index admission. Prevalence: n= 106 (3.8%)
Risk tool(s)	<u>Khorana Score</u> <ul style="list-style-type: none"> • 0 = low • 1-2 = intermediate • ≥3 high
Statistical measures	<u>Khorana Score</u> <ul style="list-style-type: none"> • Sensitivity 18.8679 • Specificity 87.1728 Calculated using 2x2 table data based on number reported as high risk on KS (n=363), prevalence of VTE (n=106) and number of those assessed as high risk developing a VTE (n=20) based on Table 1 page 502.
Source of funding	Research support from the National Heart, Lung, and Blood Institute, the Sondra and Stephen Hardis Chair in Oncology Research and the Scott Hamilton CARES Initiative.
Limitations	Predictors: Unclear if predictor assessments were made without knowledge of outcome data Outcome: Unclear if outcome assessed without knowledge of predictor information. Unclear time interval.
Comments	

Reference	Rogers 2012 ²⁷⁸
Study type	Retrospective cohort
Study methodology	Data source: Analysis for 234,032 consecutive trauma admissions between 2000 and 2009. Derivation: A literature review identified 19 variables associated with VTE for patients with trauma. Of these, 13 variables were found to be significant predictors of VTE by univariate analysis. These variables were integrated into a multivariate logistic model, and five of these risk factors proved significant for the development of VTE and these were integrated into the model. The five risk factors included were: Age, Injury Severity Score (ISS), pre-existing obesity, ventilation days, lower-extremity fracture. Validation: Internal split half validation using the National Trauma Data Bank (NTDB) for the 2007 data using 234,032 patients.

Reference	Rogers 2012 ²⁷⁸
Number of patients	n=234,032
Patient characteristics	<p>Age: <30 years 40.9%, 30-64 years 41.7%, ≥65 years 17.4%. Median (IQR) 37 (21-56)</p> <p>Gender (male to female ratio): 1.92:1</p> <p>Ethnicity: not reported.</p> <p>Condition(s): People with trauma</p> <p>Other relevant characteristics: Injury type: blunt 86.9%, burn 2.5%, penetrating 10.6% (missing data for 26,928)</p> <p>Setting: Lancaster General Hospital, a Pennsylvania State Trauma Foundation Level II trauma centre</p> <p>Country: USA</p> <p>Inclusion criteria: People with trauma (no further details reported).</p> <p>Exclusion criteria: Not reported.</p>
Target condition(s)	<p>VTE (no time point reported): DVT and PE as defined by the NTDB data set dictionary definitions. Full definitions not reported in study.</p> <p>PE: Defined as a lodging of a blood clot in a pulmonary artery with subsequent obstruction of blood supply to the lung parenchyma. The blood clots usually originate from the deep leg veins or the pelvic venous system. Consider the condition present if the patient has a V-Q scan interpreted as high probability of pulmonary embolism or a positive pulmonary arteriogram or positive CT angiogram.</p> <p>DVT: The formation, development, or existence of a blood clot or thrombus within the vascular system, which may be coupled with inflammation. This diagnosis may be confirmed by a venogram, ultrasound, or CT. The patient must be treated with anticoagulation therapy and/or placement of a vena cava filter or clipping of the vena cava.</p> <p>Prevalence: n= 4881 (1.4%)</p>
Risk tool(s)	<p><u>Trauma Embolic Scoring System (TESS)</u></p> <p>TESS was from 0-14, was used to identify low, moderate, high and very high-risk patients for VTE complications. Individually standardised VTE prophylaxis strategies for each of these four categories were created to address the particular risk.</p> <ul style="list-style-type: none"> • Injury Severity Score • Age

Reference	Rogers 2012 ²⁷⁸
	<ul style="list-style-type: none"> • Use of mechanical ventilation • Obesity status • Lower limb injuries
Statistical measures	<p><u>TESS</u></p> <ul style="list-style-type: none"> • TESS score ≥ 5: Sensitivity 77.4%; Specificity 75.6%; PPV 4.1%, NPV 99.6% • C-statistic : 0.84 (0.83-0.84) • Hosmer-Lemeshow test – p=0.101
Source of funding	No funding stated
Limitations	<p>Patient selection: Unclear study inclusion and exclusion criteria, unclear if patients enrolled at a similar state of health</p> <p>Predictors: Unclear if predictor assessments were made without knowledge of outcome data</p>
Comments	

Reference	Rothberg 2011 ²⁷⁹
Study type	Retrospective cohort
Study methodology	<p>Data source: patients discharged between 1 January 2004 and 30 June 2005 from 374 acute care facilities that participated in Premier’s Perspective, a database developed for measuring quality and healthcare utilization. Participating hospitals represented all areas of the US. Available data elements include those derived from the uniform billing 04 form, such as socio-demographic information about each patient, their ICD-9-CM diagnosis and procedure codes, as well as hospital and physician information. This information was supplemented with a date-stamped log of all items and services billed to the patient or insurer, including diagnostic tests, medications and other treatments.</p> <p>Derivation: univariate predictors of VTE were assessed using chi-square tests. Developed a multivariable regression model for VTE on an 80% randomly selected subset of eligible admissions using all measured risk factors for VTE and selected interaction terms. Generalised estimating equations models with a logistic link were used to account for the clustering of patients within hospitals. Initial models were stratified on VTE prophylaxis. Significant factors at $p < 0.05$ were retained.</p> <p>Validation: Internal, split sample. Parameter estimates derived from the model were used to compute individual VTE risk in the remaining 20% of admissions</p>
Number of patients	n= 48, 540

Reference	Rothberg 2011 ²⁷⁹
Patient characteristics	<p>Age: 18-49 years 12.9%, 50-64 years 21.1%; 65+ years 66.0%</p> <p>Gender (male to female ratio): 41.6 :58.4</p> <p>Ethnicity: White 64.4%; Black 17.1%; Hispanic 4.1%</p> <p>Primary Diagnosis: Community-Acquired Pneumonia 33.5%; Septicaemia 3.2%; Chronic Obstructive Pulmonary Disease 14.5%; Respiratory Failure 2.8%; Congestive Heart Failure 19.2%; Cardiovascular Disease 13.6%; Urinary Tract Infection 13.1%</p> <p>Any VTE Prophylaxis 29.9%</p> <p>Length of Stay ≥ 6 days 41.1%</p> <p>Paralysis 6.8%</p> <p>Metastatic Cancer 2.2%</p> <p>Solid Tumour Without Metastasis 10.4%</p> <p>Lymphoma 1.2%</p> <p>Cancer Chemotherapy/Radiation 0.5%</p> <p>Prior Venous Thromboembolism 1.2%</p> <p>Oestrogens 2.0%</p> <p>Oestrogen Modulators 0.8%</p> <p>Inflammatory Bowel Disease 0.3%</p> <p>Nephrotic Syndrome 0.2%</p> <p>Myeloproliferative disorder 0.8%</p> <p>Obesity 7.0%</p> <p>Smoking 14.5%</p> <p>Central Venous Catheter 6.3%</p> <p>Inherited or Acquired Thrombophilia 0.0%</p> <p>Steroids 34.2%</p> <p>Mechanical Ventilation 5.5%</p> <p>Urinary Catheter 16.0%</p> <p>Decubitus Ulcer 2.9%</p> <p>Statins Use 23.5%</p>

Reference	Rothberg 2011 ²⁷⁹
	<p>Use of Restraints 2.5% Diabetes Mellitus 31.1% Varicose Veins 0.1% Hypertension 49.5% Congestive Heart Failure 8.0% Peripheral Vascular Disease 6.7% Valvular Disease 5.6% Pulmonary Circulation Disease 2.3% Chronic Pulmonary Disease 29.7% Respiratory Failure Second Diagnosis 5.5% Rheumatoid Arthritis/Collagen vascular disease 2.9% Deficiency Anaemias 20.2%</p> <p>Setting: 374 acute care facilities Country: USA</p> <p>Inclusion criteria: aged 18 years or over; at moderate to high risk of VTE according to ACCP recommendations; principle diagnosis of pneumonia, heart failure, COPD, stroke, and urinary tract infection. Exclusion criteria: prescribed warfarin or therapeutic dose of heparin on hospital day 1-2; received >1 therapeutic dose of heparin but otherwise did not fulfil criteria for VTE; length of stay <3 days</p>
Target condition(s)	<p>VTE, hospital acquired (3 days after hospitalisation): diagnosis by lower extremity ultrasound, venography, CT angiogram, ventilation-perfusion scan or pulmonary angiogram on hospital day 3 or later; received treatment for VTE at least 50% of the remaining hospital stay; until initiation of warfarin; appearance of a complication (e.g. transfusion or treatment for heparin-induced thrombocytopenia) and were given secondary diagnosis of VTE</p> <p>Prevalence: n= 223 (0.46%)</p>
Risk tool(s)	<p><u>Unnamed (Rothberg 2011)</u></p> <ul style="list-style-type: none"> • No prophylaxis/Any prophylaxis • Gender (male; female) • Length of Stay (< 6 days; ≥ 6 days) • Age (18-49 years; 50-64 years; >65 years)

Reference	Rothberg 2011 ²⁷⁹
	<ul style="list-style-type: none"> • Primary Diagnosis (Pneumonia; Chronic Obstructive Pulmonary Disease; Stroke; Congestive heart failure; Urinary Tract Infection; Respiratory failure; Septicemia) ○ Inflammatory bowel disease ○ Obesity ○ Inherited thrombophilia • Cancer (Cancer 18-49 years; Cancer 50-64 years; Cancer >65 years) ○ Central venous catheter ○ Mechanical ventilation ○ Urinary catheter ○ Chemotherapy ○ Steroids
Statistical measures	<p><u>Unnamed (Rothberg 2011)</u></p> <ul style="list-style-type: none"> • c-statistic 0.75 (0.71 – 0.78)
Source of funding	Not stated
Limitations	<p>Predictors: Unclear if predictor assessments were made without knowledge of outcome data</p> <p>Analysis: No relevant performance measures evaluated</p> <p>Outcome: end point for VTE measurement not stated</p>
Comments	

Reference	Shaikh 2016 ²⁹⁵
Study type	Retrospective cohort
Study methodology	<p>Data source: Consecutive patients for reconstructive and body contouring procedures from Jan 2008 to Jan 2012 – retrospective chart review.</p> <p>Validation: External validation</p>
Number of patients	n= 1598
Patient characteristics	<p>Age, mean (range): 49.9 (14-86) years</p> <p>Gender (male to female ratio): 308:1290</p> <p>Ethnicity: Not reported</p>

Reference	Shaikh 2016 ²⁹⁵
	<p>BMI, mean (range): 28.2 (15.9-77.5) kg/m²</p> <p>Plastic surgery patients: Reconstructive and body contouring procedures including flap-based procedures, removal of facial wrinkles, tissue excision, suction assisted lipectomy, breast prosthesis, and breast reconstruction.</p> <p>Setting: University of Texas Southwestern Medical Centre associated hospitals Country: USA</p> <p>Inclusion criteria: Consecutive patients for reconstructive and body contouring procedures matching Current Procedural Terminology (CPT) codes recorded into original database by the plastic surgery department. Exclusion criteria: Inconsistency in medical records for reporting VTE within 30 days of patient procedure.</p>
Target condition(s)	<p>DVT/PE composite within 30 days of procedure – no further detail given. Prevalence: n= 24 (1.5%)</p>
Risk tool(s)	<p><u>Caprini Risk Assessment Model</u></p> <ul style="list-style-type: none"> No further tool predictor detail given
Statistical measures	<p><u>Caprini risk assessment model</u></p> <p>High risk cut-off 5+</p> <ul style="list-style-type: none"> Sensitivity 0.708 (0.489-0.874) Specificity 0.394 (0.370-0.419) <p>High risk cut-off 6+</p> <ul style="list-style-type: none"> Sensitivity 0.583 (0.366-0.779) Specificity 0.601 (0.576-0.625) <p>Highest risk cut-off 9+</p> <ul style="list-style-type: none"> Sensitivity 0.167 (0.05-0.37) Specificity 0.933 (0.92-0.94)
Source of funding	No funding
Limitations	<p>Outcome: No information on how VTE end point determined. Unclear if recorded without knowledge of risk assessment outcome. Sample size and participant flow: Low event rate compared to the number of predictors in the model</p>

Reference	Shaikh 2016 ²⁹⁵
	Applicability: US population may differ from NHS population.
Comments	

Reference	Vardi 2013 ³²⁷
Study type	Prospective cohort
Study methodology	<p>Data source: Prospective collection of data through the electronic medical record system. A computerised database was incorporated into the studies electronic medical record system. Physicians were instructed to input pre-determined supplementary data via a mandatory questionnaire that include the structured input of data, alongside automatic data gathering. Also, collected additional data from patients' charts which included information on acute and chronic VTE risk factors and rate of in-hospital. Data collected between 1 February 2008 and 30 April 2009.</p> <p>Validation: Externally validated in a cohort of general internal medicine patients ¹⁴</p>
Number of patients	n=1080
Patient characteristics	<p>Age (mean± SD): 74.68± 16.15; >70: 73.7%</p> <p>Gender (male to female ratio): 1.09:1</p> <p>Ethnicity: not reported.</p> <p>Condition(s): Patients admitted to internal medicine departments with sepsis.</p> <p>Other relevant characteristics:</p> <ul style="list-style-type: none"> • Confined to bed: 57.7% • Active cancer: 16.7% • Previous VTE: 5.5% • CHF NYHA 3 or 4: 25.1% • Infectious respiratory diseases: 42.4% • Obstructive respiratory disease: 18.4% • Obesity: 11.8% • Operation within the last 30 days: 1.9% • Varicose veins: 3.1%

Reference	Vardi 2013 ³²⁷
	<p>Setting: 110-bed department of internal medicine in a 450-bed community-based university affiliated hospital Country: Israel</p> <p>Inclusion criteria: Over 18 years old and had a presumed diagnosis compatible with sepsis. Exclusion criteria: No exclusion criteria as stated in the study</p>
Target condition(s)	<p>In hospital VTE (time point: assumption that it is between 48 hours after admission and discharge) Includes DVT and PE. Diagnosis of DVT by Duplex ultrasound or computer tomography (CT) and diagnosis of PE was based on a positive CT angiography (CTA) or a high-probability ventilation perfusion scan. Prevalence: n=14 (1.29%)</p>
Risk tool(s)	<p><u>Padua Prediction Score</u> A simple score of 11 parameters. The PPS was retrospectively calculated for every patients based on the presence of co-morbidities and clinical presentation. The presence of each medical condition granted cumulative points to the total PPS:</p> <ul style="list-style-type: none"> • Three points allocated to: Presence of active cancer, previous VTE, reduced mobility, known thrombophilia condition • Two points allocated to: Trauma and/or surgery within the last month • One point allocated to: Elderly age (>70 years), heart failure, acute myocardial infarction or ischemic stroke, acute infection and/or rheumatologic disorder, obesity, on-going hormonal treatment
Statistical measures	<p><u>Padua Prediction Score</u> C-statistic: 0.58 (0.43-0.73)</p>
Source of funding	No funding stated
Limitations	<p>Patient selection: Unclear study inclusion and exclusion criteria Sample size and participant flow: There was not a reasonable number of outcome events Analysis: No relevant performance measures evaluated Outcome: unclear timescale for the diagnosis of VTE in patients.</p>
Comments	

Reference	Vaziri 2017 ³²⁸
Study type	Retrospective cohort

Reference	Vaziri 2017 ³²⁸
Study methodology	Data source: Retrospective review of neurosurgical patients treated at the University of Florida between 1 September 2011 and 31 December 2014. Validation: Externally validated in a different surgical populations
Number of patients	n=1006
Patient characteristics	Age: not reported Gender (male to female ratio): 460:546 Ethnicity: not reported. Setting: Single hospital neurosurgical department. Country: United States Inclusion criteria: Patients with either a single neurosurgical CPT code or with two CPT codes in which a secondary CPT code indicated the use of the operating microscope. Exclusion criteria: No exclusion criteria stated in the study
Target condition(s)	VTE (time point: not reported) No details provided. Prevalence: n=13 (1.292%)
Risk tool(s)	<u>American College of Surgeons (ACS) National Surgical Quality Improvement Programme (NSQIP) universal Surgical Risk Calculator</u> No details provided.
Statistical measures	<u>ACS NSQIP universal surgical risk calculator</u> Discrimination: C-statistic: 0.767 Calibration: Intercept 0.361, slope 1.242, p value 0.164
Source of funding	No funding stated
Limitations	Patient selection: Unclear study inclusion and exclusion criteria Predictors: Predictors not presented and unknown if all assessed adequately. Sample size and participant flow: There was not a reasonable number of outcome events Outcome: unclear definition and timescale for the diagnosis of VTE in patients.

Reference	Vaziri 2017 ³²⁸
	Applicability: concerns about predictor definitions and outcome definitions.
Comments	

Reference	Winoker 2017 ³⁴⁰
Study type	Retrospective cohort
Study methodology	Data source: Random selection of patients from a prospectively maintained multi-institutional database of those treated with robot assisted partial nephrectomy (RAPN) from 2008 to 2016. Validation: Externally validated in a different surgical populations
Number of patients	n=300
Patient characteristics	Age: <65 63.7%; 65-74 26.3%; 75-84 0.3%; ≥ 61.7% Gender (male to female ratio): 185: 115 Ethnicity: not reported. BMI: <18.5 0.7%; 18.5-24.9 13.3%; 25-29.9 39.7%; ≥30 46.3% Setting: Multi-institutional. Country: United States Inclusion criteria: People treated with robot-assisted partial nephrectomy (RAPN) – urological surgery. Exclusion criteria: No exclusion criteria stated in the study
Target condition(s)	VTE (time point: not reported) No details provided. Prevalence: n=1 (0.33%)
Risk tool(s)	<u>American College of Surgeons (ACS) National Surgical Quality Improvement Programme (NSQIP) universal Surgical Risk Calculator</u> No details provided.
Statistical measures	<u>ACS NSQIP universal surgical risk calculator</u>

Reference	Winoker 2017 ³⁴⁰
	Discrimination: C-statistic: 0.670 Calibration: Brier score 0.003327
Source of funding	No funding stated
Limitations	Patient selection: Unclear study inclusion and exclusion criteria Predictors: Many variables not explicitly known or available in records. Assumptions that all were negative. Sample size and participant flow: There was not a reasonable number of outcome events Outcome: unclear definition and timescale for the diagnosis of VTE in patients. Applicability: concerns about predictor definitions and outcome definitions.
Comments	

Reference	Woller 2011 ³⁴²
Study type	Retrospective cohort
Study methodology	Data source: Data that were collected from the Intermountain Healthcare administrative and electronic medical record (EMR) systems. Admissions occurring from January 1, 2008 and December 31, 2009 served as the validation cohort (The derivation cohort were admissions from January 1,2000 until December 31, 2007) Validation: Internal split sample validation for the Intermountain risk assessment model (Woller 2011) and Kucher Score.
Number of patients	n=46856
Patient characteristics	Age (mean): 61.14 years Gender (male to female ratio): 1.17:1 Ethnicity: not reported Condition(s): Medically ill patients (conditions not reported) Setting: Intermountain Healthcare is a non-profit, university affiliated, integrated health care system with 22 hospitals and more than 150 clinics throughout Utah and South-eastern Idaho. Country:

Reference	Woller 2011 ³⁴²
	<p>Inclusion criteria: Hospital admissions involving adult patients (≥ 18 years) admitted to an Intermountain Healthcare medicine inpatient service. Patients were defined as medicine patients if they were admitted to internal medicine or medical subspecialties</p> <p>Exclusion criteria: Patients admitted to the hospital with a primary admission diagnosis code for VTE</p>
Target condition(s)	<p>VTE (90 days) (not defined)</p> <p>Prevalence: n= 2109 (4.5%)</p>
Risk tool(s)	<p><u>Intermountain risk assessment model</u></p> <p>Risk factors included in the RAM are:</p> <ul style="list-style-type: none"> • Prior VTE • An order for bed rest • PICC insertion • Diagnosis of cancer <p>The number of points allocated to each risk factor was not reported. Unclear what score = at risk.</p> <p><u>Kucher Score</u></p> <ul style="list-style-type: none"> • Three points allocated to: cancer, prior VTE, hypercoagulability • Two points allocated to: major surgery • One point allocated to: bed rest, age > 70 years, obesity (BMI > 30), hormone replacement therapy/oral contraceptives
Statistical measures	<p><u>Intermountain risk assessment model</u></p> <ul style="list-style-type: none"> • C-statistic – 0.843 (0.833-0.852) <p><u>Kucher Score</u></p> <ul style="list-style-type: none"> • C-statistic – 0.756 (0.746-0.767) • C – statistic for published bimodal cut-off with a score being ≥ 4 – 0.683
Source of funding	Grant provided by the Deseret Foundation
Limitations	<p>Analysis: No relevant performance measures evaluated</p> <p>Outcome: no definition for the target condition of VTE is reported</p>
Comments	

H.1.2 Hospital admissions

Reference	Hostler 2016 ¹⁵⁰
Study type	Prospective data collection with retrospective record review for analysis.
Study methodology	<p>Recruitment: prospectively collected characteristics on admission and VTE prophylaxis data each hospital day for all consecutive adult patients (≥18 years) admitted for a medical illness to the Walter Reed Army Medical Hospital over an 18-month admission period (Sept 2009 through March 2011).</p> <p>Validation: External validation of the IMPROVE BRS in a large group of hospitalised patients.</p>
Number of patients	<p>n=1668 (1294 admitted to a medical ward + 374 admitted to a medical ICU or cardiac care unit who met IMPROVE criteria)</p> <p>12327 patient admissions → 10594 excluded due to surgical diagnoses, hospital days <3, paediatrics, trauma, behavioural health, bleeding diagnoses, VTE, Tx dose anticoagulations → 1733 individual record search → 65 excluded due to surgery, VTE or Tx anticoagulation dose.</p>
Patient characteristics	<p>Age: <40: 234 (14%), 40-84: 1144 (68.6%), ≥85: 289 (17.3%)</p> <p>Gender (male to female ratio): 969:699</p> <p>Ethnicity: not reported</p> <p><u>Medical conditions</u></p> <p>Bleeding within 3 months: 3.2%</p> <p>Active gastroduodenal ulcer: 2%</p> <p>Platelets < 50 x 10⁹ cells/L: 2.7%</p> <p>Hepatic failure, INR > 1.5: 5.7%</p> <p>ICU/CCU: 22.4%</p> <p>Central venous catheter: 17.8%</p> <p>Current cancer: 21.6%</p> <p>GFR ≥ 60 mL/min/m²: 64.3%</p> <p>Rheumatic diseases: 1.6%</p> <p>Heart failure: 8.9%</p> <p>Thrombophilia: 0.5%</p> <p>Previous VTE: 6.1%</p>

Reference	Hostler 2016 ¹⁵⁰
	<p>Aspirin during admission: 37.1%</p> <p><u>Bleeding</u> n= 45 (31 major, 14 clinically relevant non-major) GI origin: n=18 No readily identifiable source: n=11 Haematuria: n=4 Postoperative: n=4 Intracerebral haemorrhage: n=2 Intra-abdominal haematoma: n=2 Vascular injuries: n=2 Haemothorax: n=1 Retinal haemorrhage: n=1</p> <p><u>IMPROVE scores</u> <7: 78% (n=1301 calculated based on % reported) ≥7: 22% (n=367 calculated based on % reported)</p> <p><u>IMPROVE score + bleeding</u> <7 group 1.6% major bleeding 2.7% clinically important bleeding ≥7 group 5.4% major bleeding 6.5% clinically important bleeding</p> <p><u>Chemical prophylaxis</u> n=726 (43.5%) receiving low-molecular-weight heparin (LMWH) n=509 (30.5%) receiving unfractionated heparin (UFH)</p>

Reference	Hostler 2016 ¹⁵⁰
	<p>n=8 (0.5%) receiving fondaparinux n=336 (20%) no chemoprophylaxis</p> <p>Setting: Walter Reed Army Medical Hospital Country: USA</p> <p>Inclusion criteria: 18 years or over admitted to hospital (the general medical wards and in the ICU) with a medical illness. Exclusion criteria: All patients on the database who did not meet the inclusion criteria used by the IMPROVE investigators. Patients were excluded if they were admitted for bleeding or if they were receiving treatment-dose anticoagulation on admission or during the hospitalisation.</p>
Target condition(s)	<p>Major bleeding (30 days): Inpatient and outpatient electronic medical records for new bleeding diagnoses that occurred during hospital stays and within 30 days of discharge. Used International Classification of Disease (ICD-9): 578.0 (hematemesis, vomiting blood), 578.1 (blood in stool), 578.9 (haemorrhage of GI tract unspecified), 459.0 (haemorrhage unspecified), 430 (subarachnoid haemorrhage), 431 (intracerebral haemorrhage), 432.0 (non-traumatic extradural haemorrhage), 432.1 (subdural haemorrhage), 432.9 (unspecified intracranial haemorrhage); and a haematocrit drop > 6 points to identify patients who may have bled during admission. All bleeding events were confirmed by manual chart audit.</p> <p>Bleeds were defined as major or clinically relevant non-major using the criteria outlined by the IMPROVE investigators and the International Society on Thrombosis and Haemostasis guidelines. Combined and referred to as “clinically important” bleeds. Minor bleeding events not assessed.</p>
Risk tool(s)	<p><u>The International Medical Prevention Registry on Venous Thromboembolism (IMPROVE) bleeding risk score (BRS)</u></p> <p>No further description provided. IMPROVE BRS score for each patient calculated using admission data and medical record review to identify bleeding events.</p> <p>Details of IMPROVE BRS from derivation study⁸⁰</p> <p>Factor (points/weighting)</p> <ol style="list-style-type: none"> 1. Gastro-duodenal ulcer (4.5) 2. Bleeding prior 3 months (4) 3. Admission platelets <50x10⁹ (4) 4. Hepatic failure (2.5) 5. ICU/CCU stay (2.5) 6. CV catheter (2) 7. Rheumatic diseases (2) 8. Current cancer (2)

Reference	Hostler 2016 ¹⁵⁰
	<p>9. Sex [M vs F] (1) 10. Age ≥ 85 years vs <40 years (3.5) 11. Age 40-84 vs <40 years (1.5) 12. Severe renal failure GFR <30 vs ≥60 mL/min/m² (2.5) 13. Moderate renal failure 30-59 vs ≥60 mL/min/m² (1)</p> <p>Author suggested cut-off: use caution in prescribing anticoagulant prophylaxis to patients with an admission bleeding risk score of ≥7</p>
Statistical measures	<p>IMPROVE RBS Predicting major bleeding at 14 days^a TP 11 FP 266 FN 12 TN 961 Sensitivity 48% (27, 69) Specificity 78% (76, 81) AUC (95% CI): 0.64 (0.57-0.77) <i>p</i>=0.008</p> <p>Predicting bleeding throughout hospitalisation^a TP 15 FP 266 FN 16 TN 961 Sensitivity 48% (30, 67) Specificity 78% (76, 81)</p> <p>Predicting clinically important bleeding at 14 days AUC (95% CI): 0.64 (0.55-0.73) <i>p</i>=0.006</p>
Source of funding	None reported
Limitations	<ul style="list-style-type: none"> • Risk of bias: Unclear if outcome determined without knowledge of the predictor information; Number of events less than 10 x the number of predictors in the model; unclear if all participants included in analysis as different number reported throughout the paper with bleeding events and IMPROVE score ≥7; No discrimination or calibration data reported (AUC only). • Indirectness: no serious indirectness

Reference	Hostler 2016 ¹⁵⁰
Comments	

a) Raw data for 2x2 tables provided by author correspondence

H.1.3 Risk assessment tools in patients admitted to hospital

Study	Cassidy 2014 ⁴³
Study type	Before and after study
Number of studies (number of participants)	1 (n=1569)
Countries and setting	Conducted in USA; Setting: Boston Medical Center (BMC) is a merged entity of the former Boston University Hospital and Boston City Hospital, with 509 licensed bed.
Line of therapy	Not applicable
Duration of study	Other: Before implementation: 2009; Post-implementation: July 2011-June 2012
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: National Surgical Quality Improvement Program (NSQIP) defines DVT as a new diagnosis of venous thrombosis, confirmed by imaging study or autopsy, which is treated with anticoagulation or placement of vena cava filter. PE is defined as a new diagnosis of a new blood clot in a pulmonary artery, which is confirmed by imaging or autopsy.
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	All patients who underwent an operation on the general and vascular surgery services at the institution during the specified time periods, and who were accrued to the NSQIP database, including those admitted to an ICU or to a non-ICU.
Exclusion criteria	Not reported
Recruitment/selection of patients	National Surgical Quality Improvement Program (NSQIP) data for patients in the institution.
Age, gender and ethnicity	Age: Not reported. Gender (M:F): Not reported. Ethnicity: Not reported
Indirectness of population	Serious indirectness – US population
Interventions	(n=1569) Intervention 1: No risk tool. Before development of the standardised program, no VTE prevention guidelines

were formally used. Surgeons generally acknowledged the American College of Chest Physicians guidelines, but no structured system existed and no individualised risk stratification was performed. There were no electronic reminders about VTE prophylaxis, and no surgeons used the Caprini system to guide decisions. Duration 2009. Concurrent medication/care: Pre-intervention analysis of practice revealed that patients generally remained in bed more than desired. In order to understand baseline care of post-operative patients at their institution before development of the VTE prevention program, they audited mobilisation practices in the spring of 2010. All patients who had undergone elective open abdominal or pelvic operations were visited at 8:00 AM, 1:00 PM and 6:00 PM on the day of surgery and during the 2 subsequent days. Nurses were unaware of these audits. Trained clinical staff recorded whether each patient was in bed, sitting in a chair or walking at the time of the visit. Audits were observational only and were not intended to directly alter patient management. Pre-intervention analysis revealed that patients generally remained in bed more than desired. Mobilisation orders were often absent or vague, e.g. orders might have simply stated “ambulate” without specifying a frequency and nurses were not required to document details about ambulation. Mobilisation program was fully implemented in August 2010, and further audits were performed between 8 and 14 weeks after implementation.

(n=1323) Intervention 2: Risk tool. Developed a scoring system for VTE risk assessment and integrated it into the electronic inpatient medical record. The system uses a check-box format so that each risk factor is explicitly listed and may be selected with a simple click. The risk score is calculated based on the selected factors, and the patient is placed into 1 of 5 risk categories (lowest: Caprini score = 0; low: Caprini score = 1-2; moderate: Caprini score = 3-4; high: Caprini score = 5-8 or highest risk: Caprini score = > 9). Electronic order system is customised to require that a Caprini score be calculated for every patient at the time of operation and/or admission within general surgery and vascular surgery standardised order sets. If the surgery team does not calculate the Caprini score and act on the electronic recommendations, the orders cannot be completed. Therefore, they made an effort to ensure that each patient would be scored according to the Caprini model. Standardised VTE prophylaxis regimens were created and linked to Caprini risk categories. The prophylaxis regimens provide the recommended mechanical and pharmacological prophylaxis along with suggested duration. The electronic order system was designed to require that all patients received standardised prophylaxis regimens. Electronic reminders are used for prophylaxis to encourage adherence to a standardised prevention strategy. Caprini Risk Tool. Score 1: • Age 41-59 (years) • Abnormal pulmonary function • Acute myocardial infarction (<1 month) • BMI \geq 30 (kg/m²) • Congestive heart failure (<1 month) • History of inflammatory bowel disease • History of prior major surgery (<1 month) • Sepsis (<1 month) • Serious acute lung disease (<1 month) • Swollen legs (current) • Varicose veins • Minor surgery planned • Medical patient currently on bed rest • Leg plaster cast or brace • Central venous access. Score 2: • Age 60-74 (years) • Major surgery (> 60 minutes) • Previous malignancy • Arthroscopic surgery (>60 minutes) • Laparoscopic surgery (>60 minutes) • Morbid obesity (BMI > 40 kg/m²) Score 3: • Age \geq 75 (years) • History of SVT, DVT/PE • Family history of VTE • Present cancer or chemotherapy • Positive anticardiolipin antibody • Positive Lupus anticoagulant • Acute spinal cord injury (<1 month) • Major surgery (2-3 hours) • BMI > 50 kg/m² (venous stasis syndrome) • Congenital thrombophilia: positive factor V Leiden, positive prothrombin 20210A, elevated serum homocysteine • Acquired thrombophilia: positive lupus anticoagulant, elevated anticardiolipin antibodies, HIT • Other

	<p>thrombophilia Score 5:• Elective major lower extremity arthroplasty• Hip, pelvis or leg fracture (<1 month)• Stroke (<1 month)• Multiple trauma (<1 month)• Acute spinal cord injury (paralysis) (<1 month)• Major surgery >3 hours. Duration July 2011 to June 2012. Concurrent medication/care: Increased level of adherence to recommended prophylaxis regimens after implementation of the electronic risk-stratification and prophylaxis program. Adherence to the recommended prophylaxis and duration was 77% for patients in the highest risk category. Standardised VTE prophylaxis regimens and linked them to the Caprini risk categories, the surgeon may decline VTE prophylaxis when it is contrary to his or her judgement by choosing the “opt out” selection in the order sets. This prompts an automatic drop-down menu that indicates reasons for not prescribing VTE chemoprophylaxis including active bleeding, heparin allergy, or contraindication. Combined the requirement for Caprini risk stratification and commensurate prophylaxis with a standardised post-operative mobilisation program. Created specific standardised mobilisation instructions and included them in order sets used for all general surgery and vascular surgery patients. The nursing orders require that each patient be out of bed at least 3 times daily, beginning on the day of the operation. Nurse educators and surgeons met with unit nurses, including those from the ICU to review baseline outcomes data and to establish expectations for mobilisation, program was implemented in August 2010.</p>
Funding	Funding not stated
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: RISK TOOL - BEFORE IMPLEMENTATION versus RISK TOOL - AFTER IMPLEMENTATION</p> <p>Protocol outcome 1: DVT (calculated from percentage reported in paper) - Actual outcome: DVT at 30 days; Group 1: 30/1569, Group 2: 4/1323; Risk of bias: High; Indirectness of outcome: No indirectness</p> <p>Protocol outcome 2: PE (calculated from percentage reported in paper) - Actual outcome: PE at 30 days; Group 1: 17/1569, Group 2: 7/1323; Risk of bias: High; Indirectness of outcome: No indirectness</p>	
Protocol outcomes not reported by the study	VTE (symptomatic or asymptomatic) (up to 90 days from hospital discharge); Fatal PE (up to 90 days from hospital discharge); Major bleeding (up to 90 days from hospital discharge); Quality of life (up to 90 days from hospital discharge); All-cause mortality at (up to 90 days from hospital discharge); Fatal bleeding (up to 90 days from hospital discharge) ; Length of hospital stay (up to 90 days from hospital discharge); Unplanned hospital readmission (up to 90 days from hospital discharge); Haemorrhagic stroke (up to 90 days from hospital discharge); Heparin-induced thrombocytopenia (up to 90 days from hospital discharge)
Study	Catterick 2014⁴⁴
Study type	Before and after study

Number of studies (number of participants)	(n=not reported, data reported as per 100,000)
Countries and setting	Conducted in United Kingdom; Setting: 152 hospital trusts, England
Line of therapy	Not applicable
Duration of study	Intervention time: Data from 2006/7 to 2011/12
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: ICD-10 codes used by the UK All Party Parliamentary Thrombosis Group
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Not reported
Exclusion criteria	Not reported
Recruitment/selection of patients	Obtained monthly secondary diagnoses, 30-day, 60-day and 90-day readmissions, and admissions data from the Health and Social Care Information Centre as Hospital Episode Statistics at NHS hospital trust level, from financial years 2006-2007 to 2011-2012. Readmission analyses were based on data from 152 hospital trusts in England. General mortality and population data from the Office of National Statistics.
Age, gender and ethnicity	Age: Not reported. Gender (M:F): Not reported. Ethnicity: Not reported
Indirectness of population	No indirectness
Interventions	(n=100000) Intervention 1: Risk tool. Department of Health risk assessment tool Review the patient-related factors shown on the assessment sheet against thrombosis risk, ticking each box that applies (more than one box can be ticked). Any tick for thrombosis risk should prompt thromboprophylaxis according to NICE guidance. The risk factors identified are not exhaustive. Clinicians may consider additional risks in individual patients and offer thromboprophylaxis as appropriate. Risk factors in the tool are: - Surgical patient- Medical patient expected to have ongoing reduced mobility relative to normal state- Medical patient NOT expected to have significantly reduced mobility relative to normal state- Active cancer or cancer treatment- Significantly reduced mobility for 3 days or more- Age > 60- Hip or knee replacement- Dehydration- Hip fracture- Known thrombophilias- Total anaesthetic + surgical time > 90 minutes- Obesity (BMI >30 kg/m ²)- Surgery involving pelvis or lower limb with a total anaesthetic + surgical time > 60 minutes- One or more significant medical comorbidities (for example heart disease ;metabolic, endocrine or respiratory pathologies; acute infectious diseases; inflammatory conditions)- Acute surgical admission with inflammatory or intra-abdominal condition- Personal history or first-degree relative with a history of VTE- Critical care admission- Use of hormone replacement therapy- Surgery with significant reduction in mobility- Use of oestrogen-containing contraceptive therapy- Varicose veins with phlebitis- Pregnancy or < 6 weeks post-partum (see NICE guidance for specific risk factors)- Active bleeding- Neurosurgery, spinal surgery or eye surgery- Acquired bleeding disorders (such as acute liver failure)- Other procedure with high bleeding risk- Concurrent use of anticoagulants known to increase the risk of bleeding (such as

	<p>warfarin with INR >2)- Lumbar puncture/epidural/spinal anaesthesia expected within the next 12 hours- Acute stroke- Lumbar puncture/epidural/spinal anaesthesia within the previous 4 hours- Thrombocytopenia (platelets < 75x10⁹/l)- Uncontrolled systolic hypertension (230/120 mmHg or higher)- Untreated inherited bleeding disorders (such as haemophilia and von Willebrand's disease). Duration 2010/11 (after implementation). Concurrent medication/care: n/a</p> <p>(n=100000) Intervention 2: No risk tool. Details about practice prior to implementation not reported. Duration 2009 (before implementation). Concurrent medication/care: n/a</p>
Funding	Primary author paid student internship at Sanofi, UK during the study period
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: RISK TOOL - BEFORE IMPLEMENTATION versus RISK TOOL - AFTER IMPLEMENTATION</p> <p>Protocol outcome 1: All-cause mortality (up to 90 days from hospital discharge) - Actual outcome: VTE-related mortality at 90 days (time-point provided by author); Group 1: mean: 9.8395 per 100000, Group 2: mean: 9.0059 per 100000; Risk of bias: High; Indirectness of outcome: No indirectness</p> <p>Protocol outcome 2: Unplanned hospital readmission (up to 90 days from hospital discharge) - Actual outcome: VTE-related readmission at 30 days; Group 1: mean: 126.5443 per 100000, Group 2: mean: 124.9660 per 100000; Risk of bias: High; Indirectness of outcome: No indirectness - Actual outcome: VTE-related readmission at 90 days; Group 1: 189.6489 per 100000, Group 2: 193.9462 per 100000; Risk of bias: High; Indirectness of outcome: No indirectness</p>	
Protocol outcomes not reported by the study	DVT (up to 90 days from hospital discharge); PE (up to 90 days from hospital discharge); Fatal PE (up to 90 days from hospital discharge); Major bleeding (up to 90 days from hospital discharge); Quality of life (up to 90 days from hospital discharge); Fatal bleeding (up to 90 days from hospital discharge); Length of hospital stay (up to 90 days from hospital discharge); Haemorrhagic stroke (up to 90 days from hospital discharge); Heparin-induced thrombocytopenia (up to 90 days from hospital discharge)

Study	Germini 2016¹¹⁹
Study type	Prospective cohort study
Number of studies (number of participants)	1 (n=628)
Countries and setting	Conducted in Italy; Setting: Two internal medicine sections of the University Hospital of Perugia

Line of therapy	1st line
Duration of study	Intervention time: During hospital stay
Method of assessment of guideline condition	Adequate method of assessment/diagnosis
Stratum	General medical: Hospitalised acutely ill medical patients.
Subgroup analysis within study	Not applicable
Inclusion criteria	18 years or older admitted to internal medicine.
Exclusion criteria	Expected hospital stay <48 hours, any indication for anticoagulant therapy, recent (within 2 weeks) or active major bleeding, platelet count lower than 100 x 10 ⁹ /L, creatinine clearance lower than 30 mL/min, and pregnancy.
Recruitment/selection of patients	Consecutive admissions from December 2012 to March 2014
Age, gender and ethnicity	Age - Median (IQR): Risk tool 75.1 (62.8, 81.5); no tool 72.4 (59.8, 80.5). Gender (M:F): 340/288. Ethnicity:
Further population details	High risk (PPS ≥4): PPS 32.7%; clinical judgment 39.4% Given prophylaxis: PPS 15.3%; clinical judgment 12.2% Of those at low risk (PPS <4) prophylaxis not given: PPS 94.9%; clinical judgment 96.2%
Indirectness of population	No indirectness
Interventions	(n=298) Intervention 1: Risk tool. Padua prediction score - all patients admitted to Section 1 Internal Medicine were allocated to PPS-based strategy. Physicians working in Section 1 were trained to use the PPS and a tool for PPS calculation was added to the section medical charts. Antithrombotic prophylaxis was suggested in patients with PPS score ≥4. Duration During hospital stay. Concurrent medication/care: None stated. Indirectness: No indirectness. (n=515) Intervention 2: No risk tool. No risk tool - all patients admitted to Section 2 Internal Medicine were allocated to clinical judgment-based strategy. The decision to prescribe antithrombotic prophylaxis was left to the attending physician and no specific training was performed. Duration During hospital stay. Concurrent medication/care: None stated. Indirectness: No indirectness
Funding	Funding not stated (None reported)

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: RISK TOOL versus NO RISK TOOL

Protocol outcome 1: DVT at 90 days

- Actual outcome for General medical: Symptomatic and asymptomatic DVT including proximal or distal. Complete compression ultrasonography of the lower limbs at discharge of in case of clinical suspicion of VTE. at During hospital stay; Group 1: 20/235, Group 2: 61/393

Risk of bias: All domain - Very high, Selection - Very high, Blinding - Low, Incomplete outcome data - Very high, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Baseline details: PPS group more likely to have a recent trauma or surgery. Clinical judgment group more likely to be affected by stroke. ; Group 1 Number missing: 63, Reason: No echo performed; Group 2 Number missing: 122, Reason: No echo performed

Protocol outcome 2: PE at 90 days

- Actual outcome for General medical: Pulmonary embolism confirmed by CT angiography or V/Q lung scanning at During hospital stay; Group 1: 1/235, Group 2: 0/393
Risk of bias: All domain - Very high, Selection - Very high, Blinding - Low, Incomplete outcome data - Very high, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Baseline details: PPS group more likely to have a recent trauma or surgery. Clinical judgment group more likely to be affected by stroke. ; Group 1 Number missing: 63, Reason: No echo performed; Group 2 Number missing: 122, Reason: No echo performed

Protocol outcome 3: Fatal PE at 90 days

- Actual outcome for General medical: Fatal PE at During hospital stay; Group 1: 1/235, Group 2: 0/393
Risk of bias: All domain - Very high, Selection - Very high, Blinding - Low, Incomplete outcome data - Very high, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Baseline details: PPS group more likely to have a recent trauma or surgery. Clinical judgment group more likely to be affected by stroke. ; Group 1 Number missing: 63, Reason: No echo performed; Group 2 Number missing: 122, Reason: No echo performed

Protocol outcome 4: Major bleeding at 90 days

- Actual outcome for General medical: Major bleeding - unclear definition at During hospital stay; Group 1: 0/235, Group 2: 2/393
Risk of bias: All domain - Very high, Selection - Very high, Blinding - Low, Incomplete outcome data - Very high, Outcome reporting - Low, Measurement - Very high, Crossover - Low; Indirectness of outcome: Serious indirectness, Comments: No definition of major bleeding offered. Unclear how similar to review protocol outcome definition. ; Baseline details: PPS group more likely to have a recent trauma or surgery. Clinical judgment group more likely to be affected by stroke. ; Group 1 Number missing: 63, Reason: No echo performed; Group 2 Number missing: 122, Reason: No echo performed

Protocol outcome 5: All cause mortality at 90 days

- Actual outcome for General medical: Death at During hospital stay; Group 1: 4/235, Group 2: 6/393
Risk of bias: All domain - Very high, Selection - Very high, Blinding - Low, Incomplete outcome data - Very high, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Baseline details: PPS group more likely to have a recent trauma or surgery. Clinical judgment group more likely to be affected by stroke. ; Group 1 Number missing: 63, Reason: No echo performed; Group 2 Number missing: 122, Reason: No echo performed

Protocol outcomes not reported by the study	VTE at 90 days; Quality of life at 90 days; Fatal bleeding at 90 days; Length of hospital stay at 90 days; Unplanned hospital readmission at 90 days; Post-thrombotic syndrome at 90 days; Pulmonary hypertension at 90 days; Haemorrhagic stroke at 90 days; Heparin-induced thrombocytopenia at 90 days
---	---

Study	Lester 2013²⁰⁵
Study type	Retrospective cohort study

Number of studies (number of participants)	(n=Unclear)
Countries and setting	Conducted in United Kingdom; Setting: N/A
Line of therapy	Not applicable
Duration of study	Intervention time: 21 months (July 2010-March 2012)
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: ICD10 codes - specified by the NHS-Outcome Framework 2013/14: I260, I269, I800, I801, I802, I803, I808, I809, I821, I822, I823, I829, O082, O223, O229, O870, O871, O879, O882
Stratum	Split surgical/non-surgical patients
Subgroup analysis within study	Not applicable
Inclusion criteria	All patients admitted to NHS hospitals
Exclusion criteria	Not reported
Recruitment/selection of patients	Data from 163 English NHS hospitals. Patient admissions placed in four different categories. 1) Non-surgical admissions >3 days 2) Non-surgical admissions <4 days 3) Surgical admissions >3 days 4) Surgical admissions <4 days
Age, gender and ethnicity	Age: Not reported. Gender (M:F): Not reported. Ethnicity: Not reported
Indirectness of population	No indirectness
Interventions	(n=17712681) Intervention 1: Risk tool – start of implementation. Use of Department of Health risk assessment tool in achieving ≥90% VTE risk assessment. Department of Health risk assessment tool - Review the patient-related factors shown on the assessment sheet against thrombosis risk, ticking each box that applies (more than one box can be ticked). Any tick for thrombosis risk should prompt thromboprophylaxis according to NICE guidance. The risk factors identified are not exhaustive. Clinicians may consider additional risks in individual patients and offer thromboprophylaxis as appropriate. Risk factors in the tool are: - Surgical patient- Medical patient expected to have ongoing reduced mobility relative to normal state- Medical patient NOT expected to have significantly reduced mobility relative to normal state- Active cancer or cancer treatment- Significantly reduced mobility for 3 days or more- Age > 60- Hip or knee replacement- Dehydration- Hip fracture- Known thrombophilias- Total anaesthetic + surgical time > 90 minutes- Obesity (BMI >30 kg/m ²)- Surgery involving pelvis or lower limb with a total anaesthetic + surgical time > 60 minutes- One or more significant medical comorbidities (for example heart disease; metabolic, endocrine or respiratory pathologies; acute infectious diseases; inflammatory conditions)- Acute surgical admission with inflammatory or intra-abdominal condition- Personal history or first-degree relative with a history of VTE- Critical care admission- Use of hormone replacement therapy- Surgery with significant reduction in mobility- Use of oestrogen-containing contraceptive therapy- Varicose veins with phlebitis- Pregnancy or < 6 weeks post-partum- Active bleeding- Neurosurgery, spinal surgery or eye surgery- Acquired bleeding disorders (such as acute liver failure)- Other procedure with high bleeding risk- Concurrent use of anticoagulants known to increase the risk of bleeding (such as warfarin with INR >2)- Lumbar

	<p>puncture/epidural/spinal anaesthesia expected within the next 12 hours- Acute stroke- Lumbar puncture/epidural/spinal anaesthesia within the previous 4 hours- Thrombocytopaenia (platelets < 75x10⁹/l)- Uncontrolled systolic hypertension (230/120 mmHg or higher)- Untreated inherited bleeding disorders (such as haemophilia and von Willebrand’s disease). Duration July 2010. Concurrent medication/care: N/A</p> <p>(n=17712681) Intervention 2: Risk tool – after implementation. Use of Department of Health risk assessment tool in achieving ≥90% VTE risk assessment. Duration March 2012. Concurrent medication/care: N/A</p>
Funding	Academic or government funding (Funded solely by University Hospital Birmingham NHS Foundation Trust)
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: RISK TOOL - START OF IMPLEMENTATION OF DOH TOOL versus RISK TOOL - AFTER IMPLEMENTATION OF DOH TOOL</p> <p>Protocol outcome 1: All-cause mortality (up to 90 days from hospital discharge)</p> <ul style="list-style-type: none"> - Actual outcome: Non-surgical admissions >3 days: VTE-related mortality post-discharge at 90 days; RR 0.963 (95%CI 0.814 to 1.138) (p-value 0.653); Risk of bias: Very high; Indirectness of outcome: No indirectness - Actual outcome: Non-surgical admissions <4 days: VTE-related mortality post-discharge at 90 days; RR 0.743 (95%CI 0.602 to 0.918) (p-value 0.006); Risk of bias: Very high; Indirectness of outcome: No indirectness - Actual outcome: Surgical admissions >3 days: VTE-related mortality post-discharge at 90 days; RR 0.816 (95%CI 0.646 to 1.031) (p-value 0.088); Risk of bias: Very high; Indirectness of outcome: No indirectness - Actual outcome: Surgical admissions <4 days: VTE-related mortality post-discharge at 90 days; RR 0.730 (95%CI 0.459 to 1.162) (p-value 0.184); Risk of bias: Very high; Indirectness of outcome: No indirectness - Actual outcome: Non-surgical admissions >3 days: Primary VTE-related mortality post-discharge at 90 days; RR 0.886 (95%CI 0.714 to 1.099) (p-value 0.269); Risk of bias: Very high; Indirectness of outcome: No indirectness - Actual outcome: Non-surgical admissions <4 days: Primary VTE-related mortality post-discharge at 90 days; RR 0.617 (95%CI 0.472 to 0.808) (p-value 0.001); Risk of bias: Very high; Indirectness of outcome: No indirectness - Actual outcome: Surgical admissions <4 days: Primary VTE-related mortality post-discharge at 90 days; RR 0.568 (95%CI 0.303 to 1.067) (p-value 0.078); Risk of bias: Very high; Indirectness of outcome: No indirectness - Actual outcome: Surgical admissions >3 days: Primary VTE-related mortality post-discharge at 90 days; RR 0.624 (95%CI 0.44 to 0.884) (p-value 0.008); Risk of bias: Very high; Indirectness of outcome: No indirectness 	
Protocol outcomes not reported by the study	VTE (symptomatic or asymptomatic) (up to 90 days from hospital discharge); DVT (symptomatic or asymptomatic) (up to 90 days from hospital discharge); PE (up to 90 days from hospital discharge); Fatal PE (up to 90 days from hospital discharge) ; Major bleeding (up to 90 days from hospital discharge); Quality of life (up to 90 days from hospital

	discharge); Fatal bleeding (up to 90 days from hospital discharge) ; Length of hospital stay (up to 90 days from hospital discharge); Unplanned hospital readmission (up to 90 days from hospital discharge); Haemorrhagic stroke (up to 90 days from hospital discharge); Heparin-induced thrombocytopenia at 90 days (up to 90 days from hospital discharge)
Study	Roberts 2013²⁷⁴
Study type	Before and after study
Number of studies (number of participants)	(n=302057)
Countries and setting	Conducted in United Kingdom; Setting: King's College Hospital located in south London. 900-bed tertiary referral centre which also provides secondary care for the local population with > 150,000 admissions each year.
Line of therapy	Not applicable
Duration of study	Intervention time: 2010 (April 2010-March 2011) and 2011 (April 2011-March 2012)
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: Hospital associated thrombosis (HAT): any new episode of VTE, diagnosed during hospitalisation or within 90 days of discharge following an inpatient stay of at least 2 days, or a surgical procedure under general or regional anaesthesia. VTE diagnoses were identified by the thrombosis team from screening radiology reports of CT pulmonary angiogram, ventilation/perfusion scans, upper and lower limb venous compression ultrasound, primary or secondary discharge diagnoses of VTE identified from ICD10 codes I80.0-80.9, I26.0-26.9 or O22.2, O22.3, O87.0 or O87.1, post-mortem reports, and death certificates with VTE listed as a primary cause of death.
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Patients aged > 18 years
Exclusion criteria	Not reported
Recruitment/selection of patients	Confirmed diagnoses of VTE in adults (>18 years of age) were cross-referenced with electronic patient records to identify HTA
Age, gender and ethnicity	Age: Not reported. Gender (M:F): Not reported. Ethnicity: Not reported
Indirectness of population	No indirectness
Interventions	(n=302057) Intervention 1: Risk tool. Department of Health risk assessment tool - Review the patient-related factors shown on the assessment sheet against thrombosis risk, ticking each box that applies (more than one box can be ticked).Any tick for thrombosis risk should prompt thromboprophylaxis according to NICE guidance. The risk factors identified are not exhaustive. Clinicians may consider additional risks in individual patients and offer thromboprophylaxis

as appropriate. Risk factors in the tool are: - Surgical patient- Medical patient expected to have ongoing reduced mobility relative to normal state- Medical patient NOT expected to have significantly reduced mobility relative to normal state- Active cancer or cancer treatment- Significantly reduced mobility for 3 days or more- Age > 60- Hip or knee replacement- Dehydration- Hip fracture- Known thrombophilias- Total anaesthetic + surgical time > 90 minutes- Obesity (BMI >30 kg/m²)- Surgery involving pelvis or lower limb with a total anaesthetic + surgical time > 60 minutes- One or more significant medical comorbidities (for example heart disease; metabolic, endocrine or respiratory pathologies; acute infectious diseases; inflammatory conditions)- Acute surgical admission with inflammatory or intra-abdominal condition- Personal history or first-degree relative with a history of VTE- Critical care admission- Use of hormone replacement therapy- Surgery with significant reduction in mobility- Use of oestrogen-containing contraceptive therapy- Varicose veins with phlebitis- Pregnancy or < 6 weeks post-partum (see NICE guidance for specific risk factors)- Active bleeding- Neurosurgery, spinal surgery or eye surgery- Acquired bleeding disorders (such as acute liver failure)- Other procedure with high bleeding risk- Concurrent use of anticoagulants known to increase the risk of bleeding (such as warfarin with INR >2)- Lumbar puncture/epidural/spinal anaesthesia expected within the next 12 hours- Acute stroke- Lumbar puncture/epidural/spinal anaesthesia within the previous 4 hours- Thrombocytopenia (platelets < 75x10⁹/l)- Uncontrolled systolic hypertension (230/120 mmHg or higher)- Untreated inherited bleeding disorders (such as haemophilia and von Willebrand's disease). Duration 2010 (April 2010-March 2011). Concurrent medication/care: A number of strategies were used to facilitate adoption of the VTE risk assessment tool, including the establishment of a network of VTE link nurses and midwives to ensure local expertise and leadership within each ward area. Mandatory VTE training was provided to all clinical staff (nurses, doctors, pharmacists). Engaging clinical staff with the VTE prevention process required multiple tailored approaches, e.g. education regarding patient safety and the role of thromboprophylaxis. A prompted mandatory electronic risk assessment was introduced in 2011 across all inpatient areas expect day surgery, intensive care and obstetrics. Completion of the risk assessment was linked to thromboprophylaxis guidance.

(n=302057) Intervention 2: Risk tool. Use of Department of Health risk tool to achieve sustained improvement in risk assessment on the incidence of VTE and the proportion of events attributable to inadequate prophylaxis The cut-point for comparison was delayed for 3 months following achievement of 90% risk assessment to account for potential lag in outcome improvement and the definition of VTE, including events occurring up to 90 days post-discharge. Duration 2011 (April 2011-March 2012). Concurrent medication/care: n/a

Funding No funding received

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: RISK TOOL - BEFORE DOH versus RISK TOOL - AFTER DOH RISK TOOL

Protocol outcome 1: VTE (up to 90 days from hospital discharge)

<p>- Actual outcome: Hospital associated thrombosis (HAT) - VTE at 90 days; RR 0.88 (95%CI 0.79 to 0.98) (p-value 0.014); Risk of bias: Very high; Indirectness of outcome: No indirectness</p> <p>Protocol outcome 2: DVT (up to 90 days from hospital discharge)</p> <p>- Actual outcome: DVT at 90 days; RR 0.95 (95%CI 0.83 to 1.09); Risk of bias: Very high; Indirectness of outcome: No indirectness</p> <p>Protocol outcome 3: PE at 90 days (up to 90 days from hospital discharge)</p> <p>- Actual outcome: PE at 90 days; RR 0.79 (95%CI 0.67 to 0.94) (p-value 0.004); Risk of bias: Very high; Indirectness of outcome: No indirectness</p>	
Protocol outcomes not reported by the study	Fatal PE at 90 days (up to 90 days from hospital discharge); Major bleeding (up to 90 days from hospital discharge); Quality of life (up to 90 days from hospital discharge); Fatal bleeding (up to 90 days from hospital discharge) ; Length of hospital stay (up to 90 days from hospital discharge); Unplanned hospital readmission (up to 90 days from hospital discharge); Haemorrhagic stroke (up to 90 days from hospital discharge); Heparin-induced thrombocytopenia at 90 days (up to 90 days from hospital discharge)

H.2 Risk assessment for people having day procedures

H.2.1 VTE day procedures

Reference	Ay 2010¹⁰
Study type	Prospective cohort
Study methodology	Data source: patients enrolled between October 2003 and December 2008 in CATS study Validation: split sample validation (Khorana 2008 ¹⁷¹)
Number of patients	n= 819
Patient characteristics	Age: median 62 (25 th -75 th percentile 53 – 68) Gender (male to female ratio): 56:44 Ethnicity: not reported

Reference	Ay 2010 ¹⁰
	<p><u>Site of cancer, n (%)</u></p> <p>Breast 140 (17.1)</p> <p>Lung 125 (15.3)</p> <p>Stomach 36 (4.4)</p> <p>Colorectal 112 (13.7)</p> <p>Pancreas 47 (5.7)</p> <p>Kidney 24 (2.9)</p> <p>Prostate 112 (13.7)</p> <p>Brain (high-grade glioma) 108 (13.1)</p> <p>Lymphoma 97 (11.8)</p> <p>Multiple myeloma 18 (2.2)</p> <p><u>Cancer treatment during observation period, n (%)</u></p> <p>Chemotherapy 537 (65.6)</p> <p>Surgery 334 (40.8)</p> <p>Radiotherapy 396 (48.4)</p> <p><u>Combination of treatments during observation period, n (%)</u></p> <p>Chemo- and radiotherapy 153 (18.7)</p> <p>Chemotherapy and surgery 85 (10.4)</p> <p>Surgery and radiotherapy 73 (8.9)</p> <p>Chemotherapy, surgery and radiotherapy 102 (12.5)</p> <p>Median body mass index, kg/m² (25th-75th percentile) 25.0 (22.3-28.1)</p> <p>Setting: Medical University of Vienna</p> <p>Country: Austria</p> <p>Inclusion criteria: (1) patients with newly diagnosed cancer of the brain, breast, lung, upper or lower gastrointestinal tract, pancreas, kidney, prostate or gynaecologic system; sarcoma; hematologic malignancies (myeloma, high- and low-grade lymphoma); or progression of disease after</p>

Reference	Ay 2010 ¹⁰
	<p>complete or partial remission; (2) histologic confirmation of diagnosis; (3) age more than 18 years; (4) willingness to participate; and (5) written informed consent</p> <p>Exclusion criteria: overt bacterial or viral infection within the last 2 weeks, venous or arterial thromboembolism within the last 3 months, and continuous anticoagulation with vitamin K antagonists or low molecular weight heparin (LMWH); surgery or radiotherapy within the last 2 weeks and chemotherapy within the last 3 months to exclude a transient influence of these interventions on the haemostatic system</p>
Target condition(s)	<p>VTE (180 days): no routine screening for VTE. When a patient developed symptoms of VTE, objective imaging methods were performed to confirm or exclude the diagnosis. Duplex sonography or venography were applied for diagnosis of deep vein thrombosis (DVT) and computerized tomography or ventilation/perfusion lung scan for diagnosis of pulmonary embolism (PE)</p> <p>Prevalence of VTE: n= 61 (7.4%)</p>
Risk tool(s)	<p><u>Khorana score</u></p> <p>Two points allocated to:</p> <ul style="list-style-type: none"> • Very high risk (stomach, pancreas) <p>One point allocated to:</p> <ul style="list-style-type: none"> • High risk (lung, lymphoma, gynaecologic, bladder, testicular) • Pre-chemotherapy platelet count 350 x 10⁹/L or more • Haemoglobin level less than 100 g/L or use of red cell growth factors • Pre-chemotherapy leukocyte count more than 11 x 10⁹/L • BMI 35 kg/m² or more <p>Population divided into 3 risk categories based on the score from the risk model</p> <ul style="list-style-type: none"> • Low (score 0) • Intermediate (score 1-2) • High (score ≥3)
Statistical measures	<p><u>Khorana score (≥3)</u></p> <p>Sensitivity: 31.9%</p> <p>Specificity: 91.9%</p> <p>PPV 22.1%</p> <p>NPV 94.9%</p>
Source of funding	grant from the Jubilaumsfonds of the Austrian National Bank (project numbers 10935 and 12739); unrestricted grant from Pfizer Austria
Limitations	Risk of bias: risk of bias in outcome reporting as there was no routine screening for VTE, screening only conducted when patients developed

Reference	Ay 2010¹⁰
	symptoms of VTE; there was not a reasonable number of outcome events Indirectness: no serious indirectness
Comments	

Reference	Bezan 2017²⁹
Study type	Retrospective cohort
Study methodology	Data source: Consecutive patients with testicular germ cell tumours (TGCT) across all clinical stages treated at a single University Hospital between January 2003 and December 2013. Validation: External validation
Number of patients	n= 349
Patient characteristics	Age, median: 34.9 years Gender: not reported Ethnicity: not reported <u>Histology</u> Seminoma 56.8% Non-seminoma 43.2% <u>Clinical tumour stage</u> Stage IA-B 64.8% Stage IS 2.6% Stage II1-IIC 14.3% Stage IIIA-C 18.3% <u>Prophylaxis</u> n=7 (2%) with LMWH for the duration of chemotherapy. Prescribed at individual physician's discretion. Setting: Two university hospitals.

Reference	Bezan 2017 ²⁹
	Country: Austria (derivation), Switzerland (Validation)
	Inclusion criteria: Not reported. Exclusion criteria: Not reported.
Target condition(s)	VTE (12 months) Prevalence of VTE: n= 18 (5.2%)
Risk tool(s)	<u>Unnamed (Bezan 2017)</u> Predictive model based on tumour stage and a large retroperitoneal lymphadenopathy (RPLN). VTE risk stratification rule with the following four categories: <ul style="list-style-type: none"> • cSIA-B (VTE 12 month risk 1.7%) • cS IS-IIB (5.9%) • cS IIC (14.3%) • cS IIIA-C (21.4%) Patients with cS IIC and cS III disease have a very high risk of VTE and may benefit from primary prophylaxis for the duration of chemotherapy.
Statistical measures	C-statistic: 0.84
Source of funding	No funding.
Limitations	Risk of bias: Unclear inclusion and exclusion criteria, model weighting unclear, unclear time interval between assessment of predictors and determination of outcome. Insufficient performance measures reported – no sensitivity and specificity. Indirectness: VTE not defined, unclear determination for all participants.
Comments	

Reference	Cella 2017 ⁴⁵
Study type	Prospective cohort with risk tool assessed retrospectively
Study methodology	Data source: patients with active cancers enrolled between October 2012 and April 2014. Validation: External validation
Number of patients	n= 843
Patient characteristics	Age: not reported Gender: Female 66.4%

Reference	Cella 2017 ⁴⁵
	<p>Ethnicity: not reported</p> <p><u>Primary tumour site</u> Breast 36.6% Gastroenteropancreatic 30% Genito/urinary tract 12.9% Lung 4% Metastatic patients 55.2% Other (kidney, neuroendocrine tumours, head and neck, sarcoma, GIST, hepatocellular carcinoma, skin, brain) 16.5%</p> <p>Patients undergoing chemotherapy 87.2%</p> <p>Setting: Federico II University of Naples and the University Cancer Centre Leipzig. Country: Italy and Germany</p> <p>Inclusion criteria: Patients ≥18 years with a diagnosis of solid tumours confirmed by cytology/histology at any stage and candidate to received chemotherapy, endocrine therapy, radiotherapy, target therapy, and/or surgery, alone or in combination and with at least 6 months life expectation. Exclusion criteria: end-stage renal or liver disease and disease-free patients.</p>
Target condition(s)	<p>VTE (12 months): symptomatic and asymptomatic. Confirmed by Doppler ultrasound and CT Prevalence of VTE: n= 73 (8.6%)</p>
Risk tool(s)	<p><u>Khorana Score</u> <i>Score 2</i> Very high-risk tumour (stomach pancreas) <i>Score 1</i> High-risk tumour (lung, gynaecological, genitourinary excluding prostate) Haemoglobin level <100 g/L or use of red cell growth factors Prechemotherapy leukocyte count >11 x 10⁹/L Prechemotherapy platelet count 350 x 10⁹/L or greater BMI 35 or greater</p>

Reference	Cella 2017 ⁴⁵
	<p>Calculated on 96.4% (n=813) of population:</p> <ul style="list-style-type: none"> • >2 High-risk – 56 (6.9%); with VTE events 45 (6.1%) • 1-2 Intermediate risk – 352 (43.3%); with VTE events 30 (41.1%) • 0 Low risk – 405 (49.8%); with VTE events 32 (43.8%)
Statistical measures	<p><u>Khorana score</u></p> <p>Sensitivity and specificity calculated using the risk stratification and prevalence data presented in Table 4 based on high-risk cut-off</p> <ul style="list-style-type: none"> • Sensitivity 15% (8-25) • Specificity 94% (92-96) <p>C-statistic: 0.583</p>
Source of funding	None reported
Limitations	<p>Risk of bias: Unclear if predictors assessed without knowledge of outcome and vice versa. Not all patients had Khorana score calculated (n=30)</p> <p>Indirectness: No indirectness</p>
Comments	

Reference	Khorana 2008 ¹⁷¹
Study type	Prospective cohort
Study methodology	<p>Data source: The study population comprised consecutively enrolled patients in the Awareness of Neutropenia in Chemotherapy (ANC) Study Group Registry, an observational study of cancer patients initiating a new chemotherapy regimen. Patients were followed prospectively for a maximum of 4 cycles of chemotherapy. Patients enrolled between March 2002 and October 2005 who had completed at least one cycle were included in the analysis.</p> <p>Validation: Internal split sample validation</p>
Number of patients	n= 1365
Patient characteristics	<p>Age: <65 years 62.3%; ≥65 years 37.7%</p> <p>Gender (male to female ratio): 1:2</p> <p>Ethnicity: not reported</p> <p>Cancer patients undergoing chemotherapy</p>

Reference	Khorana 2008 ¹⁷¹
	<p><u>Primary site of cancer:</u> Breast – 34.6% Colorectal – 11.9% Lung – 17.3% Gynaecologic – 10.40% Gastric and pancreatic 1.4% Lymphoma – 13.5% Other sites – 10.9%</p> <p><u>Stage of cancer:</u> 1 to 3 – 64% 4 – 34.9% Unknown – 1.1%</p> <p>Setting: 115 sites within the United States Country: USA</p> <p>Inclusion criteria: People were required to have a histologically confirmed diagnosis of cancer, with targeted enrolment of specific tumour types (breast, lung, ovarian, sarcoma, colon and lymphomas), eligible patients with other primary sites were allowed on the study. Patients were required to be at the start of a new chemotherapy regimen, expected to complete 4 cycles of chemotherapy, be aged 18 years or older with no upper age limit, and to provide informed consent</p> <p>Exclusion criteria: People who were receiving concurrent cytotoxic, biologic, or immunologic therapy for other conditions, or continuous single-agent chemotherapy, if they had a diagnosis of acute leukaemia, were pregnant or lactating, had an active infection requiring treatment, were currently participating in a double-blinded study, or had received stem cell transplant were excluded.</p>
Target condition(s)	VTE (time point and definition unclear) Prevalence of VTE: n= 28 (2.1%)
Risk tool(s)	<u>Unnamed (Khorana 2008)</u> Predictive model based on risk factors/patient characteristics for chemotherapy associated VTE Two points allocated to:

Reference	Khorana 2008 ¹⁷¹
	<ul style="list-style-type: none"> • Very high risk (stomach, pancreas) <p>One point allocated to:</p> <ul style="list-style-type: none"> • High risk (lung, lymphoma, gynaecologic, bladder, testicular) • Pre-chemotherapy platelet count $350 \times 10^9/L$ or more • Haemoglobin level less than 100 g/L or use of red cell growth factors • Pre-chemotherapy leukocyte count more than $11 \times 10^9/L$ • BMI 35 kg/m^2 or more • <p>Population divided into 3 risk categories based on the score from the risk model</p> <ul style="list-style-type: none"> • Low (score 0) • Intermediate (score 1-2) • High (score ≥ 3)
Statistical measures	<p>Sensitivity: 35.7%</p> <p>Specificity: 89.6%</p> <p>PPV: 6.7%</p> <p>NPV: 98.5%</p> <p>C-statistic: 0.70</p> <p>Hosmer-Lemeshow test $p=0.15$</p>
Source of funding	Supported by a Career Development Award to primary author from the National Cancer Institute. The Awareness of Neutropenia in Chemotherapy (ANC) Study Group received research grant support from Amgen for the development of the patient registry. Secondary author supported by a National Institutes of Health grant.
Limitations	<p>Risk of bias: Sample size and participant flow: there was not a reasonable number of outcome events, unclear time between predictor assessment and outcome assessment</p> <p>Indirectness: VTE not defined and timepoint unclear</p>
Comments	
Reference	Pannucci 2012 ²⁵⁴
Study type	Prospective cohort

Reference	Pannucci 2012 ²⁵⁴
Study methodology	<p>Data source: The American College of Surgeons' National Surgical Quality Improvement Program (ACS-NSQIP) database from 2005-2009 was used. All adult patients whose surgery was listed as outpatient and who had a length of stay equal to zero days were included for analysis in the ACS-NSQIP Patient Use File.</p> <p>Validation: Internal split validation</p>
Number of patients	n= 85,730
Patient characteristics	<p>Age: <40 years 19.28%, 40-60 years 39.59%, 61-74 years 28.4%, 75+ years 12.73%</p> <p>Gender (male to female ratio): 1:1.4</p> <p>Ethnicity: not reported</p> <p>Outpatient surgical patients:</p> <ul style="list-style-type: none"> Integument: 22% Musculoskeletal: 9.1% Respiratory and cardiovascular: 0.1% Arteries and veins: 6.4% Hemic and lymphatic system, mediastinum and diaphragm: 0.9% Head and neck, oesophagus: 1.5% Foregut (stomach, including gastric bypass procedure): 1.6% Hindgut (small bowel, large bowel, rectum and anus): 4.7% Liver, biliary system, and pancreas: 13% Miscellaneous peritoneal procedures: 0.9% Herniorrhaphy: 33% Urinary system: 1.2% Genital system (male or female): 2% Endocrine: 3.0% Nervous system structures: 0.5% <p>Setting: Not reported</p> <p>Country: USA</p>

Reference	Pannucci 2012 ²⁵⁴
	<p>Inclusion criteria: Patients who had outpatient surgery or surgery with subsequent 23-hour observation</p> <p>Exclusion criteria: Not reported</p>
Target condition(s)	<p>VTE (30 days): DVT and/or PE.</p> <p>DVT is considered to be a new thrombus within the venous system that is confirmed using an objective imaging method (e.g. duplex ultrasound or computed tomography scan). PE is defined as an obstructing thrombus within the pulmonary arterial system. PE requires confirmation using an objective imaging method (e.g. computed tomography scan or arteriogram)</p> <p>Prevalence of DVT: n= 87 (0.10%)</p> <p>Prevalence of PE: n=37 (0.043%)</p>
Risk tool(s)	<p><u>Unnamed (Pannucci 2012)</u></p> <ul style="list-style-type: none"> • Two point allocated to: Age 40-59, OR time ≥ 120 minutes, BMI ≥ 40 • Three points allocated to: age ≥ 60 • Five points allocated to: active cancer • Six points allocated to: arthroscopic surgery • Eight points allocated to: current pregnancy • Ten points allocated to: sapheno-femoral junction surgery • Eleven points allocated to: Non-GSV venous surgery <p>If patients have a total score of:</p> <ul style="list-style-type: none"> • 0-2 - classified as low risk level • 3-5 - classified as moderate risk level • 6-10 - classified as high risk level • ≥ 11 - classified as highest risk level
Statistical measures	<p>C-statistic: 0.78 (0.7212 - 0.8388). Confidence intervals calculated from standard error (SE ± 0.03)</p> <p>Hosmer-Lemeshow test p=0.826</p>
Source of funding	Dr. Pannucci (primary author) receives salary support through a NIH grant
Limitations	Risk of bias: not all relevant performance measures evaluated
Comments	

Reference	van Es 2017 ³²⁴
Study type	Prospective cohort
Study methodology	Data source: Multinational cohort recruited between July 2008 and February 2016. Validation: External validation
Number of patients	n= 876
Patient characteristics	<p>Age, mean (SD): 64 (11) years Gender: 59% male Ethnicity: not reported</p> <p>BMI, mean (SD): 25 (4)</p> <p><u>Tumour type</u> Lung 26% Oesophagus 19% Colorectal 18% Pancreas 12% Breast 9% Prostate 5% Gastric 5% Ovarian 5% Bladder 1%</p> <p>Distant metastases 66%</p> <p>Setting: Seven hospitals in four countries Country: The Netherlands, Italy, France and Mexico</p> <p>All included patients did not receive routine thromboprophylaxis in accordance with current guidelines.</p> <p>Inclusion criteria: Outpatients with lung, oesophageal, colorectal, pancreatic, breast, prostate, gastric, ovarian or bladder cancer classified as</p>

Reference	van Es 2017 ³²⁴
	stage III or IV according to the American Joint Committee on Cancer criteria if they were scheduled for chemotherapy within 7 days or had started chemotherapy in the previous 3 months. Exclusion criteria: Current prophylactic or therapeutic anticoagulation or adjuvant chemotherapy.
Target condition(s)	VTE (180 days, 6 months) Composite of objectively confirmed symptomatic or incidental PE, distal or proximal leg DVT, or non-catheter-related upper extremity DVT, or symptomatic catheter-related upper extremity DVT. Patients did not undergo screening. Prevalence: n= 53 (6.1%)
Risk tool(s)	<u>Khorana Score</u> <i>Score 2</i> Pancreatic or gastric cancer <i>Score 1</i> Lung, ovarian or bladder cancer Haemoglobin level <10 g/dL or use of erythropoietin stimulating agents Prechemotherapy white blood cell count >11 x 10 ⁹ /L Prechemotherapy platelet count ≥350 x 10 ⁹ /L BMI >35 kg/m ²
Statistical measures	C-statistic: 0.52 (0.47-0.58)
Source of funding	Unrestricted grants from participating hospitals
Limitations	Risk of bias: Unclear handling of n=33 cases with missing data. Unclear when predictor information calculated. Not all relevant performance measures evaluated (no sensitivity and specificity provided and insufficient data reported to calculate).
Comments	

Reference	Wang 2017 ³³¹
Study type	Retrospective cohort
Study methodology	Data source: Electronic medical records of Hepatocellular Carcinoma (HCC) patients who presented at a single hospital between January 2000 to July 2015 using ICD-9 codes for malignant neoplasm of liver and intrahepatic biliary duct. Validation: External validation
Number of patients	n=270

Reference	Wang 2017 ³³¹
Patient characteristics	<p>Age, mean (range): 58.5 (26-80) Gender (M/F): 50/220 Ethnicity: not reported</p> <p>HCC with Barcelona stage 0-A 42.6% Advanced HCC with Barcelona stage C or D 57.4%</p> <p>Chemotherapy: n=91 (33.7%)</p> <p>Setting: Cook County Health and Hospital System, Chicago. Country: USA</p> <p>Inclusion criteria: Reviewed and selected patients if they had histopathology-proven or radiographically proved HCC by triple-phase enhanced CT and/or MRI of the abdomen. Exclusion criteria: Incomplete data, less than 18 years, had prior VTE to the diagnosis of HCC, incomplete follow-up of less than 1 month in the institution.</p>
Target condition(s)	<p>VTE (symptomatic). Diagnosed based on radiographic examinations using compression ultrasound, contrast-enhanced CT, and pulmonary angiogram. No systemic VTE screening. Prevalence: n=16 (5.93%)</p>
Risk tool(s)	<p><u>Khorana Score</u> <i>Score 2</i> Pancreatic or gastric cancer <i>Score 1</i> Lung, ovarian or bladder cancer Haemoglobin level <10 g/dL or use of erythropoietin stimulating agents Prechemotherapy white blood cell count >11 x 10⁹/L Prechemotherapy platelet count ≥350 x 10⁹/L BMI >35 kg/m²</p> <p>Calculated based on the information collected at time of diagnosis.</p>

Reference	Wang 2017 ³³¹
	High risk ≥ 3 – 2 (0.7%) Intermediate risk 1-2 – 84 (31.1%) Low risk 0 – 184 (68.1%)
Statistical measures	Sensitivity and specificity calculated from data in Table 2 page 3. <ul style="list-style-type: none"> • Sensitivity 0% • Specificity 99.2%
Source of funding	No financial support
Limitations	Risk of bias: Unclear if predictors assessed without knowledge of outcome data and vice versa. Unclear time interval. There are not a reasonable number of outcome events in comparison to number of predictors in the model. Analyses only presented for one threshold that is not the usual one. VTE time point assessment unclear. Indirectness: no indirectness
Comments	

H.2.2 Major bleeding day procedures

No relevant studies were identified.

H.2.3 Risk assessment tools in patients who are having day procedures (including surgery and chemotherapy) at hospital

No relevant studies were identified.

H.3 Reassessment

H.3.1 Reassessment of people who are admitted to hospital

No relevant studies were identified.

H.3.2 Reassessment of people who are having day procedures at hospital

No relevant studies were identified.

H.4 Risk assessment for pregnant women and women up to 6 weeks postpartum

Reference	Sultan 2016 ³⁰⁸
Study type	Retrospective cohort (registry data)
Study methodology	Data source: The Swedish national inpatient register (IPR) and the Swedish Medical Birth Registry (SBR) for information on pregnancies in women with no history of venous thromboembolism resulting in a live birth or stillbirth between 1 July 2005 and 31 December 2011. Derivation: Records from England based Clinical Practice Research Datalink (CPRD) linked to Hospital Episode Statistics (HES). Validation: The information provided here is the first external validation.
Number of patients	n=498918 women with 662,387 deliveries
Patient characteristics	Age: mean (SD) 30.32 (5.23) Ethnicity: not reported Mean BMI (SD): 24.62 (4.57) – 8.6% missing pre-pregnancy BMI information. Varicose veins – 0.78% heart disease – 0.77% Kidney disease – 1.01% Inflammatory bowel disease – 0.80% Pre-eclampsia/eclampsia – 3.63% Diabetes – 2.26%

Reference	Sultan 2016 ³⁰⁸
	<p>Hypertension – 1.20%</p> <p>Nulliparous – 44.26%</p> <p>Para 1 – 36.59%</p> <p>Para 2 – 13.41%</p> <p>Para ≥3 – 5.75%</p> <p>Preterm birth (<37 weeks) – 4.79%</p> <p>Postpartum haemorrhage – 7.30%</p> <p>Spontaneous/assisted vaginal delivery 82.68%</p> <p>Elective caesarean – 8.76%</p> <p>Emergency caesarean – 8.56%</p> <p>Multiple delivery (twins or more) – 1.41%</p> <p>Stillbirth – 0.35%</p> <p>Puerperal acute infection – 7.30%</p> <p>Infant’s mean (SD) birth weight – 3519.80 (581.90) grams</p> <p>Postpartum venous thromboembolism: 521 women (absolute rate of 7.9 per 10,000 deliveries).</p> <p>Setting: Swedish Registry Country: Sweden</p> <p>Inclusion criteria: Women with no history of venous thromboembolism resulting in a live birth or stillbirth between 1 July 2005 and 31 December 2011. Exclusion criteria: None reported.</p>
Target condition(s)	Postpartum VTE: Occurrence of a first venous thromboembolism (deep vein thrombosis or pulmonary embolism) within the first six weeks after delivery. The algorithm used to define a valid VTE was accompanied by a prescription for an anticoagulant within 90 days of the event or if the patient died within 30 days of the event.
Risk tool(s)	<p><u>Risk prediction model</u></p> <p>Risk score from a logistic regression model to predict venous thromboembolism in the first six weeks postpartum.</p> <p>Risk score = $-9.103 + 0.94 \times (0.227 \text{smoker} + 1.221 \text{varicose veins} + 0.848 \text{comorbidities (cardiac, renal, or inflammatory bowel disease)} + 0.721 \text{pre-eclampsia/eclampsia} + 0.421 \text{diabetes} + 0.502 \text{postpartum haemorrhage} + 1.151 \text{stillbirth} + 1.097 \text{postpartum infection} + (0.750 \text{emergency section} / 0.563 \text{elective section}) + (0.165 \text{parity of 1} / 0.481 \text{parity of 2} / 0.566 \text{parity of } \geq 3) - 0.0000798 \text{age at delivery}^3 + 0.0000214 (\text{age at delivery}^3 \log (\text{age at delivery})) + 0.00026641 \text{BMI}^3 - 0.0000650 (\text{BMI}^3 \log (\text{BMI})) - 22156315 \text{infant birth weight}^{-2} + 3455223.4 (\text{infant birth weight}^{-2} \log (\text{baby's birth weight}))$</p>

Reference	Sultan 2016 ³⁰⁸
	<p><i>weight</i>)).</p> <p>All variables are coded as binary (0 or 1 for absence or presence of a risk factor), except for age, BMI, and birth weight. These variables were transformed on the basis of fractional polynomial regression analysis. The value -9.103 is the intercept, and the other numbers are the estimated regression coefficients for the predictors, which indicate their mutually adjusted relative contribution to the outcome risk. The regression coefficients represent the log odds ratio for a change of 1 unit in the corresponding predictor. The predicted risk of VTE=$1/1+e^{-\text{risk score}}$ log=natural logarithm</p> <p>In the development of this model primary candidate predictors were selected from the most recent version of the RCOG thromboprophylaxis guideline and additional predictors were added based on previous studies of important obstetric risk factors for VTE.</p>
Statistical measures	<p><u>Risk prediction model</u></p> <ul style="list-style-type: none"> • C-statistic – 0.73(0.71-0.75) • Calibration slope – 1.11 (1.01-1.20) <p>Top 1% risk score cut-off (threshold 41.2) – arbitrary threshold</p> <ul style="list-style-type: none"> • Sensitivity 9.0% (6.7-11.8) • Specificity 99.0% (98.9-99.0) • PPV 0.71 (0.52-0.94) <p>Top 5% risk score cut-off (threshold 19.7) – arbitrary threshold</p> <ul style="list-style-type: none"> • Sensitivity 26.7% (22.9-30.7) • Specificity 95.0% (95.0-95.1) • PPV 0.41 (0.35-0.50) <p>Top 6% cut-off (threshold = 18 per 10,000 deliveries) – based on number of pregnant women warranting thromboprophylaxis based on old Swedish guidelines</p> <ul style="list-style-type: none"> • Sensitivity 30.3% (26.4-34.5) • Specificity 93.8% (93.7-93.9) • PPV 0.38 <p>Top 10% risk score cut-off (threshold 14.0) – arbitrary threshold</p> <ul style="list-style-type: none"> • Sensitivity 35.5% (31.4-40.0) • Specificity 90.0% (90.0-90.1) • PPV 0.27 (0.24-0.32)

Reference	Sultan 2016 ³⁰⁸
	<p>Top 20% risk score cut-off (threshold 9.8) – arbitrary threshold</p> <ul style="list-style-type: none"> • Sensitivity 53.4% (50.0-57.7) • Specificity 80.0% (79.9-80.1) • PPV 0.21 (0.18-0.23) <p>Top 25% risk score cut-off (threshold 8.7) – arbitrary threshold</p> <ul style="list-style-type: none"> • Sensitivity 59.5% (55.1-63.7) • Specificity 75% (74.9-75.1) • PPV 0.19 (0.16-0.21) <p>Top 35% cut-off (threshold = 7.2 per 10,000 deliveries) – based on number of pregnant women warranting thromboprophylaxis based on old UK guidelines</p> <ul style="list-style-type: none"> • Sensitivity 68.1% (63.9-72.1) • Specificity 65.1% (64.9-65.2) • PPV 0.15
Source of funding	Funded by University of Nottingham/Nottingham University Hospital’s NHS Trust senior clinical research fellowship and by the Swedish Research Council (project number 2013-2429).
Limitations	Predictors: unclear if predictor assessments made without knowledge of outcome data. Similarly whether outcome determined without knowledge of predictor information. Unclear time interval between predictor assessment and outcome determination. Analysis: Thresholds not pre-specified for sensitivity and specificity ratings.
Comments	

H.5 Giving information to patients and planning for discharge (qualitative evidence)

Study	Apenteng 2016
Aim	To examine patients’ understanding of hospital-associated thrombosis and their experience with thromboprophylaxis
Population	Patients who were classed by hospital staff as being at high risk of developing VTE during a recent hospital admission

Study	Apenteng 2016
	n=31; Male: 54.8%, Female 45.2%; 9.7% aged ≤40 years, 35.5% aged 41-64 years, 38.7% aged 65-74 years, 12.9% aged ≥75 years, 12.9% unknown. 58.1% orthopaedic surgery, 22.6% gastrointestinal surgery, 19.3% other surgery. AES only 16.1%, injectable prophylaxis only 6.5%, both AES and injectable prophylaxis 77.4%.
Setting	Interviews took place in the patients' homes
Study design	In person semi-structured interviews
Methods and analysis	<p>Purposeful sampling was employed to select interview participants of maximum variety of age, gender, condition requiring hospital stay and site. Semi-structured interviews were used. These lasted between 10-45 minutes and were conducted in person at the patients' homes. The interviews were guided by a topic guide that comprised open ended questions that drew reflections on patients' recent hospital admissions. All interviews were audio recorded and transcribed verbatim. Data collection continued until theoretical saturation was attained.</p> <p>Three researchers read through the interview transcripts to familiarise themselves with the interviews and identify emerging themes. They met to compare, discuss and finalise themes for the coding frame. Based on this, one of the researchers coded the remaining interviews which were analysed using framework analysis.</p>
Findings	<p>Theme 1. Awareness of VTE risk. Patients were aware of the risk of blood clots although did not specifically refer to the terms DVT and PE. Those having orthopaedic surgery described having a discussion of the risks including blood clots, whereas other surgical patients did not report the same level of discussion. Patients' information came from information given during their work up or from previous personal experience or experience of family members. Many patients were not aware that they had a VTE risk assessment and assumed prophylaxis was a normal part of treatment.</p> <p>Theme 2. Experience of VTE prophylaxis. Patients reported mixed views on self-injecting and also reported differing levels of guidance provided on the injections. Some received training whereas others reported much less instruction. Despite this, all patients reported completing the course of injections. Most participants understood that injections were to prevent blood clots, although some demonstrated limited understanding of the rationale. Participants reported a great deal of inconsistency in terms of administration of AES and a lack of clarity on the use of AES. Adherence of AES was low, with reasons for this cited as lack of guidance, and discomfort. Participants also reported conflicting information regarding AES from nurses, doctors, and information leaflets, making it difficult for participants to know the correct course of action.</p> <p>Theme 3. Knowledge of VTE symptoms. Many participants reported that they did not think they would recognise the symptoms of a blood clot, whereas other participants could describe vague symptoms relating to DVT. There was a lack of awareness of the symptoms associated with PE, with only two participants describing PE related symptoms.</p> <p>Theme 4. Post discharge support. Many participants did not think it necessary to routinely activate GP involvement post discharge, and all reported that they had coped fine with the current system. Patients felt that they would be able to contact their GP if they did have any concerns</p> <p>Theme 5. Perceived gap in patient education. Patients reported that they would value more education in VTE, particularly in terms of how VTE prophylaxis works, clarity on AES use and some information on symptoms in order to recognise if they were having a blood clot. It was felt that it may also be useful to be warned about possible side effects of prophylaxis and some touched on the lack of public awareness and the potential need for a public health campaign.</p>

Study	Apenteng 2016
Limitations and applicability of evidence	<p>The researchers followed clear methods, although the justification of some of these methods is not clear, and the description of the data analysis methods is only briefly described. The aims and context of the research is clearly outlined and the data is rich and relevant to the aim of the study. There was no explicit mention of reflexivity. The researchers did not detail their professional backgrounds or provide insight into how this may have influenced the interview and analysis process</p> <p>The aim of the study is directly relevant to our review protocol and the population of both orthopaedic and non-orthopaedic surgical patients means that this evidence is applicable to the review question.</p>

Study	May 2006
Aim	To explore patient experiences of AES, to ascertain their perception about their use and care and to identify any limitations in the information currently provided to inform the design of a patient information leaflet
Population	<p>People who had been patients in hospital within the last two months and who had worn compression stockings for a period of 48 hours or more</p> <p>n=12; Thigh length AES 9, knee length AES 3</p>
Setting	East Kent, UK
Study design	Telephone semi-structured interviews
Methods and analysis	<p>Researchers gave patients who were interested a brief verbal introduction, consent forms and paid return envelopes. Written project information was sent to potential participants, written and verbal consent was obtained. Semi-structured interviews with 12 participants were used. An interview schedule with open ended questions which had been piloted in two subjects was used to guide the interviews. Telephone interviews were taped and transcribed, and a copy was sent to the participants to check for accuracy.</p> <p>Each researcher (eight members) individually analysed transcripts for emerging themes and consensus was obtained through discussion. Theme saturation was obtained in a sample of 12 patients</p>
Findings	<p>Theme 1. Amount and type of information received. Most patients could not remember receiving information regarding everyday care of AES. Some patients recalled having an information leaflet but remembered very little of what it said.</p> <p>Theme 2. Amount and type of information desired. Some patients perceived that nursed would have supplied necessary information. One participant thought that that in a hospital, “you do as you are told”. Some did not think that information is required and viewed it as common sense, while others thought that it is nice to have a leaflet to read and it would have been helpful to have some information in the hospital.</p> <p>Theme 3. Previous experience/secondary knowledge. Most patients had little alternative source of information other than that acquired in the hospital. The other sources were included health information from long haul flights and previous experience with VTE – either self or family.</p>

Study	May 2006
	<p>Theme 4. Reasons for wearing AES. Not all patients understood the reason to wear GCS. Some understood that it was meant to stop the blood from clotting and prevent DVT, but some could not relate this to their situation since they did not have DVT. Some patients who did not understand fully thought that AES were “given to you for a reason”, but it can be taken off if you can’t wear them after trying them on.</p> <p>Theme 5. Experiences with AES fitting and use/lack of information.</p> <ul style="list-style-type: none"> • There was a lack of information about how to put on and take off the AES, or how it should fit. Some patients obtained the information from other patients, family and friends or other health care professionals, and this resulted in a variety method which may not be appropriate. • Confusing or lack of information on duration of the AES, when to take them off/change them off, particularly whether to stop wearing them or continue wearing them at home. • Most patients did not receive information about how to take AES off and wash them, resulting them relying on “common sense” and many used inappropriate methods. • Lack of information given about prophylactic exercises.
Limitations and applicability of evidence	<p>There was a lack of information given about the data analysis methods used. The researchers did report the interview schedule and reported rich and relevant data. No explicit statement of reflexivity was made.</p> <p>The population and research aim was relevant to the review question and the evidence is applicable. The themes are relevant and are useful in addressing our question.</p>

Study	Najafzadeh 2015
Aim	To explore patients’ perceptions and understanding in regard to the benefits and risks of antithrombotic therapy for the prevention of VTE after a joint replacement surgery
Population	<p>Patients who had undergone hip or knee replacement surgery at a tertiary care hospital (Brigham and Women’s Hospital, Boston, MA) between January and June 2014 and who were 18 years of age or older</p> <p>n=12; Male: 25%, Female 75%; 33% aged 18–65 years, 25% 65–69 years, 17% 70-75 years, 8% 75-80 years, 17% ≥80 years. 75% hip replacement, 25% knee replacement. Heparin 8%, warfarin 75 %, unnamed oral antithrombotic medication 17%.</p>
Setting	Interviews took place at the tertiary care hospital or over the phone
Study design	In person or phone semi-structured interviews

Study	Najafzadeh 2015
Methods and analysis	<p>Semi-structured interviews were used. These lasted 30 minutes, and were conducted in person at the tertiary care hospital for five participants and over the phone for seven participants. The interviews were guided by a list of questions designed to address the study objective. In particular, participants were asked whether they were aware and had a clear understanding of potential complications that might occur following the surgical procedure e.g. DVT and PE, in contrast with unrelated but possibly more familiar conditions e.g. stroke and myocardial infarction; whether they knew about the benefits and risks of using ‘blood thinners’; and what factors affected their decisions to comply with (or not comply with) prophylactic antithrombotic treatment. Additionally, participants and the interviewer had the opportunity to discuss issues that they deemed to be relevant to the study topic as they emerged during the interviews.</p> <p>Interviews were recorded, transcribed and analysed using the constant comparative method. Transcripts were initially reviewed with the aim of developing an overall understanding of the scope and content of data. Issues requiring further clarification were then identified, which were included as discussion topics in the subsequent interviews. Subsequently, a line-by-line analysis of transcripts was conducted and codes were assigned to phrases and sentences as a concept became apparent. The appropriateness of code assignments was assessed by reviewing the previously coded data and ascertaining consistent assignment of codes to concepts. As more data were reviewed, the code structure was modified inductively by refining existing codes and adding new codes when necessary. Data were hand coded and reviewed separately by two investigators to identify major themes and concepts. All discrepancies were resolved by discussion.</p>
Findings	<p>Theme 1. Patients’ understanding of VTE. 67% of participants stated that they were informed about potential complications, 50% had a clear understanding of DVT and 42% had a clear understanding of PE. In contrast, all participants had a basic understanding of stroke and MI.</p> <p>Theme 2. Patients’ perceptions about the benefits of antithrombotic therapy. Nearly all participants (92%) were aware of benefits of antithrombotic therapy, describing a reduction in the risk of blood clot formation after surgery by thinning the blood. However some participants (58%) assumed that it could also reduce the risk of stroke and MI.</p> <p>Theme 3. Patients’ perceptions about the risks of antithrombotic therapy. Participants mentioned the risk of excess bleeding in case of injury and bruising as a possible side effect of treatment, however only half considered the risk of major bleeding events. Participants described the risk of bleeding associated with antithrombotic therapy as a consequence of their blood becoming too thin, and half acknowledged serious bleeding as a possible side effect.</p> <p>Theme 4. Factors influencing patients’ decision to use antithrombotic medications. Participants reported trusting their physician’s expertise as a primary reason for their decision to use antithrombotic medication as prescribed. Participants perceived bleeding as an event that could be monitored, controlled and reversed, and therefore as having less severe consequences compared to clots. Most participants were willing to trade off an increased risk of bleeding for a reduced VTE risk. Those that did report legitimate concerns about bleeding risk (family bleeding history, bleeding disorder) did not discuss these with their doctors and assumed that there was no other option, and that their physician had carefully considered their individual profile to assure benefits outweighed risks.</p>
Limitations and applicability of evidence	<p>The researchers followed clear methods to ensure the validity and rigour of their qualitative analysis. However of note is that there was no explicit mention of reflexivity. The researchers did not detail their professional backgrounds or provide insight into how this may have influenced the interview and analysis process</p>

Study	Najafzadeh 2015
	The inclusion of questions that relate to our review protocol, and a research aim clearly in line with the current topic, makes this evidence applicable to the review question. Although the study focus is quite narrow, the themes are relevant and are useful in addressing our question.

Study	Noble 2006
Aim	To find out what in patients with advanced cancer who are receiving palliative care think about the effect of thromboprophylaxis on overall quality of life
Population	Patients who had metastatic cancer or primary brain tumour with no curative treatment available n=28; age range 53-76; type of cancer breast 7, prostate 3, lung 3, unknown 3, ovarian 3, colon 4, pancreatic 3, brain 1, uterine 1
Setting	Specialist palliative care unit within the regional cancer centre (Cardiff), which had established thromboprophylaxis guidelines.
Study design	Semi-structured interviews
Methods and analysis	Semi-structured interviews were used. These were audio taped and then transcribed, and covered the following topics: cancer treatments received (such as surgery, chemotherapy, and radiotherapy); insight into prognosis; what was understood about treatment with low molecular weight heparin and thromboprophylaxis; the impact of thromboprophylaxis on overall quality of life; negative aspects of being on heparin treatment A thematic analysis was employed, using an inductive approach to obtain categories emerging from the data. Patients recruited until theoretical saturation (when no further recurring themes emerged from analysis) was achieved.
Findings	<p>Theme 1. Knowledge and understanding. All patients understood the purpose of heparin and many understood why they were at risk; immobility and surgery were identified as risk factors. All patients knew death is a consequence, but unaware of DVT symptoms such as painful swollen legs, or of pulmonary embolism, such as dyspnoea. Most knowledge was based on media coverage and association with long haul flights, but there was little understanding of the specific association with cancer.</p> <p>Theme 2. Acceptability. All patients found thromboprophylaxis with LMWH acceptable, and many could not understand why it would be considered unacceptable. Patients recognised that thromboprophylaxis with heparin was part of usual practice and described it as a reassurance that something is being done for them. They considered treatment with heparin was neither pleasant nor unpleasant, and balanced benefits against side effects.</p> <p>Theme 3. Reassurance and optimism. Patients understood that they had a terminal illness but expressed a desire to optimise quality of life not only by treating symptoms but also by taking measures to prevent other symptoms. Thromboprophylaxis with heparin reassured most patients that something was being done to prevent other problems and that the medical team had not given up on them.</p> <p>Theme 4. Views and concerns about thromboprophylaxis methods and side effects</p>

Study	Noble 2006
	<ul style="list-style-type: none"> • Bruising: Bruising was the only negative experiences reported from LMWH but that did not seem to be a big concern/bother, especially when compared with the treatments and side effects experienced for cancer. • Discomfort from AES: Several patients had worn AES during previous hospital admissions and all had found them uncomfortable (hot, itchy and tight), and not acceptable for long term wear <p>Theme 5. Terminally ill patients wish to be involved in decision making about thromboprophylaxis. Patients expressed their need to be involved in decision making, particularly with respect to the withdrawal or non-administration of treatment.</p>
Limitations and applicability of evidence	<p>The researchers provide limited information about the questions and probes used during the interviews, and how the analysis was conducted. There was a lack of reflexive statement, exploring the role of the researcher’s background and experience an how this may have influenced the interview and analysis.</p> <p>The inclusion of questions that relate to our review protocol, and a research aim clearly in line with the current topic, makes this evidence applicable to the review question. The study focus is quite narrow, concentrating on a distinct population which is a small sub-set of the population of interest in the protocol.</p>

H.6 General VTE prevention for everyone in hospital

Patient views on mechanical prophylaxis

Bibliographic reference	Study Type	Evidence level	No. of patients	Patients characteristics	Intervention	Comparison	Length of follow up	Outcome measures	Effect size	Comments
Barker and Hollingsworth, 2004 ¹⁵	Survey	3	Total: 218	Type of surgery: Mixed surgical patients from 16 wards in one hospital	Type: Graduated compression stockings (GCS)	Not applicable	1 day	No of patients wearing GCS in accordance with hospital policy	9/218 (4%)	The 5/14 wearing thigh high GCS incorrectly had them rolled down to below the knee. This leads to graduated
					Survey of	Additional non-comparative prophylaxis: Not reported		No of patients wearing any GCS	99/218 (46%)	

Bibliographic reference	Study Type	Evidence level	No. of patients	Patients characteristics	Intervention	Comparison	Length of follow up	Outcome measures	Effect size	Comments
					<p>concordance with hospital policy of wearing thigh-length stockings after surgery.</p> <p>Additional non-comparative prophylaxis:</p> <p>Not reported</p>			<p>No of patients wearing thigh GCS</p> <p>14/99 (14%)</p>	<p>compression loss and a constriction band formed by the rolled down band.</p> <p>Staff not routinely offering thigh high stockings.</p>	
							<p>No of patients wearing thigh GCS correctly</p> <p>9/14 (64%)</p>			
							<p>No of patients wearing below knee GCS</p> <p>85/99 (86%)</p>			
							<p>No of patients wearing below knee GCS correctly</p> <p>77/85 (91%)</p>			

Patient views on mechanical prophylaxis

Bibliographic reference	Study Type	Evidence level	No. of patients	Patients characteristics	Intervention	Comparison	Length of follow up	Outcome measures	Effect size	Comments
Benko et al., 2001 ²⁰	Patient views of interventions from RCT	3	Total: 200 5 randomised groups: 2 brands of thigh-length stockings with 40 patients in each arm 2 brands of knee-length stockings with 40 patients in each arm 1 group of no intervention.	Type of surgery: Orthopaedic patients	Type: Thigh-length graduated compression stockings (GCS) n = 80	Type: Below knee graduated compression stockings n = 80	1 hour	No. patients with wrinkles in stockings after 1 hour Int: 14/80 Cont: 6/80 p value: <0.05	Main aim was to investigate the difference in venous haemodynamics in inpatients prior to surgery. Only results for patient views reported here.	
					2 brands of thigh-length, 40 in each group Additional non-comparative prophylaxis: Not reported	2 brands of thigh-length, 40 in each group Additional non-comparative prophylaxis: Not reported		No. patients reporting discomfort after 1 hour Int: 17/80 Cont: 9/80 p value: <0.05		
					Additional non-comparative prophylaxis: Not reported	2 brands of thigh-length, 40 in each group Additional non-comparative prophylaxis: Not reported		No. patients unable to manage stockings independently Int: 38/80 Cont: 44/80 p value: >0.1		

Bibliographic reference	Study Type	Evidence level	No. of patients	Patients characteristics	Intervention	Comparison	Length of follow up	Outcome measures	Effect size	Comments

Patient views on mechanical prophylaxis

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
<p>Brady et al., 2007³⁴</p> <p>Study design: Observational</p> <p>Evidence level: +</p> <p>Duration of follow-up: Short term</p>	<p>Patient group: Nursing care patients in teaching hospital with orders for TEDS &/or SCD</p> <p>Setting: Teaching hospital, California, from autumn 2003 to winter 2005</p> <p>Inclusion criteria:</p> <ul style="list-style-type: none"> Randomly selected patients with orders for thromboembolic deterrent stockings (TEDS) and/or sequential compression device (SCD) admitted to any of these nursing units (neurological, transplantation, vascular, gastrointestinal; ear nose and 	<p>TEDS &/or SCD</p> <p>Types of SCDs used#:</p> <ul style="list-style-type: none"> Thigh length: 70/137 (51%) Knee length: 46/137 (34%) Unsure: 22/137 (16%) <p>Types of TEDs used:</p> <ul style="list-style-type: none"> Thigh length: 82/137 (60%)[#] Knee length: 41/137 (30%) Unsure: 14/137 (10%) <p>Methods: A survey of patient view on the following</p> <ul style="list-style-type: none"> why stockings/SCDs were being used Comfort How long they wore per 	<p>Correlation between gender and compliance</p> <p>Correlation between age and compliance</p> <p>Observation of SCD usage at time of survey</p>	<p>No correlation found. R values not reported</p> <p>Pearson r =0.247, p<0.01 (older patients more consistent in wearing stockings/SCD)</p> <p>Wearing#: 40/137 (29.2%)</p> <p>SCDs in room, but not using: 65/137 (47%)</p> <p>No SCDs visible in room: 26/137 (19%)</p> <p>Thigh length:</p> <p>Wearing: 21/70 (30%)</p> <p>Appropriate fit: 14/70 (20%)</p>	<p>Funding: Not stated</p> <p>Limitations:</p> <ul style="list-style-type: none"> No indication on how timing of checks were determined Some discrepancies in total number of patients using TEDs and SCDs in the paper. <p>Additional outcomes:</p> <p>Notes:</p>

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
prophylaxis	<p>throat, internal medicine, trauma and orthopaedics)</p> <p>Exclusion criteria</p> <ul style="list-style-type: none"> Patients who did not have sufficient stamina or mental clarity to complete the 15-minute survey, or restrained patients. <18 years old <p>All patients N: 137 out of 150 approached agreed to participate Drop outs: 5/137 ("feeling tired") Male/Female: 65/72 Age , years, range : 18 to 92</p> <p>% of patients observed to be in bed at time of survey: 117/137 (85.4%)</p>	<p>day</p> <p>Observations on the fit of TEDs and/or SCDs.</p> <p>Survey content and observational descriptors determined based on literature review and clinical observations made by nurses.</p> <p>The survey content validity established with clinical nurse experts and piloted with the data collectors for clarity and revisions were made by consensus of nurse experts. Inter-rater reliability established (93%) between the 6 data-collectors.</p>	<p>Observation of TEDs usage at time of survey</p>	<p>Discomfort reported: 39/70 (56%)</p> <p>Knee length:</p> <p>Wearing: 19/46 (41%)</p> <p>Appropriate fit: 12/46 (26%)</p> <p>Discomfort reported: 15/46 (33%)</p> <p>Overall:</p> <p>Wearing: 86/137 (62.8%)</p> <p>Not wearing: 51/137 (37%)</p> <p>Appropriate fit: 35/86(41%)</p> <p>Thigh length^{##}:</p> <p>Wearing: 58/74 (78%)</p> <p>Discomfort reported: 43/74 (58%)</p> <p>Knee length</p>	<p># Discrepancy in total number of patients using/not using SCDs- total 137 for % of patients reported types of SCDs used vs 131 for total of patients using vs not using SCDs</p> <p>## Discrepancy in reported in the report – 60% (82/137) reported using thigh length, but number of patients using vs not using totalled up to 74</p> <p>TEDS= thromboembolic deterrent stockings</p> <p>SCD = sequential compression device. This is also known as</p>

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
				<p>Wearing: 28/41(68%)</p> <p>Discomfort reported: 5/41 (12%)</p>	intermittent pneumatic compression devices (IPCD)
<p>Reasons for not using SCD (N=91)</p> <p>(multiple responses allowed: total of 149 responses)</p>	<ul style="list-style-type: none"> ▪ Had a good reason (just had a bath, ambulated): 46% ▪ SCDs were uncomfortable (hot, itchy): 39% ▪ Registered nurse had never initiated them or had not replaced them after transfer from another unit: 13% ▪ Did not know they were off: 2% 				
<p>Reasons for not using TEDS (N=51)</p> <p>(multiple responses allowed: total of 73 responses)</p>	<ul style="list-style-type: none"> ▪ TEDs were uncomfortable (hot, itchy): 43/51(84%, 59% of responses) ▪ Had a good reason (just had a bath, ambulated): 17/51 (33%, 23% of responses) ▪ Registered nurse had never initiated them or had not replaced them after transfer from another unit: 12/51(23.5%, 16% of responses) ▪ Did not know they were off: 1/51(2% of responses) 				
<p>Easy to put on</p>	<p>SCDS: 65%</p> <p>TEDS: 46% (30% reported difficult to put on and this was not related to length of stockings)</p>				

Patient views on mechanical prophylaxis

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
<p>Chan et al., 2007⁴⁷</p> <p>Study design: Observational & cross sectional survey</p> <p>Evidence level: +</p> <p>Duration of follow-up: Short term prophylaxis</p>	<p>Patient group: Lower limb arthroplasty. Trauma patients mostly excluded</p> <p>Setting: Department of Orthopaedic and Trauma surgery, Merlin Park Regional Hospital, Galway, Ireland.</p> <p>Patients were from 3 wards, recruited over a 5 months.</p> <p>Inclusion criteria: “fully evaluated to the satisfaction of the authors”. Complete scheduled observation and questionnaire completion.</p> <p>All patients</p>	<p>AV Impulse System (Orthofix Vascular Novamedix, Andover UK). Patients required to wear them at all times except during mobilisation on the first operative day.</p> <p>Patients kept on bed rest 24 hours post arthroplasty and generally commence mobilisation on the first postoperative day.</p> <p>Methods:</p> <ol style="list-style-type: none"> Spot checks randomly performed and recorded at least 1 hour apart, up to 3 checks per day, until patients were found to be non-compliant for 2 consecutive days. Checking times randomised using computer generated random number. Patients and nursing staff unaware that checks were recorded to avoid bias. % of compliance of each patient = number of compliant checks/total number of checks *100% Survey – patients completed 	<p>Level of compliance (%)</p> <p>As shown in graph (exact values not provided)</p> <p>Correlation of compliance with age</p> <p>Comfort level (measured by visual analogue scale of 1-10)</p> <p>Perceived purpose of device (question: “why are you wearing foot pumps?”)</p>	<p>Day 1: 100 Day 2: 90-100 Day 3: 80-90 Day 4: 50-60 Day 5: 30 Day 6: 20 Day 7: 10-20</p> <p>P value: <0.001 using chi-square test from day 3 to 5</p> <p>Spearman rank correlation coefficient, r = -0.495</p> <p>P value < 0.01 (compliance decrease with increasing age)</p> <p>Mean : 7.1 (definition of 7.1 not provided)</p>	<p>Funding: Foot pump manufacturer: Novamedix, Andover UK</p> <p>Limitations:</p> <ul style="list-style-type: none"> Selectiveness of patients included in the analysis – stringent requirement may have caused bias and limit external generalisability. No report of questionnaire validation Patient’s awareness and consent of participation in study may bias compliance rates Number of patients who were eligible but refused to participate/excluded was not reported

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	<p>N:30</p> <p>Type of procedures: 21 THR, 6 TKR and 3 bipolar hemiarthroplasties</p> <p>Age, years, mean ± SD: 72.4±11.2 (range 44-91)</p>	<p>questionnaire on day of discharge</p>	<p>For circulation</p> <p>Don't know 14/30 (46.7%)</p> <p>To prevent clot 8/30(26.7%)</p> <p>Help with mobility/walking 4/30(13.3%)</p> <p>To reduce leg swelling 3/30(10.0%)</p> <p>To support/splint the leg 2/30(6.7%)</p> <p>1/30(3.3%)</p> <p>Factors which discourage patients from wearing foot pumps:</p> <p>Sleep patterns disturbed</p> <p>Feet feel too hot 17/30 (56.7%)</p> <p>Disturb other patients in the ward 13/30 (43.3%)</p> <p>11/30 (36.7%)</p> <p>Too much pressure</p> <p>Noise disturbance/alarm 9/30 (30.0%)</p> <p>Pump activated too frequently 8/30 (26.7%)</p> <p>5/30 (16.7%)</p>	<p>Additional outcomes:</p> <p>Notes:</p> <p>Same foot pump as Pitto2008 and Anand2005</p>	

Patient views on mechanical prophylaxis

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
<p>Haddad et al., 2001¹³³</p> <p>Study design:</p> <p>RCT</p> <p>Evidence level:</p> <p>+</p> <p>Duration of follow-up:</p> <p>Short term</p>	<p>Patient group:</p> <p>Elective hip surgery-primary or revision</p> <p>Setting: Vancouver , Division of Reconstructive Orthopaedics in a large teaching hospital</p> <p>Inclusion criteria:</p> <p>Patients prospectively at random from 1 of 4 orthopaedic surgeons with a major interest in lower limb arthroplasty</p> <p>All patients</p> <p>Before education initiative N: 30</p> <p>After education initiative N: 49</p>	<p>IPCD –thigh length, bilateral</p> <p>Usage followed standard departmental protocol;</p> <ul style="list-style-type: none"> All patients should receive pharmacologic and IPCD for DVT and PE prevention. No GCS used IPCD should be initiated as soon as possible after surgery, ideally within 1 hour post-anaesthetic in recovery room Interruption allowed when patients were ambulant or undergoing specific treatment such as physiotherapy, change of dressings or investigations. Any single interruption expected to be , 2 hours and total time should not be >10% in the early postoperative period and not >20% at later periods. Patients should receive ≥21hours/day in the first 2 days and ≥19hours/day subsequently <p>Method:</p> <ul style="list-style-type: none"> Compliance was measure before and after the nursing education initiative recording using monitoring devices hidden at the bed of study patients for the 	<p>Compliance, % of time using the device, from start to end of study</p> <p>Duration of average interruption, hour, mean±SD, range</p> <p>Duration of longest interruption, hour, mean±SD, range</p>	<p>Before: 78±17%</p> <p>After: 80.6±14.0%</p> <p>Before: 3.6±3.0 (0.0 to 15.9)</p> <p>After: 2.6±2.7 (0.4 to 12.8)</p> <p>Before: 9.3±8.6 (0.0 to 39.6)</p> <p>After: 101.+ -11.6 (0.7 to 40.0)</p>	<p>Funding:</p> <p>John Charnley Trust and the BOA/Wishbone Trusts and Norman Capener Travelling Fellowships</p> <p>Limitations:</p> <p>Directness of evidence- Canadian study conducted in before mid 1999</p> <p>Additional outcomes:</p> <p>Notes:</p> <p>Nursing education was provided:</p> <p>Institutional and manufacturer based on the wards and post-anaesthetic recovery rooms. This</p>

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
		first 120 hours of use			comprised supplementary training

Patient views on mechanical prophylaxis

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
<p>May et al., 2006²¹⁸</p> <p>Study design: Qualitative (interview)</p> <p>Evidence level: +</p> <p>Duration of follow-up: Short term</p>	<p>Patient group: Mixed medical and surgical patients</p> <p>Setting: East Kent, UK</p> <p>Inclusion criteria: Patients who had been hospitalised in the past 2 months, and had worn stockings for ≥ 48 hours</p> <p>All patients N: 12, identified from a convenience sample of 100 patients</p> <p>9 wore thigh length, 3 wore knee length stockings.</p>	<p>Graduated compression stockings.</p> <p>Aim of study: “to explore patient experiences of GCS, to ascertain their perception about their use and care and to identify any limitations in the information currently provided to inform the design of a patient information leaflet”</p> <p>Methods: <u>Recruitment:</u> Researchers gave patients who were interested a brief verbal introduction, consent forms and paid return envelopes. Written project information was sent to potential participants, written and verbal consents obtained. <u>Data collection:</u> Telephone interviews were taped and transcribed. Semi-structured interview schedule with open ended questions which had been piloted in 2 subjects were used. <u>Data analysis:</u> Transcripts were verified by participants. Each researcher (8 of them) individually analysed transcripts for emerging themes and consensus was</p>	<p>Amount and type of information received: Most patients (8 out of 12) could not remember receiving information regarding everyday care of compression stockings.</p> <p>Amount and type of information desired:</p> <ul style="list-style-type: none"> Some patients perceived that nursed would have supplied necessary information. One participant thought that that in a hospital, “you do as you are told”. Some did not think that information is required (“common sense”), while others thought that it is nice to have a leaflet to read and it would have been helpful to have some information in the hospital. <p>Other sources of information Most patients had little alternative source of information other than that acquired in the hospital. The other sources were:</p> <ul style="list-style-type: none"> Health information from long haul flights Previous experience with VTE – self or family. <p>Reasons for wearing compression stockings:</p> <ul style="list-style-type: none"> Not all patients understood the reason to wear GCS. 		<p>Funding: Not stated</p> <p>Limitations:</p> <ul style="list-style-type: none"> Qualitative study to explore patient experience; not able to tell which concerns were those experienced by most patients <p>Additional outcomes:</p>

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
		<p>obtained through discussion. Theme saturation was obtained in a sample of 12 patients</p> <p><u>List of interview questions:</u></p> <ul style="list-style-type: none"> ▪ Have you worn compression stockings before? ▪ How long did you have to wear your stockings? ▪ How many pairs were you given and what type? ▪ Were you given a new pair? ▪ What was the reason you had to wear them? ▪ How did nursing staff prepare you for wearing stockings? <ul style="list-style-type: none"> ○ Were you measured? ○ Were you given information sheet? ○ Where you told about laundering, skin care, when to remove stockings, exercise? ▪ Did you experience any problems with your stockings? <ul style="list-style-type: none"> ○ Could you put them on/take them off yourself? ○ Were they comfortable? ○ Did they fit? ○ They you wear them for as long as recommended? ▪ What advice would you give to 	<p>Some understood that it was meant to prevent DVT, but could not relate to their situation since they did not have DVT.</p> <ul style="list-style-type: none"> ▪ Some patients who did not understand fully thought that GCS were “given to you for a reason”, but it can be taken off if you can’t wear them after trying them on. 	<p>Experiences with GCS fitting and use</p> <ul style="list-style-type: none"> ▪ Poorly fitted stockings – 7 out of 12 were not aware of measured and 2 patients were certain they had not been measured. ▪ There was a lack of information about how to put on and take off the stockings, or how it should fit. Some patients obtained the information from other patients, family and friends or other health care professionals, and this resulted in a variety method which may not be appropriate. ▪ Practical problem of putting on and taking off the stockings. Although help from nurses was received initially, this did not always continue. ▪ Latex allergy – blisters form at the top of the stocking. Patient was subsequently given instructions which would have caused wrong fitting (turn the top back slightly). ▪ Confusing or lack of information on duration of putting on the stocking, when to take them off/change them off, particularly whether to stop wearing them or continue wearing them at home. ▪ Most patients did not receive information about how to take stockings off and wash them, resulting them relying 	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
		<p>other patients with compression stockings?</p> <ul style="list-style-type: none"> ▪ Is there anything else you could like to add? 		<p>on “common sense “and used inappropriate methods.</p> <ul style="list-style-type: none"> ▪ Lack of information given about prophylactic exercises. ▪ Varied comments about appearance and comforts. <p>Patients found that the stockings were more comfortable that they had imagined.</p>	

Patient views on mechanical prophylaxis

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
<p>Murakami et al., 2003²³³</p> <p>Study design: RCT</p> <p>Evidence level: +</p> <p>Duration of follow-up: Short term</p>	<p>Patient group: trauma patients</p> <p>Setting: From emergency department until discharge</p> <p>Inclusion criteria:</p> <ul style="list-style-type: none"> ▪ Projected hospitalisation of ≥12 hours ▪ Able to have IPCDs applied to both legs ▪ ≥18 years ▪ No history of venous thromboembolism or requirement of systemic anticoagulation <p>All patients N: 33</p> <p>Revised trauma score: 11.7</p> <p>Group 1: SCD-calf length, N=16 Group 2: CECT, =17</p> <p>Type of injury: SCD/CECT</p>	<p>Group 1: SCD-calf length</p> <p>Group 2: CECT</p> <p>For all patients:</p> <ul style="list-style-type: none"> ▪ Compression begin immediately after randomisation; study end upon patient discharge ▪ Nursing staff and physicians taught how to use devices ▪ Investigators made no attempt to influence the use of devices once patients enrolled into the study. <p>Compliance measurement: counters affixed to the devices to measure the amount of time the device was applied and pumping, and this was checked twice daily to ensure they were</p>	<p>Compliance (total number of minutes device was pumping/ total number of minutes patient was enrolled) * 100%, mean±SD (n)</p>	<p><u>Emergency department</u></p> <p>Group 1: 57.8±10.5 (12) Group 2: 100.0±0.0 (11) P value: 0.002*</p> <p><u>Operating room</u></p> <p>Group 1: 22.1±22.1(4) Group 2: 57.1±20.2(7) P value: 0.28*</p> <p><u>ICU</u></p> <p>Group 1: 69.9±12.5(8) Group 2: 70.1±10.8(12) P value: 0.99*</p> <p><u>Nursing ward</u></p> <p>Group 1: 46.0±7.2(16) Group 2: 72.8±6.1(17) P value: 0.008†</p> <p><u>Total</u></p>	<p>Funding: Not stated</p> <p>Limitations:</p> <ul style="list-style-type: none"> ▪ Small sample size ▪ Paper stated no attempt was made by investigators to influence pump use after enrolment. However, awareness of RCT participation could have affected the patients and nursing staff <p>Additional outcomes: Venous flow velocities of the two devices</p> <p>Notes: SCD – sequential compression device, also known as IPCD (intermittent pneumatic compression device)</p>

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	<ul style="list-style-type: none"> ▪ Head: 3/3 ▪ Spinal cord:1/1 ▪ Pelvic :4/1 ▪ Lower extremity:1/5 ▪ Chest:1/3 ▪ Abdominal:3/1 ▪ Others:3/3 	working		<p>Group 1: 58.9±4.6 (16)</p> <p>Group 2: 77.7±3.9 (17)</p> <p>P value: 0.004†</p> <p>* calculated by authors using Mann Whitney U test</p> <p>† calculated by authors using independent student t-test</p>	<p>CECT = continuous enhanced circulation therapy group. This is a miniaturised and portable IPCD which is battery powered.</p>

Patient views on mechanical prophylaxis

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
<p>Pagella et al., 2007²⁴⁷</p> <p>Study design: RCT & cross sectional survey</p> <p>Evidence level: +</p> <p>Duration of follow-up: Short term</p>	<p>Patient group: Orthopaedic trauma with surgical procedure of THR/THR patients</p> <p>Setting: Transitional trauma and orthopaedic medical –surgical unit, Pennsylvania US, in Feb2002 to July 2002</p> <p>Inclusion criteria: Age> 18 years, physician ordered IPCD</p> <p>All patients N: 70 (74 patients approached)</p> <p>Dropouts: 5 (1 unreliable historian, 2 lost to follow up, 2 with missing data)</p>	<p>IPCD, calf length.</p> <p>Patients randomised to two devices with different sleeve materials 1) Thick stiff plastic 2) Breathable</p> <p>Methods: Patients were randomised for either type of device.</p> <p>Nursing staff continued to encourage patients to use the pumps for the maximum number of house possible per day</p> <p>Standardised informational handouts were provided to both groups.</p> <p>On day 3 or at discharge, the patients were given the questionnaire to assess comfort, satisfaction and compliance.</p>	<p>Patient questions: (5=strongly agree, 4=agree, 3=neutral, 2=disagree, 1=strongly disagree)</p> <p>Comfortable 4.3 vs 4.4</p> <p>Interfered with movement 2.1 vs 1.3</p> <p>Kept patient awake 1.7 vs 2.0</p> <p>Loud 1.5 vs 1.5</p> <p>Hot 2.2 vs 1.5</p> <p>Made leg sweat 2.6 vs 2.0</p> <p>Used in bed 4.7 vs 4.8</p> <p>Used on chair 2.0 vs 2.3</p> <p>Would not use again 2.1 vs 2.4</p> <p>Adherence (% time device was used in 24 hours)</p>	<p>Thick plastic vs breathable material 4.3 vs 4.4</p> <p>2.1 vs 1.3</p> <p>1.7 vs 2.0</p> <p>1.5 vs 1.5</p> <p>2.2 vs 1.5</p> <p>2.6 vs 2.0</p> <p>4.7 vs 4.8</p> <p>2.0 vs 2.3</p> <p>2.1 vs 2.4</p> <p>Patient reported: 81-85%, N=58</p> <p>Nursing staff reported: 66-71%, N=22</p>	<p>Funding: Not stated</p> <p>Limitations: Compliance rate generalisability limitation because:</p> <ul style="list-style-type: none"> ▪ Data obtained from a RCT setting, therefore compliance rate likely to be higher ▪ Patient self reported compliance – potential bias to be higher ▪ Nursing staff rating of their impression of compliance for all patients cared at the end of study ▪ No objective methods of compliance measurement

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
		Nursing staff complete questionnaire on their impression of the devices at end of study			<p>Additional outcomes:</p> <p>IPCD = intermittent pneumatic compression device</p>

Patient views on mechanical prophylaxis

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
<p>Parnaby, 2004²⁵⁵</p> <p>Study design: Observational</p> <p>Evidence level: +</p> <p>Duration of follow-up: Cross sectional- one day</p>	<p>Patient group: Inpatients</p> <p>Setting: 16 mixed surgical specialty wards in Middlesex Hospital, London. January 2003</p> <p>Inclusion criteria: All patients</p> <p>All patients</p> <p>N: 218</p>	<p>Hospital has an written policy that all patients should be wearing anti-DVT stockings, unless it is contraindicated (peripheral vascular disease or profound limb ulcerations)</p> <p>Methods: Each patient was asked and checked to see whether they were wearing GCS-length was noted (thigh vs knee)</p>	<p>Number of patients wearing GCS, and wearing it correctly</p>	<p>Wearing any GCS: 99/218 (45%)</p> <p>Wearing any GCS correctly: 87/218 (40%)</p> <p><u>Breakdown by stocking length</u></p> <p>Wearing above knee product: 13 (6%)</p> <p>Wearing above knee product correctly: 9/13 (69%)</p> <p>["Approximately one third wear incorrectly"- rolled or folded down the knee]</p> <p>Wearing below knee product: 86 (46%)</p> <p>Wearing below knee product correctly: 78/86(91%)</p>	<p>Funding: Not stated.</p> <p>Limitations: Study conducted</p> <p>Additional outcomes: Outcomes (comfort, quality, instruction, and ease of use) from two related trials of UCL developed GCS was also reported.</p> <p>Notes: Survey was conducted before the initiation of two trials of GCS products developed by UCL (University College London)</p>

Patient views on mechanical prophylaxis

Study details	Patients	Intervention/Methods	Outcome measures	Effect size	Comments
<p>Pitto & young, 2008²⁶¹ and Pitto & young, 2008²⁶⁰</p> <p>Study design: Observational & cross sectional survey</p> <p>Evidence level: +</p> <p>Duration of follow-up: Short term prophylaxis</p>	<p>Patient group: Total joint replacement (hip or knee), degenerative osteoarthritis</p> <p>Setting: Department of Orthopaedic surgery, Auckland</p> <p>Inclusion criteria: Consecutive patients admitted from Jan 2003 to Dec2005</p> <p>Exclusion criteria: Patients with diabetes, active malignant tumour, gastrointestinal ulcer, bleeding diathesis and superficial wounds or painful joints</p> <p>All patients</p>	<p>Group 1: Foot pump + 100mg aspirin (3 orthopaedic surgeons, 1 did not use aspirin)</p> <p>Group 2: Foot pump + GCS +100mg aspirin (3 orthopaedic surgeons)</p> <p>GCS used were either thigh or knee length Foot pump used ; AV Impulse System (Orthofix Vascular Novamedix, Andover UK)</p> <p>Foot pump usage: Nurses told to activate foot pump when patients were not weight bearing.</p> <p>Foot pump set at 20/1, with pressure of 130mmHg applied for 1s.</p> <p>Compliance measurement: by internal meter which measured the number of hours the foot pumps of switched on. Patients considered as discontinued</p>	<p>Discontinued foot pump (between days 2 and 6, mean 3.2 days.)</p> <p>Reason for termination:</p> <p>Discomfort (around the ankles)</p> <p>Sleep disturbances</p> <p>Patient opinion about foot pump:</p> <p>Painful</p> <p>Annoying/difficulty with sleeping</p> <p>Uncomfortable</p>	<p>Total: 46/846 (5.4%)</p> <p>Group1:10/416</p> <p>Group2:30/436</p> <p>RR: 0.55 (95% CI:0.31 to 0.99)</p> <p>P value:0.049[#]</p> <p>14/46(0.3%)</p> <p>32/46(69.6%)</p> <p>3/800 (0.4%)</p> <p>70/800 (8.8%)</p>	<p>Funding: Not stated</p> <p>Manufacturer: Novamedix, Andover UK</p> <p>Limitations:</p> <ul style="list-style-type: none"> Method of eliciting opinion about comfort of foot pump not described Discrepancy in number of denominator 846 vs 800 [author confirmed 46 dropped out, but did not explain the discrepancy in denominator values] <p>Additional outcomes:</p> <ul style="list-style-type: none"> Number of DVT events and side effects such as

Study details	Patients	Intervention/Methods	Outcome measures	Effect size	Comments
	N: 846	foot pump when foot pump not used for 4 continuous hours.	<p>No discomfort 10/800 (12.5%)</p> <p>Relaxing 505/800 (63.1%)</p> <p>212/800 (26.5%)</p>		<p>bleeding</p> <p>Notes:</p> <p>Same foot pump as Anand2007 and Chan2007A</p> <p>#Calculated by NCC-AC team</p>
			<p>Number of hour used per day (mean, range)</p>	15.9 (14-20.5)	

Patient views on mechanical prophylaxis

Bibliographic reference	Study Type	Evidence level	No. of patients	Patients characteristics	Intervention	Comparison	Length of follow up	Outcome measures	Effect size	Comments
Robertson et al., 2000 ²⁷⁵	Comparative study	2	Total: 224 Intervention: n = 120 Control: n = 104	Type of surgery: Hip replacement	Type: Foot pumps (Plexipus) Duration: started on day of surgery and continued until postoperative day 3 Warfarin or heparin was also given to some patients at the discretion of the surgeon Additional non-comparative prophylaxis: Not reported	Type: High sequential compression devices (SCD) (Kendall) + graduated compression stockings Duration: 4 postoperative days Warfarin or heparin was also given to some patients at the discretion of the surgeon Additional non-comparative prophylaxis: Not reported	4 days	Average no. of hours per day devices worn	Average number of hours worn per day from the day after surgery: Int: 17.4 Control: 18.1 P value: Not sig Number of hours worn on surgery day: Int : 8.8 Control: 9.8 P value: Not sig	
								No. of patients responding as 'comfortable' or no complaints with intervention	Int: 85/120 Control: 57/104 p value: 0.037	
								Reasons for non-compliance with foot pumps	Painful to foot/heal: 5/120 Forceful	

Bibliographic reference	Study Type	Evidence level	No. of patients	Patients characteristics	Intervention	Comparison	Length of follow up	Outcome measures	Effect size	Comments
									pulsation: 4/120 Tight: 3/120 Blisters: 1/120	
								Reasons for non-compliance with sequential compression	Hot/sweaty: 14/104 Stockings bothersome: 9/104 Tight: 4/104 Itchy: 4/104 Blisters: 2/104	
								Preference for device in foot pump patients having revision surgery who had previously received SCD.	Foot pump: 24/35 (68.6%) SCD: 7/35 (20%) p value: <0.005 No preference: 4/35 (11.4%)	

Patient views on mechanical prophylaxis

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
<p>Stewart et al., 2006³⁰⁵</p> <p>Study: Observational</p> <p>Evidence level: +</p> <p>Duration of follow-up: Short term</p>	<p>Patient group: Surgical patients</p> <p>Setting: Santa Barbara, California in a single community teaching hospital</p> <p>Inclusion criteria: All patients admitted to the surgical service who had IPCD ordered</p> <p>All patients</p> <p>N: not reported</p>	<p>IPCDs – all patients received</p> <p>Nurse education : “Group discussion with nurses”, to provide information on benefits and purpose of wearing IPCDs, followed by a question and answer</p> <p>Patient education: handing out a one page flier with this statement: “Please notify your nurse if your compression stockings are not on. They are important for preventing blood clots during the hospital stay”</p> <p>Method: Residents documented compliance, i.e. patients had pneumatic stockings attached to both legs and to the pump, and pump was activated. This data was collected twice daily (morning and evening) for a period of two months. Data on morning and afternoon rounds was counted as separate patient entries to evaluate the different nursing shifts</p>	<p>Compliance, observed twice daily based on number of observations.</p>	<p>Before education initiative Surgical ward: 131/213 (61.5%) Non-surgical ward: 73/152 (48%)</p> <p>After education initiative Surgical ward: 93/142 (65%) Non-surgical ward: 73/152 (48%)</p>	<p>Funding:</p> <p>Limitations: Sample size unknown, since outcome reported based on number of observations</p> <p>Additional outcomes:</p>

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
		taking care of patients None of the nurses or patients were aware of the study			

Patient views on mechanical prophylaxis

Bibliographic reference	Study Type	Evidence level	No. of patients	Patients characteristics	Intervention	Comparison	Length of follow up	Outcome measures	Effect size	Comments
Van Blerk et al., 2004 ³²³	Case series	3	Total: 30 Mean (range) age: 68 (23-97) M/F: 10/20	Type of surgery: Elective joint replacement on 2 wards 27 of the patients described as having major orthopaedic surgery Excluded patient groups: suspected of having VTE severe peripheral arterial disease severe heart failure any local condition in which garments may interfere	Type: IPCD device Flowtron [®] Universal DVT Prophylaxis System, Huntleigh Healthcare Ltd Calf garment: n=19 Foot garment: n=10 Calf & foot: n=1 Garment size determined by size of patient, size of limb and surgical procedure Duration: mean duration 7 days Additional non-comparative	Not applicable	7 days	No of patients describing the system as comfortable or very comfortable No. of nurses described as rating the device "highly positively"	23/27 20/20	Reported no patients received VTE during study period but not stated whether patients were screened Funding Not reported

Bibliographic reference	Study Type	Evidence level	No. of patients	Patients characteristics	Intervention	Comparison	Length of follow up	Outcome measures	Effect size	Comments
				such as infections, recent skin grafts or dermatitis	<p>prophylaxis:</p> <p>A range of prophylactic procedures being used, around 25% patients used IPCD alone</p>					

Patient views on mechanical prophylaxis

Bibliographic reference	Study Type	Evidence level	No. of patients	Patients characteristics	Intervention	Comparison	Length of follow up	Outcome measures	Effect size	Comments
Westrich et al., 2003 ³³⁵	Prospective case series	3	Total: 100	Type of surgery: Knee arthroplasty	Type: Pulsatile pneumatic plantar compression PlexiPluse foot wrap Observation started postoperatively and continued until device no longer used. Additional non-comparative prophylaxis: Not reported	not applicable	1 hour	Total 'compliance' recorded by observer (total time of observed use / total time observed) Actual 'compliance' recorded by observer (total time of observed use / total time observed that a patient can use the device)*	Nurses: 5537/6356 hours (87.1%) Researchers: 1314/1970 hours (66.7%) Combined nurses and researchers: 6851/8426 hours (81.3%) Nurses: 5537/5957 hours (92.9%) Researchers: 1314/1646 hours (79.8%) Combined nurses and researchers: 6851/7603 hours (90.1%)	For time used there are two lots of results assessed: nurses assessed use for 24 hours per day, research team assessed use between 9am and 5pm. *Actual compliance excluded times when the device had to be removed such as going to physiotherapy, ambulatory activities, hygiene and for tests conducted in another room.

Patient views on mechanical prophylaxis

Bibliographic reference	Study Type	Evidence level	No. of patients	Patients characteristics	Intervention	Comparison	Length of follow up	Outcome measures	Effect size	Comments
Wood et al., 1997 ³⁴³	RCT	1+	Total: 134 Intervention: n = 75 Control: n = 59	Type of surgery: Anterior lumbar interbody fusion, posterior spine fusion, posterior lumbar interbody fusion, Intervention: Mean age: 39.4 (sd 17.2) yrs M/F: 39/36 Control: Mean age: 39.6 (sd 18.5) yrs M/F: 39/20	Patients wore thigh-high compression stockings + Foot wraps Additional non-comparative prophylaxis: Not reported	Patients wore thigh-high compression stockings + Sequential Pneumatic Compression Wrap	Scanning carried out between post-operative days 5 and 7	DVT Confirmed by: Duplex US	Int: 1 Control: 0 p value: N/A	Comments: 36 patients (26%) complained of redness, itching, or actual discomfort with the use of the devices. No symptomatic DVTs of PEs Not reported: Survival, PTS, bleeding related complications, QoL and LoS
								PE Confirmed by: Duplex US	Int: 1 Control: 0 p value: N/A	
								Visual analogue comfort scale (mean \pm SD)	Int: 5.84 \pm2.8 Cont: 5.56 \pm2.9 p value: 0.88	

Patient views on heparin

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
<p>Chiou-Tan et al., 2003⁵⁰</p> <p>Study design: RCT, cross sectional observation and survey</p> <p>Evidence level: +</p> <p>Duration of follow-up: Short term</p>	<p>Patient group: Spinal cord injury</p> <p>Setting: Multiple hospitals in Houston, Texas.</p> <p>Inclusion criteria: Sequential patients with acute, complete or incomplete spinal cord injury, within 3 months of date of injury.</p> <p>All patients N: 100 patients were recruited, and 95 met all inclusion criteria. 80 patients completed questionnaires upon</p>	<p>Group 1: enoxaparin 30 mg, administered subcutaneously 12 hourly</p> <p>Group 2: dalteparin, administered once a day</p> <p>During hospitalisation the LMWH was administered by nursing staff. At discharge, the patient or family members received instructions on how to administer injections at home. They received a call every two weeks from research assistant to remind them to fill up log book and determine if there were any problems in getting refills.</p> <p>Methods: Log books to collect compliance data Questionnaires at follow up to determine pain, compliance and difficulties related to injections. Scale of 1 to 10.</p>	<p>Compliance rates (as recorded in log book of administration time)</p> <p>Painfulness of injections, mean ± sd, (range) 1=not painful at all, 10=extremely painful</p> <p>Frequency of missed injections, mean ± sd, (range) 1=never missed, 10=very frequently missed</p> <p>Hassle of injections compared to taking pills 3 times a day, mean ± sd, (range) 1= much less of a hassle, 10=very much more of a hassle)</p>	<p><u>Hospital logs</u></p> <p>Group 1: 99.2%</p> <p>Group2 : 99.5%</p> <p><u>Patients in hospital</u></p> <p>Group 1: 1.45±0.96 (1-4), n=22</p> <p>Group2 : 1.63±0.83 (1-3), n=19</p> <p>All: 1.53±0.61 (1-4)</p> <p><u>Patients in hospital</u></p> <p>Group 1: 1.05±0.24(1-2), n=22</p> <p>Group2 : 1.11±0.32(1-2), n=19</p> <p>All: 1.08±0.16, (1-2)</p> <p><u>Patients in hospital</u></p> <p>Group 1: 2.82±3(1-10), n=22</p> <p>Group2 : 2.16±1.98(1-7), n=19</p> <p>All: 2.51±2.16, (1-10)</p>	<p>Funding: Not stated</p> <p>Limitations:</p> <ul style="list-style-type: none"> No mention of questionnaire validation For questions regarding hassles, patients answered that to the hypothetical scenario of taking tablets 3 times per day Questionnaire format and answer options not provided <p>Additional outcomes: The same outcomes – compliance, pain rating and hassles were also obtained from patients who received injections at home.</p>

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	study completion. Age: 16-65 Male/female: 72/23 Most patients were recruited within 4 weeks of injury				

Patient views on heparin

Bibliographic reference	Study Type	Evidence level	No. of patients	Patients characteristics	Intervention	Comparison	Length of follow up	Outcome measures	Effect size	Comments
Colwell et al., 2005 ⁶⁷	Case series	3	<p>Total: 61</p> <p>11 excluded</p> <p>Discharged to nursing facility: 5</p> <p>Surgery cancelled: 2</p> <p>Using anticoagulant: 1</p> <p>Retinal hemorrhage before surgery: 1</p> <p>Withdrew consent: 2</p>	<p>Type of surgery:</p> <p>Primary or revision elective total hip and knee surgery.</p> <p>Age: 40 to 70 years</p>	<p>Type: Self injection of low molecular weight heparin (Enoxaparin)</p> <p>Dose:</p> <p>30mg per day at 9am and 9pm for postoperative days 1 to 7</p> <p>40mg per day at 9am for postoperative days 8 to 21</p> <p>Staff nurses gave first injections and explained purpose of heparin, discussed patient's responsibilities following discharge. Patients (or family member) demonstrated their technique.</p>	not applicable	21 days postoperatively	Concordance with self injection	<p>22/40 fully concordant:(all doses within one hour of scheduled time)</p> <p>15/40 partially concordant: (at least 6 days of 30mg every 12 hours then at least 13 days of 40mg once per day. All doses within 2 hours of scheduled time)</p> <p>3/40 non concordant</p>	<p>Comments:</p> <p>Funding: not reported but manufacturers supplied a video for each participant on injection technique.</p> <p>Also reported:</p> <p>No. of patients understanding the importance of self injection</p> <p>No. of patient comfortable giving injection</p>

Bibliographic reference	Study Type	Evidence level	No. of patients	Patients characteristics	Intervention	Comparison	Length of follow up	Outcome measures	Effect size	Comments
					<p>Patients also given a take home self injection kit that included and instructional video developed by the manufacturer and written instructional materials outlining injection technique and potential side effects.</p>					<p>Mild burning and stinging at injection site</p> <p>Mild bruising at injection site</p> <p>Not reported:</p>

Patient views on heparin

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
<p>Noble et al., 2006²⁴⁰</p> <p>Study design: Qualitative (interviews)</p> <p>Evidence level: +</p> <p>Duration of follow-up: Long term</p>	<p>Patient group: Metastatic cancer or primary brain tumour with no curative treatment available</p> <p>Setting: Specialist palliative care unit within the regional cancer centre (Cardiff), which had established thromboprophylaxis guidelines.</p> <p>Inclusion criteria:</p> <ul style="list-style-type: none"> Evidence within medical notes that the incurable nature of the disease has been discussed with the patient The patient had received 	<p>Aims of study: “To find out what inpatients with advanced cancer who are receiving palliative care think about the effect of thromboprophylaxis on overall quality of life”</p> <p>Methods: Patients identified using screening notes and drug charts.</p> <p>Data collection Semistructured interviews were audio taped and then transcribed.</p> <p>Topics covered: cancer treatments received (such as surgery, chemotherapy, and radiotherapy); insight into prognosis; what was</p>	<p>4 major themes and 3 minor themes identified</p> <p>Knowledge and understanding</p> <ul style="list-style-type: none"> All patients understood the purpose of heparin and many understood why they were at risk; immobility and surgery were identified as risk factors. All patients knew death is a consequence, but unaware of DVT symptoms such as painful swollen legs, or of pulmonary embolism, such as dyspnoea. Most knowledge was based on media coverage: Its association with long haul flights, but there were little understanding of the specific association with cancer. <p>Acceptability</p> <p>All patients found thromboprophylaxis with LMWH acceptable, and many could not understand why it would be considered unacceptable. Aspects of acceptability</p> <ul style="list-style-type: none"> Recognition that thromboprophylaxis with heparin was part of usual practice: They associate it a reassurance that something is being done for them, and getting the best care. They considered treatment with heparin was neither pleasant nor unpleasant Balance of benefits against side effects 	<p>Funding: Velindre small grants scheme</p> <p>Limitations:</p> <ul style="list-style-type: none"> Qualitative study – range of opinions elicited by % of patients with these views not known Questions and probes used not reported Aim stated as effect on overall quality of life but results focused more on acceptability <p>Additional outcomes:</p>	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	<p>LMWH prophylaxis for at least 5 consecutive days</p> <p>All patients N (all): 28</p> <p>Patients admitted after spinal cord compression</p> <p>N=14</p> <p>Age (range): 55-74</p> <p>M/F: 7/7</p> <p>Type of cancer: breast: 5; prostate 3; lung: 2; unknown:2; ovarian: 1; colon: 1</p> <p>Treatment: chemotherapy and radiotherapy 5; surgery, chemotherapy, and radiotherapy 4; radiotherapy 2; surgery and radiotherapy 2; surgery and chemotherapy 1</p> <p>Preadmission ECOG scores : 0-2</p> <p>Previous thromboprophylaxis: none 8; LWMH: 1; LMWH + GCS: 3; GCS: 3</p>	<p>understood about treatment with low molecular weight heparin and thromboprophylaxis; the impact of thromboprophylaxis on overall quality of life; negative aspects of being on heparin treatment.</p> <p><u>Analytical framework and data analysis:</u> Thematic analysis, using an inductive approach.</p> <p>Patients recruited until theoretical saturation (when no further recurring themes emerged from analysis) was achieved.</p>	<p>Reassurance and optimism</p> <ul style="list-style-type: none"> Patients understood that they had a terminal illness but expressed a desire to optimise quality of life not only by treating symptoms but also by taking measures to prevent other symptoms. Thromboprophylaxis with heparin reassured most patients that something was being done to prevent other problems and that the medical team had not given up on them. <p>Views and concerns about thromboprophylaxis methods and side effects</p> <ul style="list-style-type: none"> Bruising: Bruising was the only negative experiences reported from LMWH but that did not seem to be a big concern/bother, especially when compared with the treatments and side effects experienced for cancer. Discomfort from GCS: Several patients had worn GCS during previous hospital admissions and all had found them uncomfortable (hot, itchy and tight), and not acceptable for long term wear. LMWH would be preferable <p>Terminally ill patients wish to be involved in decision making about thromboprophylaxis</p> <ul style="list-style-type: none"> Patients uniformly expressed their need to be involved in decision making, particularly with respect to the withdrawal or non-administration of treatment. Some patients had experienced what they viewed as nihilistic paternalism, and they were angry that major decisions were made about their lives without their involvement. 		

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	<p>Patients admitted primarily for symptom control</p> <p>Age (range): 53-76</p> <p>M/F : 5/9</p> <p>Diagnoses: pancreatic: 3; ovarian: 2; colon: 3; breast: 2; lung: 1; unknown 1; brain: 1, uterine: 1</p> <p>Treatment: none 1; chemotherapy and radiotherapy 1; surgery and radiotherapy 2; surgery and chemotherapy 2; chemotherapy 2; surgery, chemotherapy, and radiotherapy 3; radiotherapy 3</p> <p>Preadmission ECOG scores: 1-3</p> <p>Previous thromboprophylaxis: none 9; LMWH: 2; GCS: 2; LMWH + GCS: 1</p>				

Patient views on heparin

Bibliographic reference	Study Type	Evidence level	No. of patients	Patients characteristics	Intervention	Comparison	Length of follow up	Outcome measures	Effect size	Comments
Spahn et al., 2002 ³⁰⁰	Case series	3	<p>Total: 207</p> <p>Age: <20 yrs: 26 20-40 yrs: 82 40-60 yrs: 51 >60 yrs: 48</p> <p>300 patients included in the study, 220 returned the questionnaire, 13</p>	<p>Type of surgery: Knee arthroplasty</p>	<p>Type: Injection of low molecular weight heparin (Fraxiparin)</p> <p>Injection by: Self: n = 160 Family member or friends: n = 31 Nursing service: 16</p> <p>Dose: Depended on body weight and further risk factors.</p> <p>Instructions were given by a physician or qualified nurse. Patients carried out first and last</p>	not applicable	10 days post-operatively	<p>Problems with self /family member injection</p> <p>None: 107/191 (56%) Initially: 72/191 (37.7%) All the time: 12/191 (6.3%)</p> <p>Perception of injection 'very unpleasant'</p> <p>Injection by: Self: 18/160 (11%) Family: 9/31 (29%) Nurses: 5/16 (31%)</p> <p>No. self/family member infection patients with unsure prophylaxis</p> <p>54/191 (28.3%)</p> <p>No. self/family member infection patients who</p> <p>34/191 (17.8%)</p>	<p>Comments: Not reported</p> <p>Funding: Not reported</p> <p>Also reported:</p> <p>Not reported: Not reported</p>	

Bibliographic reference	Study Type	Evidence level	No. of patients	Patients characteristics	Intervention	Comparison	Length of follow up	Outcome measures	Effect size	Comments
			were incomplete.		<p>injection in the presence of the instructor and got a pack containing 10 syringes, disinfection swabs and an information brochure.</p> <p>Assessment of patient use by anonymous questionnaire.</p>			<p>forgot prophylaxis</p> <p>No. self/family member infection patients discontinued injections early</p>	25/191 (13.1%)	

Patient views on pharmacological and mechanical prophylaxis

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
<p>Anand & Asumu, 2007⁶</p> <p>Study design: Cross sectional survey</p> <p>Evidence level: +</p> <p>Duration of follow-up: Short term prophylaxis</p>	<p>Patient group: Hip and knee replacement,</p> <p>Setting: Royal Oldham Hospital, Oldham, UK</p> <p>Inclusion criteria: Consecutive elective THR or TKR patients who were able to give informed consent</p> <p>Exclusion criteria: Gastrointestinal ulceration or painful foot conditions</p> <p>All patients N: 43 Male/Female: 14/29</p>	<p>All patient received:</p> <p>1. LMWH (dalteparin): once daily, subcutaneously through abdominal wall using 26 gauge needle, starting 12 hours before surgery and 24 hours thereafter</p> <p>2. Foot pumps (A-V Impulse System, Novamedix, Andover UK): applied to both feet, in the recovery room after operation, and used whenever patient not weight bearing. Pump activated every 20s to a pressure of 130mmHg for a period of 1s.</p> <p>Methods: Patients asked to inform nurses if they find any of the methods uncomfortable and wished to discontinue</p> <p>Patients surveyed on day of discharge with questionnaires which consist of a visual analogue scale (VAS) to mark level of comfort associated with thromboprophylaxis method and</p>	<p>Comfort VAS scale score, 0= most uncomfortable, 10= most comfortable</p>	<p>LMWH: 6.3</p> <p>Foot pumps:7.3</p> <p>P value (t-test): 0.07</p>	<p>Funding: Not reported. Foot pump manufactured by Novamedix, Andover UK</p> <p>Limitations:</p> <ul style="list-style-type: none"> Validation of questionnaire not reported Errors in some of the percentages reported; inclusion of neutral answers to the % of patients who would rather not have injections or foot pumps <p>Additional outcomes: For foot pumps only : comfort, restriction of mobility, soothing effect, interference with sleep, preferred time of use, willingness to us again if</p>
			<p>Painful: “agree” or “agree strongly”</p>	<p>LMWH: 5/43 (11.6%)</p> <p>Foot pumps: 6/43 (14.0%)</p>	
			<p>“rather not have these”, “agree” or “agree strongly”</p>	<p>LMWH: 6/43 (14.0%)</p> <p>Foot pumps: 16/43 (37.2%)</p>	
			<p>“ willing to continue these ... at home for 4 weeks after my discharge from the hospital” : “agree” or “agree strongly”</p>	<p>LMWH: 33/43 (76.7%)</p> <p>Foot pumps: 22/43 (51.2%)</p>	
			<p>Discontinuation of foot pump in hospital due to pain (one in day 2, the other in day 3)</p>	<p>2/43 (4.7%)</p>	
			<p>The foot pumps:</p> <ul style="list-style-type: none"> comfortable restrict mobility soothing effect 	<p>22/43 (51.2%)</p>	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	<p>Age, mean: 69.9 (range 36 to 85)</p> <p>Type of surgery:</p> <ul style="list-style-type: none"> ▪ TKR: 27/43 (one with bilateral knee replacements) ▪ THR: 16/43 <p>Length of hospital stay: mean of 6.58 days (mode of 7 days)</p>	<p>agreement to statements (choice of “strongly disagree”, “disagree”, “neutral”, “agree”, “strongly agree”)</p>	<ul style="list-style-type: none"> ▪ interfere with sleep <p>Preference for usage:</p> <ul style="list-style-type: none"> ▪ only during day time ▪ only at night ▪ during the day and the night ▪ If I have another hip or knee operation, I would like to use the foot pumps 	<p>28/43 (65.1%)</p> <p>23/43 (53.5%)</p> <p>12/43 (27.9%)</p> <p>19/43 (44.2%)</p> <p>16/43 (37.2%)</p> <p>12/43 (27.9%)</p> <p>31/43 (72.1%)</p>	<p>have another operation</p> <p>Notes:</p> <p>Same foot pump as Pitto2008 and Chan2007A</p>

Patient views on mechanical vs pharmacological

Bibliographic reference	Study Type	Evidence level	No. of patients	Patients characteristics	Intervention	Comparison	Length of follow up	Outcome measures	Effect size	Comments
Maxwell et al., 2001 ²¹⁷	Questionnaire of views and concordance carried on participants of RCT	3	<p>Total: 228</p> <p>Intervention: n = 104</p> <p>Control: n = 103</p> <p>Not all patients in trial were lost to follow up or incapable of participating in postoperative survey.</p>	<p>Type of surgery: "Major" procedure for gynaecological malignancy</p> <p>Intervention: Median age: 62 (35-85) yrs Gender not reported Mean duration of surgery: not reported</p> <p>Control: Median age: 60 (41-87) years Gender not reported Mean duration of surgery: not reported</p>	<p>Type: External pneumatic compression sleeves</p> <p>Timing: Started with induction of anaesthesia and continued for first 5 days postoperatively. Device stopped when patient was walking and restarted when back in bed.</p> <p>Additional non-comparative prophylaxis: Not reported</p>	<p>Type: Low molecular weight heparin (Dalteparin)</p> <p>Dose: 2500 units subcutaneously 1-2 hours before surgery and 2500 units 12 hours after first dose. Then from postoperative day 1 5000 units per day up to postoperative day 5. If the patient was confined to bed after day 5, continued prophylaxis until day of discharge or ambulatory.</p> <p>Additional non-</p>	<p>Control: 5 days</p> <p>Int: 5 days</p> <p>(patients also telephoned 30 days postoperatively and questioned for signs and symptoms of delayed VTE)</p>	<p>Overall comfort/pain</p>	<p>Int: 26%</p> <p>Cont: 4%</p>	<p>Comments: Screened everyone for DVTs, only reported proximal.</p> <p>Trial designed to detect differences in complications.</p> <p>Funding: not reported</p> <p>Also reported: No significant difference in proximal DVTs, median external bleeding loss, thrombocytopenia.</p>
								<p>Suboptimal performance or administration of prophylaxis</p>	<p>Int: 10/104</p> <p>Cont: 6/103</p> <p>p value: not significant</p>	
								<p>Postoperative preference for the intervention used</p>	<p>Int: 74%</p> <p>Cont: 78%</p>	
								<p>Postoperative preference for other intervention</p>	<p>Int: 3</p> <p>Cont: 4%</p>	

Bibliographic reference	Study Type	Evidence level	No. of patients	Patients characteristics	Intervention	Comparison	Length of follow up	Outcome measures	Effect size	Comments
						comparative prophylaxis: Not reported				Not reported: All DVTs, PE, post-thrombotic leg, QoL, survival, length of hospital stay

H.7 Nursing care: Early mobilisation and hydration

H.7.1 Early mobilisation and leg exercises

No relevant clinical studies were identified.

H.7.2 Hydration

Bibliographic reference	Study Type	Evidence level	No. of patients	Patients characteristics	Intervention	Comparison	Length of follow up	Outcome measures	Effect size	Comments
Janvrin et al., 1980 ¹⁵⁷	RCT	1+	Total: 60 Intervention: 30 Control:	Type of surgery: Routine abdominal surgery (any patient requiring blood transfusions)	Type: Intravenous Hartmann's solution/ Dextrose-saline Dose and timing: 1 litre of per hour	Type: No IV fluids during or postoperatively. Water by mouth.	7 days	DVT measured by FUT. Bilateral daily then alternate days.	Int: 9/30 Cont: 2/30 p value: <0.03	Comments: Three dropouts, but analysis by denominators of 30, i.e. presumably

Bibliographic reference	Study Type	Evidence level	No. of patients	Patients characteristics	Intervention	Comparison	Length of follow up	Outcome measures	Effect size	Comments
			30 Dropouts: 3	perioperatively was withdrawn from the trial). Intervention: Mean age: 57±10 yrs M/F:15/15 Control: Mean age: 58.0±12 yrs M/F: 12/18.;	of operation. 2-3 litres of dextrose saline 24hs for 2 days. Additional non-comparative prophylaxis: Not reported	Dose: "Small, increasing amounts of water were taken by mouth from the first day onwards". Timing: Not reported Additional non-comparative prophylaxis: Not reported				analysed by intention to treat. Also measured risk factors (varicose veins, smoker, etc), impedance clotting time and packed cell volume. Not reported: PE, PTS, QoL, LoS, survival, bleeding, proximal DVT.

H.8 Obesity

No relevant studies were identified.

H.9 People using antiplatelets

No relevant studies were identified

H.10 People using anticoagulation therapy

Study	Di Biase 2014 ⁸³
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=1584)
Countries and setting	Conducted in USA; Setting: Multi-centre study
Line of therapy	Not applicable
Duration of study	Follow up (post intervention): 48 hours
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: Major bleeding was defined as the occurrence of cardiac tamponade or hemopericardium requiring intervention, causing symptoms, or requiring transfusion; hematoma requiring intervention; massive hemoptysis; haemothorax; and retroperitoneal bleeding
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	People with atrial fibrillation undergoing catheter ablation, age ≥ 18 years, international normalized ratio (INR) in the range of 2.0 to 3.0 in the last 3 to 4 weeks before ablation, and CHADS2 score ≥ 1
Exclusion criteria	Known bleeding disorders or inherited thrombophilic disorder, oral contraceptives or oestrogen replacement therapy, prosthetic heart valves, and contraindications to warfarin therapy.
Recruitment/selection of patients	People presenting with AF at the participating centres between December 2009 and December 2012 were enrolled in the study
Age, gender and ethnicity	Age - Mean (range): 61-62 years. Gender (M:F): 3:1. Ethnicity: Not reported
Further population details	1. Atrial fibrillation: Atrial fibrillation (All people with AF). 2. BMI: Not stated 3. Mechanical heart valves: Not stated. 4. Medical/surgical: Surgical 5. Renal impairment: Not stated
Extra comments	Atrial fibrillation type: paroxysmal 27%, persistent 23%, LSP 50%
Indirectness of population	No indirectness
Interventions	(n=790) Intervention 1: Low molecular weight heparin (licensed in UK) - Enoxaparin (20mg once daily – 60mg twice daily). Warfarin was discontinued 2 to 3 days before the ablation, and patients were bridged with low-molecular-weight heparin. Specifically, 1 mg/kg enoxaparin was administered twice daily until the evening before the ablation procedure. A bolus of 15000 IU heparin was given intravenously before the transseptal puncture. A continuous infusion of heparin

	<p>1000 U/h was started. The infusion was adjusted to maintain an activated coagulation time (ACT) >350 seconds. During the procedures, the transseptal sheaths were continuously infused with heparinized saline. Every effort was taken to avoid air embolism.</p> <p>Protamine was administered after completion of the ablation procedure to partially reverse the heparin effect. A single 325-mg aspirin was given in the electrophysiology laboratory.</p> <p>Sheaths were pulled when the ACT was <200 seconds. Three hours after ablation, enoxaparin 0.5 mg/kg twice daily was routinely started. It was stopped when the INR was >2. Warfarin was restarted the night of the procedure. Duration 48 hours. Concurrent medication/care: All patients were on warfarin before the procedure to achieve 3 to 4 weeks of therapeutic INRs, and warfarin was monitored every week for the 3 to 4 weeks preceding the ablation.</p> <p>(n=794) Intervention 2: Vitamin K antagonists - Warfarin (all doses). All patients continued uninterrupted warfarin. If on the day of the procedure patients had an INR >3.5, they were excluded. If the INR was between 3 and 3.5, fresh-frozen plasma was administered a few hours before the procedure. Some patients presented on the day of the procedure with a subtherapeutic INR and were not excluded. A bolus of 10 000 IU unfractionated heparin in male patients and 8000 IU in female patients was given before the transseptal puncture.</p> <p>During the procedures, the ACT was kept >300 seconds, and the transseptal sheaths were continuously infused with heparinized saline. Every effort was made to avoid air embolism.</p> <p>Protamine was administered after the completed ablation procedure to partially reverse the heparin effect. Sheaths were pulled when the ACT was <200 seconds.</p> <p>Warfarin was administered the night of the procedure as per the patient's scheduled dose. Duration 48 hours. Concurrent medication/care: The INR had to be therapeutic and was monitored every week for the 3 to 4 weeks preceding the ablation.</p>
Funding	Funding not stated
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: ENOXAPARIN (20MG ONCE DAILY – 60MG TWICE DAILY) (OFF-WARFARIN) versus WARFARIN (ALL DOSES) (ON WARFARIN)</p> <p>Protocol outcome 1: Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of ≥2g/dl; a serious or life threatening clinical event at up to 45 days from hospital discharge</p> <p>- Actual outcome: Major bleeding at 48 hours; Group 1: 8/790, Group 2: 3/794; Risk of bias: Very high; Indirectness of outcome: No indirectness</p>	
Protocol outcomes not reported by the study	<p>All-cause mortality at up to 90 days from hospital discharge; Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge; Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy;</p>

echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge; Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Embolic stroke at up to 45 days from hospital discharge; Haemorrhagic stroke at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study;

Study	Santamaria 2013 ²⁸⁷
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=203)
Countries and setting	Conducted in Spain; Setting: Study conducted in ten hospitals in Spain
Line of therapy	Not applicable
Duration of study	Intervention time: 5-6 days
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: Major bleeding according to at least one of the following criteria: clinically overt bleeding associated with a fall in haemoglobin of at least 2 g/dL or requirement for a transfusion of two or more units of blood, fatal bleeding, or any bleeding requiring treatment cessation. Venous thromboembolism was defined as any symptomatic deep-vein thrombosis (DVT) or pulmonary embolism (PE) confirmed by objective methods (i.e. Doppler ultrasound or ascending contrast venography for DVT, high-probability lung scanning, pulmonary angiography, helical computed tomography for non-fatal PE or necropsy in cases of fatal PE)
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	People aged 18 years or older; taking VKA treatment for at least 3 months, required outpatient surgery, laparoscopy surgery or invasive procedures; and gave their written informed consent were included in the study.
Exclusion criteria	The exclusion criteria were the following: hypersensitivity to heparin or other pig-derived substances, a history of documented or suspected immune-mediated heparin-induced thrombocytopenia (HIT); an active haemorrhage or increased risk of bleeding due to impaired haemostasis or an organ lesion (e.g. an active peptic ulcer, haemorrhagic stroke, cerebral aneurysm or cerebral neoplasm); severe impairment of hepatic and pancreatic function; injuries to or surgery on the central nervous system, eyes and ears within the previous 2 months; disseminated intravascular

	coagulation attributable to HIT; acute or sub-acute endocarditis; use of antiplatelet drugs such as clopidogrel or aspirin; anti-thrombin, protein S or protein C deficiency; inability for the patient to be adequately followed-up; end-stage disease or a life expectancy of <3 months; and participation in another study within the previous month
Recruitment/selection of patients	Consecutive patients of both sexes who were aged 18 years or older between February 2007 to January 2009
Age, gender and ethnicity	Age - Mean (range): 71-73 years. Gender (M:F): 1.64/1. Ethnicity: Not reported
Further population details	1. Atrial fibrillation: Atrial fibrillation (Bemiparin 65.5%; UFH 57%). 2. BMI: Not obese (BMI under 30 kg/m ²) (Bemiparin 28.1 (4.1); UFH 28.3 (4.7)). 3. Mechanical heart valves: Mitral prosthetic valve 6.65%; Aortic prosthetic valve 8.4%). 4. Medical/surgical: Surgical 5. Renal impairment: Not stated
Extra comments	Type of invasive/surgical procedure: colonoscopy/gastroscopy 40.6%, arthroscopy 1.7%, cystoscopy 1.8%, bronchoscopy 1.8%, ocular surgery 16.5%, biopsy 10.8%, cutaneous surgery 2.3%, pacemaker battery replacement 2.4%, herniorrhaphy 3.3%, others 14.2% Oral anticoagulant used: acenocoumarol 91%, warfarin 9%
Indirectness of population	No indirectness
Interventions	(n=92) Intervention 1: Low molecular weight heparin (not licensed in UK) - Bemiparin (2500 units once daily - 3500 units once daily). Patients were discontinued the oral anticoagulation therapy (OAT) (day -5 or -3 for warfarin or acenocoumarol patients, respectively), they started blinded bridging therapy (on days -4 to -2 before the invasive/surgical procedure) with bemiparin (3500IU/24 hour + matching placebo 12 hour afterwards, subcutaneously). On the day of procedure, the morning dose was omitted, and all patients received only one injection in the evening (3500 IU bemiparin).The patients restarted OAT on day +1. The study medication was continued up to 5-6 days after the procedure. At the end of this period, if the INR was <1.8 or <2.5 in patients with mechanical prosthetic valves, then bemiparin was continued up to a maximum of 2 days. . Duration 5-6 days. Concurrent medication/care: N/A (n=99) Intervention 2: Unfractionated heparin - Unfractionated heparin (low dose, administered subcutaneously). Patients were discontinued the oral anticoagulation therapy (OAT) (day -5 or -3 for warfarin or acenocoumarol patients, respectively), they started blinded bridging therapy (on days -4 to -2 before the invasive/surgical procedure) with UFH (5000IU/12 hour, subcutaneously). On the day of procedure, the morning dose was omitted, and all patients received only one injection in the evening (5000IU UFH).The patients restarted OAT on day +1. The study medication was continued up to 5-6 days after the procedure. At the end of this period, if the INR was <1.8 or <2.5 in patients with mechanical prosthetic valves, then UFH was continued up to a maximum of 2 days. Duration 5-6 days. Concurrent medication/care: N/A
Funding	Study funded by industry (Sponsored by the Institut de Recerca - Hospital de la Santa Creu i Sant Pau (Barcelona, Spain) and was partially supported by grants from La Generalitat de Catalunya, Laboratorios Farmaceuticos Rovi S.A. (Madrid,

Spain) and RECAVA.)	
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: BEMIPARIN (2500 UNITS ONCE DAILY - 3500 UNITS ONCE DAILY) versus UNFRACTIONATED HEPARIN (LOW DOSE, ADMINISTERED SUBCUTANEOUSLY)</p> <p>Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge - Actual outcome: All-cause mortality at 90 days; Group 1: 0/84, Group 2: 0/93; Risk of bias: Very high; Indirectness of outcome: No indirectness</p> <p>Protocol outcome 2: Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge - Actual outcome: Major bleeding at 90 days; Group 1: 0/84, Group 2: 4/93; Risk of bias: Very high; Indirectness of outcome: No indirectness</p> <p>Protocol outcome 3: VTE at 7-90 days from hospital discharge - Actual outcome: Documented symptomatic arterial or venous thromboembolism at 90 days; Group 1: 0/84, Group 2: 2/93; Risk of bias: ; Indirectness of outcome: No indirectness</p>	
<p>Protocol outcomes not reported by the study</p>	<p>Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge; Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge; Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Embolic stroke at up to 45 days from hospital discharge; Haemorrhagic stroke at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study;</p>

H.11 Acute coronary syndromes

No relevant studies were identified.

H.12 Acute stroke patients

Study	TAIST trial: Bath 2001¹⁶
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=999)
Countries and setting	Conducted in Belgium, Canada, Denmark, Finland, France, Germany, Irish Republic, Netherlands, Norway, Sweden, United Kingdom; Setting: Multi-centre (33 centres) study
Line of therapy	Not applicable
Duration of study	Intervention time: 10 days
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: DVT (symptomatic and asymptomatic): confirmed by venography or ultrasonography PE: confirmed by high-probability ventilation perfusion scan, pulmonary angiography or necropsy and death Major bleeding: defined as clinically overt bleeding associated with one or more transfusion of at least two units of red cells, a fall in haemoglobin of 20g/L (1.24 mmol/L) or more, bleeding leading to permanent cessation of treatment.
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Patients with a clinical syndrome of a stroke were eligible for the trial if they were aged between 18 and 90 years, could be treated within 48 hours of stroke onset and had given written informed consent.
Exclusion criteria	Patients were excluded if they met one or more of the following criteria; computed tomographic evidence of intracranial haemorrhage, midline shift of more than 5 mm, or a non-stroke diagnosis; coma (including consciousness score on the Scandinavian neurological stroke scale above 53); stroke complicating trauma or a medical or a medical or surgical procedures; stroke or myocardial infarction within the previous 3 months; preceding moderate or severe disability (modified Rankin scale, 3-5); confounding neurological or psychiatric disease; a condition mimicking stroke (e.g. hypoglycaemia, Todd's paresis); a congenital bleeding disorder; clinically significant blood loss within the previous 3 months or a current active peptic ulcer, significant hypertension within 6 hours of enrolment (systolic blood pressure above 220 mmHg or diastolic above 120 mmHg); significant anaemia (haemoglobin less than 80 g/L, 4.96 mm/L), thrombocytopenia (platelet count less than 100 x10 ⁹ /L), liver dysfunction (INR >1.5, aminotransferases more than 3 times higher than normal) or renal dysfunction (creatinine more than 3 times higher than normal); clinical endocarditis; allergic asthma; recent history of long-term systemic steroid therapy, recent anticoagulant therapy or need for therapy or thrombolysis; severe concomitant medical conditions; pregnancy
Recruitment/selection of patients	June 1999 to January 2000

Age, gender and ethnicity	Age - Median (range): 74 years. Gender (M:F): 1.22/1. Ethnicity: Not reported
Further population details	1. BMI : Not applicable 2. Renal impairment: Not applicable 3. Type of stroke: Ischemic (99.5% of participants)
Indirectness of population	No indirectness
Interventions	(n=508) Intervention 1: Low molecular weight heparin (licensed in UK) - Tinzaparin (2,500 units once daily – 9,000 units once daily). Tinzaparin, 100IU/kg daily was subcutaneously administered (stated as medium-dose in the study). Each patient received one injection (LMWH) and two tablets daily (aspirin placebo). Duration 10 days or until discharge if earlier. Concurrent medication/care: Leg compression stockings were recommended in all patients who were not fully mobile. Indirectness: No indirectness (n=491) Intervention 2: Aspirin. Aspirin, 300mg (150mg x 2) once daily, orally given. Each patient received one injection (placebo) and two tablets daily (aspirin). Duration 10 days or until discharge if earlier. Concurrent medication/care: Leg compression stockings were recommended in all patients who were not fully mobile. Indirectness: No indirectness
Funding	Study funded by industry (Leo Pharmaceutical Products sponsored TAIST, provided all study medication and materials)

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: TINZAPARIN versus ASPIRIN

Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge

- Actual outcome: All-cause mortality at 90 days; Group 1: 60/507, Group 2: 58/491

Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 1, Reason: Not eligible; Group 2 Number missing: 0, Reason: n/a

Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge

- Actual outcome: DVT (symptomatic and asymptomatic) at 15 days; Group 1: 3/507, Group 2: 9/491

Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 1, Reason: Not eligible; Group 2 Number missing: 0, Reason: n/a

Protocol outcome 3: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQspect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge

- Actual outcome: PE at 15 days; Group 1: 4/507, Group 2: 4/491

Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 1, Reason: Not eligible; Group 2 Number missing: 0, Reason: n/a

Protocol outcome 4: Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular,

retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge

- Actual outcome: Major bleeding at 15 days; Group 1: 2/507, Group 2: 2/491

Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 1, Reason: Not eligible; Group 2 Number missing: 0, Reason: n/a

Protocol outcome 5: Health-related quality of life (validated scores only) at up to 90 days from hospital discharge

- Actual outcome: Modified Rankin Scale (score 0-2) at 90 days; Group 1: 188/507, Group 2: 206/491

Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low, Comments

- Evaluated the percentage of patients with a score between 0-2. Details of the scale are not reported in the study but the scale is a measure of disability, score 0-2 equate to no disability to slight disability (higher score is worse). Rationale for picking this score range is not reported. ; Indirectness of outcome: No indirectness ; Group 1

Number missing: 1, Reason: Not eligible; Group 2 Number missing: 0, Reason: n/a

- Actual outcome: Barthel Index (score 60-100) at 90 days; Group 1: 313/507, Group 2: 320/491

Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low, Comments

- Evaluated the percentage of patients with a score between 60-100. Details of the scale are not reported in the study but the scale is a measure of activities of daily living (ADL). Higher score is worse. Rationale for picking this score range is not reported. ; Indirectness of outcome: No indirectness ; Group 1 Number missing: 1, Reason: Not eligible; Group 2 Number missing: 0, Reason: n/a

Protocol outcome 6: Heparin-induced thrombocytopenia at up to 90 days from hospital discharge

- Actual outcome: Thrombocytopenia at 15 days; Group 1: 2/507, Group 2: 2/491

Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 1, Reason: Not eligible; Group 2 Number missing: 0, Reason: n/a

Protocol outcomes not reported by the study

Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Technical complications of mechanical interventions at up to 90 days from hospital discharge;

Study	Dennis 2009: CLOTS1 trial: Clots 2009 ⁵⁹
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	(n=2518)
Countries and setting	Conducted in Australia, Italy, United Kingdom; Setting: Hospital

Line of therapy	1st line
Duration of study	Intervention + follow up: Intervention till mobile. F/u around day 30.
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: DVT confirmed on a screening compression Doppler ultrasound (CDU). PE confirmed by imaging or autopsy, fatal PE confirmed by autopsy
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Admitted to hospital within seven days of acute stroke and are immobile (cannot mobilise to toilet) and were recruited within three days of admission.
Exclusion criteria	Peripheral vascular disease and where there was neuropathy where clinician felt stockings would cause skin damage. Subarachnoid haemorrhage.
Recruitment/selection of patients	No further details reported
Age, gender and ethnicity	Age - Mean: 76 years. Gender (M:F): 1:1.02. Ethnicity: Not reported
Further population details	1. BMI : Not stated 2. Renal impairment: Not stated 3. Type of stroke: Mixed (Around 9% had haemorrhagic stroke (not reported separately)).
Extra comments	For patients without capacity, proxy consent was sought.
Indirectness of population	No indirectness
Interventions	(n=1256) Intervention 1: Anti-embolism stockings - Above knee. Graduated compression stockings, sized and fitted by trained nurses, worn 24/7. Duration Until mobile or discharged, patient declined or skin damage. Concurrent medication/care: Anti-platelet and anti-coagulant therapy allowed as per usual practice in each centre (n=1262) Intervention 2: No treatment - Usual care. Avoid stockings. Duration Until discharge. Concurrent medication/care: Anti-platelet and anti-coagulant therapy allowed as per usual practice in each centre
Funding	Academic or government funding (Scottish Government and UK MRC. Stockings provided by industry with no influence on trial.)

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: ABOVE KNEE versus AVOID STOCKINGS

Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge

- Actual outcome: Dead by 30 days at 30 days from admission; Group 1: 122/1256, Group 2: 110/1262; Risk of bias: Low; Indirectness of outcome: No indirectness

Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge
 - Actual outcome: Any DVT (proximal or distal) on Doppler ultrasound (symptomatic or at screening @ around day 10 and 30) at 30 days from admission; Group 1: 205/1256, Group 2: 224/1262; Risk of bias: Low; Indirectness of outcome: No indirectness

Protocol outcome 3: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge
 - Actual outcome: PE confirmed on imaging or autopsy at 30 days from admission; Group 1: 13/1256, Group 2: 20/1262; Risk of bias: Low; Indirectness of outcome: No indirectness

Protocol outcome 4: Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge
 - Actual outcome: PE on autopsy at 30 days from admission; Group 1: 1/1256, Group 2: 1/1262; Risk of bias: Low; Indirectness of outcome: No indirectness

Protocol outcome 5: Technical complications of mechanical interventions at up to 90 days from hospital discharge
 - Actual outcome: Skin breaks/ulcers/blisters/skin necrosis at 30 days from admission; Group 1: 64/1256, Group 2: 16/1262; Risk of bias: High; Indirectness of outcome: No indirectness
 - Actual outcome: Lower limb ischaemia/amputation at 30 days from admission; Group 1: 7/1256, Group 2: 2/1262; Risk of bias: High; Indirectness of outcome: No indirectness

Protocol outcome 6: DVT (symptomatic)
 - Actual outcome: Symptomatic DVT (proximal or distal) at 30 days from admission; Group 1: 36/1256, Group 2: 43/1262;

Protocol outcome 7: DVT (proximal)
 - Actual outcome: Proximal DVT at 30 days from admission; Group 1: 126/1100, Group 2: 133/1133;

Protocol outcomes not reported by the study	Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at up to 90 days from hospital discharge;
---	---

Study	Dennis 2010: CLOTS2 trial: Clots (clots in legs or stockings after stroke) trial collaboration 2010 ⁵⁶
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=3114)
Countries and setting	Conducted in Multiple countries; Setting: Hospitals with "well-organised" inpatient stroke service and capacity to perform ultrasounds
Line of therapy	1st line
Duration of study	Intervention + follow up:
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: DVT detected by compression duplex ultrasonography or venography. PE confirmed on computed tomography pulmonary angiography or ventilation-perfusion isotope scanning or autopsy. Skin concerns confirmed by compression duplex ultrasonography.
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Suspected stroke up to a week prior to admission, enrolled within three days of admission, newly immobile (unable to mobilise to the toilet)
Exclusion criteria	Subarachnoid haemorrhage and conditions contraindicating stockings (severe peripheral vascular disease or neuropathy)
Recruitment/selection of patients	Not stated
Age, gender and ethnicity	Age - Median (range): 76 (67-83). Gender (M:F): 1540/1574. Ethnicity: NS
Further population details	1. BMI : Not stated 2. Renal impairment: Not stated 3. Type of stroke: Mixed
Indirectness of population	No indirectness
Interventions	(n=1552) Intervention 1: Anti-embolism stockings - Above knee. Applied by trained nurses. To be worn 24/7 until discharge, unless skin breaks. Duration Up to 30 days. Concurrent medication/care: Usual treatment for stroke. Drs asked to prescribe other VTE prophylaxis as per their usual practice for both groups (n=1562) Intervention 2: Anti-embolism stockings - Below knee. dose/quantity, brand name, extra details. Duration Up to 30 days. Concurrent medication/care: Usual treatment for stroke. Drs asked to prescribe other VTE prophylaxis as per their usual practice for both groups. Around 40% received some anticoagulant
Funding	Equipment / drugs provided by industry (Government funded, with stockings provided by Tyco Healthcare)
RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: ABOVE KNEE versus BELOW KNEE	

Study	Dennis 2010: CLOTS2 trial: Clots (clots in legs or stockings after stroke) trial collaboration 2010 ⁵⁶
	<p>Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge - Actual outcome: Dead by 30d at 30 days from intervention; Group 1: 182/1552, Group 2: 174/1562; Risk of bias: Low; Indirectness of outcome: No indirectness</p> <p>Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge - Actual outcome: Any DVT (proximal or distal, symptomatic or asymptomatic) confirmed by compression doppler ultrasound at 30 days from intervention; Group 1: 177/1552, Group 2: 211/1562; Risk of bias: High; Indirectness of outcome: No indirectness</p> <p>Protocol outcome 3: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge - Actual outcome: Pulmonary emboli confirmed by imaging or at autopsy at 30 days from intervention; Group 1: 23/1552, Group 2: 19/1562; Risk of bias: High; Indirectness of outcome: No indirectness</p> <p>Protocol outcome 4: Technical complications of mechanical interventions at up to 90 days from hospital discharge - Actual outcome: Stocking removed due to concern about skin at 30 days from intervention; Group 1: 61/1552, Group 2: 75/1562; Risk of bias: High; Indirectness of outcome: No indirectness - Actual outcome: Stocking removed due to patient reported discomfort at 30 days from intervention; Group 1: 127/1552, Group 2: 77/1562; Risk of bias: High; Indirectness of outcome: No indirectness</p> <p>Protocol outcome 5: DVT (symptomatic) - Actual outcome: Symptomatic DVT (proximal or distal) confirmed by compression doppler ultrasound at 30 days from intervention; Group 1: 85/1662, Group 2: 87/1562;</p> <p>Protocol outcome 6: DVT (proximal) - Actual outcome: Proximal DVT (symptomatic or asymptomatic) confirmed by compression doppler ultrasound at 30 days from intervention; Group 1: 98/1552, Group 2: 138/1562;</p>
<p>Protocol outcomes not reported by the study</p>	<p>Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge; Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major</p>

Study	Dennis 2010: CLOTS2 trial: Clots (clots in legs or stockings after stroke) trial collaboration 2010⁵⁶
	bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at up to 90 days from hospital discharge;

Study	CLOTS 3 trial: Clots (clots in legs or stockings after stroke) trials collaboration 2013⁸²
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=2876)
Countries and setting	Conducted in United Kingdom; Setting: Hospital
Line of therapy	1st line
Duration of study	Intervention + follow up: Up to 30 days with f/u at six months.
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: DVT confirmed using compression duplex ultrasound, PE confirmed using imaging, skin breaks/ulcers/blisters/ skin necrosis confirmed using imaging
Stratum	Overall
Subgroup analysis within study	Stratified then randomised: Pre-specified subgroups (all dichotomous): Randomisation more than 1 day after admission; randomisation more than 2 days after onset of stroke; Heparin, warfarin or alteplase used; Can lift both legs off the bed; Probability of a favourable outcome; High risk DVT; Haemorrhagic stroke; "Comfort" sleeve in stocking.
Inclusion criteria	Admitted into hospital within 3 days of acute stroke, cannot mobilise to toilet unaided.
Exclusion criteria	Age <16y, subarachnoid haemorrhage, contraindications to intermittent pressure compression such as dermatitis, leg ulcers, severe oedema, severe peripheral vascular dx, and congestive heart failure.
Recruitment/selection of patients	Consecutive
Age, gender and ethnicity	Age - Median (IQR): 76.5 (67-84). Gender (M:F): 1383:1493. Ethnicity: Not reported
Further population details	1. BMI : Not stated 2. Renal impairment: Not stated 3. Type of stroke: Mixed (13% confirmed haemorrhagic, not reported separately).
Indirectness of population	No indirectness
Interventions	(n=1438) Intervention 1: Intermittent pneumatic compression devices - Full leg. Kendall SCD express sequential compression system (Covividium) thigh-length, applied according to manufacturer's instructions to both legs. Worn 24/7. Duration Up to 30 days, regain mobility or discharge from hospital. Concurrent medication/care: Physicians requested to prescribe medical VTE prophylaxis as if no stockings, according to their usual practice.

Study	CLOTS 3 trial: Clots (clots in legs or stockings after stroke) trials collaboration 2013 ⁸²
	<p>Comments: 58% participants had standard sleeves, but "comfort" sleeves in second half of trial.</p> <p>(n=1438) Intervention 2: No treatment - Usual care. No intermittent compression stockings. Duration 30 days or until discharged. Concurrent medication/care: Physician asked to prescribe VTE prophylaxis according to their usual practice.</p>
Funding	Equipment / drugs provided by industry (Study funding from National Institute of Health Research (NIHR), Health Technology Assessment programme (HTA) and Scottish Government. Equipment donated by Covidien.)
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: FULL LEG IPC versus USUAL CARE</p> <p>Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge - Actual outcome: Dead at 30 days; Group 1: 156/1438, Group 2: 189/1438; Risk of bias: High; Indirectness of outcome: No indirectness</p> <p>Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge - Actual outcome: Any DVT at 30 days; Group 1: 233/1438, Group 2: 304/1438; Risk of bias: High; Indirectness of outcome: No indirectness</p> <p>Protocol outcome 3: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge - Actual outcome: All confirmed pulmonary embolism at 30 days; Group 1: 29/1438, Group 2: 35/1438; Risk of bias: Very high; Indirectness of outcome: No indirectness</p> <p>Protocol outcome 4: Technical complications of mechanical interventions at up to 90 days from hospital discharge - Actual outcome: Skin breaks at 30 days; Group 1: 44/1438, Group 2: 20/1438; Risk of bias: Very high; Indirectness of outcome: No indirectness</p> <p>Protocol outcome 5: DVT (symptomatic) - Actual outcome: Symptomatic DVT (proximal or calf) at 30 days; Group 1: 66/1438, Group 2: 90/1438;</p> <p>Protocol outcome 6: DVT (proximal) - Actual outcome: Proximal DVT at 30 days; Group 1: 122/1438, Group 2: 174/1438;</p>	
Protocol outcomes not reported by the study	Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood;

Study	CLOTS 3 trial: Clots (clots in legs or stockings after stroke) trials collaboration 2013 ⁸²
	leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge; Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at up to 90 days from hospital discharge;

Study	Duke 1983 ⁸⁹
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=65)
Countries and setting	Conducted in Canada; Setting: Two hospitals (names not reported)
Line of therapy	Not applicable
Duration of study	Intervention time: 7 days
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: DVT (symptomatic and asymptomatic): defined by fibrinogen leg scanning
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Patients with "partial stable stroke". Presence of focal cerebral neurological deficit, of presumed vascular origin; minor or moderate severity (≥ 5 MRC units combined upper and lower limb proximal strength on weaker side); deficit began within 48 hours of presentation; no alteration of consciousness.
Exclusion criteria	Sustained hypertension (diastolic blood pressure >110 mmHg); clear evidence of cardiac embolism; haemorrhagic diathesis; active peptic ulcer within 2 years; patients on anticoagulant therapy; fever $> 38.5^\circ\text{C}$; CT scan incompatible with cerebral infarction; >200 RBC/ml in CSF; pre-existing neurological deficit
Recruitment/selection of patients	14-month period (dates not reported). Patients were randomised within 48 hours onset of stroke.
Age, gender and ethnicity	Age: Not reported. Gender (M:F): Not reported. Ethnicity: Not reported
Further population details	1. BMI: Not applicable 2. Renal impairment: Not applicable 3. Type of stroke: Not applicable
Indirectness of population	No indirectness
Interventions	(n=35) Intervention 1: Unfractionated heparin - Unfractionated heparin (low dose, administered subcutaneously). UFH, 5000IU was subcutaneously administered every 8 hours (three times daily). Duration 7 days. Concurrent

Study	Duke 1983⁸⁹
	medication/care: n/a. Indirectness: No indirectness (n=30) Intervention 2: No treatment - Placebo. Placebo, no further details reported. Duration 7 days. Concurrent medication/care: n/a. Indirectness: No indirectness
Funding	Academic or government funding (Supported by grants from Ontario and Canadian Heart Foundations)
RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: UNFRACTIONATED HEPARIN versus PLACEBO	
<p>Protocol outcome 1: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge - Actual outcome: DVT (symptomatic and asymptomatic) at 7 days; Group 1: 0/35, Group 2: 3/30 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p>	
Protocol outcomes not reported by the study	All-cause mortality at up to 90 days from hospital discharge; Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge; Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge; Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at up to 90 days from hospital discharge; Technical complications of mechanical interventions at up to 90 days from hospital discharge;

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Diener et al.,	Patient group: Acute ischaemic stroke	Group 1	All-cause mortality	Treatment period Group1: 7/273	Funding:

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
<p>2006⁸⁵ (PROTECT trial)</p> <p>Country of study: EU</p> <p>Study design: RCT, double blinded, multicentre</p> <p>List who was masked to interventions : Investigators and patients. End point committee</p> <p>Evidence level: 1+</p> <p>Duration of follow-up: 3 months</p>	<p>Setting: 37 centres in EU, most patients treated in stroke units</p> <p>Inclusion criteria: Age 18 to 85 years with clinical diagnosis of ischaemic stroke NIHSS score of 4 to 30, with mild to severe paresis of a leg.</p> <p>Exclusion criteria: Indication of thrombolysis No availability of CT scan Ct documented signs of intracerebral or subarachnoid bleeding Current bleeding or thrombosis History of bleeding or thrombosis within the past 12 months Recurrent gastrointestinal ulcerations Post thrombotic syndrome Acute or unstable cardiovascular disease Major infection Currently active, recurrent or metastatic cancer within the last 5 years Platelet count <75000/microL Severe diabetic retinopathy Estimated body weight <55jg Pregnant or breast feeding</p> <p>All patients N: 545</p>	<p>UFH 5000IU, 3 times daily, subcutaneously Start: 15.4±6.2</p> <p>Group 2 Certoparin 3000U anti Xa once daily, subcutaneously, plus 2 placebo injections Start: 15.4±6.2</p> <p>All treatment started within 24 hours of stroke symptom onset Duration: 12-16 days</p> <p>Additional non-comparative prophylaxis: Ticlopidine, clopidogrel, or aspirin alone (≤325mg daily) or in combination with dipyramidole allowed</p>	<p>(confirmed by: Autopsy whenever allowed. Stroke progression as cause of death: n=4 in certoparin, n=3 in UFH during treatment period. At 3 month follow up, n=3 in certoparin, n=1 in UFH)</p> <p>Fatal pulmonary embolism (confirmed by: Not autopsy performed. Suspected, because D-dimer positive but no signs of cardiac aetiology found)</p> <p>Symptomatic pulmonary embolism (confirmed by: no clinically suspected PE)</p> <p>Proximal DVT,</p>	<p>Group 2: 7/ 272 P value: 1.0</p> <p>Between treatment period and 3 month follow up: Group1: 8/273 Group 2: 14/ 272 P value: 0.2</p> <p>Total: up to 3 month follow up: Group1: 15/273 Group 2: 21/ 272 P value: 0.31 [p values calculated by team at NCCAC suing Fisher's exact test]</p> <p>Group1: 1/273 Group 2: 0/272 P value: 1.0 [p values calculated by team at NCCAC suing Fisher's exact test]</p> <p>Group1: 1/273 Group 2: 0/272 P value: 1.0 [p values calculated by team at NCCAC suing Fisher's exact test]</p> <p>Group1: 23/273</p>	<p>Novartis</p> <p>Limitations: Percentages of patients with concurrent antiplatelet agents were not reported Seemed to have involved both stroke unit centres and non-stroke unit centres-outcomes not compared</p> <p>Outcomes not reported: Calf DVT, PTS, Pulmonary hypertension, QoL, LOS</p> <p>Additional outcomes reported: Causes of death</p> <p>Notes: Patients screened for DVT at baseline</p>

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	<p>Group 1</p> <p>No. randomised: 273</p> <p>Per protocol: 248</p> <p>M/F: 164/109</p> <p>Age (mean +SD): 67.3 +10.6</p> <p>Additional characteristics:</p> <ul style="list-style-type: none"> • Body Mass Index: 27.1±3.9 • NIHSS: 8.2±3.6 • Leg paresis:2.0±0.9 <ul style="list-style-type: none"> ○ Grade 1:91 ○ Grade 2:110 ○ Grade 3:55 ○ Grade 4:17 • Infarction in carotid territory:251 • Previous stroke:37 • Previous transient ischaemic attack: 7 • Hypertension:207 • Previous cardiac failure:8 • Previous myocardial infarction:15 • Diabetes mellitus:71 • Hyperlipidaemia: 48 • Previous severe respiratory disorder:13 • Previous thrombosis:9 <p>Group 2</p> <p>No. randomised: 272</p> <p>Age (mean +SD): 66.3 +10.9</p> <p>Per protocol: 242</p>	<p>Aspirin</p> <p>Group 1:78.4%</p> <p>Group 2:77.2%</p> <p>Aspirin + dipyramidole</p> <p>Group 1:11.7%</p> <p>Group 2:17.6%</p> <p>Clopidogrel</p> <p>Group 1: 17.6%</p> <p>Group 2: 16.9%</p> <p>Ticlopidine</p> <p>Group 1: 4.4%</p> <p>Group 2: 2.9%</p> <p>No mention of mechanical prophylaxis methods</p>	<p>asymptomatic or symptomatic (confirmed by: Duplex and compression ultrasonography. Routinely scanned at Days 3-4, 7-8, 12-16 and when clinical symptoms occurred)</p> <p>Fatal bleeding (description: 1 intracranial bleeding was confirmed by autopsy-during treatment period. At 3 month follow up, 1 severe bleeding in the UFH group was confirmed by autopsy. The bleeding type of the LMWH group was not reported)</p>	<p>Group 2: 18/272</p> <p>P value: 0.52</p> <p>[p values calculated by team at NCCAC suing Fisher’s exact test]</p> <p>Note: all were reported as proximal DVT</p> <p>During treatment period</p> <p>Group1: 1/ 273</p> <p>Group 2: 0/ 272</p> <p>P value:</p> <p>Between treatment period and 3 month follow up:</p> <p>Group1: 1/ 273</p> <p>Group 2: 1/272</p> <p>P value:</p> <p>[p values calculated by team at NCCAC suing Fisher’s exact test]</p>	<p>with duplex and compression ultrasonography.</p>

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	<p>M/F: 149/123</p> <p>Additional characteristics:</p> <ul style="list-style-type: none"> • Body Mass Index: 27.4±4.6 • NIHSS:8.7±4.0 • Leg paresis: 2.1±0.9 <ul style="list-style-type: none"> ○ Grade 1:86 ○ Grade 2:108 ○ Grade 3:55 ○ Grade 4:23 • Infarction in carotid territory:256 • Previous stroke:42 • Previous transient ischaemic attack:10 • Hypertension:210 • Previous cardiac failure:21 • Previous myocardial infarction:23 • Diabetes mellitus:81 • Hyperlipidaemia: 51 • Previous severe respiratory disorder:20 • Previous thrombosis:6 				
			<p>Major bleeding at 16 days (description: intracranial (only if parenchymal), retroperitoneal, gastrointestinal resulted in death, clinically overt and led to transfusion of ≥U of packed RBC/whole blood, or Hb fall of ≥2g/dL)</p>	<p>Group1: 5/273 Group 2: 3/272 P value: 0.73 [p values calculated by team at NCCAC using Fisher's exact test]</p>	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
			Neurological bleeding CT scan performed at baseline, Days 7 to 8 routinely and anytime in the case of clinical suspicion of intracranial haemorrhage	Group1: 3/273 Group 2: 2/272 P value: 1.0 [p values calculated by team at NCCAC using Fisher's exact test]	
			Upper GI bleeding	Group1: 2/273 Group 2: 0/272 P value: 0.5	
			Minor bleeding (description: bleedings which did not meet classification of major bleeding)	Group1: 5/273 Group 2: 7/ 272 P value: 0.58 [p values calculated by team at NCCAC using Fisher's exact test]	
			Heparin induced thrombocytopenia (suspected cases, not measurement of antibodies performed to confirm)	Group1: 2/273 Group 2: 1/ 272 P value: 1.0 [p values calculated by team at NCCAC using Fisher's exact test]	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Hillbom et al., 2002 ¹⁴⁷	Patient group: Acute ischaemic stroke	Group 1 Unfractionated heparin, 5000IU, subcutaneously, 8 hourly.	All-cause mortality 16/17 patients died of stroke within treatment period, 22/32 during the	Within treatment period (10±2 days) Group1: 8/106 Group 2: 9/106 P value: 1.00	Funding: Aventis Pharma Limitations:
Country of study:	Setting:				

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Finland	7 centres in Finland. Inpatient	Group 2 Enoxaparin (Clexane), 40mg, subcutaneously, once daily. 2 placebo injections to maintain 8 hourly interval blinding.	follow up period	[Calculated by NCC-AC team using Fisher's Exact test] At 3 month follow up Group1: 28/106 Group 2: 21/106 P value: 0.33 [Calculated by NCC-AC team using Fisher's Exact test]	Sample size of 400 was planned, but only 212 recruited and 165 patients (81 in enoxaparin and 84 in UFH) group completed study
Study design: Multicentre, double blinded, randomised study	Inclusion criteria: Acute ischaemic stroke, defined as acute onset of paralysis lasting at least 24 hours and necessitating bed rest Confirmed by CT scan	In both arms Start time: within 48 hours of stroke onset End time: 10±2 days later, or until discharge	Fatal pulmonary embolism (confirmed by: autopsy) Of all the patients who died, 14 had autopsy. 4 in UFH and 2 in enoxaparin group had PE	Group1: 2/106 Group 2: 1/106 P value: 0.62 [Calculated by NCC-AC team using Fisher's Exact test]	NO mention about mechanical prophylaxis methods Significantly more obese patients in UFH group and higher percentages of diabetic patients Outcomes not reported: Upper GI bleeding
List who was masked to interventions: Double blinded study	Exclusion criteria: Unconscious- Glasgow Coma Scale <9 Immobilised before onset of stroke Evidence of haemorrhagic stroke Stroke thought to be cardioembolic in origin History of DVT, PE myocardial infraction, recent neurosurgery (within the last 3 months) History of subarachnoid haemorrhage, gastrointestinal bleeding or active peptic ulceration	Additional non-comparative prophylaxis: Concomitant treatment with anticoagulant or antithrombotic therapy, NSAIDS, aspirin or other antiplatelet therapy, or any other treatment which could	Symptomatic pulmonary embolism (ventilation perfusion scan and pO2 when clinically indicated)	Group1: 4/106 Group 2: 2/106 P value: 0.68 [Calculated by NCC-AC team using Fisher's Exact test]	Additional outcomes reported: Haemorrhagic transformation of the brain infarction
Evidence level: 1+	Hypersensitivity to heparin, LMWH or radio opaque contrast media Severe heart failure, uncontrolled hypertension, hepatic or renal impairment, malignant disease, endocarditis or haemorrhagic diathesis Current drug abuse Requiring anticoagulant or antiplatelet therapy Pregnant or lactating Abnormal blood clotting tests Treatment would not be started with 48		Symptomatic DVT (confirmed by: unilateral phlebography within 24h of clinical indication)	Group1: 3/ 72 Group 2: 1/ 76 P value: 0.36 [Calculated by NCC-AC team using Fisher's Exact test]	
Duration of follow-up: 3 months			DVT, asymptomatic or symptomatic (confirmed by: as in symptomatic DVT, and bilateral ascending phlebography at day	Group1: 24/106 Group 2: 14/106 P value: 0.17 (# see notes) [Calculated by NCC-AC team using Fisher's Exact test]	Notes:

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	<p>hours of stroke onset</p> <p>All patients N: 212</p> <p>Group 1</p> <p>No. randomised: 106</p> <p>Efficacy population: 72</p> <p>No. of dropouts: 0</p> <p>M/F: 59/47</p> <p>Age: 69±10</p> <p>Weight (kg): 77±16</p> <p>Risk factors for DVT: Elderly (>70 years):48/106 Immobilised: 104/106</p> <p>*Obesity: 28/106</p> <p>*Alcoholism: 4/106 Varicose veins: 10/106</p> <p>History of DVT: 3/106</p> <p>Risk factors for Stroke: Hypertension: 48/106 Current smoking: 25/106</p> <p>*Diabetes mellitus: 21/106</p> <p>History of myocardial infarction: 5/106</p> <p>History of stroke or TIA: 5/106</p> <p>Group 2</p> <p>No. randomised: 106</p> <p>Efficacy population: 76 No. of dropouts: 0</p> <p>M/F: 68/38</p> <p>Age: 68±12</p> <p>Weight (kg):73±13</p>	<p>influence interpretation of study data was prohibited.</p> <p>No mention about mechanical prophylaxis methods</p>	<p>10±2 or the last assessment, and autopsy)</p> <p>Thigh (Proximal) DVT(confirmed by: as in DVT)</p> <p>Calf (Distal)DVT (confirmed by: As in DVT)</p>	<p>Group1: 4/72</p> <p>Group 2: 2/76</p> <p>P value: 0.43</p> <p>[Calculated by NCC-AC team using Fisher’s Exact test]</p> <p>Group1: 3/72</p> <p>Group 2: 1/76</p> <p>P value: 0.36</p> <p>[Calculated by NCC-AC team using Fisher’s Exact test]</p>	<p># The number of DVT cases reported was 26/106 in the UFH group and 17/106 in the LMWH group respectively. However, 2 cases in the UFH group and 3 in the LMWH group were detected after the study period. These cases were excluded.</p> <p>Patients were analysed using both randomised number, and the efficacy subgroup</p>

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	<p>Risk factors for DVT: Elderly (>70 years):53/106 Immobilised: 101 /106 *Obesity: 10/106 *Alcoholism: 12/106 Varicose veins: 10/106 History of DVT:3/106</p> <p>Risk factors for Stroke: Hypertension: 45/106 Current smoking: 28/106 *Diabetes mellitus: 12/106 History of myocardial infarction: 7/106 History of stroke or TIA: 8/106</p> <p>* Obesity (p=0.002) , diabetes (p=0.13), alcoholism (p=0.066) [Values calculated by NCCAC staff using Fisher’s exact test]</p>				
			<p>Fatal bleeding (description: autopsy)</p> <p>Major bleeding (description: intracranial haemorrhage)</p> <p>Neurological bleeding (intracerebral haemorrhage) confirmed by cerebral CT scan, within 24 hours of clinical indication and within</p>	<p>Of the patients who died, 14 had autopsy. 1 in enoxaparin group had cerebral haemorrhage</p> <p>Group1: 0/106 Group 2: 1/106 P value:</p> <p>Group1: 0/106 Group 2: 1/106 P value: 1.0 [Calculated by NCC-AC team using Fisher’s Exact test]</p>	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
			24 hours of the final administration		
			Neurological bleeding (Haemorrhagic transformation of the brain infarction) Confirmed by CT scan within 24 hours of final administration	Group1: 20/86 Group 2: 14/81 P value: 0.44 [Calculated by NCC-AC team using Fisher's Exact test]	
			Minor bleeding (description: included 3 in enoxaparin and 4 in UFH with hematomas>5cm in diameter at injection site)	Group1: 6/106 Group 2: 5/106 P value: 1.00 [Calculated by NCC-AC team using Fisher's Exact test]	

Study	Lacut 2005 ¹⁸²
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=151)
Countries and setting	Conducted in France; Setting: Brest University Hospital, France
Line of therapy	Not applicable
Duration of study	Follow up (post intervention): 10 days
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: DVT (symptomatic and asymptomatic): confirmed by compression ultrasonography
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Aged over 18 years, traumatic or spontaneous intracerebral haemorrhage with or without subarachnoidal haemorrhage, and written informed consent given by the patient or relative

Study	Lacut 2005 ¹⁸²
Exclusion criteria	Extra- or subdural haematomas, traumatic intracerebral haemorrhage due to polytrauma including the lower limbs, haemorrhagic transformation of ischemic infarct and vasculitis (when the diagnostic was established), patients or relative refusal, a deep vein thrombosis (DVT) within the previous 3 months, a lower-limb arteriopathy with an ankle-to-arm systolic pressure index <0.70, a venous graft, a wound in the lower limb related either to a vascular disease (ulcer) or a trauma, a "do not resuscitate" order, and a >24 hour delay since hospital admission.
Recruitment/selection of patients	Between February 2002 and December 2003
Age, gender and ethnicity	Age - Mean (SD): 62.8 (13.7) years. Gender (M:F): 1.4/1. Ethnicity: Not reported
Further population details	1. BMI : Not applicable 2. Renal impairment: Not applicable 3. Type of stroke: Not applicable
Indirectness of population	No indirectness
Interventions	<p>(n=74) Intervention 1: Intermittent pneumatic compression devices - Full leg. IPCD (length not specified) in combination with anti-embolism stockings (length not specified). The graded elastic stockings were put on as soon as patients were admitted to standard care. The compression device (three chambers) was applied sequentially for 11 seconds with pressures of 45, 40 and 30 mmHg at the ankle, calf, and thigh. Duration: Duration is unclear. Concurrent medication/care: N/A. Indirectness: No indirectness</p> <p>(n=77) Intervention 2: Anti-embolism stockings - Mixed above/below knee. Patients received anti-embolism stocking (length not specified). The graded elastic stockings were put on as soon as patients were admitted to standard care. Duration: Duration is unclear. Concurrent medication/care: N/A. Indirectness: No indirectness</p>
Funding	Equipment / drugs provided by industry (Tyco Healthcare France provided all of the mechanical devices (elastic graded stockings and intermittent pneumatic compression system.)

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: IPCD + GRADED ELASTIC STOCKINGS versus GRADED ELASTIC STOCKINGS

Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge

- Actual outcome: All-cause mortality at time-point not reported; Group 1: 15/74, Group 2: 24/77

Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 0, Reason: n/a; Group 2 Number missing: 0, Reason: n/a

Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge

- Actual outcome: DVT (symptomatic and asymptomatic) at time-point reported; Group 1: 3/64, Group 2: 11/69

Study	Lacut 2005¹⁸²
Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 10, Reason: Death; Group 2 Number missing: 8, Reason: Death	
Protocol outcomes not reported by the study	Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge; Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge; Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at up to 90 days from hospital discharge; Technical complications of mechanical interventions at up to 90 days from hospital discharge;

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
McCarthy et al., 1977 ²²⁰	Patient group: Stroke Patients	Group 1 Unfractionated Heparin (calcium)	All-cause mortality	Group1: 3/16 Group 2: 5/16 P value: 0.685*	Funding: No information provided
Country of study: UK	Setting: Department of Geriatric Medicine Inclusion criteria: Diagnosis of stroke within previous 48 hours	Start time: Unclear Duration: 14 days	DVT, asymptomatic or symptomatic (confirmed by: Radiofibrinogen uptake test)	Group1: 2/16 Group 2: 14/16 P value: 0.001*	
Study design: RCT	Exclusion criteria: • Blood in the cerebrospinal fluid (defined as 50 red cells per high-power field in tube 3 of a lumbar puncture)	Dose and frequency: 5000U subcutaneously every 8 hours			Limitations: No information is provided about the method of randomisation or allocation concealment. Trial is not blinded and few baseline
List who was masked to interventions: No one	• Sustained diastolic blood	Group 2 No heparin			

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
<p>Evidence level: 1+</p> <p>Duration of follow-up: 14 days for DVT 28 days for Death</p>	<p>pressure higher than 120mmHg on admission or grades 3 or 4 hypertensive retinopathy; History of active peptic ulceration; History of subarachnoid haemorrhage; Allergy to iodine;</p> <p>Goitre or thyrotoxicosis; Bleeding diathesis; Recent Myocardial infarction; or</p> <p>All patients N: 32 Age (mean): Gp1: 78.9 (S.D 8.0) Gp2: 78.2 (SD 7.4) M/F: 11:21 Additional risk factors: Mean Severity: Gp1: 4.3 ± 1.8 Gp2: 3.4 ± 21.6</p> <p>Group 1 No. randomised: 16 No. of dropouts: 0</p> <p>Group 2 No. randomised: 16 No. of dropouts: 0</p>	<p>Additional non-comparative prophylaxis: None listed</p>			<p>characteristics are provided. Pilot study for MCCARTHY1986</p> <p>Outcomes not reported: Fatal PE, Symptomatic PE, Symptomatic DVT, Bleeding, Heparin induced thrombocytopenia, , Pulmonary hypertension, Post thrombotic syndrome, quality of life, length of stay.</p> <p>Additional outcomes reported: None</p> <p>Notes: * Calculated by NCC team using Fisher Exact Test.</p>

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
<p>McCarthy & Turner, 1986²¹⁹</p> <p>Country of study: UK</p> <p>Study design: RCT</p> <p>List who was masked to interventions: No one</p> <p>Evidence level: 1+</p> <p>Duration of follow-up: 14 days for DVT 12 weeks for death</p>	<p>Patient group: Stroke Patients</p> <p>Setting: Department of Geriatric Medicine</p> <p>Inclusion criteria: Diagnosis of stroke within previous 48 hours</p> <p>Exclusion criteria:</p> <ul style="list-style-type: none"> Sustained diastolic blood pressure higher than 120mmHg on admission or grades 3 or 4 hypertensive retinopathy; History of active peptic ulceration; History of subarachnoid haemorrhage; <p>Allergy to iodine; Goitre or thyrotoxicosis; Bleeding diathesis;</p> <p>Recent Myocardial infarction; or</p> <ul style="list-style-type: none"> Diagnosed malignancy <p>All patients N: 305</p>	<p>Group 1 Unfractionated Heparin (calcium)</p> <p>Start time: Unclear Duration: 14 days</p> <p>Dose and frequency: 5000U subcutaneously every 8 hours</p> <p>Group 2 No heparin</p> <p>Additional non-comparative prophylaxis: None listed</p>	<p>All-cause mortality</p> <p>DVT, asymptomatic or symptomatic (confirmed by: Radiofibrinogen uptake test)</p>	<p>Group1: 31/144 Group 2: 53/161 P value: 0.029*</p> <p>Group1: 32/144 Group 2: 117/161 P value: <0.001*</p>	<p>Funding: Chest Heart and Stroke association, Oxford locally organised research funds and Labaz & Evans biologicals</p> <p>Limitations: No information is provided about the method of randomisation or allocation concealment. Trial is not blinded and few baseline characteristics are provided.</p> <p>Outcomes not</p>

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	<p>Age (mean): 76 (S.D 8.1) M/F: 132:173 Additional risk factors: Mean Severity: Gp1: 4.4 ± 2.38 Gp2: 4.8 ± 2.65 Group 1 No. randomised: 144 No. of dropouts: Unclear</p> <p>Group 2 No. randomised: 161 No. of dropouts: Unclear</p>				<p>reported: Fatal PE, Symptomatic PE, Symptomatic DVT, Bleeding, Heparin induced thrombocytopenia, Pulmonary hypertension, Post thrombotic syndrome, quality of life, length of stay.</p> <p>Additional outcomes reported: Pulmonary embolism at post mortem (not fatal)</p>

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Muir et al., 2000 ²³²	<p>Patient group: Stroke patients within 72 hours of stroke onset</p> <p>Setting: Acute stroke unit</p> <p>Inclusion criteria:</p> <ul style="list-style-type: none"> Clinically diagnosed acute stroke not independently ambulant within 24 hours of admission Leg weakness of National Institutes of Health Stroke Scale (NIHSS) 1 <p>Exclusion criteria: Coma patients Life threatening intercurrent illness Critical lower-limb ischaemia Severe dermatological conditions</p> <p>All patients N: 97 Age (mean): 76 M/F: NR Additional risk factors: For VTE Hypertension: 43/97 Ischaemic heart disease: 29/97 Previous stroke or TIA: 27/97 Smoker: 28/97 Diabetes: 8/97 Personal history of VTE: 4/97</p>	<p>Group 1 Standard care + leg length graduated compression stockings. Either Kendall TED (37 patients) or Brevet TX (28 patients). Compression profiles not reported. Start time: NR End time: NR Duration: 7 days</p> <p>Group 2 Standard care includes CT scanning or MRI, aspirin, IV fluids or those unable to swallow and early mobilisation within 24 hours of admission. Start time: NR End time: NR Duration: 7 days</p> <p>Additional non-comparative</p>	<p>All-cause mortality (study does not report how outcome was confirmed)</p> <p>Pulmonary embolism, asymptomatic or symptomatic (study does not report how outcome was confirmed)</p> <p>DVT, asymptomatic or symptomatic detected within the first seven days (confirmed by Acuson 128 colour-flow Doppler ultrasound with motion discrimination software)</p>	<p>Group1: 9/65 Group 2: 4/32 P value: NR in study but calculated by NCC- AC as p = 1.00 (Fishers exact test)</p> <p>Group1: 0/65 Group 2: 0/32 P value</p> <p>Group1: 7/65 Group 2: 7/32 P value: NR in study but calculated by NCC- AC as p = 0.21 (Fishers exact test)</p>	<p>Funding: Stroke Association</p> <p>Outcomes not reported: Fatal PE Symptomatic PE Symptomatic DVT Thigh DVT Calf DVT Fatal Bleeding Major Bleeding Neurological Bleeding Upper GI Bleeding Minor Bleeding Heparin induced thrombocytopenia Post thrombotic syndrome Pulmonary hypertension Quality of life Length of stay</p> <p>Additional outcomes reported: Proximal DVT Group1: 3/65</p>

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	<p>Familial history of VTE: 1/97</p> <p>Stroke categories: Oxford Community Stroke Project Scale (OCSP)</p> <p>Total Anterior Circulation Stroke: 29/97 Partial Anterior Circulation Stroke: 31/97 Lacunar Circulation Stroke: 21/97 Posterior Circulation Stroke: 8/97</p> <p>Group 1</p> <p>No. randomised: 65 (37 Kendall TEDs + 28 Brevet TX)</p> <p>No. of dropouts: 19 (29%) [11 TX and 8 in TED]</p> <p>3 patients were intolerant to stockings 4 withdrew for unstated reasons</p> <p>2 protocol violations where stockings were not worn as intended</p> <p>Age (mean): 76 (TED) 73 (TX)</p> <p>M/F: NR</p> <p>Additional risk factors:</p> <p>For VTE</p> <p>Hypertension: 15/28 (TX) 14/37 (TED)</p> <p>Ischaemic heart disease: 9/28 (TX) 11/37 (TED)</p> <p>Previous stroke or TIA: 10/28 (TX) 8/37 (TED)</p> <p>Smoker: 10/28 (TX) 9/37 (TED)</p>	<p>prophylaxis:</p> <p>Aspirin – dose not stated as standard stroke treatment</p>			<p>Group 2: 2/32</p> <p>DVT at 1st examination</p> <p>DVT at 2nd examination</p> <p>Notes:</p> <p>Computer generated randomisation with numbers placed in sealed envelopes (opacity of envelopes was not mentioned so possibly introducing selection bias).</p> <p>Power calculation assuming 50% DVT incidence and 50% relative risk reduction. The study had 80% power to detect this difference at 5% significance with 100 patients randomised in a 2:1 ratio of stockings to standard treatment.</p>

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	<p>Diabetes: 2/28 (TX) 3/37 (TED)</p> <p>Personal history of VTE: 1/28 (TX) 3/37 (TED)</p> <p>Familial history of VTE: 1/28 (TX) 0/37 (TED)</p> <p>Stroke categories: Oxford Community Stroke Project Scale (OCSP)</p> <p>Total Anterior Circulation Stroke: 9/28 (TX) 9/37 (TED)</p> <p>Partial Anterior Circulation Stroke: 7/28 (TX) 13/37 (TED)</p> <p>Lacunar Circulation Stroke: 6/28 (TX) 10/37 (TED)</p> <p>Posterior Circulation Stroke: 4/28 (TX) 2/37 (TED)</p> <p>Group 2</p> <p>No. randomised: 32</p> <p>No. of dropouts: 6 (19%)</p> <p>Age (mean): 76</p> <p>M/F: NR</p> <p>Additional risk factors:</p> <p>For VTE</p> <p>Hypertension: 14/32</p> <p>Ischaemic heart disease: 9/32</p> <p>Previous stroke or TIA: 9/32</p> <p>Smoker: 9/32 Diabetes: 3/32</p> <p>Personal history of VTE: 0/32</p> <p>Familial history of VTE: 0/32</p>				<p>1070 screened for potential inclusion, 953 (89%) excluded and 19 (2%) non-compliant. Reasons for exclusion: mobile / discharged 537, amputee 12, consent refused or unobtainable 77, coma / poor prognosis 66, peripheral vascular disease 4, dermatological (incl. MRSA) 19, non-stroke diagnosis 20, other clinical trial 59, technical / admin 17, already using stockings 34 and other 108.</p> <p>Of the 98 recruited one had „clinically manifest DVT during the study period and was not included in the results.</p>

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	<p>Stroke categories: Oxford Community Stroke Project Scale (OCSP)</p> <p>Total Anterior Circulation Stroke: 11/32 Partial Anterior Circulation Stroke: 11/32 Lacunar Circulation Stroke: 5/32 Posterior Circulation Stroke: 2/32</p> <p>No significant difference in any demographic, stroke characteristics or dropout rates between the two groups.</p>				

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
<p>Pambianco et al., 1995²⁵⁰</p> <p>Country of study: USA</p> <p>Study design: RCT</p> <p>List who was masked to interventions: No one</p>	<p>Patient group: Stroke patients (not necessarily newly defined)</p> <p>Setting: Rehabilitation centre</p> <p>Inclusion criteria: All cases with a diagnosis of non-haemorrhagic stroke identified by CT scan in the referring hospital and who have a paralysed or severely weakened lower limb.</p> <p>Exclusion criteria: Patients on anticoagulation therapy</p>	<p>Group 1 No prophylaxis</p> <p>Group 2 Standard Sodium Heparin (no brand name) Start time: 1st full day at centre End time: day 28 Duration: 28 days or discharge</p> <p>Dose and frequency: 5,000U every 8 hours, adjusted in 500U</p>	<p>All-cause mortality</p> <p>DVT, asymptomatic or symptomatic (screened for by: B-mode 2-dimensional imaging and pulsed doppler ultrasound at or above the popliteal vein twice a week until the completion of the study or discharge.)</p>	<p>Group 1: 0/115 Group 2: 0/120 Group 3: 0/117</p> <p>Group1: 6/115 (completed study) Group 2: 5/120 (completed study) Group 3: 8/117 (completed study) P value: NR</p> <p>Grp 1 v Grp 2 = 0.76 Grp 1 v Grp 3 = 0.78 Grp 2 v Grp 3 = 0.41</p> <p>2-sided Fisher's exact test calculated by NCC- AC using ITT original numbers randomised</p>	<p>Funding: US department of Education</p> <p>Limitations: No details of randomisation provided No blinding of analysts not mentioned High patient dropout rates for heparin and IPCD group. Outcomes not reported: All-cause</p>

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
<p>Evidence level: 1+ /- ?</p> <p>Duration of follow-up: 28 days</p>	<p>haemorrhagic stroke more than 10 weeks after stroke active cancer „other medical contraindications“ including dementia, amputation, stroke not identifying specific area Contraindications to heparin diabetic ulcers.</p> <p>All patients N: 360 randomised – overall baseline data provided for only those completing study Age (mean): 72.2 ± 9.5 M/F: 41/59 Additional risk factors: BMI: 26.1 ± 5.7 Time from stroke to admission: 24.2 days</p> <p>Group 1: No prophylaxis No. randomised: 115 No. of dropouts: 9 (8%)</p> <p>Group 2 (Heparin) No. randomised: 120 No. of dropouts: 30 (25%)</p> <p>Group 3 (IPCD) No. randomised: 117</p>	<p>increments to maintain daily PTT between 30.0 – 39.9. Maximum dose 10,000U every 8 hours</p> <p>Group 3 IPCD – Anti-thrombic pump (double lined stoking containing inflatable bladder) Start time: 1st full day at centre End time: day 28 Duration: 8 hours each night</p> <p>Length and compression profile: below knee.</p> <p>Group 4 Mederomic Functional Electrical Stimulation Device</p>			<p>mortality, PE (any type), Symptomatic DVT, Calf DVT, Thigh DVT, Bleeding (any type), HIT, PTS, Pulmonary Hyper tension, QoL, LoS</p> <p>Additional outcomes reported: Adverse events for heparin included: echymotic area over abdomen and areas distal to injection site. 10 point decrease in haematocrit level; nausea and vomiting with onset of heparin therapy, bleeding from the ear, haematochezia, haemepositive stools, bleeding around tracheal stoma, thrombocytopenia Adverse events for IPCD,</p>

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	<p>No. of dropouts: 26 (22%)</p> <p>Group 4 (Functional Electrical Simulation) No. randomised: 8 No. of dropouts: 6 (75%) Study arm discontinued</p>	<p>(discontinued due to adverse events)</p> <p>Additional non-comparative prophylaxis: All patients received bilateral below knee stockings (no compression).</p>			<p>bilateral skin changes</p> <p>Notes: High dropout rate in IPCD due to disruption of sleep.</p> <p>21 patients were transferred to acute care for complications unrelated to study treatment</p>

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
<p>Prasad et al., 1982²⁶⁷</p> <p>Country of study: UK</p> <p>Study design: RCT</p> <p>List who was masked to interventions:</p>	<p>Patient group: Stroke</p> <p>Setting: Geriatric ward</p> <p>Inclusion criteria:</p> <ul style="list-style-type: none"> All patients admitted for acute stroke within 72 hours Anyone with weakness up to 2/6 motor power (MRC grade) in one or both limbs on either side <p>Exclusion criteria:</p> <ul style="list-style-type: none"> Patients in a coma or with another clinically unacceptable 	<p>Group 1</p> <p>Intermittent pneumatic calf compression with Flowtron legging at 40 mmHg to both legs, each cycle lasts 4 minutes.</p> <p>Treatment continuous for 24 hours then for periods of 3 hours, 3/day for next 9 days.</p>	<p>DVT, asymptomatic or symptomatic (screened for by daily FUT scanning)</p>	<p>Group1: 6/13 Group 2: 6/13 P value: NR</p>	<p>Funding: Not reported</p> <p>Limitations: Randomisation method not explained Allocation concealment not mentioned. Blinding of investigators not mentioned. Outcomes not reported: All-cause mortality Fatal PE Symptomatic PE Symptomatic or asymptomatic</p>

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
<p>None mentioned</p> <p>Evidence level: 1+</p> <p>Duration of follow-up: 10 days</p>	<p>condition</p> <p>All patients N: 26 Age (mean): NR Age group 1 = 78 ± 4 Age group 2 = 80 ± 6</p> <p>M/F: 12/14 Additional risk factors: NR</p> <p>Group 1 No. randomised: 13 No. of dropouts: 2 patients died but data from autopsy were included</p> <p>Group 2 No. randomised: 13 No. of dropouts: 0</p>	<p>Duration: 10 days</p> <p>Group 2 No intervention</p> <p>Additional non-comparative prophylaxis: Not Applicable</p>			<p>PE</p> <p>Symptomatic DVT Thigh DVT, Calf DVT Fatal bleeding, Major bleeding, Neurological bleeding, Upper GI bleeding, Minor bleeding</p> <p>HIT, Post thrombotic syndrome, Pulmonary hypertension</p> <p>Quality of life, Length of Stay</p>

Study	Prins 1989 ²⁶⁸
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=60)
Countries and setting	Conducted in Netherlands; Setting: Department of Medicine, Bergweg Municipal Hospital, Rotterdam, The Netherlands
Line of therapy	Not applicable
Duration of study	Intervention time: 14 days
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: DVT (symptomatic and asymptomatic): confirmed by fibrinogen scan and unilateral phlebography

Study	Prins 1989 ²⁶⁸
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Patients were only eligible if they entered within 72 hours of onset of symptoms, and were neither deeply comatose nor needing or using other anticoagulant therapy.
Exclusion criteria	No further details reported
Recruitment/selection of patients	Between June 1984 to January 1986
Age, gender and ethnicity	Age - Median (range): 76 years. Gender (M:F): 1/1. Ethnicity: Not reported
Further population details	1. BMI : Not applicable 2. Renal impairment: Not applicable 3. Type of stroke: Ischemic
Indirectness of population	No indirectness
Interventions	(n=30) Intervention 1: Low molecular weight heparin (licensed in UK) - Dalteparin (1,250 units once daily - 5,000 units twice daily). Fragmin (dalteparin), 2500IU twice daily, subcutaneously administered. Duration 14 days. Concurrent medication/care: Usual care was given including early physical therapy. Indirectness: No indirectness (n=30) Intervention 2: No treatment - Placebo. Saline 0.9% was subcutaneously administered twice daily. Duration 14 days. Concurrent medication/care: Usual care was given including early physical therapy. Indirectness: No indirectness
Funding	Funding not stated

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: DALTEPARIN (1,250 UNITS ONCE DAILY - 5,000 UNITS TWICE DAILY) versus PLACEBO

Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge

- Actual outcome: All-cause mortality at 14 days; Group 1: 9/30, Group 2: 4/30

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 0, Reason: n/a; Group 2 Number missing: 0, Reason: n/a

Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge

- Actual outcome: DVT (symptomatic and asymptomatic) at 14 days; Group 1: 6/30, Group 2: 15/30

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 0, Reason: n/a; Group 2 Number missing: 0, Reason: n/a

Protocol outcome 3: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge

Study	Prins 1989 ²⁶⁸
- Actual outcome: PE at 14 days; Group 1: 1/30, Group 2: 2/30 Risk of bias: All domain - Very high, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - High, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 0, Reason: n/a; Group 2 Number missing: 0, Reason: n/a	
Protocol outcomes not reported by the study	Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge; Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at up to 90 days from hospital discharge; Technical complications of mechanical interventions at up to 90 days from hospital discharge;

Study	Sandset 1990 ²⁸⁶
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=103)
Countries and setting	Conducted in Norway; Setting: Department of Medicine, Aker University Hospital, Oslo, Norway (most patients were treated in a cerebrovascular care unit.
Line of therapy	Not applicable
Duration of study	Intervention time: 14 days or until discharge from hospital, if earlier.
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: DVT (symptomatic and asymptomatic): confirmed by venography and B-mode ultrasound scanning Major bleeding: defined as a fall in haemoglobin level of more than 20gm/litre, or led to blood transfusion, or was intracranial or fatal. Haemorrhagic transformation of brain infarction: confirmed by cerebral CT scan
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Patients admitted with clinical diagnosis of stroke.
Exclusion criteria	Haemorrhagic stroke diagnosed by obligatory cerebral computed tomography (CT) scan; stroke onset more than 72

Study	Sandset 1990 ²⁸⁶
	hours before inclusion; strokes qualifying for treatment with heparin (hospital policy at the time was most patients with embolic and progressive strokes); known bleeding diathesis; severe hypertension (persistent diastolic blood pressure more than 120 mmHg or retinal haemorrhage or papilledema); severe renal failure (serum creatinine more than 300 µmol/litre) or hepatic failure (Normotest less than 40%); severe anaemia (haemoglobin less than 90 gm/litre) or thrombocytopenia (platelet count less than 80 x 10 ⁹ /litre); patients with malignancy disease and comatose patients.
Recruitment/selection of patients	Consecutive patients admitted with clinical diagnosis of acute stroke Recruitment from February 1986 to November 1988
Age, gender and ethnicity	Age - Mean (range): 75 (47-90) years. Gender (M:F): 1/1. Ethnicity: Not reported
Further population details	1. BMI : Not applicable 2. Renal impairment: Not applicable 3. Type of stroke: Ischemic
Extra comments	Mean (range) weight of patients in study: 68 (40-112) kg
Indirectness of population	No indirectness
Interventions	<p>(n=52) Intervention 1: Low molecular weight heparin (licensed in UK) - Dalteparin (1,250 units once daily - 5,000 units twice daily). Dalteparin (Fragmin) was subcutaneously administered once daily, dose was adjusted according to body weight by the following regimen; less than 50kg, 0.30ml; 50-59 kg, 0.35ml; 60-69 kg, 0.40ml; 70-79kg, 0.45ml; 80-89kg, 0.50ml; more than 90 kg, 0.55ml. The patients in the active treatment group received 3000-5500 IU/day. The first injection was given subcutaneously at 4pm the day of randomisation followed by injections once daily at 9am. Duration 14 days or until discharge from the hospital if earlier. Concurrent medication/care: N/A. Indirectness: Serious indirectness; Indirectness comment: Dose is just outside of the standard dose range agreed for dalteparin</p> <p>(n=51) Intervention 2: No treatment - Placebo. No prophylaxis, 0.9% sodium chloride subcutaneously given once daily. Duration 14 days or until discharge from the hospital if earlier. Concurrent medication/care: N/A. Indirectness: No indirectness</p>
Funding	Study funded by industry (Supported by grants from the Norwegian Council for Cardiovascular Diseases and by Kabi, Stockholm, Sweden)

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: DALTEPARIN (STANDARD DOSE) versus PLACEBO

Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge

- Actual outcome: All-cause mortality at 14 days; Group 1: 5/52, Group 2: 1/51

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 0, Reason: n/a; Group 2 Number missing: 0, Reason: n/a

Study	Sandset 1990 ²⁸⁶
	<p>Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge - Actual outcome: DVT (symptomatic and asymptomatic) at 14 days; Group 1: 15/42, Group 2: 17/50 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 10, Reason: n/a; Group 2 Number missing: 1, Reason: n/a</p>
	<p>Protocol outcome 3: Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge - Actual outcome: Major bleeding at 14 days; Group 1: 0/52, Group 2: 0/51 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 0, Reason: n/a; Group 2 Number missing: 0, Reason: n/a</p>
	<p>Protocol outcome 4: Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge - Actual outcome: Fatal PE at 14 days; Group 1: 0/52, Group 2: 1/51 Risk of bias: All domain - Very high, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - High, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 0, Reason: n/a; Group 2 Number missing: 0, Reason: n/a</p>
	<p>Protocol outcome 5: Haemorrhagic transformation at up to 45 days from hospital discharge - Actual outcome: Haemorrhagic transformation at 14 days; Group 1: 4/50, Group 2: 3/52 Risk of bias: All domain - Very high, Selection - High, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low, Comments - The number of patients reported in each arm for this outcome was clearly reported. There are two patients lost in the LMWH arm (total is 50). One patients is added to the placebo (total is 52). Rationale for this difference is not reported. ; Indirectness of outcome: No indirectness ; Group 1 Number missing: 2, Reason: n/a; Group 2 Number missing: 0, Reason: n/a</p>
<p>Protocol outcomes not reported by the study</p>	<p>Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at up to 90 days from hospital discharge; Technical complications of mechanical interventions at up to 90 days from hospital discharge;</p>

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
<p>Sherman et al., 2007 ²⁹⁶</p> <p>Country of study: International: US, Europe and Asia</p> <p>Study design: RCT, non blinded</p> <p>List who was masked to interventions: Nil-Open label</p> <p>Evidence level: 1+</p> <p>Duration of follow-up: Total of 90 days, 14 days for main outcomes, 48 hours for bleeding events</p>	<p>Patient group: Acute Ischaemic Stroke</p> <p>Setting: 200 centres in 15 countries</p> <p>Inclusion criteria: ≥18 years Acute ischaemic stroke confirmed by computed tomography (CT) or magnetic resonance imaging (MRI) Unable to walk unassisted because of motor impairment, indicated by National Institute of Health Stroke Scale (NIHSS) ≥2 for motor function of leg Onset ≤ 48 hours of randomisation</p> <p>Exclusion criteria: Evidence of VTE at screening or active bleeding Evidence of history of intracranial haemorrhage, heparin induced or enoxaparin induced thrombocytopenia or thrombosis or both Hypersensitivity to iodinated contrast media or iodine Spinal or epidural analgesia or lumbar puncture within the preceding 24 hours Thrombolytic treatment within the preceding 24hours Comatose at screening (NIHSS score ≥2 for level of consciousness)</p>	<p>Group 1 Unfractionated heparin (UFH), Dose/route: 5000U , subcutaneously, every 12h Start: within 48 hours Duration: 10±4days</p> <p>Group 2 Enoxaparin (Clexane) Dose/route: 40mg, subcutaneously, once daily Start: within 48 hours Duration: 10±4days</p> <p>Additional non-comparative prophylaxis: Mechanical prophylaxis not mentioned. Concomitant antiplatelet</p>	All-cause mortality (up to Day 14 and 90 respectively)	<p>Day 14 Group1: 45/872 Group 2: 48/877 P value: 0.58</p> <p>Day 90 Group1: 103/872 Group 2: 100/877 P value:0.96 (P values were based on hazard ratio- log rank test)</p>	<p>Funding: Sanofi Aventis- funded and provided editorial support</p> <p>Limitations: Open label trial Safety (bleeding outcomes) not reported as stated in protocol- Minor extracranial haemorrhage (secondary safety outcome) not reported, “clinically important bleeding”- a post hoc definition was used No routine scanning of intracranial haemorrhage, a primary outcome. Use of mechanical prophylactic methods? Outcomes not reported: All-cause mortality at 48 hours, PE asymptomatic or symptomatic, Major bleeding, Neurological bleeding, Upper GI bleeding, Minor bleeding Heparin</p>
			Fatal pulmonary embolism (up to 14 days, confirmed by autopsy)	<p>Group1: 2/ 669 Group 2: 1/ 666 P value: 1.00 [Calculated by NCC-AC team using Fisher’s Exact test]</p>	
			Symptomatic pulmonary embolism (up to 14 days, confirmed by:)	<p>Group1: 6/669 Group 2: 1/666 P value: 0.059</p>	
			Symptomatic DVT (confirmed by: compression ultrasonography of the affected limb within 48 hours of symptom onset)	<p>Group1: 4/669 Group 2: 1/666 P value: 0.18 Note this was on efficacy group (screened), rather than randomised group</p>	
			DVT, asymptomatic or symptomatic (up to 14 day, confirmed by: Asymptomatic patients confirmed by bilateral contrast venography	<p>Group1: 118/669 Group 2: 67/666 P value:<0.0001 Note this was on efficacy group (screened), rather than randomised group</p>	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	<p>Known or suspected cerebral aneurysm or arteriovenous malformation</p> <p>Confirmed malignant disease that might have posed an increased risk of bleeding or compromise follow up or outcome assessment</p> <p>Impair haemostasis, e.g. baseline platelet count <100000 per microL, aPTT 1.5 times the laboratory upper limit of normal, INR>1.5</p> <p>Major surgery or trauma within the preceding 3 months</p> <p>Expected need for full-dose treatment with therapeutic levels of an anticoagulant</p> <p>Treatment with LMWH or UFH at prophylactic dose for > 48h before inclusion</p> <p>Allergy or known hypersensitivity to heparin or enoxaparin</p> <p>Bacterial endocarditis</p> <p>Prosthetic heart valve</p> <p>Known or suspected anaemia (Hb<100g/L)</p> <p>Uncontrolled arterial hypertension (systolic blood pressure (BP) >180mmHg or diastolic BP>100mmHg) at randomisation or clinical hypertensive urgency</p> <p>Life expectancy <3 months due to comorbid disorders</p> <p>Participation in another clinical study within the preceding 30 days</p> <p>Any clinically relevant serious diseases,</p>	<p>therapy was allowed.</p> <p>Number of patients receiving anti-platelet therapy:</p> <p>In the randomised group:</p> <p>At baseline:</p> <p>Enoxaparin: 825/884 (92%)</p> <p>UFH: 791/878 (90%)</p> <p>Received for >6 days after randomisation</p> <p>Enoxaparin: 82% 726/884</p> <p>UFH group: 80% 698/878</p>	<p>within 72 hours of last dose of study medication.</p> <p>Ultrasonography used for patients who were unable to do venography)</p> <p>Proximal DVT(up to 14 days, confirmed by: see DVT)</p> <p>Distal DVT (up to 14days confirmed by: see DVT)</p>	<p>Group1: 64/669</p> <p>Group 2: 30/666</p> <p>P value: 0.0003</p> <p>Group1: 85/669</p> <p>Group 2: 44/666</p> <p>P value: 0.0002</p>	<p>induced thrombocytopenia, post thrombotic syndrome, pulmonary hypertension</p> <p>QoL, LOS</p> <p>Additional outcomes reported:</p> <p>Subgroup analysis by patient characteristics (forest plots)</p> <p>Outcomes by NIHSS score (by Day 14?)</p> <p>VTE</p> <p>NIHSS<14</p> <p>Grp 1: 14.0%(10.91-17.02)</p> <p>Grp 2 : 8.3% (5.90-10.70)</p> <p>P value: 0.004</p> <p>NIHSS ≥14</p> <p>Grp 1: 29.7%(22.94-36.49)</p> <p>Grp 2 :16.3%(10.53-21.97)</p> <p>P value: 0.004</p> <p>DVT</p> <p>NIHSS<14</p> <p>Grp 1: 13.6%(10.54-</p>

Study details	Patients	Interventions	Outcome measures	Effect size	Comments																																																															
	<p>including severe liver disease or renal failure (creatinine clearance <30mL/min on ≥ 2 occasions)</p> <p>Female patients, if breast feeding, pregnant, or could become pregnant during the study</p> <p>All patients N: 1762</p> <p>Characteristics:</p> <table border="1"> <thead> <tr> <th></th> <th>Group 1</th> <th>Group 2</th> </tr> </thead> <tbody> <tr> <td>No randomised:</td> <td>878</td> <td>884</td> </tr> <tr> <td>No dropouts:</td> <td></td> <td></td> </tr> <tr> <td>For safety population</td> <td>6</td> <td>7</td> </tr> <tr> <td>For efficacy population</td> <td>209</td> <td>218</td> </tr> <tr> <td>Age (years)</td> <td>66.1±12.9</td> <td>65.9±12.9</td> </tr> <tr> <td><65</td> <td>372</td> <td>371</td> </tr> <tr> <td>65-75</td> <td>265</td> <td>312</td> </tr> <tr> <td>>75</td> <td>241</td> <td>201</td> </tr> <tr> <td>M/F</td> <td>473/405</td> <td>521/363</td> </tr> <tr> <td>BMI (kg/m³)</td> <td>27.0±5.3</td> <td>27.0±5.3</td> </tr> <tr> <td>≥30</td> <td>183</td> <td>179</td> </tr> <tr> <td>Race:</td> <td></td> <td></td> </tr> <tr> <td>White</td> <td>523</td> <td>523</td> </tr> <tr> <td>Black</td> <td>55</td> <td>68</td> </tr> <tr> <td>Asian</td> <td>193</td> <td>182</td> </tr> <tr> <td>Hispanic</td> <td>68</td> <td>73</td> </tr> <tr> <td>Others</td> <td>39</td> <td>38</td> </tr> <tr> <td>NIHSS score</td> <td></td> <td></td> </tr> <tr> <td><14</td> <td>626</td> <td>648</td> </tr> <tr> <td>≥14</td> <td>252</td> <td>236</td> </tr> </tbody> </table>		Group 1	Group 2	No randomised:	878	884	No dropouts:			For safety population	6	7	For efficacy population	209	218	Age (years)	66.1±12.9	65.9±12.9	<65	372	371	65-75	265	312	>75	241	201	M/F	473/405	521/363	BMI (kg/m ³)	27.0±5.3	27.0±5.3	≥30	183	179	Race:			White	523	523	Black	55	68	Asian	193	182	Hispanic	68	73	Others	39	38	NIHSS score			<14	626	648	≥14	252	236				<p>16.58)</p> <p>Grp 2 : 8.1%(5.73-10.48)</p> <p>P value: 0.005</p> <p>NIHSS ≥14</p> <p>Grp 1: 29.1%(22.41-35.88)</p> <p>Grp 2:16.3%(10.53-21.97)</p> <p>P value: 0.005</p> <p>Clinically significant intracranial bleeding</p> <p>NIHSS<14</p> <p>Grp 1: 0.3%(-0.12 to 0.77)</p> <p>Grp 2: 0.3% (-0.12 to 0.74)</p> <p>P value: 0.97</p> <p>NIHSS ≥14</p> <p>Grp 1: 1.6%(0.04 to 3.16)</p> <p>Grp 2:16.3%(-0.33 to 2.05)</p> <p>P value: 0.47</p> <p>Major extracranial</p> <p>NIHSS<14</p> <p>Grp 1: 0%</p> <p>Grp 2 : 0.5%(-0.06 to 0.99)</p>
	Group 1	Group 2																																																																		
No randomised:	878	884																																																																		
No dropouts:																																																																				
For safety population	6	7																																																																		
For efficacy population	209	218																																																																		
Age (years)	66.1±12.9	65.9±12.9																																																																		
<65	372	371																																																																		
65-75	265	312																																																																		
>75	241	201																																																																		
M/F	473/405	521/363																																																																		
BMI (kg/m ³)	27.0±5.3	27.0±5.3																																																																		
≥30	183	179																																																																		
Race:																																																																				
White	523	523																																																																		
Black	55	68																																																																		
Asian	193	182																																																																		
Hispanic	68	73																																																																		
Others	39	38																																																																		
NIHSS score																																																																				
<14	626	648																																																																		
≥14	252	236																																																																		

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	Motor leg function (NIHSS score): 0 0 3 1 10 16 2 381 356 3 293 316 4 387 193 Venous stasis syndrome 11 3 Varicosis 16 19 Previous VTE 14 16 Previous thrombolytic therapy 58 50 Concomitant antiplatelet: Aspirin 738 767 Aspirin with dipyridole 45 36 Clopidogrel 174 189 Dipyridole 47 40 Ticlopidine 28 28 Other 56 52				P value: 0.09 NIHSS ≥14 Grp 1: 0 Grp 2: 1.7%(0.05-3.40) P value: 0.04 Notes: Methodological paper published in year 2005
			Fatal bleeding (description: within 48 hours of stopping treatment)	Group1: 4/872 Group 2: 5/877 P value: 1.0	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
			Major bleeding (intracranial and extracranial)	Group1: 6/872 Group 2: 11/877 P value:0.33 [value calculated by NCC-AC team using Fisher's exact test]	
			Major (extracranial) bleeding (description: Within 48 hours of stopping treatment, overt bleeding resulting in either death, drop of Hb level of $\geq 30\text{g/L}$, need for transfusion ≥ 2 units of blood, surgical intervention or decompression of closed space to stop or control event, bleeding in retroperitoneal or intraocular location)	Group1: 0/872 Group 2: 7/877 P value: 0.015	
			Neurological (Intracranial) bleeding (within 48 hours of stopping treatment, symptomatic, confirmed by head CT or MRI scan, or autopsy)	Group1: 6/872 Group 2: 4/877 P value: 0.55	
			Minor (extracranial) bleeding (within 48 hours of stopping	Group1: 48/872 Group 2: 42/877 P value: 0.50	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
			<p>treatment. Description: any clinically overt bleeding not meeting the criteria for major extracranial bleeding, and associated with at least one of the following: epistaxis lasting more than 5 minute or needing intervention, ecchymosis or haematoma >5 cm at its widest point, haematuria not associated with urinary catheter trauma, gastrointestinal haemorrhage not related to intubation of nasogastric tube placement, wound haematoma or haemorrhagic wound complications not associated with features of over haemorrhage classified as major or subconjunctival haemorrhage needing end of study treatment)</p>		

Table 45: Average comparative outcomes with and without intermittent pneumatic compression (IPC) per 1000 patients who are immobile when admitted for stroke

		Standard best medical care (cases per 1000 patients)	Standard best medical care plus intermittent pneumatic compression (IPC) ^a (cases per 1000 patients, with 95% confidence interval)
	Outcomes in hospital		
	Skin breaks ^b	14	30 (between 18 and 49)
	Deep vein thrombosis that will cause symptoms and need treatment ^b	63	45 (between 34 and 62)
	Deep vein thrombosis that may or may not cause symptoms ^c	149	113 (between 94 and 136)
OHS *	Outcomes at 6 months ^{b,d}		
0-4	Alive and not severely disabled ^e	562	550 (between 517 and 590)
5	Alive but severely disabled	180	218 (between 187 and 252)
6	Dead ^f	258	232 (between 204 and 259)

^a Absolute risk: number of cases per 1000 patients (95% confidence interval).

^b Data from CLOTS-3 trial. ^{57,58}

^c Data from Lacut (2005) ¹⁸² and CLOTS-3 trial. ^{57,58}

^d These are average outcomes at 6 months after stroke, assessed using the Oxford Handicap Scale⁸. However, death rate and functional outcomes will vary depending on the severity of the initial stroke.

^e The difference between the 2 groups on this outcome is not statistically significant.

^f The difference between the 2 groups on this outcome is not statistically significant. However, when 6-month all-cause mortality data from the CLOTS-3 trial are pooled with 3-month data from the Lacut (2005) trial, the survival effect favouring IPC is statistically significant.

* The Oxford Handicap Scale is a categorical scale for measuring functional outcome after a stroke. Key: 0 = Healthy survival – fully independent; 1 = Minor symptoms – independent, no interference; 2 = Minor disability – independent, some restrictions but able to self-care; 3 = Moderate disability – significant restriction, unable to lead a totally independent existence (requires some assistance); 4 = Moderate-to-severe disability – unable to live independently but does not require constant attention; 5 = Severe disability – totally dependent, requires constant attention day and night; 6 = Death.

H.13 Acutely ill medical patients

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Cohen et al., 2006 ⁶¹	Patient group: Older acute medical patients	Group 1 Fondaparinux (Atrixa)	All-cause mortality Follow up: 1 month	Group1: 14/425 Group 2: 25/414 P value: 0.071*	Funding: Sanofi-Synthelabo and NV Organon sponsored the study and carried out on-site monitoring of all participants. The sponsors had an opportunity to comment on the manuscripts before submission. Fondaparinux is manufactured by GlaxoSmithKline Limitations: Diagnosis for fatal PE includes where death was sudden and where no other explainable
Country of study: 35 centres in 8 countries	Congestive heart failure (212/849) Acute respiratory distress (167/849) Acute infectious or inflammatory disease (214/849)	Start time: within 48 hours of admission End time: 1-13 days (median 7 days)	Fatal pulmonary embolism (confirmed by: autopsy or no other explainable reason) Follow up: 1 month	Group1: 3/425 Group 2: 7/414 P value: 0.218*	
Study design: RCT	Setting: Not stated	2.5mg in 0.5ml saline subcutaneously once per day.	Symptomatic pulmonary embolism (confirmed by: high probability lung scan, pulmonary angiography or helical computed tomography) Follow up: 1 month	Group1: 4/425 Group 2: 11/414 P value 0.212* (Includes fatal PE)	
List who was masked to interventions: Patient, clinician, outcome adjudicators	Inclusion criteria: Patients aged ≥60 years and expected to remain in bed for at least 4 days and with acute illness: Congestive heart failure class III/IV, acute respiratory illness in the presence of chronic lung disease or clinically diagnosed acute infections or inflammatory disorders such as arthritis, connective tissue diseases, or inflammatory bowel disease.	Group 2 Placebo Start time: with 48 hours of admission End time: 1-15 days (median 7 days)	Symptomatic DVT (confirmed by: bilateral venography) Follow up: 1 month	Group1: 0/429 Group 2: 0/420 P value: NS	
Evidence level: 1+	Exclusion criteria: High risk for bleeding, acute bacterial endocarditis, cerebral metastasis, recent haemorrhagic or ischaemic stroke, brain, spinal or	0.5 ml isotonic saline subcutaneously once per day.	DVT, asymptomatic or symptomatic (confirmed by venography) Follow up: 15 days	Group1: 18/321 Group 2: 29/323 P value: 0.129*	
Duration of follow-up: Asymptomatic events: 15			Thigh DVT (confirmed by: bilateral venography) Follow up: 15 days	Group1: 5/321 Group 2: 7/323 P value: 0.772*	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments												
days Symptomatic events: 1 month	ophthalmological surgery, an indwelling intrathecal or epidural catheter, a serum creatinine level >180 µmol/l in a well hydrated patient, documented hypersensitivity to contrast media, anticipated intubation for more than 24 hours, use of anti-thrombotics within 48 hours before randomisation, an indication for anticoagulant prophylaxis or therapy, or life expectancy of less than one month. All patients N: 849 M/F: 360/489 Additional risk factors: <table border="1" style="margin-left: 20px;"> <thead> <tr> <th></th> <th>Gp1</th> <th>Gp2</th> </tr> </thead> <tbody> <tr> <td>Age ≥ 75</td> <td>233</td> <td>216</td> </tr> <tr> <td>History of VTE</td> <td>18</td> <td>21</td> </tr> <tr> <td>Cancer</td> <td>62</td> <td>69</td> </tr> </tbody> </table> Group 1 No. randomised: 429 No. of dropouts: 108 Mean Age (SD): 75.0 (8.3) Group 2 No. randomised: 420 No. of dropouts: 97 Mean Age (SD): 74.4 (8.3)		Gp1	Gp2	Age ≥ 75	233	216	History of VTE	18	21	Cancer	62	69	Additional non-comparative prophylaxis: Aspirin and NSAIDs discouraged. AES and physiotherapy were allowed (no information re: how many used this)	Calf DVT (confirmed by: bilateral venography) Follow up: 15 days	Group1: 13/321 Group 2: 22/323 P value: 0.164*	reason was found. Relatively high number of patients for whom the primary outcome could not be evaluated (195/849) due to either no venography completed or venogram not evaluable. Outcomes not reported: LoS, QoL, pulmonary hypertension, post thrombotic syndrome, HIT, Neurological bleeding, upper GI bleeding. Additional outcomes reported: None.
			Gp1	Gp2													
		Age ≥ 75	233	216													
		History of VTE	18	21													
Cancer	62	69															
Fatal bleeding Follow up: 1 month	Group1: 2/425 Group 2: 1/414 P value: 1.00*																
Major bleeding (description: bleeding in a critical location, bleeding leading to surgical intervention, overt bleeding associated with a drop in haemoglobin concentration of ≥20 g/l or leading to transfusion of 2 or more units of red blood cells.) Follow up: 15 days	Group1: 1/425 Group 2: 1/414 P value: 1.00*																
Minor bleeding (description: Clinically relevant overt bleeding not meeting the criteria for major bleeding.) Follow up: 15 days	Group1: 11/424 Group 2: 4/414 P value: 0.116*																

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
					<p>Notes:</p> <p>Many of the authors participators, consultants or both for NV Organon and Sanofi-Synthelabo 2 authors were employees of Organon.</p> <p>Outcomes reported from the number analysed not number randomised.</p> <p>* p values calculated by NCC-AC using Fisher Exact test</p>

Study	Cohen 2013 ⁶³
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=8101)
Countries and setting	Conducted in Unknown multicentre; Setting: 556 sites in 52 countries
Line of therapy	Not applicable
Duration of study	Intervention time: Interventions - 10±4 days; Placebo for 35±4 days
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: Major bleeding - Bleeding leading to a ≥2 g/dl fall in haemoglobin or a transfusion of ≥2 units of packed red blood cells or whole blood, bleeding into a critical site (intracranial, intraspinal, intraocular, retroperitoneal, intra-articular, pericardial, or intramuscular with compartment syndrome) or bleeding

Study	Cohen 2013 ⁶³
	leading to death. Clinically relevant non-major bleeding - Overt bleeding not meeting the criteria for major bleeding but associated with medical intervention, unscheduled contact with a physician, temporary cessation of study treatment or discomfort for the subject such as pain, or impairment of activities of daily life.
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Age ≥40 years, Patients at risk of venous thromboembolic events hospitalized for the following acute medical conditions: Heart failure, NYHA class III or IV, active cancer (e.g. admitted for chemotherapy or for treatment of active cancer complication), acute ischemic stroke, acute infectious and inflammatory diseases, including acute rheumatic diseases, acute respiratory insufficiency; Patients with at least one additional risk factor for VTE: severe varicosis, chronic venous insufficiency, history of cancer, history of DVT/PE, history of heart failure (NYHA class III/IV), thrombophilia (hereditary or acquired), recent major surgery or serious trauma (6–12 weeks), hormone replacement therapy, advanced age ≥75 years, morbid obesity (body mass index ≥35 kg/m ²), acute infectious disease contributing to hospitalization; Anticipated complete immobilization* for ≥1 day during the hospitalization and anticipated decreased level of mobility† for ≥4 days after randomization in any type of care setting and additional anticipated on-going decreased mobility thereafter, hospitalized <72 h before randomization.
Exclusion criteria	Contraindications for the use of the LMWH enoxaparin, bleeding risk-related criteria including: clinically significant bleeding, within 30 days of randomization, major surgery, biopsy of a parenchymal organ, ophthalmic surgery, or serious trauma within 6 weeks before randomization; Concomitant conditions or diseases e.g.: Known allergy to rivaroxaban or its excipients, severe renal insufficiency; Treatment with or use of mechanical thromboprophylaxis (e.g. pneumatic compression devices, foot pumps) for VTE); pregnancy
Recruitment/selection of patients	From December 2007 through July 2010, a total of 8428 patients were enrolled at 556 sites in 52 countries.
Age, gender and ethnicity	Age - Median (range): 71.0 years. Gender (M:F): 1.18/1. Ethnicity: 68.2% White; 19.9% Asian; 7.05% Other
Further population details	1. BMI : Not obese (BMI under 30 kg/m ²) (Rivaroxaban 28.2; Enoxaparin 28.2). 2. Mobility: Not stated 3. Renal impairment: Not stated
Extra comments	Acute medical condition (mean %): Infectious disease 45.5%; Heart failure 32.4%; Respiratory insufficiency 28%; Ischemic stroke 17.3%; Active cancer 7.3%; Inflammatory or rheumatic disease 3.8%; Other 0.7%; ≥ 2 medical conditions 31%. . History of heart failure: 34.5%; History of cancer: 17%; Acute ischemic stroke with leg paresis: 16.4%; Chronic venous insufficiency 14.8%; Severe varicosis: 11.9; History of DVT or PE: 4.7%; Hormone-replacement therapy: 1.2%; Major surgery within the previous 6 to 12 weeks: 0.8%; Hereditary or acquired thrombophilia: 0.3%; Serious trauma within the previous 6 to 12 weeks: 0.2%
Indirectness of population	No indirectness
Interventions	(n=4050) Intervention 1: Rivaroxaban. 10 mg once daily subcutaneous rivaroxaban for 35±4 days and subcutaneous

Study	Cohen 2013⁶³
	<p>placebo for 10±4 days. Duration Rivaroxaban 35±4 days; Placebo for 10±4 days . Concurrent medication/care: Ultrasonography was performed in all patients for the detection asymptomatic DVT after the last dose of study medication or matching placebo was administered on day 10±4 and on day 35±4</p> <p>(n=4051) Intervention 2: Low molecular weight heparin (licensed in UK) - Enoxaparin. 40 mg once daily, subcutaneous enoxaparin for 10±4 days. Oral placebo for 35±4 days. Duration Enoxaparin 10±4 days; Placebo 35±4 days . Concurrent medication/care: Ultrasonography was performed in all patients for the detection asymptomatic DVT after the last dose of study medication or matching placebo was administered on day 10±4 and on day 35±4.</p>
Funding	Funding not stated
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: RIVAROXABAN versus ENOXAPARIN</p> <p>Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge - Actual outcome: Death from any cause at 35 days; Group 1: 159/3096, Group 2: 153/3169; Risk of bias: Low; Indirectness of outcome: No indirectness - Actual outcome: VTE-related death at 35 days; Group 1: 19/2967, Group 2: 30/3057</p> <p>Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic) at 7-90 days from hospital discharge - Actual outcome: DVT (symptomatic and asymptomatic) at 35 days; Group 1: 116/2967, Group 2: 148/3057; Risk of bias: High; Indirectness of outcome: No indirectness</p> <p>Protocol outcome 3: Pulmonary embolism at 7-90 days from hospital discharge - Actual outcome: PE at 35 days ; Group 1: 10/2967, Group 2: 14/3057; Risk of bias: High; Indirectness of outcome: No indirectness</p> <p>Protocol outcome 4: Major bleeding at up to 45 days from hospital discharge - Actual outcome: Major bleeding at 35 days; Group 1: 43/3997, Group 2: 15/4001; Risk of bias: Low; Indirectness of outcome: No indirectness</p> <p>Protocol outcome 5: Venous thromboembolism at 7-90 days from hospital discharge (not analysed) - Actual outcome: Symptomatic VTE at 35 days; Group 1: 18/3997, Group 2: 12/4001</p>	
Protocol outcomes not reported by the study	Fatal PE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding at up to 45 days from hospital discharge; Health-related quality of life at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at up to 90 days from hospital discharge; Technical complications of mechanical interventions at up to 90 days from hospital discharge

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
<p>Dahan et al., 1986⁷⁴</p> <p>Country of study: France</p> <p>Study design: RCT</p> <p>List who was masked to interventions: patients</p> <p>Evidence level: 1+</p> <p>Duration of follow-up: 10 days</p>	<p>Patient group:</p> <p>Elderly medical patients (conditions: heart failure 49, respiratory diseases 57, ischemic stroke 46, malignant diseases 35, diabetes 12, depression 10, syncope 13, infection 11, neurologic diseases 7, joint diseases 7, hepatic or biliary diseases 4, miscellaneous 8).</p> <p>Setting: hospital</p> <p>Inclusion criteria:</p> <ul style="list-style-type: none"> age >65 <p>Exclusion criteria:</p> <p>surgical patients on-going anticoagulant/platelet inhibitor therapy</p> <p>need for full anticoagulation presence of active bleeding presence of coagulation disorder predictable short-term hospitalisation (<7 days)</p> <p>All patients N: 270</p> <p>No. of dropouts: 7</p> <p>Risk Factors: Gp1 Gp2</p>	<p>Group I</p> <p>LMWH 10169 (renamed enoxaparin) 60mg in a volume of 0.3ml started on admission and continued for 10 days</p> <p>Group II</p> <p>placebo</p> <p>Additional non-comparative prophylaxis: None</p> <p>Non-steroidal anti-inflammatory drugs, aspirin or platelet inhibitor therapy forbidden.</p>	All-cause mortality	<p>Group 1: 6/135</p> <p>Group 2: 6/135</p> <p>P value: ns</p>	<p>Funding: not reported</p> <p>Limitations: Only patients appear to be masked to treatment. The study is over 20 years old, not reported if allocation to interventions was concealed from patients and participants</p> <p>Outcomes not reported: pulmonary embolism, proximal and distal DVT, major and minor bleeding, heparin induced thrombocytopenia, post-thrombotic syndrome,</p>
			DVT, asymptomatic or symptomatic (diagnosed by fibrinogen uptake test)	<p>Group 1: 4/132</p> <p>Group 2: 12/131</p> <p>P value: 0.03</p>	
			Fatal pulmonary embolism (diagnosed by autopsy)	<p>Group 1: 1/132</p> <p>Group 2: 3/131</p> <p>P value: ns</p>	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	Obesity (>10% ideal weight for age, sex and height) 13 12 Arrhythmia 23 29 Varicose veins 30 34 Previous history of VTE 6 6 Immobilisation 43 42 Dehydration 28 38 Group I No. randomised: 135 No. of dropouts: 3 Age (mean): 79.9 +6.8 M/F: 84/51 Additional risk factors: Other factors: Group II No. randomised: 135 No. of dropouts: 4 Age (mean): 80.1 +6.9 M/F: 83/52 Additional risk factors: Other factors:				quality of life, length of stay Additional outcomes reported: measurements for haemoglobin, platelets and activated partial anti-thrombin time Notes: Mean red cell count significantly lower in LMWH group (4.42 +0.63 106/mm3) compared to placebo

Study	Goldhaber 2011 ¹²³
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=6528)
Countries and setting	Conducted in Unknown multicentre; Setting: 302 centres in 35 countries
Line of therapy	Not applicable
Duration of study	Intervention time: Apixaban 30 days; Enoxaparin 6-14 days

Study	Goldhaber 2011 ¹²³
Method of assessment of guideline condition	Inadequate method of assessment/diagnosis: DVT/PE: Detected with the use of systematic bilateral compression ultrasonography; Major bleeding: . Bleeding was categorized as major if it was fatal or overt and was accompanied by one or more of the following: a decrease in haemoglobin of 2 g or more per decilitre over a 24-hour period; transfusion of 2 or more units of packed red cells; or intracranial, intraspinal, intraocular, pericardial, or retroperitoneal bleeding, bleeding that occurred in an operated joint that required reoperation or intervention, or intramuscular bleeding with the compartment syndrome. Clinically relevant non-major bleeding was defined as acute, clinically overt bleeding that did not meet the criteria for classification as a major bleeding event but did meet at least one of the following criteria: epistaxis that required medical attention or persisted for 5 minutes or more, gastrointestinal bleeding containing frank blood or coffee-ground material that tested positive for blood, endoscopically confirmed bleeding, spontaneous haematuria or haematuria persisting for 24 hours or more after urinary-tract catheterization, unusual bruising, radiographically confirmed hematoma, or haemoptysis.
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Male and female patients, 40 years of age or older, were considered for participation in the study if they were hospitalized for congestive heart failure, acute respiratory failure, infection (without septic shock), acute rheumatic disorder, or inflammatory bowel disease and had an expected hospital stay of at least 3 days.
Exclusion criteria	Patients with congestive heart failure or respiratory failure, eligible patients had to have at least one of the following additional risk factors: an age of 75 years or older, previous documented venous thromboembolism or a history of venous thromboembolism for which they received anticoagulation for at least 6 weeks, cancer, a body-mass index (the weight in kilograms divided by the square of the height in meters) of 30 or more, receipt of oestrogenic hormone therapy, or chronic heart failure or respiratory failure.
Recruitment/selection of patients	From June 2007 through February 2011, acutely ill medical patients were enrolled at 302 centres in 35 countries
Age, gender and ethnicity	Age - Median (range): 67-68 years. Gender (M:F): 1/1.04. Ethnicity: White 76%, Black 9.2%; American Indian or Alaskan Native 0.2%, Asian 9.9%, Other 4.5%
Further population details	1. BMI : Obese (BMI over 30 kg/m ²) (Apixaban 44.5%; Enoxaparin 44.3%). 2. Mobility: Mixed (Severely restricted: apixaban 26%, enoxaparin 28.4%; Moderately restricted: apixaban 73.4%, enoxaparin 71%). 3. Renal impairment: Not stated
Extra comments	Previous VTE: 4.1% ;History of cancer: 9.7%;Chronic heart failure: 47%; Chronic respiratory failure: 51.9%; Oestrogenic hormone therapy: 1.2%
Indirectness of population	No indirectness
Interventions	(n=3255) Intervention 1: Apixaban. Apixaban administered orally at a dose of 2.5 mg twice daily. Patients who were

Study	Goldhaber 2011¹²³
	<p>randomly assigned to apixaban received daily injections of an enoxaparin placebo for a minimum of 6 days. Duration 30 days. Concurrent medication/care: After 6 days, the decision to discontinue the parenteral study drug was made at the discretion of the investigators. Concomitant treatment with aspirin at doses above 165 mg per day was prohibited.</p> <p>(n=3273) Intervention 2: Low molecular weight heparin (licensed in UK) - Enoxaparin. Enoxaparin, administered subcutaneously at a dose of 40 mg once daily during their stay in the hospital, for a minimum of 6 days. Duration 6 days. Concurrent medication/care: After 6 days, the decision to discontinue the parenteral study drug was made at the discretion of the investigators. Patients who were randomly assigned to enoxaparin received tablets containing an apixaban placebo for 30 days. Concomitant treatment with aspirin at doses above 165 mg per day was prohibited.</p>
Funding	Study funded by industry (Bristol-Myers Squibb and Pfizer)
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: APIXABAN versus ENOXAPARIN</p> <p>Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge - Actual outcome: VTE-related death at 30 days; Group 1: 2/3255, Group 2: 3/3273; Risk of bias: Low; Indirectness of outcome: No indirectness</p> <p>Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic) at 7-90 days from hospital discharge (data not analysed) - Actual outcome: Symptomatic proximal DVT at 60 days; Group 1: 5/3255, Group 2: 12/3273; - Actual outcome: Asymptomatic proximal DVT at 60 days; Group 1: 52/2206, Group 2: 48/2269; - Actual outcome: Symptomatic DVT at 60 days; Group 1: 5/3255, Group 2: 16/3273;</p> <p>Protocol outcome 3: Pulmonary embolism at 7-90 days from hospital discharge - Actual outcome: Nonfatal pulmonary embolism at 60 days; Group 1: 7/3251, Group 2: 8/3266; Risk of bias: Low; Indirectness of outcome: No indirectness</p> <p>Protocol outcome 4: Major bleeding at up to 45 days from hospital discharge - Actual outcome: Major bleeding at 30 days; Group 1: 15/3184, Group 2: 6/3217; Risk of bias: Low; Indirectness of outcome: No indirectness</p> <p>Protocol outcome 5: Clinically relevant non-major bleeding at up to 45 days from hospital discharge - Actual outcome: Major bleeding and clinically relevant non-major bleeding at 30 days; Group 1: 85/3184, Group 2: 67/3217; Risk of bias: Low; Indirectness of outcome: No indirectness</p>	
Protocol outcomes not reported by the study	Deep vein thrombosis (symptomatic and asymptomatic) at 7-90 days from hospital discharge; Fatal PE at up to 90 days from hospital discharge; Health-related quality of life at up to 90 days from hospital discharge; Heparin-induced

Study	Goldhaber 2011¹²³
	thrombocytopenia at up to 90 days from hospital discharge; Technical complications of mechanical interventions at up to 90 days from hospital discharge

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
<p>Harenberg et al., 1996¹³⁸</p> <p>Country of study: Germany</p> <p>Study design: Multicentre double blind study</p> <p>List who was masked to interventions: Investigator and patients, critical event committee</p> <p>Evidence level: 1+</p> <p>Duration of follow-up: 10 days</p>	<p>Patient group: Hospitalised, bed ridden patients with increased risk of thrombosis</p> <p>Setting: Inpatient, 10 centres in Germany</p> <p>Inclusion criteria: Aged 50-80 years Expected duration of bed rest >10 days ≥ 1 of the following risk factors present: obesity varicosis chronic venous insufficiency post thrombotic syndrome intake of oral contraceptives or oestrogen thrombocytosis >450,000/microL hyperviscosity syndrome previous myocardial infarction thrombotic cerebral infarction peripheral arterial ischaemic</p> <p>Exclusion criteria: known intolerance to heparin thrombocytopenia <80m000micro/L</p>	<p>Group 1 UFH 5000IU , 3 times daily, subcutaneously, at 8 hour intervals</p> <p>Group 2 Fraxiparine 36mg (3100IU of antiXa), plus 2 placebo injections, 3 times daily, at 8 hour intervals</p> <p>Start time: within 12 hours of admission to hospital End time: day 11 Duration: 10 days</p> <p>Additional non-comparative</p>	<p>All-cause mortality</p> <p>Fatal pulmonary embolism (confirmed by: perfusion scintigraphy, additional angiography or ventilation scintiscan performed if results were low probability defects)</p> <p>Symptomatic pulmonary embolism (confirmed by: perfusion scintigraphy,</p>	<p>Group1: 9/780 Group 2: 23/810 P value: 0.02</p> <p>In group1, causes of death were carcinoma (4), pneumonia (1), chronic obstructive pulmonary disease (1), cardiac insufficiency (1), atrial fibrillation (1) and renal insufficiency (1) respectively.</p> <p>In Group 2 causes of death were carcinoma (3), pneumonia (4), stroke (4), cardiac insufficiency (9), myocardial infarction (1) and PE (1) and diabetes (1) respectively.</p> <p>Definite PE Group1: 0/780 Group 2: 1/810 P value: Probable PE Group1: 3/780 Group 2: 3/810 P value: 16 patients" death was classified as "possible" PE, but it was not stated which group they belonged to.</p> <p>Probable PE Group1: 3/780 Group 2: 3/810 P value:</p>	<p>Funding: Not stated</p> <p>Limitations: Reporting focused on safety outcomes (blood test results), DVT and PE reporting not clear Incidences of death and primary endpoints were not equally distributed between centres. In centres where no primary endpoints were observed, incidence of death the in LMWH group was 3.5x higher Outcomes not reported: PE asymptomatic or symptomatic DVT, asymptomatic or symptomatic, Thigh DVT, Calf DVT</p>

Study details	Patients	Interventions	Outcome measures	Effect size	Comments																								
	<p>hereditary or acquired coagulation disorder</p> <p>acute DVT</p> <p>pre-treatment with heparin other than study medication</p> <p>regular intake of medication influencing blood coagulation</p> <p>unfavourable short term prognosis</p> <p>septicaemia with gram negative bacteria</p> <p>disseminated intravascular coagulation</p> <p>fixed hypertension</p> <p>history of any bleeding</p> <p>creatinine >3mg/dl</p> <p>prothrombin time <60%</p> <p>The post-operative phase is not an exclusion criteria</p> <p>All patients</p> <p>N: 1968 randomised, 378 excluded from efficacy analysis</p> <table border="1"> <thead> <tr> <th>Main Diagnosis</th> <th>Gp1</th> <th>Gp2</th> </tr> </thead> <tbody> <tr> <td>Cardiac insufficiency</td> <td>143</td> <td>150</td> </tr> <tr> <td>Cerebrovascular diseases</td> <td>134</td> <td>149</td> </tr> <tr> <td>Coronary heart disease</td> <td>131</td> <td>139</td> </tr> <tr> <td>Cancer</td> <td>63</td> <td>57</td> </tr> <tr> <td>Diabetes</td> <td>57</td> <td>47</td> </tr> <tr> <td>Gastro. Or neph. Disease</td> <td>45</td> <td>38</td> </tr> <tr> <td>Chronic obstructive lung disease</td> <td></td> <td></td> </tr> </tbody> </table>	Main Diagnosis	Gp1	Gp2	Cardiac insufficiency	143	150	Cerebrovascular diseases	134	149	Coronary heart disease	131	139	Cancer	63	57	Diabetes	57	47	Gastro. Or neph. Disease	45	38	Chronic obstructive lung disease			<p>prophylaxis: (list or write not reported or not applicable)</p>	<p>additional angiography or ventilation scintiscan performed if results were low probability defects))</p> <p>DVT, asymptomatic or symptomatic</p> <p>Or</p> <p>Symptomatic DVT?? (screening at Day 1 and Day 11 and upon presentation of clinical signs)</p> <p>Major bleeding no description of criteria</p> <p>Minor bleeding no description of criteria</p>	<p>Group1: 1/780 Group 2: 3/ 810 P value:</p> <p>Not described whether symptomatic or asymptomatic. Likely to be all symptomatic cases, as none of them occurred on the day of planned scans.</p> <p>Group1: 4/780 Group 2: 5/ 810</p> <p>Group1: 7/ 780 Group 2: 3/810 P value: 0.34</p>	<p>Fatal bleeding</p> <p>Neurological bleeding</p> <p>Upper GI bleeding</p> <p>Heparin induced thrombocytopaeni</p> <p>a PTS, Pulmonary hypertension, QoL, LOS</p> <p>Additional outcomes reported: 4 cases of thrombocytopenia in UFH group, 0 in fraxiparine.</p> <p>Various clinical chemistry results</p> <p>Notes: DVT and PE events were combined and reported as "primary end points".</p> <p>Study was designed as an equivalence study. Emphasis of report was on "safety"-clinical</p>
Main Diagnosis	Gp1	Gp2																											
Cardiac insufficiency	143	150																											
Cerebrovascular diseases	134	149																											
Coronary heart disease	131	139																											
Cancer	63	57																											
Diabetes	57	47																											
Gastro. Or neph. Disease	45	38																											
Chronic obstructive lung disease																													

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	<p>46 41</p> <p>Pneumonia or infections 16 26</p> <p>Other diseases 144 166</p> <p>Group 1</p> <p>No. randomised: 985</p> <p>No. of dropouts: 205(140 dropped out, 65 not eligible)</p> <p>Age (mean): 70.4±7.9</p> <p>M/F: 372/408</p> <p>Additional risk factors:</p> <ul style="list-style-type: none"> -Smoker (no/ex/yes): 482/185/113 -Adiposity: 250 -Previous DVT:33 -Previous PE: 13 -*Varicosis: 137 -Ulcer cruris: 35 -Thrombocytosis: 33 -Peripheral AD: 160 -Previous MI: 113 -Previous stroke: 121 -Cardiac insufficiency: 343 -Hyperviscosity: 118 -Oestrogen: 2 <p>Group 2</p> <p>No. randomised: 983</p> <p>No. of dropouts: 173 (119 dropped out, 54 not eligible)</p>				chemistry.

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	Age (mean): 70.5±8.3 M/F: 344/466 Additional risk factors: -Smoker (no/ex/yes): 504/173/103 -Adiposity: 254 -Previous DVT: 50 -Previous PE: 18 -*Varicosis: 179 -Ulcer cruris: 33 -Thrombocytosis: 38 -Peripheral AD: 167 -Previous MI: 123 -Previous stroke: 119 -Cardiac insufficiency: 348 -Hyperviscosity: 112 -Oestrogen: 4 *p=0.02				

Study	Hull 2010 ¹⁵³
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=5963)
Countries and setting	Conducted in Multiple countries; Setting: 370 hospitals across 20 countries
Line of therapy	Not applicable
Duration of study	Intervention time: Enoxaparin for 10± 4 days, Placebo 28±4 days
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: DVT was diagnosed using bilateral compression ultrasonography or venography, PE was diagnosed using computed tomography or ventilation–perfusion lung scanning.
Stratum	Overall

Study	Hull 2010 ¹⁵³
Subgroup analysis within study	Not applicable
Inclusion criteria	Patients were eligible if they were at least 40 years of age, had a life expectancy of at least 6 months, and had recently reduced mobility for up to 3 days. In addition, they had to be considered by the enrolling investigator as likely to have reduced mobility for at least 3 days after enrolment. We defined “reduced mobility” as requiring total bed rest or being sedentary without bathroom privileges (level 1 immobility) or with bathroom privileges (level 2 immobility).
Exclusion criteria	Not reported
Recruitment/selection of patients	Patients enrolled from 370 hospitals across 20 countries between February 2002 and March 2006
Age, gender and ethnicity	Age - Mean (SD): 67.9 (12.1) years. Gender (M:F): 1/1. Ethnicity: 74.8% White, 6.8% Black, 13.6% Hispanic, Asian or Oriental 2.7%; Multiracial 1.5%, Other 0.5%
Further population details	1. BMI : Obese (BMI over 30 kg/m ²) (34% of population had BMI ≥ 30 kg/m ²). 2. Mobility: Mixed (Level 1 immobility (total bed or sedentary without bathroom privileges) 43.2%; Level 2 immobility (total bed rest or sedentary with bathroom privileges) 56.5%). 3. Renal impairment: Not stated
Extra comments	Primary enrolment diagnoses (%): Acute infection without septic shock 33.2%; Acute respiratory insufficiency 30.3%; Heart failure 18.7%; Post-acute ischemic stroke 6.6%; Acute rheumatic disorders 2.7%; Active cancer 1.6%; Fracture 0.7%; Multiple diagnoses 0.6%; Active inflammatory bowel disease 0.3%; Other 5.7%. Age >75 years - 29.9%; Active or previous cancer - 13.7%; History of VTE - 6.8%; Venous insufficiency - 13.7%; Hormone therapy - 2.2%; Chronic heart failure - 25.6%; Chronic respiratory failure - 39.9%; Chronic inflammatory disease - 0.5%; Family history of VTE - 0.1%; Thrombophilia - 0.1%
Indirectness of population	No indirectness
Interventions	(n=2975) Intervention 1: Low molecular weight heparin (licensed in UK) - Enoxaparin. Subcutaneous enoxaparin, 40 mg/d, for 10 ± 4 days, then further course of enoxaparin. Duration 28 ± 4 days. Concurrent medication/care: Some patients completed prophylaxis in outpatient setting (n=2988) Intervention 2: Low molecular weight heparin (licensed in UK) - Enoxaparin. Received enoxaparin for 10 ± 4 days then placebo for an additional 28 ± 4 days. Duration 28 ± 4 days. Concurrent medication/care: N/A
Funding	Study funded by industry (Sanofi-aventis)
RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: ENOXAPARIN (EXTENDED DURATION) versus ENOXAPARIN (STANDARD)	
Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge	

Study	Hull 2010 ¹⁵³
	<p>- Actual outcome: All-cause mortality at 90 days; Group 1: 105/2176, Group 2: 105/2159; Risk of bias: High; Indirectness of outcome: No indirectness</p>
	<p>Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic) at 7-90 days from hospital discharge (not analysed) - Actual outcome: Proximal DVT (symptomatic and asymptomatic) at 90 days; Group 1: 76/1867, Group 2: 45/1818</p>
	<p>Protocol outcome 3: Pulmonary embolism at 7-90 days from hospital discharge - Actual outcome: PE at 90 days; Group 1: 7/1867, Group 2: 3/1818; Risk of bias: High; Indirectness of outcome: No indirectness</p>
	<p>Protocol outcome 4: Fatal PE at up to 90 days from hospital discharge - Actual outcome: Fatal PE at 90 days; Group 1: 2/1867, Group 2: 0/1818; Risk of bias: High; Indirectness of outcome: No indirectness</p>
	<p>Protocol outcome 5: Venous thromboembolism at 7-90 days from hospital discharge (not analysed) - Actual outcome: VTE at 90 days; Group 1: 83/1867, Group 2: 48/1818</p>
	<p>Subgroup analysis evaluating patients with ischemic stroke: Turpie 2013³²⁰ RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: ENOXAPARIN (20MG ONCE DAILY – 60MG TWICE DAILY) versus PLACEBO</p>
	<p>Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge - Actual outcome: 30-day mortality at 30d from start of trial of extension; Group 1: 5/198, Group 2: 8/191; Risk of bias: High; Indirectness of outcome: No indirectness - Actual outcome: 90-day mortality at 90d from start of trial of extension; Group 1: 8/198, Group 2: 11/191; Risk of bias: High; Indirectness of outcome: No indirectness</p>
	<p>Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge - Actual outcome: DVT at During 28 day blind period (after open label treatment) plus seven days; Group 1: 4/165, Group 2: 11/150; Risk of bias: High; Indirectness of outcome: No indirectness</p>
	<p>Protocol outcome 3: Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge - Actual outcome: Major bleed (Hb decrease at least 2g/dl) at During time of trial extension, plus two day after (30d total); Group 1: 3/198, Group 2: 0/191; Risk of bias: High; Indirectness of outcome: No indirectness</p>
	<p>Protocol outcome 4: Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQspect; autopsy;</p>

Study	Hull 2010 ¹⁵³
	<p>echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge</p> <p>- Actual outcome: Fatal PE at During 28 day blind period (after open label treatment) plus seven days; Group 1: 0/166, Group 2: 1/150; Risk of bias: High; Indirectness of outcome: No indirectness</p> <p>Protocol outcome 5: DVT (symptomatic)</p> <p>- Actual outcome: Symptomatic DVT at During 28 day blind period (after open label treatment) plus seven days; Group 1: 0/166, Group 2: 2/150; Risk of bias: High; Indirectness of outcome: No indirectness</p>
Protocol outcomes not reported by the study	Deep vein thrombosis (symptomatic and asymptomatic) at 7-90 days from hospital discharge; Pulmonary embolism at 7-90 days from hospital discharge; Major bleeding at up to 45 days from hospital discharge; Clinically relevant non-major bleeding at up to 45 days from hospital discharge; Health-related quality of life at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at up to 90 days from hospital discharge; Technical complications of mechanical interventions at up to 90 days from hospital discharge

Study	Ishi 2013 ¹⁵⁶
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=92)
Countries and setting	Conducted in India; Setting: Intermediary care hospital in south India
Line of therapy	Not applicable
Duration of study	Unclear
Method of assessment of guideline condition	Inadequate method of assessment/diagnosis: No definitions reported
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Medically ill patients with high and higher risk of DVT/PE (as per the DVT/PE assessment score) in patients who required (1) at least 3 days of ICU stay or (2) same duration non-ambulatory condition in the wards among patients who were admitted to an intermediary care hospital.
Exclusion criteria	Moderate risk patients were not included in the study
Recruitment/selection of patients	March 2008 and July 2009
Age, gender and ethnicity	Age - Mean (range): 50.9-57.9 years. Gender (M:F): 2.4/1. Ethnicity: Not reported

Study	Ishi 2013 ¹⁵⁶
Further population details	1. BMI: Not stated 2. Mobility: Not stated 3. Renal impairment: Not stated
Extra comments	Diagnosis: Stroke 19.9%, cardiological dysfunction 4.8%, sepsis 11.7%, toxicological causes 26.3%, multisystem disorder 13%, others 15.2% No. of days patients received prophylaxis: 3-5 days 23.1%, 6-10 days 59.3%, > 10 days 35.1%
Indirectness of population	No indirectness
Interventions	(n=44) Intervention 1: Low molecular weight heparin (licensed in UK) - Enoxaparin. Enoxaparin 40 mg subcutaneously once daily. Thromboprophylaxis was continued until patient became ambulant and ready for discharge. Duration Unclear. Concurrent medication/care: NA (n=48) Intervention 2: Unfractionated heparin - low dose, administered subcutaneously. Unfractionated heparin - 5000 IU subcutaneously twice daily. Thromboprophylaxis was continued until patient became ambulant and ready for discharge. Duration Unclear. Concurrent medication/care: NA
Funding	Study funded by industry (Partly funded by Sanofi-Aventis Pharma the manufacturers of Clexane (Enoxaparin))
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: ENOXAPARIN versus UFH</p> <p>Protocol outcome 1: Venous thromboembolism at 7-90 days from hospital discharge (not analysed) - Actual outcome: DVT/PE (VTE) at Unclear; Group 1: 2/44, Group 2: 1/48</p> <p>Protocol outcome 2: Major bleeding at up to 45 days from hospital discharge - Actual outcome: Major bleeding at Unclear; Group 1: 0/44, Group 2: 4/48; Risk of bias: High; Indirectness of outcome: No indirectness</p> <p>Protocol outcome 3: Heparin-induced thrombocytopenia at up to 90 days from hospital discharge - Actual outcome: Heparin induced thrombocytopenia at Unclear; Group 1: 0/44, Group 2: 2/48; Risk of bias: High; Indirectness of outcome: No indirectness</p>	
Protocol outcomes not reported by the study	All-cause mortality at up to 90 days from hospital discharge; Deep vein thrombosis (symptomatic and asymptomatic) at 7-90 days from hospital discharge; Pulmonary embolism at 7-90 days from hospital discharge; Fatal PE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding at up to 45 days from hospital discharge; Health-related quality of life at up to 90 days from hospital discharge; Technical complications of mechanical interventions at up to 90 days from hospital discharge

Study	Kakkar 2011¹⁶³
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=8323)
Countries and setting	Conducted in China, India, Malaysia, Mexico, Philippines, South Korea, Tunisia; Setting: 193 sites in China, India, Korea, Malaysia, Mexico, the Philippines, and Tunisia
Line of therapy	Not applicable
Duration of study	Intervention time: 6-14 days during hospitalisation
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: A major haemorrhage was defined as overt bleeding associated with one of the following: death; the need for transfusion of at least 2 units of packed red cells or whole blood; a fall in the haemoglobin level of 20 g or more per litre; the requirement for a major therapeutic intervention (e.g., surgery) to stop or control bleeding; or a bleeding site that was retroperitoneal, intracranial, or intraocular. Clinically relevant non-major bleeding was defined as a non-major haemorrhage leading to discontinuation of the study drug or to hospitalization.
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	enrolled men and women, 40 years of age or older, who were hospitalized within 48 hours before randomization for at least one of the following conditions: acute decompensation of heart failure; active cancer (defined as histologically confirmed cancer with an initial diagnosis within the previous 6 months or with a recurrence or metastasis within the previous 6 months), unless the hospitalization was a planned hospitalization for chemotherapy; or severe systemic infection in addition to at least one of the following conditions: chronic pulmonary disease (e.g., chronic obstructive pulmonary disease, pulmonary fibrosis, or the pulmonary restrictive syndrome), obesity (a body-mass index [the weight in kilograms divided by the square of the height in meters] ≥ 30), a personal history of venous thromboembolism, or an age of 60 years or older. In addition, eligible patients were required to have an anticipated duration of hospitalization of at least 6 days and an American Society of Anesthesiologists health status score of 3 or less (on a scale of 1 to 6, with higher scores indicating more severe illness) or, for patients with cancer, an Eastern Cooperative Oncology Group performance status score of 2 or less (on a scale of 0 to 5, with higher scores indicating greater severity of illness).
Exclusion criteria	Major surgery or major trauma within the previous 6 weeks, need for ventilator support with intubation, symptomatic VTE at enrolment, multiple organ failure, evidence of an active bleeding disorder, contraindication to anticoagulation, cerebrovascular accident at inclusion or within 10 days prior to inclusion, prosthetic heart valves, confirmed cerebral metastases, known hypersensitivity to unfractionated heparin (UFH) or LMWH or pork-derived products, history of documented heparin-induced thrombocytopenia (HIT), participation in another clinical trial within the previous 30 days (patients with cancer included in a cancer-treatment protocol are allowed to participate only in cases where local

Study	Kakkar 2011 ¹⁶³
	regulations permit this and they are in the follow-up period of the cancer study and not scheduled to receive investigational cancer treatments during LIFENOX treatment/hospitalization period), persistent severe renal failure (creatinine clearance <30 mL/min on at least two occasions ≥3days before entry into the study), known or suspected severe anaemia or lumbar puncture within the preceding 24 hours, spinal or epidural analgesia with the preceding 24 hours, patients unlikely to be compliant, women of childbearing potential not protected by an effective method of birth control, refusal or inability to give informed consent to participate in the study, and inability to be followed-up after hospital discharge until day 90 after randomization.
Recruitment/selection of patients	Recruitment began in January 2008 and was completed in September 2010.
Age, gender and ethnicity	Age - Mean (range): 65.3-65.6 years. Gender (M:F): 1.7/1. Ethnicity: Not reported
Further population details	1. BMI : Obese (BMI over 30 kg/m ²) (10.5% in both the intervention and control arms). 2. Mobility: Not stated 3. Renal impairment: Renal impairment (eGFR less than 30 ml/min/1.73m ²) (Intervention (Intervention group 35.5%; Placebo group 35.8%).
Extra comments	Primary reason for hospitalisation: Heart failure 31%; Severe systemic infection 57%; Active cancer 4.4%; Heart failure and severe systemic infection 6.2%; Heart failure and active cancer 0.2%; Severe systemic infection and active cancer 1.3%; Heart failure, severe systemic infection and active cancer 0.1%; None of the above 0.6%.
Indirectness of population	No indirectness
Interventions	(n=4174) Intervention 1: Low molecular weight heparin (licensed in UK) - Enoxaparin. Subcutaneous injection with enoxaparin, at a dose of 40 mg (Lovenox [United States] or Clexane [outside the United States], Sanofi), once every 24±4 hours during hospitalisation. Duration 10±4 days. Concurrent medication/care: Knee-high AES (Ganzoni) that provided graduated pressure from 15 mm Hg (at the ankle) to 10 mm Hg (at the knee) were provided to both groups. (n=4145) Intervention 2: No treatment - Placebo. Patients were randomly assigned to receive a subcutaneous injection with placebo (0.9% saline),once every 24±4 hours during hospitalisation. Duration 10±4 days. Concurrent medication/care: Knee-high AES (Ganzoni) that provided graduated pressure from 15 mm Hg (at the ankle) to 10 mm Hg (at the knee) were provided to both groups.
Funding	Study funded by industry (Supported by Sanofi)
RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: ENOXAPARIN versus PLACEBO	
Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge - Actual outcome: All-cause mortality at 90 days; Group 1: 348/4171, Group 2: 355/4136; Risk of bias: Low; Indirectness of outcome: No indirectness	

Study	Kakkar 2011 ¹⁶³
<p>Protocol outcome 2: Major bleeding at up to 45 days from hospital discharge - Actual outcome: Major bleeding at 8 days; Group 1: 16/4174, Group 2: 11/4145; Risk of bias: Low; Indirectness of outcome: No indirectness</p> <p>Protocol outcome 3: Clinically relevant non-major bleeding at up to 45 days from hospital discharge - Actual outcome: Clinically relevant non-major bleeding at 8 days; Group 1: 18/4174, Group 2: 14/4145; Risk of bias: Low; Indirectness of outcome: No indirectness</p>	
Protocol outcomes not reported by the study	Deep vein thrombosis (symptomatic and asymptomatic) at 7-90 days from hospital discharge; Pulmonary embolism at 7-90 days from hospital discharge; Fatal PE at up to 90 days from hospital discharge; Health-related quality of life at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at up to 90 days from hospital discharge; Technical complications of mechanical interventions at up to 90 days from hospital discharge

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
<p>Kleber et al., 2003 (The PRINCE study) ¹⁷²</p> <p>Country of study: Germany</p> <p>Study design: Multicentre RCT, open label study</p> <p>List who was masked to interventions: Open label</p>	<p>Patient group: Heart failure (n=333) and respiratory disease (n=332) patients</p> <p>Setting: inpatient</p> <p>Inclusion criteria: Aged ≥18 Hospitalised for severe respiratory disease (based on lung function test or blood gas analyses outside normal range and at ≥1 of these: severe functional loss ≥2 lung segments, severe secondary pulmonary hypertension, pneumonia, interstitial lung disease, lung cancer and/or metastases with life expectancy > 2 months, or exacerbation of COPD) or heart failure (class III or IV according to New York Heart</p>	<p>Group 1 UFH 5000IU 3 times daily, subcutaneously</p> <p>Group 2 Enoxaparin 40mg once daily, subcutaneously</p> <p>Start time: Day 1 (on enrolment day) Duration: 10±2 days</p> <p>Additional non-comparative</p>	All-cause mortality (confirmed by:)	Group1: 15/333 Group 2: 9/332 P value:	<p>Funding: Aventis Pharma</p> <p>Limitations: Open label study More patients with malignancy in the enoxaparin group</p> <p>Outcomes not reported: Symptomatic DVT Calf DVT Fatal bleeding</p> <p>Neurological bleeding Upper GI bleeding Heparin induced thrombocytopenia</p>
			Fatal pulmonary embolism (confirmed by: Autopsy. 1 heart failure patient in UFH group had both PE and DVT)	Group1: 1/212 Group 2: 0/239 P value:	
			Symptomatic pulmonary embolism (confirmed by: perfusion scintigram)	Group1: 0/212 Group 2: 1/239 P value:	
			DVT, asymptomatic or symptomatic (confirmed by: patients with positive D-dimer or fibrin monomer test)	By D-dimer test Group1: 86/212 Group 2: 84/236 P value: By Venography/autopsy, including venogram conducted >24 hours	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
<p>study. Central reviewers of efficacy end points (interpreting the screening tests and assessment of venous thromboembolic events) were masked.</p> <p>Evidence level: 1+</p> <p>Duration of follow-up: 10±2 days</p>	<p>Association classification)</p> <p>Confined to bed >2/3 of the time</p> <p>Exclusion criteria:</p> <p>Advanced acquired immunodeficiency syndrome</p> <p>Contraindication to LMWH or UFH</p> <p>Hypersensitivity to contrast media</p> <p>Severe hepatic, pancreatic or renal disease, arterial hypertension</p> <p>Intracranial bleeding or haemorrhagic stroke in the preceding 6 months</p> <p>Ocular or CNS surgery in the preceding 4 weeks</p> <p>Coagulation disorders</p> <p>Drug/alcohol abuse</p> <p>Acute signs of DVT or PE</p> <p>Gastrointestinal ulcer</p> <p>Immobilised for > 24 hours before enrolment</p> <p>Patients on anticoagulants or platelet inhibitors, or NSAIDs. However, heart failure patients allowed 100mg aspirin</p> <p>All patients</p> <p>No randomised: 668 (3 withdrawn before receiving any study medication)</p> <p>No. of dropouts: 214/665</p> <p>Age (mean): 70±14</p>	<p>prophylaxis:</p> <p>Patients on anticoagulants or platelet inhibitors, or NSAIDs.</p> <p>However, heart failure patients allowed 100mg aspirin</p> <p>AES applied up to 20% of patients in each treatment group</p>	<p>underwent bilateral venography. Autopsy)</p> <p>1 heart failure patient in UFH group had both PE and DVT</p> <p>Thigh (Proximal)DVT(confirmed by:)</p> <p>Major bleeding (description: 1 urogenital –enoxaparin and 1 haemorrhoidal-UFH. Defined as retroperitoneal or intracranial bleeding, overt bleeding with Hb)</p>	<p>after last dose</p> <p>Group1: 28/235 Group 2: 26/264 P value:</p> <p>By Venography/autopsy, in primary efficacy population</p> <p>Group1: 22/212 Group 2: 19/239 P value:</p> <p>In heart failure patients: By Venography/autopsy Group1: 15/93 Group 2: 11/113 P value:</p> <p>In respiratory failure patients By Venography/autopsy Group1: 7/119 Group 2: 8/126 P value</p> <p>Group1: 4/ 212 Group 2: 9/ 239 P value:</p> <p>Group1: 1/333 Group 2: 1/332 P value:</p>	<p>a PTS, Pulmonary hypertension QoL, LOS</p> <p>Additional outcomes reported: Notes:</p>

Study details	Patients	Interventions	Outcome measures	Effect size	Comments																																																								
	<table border="0"> <tr> <td>Risk Factors</td> <td>Gp1</td> <td>Gp2</td> <td></td> </tr> <tr> <td>Immobilisation</td> <td>332</td> <td>333</td> <td></td> </tr> <tr> <td>Congestive heart failure</td> <td>186</td> <td>186</td> <td></td> </tr> <tr> <td>Age >70yr</td> <td>185</td> <td>187</td> <td></td> </tr> <tr> <td>COPD</td> <td>134</td> <td>142</td> <td></td> </tr> <tr> <td>Venous Disease</td> <td>137</td> <td>129</td> <td></td> </tr> <tr> <td>Overweight</td> <td>104</td> <td>98</td> <td></td> </tr> <tr> <td>Diabetes Mellitus</td> <td>101</td> <td>104</td> <td></td> </tr> <tr> <td>Severe infection</td> <td>61</td> <td>56</td> <td></td> </tr> <tr> <td>Pervious myocardial infarction</td> <td></td> <td></td> <td></td> </tr> <tr> <td>41</td> <td>41</td> <td></td> <td></td> </tr> <tr> <td>Pre-existing malignancy</td> <td>25</td> <td>16</td> <td></td> </tr> <tr> <td>Dehydration</td> <td>15</td> <td>23</td> <td></td> </tr> <tr> <td>History of DVT</td> <td>20</td> <td>19</td> <td></td> </tr> </table> <p>Group 1 No. randomised: 333 M/F:183/150 No evaluated: 212 Severe respiratory disease:164 Heart failure:169</p> <p>Group 2 No. randomised: 332 M/F:160/172 No evaluated: 239 Severe respiratory disease:168 Heart failure:164</p>	Risk Factors	Gp1	Gp2		Immobilisation	332	333		Congestive heart failure	186	186		Age >70yr	185	187		COPD	134	142		Venous Disease	137	129		Overweight	104	98		Diabetes Mellitus	101	104		Severe infection	61	56		Pervious myocardial infarction				41	41			Pre-existing malignancy	25	16		Dehydration	15	23		History of DVT	20	19			Minor bleeding (description:)	Group1: 11/333 Group 2: 4/332 P value:	
Risk Factors	Gp1	Gp2																																																											
Immobilisation	332	333																																																											
Congestive heart failure	186	186																																																											
Age >70yr	185	187																																																											
COPD	134	142																																																											
Venous Disease	137	129																																																											
Overweight	104	98																																																											
Diabetes Mellitus	101	104																																																											
Severe infection	61	56																																																											
Pervious myocardial infarction																																																													
41	41																																																												
Pre-existing malignancy	25	16																																																											
Dehydration	15	23																																																											
History of DVT	20	19																																																											

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
---------------	----------	---------------	------------------	-------------	----------

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
<p>Lechler et al., 1996¹⁹⁹</p> <p>Country of study: Austria and Germany</p> <p>Study design: RCT, double blinded, multi centre</p> <p>List who was masked to interventions: Patients and investigators</p> <p>Evidence level: 1+</p> <p>Duration of follow-up: 7 days</p>	<p>Patient group: Immobilised medical patients</p> <p>Setting: 26 medical centres</p> <p>Inclusion criteria: ≥18 years old expected immobilisation of >1/2 of the time for the whole study period of 7 days, and at least one of additional risk factors such as: age >60 years malignancy obesity (>20%) former thromboembolic event cardiac insufficiency (NYHA III-IV) paresis of lower limbs hemiplegia/paraplegia severe infection</p> <p>Exclusion criteria: Anticoagulation and/or treatment with aggregation inhibitors or NSAIDs for the preceding 7 days Regional anaesthesia Pregnancy or lactation Bleeding disorder Thrombocytopenia (<100,000/μL) Head trauma in the past 6 months Haemorrhagic stroke in the preceding 4</p>	<p>Group 1 UFH 5000IU 3 times daily, subcutaneously</p> <p>Group 2 Enoxaparin 40mg, daily and 2 placebo injection(isotonic mannitol solution) (total of 3 injections daily)</p> <p>All injections were 0.2 ml Start time: within 24 hours of admission Duration: 7 days</p> <p>Additional non-comparative prophylaxis: Patients on anticoagulants, aggregation inhibitors and NSAIDs were excluded from study</p>	<p>All-cause mortality (confirmed by:)</p> <p>Symptomatic pulmonary embolism (confirmed by: perfusion scan, angiography and autopsy in cases of death if permitted)</p> <p>DVT, asymptomatic or symptomatic (confirmed by: duplex sonography at end of study period, or when clinically suspected. Positive cases were confirmed with phlebography)</p> <p>Major bleeding (description: decrease in Hb≥2g/dl, transfusion of >2 units of blood and/or retroperitoneal or intracranial bleeding)</p> <p>Upper GI bleeding</p>	<p>Group1: 11/482 Group 2: 7/477 P value: 0.47 [calculated by NCCAC team using Fisher's exact test]</p> <p>Group1: 4/443 Group 2: 0/442 P value: 0.12 [calculated by NCCAC team using Fisher's exact test]</p> <p>Group1: 4/443 Group 2: 1/442 P value: 0.38 [calculated by NCCAC team using Fisher's exact test]</p> <p>Group1: 7/482 Group 2: 2/477 P value: 0.18 [calculated by NCCAC team using Fisher's exact test]</p> <p>2 patients in heparin group were reported to have "severe bleeding". However, the definition was not provided.</p> <p>9 gastrointestinal bleeding cases.</p>	<p>Funding:</p> <p>Limitations: Not reported: o Method of randomisation/ concealment o Results across centres o Mortality causes o Mechanical prophylactic methods, or ambulation policies</p> <p>Outcomes not reported: Fatal PE, Symptomatic PE, Symptomatic DVT, Major bleeding, Minor bleeding, Heparin induced thrombocytopenia a PTS, Pulmonary hypertension, QoL, LOS</p> <p>Additional outcomes reported: 8 urogenital</p>

Study details	Patients	Interventions	Outcome measures	Effect size	Comments																														
	<p>weeks</p> <p>Endocarditis</p> <p>Suspicion for internal bleeding</p> <p>Severe liver disease/renal insufficiency</p> <p>Thromboembolism on admission and participation in a clinical trial in the preceding 6 weeks</p> <p>All patients N: 959</p> <p>Age (mean): 74±13</p> <table border="1"> <tr> <td>Main Diagnoses (%):</td> <td>Gp1</td> <td>Gp2</td> </tr> <tr> <td>Cardiovascular diseases</td> <td>67.5</td> <td>70.5</td> </tr> <tr> <td>Endocrinologic diseases</td> <td>27.9</td> <td>30.1</td> </tr> <tr> <td>Respiratory diseases</td> <td>24.3</td> <td>23.4</td> </tr> <tr> <td>Gastrointestinal and urogenital diseases</td> <td>22.6</td> <td>21.8</td> </tr> <tr> <td>Central nervous diseases</td> <td>15.8</td> <td>17.8</td> </tr> <tr> <td>Cancer</td> <td>14.7</td> <td>12.9</td> </tr> <tr> <td>Bone diseases</td> <td>10.8</td> <td>12.2</td> </tr> <tr> <td>Skin diseases</td> <td>3.5</td> <td>3.1</td> </tr> <tr> <td>Others</td> <td>8.2</td> <td>8.9</td> </tr> </table> <p>Group 1</p> <p>No. randomised: 482</p> <p>Stipulated efficacy evaluation conducted: 443</p> <p>Per protocol population:377</p> <p>M/F: 178/304</p> <p>Age (mean): 74±13</p>	Main Diagnoses (%):	Gp1	Gp2	Cardiovascular diseases	67.5	70.5	Endocrinologic diseases	27.9	30.1	Respiratory diseases	24.3	23.4	Gastrointestinal and urogenital diseases	22.6	21.8	Central nervous diseases	15.8	17.8	Cancer	14.7	12.9	Bone diseases	10.8	12.2	Skin diseases	3.5	3.1	Others	8.2	8.9	Mechanical prophylaxis unknown		Not stated which group it was from.	<p>bleedings reported-not stated which group.</p> <p>Haematomas >5 cm in diameter: 52 events in UFH and 22 in enoxaparin</p> <p>Notes: All patients were screened for DVT at study entry using B- mode scan or duplex sonography.</p>
Main Diagnoses (%):	Gp1	Gp2																																	
Cardiovascular diseases	67.5	70.5																																	
Endocrinologic diseases	27.9	30.1																																	
Respiratory diseases	24.3	23.4																																	
Gastrointestinal and urogenital diseases	22.6	21.8																																	
Central nervous diseases	15.8	17.8																																	
Cancer	14.7	12.9																																	
Bone diseases	10.8	12.2																																	
Skin diseases	3.5	3.1																																	
Others	8.2	8.9																																	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	<p>Risk factors (%)</p> <ul style="list-style-type: none"> -Immobilisation: 100 -Age >60 years: 88.8 -Heart failure: 35.9 -Overweight: 32.8 -Severe infection: 19.1 -Malignant disease: 14.7 -Paresis hemiplegia, paraplegia: 7.5 -Previous VTE: 7.7 <p>Group 2</p> <p>No. randomised: 477</p> <p>Stipulated efficacy evaluation conducted: 442</p> <p>Per protocol population: 393 M/F: 183/294</p> <p>Age (mean): 74±13</p> <p>Risk factors (%)</p> <ul style="list-style-type: none"> -Immobilisation: 100 -Age >60 years: 87.2 -Heart failure: 34.2 -Overweight: 28.7 -Severe infection: 20.1 -Malignant disease: 20.1 -Paresis hemiplegia, paraplegia: 7.5 -Previous VTE: 6.1 				

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Lederle et al.,	Patient group:	LMWH	All-cause mortality	Enoxaparin: 13/140	Funding: Supported

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
2006 ²⁰²	Hospitalised general medical patients age 60 or over	Enoxaparin 40 mg syringes. Subcutaneous daily injections. First injection given immediately after randomisation.	at 90 days	Placebo: 14/140 P value: Not reported. RR (95% CI): 0.93 (0.26-1.59)	by the Cooperative Studies Program of the
Country of study: US	Setting: Medical ward, intensive care units or intermediate care		All-cause mortality at 1 year	Enoxaparin: 36/140 Placebo: 32/140 P value: Not reported. RR (95% CI): 1.13 (0.66-1.60)	Department of Veterans Affairs Office of Research and Development.
Study design: RCT	Inclusion criteria: Admitted or transferred (from home or another hospital, institution, or service) to the medical service (medical wards or intensive care units or intermediate care) of the participating Veterans Affairs medical centre on the day of randomisation or the previous day. Age 60 years or older expected to be at the medical centre for at least 3 days from the time of randomisation able and willing to give informed consent.	Placebo Group Identical syringes containing placebo. Treatment was withheld if the patient developed any of the following: need for anticoagulation or thrombolytic therapy, decrease in platelet count of 50%, systolic pressure higher than 220 mm Hg or diastolic pressure more than 110 mm Hg, other contraindication to low-dose heparin in the opinion of	Symptomatic pulmonary embolism at 90 days (ventilation perfusion scan, pulmonary angiogram or autopsy)	Reported as "Pulmonary embolism" in table Enoxaparin Group: 1/140 Placebo Group: 3/140 P value: Not reported. Difference was NS	Enoxaparin and matching placebo syringes were provided by Rhone-Poulenc Rorer Pharmaceuticals.
List who was masked to interventions: Double blind: patient, clinician and researcher			Major bleeding (description: No details provided)	Enoxaparin Group: 2/140 Placebo Group: 5/140 P value: Not reported. Difference was NS	Limitations: Very small sample size.
Evidence level: 1+	Exclusion criteria: <ul style="list-style-type: none"> Already receiving or requiring anticoagulation for reasons other than VTE prophylaxis known thrombocytopenia (platelet count < 100000/mm³) systolic blood pressure higher than 220 mm Hg diastolic blood pressure higher than 110 mm Hg other contraindication to low-dose 		Heparin induced thrombocytopenia	Enoxaparin Group: 1/140 Placebo Group: 3/140 P value: Not reported. Difference was NS	This pilot study aimed to recruit 1000 patients and only 280 patients
Duration of follow-up: 90 days (although number of deaths at 1 year is reported)			Length of stay (mean total hospital days, initial and readmissions)	Enoxaparin Group: 13.4 Placebo Group: 11.1 P value: Not reported. Difference was NS	(140 in each group) were recruited. The pilot study was not large enough to answer the study question.

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	<p>heparin in the opinion of the patient's physicians previous randomisation into the study, "supportive/palliative care only" status occurrence within the past 30 days of myocardial infarction, stroke, major surgery (defined as requiring general, spinal, or epidural anaesthesia and lasting >30 minutes), or any eye surgery.</p> <p>All patients N: 280</p> <p>Enoxaparin Group No. randomised: 140 No. of dropouts: 2</p> <p>Age (mean): 71.3 M/F: 99.3 % men</p> <p>Additional risk factors: Weight (kg): 85.1 (units not reported) White race: 83.2 % Current pneumonia: 15 % Current smoker: 17.9 % History of: Thromboembolism: 5.7 % Heparin: 9.3 % Cancer: 5.0 %</p>	<p>the attending physicians, change of status to supportive/palliative care only, of if more than 90 days had elapsed since randomisation.</p> <p>Additional non-comparative prophylaxis: Not reported</p>			<p>32 (23%) patients in enoxaparin group and 25 (18%) in the placebo group had study drug discontinued.</p> <p>Outcomes not reported: fatal pulmonary embolism; thigh & calf DVT; fatal, neurological, upper GI or minor bleeding; post thrombotic syndrome; pulmonary hypertension; quality of life</p> <p>Additional outcomes reported: stroke, myocardial infarction, no. patients readmitted, DVT</p>

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	<p>Cerebrovascular disease 8.6% Chronic obstructive lung disease 47.1 % Diabetes: 27.9 % Congestive Heart Failure: 22.1 % Myocardial infarction: 25.7 % Peripheral vascular disease: 22.0 Surgery in the past 6 months: 2.9 % Charlson Comorbidity Index (score): 2.49 % Self-reported general health: Excellent: 2.3% Good: 16.2 % Fair: 68.5% Poor: 13.1 %</p> <p>Placebo Group No. randomised: 140 No. of dropouts: 1</p> <p>Age (mean): 72.1 M/F: 97.8% men Additional risk factors: Weight (kg): 85.5 (units not reported) White race: 75.2 % Current pneumonia: 19.3 % Current smoker: 15.0 % History of: Thromboembolism: 3.6 % Heparin: 8.6 % Cancer: 4.3 %</p>				<p>but not clear how diagnosed</p> <p>Notes: Authors do not provide detailed information on how outcomes were measured. Causes of deaths and drug discontinuation are not described.</p>

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	Cerebrovascular disease 11.4% Chronic obstructive lung disease 40.0 % Diabetes: 28.6 % Congestive Heart Failure: 27.1 % Myocardial infarction: 22.9 % Peripheral vascular disease: 10.0 p= 0.02 Surgery in the past 6 months: 2.9 % Charlson Comorbidity Index (score): 2.47 % Self-reported general health: Excellent: 3.0% Good: 21.1 % Fair: 56.4% Poor: 19.5 %				

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Leizorovicz et al., 2004 ²⁰³ Prospective Evaluation of Dalteparin Efficacy for Prevention of VTE (The PREVENT	Patient group: -Acutely ill medical patients with one of: acute congestive heart failure acute respiratory failure not requiring mechanical ventilation Or one of following with >1 risk factors listed in last point: acute infection without septic shock	Group I LMWH dalteparin 5000 IU 1x/day for 14 days	All-cause mortality at day 14	Group 1: 8/1846 Group 2: 7/1831 Relative risk: 1.13 (0.41, 3.12)	Funding: Pharmacia Limitations: Not clear if clinicians treating patients were masked to
			All-cause mortality at day 21	Group 1: 43/1829 Group 2: 42/1807 Relative risk: 1.01 (0.66, 1.54)	
		Group II placebo 1x/day for 14 days	All-cause mortality at 90 days	Group 1: 107/1747 Group 2: 103/1715 Relative risk: 1.02 (0.78, 1.33)	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Study) Country of study: Multi-national Study design: RCT List who was masked to interventions: Subjects and investigators of VTE assessment Evidence level: 1+ Duration of follow-up: 14 days treatment, 90 days follow-up	episode of inflammatory bowel disease acute rheumatic disorders acute lumbar pain, sciatica or vertebral compression acute arthritis of the legs or acute episode of rheumatoid arthritis in the legs risk factors: age >75, cancer, previous VTE, obesity, varicose veins, chronic venous insufficiency, hormone therapy, chronic heart or respiratory failure or myeloproliferative disorder Setting: hospital Inclusion criteria: -immobilised but have been for <3 days -projected hospital stay of >4 days ->40 years old Exclusion criteria: -acute coronary syndrome within previous month -major surgical or invasive procedure within previous month or to be undertaken within next 2 weeks - bacterial endocarditis -immobilised lower limb due to cast or fracture	Additional non-comparative prophylaxis: Low dose aspirin (up to 325mg/day), ticlopidine and clopidogrel permitted; “Chronic use” non-steroidal anti-inflammatory drugs discourage but not forbidden. Other antithrombotic agents not permitted, anyone given one of these withdrawn from the study Numbers not given for any of the above	Fatal pulmonary embolism at day 21 (confirmed by autopsy) Symptomatic pulmonary embolism at day 21 * Symptomatic pulmonary embolism at day 90 * Symptomatic distal DVT at day 21 \$ Symptomatic proximal DVT at day 21 \$ Asymptomatic proximal DVT at day 21 \$ DVT: any proximal and symptomatic distal at day 21 Symptomatic VTE at 90 days	Group 1: 0/1829 Group 2: 2/1807 Relative risk: 0.00 Group 1: 5/1759 Group 2: 4/1740 Relative risk: 1.22 Group 1: 5/1615 Group 2: 6/1583 Relative risk: 0.82 (0.25, 2.67) Group 1: 3/1759 Group 2: 4/1739 Relative risk: 1.22 Group 1: 2/1759 Group 2: 7/1739 Relative risk: 0.28 () Group 1: 27/1507 Group 2: 53/1453 Relative risk: 0.48 (0.31, 0.77) Group 1: 32/1508 Group 2: 64/1464 Relative risk: 0.49 (0.32, 0.74) Group 1: 15/1615 Group 2: 21/1583 Relative risk: 0.70 (0.36, 1.35)	treatment, not reported if allocation to interventions was concealed from patients and participants Outcomes not reported: post-thrombotic syndrome, quality of life, length of stay Additional outcomes reported: thrombocytopenia (not stated if heparin induced thrombocytopenia), Notes: * pulmonary embolism diagnosed by ventilation-perfusion

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	<ul style="list-style-type: none"> -stroke within previous 3 months -high risk of bleeding -platelet count <100x10⁹/L -heparin or LMWH given for >48 hours before randomisation -contraindication to heparin anticoagulation -creatinine >2.0mg/dL -hepatic insufficiency or active hepatitis -pregnancy or breast feeding -life expectancy <1 month <p>All patients N: 3706 No. of dropouts: 25</p> <p>Primary Diagnosis Gp1 Gp2</p> <p>Acute congestive heart failure (NYHA class III or IV) 965 940</p> <p>Acute respiratory failure 561 560</p> <p>Infectious disease 673 687</p> <p>Rheumatological disease 200 198</p> <p>Inflammatory bowel disease 10 8</p>		<p>All symptomatic DVT at 90 days</p> <p>Major bleeding at day 21 £</p> <p>Major bleeding at day 14 £</p> <p>Fatal bleeding at day 21</p> <p>Minor bleeding at day 21</p> <p>Minor bleeding at day 14</p>	<p>Group 1: 10/1614 Group 2: 15/1579 Relative risk: 0.65 (0.29, 1.45)</p> <p>Group 1: 9/1759 Group 2: 3/1740 p value: not significant</p> <p>Group 1: 8 (unsure of denominator) Group 2: 0 (unsure of denominator) p value: not significant</p> <p>Group 1: 10/1614 Group 2: 15/1579 Relative risk: 0.65 (0.29, 1.45)</p> <p>Group 1: 19/1759 Group 2: 10/1740 p value: not significant</p> <p>Group 1: 16 (unsure of denominator) Group 2: 5 (unsure of denominator) p value: not significant</p>	<p>scanning, pulmonary angiography, spiral CT scan or MRI</p> <p>§ DVT diagnosed by compression ultrasonography or venography</p> <p>£ major bleeding defined as: intraocular, spinal/epidural, intracranial or retroperitoneal bleeding; if haemoglobin decreased by >2g/dL; if transfusion of >2 U of blood or significant medical or surgical intervention required; or it resulted in sudden death.</p>

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	<p>Group I</p> <p>No. randomised: 1848</p> <p>No. of dropouts: 8</p> <p>Age (mean): 68.5 +11.1</p> <p>M/F: 884/964</p> <p>Additional risk factors:</p> <p>age >75 33.1%;</p> <p>cancer 4.6%;</p> <p>previous VTE 3.4%;</p> <p>obesity 30.2%;</p> <p>varicose veins 26.4%;</p> <p>hormone therapy 1.8%; chronic heart failure 50.1%;</p> <p>myeloproliferative syndrome 0.3%, chronic respiratory failure 9.5%</p> <p>Group II</p> <p>No. randomised: 1833</p> <p>No. of dropouts: 7</p> <p>Age (mean): 68.5 +11.7</p> <p>M/F: 888/945</p> <p>Additional risk factors: age >75 33.6%;</p> <p>cancer 5.7%;</p> <p>previous VTE 4.4%;</p> <p>obesity 30.6%;</p> <p>varicose veins 28.9%;</p> <p>hormone therapy 1.6%; chronic heart failure 51.6%;</p> <p>myeloproliferative syndrome 0.5%,</p>				

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	chronic respiratory failure 10%				

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Mahe et al., 2005 ²¹²	Patient group: Bedridden medical patients (main	Group I LMWH	All-cause mortality	Group 1: 124/1230 Group 2: 128/1244	Funding: "supported by a

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Country of study: France	conditions at inclusion: acute cardiovascular disease 13%, atrial fibrillation 12%, acute pulmonary disease 22%, cancer 14%, sepsis (not pulmonary) 23%)	(nadroparin, 0.3ml (7500 AXa IU)) subcutaneously started within 24 hours of hospitalisation and continued for 21 days or until discharge.	Fatal pulmonary embolism by total no. deaths confirmed by autopsy	P value: 0.89 Group 1: 10/63 Group 2: 17/60 P value: 0.26	grant for Independent Research from Sanofi-Choay”
Study design: RCT	Setting: hospital	Group II placebo			Limitations: Only patients appear to be masked to treatment; not reported if allocation to interventions was concealed from patients and participants; only around half of deaths received autopsy
List who was masked to interventions: patients	Inclusion criteria: age >40 hospitalised for <24 hours before randomisation • immobilised (unable to walk 10m alone)	Additional non-comparative prophylaxis: None			Outcomes not reported: pulmonary embolism, DVT, major and minor bleeding, heparin induced thrombocytopenia, post-
Evidence level: 1+	Exclusion criteria: • conditions that could increase the risk of haemorrhage (systolic blood pressure >240mmHg, active gastroduodenal ulcer, renal failure – creatinine level >300 µmol/1, prothrombin time <50%, platelet level <50,000/mm ³ , TCA >control + 10s) • conditions requiring full anticoagulation • stroke or major surgery within previous 30 days • anticoagulant or antiplatelet therapy within last 7 days • pregnancy				
Duration of follow-up: 21 days or until discharge (mean study period 13.08 (+6.53 days)					

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	<p>All patients N: 2474 No. of dropouts: 0</p> <p>Group I No. randomised: 1230 No. of dropouts: 0 Age (mean): 76.1 M/F: 42% male Additional risk factors: chronic heart failure 26.7%, previous VTE 1.9%, chronic pulmonary disorder 18.5, smoking 15.7%, alcohol abuse 10%, previous stroke 8.5%, recent surgery or trauma (within 1-3 months) 3.7% Other factors:</p> <p>Group II No. randomised: 1244 No. of dropouts: 0 Age (mean): 76.5 M/F: 39% male Additional risk factors: chronic heart failure 24.8%, previous VTE 1.9%, chronic pulmonary disorder 17.6, smoking 14.1%, alcohol abuse 8.4%, previous stroke 7.1%, recent surgery or trauma</p>				<p>thrombotic syndrome, quality of life, length of stay</p> <p>Additional outcomes reported: venous thrombosis diagnosed at autopsy, thrombocytopenia (not stated if heparin induced thrombocytopenia)</p> <p>Notes: Study first reported as a letter in 1996 only published as an article in 2005.</p> <p>Study stopped at interim review. Power analysis determine 3000 patients would be needed to show a</p>

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	(within 1-3 months) 2.9% Other factors:				<p>difference in mortality. However, the investigators concluded that an additional 600 patients to the interim results of 2474 patients would not lead to a difference.</p> <p>Study screened 35,000 patients for inclusion, main reasons for not being included: ability to walk >10m alone (73%), age <40 years (11%), recent anticoagulation (4.5%)</p>

Study	Miranda 2017 ²²⁴
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=91)
Countries and setting	Conducted in France; Setting: A tertiary care medical centre
Line of therapy	Not applicable
Duration of study	Intervention time: 14 days

Study	Miranda 2017 ²²⁴
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: Major bleeding: defined as fatal, intracranial or retroperitoneal haemorrhage, necessity of blood transfusion (2 units) or decrease of haemoglobin level greater than 2g/dL.
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Patients aged greater than 40 years and BMI \geq 30 kg/m ² . Patients had to be hospitalised for the following medical settings: acute congestive heart failure (New York Heart Association class III or IV), acute respiratory failure that did not require ventilator support, acute infection without septic shock, acute rheumatic disorders or inflammatory bowel disease. All levels of obesity from Class 1 to Class 3 were eligible.
Exclusion criteria	Patients were pregnant or breast-feeding women, severe renal insufficiency (defined by clearance $<$ 30 mL/min), high risk of bleeding, platelet count below $50 \times 10^9/L$, hypersensitivity to heparin or heparin-induced thrombocytopenia type II, and patients already using anticoagulants.
Recruitment/selection of patients	Between September 2013 and April 2015, patients were recruited from 3 different departments: internal medicine, rheumatology and pneumology.
Age, gender and ethnicity	Age - Mean (range): 71 (43-90) years. Gender (M:F): 1/1.2. Ethnicity: Not reported
Further population details	1. BMI : Severely obese (BMI over 35 kg/m ²) (Mean BMI: enoxaparin (60mg) group 35.8; enoxaparin (40mg) 37.2). 2. Mobility: Not applicable 3. Renal impairment: No renal impairment (eGFR greater than 30ml/min/1.73m ²)
Extra comments	Medical condition: acute infection 50%, acute rheumatic disorders 18%, acute respiratory failure 10.5%, acute congestive heart failure 9%, combined indications 14%
Indirectness of population	No indirectness
Interventions	(n=46) Intervention 1: Low molecular weight heparin (licensed in UK) - Enoxaparin. Enoxaparin (60mg) was subcutaneously administered once daily during the first 14 days of hospitalisation at 12pm. Duration 14 days. Concurrent medication/care: After the 14 days, the use of enoxaparin was decided at the discretion of the physician in charge. Indirectness: No indirectness (n=45) Intervention 2: Low molecular weight heparin (licensed in UK) - Enoxaparin. Enoxaparin (40mg) was subcutaneously administered once daily during the first 14 days of hospitalisation at 12pm. Duration 14 days. Concurrent medication/care: After the 14 days, the use of enoxaparin was decided at the discretion of the physician in charge. Indirectness: No indirectness
Funding	Funding not stated
RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: ENOXAPARIN (HIGH DOSE) versus ENOXAPARIN (STANDARD DOSE)	

Study	Miranda 2017 ²²⁴
	<p>Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge - Actual outcome: All-cause mortality at 14 days; Group 1: 0/46, Group 2: 1/45 Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0</p> <p>Protocol outcome 2: Major bleeding at up to 45 days from hospital discharge - Actual outcome: Major bleeding at 14 days; Group 1: 0/46, Group 2: 0/45 Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0</p> <p>Protocol outcome 3: Heparin-induced thrombocytopenia at up to 90 days from hospital discharge - Actual outcome: Thrombocytopenia at 14 days; Group 1: 0/46, Group 2: 0/45 Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0</p>
Protocol outcomes not reported by the study	Deep vein thrombosis (symptomatic and asymptomatic) at 7-90 days from hospital discharge; Pulmonary embolism at 7-90 days from hospital discharge; Fatal PE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding at up to 45 days from hospital discharge; Health-related quality of life at up to 90 days from hospital discharge; Technical complications of mechanical interventions at up to 90 days from hospital discharge

Study	Riess 2010 ²⁷³ ; Haas 2011 ¹³⁰ – cancer subgroup; Schellong 2011 ²⁸⁹ – older adults; Tebbe 2011 – heart failure patients ³¹²
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=3239)
Countries and setting	Conducted in Germany, Unknown multicentre; Setting: 172 centres
Line of therapy	Not applicable
Duration of study	Intervention time: 8-20 days
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: The incidence of asymptomatic proximal and/or distal DVT was assessed with the use of compression ultrasonography (CUS) of the lower extremity veins at the final visit.

	Major bleeding was defined as fatal bleeding, clinically overt bleeding associated with a fall in the hemoglobin concentration of more than 20 g L ⁻¹ as compared with the baseline hemoglobin concentration, clinically overt bleeding that required transfusion of two or more units of packed red cells or whole blood, or symptomatic bleeding in a critical area or organ (intracranial, intraspinal, retroperitoneal, and pericardial).
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Hospitalised medical patients aged at least 70 years, patients had an acute medical illness with a significant decrease in mobility (bedridden or only able to walk short distances) expected for at least 4 days.
Exclusion criteria	Those with immobilization for more than 3 days prior to randomization; those with immobilization due to cast or fracture; those who were expected to undergo a major surgical or invasive procedure within 3 weeks following randomization; those with severe sepsis or a need for ventilatory support (continuous positive airway pressure, oxygen mask, etc. were permitted); those who had received LMWH/heparin for longer than 48 h in the 5 days prior to randomization; those with indications for anticoagulation or thrombolysis; those with a life-expectancy of less than 6 months, or illness with very high acute mortality rate (> 30%); those with acute symptomatic deep vein thrombosis (DVT)/pulmonary embolism (PE); those with acute heparin-induced thrombocytopenia type II (HIT-II) or a history of this; those with acute non-hemorrhagic stroke or a history of this (< 3 months); those with hemorrhagic stroke or intracranial bleeding (< 12 months); those with acute or ongoing intracranial disease; those with a high risk of gastrointestinal bleeding; those with spinal or epidural anesthesia, or lumbar puncture, within the last 12 h; those with uncontrolled hypertension; those with severe liver or renal disease; those with acute endocarditis; and those with known active retinopathy, or intravitreal or other intraocular bleeding.
Recruitment/selection of patients	Patients were recruited in 172 centres between January 2007 and June 2009, and randomized to receive certoparin or UFH
Age, gender and ethnicity	Age - Mean (SD): 78.8 (6.3). Gender (M:F): 1/1.45. Ethnicity: Not reported
Further population details	1. BMI : Not stated 2. Mobility: Mixed 3. Renal impairment: Not stated
Extra comments	Reasons for hospitalisation: Infections and infestations 27.6%, cardiac disorders 22.2%, respiratory, thoracic and mediastinal disorders 17.3%, nervous system disorders 6.6%, gastrointestinal disorders 6.6%, vascular disorders 5.8%
Indirectness of population	No indirectness
Interventions	(n=1626) Intervention 1: Low molecular weight heparin (not licensed in UK) - LMWH (not licensed in UK). Certoparin 3000 U subcutaneously given once daily. The patients in the certoparin treatment group received two additional placebo injections during the day, at 8 hour intervals. Duration 8-20 days. Concurrent medication/care: (Mono-embolex; Novartis Pharma GmbH, Nürnberg, Germany)

	(n=1618) Intervention 2: Unfractionated heparin - low dose, administered subcutaneously. 5000 IU of UFH subcutaneously given three times daily at 8 hour intervals. Duration 8-20 days. Concurrent medication/care: Liquemin N 5000; Hoffmann-LaRoche AG, Grenzach-Wyhlen, Germany
Funding	Study funded by industry (Funded by Novartis Pharma, Nurnberg, Germany)
<p>CERTIFY - RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: CERTOPARIN versus UNFRACTIONATED HEPARIN</p> <p>Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge - Actual outcome: All-cause mortality at 90 days; Group 1: 66/1488, Group 2: 72/1459; Risk of bias: High; Indirectness of outcome: No indirectness</p> <p>Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic) at 7-90 days from hospital discharge (not analysed) - Actual outcome: Symptomatic DVT at 90 days; Group 1: 3/1483, Group 2: 3/1454</p> <p>Protocol outcome 3: Pulmonary embolism at 7-90 days from hospital discharge - Actual outcome: PE at 90 days; Group 1: 3/1483, Group 2: 2/1454; Risk of bias: High; Indirectness of outcome: No indirectness</p> <p>Protocol outcome 4: Major bleeding at up to 45 days from hospital discharge - Actual outcome: Major bleeding at Unclear; Group 1: 7/1624, Group 2: 10/1615; Risk of bias: High; Indirectness of outcome: No indirectness</p> <p>Protocol outcome 5: Heparin-induced thrombocytopenia at up to 90 days from hospital discharge - Actual outcome: Heparin-induced thrombocytopenia at Unclear; Group 1: 1/1624, Group 2: 2/1615; Risk of bias: High; Indirectness of outcome: No indirectness</p> <p>Protocol outcome 6: Venous thromboembolism at 7-90 days from hospital discharge (not analysed) - Actual outcome: Symptomatic VTE (DVT or symptomatic, non-fatal PE) at 90 days; Group 1: 5/1483, Group 2: 5/1454</p> <p>Subgroup analysis evaluating cancer patients: Haas 2011 ¹³⁰</p> <p>Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge - Actual outcome: Death from any cause at 35 days; Group 1: 159/3096, Group 2: 153/3169; Risk of bias: Low; Indirectness of outcome: No indirectness - Actual outcome: VTE-related death at 35 days; Group 1: 19/2967, Group 2: 30/3057; Risk of bias: High; Indirectness of outcome: No indirectness</p> <p>Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic) at 7-90 days from hospital discharge - Actual outcome: DVT (symptomatic and asymptomatic) at 35 days; Group 1: 116/2967, Group 2: 148/3057; Risk of bias: High; Indirectness of outcome: No indirectness</p> <p>Protocol outcome 3: Pulmonary embolism at 7-90 days from hospital discharge</p>	

- Actual outcome: PE at 35 days ; Group 1: 10/2967, Group 2: 14/3057; Risk of bias: Low; Indirectness of outcome: No indirectness

Protocol outcome 4: Major bleeding at up to 45 days from hospital discharge

- Actual outcome: Major bleeding at 35 days; Group 1: 43/3997, Group 2: 15/4001;

Protocol 5: Venous thromboembolism at 7-90 days from hospital discharge (not analysed)

- Actual outcome: Symptomatic VTE at 35 days; Group 1: 18/3997, Group 2: 12/4001

Subgroup analysis evaluating age: Schellong 2011²⁹⁰

RESULTS (NUMBERS ANALYSED) FOR COMPARISON: CERTOPARIN (≥80 YEARS OLD) versus UNFRACTIONATED HEPARIN (≥80 YEARS OLD)

Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge

- Actual outcome: All-cause mortality at 8-20 days; Group 1: 10/680, Group 2: 12/645;

Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic) at 7-90 days from hospital discharge

- Actual outcome: DVT (symptomatic and asymptomatic) at 8-20 days; Group 1: 53/514, Group 2: 68/518;

Protocol outcome 3: Pulmonary embolism at 7-90 days from hospital discharge

- Actual outcome: PE at 8-20 days; Group 1: 1/652, Group 2: 1/636;

Protocol outcome 4: Major bleeding at up to 45 days from hospital discharge

- Actual outcome: Major bleeding at 8-20 days; Group 1: 4/689, Group 2: 7/676;

RESULTS (NUMBERS ANALYSED) FOR COMPARISON: CERTOPARIN (70 - <80 YEARS OLD) versus UNFRACTIONATED HEPARIN (70 - <80 YEARS OLD)

Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge

- Actual outcome: All-cause mortality at 8-20 days; Group 1: 10/911, Group 2: 9/899;

Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic) at 7-90 days from hospital discharge

- Actual outcome: DVT (symptomatic and asymptomatic) at 8-20 days; Group 1: 45/714, Group 2: 55/739;

Protocol outcome 3: Pulmonary embolism at 7-90 days from hospital discharge

- Actual outcome: PE at 8-20 days; Group 1: 6/903, Group 2: 2/893;

Protocol outcome 4: Major bleeding at up to 45 days from hospital discharge

- Actual outcome: Major bleeding at 8-20 days; Group 1: 3/935, Group 2: 3/939;

Subgroup analysis evaluating patients with heart failure: Tebbe 2011³¹²

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: CERTOPARIN versus UNFRACTIONATED HEPARIN

Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge

- Actual outcome: All-cause mortality at 8-20 days; Group 1: 6/268, Group 2: 0/260;

Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic) at 7-90 days from hospital discharge

- Actual outcome: DVT (symptomatic and asymptomatic) at 8-20 days; Group 1: 27/217, Group 2: 26/211;

Protocol outcome 3: Pulmonary embolism at 7-90 days from hospital discharge

- Actual outcome: PE at 8-20 days; Group 1: 0/262, Group 2: 0/260;

Protocol outcome 4: Major bleeding at up to 45 days from hospital discharge

- Actual outcome: Major bleeding at 8-20 days; Group 1: 2/277, Group 2: 1/265;

Protocol outcome 5: Heparin-induced thrombocytopenia at up to 90 days from hospital discharge

- Actual outcome: Heparin-induced thrombocytopenia at 8-20 days; Group 1: 1/277, Group 2: 2/265;

Protocol outcomes not reported by the study

Fatal PE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding at up to 45 days from hospital discharge; Health-related quality of life at up to 90 days from hospital discharge; Technical complications of mechanical interventions at up to 90 days from hospital discharge

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Samama et al., 1999 ²⁸⁴	Patient group: Acutely ill medical patients	Group 1 LMWH (20 mg Enoxaparin)	All-cause mortality (confirmed by:)	Treatment period (days 1-14) Group 1: 15/351 Group 2: 12/360	Funding: Supported by grant from Rhone- Poulenc Rorer (France)
MEDENOX study	Setting: General medical ward (most patients were not in an intensive care unit)	20 mg of enoxaparin (Lovenox, Clexane or Klexane, Rhone- Poulenc Rorer, Antony,		Group 3: 16/362 P: NR Study period (days 1-110) Group 1: 51/351 Group 2: 41/360	Limitations: A number of patients were not included
Country of study:	Inclusion criteria:			Group 3: 50/362	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
International: 60 centres in 9 countries	Medical patients older than 40 years, whose projected stay in hospital was at least six days and not immobilised for more than three days. Patients had to have congestive heart failure (CHF) (New York Association class III or IV), acute respiratory failure that did not require ventilatory support, or one of the following conditions if it was associated with at least one additional risk factor for VT: acute infection with septic shock, acute rheumatic disorders, acute arthritis of the legs, or an acute episode of rheumatoid arthritis in the legs; or an episode of inflammatory bowel disease. The additional risk factors were age >75 years, cancer, previous VT, obesity (BMI >=30 for men and >=28 for women), varicose veins, hormone therapy (antiandrogen or oestrogen, except for postmenopausal hormone-replacement therapy) and chronic heart or respiratory failure.	France) subcutaneously once daily. 20 mg of enoxaparin in 0.2 ml of water for injectable preparations Start time: within 24 after randomisation End time: Treatment scheduled to last 6 to 14 days in the hospital Group 2 LMWH (40 mg Enoxaparin) 40 mg of enoxaparin (Lovenox, Clexane or Klexane, Rhone- Poulenc Rorer, Antony, France) subcutaneously once daily. 40 mg of enoxaparin in 0.2 ml of water for injectable preparations Start time: within 24 after	Fatal pulmonary embolism (confirmed by autopsy)	RR (95% CI) as compared with placebo: Group 1: 1.05 (0.71-1.56) p= 0.80 Group 2: 0.83 (0.56-1.21) p=0.31	in the analyses for primary and secondary outcomes. Reasons below Outcomes not reported: pulmonary hypertension, heparin-induced thrombocytopenia; post thrombotic syndrome, quality of life, length of stay Additional outcomes reported: Local reaction at injection site (hematoma>5 cm in diameter); any thrombocytopenia Notes: * (description: If bleeding was overt
Study design: RCT				Primary outcome (VT between days 1-14) Group 1: 0/287 Group 2: 0/291 Group 3 0/288 P: NR Secondary outcome (VT between days 1-110) Group 1: 1/263 Group 2: 2/272 Group 3: 1/263 P value: NR	
List who was masked to interventions: Double-blind: Patients and investigators of VTE				Reported in text: by day 14 Group 1: 1/287 Group 2: 0/291 Group 3: 3/288 P value: NR	
Evidence level: 1+				Primary outcome (VT between days 1-14) Group 1: 1/287 Group 2: 0/291 Group 3 3/288 P value: NR Secondary outcome (VT between days 1-110) Group 1: 1/263	
Duration of follow-up: 3 months			Pulmonary embolism, asymptomatic or symptomatic (confirmed by high-probability lung scanning, pulmonary angiography, or helical computed tomography or at autopsy)		

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
		randomisation		Group 2: 0/272 Group 3: 3/263 P value: NR	and was associated with the need for transfusion of two or more units of packed red cells or whole blood or with a decrease in the haemoglobin concentration of 2.0 g per decilitre or more from baseline or if bleeding was retroperitoneal, intracranial, or fatal)
	Exclusion criteria: Women of childbearing age if pregnant, breast-feeding or not using contraception.	End time: Treatment scheduled to last 6 to 14 days in the hospital			
	Other exclusions were: stroke or major surgery within the previous three months, contraindications to use of iodinated contrast medium; known thrombophilia; a serum creatinine concentration >1.7 mg/dl, intubation, HIV, uncontrolled arterial hypertension, active peptic ulcer, bacterial endocarditis, or other conditions that could increase the risk of haemorrhage; hypersensitivity to heparin or heparin-induced thrombocytopenia; or platelet count < 100,000/mm ³ a prolonged activated partial-thromboplastin time, a prothrombin ratio of less than 50 percent, or an international normalized ratio of more than 1.2. Patients who required anticoagulant therapy and those who received any type of anticoagulant therapy for more than 48 hours.	Group 3 (Placebo) Placebo (0.2 ml of isotonic water) Start time: within 24 after randomisation End time: Treatment scheduled to last 6 to 14 days in the hospital	Symptomatic DVT (confirmed by: not reported)	Primary outcome (VT between days 1-14) Group 1: 3/287 Group 2: : 1/291 Group 3: 2/288 Secondary outcome (VT between days 1-110) Group 1: 6/263	
		Additional non-comparative prophylaxis: Elastic bandages or support stockings, and physiotherapy were used according to the usual practice at each centre.		Group 2: : 3/272 Group 3: 4/263	
		Throughout the treatment period,	DVT, asymptomatic or symptomatic (confirmed by systematic ascending contract venography of the legs between days 6 and 14, or earlier if thrombosis was clinically suspected. If venography was infeasible venous ultrasonography was performed.)	Primary outcome (VT between days 1-14) Group 1: 42/287 Group 2: : 16/291 Group 3: 41/288 RR (95% CI) as compared with placebo: Group 1: 1.05 (0.71-1.57) p= 0.81 Group 2: 0.40 (0.23-0.69) p<0.001 Secondary outcome (VT between	Reasons for patients not evaluated for primary outcome, analysis of VTE at 14 days: death 28/236; patient's refusal 62/236, investigator's

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	<p>All patients N: 1,102 No. of dropouts: There were 236 patients not evaluated for the primary outcome (VT defined as DVT, PE, or both between days 1 and 14) and 71 patients were not evaluated for the secondary outcome (VT between days 1 and 110) reasons included in table 1.</p> <p>Group 1 (20 mg Enoxaparin) No. randomised: 364 No. of dropouts No. evaluated for primary outcome: Evaluated: 287 (78.8%) Not evaluated: 77 (21.2%) No. evaluated for secondary outcome: Evaluated: 263 (72.3%) Not evaluated: 25 (6.9%) Age (mean +/- SD): 72.9 +/- 10.1 M/F: 187/176 Reasons for hospitalisation-no. (%): NYHA class III CHF: 76 (20.9) NYHA class IV CHF: 44 (12.1) Acute respiratory failure: 192 (52.9) Acute infectious disease: 194 (53.4) Acute rheumatic disorder: 40 (11.0) Inflammatory bowel disease: 1 (0.3)</p>	<p>intramuscular injections and treatment with nephrotoxic substances, particularly nephrotoxic antibiotics, were not permitted. Centres were advised to avoid giving patients nonsteroidal anti-inflammatory drugs</p>	<p>Thigh DVT Reported in table described as proximal deep- vein thrombosis. Confirmed by see above</p>	<p>days 1-110) Group 1: 44/263 Group 2: : 17/272 Group 3: 42/263 RR (95% CI) as compared with placebo: Group 1: 1.07 (0.73-1.58) p= 0.81 Group 2: 0.40 (0.23-0.69) p<0.001</p> <p>Primary outcome (VT between days 1-14) Group 1: 13/287 Group 2: 5/291 Group 3: 14/288 RR (95% CI) as compared with placebo: Group 1: 0.93 (0.45-1.94) p=0 1 Group 2: 0.35 (0.13-0.97) p=0.04</p> <p>Secondary outcome (VT between days 1-110) Group 1:14/263 Group 2: 6/272 Group 3: 17/263 RR (95% CI) as compared with placebo: Group 1: 0.83 (0.42-1.64) p= 0.71 Group 2: 0.34 (0.14-0.86) p=0.02</p>	<p>decision 62/236, venography technically unfeasible 12/236, venogram could not be evaluated 72/236, unknown, venography not performed 10/236</p> <p>Reasons for patients not evaluated for secondary outcome, analysis of VTE at 110 days: death 61/71; loss to follow up or scheduled visit before 90 days 10/71</p>
			<p>Calf DVT Reported in table described as distal deep-vein thrombosis. Confirmed by see above</p>	<p>Primary outcome (VT between days 1-14) Group 1: 30/287 Group 2: : 11/291 Group 3: 27/288 G Secondary outcome (VT between days 1-110)</p>	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	Additional risk factors- no. (%): Age>75 years: 172 (47.4) Cancer (previous or current): 56 (15.4)			Group 1: 31/263 Group 2: 12/272 Group 3: 27/263	
	History of VT: 35 (9.6) Obesity: 79 (21.8) Varicose veins: 88 (24.2) Hormone therapy: 8 (2.2) Chronic heart failure: 106 (29.2) Chronic respiratory failure: 197 (54.3) >=2 Risk factors 241 (66.4) Group 2 (40 mg Enoxaparin) No. randomised: 367 No. of dropouts: No. evaluated for primary outcome: Evaluated: 291 (79.3) Not evaluated 76 (20.7%) No. evaluated for secondary outcome: Evaluated: 272 (74.1%) Not evaluated: 20 (5.4%) Age (mean): 73.1 +/- 10.8 M/F: 171/196 Reasons for hospitalisation-no. (%): NYHA class III CHF: 103 (28.1) NYHA class IV CHF: 26 (7.1) Acute respiratory failure: 195 (53.1)		Fatal bleeding (description:)	Treatment period (days 1-14) Group 1: 0/351 Group 2: 1/360 Group 3: 0/362 P value not reported Study reports NS difference between groups Study period (days 1-110) Group 1: 1/351 Group 2: : 2/360 Group 3: 0/362 P value not reported Study reports NS difference between groups	
			Major bleeding *	Treatment period (days 1-14) Group 1: 1/351 Group 2: 6/360 Group 3: 4/362 P value not reported Study reports difference NS Study period (days 1-110) Group 1: 4/351 Group 2: 12/360 Group 3: 7/362 P value not reported Study reports difference NS	
			Minor bleeding (description: Overt but did not meet the other	Treatment period (days 1-14) Group 1: 40/351 Group 2: 39/360	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	<p>Acute infectious disease: 197 (53.7) Acute rheumatic disorder: 28 (7.6) Inflammatory bowel disease: 3 (0.8)</p> <p>Additional risk factors- no. (%): Age>75 years: 185 (50.4) Cancer (previous or current): 45 (12.3) History of VT: 30 (8.2) Obesity: 72 (19.6) Varicose veins: 98 (26.7) Hormone therapy: 5 (1.4)</p>		<p>criteria for major bleeding)</p>	<p>Group 3: 27/362 P value not reported Study reports difference NS Study period (days 1-110) Group 1: 57/351 Group 2: 51/360 Group 3: 45/362 P value not reported Study reports difference NS</p>	
	<p>Chronic heart failure: 123 (33.5) Chronic respiratory failure: 195 (53.1)</p> <p>>=2 Risk factors: 245 (66.8)</p> <p>Group 3 (Placebo) No. randomised: 371 No. of dropouts: No. evaluated for primary outcome: Evaluated: 288 (77.6 %) Not evaluated: 83 (22.4%) No. evaluated for secondary outcome: Evaluated: 263 (70.9%) Not evaluated: 26 (7.0 %)</p> <p>Age (mean): 74.1 +/- 10.6 M/F: 192/178</p>		<p>Venous thromboembolic events (defined as DVT, PE or both)</p>	<p>Primary outcome (VT between days 1-14) Group 1: 43/287 Group 2: 16/291 Group 3: 43/288 RR (95% CI) as compared with placebo: Group 1: 1.02 (0.70-1.51) p= 0.90 Group 2: 0.37 (0.22-0.63) p<0.001 Secondary outcome (VT between days 1-110) Group 1 (20 mg Enoxaparin):46/263 Group 2: 19/272 Group 3: 45/263 RR (95% CI) as compared with placebo: Group 1: 1.02 (0.70-1.49) p= 0.91 Group 2: 0.41 (0.25-0.68) p<0.001</p>	
			<p>DVT and PE</p>	<p>Primary outcome (VT between days 1-14) Group 1: 1/287 Group 2: 0/291</p>	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	<p>Reasons for hospitalisation-no. (%): NYHA class III CHF: 95 (25.7) NYHA class IV CHF: 32 (8.6) Acute respiratory failure: 202 (54.6) Acute infectious disease: 193 (52.2) Acute rheumatic disorder: 32 (8.6) Inflammatory bowel disease: 1 (0.3)</p> <p>Additional risk factors- no. (%): Age>75 years: 197 (53.2) Cancer (previous or current): 56 (15.1) History of VT: 39 (10.5) Obesity: 71 (19.2) Varicose veins: 93 (25.1) Hormone therapy: 9 (2.4) Chronic heart failure: 124 (33.5) Chronic respiratory failure: 197 (53.2)</p> <p>>=2 Risk factors: 247 (66.8)</p>		<p>Thrombocytopaenia (Thrombocytopenia was defined as a decrease in the platelet count of less than 100,000/mm³. Thrombocytopenia was considered severe if the platelet count was less than 50,000/mm³)</p>	<p>Group 3 (Placebo): 1/288</p> <p>Secondary outcome (VT between days 1-110) Group 1: 1/263 Group 2: 0/272 Group 3: 1/263</p> <p>Treatment period (days 1-14) Group 1: 10/351 (4 related to treatment) Group 2: 8/360 (2 related to treatment) Group 3: 3/362 (8 related to treatment) P value not reported Study reports NS difference Severe thrombocytopenia: Group 1: 0/351 Group 2: 0/360 Group 3: 3/362</p> <p>Study period (days 1-110) Thrombocytopenia: Group 1: 10/351 Group 2: 8/360 Group 3: 13/362 Severe thrombocytopenia: Group 1: 0/351 Group 2: 0/360 Group 3: 3/362 P value not reported Study reports NS difference</p>	

Study	Schellong 2010²⁹¹
--------------	-------------------------------------

Study	Schellong 2010 ²⁹¹
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=337)
Countries and setting	Conducted in Germany, Unknown multicentre; Setting: Not reported
Line of therapy	Not applicable
Duration of study	Intervention time: 10 (2 days)
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: DVT - assessed with the use of complete compression ultrasound (CCUS) of the lower extremity veins.
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Patients of either gender > 40 years, hospitalisation due to an acute non-surgical disease, significant recent decrease in mobility (completely bedridden or only able to walk short distances with the support of a nurse)
Exclusion criteria	Women of childbearing age unless they were post-menopausal or using a highly effective method of birth control, pregnancy or lactation, indication for anticoagulant or thrombolytic therapy, major surgery or invasive procedure within 4 weeks prior to randomisation or expected within 2 weeks after randomisation, immobilisation due to cast or fracture of the lower extremity or > 3 days prior to randomisation, heparin administration for more than 36 hour in the period prior to randomisation, acute ischemic stroke, haemorrhagic stroke, or other intracranial bleeding (acute or within the last 12 months), life expectancy <1, endocarditis, history of or current HIT type II, retinopathy, recent history of addictive disorder
Recruitment/selection of patients	February 2006-December 2007
Age, gender and ethnicity	Age - Mean (SD): 70.6 (12.3) years. Gender (M:F): Not reported. Ethnicity: Not reported
Further population details	1. BMI : Not stated 2. Mobility: Totally immobile 3. Renal impairment: Not stated
Extra comments	Mean duration of 8.5 ± 2.1 days in both groups
Indirectness of population	No indirectness
Interventions	(n=163) Intervention 1: Low molecular weight heparin (not licensed in UK) - LMWH (not licensed in UK). Single daily dose 3000 U certoparin during the treatment period. Duration 10 (2) days. Concurrent medication/care: N/A (n=174) Intervention 2: Unfractionated heparin - low dose, administered subcutaneously. 7500 IU unfractionated heparin (UFH) during the treatment period. Duration 10 (2) days. Concurrent medication/care: N/A
Funding	Study funded by industry (Study was funded by Novartis Pharma, Nurnberg, Germany.)

Study	Schellong 2010 ²⁹¹
RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: CERTOPARIN versus UNFRACTIONATED HEPARIN	
<p>Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge - Actual outcome: All-cause mortality (VTE related and unrelated death) at 90 days; Group 1: 8/163, Group 2: 12/172; Risk of bias: Low; Indirectness of outcome: No indirectness</p>	
<p>Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic) at 7-90 days from hospital discharge - Actual outcome: DVT (symptomatic and asymptomatic) at 90 days; Group 1: 10/103, Group 2: 23/100; Risk of bias: Low; Indirectness of outcome: No indirectness</p>	
<p>Protocol outcome 3: Pulmonary embolism at 7-90 days from hospital discharge - Actual outcome: PE at 90 days; Group 1: 1/103, Group 2: 2/100; Risk of bias: Low; Indirectness of outcome: No indirectness</p>	
<p>Protocol outcome 4: Heparin-induced thrombocytopenia at up to 90 days from hospital discharge - Actual outcome: Heparin-induced thrombocytopenia at 90 days; Group 1: 0/163, Group 2: 0/172; Risk of bias: Low; Indirectness of outcome: No indirectness</p>	
Protocol outcomes not reported by the study	Major bleeding at up to 45 days from hospital discharge; Fatal PE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding at up to 45 days from hospital discharge; Health-related quality of life at up to 90 days from hospital discharge; Technical complications of mechanical interventions at up to 90 days from hospital discharge

H.14 Cancer

Study	CONKO-004 trial: Pelzer 2015 ²⁵⁷
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=312)
Countries and setting	Conducted in Germany; Setting: Multicentre and group-sequential trial in patients with APC who were treated with first-line chemotherapy in an outpatient setting.
Line of therapy	1st line
Duration of study	Intervention + follow up: Primary endpoint was event rate within first 3 months; enrolment was between April 2004 and

	January 2009
Method of assessment of guideline condition	Partially adequate method of assessment/diagnosis: In cases of symptomatic disorders with suspected venous thrombosis or embolic events (e.g. unilateral oedema, local tumour/dolour/colour, and/or acute distress), further diagnostic workup (further to cancer workup with staging CT or MRI) was required.
Stratum	Overall:
Subgroup analysis within study	Stratified then randomised: Stratified by Karnofsky performance status and kidney function. patients with KPS $\geq 80\%$ and normal kidney function received GFFC therapy. Patients with KPS $\leq 80\%$ and/or increased creatinine plasma levels started gemcitabine therapy. Patients were also stratified according to tumour stage, type of tumour, and prior thrombosis.
Inclusion criteria	Histological or cytological pancreatic carcinoma, stage IV A, b, no preceding radio or chemotherapy of the primarius or the reference lesions, Karnofsky performance status $\geq 60\%$, measurable tumour lesion by spiral CT or MRT not older than 14 days, no deep venous thrombosis within the last 2 years, patient compliance and geographical proximity of the residence, which make an adequate follow up possible, sufficient bone marrow reserve: leukocyte $\geq 3.5 \times 10^9 /l$, thrombocyte $\geq 100 \times 10^9 /l$, signed informed consent, minimum age of 18 years, women/men must provide sufficient pregnancy prevention
Exclusion criteria	Pre-existing indication for anti-coagulation of other reason, bleeding in the last 2 weeks or increased bleeding risk (e.g. serious coagulating disturbance, active stomach or intestine ulcer, or had operational interferences in the last 2 weeks), body weight < 45 kg and/or > 100 kg, pregnancy or insufficient preventing methods in the study process, serious illness, which are incompatible with a study participation, hypersensitivity to study drugs, patients with serious kidney malfunction (Creatinin clearance < 30 ml/min)
Recruitment/selection of patients	Enrolment was between April 2004 and January 2009
Age, gender and ethnicity	Age - Median (range): Enoxaparin: 62 (32-81); observation: 63 (27-83). Gender (M:F): Enoxaparin: 91:69; observation: 94:58. Ethnicity: Not reported
Further population details	1. BMI : Not obese (BMI under 30 kg/m ²) (Median (range) BMI for Enoxaparin vs observation: 24.3 (15.2-43.0) vs 23.8 (16-39.2)). 2. Chemotherapy: Chemotherapy (GFFC or GEM). 3. Renal impairment: Mixed 4. Tumour: Solid (Advanced Pancreatic Cancer: pancreatic carcinoma, stage IV A, b).
Indirectness of population	No indirectness
Interventions	(n=160) Intervention 1: Low molecular weight heparin - Enoxaparin. Enoxaparin at half therapeutic dose. Duration 3 months. Concurrent medication/care: Patients with KPS $< 80\%$ and increased creatinine plasma levels (> 1.3 mg/dl) received the current standard therapy (gemcitabine 1 g/m ² (30 min), d1, 8, 15; q4w) Patients with KPS $> 80\%$ and normal kidney function receive GFFC + LMWH (gemcitabine 1 g/m ² (30 min), cisplatin 30 mg/m ² (90 min), 5-fluorouracil 750 mg/m ² (24 h), folinic acid 200 mg/m ² (30 min), d1, 8; q3w

	<p>(n=152) Intervention 2: No treatment - Usual care. Usual care. Duration 3 months. Concurrent medication/care: Patients with KPS <80 % and increased creatinine plasma levels (>1.3 mg/dl) received the current standard therapy (gemcitabine 1 g/m² (30 min), d1, 8, 15; q4w) Patients with KPS >80% and normal kidney function receive GFFC + LMWH (gemcitabine 1g/m² (30 min), cisplatin 30 mg/m² (90 min), 5-fluorouracil 750 mg/m² (24 h), folinic acid 200 mg/m² (30 min), d1, 8; q3w</p>
Funding	Other author(s) funded by industry
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: ENOXAPARIN versus USUAL CARE</p> <p>Protocol outcome 1: Deep vein thrombosis (symptomatic and asymptomatic) at 7-90 days from hospital discharge - Actual outcome: Symptomatic DVT only (not analysed) at 3 months; Group 1: 8/160, Group 2: 17/152 Risk of bias: All domain - High, Selection - Low, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - High, Crossover - Low, Subgroups - Low; Indirectness of outcome: Serious indirectness, Comments: Outcome assessment method not fully reported therefore downgraded once for indirectness ; Blinding details: Authors state that the open, non-blinded design may have resulted in patient and physician bias - ethical reasons. Also VTE diagnoses often established on nonspecific symptoms. This may have led to additional physician bias. ; Group 1 Number missing: 7, Reason: Lost to follow-up; Group 2 Number missing: 10, Reason: Lost to follow-up</p> <p>Protocol outcome 2: Pulmonary embolism at 7-90 days from hospital discharge - Actual outcome: PE (symptomatic, no confirmation details) at 3 months; Group 1: 0/160, Group 2: 3/152 Risk of bias: All domain - High, Selection - Low, Blinding - High, Incomplete outcome data - High, Outcome reporting - Low, Measurement - High, Crossover - Low, Subgroups - Low; Indirectness of outcome: Serious indirectness, Comments: Outcome assessment method not fully reported therefore downgraded once for indirectness ; Blinding details: Authors state that the open, non-blinded design may have resulted in patient and physician bias - ethical reasons. Also VTE diagnoses often established on nonspecific symptoms. This may have led to additional physician bias. ; Group 1 Number missing: 7, Reason: Lost to follow-up; Group 2 Number missing: 10, Reason: Lost to follow-up</p> <p>Protocol outcome 3: Major bleeding at up to 45 days from hospital discharge - Actual outcome: Major bleeding events at 3 months; Group 1: 7/160, Group 2: 5/152 Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - High, Measurement - Low, Crossover - Low, Subgroups - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 7, Reason: Lost to follow-up; Group 2 Number missing: 10, Reason: Lost to follow-up</p>	
Protocol outcomes not reported by the study	All-cause mortality at up to 90 days from hospital discharge; Fatal PE at up to 90 days from hospital discharge; Clinically

	relevant non-major bleeding at up to 45 days from hospital discharge; Health-related quality of life at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at up to 90 days from hospital discharge; Technical complications of mechanical interventions at up to 90 days from hospital discharge
Study	Larocca 2012¹⁸⁷
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=342)
Countries and setting	Conducted in Israel, Italy; Setting: 62 centres in Italy and Israel
Line of therapy	1st line
Duration of study	Intervention + follow up: 6 months follow-up
Method of assessment of guideline condition	Partially adequate method of assessment/diagnosis: Not all outcome assessment methods reported - major and minor bleeding reported.
Stratum	Overall
Subgroup analysis within study	Post-hoc subgroup analysis: The aim of the substudy was to compare the effectiveness and safety of ASA and LMWH as antithrombotic prophylaxis in patients receiving lenalidomide based induction and consolidation therapy.
Inclusion criteria	Previously untreated patients with NDMM, aged between 18 and 65 years, enrolled in the phase 3 trial were assessed for eligibility to be enrolled in the substudy. Eligible patients had no history of DVT or arterial thromboembolic events within the past 12 months, no clear indication or contraindication for antiplatelet or anticoagulant therapy, had no active bleeding, and were not considered to be at high risk of bleeding.
Exclusion criteria	Exclusion criteria were clear indication or contraindication for a specific antiplatelet or anticoagulant therapy (eg, cardiac arrhythmia, cardiac ischemia, or previous history of arterial or venous thromboembolism), and active bleeding or high risk of bleeding, recent orthopaedic surgery or vertebroplasty, immobilisation, allergy to ASA, concomitant thromboembolism at diagnosis, concomitant disseminated intravascular coagulation, inherited thrombophilic abnormalities, previous history of coronary ischemic disease or angioplasty
Recruitment/selection of patients	
Age, gender and ethnicity	Age - Median (range): For ASA and LMWH respectively - 57 and 58 (no range reported). Gender (M:F): For ASA and LMWH respectively - 87:89; 99:67. Ethnicity: Not reported
Further population details	1. BMI : Not applicable 2. Chemotherapy: Chemotherapy (See treatment descriptions for details). 3. Renal impairment: Not applicable 4. Tumour: Haematological (newly diagnosed multiple myeloma (NDMM)).

Extra comments	Patients with newly diagnosed multiple myeloma (NDMM).
Indirectness of population	No indirectness
Interventions	<p>(n=176) Intervention 1: Aspirin. ASA 100mg/day orally. Duration Prophylaxis was administered during the 4 cycles of Rd therapy and the 6 cycles of MPR consolidation. Patients who were assigned to the Mel200 consolidation arm stopped thromboprophylaxis at this point. Antithrombotic prophylaxis was discontinued in any patient who developed DVT, PE, arterial thrombosis, or any acute cardiovascular or bleeding event or patient who had a platelet count of <50 000/microlitres. Patients attended clinic study visits every 2 weeks during the first 2 cycles of Rd or MPR, then every 4 weeks for the last 2 cycles of Rd and the last 4 cycles of MPR to assess the effectiveness and safety of treatment. (Subsequently, patients attended visits at the physician’s discretion, and the incidence of thromboembolism in the absence of prophylaxis was also evaluated.). Concurrent medication/care: All patients received induction with lenalidomide plus low-dose dexamethasone (Rd) treatment comprising four 28-day cycles of lenalidomide (25 mg/d orally for 21 days) in combination with dexamethasone (40 mg/d orally on days 1, 8, 15, and 22), followed by cyclophosphamide (4 g/m²) for stem cell mobilization and collection before entering the consolidation phase with either MPR or Mel200. The MPR consolidation phase comprised six 28-day cycles of lenalidomide 10 mg/d for 21 days, melphalan 0.18 mg/kg for 4 days, and prednisone 2 mg/kg for 4 days.</p> <p>(n=166) Intervention 2: Low molecular weight heparin - Enoxaparin. Enoxaparin 40mg/d subcutaneously. Duration prophylaxis was administered during the 4 cycles of Rd therapy and the 6 cycles of MPR consolidation. Patients who were assigned to the Mel200 consolidation arm stopped thromboprophylaxis at this point. Antithrombotic prophylaxis was discontinued in any patient who developed DVT, PE, arterial thrombosis, or any acute cardiovascular or bleeding event or patient who had a platelet count of <50 000/microlitres. Patients attended clinic study visits every 2 weeks during the first 2 cycles of Rd or MPR, then every 4 weeks for the last 2 cycles of Rd and the last 4 cycles of MPR to assess the effectiveness and safety of treatment. (Subsequently, patients attended visits at the physician’s discretion, and the incidence of thromboembolism in the absence of prophylaxis was also evaluated.). Concurrent medication/care: All patients received induction with lenalidomide plus low-dose dexamethasone (Rd) treatment comprising four 28-day cycles of lenalidomide (25 mg/d orally for 21 days) in combination with dexamethasone (40 mg/d orally on days 1, 8, 15, and 22), followed by cyclophosphamide (4 g/m²) for stem cell mobilization and collection before entering the consolidation phase with either MPR or Mel200. The MPR consolidation phase comprised six 28-day cycles of lenalidomide 10 mg/d for 21 days, melphalan 0.18 mg/kg for 4 days, and prednisone 2 mg/kg for 4 days.</p>
Funding	Equipment / drugs provided by industry

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: ASPIRIN versus ENOXAPARIN

<p>Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge - Actual outcome: Sudden, otherwise unexplained death (presumed to be related to PE, acute myocardial infarction, or stroke) at During first 6 months of follow-up; Group 1: 0/176, Group 2: 0/166 Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low, Subgroups - High, Comments - Additional selection bias because only patient with standard risk of VTE aged <65 years were included; Indirectness of outcome: Serious indirectness, Comments: Outcome assessment method not reported therefore downgraded once for indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p>	
<p>Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic) at 7-90 days from hospital discharge - Actual outcome: DVT objectively confirmed symptomatic only (not analysed) at During first 6 months of follow-up; Group 1: 2/176, Group 2: 2/166 Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low, Subgroups - High, Comments - Additional selection bias because only patient with standard risk of VTE aged <65 years were included; Indirectness of outcome: Serious indirectness, Comments: Outcome assessment method not reported therefore downgraded once for indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p>	
<p>Protocol outcome 3: Pulmonary embolism at 7-90 days from hospital discharge - Actual outcome: PE no further details at During first 6 months of follow-up; Group 1: 3/176, Group 2: 0/166 Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low, Subgroups - High, Comments - Additional selection bias because only patient with standard risk of VTE aged <65 years were included; Indirectness of outcome: Serious indirectness, Comments: Unclear method of confirmation; Group 1 Number missing: ; Group 2 Number missing:</p>	
<p>Protocol outcome 4: Major bleeding at up to 45 days from hospital discharge - Actual outcome: Major bleeding defined as fatal bleeding, symptomatic bleeding in a crucial area or organ, bleeding causing a reduction in haemoglobin concentration of 2g.dL or that necessitated transfusion of ≥2 units of whole blood or red cells. at During first 6 months of follow-up; Group 1: 0/176, Group 2: 0/166 Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low, Subgroups - High, Comments - Additional selection bias because only patient with standard risk of VTE aged <65 years were included; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p>	
Protocol outcomes not reported by the study	Fatal PE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding at up to 45 days from hospital discharge; Health-related quality of life at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at up to 90 days from hospital discharge; Technical complications of mechanical interventions at up to 90 days from hospital discharge

Study	Levine 1994²⁰⁶
Study type	RCT (Patient randomised; Parallel)

Number of studies (number of participants)	1 (n=315)
Countries and setting	Conducted in Canada, Italy; Setting: Multicentre, international
Line of therapy	1st line
Duration of study	Intervention time: From the start of chemotherapy or within 4 weeks and continued until 1 week after termination of chemotherapy
Method of assessment of guideline condition	Adequate method of assessment/diagnosis
Stratum	Overall
Subgroup analysis within study	Stratified then randomised: By centre and presence or absence of central-venous catheter.
Inclusion criteria	Metastatic breast carcinoma and had been receiving first-line or second-line chemotherapy for 4 weeks or less.
Exclusion criteria	Eastern Cooperative Oncology Group performance status of 3 or more, an underlying bleeding disorder or active peptic ulcer disease, direct bilirubin more than twice normal, an INR of 1.3 or more, a platelet count below 50 x 10/L, a history of alcohol abuse, overt brain metastases, presence of an underlying psychiatric or affective disorder, requirement for long-term oral anticoagulant therapy, expected survival of less than 3 months, concurrent receipt of hormonal therapy, and inability to attend follow-up visits for geographical reasons.
Recruitment/selection of patients	Recruitment began in June 1989 and stopped in June 1992
Age, gender and ethnicity	Age - NR: NR. Gender (M:F): NR. Ethnicity: NR
Further population details	1. BMI : Not applicable 2. Chemotherapy: Chemotherapy 3. Renal impairment: Not applicable 4. Tumour: Solid (Metastatic breast cancer).
Indirectness of population	No indirectness
Interventions	(n=154) Intervention 1: Vitamin K antagonists - Warfarin. Very low dose warfarin 1mg daily for 6 weeks. At 6 weeks dose adjusted to produce a very slight anticoagulant effect corresponding to an INR of 1.3-1.9. Duration of chemotherapy plus 7 days, mean (SD) 199 (126). Concurrent medication/care: Chemotherapy (n=161) Intervention 2: No treatment - Placebo. Identical inert tablet. Sham INR's generated to reflect fluctuations in dose-response observed in warfarin group and number of inert tablets given accordingly. Duration of chemotherapy plus 7 days, mean (SD) 188 (137) days. Concurrent medication/care: Chemotherapy
Funding	Academic or government funding (Supported by a grant-in-aid from the National Cancer Institute of Canada)

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: WARFARIN versus PLACEBO

Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge

- Actual outcome: Survival at Approximately 6 months; Group 1: 87/152, Group 2: 99/159

Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: Serious indirectness ; Group 1 Number missing: 2; Group 2 Number missing: 2

Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic) at 7-90 days from hospital discharge

- Actual outcome: Symptomatic DVT only (extracted but not analysed) at Approximately 6 months; Group 1: 0/152, Group 2: 6/159

Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - High, Crossover - Low;

Indirectness of outcome: Serious indirectness ; Group 1 Number missing: 2; Group 2 Number missing: 2

Protocol outcome 3: Pulmonary embolism at 7-90 days from hospital discharge

- Actual outcome: Symptomatic PE confirmed by ventilation-perfusion lung scanning at Approximately 6 months; Group 1: 1/152, Group 2: 1/159

Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: Serious indirectness ; Group 1 Number missing: 2; Group 2 Number missing: 2

Protocol outcome 4: Major bleeding at up to 45 days from hospital discharge

- Actual outcome: Major bleeding associated with a fall in haemoglobin of 20 g/dL or more, or a need for transfusion of 2 or more units of blood, or if it was retroperitoneal or intracranial. at Approximately 6 months; Group 1: 1/152, Group 2: 2/159

Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: Serious indirectness ; Group 1 Number missing: 2; Group 2 Number missing: 2

Protocol outcomes not reported by the study

Fatal PE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding at up to 45 days from hospital discharge; Health-related quality of life at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at up to 90 days from hospital discharge; Technical complications of mechanical interventions at up to 90 days from hospital discharge

Study	Levine 2012²⁰⁷
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=125)
Countries and setting	Conducted in Canada, USA; Setting: Six sites in Canada and eight in the USA participated

Line of therapy	1st line
Duration of study	Intervention time: 12 weeks (84 days)
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: Major bleeding and DVT defined and method described.
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Subjects were eligible if they were over 18 years of age and receiving either first-line or second-line chemotherapy for advanced or metastatic lung, breast, GI (colon, rectum, pancreas, stomach), bladder, cancer of unknown origin, ovarian or prostate cancer, myeloma or selected lymphomas, if they were able to begin study medication within 6 weeks of starting either first-line or second-line chemotherapy, and if the expected course of chemotherapy was 90 days or more.
Exclusion criteria	Women of childbearing potential who were unwilling or unable to use an acceptable method of contraception to avoid pregnancy for the entire study period, who were using a prohibited contraceptive method, or who were pregnant or breastfeeding; prior history of documented DVT or PE; active bleeding or high risk for bleeding; having a serious hemorrhage that had required hospitalization, transfusion or surgical intervention within 4 weeks of study entry; familial bleeding diathesis; overt metastasis of cancer to the brain; expected survival of <6 months or an Eastern Cooperative Oncology Group performance status of >3; candidate for bone marrow transplantation within the 12-week treatment period or 30-day follow-up period; uncontrolled hypertension (systolic blood pressure of >200 mmHg and/or diastolic blood pressure of >110 mmHg); presence of a coagulopathy; alanine aminotransferase greater than three times the upper limit of normal (ULN); total bilirubin greater than two times the ULN; calculated creatinine clearance of <30 mL min ⁻¹ ; and requiring long-term oral anticoagulant therapy, > 165mg daily aspirin, clopidogrel, cilostazol, or aspirin–dipyridamole.
Recruitment/selection of patients	Details not reported
Age, gender and ethnicity	Age - Median (range): Apixaban 5 mg: 57 (41–67), Apixaban 10 mg: 60 (39–76), Apixaban 20 mg: 64 (25–86), Placebo: 59 (20–82). Gender (M:F): Define. Ethnicity: Not reported
Further population details	1. BMI : Not applicable 2. Chemotherapy: Chemotherapy 3. Renal impairment: Not applicable 4. Tumour: Mixed (Mixture of solid tumours, heamatologic and liver metastases).
Extra comments	See inclusion criteria. The trial was a phase II dose-ranging/tolerability study
Indirectness of population	No indirectness
Interventions	(n=30) Intervention 1: No treatment - Placebo. All subjects took four tablets orally once daily; these consisted of a combination of apixaban and matching placebo tablets for the apixaban treatment groups, or all placebo tablets for the placebo treatment group (such that the study supplies for subjects in all treatment groups were identical in appearance). Duration Each subject was to be given study tablets daily for 12 weeks, beginning within 4 weeks of the

	<p>date on which the first-line or second-line chemotherapy was begun. Mean duration 69.6 days (range 7-91). Concurrent medication/care: Chemotherapy - various regimens.</p> <p>Initially, subjects who had received bevacizumab within the previous 6 months were not eligible to participate in the study. During the trial, the protocol was amended to allow patients receiving bevacizumab to participate, provided that it was used for indications approved by local country law. Sunitinib or sorafenib were not permitted within 3 months of subjects being treated with the study drug.</p> <p>(n=95) Intervention 2: Apixaban. 5mg, 10mg or 20mg Apixaban. All subjects took four tablets orally once daily; these consisted of a combination of apixaban and matching placebo tablets for the apixaban treatment groups, or all placebo tablets for the placebo treatment group (such that the study supplies for subjects in all treatment groups were identical in appearance). Duration Each subject was to be given study tablets daily for 12 weeks, beginning within 4 weeks of the date on which the first-line or second-line chemotherapy was begun. Median duration 84 days. Range 14-92 days. Concurrent medication/care: Initially, subjects who had received bevacizumab within the previous 6 months were not eligible to participate in the study. During the trial, the protocol was amended to allow patients receiving bevacizumab to participate, provided that it was used for indications approved by local country law. Sunitinib or sorafenib were not permitted within 3 months of subjects being treated with the study drug.</p>
Funding	Study funded by industry (The study was sponsored by Bristol-Myers Squibb and Pfizer Inc)

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: APIXABAN versus PLACEBO

Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge

- Actual outcome: Death from any cause at 114-121 days (30 days after treatment completion); Group 1: 1/93, Group 2: 2/29

Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low, Other 1 - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 2; Group 2 Number missing: 1

Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic) at 7-90 days from hospital discharge

- Actual outcome: Symptomatic DVT only. Confirmed with compression ultrasound or venography. at 114-121 days (30 days after treatment completion); Group 1: 0/93, Group 2: 3/29

Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - High, Crossover - Low, Other 1 - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 2; Group 2 Number missing: 1

Protocol outcome 3: Pulmonary embolism at 7-90 days from hospital discharge

- Actual outcome: Symptomatic PE confirmed by spiral CT or ventilation/perfusion lung scan. at 114-121 days (30 days after treatment completion); Group 1: 0/93, Group 2: 1/29

Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low, Other 1 - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 2; Group 2 Number missing: 1

Protocol outcome 4: Major bleeding at up to 45 days from hospital discharge

- Actual outcome: Clinically overt, bleeding that resulted in a decrease in haemoglobin of 20g L-1 or more; bleeding that led to a transfusion of two or more units of packed red blood cells or whole blood; bleeding that occurred in a critical site (intracranial, intraspinal, intraocular, pericardial, intra-articular, intramuscular with compartment syndrome, or retroperitoneal; or bleeding that contributed to death. at 114-121 days (30 days after treatment completion); Group 1: 2/93, Group 2: 1/29

Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low, Other 1 - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 2; Group 2 Number missing: 1

Protocol outcome 5: Clinically relevant non-major bleeding at up to 45 days from hospital discharge

- Actual outcome: Bleeding not meeting the criteria for major bleeding but that in routine clinical practice would be considered to be relevant and not trivial by a patient or physician at 114-121 days (30 days after treatment completion); Group 1: 4/93, Group 2: 0/29

Risk of bias: All domain - High, Selection - Low, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low, Other 1 - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 2; Group 2 Number missing: 1

Protocol outcomes not reported by the study	Fatal PE at up to 90 days from hospital discharge; Health-related quality of life at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at up to 90 days from hospital discharge; Technical complications of mechanical interventions at up to 90 days from hospital discharge
---	---

Study	Palumbo 2011 ²⁴⁹
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=667)
Countries and setting	Conducted in Italy; Setting: 84 centres during May 2006 to January 2009
Line of therapy	Adjunctive to current care
Duration of study	Intervention + follow up: Median follow-up time was 24.9 months; primary endpoint measured within 6 months and during entire follow-up
Method of assessment of guideline condition	Partially adequate method of assessment/diagnosis: Only bleeding outcome assessment method reported
Stratum	Overall
Subgroup analysis within study	Stratified then randomised: Stratified by age ≤ 65 or >65 received different chemotherapy regimes. Only patients receiving thalidomide-based regimes in both trials were eligible for this substudy.

Inclusion criteria	Previously untreated patients with myeloma. In one of the two studies, patients age 65 years were randomly assigned to bortezomib (1.3 mg/m ² on days 1, 4, 8, and 11), thalidomide (200 mg/d), and dexamethasone (320 mg) or to thalidomide and dexamethasone in each 21-day cycle for three courses as induction therapy before autologous transplantation. In the other study, patients age 65 years were randomly assigned to bortezomib (1.3 mg/m ² on days 1, 8, 15, and 22), melphalan (9 mg/m ² on days 1 to 4), prednisone (60 mg/m ² on days 1 to 4), and thalidomide (50 mg/d) for nine courses followed by continuous therapy with bortezomib (1.3 mg/m ² every 15 days) and thalidomide (50 mg/d) or to bortezomib, melphalan, and prednisone for nine courses without any further continuous treatment. Patients randomly assigned to receive bortezomib, melphalan, and prednisone did not receive any antithrombotic prophylaxis. Patients receiving thalidomide-based regimens in both trials were eligible for the substudy.
Exclusion criteria	Exclusion criteria were allergy or intolerance to study drugs, clear indication or contraindication for a specific antiplatelet or anticoagulant therapy (eg, cardiac arrhythmia, cardiac ischemia, or previous history of arterial or venous thromboembolism), and active bleeding or high risk of bleeding.
Recruitment/selection of patients	Patients receiving thalidomide-based regimens in both of the two cancer trials from which this substudy was carried out were eligible for the substudy.
Age, gender and ethnicity	Age - Median (IQR): For ASA, warfarin and LMWH (enoxaparin): 61 (55-66); 60 (54-66); 62 (55-66). Gender (M:F): 362:297. Ethnicity: Not reported
Further population details	1. BMI : Not applicable 2. Chemotherapy: Chemotherapy (Thalidomide containing regimens). 3. Renal impairment: Not applicable 4. Tumour: Haematological (Myeloma).
Extra comments	.This was a common sub-study of two simultaneous chemotherapy phase III trials using thalidomide-based regimens in previously untreated patients with myeloma (Cavo 2010, Palumbo 2010).
Indirectness of population	No indirectness
Interventions	(n=224) Intervention 1: Aspirin. 100mg/day orally. Duration Administered during the first 3 cycles of induction therapy. Concurrent medication/care: Patients would have been on a thalidomide regimen containing arm from one of the two main trials. (n=222) Intervention 2: Vitamin K antagonists - Warfarin. 1.25mg/day orally. Duration Administered during the first 3 cycles of induction therapy. Concurrent medication/care: Patients would have been on a thalidomide regimen containing arm from one of the two main trials. (n=221) Intervention 3: Low molecular weight heparin - Enoxaparin. 40mg/day subcutaneously. Duration Patients would have been on a thalidomide regimen containing arm from one of the two main trials. Concurrent medication/care: Administered during the first 3 cycles of induction therapy

Funding	Other (Mixed - some authors funded by industry and some research funding)
RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: ASPIRIN versus WARFARIN	
<p>Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge - Actual outcome: Sudden, otherwise unexplained death (presumed to be a result of PE, acute myocardial infarction, or stroke). at 6 months; Group 1: 1/220, Group 2: 0/220 Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 4, Reason: Did not receive study drug because not treated with thalidomide; Group 2 Number missing: 2, Reason: Did not receive study drug because not treated with thalidomide</p>	
<p>Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic) at 7-90 days from hospital discharge - Actual outcome: DVT symptomatic only (not analysed) at 6 months; Group 1: 8/220, Group 2: 14/220 Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: Serious indirectness, Comments: Outcome assessment method not reported therefore downgraded once for indirectness ; Group 1 Number missing: 4, Reason: Did not receive study drug because not treated with thalidomide; Group 2 Number missing: 2, Reason: Did not receive study drug because not treated with thalidomide</p>	
<p>Protocol outcome 3: Pulmonary embolism at 7-90 days from hospital discharge - Actual outcome: PE symptomatic. Pulmonary embolism was identified by performing a high-probability lung scan; an intermediate-probability lung scan in the presence of objectively confirmed deep vein thrombosis; a diagnostic spiral computed tomography scan; diagnostic pulmonary angiography; or diagnostic transesophageal echocardiography. at 6 months; Group 1: 4/220, Group 2: 4/220 Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: Serious indirectness, Comments: Outcome assessment method not reported therefore downgraded once for indirectness ; Group 1 Number missing: 4, Reason: Did not receive study drug because not treated with thalidomide; Group 2 Number missing: 2, Reason: Did not receive study drug because not treated with thalidomide</p>	
<p>Protocol outcome 4: Major bleeding at up to 45 days from hospital discharge - Actual outcome: Major bleeding defined as fatal bleeding, symptomatic bleeding in a crucial area of organ, bleeding causing a reduction in haemoglobin concentration of >2g/dL or necessitating transfusion of > 2 units of whole blood or RBC cells. at 6 months; Group 1: 3/220, Group 2: 0/220 Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 4, Reason: Did not receive study drug because not treated with thalidomide; Group 2 Number missing: 2, Reason: Did not receive study drug because not treated with thalidomide</p>	
RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: ASPIRIN versus ENOXAPARIN	

Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge

- Actual outcome: Sudden, otherwise unexplained death (presumed to be a result of PE, acute myocardial infarction, or stroke). at 6 months; Group 1: 1/220, Group 2: 1/219

Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness; Group 1 Number missing: 4, Reason: Did not receive study drug because not treated with thalidomide; Group 2 Number missing: 2, Reason: Did not receive study drug because not treated with thalidomide

Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic) at 7-90 days from hospital discharge

- Actual outcome: DVT symptomatic only (not analysed) at 6 months; Group 1: 8/220, Group 2: 6/219

Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: Serious indirectness, Comments: Outcome assessment method not reported therefore downgraded once for indirectness ; Group 1 Number missing: 4, Reason: Did not receive study drug because not treated with thalidomide; Group 2 Number missing: 2, Reason: Did not receive study drug because not treated with thalidomide

Protocol outcome 3: Pulmonary embolism at 7-90 days from hospital discharge

- Actual outcome: PE symptomatic. Pulmonary embolism was identified by performing a high-probability lung scan; an intermediate-probability lung scan in the presence of objectively confirmed deep vein thrombosis; a diagnostic spiral computed tomography scan; diagnostic pulmonary angiography; or diagnostic transesophageal echocardiography. at 6 months; Group 1: 4/220, Group 2: 0/219

Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: Serious indirectness, Comments: Outcome assessment method not reported therefore downgraded once for indirectness ; Group 1 Number missing: 4, Reason: Did not receive study drug because not treated with thalidomide; Group 2 Number missing: 2, Reason: Did not receive study drug because not treated with thalidomide

Protocol outcome 4: Major bleeding at up to 45 days from hospital discharge

- Actual outcome: Major bleeding defined as fatal bleeding, symptomatic bleeding in a crucial area of organ, bleeding causing a reduction in haemoglobin concentration of >2g/dL or necessitating transfusion of > 2 units of whole blood or RBC cells. at 6 months; Group 1: 3/220, Group 2: 0/219

Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 4, Reason: Did not receive study drug because not treated with thalidomide; Group 2 Number missing: 2, Reason: Did not receive study drug because not treated with thalidomide

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: WARFARIN versus ENOXAPARIN

Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge

- Actual outcome: Sudden, otherwise unexplained death (presumed to be a result of PE, acute myocardial infarction, or stroke). at 6 months; Group 1: 0/220, Group 2: 1/219

Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness; Group 1 Number missing: 2, Reason: Did not receive study drug because not treated with thalidomide; Group 2 Number missing: 2, Reason: Did not receive study drug because not treated with thalidomide

Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic) at 7-90 days from hospital discharge

- Actual outcome: DVT symptomatic only (not analysed) at 6 months; Group 1: 14/220, Group 2: 6/219

Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: Serious indirectness, Comments: Outcome assessment method not reported therefore downgraded once for indirectness ; Group 1 Number missing: 2, Reason: Did not receive study drug because not treated with thalidomide; Group 2 Number missing: 2, Reason: Did not receive study drug because not treated with thalidomide

Protocol outcome 3: Pulmonary embolism at 7-90 days from hospital discharge

- Actual outcome: PE (symptomatic). Pulmonary embolism was identified by performing a high-probability lung scan; an intermediate-probability lung scan in the presence of objectively confirmed deep vein thrombosis; a diagnostic spiral computed tomography scan; diagnostic pulmonary angiography; or diagnostic transesophageal echocardiography. at 6 months; Group 1: 4/220, Group 2: 0/219

Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: Serious indirectness, Comments: Outcome assessment method not reported therefore downgraded once for indirectness ; Group 1 Number missing: 2, Reason: Did not receive study drug because not treated with thalidomide; Group 2 Number missing: 2, Reason: Did not receive study drug because not treated with thalidomide

Protocol outcome 4: Major bleeding at up to 45 days from hospital discharge

- Actual outcome: Major bleeding defined as fatal bleeding, symptomatic bleeding in a crucial area of organ, bleeding causing a reduction in haemoglobin concentration of >2g/dL or necessitating transfusion of > 2 units of whole blood or RBC cells. at 6 months; Group 1: 0/220, Group 2: 0/219

Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 4, Reason: Did not receive study drug because not treated with thalidomide; Group 2 Number missing: 2, Reason: Did not receive study drug because not treated with thalidomide

Protocol outcomes not reported by the study

Fatal PE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding at up to 45 days from hospital discharge; Health-related quality of life at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at up to 90 days from hospital discharge; Technical complications of mechanical interventions at up to 90 days from hospital discharge

Study

PRODIGE trial: Perry 2010²⁵⁸

Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=186)
Countries and setting	Conducted in Canada; Setting: 15 centres
Line of therapy	1st line
Duration of study	Intervention + follow up: 6 months + 6 months
Method of assessment of guideline condition	Adequate method of assessment/diagnosis
Stratum	Overall
Subgroup analysis within study	Stratified then randomised: Stratified according to centre, tumour grade (3 and 4), the KPS scale (≤ 60 vs 70 or more), time from surgery to randomisation (<2 weeks vs 2-4 weeks)
Inclusion criteria	Patients with malignant glioma who had completed surgery and were receiving further treatment and ongoing care. 18 years and over, newly diagnosed, pathologically confirmed WHO Grade 3 or 4 glioma (anaplastic astrocytoma, glioblastoma multiforme, gliosarcoma, anaplastic oligodendroglioma or anaplastic mixed glioma)
Exclusion criteria	acute or chronic DVT demonstrated objectively, evidence of serious haemorrhage within 4 weeks of study entry, coagulopathy, symptomatic intracranial or intratumoural bleeding, acute peptic ulcer disease, familial bleeding diathesis, a requirement for long-term anticoagulants, an expected lifespan < 6 months and body weight <40kg, or pregnancy, of childbearing potential, not using adequate contraception, geographically inaccessible for follow-up, unable to commence study drug within 4 weeks of original surgery or biopsy.
Recruitment/selection of patients	Trial began October 2002. Recruitment was lower than anticipated and the study was closed to recruitment in May 2006 as a result of expiration of the study drug.
Age, gender and ethnicity	Age - Mean (range): Dalteparin: 57 (30-81), Placebo 55 (26-77) years. Gender (M:F): 111/75. Ethnicity: NR
Further population details	1. BMI : Not applicable 2. Chemotherapy: Not applicable (unclear what further post-surgical treatment was undertaken.). 3. Renal impairment: Not applicable 4. Tumour: Solid (Malignant glioma).
Extra comments	Pre/perioperative DVT prophylaxis (patients can be in more than one group): AES: dalt 48% placebo 46% UFH: dalt 18% placebo 8% LMWH: dalt 15% placebo 15% No prophylaxis: dalt 47% placebo 43%
Indirectness of population	No indirectness
Interventions	(n=99) Intervention 1: Low molecular weight heparin - Dalteparin. Dalteparin sodium 5000 IU administered subcutaneously once daily in prefilled syringes. Duration 6 months. Concurrent medication/care: Over half (53%) of

	<p>patients received some other form of pre- or peri-operative DVT prophylaxis (AES or heparin or both). Use of concurrent acetylsalicylic acid (ASA), NSAIDs and dextran was permitted but discouraged. 78% had radiotherapy within the first month.</p> <p>(n=87) Intervention 2: No treatment - Placebo. Saline placebo administered subcutaneously once daily in prefilled syringes. Duration 6 months. Mean duration 157 days. Concurrent medication/care: Over half (57%) of patients received some other form of pre- or peri-operative DVT prophylaxis (AES or heparin or both). Use of concurrent acetylsalicylic acid (ASA), NSAIDs and dextran was permitted but discouraged. 90% had radiotherapy within the first month.</p>
Funding	Study funded by industry (Funding and research support from Pfizer Inc, Ontario Clinical Oncology Group, Crolla Chair in Brain Tumor Research)

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: DALTEPARIN versus PLACEBO

Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge

- Actual outcome: Overall mortality at 6 months; Group 1: 18/91, Group 2: 11/76

Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low, Subgroups - Low, Other 1 - Low, Other 2 - High; Indirectness of outcome: No indirectness ; Group 1 Number missing: 8; Group 2 Number missing: 11

Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic) at 7-90 days from hospital discharge

- Actual outcome: Symptomatic DVT only (not analysed) confirmed by venography or compression sonography at 6 months; Group 1: 8/91, Group 2: 10/76

Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low, Subgroups - Low, Other 1 - Low, Other 2 - High; Indirectness of outcome: No indirectness ; Group 1 Number missing: 8; Group 2 Number missing: 11

Protocol outcome 3: Pulmonary embolism at 7-90 days from hospital discharge

- Actual outcome: PE confirmed by autopsy, a high probability ventilation-perfusion lung scan, conventional pulmonary angiogram at 6 months; Group 1: 2/91, Group 2: 4/76

Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low, Subgroups - Low, Other 1 - Low, Other 2 - High; Indirectness of outcome: No indirectness ; Group 1 Number missing: 8; Group 2 Number missing: 11

Protocol outcome 4: Major bleeding at up to 45 days from hospital discharge

- Actual outcome: Clinically overt and satisfied one of: decrease in haemoglobin of 20mg/L or more over 48 hours, bleeding leading to transfusion of 2 or more units, retroperitoneal, intracranial, intraspinal, intraocular or pericardial bleeding, bleeding leading to an invasive intervention or death. at 6 months; Group 1: 3/91, Group 2: 0/76

Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low, Subgroups - Low, Other 1 - Low, Other 2 - High; Indirectness of outcome: No indirectness ; Group 1 Number missing: 8; Group 2 Number missing: 11

Protocol outcomes not reported by the study	Fatal PE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding at up to 45 days from hospital discharge; Health-related quality of life at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at up to 90 days from hospital discharge; Technical complications of mechanical interventions at up to 90 days from hospital discharge
---	--

Study	PROTECHT (Prophylaxis of Thromboembolism during Chemotherapy); ClinicalTrials.gov Identifier:NCT00951574 trial: Agnelli 2009²
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=1166)
Countries and setting	Conducted in Italy; Setting: 62 centres across Italy
Line of therapy	1st line
Duration of study	Follow up (post intervention): Recruitment was between October 2003 and May 2007. Median duration of follow-up was 111 and 113 days in the nadroparin and placebo groups respectively
Method of assessment of guideline condition	Method of assessment /diagnosis not stated
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Ambulatory patients older than 18 years of age who were receiving chemotherapy for metastatic or locally advanced lung, gastrointestinal (stomach, colon, or rectum), pancreatic, breast, ovarian, or head and neck cancer.
Exclusion criteria	Patients on adjuvant or neoadjuvant chemotherapy; objectively confirmed venous or arterial thromboembolism in the past 3 months; antithrombotic treatment for any indication; life expectancy of less than 3 months; ECOG score of >2; active bleeding or bleeding requiring hospitalization or transfusion or surgical intervention in the past 4 weeks; intracranial bleeding in the past 6 months; high risk of bleeding (INR or activated partial thromboplastin time ratio above 1.3, or platelet count <50 X 10 ⁹ /L); known active or gastric or duodenal ulcer, known cerebral metastasis; severe and uncontrolled hypertension; renal impairment (creatinine concentration >0.025 mg/mL); substantial liver insufficiency; and known hypersensitivity to heparin and derivatives.
Recruitment/selection of patients	See inclusion criteria
Age, gender and ethnicity	Age - Mean (SD): Nadroparin 62.1 (10.3); Placebo 63.7 (9.2). Gender (M:F): Nadroparin: 372:397; placebo: 183:198. Ethnicity: Not reported

Further population details	1. BMI: Not obese (BMI under 30 kg/m ²) (Nadroparin 25.4 (4.4); Placebo 25.2 (4.2)). 2. Chemotherapy: Chemotherapy (For Nadroparin and placebo respectively (n), patients were on either pyrimidine analogues: 485 vs 258; platinum compounds: 432 vs 225; anthracyclines (and related): 109 vs 58; nitrogen mustard analogues: 38 vs 18; or monoclonal antibodies: 27 vs 11). 3. Renal impairment: Not applicable 4. Tumour: Solid (For Nadroparin and placebo respectively (n), metastatic or locally advanced lung: 199 vs 80; gastrointestinal: 272 vs 148 (stomach (58 vs 40), colon (156 vs 79), or rectum (58 vs 29)), pancreatic (36 vs 17), breast (110 vs 55), ovarian (96 vs 47), or head and neck cancer (19 vs 17); other cancers: 37 vs 17).
Extra comments	Proportion of people with a central venous catheter was 41.9% in the nadroparin group and 38.6% in the placebo group. ClinicalTrials.gov Identifier:NCT00951574
Indirectness of population	No indirectness: Population directly related to review population
Interventions	<p>(n=779) Intervention 1: Low molecular weight heparin - Licensed in country other than UK. Drug: Nadroparin calcium Nadroparin calcium; Pre-filled syringes of 0.4 ml (3.800 anti-Xa IU), 1 subcutaneous injection/day (every 24 hours). Duration Study treatment was started on the same day as chemotherapy (the first cycle or a new course), and was given for the duration of chemotherapy or up to a maximum of 12 days (+ or - 10 days). If the duration of chemotherapy was <4 months, study treatment was given after the last cycle of chemotherapy for a period of time equal to the duration of the last cycle. Concurrent medication/care: Antiplatelet agents, oral anticoagulants, fibrinolytic agents, unfractionated heparin or LMWH other than nadroparin were not allowed during the study period. The administration of NSAIDs was allowed with caution if considered necessary, and was monitored closely. Paracetamol was recommended as the first step for analgesic or anti-inflammatory treatment. All concomitant therapies were fully reported in case-report forms along with their daily dosage, duration, and reason for administration.</p> <p>(n=387) Intervention 2: No treatment - Placebo. Placebo Comparator: saline solution Pre-filled syringes of 0.4 ml, 1 subcutaneous injection/day (every 24 hours). Duration Study treatment was started on the same day as chemotherapy (the first cycle or a new course), and was given for the duration of chemotherapy or up to a maximum of 12 days (+ or - 10 days). If the duration of chemotherapy was <4 months, study treatment was given after the last cycle of chemotherapy for a period of time equal to the duration of the last cycle. Concurrent medication/care: Antiplatelet agents, oral anticoagulants, fibrinolytic agents, unfractionated heparin or LMWH other than nadroparin were not allowed during the study period. The administration of NSAIDs was allowed with caution if considered necessary, and was monitored closely. Paracetamol was recommended as the first step for analgesic or anti-inflammatory treatment. All concomitant therapies were fully reported in case-report forms along with their daily dosage, duration, and reason for administration.</p>
Funding	Study funded by industry (Italfarmaco)

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: LICENSED IN COUNTRY OTHER THAN UK versus PLACEBO

Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge

- Actual outcome: Death at By end of study treatment; Group 1: 33/769, Group 2: 16/381

Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 10; Group 2 Number missing: 6

Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic) at 7-90 days from hospital discharge

- Actual outcome: DVT symptomatic of lower or upper limbs plus incidentally diagnosed asymptomatic events at Median duration of follow-up was 111 and 113 days for nadroparin and placebo groups respectively; Group 1: 14/496, Group 2: 12/270

Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - High; Indirectness of outcome: Serious indirectness, Comments: Outcome assessment method not reported therefore downgraded once for indirectness ; Group 1 Number missing: 273, Reason: Withdraw consent (57), non-compliance (31), protocol deviation (11), lost to follow-up (12), adverse events (101), death (10), disease progression (18), best interest of patient (15), other (18); Group 2 Number missing: 111, Reason: Consent withdrawn (27), non-compliance (14), protocol deviation (6), lost to follow-up (5), adverse event (33), death (3), disease progression (12), best interest of the patient (4), other (7)

Protocol outcome 3: Pulmonary embolism at 7-90 days from hospital discharge

- Actual outcome: PE symptomatic at Median duration of follow-up was 111 and 113 days for nadroparin and placebo groups respectively; Group 1: 3/496, Group 2: 3/270

Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: Serious indirectness, Comments: Outcome assessment method not reported therefore downgraded once for indirectness ; Group 1 Number missing: 273; Group 2 Number missing: 111

Protocol outcome 4: Major bleeding at up to 45 days from hospital discharge

- Actual outcome: Major bleeding (fatal or clinically overt and associated with a decrease in haemoglobin of at least 0.02 g/mL over 48 hours, or with transfusion of 2 or more units of whole blood or red cells, occurred in a critical organ, required invasive intervention). at until 48 hours after the last injection of study drug; Group 1: 5/496, Group 2: 0/270

Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low; Indirectness of outcome: No indirectness; Group 1 Number missing: 10; Group 2 Number missing: 6

Protocol outcomes not reported by the study

Fatal PE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding at up to 45 days from hospital discharge; Health-related quality of life at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at up to 90 days from hospital discharge; Technical complications of mechanical interventions at up to 90 days from hospital discharge

Study	TOPIC-1 trial: Haas 2012-1 ¹³¹
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=353)
Countries and setting	Conducted in Multiple countries; Setting: 39 centres
Line of therapy	1st line
Duration of study	Intervention + follow up: 6 months
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: First occurrence of objectively confirmed VTE during the 6 month treatment period to include symptomatic or asymptomatic DVT (proximal or distal) confirmed by venography and/or ultrasonography; symptomatic PE confirmed by CT ventilation–perfusion scintigraphy, or shown at autopsy; thrombosis of the jugular or subclavian veins confirmed by ultrasonography; and superficial thrombophlebitis (if heparin-based treatment was required).
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Adult patients with objectively proven, disseminated metastatic breast carcinoma, receiving first- or second-line chemotherapy
Exclusion criteria	Inflammatory breast cancer or were receiving anthracycline monotherapy or gemcitabine (monotherapy or in combination). Also for the following reasons: bedridden; previous VTE diagnosis; current heparin or oral anticoagulant therapy; long-term aspirin or other current antiplatelet drugs; active gastrointestinal bleeding; haemorrhagic stroke; hereditary bleeding disorder; thrombocytopenia (platelets <75 000/mL); partial thromboplastin time >2 X the upper limit of normal (ULN); osteoporotic fracture; myocardial infarction in the preceding 6 months; and participation in a clinical trial with an experimental drug in the preceding 4 weeks.
Recruitment/selection of patients	Patients were allocated to the lowest available randomization number available for each study centre. Randomization numbers were allocated sequentially as patients were enrolled at each centre
Age, gender and ethnicity	Age - Mean (SD): Certoparin: 54.6 (10.3); placebo: 56.6 (11.0). Gender (M:F): Unclear . Ethnicity: Not reported
Further population details	1. BMI : Not obese (BMI under 30 kg/m2) 2. Chemotherapy: Not applicable 3. Renal impairment: Not applicable 4. Tumour:
Extra comments	There was an extended time frame between diagnosis and study treatment initiation (mean 3.2 years). TOPIC-1 was terminated prematurely because the rate of VTE was substantially lower than anticipated, with few events - study was underpowered to detect a difference.
Indirectness of population	No indirectness

Interventions	<p>(n=174) Intervention 1: Low molecular weight heparin - Licensed in country other than UK. Certoparin sodium (Mono Embolex, Novartis GmbH, Nurnberg, Germany) Study drug was supplied as a pre-filled 3-mL multidose pen - an injection volume of 0.3 mL containing 3000 IU certoparin, or isotonic saline administered once daily. Duration once daily for 6 months. Concurrent medication/care: First- or second-line chemotherapy</p> <p>(n=179) Intervention 2: No treatment - Placebo. No details given other than 'placebo'. Duration once daily for 6 months. Concurrent medication/care: First- or second-line chemotherapy for objectively proven, disseminated metastatic breast carcinoma</p>
Funding	Study funded by industry (The TOPIC studies were supported by an unrestricted grant from Novartis Pharma GmbH, Germany. The investigators remained in control of the study database. Interpretation of data and preparation of the manuscript were undertaken by the investigators, and fulfilled a requirement within the protocol.)

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: LICENSED IN COUNTRY OTHER THAN UK versus PLACEBO

Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge

- Actual outcome: Overall mortality at 6 months; Group 1: 15/174, Group 2: 12/178

Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low, Other 1 - High; Indirectness of outcome: No indirectness ; Group 1 Number missing: 0, Reason: N/A; Group 2 Number missing: 2, Reason: 1 not treated and 1 excluded (reasons not clear)

Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic) at 7-90 days from hospital discharge

- Actual outcome: DVT: first occurrence of objectively confirmed DVT during the 6-month treatment period to include symptomatic or asymptomatic DVT (proximal or distal) at 6 months; Group 1: 7/174, Group 2: 7/177

Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low, Other 1 - High; Indirectness of outcome: No indirectness ; Group 1 Number missing: 0, Reason: N/A; Group 2 Number missing: 2, Reason: 1 not treated and 1 excluded (reasons not clear)

Protocol outcome 3: Pulmonary embolism at 7-90 days from hospital discharge

- Actual outcome: Symptomatic PE at 6 months; Group 1: 1/174, Group 2: 1/177

Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low, Other 1 - High; Indirectness of outcome: No indirectness ; Group 1 Number missing: 0, Reason: N/A; Group 2 Number missing: 2, Reason: 1 not treated and 1 excluded (reasons not clear)

Protocol outcome 4: Major bleeding at up to 45 days from hospital discharge

- Actual outcome: Bleeding events - major bleeding at 6 months; Group 1: 3/174, Group 2: 0/177

Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low, Other 1 - High; Indirectness of outcome: No indirectness ; Group 1 Number missing: 0, Reason: N/A; Group 2 Number missing: 2, Reason: 1 not treated and 1 excluded (reasons not clear)

Protocol outcome 5: Heparin-induced thrombocytopenia at up to 90 days from hospital discharge

- Actual outcome: Thrombocytopenia at 6 months; Group 1: 25/174, Group 2: 16/177

Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low, Other 1 - High; Indirectness of outcome: No indirectness ; Group 1 Number missing: 0, Reason: N/A; Group 2 Number missing: 2, Reason: 1 not treated and 1 excluded (reasons not clear)

Protocol outcomes not reported by the study	Fatal PE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding at up to 45 days from hospital discharge; Health-related quality of life at up to 90 days from hospital discharge; Technical complications of mechanical interventions at up to 90 days from hospital discharge
---	---

Study	TOPIC-2 trial: Haas 2012-2¹³¹
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=547)
Countries and setting	Conducted in Multiple countries; Setting: 39 centres
Line of therapy	1st line
Duration of study	Intervention + follow up: 6 months
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: First occurrence of objectively confirmed VTE during the 6 month treatment period to include symptomatic or asymptomatic DVT (proximal or distal) confirmed by venography and/or ultrasonography; symptomatic PE confirmed by CT ventilation–perfusion scintigraphy, or shown at autopsy; thrombosis of the jugular or subclavian veins confirmed by ultrasonography; and superficial thrombophlebitis (if heparin-based treatment was required).
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Adult patients with objectively proven, inoperable disseminated primary non–small cell lung carcinoma of stage III or IV receiving standard first- or second-line chemotherapy
Exclusion criteria	Patients were excluded from TOPIC-2 if they had small-cell lung carcinoma, brain metastases, haemoptysis of \geq grade 2,

	or a Karnofsky index <70. Also for the following reasons: bedridden; previous VTE diagnosis; current heparin or oral anticoagulant therapy; long-term aspirin or other current antiplatelet drugs; active gastrointestinal bleeding; haemorrhagic stroke; hereditary bleeding disorder; thrombocytopenia (platelets <75 000/mL); partial thromboplastin time >2 X the upper limit of normal (ULN); osteoporotic fracture; myocardial infarction in the preceding 6 months; and participation in a clinical trial with an experimental drug in the preceding 4 weeks.
Age, gender and ethnicity	Age - Mean (SD): Certoparin: 60.8 (9.5); placebo: 60.3 (10.0). Gender (M:F): Certoparin: 227:46; placebo: 227:46. Ethnicity: Not reported
Further population details	1. BMI : Not obese (BMI under 30 kg/m2) 2. Chemotherapy: Chemotherapy 3. Renal impairment: Not applicable 4. Tumour: Solid
Extra comments	The patients enrolled in TOPIC-2 were newly diagnosed with cancer, with a mean time between diagnosis and study treatment initiation of 0.3 years.
Indirectness of population	No indirectness
Interventions	(n=273) Intervention 1: Low molecular weight heparin - Licensed in country other than UK. Certoparin sodium (Mono Embolex, Novartis GmbH, Nurnberg, Germany) Study drug was supplied as a pre-filled 3-mL multidose pen - an injection volume of 0.3 mL containing 3000 IU certoparin, or isotonic saline administered once daily. Duration once daily for 6 months. Concurrent medication/care: receiving standard first- or second-line chemotherapy (n=274) Intervention 2: No treatment - Placebo. No details given other than 'placebo'. Duration once daily for 6 months. Concurrent medication/care: receiving standard first- or second-line chemotherapy
Funding	Study funded by industry (The TOPIC studies were supported by an unrestricted grant from Novartis Pharma GmbH, Germany. The investigators remained in control of the study database. Interpretation of data and preparation of the manuscript were undertaken by the investigators, and fulfilled a requirement within the protocol.)

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: LICENSED IN COUNTRY OTHER THAN UK versus PLACEBO

Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge

- Actual outcome: Overall mortality at 6 months; Group 1: 55/273, Group 2: 59/273

Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low, Other 1 - High; Indirectness of outcome: No indirectness ; Group 1 Number missing: 5, Reason: 5 excluded; Group 2 Number missing: 10, Reason: 1 not treated and 9 excluded

Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic) at 7-90 days from hospital discharge

- Actual outcome: DVT: first occurrence of objectively confirmed DVT during the 6-month treatment period to include symptomatic or asymptomatic DVT (proximal or

<p>distal) at 6 months at 6 months; Group 1: 12/268, Group 2: 22/264 Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low, Other 1 - High; Indirectness of outcome: No indirectness ; Group 1 Number missing: 5, Reason: 5 excluded; Group 2 Number missing: 10, Reason: 1 not treated and 9 excluded</p> <p>Protocol outcome 3: Pulmonary embolism at 7-90 days from hospital discharge - Actual outcome: Symptomatic PE at 6 months; Group 1: 2/268, Group 2: 4/264 Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low, Other 1 - High; Indirectness of outcome: No indirectness ; Group 1 Number missing: 5, Reason: 5 excluded; Group 2 Number missing: 10, Reason: 1 not treated and 9 excluded</p> <p>Protocol outcome 4: Major bleeding at up to 45 days from hospital discharge - Actual outcome: Bleeding events - major bleeding at 6 months; Group 1: 10/273, Group 2: 6/273 Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low, Other 1 - High; Indirectness of outcome: No indirectness ; Group 1 Number missing: 5, Reason: 5 excluded; Group 2 Number missing: 10, Reason: 1 not treated and 9 excluded</p> <p>Protocol outcome 5: Heparin-induced thrombocytopenia at up to 90 days from hospital discharge - Actual outcome: Thrombocytopenia at 6 months; Group 1: 74/273, Group 2: 86/273 Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low, Other 1 - High; Indirectness of outcome: No indirectness ; Group 1 Number missing: 5, Reason: 5 excluded; Group 2 Number missing: 10, Reason: 1 not treated and 9 excluded</p>	
Protocol outcomes not reported by the study	Fatal PE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding at up to 45 days from hospital discharge; Health-related quality of life at up to 90 days from hospital discharge; Technical complications of mechanical interventions at up to 90 days from hospital discharge

H.15 Patients with central venous catheters

Study	De Cicco 2009 ⁷⁹
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=450)
Countries and setting	Conducted in Greece, Italy
Line of therapy	Not applicable
Duration of study	Intervention time: 9-11 days

Study	De Cocco 2009 ⁷⁹
Method of assessment of guideline condition	Adequate method of assessment/diagnosis
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	cancer patient; 18 years of age or over; life expectancy of at least 3 months; scheduled for CVC insertion for chemotherapy administration
Exclusion criteria	previous CVC insertion; known hypersensitivity to X-ray contrast; renal failure (serum creatinine level >180 μmol/l); active gastric peptic ulcer or severe hepatic disease; DVT in the previous 3 months or cerebral bleeding in the previous 6 months; known cerebral metastasis; bleeding disorders [activated partial thromboplastin time (aPTT) 30% longer than the control value and international normalized ratio (INR) > 1.5]; platelet count <80 · 10 ⁹ /l; antithrombin III <60%; treatment with unfractionated heparin, LMWH, oral anticoagulants or antiplatelet agents within 5 days before CVC insertion; pregnancy and refusal to give written consent
Recruitment/selection of patients	Consecutive cancer patients who met the inclusion criteria, from February 2000 to June 2004
Age, gender and ethnicity	Age - Mean (SD): 55 (12). Gender (M:F): 165:285. Ethnicity: not reported
Further population details	1. Active cancer: Active cancer 2. BMI : Not applicable (Weight, mean (SD): acenocoumarol 70.9 (13); dalteparin 68.6 (12.8); no treatment 71 (14.7)). 3. Renal impairment: Not applicable (not stated).
Extra comments	Cancer localisation: breast 32%; gastrointestinal 28%; hepatic or biliary tract 3.3%; pancreatic 2.5%; genitourinary 12.4%; hematologic 6.2%; head and neck 5.6%; lung 2%. Metastatic 56.4%
Indirectness of population	No indirectness
Interventions	(n=150) Intervention 1: Vitamin K antagonists - Acenocoumarol . Acenocoumarol 1mg/day for 3 days before and 8 days after CVC insertion. Duration 11 days. Concurrent medication/care: Chemotherapy (n=150) Intervention 2: Low molecular weight heparin - Dalteparin. Dalteparin 500IU, 2 hours before CVC insertion and daily after for 8 days. Duration 9 days. Concurrent medication/care: Chemotherapy (n=150) Intervention 3: No treatment - No VTE prophylaxis treatment. No treatment. Duration 11 days. Concurrent medication/care: Chemotherapy
Funding	Funding not stated

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: ACENOCOUMAROL versus DALTEPARIN

Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge

Study	De Cicco 2009 ⁷⁹
	- Actual outcome: Mortality at 30 days; Group 1: 14/114, Group 2: 12/120; Risk of bias: Very high; Indirectness of outcome: No indirectness
	Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic) at 7-90 days from hospital discharge
	- Actual outcome: DVT, CVC-related (definition not reported) at 30 days; Group 1: 25/114, Group 2: 48/120; Risk of bias: High; Indirectness of outcome: Serious
	Protocol outcome 3: Major bleeding at up to 45 days from hospital discharge
	- Actual outcome: Major bleeding (clinically overt bleeding associated with a decrease in haemoglobin level of at least 2d/dL or requiring a transfusion of 2 or more units of packed red cells in any 24 hour period) at 30 days; Group 1: 0/114, Group 2: 0/120; Risk of bias: Very high; Indirectness of outcome: No indirectness
	RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: ACENOCOUMAROL versus NO VTE PROPHYLAXIS TREATMENT
	Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge
	- Actual outcome: Mortality at 30 days; Group 1: 14/114, Group 2: 11/114; Risk of bias: Very high; Indirectness of outcome: No indirectness
	Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic) at 7-90 days from hospital discharge
	- Actual outcome: DVT, CVC-related (definition not reported) at 30 days; Group 1: 25/114, Group 2: 60/114; Risk of bias: High; Indirectness of outcome: Serious
	Protocol outcome 3: Major bleeding at up to 45 days from hospital discharge
	- Actual outcome: Major bleeding (clinically overt bleeding associated with a decrease in haemoglobin level of at least 2d/dL or requiring a transfusion of 2 or more units of packed red cells in any 24 hour period) at 30 days; Group 1: 0/114, Group 2: 0/114; Risk of bias: Very high; Indirectness of outcome: No indirectness
	RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: DALTEPARIN versus NO VTE PROPHYLAXIS TREATMENT
	Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge
	- Actual outcome: Mortality at 30 days; Group 1: 12/120, Group 2: 11/114; Risk of bias: Very high; Indirectness of outcome: No indirectness
	Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic) at 7-90 days from hospital discharge
	- Actual outcome: DVT, CVC-related (definition not reported) at 30 days; Group 1: 48/120, Group 2: 60/114; Risk of bias: High; Indirectness of outcome: Serious
	Protocol outcome 3: Major bleeding at up to 45 days from hospital discharge
	- Actual outcome: Mortality (clinically overt bleeding associated with a decrease in haemoglobin level of at least 2d/dL or requiring a transfusion of 2 or more units of packed red cells in any 24 hour period) at 30 days; Group 1: 0/120, Group 2: 0/114; Risk of bias: Very high; Indirectness of outcome: No indirectness
	Protocol outcomes not reported by the study
	Pulmonary embolism at 90 days from hospital discharge; Fatal PE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding at up to 45 days from hospital discharge; Health-related quality of life at up to 90 days

Study		De Cicco 2009 ⁷⁹			
		from hospital discharge; Heparin-induced thrombocytopenia at up to 90 days from hospital discharge			
Study details	Patients	Interventions	Outcome measures	Effect size	Comments
<p>Karthaus et al.,¹⁷⁰</p> <p>Country of study: 48 centres from 12 countries</p> <p>Study design: RCT</p> <p>List who was masked to interventions: Patient, clinician and outcome assessor</p> <p>Evidence level: 1+</p> <p>Duration of follow-up: 16 weeks</p>	<p>Patient group: Patients with documented cancer with central venous catheter.</p> <p>Setting: Unclear</p> <p>Inclusion criteria: Patients with histologically confirmed malignancy; placement of a CVC for chemotherapy within 5-7 days prior to randomisation and treatment; expected length of catheter use of at least 12 weeks; age ≥ 18 years; weight ≥ 40kg; Eastern Cooperative Oncology Group performance status of 0,1 or 2; life expectancy of at least 16 weeks; adequate pre-treatment organ function as demonstrated by a platelet count of at least 100,000/mm³; absolute neutrophil count of at least 1500/mm³; total bilirubin and serum creatinine of up to 2 x the upper limit of normal; AST up to 3 x (patients without liver metastasis) or 5 x (patients with liver metastasis) the upper limit of normal; a PT/aPTT up to 1.5 x the upper limit of normal.</p> <p>Exclusion criteria: known hypersensitivity to dalteparin; other</p>	<p>Group 1</p> <p>Low Molecular Weight Heparin (Dalteparin)</p> <p>Start time: unclear</p> <p>End time: unclear</p> <p>Duration: 16 weeks</p> <p>Dose and frequency: 5000IU injected subcutaneously once daily</p> <p>Group 2</p> <p>Placebo</p> <p>Start time: Unclear</p> <p>End time: Unclear</p> <p>Duration: 16 weeks</p>	All-cause mortality	Group1: 4/285 Group 2: 1/140 P value: NS	<p>Funding: Pfizer</p> <p>Limitations: 2:1 randomisation of dalteparin: placebo. Significantly more patients had solid tumours in the Dalteparin group.</p> <p>Outcomes not reported: Deep vein thrombosis, Heparin induced thrombocytopenia , pulmonary hypertension, post thrombotic syndrome, Quality of life, length of stay</p> <p>Additional outcomes reported: Catheter related infection, non-catheter related arterial or venous</p>
			Catheter related clinically relevant pulmonary embolism (confirmed by: ventilation perfusion scan or spiral CT scan)	Group1: 1/294 Group 2: 0/145 P value: NS	
			Clinically relevant catheter related thrombosis ¹ (screened for by: upper extremity evaluation by venography, ultrasound or computed tomography CT scan)	Group1: 10/294 Group 2: 5/145 P value: 0.980*	
			Asymptomatic catheter related thrombosis ² (confirmed by: upper extremity evaluation by venography, ultrasound or computed tomography CT scan)	Group1: 10/294 Group 2: 6/145 P value: 0.788*	
			Major bleeding (description: as described by adjudication committee)	Group1: 1/294 Group 2: 1/145 P value: 0.522*	
All bleeding (Table of all	Group1: 50/285				

Study	De Ciccio 2009 ⁷⁹												
<p>LMWH or unfractionated heparin; active gastrointestinal or genitourinary tract bleeding; known coagulopathy; requirement for aspirin, dipyridamole, UFH, other LMWHs, warfarin or other anticoagulation therapy; active uncontrolled infection, including suspected catheter related infection;; known HIV positivity or AIDS related illness; eye, ear or NS surgery or a CNS trauma within the last 3 months; intracranial or intraocular haemorrhage (within 1 year) or retinal detachment (within 6 months); mental incapacitation or psychiatric illness that would prevent the provision of informed consent; uncontrolled cardiac arrhythmia; severe concurrent disease; leukaemia requiring induction/consolidation chemotherapy during the 16 study week period; requirement of high dose chemotherapy and stem cell transplantation during the 16 week study period; use of investigational or unapproved catheter devices; and pregnancy, breastfeeding or likelihood of pregnancy.</p> <p>All patients N: 439</p> <table border="0"> <tr> <td>Age (mean):</td> <td>Gp 1</td> <td>Gp2</td> </tr> <tr> <td>Mean ± SD</td> <td>55.2±12.91</td> <td>57.4 ±12.72</td> </tr> <tr> <td>M/F (% female):</td> <td>59.2</td> <td>57.2</td> </tr> </table> <p>Additional risk factors:</p>	Age (mean):	Gp 1	Gp2	Mean ± SD	55.2±12.91	57.4 ±12.72	M/F (% female):	59.2	57.2	<p>Dose and frequency: 0.2ml saline solution</p> <p>Additional non-comparative prophylaxis: Catheter flushing with unfractionated heparin (500IU)/saline boluses were allowed during catheter use.</p>	<p>recorded bleeding (including location of bleed) is provided as table 5 in the paper)</p>	<p>Group 2: 21/140 P value: 0.581*</p>	<p>thromboembolic events</p> <p>Notes: * Calculated by the NCC team using Fisher exact test. Catheter related thrombosis Clinically relevant catheter related thrombosis = thrombosis that was symptomatic or that required anticoagulant therapy or therapeutic infusion of a fibrinolytic agent with or without catheter removal Asymptomatic catheter thrombosis = not requiring any intervention.</p>
Age (mean):	Gp 1	Gp2											
Mean ± SD	55.2±12.91	57.4 ±12.72											
M/F (% female):	59.2	57.2											

Study		De Cicco 2009 ⁷⁹					
		Gp1	Gp2				
	Weight						
	mean (kg) ± SD	71.41±15.41					
		70.73±14.28					
	% Caucasian	94.6	93.8				
	Solid: Haematological tumours						
		271:23	125:20				
	Haematological						
	Group 1						
	No. randomised: 294						
	No. of dropouts:						
	9 patients did not receive 1 dose						
	94 patients withdrew early from the study (reasons provided)						
	Group 2						
	No. randomised: 145						
	No. of dropouts:						
	9 patients did not receive 1 dose						
	94 patients withdrew early from the study (reasons provided)						
Study		Lavau-denes 2013 ¹⁹⁸					
Study type		RCT (Patient randomised; Parallel)					
Number of studies (number of participants)		1 (n=420)					
Countries and setting		Conducted in France; Setting: centre hospitalier universitaire de Limoges					
Line of therapy		Not applicable					
Duration of study		Intervention time: 3 months					
Method of assessment of guideline condition		Adequate method of assessment/diagnosis					

Study	De Cicco 2009 ⁷⁹
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	historical evidence of solid invasive cancer, locally advanced or metastatic status; presence of a subclavian central venous catheter inserted for less than 7 days; starting a first line of chemotherapy; aged 18 years or over; life expectancy of more than 3 months; performance status between 0 and 2 (ambulatory); platelets greater than $100 \times 10^9/l$ and normal activated partial thromboplastin time (aPTT); capacity to provide informed consent
Exclusion criteria	renal or hepatic failure (creatinine clearance <20 ml/min); acute infectious disease; history of an allergic reaction to warfarin or heparin; uncontrolled blood pressure; ongoing haemorrhagic syndrome; concomitant disease which recommended heparin treatment; formal indication for warfarin or antiplatelets agents in preventative or curative doses; pregnant or breastfeeding woman; recent history of DVT in past 6 months; presence of cerebral metastasis; previous central venous access devices in past year
Recruitment/selection of patients	Consecutive patients enrolled from September 1999 to June 2009
Age, gender and ethnicity	Age - Mean (range): Control 60 (21-85); warfarin 59 (24-81); LMWH 61. Gender (M:F): 243:164. Ethnicity: not reported
Further population details	1. Active cancer: Active cancer (historical evidence of solid invasive cancer, locally advanced or metastatic status). 2. BMI : Mixed (<35 97.3%; ≥ 35 2.2%). 3. Renal impairment: No renal impairment (eGFR greater than 45 ml/min/1.73 m ²) (excluded people with renal failure).
Extra comments	Primary cancer location: head and neck 23.6; breast 10.6; lung or pleura 11%; colorectal and anal 14.7%; oesophagus and stomach 15.7%; pancreas and biliary tract 5%; urinary (kidney and tract) 7.9%; pelvic gynaecological 4.7%. Previous surgery 25.8%
Indirectness of population	No indirectness
Interventions	(n=141) Intervention 1: Low molecular weight heparin - Mixed. Subcutaneous LMWH (dalteparin, nadroparin or enoxaparin) at recommended doses for prevention, once daily. Doses were not adjusted. Treatment started in the first 6 days after central venous access device implementation. Duration 90 days. Concurrent medication/care: chemotherapy (n=137) Intervention 3: No treatment - No VTE prophylaxis treatment. No prophylaxis. Duration 90 days. Concurrent medication/care: chemotherapy
Funding	Other (Clinical Research and Innovation of Limoges Hospital)

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: LMWH versus NO VTE PROPHYLAXIS TREATMENT

Study		De Cicco 2009 ⁷⁹			
<p>Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge - Actual outcome: Mortality at 90 days; Group 1: 0/138, Group 2: 0/135; Risk of bias: High; Indirectness of outcome: No indirectness</p> <p>Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic) at 7-90 days from hospital discharge - Actual outcome: DVT, catheter-related (confirmed by Doppler US and venography) at 90 days; Group 1: 14/138, Group 2: 8/134; Risk of bias: High; Indirectness of outcome: No indirectness - Actual outcome: DVT, non-catheter-related (confirmed by Doppler US and venography) at 90 days; Group 1: 1/138, Group 2: 7/135; Risk of bias: High; Indirectness of outcome: No indirectness</p> <p>Protocol outcome 3: Pulmonary embolism (definition not reported) at 7-90 days from hospital discharge - Actual outcome: PE with no etiological DVT at 90 days; Group 1: 0/138, Group 2: 1/135; Risk of bias: High; Indirectness of outcome: No indirectness</p> <p>Protocol outcomes not reported by the study</p>					
		<p>All-cause mortality at up to 90 days from hospital discharge; Pulmonary embolism at 90 days from hospital discharge; Major bleeding at up to 45 days from hospital discharge; Fatal PE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding at up to 45 days from hospital discharge; Health-related quality of life at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at up to 90 days from hospital discharge</p>			
Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Monreal et al., 1996457	Patient group: Cancer patients with central venous catheters	Group 1 LMWH (Fragmin)	All-cause mortality Mortality from cancer progression	Group1: 1/17 Group 2: 2/15 P value: 0.589*	Funding: No information is provided regarding funding.
Country of study: Spain	Setting: Unclear	Start time: 2 hours before insertion of the catheter	Asymptomatic subclavian DVT (confirmed by: Venography)	Group1: 1/16 Group 2: 8/13 P value: 0.003*	Limitations: No information about randomisation method, allocation concealment in the paper.
Study design: RCT	Inclusion criteria: all cancer patients who underwent placement of a long term Port-a-Cath subclavian venous catheter and had projected survivals of over 3 months.	Duration: 90 days or until there was venographic evidence of thrombosis.	Paper reports that 8/9 events were symptomatic but does not provide details of which group they occurred in.		The paper does not state whether patients or clinicians were blind to treatment
List who was masked to interventions: Venogram interpreters.	Exclusion criteria: Patients who had baseline platelet counts under 100x10 ⁹ /l, previous subclavian vein	Dose, and frequency: 2500IU subcutaneously once daily.	Major bleeding (description: haematoma requiring	Group1: 1/16 Group 2: 0/12	

Study		De Cicco 2009 ⁷⁹																																												
Evidence level: 1+	catheters, obstructing mediastinal tumours, previous history of DVT, or anatomic lesions that bleed.	Group 2 No prophylaxis	surgical intervention)	P value: NS	allocation.																																									
Duration of follow-up: 90 days	<p>All patients N: 32 Age (mean): 54 (range 27 – 77) M/F: 17:15 Additional risk factors:</p> <table border="1"> <thead> <tr> <th>Cancer location</th> <th>Gp1</th> <th>Gp2</th> </tr> </thead> <tbody> <tr> <td>Colon</td> <td>8</td> <td>7</td> </tr> <tr> <td>Breast</td> <td>4</td> <td>2</td> </tr> <tr> <td>Sarcoma</td> <td>2</td> <td>1</td> </tr> <tr> <td>Mesothelioma</td> <td>1</td> <td>2</td> </tr> <tr> <td>Stomach</td> <td>1</td> <td>1</td> </tr> <tr> <td>Metastases</td> <td>Gp1</td> <td>Gp2</td> </tr> <tr> <td>Liver</td> <td>6</td> <td>7</td> </tr> <tr> <td>Lung</td> <td>5</td> <td>4</td> </tr> <tr> <td>Bone</td> <td>2</td> <td>1</td> </tr> <tr> <td>Brain</td> <td>1</td> <td>1</td> </tr> <tr> <td>Others</td> <td>2</td> <td>1</td> </tr> <tr> <td></td> <td>Gp1</td> <td>Gp2</td> </tr> <tr> <td>Infection</td> <td>0</td> <td>1</td> </tr> </tbody> </table> <p>Group 1 No. randomised: 17 No. of dropouts: 1 died</p>	Cancer location	Gp1	Gp2	Colon	8	7	Breast	4	2	Sarcoma	2	1	Mesothelioma	1	2	Stomach	1	1	Metastases	Gp1	Gp2	Liver	6	7	Lung	5	4	Bone	2	1	Brain	1	1	Others	2	1		Gp1	Gp2	Infection	0	1	Additional non-comparative prophylaxis: None mentioned		<p>Outcomes not reported: Pulmonary embolism, lower extremity DVT, Fatal, neurological or minor bleeding, post thrombotic syndrome, pulmonary hypertension, heparin induced thrombocytopenia , quality of life, length of stay.</p> <p>Additional outcomes reported: Infection</p> <p>Notes: * Calculated by NCC using Fisher exact tests.</p>
Cancer location	Gp1	Gp2																																												
Colon	8	7																																												
Breast	4	2																																												
Sarcoma	2	1																																												
Mesothelioma	1	2																																												
Stomach	1	1																																												
Metastases	Gp1	Gp2																																												
Liver	6	7																																												
Lung	5	4																																												
Bone	2	1																																												
Brain	1	1																																												
Others	2	1																																												
	Gp1	Gp2																																												
Infection	0	1																																												

Study	De Cicco 2009 ⁷⁹				
	Group 2 No. randomised: 15 No. of dropouts: 2 died				

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
<p>Niers et al., 2007⁴⁸⁹</p> <p>Country of study: The Netherlands</p> <p>Study design: RCT</p> <p>List who was masked to interventions: Patient, healthcare professionals and investigators assessing outcome</p>	<p>Patient group: Patients with haematologic malignancies requiring central venous catheters,</p> <p>Setting: Unclear</p> <p>Inclusion criteria: Consecutive patients with haematologic malignancies who were going to receive a CVC for high-dose chemotherapy including autologous stem cell transplantation.</p> <p>Exclusion criteria: Patients aged less than 17 years allergy to i.v. contrast medium, previous catheter related CVT, current use or indication for anticoagulant treatment</p>	<p>Group 1</p> <p>Low Molecular Weight Heparin Nandoparin (Fraxiparin)</p> <p>Start time: 2hr before CVC insertion</p> <p>End time: 3 weeks or until day of catheter removal whichever came first</p> <p>Dose, and frequency: 2850 antifactor Xa (antiFXa) units subcutaneously once daily</p> <p>Group 2</p>	<p>Symptomatic catheter related central venous thrombosis (confirmed by: venography)</p>	<p>Group1: 0/41 Group 2: 1/46 P value: NS</p>	<p>Funding: Paper states that the study drug was obtained commercially and there was 'financial support' for the study. No further details were provided.</p> <p>Limitations: No information about method of randomisation and allocation concealment. 24% of randomised patients did not complete the study</p> <p>Outcomes not reported: Pulmonary</p>
			<p>Catheter related central venous thrombosis (confirmed by: ultrasound confirmed by venography)</p>	<p>Group1: 7/41 Group 2: 4/46 P value: 0.336*</p>	
			<p>Major bleeding (description: overt bleeding with a fall in haemoglobin of 2g/dL or more, or leading to a transfusion of 2 or more units of packed red blood cells or bleeding in a critical organ such as intracranial, retroperitoneal or pericardial bleeding, or contributing to death.)</p>	<p>Group1: 0/56 Group 2:0/57 P value: NS</p>	
			<p>Clinically relevant non-</p>	<p>Group1: 2/56</p>	

<p>Evidence level: 1+</p> <p>Duration of follow-up: 3 weeks</p>	<p>acute promyelocytic leukaemia</p> <p>Previous CVC</p> <p>Evident haemorrhagic diathesis</p> <p>Renal failure (creatinine >200 µmol/L)</p> <p>All patients</p> <p>N: 202 eligible, 113 randomised</p> <p>Reasons for non-randomisation given</p> <p>Age : Gp1 Gp2</p> <p>mean ± SD 58±10 53±13</p> <p>M/F: 62:51</p> <p>Additional risk factors:</p> <p>Haematologic tumours Gp1</p> <p> Gp2</p> <p>Acute myeloid leukaemia 23</p> <p>17</p> <p>Multiple lymphoblastic leukaemia</p> <p> 2 10</p> <p>Multiple myeloma 14</p> <p>16</p> <p>(Non)-Hodgkin lymphoma – relapsed</p> <p> 17 14</p> <p>Group 1</p> <p>No. randomised: 56</p> <p>No. of dropouts: 15 (27%)</p> <p>Group 2</p> <p>No. randomised: 57</p>	<p>Placebo (no details provided)</p> <p>Dose and frequency: subcutaneous injections once daily</p> <p>Additional non-comparative prophylaxis: None indicated in the paper.</p>	<p>major bleeding (description: overt bleeding not meeting the criteria for major bleeding, and included skin haematoma if the size was larger than 100 cm², epistaxis lasting for more than 5 minutes or repetitive or leading to an intervention, macroscopic haematuria if spontaneous or lasting for more than 24 hours after instrumentation or any other bleeding type that was considered to have clinical consequences for the patient.)</p>	<p>Group 2: 2/57 P value: NS</p>	<p>Embolism, Lower limb DVT, pulmonary hypertension, post thrombotic syndrome, quality of life, length of stay, all-cause mortality.</p> <p>Additional outcomes reported: Catheter related infection</p> <p>Notes: CVT – central venous thrombosis CVC – central venous catheter *Calculated by the NCC using Fisher Exact Test</p>
			<p>Minor bleeding (description: all other bleeding episodes not meeting the criteria for clinically relevant non-major bleeding)</p>	<p>Group1:5/56 Group 2: 2/57 P value: 0.271*</p>	
			<p>Heparin induced thrombocytopenia (description: clinical suspicion and positive antibodies against the heparin-platelet FIV complex)</p>	<p>Group1: 0/56 Group 2: 0/57 P value: NS</p>	

	No. of dropouts: 11 (19%)				
--	---------------------------	--	--	--	--

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Verso et al., 2005663 Country of study: Italy Study design: RCT List who was masked to interventions: Patients, healthcare professionals and investigators assessing VTE end points Evidence level: 1+ Duration of follow-up: 3	Patient group: Cancer patients with a central venous catheter Setting: Unclear Inclusion criteria: Consecutive patients aged 18 years or older who were scheduled for CVC insertion for chemotherapy if they had a life expectancy of at least 3 months and adequate venous access to perform venography of the upper limb and if the CVC was to be left in site for longer than 6 weeks. Exclusion criteria: Renal failure (serum creatinine >2.0 mg/dL) Known hypersensitivity to x-ray contrast medium Previous CVC insertion on the ipsilateral side Cerebral thrombosis or bleeding in the previous 6 months or known cerebral metastasis	Group 1 Low Molecular Weight Heparin - Enoxaparin (Clexane) Start time: 2 hours prior to CVC insertion Duration: 42 days ±2 days Dose, and frequency: 40mg injection subcutaneously once per day. Group 2 Placebo Start time: 2 hours prior to CVC insertion Duration: 42 days ±2 days	All-cause mortality	After treatment Group1: 5/191 Group 2: 2/194 P value: 0.281* After follow up (3 months) Group1: 13/191 Group 2: 20/194 P value: 0.2875*	Funding: Supported by a grant from Aventis Pharmaceuticals. Limitations: The paper states that randomisation was completed using 'random numbers' but no indication of how these were generated. No information about allocation concealment. Outcomes not reported: Lower limb DVT, Pulmonary Embolism, Neurological bleeding, Upper GI bleeding, Heparin induced thrombocytopenia
			Fatal pulmonary embolism (confirmed by: autopsy)	Group1: 0/191 Group 2: 0/194 P value: NS	
			Symptomatic upper limb DVT (confirmed by: venography)	Group1: 2/155 Group 2: 6/155 P value: 0.283*	
			asymptomatic or symptomatic upper limb DVT (confirmed by: venography)	Group1: 22/155 Group 2: 28/155 P value: 0.44*	
			Major bleeding (description: decrease in haemoglobin level of at least 2g/dL or requiring a transfusion of two or more units of packed red cells.	Group1: 0/191 Group 2: 0/194 P value: NS	

months	<p>Bleeding disorders (APTT and/or prothrombin time 30% longer than control values) or platelet count less than 80 x 10⁹/L</p> <p>Active gastric peptic ulcer or severe hepatic disease</p> <p>Uncontrolled arterial hypertension</p> <p>Known hypersensitivity to unfractionated heparin or LMWHs</p> <p>Objectively confirmed DVT within the previous 3 months</p> <p>Treatment with heparin, LMWH, oral anticoagulants or antiplatelet agents within 5 days before CVC insertion</p> <p>Pregnancy</p> <p>Anticipated inability to participate in the study for 3 months</p> <p>Patients with CVC for parenteral nutrition only</p> <p>All patients N: 385</p> <p>Age: Gp 1 Gp2</p> <p>Mean±SD 59.1±11.9 59.5±12.4</p> <p>M/F: 176:209</p> <p>Additional risk factors:</p> <table border="1"> <thead> <tr> <th>Cancer Localisation</th> <th>Gp1</th> <th>Gp2</th> </tr> </thead> <tbody> <tr> <td>Gastrointestinal</td> <td>100</td> <td>108</td> </tr> <tr> <td>Hepatic or biliary tract</td> <td>0</td> <td></td> </tr> <tr> <td>7</td> <td></td> <td></td> </tr> <tr> <td>Pancreatic</td> <td>3</td> <td>6</td> </tr> <tr> <td>Genitourinary</td> <td>14</td> <td>10</td> </tr> </tbody> </table>	Cancer Localisation	Gp1	Gp2	Gastrointestinal	100	108	Hepatic or biliary tract	0		7			Pancreatic	3	6	Genitourinary	14	10	<p>Additional non-comparative prophylaxis:</p> <p>Paper states treatment with aspirin, antiplatelet agents or nonsteroidal anti-inflammatory agents were not allowed during the trial.</p>	<p>Intracranial, retroperitoneal, and intraocular bleeding and bleeding requiring surgical intervention)</p>	<p>Group1: 12/191</p> <p>Group 2: 7/194</p> <p>P value: 0.248*</p>	<p>, post thrombotic syndrome, pulmonary hypertension, quality of life, length of stay</p>
		Cancer Localisation	Gp1	Gp2																			
Gastrointestinal	100	108																					
Hepatic or biliary tract	0																						
7																							
Pancreatic	3	6																					
Genitourinary	14	10																					
<p>Minor bleeding (description: All other bleeding)</p>	<p>Additional outcomes reported: Thrombocytopenia</p> <p>Notes: * calculated by NCC team using Fisher Exact Test</p>																						

Lung	4	3				
Head and neck	13	6				
Breast	34	34				
Haematological	16	17				
Skin	1	2				
Other	7	3				
Unknown	2	2				
Cancer Histology	Gp1	Gp2				
Adenocarcinoma	157	162				
Lymphoma and leukaemia	13	14				
Sarcoma	4	2				
Other	15	11				
Unknown	1	4				
Cancer stage	Gp1	Gp2				
Metastatic	145	139				
Non metastatic	41	45				
Unknown	4	4				
Surgery, No of patients	Gp1	Gp2				
Previous ≤3 months	83	79				
Recent <3 months	72	68				
Planned	3	4				
Unknown	32	41				
Chemotherapy	Gp1	Gp2				
Before CVC insertion	88	75				
After CVC insertion	102					
118						
One agent	45	34				

≥2 agents	145	159				
Other risk factors	Gp1	Gp2				
Axillary node dissection	27					
28						
Previous CVC of upper limb	16					
23						
Previous chest surgery	17	11				
History of radiation to chest wall						
	15	12				
History of previous VTE (<3months)						
	1	0				
Axillary node involvement	11					
6						
Compression of superior vena cava						
	3	5				
Family history of VTE	2	4				
Oestrogen containing medications						
	1	1				
Upper limb immobilisation	0	1				
Group 1						
No. randomised: 191						
No. of dropouts: 36 (18.8%)						
Group 2						
No. randomised: 194						
No. of dropouts: 39 (20.1)						

H.16 Palliative care

No relevant studies were identified.

H.17 Critical care

Study	Cook 2011 [PROTECT] ⁷²
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=3764)
Countries and setting	Conducted in Australia, Brazil, Canada, Saudi Arabia, United Kingdom, USA; Setting: 67 ICUs in academic and community hospitals in the 6 countries.
Line of therapy	Prevention
Duration of study	Intervention time: Duration of stay in ICU
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: DVT was diagnosed on the first screening ultrasonography as prevalent DVT, reflecting a baseline characteristic. PE defined as definite (characteristic intraluminal filling defect on computed tomography of the chest, a high-probability ventilation ventilation-perfusion scan, or autopsy finding), probable (high clinical suspicion and either no test results or non-diagnostic results on noninvasive testing), or absent (negative or normal test results without reference to pretest probability). Major bleeding was defined as haemorrhage occurring at a critical site (e.g. intracranial haemorrhage), resulting in the need for a major therapeutic intervention (e.g. surgery), causing hemodynamic compromise, requiring at least 2 units of red-cell concentrates, or resulting in death.
Stratum	People who are not contraindicated for prophylaxis
Subgroup analysis within study	Not applicable
Inclusion criteria	Enrolled patients who were at least 18 years of age, weighed at least 45 kg, and were expected to remain in the ICU for at least 3 days.
Exclusion criteria	Major trauma, neurosurgery or orthopaedic surgery, need for therapeutic anticoagulant, heparin administration in the ICU for at least 3 days, contraindication to heparin or blood products, pregnancy, life support limitation, or enrollment in a related trial
Recruitment/selection of patients	Recruitment began in May 2006 and was completed in 4 years.
Age, gender and ethnicity	Age - Mean (range): 44.6-78.1. Gender (M:F): 1.32:1. Ethnicity: Not reported
Further population details	1. Active cancer: Mixed (History of cancer: Dalteparin group 4.4%; UFH group 3.7%). 2. BMI: Not obese (BMI under 30

	kg/m ²) (BMI: Dalteparin group 28.3±8.1, UFH group 28.2±7.3). 3. Renal impairment: Not applicable 4. Surgical/medical: Medical 5. Trauma: Not applicable
Extra comments	<p>Diagnosis on admission (n for dalteparin = 1865, n for UFH= 1862): Cardiovascular condition - Dalteparin 8.9%, UFH 9.1%, Respiratory condition - Dalteparin 45.8%, UFH 45.4%, Gastrointestinal condition - Dalteparin 14.2%, UFH 13.7%, Renal condition - Dalteparin 2.1%, UFH 1.3%, Neurologic condition - Dalteparin 6.2%, UFH 6.1%, Sepsis - Dalteparin 14.6%, UFH 14.9%, Metabolic condition - Dalteparin 3.9%, UFH 3.8%.</p> <p>Length of stay: Dalteparin 9 (6-15), UFH 9 (6-16);</p> <p>Personal history of VTE (n for dalteparin = 1865; n for UFH = 1862) - Dalteparin 3.2%, UFH 3.2%. Family history of VTE - Dalteparin 1.4%, UFH - 1.6%.</p> <p>Central venous catheterisation (n for dalteparin and UFH= 1862) - Dalteparin 82.9%, UFH 84.9%. History of cancer (n for dalteparin = 1865; n for UFH = 1862) - Dalteparin 4.4%, UFH 3.7%</p>
Indirectness of population	No indirectness
Interventions	<p>(n=1873) Intervention 1: Low molecular weight heparin - Dalteparin. Subcutaneous dalteparin at a dose of 5000 IU once daily. Research pharmacists prepared identical syringes for subcutaneous injection of either dalteparin once daily plus placebo once daily. Duration of the ICU stay. Concurrent medication/care: N/A</p> <p>(n=1873) Intervention 2: Unfractionated heparin - low dose, administered subcutaneously. Subcutaneous unfractionated heparin at a dose of 5000 IU twice daily. Duration of ICU stay. Concurrent medication/care: N/A</p>
Funding	Academic or government funding (Canadian Institutes of Health Research, the Heart and Stroke Foundation of Canada and the Australian and New Zealand College of Anesthetists Research Foundation)

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: DALTEPARIN versus UNFRACTIONATED HEPARIN (UFH)

Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge

- Actual outcome: Mortality (in ICU) at up to 100 days; Group 1: 284/1873, Group 2: 304/1873; Risk of bias: Low; Indirectness of outcome: No indirectness

Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic at 7-90 days from hospital discharge)

- Actual outcome: Any DVT at time of death, discharge or at 100 days if patients were still hospitalized (Baseline screening for DVT was diagnosed using ultrasonography. The assumption was made that ultrasonography was also used to detect DVT at the reported time points); Group 1: 138/1873, Group 2: 161/1873; Risk of bias: High; Indirectness of outcome: No indirectness

-Actual outcome: Proximal DVT at time of death, discharge or at 100 days if patients were still hospitalized (Baseline screening for DVT was diagnosed using ultrasonography. The assumption was made that ultrasonography was also used to detect DVT at the reported time points); Group 1: 96/1873, Group 2: 109/1873

Protocol outcome 3: Pulmonary embolism at 7-90 days from hospital discharge

- Actual outcome: PE at time of death, discharge or at 100 days if patients were still hospitalized (defined as characteristic intraluminal filling defect on computed tomography of the chest, a high probability ventilation-perfusion scan, or autopsy finding); Group 1: 18/1873, Group 2: 28/1873; Risk of bias: Low; Indirectness of outcome: No indirectness

Protocol outcome 4: Major bleeding at up to 45 days from hospital discharge

- Actual outcome: Major bleeding at time of death, discharge or at 100 days if patients were still hospitalized (defined as haemorrhage occurring at a critical site, e.g. intracranial haemorrhage, resulting in the need for a major therapeutic intervention, e.g. surgery, causing hemodynamic compromise, requiring at least 2 units of red-cell concentrates, or resulting in death); Group 1: 103/1873, Group 2: 105/1873; Risk of bias: Low; Indirectness of outcome: No indirectness

Protocol outcome 5: Heparin-induced thrombocytopenia at up to 90 days from hospital discharge

- Actual outcome: Heparin-induced thrombocytopenia at time of death, discharge or at 100 days if patients were still hospitalized (definition not reported); Group 1: 5/1873, Group 2: 12/1873; Risk of bias: Low; Indirectness of outcome: No indirectness

Protocol outcome 6: Venous thromboembolism at up to 90 days from hospital discharge (definition not reported)

-Actual outcome: VTE at time of death, discharge or at 100 days if patients were still hospitalised; Group 1: 154/1873, Group 2: 186/1873

Protocol outcomes not reported by the study

Fatal PE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding at up to 45 days from hospital discharge; Health-related quality of life at up to 90 days from hospital discharge; Technical complications of mechanical interventions at up to 90 days from hospital discharge; Line associated thrombosis at duration of study

Study	Vignon 2013 ³²⁹
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=406)
Countries and setting	Conducted in France; Setting: Nine ICUs in France
Line of therapy	Prevention
Duration of study	Intervention time: 6 days
Method of assessment of guideline condition	Inadequate method of assessment/diagnosis: DVT and PE - confirmation with compression ultrasonography (CUS)
Stratum	People who are contraindicated for pharmacological prophylaxis
Subgroup analysis within study	Not applicable
Inclusion criteria	Patients aged 18 years or older who were at high risk of bleeding on ICU admission were eligible for the trial. High risk of bleeding was defined as symptomatic bleeding or the presence of organic lesions likely to bleed, hemophilic diseases,

	hemostatic abnormalities (platelet count <50,000/mm ³ , aPTT ratio >2, prothrombin time <40% or the presence of severe anaemia (haemoglobin <7 g/dl) due to bleeding or unexplained. (Patients contraindicated to pharmacological prophylaxis)
Exclusion criteria	Patient refusal, the absence of a high risk of bleeding, the presence of a documented VTE at screening or a recent DVT (<3 months), ICU stay of more than 36 hours or likely to be <72 hour, a life-support limitation, a contraindication for mechanical prophylaxis (i.e. severe lower limb arteriopathy, any arterial graft of the legs, a wound in the lower limb related to either vascular disease or trauma), and the presence of a mechanical prosthetic heart valve.
Recruitment/selection of patients	Between 21st November 2007 and 20th December 2010, a total of 407 patients underwent randomisation
Age, gender and ethnicity	Age - Mean (SD): 55.4 (17) years. Gender (M:F): 1.96:1. Ethnicity: Not reported
Further population details	1. Active cancer: Active cancer (IPC + AES group - 13.2%, AES group 12.4%). 2. BMI: Not obese (BMI under 30 kg/m ²) (IPC + AES - 25.6±4.9, AES group BMI - 25.4±5.5). 3. Renal impairment: Not applicable 4. Surgical/medical: Not applicable 5. Trauma: Not applicable
Extra comments	Primary admission diagnostic category (%) - spontaneous intracranial haemorrhage 36%, traumatic intracranial haemorrhage 21.4%, multisystem trauma 10.8%, other haemorrhage 9.9%, severe sepsis or septic shock 9.6%, acute respiratory distress syndrome 5.9%, other diagnoses 6.4%; . Hospitalisation more than 48h prior ICU admission - 68%; Therapeutic anticoagulation - 7.1%; Thromboprophylaxis - 7.1%; Previous VTE- 3%; Cancer - 12.8%; Recent surgery or trauma - 29.1%; Pregnancy or post-partum - 1%; Oestrogen use - 1.5%; Known thrombophilia - 0.5%; Plaster cast immobilisation - 0%; Previous stroke - 3.2%; Cardiac insufficiency - 15.8%
Indirectness of population	No indirectness
Interventions	<p>(n=202) Intervention 1: Anti-embolism stockings – AES only. AES consisted of thigh-length AES. Nurses were trained in the use of mechanical devices to apply optimal compression (proper sizing of AES and their proper application). AES was applied to both legs as soon as possible after randomisation and maintained continuously until compression ultrasonography (CUS) was performed on day 6. Duration 6 days. Concurrent medication/care: AES provided from T.E.D. anti-embolism stockings; Covidien, Mansfield. Anticoagulation was not permitted during the first 6 days of the study. The AES removal date and reasons were record when applicable. The use of AES was recorded to monitor compliance and tolerance. Compliance was considered poor if the mechanical devices were used less than 80% of the time.</p> <p>(n=205) Intervention 2: IPC + AES. IPC was achieved with using a compression system with adapted tubing sets and thigh sleeves. Nurses were trained in the use of mechanical devices to apply optimal compression (proper sizing of AES and IPC sleeves and their proper application). IPC and AES was applied to both legs as soon as possible after randomisation and maintained continuously until compression ultrasonography (CUS) was performed on day 6. Duration 6 days. Concurrent medication/care: IPC was SCD EXPRESS compression system and thigh sleeve was Covidien, Mansfield. Anticoagulation was not permitted during the first 6 days of the study. After that day, the decision to maintain VTE</p>

	prophylaxis and its modality were left at the discretion of the investigators. The IPC and AES removal date and reasons were record when applicable. The use of IPC and AES was recorded to monitor compliance and tolerance. Compliance was considered poor if the mechanical devices were used less than 80% of the time.
Funding	Academic or government funding (Grant from the French Ministry of Health)
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: INTERMITTENT PNEUMATIC COMPRESSION (IPC) + AES versus ANTI-EMBOLISM STOCKINGS (AES) ONLY</p> <p>Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic) at 7-90 days from hospital discharge - Actual outcome: DVT (symptomatic and asymptomatic) at 6 days (assessed using compression ultrasonography); Group 1: 10/179, Group 2: 16/183; Risk of bias: High; Indirectness of outcome: No indirectness - Actual outcome: Symptomatic DVT at 6 days (assessed using compression ultrasonography); Group 1: 0/204, Group 2: 0/202 - Actual outcome: Asymptomatic distal DVT (assessed using compression ultrasonography); Group 1: 6/179, Group 2: 12/183 - Actual outcome: Asymptomatic proximal DVT (assessed using compression ultrasonography); Group 1: 4/179 , Group 2: 4/183</p> <p>Protocol outcome 3: Pulmonary embolism at 7-90 days from hospital discharge - Actual outcome: Symptomatic PE at 6 days (assessed using compression ultrasonography); Group 1: 0/205, Group 2: 1/202; Risk of bias: High; Indirectness of outcome: No indirectness</p> <p>Protocol outcome 4: Fatal PE at up to 90 days from hospital discharge - Actual outcome: Fatal PE at 6 days (assessed using compression ultrasonography); Group 1: 0/204, Group 2: 0/202; Risk of bias: High; Indirectness of outcome: No indirectness</p> <p>Protocol outcome 5: Venous thromboembolism (definition not reported) - Actual outcome: VTE (symptomatic and asymptomatic) at 90 days; Group 1: 14/179, Group 2: 17/184</p>	
Protocol outcomes not reported by the study	Major bleeding at up to 45 days from hospital discharge; Clinically relevant non-major bleeding at up to 45 days from hospital discharge; Health-related quality of life at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at up to 90 days from hospital discharge; Technical complications of mechanical interventions at up to 90 days from hospital discharge; Line associated thrombosis at duration of study

H.18 Pregnant women and women up to 6 weeks postpartum

Study	Burrows 2001 ³⁷
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=76)
Countries and setting	Conducted in Australia; Setting: Obstetric unit
Line of therapy	Not applicable
Duration of study	Intervention + follow up: 6 weeks
Method of assessment of guideline condition	Adequate method of assessment/diagnosis
Stratum	Pregnant women undergoing caesarean section and any other surgery during pregnancy or postpartum (including day case termination surgery and surgical management of miscarriage)
Subgroup analysis within study	Not applicable
Inclusion criteria	Women having either elective or emergency caesarean section
Exclusion criteria	History of bleeding disorder, need of therapy with anticoagulation, history of thrombotic event, sensitivity to heparin, recent (3 months) history of GI haemorrhage or peptic ulcer, hepatic encephalopathy, renal dysfunction requiring dialysis, uncontrolled hypertension (systolic >200mmHG, diastolic >110mmHg), refusal to give informed consent, insufficient command of English to provide consent
Recruitment/selection of patients	Not reported
Age, gender and ethnicity	Age - Mean (SD): LMWH group: 31.7 (4.8), control group: 31.3 (5.5). Gender (M:F): Female. Ethnicity: Not reported
Further population details	1. Assisted conception: Non-assisted conception 2. BMI : Not applicable 3. Renal impairment: Not applicable
Indirectness of population	No indirectness
Interventions	(n=39) Intervention 1: Low molecular weight heparin (licensed in UK) - Dalteparin (5,000 daily; min 1,250 units daily - max 10,000 units daily). 2500U dalteparin. The first dose was administered no sooner than 4 hours postoperatively and no later than 24 hours postoperatively. Treatment packs contained enough syringes for 5 days of treatment. Duration 5 days. Concurrent medication/care: There were no restrictions on pain medication (n=37) Intervention 2: No treatment - Placebo. Placebo (saline). Duration 5 days. Concurrent medication/care: No restrictions on pain medication
Funding	Equipment / drugs provided by industry (Dalteparin and saline placebo provided by Phamacia and Upjohn)

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: DALTEPARIN (5,000 DAILY; MIN 1,250 UNITS DAILY - MAX 10,000 UNITS DAILY) versus PLACEBO

Protocol outcome 1: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at inpatients and up to 90 days from hospital discharge

- Actual outcome for Pregnant women undergoing caesarean section and any other surgery during pregnancy or postpartum (including day case termination surgery and surgical management of miscarriage) : PE at 6 weeks; Group 1: 0/39, Group 2: 0/37

Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcome 2: Major bleeding. Meets one or more of the following criteria: results in death (including foetal death); occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event (including adverse event for the foetus) at inpatient and up to 45 days from hospital discharge

- Actual outcome for Pregnant women undergoing caesarean section and any other surgery during pregnancy or postpartum (including day case termination surgery and surgical management of miscarriage) : Major bleeding at 6 weeks; Group 1: 0/39, Group 2: 1/37

Risk of bias: All domain - Very high, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - High, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcome 3: DVT (symptomatic) at 7-90 days from hospital discharge

- Actual outcome for Pregnant women undergoing caesarean section and any other surgery during pregnancy or postpartum (including day case termination surgery and surgical management of miscarriage) : DVT at 6 weeks; Group 1: 1/39, Group 2: 0/37

Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 0 ; Group 2 Number missing: 0

Protocol outcomes not reported by the study

All-cause mortality at up to 90 days from hospital discharge; Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at inpatients and up to 90 days from hospital discharge; Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at inpatients and up to up to 90 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy (including the foetus) at inpatients and up to up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study; Infection at duration of study;

Study	Cruz 2011 ⁷³
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=646)
Countries and setting	Conducted in Spain; Setting: University hospital
Line of therapy	Not applicable
Duration of study	Intervention + follow up: 3 months
Method of assessment of guideline condition	Adequate method of assessment/diagnosis
Stratum	Pregnant women undergoing caesarean section and any other surgery during pregnancy or postpartum (including day case termination surgery and surgical management of miscarriage)
Subgroup analysis within study	Not applicable
Inclusion criteria	Women with a caesarean delivery who had not required prophylaxis or treatment with any type of LMWH during pregnancy and absence of allergy to heparin or derivatives
Exclusion criteria	Women who did not fulfil the duration of proposed prevention
Recruitment/selection of patients	Not reported
Age, gender and ethnicity	Age - Mean (SD): 31 (5.47). Gender (M:F): Female. Ethnicity: Not reported
Further population details	1. Assisted conception: Not applicable 2. BMI : Mixed (39.9% BMI>30, 9% BMI>35). 3. Renal impairment: Not applicable
Indirectness of population	No indirectness
Interventions	(n=335) Intervention 1: Low molecular weight heparin (not licensed in UK) - Bemiparin (2500 units once daily - 3500 units once daily). 3500U once daily, post caesarean. Administered at least 8 hours following caesarean. Duration 10 days. Concurrent medication/care: Not reported (n=311) Intervention 2: Low molecular weight heparin (not licensed in UK) - Bemiparin (2500 units once daily - 3500 units once daily). 3500U once daily, post caesarean. Administered at least 8 hours following caesarean. Duration 5 days. Concurrent medication/care: Not reported
Funding	Study funded by industry (Supported by a research grant from the Laboratorios Fcos. ROVI, SA)
RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: BEMIPARIN (2500 UNITS ONCE DAILY - 3500 UNITS ONCE DAILY) - EXTENDED versus BEMIPARIN (2500 UNITS ONCE DAILY - 3500 UNITS ONCE DAILY) - STANDARD	

Protocol outcome 1: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at inpatients and up to 90 days from hospital discharge
 - Actual outcome for Pregnant women undergoing caesarean section and any other surgery during pregnancy or postpartum (including day case termination surgery and surgical management of miscarriage) : PE at 3 months; Group 1: 0/335, Group 2: 0/311
 Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;
 Indirectness of outcome: Serious indirectness ; Group 1 Number missing: 0 ; Group 2 Number missing: 0

Protocol outcome 2: DVT (symptomatic) at 7-90 days from hospital discharge
 - Actual outcome for Pregnant women undergoing caesarean section and any other surgery during pregnancy or postpartum (including day case termination surgery and surgical management of miscarriage) : DVT at 3 months; Group 1: 0/335, Group 2: 0/311
 Risk of bias: All domain - Very high, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - High, Crossover - Low;
 Indirectness of outcome: Serious indirectness ; Group 1 Number missing: 0 ; Group 2 Number missing: 0

Protocol outcomes not reported by the study	All-cause mortality at up to 90 days from hospital discharge; Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at inpatients and up to 90 days from hospital discharge; Major bleeding. Meets one or more of the following criteria: results in death (including foetal death); occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event (including adverse event for the foetus) at inpatient and up to 45 days from hospital discharge; Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at inpatients and up to up to 90 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy (including the foetus) at inpatients and up to up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study; Infection at duration of study;
---	--

Study	Heilmann 2007 ¹⁴³
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=150)
Countries and setting	Conducted in Germany; Setting: Not reported
Line of therapy	Not applicable
Duration of study	Not clear:
Method of assessment of guideline condition	Adequate method of assessment/diagnosis
Stratum	Pregnant women undergoing caesarean section and any other surgery during pregnancy or postpartum (including day case termination surgery and surgical management of miscarriage)
Subgroup analysis within study	Not applicable
Inclusion criteria	Patients with uncomplicated pregnancy and without risk factors for thrombosis
Exclusion criteria	Not reported
Recruitment/selection of patients	Not reported
Age, gender and ethnicity	Age - Mean (SD): LMWH group: 28 (6), UFH: 29 (5), AES: 28 (3). Gender (M:F): Female. Ethnicity: Not reported
Further population details	1. Assisted conception: Not applicable 2. BMI : Not obese (BMI under 30 kg/m ²) (1.3% BMI >26). 3. Renal impairment: Not applicable
Indirectness of population	No indirectness
Interventions	<p>(n=50) Intervention 1: Low molecular weight heparin (licensed in UK) - Dalteparin (5,000 daily; min 1,250 units daily - max 10,000 units daily). Dalteparin 5000U/daily during 7 days postoperatively. Duration 7 days. Concurrent medication/care: Not reported</p> <p>(n=50) Intervention 2: Unfractionated heparin - Unfractionated heparin (low dose, administered subcutaneously; 15,000 units daily; third trimester increase to 20,000 units daily). 2x5000U UFH daily for 7 days postoperatively. The first dose was administered 6 hours following caesarean,. Duration 7 days. Concurrent medication/care: Not reported</p> <p>(n=50) Intervention 3: Anti-embolism stockings - Mixed above/below knee. AES were worn according to the guidelines of RCOG during hospital stays. Duration Not reported. Concurrent medication/care: Not reported</p>
Funding	Funding not stated

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: DALTEPARIN (5,000 DAILY; MIN 1,250 UNITS DAILY - MAX 10,000 UNITS DAILY) versus

UNFRACTIONATED HEPARIN (LOW DOSE, ADMINISTERED SUBCUTANEOUSLY; 15,000 UNITS DAILY; THIRD TRIMESTER INCREASE TO 20,000 UNITS DAILY)

Protocol outcome 1: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at inpatients and up to 90 days from hospital discharge

- Actual outcome for Pregnant women undergoing caesarean section and any other surgery during pregnancy or postpartum (including day case termination surgery and surgical management of miscarriage) : DVT at Up to hospital discharge; Group 1: 0/50, Group 2: 1/50

Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - High, Crossover - Low; Indirectness of outcome: -- ; Group 1 Number missing: 0 ; Group 2 Number missing: 0

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: DALTEPARIN (5,000 DAILY; MIN 1,250 UNITS DAILY - MAX 10,000 UNITS DAILY) versus MIXED ABOVE/BELOW KNEE

Protocol outcome 1: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at inpatients and up to 90 days from hospital discharge

- Actual outcome for Pregnant women undergoing caesarean section and any other surgery during pregnancy or postpartum (including day case termination surgery and surgical management of miscarriage) : DVT at Up to hospital discharge; Group 1: 0/50, Group 2: 1/50

Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - High, Crossover - Low; Indirectness of outcome: -- ; Group 1 Number missing: 0 ; Group 2 Number missing: 0

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: UNFRACTIONATED HEPARIN (LOW DOSE, ADMINISTERED SUBCUTANEOUSLY; 15,000 UNITS DAILY; THIRD TRIMESTER INCREASE TO 20,000 UNITS DAILY) versus MIXED ABOVE/BELOW KNEE

Protocol outcome 1: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at inpatients and up to 90 days from hospital discharge

- Actual outcome for Pregnant women undergoing caesarean section and any other surgery during pregnancy or postpartum (including day case termination surgery and surgical management of miscarriage) : DVT at Up to hospital discharge; Group 1: 1/50, Group 2: 1/50

Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - High, Crossover - Low; Indirectness of outcome: -- ; Group 1 Number missing: 0 ; Group 2 Number missing: 0

Protocol outcomes not reported by the study

All-cause mortality at up to 90 days from hospital discharge; Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at inpatients and up to 90 days from hospital discharge; Major bleeding. Meets one or more of the following criteria: results in death (including foetal death); occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event (including adverse event for the foetus) at inpatient and up to 45 days from hospital discharge; Fatal PE. Confirmed by: CT scan with

spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at inpatients and up to up to 90 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy (including the foetus) at inpatients and up to up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study; Infection at duration of study;

Study	Segal 1975 ²⁹³
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=210)
Countries and setting	Conducted in Israel; Setting: Hospital
Line of therapy	Not applicable
Duration of study	Intervention + follow up: 6 weeks
Method of assessment of guideline condition	Adequate method of assessment/diagnosis:
Stratum	Pregnant or postpartum women not undergoing surgery: 90% vaginal delivery
Subgroup analysis within study	Not applicable:
Inclusion criteria	Women delivering vaginally or by caesarean section
Exclusion criteria	Not reported
Recruitment/selection of patients	Not reported
Age, gender and ethnicity	Age - Other: Not reported. Gender (M:F): Female. Ethnicity: Not reported
Further population details	1. Assisted conception: Not applicable 2. BMI : Not applicable 3. Renal impairment: Not applicable
Indirectness of population	No indirectness
Interventions	<p>(n=116) Intervention 1: Unfractionated heparin - Unfractionated heparin (low dose, administered subcutaneously; 15,000 units daily; third trimester increase to 20,000 units daily). 5000U injected subcutaneously every 12 hours for 4-5 days after delivery. The initial heparin injection was given during active labour in 1/3 of the participants, the rest after delivery. In elective caesarean section, the heparin was given 2 hours before, at the end of surgery, and at 12 hour intervals, while in emergency caesarean the initial dose was administered immediately following the decision. Duration 4-5 days. Concurrent medication/care: Not reported</p> <p>(n=94) Intervention 2: No treatment - Usual care. Control group - no further details. Duration Not reported. Concurrent medication/care: Not reported</p>
Funding	Funding not stated
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: UNFRACTIONATED HEPARIN (LOW DOSE, ADMINISTERED SUBCUTANEOUSLY; 15,000 UNITS DAILY; THIRD TRIMESTER INCREASE TO 20,000 UNITS DAILY) versus USUAL CARE</p> <p>Protocol outcome 1: DVT (symptomatic) at 7-90 days from hospital discharge</p>	

<p>- Actual outcome for Pregnant or postpartum women not undergoing surgery: DVT at 6 weeks; Group 1: 1/116, Group 2: 5/94 Risk of bias: All domain - Very high, Selection - Very high, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - High, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 0 ; Group 2 Number missing: 0</p>	
<p>Protocol outcomes not reported by the study</p>	<p>All-cause mortality at up to 90 days from hospital discharge; Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at inpatients and up to 90 days from hospital discharge; Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at inpatients and up to 90 days from hospital discharge; Major bleeding. Meets one or more of the following criteria: results in death (including foetal death); occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event (including adverse event for the foetus) at inpatient and up to 45 days from hospital discharge; Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at inpatients and up to up to 90 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy (including the foetus) at inpatients and up to up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study; Infection at duration of study;</p>

H.19 People with psychiatric illness

No relevant studies were identified.

H.20 Anaesthesia

H.20.1 Regional vs general anaesthesia

Bibliographic reference	Study Type	Evidence level	No. of patients	Patients characteristics	Intervention	Comparison	Length of follow up	Outcome measures	Effect size	Comments
Mitchell et al., 1991 ²²⁶	RCT	1+	Total: 72 Intervention : n = 34 Control: n = 38	Type of surgery: total knee arthroplasty Duration of surgery: Intervention : mean 122 min Control: mean 121 min Both study groups: Mean age: 64 (range38-84) yrs M/F:45/27 No between-group differences for age or sex	Type: Epidural anaesthesia Dose: Timing: Operative period Additional non-comparative prophylaxis: Males received 650mg aspirin beginning eve pre-surgery, females received adjusted dose warfarin PTT 15- 16 secs. All patients CPM machine daily and physical therapy	Type: General anaesthesia Dose: sodium theopental Timing: Operative period Additional non-comparative prophylaxis: Males received 650mg aspirin beginning eve pre-surgery, females received adjusted dose warfarin PTT 15- 16 secs. All	Scan performed up to day 8 after surgery	DVT Confirmed by: bilateral venography 6,7 and 8th post-op days Proximal DVT Confirmed by: PE Confirmed by: V/Q scan on 6,7 and 8th post- op days Length of Hospital Stay	Int: 12/34 Control: 10/38 p value: Not significant All asymptomatic Incidence of Proximal DVT reported to be 46% in epidural and 63% in general anaesthesia groups. (actual numbers cannot be reliably calculated from these figures) 10% of patients reported as having positive V/Q scan, all asymptomatic. No information on group. Int: Mean 10.4 days	Comments: Male patients received aspirin, female warfarin. No differences in sex between study groups, and incidence and distribution of DVT not affected by pharmacological prophylaxis. Not reported: PTS, bleeding, QoL, survival, funding

Bibliographic reference	Study Type	Evidence level	No. of patients	Patients characteristics	Intervention	Comparison	Length of follow up	Outcome measures	Effect size	Comments
						patients CPM machine daily and physical therapy			Control : Mean 11.0 days p value: not reported	

Bibliographic reference	Study Type	Evidence level	No. of patients	Patients characteristics	Intervention	Comparison	Length of follow up	Outcome measures	Effect size	Comments
Modig et al., 1981 ²²⁸	RCT	1+	Total: 30 Intervention : n = 15 Control: n = 15	Type of surgery: Total hip replacement (for severe osteoarthritis) Duration of surgery: Intervention: 147±27.9min Control: 161.3±34.5 min Intervention: Mean age: 66.5±5.5 yrs M/F:7/8 Control: Mean age: 65.4±6.3 M/F:8/7	Type: Continuous lumbar epidural block Dose: 0.5% bupivacaine with epinephrine (5µg/ml) Post op: 4-6 ml of 0.5% bupivacaine with epinephrine every 4 hours for 16 hours Timing: Prolonged into post-op period for pain relief Additional non-	Type: General anaesthesia Dose: thiopentone Post-op: Parenteral analgesics on demand Timing: Intraoperatively. Additional non-comparative prophylaxis:	Scanning was performed 14 days before surgery and 14 days postoperatively	DVT Confirmed by: Bilateral venography on 14th post-op day Proximal DVT Confirmed by: PE Confirmed by: all patients had V/Q scan on 14th post-op day Bleeding related	Int: 5/15 Control: 11/15 p value: 0.0281 Int: 3/15 Control: 11/15 p value: <0.05 Int: 2/15 Control: 7/15 p value: Not significant Intraoperative blood loss:	Not reported: PTS, QoL, survival, LoS, funding

Bibliographic reference	Study Type	Evidence level	No. of patients	Patients characteristics	Intervention	Comparison	Length of follow up	Outcome measures	Effect size	Comments
					comparative prophylaxis: Physiotherapy program with early ambulation	Physiotherapy program with early ambulation		complications Intraoperative blood loss: (no measurement criteria) Post-operative blood loss: (no measurement criteria)	Int: 1100±316 ml Control: 1757±426ml p value: <0.001 (Significant) Postoperative blood loss: Int: 1200±350 ml Control: 1800±400 ml p value: <0.001 (Significant)	

Bibliographic reference	Study Type	Evidence level	No. of patients	Patients characteristics	Intervention	Comparison	Length of follow up	Outcome measures	Effect size	Comments
Nielsen et al., 1990 ²³⁹	RCT	1+	Nos	Type of surgery:	Type: lumbar epidural	Type: general	Both	DVT Confirmed	Int: 2/13	Not reported: PTS,
			randomise	primary or revision	anaesthesia Dose:	anaesthesia	groups: 9-	by: bilateral	Control: 10/16	PE, QoL, survival,
			d:	knee arthroscopy	2% mepivacain	Dose:	11 days	ascending	p value: <0.05	LoS, funding

Bibliographic reference	Study Type	Evidence level	No. of patients	Patients characteristics	Intervention	Comparison	Length of follow up	Outcome measures	Effect size	Comments
			Total: 36	Duration of			post-op	venography on 9-11th day post-op		
			Intervention: n = 18	Intervention: surgery: median	Additional non-comparative	Additional non-comparative		Proximal DVT Confirmed by: bilateral ascending venography on 9- 11th day post-op	Int: 1/13 Control: 3/16 p value: Not reported	
			Control: n = 18	80 (55-100) min	prophylaxis: Thigh-length stocking on contralateral leg pre-op until full ambulation. Calf-length stocking on	prophylaxis: Thigh-length stocking on				
			7 patients withdrawn – 5	Intervention: Median age: 70 (range 46-87) yrs	op until full ambulation. Calf-length stocking on	contralateral leg pre-op until full ambulation. Calf-length stocking on				
			epidural, 2	M/F:5/13	operated leg	length stocking on		Bleeding related complications Suction drain volume	Median suction drain volume: Int: 1060 (340-1940) ml Control: 990 (195-3275) p value: >0.4 Not significant	
			general		immediately post-op until ambulation. Quad exercises on 1st post-	operated leg immediately post-op until				
				Control: Median age: 65 (range38-						

Bibliographic reference	Study Type	Evidence level	No. of patients	Patients characteristics	Intervention	Comparison	Length of follow up	Outcome measures	Effect size	Comments
				85) M/F:6/12	op day, active knee	ambulation. Quad				
					mobilisation with full	exercises on 1st				
				Pre-existing risk factors: Cardiac disease, varicose veins. Higher BMI in control group	weight bearing from 2nd day.	post-op day, active knee mobilisation with full weight bearing from 2nd day.				

Bibliographic reference	Study Type	Evidence level	No. of patients	Patients characteristics	Intervention	Comparison	Length of follow up	Outcome measures	Effect size	Comments
Poikolainen and Hendolin 1983 ²⁶⁴	RCT	1+	Total: 38 Intervention: n = 17 Control: n = 21	Type of surgery: Prostatectomy Duration of surgery: Intervention: 71±3 min Control: 74±3 min	Type: lumbar epidural anaesthesia Dose: Butanilcaine 2% Additional non-comparative prophylaxis: Not	Type: General anaesthesia Dose: Thiopentone	NR	DVT Confirmed by: 125I FUT test (timing NR). Positive result confirmed by venography	Int: 2/17 Control: 11/21 p value: <0.02 (Significant)	Comments: Study measured changes in flow velocity in femoral vein. Induction of epidural anaesthesia led

Bibliographic reference	Study Type	Evidence level	No. of patients	Patients characteristics	Intervention	Comparison	Length of follow up	Outcome measures	Effect size	Comments
				<p>Intervention: All male Mean age: NR. No differences between groups for age</p> <p>Control: All male Mean age: NR. No differences between groups for age</p> <p>Pre-existing risk factors: NR. No differences between groups</p>	reported					to significant increase in velocity of blood flow in femoral vein (p<0.001), whereas flow velocity fell significantly with general anaesthesia.

Bibliographic reference	Study Type	Evidence level	No. of patients	Patients characteristics	Intervention	Comparison	Length of follow up	Outcome measures	Effect size	Comments
Roderick et al., 2005 ²⁷⁶	Systematic	1+	Total: 939	Type of surgery:	Regional Anaesthesia	General	Between 4	DVT confirmed by	Int : 130/417	Not reported: LoS,
	Review		Int:367	General (1 study)		Anaesthesia	to 14 days	venograph or	Cont: 198/416	QoL and PTS.

Bibliographic reference	Study Type	Evidence level	No. of patients	Patients characteristics	Intervention	Comparison	Length of follow up	Outcome measures	Effect size	Comments		
11 RCT Studies ^{35,77,78,107,144,145,158,221,227,277,338} All of these studies were included in the guideline review.	w		Cont: 384	Urological (1 study)			postoperatively	fibrinogen uptake	p value: 0.0000			
				Orthopaedic (9 studies)	Timing: Ranged from 73 mins to 3 days	Timing: Ranged from 79 – 150 mins.		PE confirmed by scan	Int : 21/281 Cont: 32/264 (reported in 6 studies) p value: 0.0672			
			Misc: 188 (not reported number in each arm)		Not addressed in 4 studies	Not addressed in 6 studies.						
					Additional non-comparative prophylaxis: LMWH + GCS (one study);	Additional non-comparative prophylaxis: LMWH + GCS (one study);					Major bleeds	Int : 0/317 Cont: 5/315 (reported in 7 studies) p value: 0.0243
					GCS (two studies);	GCS (two studies);					Proximal DVTs	Int : 14/268 Cont: 47/253 (reported in 6 studies) p value: 0.0000
					Dextran 70 (one study);	Dextran 70 (one study);						

Bibliographic reference	Study Type	Evidence level	No. of patients	Patients characteristics	Intervention	Comparison	Length of follow up	Outcome measures	Effect size	Comments
						(one study);				
					Dextran 40 + 7500 IU	Dextran 40 + 7500 IU				
					H (one study); ASA, GCS on no-op limb (one study).	Dextran 40 + 7500 IU H (one study); ASA, GCS on no-op limb (one study).				

H.20.2 Regional + general vs general anaesthesia

Bibliographic reference	Study Type	Evidence level	No. of patients	Patients characteristics	Intervention	Comparison	Length of follow up	Outcome measures	Effect size	Comments
Dauphin et al., 1997 ⁷⁶	RCT	1+	Total: 37	Type of surgery:	Type: General	Type: General	Daily 125l	DVT Confirmed	Int: 4/20	Comments:
				Total hip	anaesthesia plus	anaesthesia	scan for 3	by: 125l FUT test	Control: 4/17	Possible error in
				arthroplasty	lumbar epidural	Dose: Thiopental	days,	daily for 3 days	p value: 0.79	standard deviation
				: n = 20	anaesthesia	sodium. Specific	impedence	post-op.		of surgery duration

Bibliographic reference	Study Type	Evidence level	No. of patients	Patients characteristics	Intervention	Comparison	Length of follow up	Outcome measures	Effect size	Comments				
				Duration of	General: Thiopental	drug and dose	plethysmog	Venography on		in control group				
				Control: n = 17	surgery: Intervention 2.28±0.27 hr.	sodium. Specific drug and dose chosen by anaesthesiologist	chosen by anaesthesiologist	raphy on day of discharge		(5.3hrs!). Paper reports no				
			(40	Control: 2.5±5.3	anaesthesiologist		and 9 and					significant		
			randomised		Epidural: 10 ml 0.5%	Timing: For the operative period	venography on the planned					difference between the two groups in operation length.		
			- 3 drop-outs)	Intervention: Mean age: 70.9±6.7 yrs M/F:7/13	bupivacaine		day of					Bleeding related	Intraoperative	Not reported:
					operative period	comparative	discharge					complications	blood loss:	
			Control: Mean age: 66.2±14.3		Additional non-	Coumadin daily						Intraoperative	Int: 663.8±299.0	Proximal DVT, PE,
			M/F:7/10	comparative	from 1st post-op day until discharge.							blood loss: sponge	Control: 1259.2±366.0	PTS, QoL, LoS,
				prophylaxis: Coumadin daily from								weights and suction bottle contents	p value: <0.001	survival

Bibliographic reference	Study Type	Evidence level	No. of patients	Patients characteristics	Intervention	Comparison	Length of follow up	Outcome measures	Effect size	Comments
					1st post-op day until discharge.				Post-operative blood loss: Int: 444.0±300.8 Control: 600.8±390.8 p value: 0.18	
								Reliavac 400 system)	Total blood loss: Int: 1107.8±378.6 Control: 1860.0±616.6 p value: <0.001	

H.21 Lower limb immobilisation

Study	Domeij-arverud 2013 ⁸⁷
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=26)

Study	Domeij-arverud 2013 ⁸⁷
Countries and setting	Conducted in Sweden; Setting:
Line of therapy	Not applicable
Duration of study	Intervention + follow up: 2+6 weeks
Method of assessment of guideline condition	Adequate method of assessment/diagnosis
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Acute unilateral tendo Achillis rupture operated on within 72 hours; aged 18-75 years
Exclusion criteria	Inability to give informed consent; ongoing anticoagulation treatment; planned follow-up at another hospital; inability to follow instructions; known kidney failure; heart failure with pitting oedema; thrombophlebitis; any thromboembolic event during the previous 3 months; other surgery in past month; known malignancy; haemophilia; pregnancy; unwillingness to participate
Recruitment/selection of patients	Between February and December 2010
Age, gender and ethnicity	Age - Mean (range): intervention 39.8, control 40.4 (range 27-50). Gender (M:F): 1:1. Ethnicity: not reported
Further population details	1. Active cancer: No active cancer (people with known malignancy excluded). 2. BMI: Mixed (intervention mean 27.2 (range 21.9-39.1), control mean 24.3 (range 19.9-29.4)). 3. Renal impairment: No renal impairment (eGFR greater than 30ml/min/1.73m ²) (people with known kidney failure excluded). 4. Weight bearing: Not stated
Indirectness of population	No indirectness
Interventions	(n=14) Intervention 1: Intermittent pneumatic compression devices - Below knee. Foot IPCD beneath plaster cast. Duration 2 weeks post-op (mean 79.5 hours; SD 38; range 29 to 152 hours). Concurrent medication/care: Plaster cast, below knee (n=12) Intervention 2: No treatment - Usual care. No prophylaxis. Duration 2 weeks post-op. Concurrent medication/care: Plaster cast, below knee
Funding	No funding

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: BELOW KNEE versus USUAL CARE

Protocol outcome 1: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge
 - Actual outcome: DVT. Confirmed with colour Doppler sonography at 42 days; Group 1: 8/10, Group 2: 5/12; Risk of bias: Very high; Indirectness of outcome: No

Study	Domeij-arverud 2013 ⁸⁷
indirectness	
Protocol outcome 2: DVT (proximal) at 7-90 days from hospital discharge - Actual outcome: DVT proximal at 42 days; Group 1: 0/12, Group 2: 0/12	
Protocol outcomes not reported by the study	All-cause mortality at up to 90 days from hospital discharge; Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge; Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge; Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study

Study	Domeij-arverud 2015 ⁸⁶
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=150)
Countries and setting	Conducted in Sweden
Line of therapy	Not applicable
Duration of study	Follow up (post intervention): 6 weeks
Method of assessment of guideline condition	Adequate method of assessment/diagnosis
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Aged 18-75 years; sustained an acute unilateral rupture of the Achilles tendon and had undergone surgery within 96 hours of injury
Exclusion criteria	inability to give informed consent; anticoagulation treatment (including high dose aspirin); planned follow up at another hospital; renal failure; heart failure with pitting oedema; thrombophlebitis; thromboembolic event during the

Study	Domeij-arverud 2015 ⁸⁶
	last 3 months; other surgery during the previous month; malignancy; haemophilia; pregnancy
Recruitment/selection of patients	Between March 2011 and June 2013
Age, gender and ethnicity	Age - Mean (range): 40.9 (26-62). Gender (M:F): 88:21. Ethnicity: not reported
Further population details	1. Active cancer: No active cancer (people with malignancy excluded). 2. BMI : Mixed (mean 27.1 (range 21-41.2)). 3. Renal impairment: No renal impairment (eGFR greater than 30ml/min/1.73m ²) (people with renal failure excluded). 4. Weight bearing: Not applicable (allowed to weight bear as tolerated).
Indirectness of population	No indirectness
Interventions	(n=74) Intervention 1: Intermittent pneumatic compression devices - Below knee. Bilateral IPCD of calf for 6 hours daily, on operated leg this was applied under the plaster cast. Duration 2 weeks. Concurrent medication/care: Plaster cast (n=74) Intervention 2: No treatment - Usual care. No prophylaxis. Duration 2 weeks. Concurrent medication/care: Plaster cast
Funding	Other (Stockholm County Council and Karolinaska Institutet; Swedish National Centre for Sports Research; Swedish Research Council; DJO Vista, California)
RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: BELOW KNEE versus USUAL CARE	
<p>Protocol outcome 1: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge - Actual outcome: DVT in operated leg confirmed by compression duplex ultrasound at 6 weeks; Group 1: 36/69, Group 2: 34/71; Risk of bias: Low; Indirectness of outcome: No indirectness</p> <p>Protocol outcome 2: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQspect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge - Actual outcome: PE, clinical at 6 weeks; Group 1: 0/69, Group 2: 0/71; Risk of bias: High; Indirectness of outcome: No indirectness</p> <p>Protocol outcome 3: DVT (proximal) at 7-90 days from hospital discharge - Actual outcome: DVT proximal at 6 weeks; Group 1: 0/69, Group 2: 0/71</p>	
Protocol outcomes not reported by the study	All-cause mortality at up to 90 days from hospital discharge; Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or

Study	Domeij-arverud 2015 ⁸⁶
	life threatening clinical event at up to 45 days from hospital discharge; Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Jorgensen 2002 ¹⁶⁰	Patient group: Patients wearing below knee plaster casts on lower extremity (reasons for plaster cast: fracture (n=220); tendon ruptures (n=61); other (n=19)	Group I LMWH tinzaparin (Innohep) 3500 IU self-injected into abdominal wall once daily until plaster cast removed. Mean duration 5.5 weeks.	DVT, asymptomatic or symptomatic (diagnosed by ascending unilateral venography when plaster cast removed)	Group 1: 10/99 Group 2: 18/106 P value: 0.15	Funding: not reported Limitations Only assess one leg for DVT; patients and clinicians not masked to treatment; the reasons for two thirds of patients not reaching an endpoint are not clear for all patients
Country of study: Denmark	Setting: Outpatients	Group II no LMWH	DVT, asymptomatic or symptomatic by diagnosis (diagnosed by ascending unilateral venography when plaster cast removed)	Fractured patients Group 1: 8/73 Group 2: 10/77 P value: 0.70 Tendon ruptured patients Group 1: 2/20 Group 2: 6/21 P value: 0.24 Patients operated on Group 1: 9/86 Group 2: 16/89 P value: 0.16	Outcomes not reported: major and minor bleeding, heparin induced thrombocytopenia, post-thrombotic syndrome, quality of life
Study design: RCT	Inclusion criteria: age >18 planned lower limb plaster cast of at least 3 weeks	Additional non-comparative prophylaxis: None	Above knee DVT (diagnosed by ascending unilateral venography when plaster cast removed)	Group 1: 0/99 Group 2: 1/106 P value: not significant	Additional outcomes
List who was masked to interventions: assessors of venograms	Exclusion criteria: pregnancy allergy to heparin or contrast media known liver or renal impairment uncontrolled hypertension bleeding disorders cerebral insults due to bleeding recent gastrointestinal bleeding				
Evidence level: 1+					
Duration of follow-up:					

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
while wearing plaster cast (mean duration 5.5 weeks)	inability to self-inject All patients N: 300 No. of dropouts: 95 Group I No. randomised: 148 No. of dropouts: 49 Age (mean): 49 M/F: 69/79 BMI: 25 Additional risk factors: smokers 67; oral contraceptives 7; previous DVT 3; varicose veins 5; cardiac diseases 1 Other factors: no. having an operation 86 (58%) Group II No. randomised: 152 No. of dropouts: 46 Age (mean): 46 M/F: 59/93 BMI: 25 Additional risk factors: smokers 73; oral contraceptives 6; previous DVT 3; varicose veins 15; cardiac diseases 3 Other factors: no. having an operation 89 (59%)		Symptomatic DVT (confirmed by ascending unilateral venography when plaster cast removed)	Group 1: 0/99 Group 2: 1/106 P value: not significant	reported: Bleeding-4 hematomas (uncertain which arm) and 1 metroharrgia in LMWH arm. No. of DVTs by type of injury , no. of DVTs in those having surgery; about 60% reported no difficulty with self-injection; mean pre- and post-study platelet count; mean aspartate and alanine amino transferase, mean alkaline phosphatise Main reasons for not reaching an endpoint: discomfort with self-injection 18/95, metrorrhagia 1/95, refuse phlebography 12/95, venograph not possible or refused 26/95, miscellaneous 38/95 Notes: Bleeding data – excluded due to ambiguity in reporting
			Symptomatic pulmonary embolism	Group 1: 0/99 Group 2: 0/106 P value: not significant	
			Wound infection	Group 1: 4/99 Group 2: 1/106 P value: not significant	
			Discomfort with self-injection – stopped study	Group 1: 18/148 Group 2: Not applicable 18/95 of total drop outs due to discomfort in self injection	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
					and definition after discussions between reviewers.

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Kock 1995 ¹⁷⁵	<p>Patient group: Patients with leg injury for which conservative treatment without admission to hospital was indicated.</p> <p>Below knee cast (n=366) or above knee casts (n=62). Reasons for plaster cast: Grade II sprains and bruises (n=122); Grade III sprains (n=130); fractures (n=72); other (n=15)</p> <p>Setting: Outpatients</p> <p>Inclusion criteria:</p> <ul style="list-style-type: none"> age 18-65 <p>Exclusion criteria: previous DVT pregnancy clotting disorders or anticoagulant medication bleeding sources contraindications to heparin chronic venous insufficiency plaster cast after surgery</p>	<p>Group I LMWH (Mono-Embolex NM (Sandoz) 0.3ml per syringe with an activated partial thromboplastin time activity of 1500 units & anti-Xa activity of 3000 units. Not reported when started, self-injected until plaster cast removed</p> <p>Group II no LMWH</p> <p>Additional non-comparative prophylaxis:</p>	<p>DVT, asymptomatic or symptomatic (* confirmed by venography when plaster cast removed)</p> <p>Proximal DVT (as above)</p> <p>Calf DVT (as above)</p> <p>Mean (+SD) duration of plaster-cast immobilisation (days)</p> <p>Mean (+SD) duration of plaster-cast immobilisation (days)</p> <p>Major bleeding (not defined)</p>	<p>Group 1: 0/176 Group 2: 7/163 P value: 0.06</p> <p>Group 1: 0/176 Group 2: 3/163 P value: NS</p> <p>Group 1: 0/176 Group 2: 4/163 P value: NS</p> <p>Group 1: 15.2 +12 (n=176) Group 2: 18.8 +13 (n=163) P value: 0.008</p> <p>Patients with DVT: 11.4 +10 (n=7) Patients without DVT: 17.2 +13 (n=332) P value: 0.13</p> <p>Group 1: 0/176 Group 2: 0/163 P value: n/a</p>	<p>Funding: not reported</p> <p>Limitations Nobody masked to treatment. Does not report initial numbers randomised to each group</p> <p>Outcomes not reported: mortality, pulmonary embolism, minor bleeding, heparin induced thrombocytopenia, post-thrombotic syndrome, quality of life</p> <p>Additional outcomes reported: DVT sub grouped by</p>

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	<p>All patients N: 428 No. of dropouts: 89</p> <p>Group I No. randomised: NR No. of dropouts: NR Age (mean): 34.1 (18-63) M/F: 104/72 Weight (mean): 78.4 +13 kg Additional risk factors: age >40 (n=53); obesity (Broca index >1.2) (n=40); cigarette smoking (n=83); varicose veins (n=23); oral contraceptives (n=18);</p> <p>Group II No. randomised: NR No. of dropouts: NR Age (mean): 33 (18-63) M/F: 104/59 Weight (mean): 75.0 +14 kg Additional risk factors: age >40 (n=44); obesity (Broca index >1.2) (n=34); cigarette smoking (n=70); varicose veins (n=31); oral contraceptives (n=25)</p>	None			<p>risk factor</p> <p>Notes: * DVT checked by clinical examination, measurement of leg circumference, venous occlusion plethysmography, B-mode compression ultrasonography and duplex scanning and confirmed by venography</p>

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Kujath 1993 ¹⁷⁹	Patient group: Outpatients with leg injury treated conservatively and immobilisation by	Group I LMWH (Fraxiparin) 0.3ml	DVT, asymptomatic or symptomatic (diagnosed by ultrasound confirmed	Group 1: 6/126 Group 2: 21/127 P value: <0.01	Funding: not reported

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Country of study: Germany	plaster cast. Type of injury: soft tissue (n=176); fractures (n=77)	daily [36mg heparin fraction calcium, molecular mass 4000-5000.	by venography)		Limitations
Study design: RCT	Setting: Outpatients	Started on first day of treatment, continued until plaster cast removed	Mean (+SD) duration of plaster-cast (days)	Group 1: 15.6 +6.8 (n=126) Group 2: 15.8 +9.6 (n=127) P value: 0.85	Nobody masked to treatment.
List who was masked to interventions: no one	Inclusion criteria: age >16 immobilisation by plaster cast for at least 7 days	Group II no LMWH			Outcomes not reported: mortality, pulmonary embolism, minor bleeding, heparin induced thrombocytopenia, post-thrombotic syndrome, quality of life
Evidence level: 1+	Exclusion criteria: known thrombopathy oral anticoagulation fresh brain or gastrointestinal bleeding acute pancreatitis inflammatory heart disease	Additional non-comparative prophylaxis: None			Additional outcomes reported: DVT subgrouped by risk factor; total no. of symptomatic DVTs 9/27 (not given by group)
Duration of follow-up: until plaster cast removed	All patients N: 306 No. of dropouts: 53 Group I No. randomised: 126 No. of dropouts: NR Age (mean): 32.9 +13.8 M/F: 69/57 Weight (mean): 73.7 +14.2 kg Additional risk factors: history of thrombosis or embolism (n=9); age >40 (n=31); overweight (n=34);				Notes:

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	smoking (n=48); varicose veins (n=18); oral contraceptives (n=8); Group II No. randomised: 127 No. of dropouts: NR Age (mean): 35.6 +14.6 M/F: 77/50 Weight (mean): 74.4 +13.6 kg Additional risk factors: history of thrombosis or embolism (n=6); age >40 (n=44); overweight (n=36); smoking (n=45); varicose veins (n=15); oral contraceptives (n=13);				

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Lapidus 2007A ¹⁸⁵ Country of study: Sweden Study design: Single centre, double blinded RCT List who was masked to interventions: Investigators,	Patient group: Achilles tendon rupture, all received surgery. Setting: Stockholm Soder Hospital (Nov2001-May2004) Inclusion criteria: Consecutive patients 18-75 years old Admitted because of Achilles tendon rupture (0-72h) and accepted for surgery Exclusion criteria: Inability or refusal to sign informed consent	Group 1 LMWH Dalteparin 5000U Group 2 Placebo (9%w/v sodium chloride), 0.2 ml in identical syringes to dalteparin. Frequency: once daily Route: subcutaneous injection Start time: Within	All-cause mortality (confirmed by: No death was reported) Fatal pulmonary embolism (confirmed by: None reported) Symptomatic pulmonary embolism (confirmed by: ventilation perfusion scan or spiral CT if suspected) DVT, asymptomatic or symptomatic (screened for by: unilateral ascending	Group1: 0/52 Group 2: 0/53 P value: 1.0 Group1: 0/52 Group 2: 0/53 P value: 1.0 Group1: 0/52 Group 2: 0/53 P value: 1.0 (As reported) Up to Week 6 (by	Funding: Pfizer/Pharmacia and Karolinska Institute provided grants. Dalteparin provided by Pharmacia/ Pfizer Limitations: Positive events detected by CDS, but not confirmed by phlebography (either not performed or not interpretable) had not been included in the primary and secondary analysis of efficacy Only the affected leg was

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
<p>patients, radiologist who carried out standardised final evaluation</p> <p>Evidence level: 1+</p> <p>Duration of follow-up: Up to 6 weeks</p>	<p>form</p> <p>Ongoing treatment with anticoagulant</p> <p>Known allergy to contrast media</p> <p>Planned follow up at another hospital</p> <p>Recent surgery or thromboembolic event (during the preceding 3 months)</p> <p>Known malignancy</p> <p>Current bleeding disorder</p> <p>Pregnancy</p> <p>Treatment with high doses of acetyl salicylic acid (≥ 325 mg) or other platelet inhibitors</p> <p>Other injuries</p> <p>All patients N: 105</p> <p>Age (mean): 40 years</p> <p>M/F: 83/22</p> <p>Time to surgery (mean): 2days</p> <p>VTE history : 0/105</p> <p>Surgery method: Usually short skin incision placed medially over the rupture, end to end suture most commonly with modified Kessler technique.</p> <p>Plaster cast: Below knee plaster cast with ankle in the equinus position. At 3rd week, this was replaced by another plaster cast or orthoses at neutral position.</p> <p>Anaesthesia: spinal or local</p>	<p>hours post-surgery</p> <p>End time: up to 6th week, or mobilisation</p> <p>Duration: up to 6 weeks after surgery</p> <p>All patients given 45 syringes.</p> <p>Additional non-comparative prophylaxis: Not mentioned</p>	<p>phlebography of the affected legs, or colour duplex sonography (CDS) when phlebography fails at the 3rd week and 6th week, on the last day of the dose (or a day after), and when thrombosis is suspected, whichever earlier.</p>	<p>phlebography) ITT analysis Group1: 16/47 (34%)</p> <p>Group 2: 16/44 (36%)</p> <p>P value:0.8</p> <p>Up to Week 6 (by phlebography or CDS), ITT analysis1</p> <p>Group1: 18/49 (37%)</p> <p>Group 2: 19/47(40%)</p> <p>P value: 0.8</p> <p>Note: 24 (65% diagnosed at week 3, the rest at the end of study)</p> <p>[value calculated by NCC- AC team using Fishers' exact test]</p>	<p>scanned routine scanning</p> <p>Outcomes not reported: Symptomatic DVT, Thigh DVT; Fatal or neurological or upper GI bleeding, Heparin induced thrombocytopenia, Post thrombotic syndrome, Pulmonary hypertension, Quality of life, Length of stay</p> <p>Additional outcomes reported: Details/reasons for patients to be non-evaluable. Compliance with extended LMWH injections, duration of immobilisation, mean time to DVT diagnosis</p> <p>Number of patients treated for DVT was reported as 20/49 (40%) in the treatment and 23/47(43%) in the placebo arms respectively. An additional 1 patient from each arm was treated but not included in the ITT analysis.</p> <p>Notes: All admitted Achilles tendon</p>
			<p>Thigh DVT (screened for by: as above, defined as affecting popliteal vein or any other more proximal vein, with or without involvement of the calf veins)</p>	<p>Group1: 1/49</p> <p>Group 2: 3/47</p> <p>P value: 0.6</p>	
			<p>Fatal bleeding (description: no death or major bleeding reported)</p>	<p>Group1: 0/52</p> <p>Group 2: 0/53</p> <p>P value: 1.0</p>	
			<p>Major bleeding (description: requiring</p>	<p>Group1: 0/52</p> <p>Group 2: 0/53</p>	
	<p>Group 1</p>				

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	<p>No. randomised: 52 No. of dropouts: 2 M/F: 41/11 Age (years): 37±8 Weight (kg): 80±12 BMI (kg/m²): 26±3 Time in surgery (min): 44±18 Torniquet used, time (min): 6/52, 34±14 Local/spinal anaesthesia:48/4 Smokers:9/52, 8/53 Hormonal contraceptives: 0/11, 1/11 Diabetes: 0/52, 2/53 Varicose veins: 3/52, 6/53 Orthosis used:12/52</p> <p>Group 2 No. randomised: 53 No. of dropouts : 2 M/F: 42/11 Age (years): 42±9 Weight (kg): 81±11 BMI (kg/m²): 26±3 Time in surgery (min): 45±18 Torniquet used, time (min): 6/53, 39±17 Local/spinal anaesthesia:48/5 Smokers:8/53 Hormonal contraceptives: 1/11 Diabetes: 2/53 Varicose veins: 6/53 Orthosis used : 15/53</p>		<p>blood transfusion/ surgery, or at a critical site such as intracranial, intraocular, intraspinal, or retroperitoneal)</p> <p>Minor bleeding (description: A nose bleed)</p>	<p>P value: 1.0</p> <p>Group1: 1/ 52 Group 2: 0/53 P value: 1.0</p>	<p>rupture patients I who required surgery was assessed for eligibility (n=285), and 257 fulfilled criteria.</p> <p>Patients with asymptomatic DVT detected by CDS but not verified by phlebography were excluded (n=5, 4 in placebo)</p> <p>Subjects were trained in self-injection by study nurse in hospital.</p> <p>Patients were followed up at 3 weeks after surgery, where plaster casts were changed and screening for DVT was done, and screened again at the end of study</p>

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Lapidus 2007B ¹⁸⁶	Patient group: Acute ankle fracture, all received	Group 1 LMWH	All-cause mortality (confirmed by: No death was	Group1: 0/136 Group 2: 0/136	Funding: Pfizer/Pharmacia and

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Country of study: Sweden	surgery A majority of patient used plaster casts, 18% used orthosis	Dalteparin 5000U, once daily Subcutaneous injection	reported)	P value: 1.0	Karolinska Institute provided grants
Study design: Double blinded RCT	Setting: Stockholm Soder Hospital (May2000-March2004)	Group 2 Placebo(9%w/v sodium chloride), 0.2 ml in identical syringes to dalteparin.	Fatal pulmonary embolism (confirmed by: None reported)	Group1: 0/136 Group 2: 0/136 P value: 1.0	Limitations: Randomisation method and concealment not described.
List who was masked to interventions: All	Inclusion criteria: 18-75 years old Admitted because of acute ankle (0-72h) fracture accepted for surgery	Start time: 7 days post-surgery End time: until plaster cast removed (mean 44 days±2) Duration: up to 6 week after surgery	Symptomatic pulmonary embolism (confirmed by: ventilation perfusion scan or spiral CT if suspected)	Group1: 0/136 Group 2: 0/136 P value: 1.0	Only the affected leg was scanned.
Evidence level: 1+	Exclusion criteria: Inability or refusal to sign informed consent form Ongoing treatment with anticoagulant therapy Known allergy to contrast media Planned follow up at another hospital Recent surgery Known malignancy Current bleeding disorder Pregnancy Treatment with high doses of acetyl salicylic acid (≥325 mg) or other platelet inhibitors Multi-trauma (injuries involving >1 organ system in addition to the musculoskeletal system or multiple fractures)	cast removed (mean 44 days±2) Duration: up to 6 week after surgery	Symptomatic DVT (confirmed by: phlebography or CDS whenever indicated)	Group1: 2/136 Group 2: 6/136 P value: 0.28	Baseline risk factors and comorbidities not reported
Duration of follow-up: Up to 6 weeks		Additional non-comparative prophylaxis: Both groups received 5000Uof s/c dalteparin once daily for 7 days, starting on evening after surgery.	One of the 8 events is a calf muscle vein thrombosis, not specified which arm	Plaster cast subgroup: Group 1: 2/114 Group 2: 6/108 P value: 0.16 [value calculated by NCC-AC team using Fishers' exact test]	Outcomes not reported: Calf DVT, minor bleeding, heparin induced thrombocytopenia, post thrombotic syndrome, pulmonary hypertension, quality of life, length of stay
			DVT, asymptomatic or symptomatic (screened for by: unilateral ascending phlebography of the affected legs, or colour duplex sonography (CDS) when phlebography fails at 2nd and 6th week, on the last day of the dose (or a day after), and when thrombosis is suspected, whichever earlier.	Up to Week 6 (by phlebography) ITT analysis Group1: 21/101 (21%) Group 2: 27/96 (28%) P value:0.2 Up to Week 6 (by phlebography), per protocol Group1: 13/75 Group 2: 17/65 P value:0.2	Additional outcomes reported: Details/reasons for patients to be non-evaluable Compliance, duration of immobilisation, subgroup analysis of orthosis and casts Average age of patients

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	<p>All patients N: 272 Age (mean): 48 (18-76) years M/F: 124/148</p> <p>Group 1 No. randomised: 136 No. of dropouts (non-evaluable): 35 M/F: 62/74</p> <p>Patients Age (years): 49±14 Weight (kg): 80±16 BMI (kg/m²): 27±4 Time in surgery (min): 65±28 Tourniquet time (min): 70±28 Fracture type:</p> <ul style="list-style-type: none"> - Unimalleolar: 59/136 (43%) - Bimalleolar: 42/136 (31%) - Trimalleolar: 35/136 (26%) <p>Used plaster cast: 114/136</p> <p>Group 2 No. randomised: 136 No. of dropouts (non-evaluable): 40 M/F: 62/74</p>	<p>All received 1000mL Dextran 60 on admission</p>	<p>Thigh DVT (screened for by: as above, defined as affecting popliteal vein or any other more proximal vein, with or without involvement of the calf veins)</p> <p>Fatal bleeding (description: no death or major bleeding reported)</p>	<p>Up to Week 6 (by phlebography or CDS, ITT analysis) Group1: 24/117 Group 2:34/109 P value:0.07</p> <p>Plaster cast subgroup Up to Week 6 (by phlebography) ITT analysis Group1: 18/86 Group 2: 27/75 P value: 0.04 Up to Week 6 (by phlebography), per protocol Group1: 21/99 Group 2: 33/86 P value: 0.02</p> <p>Group1: 4/101 Group 2: 3/96 P value: 0.2</p> <p>Group1: 0/136 Group 2: 0/136 P value: 1.0</p>	<p>who used an orthosis was 45 years p=0.03 compared to plaster cast patients</p> <p>Notes: All subjects were trained in self-injection by as study nurse before leaving hospital. All ankle fracture patients admitted to hospital who</p>

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	Age (years): 48±14 Weight (kg): 78±13 BMI (kg/m ²): 26±3 Time in surgery (min): 63±28 Torniquet time (min): 68±30 Fracture type: - Unimalleolar: 44/136 (32) - Bimalleolar: 53/136 (39) - Trimalleolar: 39/136 (29) Used plaster cast: 108/136		Major bleeding (description: requiring blood transfusion/ surgery, or at a critical site such as intracranial, intraocular, intraspinal, or retroperitoneal) Minor bleeding (description: All local bleedings not classified as "major bleeding")	Group1: 0/136 Group 2: 0/ 136 P value: 1.0 Plaster cast subgroup: Group 1: 0/114 Group 2: 0/108 Group1: 1/ 136 Group 2: 1/136 P value: 1.0	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Lassen 2002 ¹⁹² Country of study: Denmark Study design: RCT List who was	Patient group: Outpatients with fracture of the leg or rupture of the Achilles tendon requiring at least five weeks immobilisation in plaster cast or brace within 4 days of injury. Setting: Outpatients Inclusion criteria: age >18	Group I LMWH (Reviparin, 1750 anti-Xa units self-injected daily Started not more than more 4 days after fractures and continued throughout immobilisation. Group II	DVT, asymptomatic or symptomatic (diagnosed by unilateral venography within a week of plaster cast removal) Symptomatic DVT (confirmed by unilateral venography) Proximal DVT (diagnosed by unilateral venography within a	Group 1: 17/183 Group 2: 35/188 P value: 0.01 Group 1: 0/217 Group 2: 4/221 P value: Group 1: 3/183 Group 2: 10/188	Funding: supported by grant from Knoll Limitations Appears a fairly well conducted study Outcomes not reported: mortality,

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
masked to interventions: Patients and investigators of venography Evidence level: 1+ Duration of follow-up: until plaster cast removed	requiring lower limb cast >5 weeks Exclusion criteria: weight <35kg pre-existing venous thromboembolism systolic blood pressure >200mmHg diastolic blood pressure >110mmHg cerebral vascular aneurysm cerebral vascular accident within preceding 3 weeks active gastroduodenal ulcer haemorrhagic diathesis bacterial endocarditis platelet count <100,000 per mm ³ previous treatment with heparin lasting >4 days <ul style="list-style-type: none"> • previous treatment with fibrinolytic agents or oral anticoagulants • immobilisation for >4 days before enrolment • known hypersensitivity to heparin or contrast medium contraindications to venography myocardial infarction in previous 3 months multiple myeloma current pregnancy or lactation current treatment with any investigational drug or such treatment within preceding 4 weeks	Placebo Additional non-comparative prophylaxis: Patients who underwent surgery were permitted to have had heparin treatment lasting up to 4 days before randomisation. Numbers treated Group I: 65 Group II: 71	week of plaster cast removal) Distal DVT (diagnosed by unilateral venography within a week of plaster cast removal) Symptomatic pulmonary embolism (confirmed by ventilation perfusion scanning) Major bleeding (defined as clinically apparent bleeding associated with a decrease of at least 2.0g per deciliter in the haemoglobin level, requirement for transfusion of at least 2 units of packed red cells, or retroperitoneal or intracranial bleeding or other bleeding that investigators decided required permanent discontinuation of treatment) Minor bleeding (defined as bleeding not meeting definition for major bleeding) Mean (+SD) duration of	P value: 0.09 Group 1: 14/183 Group 2: 25/188 P value: 0.09 Group 1: 0/217 Group 2: 2/221 P value: NS Group 1: 2/217 Group 2: 1/221 P value: NS Group 1: 12/217 Group 2: 11/221 P value: NS Group 1: 43 (n=126)	pulmonary embolism, minor bleeding, heparin induced thrombocytopenia, post-thrombotic syndrome, quality of life Notes: Discussed between reviewers: Major bleeding included “minor bleeding” cases where treatment was discontinued, based on author’s definition. Denominator for Group 1 set as 217 – the number randomised to be consistent as ITT. Paper reported safety population based on 438, but unclear which were the patients excluded.

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	<ul style="list-style-type: none"> history of drug or alcohol abuse <p>All patients N: 440 No. of dropouts: 69 Group I No. randomised: 217 No. of dropouts: 34 (reasons: withdrew consent 2; adverse events 1; venograms not evaluable 31) Age (median, interquartile range): 47 (37-55) M/F: 112/105 BMI (median, interquartile range): 25 (23-28) kg/m² Additional risk factors: previous thromboembolism (n=5); varicose veins (n=20); hypertension (n=13); hypercholesterolemia (n=14); oral contraceptives (n=14); current hormone replacement therapy (n=8); diabetes mellitus (n=5); smoking (n=79) Type of injury: tibial fracture (n=18), patellar fracture (n=7); malleolar fracture (n=127); fracture in the foot (n=15); rupture of Achilles tendon (n=52) Surgical treatment: 118</p>		immobilisation (days)	Group 2: 44 (n=127) P value: NS	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	<p>Group II</p> <p>No. randomised: 223</p> <p>No. of dropouts: 35 (reasons: no injections 2; adverse events 3; venograms not evaluable 30)</p> <p>Age (median, interquartile range): 47 (37-56)</p> <p>M/F: 114/109</p> <p>BMI (median, interquartile range): 26 (24-28) kg/m²</p> <p>Additional risk factors: previous thromboembolism (n=5); varicose veins (n=21); hypertension (n=22); hypercholesterolemia (n=15); oral contraceptives (n=11); current hormone replacement therapy (n=9); diabetes mellitus (n=5); smoking (n=105)</p> <p>Type of injury: tibial fracture (n=10), patellar fracture (n=8); malleolar fracture (n=155); fracture in the foot (n=13); rupture of Achilles tendon (n=36)</p> <p>Surgical treatment: 126</p>				

Study	POT-CAST trial: Van adrichem 2016³²²
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=1519)
Countries and setting	Conducted in Netherlands; Setting: 10 hospitals in the Netherlands (7 teaching hospitals, 2 private medical care clinics, and 1 academic medical centre)

Line of therapy	1st line
Duration of study	Intervention + follow up: Immobilisation + 3 months
Method of assessment of guideline condition	Adequate method of assessment/diagnosis
Stratum	Overall
Subgroup analysis within study	Stratified then randomised: Surgical or non-surgical treatment
Inclusion criteria	Patients 18 years or older who presented to the emergency department and were treated for at least 1 week with casting of the lower leg (with or without surgery before or after casting but without multiple traumatic injuries).
Exclusion criteria	Previous VTE, contraindications to LMWH, pregnancy, and current use of anticoagulant therapy for other indications (although the use of antiplatelet drugs were allowed).
Recruitment/selection of patients	March 2012 through January 2016 patients treated with casting of the lower leg who were enrolled in 8 trial centres.
Age, gender and ethnicity	Age - Mean (SD): LMWH 46.5 (16.5); No prophylaxis 45.6 (16.4). Gender (M:F): 716/719. Ethnicity: NR
Further population details	1. Active cancer: Mixed (Treatment group 34/674 cancer; Control group 29/674 cancer.). 2. BMI : Mixed (Treatment group 26.0 (4.4); Control group 25.7 (4.4).). 3. Renal impairment: Not applicable 4. Weight bearing: Not applicable
Extra comments	Duration of casting (wk): treatment group 4.9 (2.5); control group 4.9 (2.5) Indication for casting: Fracture 89%, Achilles' tendon rupture 7%, ankle distortion 2%, antalgic gait 1%, contusion 1% Surgery:treatment group 13%; control group 11%
Indirectness of population	No indirectness
Interventions	(n=761) Intervention 1: Low molecular weight heparin (licensed in UK) - Dalteparin (1,250 units once daily - 5,000 units twice daily). Dalteparin or Nadroparin (according to the preference of the hospital). First dose of LMWH administered in the emergency department. 2850 IU of nadroparin or 2500 IU of dalteparin was used for people who weighed 100kg or less, and a double dose (in one daily injection) was used for patients who weighted more than 100kg. Duration the full period of immobilisation. Concurrent medication/care: NR (n=758) Intervention 2: No treatment - Placebo. No anticoagulation therapy. Duration of study. Concurrent medication/care: NR
Funding	Academic or government funding (Supported by the Netherlands Organization for Health Research and Development.)
RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: DALTEPARIN (1,250 UNITS ONCE DAILY - 5,000 UNITS TWICE DAILY) versus PLACEBO	
Protocol outcome 1: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy;	

echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge
 - Actual outcome: Symptomatic PE: no definition reported at 3 months; Group 1: 3/719, Group 2: 4/716
 Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - High, Crossover - Low;
 Indirectness of outcome: No indirectness ; Group 1 Number missing: 42, Reason: 14 excluded due to inclusion/exclusion criteria. Plus lost to follow-up and withdrew consent (unclear proportion of which); Group 2 Number missing: 42, Reason: 19 excluded due to inclusion/exclusion criteria. Plus lost to follow-up and withdrew consent (unclear proportion of which)

Protocol outcome 2: Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge

- Actual outcome: Major bleeding: no definition reported at 3 months; Group 1: 0/719, Group 2: 0/716
 Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - High, Crossover - Low;
 Indirectness of outcome: No indirectness ; Group 1 Number missing: 42, Reason: 14 excluded due to inclusion/exclusion criteria. Plus lost to follow-up and withdrew consent (unclear proportion of which); Group 2 Number missing: 42, Reason: 19 excluded due to inclusion/exclusion criteria. Plus lost to follow-up and withdrew consent (unclear proportion of which)

Protocol outcome 3: Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge

- Actual outcome: Clinically relevant non-major bleeding: no definition reported at 3 months; Group 1: 1/719, Group 2: 0/716
 Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - High, Crossover - Low;
 Indirectness of outcome: No indirectness ; Group 1 Number missing: 42, Reason: 14 excluded due to inclusion/exclusion criteria. Plus lost to follow-up and withdrew consent (unclear proportion of which); Group 2 Number missing: 42, Reason: 19 excluded due to inclusion/exclusion criteria. Plus lost to follow-up and withdrew consent (unclear proportion of which)

Protocol outcome 4: DVT (symptomatic) at 7-90 days from hospital discharge

- Actual outcome: Symptomatic DVT at 3 months; Group 1: 6/719, Group 2: 8/716
 Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - High, Crossover - Low;
 Indirectness of outcome: No indirectness ; Group 1 Number missing: 42, Reason: 14 excluded due to inclusion/exclusion criteria. Plus lost to follow-up and withdrew consent (unclear proportion of which); Group 2 Number missing: 42, Reason: 19 excluded due to inclusion/exclusion criteria. Plus lost to follow-up and withdrew consent (unclear proportion of which)

Protocol outcomes not reported by the study	All-cause mortality at up to 90 days from hospital discharge; Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge; Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Health-related quality of life
---	---

(validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study; Unplanned return to theatre at up to 45 days from hospital discharge

Study	PROTECT trial: Bruntink 2017 ³⁶
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=467)
Countries and setting	Conducted in Netherlands; Setting: Seven Dutch hospitals
Line of therapy	1st line
Duration of study	Intervention time: Duration of immobilisation ~39 days
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: Thromboprophylaxis
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Adults (≥18 years) diagnosed with a fracture of the ankle or foot who required non-surgical treatment with immobilisation in a below-knee plaster cast for a minimum of four weeks.
Exclusion criteria	A delay between injury and the emergency department visit of more than 72 hours; a known hypersensitivity to nadroparin or fondaparinux; a history of VTE; already on continuous anticoagulation therapy; hypercoagulability; a bleeding tendency/disorder; pregnancy or lactation; active malignancy; severe hepatic or renal impairment; retinopathy; previous or active bleeding from the digestive tract; haemorrhagic stroke within the previous 2 months; intraocular/spinal/brain surgery within the previous year; severe hypertension.
Recruitment/selection of patients	April 2009 to December 2015
Age, gender and ethnicity	Age - Mean (SD): Control 44.5 (17.2); LMWH 47.7 (16.4); Fondaparinux 49.7 (17.3). Gender (M:F): 118/160. Ethnicity: NR
Further population details	1. Active cancer: Not applicable 2. BMI : Mixed (Control 25.1 (3.8); LMWH 26.4 (4.5); Fondaparinux 26.5 (4.1)). 3. Renal impairment: Not applicable 4. Weight bearing: Not applicable
Indirectness of population	No indirectness
Interventions	(n=156) Intervention 1: No treatment - Usual care. Control group - no VTE prophylaxis. Duration for the duration of immobilisation. Mean (SD) 40.3 (8.6) days. Concurrent medication/care: Letter explaining the clinical symptoms associated with the possible development of DVT, PE and side effects of the medication and were asked to contact the

	<p>ED if any of those occurred.</p> <p>(n=154) Intervention 2: Low molecular weight heparin (not licensed in UK) - Nadroparin (2850 units once daily - up to 57 units/kg once daily). Nadroparin 2850 IE anti/Xa=0/3 ml, given once daily by subcutaneous self-injection. Duration for the duration of immobilisation. Mean (SD) 40.2 (8.5) days. Concurrent medication/care: Letter explaining the clinical symptoms associated with the possible development of DVT, PE and side effects of the medication and were asked to contact the ED if any of those occurred.</p> <p>(n=157) Intervention 3: Fondaparinux - Fondaparinux (all doses). Fondaparinux 2.5mg=0.5ml, given once daily by subcutaneous self-injection. Duration for the duration of immobilisation. Mean (SD) 38.0 (8.7) days. Concurrent medication/care: Letter explaining the clinical symptoms associated with the possible development of DVT, PE and side effects of the medication and were asked to contact the ED if any of those occurred.</p>
Funding	Equipment / drugs provided by industry (Unrestricted educational grant from Glaxo Smith Kline.)

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: NADROPARIN (2850 UNITS ONCE DAILY - UP TO 57 UNITS/KG ONCE DAILY) versus USUAL CARE

Protocol outcome 1: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge

- Actual outcome: DVT verified by duplex sonography at duration of immobilisation; Group 1: 2/92, Group 2: 11/94

Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 62, Reason: No fracture (5), no plaster cast (18), indication for surgery (9), immobilisation < 4 weeks (5), no sonography (17), withdrew consent (6), other (2); Group 2 Number missing: 62, Reason: No fracture (2), no plaster cast (21), indication for surgery (10), immobilisation < 4 weeks (4), no sonography (23), other (2)

Protocol outcome 2: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge

- Actual outcome: Symptomatic PE verified by CT angiography at duration of immobilisation; Group 1: 0/92, Group 2: 2/94

Risk of bias: All domain - High, Selection - Low, Blinding - High, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 62, Reason: No fracture (5), no plaster cast (18), indication for surgery (9), immobilisation < 4 weeks (5), no sonography (17), withdrew consent (6), other (2); Group 2 Number missing: 62, Reason: No fracture (2), no plaster cast (21), indication for surgery (10), immobilisation < 4 weeks (4), no sonography (23), other (2)

Protocol outcome 3: Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge

- Actual outcome: Major bleeding (no definition) at duration of immobilisation; Group 1: 0/92, Group 2: 0/94
Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - High, Crossover - Low;
Indirectness of outcome: No indirectness ; Group 1 Number missing: 62, Reason: No fracture (5), no plaster cast (18), indication for surgery (9), immobilisation < 4 weeks (5), no sonography (17), withdrew consent (6), other (2); Group 2 Number missing: 62, Reason: No fracture (2), no plaster cast (21), indication for surgery (10), immobilisation < 4 weeks (4), no sonography (23), other (2)

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: FONDAPARINUX (ALL DOSES) versus USUAL CARE

Protocol outcome 1: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge

- Actual outcome: DVT verified by duplex sonography at duration of immobilisation; Group 1: 1/92, Group 2: 11/94
Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low;
Indirectness of outcome: No indirectness ; Group 1 Number missing: 65, Reason: No fracture (4), no plaster cast (18), indication for surgery (15), immobilisation < 4 weeks (7), no sonography (19), withdrew consent (2); Group 2 Number missing: 62, Reason: No fracture (2), no plaster cast (21), indication for surgery (10), immobilisation < 4 weeks (4), no sonography (23), other (2)

Protocol outcome 2: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge

- Actual outcome: Symptomatic PE verified by CT angiography at duration of immobilisation; Group 1: 0/92, Group 2: 2/94
Risk of bias: All domain - High, Selection - Low, Blinding - High, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low;
Indirectness of outcome: No indirectness ; Group 1 Number missing: 65, Reason: No fracture (4), no plaster cast (18), indication for surgery (15), immobilisation < 4 weeks (7), no sonography (19), withdrew consent (2); Group 2 Number missing: 62, Reason: No fracture (2), no plaster cast (21), indication for surgery (10), immobilisation < 4 weeks (4), no sonography (23), other (2)

Protocol outcome 3: Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge

- Actual outcome: Major bleeding (no definition) at duration of immobilisation; Group 1: 0/92, Group 2: 0/94
Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - High, Crossover - Low;
Indirectness of outcome: No indirectness ; Group 1 Number missing: 65, Reason: No fracture (4), no plaster cast (18), indication for surgery (15), immobilisation < 4 weeks (7), no sonography (19), withdrew consent (2); Group 2 Number missing: 62, Reason: No fracture (2), no plaster cast (21), indication for surgery (10), immobilisation < 4 weeks (4), no sonography (23), other (2)

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: FONDAPARINUX (ALL DOSES) versus NADROPARIN (2850 UNITS ONCE DAILY - UP TO 57 UNITS/KG ONCE DAILY)

Protocol outcome 1: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge

- Actual outcome: DVT verified by duplex sonography at duration of immobilisation; Group 1: 1/92, Group 2: 2/92

Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 65, Reason: No fracture (4), no plaster cast (18), indication for surgery (15), immobilisation < 4 weeks (7), no sonography (19), withdrew consent (2); Group 2 Number missing: 62, Reason: No fracture (5), no plaster cast (18), indication for surgery (9), immobilisation < 4 weeks (5), no sonography (17), withdrew consent (6), other (2)

Protocol outcome 2: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge

- Actual outcome: Symptomatic PE verified by CT angiography at duration of immobilisation; Group 1: 0/92, Group 2: 9/92

Risk of bias: All domain - High, Selection - Low, Blinding - High, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 65, Reason: No fracture (4), no plaster cast (18), indication for surgery (15), immobilisation < 4 weeks (7), no sonography (19), withdrew consent (2); Group 2 Number missing: 62, Reason: No fracture (5), no plaster cast (18), indication for surgery (9), immobilisation < 4 weeks (5), no sonography (17), withdrew consent (6), other (2)

Protocol outcome 3: Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge

- Actual outcome: Major bleeding (no definition) at duration of immobilisation; Group 1: 0/92, Group 2: 0/92

Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 65, Reason: No fracture (4), no plaster cast (18), indication for surgery (15), immobilisation < 4 weeks (7), no sonography (19), withdrew consent (2); Group 2 Number missing: 62, Reason: No fracture (5), no plaster cast (18), indication for surgery (9), immobilisation < 4 weeks (5), no sonography (17), withdrew consent (6), other (2)

Protocol outcomes not reported by the study

All-cause mortality at up to 90 days from hospital discharge; Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study; Unplanned return to theatre at up to 45 days from hospital discharge

Study

Samama 2013²⁸²

Study	Samama 2013 ²⁸²
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=1349)
Countries and setting	Conducted in Multiple countries; Setting:
Line of therapy	Not applicable
Duration of study	Intervention + follow up: 45 days
Method of assessment of guideline condition	Adequate method of assessment/diagnosis
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	aged ≥18 years, with non-surgical, unilateral single or multiple below-knee injury necessitating rigid or semi-rigid immobilisation (e.g. by plaster cast or brace) for at least 21 days up to 45 days, with at least one additional risk factor for VTE, requiring thromboprophylaxis up to complete mobilisation in investigator's opinion
Exclusion criteria	other traumatic injury
Age, gender and ethnicity	Age - Mean (SD): 46. Gender (M:F): 1:1. Ethnicity: not reported
Further population details	1. Active cancer: No active cancer (0.9% active cancer). 2. BMI: Not obese (BMI under 30 kg/m ²) (22.8% BMI >30). 3. Renal impairment: Not stated. 4. Weight bearing: Weight bearing (weight bearing or partial weight bearing (e.g. using crutches, walking cast, or relief shoes)).
Extra comments	plaster cast 83.8%, brace 6.2%, other type of immobilisation 10%
Indirectness of population	--
Interventions	(n=675) Intervention 1: Fondaparinux - Fondaparinux (all doses). Fondaparinux 2.5mg (or 1.5mg in people with a calculated creatinine clearance between 30-50mL min ⁻¹ . Duration 21-45 days. Concurrent medication/care: Free to take acetaminophen as needed. Use of aspirin or NSAIDs was allowed but discouraged (n=674) Intervention 2: Low molecular weight heparin (not licensed in UK) - Nadroparin (2850 units once daily - up to 57 units/kg once daily). Nadroparin 2850 units. Duration 21-45 days. Concurrent medication/care: Free to take acetaminophen as needed. Use of aspirin or NSAIDs was allowed but discouraged
Funding	Principal author funded by industry (Abbott, AstraZeneca, Baxter, Bayer, Boehringer-Ingelheim, Bristol Myers-Squibb, CSL Behring, Daichii, Fresenius-Kabi, GlaxoSmithKline, Haemonetics, LFB, Lilly, NovoNordisk, Pfizer, Rovi, Sanofi)
RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: FONDAPARINUX (ALL DOSES) versus NADROPARIN (2850 UNITS ONCE DAILY - UP TO 57 UNITS/KG ONCE DAILY)	

Study	Samama 2013 ²⁸²
Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge	- Actual outcome: All-cause mortality at 21-45 days; Group 1: 1/621, Group 2: 0/622; Risk of bias: High; Indirectness of outcome: No indirectness
Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge	- Actual outcome: DVT (asymptomatic) confirmed by ultrasonography at 21-45 days; Group 1: 11/582, Group 2: 42/585; Risk of bias: High; Indirectness of outcome: No indirectness
Protocol outcome 3: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge	- Actual outcome: PE confirmed by pulmonary angiogram at 21-45 days; Group 1: 2/621, Group 2: 0/622; Risk of bias: High; Indirectness of outcome: No indirectness
Protocol outcome 4: Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge	- Actual outcome: Major bleeding: overt and fatal, occurred in a critical organ, was associated with a fall in haemoglobin concentration $\geq 2\text{g dL}^{-1}$, or led to a transfusion ≥ 2 units of packed red blood cells or whole blood at 21-45 days; Group 1: 1/674, Group 2: 0/670; Risk of bias: High; Indirectness of outcome: No indirectness
Protocol outcome 5: Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge	- Actual outcome: Clinically relevant non-major bleeding: bleeding not qualifying as major, including bleeding leading to treatment discontinuation, gastrointestinal bleeding, haemoptysis, cutaneous hematoma $>100\text{cm}^2$, epistaxis >5 minute, recurrent or leading to intervention, spontaneous macroscopic haematuria >24 hour at 21-45 days; Group 1: 1/674, Group 2: 3/670; Risk of bias: High; Indirectness of outcome: No indirectness
Protocol outcome 6: Heparin-induced thrombocytopenia at duration of study	- Actual outcome: Thrombocytopenia at 21-45 days; Group 1: 0/674, Group 2: 1/670; Risk of bias: High; Indirectness of outcome: No indirectness
Protocol outcome 7: VTE at 7-90 days from hospital discharge	- Actual outcome: VTE (any one event) at 21-45 days; Group 1: 14/583, Group 2: 48/586
Protocol outcome 8: DVT (symptomatic) at 7-90 days from hospital discharge	- Actual outcome: DVT (symptomatic) at 21-45 days; Group 1: 2/621, Group 2: 7/622
Protocol outcome 9: DVT (distal) at 7-90 days from hospital discharge	

Study	Samama 2013 ²⁸²
	<ul style="list-style-type: none"> - Actual outcome: DVT (asymptomatic, distal) at 21-45 days; Group 1: 7/582, Group 2: 39/585 - Actual outcome: DVT (symptomatic, distal) at 21-45 days; Group 1: 2/621, Group 2: 5/622
	<p>Protocol outcome 10: DVT (proximal) at 7-90 days from hospital discharge</p> <ul style="list-style-type: none"> - Actual outcome: DVT (asymptomatic, proximal) at 21-45 days; Group 1: 4/582, Group 2: 3/585 - Actual outcome: DVT (symptomatic, proximal) at 21-45 days; Group 1: 0/621, Group 2: 2/622
Protocol outcomes not reported by the study	Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Technical complications of mechanical interventions at duration of study

Study	Selby 2015 ²⁹⁴
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=265)
Countries and setting	Conducted in Canada; Setting: 13 Canadian hospitals
Line of therapy	Not applicable
Duration of study	Intervention + follow up: 2 weeks + 12 weeks
Method of assessment of guideline condition	Adequate method of assessment/diagnosis
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Aged 16 years or over with unilateral or bilateral, close or open fractures of the tibia, fibula, or ankle requiring surgical repair
Exclusion criteria	Major trauma; refused study or were unable to consent; presented greater than 72 hours after injury; ongoing need to anticoagulation for other reasons; inability to follow-up; active uncontrolled bleeding; contraindications to contrast due to allergy, pregnancy or renal insufficiency; previous DVT or PE; active cancer; lower extremity vascular injury requiring surgical repair; known systematic bleeding disorder; intracranial or other major bleeding in past 4 weeks; known molecular hypercoagulable state
Recruitment/selection of patients	Between August 2002 and October 2006
Age, gender and ethnicity	Age - Mean (range): 48 (18-87). Gender (M:F): 139:126. Ethnicity: not reported

Study	Selby 2015 ²⁹⁴
Further population details	1. Active cancer: No active cancer (excluded). 2. BMI: Not stated. 3. Renal impairment: Not stated. 4. Weight bearing: Not stated.
Extra comments	Immobilisation in cast or splint 98.1%; unilateral fractures 97.4%
Indirectness of population	No indirectness
Interventions	(n=134) Intervention 1: Low molecular weight heparin (licensed in UK) - Dalteparin (1,250 units once daily - 5,000 units twice daily). Dalteparin 5000 units. Duration 2 weeks. Concurrent medication/care: Unilateral or bilateral plaster casts. Aspirin and other antiplatelet agents were allowed if they had been used before the injury for cardiac or stroke prophylaxis. Nonsteroidal anti-inflammatory agents were allowed (n=131) Intervention 2: No treatment - Placebo. Placebo in prefilled syringes. Duration 2 weeks. Concurrent medication/care: Unilateral or bilateral plaster casts. Aspirin and other antiplatelet agents were allowed if they had been used before the injury for cardiac or stroke prophylaxis. Nonsteroidal anti-inflammatory agents were allowed
Funding	Study funded by industry (Canadian Institutes of Health Research-industry partnership with Pfizer Canada)

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: DALTEPARIN (1,250 UNITS ONCE DAILY - 5,000 UNITS TWICE DAILY) versus PLACEBO

Protocol outcome 1: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge

- Actual outcome: DVT, asymptomatic proximal. Confirmed by bilateral Doppler ultrasound at 90 days; Group 1: 1/130, Group 2: 1/128; Risk of bias: High; Indirectness of outcome: No indirectness

Protocol outcome 2: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge

- Actual outcome: PE, symptomatic. Confirmed by positive spiral computed tomography pulmonary angiogram, high probability V/Q lung scan, or leg imaging at 90 days; Group 1: 0/130, Group 2: 1/128; Risk of bias: High; Indirectness of outcome: No indirectness

Protocol outcome 3: Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge

- Actual outcome: Major bleeding. Defined as overt bleeding that was fatal, life threatening or involved a critical organ or major joint, required surgical intervention, transfusion of 1 or more units of blood cells within 48 hours of the bleeding event, or was associated with a drop in haemoglobin of at least 20g/L within 48 hours of the bleeding event at 90 days; Group 1: 0/130, Group 2: 0/128; Risk of bias: High; Indirectness of outcome: No indirectness

Study	Selby 2015 ²⁹⁴
Protocol outcome 4: Heparin-induced thrombocytopenia at duration of study - Actual outcome: HIT at 90 days; Group 1: 0/130, Group 2: 0/128; Risk of bias: High; Indirectness of outcome: No indirectness	
Protocol outcome 5: DVT (symptomatic) at 7-90 days from hospital discharge - Actual outcome: DVT, symptomatic at 90 days; Group 1: 1/130, Group 2: 1/128	
Protocol outcomes not reported by the study	All-cause mortality at up to 90 days from hospital discharge; Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQspect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Technical complications of mechanical interventions at duration of study

H.22 Fragility fractures of the pelvis, hip and proximal femur

Study	Eriksson 2003 ⁹⁷
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=656)
Countries and setting	Conducted in Argentina, Australia, Belgium, Czech Republic, Denmark, Finland, France, Greece, Italy, Netherlands, Poland, Portugal, Spain, Sweden, Switzerland, United Kingdom; Setting: 57 centres in 16 countries
Line of therapy	Not applicable
Duration of study	Intervention time: 25-31 days
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: DVT (symptomatic and asymptomatic): confirmed by systemic ascending bilateral contrast venography. PE: confirmed by high-probability lung scanning, pulmonary angiography, spiral computed tomography. Major bleeding: defined as fatal bleeding, retroperitoneal, intracranial, or intraspinal bleeding, bleeding that involved any other critical organ, bleeding leading to reoperation, and overt bleeding with a bleeding index of 2 or more.
Stratum	Overall

Subgroup analysis within study	Not applicable
Inclusion criteria	Patients aged at least 18 years who were undergoing standard surgery for fracture of the upper third of the femur, including femoral head and neck, were considered for inclusion if surgery was planned within 48 hours after admission.
Exclusion criteria	Patients were excluded if they presented with trauma affecting more than 1 organ system or if more than 24 hours had elapsed between the causative trauma and hospital admission. Other main exclusion criteria were active bleeding; documented congenital or acquired bleeding disorder; current ulceration or angiodysplastic gastrointestinal disease; hemorrhagic stroke or brain, spinal, or ophthalmological surgery within the previous 3 months; difficulty in performing epidural or spinal anesthesia; planned indwelling intrathecal or epidural catheter for more than 6 hours after surgery; contraindication to anticoagulant therapy; pregnancy; hypersensitivity to contrast media; or serum creatinine concentration above 2.0 mg/dL (177 µmol/L) in a well-hydrated patient. Patients who required long-term anticoagulant treatment for a chronic comorbid condition or were receiving any type of anticoagulant or fibrinolytic therapy or dextran from admission to first study drug administration or surgery were also excluded.
Recruitment/selection of patients	Between June 2001 and February 2002
Age, gender and ethnicity	Age - Mean (SD): 77 (12) years. Gender (M:F): 1/2. Ethnicity: Not reported
Further population details	1. Immobilisation: Not applicable 2. BMI : Not obese (BMI under 30 kg/m ²) (Median BMI: 25). 3. Cancer status: Not applicable 4. Renal impairment: Not applicable
Extra comments	Type of fracture: cervical 41%, trochanteric 52%, subtrochanteric 8%; Median duration of surgery 1 hour 34 minutes; 46% patients used AES
Indirectness of population	No indirectness
Interventions	<p>(n=327) Intervention 1: Fondaparinux - Fondaparinux (all doses). All eligible patients were given a once-daily, subcutaneous injection of 2.5 mg of fondaparinux sodium up to 6-8 days after surgery (standard duration). Patients received a once-daily, subcutaneous injection of 2.5 mg of fondaparinux sodium for 19 to 23 additional days (extended duration), for a total duration of treatment of 25 to 31 days. The first injection was to be given less than 2 hours after randomization. Duration 25-31 days. Concurrent medication/care: Early mobilisation (physiotherapy) recommended. AES permitted. IPCD, dextran, and thrombolytic, anticoagulant, or antiplatelet agents prohibited. Centres were advised to avoid use of aspirin or NSAIDs</p> <p>(n=329) Intervention 2: Fondaparinux - Fondaparinux (all doses). All eligible patients were given a once-daily, subcutaneous injection of 2.5 mg of fondaparinux sodium up to 6-8 days after surgery. Patients receive a once-daily, subcutaneous injection of placebo for 19 to 23 additional days, for a total duration of treatment of 25 to 31 days. The first injection was to be given less than 2 hours after randomization. Duration 25-31 days. Concurrent medication/care: Early mobilisation (physiotherapy) recommended, AES permitted. IPCD, dextran, and thrombolytic, anticoagulant, or antiplatelet agents prohibited. Centres were advised to avoid use of aspirin or NSAIDs</p>

Funding	Study funded by industry (Supported by a grant from Sanofi-Synthelabo, Paris, France and NV Organon, Oss, the Netherlands)
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: FONDAPARINUX (EXTENDED DURATION) versus FONDAPARINUX (STANDARD DURATION)</p> <p>Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge - Actual outcome: All-cause mortality at 25-31 days; Group 1: 6/327, Group 2: 8/329 Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0</p> <p>Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge - Actual outcome: DVT (symptomatic and asymptomatic) at 25-32 days; Group 1: 3/208, Group 2: 74/218 Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 118, Reason: No VTE assessment, inadequate VTE assessment; Group 2 Number missing: 112, Reason: No VTE assessment, inadequate VTE assessment</p> <p>Protocol outcome 3: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge - Actual outcome: PE at 25-31 days; Group 1: 0/326, Group 2: 2/330 Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0</p> <p>Protocol outcome 4: Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of ≥ 2g/dl; a serious or life threatening clinical event at up to 45 days from hospital discharge - Actual outcome: Major bleeding at 25-31 days; Group 1: 8/327, Group 2: 2/329 Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0</p> <p>Protocol outcome 5: Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge - Actual outcome: Fatal PE at 25-31 days; Group 1: 0/326, Group 2: 1/330 Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;</p>	

Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0	
Protocol outcome 6: VTE at 7-90 days from hospital discharge - Actual outcome: VTE at 25-31 days; Group 1: 3/208, Group 2: 77/220	
Protocol outcome 7: DVT (symptomatic) at 7-90 days from hospital discharge - Actual outcome: DVT (symptomatic) at 25-31 days; Group 1: 1/326, Group 2: 6/330	
Protocol outcome 8: DVT (distal) at 7-90 days from hospital discharge - Actual outcome: DVT (distal) at 25-31 days; Group 1: 1/207, Group 2: 42/211	
Protocol outcome 9: DVT (proximal) at 7-90 days from hospital discharge - Actual outcome: DVT (proximal) at 25-31 days; Group 1: 2/221, Group 2: 35/222	
Protocol outcomes not reported by the study	Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study; Infection at duration of study

Study	Eskeland 1966 ⁹⁸
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=200)
Countries and setting	Conducted in Norway; Setting: Department II, Ullevål Hospital, Norway
Line of therapy	Not applicable
Duration of study	Intervention time: 7-14 days
Method of assessment of guideline condition	Adequate method of assessment/diagnosis
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Patients admitted with subcapital or pertrochanteric fracture of the femur
Exclusion criteria	Patients under the age of 56 (anticoagulation considered unnecessary), patients presenting special indications for or

	contraindications against anticoagulant therapy, patients in whom the effect of anticoagulation prophylaxis could not be evaluated because the guiding principles of the trial could not be followed.
Recruitment/selection of patients	December 1st 1961 to 29th June 1963
Age, gender and ethnicity	Age - Mean (SD): 76 years. Gender (M:F): 1/5. Ethnicity: Not reported
Further population details	1. Immobilisation: Not applicable 2. BMI : Not applicable 3. Cancer status: Not applicable 4. Renal impairment: Not applicable
Extra comments	Type of fracture: subcapital 60%, impacted subcapital 9%, pertrochanteric 40%; mean inpatient stay 25 days
Indirectness of population	No indirectness
Interventions	<p>(n=100) Intervention 1: Vitamin K antagonists - Phenindione (all doses). Phenindione, phenindione therapy was controlled by PP-test or the Thrombotest three times a week until a satisfactory and stable level had been achieved, and then at longer intervals. After an average of five days the PP values had fallen to the level aimed at (below 30% of normal) and there they remained for the rest of the treatment. When the time came to stop the anticoagulant therapy this was done by gradually reducing the dose to zero in the course of one or two weeks. Duration 7-14 days. Concurrent medication/care: Anticoagulant prophylaxis was started on the day of the operation or next day. If the operation was delayed for more than 5 days, and in patients not operated on, prophylactic treatment was started within 5 days of admission. Anticoagulant prophylaxis was started no later than 5 days after the injury.</p> <p>(n=100) Intervention 2: No treatment - Placebo. No anticoagulation prophylaxis received. Duration 7-14 days. Concurrent medication/care: N/A</p>
Funding	Funding not stated

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: PHENINDIONE (ALL DOSES) versus PLACEBO

Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge

- Actual outcome: All-cause mortality at 90 days; Group 1: 19/100, Group 2: 24/100

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0

Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge

- Actual outcome: DVT (symptomatic and asymptomatic) at 90 days; Group 1: 2/100, Group 2: 6/100

Risk of bias: All domain - Very high, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - High, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0	
<p>Protocol outcome 3: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge</p> <p>- Actual outcome: PE at 90 days; Group 1: 2/100, Group 2: 2/100</p> <p>Risk of bias: All domain - Very high, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - High, Crossover - Low;</p> <p>Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0</p>	
<p>Protocol outcome 4: Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge</p> <p>- Actual outcome: Fatal PE at 90 days; Group 1: 1/100, Group 2: 7/100</p> <p>Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;</p> <p>Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0</p>	
Protocol outcomes not reported by the study	Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study; Infection at duration of study;

Study	Fisher 1995 ¹⁰²
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=304)
Countries and setting	Conducted in Canada; Setting: Vancouver General Hospital Orthopaedic Trauma Service, Canada
Line of therapy	Not applicable
Duration of study	Intervention time: Mean: 14 days
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: DVT (symptomatic and asymptomatic): confirmed by Doppler

	ultrasonography PE: confirmed ventilation perfusion (VQ) lung scan
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Patients admitted with pelvic, acetabular, femoral neck, intertrochanteric, or subtrochanteric fractures. All fractures had to have occurred within the preceding 24 hours.
Exclusion criteria	Abnormal coagulation profile, current or recent use of an antiplatelet or anticoagulation medication, malignancy, severe liver disease, severe vascular disease, skin ulceration or large open wound on lower extremity, objective evidence of DVT, and severe multi-trauma.
Recruitment/selection of patients	Patients admitted between 1st March 1988 and 1st March 1991
Age, gender and ethnicity	Age - Other: >40 years: IPCD group 83%, control group 76%. Gender (M:F): Not reported. Ethnicity: Not reported
Further population details	1. Immobilisation: Not applicable 2. BMI : Not applicable 3. Cancer status: Not applicable 4. Renal impairment: Not applicable
Indirectness of population	No indirectness
Interventions	<p>(n=145) Intervention 1: Intermittent pneumatic compression devices - Full leg. Pneumatic sequential leg compression device, applied post-operatively and worn until the patient was ambulating on a routine basis. The IPCD device consisted of a portable controller and a pair of thigh length sleeves. Each sleeve contains six chambers, four calves and two thighs. Sleeves are sequentially inflated to pressures of 45 mm Hg at the ankle, 35-40 mm Hg at the calf, and 25 mm Hg at the thigh. The compression cycle was 71 seconds with each compression lasting 11 seconds, this allows for normal refilling of the venous system. Duration Mean: 14 days. Concurrent medication/care: Routine postoperative nursing care and physiotherapy. Included an active mobilisation regimen commencing on postoperative day 1.</p> <p>(n=159) Intervention 2: No treatment - Usual care. Patients received same clinical care as the intervention group. Duration Mean: 13 days. Concurrent medication/care: Routine postoperative nursing care and physiotherapy. Included an active mobilisation regimen commencing on postoperative day 1.</p>
Funding	Funding not stated

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: IPCD, THIGH-LENGTH versus USUAL CARE

Protocol outcome 1: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound;

<p>MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge - Actual outcome: DVT (symptomatic and asymptomatic) at mean: 14 days; Group 1: 9/145, Group 2: 0/159 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0</p> <p>Protocol outcome 2: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge - Actual outcome: PE at 5-10 days; Group 1: 2/145, Group 2: 6/159 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0</p>	
Protocol outcomes not reported by the study	<p>All-cause mortality at up to 90 days from hospital discharge; Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge; Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study; Infection at duration of study;</p>

Study	Galasko 1976¹¹³
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=100)
Countries and setting	Conducted in United Kingdom; Setting: Not reported
Line of therapy	Not applicable
Duration of study	Intervention time: Until discharge, transferred or fully mobilised
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: DVT: confirmed by venography PE: confirmed by clinical and radiological examinations or at autopsy

Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Female patients, over the age of 60 years, who were ambulant before the injury and who had sustained intertrochanteric or transcervical femoral fractures.
Exclusion criteria	Patients under the age of 60, who had a history of DVT, PE, haematemesis, haematuria or other bleeding disorders and patients with malignant disease were excluded from the trial
Recruitment/selection of patients	Based on inclusion criteria
Age, gender and ethnicity	Age - --: Not reported. Gender (M:F): 100% female. Ethnicity: Not reported
Further population details	1. Immobilisation: Not applicable 2. BMI : Not applicable 3. Cancer status: Not applicable 4. Renal impairment: Not applicable
Indirectness of population	No indirectness
Interventions	<p>(n=50) Intervention 1: Unfractionated heparin - Unfractionated heparin (low dose, administered subcutaneously). Unfractionated heparin, 5000IU 12 hourly (twice daily), subcutaneously. Duration Until when patients were discharged, transferred or fully mobilised (duration of hospital length of stay not reported) . Concurrent medication/care: Nursing care was identical in both groups as was the postoperative mobilisation. The operative procedure was the same.</p> <p>(n=50) Intervention 2: No treatment - Usual care. Control group. Duration Until when patients were discharged, transferred or fully mobilised (duration of hospital length of stay not reported). Concurrent medication/care: Nursing care was identical in both groups as was the postoperative mobilisation. The operative procedure was the same.</p>
Funding	Funding not stated

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: UNFRACTIONATED HEPARIN (LOW DOSE, ADMINISTERED SUBCUTANEOUSLY) versus USUAL CARE

Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge

- Actual outcome: All-cause mortality at Time-point not reported; Group 1: 15/50, Group 2: 11/50

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0

Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge

<p>- Actual outcome: DVT (symptomatic and asymptomatic) at Time-point not reported; Group 1: 8/50, Group 2: 23/50 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0</p> <p>Protocol outcome 3: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge - Actual outcome: PE at Time-point not reported; Group 1: 2/50, Group 2: 5/50 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0</p> <p>Protocol outcome 4: Infection at duration of study - Actual outcome: Wound infection/haematoma at Time-point not reported; Group 1: 7/50, Group 2: 8/50 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0</p>	
Protocol outcomes not reported by the study	<p>Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge; Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study;</p>

Study	Goel 2009 ¹²⁰
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=305)
Countries and setting	Conducted in Canada; Setting: Department of Orthopaedics, University of Calgary, Alberta, Canada

Study	Goel 2009 ¹²⁰
Line of therapy	Not applicable
Duration of study	Intervention time: 14 days
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: DVT (symptomatic and asymptomatic) confirmed by bilateral venography Major bleeding: defined as fall in haemoglobin of ≥ 2 g/dl within a 24-hour period resulting in transfusion of ≥ 2 units of blood, intracranial, intraspinal, intra-ocular, retroperitoneal or pericardial bleeding, and causing death
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Male and female patients 18-75 years of age, patients with unilateral displaced, fractures below the knee requiring operation, patients with simultaneous injury of a minor nature (e.g. conservatively managed wrist, scapula, clavicular fracture not inhibiting patient mobilisation)
Exclusion criteria	Non-surgical treatment, fractures below the knee, polytrauma patients, fractures not treated within 48 hours, patients with history of DVT or PE, patients limited from early mobilisation, patients with foot fractures, medical contraindications to surgery, patients receiving anticoagulation, inability to provide consent, patients with platelet counts less than 100, patients with elevated serum creatinine $> 200\mu\text{mol/L}$
Recruitment/selection of patients	December 2000 and July 2006, patients between the ages of 18 and 75 years admitted with unilateral isolated fractures below the knee which required operative fixation
Age, gender and ethnicity	Age - Mean (range): 40.95 years. Gender (M:F): 1.63/1. Ethnicity: Not reported
Further population details	1. BMI : Not obese (BMI under 30 kg/m ²) (Intervention group: mean 27.0; control group mean 26.7). 2. Cancer status: Not applicable 3. Renal impairment: Not applicable
Extra comments	Type of fracture: tibial plateau 13%, tibial shaft 16%, ankle 63%, pilon, 6.3%, not recorded 1.27%
Indirectness of population	No indirectness
Interventions	(n=157) Intervention 1: Low molecular weight heparin (licensed in UK) - Dalteparin (1,250 units once daily - 5,000 units twice daily). Fragmin was administered subcutaneously. 2500IU was administered subcutaneously two hours pre-operatively, followed by 2500IU eight hours post-operatively, and 5000IU on following days each morning up to and including the 14th day. Duration 14 days. Concurrent medication/care: Post-operative rehabilitation was standardised and ward-based physiotherapists directed the patients in early movement exercises. All fractures received a post-operative dressing or immobilisation in a cast depending on the type of fracture. Indirectness: No indirectness (n=148) Intervention 2: No treatment - Placebo. Saline was administered subcutaneously. Placebo (saline) was

Study	Goel 2009 ¹²⁰
	administered subcutaneously two hours pre-operatively, followed by saline subcutaneous injection eight hours post-operatively, and saline on following days each morning up to and including the 14th day. Duration 14 days. Concurrent medication/care: Post-operative rehabilitation was standardised and ward-based physiotherapists directed the patients in early movement exercises. All fractures received a post-operative dressing or immobilisation in a cast depending on the type of fracture. Indirectness: No indirectness
Funding	Funding not stated (Authors stated in-text that there was a sponsor but no further details reported)
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: DALTEPARIN (1,250 UNITS ONCE DAILY - 5,000 UNITS TWICE DAILY) versus PLACEBO</p> <p>Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge - Actual outcome: All-cause mortality at Time-point not reported; Group 1: 1/126, Group 2: 0/111 Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 31, Reason: Death, inconclusive venogram, no venogram, negative venogram; Group 2 Number missing: 37, Reason: Death, inconclusive venogram, no venogram, negative venogram</p> <p>Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge - Actual outcome: DVT (symptomatic and asymptomatic) at 14 days; Group 1: 11/126, Group 2: 14/111 Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 31, Reason: Death, inconclusive venogram, no venogram, negative venogram; Group 2 Number missing: 37, Reason: Death, inconclusive venogram, no venogram, negative venogram</p> <p>Protocol outcome 3: Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge - Actual outcome: Major bleeding at Time-point not reported; Group 1: 0/126, Group 2: 0/111 Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 31, Reason: Death, inconclusive venogram, no venogram, negative venogram; Group 2 Number missing: 37, Reason: Death, inconclusive venogram, no venogram, negative venogram</p> <p>Protocol outcomes not reported by the study</p>	
	Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge; Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for

Study	Goel 2009¹²⁰
	major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study; Infection at duration of study;

Study	Hamilton 1970¹³⁵
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=300)
Countries and setting	Conducted in Canada; Setting: Toronto Western Hospital, Canada
Line of therapy	Not applicable
Duration of study	Not clearly reported
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: DVT confirmed by ascending phlebography
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Patients admitted with a fracture near the hip
Exclusion criteria	Patients who were not treated by operation, as well as patients with any of the following conditions: recent cerebrovascular accident: diastolic blood pressure of 100 ml of mercury or more: recent head injury; recent peptic ulcer or other gastro-intestinal lesion likely to bleed; recent haemoptysis; recent haematuria; liver disease; renal disease; bleeding diathesis.
Recruitment/selection of patients	Patients admitted between July 1968 and April 1969
Age, gender and ethnicity	Age - Mean (SD): 77 years. Gender (M:F): 1/5. Ethnicity: Not reported
Further population details	1. Immobilisation: Not applicable 2. BMI : Not applicable 3. Cancer status: Not applicable 4. Renal impairment: Not applicable
Indirectness of population	No indirectness
Interventions	(n=38) Intervention 1: Vitamin K antagonists - Phenindione (all doses). Phenindione, prothrombin time to two to two

	<p>and a half times the control was the objective. The level was usually reached by the second day after operation. The prothrombin time was estimated by Quick's one-stage test using Simplastin to compare the patient's plasma with a "Diagnostic Plasma" control. Duration Unclear. Concurrent medication/care: N/A</p> <p>(n=38) Intervention 2: No treatment - Placebo. Control group, no further details reported. Duration Not clear. Concurrent medication/care: N/A</p>
Funding	Academic or government funding (Support by a grant from Ontario Geriatric Research Society)
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: PHENINDIONE (ALL DOSES) versus PLACEBO</p> <p>Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge - Actual outcome: All-cause mortality at Time-point not reported; Group 1: 4/38, Group 2: 5/38 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0</p> <p>Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge - Actual outcome: DVT (symptomatic and asymptomatic) at 5-12 days; Group 1: 10/38, Group 2: 18/37 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 1</p> <p>Protocol outcome 3: Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge - Actual outcome: Major bleeding at Time-point not reported; Group 1: 11/38, Group 2: 9/38 Risk of bias: All domain - Very high, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - High, Crossover - Low, Comments - Number of units given: VKA group 36 units, control group 22 units; Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0</p> <p>Protocol outcome 4: Infection at duration of study - Actual outcome: Deep wound infection at Time-point not reported; Group 1: 3/38, Group 2: 4/38 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0</p>	

Protocol outcomes not reported by the study	Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge; Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study;
---	---

Study	Jørgensen 1992 ¹⁵⁹
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=68)
Countries and setting	Conducted in Denmark; Setting: Department of Orthopaedics, Rigshospitalet, University Hospital, Copenhagen, Denmark
Line of therapy	Not applicable
Duration of study	Intervention time: 7 days
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: DVT (symptomatic and asymptomatic): confirmed by I125 fibrinogen uptake test and scans and ascending phlebography
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Patients admitted for hip fracture who were 40 years of age or older
Exclusion criteria	Bleeding disorders, hepatic or renal insufficiency, previous septic endocarditis, cerebral hemorrhage during the preceding six months, hypersensitivity to heparin or iodine, and anticoagulant therapy within one week of surgery. Patients from nursing homes were also excluded because they were discharged and returned to recuperate in their nursing homes soon after surgery.
Recruitment/selection of patients	April 1986 to February 1988
Age, gender and ethnicity	Age - Mean (range): 80 years. Gender (M:F): 1/3. Ethnicity: Not reported
Further population details	1. Immobilisation: Not applicable 2. BMI : Not applicable 3. Cancer status: Not applicable 4. Renal impairment: Not

	applicable
Extra comments	Mean duration of surgery: intervention group (LMWH) 57 minutes, placebo group 60 minutes. Duration of hospitalisation: intervention group (LMWH) 14 days, placebo group 16 days
Indirectness of population	No indirectness
Interventions	<p>(n=30) Intervention 1: Low molecular weight heparin (licensed in UK) - Dalteparin (1,250 units once daily - 5,000 units twice daily). Each patient received eight syringes, first and second syringes contained 2500IU and subsequent ones contained 5000IU. Injections were given subcutaneously. The first injection was administered two hours preoperatively and the second injection 12 hours postoperatively. The remaining six injections were given once each morning on the six following days. Duration 7 days. Concurrent medication/care: N/A</p> <p>(n=38) Intervention 2: No treatment - Placebo. The control group received placebo injections following the same schedule used by the LMWH group. Duration 7 days. Concurrent medication/care: N/A</p>
Funding	Funding not stated

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: DALTEPARIN (1,250 UNITS ONCE DAILY - 5,000 UNITS TWICE DAILY) versus PLACEBO

Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge

- Actual outcome: All-cause mortality at 84 days; Group 1: 3/30, Group 2: 4/38

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0

Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge

- Actual outcome: DVT (symptomatic and asymptomatic) at 9 days; Group 1: 9/30, Group 2: 22/38

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0

Protocol outcome 3: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQspect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge

- Actual outcome: PE at 84 days; Group 1: 0/30, Group 2: 1/38

Risk of bias: All domain - Very high, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - High, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0

<p>Protocol outcome 4: Infection at duration of study - Actual outcome: Superficial wound infection at 84 days; Group 1: 2/30, Group 2: 2/38 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0</p>	
<p>Protocol outcomes not reported by the study</p>	<p>Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge; Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study;</p>

Study	Lahnborg 1980 ¹⁸³
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=140)
Countries and setting	Conducted in Sweden; Setting: Serafimerlasarettet (Seraphim Hospital), Stockholm, Sweden
Line of therapy	Not applicable
Duration of study	Intervention time: 10 days
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: DVT (symptomatic and asymptomatic): confirmed by I125 fibrinogen uptake test and scans
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Patients admitted for nailing of a fractured neck of the femur, no history of venous thrombosis or pulmonary embolism during two years before the trial, no patients received oral anticoagulants for a previous thromboembolism.
Exclusion criteria	None reported

Recruitment/selection of patients	Consecutive patients admitted for nailing of a fractured neck of the femur.
Age, gender and ethnicity	Age - Mean (range): 77 (39-97) years. Gender (M:F): 1/2. Ethnicity: Not reported
Further population details	1. Immobilisation: Not applicable 2. BMI : Not applicable 3. Cancer status: Not applicable 4. Renal impairment: Not applicable
Extra comments	Mean duration of surgery, 122 minutes
Indirectness of population	No indirectness
Interventions	(n=71) Intervention 1: Unfractionated heparin - Unfractionated heparin (low dose, administered subcutaneously). Sodium heparin was given at a dosage of 5000 units subcutaneously into the thigh every 12 hours for 10 days, starting 2-3 hours before the operation. Duration 10 days. Concurrent medication/care: N/A (n=69) Intervention 2: No treatment - Placebo. Placebo, 0.5ml of 0.85% saline was given every 12 hours for 10 days starting 2-3 hours before the operation. Duration 10 days. Concurrent medication/care: N/A
Funding	Funding not stated
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: UNFRACTIONATED HEPARIN (LOW DOSE, ADMINISTERED SUBCUTANEOUSLY) versus PLACEBO</p> <p>Protocol outcome 1: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge - Actual outcome: DVT (symptomatic and asymptomatic) at 10 days; Group 1: 15/71, Group 2: 28/69 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0</p> <p>Protocol outcome 2: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQspect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge - Actual outcome: PE at Time-point not reported; Group 1: 2/71, Group 2: 0/69 Risk of bias: All domain - Very high, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - High, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0</p>	
Protocol outcomes not reported by the study	All-cause mortality at up to 90 days from hospital discharge; Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge; Fatal PE. Confirmed by: CT scan with spiral or

	contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study; Infection at duration of study;
--	--

Study	Monreal 1989 ²²⁹
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=90)
Countries and setting	Conducted in Spain; Setting: Orthopaedic Surgery and Roentgenology, Hospital de Badalona, Barcelona, Spain
Line of therapy	Not applicable
Duration of study	Intervention time: 9 days
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: PE: confirmed by ventilation-perfusion lung scanning
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Patients admitted because of hip fracture and over 40 years of age, all of them operated on the day of fracture.
Exclusion criteria	Patients with underlying bleeding disorder
Recruitment/selection of patients	Based on inclusion criteria
Age, gender and ethnicity	Age - Mean (SD): 77 (11) years. Gender (M:F): 1/5. Ethnicity: Not reported
Further population details	1. Immobilisation: Not applicable 2. BMI : Not applicable 3. Cancer status: Not applicable 4. Renal impairment: Not applicable
Extra comments	Duration of operation: mean 93 minutes
Indirectness of population	No indirectness
Interventions	(n=46) Intervention 1: Low molecular weight heparin (licensed in UK) - Dalteparin (1,250 units once daily - 5,000 units twice daily). LMWH, Kabi 2165 (dalteparin) was obtained in 0.2ml prefilled syringes with a potency of 2500IU and

	<p>5000IU. 2500IU was given 2 hours before surgery and then 5000IU subcutaneously every morning for 9 days. To observe the same injection schedule as in the UFH group, a placebo was given in the evening doses (patients received injections every 8 hours). Duration 9 days. Concurrent medication/care: Early mobilisation encouraged, it was planned to have all patients sit on the second day and stand up before the first week ended.</p> <p>(n=44) Intervention 2: Unfractionated heparin - Unfractionated heparin (low dose, administered subcutaneously). UFH, 5000IU was given subcutaneously 2 hours before operation, and then at 8 hour intervals for the next 9 days. Duration 9 days. Concurrent medication/care: Early mobilisation encouraged, it was planned to have all patients sit on the second day and stand up before the first week ended.</p>
Funding	Funding not stated
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: DALTEPARIN versus UNFRACTIONATED HEPARIN</p> <p>Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge - Actual outcome: All-cause mortality at Time-point not reported; Group 1: 2/46, Group 2: 3/44 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0</p> <p>Protocol outcome 2: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge - Actual outcome: PE at 8 days; Group 1: 6/46, Group 2: 0/44 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0</p> <p>Protocol outcome 3: DVT (symptomatic) at 7-90 days from hospital discharge - Actual outcome: DVT (symptomatic) at Time-point not reported; Group 1: 14/46, Group 2: 6/44</p>	
Protocol outcomes not reported by the study	<p>Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge; Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge; Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days</p>

from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study; Infection at duration of study;

Study	Morris 1976²³⁰
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=160)
Countries and setting	Conducted in United Kingdom; Setting: Nottingham General Hospital, Nottingham
Line of therapy	Not applicable
Duration of study	Intervention time: 90 days
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: DVT (symptomatic and asymptomatic): confirmed by I125 fibrinogen uptake test and scans PE: confirmed by clinical signs, chest X-rays, and electrocardiograms
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Patient aged 60 or over, the diagnosis of fractured neck of femur (subcapital or intertrochanteric) had been confirmed and there were no grounds for exclusion from the trial
Exclusion criteria	Prothrombin index of less than 70%, a severe unexplained anemia or bleeding tendency; active peptic ulceration; malignant hypertension; renal failure; liver disease; pathological fracture; recent stroke or severe intellectual impairment; clinical evidence of venous thrombosis.
Recruitment/selection of patients	During a 12 month period all patients aged 60 years and over who were admitted to Nottingham General Hospital with a fracture of the femoral neck were considered for entry into the trial.
Age, gender and ethnicity	Age - Mean (SD): 78.3 years. Gender (M:F): 1/7. Ethnicity: Not reported
Further population details	1. Immobilisation: Not applicable 2. BMI : Not applicable 3. Cancer status: Not applicable 4. Renal impairment: Not applicable

Extra comments	Site of hip fracture: subcapital 52%; pertochanteric 48%
Indirectness of population	No indirectness
Interventions	<p>(n=80) Intervention 1: Vitamin K antagonists - Warfarin (all doses). Oral warfarin sodium was given to the treatment group, treatment being controlled by the 'Thrombotest' method, using venous blood-samples. A thrombotest level of 10% was aimed for to achieve modest degree of anticoagulation. All patients received an oral loading dose of 30mg of warfarin sodium within 24 hours of admission. No warfarin was given on the next day. On the 3rd day a thrombotest level was obtained, and the next dose of warfarin was prescribed according to the result. Duration Until independently mobilised or 3 months. Concurrent medication/care: All patients were given routine ward physiotherapy before and after operation.</p> <p>(n=80) Intervention 2: No treatment - Usual care. Control group were not treated. No further details reported. Duration Until independently mobilised or 3 months. Concurrent medication/care: All patients were given routine ward physiotherapy before and after operation.</p>
Funding	Study funded by industry (Study was supported by a grant from Boehringer Ingelheim Ltd)

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: WARFARIN (ALL DOSES) versus CONTROL GROUP

Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge

- Actual outcome: All-cause mortality at Time-point not reported; Group 1: 16/80, Group 2: 23/80

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0

Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge

- Actual outcome: DVT (symptomatic and asymptomatic) at 10 days; Group 1: 23/75, Group 2: 50/74

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 5, Reason: Failure in supply of fibrinogen; Group 2 Number missing: 6, Reason: Failure in supply of fibrinogen

Protocol outcome 3: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge

- Actual outcome: PE at Time-point not reported; Group 1: 0/80, Group 2: 2/80

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0	
Protocol outcome 4: Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge - Actual outcome: Major bleeding at Time-point not reported; Group 1: 8/80, Group 2: 2/80 Risk of bias: All domain - Very high, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - High, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0	
Protocol outcomes not reported by the study	Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study; Infection at duration of study;

Study	Moskovitz 1978 ²³¹
Study type	RCT (randomised; Parallel)
Number of studies (number of participants)	1 (n=52)
Countries and setting	Conducted in USA; Setting: The George Washington University Hospital
Line of therapy	Not applicable
Duration of study	Intervention time: 7 days
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: DVT (symptomatic and asymptomatic): confirmed by I125 fibrinogen uptake test and scans PE: confirmed by radionuclide perfusion lung-scanning
Stratum	Overall
Subgroup analysis within study	Not applicable

Inclusion criteria	Patients admitted with diagnosis of hip fracture.
Exclusion criteria	Prior history of VTE, a history of gastric or duodenal ulcer with haemorrhage within the previous six months, a positive stool guaiac (2+ or greater), haematuria, a sensitivity to iodinated compounds, or a diastolic blood pressure greater than 110 ml of mercury. Other reasons for exclusion were a patient's refusal to be involved in the study and technical problems and errors either in the collection of data in the conduct of the protocol.
Recruitment/selection of patients	Based on inclusion criteria
Age, gender and ethnicity	Age - Other: 61% ≥70 years. Gender (M:F): 1/2. Ethnicity: 43% White
Further population details	1. Immobilisation: Not applicable 2. BMI : Not applicable 3. Cancer status: Not applicable 4. Renal impairment: Renal impairment (eGFR less than 30 ml/min/1.73m ²) (Renal stasis: 50% patients in each treatment group).
Indirectness of population	--
Interventions	<p>(n=29) Intervention 1: Unfractionated heparin - Unfractionated heparin (low dose, administered subcutaneously). UFH, 5000IU administered subcutaneously every 8 hours, first dose was given at 6am, 2pm or 10pm. All patients wore AES. Duration 7 days. Concurrent medication/care: Early mobilisation was encouraged, patients were required to stand at the bedside on the first or second postoperative day and then permitted to transfer with assistance from the bed to a char. They were allowed to stand and walk with assistance and external support on the second postoperative day, as tolerated.</p> <p>(n=23) Intervention 2: No treatment - Placebo. Placebo (saline) administered subcutaneously every 8 hours, first dose was given at 6am, 2pm or 10pm. All patients wore AES. Duration 7 days. Concurrent medication/care: Early mobilisation was encouraged, patients were required to stand at the bedside on the first or second postoperative day and then permitted to transfer with assistance from the bed to a char. They were allowed to stand and walk with assistance and external support on the second postoperative day, as tolerated.</p>
Funding	Academic or government funding (Grant from the National Heart and Lung Institute of the National Institutes of Health)

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: UNFRACTIONATED HEPARIN + AES versus PLACEBO + AES

Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge

- Actual outcome: All-cause mortality at Time-point not reported; Group 1: 0/29, Group 2: 3/23

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0

Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound;

<p>MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge - Actual outcome: DVT (symptomatic and asymptomatic) at 10 days; Group 1: 10/29, Group 2: 8/23 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0</p> <p>Protocol outcome 3: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge - Actual outcome: PE at Time-point not reported; Group 1: 2/29, Group 2: 1/23 Risk of bias: All domain - Very high, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - High, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0</p> <p>Protocol outcome 4: Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge - Actual outcome: Major bleeding at Time-point not reported; Group 1: 0/29, Group 2: 0/23 Risk of bias: All domain - Very high, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - High, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0</p> <p>Protocol outcome 5: Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge - Actual outcome: Fatal PE at Time-point not reported; Group 1: 0/29, Group 2: 1/23 Risk of bias: All domain - Very high, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - High, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0</p>	
Protocol outcomes not reported by the study	Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study; Infection at duration of study;

Study	PENTHIFRA trial: Eriksson 2001⁹³
Study type	RCT (Patient randomised; Parallel)

Number of studies (number of participants)	1 (n=1711)
Countries and setting	Conducted in Argentina, Australia, Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Hungary, Italy, Netherlands, New Zealand, Norway, Poland, Portugal, South Africa, Spain, Sweden, Switzerland, United Kingdom; Setting: 99 centres in 21 countries
Line of therapy	Not applicable
Duration of study	Intervention time: 5-9 days
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: DVT (symptomatic and asymptomatic): confirmed by systemic ascending bilateral contrast venography. PE: confirmed by high-probability lung scanning, pulmonary angiography, helical computed tomography. Major bleeding: defined as fatal bleeding, retroperitoneal, intracranial, or intraspinal bleeding, bleeding that involved any other critical organ, bleeding leading to reoperation, and overt bleeding with a bleeding index of 2 or more.
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Patients aged at least 18 years who were undergoing standard surgery for fracture of the upper third of the femur, including femoral head and neck, were considered for inclusion if surgery was planned within 48 hours after admission.
Exclusion criteria	Patients were excluded if they presented with trauma affecting more than 1 organ system or if more than 24 hours had elapsed between the causative trauma and hospital admission. Other main exclusion criteria were active bleeding; documented congenital or acquired bleeding disorder; current ulceration or angiodysplastic gastrointestinal disease; hemorrhagic stroke or brain, spinal, or ophthalmological surgery within the previous 3 months; difficulty in performing epidural or spinal anesthesia; planned indwelling intrathecal or epidural catheter for more than 6 hours after surgery; contraindication to anticoagulant therapy; pregnancy; hypersensitivity to contrast media; or serum creatinine concentration above 2.0 mg/dL (177 µmol/L) in a well-hydrated patient. Patients who required long-term anticoagulant treatment for a chronic comorbid condition or were receiving any type of anticoagulant or fibrinolytic therapy or dextran from admission to first study drug administration or surgery were also excluded.
Recruitment/selection of patients	November 1998 to October 1999
Age, gender and ethnicity	Age - Mean (SD): 77 (12.5) years. Gender (M:F): 1/3. Ethnicity: Not reported
Further population details	1. Immobilisation: Not applicable 2. BMI : Not obese (BMI under 30 kg/m ²) (Mean BMI: 24). 3. Cancer status: Not applicable 4. Renal impairment: Not applicable
Extra comments	Type of fracture: cervical 47%, trochanteric 44%, subtrochanteric 8%; Median duration of surgery 103 minutes; 49% patients used AES

Indirectness of population	No indirectness
Interventions	<p>(n=862) Intervention 1: Low molecular weight heparin (licensed in UK) - Enoxaparin (20mg once daily – 60mg twice daily). Patients were assigned to receive once-daily subcutaneous injections of 40 mg enoxaparin and a placebo. In the enoxaparin group, the first active dose was given 12±2 hours preoperatively and the second 12 to 24 hours postoperatively. Treatment was scheduled to continue until day 5 to day 9. Duration 5-9 days. Concurrent medication/care: Early mobilisation (physiotherapy) recommended. AES permitted. IPCD, dextran, and thrombolytic, anticoagulant, or antiplatelet agents prohibited. Centres were advised to avoid use of aspirin or NSAIDs</p> <p>(n=849) Intervention 2: Fondaparinux - Fondaparinux (all doses). Patients were assigned to receive once-daily subcutaneous injections of 2.5 mg of fondaparinux and a placebo. The first dose of fondaparinux was administered 6±2 hours postoperatively and the second 12 hours or more after the first. Treatment was scheduled to continue until day 5 to day 9. Duration 5-9 days. Concurrent medication/care: Early mobilisation (physiotherapy) recommended. AES permitted. IPCD, dextran, and thrombolytic, anticoagulant, or antiplatelet agents prohibited. Centres were advised to avoid use of aspirin or NSAIDs</p>
Funding	Study funded by industry (Supported by a grant from Sanofi-Synthelabo, Paris, France and NV Organon, Oss, the Netherlands)

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: LMWH (STANDARD DOSE) versus FONDAPARINUX

Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge

- Actual outcome: All-cause mortality at 49 days; Group 1: 42/842, Group 2: 38/831

Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 20, Reason: Inclusion criteria not met, technical problems, withdrawn consent, death; Group 2

Number missing: 18, Reason: Inclusion criteria not met, technical problems, withdrawn consent, death

Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge

- Actual outcome: DVT (symptomatic and asymptomatic) at 11 days; Group 1: 117/623, Group 2: 49/624

Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 239, Reason: Inclusion criteria not met, technical problems, withdrawn consent, death; Group 2

Number missing: 225, Reason: Inclusion criteria not met, technical problems, withdrawn consent, death

Protocol outcome 3: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge

- Actual outcome: PE at 11 days; Group 1: 1/831, Group 2: 1/840
 Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low;
 Indirectness of outcome: No indirectness ; Group 1 Number missing: 22, Reason: Inclusion criteria not met, technical problems, withdrawn consent, death; Group 2
 Number missing: 9, Reason: Inclusion criteria not met, technical problems, withdrawn consent, death

Protocol outcome 4: Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge

- Actual outcome: Major bleeding at 11 days; Group 1: 19/842, Group 2: 18/831
 Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;
 Indirectness of outcome: No indirectness ; Group 1 Number missing: 20, Reason: Inclusion criteria not met, technical problems, withdrawn consent, death; Group 2
 Number missing: 18, Reason: Inclusion criteria not met, technical problems, withdrawn consent, death

Protocol outcome 5: Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy;
 echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge

- Actual outcome: Fatal PE at 11 days; Group 1: 2/840, Group 2: 2/831
 Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low;
 Indirectness of outcome: No indirectness ; Group 1 Number missing: 20, Reason: Inclusion criteria not met, technical problems, withdrawn consent, death; Group 2
 Number missing: 18, Reason: Inclusion criteria not met, technical problems, withdrawn consent, death

Protocol outcome 6: VTE at 7-90 days from hospital discharge

- Actual outcome: VTE at 11 days; Group 1: 119/624, Group 2: 52/626

Protocol outcome 7: DVT (symptomatic) at 7-90 days from hospital discharge

- Actual outcome: DVT (symptomatic) at 11 days; Group 1: 1/840, Group 2: 1/831

Protocol outcome 8: DVT (distal) at 7-90 days from hospital discharge

- Actual outcome: DVT (distal) at 11 days; Group 1: 94/626, Group 2: 42/627

Protocol outcome 9: DVT (proximal) at 7-90 days from hospital discharge

- Actual outcome: DVT (proximal) at 11 days; Group 1: 28/646, Group 2: 6/650

Protocol outcomes not reported by the study	Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of
---	--

	study; Technical complications of mechanical interventions at duration of study; Infection at duration of study;
Study	PEP Trial: Pulmonary embolism prevention (pep) trial collaborative group 2000²⁶⁹
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=13356)
Countries and setting	Conducted in Australia, New Zealand, South Africa, Sweden, United Kingdom; Setting: 152 hospitals across 5 countries
Line of therapy	Not applicable
Duration of study	Intervention time: 35 days
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: PE: confirmed by pulmonary angiogram, a high-probability ventilation-perfusion scan and at necropsy. Fatal PE: confirmed by necropsy
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Patients with a femoral-neck fracture or other fracture of the proximal femur.
Exclusion criteria	Patients with clear indication for aspirin (such as a recent myocardial infarction, or clear contraindication to aspirin (such as an active peptic ulcer)
Recruitment/selection of patients	Between March 1992 and July 1998
Age, gender and ethnicity	Age - Mean (SD): 79 years. Gender (M:F): 1/4. Ethnicity: Not reported
Further population details	1. BMI : Not applicable 2. Cancer status: Not applicable 3. Renal impairment: Not applicable
Indirectness of population	No indirectness
Interventions	(n=6679) Intervention 1: Aspirin - Aspirin (up to 300mg). Aspirin, 160 mg, orally, once daily [plus adjuvant pharmacological and mechanical prophylaxis]. Duration 35 days. Concurrent medication/care: 44% also UFH or LMWH and 30% also using TED stockings (n=6677) Intervention 2: No treatment - Placebo. Placebo, orally, once daily [plus adjuvant pharmacological and mechanical prophylaxis]. Duration 35 days. Concurrent medication/care: 43% also UFH or LMWH and 29% also using TED

	stockings. Serious indirectness (combination outcome, not no prophylaxis).
Funding	Academic or government funding (Study funded by the Health Research Council of New Zealand, the National Heart Foundation of New Zealand, the Wishbone Trust of New Zealand, the Auckland Orthopaedic Society, the National Health and Medical Council of Australia, and the British Heart Foundation)
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: ASPIRIN versus PLACEBO</p> <p>Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge - Actual outcome: All-cause mortality at 35 days; Group 1: 447/6679, Group 2: 461/6677 Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0</p> <p>Protocol outcome 2: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge - Actual outcome: PE at 35 days; Group 1: 28/6679, Group 2: 38/6677 Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0</p> <p>Protocol outcome 3: Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge - Actual outcome: Fatal PE at 35 days; Group 1: 18/6679, Group 2: 43/6677 Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0</p> <p>Protocol outcome 4: Infection at duration of study - Actual outcome: Wound infection with frank pus at 35 days; Group 1: 98/6679, Group 2: 84/6677 Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0</p> <p>Protocol outcome 5: DVT (symptomatic) at 7-90 days from hospital discharge - Actual outcome: DVT (symptomatic) at 35 days; Group 1: 69/6679, Group 2: 97/6677</p>	
Protocol outcomes not reported by the study	Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography;

Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge; Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study;

Study	Svend-hansen 1981 ³⁰⁹
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=130)
Countries and setting	Conducted in Denmark; Setting: Department of Orthopaedic Surgery, Copenhagen County Hospital, Glostrup. Denmark.
Line of therapy	Not applicable
Duration of study	Intervention time: 14 days
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: DVT (symptomatic and asymptomatic): confirmed by I125 fibrinogen uptake test and scans, this was completed daily.
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Patients with proximal femoral fractures
Exclusion criteria	Patients: under 20 years of age, with coagulation disorders, with a previous history of DVT or PE, with an active malignant disease, receiving oral anticoagulants or heparin, receiving salicylates, admitted later than 6 hours after fracture. Pregnant women.
Recruitment/selection of patients	Patients with proximal femoral fractures from 3rd January 1977 until the 18th January 1979
Age, gender and ethnicity	Age - Mean (range): 73 years . Gender (M:F): 1/3. Ethnicity: Not reported
Further population details	1. Immobilisation: Not applicable 2. BMI : Not applicable 3. Cancer status: Not applicable 4. Renal impairment: Not applicable

Indirectness of population	No indirectness
Interventions	<p>(n=65) Intervention 1: Unfractionated heparin - Unfractionated heparin (low dose, administered subcutaneously). Patients received 5000 units of heparin, three times a day for 14 days, i.e. until mobilisation. The first injection was given as soon as the patients were admitted to hospital. Duration 14 days. Concurrent medication/care: N/A</p> <p>(n=65) Intervention 2: No treatment - Placebo. Placebo given three times daily (no further details reported), until mobilisation. Duration 14 days. Concurrent medication/care: N/A</p>
Funding	Funding not stated
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: UNFRACTIONATED HEPARIN (LOW DOSE, ADMINISTERED SUBCUTANEOUSLY) versus PLACEBO</p> <p>Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge - Actual outcome: All-cause mortality at Time-point not reported; Group 1: 15/65, Group 2: 6/65 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0</p> <p>Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge - Actual outcome: DVT (symptomatic and asymptomatic) at 14 days; Group 1: 15/65, Group 2: 28/65 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0</p> <p>Protocol outcome 3: Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge - Actual outcome: Fatal PE at Time-point not reported; Group 1: 1/65, Group 2: 1/65 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - High, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0</p>	
Protocol outcomes not reported by the study	Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge; Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from

	hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study; Infection at duration of study;
--	---

Study	Tang 2017 ³¹¹
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=287)
Countries and setting	Conducted in China; Setting: Orthopaedics Department of the Second Affiliated Hospital of Xi'an Jiaotong University
Line of therapy	Not applicable
Duration of study	Intervention time: 28 days
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: PE: confirmed by CT pulmonary angiogram (CTPA) when PE was suspected and/or confirmed.
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Fractures that were caused by fall-induced damage, the patients who were admitted to the hospital within 24 hours following injury, the patients who were diagnosed by X-ray and/or CT, and all patients who received internal fixation.
Exclusion criteria	Lower extremity DVT that was confirmed preoperative imaging, the patients who had a history of thromboembolic disease and were undergoing anticoagulant therapy, the patients with haemorrhagic diseases and/or major bleeding history (such as intracranial haemorrhage or gastrointestinal bleeding that required blood transfusion), the patients with coagulation disorders and/or contraindications to anticoagulation and the patients who were contraindicated to rivaroxaban and/or LMWH.
Recruitment/selection of patients	Patients with hip fracture that were admitted to the Orthopaedics Department of the Second Affiliated Hospital of Xi'an Jiaotong University from September 2011 to September 2016.
Age, gender and ethnicity	Age - Mean (SD): 70 years. Gender (M:F): 1/1.6. Ethnicity: Not reported
Further population details	1. Below knee: Not applicable 2. BMI : Not obese (BMI under 30 kg/m2) (BMI (mean): 23.5). 3. Cancer status: Not

	applicable 4. Renal impairment: Not applicable
Extra comments	Fracture site: femoral neck fracture 57.8%, intertrochanteric fracture of the femur 42.2%.
Indirectness of population	No indirectness
Interventions	<p>(n=96) Intervention 1: Rivaroxaban - Rivaroxaban (all doses). Rivaroxaban (10mg) was administered orally from 6 hours following operation. Duration 28 days. Concurrent medication/care: All patients underwent rehydration, analgesic actions, anti-infection, and correction of anaemia. Patients were encouraged to perform passive movement training of the affected limbs at day 2 after the surgery. Indirectness: No indirectness</p> <p>(n=95) Intervention 2: Low molecular weight heparin (licensed in UK) - Enoxaparin (20mg once daily – 60mg twice daily). Enoxaparin (40mg/4000IU) was administered once daily from 12 hours following the operation. Duration of LMWH unclear (assumption that it was for 28 days). Concurrent medication/care: All patients underwent rehydration, analgesic actions, anti-infection, and correction of anaemia. Patients were encouraged to perform passive movement training of the affected limbs at day 2 after the surgery. Indirectness: Serious indirectness</p> <p>(n=96) Intervention 3: Low molecular weight heparin (licensed in UK) - Enoxaparin (20mg once daily – 60mg twice daily). Enoxaparin (40mg/4000IU) was administered once daily from 12 hours following the operation for one week. Rivaroxaban (10mg) was administered orally once daily for 28 days . Duration LMWH (1 week), rivaroxaban (28 days) . Concurrent medication/care: All patients underwent rehydration, analgesic actions, anti-infection, and correction of anaemia. Patients were encouraged to perform passive movement training of the affected limbs at day 2 after the surgery. Indirectness: No indirectness</p>
Funding	No funding

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: ENOXAPARIN (EXTENDED DURATION) versus RIVAROXABAN

Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge

- Actual outcome: All-cause mortality at 30 days; Group 1: 1/95, Group 2: 0/96

Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0

Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge

- Actual outcome: DVT (symptomatic and asymptomatic) at 30 days; Group 1: 12/95, Group 2: 5/96

Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low, Comments

- Study did not seem to screen all patients for DVT using confirmation technique of Colour Doppler ultrasound. Doppler ultrasound was recommended for asymptomatic

patients. ; Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0

Protocol outcome 3: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge

- Actual outcome: PE at 30 days; Group 1: 2/95, Group 2: 1/96

Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0

Protocol outcome 4: Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge

- Actual outcome: Fatal PE at 30 days; Group 1: 1/95, Group 2: 0/96

Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0

Protocol outcome 5: VTE at 7-90 days from hospital discharge

- Actual outcome: VTE at 30 days; Group 1: 14/95, Group 2: 5/96

Protocol outcome 6: DVT (distal) at 7-90 days from hospital discharge

- Actual outcome: DVT (distal) at 30 days; Group 1: 4/95, Group 2: 2/96

Protocol outcome 7: DVT (proximal) at 7-90 days from hospital discharge

- Actual outcome: DVT (proximal) at 30 days; Group 1: 6/96, Group 2: 3/96

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: ENOXAPARIN + RIVAROXABAN versus RIVAROXABAN

Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge

- Actual outcome: All-cause mortality at 30 days;

Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0

Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge

- Actual outcome: DVT (symptomatic and asymptomatic) at 30 days; Group 1: 9/96, Group 2: 5/96

Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low, Comments

- Study did not seem to screen all patients for DVT using confirmation technique of Colour Doppler ultrasound. Doppler ultrasound was recommended for asymptomatic patients. ; Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0

Protocol outcome 3: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge

- Actual outcome: PE at 30 days; Group 1: 1/96, Group 2: 1/96

Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0

Protocol outcome 4: Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge

- Actual outcome: Fatal PE at 30 days; Group 1: 1/96, Group 2: 0/96

Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0

Protocol outcome 5: VTE at 7-90 days from hospital discharge

- Actual outcome: VTE at 30 days; Group 1: 10/96, Group 2: 5/96

Protocol outcome 6: DVT (distal) at 7-90 days from hospital discharge

- Actual outcome: DVT (distal) at 30 days; Group 1: 3/96, Group 2: 2/96

Protocol outcome 7: DVT (proximal) at 7-90 days from hospital discharge

- Actual outcome: DVT (proximal) at 30 days; Group 1: 6/96, Group 2: 3/96

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: ENOXAPARIN + RIVAROXABAN versus ENOXAPARIN (EXTENDED DURATION)

Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge

- Actual outcome: All-cause mortality at 30 days;

Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0

Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge

- Actual outcome: DVT (symptomatic and asymptomatic) at 30 days; Group 1: 9/96, Group 2: 12/95

Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low, Comments

- Study did not seem to screen all patients for DVT using confirmation technique of Colour Doppler ultrasound. Doppler ultrasound was recommended for asymptomatic patients. ; Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0

Protocol outcome 3: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge
 - Actual outcome: PE at 30 days; Group 1: 1/96, Group 2: 2/95
 Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;
 Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0

Protocol outcome 4: Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge
 - Actual outcome: Fatal PE at 30 days; Group 1: 1/96, Group 2: 1/95
 Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;
 Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0

Protocol outcome 5: VTE at 7-90 days from hospital discharge
 - Actual outcome: VTE at 30 days; Group 1: 10/96, Group 2: 14/95

Protocol outcome 6: DVT (distal) at 7-90 days from hospital discharge
 - Actual outcome: DVT (distal) at 30 days; Group 1: 3/96, Group 2: 4/95

Protocol outcome 7: DVT (proximal) at 7-90 days from hospital discharge
 - Actual outcome: DVT (proximal) at 30 days; Group 1: 6/96, Group 2: 8/95
 Risk of bias: All domain - ; Indirectness of outcome: No indirectness

Protocol outcomes not reported by the study	Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study; Infection at duration of study; D
---	---

Study	Xabregas 1978³⁴⁴
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=50)

Countries and setting	Conducted in Australia; Setting: Prince of Wales Hospital Accident Centre
Line of therapy	Not applicable
Duration of study	Intervention time: 14 days
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: DVT (symptomatic and asymptomatic): confirmed I125 fibrinogen test
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Patients with a fractured neck of the femur.
Exclusion criteria	Not reported
Recruitment/selection of patients	Between July 1975 and April 1976
Age, gender and ethnicity	Age - Mean (SD): 75.6 years (1.5). Gender (M:F): 1/3. Ethnicity: Not reported
Further population details	1. Immobilisation: Not applicable 2. BMI : Not applicable 3. Cancer status: Not applicable 4. Renal impairment: Not applicable
Indirectness of population	No indirectness
Interventions	<p>(n=25) Intervention 1: Unfractionated heparin - Unfractionated heparin (low dose, administered subcutaneously). Calcium heparin, prophylactic treatment commenced as soon as possible after the patient's admission to hospital, each patient receiving 0.01 ml/kg body weight of the solution in the ampoule subcutaneously every 8 hours. This volume represented 100 IU/kg heparin every eight hours in the treated group, the treatment was continued in each patient for a total period of 2 weeks. Duration 14 days. Concurrent medication/care: N/A</p> <p>(n=25) Intervention 2: No treatment - Placebo. Placebo, saline solution. Duration 14 days. Concurrent medication/care: N/A</p>
Funding	Funding not stated

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: UNFRACTIONATED HEPARIN (LOW DOSE, ADMINISTERED SUBCUTANEOUSLY) versus PLACEBO

Protocol outcome 1: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge

- Actual outcome: DVT (symptomatic and asymptomatic) at Time-point not reported; Group 1: 4/25, Group 2: 0/25

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

<p>Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0</p> <p>Protocol outcome 2: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge - Actual outcome: PE at Time-point not reported; Group 1: 2/25, Group 2: 0/25 Risk of bias: All domain - Very high, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - High, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0</p> <p>Protocol outcome 3: Infection at duration of study - Actual outcome: Wound infection at Time-point not reported; Group 1: 2/25, Group 2: 2/25 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0</p>	
<p>Protocol outcomes not reported by the study</p>	<p>All-cause mortality at up to 90 days from hospital discharge; Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge; Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study;</p>

H.23 Elective hip replacement

Study	EPCAT trial: Anderson 2013 ⁷
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	N/A (n=786)

Study	EPCAT trial: Anderson 2013 ⁷
Countries and setting	Conducted in Canada; Setting: Tertiary care (orthopaedic referral centres)
Line of therapy	Not applicable
Duration of study	Intervention + follow up: Intervention 28 days + Follow-up 90 days
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: Described in two related but separate articles.
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	All patients undergoing elective unilateral THA at the participating institutions (12 university-affiliated hospitals in Canada)
Exclusion criteria	Hip fracture in past 3 months; metastatic cancer; life expectancy < 6 months; bleeding that precluded use of anticoagulant prophylaxis; active peptic ulcer disease / gastritis that precluded aspirin use; aspirin allergy; heparin-induced thrombocytopenia / heparin allergy; creatinine clearance < 30mL/min per 1.73m ² ; platelet count < 100 x 10 ⁹ cells/L; need for long-term anticoagulation due to a pre-existing comorbid condition / VTE developing after surgery but before randomisation; unwillingness/inability to give informed consent
Recruitment/selection of patients	Not stated
Age, gender and ethnicity	Age - Mean (SD): Dalteparin 57.9 (12.2) vs. Aspirin 57.6 (11.9). Gender (M:F): 444:341. Ethnicity: Not reported
Further population details	1. BMI : Not applicable 2. Renal impairment: Not applicable
Indirectness of population	No indirectness: Ethnic composition of the participants is not reported.
Interventions	<p>(n=400) Intervention 1: Low molecular weight heparin (licensed in UK) - Dalteparin (1,250 units once daily - 5,000 units twice daily). Further course of 5000U of subcutaneous dalteparin injections once daily started between 8 and 10 days after surgery (i.e. after the run-in period). Duration 28 days. Concurrent medication/care: Run-in period for all participants: began in the morning after surgery with 5000U of subcutaneous dalteparin injections once daily for 10 days. Concomitant treatment: oral placebo tablets to mimic aspirin, given at the same time as dalteparin.</p> <p>(n=386) Intervention 2: Aspirin - Aspirin (up to 300mg). Oral aspirin tablets 81mg once daily. Duration 28 days. Concurrent medication/care: Run-in period for all participants: began in the morning after surgery with 5000U of subcutaneous dalteparin injections once daily for 10 days. Concomitant treatment: subcutaneous placebo injections to mimic dalteparin, given at the same time as aspirin.</p>
Funding	Academic or government funding (Canadian Institutes of Health Research)

Study	EPCAT trial: Anderson 2013 ⁷
RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: DALTEPARIN versus ASPIRIN	
<p>Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge - Actual outcome: Death at 90 days; Group 1: 1/400, Group 2: 0/385 Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low, Other 1 - Low, Comments - During the study, a novel oral anticoagulant, rivaroxaban, was approved in Canada and this had a major effect on the recruitment of the participants so the committee deemed that the study completion was no longer feasible, and after an interim analysis the committee decided to terminate recruitment after 786 patients had been randomly assigned.; Indirectness of outcome: No indirectness ; Baseline details: Ethnicity is not reported.; Group 1 Number missing: 0; Group 2 Number missing: 1, Reason: One participant failed to sign the consent form after randomisation.</p>	
<p>Protocol outcome 2: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge - Actual outcome: PE at 90 days; Group 1: 3/398, Group 2: 0/380 Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low, Other 1 - Low, Comments - Refer to outcome "Death" for early termination of the trial.; Indirectness of outcome: No indirectness ; Baseline details: Ethnicity is not reported.; Group 1 Number missing: 2, Reason: Two participants withdrew consent.; Group 2 Number missing: 6, Reason: One participant failed to sign the consent form after randomisation. Five participants withdrew consent.</p>	
<p>Protocol outcome 3: Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge - Actual outcome: Major bleeding at 90 days; Group 1: 1/400, Group 2: 0/385; Comments: Difference (95% CI) = 0.25 (-4.9 to 1.0); p=1.00 Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low, Other 1 - Low, Comments - Refer to outcome "Death" for early termination of the trial.; Indirectness of outcome: No indirectness ; Baseline details: Ethnicity is not reported.; Group 1 Number missing: 0; Group 2 Number missing: 1, Reason: One participant failed to sign the consent form after randomisation.</p>	
<p>Protocol outcome 4: Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge - Actual outcome: Fatal PE at 90 days; Group 1: 0/400, Group 2: 0/385 Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low, Other 1 - Low, Comments - Refer to outcome "Death" for early termination of the trial.; Indirectness of outcome: No indirectness ; Baseline details: Ethnicity is not reported.; Group 1 Number missing: 0; Group 2 Number missing: 1, Reason: One participant failed to sign the consent form after randomisation.</p>	
<p>Protocol outcome 5: Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge</p>	

Study	EPCAT trial: Anderson 2013 ⁷
<p>- Actual outcome: Clinically significant non-major bleeding at 90 days; Group 1: 4/400, Group 2: 2/385; Comments: Difference (95% CI) = 0.48 (-1.0) to 2.0); p=0.68 Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low, Other 1 - Low, Comments - Refer to outcome "Death" for early termination of the trial.; Indirectness of outcome: No indirectness ; Baseline details: Ethnicity is not reported.; Group 1 Number missing: 0; Group 2 Number missing: 1, Reason: One participant failed to sign the consent form after randomisation.</p> <p>Protocol outcome 6: Infection at duration of study - Actual outcome: Wound infection at 90 days; Group 1: 10/400, Group 2: 12/385; Comments: p=0.67 Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low, Other 1 - Low, Comments - Refer to outcome "Death" for early termination of the trial.; Indirectness of outcome: No indirectness ; Baseline details: Ethnicity is not reported.; Group 1 Number missing: 0; Group 2 Number missing: 1, Reason: One participant failed to sign the consent form after randomisation.</p> <p>Protocol outcome 7: DVT (proximal) at 7-90 days from hospital discharge - Actual outcome: Symptomatic proximal DVT in the leg at 90 days; Group 1: 2/398, Group 2: 1/380</p> <p>Protocol outcome 8: Site of bleeding (gastrointestinal ; surgical site; brain/spine; other) at 45 days from hospital discharge - Actual outcome: Surgical site of bleeding at 90 days; Group 1: 5/400, Group 2: 4/386</p>	
Protocol outcomes not reported by the study	Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge; Surgical site haematoma at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study;

Bibliographic reference	Study Type	Evidence level	No. of patients	Patients characteristics	Intervention	Comparison	Length of follow up	Outcome measures	Effect size	Comments
Avikainen 1995 ⁹	RCT	1+	Total: 167 Intervention : n = 83 (DVT assessed in	Type of surgery: Hip replacement (& Duration of surgery)	Type: LMWH (Enoxaparin) Dose: 40mg/0.4 ml	Type: UFH Dose: 5000 IU	Both groups: Until discharge (10th	DVT Confirmed by: US on 10-14th post-op day.	US results for 158 patients Int: 1/79 Control: 4/79 p value: >0.05	Also reported: perioperative and postoperative blood loss,

Bibliographic reference	Study Type	Evidence level	No. of patients	Patients characteristics	Intervention	Comparison	Length of follow up	Outcome measures	Effect size	Comments
			79) Control: n = 84 (DVT assessed in 79)	Intervention: Mean age: 65 (range 27-86) years M/F:30/53	Timing: Begun 12hrs pre-op and repeated daily for 10 days	Timing: Begun 2hrs pre-op and repeated twice daily for 10 days	post- op -).	PVT Confirmed by: US on 10-14th post-op day.	Int: 1/79 Control: 4/79 p value: >0.05	transfusion requirements
				Control: Mean age: 66 (range 34-86) M/F:25/59	Additional non-comparative prophylaxis: Not reported			PE Confirmed by: Not routinely assessed. Symptomatic confirmed by V/Q scan	All patients: Int: 0/84 Control: 1/83 p value: 0.4970	Not reported: PTS, QoL, survival, LoS, funding
				Pre-existing risk factors: varicose veins						

Bibliographic reference	Study Type	Evidence level	No. of patients	Patients characteristics	Intervention	Comparison	Length of follow up	Outcome measures	Effect size	Comments
Bailey 1991 ¹³	RCT	1+	Total 95 Int: 50 Cont: 45	Type of surgery: total hip replacement Mean operating time Int: 184.5 min Cont: 208.5 min Intervention: Mean age: 65.3 (range:	sequential pneumatic compression device covering legs and thighs Timing: Applied after surgery in the recovery ward and worn continuously for	low dose warfarin Dose: 10mg before surgery (7.5mg for women over 70 and patients with minor abnormalities	Control: 5 to 7 days (also day diagnostic test done for DVT) Int: 5 to 7 days	DVT Confirmed by: venography (see comments) Clinically relevant non-major bleeding (defined in the paper as "clinically	Int: 3/50 Control: 12/45 p value: <0.006 (significant) Int: 0/50 Control: 0/45 p value: N/A	Weight was significantly greater in the warfarin group to the sequential compression group. There was no significant difference in

				<p>41-88) yrs M/F:24/26</p> <p>Control: Mean age: 64.4 (range: 45-50) M/F:22/23</p>	<p>the remainder of the study (except during bathing and physical therapy).</p> <p>Additional non-comparative prophylaxis: AES applied on admission and continued until after discharge.</p>	<p>of liver function tests).</p> <p>Timing: Evening before surgery and doses given after surgery adjusted to maintain a prothrombin time at 14-16 seconds. Prothrombin times routinely obtained by postoperative day 2 or 3.</p> <p>Additional non-comparative prophylaxis: AES applied before and after surgery</p>	<p>(also day diagnostic test done for DVT)</p>	<p>important bleeding")</p>		<p>weight between groups for those who developed DVT. Diagnosis of DVT for those where there was a lack of venous access: B- mode Doppler US and technecium-pyrophosphate red-cell labelled nuclear venogram with impedance plethysmography.</p> <p>Funding: Kendall Inc supplied the stockings (not under investigation). Unclear whether they provided any other support/materials</p>
--	--	--	--	---	--	--	--	-----------------------------	--	--

Bibliographic reference	Study Type	Evidence level	No. of patients	Patients characteristics	Intervention	Comparison	Length of follow up	Outcome measures	Effect size	Comments
Bergqvist 1996 ²²	RCT	1+	Total: 262 Intervention n: 131 Control n: 131	Type of surgery: Patients scheduled for Total hip replacement surgery. Surgery was performed expeditiously with a mean duration of 1.9 hours (range 1.0 to 5.0). Intervention: Mean age: 70 (range: 44 - 87 years) M/F:56/75 Control: Mean age: 70 (Range: 44 – 87 years) M/F:57/74 Pre-existing risk factors: Previous VTE: Int:	Type, dose and timing: 40 mg of Enoxaparin injected subcutaneously into abdomen once daily. The first active dose was given 12±2 hrs preoperatively until day 21 Additional non-comparative prophylaxis: Not reported	Type, dose and timing: Placebo or Single dose of 0.4 ml saline.	3 months	DVT confirmed by bilateral ascending phlebography PE Confirmed by ventilation – perfusion lung scan or a pulmonary angiography.	Int: 21/117 Control: 43/116 p value: 0.0012 Int: 0/117 Control: 2/116 p value: 0.2468	

Bibliographic reference	Study Type	Evidence level	No. of patients	Patients characteristics	Intervention	Comparison	Length of follow up	Outcome measures	Effect size	Comments
				n = 8 Control: n = 12 Varicose veins: Int: n = 27 Control: n = 31 Leg ulcer: Int: n = 2 Control: n = 3						

Study	Bern 2015 ²⁸
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=118)
Countries and setting	Conducted in USA; Setting: New England Baptist Hospital, Boston, USA
Line of therapy	Not applicable
Duration of study	Intervention time: 26-30 days
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: DVT (symptomatic and asymptomatic): confirmed by bilateral duplex sonography PE: confirmed by ventilation/perfusion lung scan or computerised axial tomography angiogram
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Patients were recruited from among over 20 years of age planning elective primary unilateral total hip or knee replacement surgery at an orthopaedic surgery.

Study	Bern 2015 ²⁸
Exclusion criteria	Abnormal platelet count, prothrombin time or partial thromboplastin time; surgery for acute fracture (<4 weeks), septic joint, or extraction arthroplasty; history of VTE or documented hypercoagulation syndrome; increased risk of haemorrhage, as from active gastric ulcer or urinary tract bleed within the last year; haemorrhagic stroke, brain, spinal, or ophthalmologic surgery in previous 6 months; liver enzymes or bilirubin greater than 2 x normal; decreased renal function with GFR <30 ml/min; cancer in last year, other than localised cancers of the skin; requires chronic anticoagulation; requires chronic platelet function suppressive therapy; prior adverse reaction to any of the study drugs; uncontrolled hypertension; BMI >42, pregnancy
Recruitment/selection of patients	Based on inclusion criteria
Age, gender and ethnicity	Age - Mean (SD): 63 (8.2) years. Gender (M:F): 1/1. Ethnicity: Not reported
Further population details	1. BMI : Not applicable 2. Renal impairment: Not applicable
Indirectness of population	No indirectness
Interventions	<p>(n=64) Intervention 1: Fondaparinux - Fondaparinux (all doses). 2.5mg daily starting 6 or more hours following surgery, but no later than 6am the next day, or 6-8 hours after epidural catheter removal. All patients wore pneumatic compression stockings while in-patient. AES were prescribed to be used after discharge until the follow-up ultrasounds. Duration 28±2 days. Concurrent medication/care: Use of platelet function suppressive drugs, such a non-steroidal anti-inflammatory drugs (NSAIDs), was discouraged but not prohibited by the protocol.</p> <p>(n=54) Intervention 2: Vitamin K antagonists - Warfarin (all doses). 5.0mg beginning the night before surgery, followed by 5.0mg the PM of surgery, and then variable daily dose (target INR 2.0-2.5). All patients wore pneumatic compression stockings while in-patient. AES were prescribed to be used after discharge until the follow-up ultrasounds. Duration 28±2 days. Concurrent medication/care: Use of platelet function suppressive drugs, such a non-steroidal anti-inflammatory drugs (NSAIDs), was discouraged but not prohibited by the protocol.</p>
Funding	Funding not stated
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: FONDAPARINUX + IPCD + AES versus WARFARIN + IPCD + AES</p> <p>Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge - Actual outcome: All-cause mortality at 28±2 days; Group 1: 0/64, Group 2: 0/54 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0</p>	

Study	Bern 2015 ²⁸
	<p>Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge - Actual outcome: DVT (symptomatic and asymptomatic) at 28±2 days; Group 1: 0/64, Group 2: 0/54 Risk of bias: All domain - Very high, Selection - High, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0</p> <p>Protocol outcome 3: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge - Actual outcome: PE at 28±2 days; Group 1: 0/64, Group 2: 0/54 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0</p> <p>Protocol outcome 4: DVT (distal) at 7-90 days from hospital discharge - Actual outcome: DVT (distal) at 28±2 days; Group 1: 0/64, Group 2: 0/54</p> <p>Protocol outcome 5: DVT (proximal) at 7-90 days from hospital discharge - Actual outcome: DVT (proximal) at 28±2 days; Group 1: 0/64, Group 2: 0/54</p>
Protocol outcomes not reported by the study	Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of ≥2g/dl; a serious or life threatening clinical event at up to 45 days from hospital discharge; Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Surgical site haematoma at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study; Infection at duration of study;
Study	Cohen 2007 ⁶²
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=856)

Study	Cohen 2007 ⁶²
Countries and setting	Conducted in Brazil, Hong Kong (China), Spain, United Kingdom; Setting: Brazil, UK, Hong Kong and Spain
Line of therapy	Not applicable
Duration of study	Intervention time: Fondaparinux 5-9 days; AES 35-49 days
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: Venous thromboembolism was defined by at least one of the following: objectively verified, symptomatic thromboembolism (proximal or distal DVT or fatal or non-fatal pulmonary embolism), or asymptomatic proximal DVT demonstrated by bilateral proximal ultrasound or venography.
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Minimum age 18 years, primary or revision total hip replacement, surgery for fracture of the proximal third of the femur.
Exclusion criteria	Bilateral joint surgery, multiple trauma, delay > 24 hours between trauma and admission, conditions precluding use of AES, leg oedema, peripheral vascular disease, peripheral neuropathy, marked leg deformity, conditions that increase the risk of bleeding, pregnant/lactating women or those of child bearing age taking inadequate contraceptive precautions.
Recruitment/selection of patients	Between January 2002 and November 2004, patients were recruited from Brazil, UK, Hong Kong and Spain.
Age, gender and ethnicity	Age - Mean (range): 65 years (18-99). Gender (M:F): 1/1.32. Ethnicity: Not reported
Further population details	1. BMI : Not obese (BMI under 30 kg/m ²) (Mean BMI 28 (range: 15-50.1)). 2. Renal impairment: Not applicable
Extra comments	History of VTE: 12%. 96% of patients had elective total hip replacement, 5% standard fracture surgery. This study was previously included in the hip fracture evidence review in the guideline (CG92).
Indirectness of population	No indirectness
Interventions	<p>(n=426) Intervention 1: Fondaparinux - Fondaparinux (all doses). Fondaparinux (2.5 mg daily) for five to nine days. The first dose of fondaparinux was given six hours after closure of the surgical wound and the second dose 18 to 24 hours later. Subsequent doses were administered daily at a median interval of 22 to 26 hours for between five and nine days. Duration 5-9 days. Concurrent medication/care: N/A</p> <p>(n=430) Intervention 2: Fondaparinux - Fondaparinux (all doses). Fondaparinux (2.5 mg daily) for five to nine days plus AES for 35 to 49 days. The first dose of fondaparinux was given six hours after closure of the surgical wound and the second dose 18 to 24 hours later. Subsequent doses were administered daily at a median interval of 22 to 26 hours for between five and nine days. Long-leg stockings were used unless the thigh circumference necessitated the use of short-leg stockings. The stockings were applied pre-operatively and worn until the last follow-up visit (35-49 days). Duration total of 35-49 days. Concurrent medication/care: N/A</p>

Study	Cohen 2007 ⁶²
Funding	Funding not stated
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: FONDAPARINUX + AES versus FONDAPARINUX</p> <p>Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge - Actual outcome: All-cause mortality at 35-49 days; Group 1: 1/391, Group 2: 3/404 Risk of bias: All domain - Very high, Selection - High, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 39, Reason: withdrew consent, did not meet all the early criteria, postponed surgery for six months or cancelled surgery, had symptomatic venous thromboembolism, the investigator decided not to randomise them, or there was a pharmacy error.; Group 2 Number missing: 22, Reason: withdrew consent, did not meet all the early criteria, postponed surgery for six months or cancelled surgery, had symptomatic venous thromboembolism, the investigator decided not to randomise them, or there was a pharmacy error.</p> <p>Protocol outcome 2: Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge - Actual outcome: Major bleeding at 35-49 days; Group 1: 0/391, Group 2: 1/404 Risk of bias: All domain - Very high, Selection - High, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 39, Reason: withdrew consent, did not meet all the early criteria, postponed surgery for six months or cancelled surgery, had symptomatic venous thromboembolism, the investigator decided not to randomise them, or there was a pharmacy error.; Group 2 Number missing: 22, Reason: withdrew consent, did not meet all the early criteria, postponed surgery for six months or cancelled surgery, had symptomatic venous thromboembolism, the investigator decided not to randomise them, or there was a pharmacy error.</p> <p>Protocol outcome 3: Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQspect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge - Actual outcome: Fatal PE at 35-49 days; Group 1: 0/391, Group 2: 0/404 Risk of bias: All domain - Very high, Selection - High, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 39, Reason: withdrew consent, did not meet all the early criteria, postponed surgery for six months or cancelled surgery, had symptomatic venous thromboembolism, the investigator decided not to randomise them, or there was a pharmacy error.; Group 2 Number missing: 22, Reason: withdrew consent, did not meet all the early criteria, postponed surgery for six months or cancelled surgery, had symptomatic venous thromboembolism, the investigator decided not to randomise them, or there was a pharmacy error.</p> <p>Protocol outcome 4: Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge</p>	

Study	Cohen 2007⁶²
<p>- Actual outcome: Clinically relevant non-major bleeding at 35-49 days; Group 1: 16/391, Group 2: 20/404 Risk of bias: All domain - Very high, Selection - High, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 39, Reason: withdrew consent, did not meet all the early criteria, postponed surgery for six months or cancelled surgery, had symptomatic venous thromboembolism, the investigator decided not to randomise them, or there was a pharmacy error.; Group 2 Number missing: 22, Reason: withdrew consent, did not meet all the early criteria, postponed surgery for six months or cancelled surgery, had symptomatic venous thromboembolism, the investigator decided not to randomise them, or there was a pharmacy error.</p>	
Protocol outcomes not reported by the study	Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge; Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge; Surgical site haematoma at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study; Infection at duration of study;

Bibliographic reference	Study Type	Evidence level	No. of patients	Patients characteristics	Intervention	Comparison	Length of follow up	Outcome measures	Effect size	Comments
Colwell 1994 ⁶⁸	Multicent re RCT	1+	Total: 610 Multicentre study involving 32 institutions Int A: 195	Type of surgery: Hip replacement surgery, including primary and revision procedures, in patients 40 years or older	Int A: Enoxaparin 30mg every 12 hours	Int B: Enoxaparin 40mg once daily Int C: 5000 units UFH every 8 hours	Study period: 7 days	DVT Confirmed by: bilateral contrast venography Proximal DVT Confirmed by: bilateral contrast venography	Int A: 8 (n = 136) Int B: 28 (n = 136) Int C: 21 (n = 142) p value not reported Int A: 4 (n = 136) Int B: 8 (n = 136) Int C: 10 (n = 142)	Comments: Only 67.9% of patients evaluated for DVT. Multicentre study, not all centres used a valid diagnostic technique (same numbers in each group).

Bibliographic reference	Study Type	Evidence level	No. of patients	Patients characteristics	Intervention	Comparison	Length of follow up	Outcome measures	Effect size	Comments
			In B: 203 Int C: 209	Intervention A: Mean age: 65.6±10.97 yrs M/F:98/97	Timing: Administered within 24 hours after surgery and continued for a maximum of 7 days.	Timing: Administered within 24 hours after surgery and continued for a maximum of 7 days.		Distal DVT Confirmed by: bilateral contrast venography	Int A: 4 (n = 136) Int B: 20 (n = 136) Int C: 11 (n = 142) p value not reported	An intention to treat analysis was followed. Results are available for patients diagnosed by valid test alone as well as all patients.
			Intervention B: Mean age: 65.0±11.31 yrs M/F:99/104	PEs (symptomatic) (not reported how confirmed)				Int A: 0 (n = 195) Int B: 1 (n = 203) Int C: 4 (n = 209) p value: not reported		
			Intervention C: Mean age: 65.6±10.65 yrs M/F:101/108	Additional non-comparative prophylaxis: No. patients receiving epidural/spinal anaesthesia: Int A: 64/195	Additional non-comparative prophylaxis: No. patients receiving epidural/spinal anaesthesia: Int B: 72/203 Int C: 72/209	Major bleeding episodes		Int A: 8 (n = 195) Int B: 3 (n = 203) Int C: 13 (n = 209) p value: not reported	Other outcomes reported: Total proximal and distal DVTs (i.e. confirmed by venography, supportive non-invasive vascular examinations or other clinical evidence of treatment failure.)	
			Pre-existing risk factors: Excluded patients include: a history of DVT, PE or both and heparin associated thrombocytopenia			Moderate thrombocytopenia episodes (20x10 ⁹ /L to 100x10 ⁹ /L. In no case was the count <50x10 ⁹ /L).		Int A: 7 (n = 195) Int B: 3 (n = 203) Int C: 5 (n = 209) p value: not reported		

Bibliographic reference	Study Type	Evidence level	No. of patients	Patients characteristics	Intervention	Comparison	Length of follow up	Outcome measures	Effect size	Comments
				nia.				Mortality during study not due to sudden death by PE	Int A: 1 (n = 136) Int B: 0 (n = 136) Int C: 2 (n = 142) p value not reported	haemoglobin levels, minor bleeding
								Adverse events (no. of patients, none completed the study)	Int A: 7 (n = 136) Int B: 5 (n = 136) Int C: 12 (n = 142) p value not reported	Not reported: PEs in hospital PTS, QoL,
								No. of patients rehospitalised (due to symptomatic DVT or PE).	Int A: 3 (n = 136) Int B: 1 (n = 136) Int C: 4 (n = 142) p value not reported	Funding: Rhone Poulenc Pharmaceuticals

Bibliographic reference	Study Type	Evidence level	No. of patients	Patients characteristics	Intervention	Comparison	Length of follow up	Outcome measures	Effect size	Comments
Colwell 1999 ⁶⁶	RCT	1+	Total: 3011 Intervention: n =	Type of surgery: Elective total hip arthroplasty Intervention:	Type: Coumadin (adjusted dose warfarin) Dose:	Type: Enoxaparin (LMWH) Dose:	Both groups: 14 days treatment,	Symptomatic DVT Confirmed by US or venography	Int: 44/1495 Control: 40/1506 p value: 0.6592	Comments: Results not stratified by BMI. No of VTEs by

Bibliographic reference	Study Type	Evidence level	No. of patients	Patients characteristics	Intervention	Comparison	Length of follow up	Outcome measures	Effect size	Comments
			1495 Control: n = 1516	Mean age: 64.1±13.21 (range: 19-99) M/F:659/836 Control: Mean age: 63.9±13.7 yrs (range: 18-100) M/F: 678/838 Pre-existing risk factors: Significantly more obese patients in enoxoparin arm Int: 378/1376 had BMI >30kg/m2 (27.5%) (BMI reported for 92% of this group) Control: 459/1420	Started at 7.5mg, adjusted to maintain INR ratio between 2.0 to 3.0 Timing: Started between 48 hours preoperatively (at the discretion of the investigator) and 24 hours postoperatively. Administered until discharge. Additional non-comparative prophylaxis: Stockings permitted but not reported how	30mg Timing: Every 12 hours, started within 24 hours post-operatively once haemostasis (cessation of active bleeding as determined by the investigator) had been established Administered until discharge. Additional non-comparative prophylaxis:	3 month follow up	Symptomatic DVT that occurred in hospital Symptomatic DVT that occurred after discharge PE Confirmed by ventilation perfusion scan or pulmonary angiography PE that occurred in hospital PE that occurred after discharge Both DVT & PE Confirmed by one of the above methods	Int: 15/1495 Control: 2/1506 p value: 0.0012 Int: 29/1495 Control: 38/1506 p value: 0.3232 Int: 9/1495 Control: 6/1506 p value: 0.4518 Int: 2/1495 Control: 1/1506 p value: 0.6235 Int: 7/1495 Control: 5/1506 p value: 0.5789 Int: 3/1495 Control: 9/1506 p value: 0.1452	BMI: BMI >30 = 48/111 (43.2%) BMI <30 = 63/111 (56.8%) No of VTEs out of total no. of BMI group BMI >30 = 48/837 (5.73%) BMI <30 = 63/1959 (3.22%) Also reported: Minor bleeding Not reported: PTS, LoS, QoL, fatal PE Funding: No direct funding for this study.

Bibliographic reference	Study Type	Evidence level	No. of patients	Patients characteristics	Intervention	Comparison	Length of follow up	Outcome measures	Effect size	Comments
				had >30kg/m ² (32.3%) (BMI reported for 93.7% of this group) p = 0.0055	many patients received these	Stockings permitted but not reported how many patients received these		Both DVT & PE that occurred in hospital	Int: 0/1495 Control: 1/1506 p value: 1.0000	Indirect funding (i.e. authors' institution funding) Rhone Poulenc Rorer Pharmaceuticals
							Both DVT & PE that occurred after discharge	Int: 3/1495 Control: 8/1506 p value: 0.2257		
							Major bleeds	Int: 4/1495 Control:6/1516 p value: 0.2658		
							Adverse events (most commonly reported were fever, anaemia, nausea)	Int: 934/1495 Control: 987/1506 p value: 0.0870		
							Serious adverse events	Int: 134/1495 Control: 167/1506 p value: 0.0128		
							Survival (specify)	Int: 1485/1495 Control: 1497/1506 p value: 0.8226		

Study	Comp 2001 ⁷¹
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=435)
Countries and setting	Conducted in USA; Setting: Multicentre trial
Line of therapy	Not applicable
Duration of study	Intervention + follow up: 29 days
Method of assessment of guideline condition	Adequate method of assessment/diagnosis
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Patients undergoing elective hip replacement who gave written consent
Exclusion criteria	Patients undergoing multiple joint replacement or in whom haemostasis was not achieved within 12-24 hours after surgery. Patients treated with hip replacement who had undergone surgery on the ipsilateral hip in the preceding 6 months, the ipsilateral knee or contralateral knee within the previous three months. Clinical evidence of chronic or acute DVT; a history of venous thromboembolic disease within 12 months before the surgery; generalised haemorrhagic diathesis or hypercoagulable syndrome; a documented allergy to UFH or a history of heparin associated thrombocytopenia; a skin rash or necrosis; allergy to fish or swine products, iodine, or radiopaque contrast medium; current drug or alcohol abuse; surgery on the eye, spinal cord or central nervous system; documented stroke or myocardial infarction within one month before entry into the study; active ulcerative disease or angiodysplasia of the gastrointestinal tract; active gastrointestinal bleeding within the last 6 months; uncontrolled hypertensin; use of aspirin-containing products or NSAID agents daily within the four days preceding hospitalisation; receipt of another investigational drug within the preceding 4 weeks; and clinically relevant diseases or treatments that could interfere with the study medications or their evaluation.
Recruitment/selection of patients	Not reported
Age, gender and ethnicity	Age - Mean (SD): LMWH extd 64.4 (28-90); LMWH std 63.4 (26-88). Gender (M:F): 1:1. Ethnicity: Not reported
Further population details	1. BMI : Not obese (BMI under 30 kg/m ²) (Mean BMI: LMWH ext 28.4 (16.1-53.7); LMWH std 28.5 (16.6-45)). 2. Renal impairment: Not applicable
Indirectness of population	No indirectness
Interventions	(n=224) Intervention 1: Low molecular weight heparin (licensed in UK) - Enoxaparin (20mg once daily – 60mg twice daily). Enoxaparin, high dose, extended duration (30mg twice daily). Enoxaparin treatment was initiated 12-24 hours postoperatively and continued for 7-10 days. Patients were then administered 40mg once daily subcutaneously for 3 weeks. Duration 28-31 days. Concurrent medication/care: Not reported

Study	Comp 2001 ⁷¹
	(n=211) Intervention 2: Low molecular weight heparin (licensed in UK) - Enoxaparin (20mg once daily – 60mg twice daily). Enoxaparin, high dose, extended duration (30mg twice daily). Enoxaparin treatment was initiated 12-24 hours postoperatively and continued for 7-10 days. Patients were then administered saline solution once daily subcutaneously for 3 weeks. Duration 28-31 days. Concurrent medication/care: Not reported
Funding	Study funded by industry (Funds were received in total or partial support of the research from Aventis Pharmaceuticals Incorporated, Bridgewater, New Jersey and Aventis Pharma SA Antony, France)
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: ENOXAPARIN (20MG ONCE DAILY – 60MG TWICE DAILY) EXTENDED versus ENOXAPARIN (20MG ONCE DAILY – 60MG TWICE DAILY) STANDARD</p> <p>Protocol outcome 1: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge - Actual outcome: DVT (symptomatic and asymptomatic) at 29 days; Group 1: 15/152, Group 2: 39/138 Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 72; Group 2 Number missing: 73</p> <p>Protocol outcome 2: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge - Actual outcome: PE at 29 days; Group 1: 0/224, Group 2: 1/211 Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0</p> <p>Protocol outcome 3: Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge - Actual outcome: Major bleeding at 29 days; Group 1: 0/224, Group 2: 0/211 Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0</p> <p>Protocol outcome 4: Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge - Actual outcome: CRNMB at 29 days; Group 1: 2/224, Group 2: 5/211</p>	

Study	Comp 2001 ⁷¹
	<p>Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0</p> <p>Protocol outcome 5: Heparin-induced thrombocytopenia at duration of study - Actual outcome: Thrombocytopenia at 29 days; Group 1: 3/224, Group 2: 2/211 Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0</p> <p>Protocol outcome 6: DVT (distal) at 7-90 days from hospital discharge - Actual outcome: DVT (distal) at 29 days; Group 1: 10/152, Group 2: 19/138</p> <p>Protocol outcome 7: DVT (proximal) at 7-90 days from hospital discharge - Actual outcome: DVT (proximal) at 29 days; Group 1: 5/152, Group 2: 20/138</p>
Protocol outcomes not reported by the study	All-cause mortality at up to 90 days from hospital discharge; Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQScout; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Surgical site haematoma at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Technical complications of mechanical interventions at duration of study; Infection at duration of study;

Study	Dahl 1997 ⁷⁵
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=227)
Countries and setting	Conducted in Norway; Setting: Hospital
Line of therapy	Not applicable
Duration of study	Intervention + follow up: 35 days
Method of assessment of guideline condition	Adequate method of assessment/diagnosis
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Male and female patients (over 18 years of age), who were admitted to hospital for elective primary or secondary

Study	Dahl 1997 ⁷⁵
	arthroplasty of the hip (arthrosis, femoral neck fracture sequela) and from whom written consent was obtained
Exclusion criteria	Patients with known renal or liver insufficiency, cerebral bleeding less than 3 months before surgery, or known haemorrhagic diathesis, eye or ear surgery within 1 month before surgery, severe hypertension, septic endocarditis, threatened arterial circulation in the leg, a body weight less than 40kg, anticoagulant therapy less than 1 week before surgery, a known hypersensitivity to heparin, LMWH, dextran or contrast media, pregnancy or breast feeding, inability to comply with the study protocol, and previous surgery in this study
Recruitment/selection of patients	Not reported
Age, gender and ethnicity	Age - Mean (SD): LMWH group: 70.9; placebo group: 71.4. Gender (M:F): 1:2.4. Ethnicity: Not reported
Further population details	1. BMI : Not applicable 2. Renal impairment: Not applicable
Indirectness of population	No indirectness
Interventions	<p>(n=117) Intervention 1: Low molecular weight heparin (licensed in UK) - Dalteparin (1,250 units once daily - 5,000 units twice daily). Dalteparin, 5000IU once daily (standard dose), subcutaneously given from the evening before the operation until 4 weeks after. Below-knee AES was also used, on both legs before the operation and for the first post-operative week. Duration 4 weeks. Concurrent medication/care: n/a</p> <p>(n=110) Intervention 2: Low molecular weight heparin (licensed in UK) - Dalteparin (1,250 units once daily - 5,000 units twice daily). Dalteparin, 5000IU once daily (standard dose), subcutaneously administered from the evening before the operation until 7 days after then administered placebo (sodium chloride) in the evenings. Below-knee AES was also used, on both legs before the operation and for the first post-operative week. Duration 7 days. Concurrent medication/care: n/a</p>
Funding	Funding not stated

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: DALTEPARIN (EXTENDED DURATION) + AES versus DALTEPARIN (STANDARD DURATION) + AES

Protocol outcome 1: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge

- Actual outcome: DVT (symptomatic and asymptomatic) at 35 days; Group 1: 22/114, Group 2: 33/104

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 3; Group 2 Number missing: 6

Protocol outcome 2: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect;

Study	Dahl 1997 ⁷⁵
	<p>autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge</p> <p>- Actual outcome: PE at 35 days; Group 1: 0/111, Group 2: 3/106</p> <p>Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 3; Group 2 Number missing: 6</p>
Protocol outcomes not reported by the study	<p>All-cause mortality at up to 90 days from hospital discharge; Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge; Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Surgical site haematoma at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study; Infection at duration of study;</p>

Study	Eriksson 1991 ⁹²
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=LMWH: 67; Unfractionated heparin: 69)
Countries and setting	Conducted in Sweden; Setting: Not reported
Line of therapy	Not applicable
Duration of study	Intervention + follow up: 10-14 days
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: DVT confirmed by bilateral ascending phlebography. PE confirmed by pulmonary perfusion scintigraphy.
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	People who were 40 years or older and had been admitted consecutively for elective total hip replacement.
Exclusion criteria	People with a history of bleeding disorders, liver or renal disease, cerebral hemorrhage within 6 months before the time of the study, ongoing anticoagulant therapy, hypersensitivity to heparin or iodine, or previous inclusion in the

Study	Eriksson 1991 ⁹²
	study.
Recruitment/selection of patients	People admitted for total hip replacement between November 1987 and May 1989 were allocated randomly to either treatment group.
Age, gender and ethnicity	Age - Mean (SD): LMWH: 68.4 (8.2); Unfractionated heparin: 69.0 (8.0). Gender (M:F): LMWH: 26/40; Unfractionated heparin: 30/39. Ethnicity: Not reported
Further population details	1. BMI : Not applicable 2. Renal impairment: Not applicable
Indirectness of population	No indirectness
Interventions	(n=67) Intervention 1: Low molecular weight heparin (licensed in UK) - Dalteparin (1,250 units once daily - 5,000 units twice daily). 5000 IU once daily (standard dose) subcutaneously from the evening before the operation until 10 days post-operation. Placebo was also given twice daily. Duration 10-14 days. Concurrent medication/care: Mobilisation and physiotherapy started on the first day after the operation (n=69) Intervention 2: Unfractionated heparin - Unfractionated heparin (low dose, administered subcutaneously). 5000 IU three times daily, subcutaneously from two hours pre-operation for 10 days. Placebo was only given on the pre-operative evening. Duration 10-14 days. Concurrent medication/care: Mobilisation and physiotherapy started on the first day after the operation
Funding	Academic or government funding (Grants from the Swedish Medical Research Council, Project 00660; the Medical Society of Gothenburg; and Gothenburg University.)

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: DALTEPARIN (1,250 UNITS ONCE DAILY - 5,000 UNITS TWICE DAILY) versus UNFRACTIONATED HEPARIN (LOW DOSE, ADMINISTERED SUBCUTANEOUSLY)

Protocol outcome 1: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge

- Actual outcome: DVT at 12-14 days; Group 1: 19/63, Group 2: 25/59

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 4; Group 2 Number missing: 10

Protocol outcome 2: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge

- Actual outcome: PE at 12-14 days; Group 1: 1/67, Group 2: 2/69

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Study	Eriksson 1991 ⁹²
	<p>Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 3: Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge - Actual outcome: Major bleeding (definition not reported) at 10 days; Group 1: 1/67, Group 2: 5/69 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - High, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 4: Surgical site haematoma at up to 45 days from hospital discharge - Actual outcome: Haematoma > 0.5cm at site of injection at Not reported; Group 1: 2/67, Group 2: 7/68 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 5: Heparin-induced thrombocytopenia at duration of study - Actual outcome: Heparin-induced thrombocytopenia at Not reported; Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 6: DVT (distal) at 7-90 days from hospital discharge - Actual outcome: DVT distal at 12-14 days; Group 1: 12/63, Group 2: 4/59</p> <p>Protocol outcome 7: DVT (proximal) at 7-90 days from hospital discharge - Actual outcome: DVT proximal at 12-14 days; Group 1: 7/63, Group 2: 21/59</p>
Protocol outcomes not reported by the study	All-cause mortality at up to 90 days from hospital discharge; Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Technical complications of mechanical interventions at duration of study; Infection at duration of study;

Study	RENOVATE I trial: Eriksson 2007 ⁹¹
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=Dabigatran etexilate 220mg: 1146; Dabigatran etexilate 150mg: 1163; Enoxaparin: 1154)
Countries and setting	Conducted in Australia, South Africa; Setting: 115 centres in Europe, Australia, and South Africa.
Line of therapy	Not applicable
Duration of study	Intervention time: 28-35 days (treatment time included the time from first dose to 3 days after the last dose of the study drug)
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: DVT was confirmed by a consistent intraluminal filling defect on at least two venogram images. PE was established by ventilation-perfusion scintigraphy, pulmonary angiography, spiral chest CT, or by autopsy. Symptomatic DVT was confirmed by compression ultrasound or venography.
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Patients aged 18 years or older, weighing at least 40kg, who were scheduled for primary elective unilateral total hip replacement, were eligible for enrolment.
Exclusion criteria	Any bleeding diathesis; history of acute intracranial disease or haemorrhagic stroke; major surgery, trauma, uncontrolled hypertension, or myocardial infarction in the past 3 months; gastrointestinal or urogenital bleeding, or ulcer disease in the past 6 months; severe liver disease; alanine or aspartate aminotransferase concentrations greater than two times the upper limit of the normal range in the past month; severe renal insufficiency (creatinine clearance less than 30ml/min); use of long-acting non-steroidal anti-inflammatory drugs (also contraindicated during treatment); childbearing potential; allergy to radiopaque contrast media or heparin; and active malignant disease.
Recruitment/selection of patients	Not reported
Age, gender and ethnicity	Age - Mean (SD): Dabigatran etexilate 220mg: 65 (10); Dabigatran etexilate 150mg: 63 (11); Enoxaparin: 64 (11). Gender (M:F): Sex (female) - Dabigatran etexilate 220mg: 636 (56%); Dabigatran etexilate 150mg: 667 (57%); Enoxaparin: 651 (56%). Ethnicity: Not reported
Further population details	1. BMI : Not applicable 2. Renal impairment: Not applicable
Extra comments	.
Indirectness of population	No indirectness
Interventions	(n=1146) Intervention 1: Dabigatran - Dabigatran (all doses). 220mg once daily orally (started 1-4 hours after surgery with a half dose of 110mg) . Duration 28-35 days. Concurrent medication/care: Concomitant administration of low dose aspirin (less than 160mg) and selective cyclo-oxygenase-2 inhibitors was allowed during treatment. AES were

Study	RENOVATE I trial: Eriksson 2007⁹¹
	<p>also permitted.</p> <p>(n=1154) Intervention 2: Low molecular weight heparin (licensed in UK) - Enoxaparin (20mg once daily – 60mg twice daily). 40mg (standard dose) subcutaneously once a day (Sanofi-Aventis), administered from the evening before the operation. Duration 28-35 days. Concurrent medication/care: Concomitant administration of low dose aspirin (less than 160mg) and selective cyclo-oxygenase-2 inhibitors was allowed during treatment. AES were also permitted.</p>
Funding	Study funded by industry (Boehringer Ingelheim)
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: DABIGATRAN (ALL DOSES) versus ENOXAPARIN (20MG ONCE DAILY – 60MG TWICE DAILY)</p> <p>Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge - Actual outcome: Death at 28-35 days; Group 1: 3/1137, Group 2: 3/1156 Risk of bias: All domain - Very high, Selection - High, Blinding - High, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 9; Group 2 Number missing: 12</p> <p>Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge - Actual outcome: Total asymptomatic and symptomatic deep-vein thrombosis at 28-35 days; Group 1: 45/880, Group 2: 57/897; Comments: Dabigatran: 45/880 Enoxaparin: 57/897 Risk of bias: All domain - Very high, Selection - High, Blinding - High, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 266; Group 2 Number missing: 257 - Actual outcome: Proximal asymptomatic deep-vein thrombosis at 28-35 days; Group 1: 18/905, Group 2: 32/914 - Actual outcome: Distal asymptomatic deep-vein thrombosis at 28-35 days; Group 1: 22/874, Group 2: 24/894</p> <p>Protocol outcome 3: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQspect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge - Actual outcome: Symptomatic PE at 28-35 days; Group 1: 5/880, Group 2: 3/897 Risk of bias: All domain - Very high, Selection - High, Blinding - High, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 9; Group 2 Number missing: 12</p> <p>Protocol outcome 4: Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge</p>	

Study	RENOVATE I trial: Eriksson 2007 ⁹¹
	<p>- Actual outcome: Major bleeding at 28-35 days; Group 1: 23/1146, Group 2: 18/1154</p> <p>Risk of bias: All domain - Very high, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 5: Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge</p> <p>- Actual outcome: Clinically relevant non-major bleeding at 28-35 days; Group 1: 48/1146, Group 2: 40/1154</p> <p>Risk of bias: All domain - Very high, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 6: DVT (symptomatic) at 7-90 days from hospital discharge</p> <p>- Actual outcome: Symptomatic deep-vein thrombosis at 28-35 days; Group 1: 6/1137, Group 2: 1/1142</p>
Protocol outcomes not reported by the study	Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Surgical site haematoma at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study; Infection at duration of study;

Study	RECORD1 trial: Eriksson 2008 ⁹⁴
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	N/A (n=4541)
Countries and setting	Conducted in Multiple countries; Setting: Secondary care
Line of therapy	Not applicable
Duration of study	Intervention + follow up: Intervention 35 days + Follow-up maximum of 35 days after last dose of study drug
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: DVT was assessed using systematic ascending, bilateral venography. Suspected PE was confirmed using spiral computed tomography, perfusion-ventilation lung scintigraphy or pulmonary angiography. Autopsies were requested for deaths.
Stratum	Overall
Subgroup analysis within study	Not applicable

Study	RECORD1 trial: Eriksson 2008 ⁹⁴
Inclusion criteria	Aged 18 years or older who were scheduled to undergo elective total hip arthroplasty
Exclusion criteria	Scheduled for staged bilateral hip arthroplasty; pregnancy/breastfeeding; active bleeding / high risk of bleeding; contraindication for prophylaxis with enoxaparin or a condition that might require an adjusted dose of enoxaparin; conditions preventing bilateral venography; substantial liver disease; severe renal impairment (creatinine clearance < 30ml/min); concomitant use of protease inhibitors for HIV infection; planned intermittent pneumatic compression; requirement for anticoagulant therapy that could not be stopped
Recruitment/selection of patients	Not stated
Age, gender and ethnicity	Age - Mean (range): Rivaroxaban 63.1 (18-91) vs. Enoxaparin 63.3 (18-93). Gender (M:F): 1971:2462. Ethnicity: White 92.3%; Hispanic 1.2%; Black 0.9%; Asian 0.2%; Other/Missing 5.5%
Further population details	1. BMI : Not applicable 2. Renal impairment: Not applicable
Indirectness of population	No indirectness
Interventions	(n=2266) Intervention 1: Rivaroxaban - Rivaroxaban (all doses). Oral 10mg tablets once daily, started 6 to 8 hrs after wound closure. Duration 35 days. Concurrent medication/care: Placebo injections to match enoxaparin injections, given at the same time as rivaroxaban (n=2275) Intervention 2: Low molecular weight heparin (licensed in UK) - Enoxaparin (20mg once daily – 60mg twice daily). Subcutaneous injections 40mg once daily, started 12 hrs before surgery and restarted 6 to 8 hrs after wound closure. Duration 35 days. Concurrent medication/care: Placebo tablets to match rivaroxaban, given at the same time as enoxaparin
Funding	Study funded by industry (Bayer HealthCare and Johnson & Johnson)

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: RIVAROXABAN versus ENOXAPARIN

Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge

- Actual outcome: Death during treatment period at 35 days after surgery; Group 1: 4/1595, Group 2: 4/1558; Comments: ARR 0.0 (95% CI -0.4 to 0.4); p=1.00

Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low, Subgroups - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 671, Reason: 57 did not receive a study drug + 17 did not undergo planned surgery + 1 received wrong study drug + 588 had inadequate assessment of thromboembolism + 8 had inadequate evaluation of efficacy; Group 2 Number missing: 717, Reason: 51 did not receive a study drug + 21 did not undergo planned surgery + 635 had inadequate assessment of thromboembolism + 8 had inadequate evaluation of efficacy

- Actual outcome: Death during follow-up period at Up to 35 days after last dose of study drug; Group 1: 1/1595, Group 2: 0/1558; Comments: ARR 0.1 (95% CI-0.2 to

Study	RECORD1 trial: Eriksson 2008 ⁹⁴
	<p>0.4); p=1.00 Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low, Subgroups - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 671, Reason: 57 did not receive a study drug + 17 did not undergo planned surgery + 1 received wrong study drug + 588 had inadequate assessment of thromboembolism + 8 had inadequate evaluation of efficacy; Group 2 Number missing: 717, Reason: 51 did not receive a study drug + 21 did not undergo planned surgery + 635 had inadequate assessment of thromboembolism + 8 had inadequate evaluation of efficacy</p>
	<p>Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge - Actual outcome: DVT at 35 days after surgery; Group 1: 12/1595, Group 2: 53/1558; Comments: ARR -2.7 (95% CI -3.7 to -1.7); p<0.001 Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low, Subgroups - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 671, Reason: 57 did not receive a study drug + 17 did not undergo planned surgery + 1 received wrong study drug + 588 had inadequate assessment of thromboembolism + 8 had inadequate evaluation of efficacy; Group 2 Number missing: 717, Reason: 51 did not receive a study drug + 21 did not undergo planned surgery + 635 had inadequate assessment of thromboembolism + 8 had inadequate evaluation of efficacy</p>
	<p>Protocol outcome 3: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge - Actual outcome: Non-fatal PE during treatment period at 35 days after surgery; Group 1: 4/1595, Group 2: 1/1558; Comments: ARR 0.2 (95% CI -0.1 to 0.6); p=0.37 Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low, Subgroups - Low; Indirectness of outcome: Serious indirectness, Comments: It does not include fatal PE.; Group 1 Number missing: 671, Reason: 57 did not receive a study drug + 17 did not undergo planned surgery + 1 received wrong study drug + 588 had inadequate assessment of thromboembolism + 8 had inadequate evaluation of efficacy; Group 2 Number missing: 717, Reason: 51 did not receive a study drug + 21 did not undergo planned surgery + 635 had inadequate assessment of thromboembolism + 8 had inadequate evaluation of efficacy</p>
	<p>Protocol outcome 4: Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge - Actual outcome: Major bleeding at Between the first dose of study drug and up to 2 days after the last dose; Group 1: 40/2266, Group 2: 33/2275; Comments: p=0.18 Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low, Subgroups - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 57, Reason: 57 participants did not receive any study drug; Group 2 Number missing: 51, Reason: 51 participants did not receive any study drug</p>
	<p>Protocol outcome 5: Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge</p>

Study	RECORD1 trial: Eriksson 2008 ⁹⁴
	<p>- Actual outcome: Clinically relevant non-major bleeding at Between the first dose of study drug and up to 2 days after the last dose; Group 1: 65/2209, Group 2: 54/2224</p> <p>Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low, Subgroups - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 57, Reason: 57 participants did not receive any study drug; Group 2 Number missing: 51, Reason: 51 participants did not receive any study drug</p> <p>Protocol outcome 6: Infection at duration of study</p> <p>- Actual outcome: Post-operative wound infection at Between the first dose of study drug and up to 2 days after the last dose; Group 1: 8/2209, Group 2: 8/2224</p> <p>Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low, Subgroups - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 57, Reason: 57 participants did not receive any study drug; Group 2 Number missing: 51, Reason: 51 participants did not receive any study drug</p> <p>Protocol outcome 7: VTE at 7-90 days from hospital discharge</p> <p>- Actual outcome: Major VTE during treatment period at 35 days after surgery; Group 1: 4/1686, Group 2: 4/1678; Comments: ARR -1.7 (95% CI -2.5 to -1.0); p<0.001</p> <p>Protocol outcome 8: Fatal bleeding at 45 days from hospital discharge</p> <p>- Actual outcome: Fatal bleeding at Between the first dose of study drug and up to 2 days after the last dose; Group 1: 1/2209, Group 2: 0/2224; Comments: The single fatal bleeding case occurred before the administration of the first dose of rivaroxaban.</p>
Protocol outcomes not reported by the study	Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven

Study	Eriksson 2011 ⁹⁵
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=2013)
Countries and setting	Conducted in Australia, Austria, Belgium, Canada, Czech Republic, Denmark, Finland, Germany, Hungary, India, Italy, Netherlands, New Zealand, Norway, Poland, South Africa, Spain, Sweden, USA; Setting: 108 centres in 19 countries. Geographical location: Western Europe 51%, Central Europe 18%, North America 16.8%, India 8.9%, Australia/New Zealand/South Africa 5%
Line of therapy	Not applicable
Duration of study	Intervention time: 28-35 days

Study	Eriksson 2011 ⁹⁵
Method of assessment of guideline condition	<p>Adequate method of assessment/diagnosis: DVT (symptomatic and asymptomatic): confirmed by ascending, bilateral venography using a modification of the Rabinov and Paulin technique.</p> <p>PE: confirmed by ventilation-perfusion scintigraphy and chest X-ray, pulmonary angiography, spiral chest computer tomography or by autopsy.</p> <p>Major bleeding: defined as a bleeding event that meets at least one of the following criteria: fatal bleeding, critical bleeding (intracranial, intraocular, intraspinal, pericardial, retroperitoneal, in a non-operated joint, or intramuscular with compartment syndrome, clinically overt bleeding (at surgical or extra-surgical site) associated with a decrease in the haemoglobin level of more than 2 g/dL (20 g/l; 1.24 mmol/L), clinically overt bleeding (at surgical or extra-surgical site) leading to transfusion of two or more units of whole blood or packed cells, bleeding located at the surgical site and leading to re-operation or to any unusual medical intervention or procedure for relief (e.g. draining or puncture of an haematoma at the surgical site, transfer to an ICU or emergency room) [taken from European Medicines Agency guideline]</p> <p>Clinically relevant non-major bleeding: defined as any clinically overt bleeding that does not meet the criteria for major bleeding but requires medical attention (e.g. hospitalisation, medical treatment for bleeding) and/or change in antithrombotic therapy (including discontinuation or down-titration of study drug) and/or any other bleeding type considered to have clinical consequences for a patient. [taken from European Medicines Agency guideline]</p>
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Men or women aged 18 years or older and scheduled for primary, unilateral, elective total hip arthroplasty were eligible for inclusion.
Exclusion criteria	Those with bleeding-related contraindications, contraindications to enoxaparin or dabigatran treatment; elevated liver enzymes (alanine aminotransferase level [ALT] greater than three times the upper limit of the normal range [ULN]).
Recruitment/selection of patients	Patients recruited between March 2008 and May 2009
Age, gender and ethnicity	Age - Mean (SD): 62 (12) years. Gender (M:F): 1/1. Ethnicity: 90.4% White; 8.9% Asian; 0.3% Black; Other 0.5%
Further population details	1. BMI : Not obese (BMI under 30 kg/m ²) (Mean BMI for both arms: 27.8 ±4.8). 2. Renal impairment: Not
Extra comments	Duration of surgery (mean median time in minutes): 80 minutes; History of DVT or PE: 2.5%
Indirectness of population	No indirectness
Interventions	(n=1019) Intervention 1: Low molecular weight heparin (licensed in UK) - Enoxaparin (20mg once daily – 60mg twice daily). Enoxaparin, 40mg subcutaneous injections once daily with a placebo of the other study drug. Subcutaneous

Study	Eriksson 2011 ⁹⁵
	<p>treatment was started the evening before surgery (some countries started post-operatively to reflect local practice). The first oral dose was halved (placebo capsule) and given 1-4 hours after completion of surgery. Duration 28-35 days. Concurrent medication/care: If dosage was contraindicated on the day of surgery (e.g. the patient was not hemodynamically stable), a full dose of placebo was started the morning after surgery.</p> <p>(n=1036) Intervention 2: Dabigatran - Dabigatran (all doses). Dabigatran orally given (2x 110mg capsules), together with a placebo of the other study drug. Subcutaneous treatment was started the evening before surgery (some countries started post-operatively to reflect local practice) (placebo). The first oral dose was halved (one capsule 110mg) and given 1-4 hours after completion of surgery. Duration 28-25 days. Concurrent medication/care: If dosage was contraindicated on the day of surgery (e.g. the patient was not hemodynamically stable), a full dose of dabigatran (220mg) was started the morning after surgery.</p>
Funding	Funding not stated (Funding for the study not reported - disclosure of fees received by authors as a consultant or speaker for pharmaceutical companies, including AstraZeneca, Bayer, Boehringer Ingelheim and GlaxoSmithKline.)

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: ENOXAPARIN (40MG ONCE DAILY) versus DABIGATRAN

Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge

- Actual outcome: All-cause mortality at 28-35 days; Group 1: 1/992, Group 2: 0/1001

Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 27, Reason: Not treated, did not undergo surgery; Group 2 Number missing: 35, Reason: Not treated, did not undergo surgery

Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge

- Actual outcome: DVT (symptomatic and asymptomatic) at 28-35 days; Group 1: 67/783, Group 2: 60/791

Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 236, Reason: Not treated, did not undergo surgery, venography not performed; Group 2 Number missing: 245, Reason: Not treated, did not undergo surgery, venography not performed

Protocol outcome 3: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQspect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge

- Actual outcome: PE (symptomatic non-fatal) at 28-35 days; Group 1: 2/992, Group 2: 1/1001

Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Study	Eriksson 2011 ⁹⁵
	<p>Indirectness of outcome: No indirectness ; Group 1 Number missing: 27, Reason: Not treated, did not undergo surgery; Group 2 Number missing: 35, Reason: Not treated, did not undergo surgery</p> <p>Protocol outcome 4: Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge - Actual outcome: Major bleeding at 28-35 days; Group 1: 9/1003, Group 2: 14/1010 Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 16, Reason: Not treated, did not undergo surgery; Group 2 Number missing: 26, Reason: Not treated, did not undergo surgery</p> <p>Protocol outcome 5: Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge - Actual outcome: Clinically relevant non-major bleeding at 28-35 days; Group 1: 20/1003, Group 2: 23/1010 Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 16, Reason: Not treated, did not undergo surgery; Group 2 Number missing: 26, Reason: Not treated, did not undergo surgery</p> <p>Protocol outcome 6: VTE at 7-90 days from hospital discharge - Actual outcome: Symptomatic VTE at 28-35 days; Group 1: 6/992, Group 2: 1/1001</p> <p>Protocol outcome 7: DVT (symptomatic) at 7-90 days from hospital discharge - Actual outcome: DVT (symptomatic) at 28-35 days; Group 1: 4/992, Group 2: 0/1001</p> <p>Protocol outcome 8: DVT (distal) at 7-90 days from hospital discharge - Actual outcome: DVT (distal) at 28-35 days; Group 1: 35/785, Group 2: 43/792</p> <p>Protocol outcome 9: DVT (proximal) at 7-90 days from hospital discharge - Actual outcome: DVT (proximal) at 28-35 days; Group 1: 31/792, Group 2: 17/804</p>
Protocol outcomes not reported by the study	Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQspect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Surgical site haematoma at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study;

Study	Eriksson 2011⁹⁵
	Technical complications of mechanical interventions at duration of study; Infection at duration of study;

Study	Fordyce 1992¹⁰⁴
Study type	RCT (randomised; Parallel)
Number of studies (number of participants)	1 (n=79)
Countries and setting	Conducted in United Kingdom; Setting: Not reported
Line of therapy	Not applicable
Duration of study	Intervention + follow up: 6-9 days
Method of assessment of guideline condition	Adequate method of assessment/diagnosis
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Patients with osteoarthritis undergoing primary total hip replacement
Exclusion criteria	Refused venogram, venogram not possible, death
Recruitment/selection of patients	Not reported
Age, gender and ethnicity	Age - Mean (SD): Foot pump + AES group 68.1; AES group 71.2. Gender (M:F): 1:1.7. Ethnicity: Not reported
Further population details	1. BMI : Not applicable 2. Renal impairment: Not applicable
Indirectness of population	No indirectness
Interventions	<p>(n=39) Intervention 1: Foot pumps or foot impulse devices - Foot pumps. Foot pump, A-V Impulse System, an inflatable pad is placed under the foot, held in place by a slipper and connected to an air-impulse generator that provides rapid inflation and deflation for 3 seconds, cycle repeated every 20 seconds. Fitted to the foot of the operated limb, and using whenever the patient was in bed or sitting at rest. AES was also applied to both legs. . Duration Unclear. Concurrent medication/care: Patients practiced active leg exercises and were mobilised on the second postoperative day</p> <p>(n=40) Intervention 2: Anti-embolism stockings - Mixed above/below knee. Control group, AES on both legs alone. Duration Unclear. Concurrent medication/care: Patients practiced active leg exercises and were mobilised on the second postoperative day</p>

Study	Fordyce 1992¹⁰⁴
Funding	No funding
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: FOOT PUMP + AES versus AES ALONE</p> <p>Protocol outcome 1: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge - Actual outcome: DVT (symptomatic and asymptomatic) at 6-9 days; Group 1: 4/39, Group 2: 16/40 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p>	
Protocol outcomes not reported by the study	<p>All-cause mortality at up to 90 days from hospital discharge; Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge; Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge; Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Surgical site haematoma at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study; Infection at duration of study;</p>

Bibliographic reference	Study Type	Evidence level	No. of patients	Patients characteristics	Intervention	Comparison	Length of follow up	Outcome measures	Effect size	Comments
Francis 1992 ¹⁰⁵	RCT	1+	Total: Intervention	Type of surgery: Orthopaedic Total hip replacement	Type: bilateral thigh- calf IPCD Dose: 35-	Type: Warfarin Dose: low intensity	Intervention until venogra	DVT Confirmed by: Venography 6-8 days post-	Int: 26/98 Control: 32/103 p value: 0.5346	Comments: Of the initial 232 patients

Bibliographic reference	Study Type	Evidence level	No. of patients	Patients characteristics	Intervention	Comparison	Length of follow up	Outcome measures	Effect size	Comments
			: n = 98 Control: n = 103	Duration of surgery not reported Intervention: Mean age: 64±12 yrs M/F:43/55 Control: Mean age: 64±5 M/F:52/51 Pre-existing risk factors: 13 patients (Int 7, control 6 - Not significant difference) had prior history of VTE	55 mm Hg Timing: applied immediately prior to surgery. Continued until venography (6-8 day post-op). Additional non-comparative prophylaxis: bilateral thigh-high AES. Patients moved from bed to chair on 2nd day post-op, began ambulation and physical therapy on 3rd day post-op	regimen, adjusted to achieve INR of 1.5 on day of surgery, and 2.5 post-operatively Timing: Begun 10 -14 days pre-operatively. Continued until venography (6-8 day post-op). Additional non-comparative prophylaxis: bilateral thigh-high AES. Patients moved from bed to chair on 2nd day post- op, began ambulation	phy (on average around day 9)	op. Bilateral: Int. 87, control. 84. Operated-on leg only: int.11, control 19 Proximal DVT Confirmed by: venography (as above). Length of Hospital Stay	Int: 12/98 Control: 3/103 p value: <0.012 Mean LoS 9 days (s.d. not reported). LoS not reported separately for each group	randomised, 220 received prophylaxis (all assessed for bleeding/arterial thrombotic complications), 201 were assessed for DVT with venography. Overall incidence of deep calf vein (distal) thrombi significantly lower in IPCD group. Not reported: PE, Fatal PE, PTS, QoL:

Bibliographic reference	Study Type	Evidence level	No. of patients	Patients characteristics	Intervention	Comparison	Length of follow up	Outcome measures	Effect size	Comments
						and physical therapy on 3rd day post-op				

Study	Francis 1997 ¹⁰⁶
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=550)
Countries and setting	Conducted in USA; Setting: Not reported
Line of therapy	Not applicable
Duration of study	Intervention + follow up: 9 days
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: DVT confirmed by bilateral ascending venography. Major bleeding defined as fatal or if the patient required a transfusion, a reoperation or prolonged hospital stay
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	People who were 18 years of age or older and were scheduled to have a unilateral primary or revision total hip arthroplasty were eligible for the study.
Exclusion criteria	Serum creatinine level of at least 1.7mg per deciliter (150 micromoles per litre); defective haemostasis; documented gastrointestinal or other bleeding within 3 months before the operation; a cerebral haemorrhage within 3 months before the operation; an operative procedure involving the eye, ear or central nervous system within one month before the operation; a known hypersensitivity to heparin; severe hypertension; and a weight of less than 41kg; women who were pregnant or breast feeding and those with reproductive potential unless they had a negative pregnancy test
Recruitment/selection of patients	Not reported
Age, gender and ethnicity	Age - Mean (SD): Dalteparin: 63 (13); Warfarin: 63 (14). Gender (M:F): Dalteparin: 127/144; Warfarin: 132/147. Ethnicity: % white - Dalteparin: 88; Warfarin: 94

Study	Francis 1997 ¹⁰⁶
Further population details	1. BMI : Not applicable 2. Renal impairment: Not applicable
Indirectness of population	No indirectness
Interventions	<p>(n=271) Intervention 1: Low molecular weight heparin (licensed in UK) - Dalteparin (1,250 units once daily - 5,000 units twice daily). 5000 IU daily (standard dose) subcutaneously for mean of 7 days from the first postoperative day. First dose of 2500 IU was administered two hours before the operation; second dose of 2500 IU was given on the evening of the operation. Duration 9 days. Concurrent medication/care: No other investigational drugs were used concomitantly</p> <p>(n=279) Intervention 2: Vitamin K antagonists - Warfarin (all doses). Warfarin adjusted to an INR of approximately 2.5, orally. First dose administered the evening before the operation and second dose administered on the day of the operation. Dose: 5-75mg (depending on weight: 5mg for patients that weighed ≤57kg; 7.5 for patients that weighed >57kg). Duration 9 days. Concurrent medication/care: No other investigational drugs were used concomitantly</p>
Funding	-- (Grant from the National Heart, Lung and Blood Institute; National Institute of Health, Bethesda, Maryland and a grant from Pharmacia-Upjohn, Kalamazoo, Michigan.)

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: DALTEPARIN (1,250 UNITS ONCE DAILY - 5,000 UNITS TWICE DAILY) versus WARFARIN (ALL DOSES)

Protocol outcome 1: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge

- Actual outcome: DVT at 9 days; Group 1: 49/190, Group 2: 28/192

Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 79; Group 2 Number missing: 89

Protocol outcome 2: Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of ≥2g/dl; a serious or life threatening clinical event at up to 45 days from hospital discharge

- Actual outcome: Major bleeding at 9 days; Group 1: 6/271, Group 2: 4/279

Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcome 3: Surgical site haematoma at up to 45 days from hospital discharge

Study	Francis 1997 ¹⁰⁶
<p>- Actual outcome: Wound haematoma at 9 days; Group 1: 7/271, Group 2: 2/279</p> <p>Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p>	
<p>Protocol outcome 4: DVT (distal) at 7-90 days from hospital discharge</p> <p>- Actual outcome: DVT distal at 9 days; Group 1: 33/190, Group 2: 18/192</p>	
<p>Protocol outcome 5: DVT (proximal) at 7-90 days from hospital discharge</p> <p>- Actual outcome: DVT proximal at 9 days; Group 1: 16/190, Group 2: 10/192</p>	
Protocol outcomes not reported by the study	<p>All-cause mortality at up to 90 days from hospital discharge; Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge; Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study; Infection at duration of study;</p>

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
<p>Fuji 2008 ¹¹¹</p> <p>Country of study: Japan</p> <p>Study design: RCT</p> <p>List who was masked to</p>	<p>Patient group:</p> <p>Study 1: Total knee replacement (TKR) Study 2: Total hip replacement (THR)</p> <p>Setting: Department of Orthopaedic Surgery</p> <p>Inclusion criteria: Patients of either gender if their age</p>	<p>Study 1 (TKR) Group 1</p> <p>Fondaparinux (Atrixa)</p> <p>Start time: 24hr ± 2 hrs after surgery</p> <p>Duration: 10-16 days</p> <p>Daily 2.5mg</p>	<p>All cause mortality</p> <p>Fatal bleeding</p>	<p>Study 1 (TKR) Group1: 0/84 Group 2: 0/87 P value: N/A</p> <p>Study 2 (THR) Group3: 0/81 Group 4: 0/82 P value: N/A</p> <p>Study 1 (TKR) Group1: 0/84 Group 2: 0/87 P value: N/A</p> <p>Study 2 (THR) Group3: 0/81 Group 4: 0/82 P value: N/A</p>	<p>Funding: GlaxoSmithKlein, Sanovi-synthelabo and NV Organon</p> <p>Limitations: Method of randomisation not given. No details provided on allocation concealment.</p>

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
<p>interventions: Paper states that study is double blind and that the endpoint assessors were blinded.</p> <p>Evidence level: 1+</p> <p>Duration of follow-up: 11-17 days</p>	<p>was 20 years or greater, and they were scheduled for TKR or THR surgery or revision surgery for TKR or THR</p> <p>Exclusion criteria: Active, clinically significant bleeding Bleeding tendency/disorder (e.g. ulcer of the digestive tract etc.) Severe hepatic disorder Hypersensitivity to UFH or LMWH Requirement of an indwelling intrathecal or epidural catheter during the treatment period</p> <ul style="list-style-type: none"> Brain, spine or ophthalmologic surgery within 3 months preceding enrolment <p>Body weight <40kg Severe renal disorder (serum creatinine concentration >2.0mg/dL)</p> <p>Study 1 (TKR) All patients N: 426 No. of dropouts: 29 (6.8%) Age (mean): 71.0 (sd = 8.0) M/F: 75: 351 Additional risk factors: BMI ≥ 30 kg/m² = 64 (15.0%)</p> <p>Group 1</p>	<p>subcutaneous injections</p> <p>Group 2 Placebo (0.25ml isotonic sodium chloride) Start time: 24hr ± 2 hrs after surgery Duration: 10-16 days</p> <p>Daily 2.5mg subcutaneous injections</p> <p>Additional non-comparative prophylaxis: More than 50% of patients received elastic stockings /bandages for part of the study.</p> <p>Study 2 (THR) Group 3 Fondaparinux (Atrixa) Start time: 24hr ±</p>	<p>Major bleeding (description: fatal bleeding; bleeding that was retroperitoneal, intracranial, or intraspinal or that involved any other critical organ; bleeding leading to reoperation; and overt bleeding with a bleeding index of 2 or more.)</p>	<p>Study 1 (TKR) Group1: 1/84 Group 2: 1/87 P value: 1.00* Study 2 (THR) Group3: 2/81 Group 4: 0/82 P value: 0.245*</p>	<p>Outcomes not reported: DVT, PE, Heparin induced thrombocytopenia, post thrombotic syndrome, pulmonary hypertension, quality of life, length of stay</p> <p>Additional outcomes reported: Incidence of combined VTE was recorded Study 1 (TKR) Group 1: 16.2% Group 2: 65.3% P value: <0.05*</p> <p>Study 2 (THR) Group 3: 7.4% Group 4: 33.8%</p>

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	<p>No. randomised: 84</p> <p>Group 2 No. randomised: 87</p> <p>Study 2 (THR) All patients N: 406 No. of dropouts: 25 (6.2%) Age (mean): 61.6 (sd = 10.9) M/F: 73: 333 Additional risk factors: BMI ≥ 30 kg/m² = 26 (6.4%)</p> <p>Group 3 No. randomised: 81</p> <p>Group 4 No. randomised: 82</p>	<p>2 hrs after surgery Duration: 10-16 days</p> <p>Daily 2.5mg subcutaneous injections</p> <p>Group 4 Placebo (0.25ml isotonic sodium chloride) Start time: 24hr ± 2 hrs after surgery Duration: 10-16 days</p> <p>Daily 2.5mg subcutaneous injections</p> <p>Additional non-comparative prophylaxis: More than 50% of patients received elastic stockings /bandages for part of the study.</p>	<p>Minor bleeding (description: not defined)</p>	<p>Study 1 (TKR) Group1: 2/84 Group 2: 3/87 P value: 1.00*</p> <p>Study 2 (THR) Group3: 4/81 Group 4: 0/82 P value: 0.059*</p>	<p>P value: <0.05*</p> <p>Notes: * calculated by NCC using fishers exact test.</p> <p>Study was a dose ranging study with separate groups receiving 0.75, 1.5, 2.5 and 3.0mg fondaparinux. Only the group receiving 2.5 mg fondaparinux is analysed here as this is the licensed dose.</p>

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
---------------	----------	---------------	------------------	-------------	----------

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
<p>Fuji 2008A ¹¹²</p> <p>Country of study: Japan</p> <p>Study design: RCT</p> <p>List who was masked to interventions: Paper states that study is double blind (see limitations) and that the endpoint assessors were blinded.</p> <p>Evidence level: 1+</p> <p>Duration of follow-up: 90 days</p>	<p>Patient group:</p> <p>Study 1: Total knee replacement (TKR) Study 2: Total hip replacement (THR)</p> <p>Setting: Department of Orthopaedic Surgery</p> <p>Inclusion criteria: Patients aged ≥ 20 years (no upper age limit was applied) undergoing elective primary THR or TKR.</p> <p>Exclusion criteria:</p> <ul style="list-style-type: none"> • Patients requiring revision TKR or revision THR • Contraindication to heparin therapy • Positive clinical evidence of chronic (post-phlebotic syndrome) or acute DVT within 12 months of the study drug treatment • Documented allergy to iodine or contrast medium • impaired renal function (creatinine clearance <30ml/min or plasma creatinine level >1.5mg/dl) • Severe hepatic disease • Uncontrolled hypertension • Illicit drug use or alcohol abuse 	<p>Study 1 (TKR)</p> <p>Group 1 LMWH (Enoxaparin) Start time: 24-36 hrs after surgery Duration: 14 days</p> <p>Daily 20mg subcutaneous injection</p> <p>Group 2 LMWH (Enoxaparin) Start time: 24-36 hrs after surgery Duration: 14 days</p> <p>Daily 40 mg subcutaneous injection</p> <p>Group 3 LMWH (Enoxaparin) Start time: 24-36 hrs after surgery Duration: 14 days</p> <p>Twice daily 20mg</p>	<p>Symptomatic pulmonary Embolism (description: ventilation perfusion lung scans or pulmonary angiography at 90 days)</p> <p>DVT, asymptomatic or symptomatic (screened for by: Doppler ultrasound at 14 days)</p>	<p>Study 1 (TKR)</p> <p>Group 1: 1/78 Group 2: 1/74 Group 3: 0/84 Group 4: 1/79 p value: Not significant</p> <p>Study 2 (THR)</p> <p>Group 5: 0/81 Group 6: 1/80 Group 7: 0/90 Group 8: 0/86 p value: Not significant</p> <p>Study 1 (TKR)</p> <p>Group 1: 34/78 Group 2: 26/74 Group 3: 25/84 Group 4: 48/79 p value: All groups receiving LMWH (gp 1,2 & 3) had significantly less DVT than the placebo group (gp 4). Group 1 vs. Group 4 = 0.038* Group 2 vs. Group 4 = 0.002* Group 3 vs. Group 4 = <0.001* No other significant differences between groups were found.</p> <p>Study 2 (THR)</p>	<p>Funding: Sanofi-Aventis</p> <p>Limitations: Method of randomisation not given. No details provided on allocation concealment. Study reports that it was blinded but no information provided and some of the injection regimens were once daily whilst others were twice daily.</p> <p>Outcomes not reported: All cause mortality, fatal bleeding, fatal PE, heparin induced thrombocytopenia, post thrombotic syndrome, pulmonary hypertension, quality of life, length of stay</p>

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	<p>Treatment with other investigational agents within 3 months of surgery</p> <ul style="list-style-type: none"> Failure to achieve postoperative haemostasis Female subjects if pregnant or breast-feeding. <p>Study 1 (TKR) All patients N: 396 No. of dropouts: 32 (8.1%)</p> <p>Group 1 No. analysed: 78</p>	<p>subcutaneous injections</p> <p>Group 4 Placebo (saline) Start time: 24-36 hrs after surgery Duration: 14 days</p> <p>Subcutaneous injections (no frequency stated)</p> <p>Additional non-comparative prophylaxis: More than 50% of patients received elastic stockings /bandages for part of the study. No other prophylaxis was used.</p>	<p>Thigh DVT (description: screened for by: Doppler ultrasound at 14 days)</p>	<p>Group 5: 21/81 Group 6: 27/80 Group 7: 18/90 Group 8: 36/86 p value: The group receiving twice daily injections of 20mg LMWH (gp 7) had significantly less DVT than the placebo group (gp 8) p = 0.003* No other significant differences between groups were found</p> <p>Study 1 (TKR) Group 1: 6/78 Group 2: 3/74 Group 3: 0/84 Group 4: 6/79</p>	<p>Additional outcomes reported: The total number of adverse events were recorded. The authors concluded that most of these were not related to the treatment under investigation.</p> <p>Notes: * calculated by NCC using fishers exact test.</p>
	<p>Age (mean): 68.8 (sd = 9.0) M/F: 15:63 Additional risk factors: BMI ≥ 25 kg/m² = 40 (51.3%)</p> <p>Group 2 No. analysed: 74</p>	<p>Study 2 (THR) Group 5 LMWH (Enoxaparin) Start time: 24-36 hrs after surgery</p>		<p>p value: There were significantly fewer events in the twice daily 20mg LMWH group (gp3) vs the once daily 20mg LMWH group (gp 1) (p = 0.011*).</p> <p>There were significantly fewer events in the twice daily 20mg LMWh group (gp3) vs. the placebo group (gp 4) (p = 0.012*)</p>	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	<p>Age (mean): 70.0 (sd = 9.4) M/F: 11:63 Additional risk factors: BMI ≥ 25 kg/m² = 44 (59.4%)</p> <p>Group 3 No. analysed: 84 Age (mean): 68.3 (sd = 8.7) M/F: 5:79 Additional risk factors: BMI ≥ 25 kg/m² = 35 (41.7%)</p> <p>Group 4 No. analysed: 79 Age (mean): 68.7 (sd = 9.5) M/F: 15: 64 Additional risk factors: BMI ≥ 25 kg/m² = 40 (50.6%)</p> <p>Study 2 (THR) All patients N: 436 No. of dropouts: 29 (6.7%)</p> <p>Group 5 No. analysed: 81 Age (mean): 63.3 (sd = 10.4) M/F: 10: 71 Additional risk factors: BMI ≥ 25 kg/m² = 23 (28.4%)</p>	<p>Duration: 14 days</p> <p>Daily 20mg subcutaneous injections</p> <p>Group 6 LMWH (Enoxaparin) Start time: 24-36 hrs after surgery Duration: 14 days</p> <p>Daily 40 mg subcutaneous injections</p> <p>Group 7 LMWH (Enoxaparin) Start time: 24-36 hrs after surgery Duration: 14 days</p> <p>Twice daily 20mg subcutaneous injections</p> <p>Group 8 Placebo (saline) Start time: 24-36 hrs after surgery</p>	<p>Major bleeding (description: bleeding episode that was retroperitoneal, intracranial, or intraocular or if it was associated with: death; transfusion of ≥2 units of packed red blood cells or whole blood (except autologous); a reduction of ≥2 g/d; or a serious or life threatening clinical events that required medical intervention.)</p> <p>Minor bleeding (description: at least one of the following features: epistaxis lasting >5 minutes or requiring intervention; ecchymosis or hematoma with a maximum size of >5</p>	<p>Study 2 (THR) Group 5: 3/81 Group 6: 6/80 Group 7: 3/90 Group 8: 9/86 p value: No significant difference</p> <p>Study 1 (TKR) Group 1: 0/89 Group 2: 1/91 Group 3: 3/95 Group 4: 4/89 p value: Not significant</p> <p>Study 2 (THR) Group 5: 1/100 Group 6: 2/102 Group 7: 3/104 Group 8: 0/101 p value: Not significant</p> <p>Study 1 (TKR) Group 1: 5/89 Group 2: 6/91 Group 3: 10/95 Group 4: 4/89 p value: Not significant</p>	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	<p>Group 6 No. analysed: 80 Age (mean): 60.6 (sd = 9.9) M/F: 6:74 Additional risk factors: BMI \geq 25 kg/m² = 26 (35.2%)</p> <p>Group 7 No. analysed: 90 Age (mean): 63.0 (sd = 9.3) M/F: 15:75 Additional risk factors: BMI \geq 25 kg/m² = 31 (34.4%)</p> <p>Group 8 No. analysed: 86 Age (mean): 62.0 (sd =10.3) M/F: 11: 75 Additional risk factors: BMI \geq 25 kg/m² = 34 (39.5%)</p>	<p>Duration: 14 days</p> <p>Subcutaneous injections (no frequency stated)</p> <p>Additional non-comparative prophylaxis: More than 50% of patients received elastic stockings /bandages for part of the study.</p> <p>No other prophylaxis was used.</p>	<p>cm; haematuria not associated with urinary catheter trauma; gastrointestinal haemorrhage not related to intubation or a nasogastric tube; wound haematoma or haemorrhagic wound complications not associated with major haemorrhage; or subconjunctival haemorrhage requiring cessation of medication)</p>	<p>Study 2 (THR) Group 5: 1/100 Group 6: 7/102 Group 7: 4/104 Group 8: 2/101 p value: Not significant</p>	

Study	Gallus 1983 ¹¹⁴
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=90)
Countries and setting	Conducted in Australia; Setting: Medical Centre
Line of therapy	Not applicable
Duration of study	Intervention + follow up: 7 days
Method of assessment of guideline condition	Adequate method of assessment/diagnosis

Study	Gallus 1983¹¹⁴
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Aged over 50 years admitted to Flinders Medical Centre for elective hip replacement
Exclusion criteria	Refusal to participate, operated leg placed in balanced traction after surgery, refused venography, failed venography
Recruitment/selection of patients	Consecutive patients
Age, gender and ethnicity	Age - Mean (SD): IPCD group 69 (16); control group 67 (16). Gender (M:F): 1:2. Ethnicity: Not reported
Further population details	1. BMI : Not applicable 2. Renal impairment: Not applicable
Indirectness of population	No indirectness
Interventions	(n=43) Intervention 1: Intermittent pneumatic compression devices - Full leg. A B.O.C.-Roberts Venous Flow Stimulator was used for intermittent calf compression, 45 mmHg for 10 seconds each 2 minutes. Device was applied to both legs throughout surgery then day and night for 7 days. It was temporarily removed to permit physiotherapy, ambulation and skin care. Duration 7 days. Concurrent medication/care: n/a (n=47) Intervention 2: No treatment - Usual care. No further details reported. Duration 7 days. Concurrent medication/care: n/a
Funding	Funding not stated
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: IPCD versus CONTROL GROUP</p> <p>Protocol outcome 1: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge - Actual outcome: DVT (symptomatic and asymptomatic) at 7 days; Group 1: 15/43, Group 2: 25/47 Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0</p>	
Protocol outcomes not reported by the study	All-cause mortality at up to 90 days from hospital discharge; Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge; Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of

Study	Gallus 1983¹¹⁴
	≥2g/dl; a serious or life threatening clinical event at up to 45 days from hospital discharge; Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Surgical site haematoma at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study; Infection at duration of study;

Study	Hampson 1974¹³⁶
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=100)
Countries and setting	Conducted in United Kingdom; Setting:
Line of therapy	Not applicable
Duration of study	Intervention + follow up: 18 days
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: DVT confirmed by 125I fibrinogen uptake test and ultrasound investigations
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	People aged between the ages of 60-80 years undergoing hip replacement arthroplasty
Exclusion criteria	People having undergone previous hip surgery, a history of malignant disease, diabetes, rheumatoid arthritis, or previous thromboembolism.
Recruitment/selection of patients	Unclear
Age, gender and ethnicity	Age - Mean (SD): UFH: 68 (5.9); Control: 68.2 (5.0). Gender (M:F): UFH: 17/31; Control: 18/34. Ethnicity: Not reported
Further population details	1. BMI : Not applicable 2. Renal impairment: Not applicable
Indirectness of population	No indirectness
Interventions	(n=48) Intervention 1: Unfractionated heparin - Unfractionated heparin (low dose, administered subcutaneously). Calcium heparin, 5000 IU subcutaneously three times daily for 7-10 days after surgery. Duration 18 days. Concurrent medication/care: Not reported

Study	Hampson 1974¹³⁶
	(n=52) Intervention 2: No treatment - Placebo. Saline subcutaneously three times daily. Duration Not reported. Concurrent medication/care: Not reported
Funding	Funding not stated
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: UNFRACTIONATED HEPARIN (LOW DOSE, ADMINISTERED SUBCUTANEOUSLY) versus PLACEBO</p> <p>Protocol outcome 1: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge - Actual outcome: DVT at 18 days; Group 1: 22/48, Group 2: 28/52 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 2: Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge - Actual outcome: Major bleeding at 18 days; Group 1: 0/48, Group 2: 0/52 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - High, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p>	
Protocol outcomes not reported by the study	All-cause mortality at up to 90 days from hospital discharge; Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge; Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Surgical site haematoma at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study; Infection at duration of study;

Study (subsidiary papers)	Hardwick 2011 ¹³⁷ (Colwell 2010 ⁷⁰)
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	N/A (n=395)
Countries and setting	Conducted in USA; Setting: Secondary care
Line of therapy	Not applicable
Duration of study	Intervention + follow up: Intervention 10 days + Follow-up 3 months
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: The intent to detect DVT by bilateral duplex ultrasound was described in the methods section but the intended method for detecting/diagnosing PE was not described in the methods section but was later reported in the results section (spiral computed tomographic scans were used for PE).
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Older than 18 and scheduled for a unilateral total hip arthroplasty
Exclusion criteria	History of thrombosis; mental deficiency; known coagulation disorder; solid malignant tumour; peptic ulcer disease
Recruitment/selection of patients	Not stated
Age, gender and ethnicity	Age - Mean (range): MCD 63 vs. Enoxaparin 64 (20-88 for both groups). Gender (M:F): 178:214. Ethnicity: Not reported
Further population details	1. BMI : Not applicable 2. Renal impairment: Not applicable
Extra comments	.
Indirectness of population	No indirectness: Ethnicity was not reported
Interventions	<p>(n=198) Intervention 1: Intermittent pneumatic compression devices - Below knee. Mobile compression device (ActiveCare+SFT, Medical Compression Systems, Or Akiva, Israel) with its Velcro sleeves fastened around the calf was applied in the operating room and continued use for 10 days after surgery. Duration 10 days. Concurrent medication/care: Participants in this group could receive aspirin 81mg daily at the discretion of the surgeon.</p> <p>(n=194) Intervention 2: Low molecular weight heparin (licensed in UK) - Enoxaparin (20mg once daily – 60mg twice daily). Subcutaneous injection 30mg every 12 hrs starting the morning after surgery while in the hospital then 40mg once daily after hospital discharge for 10 days. Duration Average of 3 days hospital stay + 10 days post-discharge. Concurrent medication/care: Aspirin was used in addition to the compression device in 63% of patients in this group.</p>

Funding	Funding not stated
RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: MOBILE COMPRESSION DEVICE versus ENOXAPARIN	
<p>Protocol outcome 1: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge - Actual outcome: Incidence of DVT at 10 to 12 days after surgery (or 3 months - unclear); Group 1: 8/196, Group 2: 8/190; Comments: N.B. Four patients in the MCD group took aspirin 81mg daily. Risk of bias: All domain - Very high, Selection - Low, Blinding - High, Incomplete outcome data - High, Outcome reporting - Low, Measurement - High, Crossover - Low, Comments - The authors reported that 63% of the participants in the MCD group used aspirin (assumed to be on a daily basis) and this affects comparability of care. It is stated that 395 patients were randomised, however, the numbers displayed in each group are 198 for the MCD group and 194 for the enoxaparin group (392 in total). It is unknown as to what happened to the 3 participants unaccounted for. In addition, 6 people are missing from the efficacy analyses which was said to have applied "intent-to-treat method", however, it is unclear why data for 6 people are not provided. Furthermore, the method of detecting and confirming VTE events were not described fully in the method section. ; Indirectness of outcome: No indirectness, Comments: It is unclear whether the incidences of VTE events presented in the article occurred over 10 to 12 days (treatment period) or 3 months (follow-up period).; Baseline details: Except for diagnosis of osteoarthritis there is no baseline data about the health status or co-morbidities of the participants; Group 1 Number missing: 2, Reason: Unclear; Group 2 Number missing: 4, Reason: Unclear</p>	
<p>Protocol outcome 2: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge - Actual outcome: Incidence of PE at 10 to 12 days after surgery (or 3 months - unclear); Group 1: 2/196, Group 2: 2/194; Comments: N.B. One patient in the MCD group received aspirin 81mg daily. Risk of bias: All domain - Very high, Selection - Low, Blinding - High, Incomplete outcome data - High, Outcome reporting - Low, Measurement - High, Crossover - Low, Comments - The authors reported that 63% of the participants in the MCD group used aspirin (assumed to be on a daily basis) and this affects comparability of care. It is stated that 395 patients were randomised, however, the numbers displayed in each group are 198 for the MCD group and 194 for the enoxaparin group (392 in total). It is unknown as to what happened to the 3 participants unaccounted for. In addition, 6 people are missing from the efficacy analyses which was said to have applied "intent-to-treat method", however, it is unclear why data for 6 people are not provided. Furthermore, the method of detecting and confirming VTE events were not described fully in the method section. ; Indirectness of outcome: No indirectness, Comments: It is unclear whether the incidences of VTE events presented in the article occurred over 10 to 12 days (treatment period) or 3 months (follow-up period).; Baseline details: Except for diagnosis of osteoarthritis there is no baseline data about the health status or co-morbidities of the participants; Group 1 Number missing: 2, Reason: Unclear; Group 2 Number missing: 4, Reason: Unclear</p>	
<p>Protocol outcome 3: Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge - Actual outcome: Major bleeding at 10 to 12 days after surgery; Group 1: 0/198, Group 2: 11/194; Comments: $p=0.0004$ Risk of bias: All domain - Very high, Selection - Low, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - High, Crossover - Low, Comments - The authors reported that 63% of the participants in the MCD group used aspirin (assumed to be on a daily basis) and this affects comparability of care. It</p>	

is stated that 395 patients were randomised, however, the numbers displayed in each group are 198 for the MCD group and 194 for the enoxaparin group (392 in total). It is unknown as to what happened to the 3 participants unaccounted for. Furthermore, "major bleeding" has not been defined.; Indirectness of outcome: No indirectness, Comments: Definition of major bleeding not provided; Baseline details: Except for diagnosis of osteoarthritis there is no baseline data about the health status or co-morbidities of the participants; Group 1 Number missing: 0; Group 2 Number missing: 0

Protocol outcome 4: VTE at 7-90 days from hospital discharge

- Actual outcome: Incidence of VTE at 10 to 12 days after surgery (or 3 months - unclear); Group 1: 10/196, Group 2: 10/190

Protocol outcomes not reported by the study

All-cause mortality at up to 90 days from hospital discharge; Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Surgical site haematoma at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study; Infection at duration of study;

Study	Hull 1990 ¹⁵²
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=310)
Countries and setting	Conducted in Canada; Setting: Hospital
Line of therapy	Not applicable
Duration of study	Intervention + follow up: 14 days
Method of assessment of guideline condition	Adequate method of assessment/diagnosis
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Patients undergoing total hip replacement who had no history of VTE
Exclusion criteria	Allergic to venographic dye, unable to wear the compression cuffs, required treatment with aspirin, refused informed consent
Recruitment/selection of patients	Consecutive patients
Age, gender and ethnicity	Age - Mean (SD): IPCD group 64 (11); control group 66 (12). Gender (M:F): 1:1.5. Ethnicity: Not reported
Further population details	1. BMI : Not applicable 2. Renal impairment: Not applicable
Indirectness of population	No indirectness
Interventions	<p>(n=152) Intervention 1: Intermittent pneumatic compression devices - Mixed full leg/below knee. Sequential calf and thigh intermittent compression begun postoperatively in the recovery room. Each calf cuff contained four chambers, and each thigh cuff contained two chambers. Intermittent compression was achieved using an electric pump that inflated the six chambers sequentially at 5-second intervals to a pressure of 50-65 mmHg, beginning with the most distal calf chamber and progressing proximally. Pressure in all six chambers was maintained for an additional 5 seconds, for a total inflation time of 35 seconds; the six chambers were then deflated simultaneously for 25 seconds. Duration Until hospital discharge or at 14 days. Concurrent medication/care: Routine physiotherapy was given to all patients in both study groups.</p> <p>(n=158) Intervention 2: No treatment - Usual care. Control group - no further details reported. Duration Until hospital discharge or at 14 days. Concurrent medication/care: Routine physiotherapy was given to all patients in both study groups.</p>
Funding	Academic or government funding (Supported by grants from the Ontario Ministry of Health, Toronto, Canada; the Heart and Stroke Foundation of Ontario, Toronto, Canada; and the Canadian Heart Foundation, Ottawa)

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: IPCD versus CONTROL GROUP

Protocol outcome 1: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge

- Actual outcome: DVT (symptomatic and asymptomatic) at 14 days; Group 1: 36/152, Group 2: 77/158

Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0

Protocol outcome 2: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge

- Actual outcome: PE at 14 days; Group 1: 1/152, Group 2: 1/158

Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0

Protocol outcomes not reported by the study

All-cause mortality at up to 90 days from hospital discharge; Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge; Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Surgical site haematoma at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study; Infection at duration of study;

Study	Hull 2000 ¹⁵¹
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=1472)
Countries and setting	Conducted in Canada, USA; Setting: Multicentre
Line of therapy	Not applicable
Duration of study	Intervention + follow up: 8 days
Method of assessment of guideline condition	Adequate method of assessment/diagnosis
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	At least 18 years and scheduled for elective unilateral total hip arthroplasty with informed consent
Exclusion criteria	Documented bleeding within 3 months before surgery; known hypersensitivity to heparin, LMWH, warfarin, or contrast media; defective haemostasis (e.g. thrombocytopenia); ongoing anticoagulants; pregnancy or breast feeding; clinically significant hepatic dysfunction; renal insufficiency (serum creatinine level >150µmol/L [1.7mg/dL]); severe hypertension (diastolic blood pressure >120mmHg); septic endocarditis; weight of less than 40kg; eye, ear or central nervous system surgery within 1 month before surgery; diseases with unfavourable prognosis (e.g. malignant neoplasms or other intercurrent disease making study participation impractical or medically complicated); inability to follow instructions or perform procedures, including self-injections required during the home prophylaxis study; simultaneous participation in another pharmacological study or use of any investigational drug within 30 days before surgery; previous randomisation into this study; or use of pneumatic compression stockings
Recruitment/selection of patients	Consecutive patients
Age, gender and ethnicity	Age - Mean (SD): Preop LMWH 64 (12); postop LMWH 63 (13); warfarin 63 (13). Gender (M:F): 1:1.08. Ethnicity: Not reported
Further population details	1. BMI : Not obese (BMI under 30 kg/m ²) (Mean (SD) BMI: preop LMWH 29 (6), postop LMWH 29 (6), warfarin 28 (5)). 2. Renal impairment: Not applicable
Indirectness of population	--
Interventions	(n=496) Intervention 1: Low molecular weight heparin (licensed in UK) - Dalteparin (1,250 units once daily - 5,000 units twice daily). Preoperative Dalteparin - initial dose of 2500IU within 2 hours before surgery, patients then received a second dose of dalteparin (2500IU) at least 4 hours postoperatively, subcutaneously. On subsequent days, all patients receiving dalteparin were given 5000IU subcutaneously once daily each morning. Also, received placebo oral capsules. Duration 4-8 days or until discharge (duration unclear). Concurrent medication/care: n/a

	<p>(n=487) Intervention 2: Low molecular weight heparin (licensed in UK) - Dalteparin (1,250 units once daily - 5,000 units twice daily). Post-operative dalteparin - initial placebo dose within 2 hours before surgery, patients then received first active dose of dalteparin (2500IU) at least 4 hours postoperatively, subcutaneously. On subsequent days, all patients receiving dalteparin were given 5000IU subcutaneously once daily each morning. Also, received placebo oral capsules. Duration 4-8 days or until discharge (duration unclear). Concurrent medication/care: n/a</p> <p>(n=489) Intervention 3: Vitamin K antagonists - Warfarin (all doses). Patients received an initial dose postoperatively on the evening of surgery day. The initial dose was 10mg, except for patients aged 70 years or older or weighing less than 57kg who received a 5mg dose. Thereafter, warfarin doses were adjusted daily to maintain an INR from 2.0 to 3.0. Patients also received subcutaneous placebo injections. Duration 4-8 days or until discharge (duration unclear). Concurrent medication/care: n/a</p>
Funding	Study funded by industry (Support for this trial was provided through a grant-in-aid by Pharmacia & Upjohn to the University of Calgary)

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: PRE-OPERATION DALTEPARIN versus POST-OPERATION DALTEPARIN

Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge

- Actual outcome: All-cause mortality at 8 days; Group 1: 2/496, Group 2: 0/487

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0

Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge

- Actual outcome: DVT (symptomatic and asymptomatic) at 8 days; Group 1: 36/337, Group 2: 44/336

Risk of bias: All domain - Very high, Selection - High, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 159, Reason: Did not receive study medication - cancelled operation, presence of exclusion criteria, withdrawn consent, miscellaneous reasons making the patient ineligible.; Group 2 Number missing: 151, Reason: Did not receive study medication - cancelled operation, presence of exclusion criteria, withdrawn consent, miscellaneous reasons making the patient ineligible.

Protocol outcome 3: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge

- Actual outcome: PE at 8 days; Group 1: 0/496, Group 2: 0/487

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0

Protocol outcome 4: Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge

- Actual outcome: Major bleeding at 8 days; Group 1: 44/496, Group 2: 32/487

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0

Protocol outcome 5: Surgical site haematoma at up to 45 days from hospital discharge

- Actual outcome: Wound haematoma at 8 days; Group 1: 2/496, Group 2: 2/487

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: PRE-OPERATION DALTEPARIN versus WARFARIN (ALL DOSES)

Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge

- Actual outcome: All-cause mortality at 8 days; Group 1: 2/496, Group 2: 2/489

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0

Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge

- Actual outcome: DVT (symptomatic and asymptomatic) at 8 days; Group 1: 36/337, Group 2: 81/338

Risk of bias: All domain - Very high, Selection - High, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 159, Reason: Did not receive study medication - cancelled operation, presence of exclusion criteria, withdrawn consent, miscellaneous reasons making the patient ineligible.; Group 2 Number missing: 151, Reason: Did not receive study medication - cancelled operation, presence of exclusion criteria, withdrawn consent, miscellaneous reasons making the patient ineligible.

Protocol outcome 3: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge

- Actual outcome: PE at 8 days; Group 1: 0/496, Group 2: 0/489

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0

Protocol outcome 4: Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening

clinical event at up to 45 days from hospital discharge

- Actual outcome: Major bleeding at 8 days; Group 1: 44/496, Group 2: 22/489

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0

Protocol outcome 5: Surgical site haematoma at up to 45 days from hospital discharge

- Actual outcome: Wound haematoma at 8 days; Group 1: 2/496, Group 2: 1/489

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: POST-OPERATION DALTEPARIN versus WARFARIN (ALL DOSES)

Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge

- Actual outcome: All-cause mortality at 8 days; Group 1: 0/487, Group 2: 2/489

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0

Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge

- Actual outcome: DVT (symptomatic and asymptomatic) at 8 days; Group 1: 44/336, Group 2: 81/338

Risk of bias: All domain - Very high, Selection - High, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 159, Reason: Did not receive study medication - cancelled operation, presence of exclusion criteria, withdrawn consent, miscellaneous reasons making the patient ineligible.; Group 2 Number missing: 151, Reason: Did not receive study medication - cancelled operation, presence of exclusion criteria, withdrawn consent, miscellaneous reasons making the patient ineligible.

Protocol outcome 3: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpsect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge

- Actual outcome: PE at 8 days; Group 1: 0/487, Group 2: 0/489

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0

Protocol outcome 4: Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge

- Actual outcome: Major bleeding at 8 days; Group 1: 32/487, Group 2: 22/489

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0

Protocol outcome 5: Surgical site haematoma at up to 45 days from hospital discharge

- Actual outcome: Wound haematoma at 8 days; Group 1: 2/487, Group 2: 1/489

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0

Protocol outcomes not reported by the study

Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQspect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study; Infection at duration of study;

Bibliographic reference	Study Type	Evidence level	No. of patients	Patients characteristics	Intervention	Comparison	Length of follow up	Outcome measures	Effect size	Comments
Kakkar 2000 ¹⁶⁷	RCT	1+	Total: 298 Intervention n: 149 Control n: 149	Type of surgery: Patients scheduled for elective hip replacement surgery. Duration of surgery: Int: 110±55.1 Control: 100±58.7; p=0.207 Age and gender: Intervention: Mean age: 70.4 ± 10.9 years M/F:49/100 Control: Mean age: 70.5 ± 9.2 years M/F:45/104 Pre-existing risk factors: Previous DVT: Int:	Type, dose and timing: One dose daily of subcutaneous LMWH (3500 IU of Bemiparin) plus a placebo injections of 0.9% saline. Prophylaxis started 2 hours before surgery and continued for at least 8 post-operative days or longer if patient was still institutionalised. Additional non-comparative prophylaxis: Some patients	Type, dose and timing: 5000 units of Calcium heparin injected subcutaneously twice daily. Prophylaxis started 2 hours before surgery and continued for at least 8 post-operative days or longer if patient was still institutionalised. Additional non-comparative	4 weeks	VTE total	Int: 9/125 (7.2%) Cont: 25/134 (18.7%) p=0.01	Financially supported by Laboratories Farmaceuticos Rovi S.A.; (Madrid, Spain) Who also provided supply of LMWH and std UFH sodium Also reported: Operative blood loss, postoperative drain loss
								DVT confirmed by bilateral elective venography.	Int: 9/101 (8.9%) Cont: 24/116 (20.7%) p=0.03	
								Proximal DVT:	Int: 3/101 (3.0%) Cont: 5/116 (4.3%) p=0.73	

Bibliographic reference	Study Type	Evidence level	No. of patients	Patients characteristics	Intervention	Comparison	Length of follow up	Outcome measures	Effect size	Comments
				n = 4 Control: n = 12; Previous PE: Int: n = 1 Control: n = 3; Varicose veins: Int: n = 44 Control: n = 46; Varicose ulcer: Int: n = 3 Control: n = 6; obesity: Int: n = 23 Control: n = 27;	had analgesics including aspirin (LMWH 56.4% and UFH 59.1%)	prophylaxis: Some patients had analgesics including aspirin (LMWH 56.4% and UFH 59.1%)		Distal DVT:	Int: 4/101 (4.0%) Cont: 13/116 (11.2%) p=0.08	
								Proximal and Distal DVT:	Int: 2/101 (2.0%) Cont: 6/116 (5.2%) p=0.23	
								PE Confirmed by ventilation perfusion scan.	Int: 1/125 (0.8%) Cont: 2/134 (1.5%) p=1.00	
								Patient transfused	Int: n = 74/149 Control: n = 66/149; p=0.42	
								Wound hematomas	Int: n = 8/149 Control: n = 7/149; p=1.00	

Study	Kakkar 2008¹⁶²
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=2509)
Countries and setting	Conducted in Multiple countries, Unknown multicentre; Setting: 123 centres across 21 countries worldwide

Study	Kakkar 2008 ¹⁶²
Line of therapy	Not applicable
Duration of study	Intervention time: Rivaroxaban (31-39 days); LMWH (10-14 days)
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: DVT (symptomatic and asymptomatic): confirmed by venography PE: confirmed by pulmonary angiography, perfusion/ventilation lung scintigraphy with chest radiography, or spiral computed tomography. Major bleeding: defined as bleeding that was fatal, was into a critical organ (retroperitoneal, intracranial, intraocular, intraspinal), required re-operation, or clinically overt extra surgical site bleeding associated with a fall in haemoglobin of 20 g/L or more, calculated from the day 1 post-operative baseline value, or requiring infusion of two or more units of whole blood or packed cells.
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Patients aged 18 years or over, who were scheduled to undergo elective total hip arthroplasty.
Exclusion criteria	Patients scheduled to undergo staged bilateral hip arthroplasty, had active bleeding or a high risk of bleeding, or had any condition contraindicating the use of enoxaparin or that might require enoxaparin dose adjustment, including severe renal impairment. Other exclusions: significant liver disease, pregnancy or breastfeeding, concomitant use of HIV protease inhibitors, use of fibrinolytic therapy or planned intermittent pneumatic compression during the study period, conditions preventing bilateral venography.
Recruitment/selection of patients	Patients were enrolled between February 2006 and April 2007.
Age, gender and ethnicity	Age - Mean (SD): 61.6 years. Gender (M:F): 1/1. Ethnicity: White 65%, Asian 20%, Hispanic 12%, Black 3%
Further population details	1. BMI : Not obese (BMI under 30 kg/m ²) (Mean: 27 kg/m ²). 2. Renal impairment: Not applicable
Extra comments	History of VTE: rivaroxaban 0.8%; enoxaparin 1.6%.
Indirectness of population	No indirectness
Interventions	(n=1252) Intervention 1: Rivaroxaban - Rivaroxaban (all doses). Patients were given 10mg rivaroxaban once daily, orally (Xarelto, Bayer HealthCare). Course of rivaroxaban was started 6-8 hours after wound closure and continued for 31-39 days, patients also received placebo injections for 10-14 days starting 12 hours before surgery. Duration 31-39 days. Concurrent medication/care: n/a (n=1257) Intervention 2: Low molecular weight heparin (licensed in UK) - Enoxaparin (20mg once daily – 60mg twice daily). Patients were given subcutaneous injections of enoxaparin 40mg (Clexane/Lovenox, Sanofi-Aventis) once daily. Enoxaparin was initiated 12 hours before surgery and restarted 6-8 hours after wound closure and continued for 10-14 days, patients also received placebo tablets for 31-39 days starting 6-8 hours after wound closure. Duration 31-39

Study	Kakkar 2008¹⁶²
	days. Concurrent medication/care: n/a
Funding	Study funded by industry (Bayer HealthCare AG, Johnson & Johnson Pharmaceutical Research and Development LLC)
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: RIVAROXABAN (EXTENDED DURATION) versus ENOXAPARIN (STANDARD DURATION)</p> <p>Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge - Actual outcome: All-cause mortality at 30-42 days; Group 1: 17/864, Group 2: 81/869 Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 338, Reason: Details not reported; Group 2 Number missing: 388, Reason: Details not reported</p> <p>Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge - Actual outcome: DVT (symptomatic and asymptomatic) at 30-42 days; Group 1: 14/864, Group 2: 71/869 Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 338, Reason: Details not reported; Group 2 Number missing: 388, Reason: Details not reported</p> <p>Protocol outcome 3: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge - Actual outcome: PE at 30-42 days; Group 1: 1/864, Group 2: 4/869 Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 338, Reason: Details not reported; Group 2 Number missing: 388, Reason: Details not reported</p> <p>Protocol outcome 4: Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge - Actual outcome: Major bleeding at 30-42 days; Group 1: 1/1228, Group 2: 1/1229 Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 24, Reason: Details not reported; Group 2 Number missing: 28, Reason: Details not reported</p> <p>Protocol outcome 5: Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge - Actual outcome: Clinically relevant non-major bleeding at 30-42 days; Group 1: 40/1228, Group 2: 33/1229 Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - High, Crossover - Low;</p>	

Study	Kakkar 2008 ¹⁶²
<p>Indirectness of outcome: No indirectness ; Group 1 Number missing: 24, Reason: Details not reported; Group 2 Number missing: 28, Reason: Details not reported</p> <p>Protocol outcome 6: Infection at duration of study - Actual outcome: Wound infection at 30-42 days; Group 1: 8/1228, Group 2: 6/1229 Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 24, Reason: Details not reported; Group 2 Number missing: 28, Reason: Details not reported</p> <p>Protocol outcome 7: VTE at 7-90 days from hospital discharge - Actual outcome: Major VTE at 30-42 days; Group 1: 6/961, Group 2: 49/962 - Actual outcome: Symptomatic VTE at 30-42 days; Group 1: 3/1212, Group 2: 15/1207</p> <p>Protocol outcome 8: DVT (distal) at 7-90 days from hospital discharge - Actual outcome: DVT (distal) at 30-42 days; Group 1: 27/869, Group 2: 9/864</p> <p>Protocol outcome 9: DVT (proximal) at 7-90 days from hospital discharge - Actual outcome: DVT (proximal) at 30-42 days; Group 1: 5/864, Group 2: 44/869</p> <p>Protocol outcome 10: Fatal bleeding at 45 days from hospital discharge - Actual outcome: Fatal bleeding at 30-42 days; Group 1: 0/1228, Group 2: 0/1229</p>	
Protocol outcomes not reported by the study	Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Surgical site haematoma at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study;

Study	Kalodiki 1996 ¹⁶⁹
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=78)
Countries and setting	Conducted in USA
Line of therapy	Not applicable
Duration of study	Intervention + follow up: 8-12 days

Study	Kalodiki 1996 ¹⁶⁹
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: DVT confirmed by bilateral ascending venography. PE confirmed by perfusion/ventilation scan.
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	People older than 40 years who were having unilateral total hip replacement for the first time or without cement under general anaesthesia.
Exclusion criteria	Established documented bleeding disorders, abnormal preoperative coagulation tests (prothrombin time and activated partial thromboplastin time) including platelet counts below $100 \times 10^9/l$ acute bleeding and/or recently documented haemorrhage and any other bleeding risk were excluded. Other exclusion criteria included anticoagulant therapy during the 14 days before surgery or during the study, aspirin or non-steroidal anti-inflammatory drugs 5 and 2 days before surgery respectively, severe arterial hypertension, history of stroke during the previous six months and/or neurosurgery, endocarditis, acute or chronic renal failure, severe hepatic and/or pancreatic disease, hypersensitivity to heparin or metabisulphite, allergy to porcine derived products, iodine or radiopaque contrast media, history of heparin induced thrombocytopenia, previous surgery of the ipsilateral hip, surgery carried out under regional anaesthesia, clinical signs of DVT and/or history of recent DVT and/or PE, presence of malignant growths, mental disorders and/or failure to give informed consent.
Recruitment/selection of patients	Consecutive recruitment
Age, gender and ethnicity	Age - Other: Mean age: LMWH: 67; LMWH&AES: 69; Placebo: 72. Gender (M:F): LMWH: 13/18; LMWH&AES: 19/13; Placebo: 6/8. Ethnicity: Not reported
Further population details	1. BMI : Not applicable 2. Renal impairment: Not applicable
Indirectness of population	No indirectness
Interventions	<p>(n=14) Intervention 1: No treatment - Placebo. Placebo (normal saline) once daily subcutaneously. Duration 8-12 days. Concurrent medication/care: Not reported</p> <p>(n=32) Intervention 2: Low molecular weight heparin (licensed in UK) - Enoxaparin (20mg once daily – 60mg twice daily). Enoxaparin dose 40 mg (4000 Anti Xa iU) administered subcutaneously 12 hours before operation and then once daily until discharge. Duration 8-12 days. Concurrent medication/care: Not reported</p> <p>(n=32) Intervention 3: Anti-embolism stockings - Above knee. LMWH+ AES: Enoxaparin dose 40 mg (4000 Anti Xa iU) administered subcutaneously 12 hours before operation and then once daily until discharge + thigh-high TED stockings applied before operation on both legs and not taken off until patient discharged. Duration 8-12 days. Concurrent medication/care: Not reported</p>

Study	Kalodiki 1996 ¹⁶⁹
	(n=14) Intervention 4: No treatment - Placebo. Identically labelled placebo injections (normal saline) administered subcutaneously 12 hours before operation and then once daily until discharge. Duration 8-12 days. Concurrent medication/care: Not reported
Funding	Study funded by industry (Rhône-Poulenc-Rorer)
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: ENOXAPARIN (20MG ONCE DAILY – 60MG TWICE DAILY) versus PLACEBO</p> <p>Protocol outcome 1: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge - Actual outcome: DVT confirmed by venograms at 8-12 days; Group 1: 12/32, Group 2: 13/14 Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Blinding details: Patients assigned to LMWH +AES were not blinded to the AES portion of the intervention; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 2: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge - Actual outcome: PE confirmed by high probability perfusion/ventilation lung scan at 8-12 days; Group 1: 3/29, Group 2: 5/12 Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Blinding details: Patients assigned to LMWH +AES were not blinded to the AES portion of the intervention; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 3: DVT (distal) at 7-90 days from hospital discharge - Actual outcome: DVT (distal) confirmed by venograms at 8-12 days; Group 1: 3/32, Group 2: 5/14</p> <p>Protocol outcome 4: DVT (proximal) at 7-90 days from hospital discharge - Actual outcome: DVT (proximal) confirmed by venograms at 8-12 days; Group 1: 9/32, Group 2: 8/14</p> <p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: ENOXAPARIN (20MG ONCE DAILY – 60MG TWICE DAILY) versus ABOVE KNEE</p> <p>Protocol outcome 1: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler)</p>	

Study	Kalodiki 1996 ¹⁶⁹
	<p>ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge - Actual outcome: DVT confirmed by venograms at 8-12 days; Group 1: 12/32, Group 2: 8/32 Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Blinding details: Patients assigned to LMWH +AES were not blinded to the AES portion of the intervention; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 2: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge - Actual outcome: PE confirmed by high probability perfusion/ventilation lung scan at 8-12 days; Group 1: 3/29, Group 2: 2/31 Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Blinding details: Patients assigned to LMWH +AES were not blinded to the AES portion of the intervention; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 3: DVT (distal) at 7-90 days from hospital discharge - Actual outcome: DVT (distal) confirmed by venograms at 8-12 days; Group 1: 3/32, Group 2: 4/32</p> <p>Protocol outcome 4: DVT (proximal) at 7-90 days from hospital discharge - Actual outcome: DVT (proximal) confirmed by venograms at 8-12 days; Group 1: 9/32, Group 2: 4/32</p>
	<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: ABOVE KNEE versus PLACEBO</p> <p>Protocol outcome 1: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge - Actual outcome: DVT confirmed by venograms at 8-12 days; Group 1: 8/32, Group 2: 13/14 Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Blinding details: Patients assigned to LMWH +AES were not blinded to the AES portion of the intervention; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 2: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge - Actual outcome: PE confirmed by high probability perfusion/ventilation lung scan at 8-12 days; Group 1: 2/31, Group 2: 5/12 Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Blinding details: Patients assigned to LMWH +AES were not blinded to the AES portion of the intervention; Group 1 Number</p>

Study	Kalodiki 1996 ¹⁶⁹
missing: ; Group 2 Number missing:	
Protocol outcome 3: DVT (distal) at 7-90 days from hospital discharge - Actual outcome: DVT (distal) confirmed by venograms at 8-12 days; Group 1: 4/32, Group 2: 5/14	
Protocol outcome 4: DVT (proximal) at 7-90 days from hospital discharge - Actual outcome: DVT (proximal) confirmed by venograms at 8-12 days; Group 1: 4/32, Group 2: 8/14	
Protocol outcomes not reported by the study	All-cause mortality at up to 90 days from hospital discharge; Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge; Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQspect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Surgical site haematoma at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study; Infection at duration of study;

Study	Lassen 1991 ¹⁹¹
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=190)
Countries and setting	Conducted in Denmark; Setting: Aalborg Hospital and Arhus Municipal Hospital, Denmark
Line of therapy	Not applicable
Duration of study	Intervention time: 8-10 days
Method of assessment of guideline condition	Adequate method of assessment/diagnosis
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Patients aged 40 years or over scheduled for elective hip replacement

Study	Lassen 1991 ¹⁹¹
Exclusion criteria	Treatment with plasma expanders or investigational drugs within 4 weeks prior to the operation; impaired renal or hepatic function; uncontrolled hypertension (diastolic pressure >120mmHg); haemorrhagic diathesis; pregnancy; confinement to bed; revision arthroplasty; hypersensitivity to radiopaque dye, heparin, bisulfite, or benzyl alcohol; ongoing anticoagulant therapy; and lack of informed consent
Recruitment/selection of patients	Not reported
Age, gender and ethnicity	Age - Mean (range): UFH group 67 (40-85); placebo group 67 (40-86). Gender (M:F): 1:1. Ethnicity: Not reported
Further population details	1. BMI : Not applicable 2. Renal impairment: Not applicable
Indirectness of population	No indirectness
Interventions	<p>(n=93) Intervention 1: Low molecular weight heparin (not licensed in UK) - Bemiparin (2500 units once daily - 3500 units once daily). 50 units anti-Xa per kg body given subcutaneously once daily. Injections were started 2 hours preoperatively and continued for 7 days. Also, received thigh-length AES, applied to both legs 1 hour before the operation and were day and night. During the operation the AES on the operated side was pulled down to below the knee level. Duration 7 days. Concurrent medication/care: N/A</p> <p>(n=97) Intervention 2: No treatment - Placebo. Placebo, saline subcutaneously once daily. Also, received thigh-length AES, applied to both legs 1 hour before the operation and were day and night. During the operation the AES on the operated side was pulled down to below the knee level. Duration 7 days. Concurrent medication/care: N/A</p>
Funding	Funding not stated

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: BEMIPARIN (2500 UNITS ONCE DAILY - 3500 UNITS ONCE DAILY) versus PLACEBO

Protocol outcome 1: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge

- Actual outcome: DVT (symptomatic and asymptomatic) at 8-10 days; Group 1: 29/93, Group 2: 44/97

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0

Protocol outcome 2: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge

- Actual outcome: PE at 8-10 days; Group 1: 1/93, Group 2: 1/97

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Study	Lassen 1991 ¹⁹¹
Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0	
Protocol outcomes not reported by the study	All-cause mortality at up to 90 days from hospital discharge; Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge; Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Surgical site haematoma at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study; Infection at duration of study;

Study	DaPP trial: Lassen 1998 ¹⁹⁰
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=Dalteparin (extended duration): 140; Dalteparin (standard duration): 141)
Countries and setting	Conducted in Denmark; Setting: 8 Danish orthopaedic centres (Aalborg, Silkeborg, Kolding, Horsens, Holstebro, Slagelse, Viborg, and Gentofte hospitals)
Line of therapy	Not applicable
Duration of study	Intervention + follow up: 35 days
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: The criterion for DVT was presence of intraluminal filling defects in at least two projections. The criteria for DVT used in the ultrasound examinations were presence of an intraluminal echo in the deep veins and/or loss of compressibility in a venous segment. The criteria for PE were those reported by PIOPED.
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Patients admitted for total hip arthroplasty (primary or revision) between January and November 1994.
Exclusion criteria	Aged under 18 years; previous surgery in the study; simultaneous participation in other pharmacological studies;

Study	DaPP trial: Lassen 1998 ¹⁹⁰
	informed consent not obtained; high probability for drop-out; renal insufficiency (creatinine $\leq 200\mu\text{mol/l}$); hepatic insufficiency and prothrombin < 0.7 (relative activity); platelet count $< 100 \times 10^9/\text{L}$; treatment with oral anticoagulants or heparin within seven days before inclusion; hypersensitivity to heparin, LMWH or contrast media; documented bleeding within three months prior to surgery; intracranial bleeding within 3 months prior to surgery; eye, ear, or CNS surgery within one month prior to surgery; hypertension with diastolic pressure $> 120\text{mmHg}$; septic endocarditis; body weight $< 40\text{kg}$; and known pregnancy or lactation.
Recruitment/selection of patients	Not reported
Age, gender and ethnicity	Age - Median (range): Dalteparin: 68 (30-94); Placebo: 70 (28-91). Gender (M:F): Dalteparin: 66/74; Placebo: 62/79. Ethnicity: Not reported
Further population details	1. BMI : Not applicable 2. Renal impairment: Not applicable
Indirectness of population	No indirectness
Interventions	(n=140) Intervention 1: Low molecular weight heparin (licensed in UK) - Dalteparin (1,250 units once daily - 5,000 units twice daily). 5000 IU once daily (standard dose) subcutaneously from 12 hours before operation until 35 days after operation (extended duration). Duration 35 days. Concurrent medication/care: AES permitted (n=141) Intervention 2: Low molecular weight heparin (licensed in UK) - Dalteparin (1,250 units once daily - 5,000 units twice daily). 5000 IU once daily (standard dose) subcutaneously from 12 hours before operation until 7 days after operation (standard duration). Placebo, isotonic sodium chloride subcutaneously administered until 35 days. Duration 35 days. Concurrent medication/care: AES permitted
Funding	Funding not stated
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: DALTEPARIN (1,250 UNITS ONCE DAILY - 5,000 UNITS TWICE DAILY) versus DALTEPARIN (1,250 UNITS ONCE DAILY - 5,000 UNITS TWICE DAILY)</p> <p>Protocol outcome 1: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge - Actual outcome: DVT at 35 days; Group 1: 5/113, Group 2: 12/102 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Baseline details: Previous DVT - Dalteparin (extended duration): 10; Dalteparin (standard duration): 5; Group 1 Number missing: 27; Group 2 Number missing: 39</p> <p>Protocol outcome 2: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect;</p>	

Study	DaPP trial: Lassen 1998 ¹⁹⁰
	<p>autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge - Actual outcome: PE at 35 days; Group 1: 0/140, Group 2: 0/141 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Baseline details: Previous DVT - Dalteparin (extended duration): 10; Dalteparin (standard duration): 5; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 3: Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge - Actual outcome: Major bleeding (definition not reported) at 35 days; Group 1: 0/140, Group 2: 1/141 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Baseline details: Previous DVT - Dalteparin (extended duration): 10; Dalteparin (standard duration): 5; Group 1 Number missing: 27; Group 2 Number missing: 39</p> <p>Protocol outcome 4: DVT (distal) at 7-90 days from hospital discharge - Actual outcome: DVT distal at 35 days; Group 1: 4/113, Group 2: 7/102</p> <p>Protocol outcome 5: DVT (proximal) at 7-90 days from hospital discharge - Actual outcome: DVT proximal at 35 days; Group 1: 1/113, Group 2: 5/102</p>
<p>Protocol outcomes not reported by the study</p>	<p>All-cause mortality at up to 90 days from hospital discharge; Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQspect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Surgical site haematoma at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study; Infection at duration of study;</p>

Bibliographic reference	Study Type	Evidence level	No. of patients	Patients characteristics	Intervention	Comparison	Length of follow up	Outcome measures	Effect size	Comments
Lassen 2002 ¹⁸⁹	RCT	1+	Total: 2309 Intervention n: 1155 Control n: 1154	Type of surgery: Patients scheduled for primary elective total hip-replacement surgery or revision of at	2.5 mg of Fondaparinux sodium and a placebo. The first active dose was given 6±2 hrs postoperatively	40 mg of Enoxaparin 1x/day and placebo. The first active dose was given 12±2 hrs preoperatively	49 days study period 11 days	DVT Confirmed by: systematic bilateral ascending venography (number of events/ total number)	Int: 36/908 Control: 83/918 p value: <0.0001; RRR:- 56.1% (95% CI)	Funding: study supported by NV Organon and Sanofi-Synthelabo. * ** defined as fatal

Bibliographic reference	Study Type	Evidence level	No. of patients	Patients characteristics	Intervention	Comparison	Length of follow up	Outcome measures	Effect size	Comments
				Orthopaedic surgery within the previous 12 months: Intervention: 85 (9%) Control: 84 (9%)		platelet therapy (not aspirin) = 30/919 NSAIDs or aspirin: 493/919		Proximal DVT * Confirmed by: systematic bilateral ascending venography	Int: 6/922 Control: 23/927 p value: 0.002	
								Non-fatal PE Confirmed by: lung scan, pulmonary angiography or helical computed tomography or at autopsy Follow-up: 49 days	Int: 3/1129 Control: 3/1123 p value: N/A	
								Fatal PE Confirmed by: Follow-up: 49 days	Int: 1/1129 Control: 1/1123 p value: N/A	
								Major bleeding **	Int: 47/1140 Control: 32/1133 p value: 0.57	
								Fatal bleeding	Int: 0/1140 Control: 0/1133	

Bibliographic reference	Study Type	Evidence level	No. of patients	Patients characteristics	Intervention	Comparison	Length of follow up	Outcome measures	Effect size	Comments
									p value: N/A	
								Bleeding leading to re-operation	Int: 5/1140 Control: 3/1133 p value: 0.7261	
								other bleeding – number (%)	Int: 44/1140 Control: 38/1133 p value: 0.5743	
								Postoperative transfusions – number (%)	Int: 714/1140 Control: 690/1133 p value:	
								Death from any cause - number (%) Up to day 11	Int: 0/1140 Control: 2/1133 p value: 0.4122 Int: 2/1140 Control: 4/1133 p value: 0.4122	
								Death from any cause - number (%) Up to day 49		

Study	ADVANCE-3 trial: Lassen 2010 ¹⁹⁴
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	N/A (n=5407)
Countries and setting	Conducted in Multiple countries; Setting: Secondary care
Line of therapy	Not applicable
Duration of study	Intervention + follow up: Intervention 32 to 38 days + Follow-up at 65 and 95 days after surgery
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: Mandatory bilateral venography was performed on the participants on certain days, presumably for DVT assessment, but no other specific diagnostic equipments have been mentioned in the method section, for example for assessment of PE. "Objective tests were performed in patients with clinically suspected VTE to confirm or rule out the diagnosis". Autopsy was performed whenever possible.
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Anyone scheduled to undergo elective total hip replacement or revision of a previously inserted hip prosthesis
Exclusion criteria	Major exclusion criteria: active bleeding; contraindication to anticoagulant prophylaxis; need for ongoing anticoagulant/antiplatelet treatment (full list provided in an appendix)
Recruitment/selection of patients	Potentially eligible patients were identified during a screening period of up to 14 days before surgery and were randomly assigned to the interventions.
Age, gender and ethnicity	Age - Mean (range): Apixaban 60.9 (19-92) vs. Enoxaparin 60.6 (19-93). Gender (M:F): 2526:2881. Ethnicity: White 90.6%; Asian 6.8%; Black 2.4%; American Indian / Native Alaskan 0.06%; Hawaiian / Pacific Islander 0.02%; Other 0.07%
Further population details	1. BMI : Not applicable 2. Renal impairment: Not applicable
Extra comments	.
Indirectness of population	No indirectness
Interventions	(n=2708) Intervention 1: Apixaban - Apixaban (all doses). Orally 2.5mg twice daily. Duration 32 to 38 days. Concurrent medication/care: Placebo injections once daily to match enoxaparin (n=2699) Intervention 2: Low molecular weight heparin (licensed in UK) - Enoxaparin (20mg once daily – 60mg twice daily). Subcutaneous injections 40mg once daily. Duration 32 to 38 days. Concurrent medication/care: Placebo tablets twice daily to match apixaban
Funding	Study funded by industry (Bristol-Myers Squibb and Pfizer)

Study	ADVANCE-3 trial: Lassen 2010 ¹⁹⁴
RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: APIXABAN versus ENOXAPARIN	
<p>Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge</p> <p>- Actual outcome: Death during treatment period at 32 to 38 days; Group 1: 3/2708, Group 2: 1/2699</p> <p>Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;</p> <p>Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0</p> <p>- Actual outcome: Death during follow-up period at 60 days after the end of treatment period; Group 1: 2/2598, Group 2: 1/2577</p> <p>Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low;</p> <p>Indirectness of outcome: No indirectness ; Group 1 Number missing: 110, Reason: Did not complete follow-up evaluation; Group 2 Number missing: 122, Reason: Did not complete follow-up evaluation</p>	
<p>Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge</p> <p>- Actual outcome: All DVT during treatment period at 32 to 38 days; Group 1: 22/1944, Group 2: 68/1911</p> <p>Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low;</p> <p>Indirectness of outcome: No indirectness ; Group 1 Number missing: 764, Reason: Did not have adjudicated bilateral venogram that could be evaluated or did not have adjudicated symptomatic or asymptomatic DVT; Group 2 Number missing: 788, Reason: Did not have adjudicated bilateral venogram that could be evaluated or did not have adjudicated symptomatic or asymptomatic DVT</p>	
<p>Protocol outcome 3: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge</p> <p>- Actual outcome: All PE during treatment period at 32 to 38 days; Group 1: 3/2708, Group 2: 5/2699</p> <p>Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;</p> <p>Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0</p>	
<p>Protocol outcome 4: Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge</p> <p>- Actual outcome: Major bleeding during treatment period at 32 to 38 days; Group 1: 22/2673, Group 2: 18/2659; Comments: ARD 0.1 (95% CI -0.3 to 0.6); $p=0.54$</p> <p>Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low;</p> <p>Indirectness of outcome: No indirectness, Comments: Defined as the composite of adjudicated symptomatic or asymptomatic proximal DVT, non-fatal PE or death related to VTE; Group 1 Number missing: 35, Reason: Did not receive any study drug; Group 2 Number missing: 40, Reason: Did not receive any study drug</p>	
<p>Protocol outcome 5: Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy;</p>	

Study	ADVANCE-3 trial: Lassen 2010 ¹⁹⁴
	<p>echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge - Actual outcome: Fatal PE during treatment period at 32 to 38 days; Group 1: 1/2708, Group 2: 0/2699 Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0</p> <p>Protocol outcome 6: Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge - Actual outcome: Clinically relevant non-major bleeding during treatment period at 32 to 38 days; Group 1: 109/2673, Group 2: 120/2659; Comments: ARD -0.4 (95%CI -1.5 to 0.7); p=0.43 Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness, Comments: Defined as the composite of adjudicated symptomatic or asymptomatic proximal DVT, non-fatal PE or death related to VTE; Group 1 Number missing: 35, Reason: Did not receive any study drug; Group 2 Number missing: 40, Reason: Did not receive any study drug</p> <p>Protocol outcome 7: VTE at 7-90 days from hospital discharge - Actual outcome: Major VTE during treatment period at 32 to 38 days; Group 1: 10/2199, Group 2: 25/2195; Comments: RR 0.40 (95% CI 0.15 to 0.80); ARD -0.7 (95% CI -1.3 to -0.2); p=0.01</p> <p>Protocol outcome 8: DVT (symptomatic) at 7-90 days from hospital discharge - Actual outcome: Symptomatic DVT during follow-up period at 60 days after the end of treatment period; Group 1: 0/2598, Group 2: 3/2577</p> <p>Protocol outcome 9: DVT (proximal) at 7-90 days from hospital discharge - Actual outcome: DVT (proximal) at 32 to 38 days; Group 1: 7/2196, Group 2: 20/2190</p> <p>Protocol outcome 10: Fatal bleeding at 45 days from hospital discharge - Actual outcome: Fatal bleeding during treatment period at 32 to 38 days; Group 1: 0/2708, Group 2: 0/2699</p> <p>Protocol outcome 11: Site of bleeding (gastrointestinal ; surgical site; brain/spine; other) at 45 days from hospital discharge - Actual outcome: Surgical site bleeding at 32 to 38 days; Group 1: 18/2673, Group 2: 16/2659 - Actual outcome: Haemarthrosis in the operated joint at 32 to 38 days; Group 1: 2/2673, Group 2: 4/2659</p>
Protocol outcomes not reported by the study	Surgical site haematoma at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study; Infection at duration of study;

Study	Levine 1991 ²⁰⁸
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=LMWH: 333; standard heparin: 332)
Countries and setting	Conducted in Canada; Setting: Not reported
Line of therapy	Not applicable
Duration of study	Intervention + follow up: 10-14 days
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: DVT was diagnosed using venograms
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	People undergoing elective hip replacement surgery
Exclusion criteria	Less than 40 years of age; had an underlying bleeding disorder; had a history of allergy to iodine or radiopaque dye; had severe hepatic or renal disease; had had a myocardial infarction or stroke within the previous 6 months; had an underlying psychiatric or addictive disorder; or were required to receive aspirin, long-term oral anticoagulant therapy, non-steroidal anti-inflammatory medications, indomethacin, or other antiplatelet therapy during hospitalization.
Recruitment/selection of patients	Not reported
Age, gender and ethnicity	Age - Mean (SD): LMWH: 66.2 (10.39); Standard heparin: 66.8 (9.09). Gender (M:F): LMWH: 145/188; Standard heparin: 160/172. Ethnicity: Not reported
Further population details	1. BMI : Not applicable 2. Renal impairment: Not applicable
Indirectness of population	No indirectness
Interventions	(n=333) Intervention 1: Low molecular weight heparin (licensed in UK) - Enoxaparin (20mg once daily – 60mg twice daily). 30mg twice daily (high dose) subcutaneously, from 12-24 hours after surgery continued for 14 days or until discharge if sooner. Duration 10-14 days. Concurrent medication/care: Not reported (n=332) Intervention 2: Unfractionated heparin - Unfractionated heparin (low dose, administered subcutaneously). 7500 IU twice daily subcutaneously from 12-24 hours after surgery continued for 14 days or until discharge if sooner. Duration 10-14 days. Concurrent medication/care: Not reported
Funding	Other (Heart and Stroke Foundation of Ontario and the Medical Research Council of Canada)

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: ENOXAPARIN (20MG ONCE DAILY – 60MG TWICE DAILY) versus UNFRACTIONATED HEPARIN

Study	Levine 1991 ²⁰⁸
<p>(LOW DOSE, ADMINISTERED SUBCUTANEOUSLY)</p> <p>Protocol outcome 1: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge - Actual outcome: DVT at 10-14 days; Group 1: 50/258, Group 2: 61/263 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 75; Group 2 Number missing: 69</p> <p>Protocol outcome 2: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQspect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge - Actual outcome: PE at 10-14 days; Group 1: 1/333, Group 2: 1/332 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 3: Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge - Actual outcome: Major bleeding at 10-14 days; Group 1: 11/333, Group 2: 19/332 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 4: DVT (distal) at 7-90 days from hospital discharge - Actual outcome: DVT distal at 10-14 days; Group 1: 36/258, Group 2: 44/263</p> <p>Protocol outcome 5: DVT (proximal) at 7-90 days from hospital discharge - Actual outcome: DVT proximal at 10-14 days; Group 1: 14/258, Group 2: 17/263</p>	
<p>Protocol outcomes not reported by the study</p>	<p>All-cause mortality at up to 90 days from hospital discharge; Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQspect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Surgical site haematoma at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study; Infection at duration of study;</p>

Bibliographic reference	Study Type	Evidence level	No. of patients	Patients characteristics	Intervention	Comparison	Length of follow up	Outcome measures	Effect size	Comments
Manganelli 1998 ²¹³	RCT	1+	Total: 79 randomised Intervention: n = 33 Control: n = 28 18 withdrawals (8 intervention, 10 control).	Type of surgery: Elective total hip replacement	Type: Extended duration unfractionated heparin Dose: 5000 IU	Type: unfractionated heparin Dose: 5000 IU Timing: 5000 IU from 1 day pre-op, every 8hrs until discharge.	Both groups: 45 days post-op	DVT Confirmed by: unilateral ascending venography on 45th day post-op (earlier if symptomatic)	Int: 4/33 Control: 6/28 p value: 0.48	Comments: Patients randomised at discharge. 2 patients had objectively confirmed PE, but the paper does not report the study group these patients were in. Not reported: PE, PTS, QoL, Survival, funding
				Intervention: Mean age: 65±8.2 yrs M/F:10/23	Timing: 5000 IU from 1 day pre-op, every 8hrs for 30 days	Proximal DVT Confirmed by: unilateral ascending venography on 45th day post-op (earlier if symptomatic)		Int: 1/33 Control: 5/28 p value: 0.08		
				Control: Mean age: 66.2±11.5 M/F:15/23	Additional non-comparative prophylaxis: Not reported	Major haemorrhage clinically overt and associated with a decrease in haemoglobin values of 2g/dl or more, compared with the last		Int: 0/33 Control: 0/33 p value: N/A		
				Pre-existing risk factors: Obesity (no significant differences between groups)						

Bibliographic reference	Study Type	Evidence level	No. of patients	Patients characteristics	Intervention	Comparison	Length of follow up	Outcome measures	Effect size	Comments
								post- op value, or a need for blood transfusion, or if it was retroperitoneal or intracranial		
								Length of Hospital Stay	Int: 12±2 days Control: 12±3 days p value: Not significant	

Study	Mannucci 1976 ²¹⁴
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	2 (n=Trials 1: n=96, Trial 2: n=47)
Countries and setting	Conducted in Italy; Setting: Not reported
Line of therapy	Not applicable
Duration of study	Intervention + follow up: 7-15 days
Method of assessment of guideline condition	Adequate method of assessment/diagnosis
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Patients aged 40 or more and undergoing elective operation of hip replacement for osteoarthritis or elective hip arthroplasty
Exclusion criteria	Not reported
Recruitment/selection of patients	Not reported

Study	Mannucci 1976 ²¹⁴
Age, gender and ethnicity	Age - Mean (SD): Trial 1: 60.1, Trial 2: 59.4. Gender (M:F): 1:4. Ethnicity: Not reported
Further population details	1. BMI : Not applicable 2. Renal impairment: Not applicable
Indirectness of population	No indirectness
Interventions	(n=68) Intervention 1: Unfractionated heparin - Unfractionated heparin (low dose, administered subcutaneously). 5000U of subcutaneous heparin 2 hours preoperatively and 8 hourly postoperatively until patients were full ambulatory on crutches. Duration Not reported. Concurrent medication/care: Analgesic therapy using paracetamol or pentazocine (n=75) Intervention 2: No treatment - Usual care. No treatment. Duration Not reported. Concurrent medication/care: Analgesic therapy using paracetamol or pentazocine
Funding	Study funded by industry (Supported in part by a grant from the Fondazione Angelo Bianchi Bonomi)

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: UNFRACTIONATED HEPARIN (LOW DOSE, ADMINISTERED SUBCUTANEOUSLY) versus USUAL CARE

Protocol outcome 1: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge
 - Actual outcome: DVT (symptomatic and asymptomatic) at Not reported; Group 1: 14/68, Group 2: 36/75; Comments: Trial 1: UFH 9/45, Control 22/51
 Trial 2: UFH 5/23, Control 14/24

Risk of bias: All domain - High, Selection - Low, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;
 Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcome 2: Surgical site haematoma at up to 45 days from hospital discharge
 - Actual outcome: Wound haematoma at Not reported; Group 1: 12/68, Group 2: 1/75; Comments: Trial 1: UFH 9/45, Control 0/51
 Trial 2: UFH 3/23, control 1/24

Risk of bias: All domain - High, Selection - Low, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;
 Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcome 3: DVT (distal) at 7-90 days from hospital discharge
 - Actual outcome: DVT (distal) at Not reported; Group 1: 7/68, Group 2: 25/75; Comments: Trial 1: UFH 4/45, Control 15/51
 Trial 2: UFH 3/23, Control 10/24

Study	Mannucci 1976 ²¹⁴
<p>Protocol outcome 4: DVT (proximal) at 7-90 days from hospital discharge - Actual outcome: DVT (proximal) at Not reported; Group 1: 7/68, Group 2: 11/75; Comments: Trial 1: UFH 5/45, Control 7/51 Trial 2: UFH 2/23, Control 4/24</p>	
Protocol outcomes not reported by the study	<p>All-cause mortality at up to 90 days from hospital discharge; Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge; Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge; Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study; Infection at duration of study;</p>

Study	Moskovitz 1978 ²³¹
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=67)
Countries and setting	Conducted in USA; Setting: Two hospitals
Line of therapy	Not applicable
Duration of study	Not clear:
Method of assessment of guideline condition	Adequate method of assessment/diagnosis
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Patients scheduled to undergo total hip arthroplasty
Exclusion criteria	A prior history of venous thromboembolic events, a history of gastric or duodenal ulcer with haemorrhage within the previous 6 months, a positive stool guaiac, haematuria, a sensitivity to iodinated compounds, or a diastolic blood

Study	Moskovitz 1978 ²³¹
	pressure greater than 100ml of mercury. Other reasons for exclusion were a patient's refusal to be involved and technical problems and errors in the collection of data or in the conduct of the protocol.
Recruitment/selection of patients	Not reported
Age, gender and ethnicity	Age - Mean (SD): 46% ≥60 years; 54% <59 years. Gender (M:F): 1:1. Ethnicity: 76.1% white, 23.8% black
Further population details	1. BMI : Not applicable 2. Renal impairment: Not applicable
Indirectness of population	No indirectness
Interventions	<p>(n=35) Intervention 1: Unfractionated heparin - Unfractionated heparin (low dose, administered subcutaneously). UFH (sodium heparin), 5000U subcutaneously every 8 hours, beginning the day of surgery for a total of 21 doses (7 days). Patients wore AES (length unspecified), length of time AES worn for not reported. Duration Not reported. Concurrent medication/care: Not reported</p> <p>(n=32) Intervention 2: Anti-embolism stockings - Mixed above/below knee. Placebo, saline, subcutaneously given every 8 hours. Patients wore AES (length unspecified), length of time AES worn for not reported.</p> <p>. Duration Not reported. Concurrent medication/care: Not reported</p>
Funding	Funding not stated
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: UNFRACTIONATED HEPARIN (LOW DOSE, ADMINISTERED SUBCUTANEOUSLY) versus MIXED ABOVE/BELOW KNEE</p> <p>Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge - Actual outcome: All-cause mortality at Not reported; Group 1: 0/35, Group 2: 0/32 Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge - Actual outcome: DVT (symptomatic and asymptomatic) at Not reported; Group 1: 8/32, Group 2: 19/28 Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 3; Group 2 Number missing: 4</p>	

Study	Moskovitz 1978 ²³¹
	<p>Protocol outcome 3: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge - Actual outcome: PE at Not reported; Group 1: 3/35, Group 2: 1/32 Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 4: Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge - Actual outcome: Major bleeding at Not reported; Group 1: 3/35, Group 2: 0/32 Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 5: DVT (distal) at 7-90 days from hospital discharge - Actual outcome: DVT (distal) at Not reported; Group 1: 4/32, Group 2: 9/28</p> <p>Protocol outcome 6: DVT (proximal) at 7-90 days from hospital discharge - Actual outcome: DVT (proximal) at Not reported; Group 1: 4/32, Group 2: 10/28</p>
<p>Protocol outcomes not reported by the study</p>	<p>Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Surgical site haematoma at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study; Infection at duration of study;</p>

Bibliographic reference	Study Type	Evidence level	No. of patients	Patients characteristics	Intervention	Comparison	Length of follow up	Outcome measures	Effect size	Comments
Paiement 1987 ²⁴⁸	RCT	1+	Total: 165 (138 completed study) Intervention: n: n = 66 (17 left study) Control: n = 72 (8 left study)	Type of surgery: Total hip replacement Duration of surgery not reported Intervention: Mean age: Not reported M/F:70/68 in the study. Control: Mean age: Not reported M/F:70/68 in the study.	Type: Bilateral thigh-length IPCD device Dose: 45-55 mmHg Timing: Started evening before operation. Worn continuously Additional non-comparative prophylaxis: Not reported	Type: Warfarin (low-dose) Dose: 10 mg pre-op, 5 mg post-op, thereafter adjusted to maintain PTT at 15 seconds for control at 11 - 12 seconds Timing: Started evening before operation, discontinued 2 days post phlebography if negative result	10 days	DVT Confirmed by: Venography 10th day post-op. Performed on operated limb first. If negative, contralateral limb also assessed	Int: 11/66 Control: 12/72 p value: Not significant	Comments: Patients stratified by sex and previous history of VTE prior to randomisation. 4 of 17 patients who withdrew from IPCD group did so due to intolerance of IPCD device. None of DVTs occurred in patients with previous history of VTE Not reported: PTS, LoS, QoL,
								Proximal DVT Confirmed by: Venography	Int: 9/66 Control: 4/72 p value: < 0.057	
								PE Not routinely screened for. Symptomatic PE investigated by V/Q and angiogram if high probability	Int: 0 Control: 0 p value: not reported	

Bibliographic reference	Study Type	Evidence level	No. of patients	Patients characteristics	Intervention	Comparison	Length of follow up	Outcome measures	Effect size	Comments
						Additional non-comparative prophylaxis: Not reported		Bleeding related complications Major bleeding (overt and associated with decrease in haemoglobin level of $\geq 2\text{g/dl}$; required transfusion of 2 or more units; retroperitoneal or occurred in major prosthetic joint; intracranial); Intraoperative and post-operative blood loss (weight of sponges; suction drainage blood	Major bleeding: Int: 0/66 Control: 0/72 p value: N/A Overall blood loss for primary procedures: Int: 1821 ± 721 ml Control: 1861 ± 648 ml Not significant Revision cases Int: 3122 ± 1700 ml Control : 3218 ± 2076 ml Not significant loss; estimates of blood on wound drapes	Survival, Funding info

Bibliographic reference	Study Type	Evidence level	No. of patients	Patients characteristics	Intervention	Comparison	Length of follow up	Outcome measures	Effect size	Comments
Pitto 2004 259	RCT	1+	Total: 216 Intervention: n = 100 Control: n = 100	Type of surgery: Total hip replacement in patients with osteoarthritis Intervention: Mean age: 57.3±12 yrs M/F:30/70 Mean duration of surgery: 69+10 minutes Control: Mean age: 58.1±11 M/F:32/68 Mean duration of surgery: 65+11 minutes	Type: A-V Impulse System foot pump (slippers) and patient in Trendelenburg position (head-high, feet-low) Cycle: 130 mmHg for one second every 20 seconds Timing: (duration) started after surgery, not stated when stopped - could be used until discharge Additional non-comparative prophylaxis: Bilateral thigh-high anti-thromboembolic stockings.	Type: Low molecular weight heparin (Fraxiparin) continued after surgery Dose: adjusted to body weight, 0.2 to 0.6ml; 0.1ml = 950IU of anti Xa. Timing: started postoperatively, not stated when stopped but could be until discharge. Additional non-comparative	Control: 45 days Int: 45 days	DVT Confirmed by: serial bilateral duplex	Int: 3/97 Control: 6/94 p value: 0.30	Comments: Discrepancy with randomisation: computer generated numbers lead to 100 in each group but 216 were randomised. 16 dropped out of mechanical group because did not tolerate foot pump. Dropouts occurred between postoperative days 3 and 10. Not reported: PE, LoS, Post-thrombotic leg
								Proximal DVT Confirmed by: serial bilateral duplex	Int: 0/97 Control: 2/94 p value: 0.29	
								Distal DVT Confirmed by: serial bilateral duplex	Int: 3/97 Control: 4/94 p value: 0.67 Not significant	
								Symptomatic DVT Confirmed by: serial bilateral duplex	Int: 1/100 Control: 1/100 Not significant	
								PE Confirmed by:	Int: 0/100 Control: 0/100	
								Fatal PE Confirmed by:	Int: 0/100 Control: 0/100	
								Major bleeding from wound	Int: 0/100 Control: 0/100	
								Major	Int: 0/100	

Bibliographic reference	Study Type	Evidence level	No. of patients	Patients characteristics	Intervention	Comparison	Length of follow up	Outcome measures	Effect size	Comments
					Physiotherapy and mobilisation with partial weight bearing usually started on postoperative day 2. Low molecular weight heparin (Fraxiparin) administered subcutaneously 12 hours preoperatively (dose adjusted to body weight, 0.2 to 0.6ml; 0.1ml = 950IU of anti Xa).	prophylaxis: Bilateral thigh-high anti-thromboembolic stockings. Physiotherapy and mobilisation with partial weight bearing usually started on postoperative day 2. Low molecular weight heparin (Fraxiparin) administered subcutaneously 12 hours preoperatively (dose adjusted to body weight, 0.2 to 0.6ml; 0.1ml = 950IU of anti Xa).		bleeding not related to wound Heparin-induced thrombocytopenia Survival	Control: 0/100 Int: 0/100 Control: 1/100 p value not reported Int: 100/100 Control: 100/100	Also reported: Distal DVT, minor bleeding from wound; no. of hips without bruising at days 3 & 10, no. of hips without oozing at days 3 & 10 Funding: stated that authors have or will receive benefits from a commercial party directly related to the subject of this study. Does not state who the commercial party is nor what the benefits are.

Study	Planès 1990 ²⁶³
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n= Trial 1: n=100; Trial 2: n=237)
Countries and setting	Conducted in France
Line of therapy	Not applicable
Duration of study	Intervention + follow up: 12-14 days
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: DVT confirmed by bilateral ascending venography
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Trial 1: Consecutive people operated on for THR and iterative total hip replacement. Trial 2: Consecutive people who were 45 years of age or older, over 45kg and undergoing elective hip replacement.
Exclusion criteria	Trial 1: Not reported Trial 2: Patients younger than 45 years, under 45kg, with a past history of thromboembolism, those operated on under spinal anaesthesia, those undergoing revision hip surgery, with recent hip trauma, with thrombocytopenia, with renal insufficiency, with recent gastrointestinal bleeding, with a deficit in antithrombin III, under anticoagulant therapy or with an activated partial thromboplastin time (APTT) 10 sec longer than the control, under antiplatelet therapy during the 8 days prior to surgery, with an iodine sensitivity, and those who refused informed consent for the study or the phlebography.
Recruitment/selection of patients	Consecutive recruitment
Age, gender and ethnicity	Age - Other: Trail 1 (mean): 65; Trial 2 (age ± SD): Group A: 63.08 ± 9.52; Group B: 64.44 ± 9.62. Gender (M:F): Trial 1: 1:1; Trial 2: Not reported. Ethnicity: Not reported
Further population details	1. BMI : Not applicable 2. Renal impairment: Not applicable
Indirectness of population	No indirectness
Interventions	(n=150) Intervention 1: Low molecular weight heparin (licensed in UK) - Enoxaparin (20mg once daily – 60mg twice daily). Enoxaparin 40mg once daily (standard dose) subcutaneously from 12 hours pre-operation. Duration unclear, possibly until discharge. Concurrent medication/care: Not reported (n=78) Intervention 2: Low molecular weight heparin (licensed in UK) - Enoxaparin (20mg once daily – 60mg twice daily). Enoxaparin 60mg once daily (high dose) subcutaneously from 12 hours pre-operation. Duration of intervention unclear, possibly until discharge. Concurrent medication/care: Not reported

Study	Planès 1990²⁶³
	<p>(n=124) Intervention 3: Low molecular weight heparin (licensed in UK) - Enoxaparin (20mg once daily – 60mg twice daily). Enoxaparin 40mg once daily (standard dose) subcutaneously from 12 hours preoperatively for 14 days or until hospital discharge. Duration Unclear. Concurrent medication/care: Not reported</p> <p>(n=113) Intervention 4: Unfractionated heparin - Unfractionated heparin (low dose, administered subcutaneously). Calcium heparin, 5000 IU subcutaneously every 8 hours from 2 hours pre-operation for 14 days or until hospital discharge. Duration 14 days. Concurrent medication/care: Not reported</p>
Funding	Funding not stated
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: ENOXAPARIN (20MG ONCE DAILY – 60MG TWICE DAILY) versus ENOXAPARIN (20MG ONCE DAILY – 60MG TWICE DAILY)</p> <p>Protocol outcome 1: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge - Actual outcome: DVT at 12-15 days; Group 1: 12/150, Group 2: 5/78 Risk of bias: All domain - Very high, Selection - Very high, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 2: Surgical site haematoma at up to 45 days from hospital discharge - Actual outcome: Wound haematoma at 12-15 days; Group 1: 3/50, Group 2: 6/50 Risk of bias: All domain - Very high, Selection - Very high, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 100; Group 2 Number missing: 28</p> <p>Protocol outcome 3: DVT (distal) at 7-90 days from hospital discharge - Actual outcome: DVT distal at 12-15 days; Group 1: 4/150, Group 2: 2/28</p> <p>Protocol outcome 4: DVT (proximal) at 7-90 days from hospital discharge - Actual outcome: DVT proximal at 12-15 days; Group 1: 8/150, Group 2: 3/28</p> <p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: ENOXAPARIN (20MG ONCE DAILY – 60MG TWICE DAILY) versus UNFRACTIONATED HEPARIN (LOW DOSE, ADMINISTERED SUBCUTANEOUSLY)</p> <p>Protocol outcome 1: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler)</p>	

Study	Planès 1990 ²⁶³
	<p>ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge - Actual outcome: DVT at Unclear; Group 1: 15/120, Group 2: 27/106 Risk of bias: All domain - Very high, Selection - Very high, Blinding - Very high, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 4; Group 2 Number missing: 7 - Actual outcome: DVT at Unclear; Risk of bias: All domain - ; Indirectness of outcome: No indirectness</p> <p>Protocol outcome 2: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge - Actual outcome: PE at Unclear; Group 1: 0/120, Group 2: 1/106 Risk of bias: All domain - Very high, Selection - Very high, Blinding - Very high, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - High, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 4; Group 2 Number missing: 7</p> <p>Protocol outcome 3: Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge - Actual outcome: Major bleeding at Unclear; Group 1: 2/120, Group 2: 0/106 Risk of bias: All domain - Very high, Selection - Very high, Blinding - Very high, Incomplete outcome data - High, Outcome reporting - Low, Measurement - High, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 4; Group 2 Number missing: 7</p> <p>Protocol outcome 4: DVT (distal) at 7-90 days from hospital discharge - Actual outcome: DVT distal at Unclear; Group 1: 6/120, Group 2: 7/106</p> <p>Protocol outcome 5: DVT (proximal) at 7-90 days from hospital discharge - Actual outcome: DVT proximal at Unclear; Group 1: 9/120, Group 2: 20/106</p>
Protocol outcomes not reported by the study	<p>All-cause mortality at up to 90 days from hospital discharge; Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study; Infection at duration of study;</p>

Study	Planes 1996 ²⁶²
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=179)
Countries and setting	Conducted in France; Setting:
Line of therapy	Not applicable
Duration of study	Intervention + follow up: 19-23 days
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: DVT confirmed by bilateral phlebographic examination. PE confirmed by pulmonary angiography or by autopsy. Major bleeding defined as overt and associated with either a fall in haemoglobin level of $\geq 20\text{g/L}$ or a need for transfusion of 2 or more units of blood, or if it was retroperitoneal or intracranial.
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	People considered for the study were aged more than 45 years, weighed between 45 and 95 kilograms, had undergone primary THR and received enoxaparin as prophylaxis for postoperative venous thromboembolism while hospitalised. Patients could be included if after surgery, they could walk with the help of crutches - but otherwise unassisted - using the operated leg to give firm support, and if they were free of DVT as assessed by an initial bilateral ascending venography performed within the 5 days prior to discharge.
Exclusion criteria	History of documented thromboembolism during the last 6 months; cancer in progression; an underlying bleeding disorder or an abnormality in haemostasis (such as platelet count $< 100\,000/\text{mm}^3$, a prothrombin INR of > 1.5 , or an activated prothrombin time > 8 seconds longer than that of control), or active gastroduodenal ulcer; a known allergy to heparin or contrast media; renal or hepatic insufficiency; uncontrolled arterial hypertension; recent stroke; or inability to give informed consent.
Recruitment/selection of patients	Consecutive recruitment
Age, gender and ethnicity	Age - Mean (SD): LMWH: 70 (9.1); Placebo: 68 (8.2). Gender (M:F): LMWH: 47/43; Placebo: 55/34. Ethnicity: Not reported
Further population details	1. BMI : Not applicable 2. Renal impairment: Not applicable
Indirectness of population	No indirectness
Interventions	(n=90) Intervention 1: Low molecular weight heparin (licensed in UK) - Enoxaparin (20mg once daily – 60mg twice daily). 40mg once daily (standard dose), subcutaneously from 12 hours pre-operatively, 12 hours postoperatively, until 21 ± 2 days (extended duration). Duration 21 ± 2 days. Concurrent medication/care: Patients were advised to wear

	<p>elastic bandages/AES on both legs (% of patients that used AES not reported), avoid other anticoagulant treatment, aspirin, ticlopidine and NSAIDs</p> <p>(n=89) Intervention 2: No treatment - Placebo. Isotonic saline 0.4ml. Duration 21±2 days. Concurrent medication/care: Patients were advised to wear elastic bandages/AES on both legs (% of patients that used AES not reported), avoid other anticoagulant treatment, aspirin, ticlopidine and NSAIDs</p>
Funding	Funding not stated

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: ENOXAPARIN (20MG ONCE DAILY – 60MG TWICE DAILY) versus PLACEBO

Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge

- Actual outcome: All-cause mortality at 19-23 days; Group 1: 0/90, Group 2: 0/89

Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge

- Actual outcome: DVT at 19-23 days; Group 1: 6/85, Group 2: 17/88

Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 5; Group 2 Number missing: 1

Protocol outcome 3: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQspect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge

- Actual outcome: PE at 19-23 days; Group 1: 0/90, Group 2: 0/89

Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcome 4: Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of ≥2g/dl; a serious or life threatening clinical event at up to 45 days from hospital discharge

- Actual outcome: Major bleeding at 19-23 days; Group 1: 0/90, Group 2: 0/89

Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

<p>Protocol outcome 5: Surgical site haematoma at up to 45 days from hospital discharge - Actual outcome: Wound haematoma at 19-23 days; Group 1: 1/90, Group 2: 1/89 Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p>	
<p>Protocol outcome 6: DVT (distal) at 7-90 days from hospital discharge - Actual outcome: DVT distal at 19-23 days; Group 1: 1/85, Group 2: 10/88</p>	
<p>Protocol outcome 7: DVT (proximal) at 7-90 days from hospital discharge - Actual outcome: DVT proximal at 19-23 days; Group 1: 5/85, Group 2: 7/88</p>	
<p>Protocol outcomes not reported by the study</p>	<p>Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study; Infection at duration of study;</p>

Study	Prandoni 2002 ²⁶⁶
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=360)
Countries and setting	Conducted in Italy; Setting: University of Padua, Italy
Line of therapy	Not applicable
Duration of study	Follow up (post intervention): 4 weeks post-discharge
Method of assessment of guideline condition	<p>Adequate method of assessment/diagnosis: DVT (symptomatic and asymptomatic): confirmed by compression ultrasound or intraluminal filling defect on ascending phlebography PE : confirmed by a high-probability ventilation-perfusion lung scan, a spiral computed tomographic scan, or an abnormal finding on angiography or (in case of death) autopsy. Major bleeding: defined as clinically overt and associated with either a decrease in haemoglobin of at least 2.9 g/dL or</p>

Study	Prandoni 2002²⁶⁶
	a need for a transfusion of 2 or more units of red blood cells, was intracranial or retroperitoneal or resulted in the permanent discontinuation of anticoagulation.
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Consecutive patients who underwent elective total hip arthroplasty and received warfarin prophylaxis during hospitalisation were potentially eligible for the study provided they had not undergone previous hip surgery on the same side or did not have a history of thromboembolic disorders.
Exclusion criteria	Eligible patients were excluded from the study if they developed venous thromboembolic complications or major bleeding during hospitalisation. Patients with asymptomatic proximal DVT, as shown by a bilateral compression ultrasound examination performed before hospital discharge were also excluded as were those who needed long-term anticoagulation, were unavailable for long-term follow-up or refused to give their written informed consent.
Recruitment/selection of patients	From September 1998 to December 2000
Age, gender and ethnicity	Age - Median (range): 69 (44-87). Gender (M:F): 1/1.2. Ethnicity: Not reported
Further population details	1. BMI : Not applicable 2. Renal impairment: Not applicable
Extra comments	Length of hospitalisation (median): 9 days for both groups
Indirectness of population	No indirectness
Interventions	(n=184) Intervention 1: Vitamin K antagonists - Warfarin (all doses). Patients received 5 mg/d of sodium warfarin starting on the second preoperative day; after the intervention, the dosage was adjusted to increase the INR between 2.0 to 3.0. Duration 4 weeks post-discharge. Concurrent medication/care: n/a (n=176) Intervention 2: Vitamin K antagonists - Warfarin (all doses). Patients received 5 mg/d of sodium warfarin starting on the second preoperative day; after the intervention, the dosage was adjusted to increase the INR between 2.0 to 3.0. Duration Intervention stopped at discharge. Concurrent medication/care: n/a
Funding	Funding not stated

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: WARFARIN (EXTENDED DURATION) versus WARFARIN (STANDARD DURATION)

Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge

- Actual outcome: All-cause mortality at 28 days; Group 1: 0/184, Group 2: 0/176

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Study	Prandoni 2002 ²⁶⁶
Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0	
<p>Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge</p> <p>- Actual outcome: DVT (symptomatic and asymptomatic) at 28 days; Group 1: 3/184, Group 2: 8/176</p> <p>Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;</p> <p>Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0</p>	
<p>Protocol outcome 3: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge</p> <p>- Actual outcome: PE at 28 days; Group 1: 0/184, Group 2: 1/176</p> <p>Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;</p> <p>Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0</p>	
<p>Protocol outcome 4: Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge</p> <p>- Actual outcome: Major bleeding at 28 days; Group 1: 1/184, Group 2: 0/176</p> <p>Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;</p> <p>Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0</p>	
Protocol outcomes not reported by the study	<p>Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Surgical site haematoma at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study; Infection at duration of study;</p>
Study	Samama 1997 ²⁸¹
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=170)

Study	Samama 1997 ²⁸¹
Countries and setting	Conducted in France; Setting:
Line of therapy	Not applicable
Duration of study	Intervention + follow up: 12-90 days
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: DVT confirmed by ultrasonography or venography. PE confirmed by ventilation-perfusion lung scan or angiography.
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Consecutive people aged more than 18 years, weighing 45-95kg, undergoing primary THR surgery under regional anaesthesia (subarachnoid block and catheter removed at the end of the surgical procedure), wearing gradual compression stockings (started the day before surgery).
Exclusion criteria	Re-operation for THR, surgery under general anaesthesia, patients under nail extension before surgery, history of DVT, pulmonary embolism, or both, hepatic or renal insufficiency, lung or heart failure, ASA status more than III, haemorrhagic disorders contraindicating the use of antithrombotic drugs (active ulcerative disease, uncontrolled arterial hypertension, stroke within the previous 6 months or other known haemorrhagic disorders), occurrence of a bloody tap during spinal puncture, platelet count less than 100×10^9 litre ⁻¹ , history of heparin-associated thrombocytopenia or allergic reactions to heparin, low molecular weight heparin or to radiocontrast agents, and women with childbearing potential. In addition patients were excluded if they received heparin for more than 24 hours before surgery, oral anticoagulant treatment within 3 days, antiplatelet drugs within 8 days or non-steroidal anti-inflammatory agents within 2 days before surgery.
Recruitment/selection of patients	Consecutive recruitment
Age, gender and ethnicity	Age - Mean (range): LMWH: 67.2 (36.9-89.21); Placebo: 67.2 (31.6-87.5). Gender (M:F): LMWH: 58/27; Placebo: 41/44. Ethnicity: Not reported
Further population details	1. BMI : Not applicable 2. Renal impairment: Not applicable
Indirectness of population	No indirectness
Interventions	(n=85) Intervention 1: Low molecular weight heparin (licensed in UK) - Enoxaparin (20mg once daily – 60mg twice daily). Enoxaparin 40mg once daily (standard dose) subcutaneously . Duration administered for 10±2 days. Concurrent medication/care: AES (n=85) Intervention 2: No treatment - Placebo. Sodium chloride saline. Duration administered for 10±2 days. Concurrent medication/care: AES

Study	Samama 1997 ²⁸¹
Funding	Funding not stated
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: ENOXAPARIN (20MG ONCE DAILY – 60MG TWICE DAILY) versus PLACEBO</p> <p>Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge - Actual outcome: All-cause mortality at 90 days; Group 1: 0/78, Group 2: 0/75 Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 7; Group 2 Number missing: 10</p> <p>Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge - Actual outcome: DVT at 12 days; Group 1: 11/78, Group 2: 28/75 Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 7; Group 2 Number missing: 10</p> <p>Protocol outcome 3: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge - Actual outcome: PE at 90 days; Group 1: 0/78, Group 2: 0/75 Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 7; Group 2 Number missing: 10</p> <p>Protocol outcome 4: Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge - Actual outcome: Major bleeding defined as overt and associated with either a decrease in haemoglobin of 2g/dl or more, a need for transfusion of 2 units or more of packed red blood cells, if it was retroperitoneal or intracranial, or if it led to surgical re-intervention or death at 12 days; Group 1: 1/78, Group 2: 1/75 Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 7; Group 2 Number missing: 10</p> <p>Protocol outcome 5: Surgical site haematoma at up to 45 days from hospital discharge - Actual outcome: Wound haematoma at 12 days; Group 1: 33/78, Group 2: 20/75 Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 7; Group 2 Number missing: 10</p>	

Study	Samama 1997 ²⁸¹
Protocol outcome 6: DVT (distal) at 7-90 days from hospital discharge - Actual outcome: DVT distal at 12 days; Group 1: 8/78, Group 2: 13/75	
Protocol outcome 7: DVT (proximal) at 7-90 days from hospital discharge - Actual outcome: DVT proximal at 12 days; Group 1: 2/78, Group 2: 12/75	
Protocol outcomes not reported by the study	Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study; Infection at duration of study;

Study	Samama 2002 ²⁸³
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=1289)
Countries and setting	Conducted in France; Setting: Multicentre
Line of therapy	Not applicable
Duration of study	Intervention + follow up: 42-63 days
Method of assessment of guideline condition	Adequate method of assessment/diagnosis
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Patients 18 years or older scheduled to undergo elective unilateral primary total hip replacement surgery who gave informed consent
Exclusion criteria	Femoral neck fracture; current active bleeding or disorders contraindicating anticoagulant therapy; a history of DVT or PE; heparin induced thrombocytopenia; peptic ulcer; allergy to radiopaque contrast medium; use of aspirin or ticlopidine hydrochloride, renal insufficiency, liver failure; acute endocarditis; recent stroke; uncontrolled hypertension; pregnancy; alcoholism; or inability to follow instructions
Recruitment/selection of patients	Consecutive patients

Study	Samama 2002 ²⁸³
Age, gender and ethnicity	Age - Mean (SD): Reviparin group: 66 (11), Acenocoumarol group: 65 (12). Gender (M:F): 1:1. Ethnicity: Not reported
Further population details	1. BMI : Not obese (BMI under 30 kg/m2) (Mean (SD) BMI = 27 (4)). 2. Renal impairment: Not applicable
Indirectness of population	No indirectness
Interventions	(n=644) Intervention 1: Low molecular weight heparin (not licensed in UK) - Reviparin (1750 units once daily - 4200 units once daily). Reviparin, 4200IU once daily (high dose) subcutaneously, initial dose 12 hours preoperatively for 3±1 days, continued for 6 weeks (extended duration). Duration 6 weeks. Concurrent medication/care: n/a (n=645) Intervention 2: Vitamin K antagonists - Acenocoumarol (all doses). Patients given initial dose of reviparin, 4200IU (high dose) 12 hours preoperatively, crossed over to acenocoumarol for 6 weeks after surgery (extended duration). The dose was adjusted to achieve an INR between 2.0 and 3.0 for 2 consecutive days. Duration 6 weeks. Concurrent medication/care: n/a
Funding	Study funded by industry (Supported by Knoll-France, Levallois-Perret France. The local investigators received \$400 per patients included in the study, and the institution of the investigator in chief received a final grant of \$4000)

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: REVIPARIN (EXTENDED DURATION) versus ACENOCOUMAROL/VKA (EXTENDED DURATION)

Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge

- Actual outcome: All-cause mortality at 42-63 days; Group 1: 0/643, Group 2: 2/636

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 1, Reason: Details not reported; Group 2 Number missing: 9, Reason: Details not reported

Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge

- Actual outcome: DVT (symptomatic and asymptomatic) at 42-63 days; Group 1: 15/643, Group 2: 20/636

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 1, Reason: Details not reported; Group 2 Number missing: 9, Reason: Details not reported

Protocol outcome 3: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge

- Actual outcome: PE at 42-63 days; Group 1: 0/643, Group 2: 4/636

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 1, Reason: Details not reported; Group 2 Number missing: 9, Reason: Details not reported

Study	Samama 2002 ²⁸³
<p>Protocol outcome 4: Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge</p> <p>- Actual outcome: Major bleeding at 42-63 days; Group 1: 10/643, Group 2: 37/636</p> <p>Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 1, Reason: Details not reported; Group 2 Number missing: 9, Reason: Details not reported</p>	
Protocol outcomes not reported by the study	Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Surgical site haematoma at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study; Infection at duration of study;

Bibliographic reference	Study Type	Evidence level	No. of patients	Patients characteristics	Intervention	Comparison	Length of follow up	Outcome measures	Effect size	Comments
Santori 1994 ²⁸⁸	RCT	1+	Total: n = 132 Intervention: n = 67 Control:	Type of surgery: Patients undergoing total hip replacement. All patients had compression	Intermittent plantar foot pump (aka impulse group) on both feet immediately after	Calcium heparin. 5000 Units 3x per day for 10 days starting on the	Intervention for 8 to 10 days, follow-up 6	DVT (overall) Confirmed by: thermography and doppler US followed by phlebography	Int: 9/67 Control: 23/65 p value: <0.005	The paper did not report any dropouts 2 PEs (1 fatal) in the heparin

Bibliographic reference	Study Type	Evidence level	No. of patients	Patients characteristics	Intervention	Comparison	Length of follow up	Outcome measures	Effect size	Comments
			n = 65	stockings after operation Excluded: history of VTE, varicose veins, venous insufficiency in the legs, malignant neoplasm Intervention: Mean age: 72.4±6.65	the operation and used for 7 to 10 days. When patients started walking at postoperative day 4 or 5 the foot pump was only used when the patient was in	day before the operation Additional prophylaxis: AES on both legs after operation. Neither the length nor for how long they were worn was	weeks	"Major" proximal DVTs "Major" proximal & distal DVTs	Int: 2/67 Control: 11/65 p value: : 0.0083 Int: 0/67 Control: 2/65 p value: : 0.2406	group but not stated how confirmed Not reported: PTS, PE, QoL, Survival

Bibliographic reference	Study Type	Evidence level	No. of patients	Patients characteristics	Intervention	Comparison	Length of follow up	Outcome measures	Effect size	Comments
				M/F:19/48 Control Mean age: 69.8±6.22 M/F:15/50 Pre-existing risk factors: Not reported	bed. Additional prophylaxis: AES on both legs after operation. Neither the length nor for how long they were worn was stated. Physiotherapy with mobilisation started on 2nd postoperative day. Walking began on 4th or 5th postoperative day	stated. Physiotherapy with mobilisation started on 2nd postoperative day. Walking began on 4th or 5th postoperative day		Mean +SD total blood loss (ml)	Int: 490 +195.27 (n = 67) Control: 520 +189.16 (n = 65) P value: not reported	
								Mean +SD volume of blood transfused (ml)	Int: 308 +289.15 (n = 67) Control: 300 +267.7 (n = 65) P value: not reported	

Study	Tørholm 1991 ³¹³
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=112)
Countries and setting	Conducted in Denmark; Setting: Rigshospitalet University Hospital of Copenhagen
Line of therapy	Not applicable
Duration of study	--:
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: DVT confirmed by 125I fibrinogen test and ascending phlebography.
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	People who were admitted for THR and who were aged 40 years or over were eligible.
Exclusion criteria	Bleeding disorders, hepatic or renal insufficiency, previous septic endocarditis, cerebral haemorrhage during the previous six months, hypersensitivity to heparin or iodine, and anticoagulant therapy within one week of surgery.
Recruitment/selection of patients	Not reported
Age, gender and ethnicity	Age - Median (IQR): Fragmin: 67 (43-85); Placebo: 64 (43-81). Gender (M:F): Fragmin: 23/35; Placebo: 27/27. Ethnicity: Not reported
Further population details	1. BMI : Not applicable 2. Renal impairment: Not applicable
Indirectness of population	No indirectness
Interventions	(n=58) Intervention 1: Low molecular weight heparin (licensed in UK) - Dalteparin (1,250 units once daily - 5,000 units twice daily). LMWH Dalteparin, 2500 IU subcutaneously for the first two doses (2 hours before surgery and 12 hours postoperatively), then 5000 IU subcutaneously for the following six days. Duration 9 days. Concurrent medication/care: Not reported (n=54) Intervention 2: No treatment - Placebo. Sodium chloride 9g/l subcutaneously using same regimen as intervention group. Duration 9 days. Concurrent medication/care: Not reported
Funding	Funding not stated

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: DALTEPARIN (1,250 UNITS ONCE DAILY - 5,000 UNITS TWICE DAILY) versus PLACEBO

Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge

Study	Tørholm 1991 ³¹³
	<p>- Actual outcome: All-cause mortality at Time point not reported; Group 1: 1/58, Group 2: 0/54 Risk of bias: All domain - Very high, Selection - High, Blinding - Very high, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge - Actual outcome: DVT at 9 days; Group 1: 9/58, Group 2: 19/54 Risk of bias: All domain - Very high, Selection - High, Blinding - Very high, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 3: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge - Actual outcome: PE at Time point not reported; Group 1: 0/58, Group 2: 1/54 Risk of bias: All domain - Very high, Selection - High, Blinding - Very high, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - High, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 4: Infection at duration of study - Actual outcome: Wound infection at Time point not reported; Group 1: 2/58, Group 2: 0/54 Risk of bias: All domain - Very high, Selection - High, Blinding - Very high, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 5: DVT (distal) at 7-90 days from hospital discharge - Actual outcome: DVT distal at 9 days; Group 1: 9/58, Group 2: 14/54</p> <p>Protocol outcome 6: DVT (proximal) at 7-90 days from hospital discharge - Actual outcome: DVT proximal at 9 days; Group 1: 0/58, Group 2: 5/54</p>
Protocol outcomes not reported by the study	Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge; Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital

Study	Tørholm 1991³¹³
	discharge; Surgical site haematoma at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study;

Study	Turpie 1986³¹⁸
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=LMWH: 50; Placebo: 50)
Countries and setting	Conducted in Canada; Setting: Not reported
Line of therapy	Not applicable
Duration of study	Intervention + follow up: 14 days
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: DVT confirmed by venography or 125I fibrinogen scanning. Major bleeding defined as overt and associated with either a fall in the haemoglobin level of 2g/dl or more, or a need for transfusion of two or more units of blood, or if it was retroperitoneal or intracranial.
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Define
Exclusion criteria	Define
Recruitment/selection of patients	People were recruited consecutively
Age, gender and ethnicity	Age - Mean (SD): LMWH: 66.82 (9.55); Placebo: 67.3 (8.85). Gender (M:F): Define. Ethnicity: Not reported
Further population details	1. BMI : Not applicable 2. Renal impairment: Not applicable
Indirectness of population	No indirectness
Interventions	(n=50) Intervention 1: Low molecular weight heparin (licensed in UK) - Enoxaparin (20mg once daily – 60mg twice daily). 30mg twice daily (high dose) subcutaneously, from 12 to 24 hours after surgery for 14 days or until discharge. Duration 14 days. Concurrent medication/care: Not reported (n=50) Intervention 2: No treatment - Placebo. 0.3 ml saline, subcutaneously from 12 to 24 hours after surgery for 14 days. Duration 14 days. Concurrent medication/care: Not reported

Study	Turpie 1986 ³¹⁸
Funding	Academic or government funding (Supported by grants from the Heart and Stroke Foundation of Ontario and the Medical Research Council of Canada)
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: ENOXAPARIN (20MG ONCE DAILY – 60MG TWICE DAILY) versus PLACEBO</p> <p>Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge - Actual outcome: All-cause mortality at 14 days; Group 1: 0/50, Group 2: 1/50 Risk of bias: All domain - --, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge - Actual outcome: DVT at 14 days; Group 1: 4/37, Group 2: 20/39 Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 13; Group 2 Number missing: 11</p> <p>Protocol outcome 3: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQspect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge - Actual outcome: PE at 14 days; Group 1: 0/50, Group 2: 0/50 Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - High, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 4: Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge - Actual outcome: Major bleeding at 14 days; Group 1: 1/50, Group 2: 2/50 Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 5: DVT (distal) at 7-90 days from hospital discharge - Actual outcome: DVT distal at 14 days; Group 1: 2/37, Group 2: 11/39</p> <p>Protocol outcome 6: DVT (proximal) at 7-90 days from hospital discharge - Actual outcome: DVT proximal at 14 days; Group 1: 2/37, Group 2: 9/39</p>	

Study	Turpie 1986 ³¹⁸
Protocol outcomes not reported by the study	Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Surgical site haematoma at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study; Infection at duration of study;

Bibliographic reference	Study Type	Evidence level	No. of patients	Patients characteristics	Intervention	Comparison	Length of follow up	Outcome measures	Effect size	Comments		
Turpie 2002 ³¹⁹	RCT	1+	Total: 2275	Type of surgery: Patients scheduled for primary elective total hip-replacement surgery or revision of at least one component of a previously implanted total hip prosthesis. Duration of surgery:	2.5 mg of Fondaparinux sodium and a placebo. The first active dose was given 4-8 hrs after surgery and the second 12 or more after the first. Treatment was scheduled to continue until day 5 to 9. Day	30 mg of Enoxaparin twice daily. The first active dose was given 4-8 hrs after surgery and the second 12 or more after the first. Treatment was scheduled to continue until	49 days study period 11 days	DVT Confirmed by: systematic bilateral ascending venography	Int: 44/784 Control: 65/796 p value: <0.047; RRR:- 31.3% (95% CI)	Funding: study supported by NV Organon and Sanofi-Synthelabo. ** defined as fatal bleeding; bleeding that was retroperitoneal, intracranial or intraspinal or that involved any		
			Intervention n: 1138					Control n: 1137	Dropouts (not treated): Int: 10 Comp: 8		VTE	Int: 48/787 Control: 66/797 p value: 0.099 RRR (95 % CI) - 26.3 (-52.8 to -10.8)
			Dropout								Symptomatic DVT	Int: 5/1126 Control: 0/1128 p value: 0.0310

Bibliographic reference	Study Type	Evidence level	No. of patients	Patients characteristics	Intervention	Comparison	Length of follow up	Outcome measures	Effect size	Comments
			332 (not available for analysis)	2.42 hours, SD: ±0.98 Intervention: Mean age: 67, range: 26-92; M/F:386/401 Control: Mean age: 67, range: 19-91; M/F:375/422 Pre-existing risk factors: History of VTE: Intervention: 40 (5%) Control: 50 (6%). Orthopaedic surgery within the previous 12 months: Intervention: 99 (13%) Control: 84 (11%)	of surgery is day 1. Additional non-comparative prophylaxis: The use of AES and physiotherapy was recommended No. patients receiving/using: AES = 674/787 Anticoagulant/antiplatelet therapy (not aspirin) = 13/787 NSAIDs or aspirin = 107/787	day 5 to 9. Day of surgery is day 1. Additional non-comparative prophylaxis: The use of AES and physiotherapy was recommended No. patients receiving/using: AES = 676/797 Anticoagulant/antiplatelet therapy (not aspirin) = 11/797 NSAIDs or aspirin = 108/797		Proximal DVT* Confirmed by: systematic bilateral ascending venography Non-fatal PE Confirmed by: lung scan, pulmonary angiography or helical computed tomography or at autopsy Fatal PE Confirmed by: Major bleeding** Fatal bleeding Bleeding leading	Int: 14/816 Control: 10/830 p value: 0.42 Int: 5/1126 Control: 0/1128 p value: 0.0310 Int: 0/1126 Control: 1/1128 p value: 1.0000 Int: 20/1128 Control: 11/1129 p value: 0.73 Int: 0/1128 Control: 0/1129 p value: 1.0000 Int: 2/1128	other critical organ, bleeding that lead to reoperation; and overt bleeding with index of 2 or more.

Study	Warwick 1995 ³³²
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=156)
Countries and setting	Conducted in United Kingdom; Setting: Not reported
Line of therapy	Not applicable
Duration of study	Intervention + follow up: 8-10 days
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: DVT confirmed by ipsilateral venography. PE confirmed by ventilation/perfusion scan.
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	People have a primary THR
Exclusion criteria	Recent aspirin consumption, a medical requirement for continued non-steroidal medication, and a history of previous thromboembolism.
Recruitment/selection of patients	Not reported
Age, gender and ethnicity	Age - --: Not reported. Gender (M:F): Not reported. Ethnicity: Not reported
Further population details	1. BMI : Not applicable 2. Renal impairment: Not applicable
Indirectness of population	No indirectness
Interventions	(n=78) Intervention 1: Low molecular weight heparin (licensed in UK) - Enoxaparin (20mg once daily – 60mg twice daily). 40mg once daily (standard dose) subcutaneously administered from 12 hours before operation, then at 12 hours and 36 hours postoperatively. AES bilateral thigh length stockings also used. Duration 8-10 days. Concurrent medication/care: All patients were mobilised on the second postoperative day (n=78) Intervention 2: Anti-embolism stockings - Above knee. AES, bilateral thigh length alone. Duration 8-10 days. Concurrent medication/care: All patients were mobilised on the second postoperative day
Funding	Other (Wishbone Trust, the Laming Evans Orthopaedic Fellowship and the South West Regional Health Authority)

Study	Warwick 1995 ³³² Research Committee)
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: ENOXAPARIN (20MG ONCE DAILY – 60MG TWICE DAILY) versus ABOVE KNEE</p> <p>Protocol outcome 1: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge - Actual outcome: DVT at not specified; Group 1: 22/78, Group 2: 33/78 Risk of bias: All domain - Very high, Selection - Very high, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 2: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge - Actual outcome: PE at 8-10 days; Group 1: 1/78, Group 2: 2/78 Risk of bias: All domain - Very high, Selection - Very high, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 3: DVT (proximal) at 7-90 days from hospital discharge - Actual outcome: DVT proximal at not specified; Group 1: 12/78, Group 2: 14/78</p>	
<p>Protocol outcomes not reported by the study</p>	<p>All-cause mortality at up to 90 days from hospital discharge; Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge; Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Surgical site haematoma at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study; Infection at duration of study;</p>

Bibliographic reference	Study Type	Evidence level	No. of patients	Patients characteristics	Intervention	Comparison	Length of follow up	Outcome measures	Effect size	Comments
Warwick 1998 ³³³	RCT	1+	Total: n = 290 Intervention: n = 147 Control: n = 143	Type of surgery: Patients undergoing total hip replacement Intervention: Mean age: 68±11 M/F:94/53 Pre-existing risk factors: Previous thromboembolism: Int: n = 2, control:n = 3	foot pump for 7days	Enoxaparin Dose: 40mg/daily for 7 days Timing: 7days Additional prophylaxis: Not reported	Control:	DVT (overall)	Int: 24/136	Comments: 136 patients in the intervention and 138 in the comparison group completed both venography and the 3 month follow-up No patient died during follow-up Not reported: PTS, Bleeding related complications, QoL, Survival Also reported: Intraoperative blood loss, postop
							3mths	Confirmed by:venography on 6th, 7th & 8th day	Control: 18/138 (95%CI, -3.9 to +13.0%) p value: Not significant	
							Int:	Proximal vein thrombosis	Int: 17/136 Control: 12/138 (95%CI, -3.5 to +11.1%) p value: Not significant	
							3mths	Distal vein thrombosis	Int: 7/136 Control: 6/138 (95%CI, -4.2 to +5.8%) p value: Not significant	
								Symptomatic PE Confirmed by ventilation perfusion scanning	Int: 1/136 Control: 0/138 p value: Not significant	
								Fatal PE Confirmed by:	Int: 0/136 Control: 0/138 p value: Not significant	
								Readmission to hospital	Int: 1/136 Control: 1/138 p	

Bibliographic reference	Study Type	Evidence level	No. of patients	Patients characteristics	Intervention	Comparison	Length of follow up	Outcome measures	Effect size	Comments
								because of DVT:	value: Not significant	drainage, median no. of units transfused, oozing and bruising of thigh

Study	Yokote 2011 ³⁴⁷
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=255)
Countries and setting	Conducted in Japan; Setting: Nissan Tamagawa Hospital, Tokyo, Japan
Line of therapy	Not applicable
Duration of study	Intervention time: 10 days
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: DVT (symptomatic and asymptomatic): confirmed by duplex ultrasonography PE: confirmed by multi-detector CT scan Major bleeding: defined as retroperitoneal, intracranial or intraocular bleeding, or if it was associated with either death, transfusion or more than two units of packed red blood cells or whole blood (except autologous), a reduction in the level of haemoglobin of > 2g/dl, or a serious life-threatening clinical event requiring medical intervention.
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Patients undergoing elective primary unilateral total hip replacement (THR).
Exclusion criteria	Patients who had undergone bilateral and revision total hip replacement and those who were less than 20 years of age. Other exclusion criteria included long-term anticoagulation treatment such as unfractionated heparin, low-molecular-weight-heparin, vitamin-K antagonists, antiplatelet agents for pre-existing cardiac or cerebrovascular disease, a history of VTE, a coagulation disorder including antiphospholipid syndrome, the presence of a solid

Study	Yokote 2011 ³⁴⁷
	malignant tumour or a peptic ulcer, and major surgery in the preceding three months. Caucasian patients were also excluded
Recruitment/selection of patients	Between May 2008 and March 2007, consecutive patients undergoing elective primary unilateral THR.
Age, gender and ethnicity	Age - Mean (SD): 64 years. Gender (M:F): 1/4. Ethnicity: Not reported
Further population details	1. BMI : Not obese (BMI under 30 kg/m ²) (Mean BMI: 22.9 kg/m ²). 2. Renal impairment: Not applicable
Indirectness of population	No indirectness
Interventions	<p>(n=86) Intervention 1: Low molecular weight heparin (licensed in UK) - Enoxaparin (20mg once daily – 60mg twice daily). Enoxaparin, 40 mg (20mg twice daily) subcutaneously. AES, thigh-length and IPCD was applied in the operating theatre before the procedure until post-operative day 2. Duration 10 days. Concurrent medication/care: All patients began mobilisation exercises under the supervision of a physiotherapist within 24 hours (1 to 20 hours) after surgery. NSAIDs were given post-operatively for control of pain according to each individual patient's requirements.</p> <p>(n=85) Intervention 2: Fondaparinux - Fondaparinux (all doses). Fondaparinux, 2.5mg once daily, subcutaneously given. AES, thigh-length and IPCD was applied in the operating theatre before the procedure until post-operative day 2. Duration 10 days. Concurrent medication/care: All patients began mobilisation exercises under the supervision of a physiotherapist within 24 hours (1 to 20 hours) after surgery. NSAIDs were given post-operatively for control of pain according to each individual patient's requirements.</p> <p>(n=85) Intervention 3: No treatment - Placebo. Placebo, isotonic saline, 0.5 ml, subcutaneously given post-operation. AES, thigh-length and IPCD was applied in the operating theatre before the procedure until post-operative day 2. Duration 10 days. Concurrent medication/care: All patients began mobilisation exercises under the supervision of a physiotherapist within 24 hours (1 to 20 hours) after surgery. NSAIDs were given post-operatively for control of pain according to each individual patient's requirements.</p>
Funding	Funding not stated
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: ENOXAPARIN + IPCD + AES versus FONDAPARINUX + IPCD + AES</p> <p>Protocol outcome 1: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge - Actual outcome: DVT (symptomatic and asymptomatic) at 11 days; Group 1: 5/83, Group 2: 6/84 Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 3, Reason: Missed ultrasound; Group 2 Number missing: 1, Reason: Missed ultrasound</p>	

Study	Yokote 2011 ³⁴⁷
	<p>Protocol outcome 2: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge - Actual outcome: PE at 11 days; Group 1: 0/83, Group 2: 0/84 Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 3, Reason: Missed ultrasound; Group 2 Number missing: 1, Reason: Missed ultrasound</p>
	<p>Protocol outcome 3: Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge - Actual outcome: Major bleeding at 11 days; Group 1: 0/83, Group 2: 0/84 Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 3, Reason: Missed ultrasound; Group 2 Number missing: 1, Reason: Missed ultrasound</p>
	<p>Protocol outcome 4: Surgical site haematoma at up to 45 days from hospital discharge - Actual outcome: Wound haematoma (maximum size $>5\text{cm}$) at 11 days; Group 1: 3/83, Group 2: 3/84 Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 3, Reason: Missed ultrasound; Group 2 Number missing: 1, Reason: Missed ultrasound</p>
	<p>Protocol outcome 5: VTE at 7-90 days from hospital discharge - Actual outcome: VTE at 11 days; Group 1: 5/83, Group 2: 6/84</p>
	<p>Protocol outcome 6: DVT (symptomatic) at 7-90 days from hospital discharge - Actual outcome: DVT (symptomatic) at 11 days; Group 1: 0/83, Group 2: 1/84</p>
	<p>Protocol outcome 7: DVT (distal) at 7-90 days from hospital discharge - Actual outcome: DVT (distal) at 11 days; Group 1: 6/84, Group 2: 6/83</p>
	<p>Protocol outcome 8: DVT (proximal) at 7-90 days from hospital discharge - Actual outcome: DVT (proximal) at 11 days; Group 1: 0/83, Group 2: 1/84</p>
	<p>Protocol outcome 9: Site of bleeding (gastrointestinal ; surgical site; brain/spine; other) at 45 days from hospital discharge - Actual outcome: Upper gastrointestinal bleeding at 11 days; Group 1: 0/85, Group 2: 2/85</p>

Study	Yokote 2011 ³⁴⁷
RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: ENOXAPARIN + IPCD + AES versus PLACEBO + IPCD + AES	
<p>Protocol outcome 1: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge - Actual outcome: DVT (symptomatic and asymptomatic) at 11 days; Group 1: 5/83, Group 2: 6/83 Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 3, Reason: Missed ultrasound; Group 2 Number missing: 2, Reason: Missed ultrasound</p>	
<p>Protocol outcome 2: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge - Actual outcome: PE at 11 days; Group 1: 0/83, Group 2: 0/83 Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 3, Reason: Missed ultrasound; Group 2 Number missing: 2, Reason: Missed ultrasound</p>	
<p>Protocol outcome 3: Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge - Actual outcome: Major bleeding at 11 days; Group 1: 0/83, Group 2: 0/83 Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 3, Reason: Missed ultrasound; Group 2 Number missing: 2, Reason: Missed ultrasound</p>	
<p>Protocol outcome 4: Surgical site haematoma at up to 45 days from hospital discharge - Actual outcome: Wound haematoma (maximum size $>5\text{cm}$) at 11 days; Group 1: 3/83, Group 2: 1/83 Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 3, Reason: Missed ultrasound; Group 2 Number missing: 2, Reason: Missed ultrasound</p>	
<p>Protocol outcome 5: VTE at 7-90 days from hospital discharge - Actual outcome: VTE at 11 days; Group 1: 5/83, Group 2: 6/83</p>	
<p>Protocol outcome 6: DVT (symptomatic) at 7-90 days from hospital discharge - Actual outcome: DVT (symptomatic) at 11 days; Group 1: 0/83, Group 2: 0/83</p>	
<p>Protocol outcome 7: DVT (distal) at 7-90 days from hospital discharge - Actual outcome: DVT (distal) at 11 days; Group 1: 5/83, Group 2: 6/83</p>	

Study	Yokote 2011 ³⁴⁷
	<p>Protocol outcome 8: DVT (proximal) at 7-90 days from hospital discharge - Actual outcome: DVT (proximal) at 11 days; Group 1: 0/83, Group 2: 0/83</p>
	<p>Protocol outcome 9: Site of bleeding (gastrointestinal ; surgical site; brain/spine; other) at 45 days from hospital discharge - Actual outcome: Upper gastrointestinal bleeding at 11 days; Group 1: 0/85, Group 2: 1/85</p>
	<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: FONDAPARINUX + IPCD + AES versus PLACEBO + IPCD + AES</p>
	<p>Protocol outcome 1: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge - Actual outcome: DVT (symptomatic and asymptomatic) at 11 days; Group 1: 6/84, Group 2: 6/83 Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 1, Reason: Missed ultrasound; Group 2 Number missing: 2, Reason: Missed ultrasound</p>
	<p>Protocol outcome 2: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge - Actual outcome: PE at 11 days; Group 1: 0/84, Group 2: 0/83 Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 1, Reason: Missed ultrasound; Group 2 Number missing: 2, Reason: Missed ultrasound</p>
	<p>Protocol outcome 3: Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge - Actual outcome: Major bleeding at 11 days; Group 1: 0/84, Group 2: 0/83 Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 1, Reason: Missed ultrasound; Group 2 Number missing: 2, Reason: Missed ultrasound</p>
	<p>Protocol outcome 4: Surgical site haematoma at up to 45 days from hospital discharge - Actual outcome: Wound haematoma (maximum size $>5\text{ cm}$) at 11 days; Group 1: 3/84, Group 2: 1/83 Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 1, Reason: Missed ultrasound; Group 2 Number missing: 2, Reason: Missed ultrasound</p>
	<p>Protocol outcome 5: VTE at 7-90 days from hospital discharge - Actual outcome: VTE at 11 days; Group 1: 6/84, Group 2: 6/83</p>

Study	Yokote 2011 ³⁴⁷
Protocol outcome 6: DVT (symptomatic) at 7-90 days from hospital discharge - Actual outcome: DVT (symptomatic) at 11 days; Group 1: 1/84, Group 2: 0/83	
Protocol outcome 7: DVT (distal) at 7-90 days from hospital discharge - Actual outcome: DVT (distal) at 11 days; Group 1: 6/84, Group 2: 6/83	
Protocol outcome 8: DVT (proximal) at 7-90 days from hospital discharge - Actual outcome: DVT (proximal) at 11 days; Group 1: 1/84, Group 2: 0/83	
Protocol outcome 9: Site of bleeding (gastrointestinal ; surgical site; brain/spine; other) at 45 days from hospital discharge - Actual outcome: Upper gastrointestinal bleeding at 11 days; Group 1: 2/85, Group 2: 1/85	
Protocol outcomes not reported by the study	All-cause mortality at up to 90 days from hospital discharge; Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study; Infection at duration of study;

Bibliographic reference	Study Type	Evidence level	No. of patients	Patients characteristics	Intervention	Comparison	Length of follow up	Outcome measures	Effect size	Comments
Zanasi 1988 ³⁴⁸	RCT	1+	Total 63 Intervention: n = 19 Control: n = 25 (3rd arm	Type of surgery: Orthopaedic surgery (majority hip surgery) Intervention: Mean +SEM age: 69.7 +3.7 yrs	Type: aspirin: Dose: acetylsalicylic acid 100mg administered on alternate days Timing: started day	Type: unfractionated heparin: Dose: beef lung heparin 5000 units + placebo aspirin Timing: started day before	7 Post-operative days	DVT Confirmed by: FUT	Int: 7/19 Control: 10/25 p value: 0.4821	Comments: Diagnosis of DVT by ultrasonic doppler detectors in this study only permitted analysis of DVTs above the knee

			of 19 patients receiving defibrotide not reported here)	M/F: 5/14 Control: Mean +SEM age: 71.9 +2.2 yrs M/F:4/21 Pre-existing risk factors: none stated	before surgery and continued for 7 postoperative days. Additional non-comparative prophylaxis: none stated	surgery and continued for 7 postoperative days Additional non-comparative prophylaxis: none stated				Not reported PTS, QoL, bleeding complications, length of hospital stay Funding: not reported
--	--	--	---	---	--	--	--	--	--	--

H.24 Elective knee replacement

Study	Alkire 2010 ³
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	N/A (n=65)
Countries and setting	Conducted in USA; Setting: Secondary care
Line of therapy	Not applicable
Duration of study	Intervention + follow up: Intervention 3 days + Follow-up 3 months
Method of assessment of guideline condition	Method of assessment /diagnosis not stated
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Computer-assisted TKA patients with a diagnosis of rheumatoid or osteoarthritis aged greater than 18 years
Exclusion criteria	Cognitive/Sensory deficits; residence in skilled nursing facilities; non-English speaking
Recruitment/selection of patients	Not stated
Age, gender and ethnicity	Age - Other: Intervention mean age 65.6 years vs. Control mean age 66.9 years. Gender (M:F): 26:38 (one person missing due to withdrawal from the intervention group after randomisation). Ethnicity: Not reported
Further population details	1. BMI : Not obese (BMI under 30 kg/m2) (Mean BMI 26 kg/m2). 2. Renal impairment: Not applicable

Study	Alkire 2010 ³
Indirectness of population	Very serious indirectness: [1] Ambiguous statements regarding the number of patients enrolled / randomised. [2] Ethnicity of the participants is not reported. [3] Following a preliminary study, the protocol for the study was amended to allow participation of patients with comorbidities, such as DVT requiring anticoagulants, weighing >240lb, and presence of other conditions such as diabetes, hypertension, stroke and lupus.
Interventions	<p>(n=33) Intervention 1: Continuous passive motion. Danniflex 480 CPM apparatus; starting with flexion at 90 to 70 degrees in the post-anaesthesia care unit and increasing extension by 10 degrees over 4 hrs for a total of 6 hrs per day; 3 times daily for 3 days. Duration 3 days. Concurrent medication/care: Not stated Comments: Unclear if the number of participants randomised to this group is 33, 34 or 36 (descriptions given are unclear)</p> <p>(n=32) Intervention 2: No treatment - Usual care. Twice daily physiotherapy. Duration 3 days (implicitly assumed but not clearly stated) or until discharge ("during their hospital stay"). Concurrent medication/care: Not stated Comments: Physiotherapy given was not described in any detail.</p>
Funding	Funding not stated
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: CONTINUOUS PASSIVE MOTION versus NO CPM</p> <p>Protocol outcome 1: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge - Actual outcome: DVT at 3 months; Group 1: 0/33, Group 2: 0/32; Comments: The study only stated that there were no reports of DVT. Risk of bias: All domain - Very high, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - High, Crossover - Low, Comments - The definition, assessment method and time points for data collection for DVT are not reported. The participants' baseline risks for VTE (e.g. ethnicity, previous VTE, co-morbidities, medications) are not reported. Statements about the number of people enrolled, randomised and withdrawn are unclear and the exact number "randomised" cannot be established with certainty.; Indirectness of outcome: Serious indirectness ; Baseline details: Insufficient reporting of the participants' biometrics (e.g. BMI), co-morbidities, history of VTE, etc.; Blinding details: Not possible to blind participants for CPM device nor physiotherapy; Group 1 Number missing: 0; Group 2 Number missing: 0</p>	
Protocol outcomes not reported by the study	All-cause mortality at up to 90 days from hospital discharge; Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQspect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge; Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of

Study	Alkire 2010 ³
	<p>≥2g/dl; a serious or life threatening clinical event at up to 45 days from hospital discharge; Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Surgical site haematoma at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study; Infection at duration of study</p>

Bibliographic reference	Study Type	Evidence level	No. of patients	Patients characteristics	Intervention	Comparison	Length of follow up	Outcome measures	Effect size	Comments
Bauer et al., 2001 ¹⁷	RCT	1+	Total: 1049 Intervention n: 526 Control n: 523 Dropouts (not treated): Int: 9 Comp: 6 Dropout	Type of surgery: Patients undergoing elective major knee surgery. Duration of surgery: 128 minutes, SD: ±42 Intervention: Mean age: 67.5, SD: ±10.7; M/F:204/313	2.5 mg of Fondaparinux sodium postoperatively once daily and a placebo once daily subcutaneously till day 5 to 9. Day of surgery is day 1. Additional non-comparative	30 mg of Enoxaparin twice daily post-operatively until day 5 to 9. Day of surgery is day 1. Additional non-comparative prophylaxis:	49 days	DVT Confirmed by: systematic bilateral ascending venography VTE Symptomatic DVT	Int: 45/361 Control: 98/361 p value: 0.001; RR: 54.1% (95% CI) Int: 45/361 Control: 101/363 p value: <0.001 Reduction in risk (95% CI) 55.2 (36.2 to 70.2) Int: 3/517 Control: 4/517 p value: 1.000	Funding: The authors have served as consultants to NV Organon and Sanofi-Synthelabo and the study supported by NVO & SS. ** defined as fatal

Bibliographic reference	Study Type	Evidence level	No. of patients	Patients characteristics	Intervention	Comparison	Length of follow up	Outcome measures	Effect size	Comments
			5 (not available for analysis): Int: 156 Comp: 154	Control: Mean age: 67.5, SD: ±10.2; M/F:223/294 Pre-existing risk Factors: History of VTE: Intervention: 23% Control: 28%. Orthopaedic surgery within the previous 12 months: Intervention: :87% Control:: 27%	prophylaxis: The use of AES and physiotherapy was recommended No. patients receiving/using: AES = 298/361 Anticoagulant/antiplatelet therapy (not aspirin) = 4/361 NSAIDs or aspirin= 44/361	The use of AES and physiotherapy was recommended No. patients receiving/using: AES = 294/363 Anticoagulant /antiplatelet therapy (not aspirin) = 11/363 NSAIDs or aspirin= 60/363		Proximal DVT Confirmed by: systematic bilateral ascending venography Non-fatal PE Confirmed by: lung scan, pulmonary angiography or helical computed tomography or at autopsy Fatal PE Confirmed by: Major bleeding ** Bleeding leading to re-operation Other bleeding – number (%) Post-operative transfusions –	Int: 9/368 Control: 20/372 p value: 0.06 Int: 1/517 Control: 4/517 p value: 0.3738 Int: 0/517 Control: 0/517 p value: N/A Int: 11/517 Control: 1/517 p value: 0.003 Int: 2/517 Control: 1/517 p value: 1.000 Int: 14/517 Control: 19/517 p value: 0.4797 Int: 222/517	bleeding; bleeding that was retroperitoneal , intracranial or intraspinal or that involved any other critical organ, bleeding that lead to reoperation; and overt bleeding with index of 2 or more.

Bibliographic reference	Study Type	Evidence level	No. of patients	Patients characteristics	Intervention	Comparison	Length of follow up	Outcome measures	Effect size	Comments
								number (%)	Control: 197/517 p value: 0.1284	
								Death from any cause - number (%) Up to day 11	Int: 1/517 Control: 2/517 p value: 1.0000	
								Death from any cause - number (%) Up to day 49	Int: 2/517 Control: 3/517 p value: 1.0000	

Study	Bern 2015 ²⁸
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=118)
Countries and setting	Conducted in USA; Setting: New England Baptist Hospital, Boston, USA
Line of therapy	Not applicable
Duration of study	Intervention time: 26-30 days
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: DVT (symptomatic and asymptomatic): confirmed by bilateral duplex sonography PE: confirmed by ventilation/perfusion lung scan or computerised axial tomography angiogram

Study	Bern 2015 ²⁸
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Patients were recruited from among over 20 years of age planning elective primary unilateral total hip or knee replacement surgery at an orthopaedic surgery.
Exclusion criteria	Abnormal platelet count, pro-thrombin time or partial thromboplastin time; surgery for acute fracture (<4 weeks), septic joint, or extraction arthroplasty; history of VTE or documented hyper-coagulation syndrome; increased risk of haemorrhage, as from active gastric ulcer or urinary tract bleed within the last year; haemorrhagic stroke, brain, spinal, or ophthalmologic surgery in previous 6 months; liver enzymes or bilirubin greater than 2 x normal; decreased renal function with GFR <30 ml/min; cancer in last year, other than localised cancers of the skin; requires chronic anticoagulation; requires chronic platelet function suppressive therapy; prior adverse reaction to any of the study drugs; uncontrolled hypertension; BMI >42, pregnancy
Recruitment/selection of patients	Based on inclusion criteria
Age, gender and ethnicity	Age - Mean (SD): 60 (7.7) years . Gender (M:F): 1/1. Ethnicity: Not reported
Further population details	1. BMI : Not applicable 2. Renal impairment: Not applicable
Indirectness of population	No indirectness
Interventions	<p>(n=54) Intervention 1: Fondaparinux - Fondaparinux (all doses). 2.5mg daily starting 6 or more hours following surgery, but no later than 6am the next day, or 6-8 hours after epidural catheter removal. All patients wore pneumatic compression stockings while in-patient. AES were prescribed to be used after discharge until the follow-up ultrasounds. Duration 28±2 days. Concurrent medication/care: Use of platelet function suppressive drugs, such a non-steroidal anti-inflammatory drugs (NSAIDs), was discouraged but not prohibited by the protocol.</p> <p>(n=64) Intervention 2: Vitamin K antagonists - Warfarin (all doses). 5.0mg beginning the night before surgery, followed by 5.0mg the PM of surgery, and then variable daily dose (target INR 2.0-2.5). All patients wore pneumatic compression stockings while in-patient. AES were prescribed to be used after discharge until the follow-up ultrasounds. Duration 28±2 days. Concurrent medication/care: Use of platelet function suppressive drugs, such a non-steroidal anti-inflammatory drugs (NSAIDs), was discouraged but not prohibited by the protocol.</p>
Funding	Funding not stated
RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: FONDAPARINUX + IPCD + AES versus WARFARIN + IPCD + AES	

Study	Bern 2015 ²⁸
	<p>Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge - Actual outcome: All-cause mortality at 28±2 days; Group 1: 0/54, Group 2: 0/64 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0</p> <p>Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge - Actual outcome: DVT (symptomatic and asymptomatic) at 28±2 days; Group 1: 0/54, Group 2: 0/64 Risk of bias: All domain - Very high, Selection - High, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0</p> <p>Protocol outcome 3: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge - Actual outcome: PE at 28±2 days; Group 1: 0/54, Group 2: 0/64 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0</p> <p>Protocol outcome 4: DVT (distal) at 7-90 days from hospital discharge - Actual outcome: DVT (distal) at 28±2 days; Group 1: 0/54, Group 2: 0/64</p> <p>Protocol outcome 5: DVT (proximal) at 7-90 days from hospital discharge - Actual outcome: DVT (proximal) at 28±2 days; Group 1: 0/54, Group 2: 0/64</p>
<p>Protocol outcomes not reported by the study</p>	<p>Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of ≥2g/dl; a serious or life threatening clinical event at up to 45 days from hospital discharge; Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Surgical site haematoma at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study; Infection at duration of study;</p>

Bibliographic reference	Study Type	Evidence level	No. of patients	Patients characteristics	Intervention	Comparison	Length of follow up	Outcome measures	Effect size	Comments
Blanchard et al., 1999 ³¹	RCT	1+	Total: 130 Intervention: 63 Control: 67	Type of surgery: elective knee replacement. Intervention M/F: 11/52 Mean age: 72 Control M/F: 20/47 Mean age: 74	Intermittent pneumatic plantar compression (AVIS (Novomedix)) Started 12 hours preoperatively, discontinued for surgery, reapplied after surgery. Used at all times except during walking and physiotherapy Additional prophylaxis: none	LMWH (calcium nadroparin) injected subcutaneously 12 hours preoperatively the 12 hours postoperatively then once per day for 12 days. Doses adjusted to patient's body weight. Additional prophylaxis: none	2 to 3 months Diagnostic tests carried out 8 to 10 days after surgery. After screening for DVT, all patients received acenocoumarol for 6 to 8 weeks.	DVT confirmed by phlebography or venous compression US	Int: 34/63 Cont: 16/.67 p value: <0.01	At 2 to 3 month follow up no patients had symptomatic DVT or PE and none died. Also reported Median intraoperative and postoperative blood loss, total blood transfused.
								Proximal DVT confirmed by phlebography or venous compression US	Int: 4/63 Cont: 2/.67 p value: 0.4	
								Distal DVT confirmed by phlebography or venous compression US	Int: 30/63 Cont: 14/.67 p value: <0.005	
								Symptomatic PE	Int: 0/63 Cont: 0/.67 p value: N/A	
							Major bleeds	Int: 0/63 Cont: 1/67 p value: not significant		

Study	Chin 2009⁴⁹
Study type	RCT (Patient randomised; Parallel)

Study	Chin 2009 ⁴⁹
Number of studies (number of participants)	N/A (n=n=440)
Countries and setting	Conducted in Singapore; Setting: Hospital during intervention and post-discharge follow-up.
Line of therapy	Not applicable
Duration of study	Intervention + follow up: 5 to 7 days of intervention + Up to 1 month of follow-up
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: Diagnostic criteria: loss of compressibility of a vein or visualisation of thrombosis. Investigations performed: ventilation-perfusion scanning; spiral computed tomography of the chest; duplex ultrasonography.
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Low risk patients with no predisposition to thromboembolism who underwent elective TKA.
Exclusion criteria	Use of anticoagulants/ aspirin; history of PE/DVT in previous year; obesity (BMI>30); pre-operative prolonged immobilisation or being wheelchair-bound; bleeding tendency or history of GI bleeding; surgery in previous 6 months; cerebrovascular accident in previous 3 months; uncontrolled hypertension; congestive cardiac failure; renal/liver impairment; allergy to heparin / heparin-induced thrombocytopenia; varicose veins / chronic venous insufficiency; peripheral vascular disease; skin ulcers; dermatitis/wounds; malignancy.
Recruitment/selection of patients	Not reported
Age, gender and ethnicity	Age - Mean (range): Control 65 (47-77); AES 67 (51-81); Intermittent pneumatic compression 65 (49-85); Enoxaparin 67 (52-78). Gender (M:F): 43:397. Ethnicity: Chinese n=403 (91.6%); Malay n=16 (3.6%); Indian n=21 (4.8%)
Further population details	1. BMI : 2. Renal impairment:
Extra comments	.
Indirectness of population	Serious indirectness: The composition of ethnic groups is different to that of the UK population. Incidence and prevalence of VTE are significantly lower in Asian populations than in other ethnic groups.
Interventions	(n=110) Intervention 1: Low molecular weight heparin (licensed in UK) - Enoxaparin (20mg once daily – 60mg twice daily). 40mg once daily. Duration 5 to 7 days (stopped earlier if DVT/PE suspected). Concurrent medication/care: Standardised rehabilitation: continuous passive movements on day 2 then ambulation on day 3 (n=110) Intervention 2: Intermittent pneumatic compression devices - Full leg. One minute per inflation-deflation cycle and pressures from 45 to 52mmHg. Duration 5 to 7 days (stopped earlier if DVT/PE suspected). Concurrent medication/care: Standardised rehabilitation: continuous passive movements on day 2 then ambulation on day 3 Comments: Unknown whether the pressure was applied to below knees only or full legs.

Study	Chin 2009⁴⁹
	<p>(n=110) Intervention 3: Anti-embolism stockings - Mixed above/below knee. Applied directly to both legs. Duration 5 to 7 days (stopped earlier if DVT/PE suspected). Concurrent medication/care: Standardised rehabilitation: continuous passive movements on day 2 then ambulation on day 3 Comments: Stocking length unknown</p> <p>(n=110) Intervention 4: No treatment - Usual care. No prophylaxis. Duration N/A. Concurrent medication/care: Standardised rehabilitation: continuous passive movements on day 2 then ambulation on day 3</p>
Funding	Funding not stated
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: ENOXAPARIN (40MG ONCE DAILY) versus INTERMITTENT PNEUMATIC COMPRESSION (IPC)</p> <p>Protocol outcome 1: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge - Actual outcome: Overall prevalence of DVT at Up to 1 month post-surgery; Group 1: 6/110, Group 2: 9/110 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 2: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge - Actual outcome: PE at Up to 1 month post-surgery; Group 1: 0/110, Group 2: 0/110 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 3: Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge - Actual outcome: Major bleeding at time-point not reported; Group 1: 2/110, Group 2: 0/110 Risk of bias: All domain - Very high, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - High, Crossover - Low, Comments - ; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 4: Technical complications of mechanical interventions at duration of study - Actual outcome: Technical complications of mechanical interventions at time-point not reported; Group 1: 0/110, Group 2: 0/110</p>	

Study	Chin 2009 ⁴⁹
	<p>Risk of bias: All domain - Very high, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - High, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 5: Infection at duration of study - Actual outcome: Number of participants re-admitted due to superficial wound infections at Up to 1 month post-surgery; Group 1: 0/110, Group 2: 1/110 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 6: DVT (distal) at 7-90 days from hospital discharge - Actual outcome: Distal DVT at Up to 1 month post-surgery; Group 1: 5/110, Group 2: 9/110</p> <p>Protocol outcome 7: DVT (proximal) at 7-90 days from hospital discharge - Actual outcome: Proximal DVT at Up to 1 month post-surgery; Group 1: 1/110, Group 2: 0/110</p> <p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: ENOXAPARIN (40MG ONCE DAILY) versus AES</p> <p>Protocol outcome 1: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge - Actual outcome: Overall prevalence of DVT at Up to 1 month post-surgery; Group 1: 6/110, Group 2: 14/110 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 2: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQspect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge - Actual outcome: PE at Up to 1 month post-surgery; Group 1: 0/110, Group 2: 1/110 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 3: Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge - Actual outcome: Major bleeding at time-point not reported; Group 1: 2/110, Group 2: 0/110 Risk of bias: All domain - Very high, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - High, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 0 ; Group 2 Number missing: 0</p>

Study	Chin 2009 ⁴⁹
	<p>Protocol outcome 4: Technical complications of mechanical interventions at duration of study - Actual outcome: Technical complications of mechanical interventions at time-point not reported; Group 1: 0/110, Group 2: 0/110 Risk of bias: All domain - Very high, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - High, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 5: Infection at duration of study - Actual outcome: Number of participants re-admitted due to superficial wound infections at Up to 1 month post-surgery; Group 1: 0/110, Group 2: 2/110 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 6: DVT (distal) at 7-90 days from hospital discharge - Actual outcome: Distal DVT at Up to 1 month post-surgery; Group 1: 5/110, Group 2: 13/110</p> <p>Protocol outcome 7: DVT (proximal) at 7-90 days from hospital discharge - Actual outcome: Proximal DVT at Up to 1 month post-surgery; Group 1: 1/110, Group 2: 3/110</p> <p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: ENOXAPARIN (40MG ONCE DAILY) versus USUAL CARE</p> <p>Protocol outcome 1: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge - Actual outcome: Overall prevalence of DVT at Up to 1 month post-surgery; Group 1: 6/110, Group 2: 24/110; Comments: p = 0.001 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 2: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge - Actual outcome: PE at Up to 1 month post-surgery; Group 1: 0/110, Group 2: 1/110 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 3: Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge - Actual outcome: Major bleeding at time-point not reported; Group 1: 2/110, Group 2: 0/110 Risk of bias: All domain - Very high, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - High, Crossover - Low;</p>

Study	Chin 2009 ⁴⁹
	<p>Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 4: Technical complications of mechanical interventions at duration of study - Actual outcome: Technical complications of mechanical interventions at time-point not reported; Group 1: 0/110, Group 2: 0/110 Risk of bias: All domain - Very high, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - High, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 5: Infection at duration of study - Actual outcome: Number of participants re-admitted due to superficial wound infections at Up to 1 month post-surgery; Group 1: 0/110, Group 2: 2/110 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 6: DVT (distal) at 7-90 days from hospital discharge - Actual outcome: Distal DVT at Up to 1 month post-surgery; Group 1: 5/110, Group 2: 21/110</p> <p>Protocol outcome 7: DVT (proximal) at 7-90 days from hospital discharge - Actual outcome: Proximal DVT at Up to 1 month post-surgery; Group 1: 1/110, Group 2: 3/110</p> <p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: INTERMITTENT PNEUMATIC COMPRESSION (IPC) versus AES</p> <p>Protocol outcome 1: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge - Actual outcome: Overall prevalence of DVT at Up to 1 month post-surgery; Group 1: 9/110, Group 2: 14/110 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 2: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQspect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge - Actual outcome: PE at Up to 1 month post-surgery; Group 1: 0/110, Group 2: 1/110 Risk of bias: All domain - ; Indirectness of outcome: No indirectness</p> <p>Protocol outcome 3: Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge - Actual outcome: Major bleeding at time-point not reported; Group 1: 0/110, Group 2: 0/110</p>

Study	Chin 2009 ⁴⁹
	<p>Risk of bias: All domain - Very high, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - High, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 4: Technical complications of mechanical interventions at duration of study - Actual outcome: Technical complications of mechanical interventions at time-point not reported; Group 1: 0/110, Group 2: 0/110 Risk of bias: All domain - Very high, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - High, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 5: Infection at duration of study - Actual outcome: Number of participants re-admitted due to superficial wound infections at Up to 1 month post-surgery; Group 1: 1/110, Group 2: 2/110 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 6: DVT (distal) at 7-90 days from hospital discharge - Actual outcome: Distal DVT at Up to 1 month post-surgery; Group 1: 9/110, Group 2: 13/110</p> <p>Protocol outcome 7: DVT (proximal) at 7-90 days from hospital discharge - Actual outcome: Proximal DVT at Up to 1 month post-surgery; Group 1: 0/110, Group 2: 1/110</p> <p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: INTERMITTENT PNEUMATIC COMPRESSION (IPC) versus USUAL CARE</p> <p>Protocol outcome 1: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge - Actual outcome: Overall prevalence of DVT at Up to 1 month post-surgery; Group 1: 9/110, Group 2: 24/110; Comments: p = 0.032 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 2: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge - Actual outcome: PE at Up to 1 month post-surgery; Group 1: 0/110, Group 2: 1/110 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 3: Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening</p>

Study	Chin 2009 ⁴⁹
	<p>clinical event at up to 45 days from hospital discharge</p> <p>- Actual outcome: Major bleeding at time-point not reported; Group 1: 0/110, Group 2: 0/110</p> <p>Risk of bias: All domain - Very high, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - High, Crossover - Low;</p> <p>Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p>
	<p>Protocol outcome 4: Technical complications of mechanical interventions at duration of study</p> <p>- Actual outcome: Technical complications of mechanical interventions at time-point not reported; Group 1: 0/110, Group 2: 0/110</p> <p>Risk of bias: All domain - Very high, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - High, Crossover - Low;</p> <p>Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p>
	<p>Protocol outcome 5: Infection at duration of study</p> <p>- Actual outcome: Number of participants re-admitted due to superficial wound infections at Up to 1 month post-surgery; Group 1: 1/110, Group 2: 2/110</p> <p>Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;</p> <p>Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p>
	<p>Protocol outcome 6: DVT (distal) at 7-90 days from hospital discharge</p> <p>- Actual outcome: Distal DVT at Up to 1 month post-surgery; Group 1: 9/110, Group 2: 21/110</p>
	<p>Protocol outcome 7: DVT (proximal) at 7-90 days from hospital discharge</p> <p>- Actual outcome: Proximal DVT at Up to 1 month post-surgery; Group 1: 0/110, Group 2: 3/110</p>
	<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: AES versus USUAL CARE</p>
	<p>Protocol outcome 1: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge</p> <p>- Actual outcome: Overall prevalence of DVT at Up to 1 month post-surgery; Group 1: 14/110, Group 2: 24/110; Comments: p = 0.119</p> <p>Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;</p> <p>Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p>
	<p>Protocol outcome 2: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge</p> <p>- Actual outcome: PE at Up to 1 month post-surgery; Group 1: 1/110, Group 2: 1/110</p> <p>Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;</p> <p>Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p>

Study	Chin 2009 ⁴⁹
	<p>Protocol outcome 3: Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge</p> <p>- Actual outcome: Major bleeding at time-point not reported; Group 1: 0/110, Group 2: 0/110</p> <p>Risk of bias: All domain - ; Indirectness of outcome: No indirectness</p> <p>Protocol outcome 4: Technical complications of mechanical interventions at duration of study</p> <p>- Actual outcome: Technical complications of mechanical interventions at time-point not reported; Group 1: 0/110, Group 2: 0/110</p> <p>Risk of bias: All domain - Very high, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - High, Crossover - Low, Comments - ; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 5: Infection at duration of study</p> <p>- Actual outcome: Number of participants re-admitted due to superficial wound infections at Up to 1 month post-surgery; Group 1: 2/110, Group 2: 2/110</p> <p>Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 6: DVT (distal) at 7-90 days from hospital discharge</p> <p>- Actual outcome: Distal DVT at Up to 1 month post-surgery; Group 1: 13/110, Group 2: 21/110</p> <p>Protocol outcome 7: DVT (proximal) at 7-90 days from hospital discharge</p> <p>- Actual outcome: Proximal DVT at Up to 1 month post-surgery; Group 1: 1/110, Group 2: 3/110</p>
Protocol outcomes not reported by the study	All-cause mortality at up to 90 days from hospital discharge; Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Surgical site haematoma at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study;
Study	Cho 2013 ⁵¹
Study type	RCT (Patient randomised; Parallel)

Study	Cho 2013 ⁵¹
Number of studies (number of participants)	N/A (n=148)
Countries and setting	Conducted in South Korea; Setting: Secondary care
Line of therapy	Not applicable
Duration of study	Intervention + follow up: 5 to 7 days of intervention + 90-day follow-up
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: Assessment of clinical symptoms, Doppler ultrasonography, ventilation perfusion lung scan, CT pulmonary angiography
Stratum	Overall:
Subgroup analysis within study	Not applicable
Inclusion criteria	All adult patients with a diagnosis of primary osteoarthritis of the knee and undergoing elective unilateral primary TKA.
Exclusion criteria	Patients undergoing bilateral knee replacements, preoperative diagnosis of chronic or acute DVT, active bleeding, documented congenital/acquired bleeding disorders, current ulcerative/angiodysplastic GI disease, haemorrhagic stroke or brain/spinal/ophthalmologic surgery in previous 3 months, contraindication to anticoagulant therapy, serum creatinine concentration above 2mg/dl in a well-hydrated patient, platelet count below 100,000/m ³ .
Recruitment/selection of patients	From November 2008 to October 2011 patients undergoing elective primary TKA were recruited.
Age, gender and ethnicity	Age - Mean (SD): Intervention 68.5 (6.0) vs. Placebo 68.5 (5.5). Gender (M:F): 12:136. Ethnicity: East Asian
Further population details	1. BMI : Not obese (BMI under 30 kg/m ²) (Mean BMI in both groups 27.1 kg/m ²). 2. Renal impairment: Not applicable
Extra comments	.
Indirectness of population	Serious indirectness: The study participants are East Asians. Incidence and prevalence of VTE are significantly lower in Asian populations than in other ethnic groups.
Interventions	(n=74) Intervention 1: Fondaparinux - Fondaparinux (all doses). Subcutaneous injection of 2.5mg first at 6 to 8 hrs after the surgery, then the second 24hrs after the first. Daily single dose continued until day 5. Duration 5 days. Concurrent medication/care: AES and the same rehabilitation protocol were applied in all patients. Patient-controlled analgesia using IV fentanyl was used until day 2 post-operation. (n=74) Intervention 2: No treatment - Placebo. Isotonic saline injection 0.25ml once daily. First at 6 to 8 hrs after the surgery, then the second at 24hrs after the first one. Daily single dose continued until day 5. Duration 5 days. Concurrent medication/care: As per the fondaparinux group.
Funding	Funding not stated

Study	Cho 2013 ⁵¹
RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: FONDAPARINUX 2.5MG versus PLACEBO	
<p>Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge - Actual outcome: Deaths at 90 days post-surgery; Group 1: 0/74, Group 2: 0/74 Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p>	
<p>Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge - Actual outcome: Prevalence of total DVT at 7 days post-surgery; Group 1: 5/74, Group 2: 19/74 Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p>	
<p>Protocol outcome 3: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQspect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge - Actual outcome: Symptomatic PE at 7 days post-surgery; Group 1: 0/74, Group 2: 0/74 Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p>	
<p>Protocol outcome 4: Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge - Actual outcome: Incidence of major bleeding at 90 days post-surgery; Group 1: 0/74, Group 2: 0/74 Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p>	
<p>Protocol outcome 5: VTE at 7-90 days from hospital discharge - Actual outcome: Prevalence of VTE at Between day 7 and day 90 post-surgery; Group 1: 0/74, Group 2: 0/74</p>	
<p>Protocol outcome 6: DVT (distal) at 7-90 days from hospital discharge - Actual outcome: Distal DVT at 7 days; Group 1: 4/74, Group 2: 15/74</p>	
<p>Protocol outcome 7: DVT (proximal) at 7-90 days from hospital discharge - Actual outcome: Proximal DVT at 7 days; Group 1: 1/74, Group 2: 4/74</p>	

Study	Cho 2013 ⁵¹
Protocol outcome 8: Fatal bleeding at 45 days from hospital discharge - Actual outcome: Fatal bleeding at 90 days post-surgery; Group 1: 0/74, Group 2: 0/74	
Protocol outcomes not reported by the study	Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQspect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Surgical site haematoma at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study; Infection at duration of study;

Study	Colwell 1995 ⁶⁹
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=453)
Countries and setting	Conducted in USA; Setting: Multicentre
Line of therapy	Not applicable
Duration of study	Intervention + follow up: 15 days
Method of assessment of guideline condition	Adequate method of assessment/diagnosis
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Male and premenopausal (if documented to be not pregnant) or post-menopausal females patients 40 years of age or older
Exclusion criteria	Failure to achieve postoperative haemostasis; documented history or positive clinical evidence of DVT; history of generalised haemorrhagic disorders or any clinically significant diseases that might interfere with the study medications; documented allergy to UFH, fish, swine products or radiopaque dye; uncontrolled asthma, history of heparin associated thrombocytopenia or skin rash; current evidence of drug or alcohol abuse; active ulcerative disease or gastrointestinal haemorrhage within the past 6 months; uncontrolled hypertension; surgery on the eye, spinal cord, or central nervous system within 3 months; scheduled simultaneous multiple joint replacements; documented cerebral vascular accident within 3 months; treatment with other investigational therapeutic agents

Study	Colwell 1995 ⁶⁹
	within 4 weeks; or treatment with aspirin or NSAID drugs on a regular basis for 4 days preceding hospitalisation.
Recruitment/selection of patients	Not reported
Age, gender and ethnicity	Age - Mean (SD): 68.0 (9.2). Gender (M:F): 1:1.3. Ethnicity: White 92.5%, Black 5.3%, Asian 0.2%, Hispanic 1.5%, other 2%
Further population details	1. BMI : Not applicable 2. Renal impairment: Not applicable
Indirectness of population	No indirectness
Interventions	(n=228) Intervention 1: Low molecular weight heparin (licensed in UK) - Enoxaparin (20mg once daily – 60mg twice daily). Enoxaparin 30mg every 12 hours. Study medication began on the day of surgery within 8 hours of surgical closure after adequate haemostasis. The medication was continued for a minimum of 4 days and as long as 14 days. Duration 4-14 days. Concurrent medication/care: Not reported (n=225) Intervention 2: Unfractionated heparin - Unfractionated heparin (low dose, administered subcutaneously). UFH 5000U every 8 hours. Study medication began on the day of surgery within 8 hours of surgical closure after adequate haemostasis. The medication was continued for a minimum of 4 days and as long as 14 days. Duration 4-14 days. Concurrent medication/care: Not reported
Funding	Funding not stated

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: ENOXAPARIN (20MG ONCE DAILY – 60MG TWICE DAILY) versus UNFRACTIONATED HEPARIN (LOW DOSE, ADMINISTERED SUBCUTANEOUSLY)

Protocol outcome 1: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge
 - Actual outcome: DVT (symptomatic and asymptomatic) at 15 days; Group 1: 56/145, Group 2: 77/143
 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low;
 Indirectness of outcome: No indirectness ; Group 1 Number missing: 83; Group 2 Number missing: 82

Protocol outcome 2: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge
 - Actual outcome: PE at 15 days; Group 1: 0/145, Group 2: 1/143
 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low;
 Indirectness of outcome: No indirectness ; Group 1 Number missing: 83; Group 2 Number missing: 82

Study	Colwell 1995 ⁶⁹
	<p>Protocol outcome 3: Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge</p> <p>- Actual outcome: Major bleeding at 15 days; Group 1: 3/228, Group 2: 3/225</p> <p>Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - High, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0</p> <p>Protocol outcome 4: VTE at 7-90 days from hospital discharge</p> <p>- Actual outcome: VTE at 15 days; Group 1: 56/228, Group 2: 77/225</p> <p>Protocol outcome 5: DVT (distal) at 7-90 days from hospital discharge</p> <p>- Actual outcome: DVT (distal) at 15 days; Group 1: 51/145, Group 2: 54/143</p> <p>Protocol outcome 6: DVT (proximal) at 7-90 days from hospital discharge</p> <p>- Actual outcome: DVT (proximal) at 15 days; Group 1: 5/145, Group 2: 22/143</p> <p>Protocol outcome 7: Site of bleeding (gastrointestinal ; surgical site; brain/spine; other) at 45 days from hospital discharge</p> <p>- Actual outcome: Operative site bleeding at 15 days; Group 1: 9/228, Group 2: 5/225</p>
Protocol outcomes not reported by the study	All-cause mortality at up to 90 days from hospital discharge; Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQspect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Surgical site haematoma at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study; Infection at duration of study;

Study	Comp 2001 ⁷¹
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=438)
Countries and setting	Conducted in USA; Setting: Multicentre trial

Study	Comp 2001 ⁷¹
Line of therapy	Not applicable
Duration of study	Intervention + follow up: 29 days
Method of assessment of guideline condition	Adequate method of assessment/diagnosis
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Patients undergoing elective knee replacement who gave written consent
Exclusion criteria	Patients undergoing multiple joint replacement or in whom haemostasis was not achieved within 12-24 hours after surgery. Patients treated with knee replacement who had undergone surgery on the ipsilateral hip, the contralateral hip or contralateral knee within the previous three months. Clinical evidence of chronic or acute DVT; a history of venous thromboembolic disease within 12 months before the surgery; generalised haemorrhagic diathesis or hypercoagulable syndrome; a documented allergy to UFH or a history of heparin associated thrombocytopenia; a skin rash or necrosis; allergy to fish or swine products, iodine, or radiopaque contrast medium; current drug or alcohol abuse; surgery on the eye, spinal cord or central nervous system; documented stroke or myocardial infarction within one month before entry into the study; active ulcerative disease or angiodysplasia of the gastrointestinal tract; active gastrointestinal bleeding within the last 6 months; uncontrolled hypertension; use of aspirin-containing products or NSAID agents daily within the four days preceding hospitalisation; receipt of another investigational drug within the preceding 4 weeks; and clinically relevant diseases or treatments that could interfere with the study medications or their evaluation.
Recruitment/selection of patients	Not reported
Age, gender and ethnicity	Age - Mean (range): LMWH group, 66.2 (39-87); placebo group, 66.3 (34-88). Gender (M:F): 1:1.34. Ethnicity: Not reported
Further population details	1. BMI : Obese (BMI over 30 kg/m ²) (Mean BMI LMWH group = 31.4 (19.8-51.8); placebo group = 31.1 (17.2-55.7)). 2. Renal impairment: Not applicable
Indirectness of population	No indirectness
Interventions	(n=217) Intervention 1: Low molecular weight heparin (licensed in UK) - Enoxaparin (20mg once daily – 60mg twice daily). Enoxaparin, high dose, extended duration (30mg twice daily). Enoxaparin treatment was initiated 12-24 hours postoperatively and continued for 7-10 days. Patients were then administered 40mg once daily subcutaneously for 3 weeks. Duration 28-31 days. Concurrent medication/care: Not reported (n=221) Intervention 2: Low molecular weight heparin (licensed in UK) - Enoxaparin (20mg once daily – 60mg twice daily). Enoxaparin, high dose, standard duration (30mg twice daily). Enoxaparin treatment was initiated 12-24 hours

Study	Comp 2001 ⁷¹
	postoperatively and continued for 7-10 days. Patients were then administered saline solution once daily subcutaneously for 3 weeks. Duration 28-31 days. Concurrent medication/care: Not reported
Funding	Study funded by industry (Funds were received in total or partial support of the research from Aventis Pharmaceuticals Incorporated, Bridgewater, New Jersey and Aventis Pharma SA Antony, France)
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: ENOXAPARIN (20MG ONCE DAILY – 60MG TWICE DAILY) EXTENDED DURATION versus ENOXAPARIN (20MG ONCE DAILY – 60MG TWICE DAILY) STANDARD DURATION</p> <p>Protocol outcome 1: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge - Actual outcome: DVT (symptomatic and asymptomatic) at 27-29 days; Group 1: 33/155, Group 2: 37/144 Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 62; Group 2 Number missing: 77</p> <p>Protocol outcome 2: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge - Actual outcome: PE at 27-29 days; Group 1: 0/217, Group 2: 2/221 Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0</p> <p>Protocol outcome 3: Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge - Actual outcome: Major bleeding at 27-29 days; Group 1: 0/217, Group 2: 1/221 Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0</p> <p>Protocol outcome 4: Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge - Actual outcome: Clinically relevant non-major bleeding (hemorrhage) at 27-29 days; Group 1: 5/217, Group 2: 8/221 Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0</p>	

Study	Comp 2001 ⁷¹
	<p>Protocol outcome 5: Heparin-induced thrombocytopenia at duration of study - Actual outcome: Thrombocytopenia at 27-29 days; Group 1: 2/217, Group 2: 2/221 Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0</p> <p>Protocol outcome 6: DVT (distal) at 7-90 days from hospital discharge - Actual outcome: DVT (distal) at 27-29 days; Group 1: 25/155, Group 2: 26/144</p> <p>Protocol outcome 7: DVT (proximal) at 7-90 days from hospital discharge - Actual outcome: DVT (proximal) at 27-29 days; Group 1: 8/155, Group 2: 11/144</p> <p>Protocol outcome 8: Fatal bleeding at 45 days from hospital discharge - Actual outcome: Fatal bleeding at 27-29 days; Group 1: 0/217, Group 2: 0/221</p>
Protocol outcomes not reported by the study	All-cause mortality at up to 90 days from hospital discharge; Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQScpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Surgical site haematoma at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Technical complications of mechanical interventions at duration of study; Infection at duration of study;

Study	RE-MODEL trial: Eriksson 2007 ⁹⁶
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=1393)
Countries and setting	Conducted in Australia, Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Hungary, Italy, Netherlands, Poland, South Africa, Spain, Sweden; Setting: 105 centres in Europe, Australia and South Africa
Line of therapy	Not applicable
Duration of study	Intervention time: 6-10 days
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: Diagnosis of DVT was established as a consistent intraluminal filling defect on at least two venogram images. PE was established by ventilation/perfusion scintigraphy, pulmonary angiography, spiral computed tomography, or autopsy. Major bleeding defined as fatal bleeding; clinically overt bleeding associated with a decrease in the haemoglobin level

Study	RE-MODEL trial: Eriksson 2007 ⁹⁶
	<p>of more than 20 g/l compared with the pre-randomisation level; clinically overt bleeding leading to transfusion of two or more units of whole blood or packed cells; critical bleeding (intracerebral, intraocular, intraspinal, pericardial or retroperitoneal); bleeding warranting treatment cessation; bleeding located at the surgical site and leading to re-operation or to any unusual medical intervention or procedure for relief (e.g. draining or puncture of a haematoma at the surgical site, transfer to an ICU or emergency room)</p> <p>Clinically relevant non-major bleeding defined as any clinically overt bleeding that does not meet the criteria for major bleed but requires medical attention (e.g.: hospitalisation, medical treatment for bleeding) and/or a change in antithrombotic therapy (including discontinuation or down-titration of study drug) and/or any other bleeding type considered to have clinical consequences for a patient.</p>
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Patients ≥18 years and >40 kg, scheduled for primary elective unilateral total knee replacement who provided signed informed consent, were eligible for study
Exclusion criteria	Exclusion criteria included: any bleeding diathesis; history of acute intracranial disease or haemorrhagic stroke; major surgery, trauma, uncontrolled hypertension or myocardial infarction within the past 3 months; gastrointestinal or urogenital bleeding or ulcer disease within the past 6 months; severe liver disease; aspartate aminotransferase or alanine aminotransferase (ALT) levels more than two times the upper limit of the normal range (ULN) within the past month; severe renal insufficiency (creatinine clearance <30 mL min ⁻¹); concomitant long-acting non-steroidal anti-inflammatory drug therapy (also contraindicated during study treatment); active malignant disease; and being female and of childbearing potential.
Recruitment/selection of patients	Patients enrolled between November 2004 and March 2006
Age, gender and ethnicity	Age - Mean (SD): 68 (9) years. Gender (M:F): 1/2. Ethnicity: Not reported
Further population details	1. BMI : Not applicable 2. Renal impairment: Not applicable
Extra comments	Mean duration of surgery: 90.5 minutes
Indirectness of population	No indirectness
Interventions	(n=699) Intervention 1: Low molecular weight heparin (licensed in UK) - Enoxaparin (20mg once daily – 60mg twice daily). Patients were assigned to oral dabigatran etexilate enoxaparin (Sanofi-Aventis), 40 mg subcutaneously once-daily. All three groups received one active and one matching placebo treatment that were identical in appearance. Patients received two capsules in the morning and a daily subcutaneous injection in the evening. The first subcutaneous injection was given on the evening before surgery, although in some countries treatment was started postoperatively to reflect local practice. The first dose of dabigatran etexilate was one-half of subsequent doses (one

Study	RE-MODEL trial: Eriksson 2007⁹⁶
	<p>capsule), and was administered 1–4 h after completion of surgery, provided that clinical assessment of perioperative and postoperative bleeding and drainage indicated good haemostasis. If administration was delayed until the day after surgery, then a full dose (two capsules) was administered as the first dose. Duration 6-10 days. Concurrent medication/care: Concomitant treatment with low-dose aspirin (<160 mg) and selective cyclooxygenase-2 inhibitors was allowed during the treatment period. AES were permitted (percentage of patients that wore AES not reported), but intermittent pneumatic compression devices were prohibited.</p> <p>(n=694) Intervention 2: Dabigatran - Dabigatran (all doses). Patients were assigned to oral dabigatran etexilate 220 mg once-daily. All three groups received one active and one matching placebo treatment that were identical in appearance. Patients received two capsules in the morning and a daily subcutaneous injection in the evening. The first subcutaneous injection was given on the evening before surgery, although in some countries treatment was started postoperatively to reflect local practice. The first dose of dabigatran etexilate was one-half of subsequent doses (one capsule, 75 mg or 110 mg), and was administered 1–4 h after completion of surgery, provided that clinical assessment of perioperative and postoperative bleeding and drainage indicated good haemostasis. If administration was delayed until the day after surgery, then a full dose (two capsules) was administered as the first dose. Duration 6-10 days. Concurrent medication/care: Concomitant treatment with low-dose aspirin (<160 mg) and selective cyclooxygenase-2 inhibitors was allowed during the treatment period. AES were permitted (percentage of patients that wore AES not reported), but intermittent pneumatic compression devices were prohibited.</p>
Funding	Study funded by industry (Boehringer Ingelheim, Copenhagen, Denmark)
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: ENOXAPARIN (40MG) versus DABIGATRAN (ALL DOSES)</p> <p>Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge - Actual outcome: All-cause mortality at 13 days; Group 1: 1/685, Group 2: 1/675 Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low, Comments - ; Indirectness of outcome: No indirectness ; Group 1 Number missing: 14; Group 2 Number missing: 19</p> <p>Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge - Actual outcome: DVT (symptomatic and asymptomatic) at 13 days; Group 1: 192/685, Group 2: 182/675 Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low, Comments - ; Indirectness of outcome: No indirectness ; Group 1 Number missing: 188, Reason: Venography not performed; venography inadequate; Group 2 Number missing: 191, Reason: Venography not performed; venography inadequate</p>	

Study	RE-MODEL trial: Eriksson 2007 ⁹⁶
	<p>Protocol outcome 3: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge</p> <p>- Actual outcome: PE at 13 days; Group 1: 1/685, Group 2: 0/675</p> <p>Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low, Comments - ; Indirectness of outcome: No indirectness ; Group 1 Number missing: 14, Reason: Venography not performed; venography inadequate; Group 2 Number missing: 19, Reason: Venography not performed; venography inadequate</p>
	<p>Protocol outcome 4: Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge</p> <p>- Actual outcome: Major bleeding at 13 days; Group 1: 9/694, Group 2: 10/679</p> <p>Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low, Comments - ; Indirectness of outcome: No indirectness ; Group 1 Number missing: 5, Reason: Venography not performed; venography inadequate; Group 2 Number missing: 15, Reason: Venography not performed; venography inadequate</p>
	<p>Protocol outcome 5: Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge</p> <p>- Actual outcome: Fatal PE at 13 days; Group 1: 1/685, Group 2: 0/675</p> <p>Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low, Comments - ; Indirectness of outcome: No indirectness ; Group 1 Number missing: 14, Reason: Venography not performed; venography inadequate; Group 2 Number missing: 19, Reason: Venography not performed; venography inadequate</p>
	<p>Protocol outcome 6: Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge</p> <p>- Actual outcome: Clinically relevant non-major bleeding at 13 days; Group 1: 37/694, Group 2: 40/679</p> <p>Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low, Comments - ; Indirectness of outcome: No indirectness ; Group 1 Number missing: 5, Reason: Venography not performed; venography inadequate; Group 2 Number missing: 15, Reason: Venography not performed; venography inadequate</p>
	<p>Protocol outcome 7: VTE at 7-90 days from hospital discharge</p> <p>- Actual outcome: VTE ([symptomatic or venographic deep vein thrombosis (DVT) and/or symptomatic pulmonary embolism (PE)], and all-cause mortality) at 13 days; Group 1: 193/512, Group 2: 183/503</p> <p>Protocol outcome 8: DVT (symptomatic) at 7-90 days from hospital discharge</p>

Study	RE-MODEL trial: Eriksson 2007 ⁹⁶
	- Actual outcome: DVT (symptomatic) at 6-10 days; Group 1: 8/685, Group 2: 1/675
	Protocol outcome 9: DVT (distal) at 7-90 days from hospital discharge - Actual outcome: Asymptomatic DVT (distal) at 6-10 days; Group 1: 168/685, Group 2: 168/675
	Protocol outcome 10: DVT (proximal) at 7-90 days from hospital discharge - Actual outcome: Asymptomatic DVT (proximal) at 6-10 days; Group 1: 16/685, Group 2: 13/675
	Protocol outcome 11: Fatal bleeding at 45 days from hospital discharge - Actual outcome: Fatal bleeding at 13 days; Group 1: 0/694, Group 2: 0/679
	Protocol outcome 12: Site of bleeding (gastrointestinal ; surgical site; brain/spine; other) at 45 days from hospital discharge - Actual outcome: Surgical site at 13 days; Group 1: 9/694, Group 2: 10/679
Protocol outcomes not reported by the study	Surgical site haematoma at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study; Infection at duration of study

Study	Faunø 1994 ¹⁰¹
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=185)
Countries and setting	Conducted in Denmark, Finland; Setting: Multicentre trial in three hospitals in Finland and Denmark
Line of therapy	Not applicable
Duration of study	Intervention time: 7-10 days
Method of assessment of guideline condition	Adequate method of assessment/diagnosis
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	More than 40 years old, scheduled to have a primary unilateral knee replacement and diagnosed as having osteoarthritis or rheumatoid arthritis.
Exclusion criteria	Managed with anticoagulants; had received platelet aggregation inhibitors, salicylates, or non-steroidal anti-

Study	Faunø 1994 ¹⁰¹
	inflammatory drugs within seven days before the operation; had a history of bleeding disorder; had abnormal preoperative coagulation values, including a platelet count of less than 80×10^9 per litre or a prothrombin time outside the range of 80 to 120 percent of normal; had indications of internal bleeding; had untreated hypertension; had a hypersensitivity to heparins or contrast media; or had had a previous DVT or PE
Recruitment/selection of patients	Not reported
Age, gender and ethnicity	Age - Mean (SD): LMWH group: 71 (11); UFH group 70 (10). Gender (M:F): 1:1.5. Ethnicity: Not reported
Further population details	1. BMI : Not applicable 2. Renal impairment: Not applicable
Indirectness of population	No indirectness
Interventions	<p>(n=92) Intervention 1: Low molecular weight heparin (licensed in UK) - Enoxaparin (20mg once daily – 60mg twice daily). Enoxaparin, standard dose (40mg once daily) + AES. The first dose was given the evening before the operation, and continued for 7-10 days. All patients wore a short AES on the involved limb and a long AES on the contralateral limb. Duration 7-10 days. Concurrent medication/care: Not reported</p> <p>(n=93) Intervention 2: Unfractionated heparin - Unfractionated heparin (low dose, administered subcutaneously). UFH (5000U), three times daily + AES. The first dose was given the evening before the operation, and continued for 7-10 days. All patients wore a short AES on the involved limb and a long AES on the contralateral limb. Duration 7-10 days. Concurrent medication/care: Not reported</p>
Funding	Study funded by industry (Funds were received in total or partial support by Rhone-Poulenc Rorer, Helsinki, Finland, and Birkerød, Denmark)

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: ENOXAPARIN (20MG ONCE DAILY – 60MG TWICE DAILY) versus UNFRACTIONATED HEPARIN (LOW DOSE, ADMINISTERED SUBCUTANEOUSLY)

Protocol outcome 1: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge

- Actual outcome: DVT (symptomatic and asymptomatic) at 7-10 days; Group 1: 21/92, Group 2: 25/93

Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcome 2: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge

- Actual outcome: PE at 7-10 days; Group 1: 0/92, Group 2: 0/93

Study	Faunø 1994 ¹⁰¹
	<p>Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 3: Surgical site haematoma at up to 45 days from hospital discharge - Actual outcome: Wound haematoma at 7-10 days; Group 1: 8/92, Group 2: 12/93 Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 4: Infection at duration of study - Actual outcome: Wound infection at 7-10 days; Group 1: 1/92, Group 2: 3/93 Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 5: DVT (distal) at 7-90 days from hospital discharge - Actual outcome: DVT (distal) at 7-10 days; Group 1: 18/92, Group 2: 20/93</p> <p>Protocol outcome 6: DVT (proximal) at 7-90 days from hospital discharge - Actual outcome: DVT (proximal) at 7-10 days; Group 1: 3/92, Group 2: 5/93</p>
<p>Protocol outcomes not reported by the study</p>	<p>All-cause mortality at up to 90 days from hospital discharge; Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge; Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study;</p>
Study	Fitzgerald 2001 ¹⁰³
<p>Study type</p>	<p>RCT (Patient randomised; Parallel)</p>

Study	Fitzgerald 2001 ¹⁰³
Number of studies (number of participants)	1 (n=349)
Countries and setting	Conducted in USA; Setting: Multicentre
Line of therapy	Not applicable
Duration of study	Intervention time: 4-14 days
Method of assessment of guideline condition	Adequate method of assessment/diagnosis
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Men and women, 38 years of age or older, undergoing a primary unilateral knee arthroplasty
Exclusion criteria	Wound haemorrhage continuing for longer than 8 hours after wound closure, generalised haemorrhagic disorders or hypercoagulable syndrome, including clinical evidence of chronic or acute DVT or a documented history of VTE; allergy to UFH, warfarin, fish or swine products, iodine or contrast medium; a history of heparin associated thrombocytopenia or heparin or warfarin associated skin rash or necrosis; asthma not under medical control; surgery (other than knee arthroplasty); on the ipsilateral knee within the previous 6 months or on the ipsilateral hip, contralateral hip or contralateral knee within the preceding 3 months; any clinically importance disease or requirement for treatment during the study period that could interfere with the action, kinetics or evaluation of the study medications; hepatic disease with a bilirubin level of 2mg/dL; renal disease with a creatinine level of >2mg/dL; evidence of current abuse of drugs (excluding tobacco products) or alcohol; surgery involving the eye, spinal cord or central nervous system within 3 months before study entry; active ulcerative disease or angiodysplasia of the gastrointestinal tract or active gastrointestinal haemorrhage within the previous 6 months; hypertension not under medical control; stroke or myocardial infarction within the previous 3 months; and treatment with aspirin, aspirin containing products, or non-steroidal anti-inflammatory drugs on a regular basis for the four days immediately preceding hospitalisation or regular treatment with these products during hospitalisation.
Recruitment/selection of patients	Not reported
Age, gender and ethnicity	Age - Range: 38-89. Gender (M:F): 153:196. Ethnicity: Not reported
Further population details	1. BMI : Not applicable 2. Renal impairment: Not applicable
Indirectness of population	No indirectness
Interventions	(n=173) Intervention 1: Low molecular weight heparin (licensed in UK) - Enoxaparin (20mg once daily – 60mg twice daily). Enoxaparin, high dose (30mg twice daily), administered on the day of surgery, within eight hours of wound closure. The treatment drug was administered for a minimum of 4 days and a maximum of 14 days. Duration 4-14 days. Concurrent medication/care: Sequential compression devices were not permitted, but AES were. Use of continuous passive motion device was permitted for a total of 6 hours per day

Study	Fitzgerald 2001¹⁰³
	(n=176) Intervention 2: Vitamin K antagonists - Warfarin (all doses). Warfarin was initiated orally with a dose of 7.5mg, followed by subsequent daily adjustment of the dose as necessary to maintain the INR between 2-3. The treatment drug was administered for a minimum of 4 days and a maximum of 14 days. Duration 4-14 days. Concurrent medication/care: Sequential compression devices were not permitted, but AES were. Use of continuous passive motion device was permitted for a total of 6 hours per day
Funding	Study funded by industry (Funds were received in total or partial support, from Aventis Pharmaceuticals, Incorporated, Bridgewater, New Jersey)
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: ENOXAPARIN (20MG ONCE DAILY – 60MG TWICE DAILY) versus WARFARIN (ALL DOSES)</p> <p>Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge - Actual outcome: All-cause mortality at 15 days; Group 1: 1/173, Group 2: 3/176 Risk of bias: All domain - Low, Selection - Low, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge - Actual outcome: DVT (symptomatic and asymptomatic) at 15 days; Group 1: 44/173, Group 2: 79/176 Risk of bias: All domain - Low, Selection - Low, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 3: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge - Actual outcome: PE at 15 days; Group 1: 0/173, Group 2: 1/176 Risk of bias: All domain - Low, Selection - Low, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 4: Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge - Actual outcome: Major bleeding at 15 days; Group 1: 9/173, Group 2: 4/176 Risk of bias: All domain - Low, Selection - Low, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;</p>	

Study	Fitzgerald 2001 ¹⁰³
<p>Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 5: Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge - Actual outcome: Clinically relevant non-major bleeding at 15 days; Group 1: 12/173, Group 2: 6/176 Risk of bias: All domain - Low, Selection - Low, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 6: Surgical site haematoma at up to 45 days from hospital discharge - Actual outcome: Wound haematoma at 15 days; Group 1: 3/173, Group 2: 0/176 Risk of bias: All domain - Low, Selection - Low, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 7: DVT (distal) at 7-90 days from hospital discharge - Actual outcome: DVT (distal) at 15 days; Group 1: 41/173, Group 2: 59/176</p> <p>Protocol outcome 8: DVT (proximal) at 7-90 days from hospital discharge - Actual outcome: DVT (proximal) at 15 days; Group 1: 3/173, Group 2: 20/176</p> <p>Protocol outcome 9: Fatal bleeding at 45 days from hospital discharge - Actual outcome: Fatal bleeding at 15 days; Group 1: 0/173, Group 2: 1/176</p>	
Protocol outcomes not reported by the study	Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study; Infection at duration of study;

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Fuji et al., 2008 ¹¹²	Patient group: Study 1: Total knee replacement (TKR) Study 2: Total hip replacement	Study 1 (TKR) Group 1 LMWH	Symptomatic pulmonary Embolism (description: ventilation perfusion lung scans or	Study 1 (TKR) Group 1: 1/78 Group 2: 1/74	Funding: Sanofi-Aventis

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Country of study: Japan	(THR) Setting: Department of Orthopaedic Surgery	(Enoxaparin) Start time: 24-36 hrs after surgery Duration: 14 days	pulmonary angiography at 90 days)	Group 3: 0/84 Group 4: 1/79 p value: Not significant	Limitations: Method of randomisation not given. No details provided on allocation concealment. Study reports that it was blinded but no information provided and some of the injection regimens were once daily whilst others were twice daily.
Study design: RCT	Inclusion criteria: Patients aged ≥ 20 years (no upper age limit was applied) undergoing elective primary THR or TKR.	Daily 20mg subcutaneous injection		Study 2 (THR) Group 5: 0/81 Group 6: 1/80 Group 7: 0/90 Group 8: 0/86 p value: Not significant	
List who was masked to interventions: Paper states that study is double blind (see limitations) and that the endpoint assessors were blinded.	Exclusion criteria: <ul style="list-style-type: none"> Patients requiring revision TKR or revision THR Contraindication to heparin therapy Positive clinical evidence of chronic (post-phlebotic syndrome) or acute DVT within 12 months of the study drug treatment 	Group 2 LMWH (Enoxaparin) Start time: 24-36 hrs after surgery Duration: 14 days	DVT, asymptomatic or symptomatic (screened for by: Doppler ultrasound at 14 days)	Study 1 (TKR) Group 1: 34/78 Group 2: 26/74 Group 3: 25/84 Group 4: 48/79 p value: All groups receiving LMWH (gp 1,2 & 3) had significantly less DVT than the placebo group (gp 4). Group 1 vs. Group 4 = 0.038* Group 2 vs. Group 4 = 0.002* Group 3 vs. Group 4 = <0.001* No other significant differences between groups were found.	Outcomes not reported: All-cause mortality, fatal bleeding, fatal PE, heparin induced thrombocytopenia, post thrombotic syndrome, pulmonary hypertension, quality of life, length of stay
Evidence level: 1+	<ul style="list-style-type: none"> Documented allergy to iodine or contrast medium impaired renal function (creatinine clearance <30ml/min or plasma creatinine level >1.5mg/dl) Severe hepatic disease Uncontrolled hypertension Illicit drug use or alcohol abuse Treatment with other investigational agents within 3 months of surgery Failure to achieve postoperative haemostasis 	Group 3 LMWH (Enoxaparin) Start time: 24-36 hrs after surgery Duration: 14 days		Group 1 vs. Group 4 = 0.038* Group 2 vs. Group 4 = 0.002* Group 3 vs. Group 4 = <0.001* No other significant differences between groups were found.	
Duration of follow-up: 90 days		Twice daily 20mg subcutaneous injections		Study 2 (THR) Group 5: 21/81 Group 6: 27/80 Group 7: 18/90	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	<ul style="list-style-type: none"> Female subjects if pregnant or breast-feeding. <p>Study 1 (TKR) All patients N: 396 No. of dropouts: 32 (8.1%)</p> <p>Group 1 No. analysed: 78 Age (mean): 68.8 (sd = 9.0) M/F: 15:63 Additional risk factors: BMI ≥ 25 kg/m² = 40 (51.3%)</p> <p>Group 2 No. analysed: 74 Age (mean): 70.0 (sd = 9.4) M/F: 11:63 Additional risk factors: BMI ≥ 25 kg/m² = 44 (59.4%)</p>	<p>Placebo (saline) Start time: 24-36 hrs after surgery Duration: 14 days</p> <p>Subcutaneous injections (no frequency stated)</p> <p>Additional non-comparative prophylaxis: More than 50% of patients received elastic stockings /bandages for part of the study. No other prophylaxis was used.</p>	<p>Thigh DVT (description: screened for by: Doppler ultrasound at 14 days)</p>	<p>Group 8: 36/86 p value: The group receiving twice daily injections of 20mg LMWH (gp 7) had significantly less DVT than the placebo group (gp 8) p = 0.003* No other significant differences between groups were found</p> <p>Study 1 (TKR) Group 1: 6/78 Group 2: 3/74 Group 3: 0/84 Group 4: 6/79 p value: There were significantly fewer events in the twice daily 20mg LMWH group (gp3) vs the once daily 20mg LMWH group (gp 1) (p = 0.011*).</p> <p>There were significantly fewer events in the twice daily 20mg LMWh group (gp3) vs. the placebo group (gp 4) (p = 0.012*)</p> <p>Study 2 (THR) Group 5: 3/81 Group 6: 6/80 Group 7: 3/90</p>	<p>adverse events were recorded. The authors concluded that most of these were not related to the treatment under investigation.</p> <p>Notes: * calculated by NCC using fishers exact test.</p>
	<p>Group 3 No. analysed: 84 Age (mean): 68.3 (sd = 8.7) M/F: 5:79 Additional risk factors: BMI ≥ 25 kg/m² = 35 (41.7%)</p> <p>Group 4 No. analysed: 79 Age (mean): 68.7 (sd =9.5)</p>	<p>Study 2 (THR) Group 5 LMWH (Enoxaparin) Start time: 24-36 hrs after surgery Duration: 14 days</p> <p>Daily 20mg subcutaneous injections</p>			

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	M/F: 15: 64 Additional risk factors: BMI ≥ 25 kg/m ² = 40 (50.6%)	Group 6 LMWH (Enoxaparin) Start time: 24-36 hrs after surgery Duration: 14 days	Major bleeding (description: bleeding episode that was retroperitoneal, intracranial, or intraocular o if it was associated with: death; transfusion of ≥2 units of packed red blood cells or whole blood (except autologous); a reduction of ≥2 g/d; or a serious or life threatening clinical events that required medical intervention.)	Group 8: 9/86 p value: No significant difference	
	Study 2 (THR) All patients N: 436 No. of dropouts: 29 (6.7%)	Daily 40 mg subcutaneous injections		Study 1 (TKR) Group 1: 0/89 Group 2: 1/91 Group 3: 3/95 Group 4: 4/89 p value: Not significant	
	Group 5 No. analysed: 81 Age (mean): 63.3 (sd = 10.4) M/F: 10: 71 Additional risk factors: BMI ≥ 25 kg/m ² = 23 (28.4%)	Group 7 LMWH (Enoxaparin) Start time: 24-36 hrs after surgery Duration: 14 days		Study 2 (THR) Group 5: 1/100 Group 6: 2/102 Group 7: 3/104 Group 8: 0/101 p value: Not significant	
	Group 6 No. analysed: 80 Age (mean): 60.6 (sd = 9.9) M/F: 6:74 Additional risk factors: BMI ≥ 25 kg/m ² = 26 (35.2%)	Twice daily 20mg subcutaneous injections	Minor bleeding (description: at least one of the following features: epistaxis lasting >5 minutes or requiring intervention; ecchymosis or hematoma with a maximum size of >5 cm; haematuria not associated with urinary catheter trauma; gastrointestinal haemorrhage not related to intubation or a nasogastric tube;	Study 1 (TKR) Group 1: 5/89 Group 2: 6/91 Group 3: 10/95 Group 4: 4/89 p value: Not significant	
	Group 7 No. analysed: 90 Age (mean): 63.0 (sd = 9.3) M/F: 15:75 Additional risk factors: BMI ≥ 25 kg/m ² = 31 (34.4%)	Group 8 Placebo (saline) Start time: 24-36 hrs after surgery Duration: 14 days		Study 2 (THR) Group 5: 1/100 Group 6: 7/102 Group 7: 4/104 Group 8: 2/101 p value: Not significant	
	Group 8	Subcutaneous injections (no frequency stated)			

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	No. analysed: 86 Age (mean): 62.0 (sd =10.3) M/F: 11: 75 Additional risk factors: BMI ≥ 25 kg/m ² = 34 (39.5%)	Additional non-comparative prophylaxis: More than 50% of patients received elastic stockings /bandages for part of the study. No other prophylaxis was used.	wound haematoma or haemorrhagic wound complications not associated with major haemorrhage; or subconjunctival haemorrhage requiring cessation of medication)		

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Fuji et al., 2008A ¹¹¹ Country of study: Japan Study design: RCT	Patient group: Study 1: Total knee replacement (TKR) Study 2: Total hip replacement (THR) Setting: Department of Orthopaedic Surgery	Study 1 (TKR) Group 1 Fondaparinux (Atrixa) Start time: 24hr ± 2 hrs after surgery Duration: 10-16 days	All-cause mortality Fatal bleeding	Study 1 (TKR) Group1: 0/84 Group 2: 0/87 P value: N/A Study 2 (THR) Group3: 0/81 Group 4: 0/82 P value: N/A Study 1 (TKR) Group1: 0/84 Group 2: 0/87 P value: N/A Study 2 (THR) Group3: 0/81 Group 4: 0/82 P value: N/A	Funding: GlaxoSmithKlein, Sanovi-synthelabo and NV Organon Limitations: Method of randomisation not given. No details provided

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
<p>List who was masked to interventions: Paper states that study is double blind and that the endpoint assessors were blinded.</p> <p>Evidence level: 1+</p> <p>Duration of follow-up: 11-17 days</p>	<p>Inclusion criteria: Patients of either gender if their age was 20 years or greater, and they were scheduled for TKR or THR surgery or revision surgery for TKR or THR</p> <p>Exclusion criteria: Active, clinically significant bleeding Bleeding tendency/disorder (e.g. ulcer of the digestive tract etc.) Severe hepatic disorder Hypersensitivity to UFH or LMWH Requirement of an indwelling intrathecal or epidural catheter during the treatment period</p> <ul style="list-style-type: none"> Brain, spine or ophthalmologic surgery within 3 months preceding enrolment <p>Body weight <40kg Severe renal disorder (serum creatinine concentration >2.0mg/dL)</p> <p>Study 1 (TKR) All patients N: 426 No. of dropouts: 29 (6.8%) Age (mean): 71.0 (sd = 8.0) M/F: 75: 351 Additional risk factors: BMI ≥ 30 kg/m² = 64 (15.0%)</p> <p>Group 1</p>	<p>Daily 2.5mg subcutaneous injections</p> <p>Group 2 Placebo (0.25ml isotonic sodium chloride) Start time: 24hr ± 2 hrs after surgery Duration: 10-16 days</p> <p>Daily 2.5mg subcutaneous injections</p> <p>Additional non-comparative prophylaxis: More than 50% of patients received elastic stockings /bandages for part of the study.</p> <p>Study 2 (THR) Group 3 Fondaparinux (Atrixa) Start time: 24hr ± 2 hrs after surgery</p>	<p>Major bleeding (description: fatal bleeding; bleeding that was retroperitoneal, intracranial, or intraspinal or that involved any other critical organ; bleeding leading to reoperation; and overt bleeding with a bleeding index of 2 or more.)</p>	<p>Study 1 (TKR) Group1: 1/84 Group 2: 1/87 P value: 1.00* Study 2 (THR) Group3: 2/81 Group 4: 0/82 P value: 0.245*</p>	<p>on allocation concealment.</p> <p>Outcomes not reported: DVT, PE, Heparin induced thrombocytopenia, post thrombotic syndrome, pulmonary hypertension, quality of life, length of stay</p>
			<p>Minor bleeding (description: not defined)</p>	<p>Study 1 (TKR) Group1: 2/84 Group 2: 3/87 P value: 1.00* Study 2 (THR) Group3: 4/81 Group 4: 0/82 P value: 0.059*</p>	<p>Additional outcomes reported: Incidence of combined VTE was recorded Study 1 (TKR) Group 1: 16.2% Group 2: 65.3% P value: <0.05* Study 2 (THR) Group 3: 7.4% Group 4: 33.8%</p>

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	<p>No. randomised: 84</p> <p>Group 2 No. randomised: 87</p> <p>Study 2 (THR) All patients N: 406 No. of dropouts: 25 (6.2%) Age (mean): 61.6 (sd = 10.9) M/F: 73: 333 Additional risk factors: BMI ≥ 30 kg/m² = 26 (6.4%)</p> <p>Group 3 No. randomised: 81</p> <p>Group 4 No. randomised: 82</p>	<p>Duration: 10-16 days</p> <p>Daily 2.5mg subcutaneous injections</p> <p>Group 4 Placebo (0.25ml isotonic sodium chloride) Start time: 24hr ± 2 hrs after surgery Duration: 10-16 days</p> <p>Daily 2.5mg subcutaneous injections</p> <p>Additional non-comparative prophylaxis: More than 50% of patients received elastic stockings /bandages for part of the study.</p>			<p>P value: <0.05*</p> <p>Notes: * calculated by NCC using fishers exact test.</p> <p>Study was a dose ranging study with separate groups receiving 0.75, 1.5, 2.5 and 3.0mg fondaparinux. Only the group receiving 2.5 mg fondaparinux is analysed here as this is the licensed dose.</p>

Study	Fuji 2010 ¹¹⁰
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=253)
Countries and setting	Conducted in Japan; Setting: Multicentre including 38 centres in Japan
Line of therapy	Not applicable
Duration of study	Intervention time: 14 days
Method of assessment of guideline condition	Adequate method of assessment/diagnosis
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Male and female patients who were at least 20 years old; had a weight of 40kg or higher; primary, unilateral, elective TKA; and provision of signed informed consent
Exclusion criteria	Any bleeding diathesis; major surgery, trauma, uncontrolled hypertension, or myocardial infarction within the last 3 months; clinical relevant bleeding or gastric/duodenal ulcer within the last 6 months; history of haemorrhagic stroke or acute intracranial bleeding; history of VTE or pre-existing condition requiring anticoagulant therapy; severe liver disease or elevated aspartate aminotransferase or alanine aminotransferase levels to more than 2 times the upper limit or normal range; significant renal disease; treatment with anticoagulants, antiplatelet agents, or nonsteroidal anti-inflammatory drugs with t1/2 of more than 12 hours within 7 days before TKA; anticipated requirement for intermittent pneumatic compression of lower limb; pregnancy or women of childbearing potential; history of thrombocytopenia; previous leg amputation; and active malignant disease
Recruitment/selection of patients	Not reported
Age, gender and ethnicity	Age - Mean (SD): Dabigatran group 72.7 (6.8); Placebo group 71.3 (8.5). Gender (M:F): 1:1.6. Ethnicity: Not reported
Further population details	1. BMI : Not applicable 2. Renal impairment: Not applicable
Indirectness of population	No indirectness
Interventions	(n=129) Intervention 1: Dabigatran - Dabigatran (all doses). Oral dabigatran 220mg once daily. The first oral dose was administered as early as possible on the day after surgery or at least 2 hours after removing the indwelling catheter and confirming the absence of abnormal bleeding from the drainage sites. Treatment continued for 11-14 days after surgery.. Duration 11-14 days. Concurrent medication/care: The use of AES and dressings was allowed. IPCD was not permitted. (n=124) Intervention 2: No treatment - Placebo. Placebo, once daily. The first oral dose was administered as early as

Study	Fuji 2010 ¹¹⁰
	<p>possible on the day after surgery or at least 2 hours after removing the indwelling catheter and confirming the absence of abnormal bleeding from the drainage sites. Treatment continued for 11-14 days after surgery. orally given from 'as early as possible' or at least 2 hours after removing the indwelling catheter and confirming the absence of abnormal bleeding from the drainage sites for 11-14 days. Patients received two capsules per day. orally given from 'as early as possible' or at least 2 hours after removing the indwelling catheter and confirming the absence of abnormal bleeding from the drainage sites for 11-14 days. Patients received two capsules per day. Duration 11-14 days. Concurrent medication/care: The use of AES and dressings was allowed. IPCD was not permitted.</p>
Funding	Study funded by industry (Benefits of funds were received in partial or total support from Boehringer Ingelheim Co, Ltd)
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: DABIGATRAN (ALL DOSES) versus PLACEBO</p> <p>Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge - Actual outcome: All-cause mortality at 14 days; Group 1: 0/129, Group 2: 0/124 Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 0 ; Group 2 Number missing: 0</p> <p>Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge - Actual outcome: DVT (symptomatic and asymptomatic) at 14 days; Group 1: 23/96, Group 2: 57/101 Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 33; Group 2 Number missing: 23</p> <p>Protocol outcome 3: Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge - Actual outcome: Major bleeding at 14 days; Group 1: 4/129, Group 2: 1/124 Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0</p> <p>Protocol outcome 4: Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge</p>	

Study	Fuji 2010 ¹¹⁰
	<p>- Actual outcome: Clinically relevant non-major bleeding at 14 days; Group 1: 2/129, Group 2: 3/124 Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0</p> <p>Protocol outcome 5: Technical complications of mechanical interventions at duration of study - Actual outcome: PE at 14 days; Group 1: 0/129, Group 2: 0/124 Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing:0 ; Group 2 Number missing: 0</p> <p>Protocol outcome 6: DVT (symptomatic) at 7-90 days from hospital discharge - Actual outcome: DVT (symptomatic) at 14 days; Group 1: 1/129, Group 2: 2/124</p> <p>Protocol outcome 7: DVT (proximal) at 7-90 days from hospital discharge - Actual outcome: DVT (proximal) at 14 days; Group 1: 0/102, Group 2: 6/104</p> <p>Protocol outcome 8: Fatal bleeding at 45 days from hospital discharge - Actual outcome: Fatal bleeding at 14 days; Group 1: 0/129, Group 2: 0/124</p> <p>Protocol outcome 9: Site of bleeding (gastrointestinal ; surgical site; brain/spine; other) at 45 days from hospital discharge - Actual outcome: Critical organ at 14 days; Group 1: 0/129, Group 2: 0/124</p>
Protocol outcomes not reported by the study	Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge; Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Surgical site haematoma at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Infection at duration of study;

Study	Ginsberg 2009: RE-MOBILIZE trial: Re-mobilize writing committee 2009 ²⁷²
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	N/A (n=2615)

Study	Ginsberg 2009: RE-MOBILIZE trial: Re-mobilize writing committee 2009 ²⁷²
Countries and setting	Conducted in Multiple countries; Setting: Secondary care
Line of therapy	Not applicable
Duration of study	Intervention + follow up: Intervention 12 to 15 days + Follow-up 3 months
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: Diagnosis of DVT was made with bilateral venography. Diagnosis of PE was made with ventilation-perfusion scintigraphy, pulmonary angiography, spiral computed tomography, or autopsy. Symptomatic DVT was confirmed by compression ultrasound or venography.
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Patients older than 18 years and weighing more than 40kg who had undergone primary elective unilateral TKA and provided signed informed consent
Exclusion criteria	Known inherited/acquired clinically significant bleeding disorder; major surgery / trauma / uncontrolled hypertension / MI within last 3 months; history of acute intracranial disease / haemorrhagic stroke; GI/urogenital bleeding / ulcer disease within last 6 months; severe liver disease; aspartate/alanine aminotransferase levels higher than 2x the upper limit of the normal range within last month; severe renal insufficiency; need for concomitant long-acting NSAIDs / treatment with an anticoagulant during study drug treatment; active malignant disease; platelet count < 100 x 10 ⁹ /L; pregnancy / nursing / pre-menopausal women of child-bearing potential who were not practising effective birth control; failure to provide informed consent
Recruitment/selection of patients	Not reported
Age, gender and ethnicity	Age - Mean (SD): Dabigatran 220mg 66.2 ± 9.5 vs. Dabigatran 150mg 65.9 ± 9.5 vs. Enoxaparin 66.3 ± 9.6. Gender (M:F): 1098:1517. Ethnicity: Ethnicity of the participants is not reported. Participants were recruited in the US (58 centres), Canada (30 centres), Mexico (8 centres) and in the UK (1 centre).
Further population details	1. BMI : Not applicable 2. Renal impairment: Not applicable
Extra comments	.
Indirectness of population	No indirectness: Incidence and prevalence of VTE vary between different ethnicities. Ethnic composition of the participants is not reported by the study.
Interventions	(n=862) Intervention 1: Dabigatran - Dabigatran (all doses). Oral tablets: first dose of 110mg was given 6 to 12 hrs after surgery then 220mg once daily thereafter. Duration 12 to 15 days. Concurrent medication/care: One additional placebo capsule (dummy) given at the same time as a dabigatran 220mg tablet and a subcutaneous placebo injection to mimic enoxaparin injection (n=877) Intervention 2: Dabigatran - Dabigatran (all doses). Oral tablets: first dose of 75mg was given 6 to 12 hrs after

Study	Ginsberg 2009: RE-MOBILIZE trial: Re-mobilize writing committee 2009²⁷²
	<p>surgery then 150mg once daily from thereafter. Duration 12 to 15 days. Concurrent medication/care: One additional placebo capsule at the same time as the dabigatran 150mg tablet and a subcutaneous placebo injection to mimic enoxaparin injection</p> <p>(n=876) Intervention 3: Low molecular weight heparin (licensed in UK) - Enoxaparin (20mg once daily – 60mg twice daily). Subcutaneous injection: the first dose of 30mg given 12 to 24 hrs after surgery then the same dose given twice daily from thereafter. Duration 12 to 15 days. Concurrent medication/care: Two placebo tablets given in the morning to match the two dabigatran doses</p>
Funding	Study funded by industry (Boehringer Ingelheim Pharma)

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: DABIGATRAN 220MG versus ENOXAPARIN

Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge

- Actual outcome: Death during treatment period at From administration of first dose of study medication to 3 days after administration of last dose of study medication; Group 1: 1/857, Group 2: 0/868

Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 5, Reason: Missing participants were those who were not given a study treatment; reason for not receiving treatment not reported; Group 2 Number missing: 8, Reason: Missing participants were those who were not given a study treatment; reason for not receiving treatment not reported

Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge

- Actual outcome: Total DVT during treatment period at From administration of first dose of study medication to 3 days after administration of last dose of study medication; Group 1: 181/857, Group 2: 248/868

Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 253, Reason: Missing participants were those who were not given a study treatment; reason for not receiving treatment not reported; Group 2 Number missing: 225, Reason: Missing participants were those who were not given a study treatment; reason for not receiving treatment not reported

Protocol outcome 3: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge

- Actual outcome: PE at From administration of first dose of study medication to 3 days after administration of last dose of study medication; Group 1: 6/604, Group 2: 5/643

Study	Ginsberg 2009: RE-MOBILIZE trial: Re-mobilize writing committee 2009 ²⁷²
	<p>Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 253, Reason: Missing participants were those who were not given a study treatment; reason for not receiving treatment not reported; Group 2 Number missing: 225, Reason: Missing participants were those who were not given a study treatment; reason for not receiving treatment not reported</p>
	<p>Protocol outcome 4: Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge - Actual outcome: Major bleeding during treatment period at From administration of first dose of study medication to 3 days after administration of last dose of study medication; Group 1: 5/857, Group 2: 12/868</p>
	<p>Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 5, Reason: Missing participants were those who were not given a study treatment; reason for not receiving treatment not reported; Group 2 Number missing: 8, Reason: Missing participants were those who were not given a study treatment; reason for not receiving treatment not reported</p>
	<p>Protocol outcome 5: Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge - Actual outcome: Death where VTE cannot be ruled out at From administration of first dose of study medication to 3 days after administration of last dose of study medication; Group 1: 1/857, Group 2: 0/868</p>
	<p>Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 5, Reason: Missing participants were those who were not given a study treatment; reason for not receiving treatment not reported; Group 2 Number missing: 8, Reason: Missing participants were those who were not given a study treatment; reason for not receiving treatment not reported</p>
	<p>Protocol outcome 6: Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge - Actual outcome: Clinically relevant non-major bleeding during treatment period at From administration of first dose of study medication to 3 days after administration of last dose of study medication; Group 1: 23/857, Group 2: 21/868</p>
	<p>Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 5, Reason: Missing participants were those who were not given a study treatment; reason for not receiving treatment not reported; Group 2 Number missing: 8, Reason: Missing participants were those who were not given a study treatment; reason for not receiving treatment not reported</p>
	<p>Protocol outcome 7: DVT (distal) at 7-90 days from hospital discharge - Actual outcome: DVT (distal) at From administration of first dose of study medication to 3 days after administration of last dose of study medication; Group 1:</p>

Study	Ginsberg 2009: RE-MOBILIZE trial: Re-mobilize writing committee 2009 ²⁷²
	167/604, Group 2: 148/643
	<p>Protocol outcome 8: DVT (proximal) at 7-90 days from hospital discharge</p> <p>- Actual outcome: DVT (proximal) at From administration of first dose of study medication to 3 days after administration of last dose of study medication; Group 1: 14/604, Group 2: 10/643</p>
	<p>Protocol outcome 9: Fatal bleeding at 45 days from hospital discharge</p> <p>- Actual outcome: Fatal bleeding at From administration of first dose of study medication to 3 days after administration of last dose of study medication; Group 1: 0/868, Group 2: 0/876</p>
	<p>Protocol outcome 10: Site of bleeding (gastrointestinal ; surgical site; brain/spine; other) at 45 days from hospital discharge</p> <p>- Actual outcome: Surgical site bleeding at From administration of first dose of study medication to 3 days after administration of last dose of study medication; Group 1: 2/862, Group 2: 11/876</p>
Protocol outcomes not reported by the study	Surgical site haematoma at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study; Infection at duration of study;

Study	Intiyanaravut 2017 ¹⁵⁵
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=50)
Countries and setting	Conducted in Thailand; Setting: Golden Jubilee Medical Center, Mahidol University, Nakhon Pathom, Thailand
Line of therapy	Not applicable
Duration of study	Intervention time: 7-10 days
Method of assessment of guideline condition	<p>Adequate method of assessment/diagnosis: DVT (symptomatic and asymptomatic): confirmed by bilateral colour Doppler ultrasonography</p> <p>PE: confirmed by clinical signs scoring system (sudden dyspnoea, chest pain and cough of haemoptysis).</p> <p>Major bleeding: defined as the presence of grade three haematoma which requiring operative removal and bleeding that was fatal or involved a critical organ.</p>
Stratum	Overall

Study	Intiyanaravut 2017 ¹⁵⁵
Subgroup analysis within study	Not applicable
Inclusion criteria	Patients scheduled for elective primary total knee arthroplasty, aged between 50 and 85.
Exclusion criteria	History of DVT or PE, history of haemorrhagic stroke or gastro-intestinal bleeding, renal impairment, the use of anticoagulants, allergy to enoxaparin.
Recruitment/selection of patients	From October 2012 to June 2014
Age, gender and ethnicity	Age - Mean (SD): 71 years. Gender (M:F): 1/4. Ethnicity: Not reported
Further population details	1. BMI : Not obese (BMI under 30 kg/m ²) (Mean BMI: 28 kg/m ²). 2. Renal impairment: Not applicable
Extra comments	Mean length of operation: 130 minutes
Indirectness of population	No indirectness
Interventions	<p>(n=25) Intervention 1: Low molecular weight heparin (licensed in UK) - Enoxaparin (20mg once daily – 60mg twice daily). Enoxaparin (40 mg) was subcutaneously administered once daily, starting 24 hours after surgery. Duration 7-10 days. Concurrent medication/care: Postoperative protocol included compressive dressings in the first 24 hours, drain was removed in 48 to 72 hours after operation, continuous passive movement was initiated on second day, followed by active mobilisation and full weight-bearing ambulation. Indirectness: No indirectness</p> <p>(n=25) Intervention 2: No treatment - Usual care. No prophylaxis was given. Duration 7-10 days. Concurrent medication/care: Postoperative protocol included compressive dressings in the first 24 hours, drain was removed in 48 to 72 hours after operation, continuous passive movement was initiated on second day, followed by active mobilisation and full weight-bearing ambulation. Indirectness: No indirectness</p>
Funding	No funding

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: ENOXAPARIN (STANDARD DOSE) versus CONTROL GROUP

Protocol outcome 1: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge

- Actual outcome: DVT (symptomatic and asymptomatic) at 7-10 days; Group 1: 0/25, Group 2: 1/25

Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0

Protocol outcome 2: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQspect;

Study	Intiyanaravut 2017 ¹⁵⁵
	<p>autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge</p> <p>- Actual outcome: PE at time-point not reported; Group 1: 0/25, Group 2: 0/25</p> <p>Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - High, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0</p> <p>Protocol outcome 3: Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge</p> <p>- Actual outcome: Major bleeding at time-point not reported; Group 1: 0/25, Group 2: 0/25</p> <p>Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0</p>
Protocol outcomes not reported by the study	All-cause mortality at up to 90 days from hospital discharge; Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQspect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Surgical site haematoma at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study; Infection at duration of study;

Study	Lassen 2007 ¹⁹³
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=615)
Countries and setting	Conducted in Multiple countries; Setting: 97 centres in Argentina, Australia, Canada, Mexico, Denmark, Israel, Poland and the USA
Line of therapy	Not applicable
Duration of study	Intervention time: 12 +/- 2 days
Method of assessment of guideline condition	Adequate method of assessment/diagnosis
Stratum	Overall
Subgroup analysis within study	Not applicable

Study	Lassen 2007 ¹⁹³
Inclusion criteria	Patients aged 18-90 years, scheduled to have a total knee replacement
Exclusion criteria	Child-bearing potential if a woman; presence of bleeding/coagulation disorders; history of heparin induced thrombocytopenia; intracranial/intraocular haemorrhage within the past 5 years; gastrointestinal bleeding within 90 days of surgery or ulcer disease within 30 days before surgery; brain, spinal, ophthalmologic or major surgery/trauma within 90 days prior to surgery; known VTE disease within the past 12 months; uncontrolled hypertension; malignant disease; active hepatobiliary disease; known or suspected GI disease that may affect absorption of study medication; ALT, AST, or bilirubin (direct or total) >1.5 x upper limit of normal (ULN); INR >1.4 or activated partial thromboplastin time > 1.4 x control value; hypersensitivity to UFH, LMWH, warfarin or other vitamin K antagonists, porcine products or iodinated contrast medium; or treatment with medications affecting coagulation/platelet function within 7 days prior to surgery
Recruitment/selection of patients	Consecutive patients
Age, gender and ethnicity	Age - Mean (range): Apixaban 2.5mg bid group 67.6 (46-88); apixaban 5mg qd 66.9 (31-87); LMWH group 66.5 (36-88); VKA group 66.8 (43-85). Gender (M:F): 1:1.7. Ethnicity: Not reported
Further population details	1. BMI : Obese (BMI over 30 kg/m ²) (Mean BMI 30.5, 30.6, 30.4 and 30.4 respectively (range 18.3-50.1)). 2. Renal impairment: Not applicable
Indirectness of population	No indirectness
Interventions	<p>(n=152) Intervention 1: Low molecular weight heparin (licensed in UK) - Enoxaparin (20mg once daily – 60mg twice daily). Subcutaneous enoxaparin, high dose (30mg twice daily). Began 12-24 hours after skin wound closure, for a total of 12 +/- 2 days. Duration 12 +/- 2 days. Concurrent medication/care: Not reported</p> <p>(n=310) Intervention 2: Apixaban - Apixaban (all doses). Apixaban 2.5mg twice daily or 5mg once daily given orally. Began 12-24 hours after skin wound closure and continued for 12 +/- 2 days. Duration 12 +/- 2 days. Concurrent medication/care: Not reported</p> <p>(n=153) Intervention 3: Vitamin K antagonists - Warfarin (all doses). Warfarin was administered from the evening of the day of surgery, starting with a dose of 5mg and then continued once a day in the evening for 12 +/- 2 days. Warfarin dose was adjusted to maintain INR in the range of 1.8-3.0. Duration 12 +/- 2 days. Concurrent medication/care: Not reported</p>
Funding	Funding not stated

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: ENOXAPARIN (20MG ONCE DAILY – 60MG TWICE DAILY) versus APIXABAN (ALL DOSES)

Study	Lassen 2007 ¹⁹³
<p>Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge - Actual outcome: All-cause mortality at 12 +/- 2 days; Group 1: 0/109, Group 2: 1/208 Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Blinding details: Warfarin was open label; Group 1 Number missing: 43, Reason: 3 not treated, 18 no venography, 22 un evaluable venography; Group 2 Number missing: 102, Reason: 6 not treated, 40 no venography, 56 un evaluable venography</p>	
<p>Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge - Actual outcome: DVT (symptomatic and asymptomatic) at 12 +/- 2 days; Group 1: 15/109, Group 2: 21/208 Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Blinding details: Warfarin was open label; Group 1 Number missing: 43, Reason: 3 not treated, 18 no venography, 22 un evaluable venography; Group 2 Number missing: 102, Reason: 6 not treated, 40 no venography, 56 un evaluable venography</p>	
<p>Protocol outcome 3: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge - Actual outcome: PE at 12 +/- 2 days; Group 1: 2/109, Group 2: 1/208 Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Blinding details: Warfarin was open label; Group 1 Number missing: 102, Reason: 6 not treated, 40 no venography, 56 un evaluable venography; Group 2 Number missing: 44, Reason: 2 not treated, 9 no venography, 33 un evaluable venography</p>	
<p>Protocol outcome 4: Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge - Actual outcome: Major bleeding at 12 +/- 2 days; Group 1: 0/149, Group 2: 4/305 Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Blinding details: Warfarin was open label; Group 1 Number missing: 3, Reason: Not treated; Group 2 Number missing: 5, Reason: Not treated</p>	
<p>Protocol outcome 5: Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge - Actual outcome: Fatal PE at 12 +/- 2 days; Group 1: 0/109, Group 2: 1/208 Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low, Comments - ; Indirectness of outcome: No indirectness ; Blinding details: Warfarin was open label; Group 1 Number missing: 102, Reason: 6 not treated, 40 no venography, 56 un evaluable venography; Group 2 Number missing: 44, Reason: 2 not treated, 9 no venography, 33 un evaluable venography</p>	

Study	Lassen 2007 ¹⁹³
	<p>Protocol outcome 6: Infection at duration of study - Actual outcome: Wound related infections at 12 +/- 2 days; Group 1: 1/149, Group 2: 6/305 Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Blinding details: Warfarin was open label; Group 1 Number missing: 3, Reason: Not treated; Group 2 Number missing: 5, Reason: Not treated</p>
	<p>Protocol outcome 7: VTE at 7-90 days from hospital discharge - Actual outcome: Total VTE at 12 +/- 2 days; Group 1: 17/109, Group 2: 21/208</p>
	<p>Protocol outcome 8: DVT (symptomatic) at 7-90 days from hospital discharge - Actual outcome: DVT (symptomatic) at 12 +/- 2 days; Group 1: 1/109, Group 2: 1/208</p>
	<p>Protocol outcome 9: DVT (distal) at 7-90 days from hospital discharge - Actual outcome: DVT (distal) at 12 +/- 2 days; Group 1: 12/109, Group 2: 18/208</p>
	<p>Protocol outcome 10: DVT (proximal) at 7-90 days from hospital discharge - Actual outcome: DVT (proximal) at 12 +/- 2 days; Group 1: 3/109, Group 2: 3/208</p>
	<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: ENOXAPARIN (20MG ONCE DAILY – 60MG TWICE DAILY) versus WARFARIN (ALL DOSES)</p>
	<p>Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge - Actual outcome: All-cause mortality at 12 +/- 2 days; Group 1: 0/109, Group 2: 0/109 Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Blinding details: Warfarin was open label; Group 1 Number missing: 43, Reason: 3 not treated, 18 no venography, 22 un evaluable venography; Group 2 Number missing: 44, Reason: 2 not treated, 9 no venography, 33 un evaluable venography</p>
	<p>Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge - Actual outcome: DVT (symptomatic and asymptomatic) at 12 +/- 2 days; Group 1: 15/109, Group 2: 29/109 Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Blinding details: Warfarin was open label; Group 1 Number missing: 43, Reason: 3 not treated, 18 no venography, 22 un evaluable venography; Group 2 Number missing: 44, Reason: 2 not treated, 9 no venography, 33 un evaluable venography</p>
	<p>Protocol outcome 3: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQspect;</p>

Study	Lassen 2007 ¹⁹³
	<p>autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge</p> <p>- Actual outcome: PE at 12 +/- 2 days; Group 1: 2/109, Group 2: 0/109</p> <p>Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low;</p> <p>Indirectness of outcome: No indirectness ; Blinding details: Warfarin was open label; Group 1 Number missing: 102, Reason: 6 not treated, 40 no venography, 56 un evaluable venography; Group 2 Number missing: 44, Reason: 2 not treated, 9 no venography, 33 un evaluable venography</p>
	<p>Protocol outcome 4: Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge</p> <p>- Actual outcome: Major bleeding at 12 +/- 2 days; Group 1: 0/149, Group 2: 0/151</p> <p>Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;</p> <p>Indirectness of outcome: No indirectness ; Blinding details: Warfarin was open label; Group 1 Number missing: 3, Reason: Not treated; Group 2 Number missing: 2, Reason: Not treated</p>
	<p>Protocol outcome 5: Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQspect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge</p> <p>- Actual outcome: Fatal PE at 12 +/- 2 days; Group 1: 0/109, Group 2: 0/109</p> <p>Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low;</p> <p>Indirectness of outcome: No indirectness ; Blinding details: Warfarin was open label; Group 1 Number missing: 102, Reason: 6 not treated, 40 no venography, 56 un evaluable venography; Group 2 Number missing: 44, Reason: 2 not treated, 9 no venography, 33 un evaluable venography</p>
	<p>Protocol outcome 6: Infection at duration of study</p> <p>- Actual outcome: Wound related infections at 12 +/- 2 days; Group 1: 1/149, Group 2: 3/151</p> <p>Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;</p> <p>Indirectness of outcome: No indirectness ; Blinding details: Warfarin was open label; Group 1 Number missing: 3, Reason: Not treated; Group 2 Number missing: 2, Reason: Not treated</p>
	<p>Protocol outcome 7: VTE at 7-90 days from hospital discharge</p> <p>- Actual outcome: Total VTE at 12 +/- 2 days; Group 1: 17/109, Group 2: 29/109</p>
	<p>Protocol outcome 8: DVT (symptomatic) at 7-90 days from hospital discharge</p> <p>- Actual outcome: DVT (symptomatic) at 12 +/- 2 days; Group 1: 1/109, Group 2: 1/109</p>
	<p>Protocol outcome 9: DVT (distal) at 7-90 days from hospital discharge</p> <p>- Actual outcome: DVT (distal) at 12 +/- 2 days; Group 1: 12/109, Group 2: 27/109</p>

Study	Lassen 2007 ¹⁹³
	<p>Protocol outcome 10: DVT (proximal) at 7-90 days from hospital discharge - Actual outcome: DVT (proximal) at 12 +/- 2 days; Group 1: 3/109, Group 2: 2/109</p>
	<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: APIXABAN (ALL DOSES) versus WARFARIN (ALL DOSES)</p>
	<p>Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge - Actual outcome: All-cause mortality at 12 +/- 2 days; Group 1: 1/208, Group 2: 0/109 Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Blinding details: Warfarin was open label; Group 1 Number missing: 102, Reason: 6 not treated, 40 no venography, 56 un evaluable venography; Group 2 Number missing: 44, Reason: 2 not treated, 9 no venography, 33 un evaluable venography</p>
	<p>Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge - Actual outcome: DVT (symptomatic and asymptomatic) at 12 +/- 2 days; Group 1: 21/208, Group 2: 29/109 Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Blinding details: Warfarin was open label; Group 1 Number missing: 102, Reason: 6 not treated, 40 no venography, 56 un evaluable venography; Group 2 Number missing: 44, Reason: 2 not treated, 9 no venography, 33 un evaluable venography</p>
	<p>Protocol outcome 3: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge - Actual outcome: PE at 12 +/- 2 days; Group 1: 1/208, Group 2: 0/109 Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Blinding details: Warfarin was open label; Group 1 Number missing: 102, Reason: 6 not treated, 40 no venography, 56 un evaluable venography; Group 2 Number missing: 44, Reason: 2 not treated, 9 no venography, 33 un evaluable venography</p>
	<p>Protocol outcome 4: Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge - Actual outcome: Major bleeding at 12 +/- 2 days; Group 1: 4/305, Group 2: 0/151 Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Blinding details: Warfarin was open label; Group 1 Number missing: 5, Reason: Not treated; Group 2 Number missing: 2, Reason: Not treated</p>
	<p>Protocol outcome 5: Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy;</p>

Study	Lassen 2007 ¹⁹³
	<p>echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge</p> <p>- Actual outcome: Fatal PE at 12 +/- 2 days; Group 1: 1/208, Group 2: 0/109</p> <p>Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low;</p> <p>Indirectness of outcome: No indirectness ; Blinding details: Warfarin was open label; Group 1 Number missing: 102, Reason: 6 not treated, 40 no venography, 56 un evaluable venography; Group 2 Number missing: 44, Reason: 2 not treated, 9 no venography, 33 un evaluable venography</p> <p>Protocol outcome 6: Infection at duration of study</p> <p>- Actual outcome: Wound related infections at 12 +/- 2 days; Group 1: 6/305, Group 2: 3/151</p> <p>Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;</p> <p>Indirectness of outcome: No indirectness ; Blinding details: Warfarin was open label; Group 1 Number missing: 5, Reason: Not treated; Group 2 Number missing: 2, Reason: Not treated</p> <p>Protocol outcome 7: VTE at 7-90 days from hospital discharge</p> <p>- Actual outcome: Total VTE at 12 +/- 2 days; Group 1: 21/208, Group 2: 29/109</p> <p>Protocol outcome 8: DVT (symptomatic) at 7-90 days from hospital discharge</p> <p>- Actual outcome: DVT (symptomatic) at 12 +/- 2 days; Group 1: 1/208, Group 2: 1/109</p> <p>Protocol outcome 9: DVT (distal) at 7-90 days from hospital discharge</p> <p>- Actual outcome: DVT (distal) at 12 +/- 2 days; Group 1: 18/208, Group 2: 27/109</p> <p>Protocol outcome 10: DVT (proximal) at 7-90 days from hospital discharge</p> <p>- Actual outcome: DVT (proximal) at 12 +/- 2 days; Group 1: 3/208, Group 2: 2/109</p>
<p>Protocol outcomes not reported by the study</p>	<p>Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Surgical site haematoma at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study;</p>

Study	RECORD3 trial: Lassen 2008 ¹⁸⁸
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	N/A (n=2459)
Countries and setting	Conducted in Multiple countries; Setting: Secondary care
Line of therapy	Not applicable
Duration of study	Intervention + follow up: Intervention 10 to 14 days + Follow-up 30 to 35 days
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: DVT was assessed by ascending bilateral venography. Suspected DVT was confirmed by ultrasonography or venography. Suspected PE was confirmed using ventilation-perfusion scintigraphy of the lung and chest radiography or spiral computed tomography, or pulmonary angiography. Autopsies were planned if a participant died.
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Adults (>18 years) who were scheduled for total knee arthroplasty
Exclusion criteria	Active bleeding or high risk of bleeding that contraindicated use of LMWH; contraindication to use of enoxaparin or its dose adjustment; conditions preventing bilateral venography; clinically significant liver disease; concomitant use of protease inhibitors of HIV or fibrinolytic agents; planned intermittent pneumatic compression; requirement of ongoing anticoagulant therapy; pregnancy/breastfeeding
Recruitment/selection of patients	Between February 2006 and November 2006, patients were enrolled in 147 centres in 19 countries
Age, gender and ethnicity	Age - Mean (range): Rivaroxaban 67.6 (28-91) vs. Enoxaparin 67.6 (30-90). Gender (M:F): 781:1678. Ethnicity: White 81.2%; Asian 6.4%; Hispanic 4.1%; Black 1.1%; Other/Unknown 7.2%
Further population details	1. BMI : Not obese (BMI under 30 kg/m ²) (Mean rivaroxaban 29.5 kg/m ² ; mean enoxaparin 29.8 kg/m ²). 2. Renal impairment: Not applicable
Extra comments	. 3.7% of the participants had a history of VTE
Indirectness of population	No indirectness
Interventions	(n=1254) Intervention 1: Rivaroxaban - Rivaroxaban (all doses). Oral 10mg once daily; initiated 6 to 9 hrs after wound closure; administered every 24 hrs thereafter. Duration At least 10 days up to 14 days. Concurrent medication/care: Dummy placebo injection (n=1277) Intervention 2: Low molecular weight heparin (licensed in UK) - Enoxaparin (20mg once daily – 60mg twice daily). Injection 40mg once daily; given 12 hrs before surgery then 6 to 8 hrs after wound closure; administered every 24hrs thereafter. Duration At least 10 days up to 14 days. Concurrent medication/care: Dummy oral placebo tablets

Study	RECORD3 trial: Lassen 2008 ¹⁸⁸
Funding	Study funded by industry (Bayer HealthCare; Johnson & Johnson Pharmaceutical Research & Development)
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: RIVAROXABAN versus ENOXAPARIN</p> <p>Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge - Actual outcome: Death up to day 17 at 17 days; Group 1: 0/1201, Group 2: 2/1217; Comments: Absolute risk difference -0.2 (-0.6 to 0.2); p=0.21 Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - Very high, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Baseline details: Exception: slight excess of women in the rivaroxaban group (p=0.03); Group 1 Number missing: 53, Reason: Unknown ; Group 2 Number missing: 60, Reason: Unknown - Actual outcome: Death during follow-up at From day 30 to day 35 after the last dose of study medication; Group 1: 0/1201, Group 2: 4/1217; Comments: Absolute risk difference -0.3 (-0.8 to 0.0); p=0.05 Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - Very high, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Baseline details: Exception: slight excess of women in the rivaroxaban group (p=0.03); Group 1 Number missing: 53, Reason: Unknown ; Group 2 Number missing: 60, Reason: Unknown</p> <p>Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge - Actual outcome: DVT up to day 17 at 17 days; Group 1: 79/824, Group 2: 160/878; Comments: Absolute risk difference -8.4 (-11.1 to -5.2); p<0.001 Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - Very high, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Baseline details: Exception: slight excess of women in the rivaroxaban group (p=0.03); Group 1 Number missing: 430, Reason: Unknown ; Group 2 Number missing: 399, Reason: Unknown</p> <p>Protocol outcome 3: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge - Actual outcome: Pulmonary embolism up to day 17 at 17 days; Group 1: 0/1201, Group 2: 4/1217; Comments: Absolute risk difference -0.3 (-0.8 to 0.0); p=0.05 Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - Very high, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Baseline details: Exception: slight excess of women in the rivaroxaban group (p=0.03); Group 1 Number missing: 53, Reason: Unknown ; Group 2 Number missing: 60, Reason: Unknown</p> <p>Protocol outcome 4: Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of ≥2g/dl; a serious or life threatening clinical event at up to 45 days from hospital discharge - Actual outcome: Major bleeding at Between start of treatment and 2 days after last dose; Group 1: 21/1254, Group 2: 17/1277; Comments: p=0.77</p>	

Study	RECORD3 trial: Lassen 2008 ¹⁸⁸
	<p>Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Baseline details: Exception: slight excess of women in the rivaroxaban group (p=0.03); Group 1 Number missing: 0, Reason: Unknown ; Group 2 Number missing: 0, Reason: Unknown</p> <p>Protocol outcome 5: Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge - Actual outcome: Clinically relevant non-major bleeding at Between start of treatment and 2 days after last dose; Group 1: 33/1220, Group 2: 28/1239 Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - Very high, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Baseline details: Exception: slight excess of women in the rivaroxaban group (p=0.03); Group 1 Number missing: 34, Reason: Unknown ; Group 2 Number missing: 38, Reason: Unknown</p> <p>Protocol outcome 6: Infection at duration of study - Actual outcome: Post-operative infection of wound at Between start of treatment and 2 days after last dose; Group 1: 7/1220, Group 2: 11/1239 Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - Very high, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Baseline details: Exception: slight excess of women in the rivaroxaban group (p=0.03); Group 1 Number missing: 34, Reason: Unknown ; Group 2 Number missing: 38, Reason: Unknown</p> <p>Protocol outcome 7: VTE at 7-90 days from hospital discharge - Actual outcome: Symptomatic VTE up to day 17 at 17 days; Group 1: 8/1201, Group 2: 24/1217; Comments: Absolute risk difference -1.3 (-2.2 to -0.4); p=0.005 - Actual outcome: Symptomatic VTE during follow-up at From day 30 to day 35 after the last dose of study medication; Group 1: 5/1201, Group 2: 3/1217; Comments: Absolute risk difference 0.2 (-0.3 to 0.6); p=0.44</p> <p>Protocol outcome 8: DVT (distal) at 7-90 days from hospital discharge - Actual outcome: DVT (distal) at 17 days; Group 1: 70/824, Group 2: 140/878</p> <p>Protocol outcome 9: DVT (proximal) at 7-90 days from hospital discharge - Actual outcome: DVT (proximal) at 17 days; Group 1: 9/824, Group 2: 20/878</p>
<p>Protocol outcomes not reported by the study</p>	<p>Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Surgical site haematoma at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study;</p>

Study	ADVANCE-1 trial: Lassen 2009 ¹⁹⁶
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	N/A (n=3195)
Countries and setting	Conducted in Multiple countries; Setting: Secondary care
Line of therapy	Not applicable
Duration of study	Intervention + follow up: Intervention 10 to 14 days + Follow-up 60 days
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: DVT was assessed using bilateral venography and confirmed by ultrasonography or venography. Suspected PE was confirmed or ruled out using ventilation-perfusion lung scanning, spiral computer tomography or pulmonary angiography. For deaths, when possible, autopsy was carried out.
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Patients who were scheduled to undergo total knee replacement surgery for one or both knees, including revision of a previously inserted artificial joint
Exclusion criteria	Active bleeding; contraindication to anticoagulant prophylaxis; requirement of ongoing anticoagulant or antiplatelet treatment; uncontrolled hypertension; active hepatobiliary disease; clinically significant impairment of renal function; thrombocytopenia; anaemia; allergy to heparin; allergy to radiographic contrast dye; contraindication to bilateral venography
Recruitment/selection of patients	Not stated
Age, gender and ethnicity	Age - Median (range): Apixaban 65.9 (26-93) vs. Enoxaparin 65.7 (33-89). Gender (M:F): 1212:1983. Ethnicity: White 94.8%; Black 3.8%; Asian 0.8%; Other 0.6%
Further population details	1. BMI : Obese (BMI over 30 kg/m ²) (Mean 30 kg/m ²). 2. Renal impairment: Not applicable
Extra comments	.
Indirectness of population	No indirectness
Interventions	(n=1599) Intervention 1: Apixaban - Apixaban (all doses). Orally 2.5mg twice daily; first doses given at 12 to 24 hrs post-surgery. Duration 10 to 14 days. Concurrent medication/care: Injection of placebo to mimic enoxaparin injection (n=1596) Intervention 2: Low molecular weight heparin (licensed in UK) - Enoxaparin (20mg once daily – 60mg twice daily). Subcutaneous injection 30mg every 12 hrs; first doses given at 12 to 24 hrs post-surgery. Duration 10 to 14 days. Concurrent medication/care: Oral placebo tablets to mimic apixaban tablets

Study	ADVANCE-1 trial: Lassen 2009 ¹⁹⁶
Funding	Study funded by industry (Bristol-Myers Squibb and Pfizer)
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: APIXABAN versus ENOXAPARIN</p> <p>Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge - Actual outcome: Death during treatment period at 10 to 14 days; Group 1: 3/1599, Group 2: 3/1596 Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0 - Actual outcome: Death during follow-up period at Up to 60 days after last dose of study medication; Group 1: 0/1562, Group 2: 3/1554 Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 37, Reason: Not reported; Group 2 Number missing: 42, Reason: Not reported</p> <p>Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge - Actual outcome: All DVT during treatment period at 10 to 14 days; Group 1: 89/1142, Group 2: 92/1122; Comments: The numbers of people analysed are the total numbers of patients who had a bilateral venogram that was deemed suitable for evaluation or had a VTE. Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 457, Reason: The total number of participants analysed here are all patients who underwent randomisation and received at least one dose of study medication.; Group 2 Number missing: 474, Reason: The total number of participants analysed here are all patients who underwent randomisation and received at least one dose of study medication.</p> <p>Protocol outcome 3: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge - Actual outcome: All PE during treatment period at 10 to 14 days; Group 1: 17/1599, Group 2: 12/1596 Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0</p> <p>Protocol outcome 4: Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge - Actual outcome: Adjudicated major bleeding events at 10 to 14 days; Group 1: 11/1596, Group 2: 22/1588; Comments: Difference in risk (95% CI) = -0.81 (-1.49 to 0.14); $p=0.05$. The total number of participants analysed here are all patients who underwent randomisation and received at least one dose of study medication. Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 3; Group 2 Number missing: 8</p>	

Study	ADVANCE-1 trial: Lassen 2009 ¹⁹⁶
	<p>Protocol outcome 5: Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQspect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge - Actual outcome: Fatal PE during treatment period at 10 to 14 days; Group 1: 2/1599, Group 2: 0/1596 Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0</p> <p>Protocol outcome 6: Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge - Actual outcome: Adjudicated clinically relevant non-major bleeding events at 10 to 14 days; Group 1: 35/1596, Group 2: 47/1588; Comments: Difference in risk (95% CI) = -0.77 (-1.87 to 0.33). The total number of participants analysed here are all patients who underwent randomisation and received at least one dose of study medication. Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 3; Group 2 Number missing: 8</p> <p>Protocol outcome 7: Surgical site haematoma at 7-90 days from hospital discharge - Actual outcome: Haematoma at surgical site at 10 to 14 days; Group 1: 2/1596, Group 2: 2/1588; Comments: The total number of participants analysed here are all patients who underwent randomisation and received at least one dose of study medication. Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 3; Group 2 Number missing: 8</p> <p>Protocol outcome 8: DVT (symptomatic) at 7-90 days from hospital discharge - Actual outcome: Symptomatic DVT during follow-up period at Up to 60 days after last dose of study medication; Group 1: 3/1562, Group 2: 2/1554</p> <p>Protocol outcome 9: DVT (proximal) at 7-90 days from hospital discharge - Actual outcome: Proximal DVT at Up to 60 days after last dose of study medication; Group 1: 9/1254, Group 2: 11/1207</p>
Protocol outcomes not reported by the study	Surgical site haematoma at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study; Infection at duration of study;

Study	ADVANCE-2 trial: Lassen 2010 ¹⁹⁵
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	N/A (n=3057)
Countries and setting	Conducted in Multiple countries; Setting: Secondary care
Line of therapy	Not applicable
Duration of study	Intervention + follow up: Intervention 10 to 14 days + Follow-up up to 60 days
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: DVT was assessed with bilateral venography; confirmed by ultrasonography or venography. Suspected PE was assessed with ventilation-perfusion lung scanning, spiral computed tomography or pulmonary angiography. For death, autopsy was performed when possible.
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Patients scheduled to have unilateral elective total knee replacement or same-day bilateral knee replacement, including revision
Exclusion criteria	Active bleeding; contraindication to anticoagulant prophylaxis; necessity to continue anticoagulant or antiplatelet treatment; uncontrolled hypertension; active hepatobiliary disease; impaired renal function; thrombocytopenia; anaemia; heparin allergy; allergy to radiographic contrast dye; other disorders preventing bilateral venography
Recruitment/selection of patients	Not stated
Age, gender and ethnicity	Age - Median (IQR): Apixaban 67 (59-73) vs. Enoxaparin 67 (60-73). Gender (M:F): 2216:841. Ethnicity: White 76.1%; Asian 16.6%; Black 1.0%; Hawaiian/Islander 0.07%; Other 3.0%
Further population details	1. BMI : Not obese (BMI under 30 kg/m ²) (Mean BMI in both groups 29 kg/m ²). 2. Renal impairment: Not applicable
Indirectness of population	No indirectness
Interventions	(n=1528) Intervention 1: Apixaban - Apixaban (all doses). Oral tablets 2.5mg twice daily; first dose given 12 to 24 hrs after wound closure. Duration 10 to 14 days. Concurrent medication/care: Placebo injections to match enoxaparin (n=1529) Intervention 2: Low molecular weight heparin (licensed in UK) - Enoxaparin (20mg once daily – 60mg twice daily). Subcutaneous injections 40mg once daily; first injection given 12 hrs before operation then resumed after surgery according to investigators' standard of care. Duration 10 to 14 days. Concurrent medication/care: Placebo tablets to match apixaban
Funding	Study funded by industry (Bristol-Myers Squibb and Pfizer)

Study	ADVANCE-2 trial: Lassen 2010 ¹⁹⁵
RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: APIXABAN versus ENOXAPARIN	
<p>Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge</p> <p>- Actual outcome: Death during treatment period at 10 to 14 days; Group 1: 2/1528, Group 2: 0/1529</p> <p>Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;</p> <p>Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0</p> <p>- Actual outcome: Death during follow-up at Up to 60 days; Group 1: 1/1458, Group 2: 1/1469; Comments: The number analysed is the number of randomised patients who entered follow-up.</p> <p>Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low;</p> <p>Indirectness of outcome: No indirectness ; Group 1 Number missing: 70, Reason: Missing participants were those that were randomised but did not enter follow-up.; Group 2 Number missing: 60, Reason: Missing participants were those that were randomised but did not enter follow-up.</p>	
<p>Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge</p> <p>- Actual outcome: All DVT during treatment period at 10 to 14 days; Group 1: 142/971, Group 2: 243/997; Comments: The number analysed is the number of patients randomly allocated to treatment who had an adjudicated and assessable bilateral venogram or an adjudicated DVT.</p> <p>Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low;</p> <p>Indirectness of outcome: No indirectness ; Group 1 Number missing: 557, Reason: Participants without an adjudicated and assessable bilateral venogram or an adjudicated DVT were not included in the analysis.; Group 2 Number missing: 532, Reason: Participants without an adjudicated and assessable bilateral venogram or an adjudicated DVT were not included in the analysis.</p>	
<p>Protocol outcome 3: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQspect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge</p> <p>- Actual outcome: All PE during treatment period at 10 to 14 days; Group 1: 4/1528, Group 2: 0/1529</p> <p>Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;</p> <p>Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0</p> <p>- Actual outcome: All PE during follow-up at Up to 60 days; Group 1: 3/1458, Group 2: 1/1469; Comments: The number analysed is the number of randomised patients who entered follow-up.</p> <p>Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low;</p> <p>Indirectness of outcome: No indirectness ; Group 1 Number missing: 70, Reason: Missing participants were those that were randomised but did not enter follow-up.; Group 2 Number missing: 60, Reason: Missing participants were those that were randomised but did not enter follow-up.</p>	
<p>Protocol outcome 4: Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge</p>	

Study	ADVANCE-2 trial: Lassen 2010 ¹⁹⁵
	<p>- Actual outcome: Adjudicated major bleeding events at 10 to 14 days; Group 1: 9/1501, Group 2: 14/1508; Comments: The number analysed is the number of randomised patients who received the study drugs.</p> <p>Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 27, Reason: Those that did not receive any study drug were not included in the safety analysis.; Group 2 Number missing: 21, Reason: Those that did not receive any study drug were not included in the safety analysis.</p>
	<p>Protocol outcome 5: Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQspect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge</p> <p>- Actual outcome: Fatal PE during treatment period at 10 to 14 days; Group 1: 1/1528, Group 2: 0/1529</p> <p>Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0</p>
	<p>Protocol outcome 6: Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge</p> <p>- Actual outcome: Adjudicated clinically relevant non-major bleeding events at 10 to 14 days; Group 1: 44/1501, Group 2: 58/1508; Comments: The number analysed is the number of randomised patients who received the study drugs.</p> <p>Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 27, Reason: Those that did not receive any study drug were not included in the safety analysis.; Group 2 Number missing: 21, Reason: Those that did not receive any study drug were not included in the safety analysis.</p>
	<p>Protocol outcome 7: Surgical site haematoma at up to 45 days from hospital discharge</p> <p>- Actual outcome: Haematoma at surgical site at 10 to 14 days; Group 1: 1/1501, Group 2: 0/1508; Comments: The number analysed is the number of randomised patients who received the study drugs.</p> <p>Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 27, Reason: Those that did not receive any study drug were not included in the safety analysis.; Group 2 Number missing: 21, Reason: Those that did not receive any study drug were not included in the safety analysis.</p>
	<p>Protocol outcome 8: VTE at 7-90 days from hospital discharge</p> <p>- Actual outcome: VTE at 10 to 14 days; Group 1: 13/1195, Group 2: 26/1199</p>
	<p>Protocol outcome 9: DVT (symptomatic) at 7-90 days from hospital discharge</p> <p>- Actual outcome: Symptomatic DVT during follow-up at Up to 60 days; Group 1: 2/1458, Group 2: 1/1469; Comments: The number analysed is the number of randomised patients who entered follow-up.</p>

Study	ADVANCE-2 trial: Lassen 2010¹⁹⁵
Protocol outcomes not reported by the study	Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study; Infection at duration of study;

Study	Leclerc 1992²⁰⁰
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=131)
Countries and setting	Conducted in Canada; Setting: Montreal General Hospital, Centre Hospitalier de l'Universite Laval, Sunnybrook Health Science Centre, Hopital du St-Sacrement
Line of therapy	Not applicable
Duration of study	Intervention time: 14 days
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: DVT: confirmed by bilateral contrast venography Major bleeding: defined by any of the following: associated with a drop in haemoglobin of 20g/l or more, requiring transfusion with two or more units of packed red cells or occurring in any of these sites: intracranial, intra-ocular, retroperitoneal space or intra-articular.
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Patients undergoing knee arthroplasty or tibial osteomy
Exclusion criteria	Age less than 40; previous history of DVT or PE, allergy to radiographic contrast material; bleeding disorder; failure to achieve post-operative haemostasis; continuing need for aspirin, non-steroidal anti-inflammatory drugs or oral anticoagulants; active peptic ulcer; pregnancy; haemorrhagic stroke in the previous 3 months; uncontrolled arterial hypertension (systolic ≥ 200 mmHg or diastolic ≥ 120 mmHg); history of heparin induced thrombocytopenia; renal insufficiency (serum creatinine ≥ 130 umol/l)
Recruitment/selection of patients	Based on inclusion criteria
Age, gender and ethnicity	Age - Mean (SD): 69 years. Gender (M:F): 1/1.5. Ethnicity: Not reported
Further population details	1. BMI : Not applicable 2. Renal impairment: Not applicable
Extra comments	Mean duration of surgery: enoxaparin group 139 minutes, placebo group 150 minutes. Type of surgery: tibial osteotomy 19%, cemented arthroplasty 68%, uncemented arthroplasty 13%
Indirectness of population	No indirectness

Study	Leclerc 1992 ²⁰⁰
Interventions	<p>(n=66) Intervention 1: Low molecular weight heparin (licensed in UK) - Enoxaparin (20mg once daily – 60mg twice daily). LMWH, enoxaparin, 30mg every 12 hours. The administration of study medication generally started on the morning of the first post-operative day (day 1) and was continued for 14 days or until discharge. Duration 14 days or until discharge. Concurrent medication/care: The start of treatment was delayed until the evening of day 1 or the morning of day 2, at the latest, for patients who did not achieve haemostasis at the surgical site on the morning of day 1.</p> <p>(n=65) Intervention 2: No treatment - Placebo. 0.4ml of saline every 12 hours. Duration 14 days or until discharge. Concurrent medication/care: The start of treatment was delayed until the evening of day 1 or the morning of day 2, at the latest, for patients who did not achieve haemostasis at the surgical site on the morning of day 1</p>
Funding	Funding not stated

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: ENOXAPARIN (20MG ONCE DAILY – 60MG TWICE DAILY) versus PLACEBO

Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge

- Actual outcome: All-cause mortality at 14 days; Group 1: 0/66, Group 2: 0/65

Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0

Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge

- Actual outcome: DVT (symptomatic and asymptomatic) at 14 days; Group 1: 11/65, Group 2: 37/64

Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 1, Reason: Withdrawal; Group 2 Number missing: 1, Reason: Withdrawal

Protocol outcome 3: Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge

- Actual outcome: Major bleeding at 14 days; Group 1: 0/66, Group 2: 1/65

Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0

Protocol outcome 4: Surgical site haematoma at up to 45 days from hospital discharge

Study	Leclerc 1992 ²⁰⁰
	<p>- Actual outcome: Wound haematoma at 14 days; Group 1: 0/66, Group 2: 1/65</p> <p>Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0</p> <p>Protocol outcome 5: DVT (distal) at 7-90 days from hospital discharge</p> <p>- Actual outcome: DVT (distal) at 14 days; Group 1: 11/65, Group 2: 25/64</p> <p>Protocol outcome 6: DVT (proximal) at 7-90 days from hospital discharge</p> <p>- Actual outcome: DVT (proximal) at 14 days; Group 1: 0/65, Group 2: 12/64</p>
Protocol outcomes not reported by the study	<p>Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge; Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study; Infection at duration of study;</p>

Study	Leclerc 1996 ²⁰¹
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=670)
Countries and setting	Conducted in Canada; Setting: Eight hospitals
Line of therapy	Not applicable
Duration of study	Intervention time: 14 days
Method of assessment of guideline condition	Adequate method of assessment/diagnosis
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Adult patients having knee arthroplasty

Study	Leclerc 1996 ²⁰¹
Exclusion criteria	Allergy to contrast material; need for oral anticoagulant or antiplatelet agents; bleeding diathesis; gastrointestinal haemorrhage within 3 months of surgery; renal or hepatic insufficiency; uncontrolled hypertension; illicit drug use or alcohol abuse; participation in the present study within the previous 3 months; haemorrhagic stroke within 3 months of surgery; receipt of other investigational drugs in the past month; warfarin allergy
Recruitment/selection of patients	Consecutive patients
Age, gender and ethnicity	Age - Mean (SD): Warfarin group 69.2 (9.2); LMWH group 68.0 (9.4). Gender (M:F): 1:1.7. Ethnicity: Not reported
Further population details	1. BMI : Not applicable 2. Renal impairment: Not applicable
Indirectness of population	No indirectness
Interventions	<p>(n=336) Intervention 1: Low molecular weight heparin (licensed in UK) - Enoxaparin (20mg once daily – 60mg twice daily). Enoxaparin (high dose, 30mg twice daily). Therapy began on the morning of the first day after surgery and was administered for 14 days or until hospital discharge, whichever occurred first. Patients also received a warfarin placebo once daily starting the morning of the first day after surgery. Duration 14 days. Concurrent medication/care: No other thromboprophylactic agents or AES were used</p> <p>(n=334) Intervention 2: Vitamin K antagonists - Warfarin (all doses). Warfarin, initial dose not reported. The treatment goal was to maintain the INR between 2-3. Administered from the evening of the operation for 14 days or until hospital discharge, whichever occurred first. Patients also received subcutaneous saline placebo twice daily (every 12 hours). Duration 14 days. Concurrent medication/care: No other thromboprophylactic agents AES were used</p>
Funding	Study funded by industry (Supported by a research grant from Rhone-Poulenc Rorer Canada)

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: ENOXAPARIN (20MG ONCE DAILY – 60MG TWICE DAILY) versus WARFARIN (ALL DOSES)

Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge

- Actual outcome: All-cause mortality at 14 days; Group 1: 0/336, Group 2: 0/334

Risk of bias: All domain - ; Indirectness of outcome: No indirectness

Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge

- Actual outcome: DVT (symptomatic and asymptomatic) at 14 days; Group 1: 76/206, Group 2: 109/211

Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 130, Reason: Inadequate venography ; Group 2 Number missing: 123, Reason: Inadequate

Study	Leclerc 1996 ²⁰¹
venography	<p>Protocol outcome 3: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge - Actual outcome: PE at 14 days; Group 1: 1/336, Group 2: 3/334 Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0</p> <p>Protocol outcome 4: Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge - Actual outcome: Major bleeding at 14 days; Group 1: 6/336, Group 2: 5/334 Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0</p> <p>Protocol outcome 5: Surgical site haematoma at up to 45 days from hospital discharge - Actual outcome: Wound haematoma at 14 days; Group 1: 1/336, Group 2: 1/334 Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0</p> <p>Protocol outcome 6: DVT (distal) at 7-90 days from hospital discharge - Actual outcome: DVT (distal) at 14 days; Group 1: 56/206, Group 2: 87/211</p> <p>Protocol outcome 7: DVT (proximal) at 7-90 days from hospital discharge - Actual outcome: DVT (proximal) at 14 days; Group 1: 24/206, Group 2: 22/211</p> <p>Protocol outcome 8: Site of bleeding (gastrointestinal ; surgical site; brain/spine; other) at 45 days from hospital discharge - Actual outcome: Surgical site bleeding at 14 days; Group 1: 6/336, Group 2: 5/334</p>
Protocol outcomes not reported by the study	Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced

Study	Leclerc 1996²⁰¹
	thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study; Infection at duration of study;

Study	Mirdamadi 2014²²⁵
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	N/A (n=90)
Countries and setting	Conducted in Iran; Setting: Secondary care
Line of therapy	Not applicable
Duration of study	Intervention + follow up: Intervention up to 15 days + Follow-up 3 months
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: Bilateral Doppler sonography was used to detect DVT. Ventilation/perfusion scintigraphy and spiral computed tomography was used to diagnose PE.
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Patients older than 18 years with expected primary TKA
Exclusion criteria	Bleeding diathesis; history of acute intracranial disease / haemorrhagic stroke; major surgery / trauma / uncontrolled hypertension / myocardial infarction within past 3 months; GI / urogenital bleeding / ulcer disease within past 6 months; aspartate aminotransferase / alanine aminotransferase levels higher than twice the upper limit of the normal range within past month; several renal insufficiency; use of NSAID within a week prior to surgery; active malignant disease
Recruitment/selection of patients	Not stated
Age, gender and ethnicity	Age - Mean (SD): 70 ± 9. Gender (M:F): 38:52. Ethnicity: Implicitly assumed to be all Iranian
Further population details	1. BMI : Not applicable 2. Renal impairment: Not applicable
Indirectness of population	No indirectness
Interventions	(n=45) Intervention 1: Low molecular weight heparin (licensed in UK) - Enoxaparin (20mg once daily – 60mg twice daily). 40mg given 12 hrs before surgery and continued daily. Duration Up to 15 days. Concurrent medication/care: Not reported Comments: Route and frequency of administration not stated (n=45) Intervention 2: Dabigatran - Dabigatran (all doses). First dose of 150mg given 4 hrs after surgery and continued

Study	Mirdamadi 2014²²⁵
	daily at an increased dose of 225mg. Duration Up to 15 days. Concurrent medication/care: Not reported Comments: Route and frequency of administration not stated
Funding	Funding not stated
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: ENOXAPARIN versus DABIGATRAN</p> <p>Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge - Actual outcome: Death during treatment period at 15 days; Group 1: 0/45, Group 2: 0/45 Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness; Baseline details: Only the participants' age, weight and sex are reported and compared. ; Group 1 Number missing: 0, Reason: ; Group 2 Number missing: 0</p> <p>Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge - Actual outcome: Symptomatic DVT at 15 days; Group 1: 1/45, Group 2: 1/45 Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: Serious indirectness, Comments: Asymptomatic DVT is not included.; Baseline details: Only the participants' age, weight and sex are reported and compared. ; Group 1 Number missing: 0, Reason: ; Group 2 Number missing: 0</p> <p>Protocol outcome 3: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQspect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge - Actual outcome: Symptomatic PE at 15 days; Group 1: 0/45, Group 2: 0/45 Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: Serious indirectness, Comments: Asymptomatic PE is not included.; Baseline details: Only the participants' age, weight and sex are reported and compared. ; Group 1 Number missing: 0, Reason: ; Group 2 Number missing: 0</p> <p>Protocol outcome 4: Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge - Actual outcome: Major bleeding at 15 days; Group 1: 2/45, Group 2: 3/45; Comments: p=0.66 Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness; Baseline details: Only the participants' age, weight and sex are reported and compared. ; Group 1 Number missing: 0, Reason: ; Group 2 Number missing: 0</p>	

Study	Mirdamadi 2014 ²²⁵
<p>Protocol outcome 5: Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge</p> <p>- Actual outcome: Clinically relevant non-major bleeding at 15 days; Group 1: 7/45, Group 2: 8/45; Comments: p=0.81</p> <p>Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Baseline details: Only the participants' age, weight and sex are reported and compared. ; Group 1 Number missing: 0, Reason: ; Group 2 Number missing: 0</p>	
Protocol outcomes not reported by the study	Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Surgical site haematoma at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study; Infection at duration of study;

Bibliographic reference	Study Type	Evidence level	No. of patients	Patients characteristics	Intervention	Comparison	Length of follow up	Outcome measures	Effect size	Comments
Norgren 1998 ²⁴¹	RCT	1+	Total: n = 40 Intervention: n = 21 Control: n = 19 11 patients dropped out so results based on 29 patients: Int:15 &	Type of surgery: Patients scheduled for elective knee replacement. Overall M/F: 13/27 Mean age (range): 72 (49-87) years Intervention M/F: 4/11 Control	Type: foot pump (ActOne) mechanical compression plus AES Started evening before surgery, removed during surgery, reapplied	Type: LMWH 40mg once per day Not stated when first dose was administered. used until full mobilisation Additional non-comparative prophylaxis: Not reported	Control: 3mths Int: 3mths	DVT (overall) Confirmed by: venography performed on day 7-10. Fatal PE Confirmed by autopsy:	Int: 4/15 Control: 0/14 p value: <0.05 Int: 1/15 Control: 0/14 p value: Not significant	Comments: 11 patients dropped out from the study, 5 in the LMWH group and 6 in the foot pump group There were no signs of proximal thrombosis

Bibliographic reference	Study Type	Evidence level	No. of patients	Patients characteristics	Intervention	Comparison	Length of follow up	Outcome measures	Effect size	Comments
			cont:14	M/F: 7/7	immediately after and continued until full mobilisation. A tourniquet was used during surgery. Additional non-comparative prophylaxis: Not reported					Not reported: PTS, Bleeding related complications, QoL, Survival

Study	RECORD4 trial: Turpie 2009 ³²¹
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	N/A (n=3148)
Countries and setting	Conducted in Canada, USA; Setting: Secondary care
Line of therapy	Not applicable
Duration of study	Intervention + follow up: Intervention 11 to 15 days + Follow-up 30 to 35 days after last dose of intervention
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: DVT was assessed by ascending bilateral venography. Suspected symptomatic DVT was assessed by ultrasound and confirmed with venography. Suspected PE was confirmed by pulmonary angiography, by ventilation-perfusion lung scintigraphy with chest radiography, or by contrast-enhanced spiral CT.
Stratum	Overall
Subgroup analysis within study	Not applicable

Study	RECORD4 trial: Turpie 2009 ³²¹
Inclusion criteria	Aged 18 years or older and scheduled for TKA
Exclusion criteria	Active / High risk of bleeding; any disorder contraindicating the use of enoxaparin or that might necessitate enoxaparin dose adjustment; disorders preventing bilateral venography; clinically significant liver disease; severe renal impairment; concomitant use of drugs that strongly inhibit cytochrome P450; pregnancy / breastfeeding; planned intermittent pneumatic compression; requirement for ongoing anticoagulant therapy
Recruitment/selection of patients	Not stated
Age, gender and ethnicity	Age - Mean (SD): Rivaroxaban 64.4 (9.7) vs. Enoxaparin 64.7 (9.7). Gender (M:F): 1060:1974. Ethnicity: White 67.2%; Asian 19.1%; Hispanic 8.3%; Black 5.0%; American Indian 0.2%; Other / Missing data 0.2%
Further population details	1. BMI : Obese (BMI over 30 kg/m ²) (Mean BMI 31 kg/m ²). 2. Renal impairment: Not applicable
Indirectness of population	No indirectness: Prevalence and incidence of VTE are found to be lower in Asian populations. The proportion of Asians amongst the study participants is higher than what would normally be expected in studies from Europe.
Interventions	(n=1584) Intervention 1: Rivaroxaban - Rivaroxaban (all doses). Oral 10mg once daily; started 6 to 8 hrs after wound closure or after adequate haemostasis had been achieved; then every 22 to 26 hrs in the evening thereafter. Duration 11 to 15 days. Concurrent medication/care: Placebo injections to match enoxaparin every 12 hrs (n=1564) Intervention 2: Low molecular weight heparin (licensed in UK) - Enoxaparin (20mg once daily – 60mg twice daily). Subcutaneous injections 30mg; started 12 to 24 hrs after wound closure; then every 10 to 14 hrs thereafter. Duration 11 to 15 days. Concurrent medication/care: Placebo tablets to match rivaroxaban every 24 hrs
Funding	Study funded by industry (Bayer Schering Pharma AG, Johnson & Johnson Pharmaceutical Research & Development)

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: RIVAROXABAN versus ENOXAPARIN

Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge

- Actual outcome: Death during treatment period at Up to day 17; Group 1: 2/1526, Group 2: 3/1508; Comments: ARD -0.07 (-0.46 to 0.30); p=0.74

Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 58, Reason: Those missing did not take any study medication and was therefore not included in the safety analysis.; Group 2 Number missing: 56, Reason: Those missing did not take any study medication and was therefore not included in the safety analysis.

- Actual outcome: Death during follow-up period at Up to day 35; Group 1: 4/1526, Group 2: 3/1508; Comments: ARD 0.06 (-0.35 to 0.50); p=0.80

Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 58, Reason: Those missing did not take any study medication and was therefore not included in the safety analysis.; Group 2 Number missing: 56, Reason: Those missing did not take any study medication and was therefore not included in the safety analysis.

Study	RECORD4 trial: Turpie 2009 ³²¹
<p>Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge</p> <p>- Actual outcome: All DVT during treatment period at Up to day 17; Group 1: 61/965, Group 2: 86/959; Comments: The number analysed is the modified intention-to-treat population, which consisted of all patients who had taken at least one dose of study medication, had also undergone the planned surgery and had an adequate assessment for thromboembolism.</p> <p>Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low, Comments - ; Indirectness of outcome: No indirectness ; Group 1 Number missing: 619, Reason: Missing data was of those participants who were not included in the "modified ITT population". They were excluded because they did not receive any study medication and they either had incomplete assessment or did not have a planned surgery.; Group 2 Number missing: 605, Reason: Missing data was of those participants who were not included in the "modified ITT population". They were excluded because they did not receive any study medication and they either had incomplete assessment or did not have a planned surgery.</p>	
<p>Protocol 3: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge</p> <p>- Actual outcome: PE during treatment period at Up to day 17; Group 1: 5/1526, Group 2: 8/1508; Comments: ARD -0.20(-0.75 to 0.30); p=0.53</p> <p>Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 58, Reason: Those missing did not take any study medication and was therefore not included in the safety analysis.; Group 2 Number missing: 56, Reason: Those missing did not take any study medication and was therefore not included in the safety analysis.</p>	
<p>Protocol outcome 4: Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge</p> <p>- Actual outcome: Major bleeding events during treatment period at Between start of treatment and 2 days after last dose; Group 1: 27/1584, Group 2: 16/1564; Comments: The number analysed is the safety population, which is the number of participants who had taken at least one dose of study medication. p=0.11</p> <p>Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0</p>	
<p>Protocol outcome 5: Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge</p> <p>- Actual outcome: Clinically relevant non-major bleeding events at Between start of treatment and 2 days after last dose; Group 1: 39/1526, Group 2: 30/1508; Comments: The number analysed is the safety population, which is the number of participants who had taken at least one dose of study medication.</p> <p>Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 58, Reason: Those missing did not take any study medication and was therefore not included in the safety analysis.; Group 2 Number missing: 56, Reason: Those missing did not take any study medication and was therefore not included in the safety analysis.</p>	

Study	RECORD4 trial: Turpie 2009 ³²¹
<p>Protocol outcome 6: Infection at duration of study - Actual outcome: Postoperative wound infection at Unclear; Group 1: 4/1526, Group 2: 3/1508 Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 58, Reason: Those missing did not take any study medication and was therefore not included in the safety analysis.; Group 2 Number missing: 56, Reason: Those missing did not take any study medication and was therefore not included in the safety analysis.</p> <p>Protocol outcome 7: VTE at 7-90 days from hospital discharge - Actual outcome: Symptomatic VTE during follow-up period at Up to day 17; Group 1: 11/1526, Group 2: 18/1508; Comments: ARD -0.47 (-1.16 to 0.23); p=0.19 - Actual outcome: Major VTE at up to day 17; Group 1: 11/1011, Group 2: 15/1020</p> <p>Protocol outcome 8: DVT (symptomatic) at 7-90 days from hospital discharge - Actual outcome: DVT (symptomatic) at up to day 17; Group 1: 6/965, Group 2: 10/959</p> <p>Protocol outcome 9: DVT (distal) at 7-90 days from hospital discharge - Actual outcome: DVT (distal) at up to day 17; Group 1: 52/965, Group 2: 63/959</p> <p>Protocol outcome 10: DVT (proximal) at 7-90 days from hospital discharge - Actual outcome: DVT (proximal) at up to day 17; Group 1: 3/965, Group 2: 13/959</p> <p>Protocol outcome 11: Fatal bleeding at 45 days from hospital discharge - Actual outcome: Fatal bleeding at Between start of treatment and 2 days after last dose; Group 1: 1/1526, Group 2: 0/1508</p>	
<p>Protocol outcomes not reported by the study</p>	<p>Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQspect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Surgical site haematoma at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study;</p>

Bibliographic reference	Study Type	Evidence level	No. of patients	Patients characteristics	Intervention	Comparison	Length of follow up	Outcome measures	Effect size	Comments
-------------------------	------------	----------------	-----------------	--------------------------	--------------	------------	---------------------	------------------	-------------	----------

Bibliographic reference	Study Type	Evidence level	No. of patients	Patients characteristics	Intervention	Comparison	Length of follow up	Outcome measures	Effect size	Comments
Warwick 2002 ³³⁴			Total: 229 Intervention: n = 117 Control: n = 112	Type of surgery: Patients undergoing total knee replacement(TKR). All patients had AES fitted below the knee before surgery Intervention: Mean age:73±9 M/F:43/74 Control: Mean age: 71±10 M/F:37/75 Pre-existing risk factors: Previous thromboembolism: Int: n = 7, control:n = 4, Smoking, varicose veins	A- V impulse foot pump Additional non-comparative prophylaxis: Not reported	Enoxaparin - LMWH	3 months	DVT (overall) Confirmed by: Ascending venography on 6th & 8th day	Analysis based on number of patients who completed venography Int: 57/99 Control: 48/89 p value: Not significant	Study concluded that there neither method provided superior prophylaxis. All patient completed follow-up but only 99 in the intervention and 89 in the control were available for venography 4 patients were said to have PE but paper did not state which groups they belonged Not reported: PTS, QoL, Survival
								Proximal vein thrombosis	Int: 4/99 Control: 0/89 p value: Not significant	
								Fatal PE Confirmed by:	Int: 2/99 Control: 0/89 p value: Not significant	
								Bleeding related complications	Int: 0/99 Control: 4/89 p value: Not significant	

Study	Wilson 1992 ³³⁹
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=60)
Countries and setting	Conducted in United Kingdom; Setting: Kings College Hospital, London
Line of therapy	Not applicable
Duration of study	Intervention time: Unclear
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: DVT: confirmed by ascending ipsilateral venography PE: confirmed by ventilation perfusion lung scanning
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Patients undergoing elective total knee replacements with Biomet AGC 2500 or Insall-Burstein prostheses and a standard technique.
Exclusion criteria	Not reported
Recruitment/selection of patients	Based on inclusion criteria
Age, gender and ethnicity	Age - Mean (SD): 71 years. Gender (M:F): 1/3. Ethnicity: Not reported
Further population details	1. BMI : Not applicable 2. Renal impairment: Not applicable
Extra comments	Duration of surgery: foot pump group 139 minutes, control group 132 minutes
Indirectness of population	No indirectness
Interventions	(n=28) Intervention 1: Foot pumps or foot impulse devices - Foot pumps. A-V impulse system, device is an electrically driven air compressor with reservoir that intermittently inflates a pneumatic pad applied over stockinette to the sole of the foot and held in place by a slipper. The compressor rapidly inflates the pad (0.4 seconds) and then deflates it after a period of three seconds. Duration Not clearly reported. Concurrent medication/care: N/A (n=32) Intervention 2: No treatment - Usual care. Control group, no further details reported. Duration Not clearly reported. Concurrent medication/care: N/A
Funding	No funding

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: FOOT PUMPS versus USUAL CARE

Study	Wilson 1992 ³³⁹
	<p>Protocol outcome 1: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge - Actual outcome: DVT (symptomatic and asymptomatic) at 10 days; Group 1: 5/28, Group 2: 19/32 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0</p> <p>Protocol outcome 2: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge - Actual outcome: PE at Time-point not reported; Group 1: 0/28, Group 2: 0/32 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0</p> <p>Protocol outcome 3: DVT (distal) at 7-90 days from hospital discharge - Actual outcome: DVT (distal) at 10 days; Group 1: 5/28, Group 2: 13/32</p> <p>Protocol outcome 4: DVT (proximal) at 7-90 days from hospital discharge - Actual outcome: DVT (proximal) at 10 days; Group 1: 0/28, Group 2: 6/32</p>
<p>Protocol outcomes not reported by the study</p>	<p>All-cause mortality at up to 90 days from hospital discharge; Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge; Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Surgical site haematoma at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study; Infection at duration of study;</p>

Study	Zou 2014 ³⁴⁹
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=324)
Countries and setting	Conducted in China; Setting: Affiliated Hospital of Qingdao University, China
Line of therapy	Not applicable
Duration of study	Intervention + follow up: 14 days + 4 weeks
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: DVT confirmed by colour Doppler ultrasonography
Stratum	Overall
Subgroup analysis within study	Not applicable:
Inclusion criteria	Patients who were diagnosed with knee osteoarthritis, initially underwent unilateral total knee arthroplasty, were DVT-negative according to the preoperative colour Doppler ultrasonography on the deep veins of both lower extremities and gave informed consent for the therapeutic schedule.
Exclusion criteria	The exclusion criteria were as follows: patients who had a history of haemorrhagic disease or a bleeding tendency during the preoperative coagulation test, had a medical history of VTE, were infused with over 2000ml of fluids 24 hours after surgery, underwent knee arthroplasty, or used a combination of other drugs that might impact the findings
Recruitment/selection of patients	Between July 2011 and July 2013
Age, gender and ethnicity	Age - Mean (range): LMWH group 65.7 (54-80) years; Rivaroxaban group 63.5 (50-82) years; Aspirin 62.7 (47-79) years. Gender (M:F): 1/2.7. Ethnicity: Not reported
Further population details	1. BMI : Not obese (BMI under 30 kg/m ²) (Mean: 27.4). 2. Renal impairment: Not applicable
Extra comments	Operation time (mean): 87 minutes
Indirectness of population	No indirectness
Interventions	(n=112) Intervention 1: Low molecular weight heparin (licensed in UK) - Enoxaparin (20mg once daily – 60mg twice daily). LMWH, enoxaparin, 4000IU (0.4ml)/40mg once daily (standard dose) subcutaneously given. Administered from 12 hours after the operation and continued for 14 days. . Duration 14 days. Concurrent medication/care: Medical parapatellar approach with a tourniquet (pressure of 260 mmHg) was used. Patients were given antibiotics by intravenous drip for 3 days to prevent infections and oral Celecoxib capsules for analgesia after surgery. A pressure dressing was applied to the affected extremities with elastic bandages and the affected extremities were elevated. Ankle pump exercise began 6 hours after surgery. Mobilisation started 1 day after surgery, they practiced walking with walking aids two or three times a day 2 days after surgery for

Study	Zou 2014³⁴⁹
Funding	Funding not stated

10-20 minutes each time.

(n=102) Intervention 2: Rivaroxaban - Rivaroxaban (all doses). Rivaroxaban, 10mg, once daily, subcutaneously given. Administered from 12 hours after the operation and continued for 14 days.

. Duration 14 days. Concurrent medication/care: Medical parapatellar approach with a tourniquet (pressure of 260 mmHg) was used. Patients were given antibiotics by intravenous drip for 3 days to prevent infections and oral Celecoxib capsules for analgesia after surgery. A pressure dressing was applied to the affected extremities with elastic bandages and the affected extremities were elevated. Ankle pump exercise began 6 hours after surgery. Mobilisation started 1 day after surgery, they practiced walking with walking aids two or three times a day 2 days after surgery for 10-20 minutes each time.

(n=110) Intervention 3: Aspirin - Aspirin (up to 300mg). Aspirin, 100mg, once daily, subcutaneously given. Administered from 12 hours after the operation and continued for 14 days.

. Duration 14 days. Concurrent medication/care: Medical parapatellar approach with a tourniquet (pressure of 260 mmHg) was used. Patients were given antibiotics by intravenous drip for 3 days to prevent infections and oral Celecoxib capsules for analgesia after surgery. A pressure dressing was applied to the affected extremities with elastic bandages and the affected extremities were elevated. Ankle pump exercise began 6 hours after surgery. Mobilisation started 1 day after surgery, they practiced walking with walking aids two or three times a day 2 days after surgery for 10-20 minutes each time.

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: ENOXAPARIN (40MG) versus RIVAROXABAN

Protocol outcome 1: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge

- Actual outcome: DVT (symptomatic and asymptomatic) at 28 days (4 weeks); Group 1: 14/112, Group 2: 3/102

Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0

Protocol outcome 2: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge

Study	Zou 2014 ³⁴⁹
	<p>- Actual outcome: PE at 28 days (4 weeks); Group 1: 0/112, Group 2: 0/102 Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - High, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0</p> <p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: ENOXAPARIN (40MG) versus ASPIRIN (UP TO 300MG)</p> <p>Protocol outcome 1: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge - Actual outcome: DVT (symptomatic and asymptomatic) at 28 days (4 weeks); Group 1: 14/112, Group 2: 18/110 Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0</p> <p>Protocol outcome 2: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge - Actual outcome: PE at 28 days (4 weeks); Group 1: 0/102, Group 2: 0/110 Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - High, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0</p> <p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: RIVAROXABAN versus ASPIRIN (UP TO 300MG)</p> <p>Protocol outcome 1: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge - Actual outcome: DVT (symptomatic and asymptomatic) at 28 days (4 weeks); Group 1: 3/102, Group 2: 18/110 Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0</p> <p>Protocol outcome 2: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge - Actual outcome: PE at 28 days (4 weeks); Group 1: 0/102, Group 2: 0/110 Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - High, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0</p>
Protocol outcomes not reported by the study	All-cause mortality at up to 90 days from hospital discharge; Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal);

Study	Zou 2014 ³⁴⁹
	results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge; Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Surgical site haematoma at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study; Infection at duration of study;

H.25 Non-arthroplasty orthopaedic knee surgery

Study	Camporese 2008 ⁴¹
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=1761)
Countries and setting	Conducted in Italy; Setting: Department of Knee Surgery of the Abano Terme Clinic and the Unit of Angiology of the University Hospital of Padua
Line of therapy	Not applicable
Duration of study	Intervention + follow up: 3 months
Method of assessment of guideline condition	Adequate method of assessment/diagnosis
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	All consecutive outpatients having a diagnostic arthroscopy or assisted knee surgery for partial meniscectomy, cartilage shaving, cruciate ligament reconstruction, synovial resection or combined surgical procedures
Exclusion criteria	Patients younger than 18 years of age, pregnant, previous venous thromboembolism, active cancer, known thrombophilia, receiving mandatory anticoagulation, hypersensitive to LMWH, recent major bleeding event, severe renal or hepatic failure, anticipated poor adherence, geographic inaccessibility, or tourniquet thigh time greater than 1 hour

Recruitment/selection of patients	Consecutive patients
Age, gender and ethnicity	Age - Mean (SD): AES group: 42.3 (14.4), LMWH 14 days: 42.5 (16.7), LMWH 7 days: 41.9 (15.1). Gender (M:F): AES group: 1.66:1, LMWH 14 days: 1.60:1, LMWH 7 days: 1.62:1. Ethnicity: Not reported
Further population details	1. BMI : Not applicable 2. Cancer status: No active cancer 3. Renal impairment: Not applicable
Indirectness of population	No indirectness
Interventions	(n=660) Intervention 1: Anti-embolism stockings - Above knee. AES full length on the operated leg for 7 days, application before weight bearing. Duration 7 days. Concurrent medication/care: Not reported (n=444) Intervention 2: Low molecular weight heparin (not licensed in UK) - Nadroparin (2850 units once daily - up to 57 units/kg once daily). Nadroparin, 3800U, subcutaneously once daily. First dose at hospital 8 hours after the procedure. Duration 14 days. Concurrent medication/care: Not stated (n=657) Intervention 3: Low molecular weight heparin (not licensed in UK) - Nadroparin (2850 units once daily - up to 57 units/kg once daily). Nadroparin, 3800U, subcutaneously once daily. First dose at hospital 8 hours after the procedure. Duration 7 days. Concurrent medication/care: Not reported
Funding	Funding not stated

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: NADROPARIN (2850 UNITS ONCE DAILY - UP TO 57 UNITS/KG ONCE DAILY) EXTENDED DURATION versus ABOVE KNEE

Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge

- Actual outcome: All-cause mortality at 8 days; Group 1: 0/444, Group 2: 0/660; Risk of bias: High; Indirectness of outcome: No indirectness

Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge

- Actual outcome: DVT at 8 days; Group 1: 9/444, Group 2: 29/660; Risk of bias: High; Indirectness of outcome: No indirectness

Protocol outcome 3: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge

- Actual outcome: PE at 8 days; Group 1: 2/444, Group 2: 2/660; Risk of bias: High; Indirectness of outcome: No indirectness

Protocol outcome 4: Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge

- Actual outcome: Major bleeding at 8 days; Group 1: 1/444, Group 2: 1/660; Risk of bias: High; Indirectness of outcome: No indirectness

Protocol outcome 5: DVT (symptomatic) at 7-90 days from hospital discharge

- Actual outcome: DVT symptomatic at 8 days; Group 1: 2/444, Group 2: 12/660; Risk of bias: ; Indirectness of outcome: No indirectness

Protocol outcome 6: DVT (distal) at 7-90 days from hospital discharge

- Actual outcome: DVT distal at 8 days; Group 1: 8/444, Group 2: 21/660; Risk of bias: ; Indirectness of outcome: No indirectness

Protocol outcome 7: DVT (proximal) at 7-90 days from hospital discharge

- Actual outcome: DVT proximal at 8 days; Group 1: 1/444, Group 2: 8/660; Risk of bias: ; Indirectness of outcome: No indirectness

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: NADROPARIN (2850 UNITS ONCE DAILY - UP TO 57 UNITS/KG ONCE DAILY) EXTENDED DURATION versus NADROPARIN (2850 UNITS ONCE DAILY - UP TO 57 UNITS/KG ONCE DAILY) STANDARD DURATION

Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge

- Actual outcome: All-cause mortality at 8 days; Group 1: 0/444, Group 2: 0/657; Risk of bias: High; Indirectness of outcome: No indirectness

Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge

- Actual outcome: DVT at 8 days; Group 1: 9/444, Group 2: 10/657; Risk of bias: High; Indirectness of outcome: No indirectness

Protocol outcome 3: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge

- Actual outcome: PE at 8 days; Group 1: 2/444, Group 2: 2/657; Risk of bias: High; Indirectness of outcome: No indirectness

Protocol outcome 4: Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge

- Actual outcome: Major bleeding at 8 days; Group 1: 1/444, Group 2: 2/657; Risk of bias: High; Indirectness of outcome: No indirectness

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: NADROPARIN (2850 UNITS ONCE DAILY - UP TO 57 UNITS/KG ONCE DAILY) STANDARD DURATION versus ABOVE KNEE

Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge

- Actual outcome: All-cause mortality at 8 days; Group 1: 0/657, Group 2: 0/660; Risk of bias: High; Indirectness of outcome: No indirectness

Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge

- Actual outcome: DVT at 8 days; Group 1: 10/657, Group 2: 29/660; Risk of bias: High; Indirectness of outcome: No indirectness

Protocol outcome 3: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge

- Actual outcome: PE at 8 days; Group 1: 2/657, Group 2: 2/660; Risk of bias: High; Indirectness of outcome: No indirectness

Protocol outcome 4: Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge

- Actual outcome: Major bleeding at 8 days; Group 1: 2/657, Group 2: 1/660; Risk of bias: High; Indirectness of outcome: No indirectness

Protocol outcomes not reported by the study

Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study; Infection at duration of study; Unplanned return to theatre at up to 45 days from hospital discharge

Study	Camporese 2016 ⁴⁰
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=241)
Countries and setting	Conducted in Italy; Setting: Nine Italian hospitals
Line of therapy	Not applicable
Duration of study	Intervention + follow up: 6 days + 3 months
Method of assessment of guideline condition	Adequate method of assessment/diagnosis
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Patients aged at least 18 years, scheduled for non-diagnostic arthroscopy assisted knee surgery, not combined with open surgery
Exclusion criteria	Concomitant strong concurrent CYP3A4-inhibitors and/or P=gp-inhibitors; proven hypersensitivity to the study drug; pregnancy or lactation; advanced hepatic disease (child-Pugh B and C); known thrombophilia; mandatory anticoagulation; previous objectively documented VTE; known severe bleeding tendency; clinically significant active bleeding; severe renal failure (creatinine clearance <30ml/min estimate with the Cockcroft-Gault method); recent (6-12 weeks) major surgery; current involvement in another clinical trial
Recruitment/selection of patients	Consecutive patients
Age, gender and ethnicity	Age - Mean (SD): Rivaroxaban group: 44.9 (12.8); control group 45.9 (13.9). Gender (M:F): 162:89. Ethnicity: Not reported
Further population details	1. BMI : Not obese (BMI under 30 kg/m ²) (Mean BMI: rivaroxaban 27.6 (16.0); control 28.1 (20.7)). 2. Cancer status: Not applicable 3. Renal impairment: No renal impairment (eGFR greater than 30ml/min/1.73m ²)
Indirectness of population	No indirectness
Interventions	(n=122) Intervention 1: Rivaroxaban - Rivaroxaban (all doses). Rivaroxaban (10mg, once daily). Started 8-10 hours postoperatively, for 6 days. Duration 6 days. Concurrent medication/care: The use of any other prophylactic regimen such as LMWH and/or AES, was strongly discouraged throughout the study period (n=119) Intervention 2: No treatment - Placebo. Placebo, started 8-10 hours postoperatively for 6 days. Duration 6 days . Concurrent medication/care: The use of any other prophylactic regimen such as LMWH and/or AES, was strongly discouraged throughout the study period
Funding	Study funded by industry (Bayer SpA provided the study drugs and covered the insurance costs)

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: RIVAROXABAN (ALL DOSES) versus PLACEBO

Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge

- Actual outcome: All-cause mortality at 3 months; Group 1: 0/120, Group 2: 0/114

Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 2; Group 2 Number missing: 5

Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge

- Actual outcome: DVT at 3 months; Group 1: 2/120, Group 2: 8/114

Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 2; Group 2 Number missing: 5

Protocol outcome 3: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge

- Actual outcome: PE at 3 months; Group 1: 0/120, Group 2: 0/114

Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 2; Group 2 Number missing: 5

Protocol outcome 4: Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge

- Actual outcome: Fatal PE at 3 months; Group 1: 0/120, Group 2: 0/114

Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 2; Group 2 Number missing: 5

Protocol outcomes not reported by the study

Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study; Infection at duration of study; Unplanned return to theatre at up to 45 days from hospital discharge

Study	Marlovits 2007 ²¹⁶
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=175)
Countries and setting	Conducted in Austria; Setting: Hospital
Line of therapy	Not applicable
Duration of study	Intervention + follow up: 23-28 days
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: People having arthroscopic ACL surgery
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Patients aged 19-55 years with a maximum weight of 100kg who were admitted to the hospital for arthroscopic ACL surgery
Exclusion criteria	Patients were excluded if they had participated in another clinical trial in the 4 weeks before this trial, if they had a diagnosis of DVT confirmed by magnetic resonance venography on admission, were receiving oral anticoagulation therapy, or were allergic to heparin, presence of haemophilia, or other blood disorders, pregnancy, and presence of any other serious illness such as proliferative diabetic retinopathy, liver or pancreatic illness, multiple trauma, uncontrollable hypertension or endocarditis lenta
Recruitment/selection of patients	Not reported
Age, gender and ethnicity	Age - Mean (SD): Extended: 29.9 (7.4), standard group: 30.2 (6.9). Gender (M:F): 108:67. Ethnicity: Not reported
Further population details	1. BMI : Not applicable 2. Cancer status: Not applicable 3. Renal impairment: Not applicable
Indirectness of population	No indirectness
Interventions	(n=87) Intervention 1: Low molecular weight heparin (licensed in UK) - Enoxaparin (20mg once daily – 60mg twice daily). Enoxaparin 40mg, subcutaneously, once daily, starting 12-18 hours preoperatively and continuing for 3-8 days in hospital after surgery. Followed by an additional 20 days treatment. Duration 23-28 days. Concurrent medication/care: Not reported (n=88) Intervention 2: Low molecular weight heparin (licensed in UK) - Enoxaparin (20mg once daily – 60mg twice daily). Enoxaparin 40mg, subcutaneously, once daily, starting 12-18 hours preoperatively and continuing for 3-8 days in hospital after surgery. Followed by a placebo for an additional 20 days. Duration 23-28 days. Concurrent medication/care: Not reported
Funding	Study funded by industry (Supported by an educational grant from SanofiAventis, Paris, France)

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: ENOXAPARIN (20MG ONCE DAILY – 60MG TWICE DAILY) EXTENDED DURATION versus ENOXAPARIN (20MG ONCE DAILY – 60MG TWICE DAILY) STANDARD DURATION

Protocol outcome 1: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge

- Actual outcome: DVT at 23-28 days; Group 1: 2/72, Group 2: 28/68; Risk of bias: High; Indirectness of outcome: No indirectness

Protocol outcome 2: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge

- Actual outcome: PE at 23-28 days; Group 1: 0/72, Group 2: 0/68; Risk of bias: High; Indirectness of outcome: No indirectness

Protocol outcome 3: Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge

- Actual outcome: Major bleeding at 23-28 days; Group 1: 0/72, Group 2: 0/68; Risk of bias: High; Indirectness of outcome: No indirectness

Protocol outcomes not reported by the study

All-cause mortality at up to 90 days from hospital discharge; Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study; Infection at duration of study; Unplanned return to theatre at up to 45 days from hospital discharge

Study	POST-KAST trial: Van Adrichem 2017 ³²²
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=1543)
Countries and setting	Conducted in Netherlands; Setting: 10 hospitals
Line of therapy	Not applicable
Duration of study	Intervention + follow up: 3 months
Method of assessment of guideline condition	Adequate method of assessment/diagnosis
Stratum	Minor arthroscopic surgery (combined anaesthetic and surgery less than 1 hour):
Subgroup analysis within study	Not applicable
Inclusion criteria	Patients 18 years of age or older who were scheduled to undergo knee arthroscopy for meniscectomy, diagnostic arthroscopy, removal for loose bodies, or other indications
Exclusion criteria	History of venous thromboembolism, contraindications to LMWH therapy, pregnancy, and current use of anticoagulant therapy for other indications
Recruitment/selection of patients	Not reported
Age, gender and ethnicity	Age - Mean (SD): Treatment group: 48.1 (12.8), control group: 49.1 (12.3). Gender (M:F): 810:641. Ethnicity: Not reported
Further population details	1. BMI : Mixed (20.7% obese (BMI >30)). 2. Cancer status: Not applicable (Mixed (0.8% <1 year before enrolment)). 3. Renal impairment: Not applicable
Indirectness of population	No indirectness
Interventions	(n=773) Intervention 1: Low molecular weight heparin (licensed in UK) - Dalteparin (1,250 units once daily - 5,000 units twice daily). LMWH once daily for the 8 days after arthroscopy, the first dose was administered postoperatively but before discharge on the day of surgery. The drug was nadroparin or dalteparin (according to the preference of the hospital). A dose of 2850U nadroparin, or 2500U dalteparin (a double dose was used for those who weighed more than 100kg). Duration 8 days. Concurrent medication/care: Not reported (n=770) Intervention 2: No treatment - Usual care. No anticoagulant therapy. Duration Not reported. Concurrent medication/care: Not reported
Funding	Academic or government funding (Supported by the Netherlands Organisation for Health Related and Development)

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: DALTEPARIN (1,250 UNITS ONCE DAILY - 5,000 UNITS TWICE DAILY) versus USUAL CARE

Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge

- Actual outcome for Minor arthroscopic surgery (combined anaesthetic and surgery less than 1 hour): All-cause mortality at 3 months; Group 1: 0/731, Group 2: 0/720; Risk of bias: Low; Indirectness of outcome: No indirectness

Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge

- Actual outcome for Minor arthroscopic surgery (combined anaesthetic and surgery less than 1 hour): DVT at 3 months; Group 1: 4/731, Group 2: 2/720; Risk of bias: Low; Indirectness of outcome: No indirectness

Protocol outcome 3: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge

- Actual outcome for Minor arthroscopic surgery (combined anaesthetic and surgery less than 1 hour): PE at 3 months; Group 1: 1/731, Group 2: 1/720; Risk of bias: Low; Indirectness of outcome: No indirectness

Protocol outcome 4: DVT (symptomatic) at 7-90 days from hospital discharge

- Actual outcome for Minor arthroscopic surgery (combined anaesthetic and surgery less than 1 hour): DVT at 3 months; Risk of bias: ; Indirectness of outcome: No indirectness

Protocol outcomes not reported by the study

Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study; Infection at duration of study; Unplanned return to theatre at up to 45 days from hospital discharge

Study	Wirth 2001 ³⁴¹
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=239)
Countries and setting	Conducted in Germany; Setting: Hospital
Line of therapy	Not applicable
Duration of study	Intervention + follow up: 10 days
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: Patients scheduled for knee arthroplasty
Stratum	Major arthroscopic surgery (combined anaesthetic and surgery longer than 1 hour): Mean duration of anaesthesia: 68 (46) minutes
Subgroup analysis within study	Not applicable
Inclusion criteria	Patients scheduled for knee arthroplasty
Exclusion criteria	Patients were excluded if they were pregnant, younger than 18 years, had personal history of DVT, or if there was a contraindication to contrast venography or trial medication
Recruitment/selection of patients	Not reported
Age, gender and ethnicity	Age - Mean (SD): LMWH group: 37.6 (13.0), control group: 38.5 (11.6). Gender (M:F): 179:60. Ethnicity: Not reported
Further population details	1. BMI : Not applicable 2. Cancer status: Not applicable 3. Renal impairment: Not applicable
Indirectness of population	No indirectness
Interventions	(n=117) Intervention 1: Low molecular weight heparin (not licensed in UK) - Reviparin (1750 units once daily - 4200 units once daily). Reviparin, 1750U injected subcutaneously once daily. Duration Mean (SD): 8.1 (11.3) days. Concurrent medication/care: Not reported (n=122) Intervention 2: No treatment - Usual care. No drug treatment for prevention of thromboembolism, consistent with usual practice. Duration Not reported. Concurrent medication/care: Not reported
Funding	Funding not stated

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: REVIPARIN (1750 UNITS ONCE DAILY - 4200 UNITS ONCE DAILY) versus USUAL CARE

Protocol outcome 1: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge

- Actual outcome for Major arthroscopic surgery (combined anaesthetic and surgery longer than 1 hour): DVT at 10 days; Group 1: 1/117, Group 2: 5/122; Risk of bias: High; Indirectness of outcome: No indirectness

Protocol outcome 2: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge
- Actual outcome for Major arthroscopic surgery (combined anaesthetic and surgery longer than 1 hour): PE at 10 days; Group 1: 0/117, Group 2: 0/122; Risk of bias: High; Indirectness of outcome: No indirectness

Protocol outcome 3: Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge
- Actual outcome for Major arthroscopic surgery (combined anaesthetic and surgery longer than 1 hour): Major bleeding at 10 days; Group 1: 0/117, Group 2: 0/122; Risk of bias: High; Indirectness of outcome: Serious indirectness

Protocol outcome 4: Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge
- Actual outcome for Major arthroscopic surgery (combined anaesthetic and surgery longer than 1 hour): Clinically relevant non-major bleeding at 10 days; Group 1: 1/117, Group 2: 4/122; Risk of bias: High; Indirectness of outcome: No indirectness

Protocol outcome 5: DVT (distal) at 7-90 days from hospital discharge
- Actual outcome for Major arthroscopic surgery (combined anaesthetic and surgery longer than 1 hour): DVT (distal) at 10 days; Group 1: 1/117, Group 2: 5/122; Risk of bias: ; Indirectness of outcome: No indirectness

Protocol outcomes not reported by the study	All-cause mortality at up to 90 days from hospital discharge; Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study; Infection at duration of study; Unplanned return to theatre at up to 45 days from hospital discharge
---	--

H.26 Foot and ankle orthopaedic surgery

No relevant clinical studies were identified.

H.27 Upper limb orthopaedic surgery

No relevant clinical studies were identified.

H.28 Spinal surgery

Study	Du 2015 ⁸⁸
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=665)
Countries and setting	Conducted in China; Setting: Department of Orthopedic Surgery, Qilu Hospital and the department of Spine Surgery, Yantaishan Hospital
Line of therapy	Not applicable
Duration of study	Intervention time: 14 days
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: DVT confirmed by Doppler ultrasonography. Spiral computed tomography (CT) was conducted as soon as possible to determine pulmonary angiography. Major bleeding was defined as fatal bleeding, bleeding in inflow critical organs (such as the posterior peritoneum, intracranium, intraocular, and intraspinal canal), bleeding-induced reoperation, or clinically significant bleeding outside the surgical site with a decrease of ≥ 20 g/L in hemoglobin level (with the level from the first postoperative day as the reference value), or the need to transfuse ≥ 2 units of whole blood or packed red blood cells. Clinically relevant non-major bleeding included skin bruising, gastrointestinal bleeding, fecal occult blood, and urine erythrocytes) during the treatment and bleeding wound complications (a composite indicator of wound hematoma and surgical site bleeding).
Stratum	Overall

Subgroup analysis within study	Not applicable
Inclusion criteria	Patients who underwent lumbar surgery
Exclusion criteria	1) oral anticoagulant therapy 3 months prior to the operation; 2) vein thrombosis on preoperative B-ultrasound; 3) preoperative urinalysis positive for red blood cells, fecal occult blood, skin purpura, or hematoma; 4) active bleeding or high risk of bleeding; and 5) contraindication towards rivaroxaban and parnaparin or patients whose parnaparin dose needed to be adjusted
Recruitment/selection of patients	Patients who underwent lumbar surgery between August 2009 and December 2012
Age, gender and ethnicity	Age - Mean (SD): ≥60 years, 40% (no further details reported). Gender (M:F): Not reported. Ethnicity: Not reported
Further population details	1. Active cancer: Not applicable 2. BMI: Obese (BMI over 30 kg/m ²) (46% of participants had a BMI ≥30 kg/m ²). 3. Renal impairment: Not applicable 4. Weight bearing: Not applicable
Extra comments	.
Indirectness of population	No indirectness
Interventions	(n=324) Intervention 1: Low molecular weight heparin (not licensed in UK) - Parnaparin (3200 units once daily - 4250 units once daily). Patients received subcutaneous injections of 40 mg parnaparin (Sanofi-Aventis, France 1–13, Boulevard Romain Rolland 75014 Paris, France) 6 to 8 h after surgery and once per day until the 14th day, when they could fully ambulate. Duration 14 days. Concurrent medication/care: N/A (n=341) Intervention 2: Rivaroxaban - Rivaroxaban (all doses). Patients began daily oral treatment with 10 mg rivaroxaban (Bayer Schering Pharma AG, Leverkusen, D-51368, Germany) 6 to 8 h after surgery, and the treatment continued until the 14th day, when the patients could fully ambulate. Duration 14 days. Concurrent medication/care: N/A
Funding	Funding not stated

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: PARNAPARIN versus RIVAROXABAN

Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge

- Actual outcome: All-cause mortality at 14 days; Group 1: 1/324, Group 2: 0/341; Risk of bias: High; Indirectness of outcome: No indirectness

Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge

- Actual outcome: DVT (symptomatic and asymptomatic) at 14 days; Group 1: 8/324, Group 2: 6/341; Risk of bias: High; Indirectness of outcome: No indirectness

Protocol outcome 3: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge

- Actual outcome: PE at 14 days; Group 1: 1/324, Group 2: 1/341; Risk of bias: High; Indirectness of outcome: No indirectness

Protocol outcome 4: Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge

- Actual outcome: Major bleeding at 14 days; Group 1: 1/324, Group 2: 2/341; Risk of bias: High; Indirectness of outcome: No indirectness

Protocol outcome 5: Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge

- Actual outcome: Clinically relevant non-major bleeding at 14 days; Group 1: 6/324, Group 2: 6/341; Risk of bias: High; Indirectness of outcome: No indirectness

Protocol outcome 6: VTE at 7-90 days from hospital discharge

- Actual outcome: VTE (symptomatic) at 14 days; Group 1: 6/324, Group 2: 3/341;

Protocol outcome 7: DVT (distal) at 7-90 days from hospital discharge

- Actual outcome: Distal DVT at 14 days; Group 1: 5/324, Group 2: 4/341; Risk of bias: ; Indirectness of outcome: No indirectness

Protocol outcome 8: DVT (proximal) at 7-90 days from hospital discharge

- Actual outcome: Proximal DVT at 14 days; Group 1: 3/324, Group 2: 2/341; Risk of bias: ; Indirectness of outcome: No indirectness

Protocol outcome 9: Fatal bleeding at 45 days from hospital discharge

- Actual outcome: Fatal bleeding at 14 days; Group 1: 0/324, Group 2: 0/341; Risk of bias: ; Indirectness of outcome: No indirectness

Protocol outcome 10: Site of bleeding (gastrointestinal ; surgical site; brain/spine; other) at 45 days from hospital discharge

- Actual outcome: Reoccurrence of surgical bleeding at 14 days; Group 1: 0/324, Group 2: 1/341; Risk of bias: ; Indirectness of outcome: No indirectness

- Actual outcome: Bleeding into important organs at 14 days; Group 1: 0/324, Group 2: 1/341; Risk of bias: ; Indirectness of outcome: No indirectness

Protocol outcomes not reported by the study

Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study; Unplanned return to theatre at up to 45 days from hospital discharge

Study	Wood 1997 ³⁴³
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=134)
Countries and setting	Conducted in USA; Setting: Twin Cities Scoliosis Spine Center, USA
Line of therapy	Not applicable
Duration of study	Not clear: Patients used the interventions till hospital discharge - length of stay not reported
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: DVT confirmed by duplex ultrasonography. No confirmation technique reported for PE
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Patients having major thoracolumbar reconstructive spinal procedures. Major reconstructive spinal procedures were defined as those involving anterior or posterior (or both) thoracic, lumbar, or thoracolumbar spine fusions or multilevel decompressions, or a combination of these.
Exclusion criteria	Patients were excluded if they had: cervical procedures, discectomies, laminectomies, hardware removal, irrigation and debridements, and posterior spine decompressions of only one level. Patients were excluded with a history of DVT or who preoperatively had such a medical risk for DVT as to require prophylaxis. Patients also were excluded from the study if they had a history of any of the following: pulmonary embolism, congestive heart failure, previous treatment with anticoagulants, or external conditions precluding the application of compression devices such as infection, neuropathy, or chronic venous stasis.
Recruitment/selection of patients	Between March 1, 1994, and April 1, 1995
Age, gender and ethnicity	Age - Mean (SD): 39.5 years. Gender (M:F): 1.4/1. Ethnicity: Not reported
Further population details	1. Active cancer: Not applicable 2. BMI : Not applicable 3. Renal impairment: Not applicable 4. Weight bearing: Not applicable
Indirectness of population	No indirectness
Interventions	(n=75) Intervention 1: Foot pumps or foot impulse devices - Foot pumps. Patients wore AES (thigh-length) in addition to foot wraps/foot pumps. AES was placed on all patients shortly before and during surgery and were worn for the remainder of the hospital course. Foot wraps were worn during and after surgery. Foot wraps used were inflatable wraps and were secured around and under the arch of each foot and behind the ankle and connected through tubing to a pneumatic control unit that generated cyclic intermittent compression. Inflation was <0.4 seconds, and the cycle is

	<p>repeated every 20 seconds. Duration Until discharge (time-point not reported). Concurrent medication/care: Patients were moved from bed to chair as soon as they were able, typically on the next day. They then began ambulating on day 1, 2, 3 or occasionally 4. The thigh-high stocking were worn at all times, except for bathing.</p> <p>(n=59) Intervention 2: Intermittent pneumatic compression devices - Below knee. Patients wore graduated compression stockings and a sequential pneumatic compression wrap (IPCD). AES were placed on all patients short before and during the surgery and were worn for the remainder of the hospital course. Compression devices were worn post-operatively until ambulation was resume and, thereafter, when in bed until discharge. Duration Until discharge (time-point not reported). Concurrent medication/care: Patients were moved from bed to chair as soon as they were able, typically on the next day. They then began ambulating on day 1, 2, 3 or occasionally 4. The thigh-high stocking were worn at all times, except for bathing.</p>
Funding	Funding not stated
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: FOOT PUMPS versus IPCD (ABOVE-KNEE)</p>	
<p>Protocol outcome 1: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge - Actual outcome: DVT (symptomatic and asymptomatic) at 5-7 days; Group 1: 0/75, Group 2: 0/59; Risk of bias: High; Indirectness of outcome: No indirectness</p>	
<p>Protocol outcome 2: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge - Actual outcome: PE at 5-7 days; Group 1: 0/75, Group 2: 0/59; Risk of bias: Very high; Indirectness of outcome: No indirectness</p>	
<p>Protocol outcome 3: Health-related quality of life (validated scores only) at up to 90 days from hospital discharge - Actual outcome: Visual analogue comfort scale at Hospital discharge - time-point not reported; Group 1: mean 5.84 cm (SD 2.8); n=75, Group 2: mean 5.56 cm (SD 2.9); n=59; Visual analogue comfort scale 0-10 Top=High is poor outcome; Risk of bias: Very high; Indirectness of outcome: No indirectness</p>	
Protocol outcomes not reported by the study	<p>All-cause mortality at up to 90 days from hospital discharge; Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge; Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study; Unplanned return to theatre at up to 45</p>

days from hospital discharge

H.29 Cranial surgery

Study	Cerrato 1978 ⁴⁶
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=100)
Countries and setting	Conducted in Italy; Setting: Neurological Institute of Milan, Italy
Line of therapy	Not applicable
Duration of study	Intervention time: 7 days
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: Confirmed by fibrinogen test using a Pitaman 235 isotope localisation
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	People underwent elective intracranial surgical procedures; all over 40 years of age;
Exclusion criteria	Not reported
Recruitment/selection of patients	Not reported
Age, gender and ethnicity	Age - Mean (SD): 52 years. Gender (M:F): 1/1. Ethnicity: Not reported
Further population details	1. Active cancer: Not applicable 2. BMI : Not applicable 3. Mobility: Not applicable 4. Renal impairment: Not applicable
Indirectness of population	No indirectness
Interventions	(n=50) Intervention 1: Unfractionated heparin - Unfractionated heparin (low dose, administered subcutaneously). UFH (calcium heparin), 5000IU subcutaneously administered every 8 hours. Duration 7 days. Concurrent medication/care: 5000IU was considered to be a safe prophylactic dose if the patient's plasma heparin concentration was less than 0.18 units/ml 3 hours after administration. Otherwise, a lower dose was given and the patient's plasma heparin concentration was tested again after 3 hours. Once established, the safe prophylactic dose was given 2 hours before surgery and every 8 hours thereafter for at least 7 days. Indirectness: No indirectness (n=50) Intervention 2: No treatment - Placebo. No VTE prophylaxis (further details not provided). Duration 7 days.

Study	Cerrato 1978⁴⁶
	Concurrent medication/care: n/a. Indirectness: No indirectness
Funding	Funding not stated
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: UNFRACTIONATED HEPARIN versus CONTROL GROUP</p> <p>Protocol outcome 1: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge - Actual outcome: DVT (symptomatic and asymptomatic) at 8 days; Group 1: 3/50, Group 2: 17/50 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0</p>	
Protocol outcomes not reported by the study	All-cause mortality at up to 90 days from hospital discharge; Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge; Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge; Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study;

Bibliographic reference	Study Type	Evidence level	No. of patients	Patients characteristics	Intervention	Comparison	Length of follow up	Outcome measures	Effect size	Comments
Collins 1988 ⁶⁵	Systematic Review	1+	Total: 100 Intervention : 50 Control: 50 7486	People having elective neurosurgery	UFH 5000U, given 2 hours before surgery and 3x daily after for at least 7 days	No prophylaxis	8 days	DVT confirmed by radiolabelled fibrinogen	Int: 3/50 Cont: 17/50	Not reported: Funding, QoL, LoS or PTS. Event rates
74 studies included, 1 included										

Bibliographic reference	Study Type	Evidence level	No. of patients	Patients characteristics	Intervention	Comparison	Length of follow up	Outcome measures	Effect size	Comments
in this review - Cerrato 1978 ⁴⁶										reported here are for all studies as published in the systematic review.

Bibliographic reference	Study Type	Evidence level	No. of patients	Patients characteristics	Intervention	Comparison	Length of follow up	Outcome measures	Effect size	Comments
Dickinson 1998 ⁸⁴	RCT	1+	Total: 66 Int1: n= 21 Int 2: n=23 Control: n=22	Type of surgery: Neurosurgery for intracranial neoplasms Intervention 1: Mean age: 43 (28-61) yrs Intervention 2: Mean age: 50 (29-72) yrs Control: Mean age: 49 (20-	Int 1: LWMH (Enoxaparin) Dose: administered subcutaneously at a dose of 30mg in the anaesthesia holding room. He dose was continued at a dose of 30mg every 12 hours Int 2: Combination of Enoxaparin and SCD Dose: as before	Type: High high sequential compression device Timing: started before induction of anaesthesia and continued postoperatively until	1 month	DVT Confirmed by: duplex imaging (on four occasions in the first 1 month after surgery) Symptomatic PE Bleeding related complications (intracerebral haemorrhage)	Int 1: 1/21 Control: 3/22 p value = 0.53 Int 2: 4/23 Comp: 3/22 P=0.90 Int 1: 0/21 Int 2: 0/23 Comp: 0/22 Int 1: 2/21 Int 2: 3/23 Comp: 0/22	Comments: Study terminated early when it was determined that the enoxaparin treated groups exhibited a greater incidence of postoperative neurological deficits secondary to

Bibliographic reference	Study Type	Evidence level	No. of patients	Patients characteristics	Intervention	Comparison	Length of follow up	Outcome measures	Effect size	Comments
				72) M/F numbers not reported Pre-existing Risk Factors: Not reported Excluded patients: history of DVT or PE, allergy to heparin or other anticoagulant agents, history of surgery or major trauma to the lower extremities, concurrent condition requiring anticoagulation therapy; cranial base neoplasms and pituitary adenomas	Timing: started before induction of anaesthesia until discharge from Neurosurgery Service. Additional non-comparative prophylaxis: AES on lower extremities at time of admission to the hospital Int 2: Combination of LMWH and thigh high sequential compression device.	patient was walking without assistance Additional non-comparative prophylaxis: AES on lower extremities at time of admission to the hospital		or epidural haematoma) Mortality	Int 1: 0/21 Int 2: 1/23 Comp: 1/22	intracranial haemorrhage. Not reported: Post thrombotic leg, length of stay. Funding: NR

Bibliographic reference	Study Type	Evidence level	No. of patients	Patients characteristics	Intervention	Comparison	Length of follow up	Outcome measures	Effect size	Comments
-------------------------	------------	----------------	-----------------	--------------------------	--------------	------------	---------------------	------------------	-------------	----------

Bibliographic reference	Study Type	Evidence level	No. of patients	Patients characteristics	Intervention	Comparison	Length of follow up	Outcome measures	Effect size	Comments
Goldhaber 2002 ¹²¹	RCT	1+	Total: 150 Intervention: n = 75 (DVT assessed in) Control: n = 75 (DVT assessed in)	Type of surgery: Patients undergoing craniotomy with suspected or metastatic brain tumour Excluded people with a history of overt bleeding, heparin allergy or VTE within the prior 6 months Intervention: Mean age: 48.33 (+15.07) yrs M/F:39/36 Control: Mean age: 48.87 (+12.52) yrs M/F:40/35 Pre-existing risk	Type: LMWH (Enoxaparin) Dose: 40mg/ in the morning, placebo in the evening Timing: Begun morning of 1st postoperative day and continued until discharge or VTE diagnosed. Additional non-comparative prophylaxis: AES (73/75 participants) intermittent pneumatic compression devices (72/75 participants)	Type: UFH Dose: 5000 IU twice per day Timing: Begun morning of 1st postoperative day and continued until discharge or VTE diagnosed. Additional non-comparative prophylaxis: AES (72/75 participants) intermittent pneumatic compression devices (71/75 participants)	30 days	DVT Confirmed by duplex ultrasonography	Int: 9/75 Control: 5/75 p value: 0.401	Patients scanned one day prior to, or on day of discharge Funding Research grant from Aventis Not reported: PTS, QoL
								Symptomatic DVT Confirmed by duplex ultrasonography	Int: 0/75 Control: 0/75 p value: not sig	
								Proximal DVT Confirmed by duplex ultrasonography	Int: 2/75 Control: 2/75 p value: 1	
								Unilateral calf DVT Confirmed by duplex ultrasonography	Int: 6/75 Control: 2/75 p value: 0.276	
								Bilateral calf DVT Confirmed by duplex ultrasonography	Int: 1/75 Control: 1/75 p value: 1	
								Major postoperative	Int: 2/75 Control: 1/75 p	

Bibliographic reference	Study Type	Evidence level	No. of patients	Patients characteristics	Intervention	Comparison	Length of follow up	Outcome measures	Effect size	Comments
				factors: not reported				bleeding complications	value: 0.57	
								Length of stay	Int: 6.07 +3.56 days Control: 5.75 +3.24 days p value: 0.566	
								Mortality	Int: 0/75 Control: 0/75 p value: not sig	

Bibliographic reference	Study Type	Evidence level	No. of patients	Patients characteristics	Intervention	Comparison	Length of follow up	Outcome measures	Effect size	Comments
Macdonald 2003 ²¹¹	RCT	1+	Total: 100 Intervention: n = 51 Control: n = 49	Type of surgery: Patients undergoing craniotomy for brain neoplasm, including transphenoidal surgery, intracranial aneurysm, vascular malformation,	Type: LMWH (Dalteparin) Dose: 2500 IU once per day Timing: Begun at time of surgery and continued for 1 week Additional non-	Type: UFH, low dose Dose: 5000 IU twice per day Timing: Begun at time of surgery and continued for 1 week	1 month	DVT Confirmed by: Doppler US (on 7th post-op day?) Symptomatic pulmonary embolism confirmed by ventilation perfusion scan or spiral CT.	Int: 2/51 Control: 0/49 p value: 0.30 Int: 0/51 Control: 0/49 p value: not sig	Comments: Excluded patients with VTE, thrombocytopenia, abnormal prothrombin time, abnormal partial thromboplastin time, abnormal bleeding time,

Bibliographic reference	Study Type	Evidence level	No. of patients	Patients characteristics	Intervention	Comparison	Length of follow up	Outcome measures	Effect size	Comments
				infection, spontaneous intracranial hematoma, closed head injury or cortical resection for epilepsy. Age & Gender: Intervention: Mean age: 51 ±15 yrs M/F:23/28 Control: Mean age: 49 ±15 yrs M/F: 23/26	comparative prophylaxis: Thigh length intermittent pneumatic compression devices worn from time of admission until discharge or the patient was ambulatory for more than 3 hours per day.	Additional non-comparative prophylaxis: Thigh length intermittent pneumatic compression devices worn from time of admission until discharge or the patient was ambulatory for more than 3 hours per day.		Intracranial haemorrhage confirmed by CT scan and MRI Thrombocytopenia Mortality	Int: 2/51 Control: 1/49 p value: 0.59 Int: 2/51 Control: 0/49 p value: 0.30 Int: 0/51 Control: 1/49 p value: 0.48	history of hypersensitivity to heparin or pork products, penetrating head injury or pregnancy. Not reported: Proximal DVT, PTS, QoL, LoS Also reported: anaesthesia time; blood loss; no. of patients requiring intraoperative transfusion, surgeon's impression of haemostasis, no. of patients requiring erythrocyte transfusion

Study	Sobieraj-teague 2012²⁹⁷
Study type	RCT (Patient randomised; Parallel)

Study	Sobieraj-teague 2012 ²⁹⁷
Number of studies (number of participants)	1 (n=150)
Countries and setting	Conducted in Canada; Setting: Hamilton General Hospital
Line of therapy	Not applicable
Duration of study	Intervention + follow up: 7-11 days
Method of assessment of guideline condition	Adequate method of assessment/diagnosis
Stratum	People who are contraindicated for pharmacological prophylaxis:
Subgroup analysis within study	Not applicable
Inclusion criteria	Neurosurgical patients aged 18 years or older admitted to Hamilton General Hospital for cranial or spinal neurosurgery; neuro-surgical patients admitted with intracranial haemorrhage (sub-arachnoid, intracerebral, or subdural) who had motor deficits but were not undergoing surgery were eligible if consent was obtained within 24 h of hospital admission.
Exclusion criteria	contraindications to the use of mechanical compression devices, including leg ulceration, symptomatic peripheral neuropathy, or peripheral arterial disease; patients who could not undergo venography because of allergy to contrast medium or pre-existing renal impairment (defined as a glomerular filtration rate of < 50 mL min ⁻¹)
Recruitment/selection of patients	May 2009 and November 2010
Age, gender and ethnicity	Age - Mean (range): 62 (29-86). Gender (M:F): 90:60. Ethnicity: Not reported
Further population details	1. Active cancer: Active cancer 56.7% (glioma 20%, meningioma 11.3%, carcinoma metastasis 25.3%). 2. BMI: Obese (BMI over 30 kg/m ²) intervention 33.3%, control 34.7%. 3. Mobility: Immobile (Intervention 37.3%, control 32%). 4. Renal impairment: No renal impairment (eGFR greater than 30ml/min/1.73m ²) (Excluded people with pre-existing renal impairment).
Indirectness of population	Serious indirectness: Intracranial surgery 75.3%, spinal surgery 10.6%, no surgery 7.3%
Interventions	(n=75) Intervention 1: Intermittent pneumatic compression devices - Below knee. Venowave calf compression device, applied to both calves within 4 hours of surgery or within 24 hours of admission to hospital in non-operated patients. Venowave devices were worn continuously (removed for showering only), and their use was continued until the development of symptomatic VTE, patient refusal, or veno-graphic or ultrasound examination. Duration 7-11 days. Concurrent medication/care: Pharmacological prophylaxis given at the discretion of the neurosurgeon (aspirin 5.3%; unfractionated heparin, or low molecular weight heparin 20%) (n=75) Intervention 2: No treatment - Placebo. Placebo. Duration 7-11 days. Concurrent medication/care: Pharmacological prophylaxis given at the discretion of the neurosurgeon (aspirin 9.3%; unfractionated heparin, or low

Study	Sobieraj-teague 2012²⁹⁷
	molecular weight heparin 25.3%)
Funding	Study funded by industry (Golden Horseshoe Bioscience Network; Saringer Incorporated)
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: IPCD BELOW KNEE versus PLACEBO</p> <p>Protocol outcome 1: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge - Actual outcome for People who are contraindicated for pharmacological prophylaxis: DVT (symptomatic and asymptomatic): detected by screening venography or compression ultrasound at 7-11 days; Group 1: 3/75, Group 2: 14/75; Risk of bias: --; Indirectness of outcome: No indirectness</p> <p>Protocol outcome 2: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge - Actual outcome for People who are contraindicated for pharmacological prophylaxis: PE (symptomatic). confirmed by computed tomography pulmonary angiography at 7-11 days; Risk of bias: ; Indirectness of outcome: No indirectness</p> <p>Protocol outcomes not reported by the study</p>	
	All-cause mortality at up to 90 days from hospital discharge; Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge; Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study

H.30 Spinal injury

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Green 1990 ¹²⁸	Patient group: Trauma, complete motor paralysis after spinal cord injury	Group 1	All-cause mortality (confirmed by:)	Group1: 2/21	Funding: National Institute of

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Country of study: USA	Setting: A regional spinal cord injury care centre in US	Heparin 5000unit, 8 hourly, subcutaneous.		Group 2: 0/20 P value: 0.49 [calculated by NCC-AC team from numbers randomised using Fishers exact test]	Disability and Rehabilitation Research, Department of Education. Novo Lab supplied logiparin. Limitations: Unmasked: different dosing regimen Duration of prophylaxis not stated a priori, criteria for discontinuation not stated. Haematoma, melaena and haematuria were considered bleeding events if they necessitated the discontinuation of prophylactic therapy and decisions made by ward physicians not participating in the study. Unclear if they were blinded to the study. 2 patients from each arm transferred out – not stated whether analysis based on randomised patient.
Study design: RCT	Inclusion criteria: Complete motor and spinal surgery sustained within the preceding 72 hours	Group 2 logiparin (tinzaparin) 3500anti-Xa, subcutaneously, once daily	Fatal pulmonary embolism (confirmed by: autopsy)	Group1: 2/21 Group 2: 0/20 P value: 0.49 [calculated by NCC-AC team from numbers randomised using Fishers exact test]	
List who was masked to interventions : unclear	Exclusion criteria: Bleeding injuries not accessible to haemostatic control Severe trauma to the head or lower extremities as well as spinal column Coagulopathy or evidence of thrombosis at baseline examination Pregnancy Cardiovascular instability Refusal by patient or next of kin to give informed, written consent	Start time: at least 24 hours after injury. If patient require surgery, morning dose of either heparin or LMWH was withheld, and treatment resumed the following morning	Symptomatic DVT (confirmed by: abnormal flow study)	Group1: 1/21 Group 2: 0/20 P value: 1.0 [calculated by NCC-AC team from numbers randomised using Fishers exact test]	
Evidence level: 1+		End time not explicitly stated. Patients on heparin received drugs for an	DVT, asymptomatic or symptomatic (confirmed by: 2 patients confirmed by venography, 3rd patients confirmed by symptom and abnormal flow study. Patients screened with impedance plethysomography, Doppler flow measurement and DUS twice weekly in the first 2 weeks, once	Group1: 3/21 Group 2: 0/20 P value reported: 0.02 (Kaplan Meier Log rank test.) P value: 0.23 [calculated by NCC-AC team from numbers randomised using Fishers exact test]	
Duration of follow-up: 8 weeks	All patients N: 41 2 patients in each group failed to complete the planned 8 week trial, because they were transferred 4-29 days after initiation of therapy to other institutions. None of these patients experienced bleeding or thrombosis				
	Group 1				

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	<p>No. randomised: 21 No. of dropouts: 2 Age (mean): 31.4±15.5 M/F: 17/4 Additional risk factors: Spinal injury location: Cervical:13 Thoracic:6 Lumbar:2 Baseline activate thromboplastin time, aPTT (s): 28.0±2.5</p> <p>Group 2 No. randomised: 20 No. of dropouts: 4 Age (mean): 28.3±11.8 M/F: 17/3 Additional risk factors: Spinal injury location: Cervical: 10 Thoracic: 9 Lumbar: 1 Baseline activate thromboplastin time, aPTT(s): 27.7±3.3</p>	<p>average of 40±19 days (total of 843 days for 21 patients).</p> <p>Patients on LMWH received drugs for an average of 47±16 days (total of 945 days for 20 patients).</p> <p>Additional non-comparative prophylaxis: Other prophylactic measures such as calf-compression boots, AES and aspirin were withheld.</p>	<p>weekly for the next two weeks, and biweekly for the next 4 weeks)</p> <p>Thigh DVT (confirmed by: see DVT. 1 patient; superficial femoral vein, 1 patient popliteal vein, patient had both femoral and popliteal vein)</p> <p>Fatal bleeding (description:)</p> <p>Upper GI bleeding</p> <p>Minor bleeding (description: “ 2 patients had bleeding severe enough to require discontinuation of heparin therapy; in both the aPTT was considerably prolonged” Patient 1: neck hematoma, aPTT:</p>	<p>Group1: 3/21 Group 2: 0/20 P value: 0.23 [calculated by NCC-AC team from numbers randomised using Fishers exact test]</p> <p>Group1: 0/21 Group 2: 0/20 P value: 1.0 [calculated by NCC-AC team from numbers randomised using Fishers exact test]</p> <p>Group1: 1/ 21 Group 2: 0/ 0 P value: NS</p> <p>Group1: 2/21 Group 2: 0/20 P value: 0.49 [calculated by NCC-AC team from numbers randomised using Fishers exact test]</p>	<p>Outcomes not reported: Symptomatic PE, PE asymptomatic or symptomatic, Calf DVT , Heparin induced thrombocytopenia, PTS, Pulmonary hypertension, QoL</p> <p>Additional outcomes reported: aPTT for bleeding and thrombotic events Patients on LMWH had more venous studies completed, and more days on prophylaxis.</p> <p>Notes: Study did not report exclusion criteria based on age. Uncertain whether children/teenagers were included 2 patients in LMWH temporarily switched to heparin at Day 22 and Day 23 because LMWH was temporarily not available</p>

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
			44.5s Patient 2: gastrointestinal and genitourinary bleeding, aPTT: 38.0		
			Length of stay	Group1: 40±19 days Group 2: 47±16 days P value: not reported	

Study	Halim 2014 ¹³⁴
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=74)
Countries and setting	Conducted in India; Setting: Indian Spinal Injuries Centre
Line of therapy	Not applicable
Duration of study	2 weeks
Method of assessment of guideline condition	Adequate method of assessment/diagnosis
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	People with acute spinal cord injury (≤5 days)
Exclusion criteria	Previous history of DVT; chronic venous insufficiency; recent myocardial infarction; heart failure; taking oral contraceptive pills, steroids or hormonal or anticoagulant drugs
Recruitment/selection of patients	December 2006 - December 2010
Age, gender and ethnicity	Age: not reported. Gender (M:F): 60:14. Ethnicity: Indian
Further population details	1. Active cancer: Not applicable (not stated). 2. BMI : Not applicable(not stated). 3. Renal impairment: Not applicable(not stated).
Indirectness of population	No indirectness

Interventions	<p>(n=37) Intervention 1: Low molecular weight heparin (licensed in UK) - Enoxaparin (20mg once daily – 60mg twice daily). LMWH, standard dose (enoxaparin 40mg 1x daily), started on day of admission and continued for 8 weeks. Duration 8 weeks. Concurrent medication/care: mechanical prophylaxis such as AES</p> <p>(n=37) Intervention 2: No treatment - Usual care. No pharmacological VTE prophylaxis. Duration 8 weeks. Concurrent medication/care: mechanical prophylaxis such as AES</p>
Funding	Funding not stated
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: ENOXAPARIN (20MG ONCE DAILY – 60MG TWICE DAILY) versus USUAL CARE</p> <p>Protocol outcome 1: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge - Actual outcome: DVT: confirmed by colour Doppler venous ultrasonography at 12-16 days; Group 1: 2/37, Group 2: 8/37; Risk of bias: --; Indirectness of outcome: No indirectness</p> <p>Protocol outcome 2: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge - Actual outcome: PE: symptomatic, identified by clinical assessment at 12-16 days; Group 1: 0/37, Group 2: 0/37; Risk of bias: High; Indirectness of outcome: No indirectness - Actual outcome: Fatal PE: symptomatic, identified by clinical assessment at 12-16 days; Group 1: 0/37, Group 2: 0/37; Risk of bias: High; Indirectness of outcome: No indirectness</p> <p>Protocol outcome 3: DVT (symptomatic) at 7-90 days from hospital discharge - Actual outcome: DVT symptomatic at 12-16 days; Group 1: 2/37, Group 2: 2/37; Risk of bias: ; Indirectness of outcome: No indirectness</p>	
Protocol outcomes not reported by the study	<p>All-cause mortality at up to 90 days from hospital discharge; Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge; Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study</p>

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
<p>Merli 1988²²³</p> <p>Country of study: USA</p> <p>Study design: RCT</p> <p>List who was masked to interventions: investigators & patients blinded to heparin and placebo but not electrical stimulation</p> <p>Evidence level: 1+</p> <p>Duration of follow-up: at least 28 days, study aim was for 42 days</p>	<p>Patient group: Acute spinal cord injury</p> <p>Setting: Hospital</p> <p>Inclusion criteria: >15 years old injured <2 weeks before initial evaluation classified as having either motor complete or incomplete-preserved motor, non-functional (C2 to T11) lesions</p> <p>Exclusion criteria: underlying bleeding disorder myocardial infarction <6 months long bone fractures arterial trauma post-phlebotic syndrome lower extremity cellulitis hepatic or renal function twice normal pregnant receiving anticoagulant drugs</p> <p>All patients N: 53 * No. of dropouts: 5</p> <p>Group I</p>	<p>Group I Unfractionated Heparin</p> <p>Start: Unclear Duration: 28 days</p> <p>Dose and Frequency: 5000 IU every 8 hours</p> <p>Group II placebo</p> <p>* 3rd group in trial of UFH + electrical stimulation not reported in this table</p> <p>88 patients evaluated for the study, 34 excluded because of venographically proven DVT before randomisation.</p> <p>Additional non-comparative prophylaxis:</p>	<p>DVT (asymptomatic & symptomatic) (diagnosed by fibrinogen uptake test confirmed by venography. All patients who had normal fibrinogen uptake tests were also screened with bilateral venography to rule out DVT)</p>	<p>Group 1: 8/16 Group 2: 8/17 P value: not significant</p>	<p>Funding: Regional Spinal Cord Injury Centre of Delaware Valley Model SCI Systems grant from National Institute for Disability Research and Rehabilitation</p> <p>Limitations Treatment reduced from 42 to 28 days once found patients being discharged earlier. Unclear how many received 42 days treatment.</p> <p>Outcomes not reported: pulmonary embolism, DVT, major and minor bleeding, heparin induced thrombocytopenia, post-thrombotic syndrome, quality of life, length of stay</p> <p>Additional</p>

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	<p>No. randomised: 19 No. of dropouts: 3 Age (mean): NR M/F: NR Additional risk factors: NR Other factors:</p> <p>Group II No. randomised: 17 No. of dropouts: 0 Age (mean): NR M/F: NR Additional risk factors: NR Other factors:</p>	None reported			<p>outcomes reported:</p> <p>Notes: Study terminated early as investigators in review board concerned about ethics of continuing a trial with 3 groups as 3rd group (UFH + electrical stimulation) significantly better than UFH or placebo.</p>

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
<p>Spinal Cord Injury Thromboprophylaxis Investigators 2003³⁰²</p> <p>Country of study: Multi-centre</p>	<p>Patient group: Spinal Cord Injury (SCI)</p> <p>Setting: Acute SCI treatment unit</p> <p>Inclusion criteria: Age 15 or older Sustained traumatic SCI from spinal cord level C2 to T12 within previous</p>	<p>Group 1 Low Dose Heparin 5000 U subcutaneously every 8 hours + various IPCD to be used at least 22 hours/day Start time: within 72 hours of injury</p>	<p>All-cause mortality (confirmed by: NR)</p>	<p>Group1: 2/246 Group 2: 2/230 P value:</p>	<p>Funding: Rhone-Poulenc Rorer/Aventis Pharmaceuticals manufacturers of enoxaparin Limitations: Over 3/4 of patients randomised were excluded from</p>

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
<p>study in 27 sites across US & Canada</p> <p>Study design: RCT</p> <p>List who was masked to interventions: Investigators blinded</p> <p>Evidence level: 1+</p> <p>Duration of follow-up: 8 weeks</p>	<p>72 hours</p> <p>American Spinal Injury Association (ASIA) classification of A (complete motor or sensory deficit) or B (complete motor and incomplete sensory deficit) or C (incomplete motor deficit and sensory deficit with > half muscles having strength grade <3)</p> <p>Exclusion criteria:</p> <ul style="list-style-type: none"> Objective evidence of bleeding around spinal cord Intracranial bleeding Uncontrolled bleeding at other sites or coagulopathy GI bleeding within previous 2 weeks Pregnancy Conditions precluding use of bilateral IPCD, lower extremity ultrasound or contrast venography Allergy to sulphating agents, heparin or contrast media Uncontrolled hypertension Serum creatinase >2 mg/dL Requirement for anticoagulation as treatment Spinal cord surgery planned for 2 weeks after injury Planned use of aspirin or NSAIDs <p>All patients</p>	<p>Duration: 2 weeks</p> <p>Group 2 LMWH Enoxaparin 30 mg subcutaneously every 12 hours</p> <p>Start time: within 72 hours of injury</p> <p>Duration: 2 weeks</p> <p>Additional non-comparative prophylaxis: Not Applicable</p>			<p>efficacy analysis because they either failed to receive adequate proximal and distal imaging, or discontinued study due to bleeding or platelet counts <100 x 10⁹/L .Data collected for 107 (22.5%) patients remaining were reported with similar baseline characteristics. Outcomes not reported: Symptomatic PE Thigh DVT, Calf DVT Fatal bleeding, Neurological Bleeding Upper GI bleeding, HIT, Post thrombotic syndrome, Pulmonary hypertension Quality of life, Length of Stay</p> <p>Additional</p>

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	<p>N: 476 Age (mean): 36.9 M/F: 389/87 Additional risk factors: BMI: 25.3 ± 4.9 Previous VTE: 3/476 Active Cancer: 3/476 Tetraplegia: 277/476 Paraplegia: 140/476</p> <p>Group 1 No. randomised: 246 No. of dropouts: 2 patients died during treatment phase. 9 discontinued due to bleeding. Dropouts due to other reasons NR</p> <p>Group 2 No. randomised: 230 No. of dropouts: 2 patients died during treatment phase. 6 discontinued due to bleeding. Dropouts due to other reasons NR</p>				<p>outcomes reported: Discontinuations due to bleeding Group 1: 9/246 Group 2: 6/230</p> <p>Proximal DVT Group 1: 6/92 (7%) Group 2: 8/89 (9%)</p> <p>Notes: Randomisation by use of sequential sealed envelopes containing computer generated allocations</p>

H.31 Major trauma

Study	Anglen 1998 ⁸
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=117)

Study	Anglen 1998 ⁸
Countries and setting	Conducted in USA; Setting: Hospital
Line of therapy	Not applicable
Duration of study	Intervention + follow up: 14 days
Method of assessment of guideline condition	Unclear method of assessment/diagnosis: IPCD group: 38 (17-82), FID group: 41 (18-88)
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	All adult trauma patients with a fracture of the pelvic ring, acetabulum, or femur were considered for inclusion in the study
Exclusion criteria	Inability to give informed consent, pre-existing thrombosis or active anticoagulation, or the inability to be randomised because at least one of the devices could not be used
Recruitment/selection of patients	Not reported
Age, gender and ethnicity	Age - Mean (range): IPCD group 41 (18-88), foot pump group 38 (17-82): . Gender (M:F): 65:52. Ethnicity: Not reported
Further population details	1. Active cancer: Not applicable 2. BMI : Not applicable 3. Renal impairment: Not applicable
Indirectness of population	No indirectness
Interventions	<p>(n=72) Intervention 1: Intermittent pneumatic compression devices - Below knee. Knee length IPCD placed on the calf of both legs instituted after surgery or in the case of significant preoperative delay, before surgery. Duration Not stated. Concurrent medication/care: All other aspects of care, including pain medication, therapy, use of continuous passive motion, and mobilisation of the patients were the same for the two groups and were dictated by the treating physicians</p> <p>(n=52) Intervention 2: Foot pumps or foot impulse devices - Foot pumps. NuTech Plexipulse foot pumps were placed on both feet. Duration Not stated. Concurrent medication/care: All other aspects of care, including pain medication, therapy, use of continuous passive motion, and mobilisation of the patients were the same for the two groups and were dictated by the treating physicians</p>
Funding	Funding not stated

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: BELOW KNEE versus FOOT PUMPS

Study	Anglen 1998 ⁸
	<p>Protocol outcome 1: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge - Actual outcome: DVT at 14 days; Group 1: 0/68, Group 2: 3/49; Risk of bias: High; Indirectness of outcome: No indirectness</p> <p>Protocol outcome 2: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge - Actual outcome: PE at 2 months; Risk of bias: High; Indirectness of outcome: Serious indirectness</p>
Protocol outcomes not reported by the study	All-cause mortality at up to 90 days from hospital discharge; Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge; Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study;

Study	Dennis 1993 ⁸¹
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=395)
Countries and setting	Conducted in USA; Setting: Level 1 trauma centre
Line of therapy	Not applicable
Duration of study	Intervention + follow up: Up to 125 days
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: ISS >9
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Not reported
Exclusion criteria	ISS of 9 or less, aged less than 18 years

Study	Dennis 1993 ⁸¹
Recruitment/selection of patients	Not reported
Age, gender and ethnicity	Age - Mean (SD): Prophylaxis groups: 28.6, Control: 27.4. SD not reported. Gender (M:F): Not reported. Ethnicity: Not reported
Further population details	1. Active cancer: Not applicable 2. BMI : Not applicable 3. Renal impairment: Not applicable
Indirectness of population	No indirectness
Interventions	<p>(n=189) Intervention 1: Intermittent pneumatic compression devices - Full leg. Full-length lower extremity sequential compression device. Duration Not reported. Concurrent medication/care: Not reported</p> <p>(n=92) Intervention 2: Unfractionated heparin - Unfractionated heparin (low dose, administered subcutaneously). 5000U twice daily. Duration Not reported. Concurrent medication/care: Not reported</p> <p>(n=114) Intervention 3: No treatment - Usual care. No VTE prophylaxis. Duration Not reported. Concurrent medication/care: Not reported</p>
Funding	Funding not stated

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: FULL LEG versus UNFRACTIONATED HEPARIN (LOW DOSE, ADMINISTERED SUBCUTANEOUSLY)

Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge

- Actual outcome: All-cause mortality at Not reported; Group 1: 2/189, Group 2: 1/92; Risk of bias: Very high; Indirectness of outcome: No indirectness

Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge

- Actual outcome: DVT at Not reported; Group 1: 5/189, Group 2: 3/92; Risk of bias: Very high; Indirectness of outcome: No indirectness

Protocol outcome 3: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge

- Actual outcome: PE at Not reported; Group 1: 0/189, Group 2: 0/92; Risk of bias: Very high; Indirectness of outcome: Serious indirectness

Protocol outcome 4: Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge

- Actual outcome: Fatal PE at Not reported; Group 1: 1/189, Group 2: 1/92; Risk of bias: Very high; Indirectness of outcome: No indirectness

Study	Dennis 1993 ⁸¹
RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: FULL LEG versus USUAL CARE	
<p>Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge - Actual outcome: All-cause mortality at Not reported; Group 1: 2/189, Group 2: 4/114; Risk of bias: Very high; Indirectness of outcome: No indirectness</p>	
<p>Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge - Actual outcome: DVT at Not reported; Group 1: 5/189, Group 2: 10/114; Risk of bias: Very high; Indirectness of outcome: No indirectness</p>	
<p>Protocol outcome 3: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge - Actual outcome: PE at Not reported; Group 1: 0/189, Group 2: 1/114; Risk of bias: Very high; Indirectness of outcome: Serious indirectness</p>	
<p>Protocol outcome 4: Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge - Actual outcome: Fatal PE at Not reported; Group 1: 1/189, Group 2: 1/114; Risk of bias: Very high; Indirectness of outcome: No indirectness</p>	
RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: UNFRACTIONATED HEPARIN (LOW DOSE, ADMINISTERED SUBCUTANEOUSLY) versus USUAL CARE	
<p>Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge - Actual outcome: All-cause mortality at Not reported; Group 1: 1/92, Group 2: 4/114; Risk of bias: Very high; Indirectness of outcome: No indirectness</p>	
<p>Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge - Actual outcome: DVT at Not reported; Group 1: 3/92, Group 2: 10/114; Risk of bias: Very high; Indirectness of outcome: No indirectness</p>	
<p>Protocol outcome 3: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge - Actual outcome: PE at Not reported; Group 1: 0/92, Group 2: 1/114; Risk of bias: Very high; Indirectness of outcome: Serious indirectness</p>	
<p>Protocol outcome 4: Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge - Actual outcome: Fatal PE at Not reported; Group 1: 1/92, Group 2: 1/114; Risk of bias: Very high; Indirectness of outcome: No indirectness</p>	

Study	Dennis 1993 ⁸¹
Protocol outcomes not reported by the study	Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study;

Study	Elliott 1999 ⁹⁰
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=149)
Countries and setting	Conducted in USA; Setting: Shock Trauma-Respiratory Intensive Care Unit
Line of therapy	Not applicable
Duration of study	Intervention + follow up: 8 days
Method of assessment of guideline condition	Unclear method of assessment/diagnosis: ISS not included as inclusion criteria
Stratum	Overall
Subgroup analysis within study	Stratified then randomised: stratified by presence or absence of femoral venous catheters
Inclusion criteria	Patients who were more than 13 years old with recent (within 24 hours) severe head injury (Glasgow Coma Scale score <9) and/or major trauma and were expected to be bedridden for more than 72 hours
Exclusion criteria	Patients with external fixation devices or casts that precluded the use of calf-thigh sequential pneumatic compression devices on either or both legs, patients who were not expected to live more than 24 hours, and patients in whose injuries occurred more than 24 hours before admission to the unit
Recruitment/selection of patients	Consecutive patients
Age, gender and ethnicity	Age - Mean (SD): IPCD group: 33.9 (19.7), FID group: 30.2 (16.0). Gender (M:F): 100:49. Ethnicity: NR
Further population details	1. Active cancer: 2. BMI : 3. Renal impairment:
Indirectness of population	No indirectness
Interventions	(n=74) Intervention 1: Intermittent pneumatic compression devices - Full leg. Calf-thigh sequential pneumatic compression device (Kendall, SCD Compression System, Mansfield, Mass), consisting of four calf and two thigh plastic chambers that inflate sequentially to a pressure of 45mm HG . Duration 8 days . Concurrent medication/care: No AES

Study	Elliott 1999⁹⁰
	<p>or dextran, demopressin acetate, heparin, oral anticoagulants, fibrinolytic agents, dipyridimole, or aspirin were permitted</p> <p>(n=75) Intervention 2: Foot pumps or foot impulse devices - Foot pumps. Plantar venous intermittent pneumatic compression device (PlexipulseR, NuTech, San Antonio, Tex), with a single chamber that inflates for 2 seconds and cycles every 20 seconds. The chamber pressure was set to 160mm Hg. Duration 8 days. Concurrent medication/care: No AES or dextran, demopressin acetate, heparin, oral anticoagulants, fibrinolytic agents, dipyridimole, or aspirin were permitted</p>
Funding	Funding not stated
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: FULL LEG versus FOOT PUMPS</p> <p>Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge - Actual outcome: All-cause mortality at time point not reported; Group 1: 6/74, Group 2: 5/75; Risk of bias: High; Indirectness of outcome: No indirectness</p> <p>Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge - Actual outcome: DVT at 8 days; Group 1: 4/62, Group 2: 13/62; Risk of bias: High; Indirectness of outcome: No indirectness</p> <p>Protocol outcome 3: Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge - Actual outcome: Major bleeding at 8 days; Group 1: 0/62, Group 2: 0/62; Risk of bias: High; Indirectness of outcome: Serious indirectness</p>	
Protocol outcomes not reported by the study	<p>Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge; Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study;</p>

Study	Fuchs 2005 ¹⁰⁹
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=227)
Countries and setting	Conducted in Germany; Setting: Not stated
Line of therapy	Not applicable
Duration of study	Intervention + follow up: 3 months
Method of assessment of guideline condition	Unclear method of assessment/diagnosis
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Patients between 18 and 80 years old, had suffered bony or ligamentous trauma to the spine, the pelvis including the acetabulum or the femur, tibia, or ankle. Those who had total hip replacement following a fracture of the femoral neck were also included.
Exclusion criteria	Patients with multiple trauma, had evidence of decompensated coronary heart disease, advanced peripheral arterial occlusion, severe liver failure, haemorrhagic diathesis, stroke, pregnancy, malignant neoplasia, arthritis and arthrodesis of the lower limb, manifest acute thrombosis or thrombophlebitis, pulmonary embolism, paraplegia, chronic muscular dystrophy, and lack of compliance
Recruitment/selection of patients	Not stated
Age, gender and ethnicity	Age - Mean (SD): Continual motion group: 47.1 (19.7), UFH alone group: 51.9 (19.5). Gender (M:F): 131:96. Ethnicity: NR
Further population details	1. Active cancer: 2. BMI : 3. Renal impairment:
Indirectness of population	No indirectness
Interventions	(n=111) Intervention 1: Continuous passive motion. Passive exercises with Arthroflow device, three times daily for 30 minutes + UFH 5000U three times daily. Duration Not reported . Concurrent medication/care: AES were not used. All patients had intense physiotherapy including breathing exercises, isometric muscle contraction, kinetotherapy, and early mobilisation (n=116) Intervention 2: Unfractionated heparin - Unfractionated heparin (low dose, administered subcutaneously). UFH 5000U 3 times daily. Duration Not reported. Concurrent medication/care: AES were not used. All patients had intense physiotherapy including breathing exercises, isometric muscle contraction, kinetotherapy, and early mobilisation

Study	Fuchs 2005¹⁰⁹
Funding	No funding
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: CONTINUOUS PASSIVE MOTION + UFH versus UNFRACTIONATED HEPARIN (LOW DOSE, ADMINISTERED SUBCUTANEOUSLY)</p> <p>Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge - Actual outcome: All-cause mortality at 3 months; Group 1: 0/111, Group 2: 0/116; Risk of bias: High; Indirectness of outcome: No indirectness</p> <p>Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge - Actual outcome: DVT at 3 months; Group 1: 4/111, Group 2: 29/116; Risk of bias: High; Indirectness of outcome: No indirectness</p> <p>Protocol outcome 3: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge - Actual outcome: PE at 3 months; Group 1: 0/111, Group 2: 0/116; Risk of bias: High; Indirectness of outcome: No indirectness</p>	
Protocol outcomes not reported by the study	Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge; Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study;

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Geerts 1996 218	Patient group: Major trauma patients, adult	Group 1 heparin calcium,	All-cause mortality	Group1: 0/173 Group 2: 2/171	Funding: Ontario Ministry of

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Country of study: Canada	Setting: Level I trauma facility in Canada	5000u, 12hourly.		P value: 0.25 [calculated by NCC-AC team from numbers randomised using Fishers exact test]	Health, Rhone Poulenc Rorer provided study medications, Mallinckrodt Medical Inc. provided contrast agent for venography Limitations: -Single site study -Method of randomisation concealment not well described Outcomes not reported: Upper GI bleeding QoL, Pulmonary hypertension Additional outcomes reported: Blood transfusions: Heparin: 99/173, 3.8±2.6 units Enoxaparin: 101/171, 4.2±3.1 units Marder Scores:
Study design: RCT, double blinded, patients stratified according to the presence or absence of lower extremity fractured	Inclusion criteria: Consecutive adult trauma patients admitted to the trauma centre, who did not have any of the exclusion criteria Exclusion criteria: Any of the following Injury severity score (ISS) <9 Likely to survive or remain in hospital for <7 days Frank intracranial bleeding on computed tomographic scans (cerebral contusion, localized petechial haemorrhages, or diffuse axonal damage were not excluded) Bleeding that remained uncontrolled 36 hours after the injury	Group 2 Enoxaparin (Clexane), 30 mg For both groups: Given as 0.3-ml subcutaneous injections every 12 hours in a blinded fashion with preloaded syringes. Start: within 36 hours of the injury Duration: up to 14 days.	Fatal pulmonary embolism (confirmed by: autopsy)	Group1: 0/173 Group 2: 0/171 P value: 1.00 [calculated by NCC-AC team from numbers randomised using Fishers exact test]	
List who was masked to interventions: Patients and investigators	Systemic coagulopathy; prothrombin time (PTT) >3s above control value Platelet count <50,000/mm ³ Needed therapeutic anticoagulation	Additional non-comparative prophylaxis: No mechanical or other pharmacologic methods of antithrombotic	Symptomatic pulmonary embolism (Confirmed by: ventilation perfusion scan in patients with clinical presentation. Patients with non-diagnostic scans underwent pulmonary angiography, venous ultrasonography, contrast venography, or a combination of these, if necessary, within 24 hours after the scanning)	Group1: 0/136 Group 2: 1/129 P value: 0.49 [calculated by NCC-AC team from numbers randomised using Fishers exact test]	
Evidence level: 1++					

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Duration of follow-up: Up to 14 days	Cannot undergo venography (allergy to contrast material) renal failure (defined as a serum creatinine level higher than 3.4 mg per decilitre [300 µmol per litre]) pregnant venous access could not be achieved because of amputation or a major foot injury All patients N: 344 No of dropouts: 13 No of patients with sufficient venography: 265 (77%) M/F: 192/265* 99/136 group 1, 93/129 Group2 Group 1 No. randomised: 173 No. of dropouts: 7 Additional risk factors*: - Age (year): 37.0±16.5 - ISS: 22.7±9.0 Predicted risk of DVT [†] : 54.7±26.3 Surgery performed: 119/136, Blood transfusion in the first 24 hours: 48/136, Maximal mobility (mean of daily corrected score): 2.4±1.0	prophylaxis were allowed by the protocol The study drug was generally not withheld in the event of a surgical procedure, although in exceptional circumstances such as spinal fixation, a single preoperative dose was permitted to be withheld. Treatment with the study medication was then resumed at the first dosing time after the operation.	DVT, asymptomatic or symptomatic (confirmed by: venography of both legs with ioversol, a non-ionic contrast agent between Day 10 and 14, or just before discharged if it occurred earlier. DVT was defined as a constant intraluminal filling defect in a deep leg vein that was seen on ≥2. See above for symptomatic DVT))	Group1: 60/136 Group 2: 40/129 P value: 0.014 (reported) [P=0.03, calculated by NCC-AC team from numbers randomised using Fishers exact test]	Heparin (n=136): 2.3±5.0 Enoxaparin (n=129): 1.0±2.8 (P value: 0.012 by Wilcoxon rank sum test provided by report) Notes: Out of 1076 admissions into the unit, 698 (64.9%) were not eligible The neurological bleeding cases were included in major bleeding.
			Thigh DVT (confirmed by: Proximal-vein thrombosis was defined as thrombosis involving the popliteal or more proximal veins.)	Group1: 20/136 Group 2: 8/129 P value: 0.012 [P=0.03, calculated by NCC-AC team from numbers randomised using Fishers exact test]	
			Calf DVT (confirmed by: see DVT)	Group1: 40/136 Group 2: 32/129 P value: 0.27 [calculated by NCC-AC team from numbers randomised using Fishers exact test]	
			Fatal bleeding (description: confirmed by autopsy)	Group1: 0/173 Group 2: 0/171 P value: 1.0	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	<p>Hospital stay (days): 23.5±13.8</p> <p>Site of major injury:</p> <p>Head: 6/136</p> <p>Face, chest, abdomen: 53/136 Spine: 24/136</p> <p>Lower limb (orthopaedic injury): 75/136</p> <p>Group 2</p> <p>No. randomised: 171 No. of dropouts: 6</p> <p>Additional risk factors*:</p> <ul style="list-style-type: none"> - Age (year): 39.1±16.8 - ISS: 23.1±8.3 <p>Predicted risk of DVT†: 53.5±25.4</p> <p>Surgery performed: 107/129</p> <p>Blood transfusion in the first 24 hours: 55/129</p> <p>Maximal mobility (mean of daily corrected score): 22.4±1.0</p> <p>Hospital stay (days): 26.0± 15.4</p> <p>Site of major injury:</p> <p>Head: 7/129</p> <p>Face, chest, abdomen: 47/129</p> <p>Spine: 16/129</p> <p>Lower limb (orthopaedic injury): 69/129</p> <p>* Information based on patients with adequate venography (n=265)</p> <p>†Predicted risk of thrombosis was</p>		<p>Major bleeding (description: Sites: chest tube, 1000ml of epistaxis, intraoperative, subdural haematoma, facial soft tissues, retroperitoneum)</p> <p>Neurological bleeding (Subdural haematoma with hemiparesis 4 days after craniotomy for severe skull fracture)</p> <p>Heparin induced thrombocytopenia (confirmed by heparin-dependent IgG antibodies)</p> <p>Length of stay</p>	<p>Group1: 1/173</p> <p>Group 2: 5/ 171</p> <p>P value: 0.12</p> <p>[calculated by NCC-AC team from numbers randomised using Fishers exact test]</p> <p>Group1: 0/ 173</p> <p>Group 2: 1/171</p> <p>P value: 0.50</p> <p>[calculated by NCC-AC team from numbers randomised using Fishers exact test]</p> <p>Group1: 2/173</p> <p>Group 2: 0/ 171</p> <p>P value: 0.50</p> <p>[calculated by NCC-AC team from numbers randomised using Fishers exact test]</p> <p>Group1: 23.5±13.8</p> <p>Group 2: 26.0± 15.4</p> <p>P value:</p>	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	calculated using this formula: $e^x / 1 + e^x$				

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Ginzburg 2003 222	Patient group: High risk trauma patients with injury severity score >9	Group 1 IPCD (Huntleigh Flowtron).	All-cause mortality (confirmed by:)	Group1: 0/224 Group 2: 0/218 P value: NR	Funding: Partly funded by Huntleigh Flowtron. Limitations: Statistics analysis changed part way through due to low incidence of DVT identified.
Country of study: USA	259/422 ISS 9-19 148/422 ISS >19	Start time: within 24hrs of trauma	Fatal pulmonary embolism (confirmed by:)	Group1: 0/224 Group 2: 0/218 P value: NR	
Study design: RCT	Setting: Trauma centre	End time: until walking independently or discharge from hospital	Symptomatic pulmonary embolism (confirmed by: clinical suspicion verified by spiral computed tomography or ventilation-perfusion scintigraphy)	Group1: 1/224 Group 2: 1/218 P value: Not significant.	
List who was masked to	Inclusion criteria: <ul style="list-style-type: none"> At least one leg and one arm available for IPCD 	Duration: Maximum disuse			

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
<p>interventions: No one</p> <p>Evidence level: 1+</p> <p>Duration of follow- up: 30 days or until discharge from hospital.</p>	<p>No need systemic anticoagulation No contraindications to LMWH</p> <p>Exclusion criteria: <18's ISS <9 Patients who were unlikely to survive for at least 7 days Renal failure Pregnant patients Patients unable to undergo Doppler US screening Patients with BMI>25kg/m2 Patients with contraindication to anticoagulation, e.g. intracranial bleeding or uncontrolled haemorrhage.</p> <p>All patients N: 422 Age (mean): Group 1- 40 Group 2 - 42 M/F: 337:115 Additional risk factors: MI: 12 CHF: 7 COPD:8 Obesity: 7 Cancer: 6</p> <p>Group 1 No. randomised: 224 No. of dropouts: 15</p>	<p>allowed– 8 hours consecutively</p> <p>Length: calf length (DVT10), compression: 40mmHg on a 60s cycle. First sleeve inflate 12 secs, deflate 48s then repeated in second sleeve.</p> <p>Group 2 LMWH (enoxaparin) Start time: within 24 hrs of trauma End time: until walking independently or discharge from hospital Duration: Dose and frequency: 30mg subcutaneously every 12hrs. Withheld 12hrs before any surgical intervention (max 2 doses missed).</p>	<p>DVT, asymptomatic or symptomatic (screened for by: Doppler ultrasonography weekly and when DVT was suspected.)</p> <p>Fatal bleeding (description:)</p> <p>Major bleeding (description: haemorrhage leading to a fall in haemoglobin conc. of 2 g/dl, transfusion of 2 or more of packed red blood cells, intracranial or retroperitoneal bleeding or bleeding requiring surgical intervention)</p> <p>Minor bleeding (description: excessive bleeding from operative sites, gastrointestinal bleeding and/ or haematuria that did not meet the criteria for major bleeding)</p> <p>Length of stay</p>	<p>Group1: 6/224 Group 2: 1/218 P value: 0.122 Break down is provided for severity USS 9- 19: Gp 1: 4 Gp2: 1 USS >19: Gp 1: 2 Gp2: 0</p> <p>Group1: 0/224 Group 2: 0/218 P value: NR</p> <p>Group1: 4/224 Group 2: 4/218 P value: NR</p> <p>Group1: 4/224 Group 2: 9/218 P value: 0.245</p> <p>Group1: 20.9 (33.4) Group 2: 15.5 (15.0) P value: 0.040</p>	<p>Intention to treat analysis not completed.</p> <p>Outcomes not reported: Asymptomatic PE, location of DVT, HIT, PTS, Pulmonary hypertension, QoL</p> <p>Notes: Where patients could not use leg for IPCD – it was placed on arm. 2 DVTs occurred in patients with IPCD on one leg and one arm. Subgroups by injury severity.</p> <p>Some patients underwent surgery during the study but there is no indication of</p>

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	Group 2 No. randomised: 218 No. of dropouts: 29	Additional non-comparative prophylaxis: None			how many and in which groups.

Study	Knudson 1994 ¹⁷³
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=251)
Countries and setting	Conducted in USA; Setting: Trauma centre
Line of therapy	Not applicable
Duration of study	Intervention + follow up: At least 3 weeks
Method of assessment of guideline condition	Unclear method of assessment/diagnosis
Stratum	Overall
Subgroup analysis within study	Not applicable

Study	Knudson 1994 ¹⁷³
Inclusion criteria	One of the following: laparotomy, thoracotomy, ventilated >24 hours, spine fracture, pelvic fracture, femur fracture
Exclusion criteria	Patients who were younger than 18 years, pregnant or prisoners, and those found to already have DVT on the initial venous imaging study
Recruitment/selection of patients	Not reported
Age, gender and ethnicity	Age - Mean (range): 38 (18-90). Gender (M:F): 200:51. Ethnicity: Not reported
Further population details	1. Active cancer: Not applicable 2. BMI : Not applicable3. Renal impairment: Not applicable
Indirectness of population	No indirectness
Interventions	<p>(n=63) Intervention 1: Unfractionated heparin - Unfractionated heparin (low dose, administered subcutaneously). Low dose heparin administered subcutaneously every 12 hours. Duration Not reported. Concurrent medication/care: Not reported</p> <p>(n=58) Intervention 2: Intermittent pneumatic compression devices - Full leg. Thigh length sequential gradient pneumatic compression devices and AES. Prophylactic measures were instituted as soon as possible following the screening duplex venous examination and always within 24 hours of admission. Duration Not reported . Concurrent medication/care: Not reported</p> <p>(n=130) Intervention 3: No treatment - Usual care. No treatment group. Duration Not reported . Concurrent medication/care: Not reported</p>
Funding	Study funded by industry (Supported by the Kendall Healthcare Products Company)

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: UNFRACTIONATED HEPARIN (LOW DOSE, ADMINISTERED SUBCUTANEOUSLY) versus FULL LEG + AES

Protocol outcome 1: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge

- Actual outcome: DVT at 3 weeks; Group 1: 1/44, Group 2: 4/32; Risk of bias: ; Indirectness of outcome: No indirectness

Protocol outcome 2: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpsect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge

- Actual outcome: PE at 3 weeks; Group 1: 0/44, Group 2: 0/32; Risk of bias: ; Indirectness of outcome: No indirectness

Study	Knudson 1994 ¹⁷³
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: UNFRACTIONATED HEPARIN (LOW DOSE, ADMINISTERED SUBCUTANEOUSLY) versus USUAL CARE</p>	
<p>Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge - Actual outcome for People who are contraindicated for mechanical prophylaxis: All-cause mortality at 3 weeks; Group 1: 0/19, Group 2: 1/27; Risk of bias: ; Indirectness of outcome: No indirectness</p> <p>Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge - Actual outcome: DVT at 3 weeks; Group 1: 1/44, Group 2: 2/64; Risk of bias: ; Indirectness of outcome: No indirectness - Actual outcome for People who are contraindicated for mechanical prophylaxis: DVT at 3 weeks; Group 1: 1/19, Group 2: 2/27; Risk of bias: ; Indirectness of outcome: No indirectness</p> <p>Protocol outcome 3: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQspect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge - Actual outcome: PE at 3 weeks; Group 1: 0/44, Group 2: 1/64; Risk of bias: ; Indirectness of outcome: No indirectness</p>	
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: FULL LEG + AES versus USUAL CARE</p>	
<p>Protocol outcome 1: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge - Actual outcome: DVT at 3 weeks; Group 1: 4/32, Group 2: 2/64; Risk of bias: Very high; Indirectness of outcome: No indirectness - Actual outcome for People who are contraindicated for pharmacological prophylaxis: DVT at 3 weeks; Group 1: 0/26, Group 2: 5/39; Risk of bias: ; Indirectness of outcome: No indirectness</p> <p>Protocol outcome 2: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQspect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge - Actual outcome: PE at 3 weeks; Group 1: 0/32, Group 2: 1/64; Risk of bias: ; Indirectness of outcome: No indirectness</p>	
<p>Protocol outcomes not reported by the study</p>	<p>Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge; Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQspect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days</p>

Study	Knudson 1994¹⁷³
	from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study;

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
---------------	----------	---------------	------------------	-------------	----------

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
<p>Knudson 1996¹⁷⁴</p> <p>Country of study: USA</p> <p>Study design: RCT</p> <p>List who was masked to interventions: None</p> <p>Evidence level: 1+</p> <p>Duration of follow-up: Not reported.</p>	<p>Patient group: Trauma</p> <p>Setting: San Fransisco General Hospital Trauma Center.</p> <p>Inclusion criteria: Patients admitted to trauma centre meeting one or more of the following conditions: Injury Severity Score >10 Abbreviated Injury Scale score >3 in any category (n=316) Head injury with Glasgow Coma Scale <8 (n=42) unstable spine fracture without neurologic deficit (n=16) stable spine fracture with deficit (n=25) major pelvic fracture (n=13) fracture of the lower extremity above the ankle (n=101) age >50 (n=78)</p> <p>Exclusion criteria:</p>	<p>All interventions started within 24 hours of admission. Not stated for how long the study continued. Possibly until discharge or transfer to another unit.</p> <p>Group 1 LMWH (enoxaparin, Rhone Poulne), 30mg subcutaneously every 12 hours</p> <p>Group 2 bilateral sequential gradient compression devices (SCD) (length not stated) and AES</p>	<p>All-cause mortality</p> <p>Fatal pulmonary embolism (confirmed by: autopsy)</p>	<p>Group1: 0/120 Group 2: 0/82 P value: NA</p> <p>Group1: 0/120 Group 2: 0/82 P value: NA</p>	<p>Funding: Supported by grant from Rhone Poulne</p> <p>Outcomes not reported: All-cause mortality, symptomatic, calf, thigh and/or proximal DVT, heparin induced thrombocytopenia, post-thrombotic syndrome, bleeding outcomes, pulmonary hypertension, quality of life & length of stay</p> <p>Additional outcomes reported: Bleeding from drain site, reoperation for bleeding, drop in haematocrit, bruise at injection site, non-compliance</p>

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	<p>presence of DVT</p> <p>major neurologic injury (head or spinal)</p> <p>presence of solid organ injury managed non-operatively</p> <p>coagulation abnormalities or active bleeding beyond 36 hours</p> <p>neck hematomas secondary to initial trauma</p> <p>platelet counts <50,000 at 24 hours after injury</p> <p>All patients</p> <p>N: 202</p> <p>Age (mean): 38.6 years</p> <p>M/F: NR</p> <p>Additional risk factors: NR</p> <p>Group 1</p> <p>No. randomised: 120</p> <p>No. of dropouts: 0</p> <p>Group 2</p> <p>No. randomised: 82</p> <p>No. of dropouts: 0</p>	<p>TED (Kendall Healthcare Products) 61/82</p> <p>OR</p> <p>arteriovenous impulse device (AVI) requiring only a foot pad if unable to wear</p> <p>SCD 21/82</p> <p>Additional non-comparative prophylaxis: none</p>	<p>Symptomatic pulmonary embolism (confirmed by: ventilation perfusion scan)</p> <p>DVT, asymptomatic or symptomatic (confirmed by: duplex ultrasonography)</p>	<p>Group1: 0/120</p> <p>Group 2: 0/82</p> <p>P value: NA</p> <p>Group1: 1/120</p> <p>Group 2: 2/82</p> <p>P value: NR</p> <p>p = 0.57 *</p>	<p>rate, units of blood transfusion</p> <p>Specific details of patients with DVT occurring during study period.</p> <p>Notes:</p> <p>* p values calculated by NCC-AC using Fisher Exact test.</p> <p>The paper also includes a 3rd arm of patients (not reported here) of patients excluded from this randomised part and all assigned to mechanical compression</p>

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
			Length of stay (mean no. of hospital days)	Group1: 12.7 days (n=120) Group 2: 11 days (n=82) P value: not significant	

Study	Kurtoglu 2004 ¹⁸⁰
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=120)
Countries and setting	Conducted in Turkey; Setting: ICU
Line of therapy	Not applicable
Duration of study	Intervention + follow up: 1 week post discharge
Method of assessment of guideline condition	Unclear method of assessment/diagnosis
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Patients with severe head/spinal injuries
Exclusion criteria	Patients younger than 14 years old, those with hepatic or urinary dysfunction, a spinal cord injury, a history of DVT, or a high bleeding risk, and those using anticoagulants

Study	Kurtoglu 2004 ¹⁸⁰
Recruitment/selection of patients	Not stated
Age, gender and ethnicity	Age - Median (range): 37.1 (18-76). Gender (M:F): 47:73. Ethnicity: not reported
Further population details	1. Active cancer: Not applicable 2. BMI : Not applicable 3. Renal impairment: Not applicable
Indirectness of population	No indirectness
Interventions	<p>(n=60) Intervention 1: Intermittent pneumatic compression devices - Below knee. Below knee IPCD (prophylactic DVT system, model AC 550; Flowtron Excell or AV impulse system, Duo; Novamedix) applied following admission to ICU. Duration Not reported. Concurrent medication/care: Not reported</p> <p>(n=60) Intervention 2: Low molecular weight heparin (licensed in UK) - Enoxaparin (20mg once daily – 60mg twice daily). 40mg 1 x daily. Duration Not reported. Concurrent medication/care: All patients received IPCD on admission, and initiation of LMWH was determined after CT within 24 hours of admission</p>
Funding	Funding not stated

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: BELOW KNEE versus ENOXAPARIN (20MG ONCE DAILY – 60MG TWICE DAILY)

Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge

- Actual outcome: All-cause mortality at not reported; Group 1: 7/60, Group 2: 8/60; Risk of bias: Very high; Indirectness of outcome: No indirectness

Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge

- Actual outcome: DVT at not reported; Group 1: 4/60, Group 2: 3/60; Risk of bias: High; Indirectness of outcome: No indirectness

Protocol outcome 3: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQspect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge

- Actual outcome: PE at not reported; Group 1: 0/60, Group 2: 0/60; Risk of bias: High; Indirectness of outcome: No indirectness

Protocol outcome 4: Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge

- Actual outcome: Major bleeding at not reported; Group 1: 0/60, Group 2: 0/60; Risk of bias: High; Indirectness of outcome: Serious indirectness

Study	Kurtoglu 2004¹⁸⁰
<p>Protocol outcome 5: Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge - Actual outcome: Fatal PE at not reported; Group 1: 5/60, Group 2: 4/60; Risk of bias: High; Indirectness of outcome: No indirectness</p>	
Protocol outcomes not reported by the study	Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study;

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Stannard et al., 2006 620 [US] Study design: RCT List who was masked to interventions:	Patient group: Patients with recent blunt skeletal trauma (i.e. starting at admission) Setting: Hospital admission / ward Inclusion criteria: blunt trauma and at least one of the following –	Group 1 Enoxaparin (30mg administered subcutaneously twice a day) Start time: 24 – 48 hours after blunt trauma once severe bleeding associated with trauma had been	All-cause mortality Fatal pulmonary embolism Symptomatic pulmonary embolism, (not stated how confirmed only states „underwent test“ to exclude)	Group1: 0/103 Group 2: 0/97 P value: NA Group1: 0/103 Group 2: 0/97 P value: NA Group1: 0/103 Group 2: 2/97 P value: 1.00 (Not Sig)	Funding: "In support of their research for or preparation of this manuscript one or more of the authors received grants or outside funding from Aventis Pharmaceutical

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
<p>NA</p> <p>Evidence level: 1+</p> <p>Duration of follow-up: Mean 17 months (range 6 – 38months)</p>	<ul style="list-style-type: none"> An Abbreviated Injury score of 3 or more and a long bone fracture Multiple (2 or more) long bone fractures An age of more than 55 years and a long bone fracture. <p>All patients were 18+ yrs, had no contraindication for anticoagulation and had been admitted to hospital less than 2 hours after time of trauma or had a negative magnetic resonance venogram prior to enrolment.</p> <p>Exclusion criteria: renal insufficiency, severe cranial or spinal cord injury; the use of anticoagulants; any contraindication to anticoagulation, including severe active bleeding; pregnancy; a history of venous thromboembolic disease; any contraindication to magnetic resonance venography; the presence of vena cava filters; and severe ocular trauma.</p> <p>All patients N: 200 Age (mean): 39.6 (range 19-80) M/F: NR</p>	<p>controlled. Anyone not able to start within 72 hours excluded from study.</p> <p>Group 2 Pulsatile foot pumps at time of admission (patients asked to use it for at least 12 hours per day) combined with enoxaparin on a delayed basis (5 days after admission) after all acute bleeding from blunt trauma had been resolved.</p> <p>NB: Prophylaxis was given for duration of hospital stay.</p> <p>If patients required a return to the operating theatre, the enoxaparin was</p>	<p>DVT, asymptomatic or symptomatic (confirmed by: bilateral magnetic resonance venography and ultrasonography within 24 hours before discharge or as soon as they developed signs or symptoms of DVT)</p> <p>Symptomatic DVT (confirmed by: magnetic resonance venography and ultrasonography within 24 hours before discharge or as soon as they developed signs or symptoms of DVT)</p> <p>Fatal bleeding</p> <p>Neurological bleeding</p>	<p>Group1: 9/103 Group 2: 13/97 P value: 0.2365 (Not Sig)</p> <p>Group1: 1/103 Group 2: 1/97 P value: NS</p> <p>Group1: 0/103 Group 2: 0/97 P value: NA</p> <p>Group 1: 1/103 Group2: 1/97 P value: 0.7362 (Not Sig)</p>	<p>Grant in Aid. No commercial entity paid or directed, or agreed to pay or direct, any benefits to any research fund, foundation, educational institution, or other charitable or non-profit organisation with which the authors are affiliated or associated".</p> <p>Limitations: unclear how patients were randomised. No intention to treat analysis (10.7% dropout rate). Lack of bleeding data.</p> <p>Outcomes not</p>

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
		discontinued on the night prior to surgery and resumed within 12 hours after surgery.			reported: Upper GI bleeding Major bleeding Minor bleeding Heparin induced thrombocytopenia Post thrombotic syndrome Quality of life Pulmonary hypertension
	<p>Additional risk factors: Injury severity score (mean): 14.42 (range 4-57) Weight (mean): In kgs: 85.7 (range: 45.4 – 158.8) In lbs: 189 (range: 100 – 350)</p> <p>Group 1 No. randomised: 103 No. of dropouts: 0 Age (mean): 41.0(range 19-80) Additional risk factors: Injury severity score (mean): 14.43 (range 4-41) Weight (mean): In kgs: 86.2 (range: 45.4 – 158.8) In lbs: 190 (range: 100 – 350)</p> <p>Group 2</p>		Length of stay	Group 1: 13.8 days (range: 3-68 days) Group2: 11.2 (range: 1-119 days) P value: NR (unable to calculate)	Additional outcomes reported: No. of DVTs that were occlusive (significantly more in Group 1 i.e. 11 compared to 3, p=0.025) Mean number of fractures per patient (by DVT vs. no DVT). % with acetabular fracture for DVT vs no DVT in each group. Mean duration of prophylaxis by DVT development. Mean duration of foot pump use

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	<p>No. randomised: 97 No. of dropouts: 0 Age (mean): 38.2(range 19-75) Additional risk factors: Injury severity score (mean): 14.41 (range 8-57) Weight (mean): In kgs: 84.8 (range: 46.3 – 153.3) In lbs: 187 (range: 102 – 338)</p> <p>[NB: 24/224 (10.7%) did not complete the protocol and are excluded from the results, 5 because of erroneous discharge before studies were obtained, 5 because of claustrophobia in MRI scanner, 5 because of bleeding that required discontinuation of anticoagulants, 4 withdrew from the study, 3 had errors in medication and two had other medical problems that required discontinuation of anticoagulants.]</p>				<p>(13.3 hrs per day, range 1-23 hrs) Time of prophylaxis initiation against DVT Mean number of surgical procedures per patient (by DVT vs. no DVT). No. of wound infections, wound hematomas at surgical site and other site, pseudoaneurysm, large hematoma. Prevalence of high risk skeletal injuries</p>

H.32 Abdominal surgery (excluding bariatric surgery)

Study	Agnelli 2005 ¹
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=2927)
Countries and setting	Conducted in Multiple countries; Setting: Hospital
Line of therapy	--Please Select--
Duration of study	Intervention + follow up: 30 days
Method of assessment of guideline condition	Adequate method of assessment/diagnosis
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Patients due to undergo abdominal surgery expected to last more than 45 minutes and were aged over 60 year, or aged over 40 years with one or more additional risk factors for thromboembolic complications, including obesity (BMI >30 for men and >28.6 for women), a history of venous thromboembolism, congestive obstructive pulmonary disease, inflammatory bowel disease, or surgery for cancer
Exclusion criteria	Patients who were having urological, gynaecological, laparoscopic, vascular or emergency trauma surgery. Also, patients with a life expectancy less than 2 months, active bleeding, a document bleeding disorder or thrombocytopenia, ulcerating or angiodysplastic gastrointestinal disease that was not the reason for surgery, a haemorrhagic stroke or surgery of the brain, spine or eye within the previous 3 months, bacterial endocarditis or another contraindication to anticoagulant therapy, pregnancy, hypersensitivity to contrast media, or a serum creatinine concentration above 180 µmol/l in a well hydrated patient
Recruitment/selection of patients	Not reported
Age, gender and ethnicity	Age - Median (range): Fondaparinux group: 66 (31-92), LMWH group: 65 (17-93). Gender (M:F): 1584:1274. Ethnicity: Not reported
Further population details	1. Active cancer: Not applicable (Mixed population (67-70% cancer surgery)). 2. Acute/elective: Not applicable 3. BMI : Mixed (22% BMI >30). 4. Laparoscopic/open surgery: Open surgery (Laparoscopic surgery was excluded). 5. Renal impairment: Not applicable
Indirectness of population	No indirectness
Interventions	(n=1465) Intervention 1: Fondaparinux - Fondaparinux (all doses). Fondaparinux 2.5mg. The first injection was 6 hours after surgical closure. Patients received a placebo injection 2 hours before surgery and again 12 hours later to

	<p>correspond with the LMWH schedule. Duration 5-9 days. Concurrent medication/care: Patients were discouraged from using aspirin, thienopyridines and non-steroidal anti-inflammatory drugs, but the use of AES was permitted and early mobilisation was recommended. Indirectness: No indirectness</p> <p>(n=1462) Intervention 2: Low molecular weight heparin (licensed in UK) - Dalteparin (1,250 units once daily - 5,000 units twice daily). 2500 units given 2 hours before induction of anaesthesia and 12 hours later, then once daily at a dose of 5000 units. Patients received a placebo injection 6 hours after surgery to correspond with the fondaparinux schedule. Duration 5-9 days. Concurrent medication/care: Patients were discouraged from using aspirin, thienopyridines and non-steroidal anti-inflammatory drugs, but the use of AES was permitted and early mobilisation was recommended. Indirectness: No indirectness</p>
Funding	Study funded by industry (Supported by a grant Sanofi-Synthelabo and NV Organon)
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: FONDAPARINUX (ALL DOSES) versus DALTEPARIN (1,250 UNITS ONCE DAILY - 5,000 UNITS TWICE DAILY)</p> <p>Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge - Actual outcome: All-cause mortality at 32 days; Group 1: 40/1433, Group 2: 55/1425 Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 32; Group 2 Number missing: 37</p> <p>Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge - Actual outcome: DVT at 32 days; Group 1: 43/1024, Group 2: 59/1018 Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 441; Group 2 Number missing: 444</p> <p>Protocol outcome 3: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge - Actual outcome: PE at 32 days; Group 1: 2/1465, Group 2: 0/1462 Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0</p> <p>Protocol outcome 4: Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening</p>	

clinical event at up to 45 days from hospital discharge

- Actual outcome: Major bleeding at 7-11 days; Group 1: 49/1433, Group 2: 34/1425

Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 32; Group 2 Number missing: 37

Protocol outcome 5: Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge

- Actual outcome: Fatal PE at 7-11 days; Group 1: 3/1465, Group 2: 3/1462

Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0

Protocol outcomes not reported by the study

Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study;

Study	Allan 1983 ⁴
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=200)
Countries and setting	Conducted in United Kingdom; Setting: Hospital
Line of therapy	1st line
Duration of study	Intervention + follow up: 7 days
Method of assessment of guideline condition	Adequate method of assessment/diagnosis
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Patients over the age of 40 years undergoing elective abdominal surgery of at least 30 minutes duration
Exclusion criteria	Patients with a history of previous DVT or PE, or found to have varicose veins or superficial vein thrombosis, or receiving steroid or anticoagulation
Recruitment/selection of patients	Not reported
Age, gender and ethnicity	Age - Range: 40-80+. Gender (M:F): 100:100. Ethnicity: Not reported
Further population details	1. Active cancer: Not applicable (50% had a malignant disease). 2. Acute/elective: Elective 3. BMI : Not applicable 4. Laparoscopic/open surgery: Not applicable 5. Renal impairment: Not applicable
Indirectness of population	No indirectness
Interventions	(n=97) Intervention 1: Anti-embolism stockings - Mixed above/below knee. TED stockings on both legs, fitted the evening before the operation and worn for at least 7 days after. Duration 7 days . Concurrent medication/care: Not stated . Indirectness: No indirectness (n=103) Intervention 2: No treatment - Usual care. Control group did not wear AES. No further details reported . Duration Not reported. Concurrent medication/care: Not reported. Indirectness: No indirectness
Funding	Equipment / drugs provided by industry (Stockings and fibrinogen supplied by Kendall Company)
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: MIXED ABOVE/BELOW KNEE versus USUAL CARE</p> <p>Protocol outcome 1: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge - Actual outcome: DVT at 7 days; Group 1: 15/97, Group 2: 37/103</p>	

Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Baseline details: Only age and sex reported; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcomes not reported by the study

All-cause mortality at up to 90 days from hospital discharge; Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge; Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge; Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study;

Study	Allen 1978 ⁵
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=60)
Countries and setting	Conducted in United Kingdom; Setting: Hospital
Line of therapy	1st line
Duration of study	Not clear:
Method of assessment of guideline condition	Adequate method of assessment/diagnosis
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Patients undergoing transurethral prostatectomy
Exclusion criteria	Not reported
Recruitment/selection of patients	Not reported
Age, gender and ethnicity	Age - Other: Average age - UFH group: 71.2, control group: 71.9. Gender (M:F): Not reported. Ethnicity: Not reported
Further population details	1. Active cancer: Not applicable 2. Acute/elective: Not applicable 3. BMI : Not applicable 4. Laparoscopic/open surgery: Not applicable 5. Renal impairment: Not applicable
Indirectness of population	No indirectness
Interventions	(n=30) Intervention 1: Unfractionated heparin - Unfractionated heparin (low dose, administered subcutaneously). 5000 units of subcutaneous calcium heparin, administered 2 hours before operation and then 12-hourly until the patient left hospital . Duration Not reported . Concurrent medication/care: Not reported . Indirectness: No indirectness (n=30) Intervention 2: No treatment - Usual care. Control group. No further details given . Duration Not reported. Concurrent medication/care: Not reported. Indirectness: No indirectness
Funding	Funding not stated
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: UNFRACTIONATED HEPARIN (LOW DOSE, ADMINISTERED SUBCUTANEOUSLY) versus USUAL CARE</p> <p>Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge - Actual outcome: All-cause mortality at Time-point not reported; Group 1: 0/30, Group 2: 0/30</p>	

Risk of bias: All domain - High, Selection - Very high, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge

- Actual outcome: DVT at Time-point not reported; Group 1: 0/30, Group 2: 0/30

Risk of bias: All domain - High, Selection - Very high, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - High, Crossover - Low;

Indirectness of outcome: Serious indirectness, Comments: Method of confirmation not reported; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcome 3: Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge

- Actual outcome: Major bleeding at Time-point not reported; Group 1: 6/30, Group 2: 0/30

Risk of bias: All domain - High, Selection - Very high, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcomes not reported by the study

Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge; Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study;

Study	Bejjani 1983 ¹⁸
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=34)
Countries and setting	Conducted in USA; Setting: Not reported
Line of therapy	Not applicable
Duration of study	Not clear:
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: Patients undergoing transurethral prostatectomy
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Not reported
Exclusion criteria	Patients who had bleeding disorders, a contraindication for anticoagulation, or were on drugs affecting coagulation
Recruitment/selection of patients	Not reported
Age, gender and ethnicity	Age - Mean (SD): Not reported. Gender (M:F): Not reported. Ethnicity: Not reported
Further population details	1. Active cancer: Not applicable (Mixed 38% had cancer). 2. Acute/elective: Not applicable 3. BMI : Not applicable 4. Laparoscopic/open surgery: Not applicable 5. Renal impairment: Not applicable
Indirectness of population	No indirectness
Interventions	(n=17) Intervention 1: Unfractionated heparin - Unfractionated heparin (low dose, administered subcutaneously). UFH 5000 units of sodium heparin, started 3 hours preoperatively and every 12 hours thereafter for 48 hours. Duration 2 days. Concurrent medication/care: Not reported. Indirectness: No indirectness (n=17) Intervention 2: No treatment - Placebo. Placebo. 2ml of normal saline three hours preoperatively and every 12 hours thereafter for 48 hours . Duration 2 days. Concurrent medication/care: Not reported. Indirectness: No indirectness
Funding	Funding not stated
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: UNFRACTIONATED HEPARIN (LOW DOSE, ADMINISTERED SUBCUTANEOUSLY) versus PLACEBO</p> <p>Protocol outcome 1: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQspect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge - Actual outcome: PE at time-point not reported; Group 1: 0/17, Group 2: 1/17</p>	

Risk of bias: All domain - High, Selection - Very high, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcome 2: Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge

- Actual outcome: Major bleeding at time-point not reported; Group 1: 1/17, Group 2: 0/17

Risk of bias: All domain - High, Selection - Very high, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcomes not reported by the study

All-cause mortality at up to 90 days from hospital discharge; Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge; Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study;

Study	Bergqvist 1980 ²⁶
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=97)
Countries and setting	Conducted in Sweden; Setting: Hospital
Line of therapy	Not applicable
Duration of study	Intervention + follow up: 7 days
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: General and urological surgery (>80% abdominal)
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Patients over the age of 50 admitted for elective general and urologic surgery
Exclusion criteria	Not reported
Recruitment/selection of patients	Not reported
Age, gender and ethnicity	Age - Mean (range): LMWH group: 66.7 (52-89), control group: 66.7 (51-85). Gender (M:F): 66:34. Ethnicity: Not reported
Further population details	1. Active cancer: Not applicable (Mixed 22% malignant disease). 2. Acute/elective: Elective 3. BMI : Not applicable 4. Laparoscopic/open surgery: Not applicable 5. Renal impairment: Not applicable
Indirectness of population	No indirectness
Interventions	(n=53) Intervention 1: Unfractionated heparin - Unfractionated heparin (low dose, administered subcutaneously). Low dose heparin in a dose of 5000U injected subcutaneously 2 hours before operation and at 12 hourly intervals for 5 days post operatively. Duration 5 days. Concurrent medication/care: All groups had conventional physiotherapy and early mobilisation according to the department of surgery routine. Indirectness: No indirectness (n=58) Intervention 2: No treatment - Usual care. No specific prophylaxis . Duration 5 days. Concurrent medication/care: All groups had conventional physiotherapy and early mobilisation according to the department of surgery routine. Indirectness: No indirectness
Funding	Funding not stated
RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: UNFRACTIONATED HEPARIN (LOW DOSE, ADMINISTERED SUBCUTANEOUSLY) versus USUAL CARE	

Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge
 - Actual outcome: All-cause mortality at 7 days; Group 1: 2/46, Group 2: 7/51
 Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;
 Indirectness of outcome: No indirectness ; Group 1 Number missing: 7; Group 2 Number missing: 7

Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge
 - Actual outcome: DVT at 7 days; Group 1: 6/46, Group 2: 14/51
 Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;
 Indirectness of outcome: No indirectness ; Group 1 Number missing: 7; Group 2 Number missing: 7

Protocol outcome 3: Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge
 - Actual outcome: Fatal PE at 7 days; Group 1: 0/46, Group 2: 0/51
 Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;
 Indirectness of outcome: No indirectness ; Group 1 Number missing: 7; Group 2 Number missing: 7

Protocol outcomes not reported by the study

Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge; Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study;

Study	Bergqvist 1986 ²⁴
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=432)
Countries and setting	Conducted in Sweden; Setting: Department of surgery
Line of therapy	Not applicable
Duration of study	Intervention + follow up: 30 days
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: Patients undergoing elective general abdominal surgery
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Patients aged over 40 who were undergoing elective general abdominal surgery of more than 30 minutes duration
Exclusion criteria	Heparin or iodine hypersensitivity, impaired renal function, septic endocarditis, stroke, haemorrhagic diathesis, treatment with anticoagulants, pregnancy
Recruitment/selection of patients	Not reported
Age, gender and ethnicity	Age - Mean (SD): Not reported. Gender (M:F): Not reported. Ethnicity: Not reported
Further population details	1. Active cancer: Not applicable (Mixed 45% malignancies). 2. Acute/elective: Elective 3. BMI : Not applicable 4. Laparoscopic/open surgery: Not applicable 5. Renal impairment: No renal impairment (eGFR greater than 30ml/min/1.73m ²) (Doesn't specify eGFR but says it excludes 'impaired renal function').
Indirectness of population	No indirectness
Interventions	(n=215) Intervention 1: Low molecular weight heparin (licensed in UK) - Dalteparin (1,250 units once daily - 5,000 units twice daily). 5000U given 2 hours before surgery and then every morning for 5-7 days. Duration 5-7 days. Concurrent medication/care: Not reported. Indirectness: No indirectness (n=217) Intervention 2: Unfractionated heparin - Unfractionated heparin (low dose, administered subcutaneously). Heparin 5000U given subcutaneously 2 hours before operation and at 12 hour intervals for 5-7 days. Duration 5-7 days. Concurrent medication/care: Not reported . Indirectness: No indirectness
Funding	Academic or government funding (Supported by a grant from the Swedish Medical Research council)
RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: DALTEPARIN (1,250 UNITS ONCE DAILY - 5,000 UNITS TWICE DAILY) versus UNFRACTIONATED HEPARIN (LOW DOSE, ADMINISTERED SUBCUTANEOUSLY)	

Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge
 - Actual outcome: All-cause mortality at 30 days; Group 1: 5/215, Group 2: 5/217
 Risk of bias: All domain - High, Selection - Very high, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;
 Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge
 - Actual outcome: DVT at 30 days; Group 1: 13/215, Group 2: 9/217
 Risk of bias: All domain - High, Selection - Very high, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;
 Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcome 3: Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge
 - Actual outcome: Major bleeding at 30 days; Group 1: 20/215, Group 2: 2/217
 Risk of bias: All domain - High, Selection - Very high, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;
 Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcomes not reported by the study

Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge; Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study;

Study	Bergqvist 1988 ²⁷
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=1002)
Countries and setting	Conducted in Sweden; Setting: Hospital
Line of therapy	Not applicable
Duration of study	Intervention + follow up: 30 days
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: Patients undergoing elective abdominal surgery
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Patients who were 40 years of age or older and scheduled to undergo major elective general abdominal surgery of more than 30 minutes duration with an expected postoperative stay in hospital of at least 5 days
Exclusion criteria	Vascular and urogenital surgery, heparin or iodine hypersensitivity, impaired renal function (creatinine >200µmol/l), septic endocarditis, haemorrhagic stroke, known bleeding diathesis, treatment with oral anticoagulants or dextran within 14 days, pregnancy
Recruitment/selection of patients	Not reported
Age, gender and ethnicity	Age - Mean (range): LMWH group: 68 (41-91), UFH group: 69 (41-91). Gender (M:F): 488:514. Ethnicity: Not reported
Further population details	1. Active cancer: Not applicable 2. Acute/elective: Elective 3. BMI : Not applicable 4. Laparoscopic/open surgery: Not applicable 5. Renal impairment: No renal impairment (eGFR greater than 30ml/min/1.73m ²) (Excludes creatinine >200µmol/l).
Indirectness of population	No indirectness
Interventions	(n=505) Intervention 1: Low molecular weight heparin (licensed in UK) - Dalteparin (1,250 units once daily - 5,000 units twice daily). Dalteparin, 5000U. Patients were given the first injection the evening before surgery, and the second 2 hours before surgery, and then once daily for 5-8 days. Duration 5-8 days. Concurrent medication/care: Not reported . Indirectness: No indirectness (n=497) Intervention 2: Unfractionated heparin - Unfractionated heparin (low dose, administered subcutaneously). 5000U. Patients were given the first injection the evening before surgery, and the second 2 hours before surgery, and then twice daily for 5-8 days. Duration 5-8 days. Concurrent medication/care: Not reported. Indirectness: No indirectness
Funding	Academic or government funding (Supported by a grant from the Swedish Medical Research Council)

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: DALTEPARIN (1,250 UNITS ONCE DAILY - 5,000 UNITS TWICE DAILY) versus UNFRACTIONATED HEPARIN (LOW DOSE, ADMINISTERED SUBCUTANEOUSLY)

Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge

- Actual outcome: All-cause mortality at 30 days; Group 1: 10/505, Group 2: 10/497

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low, Comments - 38 patients excluded due to fine reasons but not reported which group they were in; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge

- Actual outcome: DVT at 30 days; Group 1: 28/505, Group 2: 41/497

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low, Comments - 38 patients excluded due to fine reasons but not reported which group they were in; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcome 3: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge

- Actual outcome: PE at 30 days; Group 1: 0/505, Group 2: 4/497

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low, Comments - 38 patients excluded due to fine reasons but not reported which group they were in; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcome 4: Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge

- Actual outcome: Fatal PE at 30 days; Group 1: 0/505, Group 2: 1/497

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low, Comments - 38 patients excluded due to fine reasons but not reported which group they were in; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcomes not reported by the study

Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge;

Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study;

Study	Bergqvist 1995 ²³
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=2070)
Countries and setting	Conducted in Sweden; Setting: One of 7 centres
Line of therapy	Not applicable
Duration of study	Intervention + follow up: 30 days
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: Patients having elective general abdominal surgery
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Patients above 40 years of age undergoing elective general abdominal surgery lasting at least 30 minutes and with an expected postoperative stay of at least 5 days
Exclusion criteria	Vascular, thoracic, thyroid and urogenital operations, heparin or iodine hypersensitivity, serum creatinine level above 200µmol/l, septic endocarditis, haemorrhagic stroke, bleeding diathesis, treatment with anticoagulants or dextran within 14 days, pregnancy; and previous inclusion in the trial
Recruitment/selection of patients	Not reported
Age, gender and ethnicity	Age - Median (range): low dose group: 69 (40-95), standard dose group: 70 (40-90). Gender (M:F): 985:1085. Ethnicity: Not reported
Further population details	1. Active cancer: Not applicable 2. Acute/elective: Elective 3. BMI : Not applicable 4. Laparoscopic/open surgery: Not applicable 5. Renal impairment: No renal impairment (eGFR greater than 30ml/min/1.73m ²) (Serum creatinine level above 200µmol/l was excluded).
Indirectness of population	No indirectness
Interventions	(n=1034) Intervention 1: Low molecular weight heparin (licensed in UK) - Dalteparin (1,250 units once daily - 5,000 units twice daily). Dalteparin 2500U, once daily. First dose given subcutaneously the evening before surgery and repeated daily. Duration 7 days. Concurrent medication/care: Dextran or additional heparin was now allowed. Indirectness: No indirectness (n=1036) Intervention 2: Low molecular weight heparin (licensed in UK) - Dalteparin (1,250 units once daily - 5,000 units twice daily). Dalteparin 5000U, once daily. First dose given subcutaneously the evening before surgery and repeated daily. Duration 7 days. Concurrent medication/care: Dextran or additional heparin was now allowed. Indirectness: No indirectness

Funding	Academic or government funding (Supported by Swedish Medical Research Council grant)
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: DALTEPARIN LOW DOSE (1,250 UNITS ONCE DAILY - 5,000 UNITS TWICE DAILY) versus DALTEPARIN STANDARD DOSE (1,250 UNITS ONCE DAILY - 5,000 UNITS TWICE DAILY)</p> <p>Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge - Actual outcome: All-cause mortality at 30 days; Group 1: 35/1034, Group 2: 32/1036 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0</p> <p>Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge - Actual outcome: DVT at 30 days; Group 1: 124/976, Group 2: 65/981 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 58; Group 2 Number missing: 55</p> <p>Protocol outcome 3: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQspect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge - Actual outcome: PE at 30 days; Group 1: 4/976, Group 2: 6/981 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 58; Group 2 Number missing: 55</p> <p>Protocol outcome 4: Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge - Actual outcome: Major bleeding at 30 days; Group 1: 3/1034, Group 2: 13/1036 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0</p>	
Protocol outcomes not reported by the study	<p>Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQspect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study;</p>

Study	Bergqvist 1996 ²⁵
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=80)
Countries and setting	Conducted in Sweden; Setting: Three centre's
Line of therapy	Not applicable
Duration of study	Intervention + follow up: 30 days
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: People undergoing emergency general abdominal surgery
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Patients above 40 years of age if they underwent emergency general abdominal surgery within 48 hours from admission with an expected operation time of more than 30 minutes and an estimates hospital stay of 5 days or more
Exclusion criteria	Preoperative treatment with heparin, acute re-operation, serum creatinine >200µmol/l, hepatic failure, childbearing potential, head injury or multi-trauma, allergy to iodine or heparin, treatment with oral anticoagulants or fibrinolytic agents or inability to give informed consent
Recruitment/selection of patients	Not reported
Age, gender and ethnicity	Age - Median (range): LMWH group: 69 (41-87), placebo group: 71 (43-92). Gender (M:F): 37:43. Ethnicity: Not reported
Further population details	1. Active cancer: Not applicable (Mixed - 13.8% malignant disease). 2. Acute/elective: Acute 3. BMI : Not applicable 4. Laparoscopic/open surgery: Not applicable 5. Renal impairment: No renal impairment (eGFR greater than 30ml/min/1.73m ²) (Excluded serum creatinine >200µmol/).
Indirectness of population	No indirectness
Interventions	(n=39) Intervention 1: Low molecular weight heparin (licensed in UK) - Tinzaparin (2,500 units once daily – 9,000 units once daily). 3500U tinzaparin, started postoperatively, given once daily. Duration 5 days. Concurrent medication/care: Not reported. Indirectness: No indirectness (n=41) Intervention 2: No treatment - Placebo. Placebo (0.9% saline) once daily. Duration 5 days. Concurrent medication/care: Not reported. Indirectness: No indirectness
Funding	Funding not stated
RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: TINZAPARIN (2,500 UNITS ONCE DAILY – 9,000 UNITS ONCE DAILY) versus PLACEBO	

Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge

- Actual outcome: All-cause mortality at 30 days; Group 1: 0/39, Group 2: 2/41

Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge

- Actual outcome: DVT at 30 days; Group 1: 3/39, Group 2: 9/41

Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcome 3: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge

- Actual outcome: PE at 30 days; Group 1: 0/39, Group 2: 1/41

Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcome 4: Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge

- Actual outcome: Major bleeding at 30 days; Group 1: 1/39, Group 2: 0/41

Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcomes not reported by the study

Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study;

Study	Borstad 1988 ³²
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=215)
Countries and setting	Conducted in Norway; Setting: Not reported
Line of therapy	Not applicable
Duration of study	Intervention + follow up: 7 days
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: Patients having major gynaecological surgery
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Patients aged 40 years or more, undergoing major gynaecological surgery lasting more than 30 min. Further inclusion criteria were: previous history of thromboembolism or malignancy, oestrogen medication for the last 30 days, serious varicose veins or overweight exceeding 20%.
Exclusion criteria	Patients were excluded if they had a known bleeding tendency, a history of CNS bleeding, impaired renal function, hypersensitivity to heparin, decreased level of antithrombin, or if they received anticoagulation therapy. Pregnant women and patients having epidural anesthesia were also excluded
Recruitment/selection of patients	Not reported
Age, gender and ethnicity	Age - Mean (SD): LMWH group: 53.4 (11.6), UFH group: 53.6 (10.4). Gender (M:F): Female. Ethnicity: Not reported
Further population details	1. Active cancer: Not applicable (Mixed - 6%). 2. Acute/elective: Not applicable 3. BMI : Not applicable 4. Laparoscopic/open surgery: Not applicable 5. Renal impairment: No renal impairment (eGFR greater than 30ml/min/1.73m2) (Excluded impaired renal function).
Indirectness of population	No indirectness
Interventions	(n=105) Intervention 1: Low molecular weight heparin (licensed in UK) - Dalteparin (1,250 units once daily - 5,000 units twice daily). 5000U LMWH (Heparin fragment KABI 2165, KabiVitrum, Sweden) 1 hour preoperatively and then every 24 hours for 7 days. Duration 7 days. Concurrent medication/care: Not reported (n=110) Intervention 2: Unfractionated heparin - Unfractionated heparin (low dose, administered subcutaneously). 5000U UFH (conventional heparin from pig mucosa, KabiVitrum Sweden) subcutaneously every 12 hours. Duration 7 days. Concurrent medication/care: Not reported. Indirectness: No indirectness
Funding	Funding not stated

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: DALTEPARIN (1,250 UNITS ONCE DAILY - 5,000 UNITS TWICE DAILY) versus UNFRACTIONATED HEPARIN (LOW DOSE, ADMINISTERED SUBCUTANEOUSLY)

Protocol outcome 1: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge

- Actual outcome: DVT at 7 days; Group 1: 0/105, Group 2: 0/110

Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcome 2: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQspect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge

- Actual outcome: PE at 7 days; Group 1: 0/105, Group 2: 0/110

Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcome 3: Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge

- Actual outcome: Major bleeding at 7 days; Group 1: 32/105, Group 2: 13/110

Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcomes not reported by the study

All-cause mortality at up to 90 days from hospital discharge; Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQspect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study;

Study	Borstad 1992 ³³
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=152)
Countries and setting	Conducted in Norway; Setting: Not reported
Line of therapy	Not applicable
Duration of study	Intervention + follow up: 1 month
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: Patients undergoing major gynaecological surgery, laparotomy, vaginal repair or colposuspension
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Age over 40 years, previous history of thromboembolism or malignancy, hormone replacement therapy during the last 30 days, serious varicose veins or overweight exceeding 2-%
Exclusion criteria	Haemorrhagic diathesis, known antithrombin deficiency, treated with anticoagulants during the last 14 days, had recent cerebro-vascular hemorrhage or impaired renal function (creatinine >300umol/l), women with hypersensitivity to heparin, pregnant women and those who were going to have epidural anesthesia
Recruitment/selection of patients	Not reported
Age, gender and ethnicity	Age - Mean (SD): LMWH group: 56.3 (10.4), UFH group: 57.1 (12.7). Gender (M:F): Female. Ethnicity: Not reported
Further population details	1. Active cancer: Not applicable 2. Acute/elective: Not applicable 3. BMI : Not applicable 4. Laparoscopic/open surgery: Not applicable 5. Renal impairment: No renal impairment (eGFR greater than 30ml/min/1.73m2) (Excluded impaired renal function (creatinine >300umol/l)).
Indirectness of population	No indirectness
Interventions	(n=77) Intervention 1: Low molecular weight heparin (licensed in UK) - Dalteparin (1,250 units once daily - 5,000 units twice daily). 2500U of Fragmin (Kabi Pharmacia Sweden), 1 hour preoperatively and then every 24 hours for 7 days. Duration 7 days. Concurrent medication/care: Not reported. Indirectness: No indirectness (n=75) Intervention 2: Unfractionated heparin - Unfractionated heparin (low dose, administered subcutaneously). 5000U of UFH (kabi Pharmacia, Sweden) every 12 hours. Duration 7 days. Concurrent medication/care: Not reported. Indirectness: No indirectness
Funding	Funding not stated

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: DALTEPARIN (1,250 UNITS ONCE DAILY - 5,000 UNITS TWICE DAILY) versus UNFRACTIONATED HEPARIN (LOW DOSE, ADMINISTERED SUBCUTANEOUSLY)

Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge

- Actual outcome: All-cause mortality at 1 month; Group 1: 2/71, Group 2: 0/70

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 6, Reason: ; Group 2 Number missing: 5

Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge

- Actual outcome: DVT at 1 month; Group 1: 0/71, Group 2: 0/70

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - High, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 6, Reason: ; Group 2 Number missing: 5

Protocol outcome 3: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge

- Actual outcome: PE at 1 month; Group 1: 1/71, Group 2: 0/70

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - High, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 6, Reason: ; Group 2 Number missing: 5

Protocol outcome 4: Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge

- Actual outcome: Major bleeding at 5 days; Group 1: 14/71, Group 2: 9/70

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 6, Reason: ; Group 2 Number missing: 5

Protocol outcomes not reported by the study

Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study;

Study	Butson 1981 ³⁸
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=119)
Countries and setting	Conducted in Canada; Setting: Hospital
Line of therapy	Not applicable
Duration of study	Intervention + follow up: Up to 90 days
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: Patients undergoing abdominal surgery
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Only patients undergoing an abdominal surgery procedure of a severity equal to or greater than that of cholecystectomy
Exclusion criteria	Not reported
Recruitment/selection of patients	Not reported
Age, gender and ethnicity	Age - Mean (range): IPCD group: 52.4 (20-89), control group:57.5 (25-91). Gender (M:F): 52:67. Ethnicity: Not reported
Further population details	1. Active cancer: Not applicable 2. Acute/elective: Not applicable 3. BMI : Not applicable 4. Laparoscopic/open surgery: Not applicable 5. Renal impairment: Not applicable
Indirectness of population	No indirectness
Interventions	(n=62) Intervention 1: Intermittent pneumatic compression devices - Below knee. Inflatable plastic knee length leggings were inflated by compressed air pumps (PED-90, Lyne-Nicholson Inc., Needham Heights, Massachusetts). IPCD was started in the operating room immediately after anesthesia and was continued until the patient was ambulatory, usually 24-48 hours. A few patients were kept on IPCD for up to 4 days. Duration 24-48 hours. Concurrent medication/care: Both groups had routine daily postoperative physiotherapy. Indirectness: No indirectness (n=57) Intervention 2: No treatment - Usual care. Control group. Duration Not reported. Concurrent medication/care: Both groups had routine daily postoperative physiotherapy. Indirectness: No indirectness
Funding	Funding not stated
RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: BELOW KNEE versus USUAL CARE	
Protocol outcome 1: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler)	

ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge

- Actual outcome: DVT at 14-90 days; Group 1: 6/62, Group 2: 4/57

Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcome 2: Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge

- Actual outcome: Fatal PE at 14-90 days; Group 1: 0/62, Group 2: 1/57

Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcomes not reported by the study

All-cause mortality at up to 90 days from hospital discharge; Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge; Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study;

Study	Caen 1988 ³⁹
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=391)
Countries and setting	Conducted in France; Setting: 5 hospitals
Line of therapy	Not applicable
Duration of study	Intervention + follow up: 30 days
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: Patients undergoing major abdominal surgery
Stratum	Overall:
Subgroup analysis within study	Not applicable
Inclusion criteria	Patients aged 40 years or above and scheduled to undergo abdominal surgery of a duration of more than 30 minutes under general anaesthesia
Exclusion criteria	Haemorrhagic diathesis, impaired renal function, severe hepatic insufficiency, cerebral haemorrhage within the last 6 months, septic endocarditis, heparin or iodine hypersensitivity, treatment with oral anticoagulants within the last 3 months
Recruitment/selection of patients	Not reported
Age, gender and ethnicity	Age - Mean (SD): LMWH group 52.2 (11.9), UFH group 59.7 (11.8). Gender (M:F): 188:197. Ethnicity: Not reported
Further population details	1. Active cancer: Not applicable 2. Acute/elective: Not applicable 3. BMI : Not applicable 4. Laparoscopic/open surgery: Not applicable 5. Renal impairment: No renal impairment (eGFR greater than 30ml/min/1.73m ²) (Excluded impaired renal function).
Indirectness of population	No indirectness
Interventions	(n=195) Intervention 1: Low molecular weight heparin (licensed in UK) - Dalteparin (1,250 units once daily - 5,000 units twice daily). Kabi 2165 2500U given subcutaneously 2 hours before operation and then every morning for the next 7 postoperative days. Duration 7 days. Concurrent medication/care: Not reported. Indirectness: No indirectness (n=190) Intervention 2: Unfractionated heparin - Unfractionated heparin (low dose, administered subcutaneously). Low dose standard heparin, 5000U given subcutaneously, 2 hours before operation and at 12 hourly intervals for the next 7 days. Duration 7 days. Concurrent medication/care: Not reported . Indirectness: No indirectness
Funding	Funding not stated
RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: DALTEPARIN (1,250 UNITS ONCE DAILY - 5,000 UNITS TWICE DAILY) versus UNFRACTIONATED	

HEPARIN (LOW DOSE, ADMINISTERED SUBCUTANEOUSLY)

Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge

- Actual outcome: All-cause mortality at 30 days; Group 1: 2/195, Group 2: 3/190

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: , Reason: 6 patients excluded but not clear which group they were in; Group 2 Number missing:

Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge

- Actual outcome: DVT at 30 days; Group 1: 6/195, Group 2: 7/190

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: , Reason: 6 patients excluded but not clear which group they were in; Group 2 Number missing:

Protocol outcome 3: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge

- Actual outcome: PE at 30 days; Group 1: 0/195, Group 2: 0/190

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - High, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: , Reason: 6 patients excluded but not clear which group they were in; Group 2 Number missing:

Protocol outcome 4: Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge

- Actual outcome: Fatal PE at 30 days; Group 1: 0/195, Group 2: 0/190

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - High, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: , Reason: 6 patients excluded but not clear which group they were in; Group 2 Number missing:

Protocol outcomes not reported by the study

Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study;

Study	CANBESURE trial: Kakkar 2010 ¹⁶⁴
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	N/A (n=626)
Countries and setting	Conducted in Multiple countries; Setting: Secondary/Tertiary care
Line of therapy	Not applicable
Duration of study	Intervention + follow up: Interventions 20 days + Follow-up maximum 90 days
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: Bilateral venograms were performed on all participants 20 days after randomisation. Suspected DVT were confirmed by unilateral venography or Doppler ultrasound. Non-fatal PE was verified by perfusion/ventilation lung scintigraphy, pulmonary arteriography or spiral computed tomography.
Stratum	Overall
Subgroup analysis within study	Not applicable:
Inclusion criteria	Aged 40 years or older admitted to undergo elective, open, curative or palliative surgery for a malignant disease of the gastrointestinal tract (excluding oesophagus), genitourinary tract or female reproductive organs
Exclusion criteria	Active haemorrhage / High risk of bleeding; known hypersensitivity to unfractionated/fractionated heparins, radiological contrast media or anaesthetic drugs; tumour of / surgical intervention in the central nervous system within the previous 6 months; endocarditis; treatment with oral/parenteral anticoagulants within 5 days before surgery; history of heparin-induced thrombocytopenia / baseline platelet count < 75,000 μ /L; severe renal/hepatic insufficiency; severe arterial hypertension; VTE within the previous 3 months; inability to comply with the study treatment and/or follow-up; cava filter; receiving prohibited medications; pregnancy/lactation; surgery for liver cancer, biliary tract or pancreas
Recruitment/selection of patients	Consecutive patients
Age, gender and ethnicity	Age - Mean (SD): Bemiparin 64.1 (10.3) vs. Placebo 64.6 (9.9). Gender (M:F): 330:295. Ethnicity: Caucasian 99.7%; Other 0.3%
Further population details	1. Active cancer: Active cancer (GI tract = 80.6%; Female reproductive organs = 11.4%; Urologic = 7.5%; Retroperitoneal = 0.5%). 2. Acute/elective: Elective (Elective = 100%). 3. BMI : Obese (BMI over 30 kg/m ²) (Obesity = 18.6%). 4. Laparoscopic/open surgery: Open surgery (Open = 100%). 5. Renal impairment: Not applicable(Not stated).
Indirectness of population	No indirectness
Interventions	(n=316) Intervention 1: Low molecular weight heparin (not licensed in UK) - Bemiparin (2500 units once daily - 3500 units once daily). Subcutaneous injections of bemiparin 3500IU (0.2ml) once daily . Duration 20 \pm 2 days. Concurrent medication/care: Run-in period before randomisation: subcutaneous injections of bemiparin 3500IU (0.2ml) for 8 \pm 2 days. Indirectness: Serious indirectness; Indirectness comment: Bemiparin is not licensed in UK

	(n=310) Intervention 2: No treatment - Placebo. Subcutaneous injections of placebo (0.9% NaCl, 0.2ml) once daily . Duration 20 ± 2 days. Concurrent medication/care: Run-in period before randomisation: subcutaneous injections of bemiparin 3500IU (0.2ml) for 8 ± 2 days. Indirectness: No indirectness
Funding	Study funded by industry (Laboratorios Farmacéuticos Rovi S.A.)

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: BEMIPARIN versus PLACEBO

Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge

- Actual outcome: All-cause death during intervention period at 20 ± 2 days; Group 1: 6/248, Group 2: 3/240; Comments: RRR -93.6 (95% CI -665.1 to 51.0); p=0.50

Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 68, Reason: 1 participant was not treated + Venography not performed for 44 participants + Venography was of poor quality in 18 participants + 5 had unilateral venography; Group 2 Number missing: 70, Reason: Venography not performed for 42 participants + Venography was of poor quality in 17 participants + 11 had unilateral venography

- Actual outcome: All-cause death during intervention and follow-up period at Up to 90 days; Group 1: 8/248, Group 2: 6/240; Comments: RRR -29.0 (95% CI -266.4 to 54.6); p=0.63

Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 68, Reason: 1 participant was not treated + Venography not performed for 44 participants + Venography was of poor quality in 18 participants + 5 had unilateral venography; Group 2 Number missing: 70, Reason: Venography not performed for 42 participants + Venography was of poor quality in 17 participants + 11 had unilateral venography

Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge

- Actual outcome: DVT during intervention period at 20 ± 2 days; Group 1: 19/248, Group 2: 29/240; Comments: RRR 36.6 (95% CI -10.0 to 63.4); p=0.10

Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 68, Reason: 1 participant was not treated + Venography not performed for 44 participants + Venography was of poor quality in 18 participants + 5 had unilateral venography; Group 2 Number missing: 70, Reason: Venography not performed for 42 participants + Venography was of poor quality in 17 participants + 11 had unilateral venography

Protocol outcome 3: Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of ≥2g/dl; a serious or life threatening clinical event at up to 45 days from hospital discharge

- Actual outcome: Major bleeding during intervention period at 20 ± 2 days; Group 1: 2/315, Group 2: 1/310

Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 1, Reason: 1 participant was not treated; Group 2 Number missing: 0

Protocol outcome 4: Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge

- Actual outcome: Clinically relevant non-major bleeding during intervention period at 20 ± 2 days; Group 1: 1/315, Group 2: 1/310

Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 1, Reason: 1 participant was not treated; Group 2 Number missing: 0

Protocol outcome 5: VTE at 7-90 days from hospital discharge - Actual outcome: Major VTE during intervention period at 20 ± 2 days; Group 1: 2/248, Group 2: 11/240;

Comments: RRR 82.4 (95% CI 21.5 to 96.1); p=0.01; "Major VTE" = Composite of symptomatic & asymptomatic proximal DVT, non-fatal PE and VTE-related deaths

Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 68, Reason: 1 participant was not treated + Venography not performed for 44 participants + Venography was of poor quality in 18 participants + 5 had unilateral venography; Group 2 Number missing: 70, Reason: Venography not performed for 42 participants + Venography was of poor quality in 17 participants + 11 had unilateral venography

- Actual outcome: Major VTE during intervention and follow-up period at Up to 90 days; Group 1: 3/248, Group 2: 11/240; Comments: RRR 73.6 (95% CI 6.6 to 92.5); p=0.03

Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 68, Reason: 1 participant was not treated + Venography not performed for 44 participants + Venography was of poor quality in 18 participants + 5 had unilateral venography; Group 2 Number missing: 70, Reason: Venography not performed for 42 participants + Venography was of poor quality in 17 participants + 11 had unilateral venography

Protocol outcomes not reported by the study

Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge; Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study;

Study	Caprini 1983 ⁴²
Study type	Systematic Review
Number of studies (number of participants)	1 (n=102)
Countries and setting	Conducted in USA; Setting: Department of surgery
Line of therapy	Not applicable
Duration of study	Intervention + follow up: 72 hours + follow up not reported
Method of assessment of guideline condition	Unclear method of assessment/diagnosis
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Not reported
Exclusion criteria	Patients taking anti-coagulants, sensitive to iodine or having operations on the breast or leg
Recruitment/selection of patients	Not reported
Age, gender and ethnicity	Age - Other: 92.3% >40 years. Gender (M:F): 31:46. Ethnicity: Not reported
Further population details	1. Active cancer: Not applicable (16.7% malignant condition). 2. Acute/elective: Not applicable 3. BMI : Not applicable(26% 'obese'). 4. Laparoscopic/open surgery: Not applicable 5. Renal impairment: Not applicable
Indirectness of population	No indirectness
Interventions	<p>(n=38) Intervention 1: Intermittent pneumatic compression devices - Full leg. Long TED stockings applied bilaterally upon all patients during the preoperative period. Patients were then randomised to either SCD or TED. Prior to onset of anesthesia, the TES were removed and IPCD applied to those in SCD group. This was maintained for at least 72 hours or until the patient was ambulatory. When the IPCD was removed, stockings were reapplied until discharge. Duration at least 3 days. Concurrent medication/care: Not stated. Indirectness: No indirectness</p> <p>(n=39) Intervention 2: Anti-embolism stockings - Above knee. Long TED stockings applied bilaterally upon all patients during the preoperative period. Patients were then randomised to either SCD or TED. Those in the TED group wore stockings until discharge. Duration until discharge. Concurrent medication/care: Not reported. Indirectness: No indirectness</p>
Funding	Study funded by industry (Supported in part by a grant from the Kendall Corporation and the Dee and Moody Fund, Evanston Hospital, Evanston, Illinois)

Protocol outcomes not reported by the study

All-cause mortality at up to 90 days from hospital discharge; Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study;

Study	Chandhoke 1992 ⁴⁸
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=100)
Countries and setting	Conducted in USA; Setting: Hospital
Line of therapy	Not applicable
Duration of study	Intervention + follow up: 1-2 weeks
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: Major open urological operation
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Major open urological operation lasting more than 2 hours
Exclusion criteria	Not reported
Recruitment/selection of patients	Not reported
Age, gender and ethnicity	Age - Mean (SD): IPCD group: 67.5 (7.1), warfarin group: 66.1 (6.4). Gender (M:F): 99:1. Ethnicity: 1
Further population details	1. Active cancer: Active cancer (99% urological malignancy). 2. Acute/elective: Not applicable 3. BMI : Not applicable 4. Laparoscopic/open surgery: Open surgery 5. Renal impairment: Not applicable
Indirectness of population	No indirectness
Interventions	<p>(n=47) Intervention 1: Intermittent pneumatic compression devices - Full leg. Sequential leg and thigh intermittent pneumatic leg compression was instituted intraoperatively and continued for 5 days or until the patient became fully ambulatory . Duration 5 days. Concurrent medication/care: Not reported. Indirectness: No indirectness</p> <p>(n=53) Intervention 2: Vitamin K antagonists - Warfarin (variable dose). Low dose warfarin prophylaxis was begun on the night of the operation and continued postoperatively until the patient was discharged from hospital (1 to 2 weeks). The goal of low dose warfarin prophylaxis was to achieve a prothrombin time of approximately 1.5 times the preoperative value by 3 or 4 days postoperatively. The dose of warfarin was adjusted thereafter to maintain the prothrombin time at this level (approximately 16-18 seconds). Duration 1-2 weeks. Concurrent medication/care: Not reported. Indirectness: No indirectness</p>
Funding	Funding not stated
RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: FULL LEG versus WARFARIN (VARIABLE DOSE)	

Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge
 - Actual outcome: All-cause mortality at 1-2 weeks; Group 1: 0/47, Group 2: 0/53
 Risk of bias: All domain --, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;
 Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge
 - Actual outcome: DVT at 1-2 weeks; Group 1: 2/47, Group 2: 0/53
 Risk of bias: All domain --, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;
 Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcome 3: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge
 - Actual outcome: PE at 1-2 weeks; Group 1: 1/47, Group 2: 0/53
 Risk of bias: All domain --, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;
 Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcomes not reported by the study

Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge; Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study;

Study	Clarke-pearson 1983 ⁵²
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=200)
Countries and setting	Conducted in USA; Setting: Division of Gynecologic Oncology, Duke University Medical Center
Line of therapy	Not applicable
Duration of study	Intervention + follow up: 42 days
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: Patients undergoing a major operative procedure for known or presumed gynaecologic malignancy
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Patients undergoing a major operative procedure for known or presumed gynaecologic malignancy
Exclusion criteria	Patients with evidence of thrombosis on preoperative fibrinogen 1 counting and/or impedance plethysmography, patients having received anticoagulants within 6 weeks preoperatively, and patients with decreased platelet counts (less than 100,000/mm ³) or a preoperative partial thromboplastin time or prothrombin time greater than one and one half times the control value
Recruitment/selection of patients	All admitted patients
Age, gender and ethnicity	Age - Other: 20-70+. Gender (M:F): Female. Ethnicity: White = 76.2%, black = 23.8%
Further population details	1. Active cancer: Active cancer 2. Acute/elective: Not applicable 3. BMI : Not applicable 4. Laparoscopic/open surgery: Not applicable 5. Renal impairment: Not applicable
Indirectness of population	No indirectness
Interventions	(n=95) Intervention 1: Unfractionated heparin - Unfractionated heparin (low dose, administered subcutaneously). 5000 U of sodium heparin (The Upjohn Company, Kalamazoo, Michigan) subcutaneously 2 hours preoperatively and every 12 hours postoperatively for the first 7 postoperative days. Duration 7 days. Concurrent medication/care: Foot of the bed was elevated 20-30 degrees above the horizontal, and early postoperative ambulation. Indirectness: No indirectness (n=105) Intervention 2: No treatment - Usual care. No specific thromboembolic prophylaxis. Duration 7 days. Concurrent medication/care: Foot of the bed was elevated 20-30 degrees above the horizontal, and early postoperative ambulation. Indirectness: No indirectness
Funding	Funding not stated

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: UNFRACTIONATED HEPARIN (LOW DOSE, ADMINISTERED SUBCUTANEOUSLY) versus USUAL CARE

Protocol outcome 1: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge

- Actual outcome: DVT at 42 days; Group 1: 11/88, Group 2: 11/97

Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 7, Reason: ; Group 2 Number missing: 8

Protocol outcome 2: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge

- Actual outcome: PE at 42 days; Group 1: 4/88, Group 2: 0/97

Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 7, Reason: ; Group 2 Number missing: 8

Protocol outcome 3: Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge

- Actual outcome: Fatal PE at 42 days; Group 1: 0/88, Group 2: 1/97

Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 7, Reason: ; Group 2 Number missing: 8

Protocol outcomes not reported by the study

All-cause mortality at up to 90 days from hospital discharge; Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study;

Study	Clarke-pearson 1984 ⁵³
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=209)
Countries and setting	Conducted in USA; Setting: Division of Gynecologic Oncology, Duke University Medical Centre
Line of therapy	Not applicable
Duration of study	Intervention + follow up: 42 days
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: Major surgery for known or presumed gynaecologic malignancies
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Patients having major surgery for known or presumed gynaecologic malignancies
Exclusion criteria	Patients with acute venous thromboembolic complications within 3 months of surgery and those who had received anticoagulants within 6 weeks of the operative procedure
Recruitment/selection of patients	Not reported
Age, gender and ethnicity	Age - Other: Not reported. Gender (M:F): Female. Ethnicity: Not reported
Further population details	1. Active cancer: Active cancer 2. Acute/elective: Not applicable 3. BMI : Not applicable 4. Laparoscopic/open surgery: Not applicable 5. Renal impairment: Not applicable
Indirectness of population	No indirectness
Interventions	<p>(n=105) Intervention 1: Intermittent pneumatic compression devices - Below knee. External pneumatic calf compression, applied at the time of induction of anesthesia in the operating room, and continued until discharge from recovery from or through the first 24 hours postoperatively. Duration 24 hours. Concurrent medication/care: Foot of beds were elevated 20-30 degrees and were encouraged to ambulate in the immediate post-operative period. Anti-embolism stockings were not worn. Indirectness: No indirectness</p> <p>(n=104) Intervention 2: No treatment - Usual care. No specific thromboembolic prophylaxis. Duration Not reported. Concurrent medication/care: Foot of beds were elevated 20-30 degrees and were encouraged to ambulate in the immediate post-operative period. Anti-embolism stockings were not worn. Indirectness: No indirectness</p>
Funding	Funding not stated

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: BELOW KNEE versus USUAL CARE

Protocol outcome 1: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge

- Actual outcome: DVT at 42 days; Group 1: 14/97, Group 2: 11/97

Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 7; Group 2 Number missing: 8

Protocol outcome 2: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge

- Actual outcome: PE at 42 days; Group 1: 4/97, Group 2: 1/97

Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 7; Group 2 Number missing: 8

Protocol outcome 3: Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge

- Actual outcome: Fatal PE at 42 days; Group 1: 1/97, Group 2: 1/97

Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 7; Group 2 Number missing: 8

Protocol outcomes not reported by the study

All-cause mortality at up to 90 days from hospital discharge; Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study;

Study	Clarke-pearson 1984 ⁵⁵
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=107)
Countries and setting	Conducted in USA; Setting: Division of Gynecologic Oncology, Duke Medical Center
Line of therapy	Not applicable
Duration of study	Intervention + follow up: 42 days
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: Major surgery for known or presumed gynaecologic malignancies
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Major surgery for known or presumed gynaecologic malignancies
Exclusion criteria	Patients who had received anticoagulants within 6 weeks of surgery, or patients with acute venous thromboembolic complications
Recruitment/selection of patients	Not reported
Age, gender and ethnicity	Age - Other: 20-70+. Gender (M:F): Female. Ethnicity: White 68.2%, black 28%, other 3.7%
Further population details	1. Active cancer: Active cancer 2. Acute/elective: Not applicable 3. BMI : Not applicable 4. Laparoscopic/open surgery: Not applicable 5. Renal impairment: Not applicable
Indirectness of population	No indirectness
Interventions	<p>(n=59) Intervention 1: Intermittent pneumatic compression devices - Below knee. External pneumatic calf compression device (Venogyne, Lyne-Nicholson, Inc., Needham Heights, MA), applied at the time of induction of anesthesia in the operation room. Calf compression was maintained intraoperatively and throughout the first 5 postoperative days. The sleeves were removed only when the patient was out of bed to ambulate. Duration 5 days. Concurrent medication/care: Both groups had the foot of their beds elevated to 20-30 degrees and were encouraged to ambulate in the immediate postoperative period. Indirectness: No indirectness</p> <p>(n=57) Intervention 2: No treatment - Usual care. No specific prophylaxis. Duration Not reported. Concurrent medication/care: Both groups had the foot of their beds elevated to 20-30 degrees and were encouraged to ambulate in the immediate postoperative period. Indirectness: No indirectness</p>

Funding	Funding not stated
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: BELOW KNEE versus USUAL CARE</p> <p>Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge - Actual outcome: All-cause mortality at 42 days; Group 1: 0/55, Group 2: 0/52 Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 4, Reason: ; Group 2 Number missing: 5</p> <p>Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge - Actual outcome: DVT at 42 days; Group 1: 5/55, Group 2: 17/52 Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 4, Reason: ; Group 2 Number missing: 5</p> <p>Protocol outcome 3: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge - Actual outcome: PE at 42 days; Group 1: 2/55, Group 2: 1/52 Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 4, Reason: ; Group 2 Number missing: 5</p>	
<p>Protocol outcomes not reported by the study</p>	<p>Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge; Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study;</p>

Study	Clarke-pearson 1993 ⁵⁴
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=218)
Countries and setting	Conducted in USA; Setting: Division of Gynecologic Oncology
Line of therapy	Not applicable
Duration of study	Intervention + follow up: 30 days
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: Major surgery for presumed or known gynaecologic malignancy
Stratum	Overall
Subgroup analysis within study	Stratified then randomised: Patients were stratified before randomisation if they were to undergo a pelvic exeneration
Inclusion criteria	Patients having major surgery for presumed or known gynaecologic malignancy
Exclusion criteria	Patients with a past history of a bleeding diathesis, thromboembolism within the past 3 months, anticoagulant use in the previous 6 weeks
Recruitment/selection of patients	Not reported
Age, gender and ethnicity	Age - Median (range): UFH group: 57 (22-89), IPCD group: 55 (27-84). Gender (M:F): Female. Ethnicity: White 78.8%, other 21.2%
Further population details	1. Active cancer: Not applicable (Mixed 76.4%). 2. Acute/elective: Not applicable 3. BMI : Not applicable 4. Laparoscopic/open surgery: Not applicable 5. Renal impairment: Not applicable
Indirectness of population	No indirectness
Interventions	<p>(n=107) Intervention 1: Unfractionated heparin - Unfractionated heparin (low dose, administered subcutaneously). Low dose heparin, 5000U given subcutaneously at 2pm, 10pm and 6am before starting surgery at 8am. If a patient was admitted several days before surgery, heparin was started on admission and continued every 8 hours until surgery. Postoperatively, patients received 5000U of heparin every 8 hours for 7 days. If the patient was not fully ambulatory by the 7th day, heparin was continued until full ambulation was established. Duration 7 days. Concurrent medication/care: Not reported. Indirectness: No indirectness</p> <p>(n=101) Intervention 2: Intermittent pneumatic compression devices - Below knee. Intermittent pneumatic calf compression (Venodyne, Needham, Mass) initiated at the induction of anesthesia and continued while the patient was in the operating room, recovery room, and recumbent in their hospital bed. IPCD was continued for 5 days, or until the patient ambulated fully. Duration 5 days. Concurrent medication/care: Not reported. Indirectness: No indirectness</p>

Funding	Funding not stated
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: UNFRACTIONATED HEPARIN (LOW DOSE, ADMINISTERED SUBCUTANEOUSLY) versus BELOW KNEE</p> <p>Protocol outcome 1: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge - Actual outcome: DVT at 30 days; Group 1: 7/107, Group 2: 4/101 Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low, Comments - 10 patients excluded but not reported which groups they were in ; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 2: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge - Actual outcome: PE at 30 days; Group 1: 0/107, Group 2: 0/101 Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low, Comments - 10 patients excluded but not reported which groups they were in ; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p>	
Protocol outcomes not reported by the study	<p>All-cause mortality at up to 90 days from hospital discharge; Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge; Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study;</p>

Study	Coe 1978 ⁶⁰
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=83)
Countries and setting	Conducted in USA; Setting: Not reported
Line of therapy	Not applicable
Duration of study	Not clear:
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: Patients undergoing open urological operations
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Patients undergoing open urological operations
Exclusion criteria	Not reported
Recruitment/selection of patients	Not reported
Age, gender and ethnicity	Age - Mean (SD): Intervention 1 = 63 (16) intervention 2 = 55 (11), control = 51 (18) . Gender (M:F): Not reported. Ethnicity: Not reported
Further population details	1. Active cancer: Not applicable 2. Acute/elective: Not applicable 3. BMI : Not applicable 4. Laparoscopic/open surgery: Open surgery 5. Renal impairment: Not applicable
Indirectness of population	--
Interventions	<p>(n=28) Intervention 1: Unfractionated heparin - Unfractionated heparin (low dose, administered subcutaneously). Sodium heparin (5000U subcutaneously) 2 hours before the operation and every 12 hours thereafter for the duration of their hospital stay. Duration Not reported. Concurrent medication/care: Not reported. Indirectness: No indirectness</p> <p>(n=31) Intervention 2: Intermittent pneumatic compression devices - Below knee. External pneumatic compression of both calves by means of inflatable boots. Applied after induction of anesthesia and was maintained during the operative procedure and for the duration of hospitalisation. Short periods were allowed in which the boots were removed for patient comfort, nursing care, and ambulation. Duration Not reported. Concurrent medication/care: Not reported. Indirectness: No indirectness</p> <p>(n=24) Intervention 3: No treatment - Usual care. Control group. No further details. Duration Not reported. Concurrent medication/care: Not reported. Indirectness: No indirectness</p>
Funding	Funding not stated

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: UNFRACTIONATED HEPARIN (LOW DOSE, ADMINISTERED SUBCUTANEOUSLY) versus BELOW KNEE

Protocol outcome 1: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge

- Actual outcome: DVT at Not reported; Group 1: 6/28, Group 2: 2/29

Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Baseline details: Not all important factors reported e.g. gender; Group 1 Number missing: 0; Group 2 Number missing: 2

Protocol outcome 2: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge

- Actual outcome: PE at Not reported; Group 1: 1/28, Group 2: 1/29

Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Baseline details: Not all important factors reported e.g. gender; Group 1 Number missing: 0; Group 2 Number missing: 0

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: UNFRACTIONATED HEPARIN (LOW DOSE, ADMINISTERED SUBCUTANEOUSLY) versus USUAL CARE

Protocol outcome 1: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge

- Actual outcome: DVT at Not reported; Group 1: 6/28, Group 2: 6/24

Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Baseline details: Not all important factors reported e.g. gender; Group 1 Number missing: 0; Group 2 Number missing: 0

Protocol outcome 2: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge

- Actual outcome: PE at Not reported; Group 1: 1/28, Group 2: 1/24

Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Baseline details: Not all important factors reported e.g. gender; Group 1 Number missing: 0; Group 2 Number missing: 0

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: BELOW KNEE versus USUAL CARE

Protocol outcome 1: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge

- Actual outcome: DVT at Not reported; Group 1: 2/29, Group 2: 6/24

Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;
Indirectness of outcome: No indirectness ; Baseline details: Not all important factors reported e.g. gender; Group 1 Number missing: 2; Group 2 Number missing: 0

Protocol outcome 2: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect;
autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge

- Actual outcome: PE at Not reported; Group 1: 1/29, Group 2: 1/24

Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Baseline details: Not all important factors reported e.g. gender; Group 1 Number missing: 2; Group 2 Number missing: 0

Protocol outcomes not reported by the study

All-cause mortality at up to 90 days from hospital discharge; Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge; Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study;

Study	EMRO trial: Gonzalez 1996 ¹²⁴
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=166)
Countries and setting	Conducted in Spain; Setting:
Line of therapy	Not applicable
Duration of study	Intervention + follow up: 8 days
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: Elective abdominal surgery
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Patients of both sexes, over 40 years of age, undergoing elective abdominal surgery who had previously signed the informed consent
Exclusion criteria	Pregnancy, cerebral or gastrointestinal bleeding, allergy to heparin and/or iodine contrast medium, DVT and/or PE in the 6 previous months, bleeding disease and thrombophilia, heparin induced thrombocytopenia or platelet count <100,000/mm ³ , arterial hypertension, severe renal failure requiring haemodialysis, chronic hepatic failure, oral anticoagulant treatment or treatment with unfractionated heparin or LMWH in previous 24 hours, antiplatelet drugs in previous 7 days, participation in another trial
Age, gender and ethnicity	Age - Mean (SD): LMWH group: 61.48 (12.21), UFH: 63.01 (11.39). Gender (M:F): 65:101. Ethnicity: Not reported
Further population details	1. Active cancer: Not applicable 2. Acute/elective: Elective 3. BMI : Not applicable 4. Laparoscopic/open surgery: Not applicable 5. Renal impairment: No renal impairment (eGFR greater than 30ml/min/1.73m ²) (Excluded severe renal failure requiring haemodialysis).
Indirectness of population	No indirectness

Interventions	<p>(n=84) Intervention 1: Low molecular weight heparin (not licensed in UK) - Bemiparin (2500 units once daily - 3500 units once daily). RO-11 2500U administered 2 hours before surgery and a placebo injection 12 hours after the first one. Thereafter, and during the following 7 days, RO-11 was administered once daily in the morning, and the placebo 12 hours after the morning injection. Duration 7 days. Concurrent medication/care: Not reported. Indirectness: No indirectness</p> <p>(n=82) Intervention 2: Unfractionated heparin - Unfractionated heparin (low dose, administered subcutaneously). Calcium heparin 5000U administered 2 hours before he surgery and 12 hours after the first dose. Thereafter, 5000U were administered every 12 hours for 7 days. Duration 7 days. Concurrent medication/care: Not reported. Indirectness: No indirectness</p>
Funding	Funding not stated

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: BEMIPARIN (2500 UNITS ONCE DAILY - 3500 UNITS ONCE DAILY) versus UNFRACTIONATED HEPARIN (LOW DOSE, ADMINISTERED SUBCUTANEOUSLY)

Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge

- Actual outcome: All-cause mortality at 8 days; Group 1: 0/84, Group 2: 0/82

Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge

- Actual outcome: DVT at 8 days; Group 1: 0/84, Group 2: 0/82

Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcome 3: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge

- Actual outcome: PE at 8 days;

Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcome 4: Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening

clinical event at up to 45 days from hospital discharge

- Actual outcome: Major bleeding at 8 days; Group 1: 0/84, Group 2: 5/82

Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcomes not reported by the study

Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQspect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study;

Study	ENOXACAN II trial: Bergqvist 2002 ²¹
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=501)
Countries and setting	Conducted in Multiple countries
Line of therapy	Not applicable
Duration of study	Intervention + follow up: 3 months
Method of assessment of guideline condition	--
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Define
Exclusion criteria	Define
Age, gender and ethnicity	Age - --: . Gender (M:F): Define. Ethnicity: Not reported
Further population details	1. Active cancer: Active cancer 2. Acute/elective: Elective 3. BMI : Mixed (Range 15-45). 4. Laparoscopic/open surgery: Open surgery 5. Renal impairment: No renal impairment (eGFR greater than 30ml/min/1.73m ²) (Excluded renal insufficiency).
Indirectness of population	No indirectness
Interventions	<p>(n=253) Intervention 1: Low molecular weight heparin (licensed in UK) - Enoxaparin (20mg once daily – 60mg twice daily). 40mg enoxaparin (Lovenox or Clexane, Aventis Pharmaceuticals, Paris), once daily. First dose given 10-14 hours preoperatively, for 6-10 days. Then randomised to 40mg enoxaparin for a further 19-21 days for a total of 25-31 days. Duration 25-31 days. Concurrent medication/care: AES were allowed but IPCD and electrical calf stimulation was not. Indirectness: No indirectness</p> <p>(n=248) Intervention 2: Low molecular weight heparin (licensed in UK) - Enoxaparin (20mg once daily – 60mg twice daily). 40mg enoxaparin (Lovenox or Clexane, Aventis Pharmaceuticals, Paris), once daily. First dose given 10-14 hours preoperatively, for 6-10 days. Then randomised to placebo for a further 19-21 days for a total of 25-31 days. Duration 6-10 days. Concurrent medication/care: AES were allowed but IPCD and electrical calf stimulation was not. Indirectness: No indirectness</p>
Funding	Academic or government funding (Supported by a grant from the Swedish Medical Research Council and by Aventis Pharmaceuticals)

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: ENOXAPARIN EXTENDED DURATION (20MG ONCE DAILY – 60MG TWICE DAILY) versus ENOXAPARIN STANDARD DURATION (20MG ONCE DAILY – 60MG TWICE DAILY)

Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge

- Actual outcome: All-cause mortality at 2 months; Group 1: 3/165, Group 2: 6/167

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 88; Group 2 Number missing: 81

Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge

- Actual outcome: DVT at 3 months; Group 1: 9/165, Group 2: 21/167

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 88; Group 2 Number missing: 81

Protocol outcome 3: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge

- Actual outcome: PE at 3 months; Group 1: 0/165, Group 2: 2/167

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 88; Group 2 Number missing: 81

Protocol outcome 4: Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge

- Actual outcome: Major bleeding at 3 months; Group 1: 3/253, Group 2: 1/248

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0

Protocol outcome 5: Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge

- Actual outcome: Fatal PE at 3 months; Group 1: 0/165, Group 2: 1/167

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 88; Group 2 Number missing: 81

Protocol outcomes not reported by the study

Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration

of study; Technical complications of mechanical interventions at duration of study;

Study	Fasting 1985 ¹⁰⁰
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=97)
Countries and setting	Conducted in Denmark; Setting: Hospital
Line of therapy	Not applicable
Duration of study	Not clear:
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: Elective major surgery
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Patients aged above 40 years old, admitted to the County Hospital of Aarhus for elective general surgery, involving general anesthesia of more than one hours duration
Exclusion criteria	Patients already treated with anticoagulants, patients with severe heart failure or haemorrhagic diathesis were not included in the study
Recruitment/selection of patients	Not reported
Age, gender and ethnicity	Age - Mean (range): UFH group: 60 (39-80), AES group: 60 (39-87). Gender (M:F): 49:48. Ethnicity: Not reported
Further population details	1. Active cancer: Not applicable (31.9% malignant cases). 2. Acute/elective: Elective 3. BMI : Not applicable(20.6% obese (>1.25 Natvig's Index)). 4. Laparoscopic/open surgery: Not applicable 5. Renal impairment: Not applicable
Indirectness of population	No indirectness
Interventions	(n=61) Intervention 1: Anti-embolism stockings - Above knee. AES of thigh length, starting the evening before operation and continued for 5 days after the operation and were only stopped when patients were mobile . Duration At least 5 days. Concurrent medication/care: Not reported. Indirectness: No indirectness (n=51) Intervention 2: Unfractionated heparin - Unfractionated heparin (low dose, administered subcutaneously). Low dose heparin 5000U was given subcutaneously, starting the 2-3 hours before operation and continued every 12 hours for at least 5 days and only stopped when patients were mobile. Duration At least 5 days. Concurrent medication/care: Not reported. Indirectness: No indirectness
Funding	Funding not stated
RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: ABOVE KNEE versus UNFRACTIONATED HEPARIN (LOW DOSE, ADMINISTERED SUBCUTANEOUSLY)	

Protocol outcome 1: Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge

- Actual outcome: Major bleeding at Not reported; Group 1: 0/52, Group 2: 0/45

Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 9; Group 2 Number missing: 6

Protocol outcome 2: Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge

- Actual outcome: Fatal PE at Not reported; Group 1: 0/52, Group 2: 1/45

Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 9; Group 2 Number missing: 6

Protocol outcomes not reported by the study

All-cause mortality at up to 90 days from hospital discharge; Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge; Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study;

Study	Fricker 1988 ¹⁰⁸
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=80)
Countries and setting	Conducted in France; Setting: Not reported
Line of therapy	Not applicable
Duration of study	Intervention + follow up: Up to 8 weeks
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: Surgery of a primary or secondary malignant tumour of the abdomen or pelvis
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Patients who were 40 years of age or older and awaiting surgery of a primary or secondary malignant tumour of the abdomen or pelvis, lasting at least 30 minutes and under general anesthesia
Exclusion criteria	Infectious endocarditis, previous bleeding disorders, hepato-cellular failure with a prothrombin time less than 50%, serum creatinine levels high than 200 µmol l ⁻¹ , cerebral haemorrhage in the last 6 months, suspected hypersensitivity to heparin or iodine, anticoagulation stopped for less than 14 days before operation, treatment by Amiodaron stopped for less than 3 months before surgery
Recruitment/selection of patients	Not reported
Age, gender and ethnicity	Age - Mean (range): LMWH group: 58.2 (40-78), UFH group: 57.0 (41-75). Gender (M:F): 8:72. Ethnicity: Not reported
Further population details	1. Active cancer: Active cancer 2. Acute/elective: Not applicable 3. BMI : Not applicable 4. Laparoscopic/open surgery: Not applicable 5. Renal impairment: Not applicable
Indirectness of population	No indirectness
Interventions	(n=40) Intervention 1: Low molecular weight heparin (licensed in UK) - Dalteparin (1,250 units once daily - 5,000 units twice daily). 2500U Fragmin 2 hours before surgery and 12 hours after first injection every morning for 10 days. Duration 10 days. Concurrent medication/care: Not reported. Indirectness: No indirectness (n=40) Intervention 2: Unfractionated heparin - Unfractionated heparin (low dose, administered subcutaneously). Calcium heparin 5000U injection 2 hours before surgery and then at 8 hour intervals for the next 10 days. Duration 10 days. Concurrent medication/care: Not reported. Indirectness: No indirectness
Funding	Funding not stated

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: DALTEPARIN (1,250 UNITS ONCE DAILY - 5,000 UNITS TWICE DAILY) versus UNFRACTIONATED HEPARIN (LOW DOSE, ADMINISTERED SUBCUTANEOUSLY)

Protocol outcome 1: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge

- Actual outcome: DVT at 8 weeks; Group 1: 3/40, Group 2: 1/40

Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 1; Group 2 Number missing: 0

Protocol outcome 2: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge

- Actual outcome: PE at 8 weeks; Group 1: 0/40, Group 2: 5/40

Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 1; Group 2 Number missing: 0

Protocol outcome 3: Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge

- Actual outcome: Major bleeding at 8 weeks; Group 1: 2/40, Group 2: 1/40

Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 1; Group 2 Number missing: 0

Protocol outcomes not reported by the study

All-cause mortality at up to 90 days from hospital discharge; Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study;

Study	Gallus 1973 ¹¹⁶
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=226)
Countries and setting	Conducted in Canada; Setting: Not reported
Line of therapy	Not applicable
Duration of study	Not clear:
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: People having elective surgery
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Patients over 40 years old admitted for elective surgery
Exclusion criteria	Bleeding tendency, iodine allergy, or history of pulmonary embolism or venous thrombosis within the past year
Recruitment/selection of patients	Not reported
Age, gender and ethnicity	Age - Mean (range): UFH group: 60 (44-79), control group: 59 (41-83). Gender (M:F): 92:134. Ethnicity: Not reported
Further population details	1. Active cancer: Not applicable (Cancer 15.5%). 2. Acute/elective: Elective 3. BMI : Not applicable 4. Laparoscopic/open surgery: Not applicable 5. Renal impairment: Not applicable
Indirectness of population	No indirectness
Interventions	(n=108) Intervention 1: Unfractionated heparin - Unfractionated heparin (low dose, administered subcutaneously). UFH 5000U of aqueous sodium heparin by subcutaneous injection 2 hours before surgery and then 3 times daily starting 8 to 10 hours after the preoperative dose. Treatment was continued until the patient was fully mobile. Duration Not reported. Concurrent medication/care: Not reported. Indirectness: No indirectness (n=118) Intervention 2: No treatment - Usual care. Untreated group. Duration Not reported. Concurrent medication/care: Not reported. Indirectness: No indirectness
Funding	Academic or government funding (Supported in part by an Ontario Provincial Health Research grant)
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: UNFRACTIONATED HEPARIN (LOW DOSE, ADMINISTERED SUBCUTANEOUSLY) versus USUAL CARE</p> <p>Protocol outcome 1: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge</p>	

- Actual outcome: DVT at Up to 32 days; Group 1: 1/108, Group 2: 4/118

Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcomes not reported by the study

All-cause mortality at up to 90 days from hospital discharge; Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge; Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge; Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study;

Study	Gallus 1976 ¹¹⁵
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=820)
Countries and setting	Conducted in Canada; Setting: Hospital
Line of therapy	Not applicable
Duration of study	Not clear:
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: People having abdominothoracic surgery
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Patients more than 40 years old who had had major elective abdominothoracic surgery
Exclusion criteria	Contraindication to heparin treatment, thromboembolism had occurred within previous 12 months
Recruitment/selection of patients	Consecutive patients
Age, gender and ethnicity	Age - Mean (range): UFH group: 59 (40-87), control group: 60 (40-87). Gender (M:F): Not reported. Ethnicity: Not reported
Further population details	1. Active cancer: Not applicable (Mixed 17%). 2. Acute/elective: Elective 3. BMI : Not applicable 4. Laparoscopic/open surgery: Not applicable 5. Renal impairment: Not applicable
Indirectness of population	No indirectness
Interventions	(n=408) Intervention 1: Unfractionated heparin - Unfractionated heparin (low dose, administered subcutaneously). 50000U aqueous heparin sodium by subcutaneous injection two hours before surgery and then eight hourly, starting 8-10 hours after surgery. Treatment continued for 7 days or until discharged/ambulant. Duration 7 days (mean 6.4, range 1-20 days). Concurrent medication/care: Not reported. Indirectness: No indirectness (n=412) Intervention 2: No treatment - Usual care. Untreated group. Duration Not reported. Concurrent medication/care: Not reported. Indirectness: No indirectness
Funding	Academic or government funding (Supported by Ontario Provincial Government Health research grants and the St Josephs Hospital Foudation)
RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: UNFRACTIONATED HEPARIN (LOW DOSE, ADMINISTERED SUBCUTANEOUSLY) versus USUAL CARE	

Protocol outcome 1: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge
 - Actual outcome: DVT at Not reported; Group 1: 4/408, Group 2: 12/412
 Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;
 Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcomes not reported by the study

All-cause mortality at up to 90 days from hospital discharge; Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge; Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge; Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study;

Study	Gao 2012 ¹¹⁷
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	N/A (n=116)
Countries and setting	Conducted in China; Setting: Secondary care
Line of therapy	Not applicable
Duration of study	Not clear:
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: DVT was diagnosed using colour Doppler flow imaging. PE was diagnosed using computed tomographic pulmonary angiography.
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Patients with high risk factors for DVT (e.g. history of VTE, hypercoagulopathy, aged > 60 years, heart disease, varicose veins) who underwent gynaecological pelvic surgery for various gynaecological diseases
Exclusion criteria	Thrombophlebitis; acute deep venous thrombosis; platelet count < (100x10 ⁹)/L or coagulopathy; spontaneous bleeding in the last 6 months; congestive heart failure / pulmonary oedema / leg oedema; haematologic disorders; leg abnormalities / severe atherosclerosis of lower extremity vessels / ischaemic vascular diseases / severe leg deformities
Recruitment/selection of patients	Not stated
Age, gender and ethnicity	Age - Mean (SD): AES+IPC 60.9 (11.6) vs. AES only 59.4 (10.2). Gender (M:F): 0:108. Ethnicity: Implicitly assumed to be Chinese
Further population details	1. Active cancer: Active cancer (No. in (AES+IPC vs. AES only): Malignant tumour (16 vs. 19), Ovarian cancer (8 vs. 7), Endometrial carcinoma (3 vs. 6), Cervical cancer (5 vs. 6)). 2. Acute/elective: Not applicable 3. BMI : Not applicable 4. Laparoscopic/open surgery: Systematic review: mixed (No. in (AES+IPC vs. AES only): Laparotomy (10 vs. 17), Laparoscopic surgery (32 vs. 28), Vaginal surgery (10 vs. 11)). 5. Renal impairment: Not applicable
Extra comments	It is unclear at which exact point the participants were randomised to the interventions. It is reported that 116 patients were enrolled during the study period and 8 were excluded (but reasons for exclusion are not given), then subsequently 2 had their surgeries cancelled, 4 did not receive ultrasonography and 2 complained of sleep disturbances and discomfort due to IPC, and that ultimately 108 patients completed the study. However, it is reported several times in the article that 52 patients and 56 patients were randomly assigned to the AES+IPC and AES group, respectively. This gives the impression that 108 patients were randomised but this may not be the original number of people randomised.
Indirectness of population	Serious indirectness: Incidence of VTE is lower in Asian populations. Ethnicity of the participants is not reported in this

	study, however, it has been implicitly assumed that majority are Chinese.
Interventions	<p>(n=52) Intervention 1: Intermittent pneumatic compression devices - Full leg. Three-chamber SCD, Kendall®, USA (Tyco International Inc.), applied during and after operation, sequentially for 11 seconds with pressures of 45, 35 and 30mmHg at the ankle, calf and thigh, respectively. Duration Until ambulation (exact duration unclear). Concurrent medication/care: AES applied pre-operatively only. Indirectness: No indirectness</p> <p>(n=56) Intervention 2: Anti-embolism stockings - Mixed above/below knee. Adequately sized AES for above knee and below knee, worn pre-operatively. Duration Until normal ambulation (exact duration unclear). Concurrent medication/care: None. Indirectness: No indirectness</p>
Funding	Funding not stated

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: IPC+AES versus AES ONLY

Protocol outcome 1: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge

- Actual outcome: Number of DVT at Unclear; Group 1: 5/52, Group 2: 14/56

Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - High, Crossover - Low, Comments - Data of 8 participants who were excluded (for various reasons) are missing and it is unclear whether they were excluded before or after randomisation.

Moreover, the exact timings of interventions and the time points at which the data were collected are not reported.; Indirectness of outcome: No indirectness, Comments: The time period for outcome measurement has not been specified.; Group 1 Number missing: , Reason: The study reports that 116 patients were enrolled during the study period but eight were excluded, and subsequently, 2 had their surgeries cancelled, 4 did not receive ultrasonography and 2 complained of sleep disturbances and discomfort due to IPC. The study states that as a result, 108 patients completed the study.; Group 2 Number missing: , Reason: Unclear exactly how many are missing from each group.

Protocol outcome 2: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge

- Actual outcome: PE at Unclear; Group 1: 1/52, Group 2: 1/56

Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - High, Crossover - Low, Comments - Data of 8 participants who were excluded (for various reasons) are missing and it is unclear whether they were excluded before or after randomisation.

Moreover, the exact timings of interventions and the time points at which the data were collected are not reported.; Indirectness of outcome: No indirectness, Comments: The time period for outcome measurement has not been specified.; Group 1 Number missing: , Reason: The study reports that 116 patients were enrolled during the study period but eight were excluded, and subsequently, 2 had their surgeries cancelled, 4 did not receive ultrasonography and 2 complained of sleep disturbances and discomfort due to IPC. The study states that as a result, 108 patients completed the study.; Group 2 Number missing: , Reason: Unclear exactly how many are missing from each group.

Protocol outcomes not reported by the study	All-cause mortality at up to 90 days from hospital discharge; Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge; Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study;
---	--

Study	Gordon-smith 1972 ¹²⁵
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=98)
Countries and setting	Conducted in United Kingdom; Setting: Not reported
Line of therapy	Not applicable
Duration of study	Not clear:
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: Major abdominal operation or one of the following operations: prostatectomy, nephrectomy, ureterolithotomy, and radical mastectomy
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Over 40 years of age undergoing either a major abdominal operation or one of the following operations: prostatectomy, nephrectomy, ureterolithotomy, and radical mastectomy.
Exclusion criteria	Patients with a history of hepatitis, patients having elective splenectomy, patients who were the subject of a separate study
Recruitment/selection of patients	Not reported
Age, gender and ethnicity	Age - Mean (SD): UFH group: 61.5 (10.2), control group: 63.6 (12.1). Gender (M:F): 49:49. Ethnicity: Not reported
Further population details	1. Active cancer: Not applicable (32.7% malignant). 2. Acute/elective: Not applicable 3. BMI : Not applicable 4. Laparoscopic/open surgery: Not applicable 5. Renal impairment: Not applicable
Indirectness of population	No indirectness
Interventions	<p>(n=48) Intervention 1: Unfractionated heparin - Unfractionated heparin (low dose, administered subcutaneously). 5000U sodium heparin given subcutaneously 1 hour before operation, and thereafter the same dose was given 12 hourly until the fifth post-operative day. Duration 5 days. Concurrent medication/care: No other method of prophylaxis was used apart from routine ward exercises, physiotherapy and mobilisation according to the wishes of the surgeon in charge of each patient. Indirectness: No indirectness</p> <p>(n=50) Intervention 2: No treatment - Usual care. No heparin. Duration Not reported . Concurrent medication/care: No other method of prophylaxis was used apart from routine ward exercises, physiotherapy and mobilisation according to the wishes of the surgeon in charge of each patient. Indirectness: No indirectness</p>
Funding	Funding not stated

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: UNFRACTIONATED HEPARIN (LOW DOSE, ADMINISTERED SUBCUTANEOUSLY) versus USUAL CARE

Protocol outcome 1: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge

- Actual outcome: DVT at Not reported; Group 1: 4/48, Group 2: 21/50

Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low, Comments - ; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcome 2: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge

- Actual outcome: PE at Not reported; Group 1: 2/48, Group 2: 0/50

Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low, Comments - ; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcomes not reported by the study

All-cause mortality at up to 90 days from hospital discharge; Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge; Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study;

Study	Hartl 1990 ¹³⁹
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=250)
Countries and setting	Conducted in Austria; Setting: Not reported
Line of therapy	Not applicable
Duration of study	Not clear:
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: Elective abdominal surgery
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Patients over the age of 40 who had to undergo elective abdominal surgery except appendectomy and herniotomy were included
Exclusion criteria	Volume substitution with dextran or HES, oral anticoagulant therapy, patients on heparin, administration of drugs containing platelet function inhibitors, coagulation defects and recent preoperative thrombosis as well as allergy to iodine or heparin
Recruitment/selection of patients	Not reported
Age, gender and ethnicity	Age - Mean (SD): LMWH group: 64.6 (11.3), UFH group: 62.9 (12.6). Gender (M:F): 144:106. Ethnicity: Not reported
Further population details	1. Active cancer: Not applicable (Cancer 29.6%). 2. Acute/elective: Elective 3. BMI : Not applicable 4. Laparoscopic/open surgery: Not applicable 5. Renal impairment: Not applicable
Indirectness of population	No indirectness
Interventions	(n=126) Intervention 1: Low molecular weight heparin (licensed in UK) - Dalteparin (1,250 units once daily - 5,000 units twice daily). Fragmin 2500U once daily, started 2 hours preoperatively and was maintained until the patients were fully mobilized but at least for one week. Duration 7 days. Concurrent medication/care: Not reported (n=124) Intervention 2: Unfractionated heparin - Unfractionated heparin (low dose, administered subcutaneously). UFH 5000IU twice daily, started 2 hours preoperatively and was maintained until the patients were fully mobilized but at least for one week. Duration 7 days. Concurrent medication/care: Not reported. Indirectness: No indirectness
Funding	Funding not stated
RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: DALTEPARIN (1,250 UNITS ONCE DAILY - 5,000 UNITS TWICE DAILY) versus UNFRACTIONATED HEPARIN (LOW DOSE, ADMINISTERED SUBCUTANEOUSLY)	

Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge
 - Actual outcome: All-cause mortality at Not reported; Group 1: 5/126, Group 2: 3/124
 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0

Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge
 - Actual outcome: DVT at Not reported; Group 1: 5/112, Group 2: 5/115
 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 14; Group 2 Number missing: 9

Protocol outcome 3: Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge
 - Actual outcome: Major bleeding at Not reported; Group 1: 2/112, Group 2: 15/115
 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 14; Group 2 Number missing: 9

Protocol outcome 4: Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge
 - Actual outcome: Fatal PE at Not reported; Group 1: 1/112, Group 2: 1/115
 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 14; Group 2 Number missing: 9

Protocol outcomes not reported by the study

Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study;

Study	Hata 2016 ¹⁴⁰
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=298)
Countries and setting	Conducted in Japan; Setting: Hospital
Line of therapy	Not applicable
Duration of study	Intervention time: 5 days
Method of assessment of guideline condition	Adequate method of assessment/diagnosis
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Patients with urological malignancy aged 40 or older, scheduled for surgery at Jikei University Hospital from January 2011-December 2012, considered candidates for open or laparoscopic surgery of >45 minutes in length and with a life expectancy of at least 6 months after surgery
Exclusion criteria	Body weight >40kg; hypersensitivity to fondaparinux or LMWH; contraindication to anticoagulant therapy; active bleeding; documented bleeding disorder or thrombocytopenia; perioperative VTE within the previous year; severe hepatic dysfunction; severe renal dysfunction (eGFR <30mL/min/1.73m ²); concurrent disorder such as gastrointestinal ulceration or diverticulitis, colitis, bacterial endocarditis, severe diabetes mellitus, severe hypertension or disseminated intravascular coagulation; haemorrhagic stroke; brain, spine or eye surgery within the previous 3 months; HIT; or pregnancy
Recruitment/selection of patients	Not reported
Age, gender and ethnicity	Age - Mean (SD): Fonda group 64.7 (7.5); LMWH group 63.9 (7.5). Gender (M:F): 282:16. Ethnicity: Not reported
Further population details	1. Active cancer: Active cancer 2. Acute/elective: Not applicable 3. BMI : Not applicable 4. Laparoscopic/open surgery: Not applicable (Mixed). 5. Renal impairment: No renal impairment (eGFR greater than 30ml/min/1.73m ²)
Indirectness of population	No indirectness
Interventions	(n=152) Intervention 1: Fondaparinux - Fondaparinux (all doses). Fondaparinux (2.5mg), once daily, starting on postoperative day 2 until day 5. Plus UFH (5000U) started 6 hours after wound closure and continued every 12 hours until the day after surgery. Plus mechanical thromboprophylaxis (AES and IPCD) worn until ambulatory. If eGFR ranged from 30-50 mL/min/1.732 and the risk of bleeding was high, prophylaxis could be reduced to 1.5mg (fondaparinux) or 2000U daily (enoxaparin), at the discretion of the physician. Duration 5 days. Concurrent medication/care: Not reported. Indirectness: No indirectness (n=146) Intervention 2: Low molecular weight heparin (licensed in UK) - Enoxaparin (20mg once daily – 60mg twice

	<p>daily). LMWH (enoxaparin, 2000U, twice daily) starting on postoperative day 2 until day 5. Plus UFH (5000U) started 6 hours after wound closure and continued every 12 hours until the day after surgery. Plus mechanical thromboprophylaxis (AES and IPCD) worn until ambulatory. If eGFR ranged from 30-50 mL/min/1.732 and the risk of bleeding was high, prophylaxis could be reduced to 1.5mg (fondaparinux) or 2000U daily (enoxaparin), at the discretion of the physician. Duration 5 days. Concurrent medication/care: Not reported. Indirectness: No indirectness</p>
<p>Funding</p>	<p>Study funded by industry (This study was financially supported by Glaxo Smith Kline K. K. and Kalen Pharmaceutical Co. LTD.)</p>
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: FONDAPARINUX (ALL DOSES) versus ENOXAPARIN (20MG ONCE DAILY – 60MG TWICE DAILY)</p> <p>Protocol outcome 1: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge - Actual outcome: PE at Not reported; Group 1: 0/130, Group 2: 2/128 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - High, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 22, Reason: ; Group 2 Number missing: 18</p> <p>Protocol outcome 2: Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge - Actual outcome: Major bleeding at Not reported; Group 1: 2/152, Group 2: 1/146 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 0, Reason: ; Group 2 Number missing: 0</p>	
<p>Protocol outcomes not reported by the study</p>	<p>All-cause mortality at up to 90 days from hospital discharge; Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge; Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study;</p>

Study	Hauch 1988 ¹⁴¹
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=63)
Countries and setting	Conducted in Denmark; Setting: Hospital
Line of therapy	Not applicable
Duration of study	Intervention + follow up: 7 days
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: Elective major abdominal surgery
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Patients aged 40 or over scheduled for elective major abdominal surgery, provided it was possible to place a central venous catheter and the expected postoperative hospitalisation was at least 7 days
Exclusion criteria	Hepatic or renal insufficiency, normosion test below 60%, haemorrhagic diathesis, history of cerebral vascular disease, pregnancy, thrombocytopenia, anticoagulation or fibrinolytic treatment within one month before surgery, untreated hypertension and allergy to heparin or iodine.
Recruitment/selection of patients	Not reported
Age, gender and ethnicity	Age - Median (range): low dose group: 68 (41-85), standard dose group: 72 (40-88). Gender (M:F): 13:22. Ethnicity: Not stated
Further population details	1. Active cancer: 2. Acute/elective: 3. BMI : 4. Laparoscopic/open surgery: 5. Renal impairment:
Indirectness of population	No indirectness
Interventions	(n=22) Intervention 1: Low molecular weight heparin (licensed in UK) - Tinzaparin (2,500 units once daily – 9,000 units once daily). LMWH 2500U administered subcutaneously 2 hours preoperatively and once daily in the postoperative period for 7 days or until discharge. Duration 7 days. Concurrent medication/care: Not reported. Indirectness: No indirectness (n=20) Intervention 2: Low molecular weight heparin (licensed in UK) - Tinzaparin (2,500 units once daily – 9,000 units once daily). LMWH 3500U administered subcutaneously 2 hours preoperatively and once daily in the postoperative period for 7 days or until discharge. Duration 7 days. Concurrent medication/care: Not reported. Indirectness: No indirectness
Funding	Funding not stated

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: TINZAPARIN LOW DOSE (2,500 UNITS ONCE DAILY – 9,000 UNITS ONCE DAILY) versus TINZAPARIN STANDARD DOSE (2,500 UNITS ONCE DAILY – 9,000 UNITS ONCE DAILY)

Protocol outcome 1: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge

- Actual outcome: DVT at 7 days; Group 1: 2/16, Group 2: 0/19

Risk of bias: All domain - Very high, Selection - Very high, Blinding - High, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Baseline details: Low dose group had a lot more predisposing risk factors; Group 1 Number missing: 6; Group 2 Number missing: 1

Protocol outcome 2: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge

- Actual outcome: PE at 7 days; Group 1: 0/16, Group 2: 0/19

Risk of bias: All domain - Very high, Selection - Very high, Blinding - High, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Baseline details: Low dose group had a lot more predisposing risk factors; Group 1 Number missing: 6; Group 2 Number missing: 1

Protocol outcome 3: Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge

- Actual outcome: Major bleeding at 7 days; Group 1: 0/16, Group 2: 1/19

Risk of bias: All domain - Very high, Selection - Very high, Blinding - High, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Baseline details: Low dose group had a lot more predisposing risk factors; Group 1 Number missing: 6; Group 2 Number missing: 1

Protocol outcome 4: Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge

- Actual outcome: Fatal PE at 7 days; Group 1: 0/16, Group 2: 0/19

Risk of bias: All domain - Very high, Selection - Very high, Blinding - High, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Baseline details: Low dose group had a lot more predisposing risk factors; Group 1 Number missing: 6; Group 2 Number missing: 1

Protocol outcomes not reported by the study

All-cause mortality at up to 90 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical

interventions at duration of study;

Study	Holford 1976 ¹⁴⁹
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=98)
Countries and setting	Conducted in United Kingdom; Setting: Not reported
Line of therapy	Not applicable
Duration of study	Not clear:
Method of assessment of guideline condition	Unclear method of assessment/diagnosis: Elective major surgery
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Patients over 40 years of age about to undergo elective major surgery
Exclusion criteria	Not reported
Recruitment/selection of patients	Not reported
Age, gender and ethnicity	Age - Mean (SD): Stockings group: 58 (10.7), control 59 (9.5). Gender (M:F): Not reported. Ethnicity: Not reported
Further population details	1. Active cancer: Not applicable (Mixed 20% malignancy). 2. Acute/elective: Elective 3. BMI : Not applicable 4. Laparoscopic/open surgery: Not applicable 5. Renal impairment: Not applicable
Indirectness of population	No indirectness
Interventions	<p>(n=48) Intervention 1: Anti-embolism stockings - Above knee. AES, full length, fitted 12 hours before operation and not removed until the patient was fully ambulant, usually on the 4th or 5th day after the operation. Duration 4-5 days. Concurrent medication/care: No other specific method for preventing DVT was used, but all patients underwent the usual ward routine of encouraging early leg activity while in bed and early ambulation whenever possible. Indirectness: No indirectness</p> <p>(n=47) Intervention 2: No treatment - Usual care. Control group. Duration Not reported. Concurrent medication/care: No other specific method for preventing DVT was used, but all patients underwent the usual ward routine of encouraging early leg activity while in bed and early ambulation whenever possible. Indirectness: No indirectness</p>
Funding	Equipment / drugs provided by industry (Stockings provided by the Kendall Company)
RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: ABOVE KNEE versus USUAL CARE	
Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge	

- Actual outcome: All-cause mortality at Not reported; Group 1: 0/48, Group 2: 0/47
 Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;
 Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge

- Actual outcome: DVT at Not reported; Group 1: 11/48, Group 2: 23/47
 Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;
 Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcome 3: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge

- Actual outcome: PE at Not reported; Group 1: 0/48, Group 2: 1/47
 Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;
 Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcomes not reported by the study

Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge; Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study;

Study	Kaaja 1992 ¹⁶¹
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=68)
Countries and setting	Conducted in Finland; Setting: Two centres
Line of therapy	Not applicable
Duration of study	Intervention + follow up: 3-4 weeks
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: Abdominal hysterectomy
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Patients were enrolled in the trial if they were aged between 35 and 75, were scheduled for abdominal hysterectomy and under general anaesthesia and exhibited at least one of the following risk factors: a history of DVT and/or PE, varicose veins, congestive heart failure, chronic bronchitis, oestrogen treatment, obesity (>20% ideal body weight) and carcinoma of the uterine corpus
Exclusion criteria	Known bleeding tendency, abnormal coagulation test results, thrombocytopenia, acute bleeding, severe arterial hypertension, impaired renal or hepatic function, hypersensitivity to heparin, metabisulphite or dihydroergotamine or mental disorder
Recruitment/selection of patients	Not reported
Age, gender and ethnicity	Age - Mean (SD): LMWH group: 48.1 (8.6), UFH group: 50.4 (8.8). Gender (M:F): Female. Ethnicity: Not reported
Further population details	1. Active cancer: Not applicable (25% malignancy). 2. Acute/elective: Not applicable 3. BMI : Mixed (33.8% obese). 4. Laparoscopic/open surgery: Not applicable 5. Renal impairment: No renal impairment (eGFR greater than 30ml/min/1.73m2) (Excluded impaired renal function).
Indirectness of population	No indirectness
Interventions	(n=37) Intervention 1: Low molecular weight heparin (licensed in UK) - Enoxaparin (20mg once daily – 60mg twice daily). 20mg enoxaparin subcutaneously once a day, administered 2 hours before operation and continued for 3 day. Duration 3 days. Concurrent medication/care: Not reported. Indirectness: No indirectness (n=31) Intervention 2: Unfractionated heparin - Unfractionated heparin (low dose, administered subcutaneously). Heparin 5000U twice daily, administered 2 hours before operation and continued for 3 days. Duration 3 days. Concurrent medication/care: Not reported. Indirectness: No indirectness
Funding	Funding not stated

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: ENOXAPARIN (20MG ONCE DAILY – 60MG TWICE DAILY) versus UNFRACTIONATED HEPARIN (LOW DOSE, ADMINISTERED SUBCUTANEOUSLY)

Protocol outcome 1: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge

- Actual outcome: DVT at 3-4 weeks; Group 1: 0/37, Group 2: 0/31

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Baseline details: 35.1% versus 51.6% obese; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcome 2: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge

- Actual outcome: PE at 3-4 weeks; Group 1: 0/37, Group 2: 0/31

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Baseline details: 35.1% versus 51.6% obese; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcome 3: Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge

- Actual outcome: Major bleeding at 3-4 weeks; Group 1: 0/37, Group 2: 6/31

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Baseline details: 35.1% versus 51.6% obese; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcomes not reported by the study

All-cause mortality at up to 90 days from hospital discharge; Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study;

Study	Kakkar 1972 ¹⁶⁶
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=78)
Countries and setting	Conducted in United Kingdom; Setting: Not reported
Line of therapy	Not applicable
Duration of study	Intervention time: 7 days
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: Major surgery
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Patients aged over 40 years undergoing major surgery
Exclusion criteria	Patients with clinical signs of recent DVT, operations on the thyroid gland, patents already on prophylactic anticoagulants
Recruitment/selection of patients	Not reported
Age, gender and ethnicity	Age - Mean (range): UFH group: 63.7 (42-90), control group: 64.4 (40-88). Gender (M:F): 45:33. Ethnicity: Not reported
Further population details	1. Active cancer: Not applicable (34.6% malignancy). 2. Acute/elective: Not applicable 3. BMI : Mixed (24.4% obese (undefined)). 4. Laparoscopic/open surgery: Not applicable 5. Renal impairment: Not applicable
Indirectness of population	No indirectness
Interventions	(n=39) Intervention 1: Unfractionated heparin - Unfractionated heparin (low dose, administered subcutaneously). Calcium heparin injected 2 hours before operation and thereafter every 12 hours for 7 days. Duration 7 days. Concurrent medication/care: Routine physiotherapy was used in all patients. Indirectness: No indirectness (n=39) Intervention 2: No treatment - Placebo. Placebo solution of gelatin, injected 2 hours before operation and thereafter every 12 hours for 7 days. Duration 7 days. Concurrent medication/care: Routine physiotherapy was used in all patients. Indirectness: No indirectness
Funding	Other (Financial support from the Kings College Hospital Research Trust, Pfizer Ltd financed a research fellowship)
RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: UNFRACTIONATED HEPARIN (LOW DOSE, ADMINISTERED SUBCUTANEOUSLY) versus PLACEBO	
Protocol outcome 1: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler)	

ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge

- Actual outcome: DVT at 10 days; Group 1: 3/39, Group 2: 17/39

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcome 2: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge

- Actual outcome: PE at Not reported; Group 1: 0/39, Group 2: 0/39

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcomes not reported by the study

All-cause mortality at up to 90 days from hospital discharge; Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge; Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study;

Study	Kakkar 1993 ¹⁶⁵
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=3938)
Countries and setting	Conducted in United Kingdom; Setting: 19 hospitals in the Midlands and South East England
Line of therapy	Not applicable
Duration of study	Intervention + follow up: 4-8 weeks
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: Major elective abdominal surgery
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Male and female patients over 40 years of age, scheduled to undergo major elective abdominal surgery
Exclusion criteria	Known allergy to heparin, taking oral anticoagulants immediately before admission, had had a severe haemorrhagic episode in the previous 3 months unrelated to the proposed surgery, had a known bleeding diathesis, scheduled for reoperation during the study period, were women of childbearing age not actively avoiding pregnancy, or had any other contraindication to heparin
Recruitment/selection of patients	Not reported
Age, gender and ethnicity	Age - Other: 40-80+. Gender (M:F): 1314:2495. Ethnicity: Not reported
Further population details	1. Active cancer: Not applicable (Mixed 36.9%). 2. Acute/elective: Elective 3. BMI : Not applicable 4. Laparoscopic/open surgery: Not applicable 5. Renal impairment: Not applicable
Indirectness of population	No indirectness
Interventions	(n=1960) Intervention 1: Low molecular weight heparin (licensed in UK) - Dalteparin (1,250 units once daily - 5,000 units twice daily). 2500U once daily plus placebo injection, starting 1-4 hours before surgery for at least 5 postoperative days and discontinued when the patient was fully mobile. Duration 5 days. Concurrent medication/care: Not reported. Indirectness: No indirectness (n=1978) Intervention 2: Unfractionated heparin - Unfractionated heparin (low dose, administered subcutaneously). 5000U UFH, begun 1-4 hours before surgery and continued for at least 5 days postoperatively and only discontinued when the patient was fully mobile . Duration 5 days. Concurrent medication/care: Not reported. Indirectness: No indirectness
Funding	Other (Supported by a grant from Thrombosis Research Trust and medication provided by Kabi Pharmacia)

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: DALTEPARIN (1,250 UNITS ONCE DAILY - 5,000 UNITS TWICE DAILY) versus UNFRACTIONATED HEPARIN (LOW DOSE, ADMINISTERED SUBCUTANEOUSLY)

Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge

- Actual outcome: All-cause mortality at 4-8 weeks; Group 1: 63/1894, Group 2: 47/1915

Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 66; Group 2 Number missing: 62

Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge

- Actual outcome: DVT at 4-8 weeks; Group 1: 11/1894, Group 2: 11/1915

Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 66; Group 2 Number missing: 62

Protocol outcome 3: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge

- Actual outcome: PE at 4-8 weeks; Group 1: 8/1894, Group 2: 11/1915

Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 66; Group 2 Number missing: 62

Protocol outcome 4: Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge

- Actual outcome: Major bleeding at 4-8 weeks; Group 1: 69/1894, Group 2: 91/1915

Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 66; Group 2 Number missing: 62

Protocol outcome 5: Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge

- Actual outcome: Fatal PE at 4-8 weeks; Group 1: 5/1894, Group 2: 3/1915

Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 66; Group 2 Number missing: 62

Protocol outcomes not reported by the study

Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration

of study; Technical complications of mechanical interventions at duration of study;

Study	Koller 1986-1 ¹⁷⁶
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=43)
Countries and setting	Conducted in Switzerland; Setting: Not reported
Line of therapy	Not applicable
Duration of study	Not clear:
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: Elective visceral surgery
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Patients between 20 and 80 years undergoing the following elective operations: thoracotomy, cholecystectomy, colon resection, proximal selective vagotomy, herniotomy, breast operation and other visceral operations
Exclusion criteria	Previous history of a bleeding disorder, pregnancy, ingestion of acetylsalicylic during the last 5 days before operation and any type of anticoagulation before the operation
Recruitment/selection of patients	Not reported
Age, gender and ethnicity	Age - Mean (SD): LMWH group: 52.8 (15.0), UFH group: 57.3 (15.1). Gender (M:F): 28:15. Ethnicity: Not reported
Further population details	1. Active cancer: Not applicable 2. Acute/elective: Elective 3. BMI : Not applicable 4. Laparoscopic/open surgery: Not applicable 5. Renal impairment: Not applicable
Indirectness of population	No indirectness
Interventions	(n=23) Intervention 1: Low molecular weight heparin (licensed in UK) - Dalteparin (1,250 units once daily - 5,000 units twice daily). 7500U once daily, first dose given 1 hour before operation, the second at 6pm, thereafter 12 hourly for a minimum of 5 days. The evening injection contained placebo. Duration 5 days. Concurrent medication/care: Not reported (n=20) Intervention 2: Unfractionated heparin - Unfractionated heparin (low dose, administered subcutaneously). 5000 U twice daily. Duration 5 days. Concurrent medication/care: Not reported. Indirectness: No indirectness
Funding	Study funded by industry (Study supported by KabiVitrum AB, Stockholm, Sweden)
RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: DALTEPARIN (1,250 UNITS ONCE DAILY - 5,000 UNITS TWICE DAILY) versus UNFRACTIONATED HEPARIN (LOW DOSE, ADMINISTERED SUBCUTANEOUSLY)	

Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge
 - Actual outcome: All-cause mortality at 30 days; Group 1: 0/23, Group 2: 0/20
 Risk of bias: All domain - High, Selection - Very high, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;
 Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge
 - Actual outcome: DVT at 30 days; Group 1: 0/23, Group 2: 0/20
 Risk of bias: All domain - High, Selection - Very high, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;
 Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcome 3: Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge
 - Actual outcome: Major bleeding at 30 days; Group 1: 6/23, Group 2: 1/20
 Risk of bias: All domain - High, Selection - Very high, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;
 Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcomes not reported by the study

Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge; Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study;

Study	Koller 1986-2 ¹⁷⁶
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=146)
Countries and setting	Conducted in Switzerland
Line of therapy	Not applicable
Duration of study	Intervention + follow up: 30 days
Method of assessment of guideline condition	--
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Define
Exclusion criteria	Define
Age, gender and ethnicity	Age - --: . Gender (M:F): Define. Ethnicity: Not reported
Further population details	1. Active cancer: Not applicable (Mixed 14.4% malignancy). 2. Acute/elective: Elective 3. BMI : Not applicable 4. Laparoscopic/open surgery: Not applicable 5. Renal impairment: Not applicable
Indirectness of population	--
Interventions	(n=75) Intervention 1: Low molecular weight heparin (licensed in UK) - Dalteparin (1,250 units once daily - 5,000 units twice daily). 2500U once a day. Duration 5 days. Concurrent medication/care: Not reported. Indirectness: No indirectness (n=75) Intervention 2: Unfractionated heparin - Unfractionated heparin (low dose, administered subcutaneously). UFH 5000U twice daily. Duration 5 days. Concurrent medication/care: Not reported. Indirectness: No indirectness
Funding	Funding not stated

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: DALTEPARIN (1,250 UNITS ONCE DAILY - 5,000 UNITS TWICE DAILY) versus UNFRACTIONATED HEPARIN (LOW DOSE, ADMINISTERED SUBCUTANEOUSLY)

Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge

- Actual outcome: All-cause mortality at 30 days; Group 1: 0/74, Group 2: 0/72

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 1; Group 2 Number missing: 3

Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge

- Actual outcome: DVT at 30 days; Group 1: 2/74, Group 2: 1/72

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 1; Group 2 Number missing: 3

Protocol outcome 3: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQspect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge

- Actual outcome: PE at 30 days; Group 1: 0/74, Group 2: 1/72

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 1; Group 2 Number missing: 3

Protocol outcome 4: Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge

- Actual outcome: Major bleeding at 30 days; Group 1: 17/74, Group 2: 23/72

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 1; Group 2 Number missing: 3

Protocol outcomes not reported by the study

Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQspect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study;

Study	Kutnowski 1977 ¹⁸¹
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=47)
Countries and setting	Conducted in Belgium; Setting: Hospital
Line of therapy	Not applicable
Duration of study	Not clear:
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: Major urological operation
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Patients aged 40 years or over admitted to the hospital for a major urological operation lasting more than half an hour and requiring at least 7 days of postoperative hospital care
Exclusion criteria	Patients with thyroid disease, recent venous thrombosis or lower limb amputation. Patients having emergency surgery, taking anticoagulants or antiagregating drugs
Recruitment/selection of patients	Not reported
Age, gender and ethnicity	Age - Mean (SD): UFH group: 70.5, control group: 60.7. Gender (M:F): 37:10. Ethnicity: Not reported
Further population details	1. Active cancer: Not applicable (Mixed 10.6% malignant disease). 2. Acute/elective: Not applicable 3. BMI : Not applicable 4. Laparoscopic/open surgery: Not applicable 5. Renal impairment: Not applicable
Indirectness of population	No indirectness
Interventions	(n=22) Intervention 1: Unfractionated heparin - Unfractionated heparin (low dose, administered subcutaneously). 5000U calcium heparin, given 2 hours before operation and then every 8 hours for 6 days. Duration 6 days. Concurrent medication/care: All patients underwent physiotherapy with passive and active exercises for the legs. Patients with varicose veins wore elastic stockings during and after operation. Indirectness: No indirectness (n=25) Intervention 2: No treatment - Placebo. 0.2ml distilled water. Duration 6 days. Concurrent medication/care: All patients underwent physiotherapy with passive and active exercises for the legs. Patients with varicose veins wore elastic stockings during and after operation. Indirectness: No indirectness
Funding	Funding not stated

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: UNFRACTIONATED HEPARIN (LOW DOSE, ADMINISTERED SUBCUTANEOUSLY) versus PLACEBO

Protocol outcome 1: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge
 - Actual outcome: DVT at Not reported; Group 1: 3/22, Group 2: 12/25
 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;
 Indirectness of outcome: No indirectness ; Baseline details: Difference of 10 years in average age; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcomes not reported by the study

All-cause mortality at up to 90 days from hospital discharge; Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge; Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge; Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study;

Study	Lahnborg 1975 ¹⁸⁴
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=112)
Countries and setting	Conducted in Sweden; Setting: Not reported
Line of therapy	Not applicable
Duration of study	Intervention + follow up: 5 days
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: Major elective abdominal surgery
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Patients admitted for elective major abdominal surgery
Exclusion criteria	Patients with allergy to iodine or with cardiopulmonary disease
Recruitment/selection of patients	Not reported
Age, gender and ethnicity	Age - Mean (range): UFH group: 62 (40-86), control group: 63 (40-80). Gender (M:F): Not reported. Ethnicity: Not reported
Further population details	1. Active cancer: Not applicable 2. Acute/elective: Elective 3. BMI : Not applicable 4. Laparoscopic/open surgery: Not applicable 5. Renal impairment: Not applicable
Indirectness of population	No indirectness
Interventions	(n=58) Intervention 1: Unfractionated heparin - Unfractionated heparin (low dose, administered subcutaneously). UFH 5000U of sodium heparin, subcutaneously 2-5 hours before surgery and twice daily starting 12 hours after the preoperative dose and then for 5 days . Duration 5 days. Concurrent medication/care: All patients had physiotherapy before and after the operation, including leg and breathing exercises (n=54) Intervention 2: No treatment - Placebo. 0.5ml of 0.85% saline. Duration 5 days. Concurrent medication/care: All patients had physiotherapy before and after the operation, including leg and breathing exercises. Indirectness: No indirectness
Funding	Funding not stated
RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: UNFRACTIONATED HEPARIN (LOW DOSE, ADMINISTERED SUBCUTANEOUSLY) versus PLACEBO	
Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge	

- Actual outcome: All-cause mortality at 5 days; Group 1: 0/58, Group 2: 0/54
 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;
 Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcome 2: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge

- Actual outcome: PE at Not reported; Group 1: 9/58, Group 2: 24/54
 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;
 Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcome 3: Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge

- Actual outcome: Major bleeding at Not reported; Group 1: 0/58, Group 2: 0/54
 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;
 Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcomes not reported by the study

Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge; Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study;

Study	Leizorovicz 1991 ²⁰⁴
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=1290)
Countries and setting	Conducted in France, United Kingdom; Setting: 23 centres located in France and the UK
Line of therapy	Not applicable
Duration of study	Intervention + follow up: 1 month
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: General surgery (71.4% abdominal, 13.5% gynaecological, 9.8% urological, 5.3% thoracic)
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Patients undergoing general surgery (abdominal, gynaecological, urological, thoracic, but not cardiac surgery) who were 40 years or older and in whom general anaesthesia longer than 30 minutes was anticipated. Only patients with at least one of the following risk factors were included: previous history of VTE, varicose veins, obesity, contraceptive pill, hormonal replacement therapy, chronic respiratory insufficiency, heart failure, malignancy, previous long bone fracture of lower limb, bed rest >5 days before surgery, predicted duration of surgery >4 hours, >60 years of age
Exclusion criteria	Not reported
Recruitment/selection of patients	Not reported
Age, gender and ethnicity	Age - Mean (SD): 61 (SD not reported). Gender (M:F): 513:777. Ethnicity: Not reported
Further population details	1. Active cancer: Not applicable (38.5% malignancy). 2. Acute/elective: Elective 3. BMI : Not applicable (Obesity (overweight >20%) = 28%). 4. Laparoscopic/open surgery: Not applicable 5. Renal impairment: Not applicable

Indirectness of population	No indirectness
Interventions	<p>(n=431) Intervention 1: Low molecular weight heparin (licensed in UK) - Tinzaparin (2,500 units once daily – 9,000 units once daily). Logiparin 2500U once a day, started 2 hours before surgical intervention. The second injection was given 12 hours later, and treatment was continued for at least 7 days and for a maximum of 10 days . Duration 7-10 days. Concurrent medication/care: Stockings and other forms of DVT prophylaxis were not allowed. Indirectness: No indirectness</p> <p>(n=430) Intervention 2: Low molecular weight heparin (licensed in UK) - Tinzaparin (2,500 units once daily – 9,000 units once daily). 3500U once a day starting 2 hours before surgical intervention. Duration 7-10 days. Concurrent medication/care: Stockings and other forms of DVT prophylaxis were not allowed. Indirectness: No indirectness</p> <p>(n=429) Intervention 3: Unfractionated heparin - Unfractionated heparin (low dose, administered subcutaneously). Sodium heparin 5000U twice daily. Duration 7-10 days. Concurrent medication/care: Stockings and other forms of DVT prophylaxis were not allowed. Indirectness: No indirectness</p>
Funding	Funding not stated
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: TINZAPARIN LOW DOSE (2,500 UNITS ONCE DAILY – 9,000 UNITS ONCE DAILY) versus TINZAPARIN STANDARD DOSE (2,500 UNITS ONCE DAILY – 9,000 UNITS ONCE DAILY)</p> <p>Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge - Actual outcome: All-cause mortality at 1 month; Group 1: 10/431, Group 2: 10/430 Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge - Actual outcome: DVT at 8 days; Group 1: 16/431, Group 2: 7/430 Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 3: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast: pulmonary angiogram: ventilation/ perfusion scan including VQScpect: autoosv:</p>	

echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge

- Actual outcome: PE at 1 month; Group 1: 4/431, Group 2: 1/430

Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcome 4: Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge

- Actual outcome: Major bleeding at 1 month; Group 1: 14/431, Group 2: 10/430

Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: TINZAPARIN LOW DOSE (2,500 UNITS ONCE DAILY – 9,000 UNITS ONCE DAILY) versus UNFRACTIONATED HEPARIN (LOW DOSE, ADMINISTERED SUBCUTANEOUSLY)

Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge

- Actual outcome: All-cause mortality at 1 month; Group 1: 10/431, Group 2: 9/429

Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge

- Actual outcome: DVT at 8 days; Group 1: 16/431, Group 2: 7/429

Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

- Actual outcome: DVT at 8 days; Group 1: 16/431, Group 2: 7/429

Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcome 3: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQspect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge

- Actual outcome: PE at 1 month; Group 1: 4/431, Group 2: 2/429

Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcome 4: Major bleeding. Meets one or more of the following criteria: results in death: occurs at a critical site (intracranial, intraspinal, pericardial.

intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge

- Actual outcome: Major bleeding at 1 month; Group 1: 14/431, Group 2: 12/429

Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: TINZAPARIN STANDARD DOSE (2,500 UNITS ONCE DAILY – 9,000 UNITS ONCE DAILY) versus UNFRACTIONATED HEPARIN (LOW DOSE, ADMINISTERED SUBCUTANEOUSLY)

Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge

- Actual outcome: All-cause mortality at 1 month; Group 1: 10/430, Group 2: 9/429

Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcome 2: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge

- Actual outcome: PE at 1 month; Group 1: 1/430, Group 2: 2/429

Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcome 3: Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge

- Actual outcome: Major bleeding at 1 month; Group 1: 10/430, Group 2: 12/429

Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcomes not reported by the study

Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study;

Study	Marassi 1993 ²¹⁵
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=64)
Countries and setting	Conducted in Italy; Setting: Not reported
Line of therapy	Not applicable
Duration of study	Intervention + follow up: 7 days
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: elective major abdominal surgery
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Patients aged over 40 years and scheduled to undergo elective major abdominal surgery for cancer of the gastrointestinal tract
Exclusion criteria	Patients with severe renal or liver dysfunction, jaundice, abnormalities of haemostasis, active peptic ulcer, previous stroke
Recruitment/selection of patients	Not reported
Age, gender and ethnicity	Age - Mean (range): LMWH group: 64 (41-82), control group: 66 (47-79). Gender (M:F): 36:25. Ethnicity: Not reported
Further population details	1. Active cancer: Active cancer 2. Acute/elective: Elective 3. BMI : Not applicable 4. Laparoscopic/open surgery: Not applicable 5. Renal impairment: Not applicable (Excluded severe renal dysfunction).
Indirectness of population	No indirectness
Interventions	(n=31) Intervention 1: Low molecular weight heparin (not licensed in UK) - Nadroparin (2850 units once daily - up to 57 units/kg once daily). Subcutaneous injection of Seleparina starting on the day of surgery, then daily for 7 days. Duration 7 days. Concurrent medication/care: Not reported. Indirectness: No indirectness (n=33) Intervention 2: No treatment - Usual care. No form of prophylaxis . Duration 7 days . Concurrent medication/care: Not reported. Indirectness: No indirectness
Funding	Study funded by industry (Supported in part by a grant from "Programma Nazionale di Ricerca Farmaci, Consorzio Antitrombotici")
RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: NADROPARIN (2850 UNITS ONCE DAILY - UP TO 57 UNITS/KG ONCE DAILY) versus USUAL CARE	
Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge	

- Actual outcome: All-cause mortality at 7 days; Group 1: 0/30, Group 2: 0/31
 Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;
 Indirectness of outcome: No indirectness ; Group 1 Number missing: 1; Group 2 Number missing: 2

Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge

- Actual outcome: DVT at 7 days; Group 1: 2/30, Group 2: 11/31
 Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;
 Indirectness of outcome: No indirectness ; Group 1 Number missing: 1; Group 2 Number missing: 2

Protocol outcomes not reported by the study

Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge; Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge; Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study;

Study	Maxwell 2001 ²¹⁷
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=228)
Countries and setting	Conducted in USA; Setting: Gynecologic Oncology service at Duke University Medical Center
Line of therapy	Not applicable
Duration of study	Intervention + follow up: 30 days
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: Major abdominal or pelvic surgery
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	All patients over 40 years of age admitted to the Gynecologic Oncology service at Duke University Medical Center, undergoing major abdominal or pelvic surgery for known or suspected gynaecologic malignancy
Exclusion criteria	Deep vein thrombosis or pulmonary embolism in the previous 6 months, contraindication to heparin therapy, conduction anesthesia, history of heparin sensitivity, pregnancy, or history of coagulation abnormalities. Also, platelet count less than 100,000 or if the activated partial thromboplastin time or prothrombin time was over 1.5 times the control value
Recruitment/selection of patients	Not reported
Age, gender and ethnicity	Age - Median (range): IPCD group: 62 (35-85), LMWH group: 60 (41-87). Gender (M:F): Female. Ethnicity: Not reported
Further population details	1. Active cancer: Not applicable (Mixed 75% cancer). 2. Acute/elective: Not applicable 3. BMI : Not applicable 4. Laparoscopic/open surgery: Not applicable 5. Renal impairment: Not applicable
Indirectness of population	No indirectness
Interventions	<p>(n=106) Intervention 1: Intermittent pneumatic compression devices - Mixed full leg/below knee. External pneumatic compression sleeves, length not reported. Applied in the operating room with the induction of anesthesia and continued throughout the operative procedure as well as the first 5 days post operatively. When the patient was fully ambulatory, the device was temporarily removed and reinstated when the patient returned to bed. Duration 5 days. Concurrent medication/care: Not reported. Indirectness: No indirectness</p> <p>(n=105) Intervention 2: Low molecular weight heparin (licensed in UK) - Dalteparin (1,250 units once daily - 5,000 units twice daily). Dalteparin 2500U subcutaneously 1-2 hours before surgery. Post operatively patients received 2500U 12 hours after the first dose. After the perioperative split dose on the day of surgery, patients received a daily dose of 5000U, starting on the first postoperative days until the 5th postoperative day or day of discharge. Duration 5 days. Concurrent medication/care: Not reported. Indirectness: No indirectness</p>

Funding	Study funded by industry (Supported in part by unrestricted educational grants from the Pharmacia Corporation and Venodyne, and the ACOG/Ethicon Research Award for Innovations in Gynecologic surgery)
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: MIXED FULL LEG/BELOW KNEE versus DALTEPARIN (1,250 UNITS ONCE DAILY - 5,000 UNITS TWICE DAILY)</p> <p>Protocol outcome 1: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge - Actual outcome: DVT at 30 days; Group 1: 1/106, Group 2: 2/105 Risk of bias: All domain - High, Selection - Low, Blinding - High, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low, Comments - 17 patients excluded but unclear which groups they were in; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 2: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge - Actual outcome: PE at 30 days; Group 1: 0/106, Group 2: 0/105 Risk of bias: All domain - High, Selection - Low, Blinding - High, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low, Comments - 17 patients excluded but unclear which groups they were in; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 3: Heparin-induced thrombocytopenia at duration of study - Actual outcome: Thrombocytopenia at 3 days; Group 1: 4/106, Group 2: 2/105 Risk of bias: All domain - High, Selection - Low, Blinding - High, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low, Comments - 17 patients excluded but unclear which groups they were in; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p>	
Protocol outcomes not reported by the study	All-cause mortality at up to 90 days from hospital discharge; Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge; Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Health-related quality of life (validated scores only)

at up to 90 days from hospital discharge; Technical complications of mechanical interventions at duration of study;

Study	Mcleod 2001 ²²²
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=1349)
Countries and setting	Conducted in Canada; Setting: 10 university hospitals in Canada
Line of therapy	Not applicable
Duration of study	Intervention + follow up: 9 days
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: Patients undergoing colorectal surgery
Stratum	Overall
Subgroup analysis within study	Stratified then randomised: Before randomisation, patients were stratified by institution, nature of disease and the extent of anticipated dissection
Inclusion criteria	All adult patients undergoing surgery during which part or all of their colon or rectum was resected or in whom a complete rectal dissection was performed were eligible, provided the procedure was performed under general anesthesia and was at least 1 hour long
Exclusion criteria	Patients were excluded if they required anticoagulant, anti-inflammatory, or antiplatelet therapy that could not be discontinued, had hepatic or renal failure, had a history of a systemic bleeding diathesis or heparin induced thrombocytopenia, uncontrolled hypertension, haemorrhagic stroke or gastrointestinal hemorrhage in the previous 3 months, a major psychiatric disorder or a systemic allergy to contrast material, or were pregnant or lactating
Age, gender and ethnicity	Age - Mean (SD): LMWH group: 52 (18), UFH group: 50 (17). Gender (M:F): 731:618). Ethnicity: Not reported
Further population details	1. Active cancer: Not applicable (Mixed 35% cancer). 2. Acute/elective: Not applicable 3. BMI : Mixed (14.6% BMI >30%). 4. Laparoscopic/open surgery: Not applicable 5. Renal impairment: Not applicable (Excluded renal failure).
Indirectness of population	No indirectness
Interventions	<p>(n=674) Intervention 1: Low molecular weight heparin (licensed in UK) - Enoxaparin (20mg once daily – 60mg twice daily). Enoxaparin 40mg subcutaneously once daily in the morning plus 2 placebo injections. Initiated 2 hours before surgery and one further placebo injection was given at 8pm on the day of surgery. Thereafter patients received injections for up to 10 days. Duration 10 days. Concurrent medication/care: Other methods of pharmacologic or mechanical prophylaxis including AES were not allowed, nor was the use of nonsteroidal anti-inflammatory agents. Indirectness: No indirectness</p> <p>(n=675) Intervention 2: Unfractionated heparin - Unfractionated heparin (low dose, administered subcutaneously). Calcium heparin 5000U subcutaneously every 8 hours. Initiated 2 hours before surgery and one further placebo injection was given at 8pm on the day of surgery. Thereafter patients received injections for up to 10 days. Duration 10 days. Concurrent medication/care: Other methods of pharmacologic or mechanical prophylaxis including AES were</p>

	not allowed, nor was the use of nonsteroidal anti-inflammatory agents. Indirectness: No indirectness
Funding	Study funded by industry (Supported by a grant from Rhone-Poulenc Rorer Canada Inc)
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: ENOXAPARIN (20MG ONCE DAILY – 60MG TWICE DAILY) versus UNFRACTIONATED HEPARIN (LOW DOSE, ADMINISTERED SUBCUTANEOUSLY)</p> <p>Protocol outcome 1: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge - Actual outcome: PE at 9 days; Group 1: 1/468, Group 2: 0/648 Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 206; Group 2 Number missing: 207</p> <p>Protocol outcome 2: Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge - Actual outcome: Major bleeding at 9 days; Group 1: 18/653, Group 2: 10/643 Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 21; Group 2 Number missing: 32</p>	
Protocol outcomes not reported by the study	All-cause mortality at up to 90 days from hospital discharge; Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge; Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study;

Study	Nagata 2015 ²³⁵
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	N/A (n=35)
Countries and setting	Conducted in Japan; Setting: Secondary/Tertiary care
Line of therapy	Not applicable
Duration of study	Intervention time: Up to 11 days
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: VTE was evaluated by chest, abdominal and lower extremities contrast-enhanced CT scan. VTE was diagnosed after discussion with board-certified radiologists who were blinded to interventions.
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Women aged > 40 years and weighed >40kg who were undergoing major abdominal or pelvic surgery for diagnosed or suspected gynaecologic malignancy
Exclusion criteria	Pre-operative VTE; hypersensitivity to enoxaparin / heparin / heparin derivatives; active bleeding and/or risk of bleeding; acute bacterial endocarditis; renal dysfunction of estimated glomerular filtration rate < 40ml/min/1.73m ² ; severe liver dysfunction; previous history of thrombosis and/or thrombophilia and/or current use of anticoagulant, platelet aggregation inhibitor, salicylic acid derivative or thrombolytic drug
Recruitment/selection of patients	Not stated
Age, gender and ethnicity	Age - Mean (SD): Enoxaparin 60.5 (10.7) vs. IPC alone 53.2 (10.9); p=0.08. Gender (M:F): 35 female patients. Ethnicity: Implicitly assumed to be all Japanese
Further population details	1. Active cancer: Active cancer (Uterine corpus cancer 43.3%: Ovarian cancer 40%: Cervical cancer 13.3%: Other cancer

	3.3%). 2. Acute/elective: Elective 3. BMI : Obese (BMI over 30 kg/m ²) (Obesity (BMI > 25) in enoxaparin group 31.3% vs. IPC alone group 7.1%; p=0.18). 4. Laparoscopic/open surgery: Not applicable 5. Renal impairment: No renal impairment (eGFR greater than 30ml/min/1.73m ²) (Renal dysfunction (eGFR < 40ml/min/1.73m ²) was a criterion for exclusion).
Indirectness of population	Serious indirectness: The participants are implicitly assumed to be all Japanese. Risk of developing VTE and incidence of VTE are lower amongst Asian populations compared to other populations.
Interventions	(n=16) Intervention 1: Low molecular weight heparin (licensed in UK) - Enoxaparin (20mg once daily – 60mg twice daily). Subcutaneous injections 20mg every 12 hrs; started on post-operative day 2. Duration 7 days. Concurrent medication/care: All patients used IPC immediately prior to surgery and the enoxaparin group continued its use until the first enoxaparin injection. Indirectness: No indirectness (n=14) Intervention 2: Intermittent pneumatic compression devices - Below knee. Pre-surgery: IPC only applied to feet and ankles (Novamedix A-V Impulse System). Post-surgery: IPC applied to all areas below knees (Veno Stream, Terumo Corporation). Duration Until full ambulation. Concurrent medication/care: All patients used IPC immediately prior to surgery. Indirectness: No indirectness
Funding	Funding not stated

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: ENOXAPARIN versus IPC ALONE

Protocol outcome 1: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge
 - Actual outcome: Incidence of DVT at Between 9 and 11 days after surgery; Group 1: 1/16, Group 2: 3/14; Comments: RR 3.43 (95% CI 0.40 to 29.33); p=0.32
 Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;
 Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0

Protocol outcome 2: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQspect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge
 - Actual outcome: Incidence of PE at Between 9 and 11 days after surgery; Group 1: 0/15, Group 2: 3/14; Comments: RR 7.47 (95% CI 0.42 to 132.78); p=0.10
 Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;
 Indirectness of outcome: No indirectness ; Group 1 Number missing: 1, Reason: One case was excluded from the analyses related to PE because PE was not evaluated due to the participant's allergy to the contrast medium so ultrasound was used only to evaluate DVT.: Group 2 Number missing: 0

Protocol outcome 3: Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge

- Actual outcome: Clinically apparent bleeding events at Between 9 and 11 days after surgery; Group 1: 2/16, Group 2: 1/14; Comments: p=1.0

Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness, Comments: Defined as one or more of the following events: RBC transfusion of $> 2\text{units}$; a decrease in Hb conc. of $> 2\text{g/dl}$; intracranial/intraocular/GI/epidural haemorrhage; bleeding from wounds/abdomen/retroperitoneal cavity that required surgical treatment which occurred after the timing of the 1st injection of enoxaparin; Group 1 Number missing: 0; Group 2 Number missing: 0

Protocol outcomes not reported by the study

All-cause mortality at up to 90 days from hospital discharge; Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study;

Study	Nicolaides 1983 ²³⁸
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=150)
Countries and setting	Conducted in United Kingdom; Setting: Not reported
Line of therapy	Not applicable
Duration of study	Not clear:
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: Major abdominal surgery
Stratum	Overall
Subgroup analysis within study	Stratified then randomised: Stratified into 4 groups according to the risk of DVT
Inclusion criteria	Over the age of 30 years, undergoing major abdominal operations
Exclusion criteria	Not reported
Recruitment/selection of patients	Not reported
Age, gender and ethnicity	Age - Mean (SD): ECS group: 59.2 (16.6), UFH group: 58.6 (13.3), mechanical group: 57.3 (13.4). Gender (M:F): Not reported. Ethnicity: Not reported
Further population details	1. Active cancer: Not applicable (Mixed 37.3% malignancy). 2. Acute/elective: Not applicable 3. BMI : Not applicable 4. Laparoscopic/open surgery: Not applicable 5. Renal impairment: Not applicable
Indirectness of population	No indirectness
Interventions	<p>(n=50) Intervention 1: Electrical stimulation. Electrical calf stimulation applied as soon as the patient was anaesthetised and continued throughout the operation. Duration During operation only . Concurrent medication/care: Additional prophylactic measures were not used in the postoperative period. Indirectness: No indirectness</p> <p>(n=50) Intervention 2: Intermittent pneumatic compression devices - Full leg. Intermittent sequential compression of the legs, used continually during operation and for a minimum of 72 hours in the postoperative period. If after this time the patient was ambulant, the IPCD was discontinued and TED stockings were applied on both legs. These were worn continuously for the rest of the patients stay in hospital. The maximum period of continuous use was 2 weeks. Duration Until discharge. Concurrent medication/care: Not reported. Indirectness: No indirectness</p> <p>(n=50) Intervention 3: Unfractionated heparin - Unfractionated heparin (low dose, administered subcutaneously). 5000U subcutaneous heparin administered 2 hours before operation and then every 12 hours until discharge. Duration Until discharge. Concurrent medication/care: Not reported. Indirectness: No indirectness</p>

Funding	Equipment / drugs provided by industry (Berk Pharmaceuticals UK provided the heparin, the Research Division of Kendall Corporation provided the intermittent sequential compression devices and TED stockings, and the A. G. Leventis Foundation provided a research grant)
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: ELECTRICAL STIMULATION versus FULL LEG</p> <p>Protocol outcome 1: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge - Actual outcome: DVT at Not reported; Group 1: 12/50, Group 2: 3/50 Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Baseline details: Gender not reported, BMI not reported ; Group 1 Number missing: ; Group 2 Number missing:</p> <p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: ELECTRICAL STIMULATION versus UNFRACTIONATED HEPARIN (LOW DOSE, ADMINISTERED SUBCUTANEOUSLY)</p> <p>Protocol outcome 1: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge - Actual outcome: DVT at Not reported; Group 1: 12/50, Group 2: 7/50 Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Baseline details: Gender not reported, BMI not reported ; Group 1 Number missing: ; Group 2 Number missing:</p> <p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: UNFRACTIONATED HEPARIN (LOW DOSE, ADMINISTERED SUBCUTANEOUSLY) versus FULL LEG</p> <p>Protocol outcome 1: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge - Actual outcome: DVT at Not reported; Group 1: 7/50, Group 2: 3/50 Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Baseline details: Gender not reported, BMI not reported ; Group 1 Number missing: ; Group 2 Number missing:</p>	
Protocol outcomes not reported by the study	All-cause mortality at up to 90 days from hospital discharge; Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge; Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of

≥2g/dl; a serious or life threatening clinical event at up to 45 days from hospital discharge; Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study;

Study	Nurmohamed 1995 ²⁴²
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=1471)
Countries and setting	Conducted in Multiple countries; Setting: 20 centres
Line of therapy	Not applicable
Duration of study	Intervention + follow up: 10 days
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: Major general surgery
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Patients over the age of 40 years if they underwent major general surgery lasting more than 45 minutes
Exclusion criteria	Allergy for heparin, iodine or contrast material, document bleeding tendency, pregnancy and the use of drugs interfering with coagulation
Recruitment/selection of patients	Not reported
Age, gender and ethnicity	Age - Mean (SD): UFH group: 61 (11), LMWH group: 61 (11). Gender (M:F): 670:734. Ethnicity: Not reported
Further population details	1. Active cancer: Not applicable (35.8% cancer). 2. Acute/elective: Not applicable 3. BMI : Mixed (35.9% obese). 4. Laparoscopic/open surgery: Not applicable 5. Renal impairment: Not applicable
Indirectness of population	No indirectness
Interventions	(n=725) Intervention 1: Low molecular weight heparin (licensed in UK) - Enoxaparin (20mg once daily – 60mg twice daily). Enoxaparin 20mg administered for 10 days or until discharge, starting 2 hours preoperatively. Duration 10 days. Concurrent medication/care: Not reported. Indirectness: No indirectness (n=719) Intervention 2: Unfractionated heparin - Unfractionated heparin (low dose, administered subcutaneously). 5000U three times daily started 2 hours preoperatively for 10 days. Duration 10 days. Concurrent medication/care: Not reported. Indirectness: No indirectness
Funding	Funding not stated
RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: ENOXAPARIN (20MG ONCE DAILY – 60MG TWICE DAILY) versus UNFRACTIONATED HEPARIN (LOW DOSE, ADMINISTERED SUBCUTANEOUSLY)	
Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge	

- Actual outcome: All-cause mortality at Not reported; Group 1: 4/718, Group 2: 6/709
 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;
 Indirectness of outcome: No indirectness ; Group 1 Number missing: 6; Group 2 Number missing: 10

Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge
 - Actual outcome: DVT at 10 days; Group 1: 25/718, Group 2: 8/709
 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;
 Indirectness of outcome: No indirectness ; Group 1 Number missing: 6; Group 2 Number missing: 10

Protocol outcome 3: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge
 - Actual outcome: PE at Not reported; Group 1: 0/718, Group 2: 0/709
 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;
 Indirectness of outcome: No indirectness ; Group 1 Number missing: 6; Group 2 Number missing: 10

Protocol outcome 4: Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge
 - Actual outcome: Major bleeding at Not reported; Group 1: 11/725, Group 2: 18/719
 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;
 Indirectness of outcome: No indirectness ; Group 1 Number missing: 6; Group 2 Number missing: 10

Protocol outcome 5: Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge
 - Actual outcome: Fatal PE at Not reported; Group 1: 1/718, Group 2: 0/709
 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;
 Indirectness of outcome: No indirectness ; Group 1 Number missing: 6; Group 2 Number missing: 10

Protocol outcomes not reported by the study	Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study;
---	---

Study	Ockelford 1989 ²⁴⁴
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=197)
Countries and setting	Conducted in New Zealand; Setting: Hospital
Line of therapy	Not applicable
Duration of study	Intervention + follow up: 42 days
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: Major abdominal surgery
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	More than 40 years of age, had a major abdominal surgery procedure exceeding 30 minutes, and an expected hospital stay of greater than 5 days
Exclusion criteria	Patients with a past history of a multiple VTE, concurrent antiplatelet or anticoagulant medication, significant renal failure and active peptic ulceration
Recruitment/selection of patients	Consecutive patients
Age, gender and ethnicity	Age - Mean (SD): LMWH group: 64.8 (21.1), placebo group: 64.3 (12.4. Gender (M:F): 1:1.04 LMWH, 1:1.5 placebo. Ethnicity: Not reported
Further population details	1. Active cancer: Not applicable (43% cancer). 2. Acute/elective: Not applicable 3. BMI : Not applicable 4. Laparoscopic/open surgery: Not applicable 5. Renal impairment: Not applicable (Excluded renal failure).
Indirectness of population	No indirectness

Interventions	<p>(n=102) Intervention 1: Low molecular weight heparin (licensed in UK) - Dalteparin (1,250 units once daily - 5,000 units twice daily). Fragmin 2500U administered 1-2 hours preoperatively and then once daily for 5-9 days. Duration 5-9 days. Concurrent medication/care: Not reported</p> <p>(n=95) Intervention 2: No treatment - Placebo. Normal saline solution. Duration 5-9 days. Concurrent medication/care: Not reported. Indirectness: No indirectness</p>
Funding	Study funded by industry (Financial support provided by Kabi Vitrum AB, Stockholm)

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: DALTEPARIN (1,250 UNITS ONCE DAILY - 5,000 UNITS TWICE DAILY) versus PLACEBO

Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge

- Actual outcome: All-cause mortality at 42 days; Group 1: 0/95, Group 2: 2/88

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 7; Group 2 Number missing: 7

Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge

- Actual outcome: DVT at 42 days; Group 1: 4/95, Group 2: 14/88

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 7; Group 2 Number missing: 7

Protocol outcome 3: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQspect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge

- Actual outcome: PE at 42 days; Group 1: 0/95, Group 2: 2/88

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 7; Group 2 Number missing: 7

Protocol outcome 4: Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge

- Actual outcome: Major bleeding at 42 days; Group 1: 4/95, Group 2: 4/88

Risk of bias: All domain - High. Selection - High. Blinding - Low. Incomplete outcome data - Low. Outcome reporting - Low. Measurement - Low. Crossover - Low;

<p>Indirectness of outcome: No indirectness ; Group 1 Number missing: 7; Group 2 Number missing: 7</p> <p>Protocol outcome 5: Heparin-induced thrombocytopenia at duration of study - Actual outcome: Thrombocytopenia at 42 days; Group 1: 0/95, Group 2: 0/88 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 7; Group 2 Number missing: 7</p>	
<p>Protocol outcomes not reported by the study</p>	<p>Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Technical complications of mechanical interventions at duration of study;</p>

Study	Onarheim 1986 ²⁴⁵
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	2 (n=52)
Countries and setting	Conducted in Norway; Setting: Not reported
Line of therapy	Not applicable
Duration of study	Intervention + follow up: 30 days
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: Surgical treatment of gastric, colonic or rectal malignancy
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Age >40 years, no contraindication to heparin treatment or hypersensitivity to iodine, no preceding anticoagulant medication, and informed consent
Exclusion criteria	Not reported
Recruitment/selection of patients	Not reported
Age, gender and ethnicity	Age - Mean (SD): LMWH group: 70.7 (8.9), UFH group: 70.0 (8.9). Gender (M:F): Not reported. Ethnicity: Not reported
Further population details	1. Active cancer: Active cancer 2. Acute/elective: Not applicable 3. BMI : Not applicable 4. Laparoscopic/open surgery: Not applicable 5. Renal impairment: Not applicable
Indirectness of population	No indirectness
Interventions	(n=25) Intervention 1: Low molecular weight heparin (licensed in UK) - Dalteparin (1.250 units once daily - 5.000 units

	<p>twice daily). KABI 2165 5000U given subcutaneously starting 2 hours before surgery and then every morning for 6 days. Duration 6 days. Concurrent medication/care: Not reported. Indirectness: No indirectness</p> <p>(n=27) Intervention 2: Unfractionated heparin - Unfractionated heparin (low dose, administered subcutaneously). Heparin 5000U given subcutaneously starting 2 hours before surgery, then at 8pm on the day of operation and later twice daily for the following 6 days. Duration 6 days. Concurrent medication/care: Not reported. Indirectness: No indirectness</p>
<p>Funding</p>	<p>Other (KabiVitrum made the study possible)</p>
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: DALTEPARIN (1,250 UNITS ONCE DAILY - 5,000 UNITS TWICE DAILY) versus UNFRACTIONATED HEPARIN (LOW DOSE, ADMINISTERED SUBCUTANEOUSLY)</p> <p>Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge - Actual outcome: All-cause mortality at 30 days; Group 1: 0/25, Group 2: 0/27 Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Baseline details: Some factors not reported e.g. gender; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge - Actual outcome: DVT at 30 days; Group 1: 1/25, Group 2: 0/27 Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Baseline details: Some factors not reported e.g. gender; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 3: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQspect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge - Actual outcome: PE at 30 days; Group 1: 0/25, Group 2: 0/27 Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: Serious indirectness, Comments: Method of confirmation not reported; Baseline details: Some factors not reported e.g. gender; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 4: Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood: leads to a drop in haemoglobin of $\geq 2g/dl$: a serious or life threatening</p>	

<p>clinical event at up to 45 days from hospital discharge - Actual outcome: Major bleeding at 30 days; Group 1: 1/25, Group 2: 1/27 Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Baseline details: Some factors not reported e.g. gender; Group 1 Number missing: ; Group 2 Number missing:</p>	
<p>Protocol outcomes not reported by the study</p>	<p>Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study;</p>

Study	Osman 2007 ²⁴⁶
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=75)
Countries and setting	Conducted in Egypt; Setting: Not reported
Line of therapy	Not applicable
Duration of study	Intervention + follow up: 2 weeks
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: Live donor renal transplant
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Live donor renal transplant patients
Exclusion criteria	Younger than 16 years, grafts with multiple arteries, a history of thromboembolic disease, atheromatous arteris, collagen vascular disease, intraoperative technical difficulties
Recruitment/selection of patients	Consecutive patients
Age, gender and ethnicity	Age - --: Control group: 26 (6), LMWH group: 28.3 (8), UFH group: 29.4 (8). Gender (M:F): 52:23. Ethnicity: Not reported
Further population details	1. Active cancer: Not applicable 2. Acute/elective: Not applicable 3. BMI : Not applicable 4. Laparoscopic/open surgery: Open surgery 5. Renal impairment: Not applicable
Indirectness of population	No indirectness
Interventions	(n=25) Intervention 1: Low molecular weight heparin (licensed in UK) - Tinzaparin (2.500 units once daily – 9.000 units

	<p>once daily). Subcutaneous tinzaparin sodium once daily 3500U, started postoperatively. Duration 1 week. Concurrent medication/care: Not reported. Indirectness: No indirectness</p> <p>(n=25) Intervention 2: Unfractionated heparin - Unfractionated heparin (low dose, administered subcutaneously). Subcutaneous conventional UFH 5000U twice daily, started postoperatively . Duration 1 week. Concurrent medication/care: Not reported. Indirectness: No indirectness</p> <p>(n=25) Intervention 3: No treatment - Usual care. No heparinisation. No further details. Duration 1 week. Concurrent medication/care: Not reported. Indirectness: No indirectness</p>
Funding	Funding not stated
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: TINZAPARIN (2,500 UNITS ONCE DAILY – 9,000 UNITS ONCE DAILY) versus UNFRACTIONATED HEPARIN (LOW DOSE, ADMINISTERED SUBCUTANEOUSLY)</p> <p>Protocol outcome 1: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge - Actual outcome: DVT at 2 weeks; Group 1: 0/25, Group 2: 0/25 Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 2: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge - Actual outcome: PE at 2 weeks; Group 1: 0/25, Group 2: 0/25 Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 3: Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge - Actual outcome: Major bleeding at 2 weeks; Group 1: 1/25, Group 2: 0/25 Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness : Group 1 Number missing: : Group 2 Number missing:</p>	

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: TINZAPARIN (2,500 UNITS ONCE DAILY – 9,000 UNITS ONCE DAILY) versus USUAL CARE

Protocol outcome 1: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge

- Actual outcome: DVT at 2 weeks; Group 1: 0/25, Group 2: 0/25

Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcome 2: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQspect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge

- Actual outcome: PE at 2 weeks; Group 1: 0/25, Group 2: 0/25

Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcome 3: Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge

- Actual outcome: Major bleeding at 2 weeks; Group 1: 1/25, Group 2: 0/25

Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: UNFRACTIONATED HEPARIN (LOW DOSE, ADMINISTERED SUBCUTANEOUSLY) versus USUAL CARE

Protocol outcome 1: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge

- Actual outcome: DVT at 2 weeks; Group 1: 0/25, Group 2: 0/25

Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcome 2: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQspect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge

- Actual outcome: PE at 2 weeks; Group 1: 0/25, Group 2: 0/25

Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcome 3: Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge

- Actual outcome: Major bleeding at 2 weeks; Group 1: 0/25, Group 2: 0/25

Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcomes not reported by the study

All-cause mortality at up to 90 days from hospital discharge; Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study;

Study	Porteous 1989 ²⁶⁵
Study type	RCT (randomised; Parallel)
Number of studies (number of participants)	1 (n=124)
Countries and setting	Conducted in United Kingdom; Setting: Not reported
Line of therapy	Not applicable
Duration of study	Not clear:
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: Major abdominal surgery
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Over 40 years of age undergoing major abdominal surgery
Exclusion criteria	Patients with varicose veins, a past history of DVT or myocardial infarction, premenopausal females, and patients undergoing peripheral vascular surgery
Recruitment/selection of patients	Not reported
Age, gender and ethnicity	Age - Mean (SD): Above knee group: 68 (11), below knee group: 63.5 (11.2). Gender (M:F): 49:65. Ethnicity: Not reported
Further population details	1. Active cancer: Not applicable (Malignant disease 40.4%). 2. Acute/elective: Not applicable 3. BMI : Not applicable 4. Laparoscopic/open surgery: Not applicable 5. Renal impairment: Not applicable
Indirectness of population	No indirectness

Interventions	<p>(n=60) Intervention 1: Anti-embolism stockings - Above knee. Above knee stockings fitted on the morning of operation, worn until discharge. Duration Until discharge. Concurrent medication/care: No other form of VTE prophylaxis was used, but leg movement in bed was encouraged and early mobilisation was routine. Indirectness: No indirectness</p> <p>(n=64) Intervention 2: Anti-embolism stockings - Below knee. Below knee stockings fitted on the morning of operation, worn until discharge. Duration Until discharge. Concurrent medication/care: No other form of VTE prophylaxis was used, but leg movement in bed was encouraged and early mobilisation was routine. Indirectness: No indirectness</p>
Funding	Equipment / drugs provided by industry (Stockings and I-labelled fibrinogen provided by Brevet Hospital Products LTD)
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: ABOVE KNEE versus BELOW KNEE</p> <p>Protocol outcome 1: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge - Actual outcome: DVT at Not reported; Group 1: 3/56, Group 2: 1/58 Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 4; Group 2 Number missing: 6</p>	
Protocol outcomes not reported by the study	<p>All-cause mortality at up to 90 days from hospital discharge; Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge; Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge; Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study;</p>

Study	Rasmussen 1988 ²⁷⁰
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=248)
Countries and setting	Conducted in Denmark; Setting: Not reported
Line of therapy	Not applicable
Duration of study	Not clear:
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: Major abdominal surgery
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Patients admitted for major abdominal surgery (duration of anaesthesia more than 1 hour and of age more than 40 years)
Exclusion criteria	Not reported
Recruitment/selection of patients	Not reported
Age, gender and ethnicity	Age - Mean (range): AES group: 63 (41-87), UFH group: 62 (40-90), AES+UFH: 61 (40-87). Gender (M:F): 109:139. Ethnicity: Not reported
Further population details	1. Active cancer: Not applicable 2. Acute/elective: Not applicable 3. BMI : Mixed (60% obesity (not defined)). 4. Laparoscopic/open surgery: Not applicable 5. Renal impairment: Not applicable
Indirectness of population	No indirectness

Interventions	<p>(n=74) Intervention 1: Anti-embolism stockings - Below knee. Bilateral AES from the toes to the knee were applied from the evening for operation to complete mobilisation, or for not less than 5 days postoperatively. Duration 5 days. Concurrent medication/care: Not reported. Indirectness: No indirectness</p> <p>(n=85) Intervention 2: Unfractionated heparin - Unfractionated heparin (low dose, administered subcutaneously). Sodium heparin 5000U administered subcutaneously every 12 hours beginning on the evening before operation and continued to complete mobilisation or for not less than 5 days postoperatively. Duration 5 days. Concurrent medication/care: Not reported. Indirectness: No indirectness</p> <p>(n=89) Intervention 3: Anti-embolism stockings - Below knee. AES below knee + UFH 5000U. Duration 5 days. Concurrent medication/care: Not reported. Indirectness: No indirectness</p>
Funding	Equipment / drugs provided by industry (The 99mTc-labelled plasmin and a Novo thrombograph was provided by Novo Ltd and Novo diagnostics)
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: BELOW KNEE versus UNFRACTIONATED HEPARIN (LOW DOSE, ADMINISTERED SUBCUTANEOUSLY)</p> <p>Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge - Actual outcome: All-cause mortality at Not reported; Group 1: 0/74, Group 2: 0/85 Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 2: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge - Actual outcome: PE at Not reported; Group 1: 0/74, Group 2: 0/85 Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 3: Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2g/dl$; a serious or life threatening clinical event at up to 45 days from hospital discharge - Actual outcome: Major bleeding at Not reported; Group 1: 0/74, Group 2: 0/85 Risk of bias: All domain - High. Selection - High. Blinding - High. Incomplete outcome data - Low. Outcome reporting - Low. Measurement - Low. Crossover - Low:</p>	

Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: BELOW KNEE + UFH versus BELOW KNEE

Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge

- Actual outcome: All-cause mortality at Not reported; Group 1: 0/89, Group 2: 0/74

Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcome 2: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge

- Actual outcome: PE at Not reported; Group 1: 0/89, Group 2: 0/74

Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcome 3: Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge

- Actual outcome: Major bleeding at Not reported; Group 1: 0/89, Group 2: 0/74

Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: BELOW KNEE + UFH versus UNFRACTIONATED HEPARIN (LOW DOSE, ADMINISTERED SUBCUTANEOUSLY)

Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge

- Actual outcome: All-cause mortality at Not reported; Group 1: 0/89, Group 2: 0/85

Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcome 2: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge

- Actual outcome: PE at Not reported; Group 1: 0/89, Group 2: 0/85

Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcome 3: Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge

- Actual outcome: Major bleeding at Not reported; Group 1: 0/89, Group 2: 0/85

Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcomes not reported by the study

Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge; Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study;

Study	Rasmussen 2006 ²⁷¹
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=427)
Countries and setting	Conducted in Denmark, Norway; Setting: University and large community hospitals
Line of therapy	Not applicable
Duration of study	Intervention + follow up: 2 months
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: Major abdominal surgery
Stratum	Overall
Subgroup analysis within study	Not applicable:
Inclusion criteria	Hospitalised for major abdominal surgery, gave written informed consent, and were over 18 years old. Surgery was more than 1 hour
Exclusion criteria	Severe peripheral arterial insufficiency (absence of a palpable pulsation in the dorsalis pedis artery), pregnancy, allergy to radiographic contrast medium, acid sulfite or LMWH, hepatic insufficiency, acute stroke within the last 3 months, gastrointestinal bleeding within the last month, haemorrhagic diathesis, anticoagulation treatment, treatment with dextran, psychosis or severe dementia, simultaneous participation in another clinical study or previous participation in the present study
Recruitment/selection of patients	Not reported
Age, gender and ethnicity	Age - Mean (range): Standard duration group: 67 (22-93), extended duration group: 67 (25-91). Gender (M:F): 174:169. Ethnicity: Not reported
Further population details	1. Active cancer: Not applicable 2. Acute/elective: Not applicable 3. BMI : Not applicable 4. Laparoscopic/open surgery: Not applicable 5. Renal impairment: Not applicable

Indirectness of population	No indirectness
Interventions	<p>(n=222) Intervention 1: Low molecular weight heparin (licensed in UK) - Dalteparin (1,250 units once daily - 5,000 units twice daily). Dalteparin 5000U once daily and AES for 7 days. The first dose was administered on the evening prior to surgery, or a reduced dose of 2500U was administered 2 hours prior to surgery and repeated 12 hours later. Patients were randomised to receive no further treatment. Duration 7 days. Concurrent medication/care: Not reported. Indirectness: No indirectness</p> <p>(n=205) Intervention 2: Low molecular weight heparin (licensed in UK) - Dalteparin (1,250 units once daily - 5,000 units twice daily). Dalteparin 5000U once daily and AES for 7 days. The first dose was administered on the evening prior to surgery, or a reduced dose of 2500U was administered 2 hours prior to surgery and repeated 12 hours later. Patients were randomised to receive treatment for a further 28 days. Duration 28 days. Concurrent medication/care: Not reported. Indirectness: No indirectness</p>
Funding	Study funded by industry (Supported by grants from Pfizer Global Pharmaceuticals, the Apoteker Foundation of 1991, the Foundation of 1870, Nycomed Denmark, the Lily Benthine Lunds Foundation, the J and L Boserups Foundation, the Beckett Foundation, the S and I Hansens Foundation, the TM Hansen Foundation and the Else and Mogens Wedell-Wedellsborgs Foundation, Denmark)
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: DALTEPARIN STANDARD DURATION (1,250 UNITS ONCE DAILY - 5,000 UNITS TWICE DAILY) + AES versus DALTEPARIN EXTENDED DURATION (1,250 UNITS ONCE DAILY - 5,000 UNITS TWICE DAILY) + AES</p> <p>Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge - Actual outcome: All-cause mortality at 3 months; Group 1: 17/222, Group 2: 20/205 Risk of bias: All domain - High, Selection - Low, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0</p> <p>Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge - Actual outcome: DVT at 28 days; Group 1: 26/178, Group 2: 12/165 Risk of bias: All domain - High, Selection - Low, Blinding - High, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 44; Group 2 Number missing: 40</p>	

Protocol outcome 3: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge
 - Actual outcome: PE at 2 months; Group 1: 3/178, Group 2: 0/165
 Risk of bias: All domain - High, Selection - Low, Blinding - High, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low;
 Indirectness of outcome: No indirectness ; Group 1 Number missing: 44; Group 2 Number missing: 40

Protocol outcome 4: Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge
 - Actual outcome: Major bleeding at 2 months; Group 1: 4/222, Group 2: 1/205
 Risk of bias: All domain - High, Selection - Low, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;
 Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0

Protocol outcome 5: Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge
 - Actual outcome: Fatal PE at 28 days; Group 1: 0/222, Group 2: 0/205
 Risk of bias: All domain - High, Selection - Low, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;
 Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0

Protocol outcomes not reported by the study	Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study;
---	---

Study	Sakon 2010 ²⁸⁰
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=151)
Countries and setting	Conducted in Japan
Line of therapy	Not applicable
Duration of study	Intervention + follow up: 14 days
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: Abdominal cancer surgery
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Male and female patients were eligible if they were >40 years old and were undergoing a planned, curative laparotomy for cancer of >45 minutes duration. Abdominal cancer surgery was defined as including all intrapelvic and upper intra-abdominal operations between the diaphragm and the pelvic floor. Only patients with a life expectancy of 6 months or more after surgery were considered for study enrolment
Exclusion criteria	Patients were excluded if they only received surgery under laparoscopy or other endoscopic conditions, had a hypersensitivity to heparin or thrombocytopenia due to heparin, had clinical signs of DVT at screening or evidence of thromboembolic disease within 1 year before surgery, or had received systemic chemotherapy within 3 weeks before study drug initiation. Women of childbearing potential and those who were pregnant or lactating were also excluded.
Age, gender and ethnicity	Age - Mean (SD): LMWH + IPCD group: 67.7 (10.1), IPCD group: 66.1 (10.1). Gender (M:F): 69:45. Ethnicity: Not reported
Further population details	1. Active cancer: Active cancer 2. Acute/elective: Not applicable 3. BMI : Mixed (21% obese (>25 BMI)). 4. Laparoscopic/open surgery: Open surgery 5. Renal impairment: Not applicable
Indirectness of population	No indirectness

Interventions	<p>(n=113) Intervention 1: Low molecular weight heparin (licensed in UK) - Enoxaparin (20mg once daily – 60mg twice daily). Subcutaneous injection of enoxaparin 20mg twice daily, started 24-36 hours after surgery and continued for 14 days. All patients received at least one course of post-surgical IPCD before administration of the first enoxaparin dose. Duration 14 days. Concurrent medication/care: Not reported. Indirectness: No indirectness</p> <p>(n=38) Intervention 2: Intermittent pneumatic compression devices - Mixed full leg/below knee. IPCD prophylaxis alone. Length not reported. Duration Not reported. Concurrent medication/care: Not reported. Indirectness: No indirectness</p>
Funding	Study funded by industry (Financially supported by sanofi-aventis K K, Japan)
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: ENOXAPARIN (20MG ONCE DAILY – 60MG TWICE DAILY) + IPCD versus MIXED FULL LEG/BELOW KNEE</p> <p>Protocol outcome 1: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge - Actual outcome: DVT at 14 days; Group 1: 1/83, Group 2: 6/31 Risk of bias: All domain - Very high, Selection - High, Blinding - High, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 30; Group 2 Number missing: 7</p> <p>Protocol outcome 2: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge - Actual outcome: PE at 14 days; Group 1: 0/83, Group 2: 0/31 Risk of bias: All domain - Very high, Selection - High, Blinding - High, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 30; Group 2 Number missing: 7</p> <p>Protocol outcome 3: Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2g/dl$; a serious or life threatening clinical event at up to 45 days from hospital discharge - Actual outcome: Major bleeding at 14 days; Group 1: 5/109, Group 2: 1/38 Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 4; Group 2 Number missing: 0</p>	

Protocol outcomes not reported by the study	All-cause mortality at up to 90 days from hospital discharge; Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study;
---	--

Study	Scurr 1981 ²⁹²
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=66)
Countries and setting	Conducted in United Kingdom; Setting: Not reported
Line of therapy	Not applicable
Duration of study	Intervention + follow up: 7 days
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: Major abdominal surgery
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Patients over the age of 40 who were about to undergo major abdominal surgery
Exclusion criteria	Patients with a history of DVT or PE
Recruitment/selection of patients	Not reported
Age, gender and ethnicity	Age - Mean (SD): Foot pump: 57.3 (40-82), control: 57.8 (40-83). Gender (M:F): Not reported. Ethnicity: Not reported
Further population details	1. Active cancer: Not applicable (77% malignancy). 2. Acute/elective: Not applicable 3. BMI : Not applicable 4. Laparoscopic/open surgery: Not applicable 5. Renal impairment: Not applicable
Indirectness of population	No indirectness
Interventions	(n=33) Intervention 1: Foot pumps or foot impulse devices - Foot pumps. Pedi-Pulsor, from the beginning of the procedure until the patient regained consciousness on the operating table. Duration Not reported. Concurrent medication/care: Not reported (n=33) Intervention 2: No treatment - Usual care. Control group, legs were immobile on the operating table. Duration Not reported. Concurrent medication/care: Not reported. Indirectness: No indirectness
Funding	Funding not stated
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: FOOT PUMPS versus USUAL CARE</p> <p>Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge - Actual outcome: All-cause mortality at Not reported; Group 1: 0/33, Group 2: 1/33 Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p>	

Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge

- Actual outcome: DVT at Not reported; Group 1: 6/33, Group 2: 15/33

Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcomes not reported by the study

Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge; Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge; Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study;

Study	Soderdahl 1997 ²⁹⁸
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=90)
Countries and setting	Conducted in USA; Setting: Not reported
Line of therapy	Not applicable
Duration of study	Intervention + follow up: 3 months
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: Major urological surgery
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Patients scheduled for major urological surgery
Exclusion criteria	Not reported
Recruitment/selection of patients	Not reported
Age, gender and ethnicity	Age - Mean (SD): Thigh length group: 64.8 (46-80), calf length group: 58.6 (24-77). Gender (M:F): Not reported. Ethnicity: Not reported
Further population details	1. Active cancer: Not applicable 2. Acute/elective: Not applicable 3. BMI : Not applicable 4. Laparoscopic/open surgery: Not applicable 5. Renal impairment: Not applicable
Indirectness of population	No indirectness
Interventions	(n=47) Intervention 1: Intermittent pneumatic compression devices - Full leg. Thigh length IPCD individually fitted

	<p>postoperatively, and compression applied before induction of anesthesia and continued at all times while the patient was in bed until fully ambulatory or hospital discharge. AES was not used. Duration Not reported. Concurrent medication/care: Not reported. Indirectness: No indirectness</p> <p>(n=43) Intervention 2: Intermittent pneumatic compression devices - Below knee. Calf length IPCD individually fitted postoperatively, and compression applied before induction of anesthesia and continued at all times while the patient was in bed until fully ambulatory or hospital discharge. AES was not used. Duration Not reported. Concurrent medication/care: Not reported. Indirectness: No indirectness</p>
Funding	Funding not stated
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: FULL LEG versus BELOW KNEE</p> <p>Protocol outcome 1: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge - Actual outcome: DVT at 3 months; Group 1: 0/47, Group 2: 1/43 Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Baseline details: Not all factors reported; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 2: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge - Actual outcome: PE at 3 months; Group 1: 1/47, Group 2: 0/43 Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Baseline details: Not all factors reported; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 3: Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge - Actual outcome: Fatal PE at 3 months; Group 1: 0/47, Group 2: 1/43 Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Baseline details: Not all factors reported; Group 1 Number missing: ; Group 2 Number missing:</p>	
Protocol outcomes not reported by the studv	All-cause mortality at up to 90 days from hospital discharge: Major bleeding. Meets one or more of the following

criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study;

Study	Song 2014 ²⁹⁹
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=220)
Countries and setting	Conducted in South Korea; Setting: Not reported
Line of therapy	Not applicable
Duration of study	Intervention + follow up: 30 days
Method of assessment of guideline condition	Adequate method of assessment/diagnosis
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Gastric cancer patients undergoing surgery, patients with histologically proven adenocarcinoma through endoscopic biopsy
Exclusion criteria	History of PTE, or DVT in the previous 1 years, preoperative prolonged immobilisation or being wheelchair bound, diseases of bleeding tendency, major surgery in the previous 6 months, cerebrovascular accident in the previous 3 months, uncontrolled hypertension, congestive cardiac failure, renal or liver impairment, allergy to heparin or heparin induced thrombocytopenia, varicose veins or chronic venous insufficiency, previous chemotherapy, radiotherapy, anticoagulation therapy, transfusion, BMI <18.5kg/m ² , pregnancy or plan to become pregnant
Recruitment/selection of patients	Not reported
Age, gender and ethnicity	Age - Mean (SD): LMWH + IPCD group: 56.31 (11.15), IPCD group: 58.77 (9.67). Gender (M:F): 150:70. Ethnicity: Not reported
Further population details	1. Active cancer: Active cancer 2. Acute/elective: Not applicable 3. BMI : Not obese (BMI under 30 kg/m ²) (Mean BMI 23.76 (2.65)). 4. Laparoscopic/open surgerv: Not applicable (47% laparoscopic. 53% open). 5. Renal impairment: No

	renal impairment (eGFR greater than 30ml/min/1.73m2) (Excluded renal impairment but not defined).
Indirectness of population	No indirectness
Interventions	<p>(n=108) Intervention 1: Low molecular weight heparin (licensed in UK) - Enoxaparin (20mg once daily – 60mg twice daily). Enoxaparin was administered at 24 hour intervals in a daily dose of 40mg, starting postoperatively. IPCD (length not reported) was initiated preoperatively and continued until postoperative discharge. Duration Not reported. Concurrent medication/care: Not reported. Indirectness: No indirectness</p> <p>(n=112) Intervention 2: Intermittent pneumatic compression devices - Mixed full leg/below knee. IPCD (length not reported) was initiated preoperatively and continued until postoperative discharge. Duration Not reported. Concurrent medication/care: Not reported. Indirectness: No indirectness</p>
Funding	Study funded by industry (Supported by Covidien)

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: ENOXAPARIN (20MG ONCE DAILY – 60MG TWICE DAILY) + IPCD (UNDEFINED) versus MIXED FULL LEG/BELOW KNEE

Protocol outcome 1: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge

- Actual outcome: DVT at 30 days; Group 1: 0/109, Group 2: 3/112

Risk of bias: All domain - High, Selection - Low, Blinding - High, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: , Reason: Overall 3 people excluded from analysis (1 had HIT, 1 withdrew consent, 1 underwent bypass surgery that led to noncurative operation); Group 2 Number missing: , Reason: Overall 3 people excluded from analysis (1 had HIT, 1 withdrew consent, 1 underwent bypass surgery that led to noncurative operation)

Protocol outcome 2: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge

- Actual outcome: PE at 30 days; Group 1: 0/108, Group 2: 0/112

Risk of bias: All domain - High, Selection - Low, Blinding - High, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: , Reason: Overall 3 people excluded from analysis (1 had HIT, 1 withdrew consent, 1 underwent bypass surgery that led to noncurative operation); Group 2 Number missing: , Reason: Overall 3 people excluded from analysis (1 had HIT, 1 withdrew consent, 1 underwent bypass surgery that led to noncurative operation)

Protocol outcome 3: Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge

- Actual outcome: Major bleeding at 30 days; Group 1: 2/108, Group 2: 0/112

Risk of bias: All domain - High, Selection - Low, Blinding - High, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: , Reason: Overall 3 people excluded from analysis (1 had HIT, 1 withdrew consent, 1 underwent bypass surgery that led to noncurative operation); Group 2 Number missing: , Reason: Overall 3 people excluded from analysis (1 had HIT, 1 withdrew consent, 1 underwent bypass surgery that led to noncurative operation)

Protocol outcomes not reported by the study

All-cause mortality at up to 90 days from hospital discharge; Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study;

Study	Strand 1975 ³⁰⁶
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=100)
Countries and setting	Conducted in Denmark; Setting: Not reported
Line of therapy	Not applicable
Duration of study	Intervention + follow up: 10 weeks
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: Gastrointestinal or urinary tract surgery
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Patients undergoing surgery on the gastrointestinal or urinary tract and some undergoing other major surgery procedures
Exclusion criteria	Patients undergoing minor surgery, subjects less than 30 years old, patients with fractures, subjects suffering from either spontaneous or drug induced haemorrhagic diathesis, patients requiring acute surgical intervention, and patients with wound haematomas or superficial phlebitis of the lower extremities
Recruitment/selection of patients	Not reported
Age, gender and ethnicity	Age - Range: 31-90. Gender (M:F): 49:51. Ethnicity: Not reported
Further population details	1. Active cancer: Not applicable (28% malignant disease). 2. Acute/elective: Not applicable 3. BMI : Not applicable 4. Laparoscopic/open surgery: Not applicable 5. Renal impairment: Not applicable
Indirectness of population	No indirectness

Interventions	<p>(n=50) Intervention 1: Unfractionated heparin - Unfractionated heparin (low dose, administered subcutaneously). Heparin given subcutaneously every 12 hours, the first dose was given 1-3 hours before surgery and the last dose on the morning of the 7th postoperative day. Duration 7 days . Concurrent medication/care: All patients were subject to routine procedures of the department. Indirectness: No indirectness</p> <p>(n=50) Intervention 2: No treatment - Placebo. Placebo solution, every 12 hours, the first dose was given 1-3 hours before surgery and the last dose on the morning of the 7th postoperative day. Duration 7 days . Concurrent medication/care: All patients were subjected to the routine procedures of the department . Indirectness: No indirectness</p>
Funding	Other (Supported by the heart foundation)
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: UNFRACTIONATED HEPARIN (LOW DOSE, ADMINISTERED SUBCUTANEOUSLY) versus PLACEBO</p> <p>Protocol outcome 1: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge - Actual outcome: DVT at 10 weeks ; Group 1: 3/50, Group 2: 10/50 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low, Comments - 10 participants dropped out but unclear which groups they were in ; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 2: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge - Actual outcome: PE at 10 weeks ; Group 1: 0/50, Group 2: 0/50 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low, Comments - 10 participants dropped out but unclear which groups they were in ; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 3: Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge - Actual outcome: Fatal PE at 10 weeks ; Group 1: 0/50, Group 2: 0/50 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low, Comments - 10 participants dropped out but unclear which groups they were in : Indirectness of outcome: No indirectness : Group 1 Number missing: : Group 2 Number</p>	

missing:	
Protocol outcomes not reported by the study	All-cause mortality at up to 90 days from hospital discharge; Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study;

Study	Taberner 1978 ³¹⁰
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=145)
Countries and setting	Conducted in United Kingdom; Setting: Not reported
Line of therapy	Not applicable
Duration of study	Intervention + follow up: 7 days
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: Major abdominal or vaginal surgery
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Not reported
Exclusion criteria	Patients with a history of DVT
Recruitment/selection of patients	Not reported
Age, gender and ethnicity	Age - Mean (SD): VKA group: 51.6, UFH group 52.4, placebo group: 50.3 SD not reported. Gender (M:F): Not reported. Ethnicity: Not reported
Further population details	1. Active cancer: Not applicable (5.5% cancer). 2. Acute/elective: Not applicable 3. BMI : Not applicable 4. Laparoscopic/open surgery: Not applicable 5. Renal impairment: Not applicable
Indirectness of population	No indirectness
Interventions	(n=48) Intervention 1: Vitamin K antagonists - Acenocoumarol (all doses). 6mg nicoumalone initiated at least 5 days

	<p>before surgery. The optimum preoperative prothrombin ratio was considered to be 2.0-2.5 using the BCT. Duration 14 days. Concurrent medication/care: Not reported. Indirectness: No indirectness</p> <p>(n=49) Intervention 2: Unfractionated heparin - Unfractionated heparin (low dose, administered subcutaneously). Twice daily doses of calcium heparin (Choay) 5000U subcutaneously, treatment began 2 hours preoperatively and continued for 7 days. Duration 7 days. Concurrent medication/care: Not reported. Indirectness: No indirectness</p> <p>(n=48) Intervention 3: No treatment - Placebo. Saline subcutaneously twice daily beginning 2 hours preoperatively and continuing for 7 days. Duration 7 days. Concurrent medication/care: Not reported. Indirectness: No indirectness</p>
<p>Funding</p>	<p>Equipment / drugs provided by industry (Heparin supplied by Choay Pharmaceuticals)</p>
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: ACENOCOUMAROL (ALL DOSES) versus UNFRACTIONATED HEPARIN (LOW DOSE, ADMINISTERED SUBCUTANEOUSLY)</p> <p>Protocol outcome 1: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge - Actual outcome: DVT at 7 days; Group 1: 3/48, Group 2: 3/49 Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p> <p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: ACENOCOUMAROL (ALL DOSES) versus PLACEBO</p> <p>Protocol outcome 1: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge - Actual outcome: DVT at 7 days; Group 1: 3/48, Group 2: 11/48 Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p> <p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: UNFRACTIONATED HEPARIN (LOW DOSE, ADMINISTERED SUBCUTANEOUSLY) versus PLACEBO</p> <p>Protocol outcome 1: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge</p>	

<p>- Actual outcome: DVT at 7 days; Group 1: 3/49, Group 2: 11/48 Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p>	
<p>Protocol outcomes not reported by the study</p>	<p>All-cause mortality at up to 90 days from hospital discharge; Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge; Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge; Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study;</p>

Study	Törngren 1978 ³¹⁴
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=124)
Countries and setting	Conducted in Sweden; Setting: Not reported
Line of therapy	Not applicable
Duration of study	Intervention time: 6-8 days
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: Major gastrointestinal surgery
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Patients with planned major gastrointestinal surgery
Exclusion criteria	Patients with a history of bleeding tendency, iodine allergy, age below 40 years and previous thyroid resections or hypothyroidism
Recruitment/selection of patients	Consecutive patients
Age, gender and ethnicity	Age - Mean (range): UFH group: 66.1 (40-85), control group: 65.9 (40-83). Gender (M:F): 66:58. Ethnicity: Not reported
Further population details	1. Active cancer: Not applicable (24% cancer). 2. Acute/elective: Not applicable 3. BMI : Not applicable 4. Laparoscopic/open surgery: Not applicable 5. Renal impairment: Not applicable
Indirectness of population	No indirectness
Interventions	(n=66) Intervention 1: Unfractionated heparin - Unfractionated heparin (low dose. administered subcutaneouslv).

	<p>Calcium heparin 5000U given 12 hourly. Injections were given subcutaneously starting 2 hours before surgery and continuing for 6-8 days postoperatively . Duration 6-8 days. Concurrent medication/care: Not reported . Indirectness: No indirectness</p> <p>(n=62) Intervention 2: No treatment - Placebo. 5% glucose solution given 12 hourly. Injections were given subcutaneously starting 2 hours before surgery and continuing for 6-8 days postoperatively . Duration 6-8 days. Concurrent medication/care: Not reported. Indirectness: No indirectness</p>
<p>Funding</p>	<p>Academic or government funding (Supported by grants from Karolinska Institutet, Stockholm)</p>
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: UNFRACTIONATED HEPARIN (LOW DOSE, ADMINISTERED SUBCUTANEOUSLY) versus PLACEBO</p> <p>Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge - Actual outcome: All-cause mortality at 6-8 days; Group 1: 1/63, Group 2: 2/61 Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 3, Reason: Allergic reaction, patient refused, discharged; Group 2 Number missing: 1, Reason: Not reported</p> <p>Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge - Actual outcome: DVT at Mean 10.5 days; Group 1: 10/63, Group 2: 20/61 Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 3, Reason: Allergic reaction, patient refused, discharged; Group 2 Number missing: 1, Reason: Not reported</p> <p>Protocol outcome 3: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge - Actual outcome: PE at 6-8 days; Group 1: 1/63, Group 2: 2/61 Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 3, Reason: Allergic reaction, patient refused, discharged; Group 2 Number missing: 1, Reason: Not reported</p> <p>Protocol outcome 4: Major bleeding. Meets one or more of the following criteria: results in death: occurs at a critical site (intracranial, intraspinal, pericardial.</p>	

intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge

- Actual outcome: Major bleeding at 6-8 days; Group 1: 24/63, Group 2: 23/61

Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 3, Reason: Allergic reaction, patient refused, discharged; Group 2 Number missing: 1, Reason: Not reported

Protocol outcome 5: Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge

- Actual outcome: Fatal PE at 6-8 days; Group 1: 0/63, Group 2: 0/61

Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 3, Reason: Allergic reaction, patient refused, discharged; Group 2 Number missing: 1, Reason: Not reported

Protocol outcomes not reported by the study

Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study;

Study	Tsapogas 1971 ³¹⁵
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=95)
Countries and setting	Conducted in USA; Setting: Hospital
Line of therapy	Not applicable
Duration of study	Intervention + follow up: 7 days
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: Major abdominal surgery
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Not reported
Exclusion criteria	Patients who were to have operations on the lower limbs
Recruitment/selection of patients	Not reported
Age, gender and ethnicity	Age - Mean (range): 56.1 (40-83). Gender (M:F): 93:2. Ethnicity: Not reported
Further population details	1. Active cancer: Not applicable 2. Acute/elective: Not applicable 3. BMI : Not applicable 4. Laparoscopic/open surgery: Not applicable 5. Renal impairment: Not applicable
Indirectness of population	No indirectness
Interventions	(n=51) Intervention 1: Anti-embolism stockings - Below knee. Prior to operation each patient was fitted with below knee AES used until discharge from hospital. Throughout the postoperative period, the foot of the bed was elevated 30

	<p>degrees to reduce venous stasis. Early ambulation was encouraged. Passive and active dorsal and plantar flexion of the feet was started in the recovery room and continued for 5 minutes at 2 hour intervals throughout the day. Duration Until discharge. Concurrent medication/care: Not reported. Indirectness: No indirectness</p> <p>(n=44) Intervention 2: No treatment - Usual care. None of the measures taken in the AES group were applied to the control group. Duration Not reported. Concurrent medication/care: Not reported. Indirectness: No indirectness</p>
<p>Funding</p>	<p>Other (Cutter Laboratories Inc, Berkeley, Calif, and A B Kabi, Stockholm provided the fibrinogen and plasminogen for the laboratory testing)</p>
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: BELOW KNEE versus USUAL CARE</p> <p>Protocol outcome 1: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge - Actual outcome: DVT at 7 days; Group 1: 2/51, Group 2: 6/44 Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p>	
<p>Protocol outcomes not reported by the study</p>	<p>All-cause mortality at up to 90 days from hospital discharge; Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge; Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge; Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study;</p>

Study	Turner 1984 ³¹⁶
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=196)
Countries and setting	Conducted in United Kingdom; Setting: University of Bristol Department of Gynaecology
Line of therapy	Not applicable
Duration of study	Not clear:
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: Major gynaecological surgery
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Patients >35 years of age admitted for elective major gynaecological surgery
Exclusion criteria	Malignant disease, diabetic, pregnant, history of thromboembolism, or other indication for anticoagulant prophylaxis or therapy
Recruitment/selection of patients	All patients admitted
Age, gender and ethnicity	Age - Mean (SD): AES group: 47.6 (9.8), control 45.6 (9.4). Gender (M:F): Female. Ethnicity: Not reported
Further population details	1. Active cancer: No active cancer 2. Acute/elective: Elective 3. BMI : Not applicable 4. Laparoscopic/open surgery: Not applicable 5. Renal impairment: Not applicable
Indirectness of population	No indirectness
Interventions	(n=104) Intervention 1: Anti-embolism stockings - Above knee. AES above knee. fitted on the day of admission and

	<p>worn throughout their stay in hospital. Duration Not reported. Concurrent medication/care: The usual routine of physiotherapy to encourage early leg activity in bed and early ambulation was followed, but no other specific measures for preventing DVT were used. Indirectness: No indirectness</p> <p>(n=92) Intervention 2: No treatment - Usual care. No stockings. Duration Not reported. Concurrent medication/care: The usual routine of physiotherapy to encourage early leg activity in bed and early ambulation was followed, but no other specific measures for preventing DVT were used. Indirectness: No indirectness</p>
Funding	Other (Stockings supplied by the Kendall Company Hospital Products Division)
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: ABOVE KNEE versus USUAL CARE</p> <p>Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge - Actual outcome: All-cause mortality at Not reported; Group 1: 0/104, Group 2: 0/92 Risk of bias: All domain - Low, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge - Actual outcome: DVT at Not reported; Group 1: 0/104, Group 2: 4/92 Risk of bias: All domain - Low, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 3: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge - Actual outcome: PE at Not reported; Group 1: 0/104, Group 2: 0/92 Risk of bias: All domain - Low, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p>	
Protocol outcomes not reported by the study	Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2g/dl$: a serious or life threatening clinical event at up to 45 days from hospital

discharge; Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study;

Study	Turpie 2007 ³¹⁷
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=1309)
Countries and setting	Conducted in USA; Setting: Hospital
Line of therapy	Not applicable
Duration of study	Intervention + follow up: 32 days
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: Abdominal surgery
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Patients over 40 years, weighing over 50kg and scheduled to undergo abdominal surgery expected to last longer than 45 minutes
Exclusion criteria	Patients due to undergo vascular surgery, with evidence of leg ischemia caused by peripheral vascular disease, or unable to receive intermittent pneumatic compression or elastic stockings, pregnant women and women of childbearing age not using effective contraception, life expectancy < 6 months, clinical signs of DVT and/or history of VTE within the previous 3 months, active bleeding, documented congenital or acquired bleeding disorder, active ulcerative gastrointestinal disease unless it was the reason for surgery, haemorrhagic stroke or surgery on the brain, spine or eyes within the previous 3 months, bacterial endocarditis or other contraindication for anticoagulant therapy, planned indwelling intrathecal or epidural catheter for more than 6 hours after surgical closure, unusual difficulty in achieving epidural or spinal anesthesia, known hypersensitivity to fondaparinux or iodinated contrast medium, current addictive disorders, serum creatinine concentration above 2.0mg dL-1 in a well hydrated patient and platelet count below 100 000mm-3, patients requiring anticoagulant therapy, or other pharmacologic prophylaxis besides IPC according to the investigator
Recruitment/selection of patients	Not reported

Age, gender and ethnicity	Age - Mean (SD): Fondaparinux group: 60 (40-93), placebo group: 59 (40-95). Gender (M:F): 635:650. Ethnicity: Not reported
Further population details	1. Active cancer: Not applicable (38.8% cancer). 2. Acute/elective: Not applicable 3. BMI : Mixed (41% obese (men BMI >30kgm-2, women BMI 28.6kg m-2)). 4. Laparoscopic/open surgery: Not applicable 5. Renal impairment: Mixed (1% creatinine clearance <30mL min-1).
Indirectness of population	No indirectness
Interventions	<p>(n=650) Intervention 1: Fondaparinux - Fondaparinux (all doses). Fondaparinux 2.5mg, starting 6-8 hours after surgical closure. During the on-study drug period of 5-9 days, all patients received IPCD using any type of device except a foot pump, for a duration left to the investigators discretion. The use of elastic stockings was left to the investigators discretion . Duration 5-9 days. Concurrent medication/care: Not reported. Indirectness: No indirectness</p> <p>(n=659) Intervention 2: Intermittent pneumatic compression devices - Mixed full leg/below knee. Placebo + IPCD. During the on-study drug period of 5-9 days, all patients received IPCD (length not reported) using any type of device except a foot pump, for a duration left to the investigators discretion. The use of elastic stockings was left to the investigators discretion . Duration Not reported. Concurrent medication/care: Not reported. Indirectness: No indirectness</p>
Funding	Study funded by industry (Funded by Sanofi-Synthelabo and then GlaxoSmithKline)

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: FONDAPARINUX (ALL DOSES) + IPCD versus MIXED FULL LEG/BELOW KNEE (+ PLACEBO)

Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge

- Actual outcome: All-cause mortality at 32 days; Group 1: 8/635, Group 2: 5/650

Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 15; Group 2 Number missing: 9

Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge

- Actual outcome: DVT at 32 days: Group 1: 7/424. Group 2: 22/418

Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low;
Indirectness of outcome: No indirectness ; Group 1 Number missing: 226; Group 2 Number missing: 241

Protocol outcome 3: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy;
echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge

- Actual outcome: PE at 32 days; Group 1: 1/424, Group 2: 3/418

Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low;
Indirectness of outcome: No indirectness ; Group 1 Number missing: 226; Group 2 Number missing: 241

Protocol outcome 4: Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial,
intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening
clinical event at up to 45 days from hospital discharge

- Actual outcome: Major bleeding at 32 days; Group 1: 10/635, Group 2: 1/650

Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;
Indirectness of outcome: No indirectness ; Group 1 Number missing: 15; Group 2 Number missing: 9

Protocol outcome 5: Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy;
echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge

- Actual outcome: Fatal PE at 32 days; Group 1: 1/635, Group 2: 1/650

Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low;
Indirectness of outcome: No indirectness ; Group 1 Number missing: 226; Group 2 Number missing: 241

Protocol outcomes not reported by the study

Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study;

Study	Van vroomhoven 1974 ³²⁵
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=100)
Countries and setting	Conducted in Netherlands; Setting: Hospital
Line of therapy	Not applicable
Duration of study	Not clear:
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: Elective general surgery
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Patients over 40 years admitted to hospital for an elective general surgical procedure
Exclusion criteria	Patients already on oral anticoagulants and patients undergoing vascular or thyroid surgery
Recruitment/selection of patients	Not reported
Age, gender and ethnicity	Age - Range: 40-80+. Gender (M:F): Not reported. Ethnicity: Not reported
Further population details	1. Active cancer: Not applicable (18% cancer). 2. Acute/elective: Elective 3. BMI : Mixed (20% obesity (not defined)). 4. Laparoscopic/open surgery: Not applicable 5. Renal impairment: Not applicable
Indirectness of population	No indirectness
Interventions	<p>(n=50) Intervention 1: Vitamin K antagonists - Acenocoumarol (all doses). Acenocoumarol (nicoumalone, 'Sintrom') by mouth. Started as soon after the operation as possible, usually on the evening after the operation or on the first post operative day. The dose was regulated according to the results of daily thrombotests, the aim was a thrombotest value of 5-10% of normal. Duration 7 days. Concurrent medication/care: Not reported. Indirectness: No indirectness</p> <p>(n=50) Intervention 2: Unfractionated heparin - Unfractionated heparin (low dose, administered subcutaneously). Subcutaneous injection of calcium heparin 2 hours before the operation and 12 hourly thereafter for 8 days. Duration 8 days. Concurrent medication/care: Not reported. Indirectness: No indirectness</p>
Funding	Equipment / drugs provided by industry (Choay Pharmaceuticals supplied Calciparin)
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: UNFRACTIONATED HEPARIN (LOW DOSE, ADMINISTERED SUBCUTANEOUSLY) versus ACENOCOUMAROL (ALL DOSES)</p> <p>Protocol outcome 1: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler)</p>	

ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge

- Actual outcome: DVT at Not reported; Group 1: 1/50, Group 2: 9/50

Risk of bias: All domain - Very high, Selection - Very high, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcome 2: Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge

- Actual outcome: Major bleeding at Not reported; Group 1: 0/50, Group 2: 0/50

Risk of bias: All domain - Very high, Selection - Very high, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcomes not reported by the study

All-cause mortality at up to 90 days from hospital discharge; Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge; Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study;

Study	Vandendris 1980 ³²⁶
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=64)
Countries and setting	Conducted in Belgium; Setting: Hospital
Line of therapy	Not applicable
Duration of study	Intervention time: 6 days
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: Open prostatectomy
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Patients having open prostatectomy performed under general anesthesia and required at least 7 days of hospital stay
Exclusion criteria	Patients with thyroid disease, recent VTE or lower limb amputation, and patients taking anticoagulants or antiaggregating drugs
Recruitment/selection of patients	Not reported
Age, gender and ethnicity	Age - Mean (SD): UFH group: 72.2, placebo group: 70.0. Gender (M:F): Not reported. Ethnicity: Not reported
Further population details	1. Active cancer: Not applicable 2. Acute/elective: Not applicable 3. BMI : Not applicable 4. Laparoscopic/open surgery: Open surgery 5. Renal impairment: Not applicable
Indirectness of population	No indirectness
Interventions	(n=31) Intervention 1: Unfractionated heparin - Unfractionated heparin (low dose, administered subcutaneously). Calcium heparin 5000U, given 2 hours before operation and then every 8 hours for 6 days. Duration 6 days. Concurrent medication/care: Not reported. Indirectness: No indirectness (n=33) Intervention 2: No treatment - Placebo. 0.2ml distilled water subcutaneous injection, given 2 hours before operation and then every 8 hours for 6 days. Duration 6 days. Concurrent medication/care: Not reported. Indirectness: No indirectness
Funding	Funding not stated
RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: UNFRACTIONATED HEPARIN (LOW DOSE, ADMINISTERED SUBCUTANEOUSLY) versus PLACEBO	
Protocol outcome 1: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge	

- Actual outcome: DVT at Not reported; Group 1: 3/31, Group 2: 13/33
 Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;
 Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcome 2: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge

- Actual outcome: PE at Not reported; Group 1: 0/31, Group 2: 0/33
 Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;
 Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcomes not reported by the study

All-cause mortality at up to 90 days from hospital discharge; Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge; Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study;

Study	Wille-jørgensen 1985 ³³⁷
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=196)
Countries and setting	Conducted in Denmark; Setting: Not reported
Line of therapy	Not applicable
Duration of study	Intervention + follow up: 30 days
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: Elective major abdominal surgery
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Patients scheduled for elective major abdominal surgery provided they fulfilled one of the following criteria: age above 39, malignancy suspected, weight more than 19% above normal, varicose veins of the lower extremities, diabetes mellitus, hypertension, previous thromboembolism or cardiac failure
Exclusion criteria	Hepatic disease with coagulation factors II, VII and X below 40%, anticoagulation treatment, a history of peripheral arterial insufficiency and allergy to iodine
Recruitment/selection of patients	Not reported
Age, gender and ethnicity	Age - Median (range): AES + UFH group: 61 (36-90), UFH group: 59 (40-87). Gender (M:F): 105:71. Ethnicity: Not reported
Further population details	1. Active cancer: Not applicable 2. Acute/elective: Elective 3. BMI : Not applicable 4. Laparoscopic/open surgery: Not applicable 5. Renal impairment: Not applicable
Indirectness of population	No indirectness
Interventions	(n=94) Intervention 1: Anti-embolism stockings - Above knee. Thigh length AES fitted on both legs before surgery and used day and night during the observation period. UFH 5000U was administered twice daily subcutaneously, starting one hour preoperatively and continued for 7 days or until discharge. Duration 7 days. Concurrent medication/care: Not reported. Indirectness: No indirectness (n=102) Intervention 2: Unfractionated heparin - Unfractionated heparin (low dose, administered subcutaneously). UFH 5000U was administered twice daily subcutaneously, starting one hour preoperatively and continued for 7 days or until discharge. Duration 7 days. Concurrent medication/care: Not reported. Indirectness: No indirectness
Funding	Equipment / drugs provided by industry (Heparin and stockings were supplied by Novo and Kendall. A Novo thrombography was supplied by Novo Diagnostics)

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: ABOVE KNEE + UFH versus UNFRACTIONATED HEPARIN (LOW DOSE, ADMINISTERED SUBCUTANEOUSLY)

Protocol outcome 1: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge

- Actual outcome: DVT at 7 days; Group 1: 1/86, Group 2: 7/90

Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 8; Group 2 Number missing: 12

Protocol outcome 2: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge

- Actual outcome: PE at 7 days; Group 1: 2/86, Group 2: 6/90

Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 8; Group 2 Number missing: 12

Protocol outcome 3: Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge

- Actual outcome: Fatal PE at 7 days; Group 1: 0/86, Group 2: 1/90

Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 8; Group 2 Number missing: 12

Protocol outcomes not reported by the study

All-cause mortality at up to 90 days from hospital discharge; Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study;

Study	Wille-jorgensen 1991 ³³⁶
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=178)
Countries and setting	Conducted in Denmark; Setting: Not reported
Line of therapy	Not applicable
Duration of study	Intervention + follow up: 30 days
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: Acute abdominal operations
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Patients undergoing acute abdominal operations, provided they fulfilled at least one of these risk factors: more than 39 years of age, malignant lesions suspected, varicose veins, cardiac disease or hypertension, diabetes mellitus, obesity or earlier thromboembolic episodes. The operation had to be considered to last for more than 1 hour
Exclusion criteria	Allergy to iodine, dextran or heparin use, hepatic or untreated cardiac failure, severe peripheral arterial insufficiency, pregnancy or bleeding in the gastrointestinal tract
Recruitment/selection of patients	Not reported
Age, gender and ethnicity	Age - Median (range): AES + UFH group: 72 (40-95), UFH group: 70.7 (37-91). Gender (M:F): 58:102. Ethnicity: Not reported
Further population details	1. Active cancer: Not applicable 2. Acute/elective: Acute 3. BMI : Not applicable 4. Laparoscopic/open surgery: Not applicable 5. Renal impairment: Not applicable
Indirectness of population	No indirectness
Interventions	(n=84) Intervention 1: Unfractionated heparin - Unfractionated heparin (low dose, administered subcutaneously). 5000U sodium heparin administered subcutaneously preoperatively and continued twice daily for 7 days or until the patient was fully mobile. Duration 7 days. Concurrent medication/care: Not reported. Indirectness: No indirectness (n=94) Intervention 2: Anti-embolism stockings - Above knee. Thigh length AES plus 5000U sodium heparin were given in combination. AES were applied preoperatively and worn day and night until full mobilisation occurred. Duration 7 days. Concurrent medication/care: Not reported. Indirectness: No indirectness
Funding	Study funded by industry (Supported in part by grants from NOVO A/S Kabi Vitrum A/S and the Kendall Company)
RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: ABOVE KNEE + UFH versus UNFRACTIONATED HEPARIN (LOW DOSE, ADMINISTERED	

SUBCUTANEOUSLY)

Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge
- Actual outcome: All-cause mortality at 30 days; Group 1: 16/79, Group 2: 11/81

Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;
Indirectness of outcome: No indirectness ; Group 1 Number missing: 13; Group 2 Number missing: 3

Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge

- Actual outcome: DVT at 30 days; Group 1: 2/79, Group 2: 12/81

Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;
Indirectness of outcome: No indirectness ; Group 1 Number missing: 13; Group 2 Number missing: 3

Protocol outcome 3: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge

- Actual outcome: PE at 30 days; Group 1: 0/79, Group 2: 0/81

Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;
Indirectness of outcome: No indirectness ; Group 1 Number missing: 13; Group 2 Number missing: 3

Protocol outcomes not reported by the study

Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge; Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study;

H.33 Bariatric surgery

Study	Imberti 2014 ¹⁵⁴
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=250)
Countries and setting	Conducted in Italy; Setting: Italian centres were eligible for inclusion
Line of therapy	Not applicable
Duration of study	Intervention time: 9±2 days
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: DVT (symptomatic and asymptomatic): confirmed by bilateral colour Doppler ultrasound of the lower limb venous system. PE: confirmed by perfusion lung scan matched with chest X-ray, ventilation/perfusion scan, computed tomography, angiography Major bleeding: defined as fatal bleeding, bleeding in vital organs (intracranial, intraspinal, retroperitoneal, intraarticular, pericardial, intraocular); bleeding at the surgical site requiring reoperation; and bleeding associated with a reduction in Hb of at least 2 g/dL or requiring transfusion of at least 2 units of packed red cells/whole blood. Bleeding was defined as clinically relevant if it was overt but did not meet the other criteria for major bleeding.
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Consecutive morbidly obese patients aged >18 years with a BMI >36 kg/m ² who were scheduled to undergo open and laparoscopic primary or revisional bariatric surgery under general anaesthesia
Exclusion criteria	Presence of liver disease (acute and chronic hepatitis, cirrhosis, aminotransferases >3 times the normal upper limit); kidney disease (creatinine levels >1.2 mg/dL); platelet count <100,000/mm ³ ; documented history of DVT/PE in the last 6 months; documented congenital/acquired coagulation disorders; concomitant anticoagulant/antiplatelet therapy for other risk factors; known hypersensitivity to heparin and derivatives; pregnancy; previous heparin-induced thrombocytopenia; active peptic ulcer or known angiodysplasia of the colon, severe uncontrolled hypertension (systolic blood pressure ≥200 mmHg, diastolic ≥110 mmHg); previous haemorrhagic stroke, recent brain surgery (<3 months from randomization), recent major bleeding (<3 months of randomization), poor adherence to the study, withdrawal of informed consent; and participation in another clinical trial within the last 4 weeks or during the current trial.
Recruitment/selection of patients	Between April 2004 and February 2012, 258 consecutive morbidly obese patients (BMI >36) undergoing bariatric surgery were enrolled in this study
Age, gender and ethnicity	Age - Mean (range): 40.9 (18-64) years. Gender (M:F): 1/4. Ethnicity: Not reported
Further population details	1. Active cancer: Not applicable 2. Renal impairment: Not applicable

Extra comments	Type of surgery: laparoscopic gastric bypass 68%, laparoscopic sleeve gastrectomy 8.8%, laparoscopic gastric banding 8.4%, biliopancreatic diversion 9.6%, vertical gastropasty 0.4%). BMI (mean (SD)): 6400IU group 44.2 (5.4), 44.6 (5.4) 4250IU group; operating time: 6400IU group 187 minutes, 4250IU group 176 minutes
Indirectness of population	No indirectness
Interventions	<p>(n=119) Intervention 1: Low molecular weight heparin (not licensed in UK) - Parnaparin (3200 units once daily - 4250 units once daily). 6,400 IU/day (group B) of subcutaneous parnaparin starting 12 h preoperatively was administered. The second dose 24 h later and in any case at least 6 h after the closure of the surgical wound, once adequate hemostasis has been achieved. Subsequent injections were performed once a day for a period of 9 ± 2 days. Where the patient was discharged prior to completion of the treatment, the treatment was completed at home. Duration mean 14 days. Concurrent medication/care: Patients were recommended to use graduated compression stockings and intermittent pneumatic compression; early deambulation was strongly encouraged. Patients who received heparin + IPCD + AES + early deambulation: 62.2%. Indirectness: Serious indirectness</p> <p>(n=131) Intervention 2: Low molecular weight heparin (not licensed in UK) - Parnaparin (3200 units once daily - 4250 units once daily). 4,250 IU/day (group B) of subcutaneous parnaparin (Alfa Wassermann, Bologna, Italy) starting 12 h preoperatively, the second dose 24 h later and in any case at least 6 h after the closure of the surgical wound, once adequate hemostasis has been achieved. Subsequent injections were performed once a day for a period of 9 ± 2 days. Where the patient was discharged prior to completion of the treatment, the treatment was completed at home. Duration mean 14 days. Concurrent medication/care: Patients were recommended to use graduated compression stockings and intermittent pneumatic compression; early deambulation was strongly encouraged. Patients who received heparin + IPCD + AES + early deambulation: 58%. Indirectness: No indirectness</p>
Funding	Funding not stated

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: PARNAPARIN (6400IU/DAY) + IPCD + AES versus PARNAPARIN (4250IU/DAY) + IPCD + AES

Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge

- Actual outcome: All-cause mortality at 90 days; Group 1: 0/119, Group 2: 0/131

Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0

Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge

- Actual outcome: DVT (symptomatic and asymptomatic) at 11 days; Group 1: 1/119, Group 2: 1/131

Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0	
<p>Protocol outcome 3: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge</p> <p>- Actual outcome: PE at 11 days; Group 1: 0/119, Group 2: 1/131</p> <p>Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;</p> <p>Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0</p>	
<p>Protocol outcome 4: Heparin-induced thrombocytopenia at duration of study</p> <p>- Actual outcome: Heparin-induced thrombocytopenia at 11 days; Group 1: 1/119, Group 2: 1/131</p> <p>Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;</p> <p>Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0</p>	
Protocol outcomes not reported by the study	Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge; Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Technical complications of mechanical interventions at duration of study;

Study	Kalfarentzos 2001¹⁶⁸
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=60)
Countries and setting	Conducted in Greece; Setting: University Hospital of Patras, Patras, Greece
Line of therapy	Not applicable
Duration of study	Intervention time: Until discharge
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: DVT (symptomatic and asymptomatic): confirmed by compression ultrasonography (Doppler)

	Major bleeding: defined as haemorrhage associated with a decrease in haemoglobin levels of >2 g per decilitre or an episode requiring transfusion of >2 units of blood.
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	All patients aged >18 years, presenting with clinical morbid obesity (with a BMI >36) scheduled to undergo RYGBP12 were eligible.
Exclusion criteria	Pregnancy, active clinically significant bleeding, recent gastrointestinal bleeding or documented congenital bleeding tendency/disorder(s); thrombocytopenia or a previous history of thrombocytopenia (platelet count below 100x 10 ⁹ /L; hepatic or renal dysfunction; uncontrolled hypertension (blood pressure ≥200 mmHg systolic and/or ≥110 mmHg diastolic); acute bacterial endocarditis or conditions with a poor prognosis unrelated to morbid obesity; a history of haemorrhagic stroke; recent (<3 months prior to randomisation) brain, spinal or ophthalmological surgery; or a known hypersensitivity to heparin or LMWH. Patients for whom anticoagulation therapy was contraindicated, and those who had, in the 90 days, participated in any other therapeutic study evaluating DVT prophylaxis
Recruitment/selection of patients	Patients enrolled from March 1999 to August 2000
Age, gender and ethnicity	Age - Mean (SD): 35 (11) years. Gender (M:F): 1/4. Ethnicity: Not reported
Further population details	1. Active cancer: Not applicable 2. Renal impairment: Not applicable
Extra comments	BMI (mean (SD)): 0.6ml nadroparin group 48.8 (8), 1.0ml nadroparin group 48.6 (7.3). Operating time: 0.6ml nadroparin group 185.6 minutes, 1.0ml nadroparin group 196.7 minutes.
Indirectness of population	No indirectness
Interventions	(n=30) Intervention 1: Low molecular weight heparin (not licensed in UK) - Nadroparin (2850 units once daily - up to 57 units/kg once daily). 9500IU (1.0ml) administered subcutaneously once pre-operatively and once daily postoperatively until the day of discharge (10.2 days). Duration Until discharge (10.2 days). Concurrent medication/care: Average weight (mean (SD)): 134.4 (26.3). No other drugs with effects on coagulation were permitted. Indirectness: Serious indirectness (n=30) Intervention 2: Low molecular weight heparin (not licensed in UK) - Nadroparin (2850 units once daily - up to 57 units/kg once daily). 5700IU (0.6ml) administered subcutaneously once pre-operatively and once daily postoperatively until the day of discharge (10.2 days). Duration Until discharge (mean 9.4 days). Concurrent medication/care: Average weight (mean (SD)): 131 (24). No other drugs with effects on coagulation were permitted. Indirectness: No indirectness
Funding	Funding not stated
RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: NADROPARIN (ABOVE MAX. DOSE) versus NADROPARIN (HIGH DOSE)	

Protocol outcome 1: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge
 - Actual outcome: DVT (symptomatic and asymptomatic) at 90 days; Group 1: 0/30, Group 2: 0/30
 Risk of bias: All domain - Very high, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;
 Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0
 - Actual outcome: Major bleeding at Unclear; Group 1: 2/30, Group 2: 0/30
 Risk of bias: All domain - Very high, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;
 Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0

Protocol outcomes not reported by the study	All-cause mortality at up to 90 days from hospital discharge; Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge; Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge; Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at duration of study; Technical complications of mechanical interventions at duration of study;
---	---

Study	EFFORT trial: Steele 2015³⁰⁴
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=198)
Countries and setting	Conducted in USA; Setting: Academic institution that is accredited by the American College of Surgeons and ASMBS Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program
Line of therapy	Not applicable
Duration of study	Intervention + follow up: Intervention duration of hospitalisation, follow up 10-14 days
Method of assessment of guideline condition	Adequate method of assessment/diagnosis
Stratum	Overall

Subgroup analysis within study	Not applicable
Inclusion criteria	18 years or over; BMI 35-59kg/m ² ; undergoing laproscopic vertical sleeve gastrectomy or laproscopic Roux-en Y gastric bypass
Exclusion criteria	BMI >60; contraindications to LMWH or selective antithrombin III agonists; previous history of DVT or PE, documented clotting/coagulation disorders; history of treatment of cancer within last year; history of venous stasis or superficial thrombophlebitis, vein stripping or ligation, obesity hypoventilation syndrome; recent history of smoking (within last year)
Recruitment/selection of patients	Consecutive bariatric surgery patients from an academic institution from July 2010 to August 2013,
Age, gender and ethnicity	Age - Mean (SD): 41.1±9.6 (range 18-68). Gender (M:F): 32:166. Ethnicity: white non-hispanic 64.6%, black non-hispanic 32.3%, hispanic 2%
Further population details	1. Active cancer: No active cancer (Cancer 1.5%). 2. Renal impairment: Not stated
Extra comments	laproscopic vertical sleeve gastrectomy 37.9%; laproscopic Roux-en Y gastric bypass 62.1%
Indirectness of population	No indirectness
Interventions	(n=98) Intervention 1: Low molecular weight heparin (licensed in UK) - Enoxaparin (20mg once daily – 60mg twice daily). Enoxaparin 40mg 1x pre-op and 40mg x2 daily post-op, administered subcutaneously. Duration Until discharge, average length of stay 2.5 days. Concurrent medication/care: Sequential compression devices and antiembolic stockings 4-6 hours post-op, early mobilisation (n=100) Intervention 2: Fondaparinux - Fondaparinux (all doses). 5mg once daily post-operatively. Duration Until discharge, average length of stay 2.5 days. Concurrent medication/care: Sequential compression devices and antiembolic stockings 4-6 hours post-op, early mobilisation
Funding	Study funded by industry (GlaxoSmithKline)

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: ENOXAPARIN (20MG ONCE DAILY – 60MG TWICE DAILY) versus FONDAPARINUX (ALL DOSES)

Protocol outcome 1: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge

- Actual outcome: DVT (symptomatic and asymptomatic). confirmed by magnetic resonance venography at 14 days; Group 1: 2/83, Group 2: 2/94; Risk of bias: High; Indirectness of outcome: No indirectness

Protocol outcome 2: Heparin-induced thrombocytopenia at duration of study

- Actual outcome: Thrombocytopenia at 14 days; Group 1: 0/83, Group 2: 1/94; Risk of bias: High; Indirectness of outcome: No indirectness

<p>Protocol outcome 3: DVT (symptomatic) at 7-90 days from hospital discharge - Actual outcome: DVT (symptomatic) at 14 days; Group 1: 2/98, Group 2: 2/100</p>	
<p>Protocol outcomes not reported by the study</p>	<p>All-cause mortality at up to 90 days from hospital discharge; Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge; Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge; Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Technical complications of mechanical interventions at duration of study</p>

H.34 Cardiac surgery

Study	ATACAS trial: Myles 2016²³⁴
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=2100)
Countries and setting	Conducted in Australia, Canada, Hong Kong (China), Italy, New Zealand, United Kingdom
Line of therapy	Not applicable

Study	ATACAS trial: Myles 2016 ²³⁴
Duration of study	Intervention + follow up: Patients were assessed daily during their hospital stay and were contacted by telephone 30 days after surgery.
Method of assessment of guideline condition	Adequate method of assessment/diagnosis
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Adults at increased risk for major complications related to age or coexisting conditions and were about to undergo on-pump (with cardiopulmonary bypass) or off-pump (without cardiopulmonary bypass) coronary artery surgery, with or without cardiac-valve placement or another procedure. Patients were eligible if they had not been taking aspirin regularly before the trial or had stopped taking aspirin at least 4 days before CABG surgery.
Exclusion criteria	Poor English language comprehension. Clinician preference for antifibrinolytic therapy. Urgent surgery for unstable coronary syndromes where for clinical reasons antiplatelet medication cannot be discontinued. Active peptic ulceration. Allergy or contraindication to aspirin or tranexamic acid. Aspirin therapy within 4 days of surgery. Warfarin or clopidogrel therapy within 7 days of surgery, or GIIb/IIIa antagonists within 24 hours of surgery. Thrombocytopenia or any other known history of bleeding disorder. Severe renal impairment (serum creatinine >250 micro mol/l or estimated creatinine clearance <25 ml/min). Recent haematuria. Thromboembolic disease relating to: history of postoperative or spontaneous pulmonary embolism, spontaneous arterial thrombosis or familial hypercoaguability (eg. lupus anticoagulant, protein C deficiency). Pregnancy.
Age, gender and ethnicity	Age - Mean (SD): Aspirin: 66.5 (9.7) Placebo: 66.2 (10.2) . Gender (M:F): Aspirin: 83.3% male, Placebo: 81.5%. Ethnicity: Not stated
Further population details	1. Active cancer: Not applicable 2. Antiplatelet therapy: Not applicable (Clopidogrel therapy within 7 days of surgery excluded, other antiplatelets not stated). 3. BMI : Mixed 4. Bowel surgery: Not applicable 5. Cardiac bypass: Systematic review: mixed (Not Systematic review, but mixed population). 6. Renal impairment: Mixed
Extra comments	A. At risk of major complications defined by any of: Age ≥70 years. Left ventricular impairment (fractional area change <20%, ejection fraction <40%, or at least moderate impairment on

Study	ATACAS trial: Myles 2016²³⁴
	<p>ventriculography). Concomitant valvular or aortic surgery. Left ventricular aneurysmectomy. Repeat cardiac surgery ("re-do"). Chronic obstructive pulmonary disease. Renal impairment (se. creatinine >150 micromol/l or creatinine clearance <45 ml/min). Obesity (BMI >25 kg/m²). Pulmonary hypertension (mPAP >25 mmHg). Peripheral vascular disease.</p>
Indirectness of population	No indirectness
Interventions	<p>(n=1059) Intervention 1: Aspirin. 100mg aspirin administered 1 to 2 hours before surgery, with or without anxiolytic premedication. Duration Daily assessment during hospital stay and phone call 30 days after surgery. Concurrent medication/care: All patients received standard surgical and other perioperative care, including selection of vein and artery conduit harvesting, determination of the extent of grafting needed according to the results of coronary angiography, myocardial protection, surgical haemostatis, inotrope therapy, and postoperative care. There was no limitation to the use or postoperative aspirin or other antiplatelet therapy, and such therapy was administered in accordance with local practices. Indirectness: No indirectness</p> <p>(n=1068) Intervention 2: No treatment - Placebo. Matched placebo tablets 1 to 2 hours before surgery, with or without anxiolytic premedication. Duration Daily assessment during hospital stay and phone call 30 days after surgery. Concurrent medication/care: All patients received standard surgical and other perioperative care, including selection of vein and artery conduit harvesting, determination of the extent of grafting needed according to the results of coronary angiography, myocardial protection, surgical haemostatis, inotrope therapy, and postoperative care. There was no limitation to the use or postoperative aspirin or other antiplatelet therapy, and such therapy was administered in accordance with local practices. Indirectness: No indirectness</p>
Funding	Equipment / drugs provided by industry (Bayer Pharma provided the aspirin and matched placebo tablets. Other funding received from the Australian National Health and Medical research Council, the Australian and New Zealand College of Anaesthetists and the National Institute of Health Research.)
RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: ASPIRIN versus PLACEBO	

Study	ATACAS trial: Myles 2016 ²³⁴
	<p>Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge - Actual outcome: Death at Within 30 days after surgery; Group 1: 14/1047, Group 2: 9/1053 Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Blinding details: Postoperative therapy administered in accordance with local practices. ; Group 1 Number missing: 12, Reason: 6 withdrew consent, 4 had surgery cancelled, 2 underwent duplicate randomisation.; Group 2 Number missing: 15, Reason: 11 withdrew consent, 2 had surgery cancelled, 2 underwent duplicate randomisation.</p>
	<p>Protocol outcome 2: Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpec; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge - Actual outcome: Pulmonary embolism at Within 30 days after surgery; Group 1: 8/1047, Group 2: 10/1053 Indirectness of outcome: No indirectness ; Blinding details: Postoperative therapy administered in accordance with local practices. ; Group 1 Number missing: 12, Reason: 6 withdrew consent, 4 had surgery cancelled, 2 underwent duplicate randomisation.; Group 2 Number missing: 15, Reason: 11 withdrew consent, 2 had surgery cancelled, 2 underwent duplicate randomisation.</p>
	<p>Protocol outcome 3: Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of $\geq 2\text{g/dl}$; a serious or life threatening clinical event at up to 45 days from hospital discharge - Actual outcome: Reoperation for hemorrhage at Within 30 days after surgery; Group 1: 19/1047, Group 2: 22/1053 Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Blinding details: Postoperative therapy administered in accordance with local practices. ; Group 1 Number missing: 12, Reason: 6 withdrew consent, 4 had surgery cancelled, 2 underwent duplicate randomisation.; Group 2 Number missing: 15, Reason: 11 withdrew consent, 2 had surgery cancelled, 2 underwent duplicate randomisation.</p>
	<p>Protocol outcome 4: Major cardiac events at up to 90 days from hospital discharge - Actual outcome: Myocardial infarction at Within 30 days after surgery; Group 1: 144/1047, Group 2: 166/1053 Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Blinding details: Postoperative therapy administered in accordance with local practices. ; Group 1 Number missing: 12, Reason: 6 withdrew consent, 4 had surgery cancelled, 2 underwent duplicate randomisation.; Group 2 Number missing: 15, Reason: 11 withdrew consent, 2 had surgery cancelled, 2 underwent duplicate randomisation. - Actual outcome: Stroke at Within 30 days after surgery; Group 1: 14/1047, Group 2: 12/1053 Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Blinding details: Postoperative therapy administered in accordance with local practices. ; Group 1 Number missing: 12, Reason: 6 withdrew consent, 4 had surgery cancelled, 2 underwent duplicate randomisation.; Group 2 Number missing: 15, Reason: 11 withdrew consent, 2 had surgery cancelled, 2 underwent duplicate randomisation.</p>

Study ATACAS trial: Myles 2016²³⁴

Bibliographic reference	Study Type	Evidence level	No. of patients	Patients characteristics	Intervention	Comparison	Length of follow up	Outcome measures	Effect size	Comments
Goldhaber et al., 1995 ¹²²	RCT	1+	Total: 344 Intervention : n=172	Type of surgery: Coronary	Type: Thigh-length IPCD device	Graduated compression stocking	Both groups: followed	DVT Confirmed by: bilateral	Intervention: 31/164	Comments: 14 participants dropped out after

Protocol outcomes not reported by the study	Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge; Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at up to 90 days from hospital discharge; Technical complications of mechanical interventions at up to 90 days from hospital discharge;
---	--

			Control: n= 172	artery bypass. Duration: not reported. Intervention: Mean age: 63.2 ± 9.7 years M/F: 137/35 Control: Mean age: not reported M/F: 92/77 Pre-existing risk factors: Significantly greater proportion of patients in the comparison group had cancer	Dose: 30– 45 mmHg Timing: First 98 patients started >24 hours post- operatively Patients 99 to 344 began 4–12 hours post- surgery. Appeared to be worn until discharge Additional non- comparative prophylaxis: Graduated compression stocking (length unknown). Appears to be begun immediately post-op.	(length unknown). Appears to be begun immediately post-op. Aspirin 325 mg/day (unless contra- indicated)	up until discharge	Doppler ultrasound on or after 4 post- op day	Control: 36/166 p value: 0.62	randomisation (8 IPCD + AES; and 6 AES). First 98 patients enrolled had delayed initiation of prophylaxis (outcome for these patients were not significantly different). Any interruption of prophylaxis > 3 hours was recorded. Significantly more non-compliance in the IPCD group. Difference between groups still not significant when analysed with only those whose compliance had not been interrupted. Age was a significant predictor of DVT.
								Proximal DVT Confirmed by: As above	Intervention: 5/164 Control: 6/166 p value: 0.98	
								PE Not routinely screened for. Non-fatal PE in control group confirmed by high probability V/Q scan	Intervention: 1/164 Control: 1/166 p value: 1.0000	
								Fatal PE Confirmed by: clinical evaluation (presumably). Patient underwent pulmonary emo- bolectomy procedure so diagnosis reliable	Intervention: 1 Control: 0/166 Patient had not received the intervention and is not included in any other analysis as no DVT measure had been	

					Aspirin 325 mg/day (unless contra- indicated)				obtained. (therefore 1/165)	Not reported: PTS, QoL, bleeding Funding: not reported
									Survival	Intervention: 2/164 Control: 0/166 p value: 0.2462
									Length of hospital stay	Intervention: Median 9 Control: Median 9 p value: 0.36 Not significant

Study	Kolluri 2016¹⁷⁷
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=78)
Countries and setting	Conducted in USA; Setting: Hospital - single centre
Line of therapy	Not applicable

Study	Kolluri 2016 ¹⁷⁷
Duration of study	Intervention + follow up: After discharge patients were contacted by phone or scheduled for follow-up at 25 to 35 days after CABG.
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: Patients who developed symptomatic DVT or VTE underwent DUS scan of the lower extremities.
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	All patients scheduled to undergo a first or repeat isolated CABG operation.
Exclusion criteria	<p>Long-term anticoagulation with unfractionated or low-molecular-weight heparin, coumadin or heparinoids.</p> <p>Contraindication to anticoagulation.</p> <p>Creatinine clearance <30 mL/min.</p> <p>Body weight <50kg.</p> <p>Presence of indwelling epidural catheter.</p> <p>Hepatic failure.</p> <p>Pregnant state.</p> <p><6 months life expectancy.</p> <p>Platelet count <100,00/mm³.</p> <p>Whole blood haemoglobin concentration <d g/dL.</p> <p>VTE documented within last 3 months.</p> <p>Acute bacterial endocarditis.</p> <p>Cerebral metastasis or abscess.</p> <p>History of heparin-induced thrombocytopenia.</p> <p>Presence of acute deep venous thrombosis on a preoperative duplex ultrasound of the lower extremities.</p> <p>Inability to undergo venous duplex of lower extremities.</p> <p>Inability to consent.</p> <p>Refusal by treating physician.</p>
Recruitment/selection of patients	All patients scheduled to undergo a first or repeat isolated CABG operation were considered for enrolment. On the day of admission to the hospital, before undergoing CABG surgery, the patients were randomly assigned to receive subcutaneous injections of saline versus subcutaneous injections of 2.5mg fondaparinux.
Age, gender and ethnicity	Age - Mean (SD): Placebo: 62 (8.9) Fondaparinux: 64.4 (8.9). Gender (M:F): 57:21 (73% male). Ethnicity: Not reported
Further population details	1. Active cancer: Not applicable 2. Antiplatelet therapy: Not applicable 3. BMI : Not applicable (Weight stated, but BMI unclear.). 4. Bowel surgery: Not applicable 5. Cardiac bypass: Cardiac bypass (All undergoing CABG). 6. Renal impairment: No renal impairment (eGFR greater than 30ml/min/1.73m2) (Creatinine clearance <30 mL/min excluded).

Study	Kolluri 2016 ¹⁷⁷
Indirectness of population	No indirectness
Interventions	<p>(n=41) Intervention 1: Fondaparinux. 2.5 mg subcutaneous injections of fondaparinux sodium daily, starting at a mean of 12 ± 2 hours after wound closure or in the morning of the first postoperative day. The second dose was administered at a mean of 24 ± 2 hours after the first dose, and the subsequent injections were administered once daily for 9 days or until discharge of the patient from the hospital. Duration 9 days, or until discharge, whichever happened first. Concurrent medication/care: Graduated compression stockings and/or intermittent pneumatic compression (mechanical antithrombotic prophylaxis). Indirectness: No indirectness</p> <p>(n=37) Intervention 2: No treatment - Placebo. Subcutaneous injections of isotonic saline on the same schedule as the intervention group. Duration 9 days or until discharge, whichever happened first. Concurrent medication/care: Graduated compression stockings and/or intermittent pneumatic compression (mechanical antithrombotic prophylaxis). Indirectness: No indirectness</p>
Funding	Equipment / drugs provided by industry (Glaxo Smith Kline provided the study drug, further funding received from the American College of Phlebology Foundation educational grant.)
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: FONDAPARINUX versus PLACEBO</p> <p>Protocol outcome 1: Deep vein thrombosis (symptomatic and asymptomatic). Confirmed by: radioiodine fibrinogen uptake test; venography; Duplex (Doppler) ultrasound; MRI; Impedance Plethysmography (used as rule out tool) at 7-90 days from hospital discharge - Actual outcome: Asymptomatic right peroneal DVT detected by DUS at time of discharge; Group 1: 0/35, Group 2: 1/32 Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 6, Reason: 2 withdrew consent. Others not stated.; Group 2 Number missing: 5, Reason: Not stated.</p>	
Protocol outcomes not reported by the study	All-cause mortality at up to 90 days from hospital discharge; Pulmonary embolism. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at 7-90 days from hospital discharge; Major bleeding. Meets one or more of the following criteria: results in death; occurs at a critical site (intracranial, intraspinal, pericardial, intraocular, retroperitoneal); results in the need for a transfusion of at least 2 units of blood; leads to a drop in haemoglobin of ≥2g/dl; a serious or life threatening clinical event at up to 45 days from hospital discharge; Fatal PE. Confirmed by: CT scan with spiral or contrast; pulmonary angiogram; ventilation/ perfusion scan including VQSpect; autopsy; echocardiography; clinical diagnosis with the presence of proven VTE at up to 90 days from hospital discharge;

Study	Kolluri 2016 ¹⁷⁷
	Clinically relevant non-major bleeding: bleeding that does not meet the criteria for major bleed but requires medical attention and/or a change in antithrombotic therapy at up to 45 days from hospital discharge; Health-related quality of life (validated scores only) at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at up to 90 days from hospital discharge; Technical complications of mechanical interventions at up to 90 days from hospital discharge; Major cardiac events at up to 90 days from hospital discharge;

H.35 Thoracic surgery

No relevant clinical studies were identified.

H.36 Vascular surgery

Study	Ayo 2017 ¹¹
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=70)
Countries and setting	Conducted in USA; Setting: Hospital
Line of therapy	1st line
Duration of study	Follow up (post intervention): 90 days
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: Undergoing endovascular ablation for great saphenous vein valvular incompetence
Stratum	People undergoing varicose vein surgery
Subgroup analysis within study	Not applicable
Inclusion criteria	Documented great saphenous vein reflux on venous duplex, CEAP disease, palpable pulse of ankle brachial index >0.9.
Exclusion criteria	Previous ipsilateral intervention, history of deep vein thrombosis, hypercoagulable state, concomitant phlebectomy,

	CEAP class 6 disease.
Recruitment/selection of patients	Eligible patients, 2009-2013, New York Langone Medical Centre
Age, gender and ethnicity	Age - Other: Mean (SD not reported): compression: 52; usual care 49 years. Gender (M:F): 20/65. Ethnicity: NR
Further population details	1. Active cancer: No active cancer 2. BMI : Not applicable 3. Open versus endovascular: Endovascular (Endovascular radiofrequency or laser ablation). 4. Renal impairment: Not applicable
Extra comments	.
Indirectness of population	No indirectness
Interventions	<p>(n=39) Intervention 1: Anti-embolism stockings - Above knee. Post-procedural compression therapy using thigh-high compression stockings (30-40mmHg) for 24 hours post procedure and then daily during waking hours for 7 days. The procedure was endovenous radiofrequency or laser ablation of great saphenous vein for valvular incompetence. If the patient required bilateral treatment, this was done on a separate occasion and for the subsequent procedure they were assigned to the opposite group. Duration 7 days post-procedure. Concurrent medication/care: NR (did not assess post-procedural doses of pain relief or compliance to stocking use). Indirectness: Serious indirectness; Indirectness comment: Some people were included in the study twice if they required bilateral treatment (number of people = 70, number of cases = 85)</p> <p>(n=46) Intervention 2: No treatment - Usual care. Usual care was 24 hours of post-procedural bandages (no compression therapy). The procedure was endovenous radiofrequency or laser ablation of great saphenous vein for valvular incompetence. If the patient required bilateral treatment, this was done on a separate occasion and for the subsequent procedure they were assigned to the opposite group. Duration 24 hours post-procedure. Concurrent medication/care: NR (did not assess post-procedural doses of pain relief). Indirectness: Serious indirectness; Indirectness comment: Some people were included in the study twice if they required bilateral treatment (number of people = 70, number of cases = 85)</p>
Funding	Funding not stated

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: COMPRESSION STOCKINGS (ABOVE KNEE) versus USUAL CARE

Protocol outcome 1: Health-related quality of life at up to 90 days from hospital discharge

- Actual outcome for People undergoing varicose vein surgery: Venous clinical severity score (VCSS) at day 7; MD; -1.23 (SEM: 1.78), Comments: Only mean final values reported for each group, along with the P value from a t-test. Therefore, the SEM was calculated for the mean difference.);

Risk of bias: All domain - Very high, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

- Actual outcome for People undergoing varicose vein surgery: Chronic venous insufficiency questionnaire (CIVIQ-2) at day 90; MD; 6.6 (SEM: 7.28), Comments: Only mean final values reported for each group, along with the P value from a t-test. Therefore, the SEM was calculated for the mean difference.);
 Risk of bias: All domain - Very high, Selection - High, Blinding - High, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low;
 Indirectness of outcome: No indirectness ; Group 1 Number missing: around 80% missing, Reason: loss to follow-up; Group 2 Number missing: around 80% missing, Reason: loss to follow-up

Protocol outcomes not reported by the study	All-cause mortality at up to 90 days from hospital discharge; Deep vein thrombosis (symptomatic and asymptomatic) at 7-90 days from hospital discharge; Pulmonary embolism at 7-90 days from hospital discharge; Major bleeding at up to 45 days from hospital discharge; Fatal PE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding at up to 45 days from hospital discharge; Heparin-induced thrombocytopenia at up to 90 days from hospital discharge; Technical complications of mechanical interventions at up to 90 days from hospital discharge;
---	--

Bibliographic reference	Study Type	Evidence level	No. of patients	Patients characteristics	Intervention	Comparison	Length of follow up	Outcome measures	Effect size	Comments
Collins 1988 (74 studies included – including Belch 1980 ¹⁹ and Spebar 1981 ³⁰¹)	Systematic Review	1+	Total: 15598 Intervention: 8112 Control: 7486	Type of surgery: general, orthopaedic and urological.	UFH Dose: Subcutaneous and given perioperatively. Additional non-comparative prophylaxis: AES: 8 studies Aspirin: 2 studies Dextran: 1 study IPCD: 1 study	No prophylaxis Additional non-comparative prophylaxis: AES: 8 studies Aspirin: 2 studies Dextran: 1 study IPCD: 1 study	Given for 2-16 days or until ambulatory or discharged.	DVT confirmed by radiolabelled fibrinogen or scanning	Int: 436/3677 Cont: 922/3389 p value: 0.0000	Not reported: Funding, QoL, LoS or PTS. Event rates reported here are for all studies as published in the systematic review.
								PE	Int: 74/1840 Cont: 104/1837 p value: 0.0212	
								Major bleeds	Int: 168/4433 Cont: 110/4177 p value: 0.0027	

Bibliographic reference	Study Type	Evidence level	No. of patients	Patients characteristics	Intervention	Comparison	Length of follow up	Outcome measures	Effect size	Comments
								Proximal DVT	Int: 54/1563 Cont: 114/1563 p value: 0.0000	

Bibliographic reference	Study Type	Evidence level	No. of patients	Patients characteristics	Intervention	Comparison	Length of follow up	Outcome measures	Effect size	Comments
Farkas 1993 ⁹⁹	RCT	1+	Total: 233 Intervention : n = 122 Control: n = 111 269 patients randomised, 36 excluded	Type of surgery: Vascular surgery – aortic or aortoiliac and aneurysmectomy; aorto-femoral bypass for atherosclerotic disease; and femoropopliteal or femorodistal bypass.	Type: LMWH (Enoxaparin) Dose: 2100 IU pre-op, then 4200 IU	Type: Unfractionated heparin Dose: 5000 units pre-op, 7500 units post-op	1 month	DVT Confirmed by: Duplex US, confirmed by venography on 7th-10th day post- op. Earlier if clinical suspicion	Int: 10/122 Control: 4/111 p value: Not significant)	Comments: Numbers in each group for baseline data do not tally with text. Arterial patency also assessed by duplex US scanning. No significant differences observed between groups in terms of development of post-op arterial thrombosis.
				Mean duration of surgery: Intervention: 4.2±1.4 h Control: 4.2±1.5h	Timing: Begun day pre-op and repeatedly daily until 7th day post- op	Timing: Begun day pre-op and repeated twice daily until 7th day post-op		PE Confirmed by: Clinical suspicion investigated by angiogram	Int: 0/122 Control: 0/111 p value: N/A	
				Intervention: Mean age:	Additional non-	Additional non-comparative		Preoperative red blood	Int: 3.91±2.79	

Bibliographic reference	Study Type	Evidence level	No. of patients	Patients characteristics	Intervention	Comparison	Length of follow up	Outcome measures	Effect size	Comments
				65±11 yrs M/F:101/25	comparative prophylaxis: Intraoperative use of UFH (94.4%) or protamine (7.9%) was authorised in both groups	prophylaxis: Intraoperative use of UFH (97.4%) or protamine (9.4%) was authorised in both groups		cell units	units Control: 3.61±1.91 p value: Not significant	Thrombocytopenia (which resolved spontaneously within 3 days) reported in 2 LMWH patients. Not reported: PVT, PTS, QoL, LoS, Funding: Trial supported by grant from Laboratoires Pharmuka, France.
			Control: Mean age: 64±11 yrs M/F:99/18				Post-operative suction drain volume	Int: 423±438ml Control: 408±455ml p value: Not significant		
			Pre-existing risk factors: Past history of VTE, age, obesity, varicose veins, COPD (no significant diffs between groups apart from COPD – more in LMWH group, p=0.02).				Survival	Int: 120 /122 Control: 111/111 p value: not reported		

Bibliographic reference	Study Type	Evidence level	No. of patients	Patients characteristics	Intervention	Comparison	Length of follow up	Outcome measures	Effect size	Comments
-------------------------	------------	----------------	-----------------	--------------------------	--------------	------------	---------------------	------------------	-------------	----------

Bibliographic reference	Study Type	Evidence level	No. of patients	Patients characteristics	Intervention	Comparison	Length of follow up	Outcome measures	Effect size	Comments
Lastoria 2006 ¹⁹⁷	RCT	1+	Total: 75 M/F: 59/16 Int: 41 Cont: 34	Type of surgery: Vascular: Major lower extremity amputation (30 above-knee and 45 below-knee) Inclusion criteria: Patients over 18 years, undergoing elective or emergency lower-limb amputation for critical-limb ischemia. Excluded if had previous venous thrombo-embolism, and patients with contra-indication for anticoagulant prophylaxis.	LMWH (enoxaparin) Dose: 40mg/day Timing: 12 hours before surgery or in emergency cases in the first postoperative day. Duration: During hospitalisation Additional non-comparative prophylaxis: Not reported	UFH Dose: 5000 IU (subcutaneously) Timing: 12 hours before surgery or in emergency cases in the first postoperative day. Duration: During hospitalisation Additional non-comparative prophylaxis: Not reported	NR	DVT confirmed by duplex scanning (5-8 days after surgery) Major bleeding	Int: 4 (9.7%) Cont: 4 (11.7%) P=0.92 Int: 0 Cont: 0	Funding: Paulista State University. Not reported: Proximal DVT's, PEs, duration of hospital stay, QoL or post-thrombotic syndrome. Notes: DVT: 1 bilateral thrombosis in each group. No significant difference between interventions in DVTs in level of amputation or sex of patient.

Study San Norberto Garcia 2013²⁸⁵

Study	San Norberto Garcia 2013 ²⁸⁵
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=264)
Countries and setting	Conducted in Spain; Setting:
Line of therapy	1st line
Duration of study	Not clear: 6 months
Method of assessment of guideline condition	Adequate method of assessment/diagnosis
Stratum	Overall: Patients with moderate thromboembolism risk
Subgroup analysis within study	Stratified then randomised
Inclusion criteria	People 18-80 years who were schedule to undergo elective varicose vein surgery
Exclusion criteria	People with low, high or highest risk for VTE; active bleeding; high risk of bleeding; contraindication to bemiparin; condition that might require bemiparin dose adjustment, including severe renal impairment; renal insufficiency; need for anticoagulant therapy; significant liver disease; pregnancy or breastfeeding; concomitant use of HIV protease inhibitors; use of fibrinolytic therapy
Recruitment/selection of patients	Consecutively recruited between 1 January 2010 and 31 March 2010
Age, gender and ethnicity	Age - Mean (range): 67 (18-75). Gender (M:F): 104:162. Ethnicity: Not reported
Further population details	1. Active cancer: No active cancer (No malignancy in either group). 2. BMI : Mixed (obesity (>25kg/m2): LMWH n=66; control n=58). 3. Open versus endovascular: Not stated 4. Renal impairment: Mixed (LMWH n=2; control n=4).
Indirectness of population	No indirectness
Interventions	(n=132) Intervention 1: Low molecular weight heparin (not licensed in UK) - Bemiparin. Bemiparin 2500/3500 IU/day for 10 days at a prophylactic dose plus AES (thigh length) for 3 months, and early ambulation. Bemiparin was started 6 hours after wound closure. Mobilisation consisted of bed to chair at day 1 and ambulation as of day 2. Duration 6 months. Concurrent medication/care: Varicose vein surgery (n=130) Intervention 2: Intermittent pneumatic compression devices - Mixed full leg/below knee. IPCD compression bandages at 20 to 25 mmHg (Bi-Flex 16; Thuane, France) during first 7 days and then AES at 12-15 mmHg (TED; Codiven, UK). Duration 3 months. Concurrent medication/care: Varicose vein surgery
Funding	Funding not stated

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: BEMIPARIN versus COMPRESSION BANDAGES

Study	San Norberto Garcia 2013 ²⁸⁵
Protocol outcome 1: Deep vein thrombosis (symptomatic and asymptomatic) at 7-90 days from hospital discharge - Actual outcome for People undergoing varicose vein surgery: DVT at 3 months; Group 1: 0/132, Group 2: 0/130; Risk of bias: Very high; Indirectness of outcome: No indirectness	
Protocol outcome 2: Pulmonary embolism at 7-90 days from hospital discharge - Actual outcome for People undergoing varicose vein surgery: Symptomatic PE at 3 months; Group 1: 0/130, Group 2: 0/132; Risk of bias: Very high; Indirectness of outcome: No indirectness	
Protocol outcome 3: Major bleeding at up to 45 days from hospital discharge - Actual outcome for People undergoing varicose vein surgery: Major bleeding at 3 months; Group 1: 0/130, Group 2: 0/132; Risk of bias: Very high; Indirectness of outcome: No indirectness	
Protocol outcomes not reported by the study	All-cause mortality at up to 90 days from hospital discharge; Fatal PE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding at up to 45 days from hospital discharge; Health-related quality of life at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at up to 90 days from hospital discharge; Technical complications of mechanical interventions at up to 90 days from hospital discharge

Study	Wang 2015 ³³⁰
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	(n=2196)
Countries and setting	Conducted in China; Setting: Vascular Surgery Department of The 2nd Affiliated Hospital of Harbin Medical University of China
Line of therapy	1st line
Duration of study	Intervention + follow up: 30 days
Method of assessment of guideline condition	Adequate method of assessment/diagnosis
Stratum	Overall: Isolated varicose veins of the lower extremity requiring conventional surgery (high ligation and stripping of the great saphenous vein, and removal of superficial varicosities)
Subgroup analysis within study	Stratified then randomised:
Inclusion criteria	Isolated varicose veins of the lower extremity requiring conventional surgery (high ligation and stripping of the great saphenous vein, and removal of superficial varicosities)
Exclusion criteria	prior varicose vein procedure (i.e. surgical stripping, endovenous ablation, sclerotherapy); prior VTE; leg trauma

Study	Wang 2015 ³³⁰
	within 2 years; congenital venous malformations (i.e. Klippel–Trenaunay syndrome); autoimmune diseases (i.e. systemic lupus erythematosus, rheumatoid arthritis, antiphospholipid syndrome); stenosis or occlusion of the inferior vena cava; anticoagulant, antiplatelet, or hormonal therapy; cancers; or nephrotic syndrome.
Age, gender and ethnicity	Age - Mean (SD): Group A (n=542) 49.95 (10.62); Group B (n=531) 7.84 (11.46); Group C (n=573) 46.86 (11.07); Group D (n=550) 45.92 (9.71). Gender (M:F): Not reported in raw numbers overall. Ethnicity:
Further population details	1. Active cancer: Not stated 2. BMI: Not stated 3. Open versus endovascular: Not stated 4. Renal impairment: Not stated
Indirectness of population	No indirectness
Interventions	<p>(n=542) Intervention 1: No treatment - Usual care. No VTE prophylaxis. Duration 3 days. Concurrent medication/care: Surgery for varicose veins</p> <p>(n=531) Intervention 2: Unfractionated heparin - low dose, administered subcutaneously. Low-dose unfractionated heparin, 125 U/kg per day divided into thrice daily subcutaneous injections . Duration 3 days. Concurrent medication/care: Surgery for varicose veins</p> <p>(n=573) Intervention 3: Low molecular weight heparin (licensed in UK) - Enoxaparin. Enoxaparin sodium 6000 IU once daily. Duration 3 days. Concurrent medication/care: surgery for varicose veins</p> <p>(n=550) Intervention 4: Low molecular weight heparin (licensed in UK) - Enoxaparin. Enoxaparin sodium 4000 IU once daily. Duration 3 days. Concurrent medication/care: surgery for varicose veins</p>
Funding	No funding

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: UFH versus NO VTE PROPHYLAXIS

Protocol outcome 1: Deep vein thrombosis (symptomatic and asymptomatic) at 7-90 days from hospital discharge

- Actual outcome for People undergoing varicose vein surgery: DVT at 30 days; Group 1: 28/542, Group 2: 3/573; Risk of bias: Low; Indirectness of outcome: No indirectness

- Actual outcome for People undergoing varicose vein surgery: PE at 30 days; Group 1: 8/542, Group 2: 0/531; Risk of bias: Low; Indirectness of outcome: No indirectness

- Actual outcome for People undergoing varicose vein surgery: Haemorrhage at 30 days; Group 1: 41/531, Group 2: 1/542; Risk of bias: Low; Indirectness of outcome: Serious indirectness

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: ENOXAPARIN 6000 IU versus NO VTE PROPHYLAXIS

Study	Wang 2015 ³³⁰
	<p>Protocol outcome 1: Deep vein thrombosis (symptomatic and asymptomatic) at 7-90 days from hospital discharge - Actual outcome for People undergoing varicose vein surgery: DVT at 30 days; Group 1: 28/542, Group 2: 2/573; Risk of bias: Low; Indirectness of outcome: No indirectness</p> <p>Protocol outcome 2: Pulmonary embolism at 7-90 days from hospital discharge - Actual outcome for People undergoing varicose vein surgery: PE at 30 days; Group 1: 8/543, Group 2: 0/573; Risk of bias: Low; Indirectness of outcome: No indirectness</p> <p>Protocol outcome 3: Major bleeding at up to 45 days from hospital discharge - Actual outcome for People undergoing varicose vein surgery: Haemorrhage at 30 days; Risk of bias: Low; Indirectness of outcome: Serious indirectness</p> <p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: ENOXAPARIN 6000 IU versus UFH</p>
	<p>Protocol outcome 1: Deep vein thrombosis (symptomatic and asymptomatic) at 7-90 days from hospital discharge - Actual outcome for People undergoing varicose vein surgery: DVT at 30 days; Group 1: 2/573, Group 2: 3/531; Risk of bias: Low; Indirectness of outcome: No indirectness</p> <p>Protocol outcome 2: Pulmonary embolism at 7-90 days from hospital discharge - Actual outcome for People undergoing varicose vein surgery: PE at 30 days; Group 1: 0/573, Group 2: 0/531; Risk of bias: Low; Indirectness of outcome: No indirectness</p> <p>Protocol outcome 3: Major bleeding at up to 45 days from hospital discharge - Actual outcome for People undergoing varicose vein surgery: Haemorrhage at 30 days; Group 1: 1/573, Group 2: 4/531; Risk of bias: Low; Indirectness of outcome: Serious indirectness</p> <p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: ENOXAPARIN 6000 IU versus ENOXAPARIN 4000 IU</p>
	<p>Protocol outcome 1: Deep vein thrombosis (symptomatic and asymptomatic) at 7-90 days from hospital discharge - Actual outcome for People undergoing varicose vein surgery: DVT at 30 days; Group 1: 2/573, Group 2: 2/550; Risk of bias: Low; Indirectness of outcome: No indirectness</p> <p>Protocol outcome 2: Pulmonary embolism at 7-90 days from hospital discharge - Actual outcome for People undergoing varicose vein surgery: PE at 30 days; Group 1: 0/573, Group 2: 0/550; Risk of bias: Low; Indirectness of outcome: No indirectness</p>

Study	Wang 2015 ³³⁰
	<p>Protocol outcome 3: Major bleeding at up to 45 days from hospital discharge - Actual outcome for People undergoing varicose vein surgery: Haemorrhage at 30 days; Group 1: 1/573, Group 2: 1/550; Risk of bias: Low; Indirectness of outcome: Serious indirectness</p> <p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: ENOXAPARIN 4000 IU versus NO VTE PROPHYLAXIS</p> <p>Protocol outcome 1: Deep vein thrombosis (symptomatic and asymptomatic) at 7-90 days from hospital discharge - Actual outcome for People undergoing varicose vein surgery: DVT at 30 days; Group 1: 28/542, Group 2: 3/531; Risk of bias: Low; Indirectness of outcome: No indirectness - Actual outcome for People undergoing varicose vein surgery: PE at 30 days; Group 1: 8/542, Group 2: 0/550; Risk of bias: Low; Indirectness of outcome: No indirectness</p> <p>Protocol outcome 2: Major bleeding at up to 45 days from hospital discharge - Actual outcome for People undergoing varicose vein surgery: Haemorrhage at 30 days; Risk of bias: Low; Indirectness of outcome: Serious indirectness</p> <p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: ENOXAPARIN 4000 IU versus UFH</p> <p>Protocol outcome 1: Deep vein thrombosis (symptomatic and asymptomatic) at 7-90 days from hospital discharge - Actual outcome for People undergoing varicose vein surgery: DVT at 30 days; Group 1: 2/550, Group 2: 3/531; Risk of bias: Low; Indirectness of outcome: No indirectness</p> <p>Protocol outcome 2: Pulmonary embolism at 7-90 days from hospital discharge - Actual outcome for People undergoing varicose vein surgery: PE at 30 days; Group 1: 0/550, Group 2: 0/531; Risk of bias: Low; Indirectness of outcome: No indirectness</p> <p>Protocol outcome 3: Major bleeding at up to 45 days from hospital discharge - Actual outcome for People undergoing varicose vein surgery: Haemorrhage at 30 days; Group 1: 0/550, Group 2: 0/531; Risk of bias: Low; Indirectness of outcome: Serious indirectness</p>
<p>Protocol outcomes not reported by the study</p>	<p>All-cause mortality at up to 90 days from hospital discharge; Fatal PE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding at up to 45 days from hospital discharge; Health-related quality of life at up to 90 days from hospital discharge; Heparin-induced thrombocytopenia at up to 90 days from hospital discharge; Technical complications of mechanical interventions at up to 90 days from hospital discharge</p>

Study	Ye 2016 ³⁴⁶
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=400)
Countries and setting	Conducted in China; Setting: Hospital
Line of therapy	1st line
Duration of study	Follow up (post intervention): 4 weeks
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: People undergoing endovenous ablation for primary unilateral great saphenous vein incompetence
Stratum	People undergoing varicose vein surgery:
Subgroup analysis within study	Not applicable
Inclusion criteria	Age between 18 and 75 years; primary unilateral great saphenous vein incompetence; C2 clinical type according to the CEAP classification system; no contraindication to surgery.
Exclusion criteria	Previous varicose vein surgery, bilateral treatment during the same procedure, patient refusal to participate in the trial, not suitable for day case surgery, unable to wear elastic stockings, already used elastic stockings or an elastic bandage and patients with arterial disease (ankle brachial index < 0.9).
Recruitment/selection of patients	Enrolled between January 2012 and November 2013
Age, gender and ethnicity	Age - Median (IQR): Compression group 48 (37-59); usual care 49 (40-60). Gender (M:F): 165/235. Ethnicity: NR
Further population details	1. Active cancer: No active cancer 2. BMI : Not obese (BMI under 30 kg/m ²) (Mean BMI under 30 kg/m ² : compression group 22.5 (3.9), usual care 23.2 (4.1)). 3. Open versus endovascular: Endovascular (endovascular laser ablation). 4. Renal impairment: Not applicable
Indirectness of population	No indirectness
Interventions	(n=200) Intervention 1: Anti-embolism stockings - Above knee. Elastic compression stockings. An elastic bandage was placed on the treated limb after the procedure, while the patient was still on the operating table and left in position during the first night. Patients then wore a thigh-high elastic compression stocking (class II, ankle pressure of 23-32 mmHg) with an open toe distally, during the daytime for at least 2 weeks. Procedure was endovenous laser ablation combined with a high ligation of the great saphenous vein. Duration NR. Concurrent medication/care: Pharmacological prophylaxis for deep vein thrombosis and wound infection were not prescribed. No patients were prescribed analgesics. Patients encouraged to resume their daily activities and return to work as soon as possible. Indirectness: No indirectness

	(n=200) Intervention 2: No treatment - Usual care. Usual care. An elastic bandage was placed on the treated limb after the procedure, while the patient was still on the operating table and left in position during the first night (same as intervention group, then compression stockings were not recommended). Procedure was endovenous laser ablation combined with a high ligation of the great saphenous vein. Duration NR. Concurrent medication/care: Pharmacological prophylaxis for deep vein thrombosis and wound infection were not prescribed. No patients were prescribed analgesics. Patients encouraged to resume their daily activities and return to work as soon as possible. Indirectness: No indirectness
Funding	Academic or government funding (National Natural Science Foundation of China, Science and Technology Committee of Shanghai and China Postdoctoral Science Foundation)
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: COMPRESSION STOCKINGS (ABOVE KNEE) versus USUAL CARE</p> <p>Protocol outcome 1: All-cause mortality at up to 90 days from hospital discharge - Actual outcome for People undergoing varicose vein surgery: Mortality at 2 weeks; Group 1: 0/200, Group 2: 0/200 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 31; Group 2 Number missing: 29</p> <p>Protocol outcome 2: Deep vein thrombosis (symptomatic and asymptomatic) at 7-90 days from hospital discharge - Actual outcome for People undergoing varicose vein surgery: DVT found by US duplex at 2 weeks; Group 1: 0/200, Group 2: 0/200 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 31; Group 2 Number missing: 29</p> <p>Protocol outcome 3: Pulmonary embolism at 7-90 days from hospital discharge - Actual outcome for People undergoing varicose vein surgery: Symptomatic pulmonary embolism at 2 weeks; Group 1: 0/200, Group 2: 0/200 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 31; Group 2 Number missing: 29</p> <p>Protocol outcome 4: Health-related quality of life at up to 90 days from hospital discharge - Actual outcome for People undergoing varicose vein surgery: Aberdeen Varicose Vein Symptoms Severity Score (AVVSS) at 4 weeks; Group 1: mean 8.5 (SD 3.6); n=200, Group 2: mean 8 (SD 3.4); n=200 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 31; Group 2 Number missing: 29</p>	
Protocol outcomes not reported by the study	Major bleeding at up to 45 days from hospital discharge; Fatal PE at up to 90 days from hospital discharge; Clinically relevant non-major bleeding at up to 45 days from hospital discharge; Heparin-induced thrombocytopenia at up to 90 days from hospital discharge; Technical complications of mechanical interventions at up to 90 days from hospital

discharge;

H.37 Head and neck surgery

H.37.1 Oral and maxillofacial surgery

No relevant clinical studies were identified.

H.37.2 Ear, nose and throat (ENT) surgery

No relevant clinical studies were identified.

Appendix I: References

1. Agnelli G, Bergqvist D, Cohen AT, Gallus AS, Gent M. Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery. *British Journal of Surgery*. 2005; 92(10):1212-1220
2. Agnelli G, Gussoni G, Bianchini C, Verso M, Mandala M, Cavanna L et al. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. *Lancet Oncology*. 2009; 10(10):943-949
3. Alkire MR, Swank ML. Use of inpatient continuous passive motion versus no CPM in computer-assisted total knee arthroplasty. *Orthopaedic Nursing*. 2010; 29(1):36-40
4. Allan A, Williams JT, Bolton JP, Le Quesne LP. The use of graduated compression stockings in the prevention of postoperative deep vein thrombosis. *British Journal of Surgery*. 1983; 70(3):172-174
5. Allen NH, Jenkins JD, Smart CJ. Surgical haemorrhage in patients given subcutaneous heparin as prophylaxis against thromboembolism. *British Medical Journal*. 1978; 1(6123):1326
6. Anand S, Asumu T. Patient acceptance of a foot pump device used for thromboprophylaxis. *Acta Orthopaedica Belgica*. 2007; 73(3):386-389
7. Anderson DR. Aspirin after dalteparin was noninferior to continued dalteparin for preventing VTE after total hip arthroplasty. *Annals of Internal Medicine*. 2013; 159(6):JC12
8. Anglen JO, Bagby C, George R. A randomized comparison of sequential-gradient calf compression with intermittent plantar compression for prevention of venous thrombosis in orthopedic trauma patients: preliminary results. *American Journal of Orthopedics*. 1998; 27(1):53-58
9. Avikainen V, von Bonsdorff H, Partio E, Kaira P, Hakkinen S, Usenius JP et al. Low molecular weight heparin (enoxaparin) compared with unfractionated heparin in prophylaxis of deep venous thrombosis and pulmonary embolism in patients undergoing hip replacement. *Annales Chirurgiae et Gynaecologiae*. 1995; 84(1):85-90
10. Ay C, Dunkler D, Marosi C, Chiriack AL, Vormittag R, Simanek R et al. Prediction of venous thromboembolism in cancer patients. *Blood*. 2010; 116(24):5377-5382
11. Ayo D, Blumberg SN, Rockman CR, Sadek M, Cayne N, Adelman M et al. Compression versus no compression after endovenous ablation of the great saphenous vein: a randomized controlled trial. *Annals of Vascular Surgery*. 2017; 38:72-77
12. Bahl V, Hu HM, Henke PK, Wakefield TW, Campbell DA, Jr., Caprini JA. A validation study of a retrospective venous thromboembolism risk scoring method. *Annals of Surgery*. 2010; 251(2):344-350
13. Bailey JP, Kruger MP, Solano FX, Zajko AB, Rubash HE. Prospective randomized trial of sequential compression devices vs low-dose warfarin for deep venous thrombosis prophylaxis in total hip arthroplasty. *Journal of Arthroplasty*. 1991; 6(Suppl):S29-S35
14. Barbar S, Noventa F, Rossetto V, Ferrari A, Brandolin B, Perlati M et al. A risk assessment model for the identification of hospitalized medical patients at risk for venous

- thromboembolism: the Padua Prediction Score. *Journal of Thrombosis and Haemostasis*. 2010; 8(11):2450-2457
15. Barker SGE, Hollingsworth SJ. Wearing graduated compression stockings: The reality of everyday deep vein thrombosis prophylaxis. *Phlebology*. 2004; 19(1):52-53
 16. Bath PM, Lindenstrom E, Boysen G, De Deyn P, Friis P, Leys D et al. Tinzaparin in acute ischaemic stroke (TAIST): a randomised aspirin-controlled trial. *Lancet*. 2001; 358(9283):702-710
 17. Bauer KA, Eriksson B, Lassen MR, Turpie AG. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. *New England Journal of Medicine*. 2001; 345(18):1305-1310
 18. Bejjani BB, Chen DC, Nolan NG, Edson M. Minidose heparin in transurethral prostatectomy. *Urology*. 1983; 22(3):251-254
 19. Belch JJ, Lowe GD, Pollock JG, Forbes CD, Prentice CR. Low dose heparin in the prevention of deep-vein thrombosis after aortic bifurcation graft surgery. *Thrombosis and Haemostasis*. 1980; 42(5):1429-1433
 20. Benkö T, Cooke EA, McNally MA, Mollan RA. Graduated compression stockings: knee length or thigh length. *Clinical Orthopaedics and Related Research*. 2001; 383:197-203
 21. Bergqvist D, Agnelli G, Cohen AT, Eldor A, Nilsson PE, Le Moigne-Amrani A et al. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. *New England Journal of Medicine*. 2002; 346(13):975-980
 22. Bergqvist D, Benoni G, Björgell O, Fredin H, Hedlundh U, Nicolas S et al. Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement. *New England Journal of Medicine*. 1996; 335(10):696-700
 23. Bergqvist D, Burmark US, Flordal PA, Frisell J, Hallböök T, Hedberg M et al. Low molecular weight heparin started before surgery as prophylaxis against deep vein thrombosis: 2500 versus 5000 Xal units in 2070 patients. *British Journal of Surgery*. 1995; 82(4):496-501
 24. Bergqvist D, Burmark US, Frisell J, Hallbook T, Lindblad B, Risberg B et al. Low molecular weight heparin once daily compared with conventional low-dose heparin twice daily. A prospective double-blind multicentre trial on prevention of postoperative thrombosis. *British Journal of Surgery*. 1986; 73(3):204-208
 25. Bergqvist D, Flordal PA, Friberg B, Frisell J, Hedberg M, Ljungström KG et al. Thromboprophylaxis with a low molecular weight heparin (tinzaparin) in emergency abdominal surgery. A double-blind multicenter trial. *Vasa*. 1996; 25(2):156-160
 26. Bergqvist D, Hallbook T. Prophylaxis of postoperative venous thrombosis in a controlled trial comparing dextran 70 and low-dose heparin. *World Journal of Surgery*. 1980; 4(2):239-243
 27. Bergqvist D, Matzsch T, Burmark US, Frisell J, Guilbaud O, Hallbook T et al. Low molecular weight heparin given the evening before surgery compared with conventional low-dose heparin in prevention of thrombosis. *British Journal of Surgery*. 1988; 75(9):888-891
 28. Bern MM, Hazel D, Deeran E, Richmond JR, Ward DM, Spitz DJ et al. Low dose compared to variable dose warfarin and to fondaparinux as prophylaxis for thromboembolism after elective hip or knee replacement surgery; a randomized, prospective study. *Thrombosis Journal*. 2015; 13:32

29. Bezan A, Posch F, Ploner F, Bauernhofer T, Pichler M, Szkandera J et al. Risk stratification for venous thromboembolism in patients with testicular germ cell tumors. *PloS One*. 2017; 12(4):e0176283
30. Bilimoria KY, Liu Y, Paruch JL, Zhou L, Kmieciak TE, Ko CY et al. Development and evaluation of the universal ACS NSQIP surgical risk calculator: A decision aid and informed consent tool for patients and surgeons. *Journal of the American College of Surgeons*. 2013; 217(5):833-842.e833
31. Blanchard J, Meuwly JY, Leyvraz PF, Miron MJ, Bounameaux H, Hoffmeyer P et al. Prevention of deep-vein thrombosis after total knee replacement. Randomised comparison between a low-molecular-weight heparin (nadroparin) and mechanical prophylaxis with a foot-pump system. *Journal of Bone and Joint Surgery (British Volume)*. 1999; 81(4):654-659
32. Borstad E, Urdal K, Handeland G, Abildgaard U. Comparison of low molecular weight heparin vs. unfractionated heparin in gynecological surgery. *Acta Obstetrica et Gynecologica Scandinavica*. 1988; 67(2):99-103
33. Borstad E, Urdal K, Handeland G, Abildgaard U. Comparison of low molecular weight heparin vs. unfractionated heparin in gynecological surgery. II: Reduced dose of low molecular weight heparin. *Acta Obstetrica et Gynecologica Scandinavica*. 1992; 71(6):471-475
34. Brady D, Raingruber B, Peterson J, Varnau W, Denman J, Resuello R et al. The use of knee-length versus thigh-length compression stockings and sequential compression devices. *Critical Care Nursing Quarterly*. 2007; 30(3):255-262
35. Brichant JF, Blom-Peters L, Buffels R, Lamy M. Central neural blockade failed to decrease deep venous thrombosis in patients undergoing hip surgery and receiving low molecular weight heparin. *British Journal of Anaesthesia*. 1995; 74(Suppl. 1):75
36. Bruntink MM, Groutars YM, Schipper IB, Breederveld RS, Tuinebreijer WE, Derksen RJ. Nadroparin or fondaparinux versus no thromboprophylaxis in patients immobilised in a below-knee plaster cast (PROTECT): A randomised controlled trial. *Injury*. 2017; 48(4):936-940
37. Burrows RF, Gan ET, Gallus AS, Wallace EM, Burrows EA. A randomised double-blind placebo controlled trial of low molecular weight heparin as prophylaxis in preventing venous thrombotic events after caesarean section: a pilot study. *British Journal of Obstetrics and Gynaecology*. 2001; 108(8):835-839
38. Butson AR. Intermittent pneumatic calf compression for prevention of deep venous thrombosis in general abdominal surgery. *American Journal of Surgery*. 1981; 142(4):525-527
39. Caen JP. A randomized double-blind study between a low molecular weight heparin Kabi 2165 and standard heparin in the prevention of deep vein thrombosis in general surgery. A French multicenter trial. *Thrombosis and Haemostasis*. 1988; 59(2):216-220
40. Camporese G, Bernardi E, Noventa F, Bosco M, Monteleone G, Santoro L et al. Efficacy of Rivaroxaban for thromboprophylaxis after Knee Arthroscopy (ERIKA). A phase II, multicentre, double-blind, placebo-controlled randomised study. *Thrombosis and Haemostasis*. 2016; 116(2):349-355
41. Camporese G, Bernardi E, Prandoni P, Noventa F, Verlato F, Simioni P et al. Low-molecular-weight heparin versus compression stockings for thromboprophylaxis after knee arthroscopy: a randomized trial. *Annals of Internal Medicine*. 2008; 149(2):73-82

42. Caprini JA, Chucker JL, Zuckerman L. Thrombosis prophylaxis using external compression. *Surgery, Gynecology and Obstetrics*. 1983; 156(5):599-604
43. Cassidy MR, Rosenkranz P, McAneny D. Reducing postoperative venous thromboembolism complications with a standardized risk-stratified prophylaxis protocol and mobilization program. *Journal of the American College of Surgeons*. 2014; 218(6):1095-1104
44. Catterick D, Hunt BJ. Impact of the national venous thromboembolism risk assessment tool in secondary care in England: retrospective population-based database study. *Blood Coagulation and Fibrinolysis*. 2014; 25(6):571-576
45. Cella CA, Di Minno G, Carlomagno C, Arcopinto M, Cerbone AM, Matano E et al. Preventing Venous Thromboembolism in Ambulatory Cancer Patients: The ONKOTEV Study. *Oncologist*. 2017; 22(5):601-608
46. Cerrato D, Ariano C, Fiacchino F. Deep vein thrombosis and low-dose heparin prophylaxis in neurosurgical patients. *Journal of Neurosurgery*. 1978; 49(3):378-381
47. Chan JC, Roche SJ, Lenehan B, O'sullivan M, Kaar K. Compliance and satisfaction with foot compression devices: an orthopaedic perspective. *Archives of Orthopaedic and Trauma Surgery*. 2007; 127(7):567-571
48. Chandhoke PS, Gooding GA, Narayan P. Prospective randomized trial of warfarin and intermittent pneumatic leg compression as prophylaxis for postoperative deep venous thrombosis in major urological surgery. *Journal of Urology*. 1992; 147(4):1056-1059
49. Chin PL, Amin MS, Yang KY, Yeo SJ, Lo NN. Thromboembolic prophylaxis for total knee arthroplasty in Asian patients: a randomised controlled trial. *Journal of Orthopaedic Surgery*. 2009; 17(1):1-5
50. Chiou-Tan FY, Garza H, Chan KT, Parsons KC, Donovan WH, Robertson CS et al. Comparison of dalteparin and enoxaparin for deep venous thrombosis prophylaxis in patients with spinal cord injury. *American Journal of Physical Medicine and Rehabilitation*. 2003; 82(9):678-685
51. Cho KY, Kim KI, Khurana S, Bae DK, Jin W. Is routine chemoprophylaxis necessary for prevention of venous thromboembolism following knee arthroplasty in a low incidence population? *Archives of Orthopaedic and Trauma Surgery*. 2013; 133(4):551-559
52. Clarke-Pearson DL, Coleman RE, Synan IS, Hinshaw W, Creasman WT. Venous thromboembolism prophylaxis in gynecologic oncology: a prospective, controlled trial of low-dose heparin. *American Journal of Obstetrics and Gynecology*. 1983; 145(5):606-613
53. Clarke-Pearson DL, Creasman WT, Coleman RE, Synan IS, Hinshaw WM. Perioperative external pneumatic calf compression as thromboembolism prophylaxis in gynecologic oncology: report of a randomized controlled trial. *Gynecologic Oncology*. 1984; 18(2):226-232
54. Clarke-Pearson DL, Synan IS, Dodge R, Soper JT, Berchuck A, Coleman RE. A randomized trial of low-dose heparin and intermittent pneumatic calf compression for the prevention of deep venous thrombosis after gynecologic oncology surgery. *American Journal of Obstetrics and Gynecology*. 1993; 168(4):1146-1153
55. Clarke-Pearson DL, Synan IS, Hinshaw WM, Coleman RE, Creasman WT. Prevention of postoperative venous thromboembolism by external pneumatic calf compression in patients with gynecologic malignancy. *Obstetrics and Gynecology*. 1984; 63(1):92-98

56. CLOTS (Clots in Legs Or sTockings after Stroke) Trial Collaboration. Thigh-length versus below-knee stockings for deep venous thrombosis prophylaxis after stroke: a randomized trial. *Annals of Internal Medicine*. 2010; 153(9):553-562
57. CLOTS (Clots in Legs Or sTockings after Stroke) Trials Collaboration. Effect of intermittent pneumatic compression on disability, living circumstances, quality of life, and hospital costs after stroke: secondary analyses from CLOTS 3, a randomised trial. *Lancet Neurology*. 2014; 13(12):1186-1192
58. CLOTS (Clots in Legs Or sTockings after Stroke) Trials Collaboration, Dennis M, Sandercock P, Reid J, Graham C, Forbes J et al. Effectiveness of intermittent pneumatic compression in reduction of risk of deep vein thrombosis in patients who have had a stroke (CLOTS 3): a multicentre randomised controlled trial. *Lancet*. 2013; 382(9891):516-524
59. CLOTS Trials Collaboration, Dennis M, Sandercock PAG, Reid J, Graham C, Murray G et al. Effectiveness of thigh-length graduated compression stockings to reduce the risk of deep vein thrombosis after stroke (CLOTS trial 1): a multicentre, randomised controlled trial. *Lancet*. 2009; 373(9679):1958-1965
60. Coe NP, Collins RE, Klein LA, Bettmann MA, Skillman JJ, Shapiro RM et al. Prevention of deep vein thrombosis in urological patients: a controlled, randomized trial of low-dose heparin and external pneumatic compression boots. *Surgery*. 1978; 83(2):230-234
61. Cohen AT, Davidson BL, Gallus AS, Lassen MR, Prins MH, Tomkowski W et al. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. *British Medical Journal*. 2006; 332(7537):325-329
62. Cohen AT, Skinner JA, Warwick D, Brenkel I. The use of graduated compression stockings in association with fondaparinux in surgery of the hip: a multicentre, multinational, randomised, open-label, parallel-group comparative study. *Journal of Bone and Joint Surgery (British Volume)*. 2007; 89-B(7):887-892
63. Cohen AT, Spiro TE, Buller HR, Haskell L, Hu D, Hull R et al. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. *New England Journal of Medicine*. 2013; 368(6):513-523
64. Cohen ME, Bilimoria KY, Ko CY, Hall BL. Development of an American college of surgeons national surgery quality improvement program: morbidity and mortality risk calculator for colorectal surgery. *Journal of the American College of Surgeons*. 2009; 208(6):1009-1016
65. Collins R, Scrimgeour A, Yusuf S, Peto R. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. Overview of results of randomized trials in general, orthopedic, and urologic surgery. *New England Journal of Medicine*. 1988; 318(18):1162-1173
66. Colwell CW, Jr., Collis DK, Paulson R, McCutchen JW, Bigler GT, Lutz S et al. Comparison of enoxaparin and warfarin for the prevention of venous thromboembolic disease after total hip arthroplasty. Evaluation during hospitalization and three months after discharge. *Journal of Bone and Joint Surgery (American Volume)*. 1999; 81(7):932-940
67. Colwell CW, Jr., Pulido P, Hardwick ME, Morris BA. Patient compliance with outpatient prophylaxis: An observational study. *Orthopedics*. 2005; 28(2):143-147
68. Colwell CW, Jr., Spiro TE, Trowbridge AA, Morris BA, Kwaan HC, Blaha JD et al. Use of enoxaparin, a low-molecular-weight heparin, and unfractionated heparin for the prevention of deep venous thrombosis after elective hip replacement. A clinical trial comparing efficacy

- and safety. Enoxaparin Clinical Trial Group. *Journal of Bone and Joint Surgery*. 1994; 76(1):3-14
69. Colwell CW, Spiro TE, Trowbridge AA, Stephens JW, Gardiner GA, Ritter MA. Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep venous thrombosis after elective knee arthroplasty. Enoxaparin Clinical Trial Group. *Clinical Orthopaedics and Related Research*. 1995; 321:19-27
70. Colwell CWJ, Froimson MI, Mont MA, Ritter MA, Trousdale RT, Buehler KC et al. Thrombosis prevention after total hip arthroplasty: a prospective, randomized trial comparing a mobile compression device with low-molecular-weight heparin. *Journal of Bone and Joint Surgery - American Volume*. 2010; 92(3):527-535
71. Comp PC, Spiro TE, Friedman RJ, Whitsett TL, Johnson GJ, Gardiner GA, Jr. et al. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. *Journal of Bone and Joint Surgery (American Volume)*. 2001; 83(3):336-345
72. Cook D, Meade M, Guyatt G, Walter S, Heels-Ansdell D, Warkentin TE et al. Dalteparin versus unfractionated heparin in critically ill patients. *New England Journal of Medicine*. 2011; 364(14):1305-1314
73. Cruz M, Fernandez-Alonso AM, Rodriguez I, Garrigosa L, Cano A, Carretero P et al. Postcesarean thromboprophylaxis with two different regimens of bemiparin. *Obstetrics and Gynecology International*. 2011; 2011:548327
74. Dahan R, Houlbert D, Caulin C. Prevention of deep vein thrombosis in elderly medical in-patients by a low molecular weight heparin : a randomized double-blind trial. *Haemostasis*. 1986; 16:159-164
75. Dahl OE, Andreassen G, Aspelin T, Müller C, Mathiesen P, Nyhus S et al. Prolonged thromboprophylaxis following hip replacement surgery -- results of a double-blind, prospective, randomised, placebo-controlled study with dalteparin (Fragmin). *Thrombosis and Haemostasis*. 1997; 77(1):26-31
76. Dauphin A, Raymer KE, Stanton EB, Fuller HD. Comparison of general anesthesia with and without lumbar epidural for total hip arthroplasty: effects of epidural block on hip arthroplasty. *Journal of Clinical Anesthesia*. 1997; 9(3):200-203
77. Davis FM, Laurenson VG. Spinal anaesthesia or general anaesthesia for emergency hip surgery in elderly patients. *Anaesthesia and Intensive Care*. 1981; 9(4):352-358
78. Davis FM, Laurenson VG, Gillespie WJ, Wells JE, Foate J, Newman E. Deep vein thrombosis after total hip replacement. A comparison between spinal and general anaesthesia. *Journal of Bone and Joint Surgery British Volume*. 1989; 71(2):181-185
79. De Cicco M, Matovic M, Balestreri L, Steffan A, Pacenzia R, Malafrente M et al. Early and short-term acenocumarine or dalteparin for the prevention of central vein catheter-related thrombosis in cancer patients: a randomized controlled study based on serial venographies. *Annals of Oncology*. 2009; 20(12):1936-1942
80. Decousus H, Tapson VF, Bergmann JF, Chong BH, Froehlich JB, Kakkar AK et al. Factors at admission associated with bleeding risk in medical patients: findings from the IMPROVE investigators. *Chest*. 2011; 139(1):69-79
81. Dennis JW, Menawat S, Von Thron J, Fallon WF, Jr., Vinsant GO, Laneve LM et al. Efficacy of deep venous thrombosis prophylaxis in trauma patients and identification of high-risk groups. *Journal of Trauma*. 1993; 35(1):132-138

82. Dennis M, Sandercock P, Graham C, Forbes J, Smith J. The Clots in Legs Or sTockings after Stroke (CLOTS) 3 trial: a randomised controlled trial to determine whether or not intermittent pneumatic compression reduces the risk of post-stroke deep vein thrombosis and to estimate its cost-effectiveness. *Health Technology Assessment*. 2015; 19(76):1-90
83. Di Biase L, Burkhardt JD, Santangeli P, Mohanty P, Sanchez JE, Horton R et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the role of coumadin in preventing thromboembolism in atrial fibrillation (AF) patients undergoing catheter ablation (COMPARE) randomized trial. *Circulation*. 2014; 129(25):2638-2644
84. Dickinson LD, Miller LD, Patel CP, Gupta SK. Enoxaparin increases the incidence of postoperative intracranial hemorrhage when initiated preoperatively for deep venous thrombosis prophylaxis in patients with brain tumors. *Neurosurgery*. 1998; 43(5):1074-1081
85. Diener HC, Ringelstein EB, von Kummer R, Landgraf H, Koppenhagen K, Harenberg J et al. Prophylaxis of thrombotic and embolic events in acute ischemic stroke with the low-molecular-weight heparin certoparin: results of the PROTECT Trial. *Stroke*. 2006; 37(1):139-144
86. Domeij-Arverud E, Labruto F, Latifi A, Nilsson G, Edman G, Ackermann PW. Intermittent pneumatic compression reduces the risk of deep vein thrombosis during post-operative lower limb immobilisation: a prospective randomised trial of acute ruptures of the Achilles tendon. *Bone and Joint Journal*. 2015; 97-B(5):675-680
87. Domeij-Arverud E, Latifi A, Labruto F, Nilsson G, Ackermann PW. Can foot compression under a plaster cast prevent deep-vein thrombosis during lower limb immobilisation? *Bone and Joint Journal*. 2013; 95-B(9):1227-1231
88. Du W, Zhao C, Wang J, Liu J, Shen B, Zheng Y. Comparison of rivaroxaban and parnaparin for preventing venous thromboembolism after lumbar spine surgery. *Journal of Orthopaedic Surgery and Research*. 2015; 10:78
89. Duke RJ, Turpie AGG, Bloch RF, Trebilcock RG. Clinical trial of low-dose subcutaneous heparin for the prevention of stroke progression: natural history of acute partial stroke and stroke-in-evolution. 'In:' Reivich M, Hurtig HI, editors. *Cerebrovascular disease*. New York, NY: Raven Press. 1983. p. 399-405.
90. Elliott CG, Dudney TM, Egger M. Calf-thigh sequential pneumatic compression compared with plantar venous pneumatic compression to prevent deep-vein thrombosis after non-lower extremity trauma. *Journal of Trauma*. 1999; 47(1):25-32
91. Eriksson B, Dahl OE, Rosencher N, Kurth A, Niek van Dijk C, Frostick S et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. *Lancet*. 2007; 370(9591):949-956
92. Eriksson B, I, Kälebo P, Anthymyr BA, Wadenvik H, Tengborn L, Risberg B. Prevention of deep-vein thrombosis and pulmonary embolism after total hip replacement. Comparison of low-molecular-weight heparin and unfractionated heparin. *Journal of Bone and Joint Surgery*. 1991; 73(4):484-493
93. Eriksson BI, Bauer KA, Lassen MR, Turpie AG. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. *New England Journal of Medicine*. 2001; 345(18):1298-1304

94. Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. *New England Journal of Medicine*. 2008; 358(26):2765-2775
95. Eriksson BI, Dahl OE, Huo MH, Kurth AA, Hantel S, Hermansson K et al. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial. *Thrombosis and Haemostasis*. 2011; 105(4):721-729
96. Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP et al. Dabigatran etexilate versus enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. *Journal of Thrombosis and Haemostasis*. 2007; 5(11):2178-2185
97. Eriksson BI, Lassen MR. Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery: a multicenter, randomized, placebo-controlled, double-blind study. *Archives of Internal Medicine*. 2003; 163(11):1337-1342
98. Eskeland G, Solheim K, Skjorten F. Anticoagulant prophylaxis, thromboembolism and mortality in elderly patients with hip fractures. A controlled clinical trial. *Acta Chirurgica Scandinavica*. 1966; 131(1):16-29
99. Farkas JC, Chapuis C, Combe S, Silsiguen M, Marzelle J, Laurian C et al. A randomised controlled trial of a low-molecular-weight heparin (Enoxaparin) to prevent deep-vein thrombosis in patients undergoing vascular surgery. *European Journal of Vascular Surgery*. 1993; 7(5):554-560
100. Fasting H, Andersen K, Kraemmer-Nielsen H, Husted SE, Koopmann HD, Simonsen O et al. Prevention of postoperative deep venous thrombosis. Low-dose heparin versus graded pressure stockings. *Acta Chirurgica Scandinavica*. 1985; 151(3):245-248
101. Faunø P, Suomalainen O, Rehnberg V, Hansen TB, Krøner K, Soimakallio S et al. Prophylaxis for the prevention of venous thromboembolism after total knee arthroplasty. A comparison between unfractionated and low-molecular-weight heparin. *Journal of Bone and Joint Surgery*. 1994; 76(12):1814-1818
102. Fisher CG, Blachut PA, Salvian AJ, Meek RN, O'Brien PJ. Effectiveness of pneumatic leg compression devices for the prevention of thromboembolic disease in orthopaedic trauma patients: a prospective, randomized study of compression alone versus no prophylaxis. *Journal of Orthopaedic Trauma*. 1995; 9(1):1-7
103. Fitzgerald RH, Jr., Spiro TE, Trowbridge AA, Gardiner GA, Jr., Whitsett TL, O'Connell MB et al. Prevention of venous thromboembolic disease following primary total knee arthroplasty. A randomized, multicenter, open-label, parallel-group comparison of enoxaparin and warfarin. *Journal of Bone and Joint Surgery*. 2001; 83-A(6):900-906
104. Fordyce MJ, Ling RS. A venous foot pump reduces thrombosis after total hip replacement. *Journal of Bone and Joint Surgery (British Volume)*. 1992; 74(1):45-49
105. Francis CW, Pellegrini Jr V, Marder VJ, Totterman S, Harris CM, Gabriel KR et al. Comparison of warfarin and external pneumatic compression in prevention of venous thrombosis after total hip replacement. *JAMA*. 1992; 267(21):2911-2915
106. Francis CW, Pellegrini VD, Totterman S, Boyd AD, Marder VJ, Liebert KM et al. Prevention of deep-vein thrombosis after total hip arthroplasty. Comparison of warfarin and dalteparin. *Journal of Bone and Joint Surgery (American Volume)*. 1997; 79(9):1365-1372

107. Fredin H, Rosberg B. Anaesthetic techniques and thromboembolism in total hip arthroplasty. *European Journal of Anaesthesiology*. 1986; 3(4):273-281
108. Fricker JP, Vergnes Y, Schach R, Heitz A, Eber M, Grunebaum L et al. Low dose heparin versus low molecular weight heparin (Kabi 2165, Fragmin) in the prophylaxis of thromboembolic complications of abdominal oncological surgery. *European Journal of Clinical Investigation*. 1988; 18(6):561-567
109. Fuchs S, Heyse T, Rudofsky G, Gosheger G, Chylarecki C. Continuous passive motion in the prevention of deep-vein thrombosis: a randomised comparison in trauma patients. *Journal of Bone and Joint Surgery (British Volume)*. 2005; 87(8):1117-1122
110. Fuji T, Fujita S, Ujihira T, Sato T. Dabigatran etexilate prevents venous thromboembolism after total knee arthroplasty in Japanese patients with a safety profile comparable to placebo. *Journal of Arthroplasty*. 2010; 25(8):1267-1274
111. Fuji T, Fujita S, Ochi T. Fondaparinux prevents venous thromboembolism after joint replacement surgery in Japanese patients. *International Orthopaedics*. 2008; 32(4):443-451
112. Fuji T, Ochi T, Niwa S, Fujita S. Prevention of postoperative venous thromboembolism in Japanese patients undergoing total hip or knee arthroplasty: Two randomized, double-blind, placebo-controlled studies with three dosage regimens of enoxaparin. *Journal of Orthopaedic Science*. 2008; 13(5):442-451
113. Galasko CS, Edwards DH, Fearn CB, Barber HM. The value of low dosage heparin for the prophylaxis of thromboembolism in patients with transcervical and intertrochanteric femoral fractures. *Acta Orthopaedica Scandinavica*. 1976; 47(3):276-282
114. Gallus A, Raman K, Darby T. Venous thrombosis after elective hip replacement--the influence of preventive intermittent calf compression and of surgical technique. *British Journal of Surgery*. 1983; 70(1):17-19
115. Gallus AS, Hirsh J, O'Brien SE, McBride JA, Tuttle RJ, Gent M. Prevention of venous thrombosis with small, subcutaneous doses of heparin. *JAMA*. 1976; 235(18):1980-1982
116. Gallus AS, Hirsh J, Tuttle RJ, Trebilcock R, O'Brien SE, Carroll JJ et al. Small subcutaneous doses of heparin in prevention of venous thrombosis. *New England Journal of Medicine*. 1973; 288(11):545-551
117. Gao J, Zhang ZY, Li Z, Liu CD, Zhan YX, Qiao BL et al. Two mechanical methods for thromboembolism prophylaxis after gynaecological pelvic surgery: a prospective, randomised study. *Chinese Medical Journal*. 2012; 125(23):4259-4263
118. Gearhart MM, Luchette FA, Proctor MC, Lutomski DM, Witsken C, James L et al. The risk assessment profile score identifies trauma patients at risk for deep vein thrombosis. *Surgery*. 2000; 128(4):631-640
119. Germini F, Agnelli G, Fedele M, Galli MG, Giustozzi M, Marcucci M et al. Padua prediction score or clinical judgment for decision making on antithrombotic prophylaxis: a quasi-randomized controlled trial. *Journal of Thrombosis and Thrombolysis*. 2016; 42(3):336-339
120. Goel DP, Buckley R, deVries G, Abelseth G, Ni A, Gray R. Prophylaxis of deep-vein thrombosis in fractures below the knee: a prospective randomised controlled trial. *Journal of Bone and Joint Surgery (British Volume)*. 2009; 91(3):388-394

121. Goldhaber SZ, Dunn K, Gerhard-Herman M, Park JK, Black PM. Low rate of venous thromboembolism after craniotomy for brain tumor using multimodality prophylaxis. *Chest*. 2002; 122(6):1933-1937
122. Goldhaber SZ, Hirsch DR, MacDougall RC, Polak JF, Creager MA, Cohn LH. Prevention of venous thrombosis after coronary artery bypass surgery (a randomized trial comparing two mechanical prophylaxis strategies). *American Journal of Cardiology*. 1995; 76(14):993-996
123. Goldhaber SZ, Leizorovicz A, Kakkar AK, Haas SK, Merli G, Knabb RM et al. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. *New England Journal of Medicine*. 2011; 365(23):2167-2177
124. Gonzalez EM, Fontcuberta J, De I. Prophylaxis of thromboembolic disease with RO-11 (ROVI), during abdominal surgery. *Hepato Gastroenterology*. 1996; 43(9):744-747
125. Gordon-Smith IC, Le Quesne LP, Grundy DJ, Newcombe JF, Bramble FJ. Controlled trial of two regimens of subcutaneous heparin in prevention of postoperative deep-vein thrombosis. *Lancet*. 1972; 1(7761):1133-1135
126. Gould MK, Garcia DA, Wren SM, Karanicolas PJ, Arcelus JI, Heit JA et al. Prevention of VTE in nonorthopedic surgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest*. 2012; 141(2 Suppl):e227S-277S
127. Grant PJ, Greene MT, Chopra V, Bernstein SJ, Hofer TP, Flanders SA. Assessing the Caprini score for risk assessment of venous thromboembolism in hospitalized medical patients. *American Journal of Medicine*. 2016; 129(5):528-535
128. Green D, Lee MY, Lim AC. Prevention of thromboembolism after spinal cord injury using low-molecular-weight heparin. *Annals of Internal Medicine*. 1990; 113(8):571-574
129. Greene MT, Spyropoulos AC, Chopra V, Grant PJ, Kaatz S, Bernstein SJ et al. Validation of risk assessment models of venous thromboembolism in hospitalized medical patients. *The American Journal of Medicine*. 2016; 129(9):1001.e1009–1001.e1018
130. Haas S, Schellong SM, Tebbe U, Gerlach HE, Bauersachs R, Melzer N et al. Heparin based prophylaxis to prevent venous thromboembolic events and death in patients with cancer - a subgroup analysis of CERTIFY. *BMC Cancer*. 2011; 11:316
131. Haas SK, Freund M, Heigener D, Heilmann L, Kemkes-Matthes B, von Tempelhoff GF et al. Low-molecular-weight heparin versus placebo for the prevention of venous thromboembolism in metastatic breast cancer or stage III/IV lung cancer. *Clinical and Applied Thrombosis/Hemostasis*. 2012; 18(2):159-165
132. Hachey KJ, Hewes PD, Porter LP, Ridyard DG, Rosenkranz P, McAneny D et al. Caprini venous thromboembolism risk assessment permits selection for postdischarge prophylactic anticoagulation in patients with resectable lung cancer. *Journal of Thoracic and Cardiovascular Surgery*. 2016; 151(1):37-44.e31
133. Haddad FS, Kerry RM, McEwen JA, Appleton L, Garbuz DS, Masri BA et al. Unanticipated variations between expected and delivered pneumatic compression therapy after elective hip surgery: A possible source of variation in reported patient outcomes. *Journal of Arthroplasty*. 2001; 16(1):37-46
134. Halim TA, Chhabra HS, Arora M, Kumar S. Pharmacological prophylaxis for deep vein thrombosis in acute spinal cord injury: an Indian perspective. *Spinal Cord*. 2014; 52(7):547-550

135. Hamilton HW, Crawford JS, Gardiner JH, Wiley AM. Venous thrombosis in patients with fracture of the upper end of the femur. A phlebographic study of the effect of prophylactic anticoagulation. *Journal of Bone and Joint Surgery (British Volume)*. 1970; 52(2):268-289
136. Hampson WG, Harris FC, Lucas HK, Roberts PH, McCall IW, Jackson PC et al. Failure of low-dose heparin to prevent deep-vein thrombosis after hip-replacement arthroplasty. *Lancet*. 1974; 2(7884):795-797
137. Hardwick ME, Pulido PA, Colwell CWJ. A mobile compression device compared with low-molecular-weight heparin for prevention of venous thromboembolism in total hip arthroplasty. *Orthopaedic Nursing*. 2011; 30(5):312-316
138. Harenberg J, Roebruck P, Heene DL. Subcutaneous low-molecular-weight heparin versus standard heparin and the prevention thromboembolism in medical inpatients. *Haemostasis*. 1996; 26(3):127-139
139. Hartl P, Brucke P, Dienstl E, Vinazzer H. Prophylaxis of thromboembolism in general surgery: comparison between standard heparin and fragmin. *Thrombosis Research*. 1990; 57(4):577-584
140. Hata K, Kimura T, Tsuzuki S, Ishii G, Kido M, Yamamoto T et al. Safety of fondaparinux for prevention of postoperative venous thromboembolism in urological malignancy: A prospective randomized clinical trial. *International Journal of Urology*. 2016; 23(11):923-928
141. Hauch O, Jorgensen LN, Kolle TR, Nerstrom H, Schebye O, Wille-Jorgensen P et al. Low molecular weight heparin (Logiparin(TM)) as thromboprophylaxis in elective abdominal surgery. A dose finding study. *Acta Chirurgica Scandinavica Supplementum*. 1988; 543:90-95
142. Hegsted D, Gritsiouk Y, Schlesinger P, Gardiner S, Gubler KD. Utility of the risk assessment profile for risk stratification of venous thrombotic events for trauma patients. *American Journal of Surgery*. 2013; 205(5):517-520; discussion 520
143. Heilmann L, Rath W, Pollow K, Bick RL. The rheological changes after cesarean section: The influence of low molecular weight or unfractionated heparin on the rheological properties of blood. *Clinical Hemorheology and Microcirculation*. 2007; 37(3):211-218
144. Hendolin H, Mattila MA, Poikolainen E. The effect of lumbar epidural analgesia on the development of deep vein thrombosis of the legs after open prostatectomy. *Acta Chirurgica Scandinavica*. 1981; 147(6):425-429
145. Hendolin H, Tuppurainen T, Lahtinen J. Thoracic epidural analgesia and deep vein thrombosis in cholecystomized patients. *Acta Chirurgica Scandinavica*. 1982; 148(5):405-409
146. Hewes PD, Hachey KJ, Zhang XW, Tripodis Y, Rosenkranz P, Ebright MI et al. Evaluation of the Caprini model for venothromboembolism in esophagectomy patients. *Annals of Thoracic Surgery*. 2015; 100(6):2072-2078
147. Hillbom M, Erila T, Sotaniemi K, Tatlisumak T, Sarna S, Kaste M. Enoxaparin vs heparin for prevention of deep-vein thrombosis in acute ischaemic stroke: a randomized, double blind study. *Acta Neurologica Scandinavica*. 2002; 106(2):84-92
148. Ho KM, Rao S, Rittenhouse KJ, Rogers FB. Use of the Trauma Embolic Scoring System (TESS) to predict symptomatic deep vein thrombosis and fatal and non-fatal pulmonary embolism in severely injured patients. *Anaesthesia and Intensive Care*. 2014; 42(6):709-714
149. Holford CP. Graded compression for preventing deep venous thrombosis. *British Medical Journal*. 1976; 2(6042):969-970

150. Hostler DC, Marx ES, Moores LK, Petteys SK, Hostler JM, Mitchell JD et al. Validation of the international medical prevention registry on venous thromboembolism bleeding risk score. *Chest*. 2016; 149(2):372-379
151. Hull RD, Pineo GF, Francis C, Bergqvist D, Fellenius C, Soderberg K et al. Low-molecular-weight heparin prophylaxis using dalteparin in close proximity to surgery vs warfarin in hip arthroplasty patients: a double-blind, randomized comparison. The North American Fragmin Trial Investigators. *Archives of Internal Medicine*. 2000; 160(14):2199-2207
152. Hull RD, Raskob GE, Gent M, McLoughlin D, Julian D, Smith FC et al. Effectiveness of intermittent pneumatic leg compression for preventing deep vein thrombosis after total hip replacement. *JAMA*. 1990; 263(17):2313-2317
153. Hull RD, Schellong SM, Tapson VF, Monreal M, Samama MM, Nicol P et al. Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial. *Annals of Internal Medicine*. 2010; 153(1):8-18
154. Imberti D, Baldini E, Pierfranceschi MG, Nicolini A, Cartelli C, De Paoli M et al. Prophylaxis of venous thromboembolism with low molecular weight heparin in bariatric surgery: a prospective, randomised pilot study evaluating two doses of parnaparin (BAFLUX Study). *Obesity Surgery*. 2014; 24(2):284-291
155. Intiyanaravut T, Thongpulsawasdi N, Sinthuvanich N, Teavirat S, Kunopart M. Enoxaparin versus no anticoagulation prophylaxis after total knee arthroplasty in Thai patients: A randomized controlled trial. *Journal of the Medical Association of Thailand*. 2017; 100(1):42-49
156. Ishi SV, Lakshmi M, Kakde ST, Sabnis KC, Jagannati M, Girish TS et al. Randomised controlled trial for efficacy of unfractionated heparin (UFH) versus low molecular weight heparin (LMWH) in thrombo-prophylaxis. *Journal of the Association of Physicians of India*. 2013; 61(12):882-886
157. Janvrin SB, Davies G, Greenhalgh RM. Postoperative deep vein thrombosis caused by intravenous fluids during surgery. *British Journal of Surgery*. 1980; 67(10):690-693
158. Jorgensen LN, Rasmussen LS, Nielsen PT, Leffers A, Albrecht-Beste E. Antithrombotic efficacy of continuous extradural analgesia after knee replacement. *British Journal of Anaesthesia*. 1991; 66(1):8-12
159. Jørgensen PS, Knudsen JB, Broeng L, Josephsen L, Bjerregaard P, Hagen K et al. The thromboprophylactic effect of a low-molecular-weight heparin (Fragmin) in hip fracture surgery. A placebo-controlled study. *Clinical Orthopaedics and Related Research*. 1992; 278:95-100
160. Jorgensen PS, Warming T, Hansen K, Paltved C, Vibeke Berg H, Jensen R et al. Low molecular weight heparin (Innohep) as thromboprophylaxis in outpatients with a plaster cast: a venographic controlled study. *Thrombosis Research*. 2002; 105(6):477-480
161. Kaaja R, Lehtovirta P, Venesmaa P, Kajanoja P, Halonen P, Gummerus M et al. Comparison of enoxaparin, a low-molecular-weight heparin, and unfractionated heparin, with or without dihydroergotamine, in abdominal hysterectomy. *European Journal of Obstetrics, Gynecology, and Reproductive Biology*. 1992; 47(2):141-145
162. Kakkar AK, Brenner B, Dahl OE, Eriksson BI, Mouret P, Muntz J et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. *Lancet*. 2008; 372(9632):31-39

163. Kakkar AK, Cimminiello C, Goldhaber SZ, Parakh R, Wang C, Bergmann JF et al. Low-molecular-weight heparin and mortality in acutely ill medical patients. *New England Journal of Medicine*. 2011; 365(26):2463-2472
164. Kakkar VV, Balibrea JL, Martinez-Gonzalez J, Prandoni P, Group CS. Extended prophylaxis with bemiparin for the prevention of venous thromboembolism after abdominal or pelvic surgery for cancer: the CANBESURE randomized study. *Journal of Thrombosis and Haemostasis*. 2010; 8(6):1223-1229
165. Kakkar VV, Cohen AT, Edmonson RA, Phillips MJ, Cooper DJ, Das SK et al. Low molecular weight versus standard heparin for prevention of venous thromboembolism after major abdominal surgery. *Lancet*. 1993; 341(8840):259-265
166. Kakkar VV, Corrigan T, Spindler J, Fossard DP, Flute PT, Crellin RQ et al. Efficacy of low doses of heparin in prevention of deep-vein thrombosis after major surgery. A double-blind, randomised trial. *Lancet*. 1972; 2(7768):101-106
167. Kakkar VV, Howes J, Sharma V, Kadziola Z. A comparative double-blind, randomised trial of a new second generation LMWH (bemiparin) and UFH in the prevention of post-operative venous thromboembolism. The Bemiparin Assessment group. *Thrombosis and Haemostasis*. 2000; 83(4):523-529
168. Kalfarentzos F, Stavropoulou F, Yarmenitis S, Kehagias I, Karamesini M, Dimitrakopoulos A et al. Prophylaxis of venous thromboembolism using two different doses of low-molecular-weight heparin (nadroparin) in bariatric surgery: a prospective randomized trial. *Obesity Surgery*. 2001; 11(6):670-676
169. Kalodiki EP, Hoppensteadt DA, Nicolaidis AN, Fareed J, Gill K, Regan F et al. Deep venous thrombosis prophylaxis with low molecular weight heparin and elastic compression in patients having total hip replacement. A randomised controlled trial. *International Angiology*. 1996; 15(2):162-168
170. Karthaus M, Kretzschmar A, Kroning H. Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial. *Annals of Oncology*. 2006; 17(2):289-296
171. Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. *Blood*. 2008; 111(10):4902-4907
172. Kleber FX, Witt C, Vogel G. Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease. *American Heart Journal*. 2003; 145(4):614-621
173. Knudson MM, Lewis FR, Clinton A, Atkinson K, Megerman J. Prevention of venous thromboembolism in trauma patients. *Journal of Trauma*. 1994; 37(3):480-487
174. Knudson MM, Morabito D, Paiement GD. Use of low molecular weight heparin in preventing thromboembolism in trauma patients. *Journal of Trauma*. 1996; 41(3):446-459
175. Kock H-J, Schmit-Neuerburg KP, Hanke J, Rudofsky G, Hirche H. Thromboprophylaxis with low-molecular-weight heparin in outpatients with plaster-cast immobilisation of the leg. *Lancet*. 1995; 346(8973):459-461
176. Koller M, Schoch U, Buchmann P, Largiadèr F, Von Felten A, Frick PG. Low molecular weight heparin (KABI 2165) as thromboprophylaxis in elective visceral surgery. A randomized,

- double-blind study versus unfractionated heparin. *Thrombosis and Haemostasis*. 1986; 56(3):243-246
177. Kolluri R, Plessa AL, Sanders MC, Singh NK, Lucore C. A randomized study of the safety and efficacy of fondaparinux versus placebo in the prevention of venous thromboembolism after coronary artery bypass graft surgery. *American Heart Journal*. 2016; 171(1):1-6
178. Kucher N, Koo S, Quiroz R, Cooper JM, Paterno MD, Soukonnikov B et al. Electronic alerts to prevent venous thromboembolism among hospitalized patients. *New England Journal of Medicine*. 2005; 352(10):969-977
179. Kujath P, Spannagel U, Habscheid W. Incidence and prophylaxis of deep venous thrombosis in outpatients with injury of the lower limb. *Haemostasis*. 1993; 23(Suppl 1):20-26
180. Kurtoglu M, Yanar H, Bilsel Y, Guloglu R, Kizilirmak S, Buyukkurt D et al. Venous thromboembolism prophylaxis after head and spinal trauma: Intermittent pneumatic compression devices versus low molecular weight heparin. *World Journal of Surgery*. 2004; 28(8):807-811
181. Kutnowski M, Vandendris M, Steinberger R, Kraytman M. Prevention of postoperative deep-vein thrombosis by low-dose heparin in urological surgery. A double-blind, randomised study. *Urological Research*. 1977; 5(3):123-125
182. Lacut K, Bressollette L, Le Gal G, Etienne E, De Tinteniak A, Renault A et al. Prevention of venous thrombosis in patients with acute intracerebral hemorrhage. *Neurology*. 2005; 65(6):865-869
183. Lahnborg G. Effect of low-dose heparin and dihydroergotamine on frequency of postoperative deep-vein thrombosis in patients undergoing post-traumatic hip surgery. *Acta Chirurgica Scandinavica*. 1980; 146(5):319-322
184. Lahnborg G, Bergström K. Clinical and haemostatic parameters related to thromboembolism and low-dose heparin prophylaxis in major surgery. *Acta Chirurgica Scandinavica*. 1975; 141(7):590-595
185. Lapidus LJ. Prolonged thromboprophylaxis with dalteparin after surgical treatment of achilles tendon rupture: A randomized, placebo-controlled study. *Journal of Orthopaedic Trauma*. 2007; 21(1):52-57
186. Lapidus LJ. Prolonged thromboprophylaxis with Dalteparin during immobilization after ankle fracture surgery: A randomized placebo-controlled, double-blind study. *Acta Orthopaedica*. 2007; 78(4):528-535
187. Larocca A, Cavallo F, Bringhen S, Di Raimondo F, Falanga A, Evangelista A et al. Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. *Blood*. 2012; 119(4):933-1093
188. Lassen MR, Ageno W, Borris LC, Lieberman JR, Rosencher N, Bandel TJ et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. *New England Journal of Medicine*. 2008; 358(26):2776-2786
189. Lassen MR, Bauer KA, Eriksson BI, Turpie AGG. Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison. *Lancet*. 2002; 359(9319):1715-1720

190. Lassen MR, Borris LC, Anderson BS, Jensen HP, Skejød Bro HP, Andersen G et al. Efficacy and safety of prolonged thromboprophylaxis with a low molecular weight heparin (dalteparin) after total hip arthroplasty--the Danish Prolonged Prophylaxis (DaPP) Study. *Thrombosis Research*. 1998; 89(6):281-287
191. Lassen MR, Borris LC, Christiansen HM, Boll KL, Eiskjaer SP, Nielsen BW et al. Prevention of thromboembolism in 190 hip arthroplasties. Comparison of LMW heparin and placebo. *Acta Orthopaedica Scandinavica*. 1991; 62(1):33-38
192. Lassen MR, Borris LC, Nakov RL. Use of the low-molecular-weight heparin reviparin to prevent deep-vein thrombosis after leg injury requiring immobilization. *New England Journal of Medicine*. 2002; 347(10):726-730
193. Lassen MR, Davidson BL, Gallus A, Pineo G, Ansell J, Deitchman D. The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. *Journal of Thrombosis and Haemostasis*. 2007; 5(12):2368-2375
194. Lassen MR, Gallus A, Raskob GE, Pineo G, Chen D, Ramirez LM et al. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. *New England Journal of Medicine*. 2010; 363(26):2487-2498
195. Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Hornick P et al. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. *Lancet*. 2010; 375(9717):807-815
196. Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Portman RJ. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. *New England Journal of Medicine*. 2009; 361(6):594-604
197. Lastória S, Rollo HA, Yoshida WB, Giannini M, Moura R, Maffei F-HA. Prophylaxis of deep-vein thrombosis after lower extremity amputation. Comparison of low molecular weight heparin with unfractionated heparin. *Acta Cirurgica Brasileira*. 2006; 21(3):184-186
198. Lavau-Denes S, Lacroix P, Maubon A, Preux PM, Genet D, Venat-Bouvet L et al. Prophylaxis of catheter-related deep vein thrombosis in cancer patients with low-dose warfarin, low molecular weight heparin, or control: a randomized, controlled, phase III study. *Cancer Chemotherapy and Pharmacology*. 2013; 72(1):65-73
199. Lechler E, Schramm W, Flosbach CW. The venous thrombotic risk in non-surgical patients: epidemiological data and efficacy/safety profile of a low-molecular-weight heparin (enoxaparin). The Prime Study Group. *Haemostasis*. 1996; 26(Suppl 2):49-56
200. Leclerc JR, Geerts WH, Desjardins L, Jobin F, Laroche F, Delorme F et al. Prevention of deep vein thrombosis after major knee surgery -- a randomized, double-blind trial comparing a low molecular weight heparin fragment (enoxaparin) to placebo. *Thrombosis and Haemostasis*. 1992; 67(4):417-423
201. Leclerc JR, Geerts WH, Desjardins L, Laflamme GH, L'Espérance B, Demers C et al. Prevention of venous thromboembolism after knee arthroplasty. A randomized, double-blind trial comparing enoxaparin with warfarin. *Annals of Internal Medicine*. 1996; 124(7):619-626
202. Lederle FA, Sacks JM, Fiore L, Landefeld CS, Steinberg N, Peters RW. The prophylaxis of medical patients for thromboembolism pilot study. *American Journal of Medicine*. 2006; 119(1):54-59

203. Leizorovicz A, Cohen AT, Turpie AGG. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. *Circulation*. 2004; 110(7):874-879
204. Leizorovicz A, Picolet H, Peyrieux JC, Boissel JP. Prevention of perioperative deep vein thrombosis in general surgery: a multicentre double blind study comparing two doses of Logiparin and standard heparin. H.B.P.M. Research Group. *British Journal of Surgery*. 1991; 78(4):412-416
205. Lester W, Freemantle N, Begaj I, Ray D, Wood J, Pagano D. Fatal venous thromboembolism associated with hospital admission: a cohort study to assess the impact of a national risk assessment target. *Heart*. 2013; 99(23):1734-1739
206. Levine M, Hirsh J, Gent M. Double-blind randomized trial of very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. *Lancet*. 1994; 343(8902):886-889
207. Levine MN, Gu C, Liebman HA, Escalante CP, Solymoss S, Deitchman D et al. A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer. *Journal of Thrombosis and Haemostasis*. 2012; 10(5):807-814
208. Levine MN, Hirsh J, Gent M, Turpie AG, Leclerc J, Powers PJ et al. Prevention of deep vein thrombosis after elective hip surgery. A randomized trial comparing low molecular weight heparin with standard unfractionated heparin. *Annals of Internal Medicine*. 1991; 114(7):545-551
209. Liu LP, Zheng HG, Wang DZ, Wang YL, Hussain M, Sun HX et al. Risk assessment of deep-vein thrombosis after acute stroke: a prospective study using clinical factors. *CNS Neuroscience & Therapeutics*. 2014; 20(5):403-410
210. Lobastov K, Barinov V, Schastlivtsev I, Laberko L, Rodoman G, Boyarintsev V. Validation of the Caprini risk assessment model for venous thromboembolism in high-risk surgical patients in the background of standard prophylaxis. *Journal of Vascular Surgery*. 2016; 4(2):153-160
211. Macdonald RL, Amidei C, Baron J, Weir B, Brown F, Erickson RK et al. Randomized, pilot study of intermittent pneumatic compression devices plus dalteparin versus intermittent pneumatic compression devices plus heparin for prevention of venous thromboembolism in patients undergoing craniotomy. *Surgical Neurology*. 2003; 59(5):363-372
212. Mahe I, Bergmann JF, d'Azemar P, JJ V, Caulin C. Lack of effect of low molecular weight heparin (nadroparin) on mortality in bedridden medical in-patients: a prospective randomised double blind study. *European Journal of Clinical Pharmacology*. 2005; 61(5-6):347-351
213. Manganelli D, Pazzagli M, Mazzantini D, Punzi G, Manca M, Vignali C et al. Prolonged prophylaxis with unfractionated heparin is effective to reduce delayed deep vein thrombosis in total hip replacement. *Respiration*. 1998; 65(5):369-374
214. Mannucci PM, Citterio LE, Panajotopoulos N. Low-dose heparin and deep-vein thrombosis after total hip replacement. *Thrombosis and Haemostasis*. 1976; 36(1):157-164
215. Marassi A, Balzano G, Mari G, D'Angelo SV, Della Valle P, Di Carlo V et al. Prevention of postoperative deep vein thrombosis in cancer patients. A randomized trial with low molecular weight heparin (CY 216). *International Surgery*. 1993; 78(2):166-170
216. Marlovits S, Striessnig G, Schuster R, Stocker R, Luxl M, Trattinig S et al. Extended-duration thromboprophylaxis with enoxaparin after arthroscopic surgery of the anterior cruciate

- ligament: a prospective, randomized, placebo-controlled study. *Arthroscopy*. 2007; 23(7):696-702
217. Maxwell GL, Synan I, Dodge R, Carroll B, Clarke-Pearson DL. Pneumatic compression versus low molecular weight heparin in gynecologic oncology surgery: a randomized trial. *Obstetrics and Gynecology*. 2001; 98(6):989-995
218. May V, Clarke T, Coulling S, Cowie L, Cox R, Day D et al. What information patients require on graduated compression stockings. *British Journal of Nursing*. 2006; 15(5):263-270
219. McCarthy ST, Turner J. Low-dose subcutaneous heparin in the prevention of deep-vein thrombosis and pulmonary emboli following acute stroke. *Age and Ageing*. 1986; 15(2):84-88
220. McCarthy ST, Turner JJ, Robertson D, Hawkey CJ. Low-dose heparin as a prophylaxis against deep-vein thrombosis after acute stroke. *Lancet*. 1977; 310(8042):800-801
221. McKenzie PJ, Wishart HY, Gray I, Smith G. Effects of anaesthetic technique on deep vein thrombosis. A comparison of subarachnoid and general anaesthesia. *British Journal of Anaesthesia*. 1985; 57(9):853-857
222. McLeod RS, Geerts WH, Sniderman KW, Greenwood C, Gregoire RC, Taylor BM et al. Subcutaneous heparin versus low-molecular-weight heparin as thromboprophylaxis in patients undergoing colorectal surgery: results of the canadian colorectal DVT prophylaxis trial: a randomized, double-blind trial. *Annals of Surgery*. 2001; 233(3):438-444
223. Merli GJ, Herbison GJ, Ditunno JF. Deep vein thrombosis : prophylaxis in acute spinal cord injured patients. *Archives of Physical Medicine and Rehabilitation*. 1988; 69:661-664
224. Miranda S, Le Cam-Duchez V, Benichou J, Donnadieu N, Barbay V, Le Besnerais M et al. Adjusted value of thromboprophylaxis in hospitalized obese patients: A comparative study of two regimens of enoxaparin: The ITOHENOX study. *Thrombosis Research*. 2017; 155:1-5
225. Mirdamadi A, Dashtkar S, Kaji M, Pazhang F, Haghpanah B, Gharipour M. Dabigatran versus Enoxaparin in the prevention of venous thromboembolism after total knee arthroplasty: A randomized clinical trial. *ARYA Atherosclerosis*. 2014; 10(6):292-297
226. Mitchell D, Friedman RJ, Baker JD, III, Cooke JE, Darcy MD, Miller MC, III. Prevention of thromboembolic disease following total knee arthroplasty. Epidural versus general anesthesia. *Clinical Orthopaedics and Related Research*. 1991; 269:109-112
227. Modig J. The role of lumbar epidural anaesthesia as antithrombotic prophylaxis in total hip replacement. *Acta Chirurgica Scandinavica*. 1985; 151(7):589-594
228. Modig J, Hjelmstedt A, Sahlstedt B, Maripuu E. Comparative influences of epidural and general anaesthesia on deep venous thrombosis and pulmonary embolism after total hip replacement. *Acta Chirurgica Scandinavica*. 1981; 147(2):125-130
229. Monreal M, Lafoz E, Navarro A, Granero X, Caja V, Caceres E et al. A prospective double-blind trial of a low molecular weight heparin once daily compared with conventional low-dose heparin three times daily to prevent pulmonary embolism and venous thrombosis in patients with hip fracture. *Journal of Trauma*. 1989; 29(6):873-875
230. Morris GK, Mitchell JR. Warfarin sodium in prevention of deep venous thrombosis and pulmonary embolism in patients with fractured neck of femur. *Lancet*. 1976; 2(7991):869-872

231. Moskovitz PA, Ellenberg SS, Feffer HL, Kenmore P, I, Neviasser RJ, Rubin BE et al. Low-dose heparin for prevention of venous thromboembolism in total hip arthroplasty and surgical repair of hip fractures. *Journal of Bone and Joint Surgery*. 1978; 60(8):1065-1070
232. Muir KW, Watt A, Baxter G, Grosset DG, Lees KR. Randomized trial of graded compression stockings for prevention of deep vein thrombosis after acute stroke. *Quarterly Journal of Medicine*. 2000; 93(6):359-364
233. Murakami M, McDill TL, Cindrick-Pounds C. Deep vein thrombosis prophylaxis in trauma: improved compliance with a novel miniaturized pneumatic compression device. *Journal of Vascular Surgery*. 2003; 38(5):923-927
234. Myles PS, Smith JA, Forbes A, Silbert B, Jayarajah M, Painter T et al. Stopping vs. Continuing Aspirin before Coronary Artery Surgery. *New England Journal of Medicine*. 2016; 374(8):728-737
235. Nagata C, Tanabe H, Takakura S, Narui C, Saito M, Yanaihara N et al. Randomized controlled trial of enoxaparin versus intermittent pneumatic compression for venous thromboembolism prevention in Japanese surgical patients with gynecologic malignancy. *Journal of Obstetrics and Gynaecology Research*. 2015; 41(9):1440-1448
236. National Institute for Health and Care Excellence. Developing NICE guidelines: the manual. London. National Institute for Health and Care Excellence, 2014. Available from: <http://www.nice.org.uk/article/PMG20/chapter/1%20Introduction%20and%20overview>
237. Nendaz M, Spirk D, Kucher N, Aujesky D, Hayoz D, Beer JH et al. Multicentre validation of the Geneva risk score for hospitalised medical patients at risk of venous thromboembolism. Explicit assessment of thromboembolic risk and prophylaxis for medical patients in Switzerland (ESTIMATE). *Thrombosis and Haemostasis*. 2014; 111(3):531-538
238. Nicolaides AN, Miles C, Hoare M, Jury P, Helms E, Venniker R. Intermittent sequential pneumatic compression of the legs and thromboembolism-deterrent stockings in the prevention of postoperative deep venous thrombosis. *Surgery*. 1983; 94(1):21-25
239. Nielsen PT, Jørgensen LN, Albrecht-Beste E, Leffers AM, Rasmussen LS. Lower thrombosis risk with epidural blockade in knee arthroplasty. *Acta Orthopaedica Scandinavica*. 1990; 61(1):29-31
240. Noble SI, Nelson A, Turner C, Finlay IG. Acceptability of low molecular weight heparin thromboprophylaxis for inpatients receiving palliative care: qualitative study. *BMJ*. 2006; 332(7541):577-580
241. Norgren L, S. T-L, Magyar G, Lindstrand A, Albrechtsson U. Prevention of deep vein thrombosis in knee arthroplasty. Preliminary results from a randomized controlled study of low molecular weight heparin vs foot pump compression. *International Angiology*. 1998; 17(2):93-96
242. Nurmohamed MT, Verhaeghe R, Haas S, Iriarte JA, Vogel G, van Rij AM et al. A comparative trial of a low molecular weight heparin (enoxaparin) versus standard heparin for the prophylaxis of postoperative deep vein thrombosis in general surgery. *American Journal of Surgery*. 1995; 169(6):567-571
243. Obi AT, Pannucci CJ, Nackashi A, Abdullah N, Alvarez R, Bahl V et al. Validation of the Caprini venous thromboembolism risk assessment model in critically ill surgical patients. *JAMA surgery*. 2015; 150(10):941-948

244. Ockelford PA, Patterson J, Johns AS. A double-blind randomized placebo controlled trial of thromboprophylaxis in major elective general surgery using once daily injections of a low molecular weight heparin fragment (Fragmin). *Thrombosis and Haemostasis*. 1989; 62(4):1046-1049
245. Onarheim H, Lund T, Heimdal A, Arnesjo B. A low molecular weight heparin (KABI 2165) for prophylaxis of postoperative deep venous thrombosis. *Acta Chirurgica Scandinavica*. 1986; 152:593-596
246. Osman Y, Kamal M, Soliman S, Sheashaa H, Shokeir A, Shehab el-Dein AB. Necessity of routine postoperative heparinization in non-risky live-donor renal transplantation: results of a prospective randomized trial. *Urology*. 2007; 69(4):647-651
247. Pagella P, Cipolle M, Sacco E, Matula P, Karoly E, Bokovoy J. A randomized trial to evaluate compliance in terms of patient comfort and satisfaction of two pneumatic compression devices. *Orthopaedic Nursing*. 2007; 26(3):169-174
248. Paiement GD, Wessinger SJ, Walter AC, Harris WH. Low dose warfarin versus external pneumatic compression against venous thromboembolism following total hip replacement. *Journal of Arthroplasty*. 1987; 2(1):23-26
249. Palumbo A, Cavo M, Bringham S, Zamagni E, Romano A, Patriarca F et al. Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. *Journal of Clinical Oncology*. 2011; 29(8):986-993
250. Pambianco G, Orchard T, Landau P. Deep vein thrombosis: prevention in stroke patients during rehabilitation. *Archives of Physical Medicine and Rehabilitation*. 1995; 76(4):324-330
251. Pannucci CJ, Bailey SH, Dreszer G, Fisher Wachtman C, Zumsteg JW, Jaber RM et al. Validation of the Caprini risk assessment model in plastic and reconstructive surgery patients. *Journal of the American College of Surgeons*. 2011; 212(1):105-112
252. Pannucci CJ, Laird S, Dimick JB, Campbell DA, Henke PK. A validated risk model to predict 90-day VTE events in postsurgical patients. *Chest*. 2014; 145(3):567-573
253. Pannucci CJ, Osborne NH, Wahl WL. Creation and validation of a simple venous thromboembolism risk scoring tool for thermally injured patients: analysis of the National Burn Repository. *Journal of Burn Care & Research*. 2012; 33(1):20-25
254. Pannucci CJ, Shanks A, Moote MJ, Bahl V, Cederna PS, Naughton NN et al. Identifying patients at high risk for venous thromboembolism requiring treatment after outpatient surgery. *Annals of Surgery*. 2012; 255(6):1093-1099
255. Parnaby C. A new anti-embolism stocking. Use of below-knee products and compliance. *British Journal of Perioperative Nursing*. 2004; 14(7):302-304
256. Patell R, Rybicki L, McCrae KR, Khorana AA. Predicting risk of venous thromboembolism in hospitalized cancer patients: Utility of a risk assessment tool. *American Journal of Hematology*. 2017; 92(6):501-507
257. Pelzer U, Opitz B, Deutschinoff G, Stauch M, Reitzig PC, Hahnfeld S et al. Efficacy of prophylactic low-molecular weight heparin for ambulatory patients with advanced pancreatic cancer: Outcomes from the CONKO-004 trial. *Journal of Clinical Oncology*. 2015; 33(18):2028-2034
258. Perry JR, Julian JA, Laperriere NJ, Geerts W, Agnelli G, Rogers LR et al. PRODIGE: a randomized placebo-controlled trial of dalteparin low-molecular-weight heparin

- thromboprophylaxis in patients with newly diagnosed malignant glioma. *Journal of Thrombosis and Haemostasis*. 2010; 8(9):1959-1965
259. Pitto RP, Hamer H, Heiss-Dunlop W, Kuehle J. Mechanical prophylaxis of deep-vein thrombosis after total hip replacement a randomised clinical trial. *Journal of Bone and Joint Surgery (British Volume)*. 2004; 86(5):639-642
260. Pitto RP, Young S. Foot-pumps without graduated compression stockings for prevention of deep-vein thrombosis in total joint replacement: Efficacy, safety and patient compliance - A comparative, prospective clinical trial. *International Orthopaedics*. 2008; 32(3):337
261. Pitto RP, Young S. Foot pumps without graduated compression stockings for prevention of deep-vein thrombosis in total joint replacement: efficacy, safety and patient compliance. A comparative, prospective clinical trial. *International Orthopaedics*. 2008; 32(3):331-336
262. Planes A, Vochelle N, Darmon JY, Fagola M, Bellaud M, Compan D et al. Efficacy and safety of postdischarge administration of enoxaparin in the prevention of deep venous thrombosis after total hip replacement. A prospective randomised double-blind placebo-controlled trial. *Drugs*. 1996; 52(Suppl 7):47-54
263. Planès A, Vochelle N, Fagola M, Bellaud M, Feret J, Salzard C et al. Once-daily dosing of enoxaparin (a low molecular weight heparin) in prevention of deep vein thrombosis after total hip replacement. *Acta Chirurgica Scandinavica Supplementum*. 1990; 556:108-115
264. Poikolainen E, Hendolin H. Effects of lumbar epidural analgesia and general anaesthesia on flow velocity in the femoral vein and postoperative deep vein thrombosis. *Acta Chirurgica Scandinavica*. 1983; 149(4):361-364
265. Porteous MJ, Nicholson EA, Morris LT, James R, Negus D. Thigh length versus knee length stockings in the prevention of deep vein thrombosis. *British Journal of Surgery*. 1989; 76(3):296-297
266. Prandoni P, Bruchi O, Sabbion P, Tanduo C, Scudeller A, Sardella C et al. Prolonged thromboprophylaxis with oral anticoagulants after total hip arthroplasty: a prospective controlled randomized study. *Archives of Internal Medicine*. 2002; 162(17):1966-1971
267. Prasad BK, Banerjee AK, Howard H. Incidence of deep vein thrombosis and the effect of pneumatic compression of the calf in elderly hemiplegics. *Age and Ageing*. 1982; 11(1):42-44
268. Prins MH, Gelsema R, Sing AK, van Heerde LR, den Ottolander GJH. Prophylaxis of deep venous thrombosis with a low-molecular-weight heparin (Kabi 2165/Fragmin) in stroke patients. *Haemostasis*. 1989; 19(5):245-250
269. Pulmonary Embolism Prevention (PEP) Trial Collaborative Group. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. *Lancet*. 2000; 355(9212):1295-1302
270. Rasmussen A, Hansen PT, Lindholt J, Poulsen TD, Toftdahl DB, Gram J et al. Venous thrombosis after abdominal surgery. A comparison between subcutaneous heparin and antithrombotic stockings, or both. *Journal of Medicine*. 1988; 19(3-4):193-201
271. Rasmussen MS, Jorgensen LN, Wille-Jorgensen P, Nielsen JD, Horn A, Mohn AC et al. Prolonged prophylaxis with dalteparin to prevent late thromboembolic complications in patients undergoing major abdominal surgery: a multicenter randomized open-label study. *Journal of Thrombosis and Haemostasis*. 2006; 4(11):2384-2390

272. RE-MOBILIZE Writing Committee, Ginsberg JS, Davidson BL, Comp PC, Francis CW, Friedman RJ et al. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. *Journal of Arthroplasty*. 2009; 24(1):1-9
273. Riess H, Haas S, Tebbe U, Gerlach HE, Abletshauer C, Sieder C et al. A randomized, double-blind study of certoparin vs. unfractionated heparin to prevent venous thromboembolic events in acutely ill, non-surgical patients: CERTIFY Study. *Journal of Thrombosis and Haemostasis*. 2010; 8(6):1209-1215
274. Roberts LN, Porter G, Barker RD, Yorke R, Bonner L, Patel RK et al. Comprehensive VTE prevention program incorporating mandatory risk assessment reduces the incidence of hospital-associated thrombosis. *Chest*. 2013; 144(4):1276-1281
275. Robertson KA, Bertot AJ, Wolfe MW, Barrack RL. Patient compliance and satisfaction with mechanical devices for preventing deep venous thrombosis after joint replacement. *Journal of the Southern Orthopaedic Association*. 2000; 9(3):182-186
276. Roderick P, Ferris G, Wilson K, Halls H, Jackson D, Collins R et al. Towards evidence-based guidelines for the prevention of venous thromboembolism: systematic reviews of mechanical methods, oral anticoagulation, dextran and regional anaesthesia as thromboprophylaxis. *Health Technology Assessment*. 2005; 9(49)
277. Rodrigo P, Alvarez M, Olmos M, Santos I, Velasco A. Deep vein thrombosis following knee replacement: the role of thrombosis prophylaxis combined with epidural anesthesia. *Haemostasis*. 1994; 24(Suppl 1):235
278. Rogers FB, Shackford SR, Horst MA, Miller JA, Wu D, Bradburn E et al. Determining venous thromboembolic risk assessment for patients with trauma: the trauma embolic scoring system. *Journal of Trauma and Acute Care Surgery*. 2012; 73(2):511-515
279. Rothberg MB, Lindenauer PK, Lahti M, Pekow PS, Selker HP. Risk factor model to predict venous thromboembolism in hospitalized medical patients. *Journal of Hospital Medicine*. 2011; 6(4):202-209
280. Sakon M, Kobayashi T, Shimazui T. Efficacy and safety of enoxaparin in Japanese patients undergoing curative abdominal or pelvic cancer surgery: results from a multicenter, randomized, open-label study. *Thrombosis Research*. 2010; 125(3):e65-e70
281. Samama CM, Clergue F, Barre J, Montefiore A, Ill P, Samii K. Low molecular weight heparin associated with spinal anaesthesia and gradual compression stockings in total hip replacement surgery. Arar study group. *British Journal of Anaesthesia*. 1997; 78(6):660-665
282. Samama CM, Lecoules N, Kierzek G, Claessens YE, Riou B, Rosencher N et al. Comparison of fondaparinux with low molecular weight heparin for venous thromboembolism prevention in patients requiring rigid or semi-rigid immobilization for isolated non-surgical below-knee injury. *Journal of Thrombosis and Haemostasis*. 2013; 11(10):1833-1843
283. Samama CM, Vray M, Barré J, Fiessinger JN, Rosencher N, Lecompte T et al. Extended venous thromboembolism prophylaxis after total hip replacement: a comparison of low-molecular-weight heparin with oral anticoagulant. *Archives of Internal Medicine*. 2002; 162(19):2191-2196
284. Samama MM, Cohen AT, Darmon JY, Desjardins L, Eldor A, Janbon C et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in medical patients with enoxaparin study group. *New England Journal of Medicine*. 1999; 341(11):793-800

285. San Norberto Garcia EM, Merino B, Taylor JH, Vizcaino I, Vaquero C. Low-molecular-weight heparin for prevention of venous thromboembolism after varicose vein surgery in moderate-risk patients: a randomized, controlled trial. *Annals of Vascular Surgery*. 2013; 27(7):940-946
286. Sandset PM, Dahl T, Stiris M, Rostad B, Scheel B, Abildgaard U. A double-blind and randomized placebo-controlled trial of low molecular weight heparin once daily to prevent deep-vein thrombosis in acute ischemic stroke. *Seminars in Thrombosis and Hemostasis*. 1990; 16(Suppl):25-33
287. Santamaria A, Ugarriza A, Munoz C, De D, I, Lopez-Chulia F, Benet C et al. Bemiparin versus unfractionated heparin as bridging therapy in the perioperative management of patients on vitamin K antagonists: The BERTA study. *Clinical Drug Investigation*. 2013; 33(12):921-928
288. Santori FS, Vitullo A, Stopponi M, Santori N, Ghera S. Prophylaxis against deep-vein thrombosis in total hip replacement. Comparison of heparin and foot impulse pump. *Journal of Bone and Joint Surgery (British Volume)*. 1994; 76(4):579-583
289. Schellong SM, Gerlach H-E, Tebbe U, Haas S, Abletshauser C, Sieder C et al. CERTIFY: Certoparin versus UFH to prevent venous thromboembolic events in the very elderly patient. *Hamostaseologie*. 2011; 31(1):A87
290. Schellong SM, Gerlach HE, Tebbe U, Haas S, Melzer N, Abletshauser C et al. Certoparin versus UFH to prevent venous thromboembolic events in the very elderly patient: an analysis of the CERTIFY study. *Thrombosis Research*. 2011; 128(5):417-421
291. Schellong SM, Haas S, Greinacher A, Schwanebeck U, Sieder C, Abletshauser C et al. An open-label comparison of the efficacy and safety of certoparin versus unfractionated heparin for the prevention of thromboembolic complications in acutely ill medical patients: CERTAIN. *Expert Opinion on Pharmacotherapy*. 2010; 11(18):2953-2961
292. Scurr JH, Robbe IJ, Ellis H, Goldsmith HS. Simple mechanical method for decreasing the incidence of thromboembolism. *American Journal of Surgery*. 1981; 141(5):582-585
293. Segal S, Sadovsky E, Weinstein D, Polishuk WZ. Prevention of postpartum venous thrombosis with low doses of heparin. *European Journal of Obstetrics, Gynecology, and Reproductive Biology*. 1975; 5(5):273-276
294. Selby R, Geerts WH, Kreder HJ, Crowther MA, Kaus L, Sealey F et al. A double-blind, randomized controlled trial of the prevention of clinically important venous thromboembolism after isolated lower leg fractures. *Journal of Orthopaedic Trauma*. 2015; 29(5):224-230
295. Shaikh MA, Jeong HS, Mastro A, Davis K, Lysikowski J, Kenkel JM. Analysis of the American Society of Anesthesiologists Physical Status Classification System and Caprini Risk Assessment Model in predicting venous thromboembolic outcomes in plastic surgery patients. *Aesthetic Surgery Journal*. 2016; 36(4):497-505
296. Sherman DG, Albers GW, Bladin C, Fieschi C, Gabbai AA, Kase CS et al. The efficacy and safety of enoxaparin versus unfractionated heparin for the prevention of venous thromboembolism after acute ischaemic stroke (PREVAIL Study): an open-label randomised comparison. *Lancet*. 2007; 369(9570):1347-1355
297. Sobieraj-Teague M, Hirsh J, Yip G, Gastaldo F, Stokes T, Sloane D et al. Randomized controlled trial of a new portable calf compression device (Venowave) for prevention of venous thrombosis in high-risk neurosurgical patients. *Journal of Thrombosis and Haemostasis*. 2012; 10(2):229-235

298. Soderdahl DW, Henderson SR, Hansberry KL. A comparison of intermittent pneumatic compression of the calf and whole leg in preventing deep venous thrombosis in urological surgery. *Journal of Urology*. 1997; 157(5):1774-1776
299. Song KY, Yoo HM, Kim EY, Kim JI, Yim HW, Jeon HM et al. Optimal prophylactic method of venous thromboembolism for gastrectomy in Korean patients: an interim analysis of prospective randomized trial. *Annals of Surgical Oncology*. 2014; 21(13):4232-4238
300. Spahn G. Compliance with self-administration of heparin injections in outpatients. *European Journal of Trauma*. 2002; 28(2):104-109
301. Spebar MJ, Collins GJ, Jr., Rich NM, Kang IY, Clagett GP, Salander JM. Perioperative heparin prophylaxis of deep venous thrombosis in patients with peripheral vascular disease. *American Journal of Surgery*. 1981; 142(6):649-650
302. Spinal Cord Injury Thromboprophylaxis Investigators. Prevention of venous thromboembolism in the acute treatment phase after spinal cord injury : a randomized, multicenter trial comparing low-dose heparin plus intermittent pneumatic compression with enoxaparin. *Journal of Trauma*. 2003; 54(6):1116-1126
303. Spyropoulos AC, Anderson FA, Jr., Fitzgerald G, Decousus H, Pini M, Chong BH et al. Predictive and associative models to identify hospitalized medical patients at risk for VTE. *Chest*. 2011; 140(3):706-714
304. Steele KE, Canner J, Prokopowicz G, Verde F, Beselman A, Wyse R et al. The EFFORT trial: Preoperative enoxaparin versus postoperative fondaparinux for thromboprophylaxis in bariatric surgical patients: a randomized double-blind pilot trial. *Surgery for Obesity and Related Diseases*. 2015; 11(3):672-683
305. Stewart D, Zalamea N, Waxman K, Schuster R, Bozuk M. A prospective study of nurse and patient education on compliance with sequential compression devices. *American Surgeon*. 2006; 72(10):921-923
306. Strand L, Bank-Mikkelsen OK, Lindewald H. Small heparin doses as prophylaxis against deep-vein thrombosis in major surgery. *Acta Chirurgica Scandinavica*. 1975; 141(7):624-627
307. Stroud W, Whitworth JM, Miklic M, Schneider KE, Finan MA, Scalici J et al. Validation of a venous thromboembolism risk assessment model in gynecologic oncology. *Gynecologic Oncology*. 2014; 134(1):160-163
308. Sultan AA, West J, Grainge MJ, Riley RD, Tata LJ, Stephansson O et al. Development and validation of risk prediction model for venous thromboembolism in postpartum women: multinational cohort study. *BMJ*. 2016; 355:i6253
309. Svend-Hansen H, Bremerskov V, Gotrik J, Ostri P. Low-dose heparin in proximal femoral fractures. Failure to prevent deep-vein thrombosis. *Acta Orthopaedica Scandinavica*. 1981; 52(1):77-80
310. Taberner DA, Poller L, Burslem RW, Jones JB. Oral anticoagulants controlled by the British comparative thromboplastin versus low-dose heparin in prophylaxis of deep vein thrombosis. *British Medical Journal*. 1978; 1(6108):272-274
311. Tang Y, Wang K, Shi Z, Yang P, Dang X. A RCT study of Rivaroxaban, low-molecular-weight heparin, and sequential medication regimens for the prevention of venous thrombosis after internal fixation of hip fracture. *Biomedicine and Pharmacotherapy*. 2017; 92:982-988

312. Tebbe U, Schellong SM, Haas S, Gerlach HE, Abletshauser C, Sieder C et al. Certoparin versus unfractionated heparin to prevent venous thromboembolic events in patients hospitalized because of heart failure: a subgroup analysis of the randomized, controlled CERTIFY study. *American Heart Journal*. 2011; 161(2):322-328
313. Tørholm C, Broeng L, Jørgensen PS, Bjerregaard P, Josephsen L, Jørgensen PK et al. Thromboprophylaxis by low-molecular-weight heparin in elective hip surgery. A placebo controlled study. *Journal of Bone and Joint Surgery (British Volume)*. 1991; 73(3):434-438
314. Törngren S, Forsberg K. Concentrated or diluted heparin prophylaxis of postoperative deep venous thrombosis. *Acta Chirurgica Scandinavica*. 1978; 144(5):283-288
315. Tsapogas MJ, Goussous H, Peabody RA, Karmody AM, Eckert C. Postoperative venous thrombosis and the effectiveness of prophylactic measures. *Archives of Surgery*. 1971; 103(5):561-567
316. Turner GM, Cole SE, Brooks JH. The efficacy of graduated compression stockings in the prevention of deep vein thrombosis after major gynaecological surgery. *British Journal of Obstetrics and Gynaecology*. 1984; 91(6):588-591
317. Turpie AG, Bauer KA, Caprini JA, Comp PC, Gent M, Muntz JE et al. Fondaparinux combined with intermittent pneumatic compression vs. intermittent pneumatic compression alone for prevention of venous thromboembolism after abdominal surgery: a randomized, double-blind comparison. *Journal of Thrombosis and Haemostasis*. 2007; 5(9):1854-1861
318. Turpie AG, Levine MN, Hirsh J, Carter CJ, Jay RM, Powers PJ et al. A randomized controlled trial of a low-molecular-weight heparin (enoxaparin) to prevent deep-vein thrombosis in patients undergoing elective hip surgery. *New England Journal of Medicine*. 1986; 315(15):925-929
319. Turpie AGG, Bauer KA, Eriksson BI, Lassen MR. Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial. *Lancet*. 2002; 359(9319):1721-1726
320. Turpie AGG, Hull RD, Schellong SM, Tapson VF, Monreal M, Samama MM et al. Venous thromboembolism risk in ischemic stroke patients receiving extended-duration enoxaparin prophylaxis: results from the EXCLAIM study. *Stroke*. 2013; 44(1):249-251
321. Turpie AGG, Lassen MR, Davidson BL, Bauer KA, Gent M, Kwong LM et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. *Lancet*. 2009; 373(9676):1673-1680
322. van Adrichem RA, Nemeth B, Algra A, le Cessie S, Rosendaal FR, Schipper IB et al. Thromboprophylaxis after knee arthroscopy and lower-leg casting. *New England Journal of Medicine*. 2017; 376(6):515-525
323. Van Blerk D. Evaluating an intermittent compression system for thromboembolism prophylaxis. *Professional Nurse*. 2004; 20(4):48-49
324. van Es N, Di Nisio M, Cesarman G, Kleinjan A, Otten HM, Mahe I et al. Comparison of risk prediction scores for venous thromboembolism in cancer patients: a prospective cohort study. *Haematologica*. 2017; Epublication
325. Van Vroonhoven TJMV, Van Zijl J, Muller H. Low dose subcutaneous heparin versus oral anticoagulants in the prevention of postoperative deep venous thrombosis. A controlled clinical trial. *Lancet*. 1974; 1(7854):375-378

326. Vandendris M, Kutnowski M, Futeral B, Gianakopoulos X, Kravtman M, Gregoir W. Prevention of postoperative deep-vein thrombosis by low-dose heparin in open prostatectomy. *Urological Research*. 1980; 8(4):219-221
327. Vardi M, Ghanem-Zoubi NO, Zidan R, Yurin V, Bitterman H. Venous thromboembolism and the utility of the Padua Prediction Score in patients with sepsis admitted to internal medicine departments. *Journal of Thrombosis and Haemostasis*. 2013; 11(3):467-473
328. Vaziri S, Wilson J, Abbatematteo J, Kubilis P, Chakraborty S, Kshitij K et al. Predictive performance of the American College of Surgeons universal risk calculator in neurosurgical patients. *Journal of Neurosurgery*. 2017:1-6
329. Vignon P, Dequin PF, Renault A, Mathonnet A, Paleiron N, Imbert A et al. Intermittent pneumatic compression to prevent venous thromboembolism in patients with high risk of bleeding hospitalized in intensive care units: the CIREA1 randomized trial. *Intensive Care Medicine*. 2013; 39(5):872-880
330. Wang H, Sun Z, Jiang W, Zhang Y, Li X, Wu Y. Postoperative prophylaxis of venous thromboembolism (VTE) in patients undergoing high ligation and stripping of the great saphenous vein (GSV). *Vascular Medicine*. 2015; 20(2):117-121
331. Wang Y, Attar BM, Fuentes HE, Yu J, Zhang H, Tafur AJ. Performance of Khorana Risk Score for Prediction of Venous Thromboembolism in Patients With Hepatocellular Carcinoma. *Clinical and Applied Thrombosis/Hemostasis*. 2017:1076029617699088
332. Warwick D, Bannister GC, Glew D, Mitchelmore A, Thornton M, Peters TJ et al. Perioperative low-molecular-weight heparin. Is it effective and safe. *Journal of Bone and Joint Surgery (British Volume)*. 1995; 77(5):715-719
333. Warwick D, Harrison J, Glew D, Mitchelmore A, Peters TJ, Donovan J. Comparison of the use of a foot pump with the use of low-molecular-weight heparin for the prevention of deep-vein thrombosis after total hip replacement. A prospective, randomized trial. *Journal of Bone and Joint Surgery (American Volume)*. 1998; 80(8):1158-1166
334. Warwick D, Harrison J, Whitehouse S, Mitchelmore A, Thornton M. A randomised comparison of a foot pump and low-molecular-weight heparin in the prevention of deep-vein thrombosis after total knee replacement. *Journal of Bone and Joint Surgery (British Volume)*. 2002; 84(3):344-350
335. Westrich GH, Jhon PH, Sánchez PM. Compliance in using a pneumatic compression device after total knee arthroplasty. *American Journal of Orthopedics*. 2003; 32(3):135-140
336. Wille-Jørgensen P, Hauch O, Dimo B, Christensen SW, Jensen R, Hansen B. Prophylaxis of deep venous thrombosis after acute abdominal operation. *Surgery, Gynecology and Obstetrics*. 1991; 172(1):44-48
337. Wille-Jørgensen P, Thorup J, Fischer A, Holst-Christensen J, Flamsholt R. Heparin with and without graded compression stockings in the prevention of thromboembolic complications of major abdominal surgery: a randomized trial. *British Journal of Surgery*. 1985; 72(7):579-581
338. Williams-Russo P, Sharrock NE, Haas SB, Insall J, Windsor RE, Laskin RS et al. Randomized trial of epidural versus general anesthesia: outcomes after primary total knee replacement. *Clinical Orthopaedics and Related Research*. 1996; 331:199-208
339. Wilson NV, Das SK, Kakkar VV, Maurice HD, Smibert JG, Thomas EM et al. Thrombo-embolic prophylaxis in total knee replacement. Evaluation of the A-V impulse system. *Journal of Bone and Joint Surgery (British Volume)*. 1992; 74(1):50-52

340. Winoker JS, Paulucci DJ, Anastos H, Waingankar N, Abaza R, Eun DD et al. Predicting complications following robot-assisted partial nephrectomy with the ACS-NSQIP Universal Surgical Risk Calculator. *Journal of Urology*. 2017; Epublication
341. Wirth T, Schneider B, Misselwitz F, Lomb M, Tüylü H, Egbring R et al. Prevention of venous thromboembolism after knee arthroscopy with low-molecular weight heparin (reviparin): Results of a randomized controlled trial. *Arthroscopy*. 2001; 17(4):393-399
342. Woller SC, Stevens SM, Jones JP, Lloyd JF, Evans RS, Aston VT et al. Derivation and validation of a simple model to identify venous thromboembolism risk in medical patients. *American Journal of Medicine*. 2011; 124(10):947-954.e942
343. Wood KB, Kos PB, Abnet JK, Ista C. Prevention of deep-vein thrombosis after major spinal surgery: a comparison study of external devices. *Journal of Spinal Disorders*. 1997; 10(3):209-214
344. Xabregas A, Gray L, Ham JM. Heparin prophylaxis of deep vein thrombosis in patients with a fractured neck of the femur. *Medical Journal of Australia*. 1978; 1(11):620-622
345. Yarlagadda BB, Brook CD, Stein DJ, Jalisi S. Venous thromboembolism in otolaryngology surgical inpatients receiving chemoprophylaxis. *Head and Neck*. 2014; 36(8):1087-1093
346. Ye K, Wang R, Qin J, Yang X, Yin M, Liu X et al. Post-operative benefit of compression therapy after endovenouslaser ablation for uncomplicated varicose veins: a randomised clinical trial. *European Journal of Vascular and Endovascular Surgery*. 2016; 52(6):847-853
347. Yokote R, Matsubara M, Hirasawa N, Hagio S, Ishii K, Takata C. Is routine chemical thromboprophylaxis after total hip replacement really necessary in a Japanese population? *Journal of Bone and Joint Surgery (British Volume)*. 2011; 93(2):251-256
348. Zanasi R, Fioretta G, Ciocia G, Bergonzi M. Prevention of deep venous thrombosis in orthopedic surgery: effects of defibrotide. *Clinical Therapeutics*. 1988; 10(4):350-357
349. Zou Y, Tian S, Wang Y, Sun K. Administering aspirin, rivaroxaban and low-molecular-weight heparin to prevent deep venous thrombosis after total knee arthroplasty. *Blood Coagulation and Fibrinolysis*. 2014; 25(7):660-664